DrugCom_ID	DrugID_1	Drug_Name_1	Highest_status_1	order_1	DrugID_2	Drug_Name_2	Highest_status_2	order_2	DrugID_3	Drug_Name_3	DrugID_4	Drug_Name_4	Disease_Entry	Source	Highest_status	Cell Line	ZIP	Bliss	Loewe	HSA
DC4XUHV	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	3.1	8.53	5.64	9.56
DC042HW	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	2.16	10.38	9.43	11.39
DCSYKKN	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	13.57	15.29	10.03	17.14
DCOPX9G	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	9.48	13.82	6.03	17.12
DC9MNFP	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	2.57	2.77	0.55	3.6
DCJ1G8L	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.79	11.23	2.49	13.31
DCDBYUC	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	3.04	4.95	1.64	7.92
DC0PXP4	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	0	4.31	2.93	8.54
DC6GJ5O	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	1.1	6.14	11.04	6.05
DCH1B10	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.31	14.82	18.23	19.36
DC158YT	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	5.37	6.3	5.55	7.84
DCMTG98	DMUM7HZ	Fluorouracil	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	2.82	4.05	4.9	7.83
DC1OA37	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.38	4.46	0.03	8.34
DCI2O36	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	13.76	14.63	12.56	17.09
DCOTB31	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	7.85	8.1	6.1	8.89
DC2FVX8	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	13.76	13.6	4.13	15.59
DC6EJAY	DMUM7HZ	Fluorouracil	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	9.34	11.63	21.63	9.56
DC3VSIP	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	6.99	15.25	9.58	11.85
DCADKI9	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	7.99	7.87	8.26	12.51
DC1PTVD	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	5.26	5.84	11.74	15.39
DCMJ4QJ	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	0.16	2.98	5.12	5.12
DC7HONE	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	0.33	3.92	6.04	6.89
DC5X7DL	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.62	2.56	4.32	8.92
DCZBRAF	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.1	1.48	2.07	6.19
DCDZFYY	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.65	4.38	3.49	11.21
DCBAAWV	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.6	0.68	2.28	5.88
DCGQHNK	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	4.11	6.32	6.31	6.42
DC22TXQ	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	5.98	7.91	8.43	9.54
DCTG9JF	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.55	1.07	1.74	11.59
DC91D7D	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.34	7.79	4.51	9.47
DCK7CYM	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.15	2.72	6.7	7.15
DC6MMP7	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	5.94	5.4	1.29	7.81
DCN25FH	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.04	3.26	4.46	8.92
DCDPWLJ	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	9.08	9.9	7.99	13.8
DCYNRI3	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.97	6.63	11.94	15.38
DCEPSYD	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.57	8.52	12.32	13.62
DC3FD7A	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.55	10.27	6.39	10.89
DCQHOGW	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.21	2.49	16.68	18.06
DCQYT8T	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	9.69	13.29	13.65	15.71
DC5P376	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.71	8.19	15.78	17.54
DCODSY6	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	8.21	9.91	12.14	18.41
DC5NCO4	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.1	2.38	3.76	7.61
DC631VR	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.48	3.34	6.89	11
DCNHKBV	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	8.99	9.03	9.93	14.77
DCPJ54L	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.32	10.17	2.35	11.52
DCXXE5L	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	8.81	8.7	16.57	19.24
DC4JQTY	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.56	6.82	0.67	9.7
DC9P428	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.98	9.29	12.19	15.54
DCMW289	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	5.84	7.57	10.1	13.36
DC6857R	DMUM7HZ	Fluorouracil	Approved	34	DMMWZET	Dexamethasone	Phase 3 Trial	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.15	5.95	7.97	14.25
DC4A3FP	DMUM7HZ	Fluorouracil	Approved	34	DMMWZET	Dexamethasone	Phase 3 Trial	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.81	6.91	2.44	4.56
DCGJ44Y	DMUM7HZ	Fluorouracil	Approved	34	DMMWZET	Dexamethasone	Phase 3 Trial	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	7.25	7.3	13.66	19.13
DCHTSSM	DMUM7HZ	Fluorouracil	Approved	34	DMMWZET	Dexamethasone	Phase 3 Trial	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	5.02	7.58	2.22	4.13
DCNTWNJ	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	5	6.17	4.1	8.71
DCQ5WMI	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.49	4.26	4.29	9.48
DCHJLMV	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	3.11	2.71	5.21	9.41
DCSNU3J	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	7.47	8.18	5.18	10.8
DCDHCZI	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.37	2.68	5.18	7.82
DCKI9K3	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.78	2.33	6.51	9.82
DCZDAEL	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	17.25	17.46	11.88	20.55
DCLP3LF	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.81	8.94	3.69	11.6
DCDF0AX	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.99	11.03	0.1	12.39
DCC3NNC	DMUM7HZ	Fluorouracil	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.57	3.68	1.31	7.6
DCA10WS	DMUM7HZ	Fluorouracil	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	5.27	3.89	3.56	4.2
DCYEO3D	DMUM7HZ	Fluorouracil	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.94	1.08	0.64	7.01
DCZXIUO	DMUM7HZ	Fluorouracil	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.61	2.25	2.49	6.04
DCIVGRH	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	9.96	6.09	4.05	8.24
DC6NZAA	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.18	0.3	1.49	4.37
DCKUELH	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	7.32	12.69	7.1	14.03
DCRFSIY	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	15.63	15.06	11.74	16.93
DCDW3EN	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.2	3.68	6.26	8.45
DCEQ7KQ	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	15.15	17.16	8.27	16.34
DCK0IM6	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	5.16	3.59	4.56	10.86
DC3EIVI	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	16.3	18.24	1.36	19.74
DC5FPC4	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.72	1.81	5.98	8.38
DC66YRL	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	15.39	9.76	22.76	9.4
DCG6R2J	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.72	4.13	5.18	8.75
DCZ765I	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.75	1.74	3.67	8.04
DCLM10J	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.16	0.74	4.67	8.43
DCO29V1	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.72	2.41	4.32	8.75
DCU3Q8W	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.44	3.82	8.18	10.99
DCLWLID	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.14	0.97	8.08	11.11
DCQGEN5	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	7.13	6.93	7.86	11.35
DCEGTQB	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.38	4.81	5.84	9.19
DCUEXMJ	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.47	3.9	1.53	6.06
DCWJWRH	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.78	0.22	2.32	1.12
DCVG2RL	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.95	0.85	6.13	8.95
DCUP3WX	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.54	1.99	4.73	7.3
DCLL34N	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.54	3.23	1.65	6.74
DCOUDM4	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.83	1.18	7.1	9.13
DCBJGZ2	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.99	6.48	4.19	10.33
DCZ32VP	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.08	14.08	2.4	9.2
DCU1EKM	DMUM7HZ	Fluorouracil	Approved	34	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.52	2.61	6.93	11.17
DCM7JP9	DMUM7HZ	Fluorouracil	Approved	34	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	10.97	7.19	0.58	9.25
DCAHIF1	DMUM7HZ	Fluorouracil	Approved	34	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.29	2.25	8.47	12.27
DC2YD4T	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.08	5.65	8.57	10.58
DC8LLV4	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.33	8.34	12.19	14.05
DCXKB9R	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.51	2.59	2.14	7.93
DCI46IY	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.47	2.9	6.81	9.94
DC9UZUW	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	18.04	17.41	12.79	20.36
DCDYB8W	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.15	4.38	6.87	13.06
DCQVW73	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	16.67	12.7	16.24	12.75
DC7PUKI	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.12	4.17	0.32	5.33
DC30EOL	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.1	3.07	1.43	5.34
DC15OQS	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	5.61	7.08	4.71	7.69
DCLJ2EH	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.47	4.46	4.87	5.92
DCR9GPB	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.46	10.36	9.72	11.94
DCZ37GI	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	0.01	0.64	3.92	5.01
DCBU8L8	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.72	3.4	4.13	8.88
DC1S8V2	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.08	0.48	5.67	9.05
DCMXOVM	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	0.71	1.54	8.57	11.21
DC09CDH	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.04	2.16	5.5	11.6
DC48PJC	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.78	2.55	7.01	12
DCH3H6P	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.63	3.32	7.73	14.19
DCL8X1Q	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	22.28	22.53	9.9	20.8
DCW2L30	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.12	1.12	3.55	6.76
DCMSHKT	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	5.19	5.26	9.95	13.07
DCWW9WK	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	3.49	4.58	4	8.47
DCISOID	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.11	2.16	1.32	7.17
DCW622Q	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.99	3.08	9.97	14.88
DCPS2ZQ	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	16.86	17.32	14.8	19.25
DCTZ8JI	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.49	2.2	4.78	7.69
DCGU6MD	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	6.78	7.05	4.41	14.73
DCOQHJN	DMUM7HZ	Fluorouracil	Approved	34	DMDASC6	Metformin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	6.74	8.3	2.99	9.6
DCOUD0D	DMUM7HZ	Fluorouracil	Approved	34	DMDASC6	Metformin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.02	2.87	2.1	2.99
DCQ8BUA	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.07	1.54	2.22	5.88
DC0T007	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	4.39	7.13	9.77	12.26
DCAYR7Q	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.87	1.73	2.48	6.94
DC6S4TQ	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	10.64	10.53	10.22	13.91
DC3MQS4	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.73	6.85	9.44	12.13
DCU6D6H	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	0.97	5.64	5.76	9.14
DCO3423	DMUM7HZ	Fluorouracil	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.26	2.31	4.78	8.17
DCYS5SM	DMUM7HZ	Fluorouracil	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.19	0.37	5.82	8.53
DC37RHA	DMUM7HZ	Fluorouracil	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.75	2.54	3.51	8.77
DC75LWR	DMUM7HZ	Fluorouracil	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.66	5.51	2.96	6.5
DCCWWH1	DMUM7HZ	Fluorouracil	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	6	6.43	5.08	6.14
DCEPLSW	DMUM7HZ	Fluorouracil	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.84	9.59	10.03	12.69
DCFECAP	DMUM7HZ	Fluorouracil	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.99	1.56	7.05	9.27
DCDVDSK	DMUM7HZ	Fluorouracil	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.56	0.59	1.22	6.27
DCN7R2N	DMUM7HZ	Fluorouracil	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	6.57	5.96	6.99	15.75
DCVOTYU	DMUM7HZ	Fluorouracil	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.2	4.28	2.05	8.08
DCWEHB8	DMUM7HZ	Fluorouracil	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.05	4.64	7.55	10.66
DCOW8Q8	DMUM7HZ	Fluorouracil	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.23	3.98	1.1	6.17
DCBAU8D	DMUM7HZ	Fluorouracil	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	4.77	3.11	1.62	5.02
DCINCZD	DMUM7HZ	Fluorouracil	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.19	3.48	0.41	2.76
DCL2A35	DMUM7HZ	Fluorouracil	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	0.16	1.36	0.87	5.12
DCG10K0	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	0.97	0.4	2.26	4.54
DCOSN5K	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	8.55	8.68	11.3	13.79
DC05P9A	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.32	3.83	9.27	11.96
DCNWE86	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.47	4.43	12	14.07
DCZEIZS	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	4.86	6.91	2.37	11.33
DC07NMT	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.71	3.39	0.3	5
DCT785J	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	5.84	5.73	16.17	17.94
DC6DV7S	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.38	5.4	6.67	7.87
DC9OP8K	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	10.82	11.22	14.78	16.52
DCH4LI2	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	0.83	4.87	11.66	11.93
DC9QC0E	DMUM7HZ	Fluorouracil	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.51	15.15	14.82	15.18
DCLI7MH	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.76	4.29	0.32	5.01
DCD2GP2	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.23	2.06	3.16	5.71
DC2HOI2	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.47	3.19	1.04	3.41
DC3V4UM	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.68	2.68	1.17	4.46
DCVVB74	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.13	7.26	1.63	7.61
DCJ0V7B	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.76	6.6	6.66	9.16
DCT8NSH	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.38	0.88	2.55	2.99
DCQFPBN	DMUM7HZ	Fluorouracil	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.08	1.02	3.32	7.86
DCVXN69	DMUM7HZ	Fluorouracil	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.31	2.42	6.92	10
DCSN8PB	DMUM7HZ	Fluorouracil	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.42	2.94	4.49	9.5
DCZUO0V	DMUM7HZ	Fluorouracil	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	5.33	9.81	7.07	9.63
DCM6Z4C	DMUM7HZ	Fluorouracil	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2	7.54	3.64	10.9
DCD36JN	DMUM7HZ	Fluorouracil	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.95	12.6	0.15	11.1
DCGFOWN	DMUM7HZ	Fluorouracil	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	16.31	16.43	10.14	20
DCP7MKO	DMUM7HZ	Fluorouracil	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	8.87	8.46	11.87	12.78
DCFTSG6	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.73	4.03	2.34	8.13
DCTQ3GZ	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.43	2.84	1.17	8.01
DCIQXOM	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	13.1	12.11	19.99	22.29
DC7WUBU	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.97	1.45	1.25	8.08
DCDC8RI	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	9.46	8.64	7.72	15.26
DCHI12T	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.99	4.18	5.77	11.55
DCNV46J	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.97	10.4	2.61	6.71
DC8LUK7	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	19.27	19.92	9.11	22.09
DCOZXUJ	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.55	9.54	9.22	14.79
DCLRWZY	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	10.51	9.17	9.47	11.53
DC20KMI	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.63	3.57	4.24	6.78
DCBN8GW	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.02	5.36	6.78	9.68
DC5RLZZ	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.29	1.3	2.45	6.85
DCA5Y90	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.15	3.28	10.4	12.54
DCWXNMA	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.4	6.5	3.38	7.88
DCKYPZD	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.58	0.43	9.11	11.01
DC3G0Y5	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.72	5.77	3.17	8.36
DC13WV0	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.66	4.39	13.4	15.17
DCBPUXA	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.92	3.28	6.37	10.07
DCTE1J7	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	5.71	3.64	4.13	7.9
DC67GFZ	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.26	0.01	2.25	5.73
DC10K8O	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.94	2.85	9.24	11.28
DC3A7DU	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.94	1.54	4.94	8.78
DC0JHJB	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.4	3.58	2.31	6.4
DCC6H99	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.31	4.05	11.48	13.58
DCKDNVO	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	7.58	8.08	4.53	10.05
DC58VZO	DMUM7HZ	Fluorouracil	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.41	1.49	0.41	6.48
DC6YBB6	DMUM7HZ	Fluorouracil	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.85	1.97	0.6	10.71
DCLIFSW	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.79	4.79	3.11	7.06
DCRCLI4	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.64	1.59	2.48	6.29
DCUD209	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.17	1.28	5.89	8.37
DCK7RQX	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.03	2.02	2.28	7.53
DCPTGX2	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.13	0.03	4.33	8.96
DC3CU0I	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.28	3.91	0.82	6.07
DCDCXNB	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.97	5.32	11.2	12.65
DCA0WA1	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.04	6.77	3.51	8.97
DCF67C7	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	6.56	6.23	1.06	9.84
DCKAO70	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	6.37	6.12	7.62	12.06
DCRBV5T	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.58	3.46	9.91	12.04
DC5BBUS	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.23	3.83	5.42	10.86
DCDPN2G	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	4.6	4.4	8.98	13.2
DC0I5SA	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.5	4.03	0.21	7.33
DCEMXZ5	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.93	2.43	1.48	8.7
DC3391I	DMUM7HZ	Fluorouracil	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.61	2.92	2.35	6.72
DCQEYCI	DMUM7HZ	Fluorouracil	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.36	7.08	1.93	9.16
DC45OUK	DMUM7HZ	Fluorouracil	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.42	5.26	4.31	6.89
DCPGDU7	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	8.26	0.58	1.92	5.1
DCSRGQ8	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.2	1.09	3.57	6.46
DCTGQMW	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	5.33	11.25	13.22	15.02
DCFAKLL	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.68	2.9	3.75	7
DC73FQA	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.25	4.28	10.69	12.82
DCNJBAF	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	8.68	12.23	15.62	16.81
DCK2KXI	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.37	9.97	8.25	11.03
DC74B5F	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.36	1.6	11.82	13.21
DCCF4DR	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	5.74	6.5	0.79	13.53
DCA2TH2	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.8	3.63	1.32	6.77
DCRMWFV	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.69	7.76	14.69	15.31
DCIO4WY	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.9	4.24	2.18	10.64
DC4TJW5	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	2.4	4.02	1.51	9.79
DCOJJMV	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	2.62	5.15	1.37	6.57
DCIII14	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	10.49	9.94	3.16	11.71
DC04YQK	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	8.64	9.67	7.88	15.23
DCTJ9L3	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	12.4	11.11	9.82	13.4
DCJYHPK	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	4.48	7.12	7.09	11.24
DC7RGZA	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	8.53	10.68	4.52	13.6
DCCPCYU	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.94	6.31	1.51	10.29
DCL1UMP	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	6.11	8.09	2.43	9.7
DCOM8WN	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	8.6	9.88	3.64	11.83
DCJVOG0	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.25	4.3	2.18	5.47
DCNEQ35	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	13.85	16.92	5.66	15.3
DCURTXP	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.38	4.16	5.15	7.14
DCVCSVJ	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	11.94	12.24	17.83	18.61
DC7T3FD	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	7.16	6.07	3.26	8.62
DCWCK5H	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	9.13	8.8	0.42	12.99
DCWJ31F	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.24	11.14	5.52	10.69
DCTKYQJ	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	8.12	14.11	6.27	12.87
DCEDZFB	DMUM7HZ	Fluorouracil	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	14.04	17.13	21.33	21.56
DCE0NWM	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	10.77	13.07	12.03	15.13
DCPM3UR	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.89	4.47	11.25	12.48
DC344QR	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	9.26	9.09	11.93	15.78
DC8IL4R	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	2.82	4.17	9.36	11.43
DCLOTM5	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	12.16	15.68	14.33	19.93
DCY3QKH	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.13	5.12	3.35	6.63
DCDZIFI	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	7.84	9.41	7.33	12.28
DCGF9B9	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.34	6.33	0.55	8.54
DCYXUSM	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.75	6.93	9.1	11.85
DCV5BD5	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.02	7.72	6.44	10.92
DCDCQ05	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	11.84	12.46	8.82	16.74
DCIP280	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.87	11.46	8.87	9.45
DCBOX6B	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	9.88	18.32	5.99	18.14
DC2IGMG	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	15.95	20.03	20.05	22.66
DCKVIMN	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	6.53	15.96	12.76	16.66
DCNRCUM	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	2.19	7.77	0.08	12.83
DCJG998	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	14.88	18.52	16.6	19.03
DCAC28O	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	17.61	21.68	13.27	21.66
DC1YNWU	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.18	12.1	14.61	16.21
DCLEWTG	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	13.34	12.71	15.26	17.72
DCO7O18	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	1.12	2.34	2.04	9.15
DC3HPXN	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	12.58	14.54	11.68	16.02
DC9CG9Q	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.96	12.82	11.8	13.7
DCCVRAG	DMUM7HZ	Fluorouracil	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	4.91	9.1	7.62	8.74
DCWZYKI	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.95	7.13	2.35	8.14
DCWZTBH	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.05	6.71	5.46	13.77
DCQ4T8E	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.66	14.46	16.82	18.59
DCQ5MYW	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.64	9.55	4.99	11.55
DCTV9MU	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	1.75	0.83	5.37	9.47
DCE3BWE	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	7.49	11.98	7.52	14.47
DC353UD	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.54	2.75	1.48	6.48
DCLJJ4D	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	10.61	11.65	6.9	14.52
DCWAD6Y	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	9.91	11.61	1.68	13.04
DC5VH5L	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.69	7.05	5.4	10.93
DC00UCH	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	7.77	5.22	2.04	7.15
DCXGTM0	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.07	12.66	10.22	13.17
DCX73JT	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	5.9	10.43	2.35	10.34
DC4UY4A	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	20.38	20.78	25.32	26.97
DCAZQB6	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	12.17	12.08	11.13	16.86
DC3I9NU	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.76	9.36	3.34	8.91
DCUNP29	DMUM7HZ	Fluorouracil	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	0.23	10.53	2.75	10.09
DCRSD1L	DMUM7HZ	Fluorouracil	Approved	34	DMMWZET	Dexamethasone	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	0.68	4.5	5.02	9.25
DCJ2NML	DMUM7HZ	Fluorouracil	Approved	34	DMMWZET	Dexamethasone	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	12.35	18.28	9.57	16.19
DCI6PEP	DMUM7HZ	Fluorouracil	Approved	34	DMMWZET	Dexamethasone	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.16	5.17	5.88	10.12
DCHTBPQ	DMUM7HZ	Fluorouracil	Approved	34	DMMWZET	Dexamethasone	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.41	8.73	1.62	7.5
DCZ1L20	DMUM7HZ	Fluorouracil	Approved	34	DMMWZET	Dexamethasone	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.59	9.13	6.05	7.35
DCHATNG	DMUM7HZ	Fluorouracil	Approved	34	DMMWZET	Dexamethasone	Phase 3 Trial	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	6.57	13.91	2.57	3.49
DCHQETP	DMUM7HZ	Fluorouracil	Approved	34	DMMWZET	Dexamethasone	Phase 3 Trial	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	9.11	13.5	11.52	17.45
DCFR4X8	DMUM7HZ	Fluorouracil	Approved	34	DMMWZET	Dexamethasone	Phase 3 Trial	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.77	8.2	3.09	8.77
DCJUCI5	DMUM7HZ	Fluorouracil	Approved	34	DMMWZET	Dexamethasone	Phase 3 Trial	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2	9.66	6.65	9.76
DC1JE9J	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.47	5.69	3.09	7.17
DCZRPB3	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	11.92	13.39	12.34	16.89
DC5LD0Y	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	6.55	7.91	7.78	12.06
DCPHJ1U	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.16	6.58	0.36	9.38
DCVF79Y	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.95	9.04	2.45	9.71
DCPDRF8	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	5.14	4.24	1.17	5.17
DCYNZII	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	7	10.34	1	11.62
DC31Q43	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	3.84	7.26	3.29	9.89
DCJELQ3	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	6	10	5.08	13.28
DCAKOF7	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.23	4.07	2.54	9.03
DCUORU1	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	7.97	10.03	5.68	10.98
DCEKOL5	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	10.16	15	8.12	16.21
DCU7U7Q	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.88	5.44	3.05	5.95
DCSI37N	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	15.46	17.65	7.87	15.89
DCVOHI1	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.02	5.12	5.09	7.39
DCFD7VJ	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	5.89	4.6	2.67	10.6
DCL8RC6	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.75	7.13	7.63	10.16
DCD7OX3	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.44	5.14	0.73	6.87
DCJ09HG	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.8	9.11	3.32	8.89
DCZ1J4V	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	3.64	3.08	6.13	9.99
DCWAWIT	DMUM7HZ	Fluorouracil	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	5.03	12.54	0.01	13.1
DCGX3V1	DMUM7HZ	Fluorouracil	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.67	14.14	1.89	8.51
DC0YQ4U	DMUM7HZ	Fluorouracil	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.84	8.07	0.73	1.98
DC7V6VG	DMUM7HZ	Fluorouracil	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	10.33	11.95	3.98	4.89
DCK7825	DMUM7HZ	Fluorouracil	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	9.69	12.36	4.48	9.42
DCF32CP	DMUM7HZ	Fluorouracil	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.54	20.45	7.44	15.04
DCU11IM	DMUM7HZ	Fluorouracil	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	7.65	6.7	0.64	7.97
DC76WFZ	DMUM7HZ	Fluorouracil	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.39	0.9	0.55	2.39
DCXOF6Z	DMUM7HZ	Fluorouracil	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	11.6	10.78	3.17	11.24
DCKQR25	DMUM7HZ	Fluorouracil	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.45	2.29	1.35	5.28
DCWHU6J	DMUM7HZ	Fluorouracil	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.09	9.78	8.63	8.78
DC5AND3	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	8.26	6.81	4.3	8.16
DCFE57P	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	10.84	9.59	2.18	13.52
DC56B6L	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	4.8	3.31	6.47	10.19
DCKN9F4	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	7.16	9.63	3.47	15.18
DCER0C9	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	16.68	15.4	15.26	17.9
DCAXXY6	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	7.46	6.88	2.9	8.48
DCV12ZW	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	2.95	1.19	4.25	7.98
DC09FAG	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	10.61	11.63	9.89	9.96
DCAEZL0	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	8.36	8.22	7.25	12.83
DC4Q2N9	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	9.69	9.97	6.93	13.36
DCS9C87	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.72	4.71	3.6	7.16
DCMAX6Z	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	5.47	10.08	7.43	10.96
DCI8H2E	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.7	7.07	5.15	10.37
DC9PFU0	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	16.87	16.74	13.64	17.93
DC9C0EB	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	4.45	6.22	4.59	11.74
DC77PEW	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	9.11	12.63	11.05	13.11
DCJ4ACO	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	13.17	14.7	9.1	15.18
DC5FPIE	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	8.71	8.99	9.47	12.94
DC1ZX8G	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	17.9	17.94	6.35	19.57
DCJ3MOT	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	7.56	5.06	4.79	10.06
DCC2I52	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	11.2	9.31	7.52	13.05
DCLH3Q3	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	17.88	20.39	16.05	19.92
DCK9GF9	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	7.79	2.32	4.06	9.02
DCMC78C	DMUM7HZ	Fluorouracil	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	17.62	16.06	10.36	14.08
DC17AQ8	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	7.48	7.21	5.82	9.99
DC7XW6B	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	9.4	9.49	1.14	17.95
DC6ACPP	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	8.77	8.34	14.82	17.58
DCM4AKW	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.36	2.47	5.39	8.55
DCCOZY4	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	10.45	13.99	5.39	16.8
DCY7J4Q	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	6.17	6.18	3.7	8.77
DCKQ07R	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	8.51	6.91	10.34	14.27
DCKU4TI	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	6.89	7.19	0.66	10.96
DCS4E7G	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	1.4	2.78	2.72	7.34
DCYGLLU	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.67	6.17	2.68	10.08
DCFE547	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	8.11	8.03	12.69	16.09
DCIOLQJ	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	8.53	7.04	7.93	11.85
DCC1IC6	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.61	0.64	1.54	5.9
DCNYI0V	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	10.94	10.2	6.64	12.09
DCBPVI0	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	8.26	8.11	7.62	9.57
DCZ1YYG	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	6.29	6.62	3.75	9.11
DCV659D	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	8.68	8.67	0.94	14.5
DCWW2DS	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	13.37	12.37	10.75	15.69
DCR1FWK	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	13.67	14.96	11.67	15.2
DCR8D0T	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	7.66	5.68	8.38	12.02
DCPV2CR	DMUM7HZ	Fluorouracil	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	10.82	14.37	4.19	15.58
DCRMG4Y	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	0.79	5.1	7.08	9.1
DCS0473	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.45	1.44	3.18	6.63
DCYN63P	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	1.87	0.83	4.61	8.64
DC6MPZJ	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	9.62	9.89	10.52	15
DCL2671	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	3.84	3.14	2.59	5.94
DCS3HUI	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	6.52	6.78	2.74	8.82
DC2QNN5	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	1.16	1.06	6.05	9.65
DCV3SUT	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	12.21	11.98	12.56	14.75
DCSGNF4	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.98	4.43	3.88	6.6
DC767LN	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.03	2.78	5.56	10.2
DCP8QBU	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.35	2.53	2.11	2.8
DC4IO3Q	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	1.23	6.81	7.26	11.39
DCOFHPJ	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	2.62	10.76	9.42	13.19
DCKWYOV	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	10.99	9.88	7.7	10.47
DCNCE0A	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	12.39	10.88	8.59	14.45
DCVBV2H	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.58	4.83	8.46	10.23
DCLF6OC	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	5.63	4.57	2.29	7.82
DCUAKX2	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.67	7.99	7.52	10.66
DC566F3	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	10.83	11.78	5.63	10.61
DCDOPFF	DMUM7HZ	Fluorouracil	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	2.91	10.16	10.1	12.07
DCDI7RL	DMUM7HZ	Fluorouracil	Approved	34	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.16	0.42	0.25	0.89
DCZV1CV	DMUM7HZ	Fluorouracil	Approved	34	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	6.99	0.05	2.64	5.45
DC8XZDL	DMUM7HZ	Fluorouracil	Approved	34	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.96	0.46	0.25	1.11
DCI7OR3	DMUM7HZ	Fluorouracil	Approved	34	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	6.97	5.69	0.43	9.05
DC3DDW2	DMUM7HZ	Fluorouracil	Approved	34	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.81	3.41	4.42	10.89
DCA53PF	DMUM7HZ	Fluorouracil	Approved	34	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	16.32	12.42	9.24	15.98
DC942A5	DMUM7HZ	Fluorouracil	Approved	34	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	10.1	7.04	0.39	10.04
DC34U36	DMUM7HZ	Fluorouracil	Approved	34	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	10.58	3.94	3.84	4.69
DCSVNOF	DMUM7HZ	Fluorouracil	Approved	34	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	3.99	0.43	0.47	5
DCENY78	DMUM7HZ	Fluorouracil	Approved	34	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.9	11.24	2.3	10.79
DCPD1NU	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	11.51	12.07	6.25	12.49
DC3CVP4	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	4.57	3.84	2.35	9.29
DCGO3UW	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.88	7.53	1.53	12.5
DC6CRUS	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	8.79	11.2	4.65	12.59
DCYRJ4S	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.04	7.51	2.49	11.63
DC956OX	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.73	4.98	1.43	9.17
DCBL645	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	11.84	12.03	10.16	14.99
DCRGG7P	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.1	4.95	7.34	9.59
DCWEM7J	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	9.91	12.03	5.56	13.48
DCED75J	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	10.35	12.65	11.11	13.96
DC06DKX	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	11.04	13.01	3.93	13.77
DCC9M3U	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.4	2.76	2.64	7.69
DCM5FI4	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	2.38	3.81	0.87	8.17
DCY7K0S	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	1.06	6.26	10.81	12.16
DC8WTOF	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	12.61	13.06	9.2	16.7
DC83KN7	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	14.46	17.66	19.83	16.3
DCHADAA	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	7.53	8.44	11.66	15.76
DCABMER	DMUM7HZ	Fluorouracil	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.89	9.34	7.41	8.23
DCB459C	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	5.49	7.41	2.09	6.51
DCUMV1B	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.21	7.95	9.6	10.48
DCPVN2O	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	5.8	4.47	4.58	9.38
DCS5VV4	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	1.29	2.23	2	6.25
DCFIFIE	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	0.11	4.36	2.23	3.96
DCQ2IKJ	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	3.16	3.19	2.8	6.86
DCORYRC	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.34	0.08	0.79	5.07
DC7G1VN	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.54	9.56	6.64	12.26
DCSE9TB	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	3.38	7.55	4.27	9.22
DCSSP2O	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.23	5.56	3.19	7.83
DCDXQFA	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.74	7.61	3.87	7.37
DC7Q5LA	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.72	5.14	6.07	4.7
DC5A7BY	DMUM7HZ	Fluorouracil	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	11.75	11.85	15.89	18.99
DCYUJLJ	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	8.1	9.69	5.55	12.92
DCRNCMM	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	12.14	11.88	11.75	20.57
DC831GZ	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	5.47	8.45	12.92	15.2
DCI7RXL	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	17.96	17.23	21.15	18
DC0X9WM	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	10.23	12.49	3.12	15.03
DCG6BQX	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	16.78	16.94	14.49	22.56
DCK3AOJ	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	13.87	13.66	9.71	18.36
DCQK8AH	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	6.01	4.49	3.37	9.63
DCWQKGT	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	12.1	11.43	2.65	15.5
DCSMIZR	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	16.35	16.02	14.9	23.98
DC04700	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	18.15	20.05	3.82	19.83
DCPTEVM	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	14.83	18.97	12.13	21.96
DCIKPVF	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	11.07	11.76	4.22	14.61
DC569MT	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	0.12	5.01	8.17	12.04
DC9IR3D	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	8.16	9.49	13.63	8.84
DCUWABS	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	16.43	18.27	9.99	21.6
DC6YH9L	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.25	6.5	9.68	12.55
DC1L5UZ	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	5.95	6.46	4.39	12.38
DCRP1YB	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	9.88	10.05	0.04	15.81
DCBSK0K	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.73	7.98	3.93	13.35
DCTC3K1	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	12.11	11.9	4.73	12.54
DCZ3H5M	DMUM7HZ	Fluorouracil	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	9.91	14.09	1.29	14
DCRDQ10	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.44	4.96	5.03	8.27
DCVWULN	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.3	3.75	7.37	13.58
DCYAQ85	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.96	4.17	6.25	11.32
DC1FKDB	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	7.86	7.88	9.63	14.41
DCQLUV5	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	9.6	9.84	3.17	13.79
DC3DZHV	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	7.72	11.53	9.28	13.99
DCGPT6R	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	3.61	4.18	3.71	7.94
DCZZ5XF	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.08	0.57	2.07	4.56
DCQVIX9	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.84	9.61	6.39	12.49
DCECZA8	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	9.63	10.89	10.59	15.58
DCA04XA	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.55	6.61	10.12	4.61
DC48752	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	9.57	11.46	6.96	12.52
DCJUCAV	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	5.82	10.33	5.73	11.8
DC3I5GN	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.85	8.07	6.74	9.08
DC3GSPS	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	4.66	6.14	1.13	7.23
DCSUB9D	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.19	6.9	8.95	12.41
DCEYIS9	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	13.63	9.79	11.06	16.18
DCSC54Z	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	1.61	2.56	2.69	8.62
DCFE5XZ	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	12.24	12.89	10.44	15.06
DCDM2MA	DMUM7HZ	Fluorouracil	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.85	10.22	6.74	10.69
DCW8FFN	DMUM7HZ	Fluorouracil	Approved	34	DMDASC6	Metformin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	0.73	9.33	7.29	9.81
DC2VY7E	DMUM7HZ	Fluorouracil	Approved	34	DMDASC6	Metformin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.43	8.32	6.46	8.46
DC0Y44F	DMUM7HZ	Fluorouracil	Approved	34	DMDASC6	Metformin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.2	8.78	5.07	8.21
DCNODXQ	DMUM7HZ	Fluorouracil	Approved	34	DMDASC6	Metformin	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	14.21	19.61	14.49	16.33
DC5B4OB	DMUM7HZ	Fluorouracil	Approved	34	DMDASC6	Metformin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	19.75	22.72	3.09	22.85
DCZ8NYZ	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	7.72	12.74	7.61	13.37
DCAF4PR	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.05	0.05	1.74	6.48
DCA6FWF	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	2.23	6.98	6.11	10.04
DCN3W7D	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	1.94	4.49	4.59	8.57
DCPSPHV	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.8	4.53	1.28	7.75
DCWJOGL	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.07	3.54	2.72	7.68
DCZ2KI1	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	2.82	1.78	0.4	3.71
DCB0IZO	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	2.59	4.29	0.82	6.35
DCQ2ZZ3	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.27	7.03	5.88	8.24
DCB3ZKZ	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	6.96	8.35	7.51	11.1
DCA13HV	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.7	2.75	6.73	10.42
DCA0TTX	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.4	5.88	2.29	9.72
DC2EV2B	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.1	9.86	3.07	9
DCZ4YOI	DMUM7HZ	Fluorouracil	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	8.94	8.7	13.88	17.11
DCBAMAA	DMUM7HZ	Fluorouracil	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	4.19	6.46	1.26	7.39
DCUJCNR	DMUM7HZ	Fluorouracil	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	1.03	0.53	1.55	7.23
DC4U7JQ	DMUM7HZ	Fluorouracil	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	6.44	11.41	14.74	15.84
DC41DNU	DMUM7HZ	Fluorouracil	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.66	4.81	1.84	7.56
DCJDN30	DMUM7HZ	Fluorouracil	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	1.33	4.71	3.31	7.87
DCSVXSP	DMUM7HZ	Fluorouracil	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.87	0.36	0.26	5.09
DC8Q4TK	DMUM7HZ	Fluorouracil	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.02	7.98	5.63	10.49
DC7B8OW	DMUM7HZ	Fluorouracil	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	6.11	5.92	4.79	9.99
DCNZ1FN	DMUM7HZ	Fluorouracil	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	4.74	9.3	6.21	8.21
DCL9MMF	DMUM7HZ	Fluorouracil	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.99	4.41	2.24	5.01
DCJ0W1R	DMUM7HZ	Fluorouracil	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	0.94	5.03	1.61	5.3
DC868I4	DMUM7HZ	Fluorouracil	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	3.94	6.69	5.46	11.35
DCJL3S3	DMUM7HZ	Fluorouracil	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.05	11.35	11.28	10.35
DC2LV6T	DMUM7HZ	Fluorouracil	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	8.82	7.26	5.33	9.45
DCX6QYU	DMUM7HZ	Fluorouracil	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	9.22	9.31	8.38	15.31
DCEJJ9K	DMUM7HZ	Fluorouracil	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.74	4.75	0.96	6.88
DCVIZPG	DMUM7HZ	Fluorouracil	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	0.47	3.7	4.21	8.24
DCKN7CW	DMUM7HZ	Fluorouracil	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.74	5.67	10.7	14.63
DCQEREL	DMUM7HZ	Fluorouracil	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	9.53	9.3	9.08	13.64
DCHY7NU	DMUM7HZ	Fluorouracil	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	7.11	8.42	3.68	9.87
DCKRLLF	DMUM7HZ	Fluorouracil	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	4.75	4.63	5.5	9.35
DC55XED	DMUM7HZ	Fluorouracil	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.49	6.13	3.24	10.97
DC5Z402	DMUM7HZ	Fluorouracil	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.54	7.9	2.22	7
DCBTUEN	DMUM7HZ	Fluorouracil	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.05	2.85	1.71	7.66
DC7P7DK	DMUM7HZ	Fluorouracil	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	5.4	6.45	6.13	7.97
DCHKCZU	DMUM7HZ	Fluorouracil	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.48	6.44	0.43	7.08
DCMAB1Z	DMUM7HZ	Fluorouracil	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	3.79	4.78	3.41	7.44
DC9D2SW	DMUM7HZ	Fluorouracil	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	4.27	5.67	0.92	7.6
DCHY948	DMUM7HZ	Fluorouracil	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.27	3.95	0.77	6.3
DCMWW4Q	DMUM7HZ	Fluorouracil	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	2.89	4.73	0.32	5.9
DCGRAST	DMUM7HZ	Fluorouracil	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	8.48	10.11	2.13	9.83
DCP7FYQ	DMUM7HZ	Fluorouracil	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.32	5.03	2.22	4.67
DCS95YE	DMUM7HZ	Fluorouracil	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	1.06	3.13	3.74	6.97
DCD7TJ8	DMUM7HZ	Fluorouracil	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	3.92	4.41	0.33	5.26
DCDAQ3J	DMUM7HZ	Fluorouracil	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8.63	12.58	3.22	8.73
DCX6MDG	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.97	5.72	7.12	8.83
DCGDNQX	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.46	8.33	14.25	15.3
DCV8TUR	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.17	2.13	8.04	9.05
DCWJWNP	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	4.1	6.69	12.53	13.5
DC65EO8	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	0.15	0.18	2.75	3.32
DCMUOLT	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.18	7.02	7.99	10.16
DCW4TYL	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	6.93	6.62	13.04	15.47
DCBQXAQ	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	7.25	10.98	12.61	13.01
DCYZMU9	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.47	4.74	7.56	8.25
DCBJNI9	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.34	7.96	8.66	8.31
DCJKJF3	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.73	8.18	14.13	15.34
DCQ4ON8	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	6.21	12.18	3.75	12
DC8EEN4	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	3.47	6.93	10.23	11.6
DCVSPF4	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	2.92	7.2	7.18	7.66
DCLNK6P	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.67	4.62	5.83	6.71
DC1I1I5	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	1.63	10.18	10.77	11.4
DCS82RE	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	9.31	13.24	12.96	15.84
DC5MO8P	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	8.44	8.78	12.52	13.55
DCC1TVY	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	15.46	15.49	18.35	21.33
DCXM7SC	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	17.23	17.55	16.65	18.31
DCJMN6N	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	1.38	1.61	7.31	10.44
DCFMZ2J	DMUM7HZ	Fluorouracil	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.58	8.87	7.03	8.1
DCKS576	DMUM7HZ	Fluorouracil	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	6.38	6.57	7.39	16.77
DCOZD4A	DMUM7HZ	Fluorouracil	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	2.35	6.91	6.76	7.69
DCYUGOD	DMUM7HZ	Fluorouracil	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	4.6	5.9	12.13	12.78
DCMJH9X	DMUM7HZ	Fluorouracil	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.53	0.9	1.17	2.25
DCJ0TFY	DMUM7HZ	Fluorouracil	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	3.8	4.13	0.04	4.31
DCWGBQB	DMUM7HZ	Fluorouracil	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	2.96	9.26	1.47	9.75
DCP73WX	DMUM7HZ	Fluorouracil	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	1.32	5.24	2.57	4.59
DC0HO1F	DMUM7HZ	Fluorouracil	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	6.68	7.64	6.83	9.1
DC7N28I	DMUM7HZ	Fluorouracil	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	8.35	10.46	6.52	10.87
DC758DG	DMUM7HZ	Fluorouracil	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	14.98	16.19	7.25	14.52
DCYE3G3	DMUM7HZ	Fluorouracil	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	2.09	4.93	5.38	8.74
DCPHRJD	DMUM7HZ	Fluorouracil	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.57	4.64	4.08	9.62
DCCQE92	DMUM7HZ	Fluorouracil	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	1.34	2.29	3.71	8.07
DCZ205Z	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	9.27	11.31	4.25	10.8
DC2TZE7	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.6	6.21	5.53	8.6
DC9BLAS	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.43	4.45	2.07	6.36
DCLMC9Q	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	4.03	3.65	3.38	5.37
DCNV7X6	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	19.7	17.28	14.66	17.47
DC04RGO	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.84	4.91	0.76	5.85
DCOCSVX	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.24	8.4	5.6	8.73
DC62YJV	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	10.3	13.21	7.63	10
DC1XZ4B	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	5.68	7.29	1.98	8.52
DC6V07Q	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.94	8.45	6.96	10.92
DC4T49S	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	8.47	8.09	2.57	8.14
DC4AQBY	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.63	3.65	0.56	3.13
DC438XI	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	13.9	11.87	10.45	13.64
DCR0HFH	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	1.05	1.23	3.03	4.42
DCLNO8W	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.16	5.02	1.43	6.17
DCUR7DU	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.88	6.12	1.95	6.49
DCLXNJX	DMUM7HZ	Fluorouracil	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	3.02	3.5	2.83	5.59
DCZM2PH	DMUM7HZ	Fluorouracil	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	5.92	7.55	2.04	8.65
DC25NR0	DMUM7HZ	Fluorouracil	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	5.89	6.42	6.87	14.23
DC661LB	DMUM7HZ	Fluorouracil	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.24	2.95	0.86	6.09
DCUL2DD	DMUM7HZ	Fluorouracil	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	1.11	3.64	3.74	9.03
DC633RQ	DMUM7HZ	Fluorouracil	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.71	1.31	1.06	6.88
DCOS8R7	DMUM7HZ	Fluorouracil	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.84	4.52	4.24	11.1
DCN7AI7	DMUM7HZ	Fluorouracil	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.35	5.2	0.74	6.85
DCC80SK	DMUM7HZ	Fluorouracil	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	25.04	26.81	19.8	26.55
DCEVR8X	DMUM7HZ	Fluorouracil	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	6.42	5.93	5.13	10.4
DCUVC7L	DMUM7HZ	Fluorouracil	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	18.16	18.16	8.88	19.25
DCMZYDR	DMUM7HZ	Fluorouracil	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.4	3.24	2.82	5.23
DC9P84L	DMUM7HZ	Fluorouracil	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	5.34	5.64	0.05	8.05
DCUL5L3	DMUM7HZ	Fluorouracil	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.4	6.26	11.87	13.74
DCT0S2E	DMUM7HZ	Fluorouracil	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	11.55	11.92	8.88	15.57
DC9J3N0	DMUM7HZ	Fluorouracil	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	6.52	10.31	1.16	9.04
DCS7DXH	DMUM7HZ	Fluorouracil	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.54	8.16	7.54	10.75
DC4SGAW	DMUM7HZ	Fluorouracil	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	6.25	6.73	5.91	14.53
DCGFS5W	DMUM7HZ	Fluorouracil	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	6.95	10.2	7.07	11.7
DC8CRK7	DMUM7HZ	Fluorouracil	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.36	6.1	4.36	5.66
DC384GJ	DMUM7HZ	Fluorouracil	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	2.06	12.06	10.71	11.24
DCZJ4Q3	DMUM7HZ	Fluorouracil	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	9.29	13.63	1	13.56
DCHTGXY	DMUM7HZ	Fluorouracil	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	5.5	8.22	7.79	8.78
DCRBQ6P	DMUM7HZ	Fluorouracil	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	0.89	1.47	1.43	5.02
DC245NF	DMUM7HZ	Fluorouracil	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	0.57	5.46	2.2	6.79
DCMWW3R	DMUM7HZ	Fluorouracil	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.54	12.3	11.62	13.44
DC6G3CR	DMUM7HZ	Fluorouracil	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.74	18.79	8.71	16.19
DCUB79E	DMUM7HZ	Fluorouracil	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	16.97	21.06	7.14	14.63
DC6I9M1	DMUM7HZ	Fluorouracil	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	12.98	16.15	15.7	22.15
DCD61BM	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	13.38	15.25	3.78	14.72
DCJ9YIM	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	14.13	9.38	11.23	4.09
DC2A9B7	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	7.16	4.12	4.23	10.53
DC0942V	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.73	3.35	0.59	3.72
DC0X6ZR	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.18	5.83	3.63	8.03
DCJXFRZ	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	8.69	9.05	0.69	11.39
DCQNWMG	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	10.07	8.46	10.57	17.67
DCKPDOA	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	11.6	12.01	5.52	15.31
DC8L0XO	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	10.82	10.85	4.79	15.64
DC37X0U	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	9.37	9.25	0.31	12.89
DC23U0V	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.57	6.17	2.6	12.17
DCUCN2J	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	12.25	13.28	1.34	12.89
DC3RDB7	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	17.65	18.92	7.03	16.7
DCFIV0U	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	5.97	6.64	3.87	10.09
DCMUSHW	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	9.77	10.18	4.28	13.55
DCV48SI	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	15.16	15.28	5.38	17.43
DCRG3OY	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	5.15	6.57	0.73	11.75
DCX3HRI	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.66	5.48	1.66	6.13
DC4R2WU	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	7.75	8.07	5.86	12.9
DC4FGYG	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.53	7.03	3.33	10.28
DCM7XB1	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	7.86	7.43	5.06	8.95
DCGJ49J	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	15.1	15.07	14.28	18.03
DC71C2M	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.41	6.72	2.08	10.36
DC08FW9	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	25.54	30.09	19.51	28.91
DCV07OB	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	3.13	1.22	2.06	7.01
DCEAFZX	DMUM7HZ	Fluorouracil	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	12.66	15.47	7.83	13.79
DC0I8DG	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.58	10.09	9.6	11.53
DC0KWKG	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.29	5.03	2.66	13.34
DCJCQM2	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	7.61	7.92	12.62	15.61
DCN9WRO	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	2.18	9.51	15.01	16.23
DCMXC3E	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	6.43	6.68	7.1	11.79
DC633P7	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.56	9.82	8.73	12.15
DCLJ2W7	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	1.6	2.04	8.63	11.52
DCXXULC	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	7.18	8.07	5.95	13.79
DCH3QKJ	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	1.38	6.26	6.7	9.51
DCMTF3U	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.56	6.98	4.53	8.61
DCR45E7	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	9.15	10.05	14.19	18.23
DCDFKU4	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.96	7.32	8.72	9.43
DC3MNK5	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	12.7	17.47	4.25	17.66
DCD0A69	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	9.96	13.17	13.77	17.23
DCRGFBL	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	9.29	12.37	10.07	12.6
DCO2LUU	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	0.98	6.02	13.23	13.36
DCYIN0N	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.63	4.27	4.2	6.1
DCCPCMI	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	5.14	13.32	10.12	13.63
DCQV0W9	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.89	1.57	7.93	9.36
DCYJSSX	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	5.4	3.66	4.28	9.38
DCTEETI	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	6.46	8.66	14.97	17.78
DCXXOGQ	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	16.32	16.42	18.46	21.76
DCYT3GM	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	10.53	14.9	12.1	15.37
DCKRQ3L	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	1.94	1.14	5.13	7.84
DCRT2ZU	DMUM7HZ	Fluorouracil	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	9.06	10.58	0.51	13.6
DCEC8CX	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	7.08	3.75	1.63	5.43
DCIRXH1	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.22	1.44	4.45	6.22
DC9W2G0	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.42	2.55	3.2	7.89
DCB9UB3	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.51	4.56	0.61	6.13
DCEZRBQ	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	2.05	0.53	3.23	6.82
DC05QNU	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	22.28	21.98	22.54	22.76
DCILUE1	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	14.13	13.17	10.32	16.68
DCAP35Z	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	6.69	5.49	2.75	8.05
DC4WJKZ	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.67	4.72	4.1	8.95
DCNQGE1	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	8.52	8.59	5.89	10.97
DCNZOVJ	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.41	4.82	4.15	9.24
DCEZPA1	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	19.18	17.53	13.52	18.87
DC0INP8	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	7.28	7.21	2.43	13.34
DCDVT1R	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.95	5.75	4.88	6.84
DCX4ZV9	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	6.47	5.29	5.14	9.13
DC8JPSR	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	14.59	12.33	10.58	14.73
DC334CL	DMUM7HZ	Fluorouracil	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.56	10.81	7.09	10.67
DC061HP	DMUM7HZ	Fluorouracil	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	4.89	4.95	1.61	6.67
DCNNR32	DMUM7HZ	Fluorouracil	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.48	3.59	0.26	5.35
DCK13WM	DMUM7HZ	Fluorouracil	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.81	2.84	2.17	7.87
DC5XC55	DMUM7HZ	Fluorouracil	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.43	0.17	0.79	7.58
DC1UYX0	DMUM7HZ	Fluorouracil	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	0.82	0.19	0.26	0.45
DC0QZAW	DMUM7HZ	Fluorouracil	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	4.77	5.72	1.55	7.8
DCW8KS7	DMUM7HZ	Fluorouracil	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.9	3.24	1.97	4.42
DCLM2U9	DMUM7HZ	Fluorouracil	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	2.29	1.54	0.04	5.77
DCMR0KB	DMUM7HZ	Fluorouracil	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.11	6.19	4.76	9.82
DC2RLHK	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	6.28	5.77	1.62	6.66
DC7UFC0	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	9.03	10.81	9.3	9.33
DCFNYCJ	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	3.5	5.37	1.19	7.79
DCPYQ2P	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.65	4.05	1.2	6.2
DCQHWJZ	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.84	4.33	2	6.75
DCJKC0A	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	1.69	3.28	0.42	5.46
DCTWB80	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.94	2.4	0.06	5.37
DCEZWQI	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	16.43	13.9	10.56	15.21
DCA2ANA	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.52	5.89	4.04	6.47
DCDNTL5	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	7.39	6.68	3.75	7.96
DCUZNZP	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.69	6.75	1.69	8.02
DC9APMC	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.67	12.56	8.98	12.57
DC7PKTN	DMUM7HZ	Fluorouracil	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	5.27	4.05	4.26	7.73
DCW836T	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	18.22	12.87	9.59	14.28
DC2FSRF	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.09	0.77	3.44	7.88
DC5QHGP	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	2.38	1.52	0.43	4.88
DCV83WK	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	0.75	0.68	8.03	11.43
DCILVFP	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	11.28	9.81	5.72	11.31
DCEBINH	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	7.43	5.97	5.17	10.42
DCKOLOP	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	9.17	7.95	6	11.63
DCHJD2C	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.32	4.54	4.43	9.96
DCK4R7R	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.95	4.63	4.51	5.49
DC1N0E8	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	10.75	9	6.77	11.92
DC7KNJ5	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	14.86	13.74	8.44	14.88
DCR7WDK	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	20.72	15.51	14.43	16.63
DCAUUXL	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	9.41	9.23	9.48	13.47
DCMZ78E	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.85	1.58	1.03	7.06
DCG7SM4	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	16.45	12.04	0.33	15.4
DCU7ZMB	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	17.78	16.76	16.79	20.22
DC52G1F	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	11.67	10.71	10.49	14.26
DCGD4J5	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	20.57	19.71	14.93	19.71
DC619NY	DMUM7HZ	Fluorouracil	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	5.87	12.88	5.2	14.42
DCNMZTZ	DMUM7HZ	Fluorouracil	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	7.28	6.25	8.84	12.4
DCQAC7B	DMUM7HZ	Fluorouracil	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.97	6.01	1.38	7.71
DC1HNM3	DMUM7HZ	Fluorouracil	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	0.24	11.99	11.88	15.1
DCKS94D	DMUM7HZ	Fluorouracil	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	17.51	15.55	12.82	15.6
DCEXSZU	DMUM7HZ	Fluorouracil	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.52	4.93	2.73	7.42
DCDL0QH	DMUM7HZ	Fluorouracil	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	2.9	11.1	1.47	9.88
DCLG5ZV	DMUM7HZ	Fluorouracil	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	13.19	16.35	4.13	13.27
DCQ1IC9	DMUM7HZ	Fluorouracil	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.56	8.32	7.4	9.9
DCQOS6W	DMUM7HZ	Fluorouracil	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	9.82	10.54	8.47	12
DCHKTGK	DMUM7HZ	Fluorouracil	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	12.68	13.17	13.23	17.04
DCN500T	DMUM7HZ	Fluorouracil	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.88	8.8	0.92	7.6
DCS1FGD	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.85	2.24	4.01	5.78
DCR36T2	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.59	4.59	8.77	13.27
DCLZP7J	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	5.26	5.11	13.91	15.56
DC7PK1R	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.43	5.86	8.06	9.92
DC3SSLW	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	1.78	1.75	14.38	14.74
DCVPOSZ	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	16.33	18.07	14.28	18.31
DCBM1I7	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.17	4.14	6.3	8.42
DC4HPQT	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	1.82	4.81	1.15	6.64
DCYM085	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.05	0.55	1.24	1.9
DCJ4DG3	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	9.66	7	12.53	14.01
DC4CFT1	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	8.57	7.7	0.71	14.12
DCKEGOE	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	18.47	18.67	24.18	24.77
DC59XH6	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.65	1.64	0.67	2.12
DCHOLHX	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	3.14	1.13	8.83	10.44
DC36HKG	DMUM7HZ	Fluorouracil	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	5.39	14.46	11.9	13.14
DCHCXN7	DM27D4J	PD-0325901	Phase 2	21	DMBL3VD	PF-05212384	Phase 2	21	.	.	.	.	Advanced Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCS8A41	DM27D4J	PD-0325901	Phase 2	21	DMDI269	Docetaxel	Approved	34	DMOH8VY	Dacomitinib	.	.	Colorectal Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCCCPG1	DM27D4J	PD-0325901	Phase 2	21	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	8.652	7.918	5.642	6.948
DCJY4RK	DM27D4J	PD-0325901	Phase 2	21	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	8.66	7.92	5.71	6.95
DC49TEV	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	5.08	4.02	3.16	7.51
DCERNQ6	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	3.88	8.63	4.24	8.12
DCODYQX	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	12.8	13.77	8.72	15.07
DCQSVFV	DM27D4J	PD-0325901	Phase 2	21	DM3XQDH	JQ1	Investigative	0	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	16.497	18.126	16.696	16.151
DC9CNJ3	DM27D4J	PD-0325901	Phase 2	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	0.2	5.74	2.1	3.83
DCV5PRI	DM27D4J	PD-0325901	Phase 2	21	DM53SRA	Prochlorperazine	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	1.293	0.659	2.711	3.357
DCVPAAL	DM27D4J	PD-0325901	Phase 2	21	DM53SRA	Prochlorperazine	Approved	34	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	1.29	0.66	2.71	3.36
DC06ALU	DM27D4J	PD-0325901	Phase 2	21	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	12.932	11.677	12.065	15.864
DC8IXDY	DM27D4J	PD-0325901	Phase 2	21	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	10.84	11.69	11.45	9.61
DCHG6IW	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	8.51	7.89	5.7	11.32
DCTPGKQ	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	26.48	23.11	17.35	24.65
DCIY37S	DM27D4J	PD-0325901	Phase 2	21	DM6KU93	Alvespimycin hydrochloride	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	4.79	4.98	0.04	4.55
DC5C5RU	DM27D4J	PD-0325901	Phase 2	21	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	7.04	12.07	3.47	5.63
DCB66T4	DM27D4J	PD-0325901	Phase 2	21	DM8QB1D	Olaparib	Approved	34	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	EW-8	7.66	9.63	4.64	8.55
DCW2KK0	DM27D4J	PD-0325901	Phase 2	21	DM93VBZ	LY2835219	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	8.35	9.94	2.29	2.33
DC3M3GN	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	8.73	10.37	2.55	11.5
DCO2LUW	DM27D4J	PD-0325901	Phase 2	21	DM9ZOMD	CUDC-101	Phase 1	17	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	28.06	26.76	10.79	10.22
DC6KGR0	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	3.8	10.73	4.98	11.38
DCWYGRN	DM27D4J	PD-0325901	Phase 2	21	DMD7L48	Plinabulin	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	5.93	6.36	6.17	8.28
DC4296D	DM27D4J	PD-0325901	Phase 2	21	DMDMQIE	THAPSIGARGIN	Preclinical	2.1	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	10.13	9.456	11.44	12.788
DCVZCFW	DM27D4J	PD-0325901	Phase 2	21	DMDMQIE	THAPSIGARGIN	Preclinical	2.1	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	10.13	9.46	11.44	12.79
DC8E6S6	DM27D4J	PD-0325901	Phase 2	21	DME9QGW	Marizomib	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	0.64	0.62	0.32	3.05
DCP1163	DM27D4J	PD-0325901	Phase 2	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	5.32	9.28	2.88	9.54
DC62387	DM27D4J	PD-0325901	Phase 2	21	DMLB0EZ	Tamoxifen	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	6.784	8.876	2.516	4.873
DCOQE2L	DM27D4J	PD-0325901	Phase 2	21	DMLB0EZ	Tamoxifen	Approved	34	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	6.78	8.88	2.51	4.87
DC6ALAV	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.74	8.91	10.03	11.17
DC3NU0M	DM27D4J	PD-0325901	Phase 2	21	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	25.04	25.04	32.83	32.83
DCTIPEI	DM27D4J	PD-0325901	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	1.4	6.92	0.56	8.29
DCURBNN	DM27D4J	PD-0325901	Phase 2	21	DMN5T2A	Ciclopirox	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	7.007	8.115	6.601	8.641
DC2MZ9T	DM27D4J	PD-0325901	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.88	5.32	0.31	5.42
DC9VZXK	DM27D4J	PD-0325901	Phase 2	21	DMPK32V	BMS-754807	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	12.75	12.32	13.88	15.5
DCS22C5	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	9.99	10.9	4.51	13.87
DCKWZGL	DM27D4J	PD-0325901	Phase 2	21	DMCD9YG	Prazosin	Phase 2 Trial	21	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	0.045	0.716	0.027	1.717
DCFMSWD	DM27D4J	PD-0325901	Phase 2	21	DMSLE03	PF-562271	Phase 1	17	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	16.59	21.83	0.4	8.89
DCOOVFX	DM27D4J	PD-0325901	Phase 2	21	DMSLE03	PF-562271	Phase 1	17	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	16.5	18.13	16.69	16.15
DCMW9C0	DM27D4J	PD-0325901	Phase 2	21	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	9.81	10.41	0.01	3.57
DCRXA9P	DM27D4J	PD-0325901	Phase 2	21	DMWE2N4	Auranofin	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	4.132	6.485	0.968	3.633
DCK92WD	DM27D4J	PD-0325901	Phase 2	21	DMWE2N4	Auranofin	Approved	34	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	4.13	6.48	0.97	3.63
DCLVSII	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	0.67	4.57	0.77	2.42
DCKKWU2	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	2.27	1.17	1.22	5.65
DCWFXV9	DM27D4J	PD-0325901	Phase 2	21	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	9.79	8.64	11.88	14.37
DCC9DG6	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	15.26	21	3.99	19.05
DCB7YDY	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.3	3.07	1.83	5.59
DC16S71	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.04	5.44	2.72	5.73
DCSFR7G	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.44	3.07	7.67	9.68
DCJSCJG	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.24	0.04	0.99	4.06
DCZT5DU	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.85	8.55	10.1	10.49
DCKKNGJ	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	5.09	9.79	9.5	12.29
DC2J4BT	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	7.92	6.68	10.68	14.85
DCR6XGK	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	6.13	6.33	11.69	15.06
DC6PCU2	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.46	6.11	4.55	8.79
DCUI661	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.33	0.26	6.24	12.97
DCJRTDJ	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	6.62	7.13	6.48	10.15
DCCB57U	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.78	3.07	8.17	9.01
DCUY2HO	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	8.51	7.75	15.91	18.31
DC7O6JW	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	5.06	7.03	9.69	12.55
DC7OQUQ	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	45.13	41.1	34.82	46.71
DCTK7SR	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.41	8.2	1.06	10.73
DCI5H81	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	11.53	13.98	9.69	18.34
DCRYJXE	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.49	1.45	8.2	11.12
DC5DWQJ	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1	0.78	3.62	8.6
DCPUR97	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	16.31	14.98	13.47	18.04
DCKVWNX	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.93	3.63	9.78	10.1
DCTQ4YH	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	9.43	9.29	5.14	16.13
DCTM3VE	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.98	1.44	7.65	10.63
DCKZH62	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.86	2.42	8.07	11.81
DCEDYFA	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	2.57	2.3	8.82	13.38
DC2ILKL	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	6.81	6.18	7.68	11.81
DCPM3II	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	7.86	7.45	7.85	13.4
DCN3XQN	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	6.77	5.87	5.52	10.61
DC6WT64	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	5.84	5.55	6.95	11.27
DCPUY32	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	6.02	5.91	11.9	15.22
DCN0JL8	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.17	0.06	7.65	11.1
DCH9U1A	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	12.09	10.66	11.56	16.13
DCRND9F	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	13.44	16.07	17.29	18.33
DC86USJ	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	8.16	7.68	9.55	14.83
DCJD918	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.47	2.01	3.22	7.91
DCDJ47S	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.18	1.02	8.55	5.63
DC2KRHM	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	3.8	5.7	16.68	16.88
DCIJO1L	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	5.92	5.79	9.87	12.45
DCRV0EF	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	23.48	23.22	21.86	30.91
DCU8VN3	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	11.32	10.56	11.01	14.53
DC0DYS3	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	18.43	18.38	5.68	25.8
DCJBXEG	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	15.12	16.44	19.21	23.59
DCKUOMF	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	12.96	9.42	12.85	18.79
DC8ER24	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	28.11	24.02	23.56	28.65
DCCTA4P	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.93	10.55	2.09	4.87
DCPN5FX	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	12.98	12.74	15.45	19.66
DCULI4N	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	6.99	6.63	11.83	12.3
DCLZJYD	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	7.99	9.23	7.01	14.37
DCCBSPR	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.07	1.75	5.16	7.79
DC0IGVP	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.71	3.54	3.61	9.58
DCOULPS	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.37	1.5	4.47	9.16
DCQ6IVY	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	5.63	6.89	6.67	12.07
DCWP4UV	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	8.54	7.89	14.41	16
DCORORD	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	0.97	2.41	9.54	11.47
DCMYQS5	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.47	2.06	4.87	7.96
DC0GK1Z	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.46	7.47	5.85	6.82
DCNRE8I	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	3.1	0.96	4.83	7.9
DCJDKVF	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.55	0.82	3.96	7.73
DC1FG8K	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.4	3.42	4.7	8.64
DCNG1JW	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.95	0.65	1.73	3.97
DC4Q9RT	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	9.76	11.04	6.07	13.09
DC31BKC	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.29	4.85	5.97	7.11
DCWCK4J	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.52	4.36	10.67	13.77
DCKR6RN	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	6.54	7.97	6.74	10.37
DCZDWP3	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.63	2.88	0.22	7.86
DCD2M1L	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	5.12	5.37	6.06	10.96
DC207QM	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.39	0.1	2.33	6.55
DCQNU1I	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	16.81	17.26	10.19	19.82
DCLFMBZ	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.81	4.81	11.19	15.05
DCL0UVU	DM27D4J	PD-0325901	Phase 2	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.39	2.82	5.98	8.92
DCZ63ZD	DM27D4J	PD-0325901	Phase 2	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.15	6.13	3.94	12
DC9H9ZR	DM27D4J	PD-0325901	Phase 2	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.4	3.43	1.07	8.9
DC13JAN	DM27D4J	PD-0325901	Phase 2	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.26	6.1	2.04	8.66
DCPK3XK	DM27D4J	PD-0325901	Phase 2	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.19	6.34	11.52	12.3
DC43W7M	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.09	3.59	1.46	4.86
DCDDROZ	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	7.13	4.84	3.51	3.59
DC0360N	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.54	5.14	0.26	7.88
DCKRH4A	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	6.77	7.92	10.84	13.26
DCP4H5P	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.65	8.67	3.54	10.34
DC7PT5Z	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.68	3.6	1.08	7.48
DC7RHBL	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.3	4.59	9.23	12.04
DCT1DD8	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.09	0.05	5.35	5.84
DCHE11I	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	11.38	11.56	11.97	15.21
DCZB8XI	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	13.15	13.09	17.78	21
DCDYPBP	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	3.23	3.77	5.93	10.35
DCFMCTM	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.2	6.18	11.1	13.97
DCSZ68H	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.34	3.24	9.41	11.17
DC3BO78	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.24	1.47	8.89	10.82
DCU8IG6	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	8.65	12.15	13.26	15.57
DCHAHNU	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.75	9.05	7.74	12.27
DC2IQNQ	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.15	4.62	9.62	10.33
DCR43TM	DM27D4J	PD-0325901	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.09	3.65	3.72	3.81
DCQZSFA	DM27D4J	PD-0325901	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	8.6	9.13	8.96	14.5
DC0WKM8	DM27D4J	PD-0325901	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.59	1.56	1.57	7.27
DCBVC8K	DM27D4J	PD-0325901	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.11	4.24	5.08	5.04
DC88KZ8	DM27D4J	PD-0325901	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.18	2.88	2.81	3.62
DCUI1S7	DM27D4J	PD-0325901	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	2.3	1.05	1	7.11
DC5SK21	DM27D4J	PD-0325901	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.34	2.02	0.39	4.29
DC6J6U9	DM27D4J	PD-0325901	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.72	2.05	1.11	5.34
DC9VRRN	DM27D4J	PD-0325901	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.15	2.21	1.33	4.05
DCUMFU0	DM27D4J	PD-0325901	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2	0.49	2.42	5.19
DCVYBRZ	DM27D4J	PD-0325901	Phase 2	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.6	0.81	0.05	0.83
DC5SDMT	DM27D4J	PD-0325901	Phase 2	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.73	5.9	5.24	4.25
DCC82Q6	DM27D4J	PD-0325901	Phase 2	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.68	6.88	1.09	4.87
DC560M7	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	7.34	7	11.12	11.34
DCTKU3C	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	8.02	7.38	10.64	10.97
DC50RW8	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	4.96	3.41	15.67	16.8
DC76ANC	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.56	2.4	3.35	7.07
DC3IV0K	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.01	5.21	1.95	11.47
DCTXBBQ	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.74	1.51	1.86	6.24
DCUD4H1	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.2	2.46	2.23	2.01
DCXLCWZ	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.01	1.06	3.34	6.95
DCVU0DP	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.39	5.4	0.34	7.63
DC596MY	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.72	6.68	7.22	8.54
DCQ3734	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	5.17	4.61	6.62	10.29
DC6ED9P	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.13	3.73	4.24	9.73
DCNQ1T8	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	5.64	5.56	10.41	12.83
DCGL1QF	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.11	1.89	1.62	7.19
DCPW344	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.93	2.91	6.12	8.87
DCQROCU	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.44	2.69	4.97	8.98
DCYHVE4	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	5.64	7.49	10.66	13.13
DCIQZ0R	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.72	6.28	6.8	9.7
DC1LZNS	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.49	1.87	0.93	6.52
DC69JPT	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.54	0.87	2.64	9.94
DCPR3JG	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.34	1.58	7.36	10.69
DCMHLSU	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.13	4.6	6.55	9.04
DCRGZPJ	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.97	2.66	6.78	9.3
DC87UQ0	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	12.48	12.27	15.08	19.06
DC128K8	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.53	4	10.2	13.3
DCW66OZ	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.96	1.63	6.8	9.1
DC0CIZE	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.89	7.19	4.9	8.42
DCSDKWT	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.66	2.15	7.75	11.86
DCFZMUL	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	3.32	3.89	4.1	5.95
DCO7WUY	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.31	6.33	1.99	10.22
DCXMAB7	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	7.11	8.01	11.01	13.8
DCE34VG	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	5.97	7.95	3.11	14.79
DCXLPF4	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	10.1	12.94	4.87	18.6
DCDCPW3	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	7.01	9.45	9.21	11.66
DCR02ZL	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.29	3.26	8.09	9.33
DC34X96	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.88	4.65	13.97	16.24
DCMJKY3	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.07	1.95	7.9	10.9
DC6EVMQ	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.78	4.32	6.09	10.17
DCU944I	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	1.17	1.66	6.4	8.78
DCAIWGQ	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.19	0.29	2.51	4.37
DCBXZMB	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.49	4.58	1.42	6.09
DC8FWEY	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.31	0.84	3.94	7.21
DC620KT	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	5.14	6.69	4.48	6.81
DC21YHR	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	1.56	1.76	3.5	5.21
DCLGE25	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.47	3.22	3.76	8.21
DCP9VR7	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.81	0.93	0.61	5.48
DC3CEY8	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	2.62	3.02	2.71	6.65
DC3KHJ2	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	0.64	4.73	4.53	6.42
DCFXDKP	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.07	5.59	8.13	9.01
DC70KM1	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	1.54	1.46	5.29	9.13
DCU2KP6	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	7.04	7.05	0.72	12.19
DC4H8TI	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.15	0.52	4.77	8.02
DC1O11K	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	4.31	4.73	0.96	7.41
DCV9YR2	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	6.16	5.04	7.43	10.8
DC90I1V	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	14.37	14.28	18.88	22.31
DCHRTPQ	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.88	2.77	2.32	5.04
DCBBCL0	DM27D4J	PD-0325901	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	3.93	5.5	0.78	3.67
DCXSDN6	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	10.01	9.38	14.41	16.42
DCXJO0W	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	4.44	6.09	6.76	11.47
DCR78NF	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	1.62	1.67	4.32	11.19
DCVT3VI	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.78	6.32	2.69	8.04
DCOJZFW	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.09	4.23	0.54	7.49
DC0HN10	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	9.94	11.32	4	12.43
DC94F7Y	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	10.31	9.69	5.62	11.58
DCQQMQK	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	5.73	6.9	8.97	11.62
DCLP8DL	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	6.82	9.31	4.24	11.03
DCMASXK	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	10.65	14.76	0.23	15.44
DCXY24W	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	3.5	7.13	1.69	9.7
DCQH2CL	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	6.55	7.52	4.59	9.62
DC6XLIR	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	7.52	13.62	1.62	10.36
DCHTPI1	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.31	7.06	5.26	7.56
DCN7XNQ	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	8.54	10.9	2.66	15.45
DC7BUTH	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.29	1	0.56	6.54
DCEJZX3	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	11.52	12.89	6.01	15.29
DC1XLUB	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.26	7.68	12.05	14.06
DC51RDB	DM27D4J	PD-0325901	Phase 2	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.45	6.31	0.11	5.43
DC52AAC	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	0.91	0.13	1.07	6.18
DCBKUKX	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	10.29	12.23	1.87	17.64
DC28KYC	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	20.36	22.01	18.49	23.48
DCO2K32	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.58	4.84	2.14	8.86
DCT7X54	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	4.59	3.7	3.7	8.59
DCWY96T	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.01	5.95	0.07	7.65
DCDCKX0	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.33	3.8	1.91	7.29
DC7WLDW	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	9.43	12.55	4.8	14.32
DCL4ZJK	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	8.68	8.04	3.96	14.2
DCETMOX	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	20.55	18.22	14.75	23.42
DCYA9O9	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Embryonal rhabdomyosarcoma	SYNERGxDB Database	Investigative	Rh36	1.29	3.39	0.72	5.4
DCVBZ23	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	22.37	20.48	15.82	22.47
DCS9I1Z	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	U-HO1	2.27	7.06	4	6.72
DC65KUW	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	14.39	20.67	7.66	23.48
DCJJM4H	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	9.82	9.44	10.3	15.57
DCRE1RK	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	3.86	12.15	13.03	15.33
DCFHXFG	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	8.6	10.75	6.92	13
DC7Z7WH	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	19.21	21.9	9.81	18.85
DC17Y5D	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.04	6.05	3.21	7.14
DCHZLFO	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	9.43	8.83	4.81	10.99
DCNY7EA	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	12.14	11.77	13.27	19.53
DC9PZHI	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	6.26	6.12	12.96	17.86
DCXVYDI	DM27D4J	PD-0325901	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	5.77	12.22	2.18	11.43
DCFB7O3	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.59	3.45	10.85	14.66
DC5NU0B	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.21	1.21	4.01	10.23
DCHYLB2	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	7.13	6.79	10.06	14.49
DCY3E9X	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	5.11	4.79	9.34	13.28
DCHX48N	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	10.88	10.36	7.16	11.98
DCZSQAH	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.73	4.93	5.7	10.79
DC7NVA4	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	20.95	16.57	14.18	20.31
DCLN7SX	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	10.85	11.31	10.06	15.39
DCN3FID	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	10.51	9.99	9.58	14.71
DCW0LPT	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	12.7	9.43	7.08	13.04
DCIUYQX	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	14.99	15.3	14.15	19.66
DCFV71Z	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	9.33	8.78	9.29	14.98
DCBI61E	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	6.46	4.6	3.17	9.4
DCZZBRM	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	12.06	11.61	9.81	15.3
DCEPD3N	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	10.52	10.66	9.81	13.76
DC7FWAR	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	20.37	17.89	18.85	23.79
DC9WGZO	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	12.08	11.82	9.36	16.23
DC3VYTE	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	11.23	10.25	10.67	16.8
DCUX0F4	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	15.06	14.67	7.51	14.74
DCGAX8R	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.98	5.42	1.48	9.68
DC6R2WZ	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	13.67	13.24	11.49	17.48
DC9WT2Z	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	12.04	11.89	10.73	16.05
DCE7LLI	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	13.59	12.59	12.11	17.97
DCPRLUJ	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	12.13	11.86	9.9	17.29
DCD8UNT	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	8.1	4.95	9.28	13.76
DC4ZVBR	DM27D4J	PD-0325901	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	10.38	11.57	5.57	11.97
DCYANX5	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.98	1.38	4.71	15.86
DC5ESLA	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	16.75	16.57	15.48	22.89
DCJBZHM	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	29.59	27.39	20.14	34.32
DCTJ42V	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	11.88	11.35	9.87	18.12
DCLTK66	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	24.85	20.66	15.31	22.77
DCY6D4G	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	20.53	19.92	10.52	24.27
DCYS15M	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	17.18	13.58	12.13	18.93
DCZX04W	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	29.34	24.92	20.62	27.45
DCT9MXN	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	6.68	7.29	5.88	9.84
DCDUUL8	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	20.25	18.51	17.31	20.83
DC7HB22	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	26.66	25.8	23.18	29.72
DC22HS5	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	36.12	31.63	27.19	36.75
DCGR703	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	28.69	25.89	22.08	27.63
DCRM7NJ	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	13.31	12.39	11.23	14.62
DCUA35G	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	31.78	28	27.06	33.77
DCUO06E	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	11.58	11.51	13.09	16
DCGU16B	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	25.47	24.64	23.27	28.74
DCYXXVZ	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	38.11	32.52	19.52	33.27
DCCQ6JF	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	14.22	14.83	15.31	17.95
DC2S567	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	24.99	24.38	17.71	24.76
DCRVE4Y	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	10.24	8.43	7.03	12.59
DC9BXKS	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	31.46	30.13	25.64	34.84
DCYRM3Z	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	26.42	26.28	23.25	28.83
DCGPVZF	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	31.3	30.98	24.49	31.1
DC86OK9	DM27D4J	PD-0325901	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	13.07	12.64	0.39	21.7
DC3CAQ5	DM27D4J	PD-0325901	Phase 2	21	DM6VOWQ	Fomepizole	Approved	34	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	U-HO1	16.24	15.36	0.86	1.35
DCJ4X5T	DM27D4J	PD-0325901	Phase 2	21	DM7WFZ8	Formononetin	Investigative	0	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	U-HO1	21.23	21.64	6.25	10.17
DCJLT0K	DM27D4J	PD-0325901	Phase 2	21	DM8QB1D	Olaparib	Approved	34	.	.	.	.	Embryonal rhabdomyosarcoma	SYNERGxDB Database	Investigative	Rh36	1.99	2.91	0.43	5.83
DCAL6KB	DM27D4J	PD-0325901	Phase 2	21	DM8QB1D	Olaparib	Approved	34	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	U-HO1	6.95	9.25	6.4	9.04
DCSW617	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	8.05	6.65	6.49	11.63
DCGQGLV	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	22.28	20.31	26.91	27.51
DC512IH	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	6.68	6.14	2.37	10.68
DCRQTO0	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	3.29	6.06	7.01	8.15
DC1Z2PU	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	2.34	1.93	6.41	9.33
DCRC4QZ	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	3.08	7.5	4	12.49
DC0JW1U	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	9.06	9.86	5.14	12.1
DC3NEQQ	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	2.79	6.29	5.45	9.18
DCUY83H	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	15.38	14.35	7.52	16.72
DCW661X	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.79	4.63	2.34	9.09
DCWYFIN	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	10.08	10.16	4.72	13
DCMQVWX	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	11.94	12.77	4.4	14.82
DCPE1GD	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.31	2.51	3.19	5.57
DCJUER8	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	1.38	3.7	0.93	7.62
DCBCZNG	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	2.3	4.34	6.71	8.77
DCC3175	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.81	5.63	2.36	9.78
DC11Z6W	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	13.5	16.4	0.55	13.76
DCVARCZ	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.25	8.07	2.77	10.94
DCUW7E7	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	17.6	16.22	12.1	20.82
DCFKJTR	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	4.76	3.76	2.47	5.86
DCSJ851	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.61	5.16	3.45	10.72
DCIS3V1	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	10.23	9.02	12.44	10.5
DCQAGLU	DM27D4J	PD-0325901	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	5.73	9.31	6.7	8.03
DCU94VI	DM27D4J	PD-0325901	Phase 2	21	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	U-HO1	6.33	5.34	2.55	6.02
DCSNDDE	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	4.47	3.53	3.79	7.21
DCHKH6K	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.82	4.44	2.91	4.64
DCNG18D	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	1.29	0.23	2.96	4.76
DCHEDLT	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	3.29	3.29	3.51	6.05
DCZSRN6	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	6.53	4.61	5.47	7.67
DCTARXD	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.3	0.12	3.89	5.31
DC0DDO9	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	2.62	4.63	4.06	4.19
DC18WEJ	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.63	2.65	2.26	6.37
DCUCKY0	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	9.75	9	5.54	11.51
DC8UMZO	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.38	2.92	0.99	6.77
DCHG904	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	11.71	10.91	8.11	14.77
DCIGNFI	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	7.59	10.82	4.33	11.46
DC1JPAP	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.86	3.43	0.14	4.65
DCND25H	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	10.97	11.06	11.35	16.27
DC8QBIQ	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	8.76	10.29	9.27	13.25
DCE9H80	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	16.42	18.53	6.66	16.32
DC4V47F	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	8.01	7.92	5.58	9.89
DCHHMER	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	10.91	11.86	7.31	13.69
DC3SVN9	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.58	1.37	0.45	5.48
DCWXOYW	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.88	4.73	1.62	8.11
DCNFV5E	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.82	1.43	0.27	4.77
DCY12SD	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	3.48	1.89	3.73	5.56
DCZQBMQ	DM27D4J	PD-0325901	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.91	1.12	1.32	0.11
DCS1OFB	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.2	2.95	11.69	14.29
DC4EQK5	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.35	2.15	7.8	11.72
DCNSLLU	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.41	2.74	2.47	8.56
DCG03OG	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	8.34	7.81	3.57	9.87
DCL58UE	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.37	1.51	1.43	6.25
DCD9KRE	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	2.81	6.3	0.49	8.38
DC64NG3	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	4.54	4.22	2.37	7.7
DCH3APZ	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	8.6	8.27	9.03	12.44
DCAYCOB	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.97	3.93	0.44	6.43
DCI9DLZ	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.41	2.52	19.71	3.33
DCZUCBM	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	4.16	7.42	2.58	10.26
DCCE7WG	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	5.39	6.5	1.92	7.22
DCR88YR	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	2.21	2.57	1.23	6.62
DCSDME4	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	2.13	4.27	4.56	7.15
DCM59RN	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.36	3.31	1.68	6.79
DC4WV0I	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	16.12	16.85	7.18	14.59
DC6YBKD	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.62	4.94	5.14	7.93
DCYOI3N	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	26.64	23.94	25.64	29.18
DCW9C55	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	0.99	0.63	3.77	6.67
DCU8U0N	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.56	6.96	5.67	10.79
DCMCTUX	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.64	0.58	1.64	5.86
DCXKENI	DM27D4J	PD-0325901	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.75	8.64	2.4	7.8
DCIAW22	DM27D4J	PD-0325901	Phase 2	21	DMDMQIE	THAPSIGARGIN	Preclinical	2.1	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	U-HO1	1.78	0.64	1.98	3.98
DC9AOIQ	DM27D4J	PD-0325901	Phase 2	21	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	U-HO1	26.6	23.78	4.24	7.3
DC4VG20	DM27D4J	PD-0325901	Phase 2	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.97	3.4	4.94	10.08
DCLIQTL	DM27D4J	PD-0325901	Phase 2	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.63	3.41	0.5	8.95
DC2BD8G	DM27D4J	PD-0325901	Phase 2	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	6.68	5.57	3.53	9.86
DC6X43X	DM27D4J	PD-0325901	Phase 2	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	4.59	4.85	1.94	7.86
DCLPDB2	DM27D4J	PD-0325901	Phase 2	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	1.68	5.14	5.34	8.3
DCX21OX	DM27D4J	PD-0325901	Phase 2	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	6.83	6.45	2.77	9.66
DCRABSY	DM27D4J	PD-0325901	Phase 2	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	8.66	8.73	10.85	11.68
DCMELQV	DM27D4J	PD-0325901	Phase 2	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.85	3.28	2.67	7.86
DC6KJQX	DM27D4J	PD-0325901	Phase 2	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	8.15	8.66	7.64	10.84
DCQ8YCC	DM27D4J	PD-0325901	Phase 2	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	12.79	9.64	6.97	13.8
DCHTKG1	DM27D4J	PD-0325901	Phase 2	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	9.12	8.92	9.5	16
DCE0KO9	DM27D4J	PD-0325901	Phase 2	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	1.41	1.45	7.39	13.09
DC9KS55	DM27D4J	PD-0325901	Phase 2	21	DMGDA3C	Cycloheximide	Investigative	0	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	U-HO1	26.99	26.42	0.88	2.9
DCX0M44	DM27D4J	PD-0325901	Phase 2	21	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	U-HO1	19.87	21.3	2.22	6.74
DCEVYM5	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	6.21	5.74	3.79	6.61
DC8N5SP	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	2.58	3.25	2.66	5.3
DC3PBHC	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.9	0.22	1.91	4.02
DCHZ8B1	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	8.31	9.76	2.83	11.66
DCM046F	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	4.76	5.26	1.34	7.32
DC68T45	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.89	7.08	0.91	7.96
DC7DLDF	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	8.96	8.18	2.92	10.58
DC1OJAA	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	0.8	4.18	3.37	5.46
DC3PYGS	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	6.47	4.88	0.1	6.77
DCOKIS0	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	0.69	0.77	1.48	5.38
DC8HXZC	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	12.82	10.85	5.56	13.57
DCKYXD2	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.59	6.78	0.85	8.59
DCXDY12	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.18	6.48	0.97	4.51
DC4AWUB	DM27D4J	PD-0325901	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	6.78	5.14	2.05	9.19
DCBMWSA	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.52	4.79	12.98	14.06
DCUN9PE	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.11	4.82	9.34	10.39
DCKQZEF	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	5.19	7.38	10.67	12.45
DCNS8GB	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.87	3.01	8.01	9.24
DC9XLJI	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	6.04	7.28	7.15	8.44
DCSQA1C	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.1	1.42	11.1	12.3
DCIVPT4	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	3.2	6.7	7.47	11.51
DC533HJ	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	5.01	5.66	5.01	5.97
DC1GC43	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	11.6	13.41	16.2	17.24
DC3TPSP	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.36	1.33	1.54	1.68
DCUQR5Y	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.83	9.82	12.7	13.92
DCULF2N	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.2	5.77	9.16	10.83
DC3JIBR	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	20.22	20.56	22.71	24.58
DCF42NZ	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	6.96	7.12	7.33	9.33
DCYS8IE	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.1	6.49	8.35	8.46
DC8D6F1	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	16.72	15.85	16.89	17.61
DC2QPO9	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	6.63	11.55	13.81	14.57
DCFV4A7	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	9.61	9.43	16.17	17.84
DCHIK8R	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	9.45	13.07	9.44	10.9
DCIVDQA	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	8.81	8.75	11.24	12.56
DCC1OLM	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	16.36	16.87	15.27	18.66
DCH1X7C	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	11.67	10.9	10.72	12.41
DCLYF7K	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	15.54	15.24	20.32	23.73
DCBM9WB	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	15.42	15.36	19.69	21
DC2354G	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	3.19	7.3	4.14	5.94
DC6COC0	DM27D4J	PD-0325901	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	2.76	1.83	10.08	13.41
DCZLEPN	DM27D4J	PD-0325901	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.25	1.47	3.07	10.25
DCONEFB	DM27D4J	PD-0325901	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	1.74	2.04	1.95	5.71
DCCWQLL	DM27D4J	PD-0325901	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	1.77	2.12	5.63	5.95
DCV0LO7	DM27D4J	PD-0325901	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	8.08	6.12	0.25	9.31
DCEB44G	DM27D4J	PD-0325901	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	11.43	10.08	9.1	11.21
DCSXML4	DM27D4J	PD-0325901	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	3.09	2.84	0.24	5.42
DCA7M07	DM27D4J	PD-0325901	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	4.38	4.67	5.5	8.39
DCXJ05J	DM27D4J	PD-0325901	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.6	1.41	0.73	6.52
DCOYUMY	DM27D4J	PD-0325901	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	17.24	16.91	6.2	19.63
DC5S7V4	DM27D4J	PD-0325901	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	8.47	8.13	8.54	15.92
DCKC0C4	DM27D4J	PD-0325901	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	2.99	0.9	2.52	8.41
DCNWPVH	DM27D4J	PD-0325901	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.94	4.67	0.37	5.09
DCDZBJU	DM27D4J	PD-0325901	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	6.19	6.36	5.11	8.62
DCD6TDK	DM27D4J	PD-0325901	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	10.16	12.08	7.03	11.99
DCX8LC8	DM27D4J	PD-0325901	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.13	5.88	3.88	7.83
DCGK8LO	DM27D4J	PD-0325901	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	2.01	2.41	0.47	3.68
DCGJTQ8	DM27D4J	PD-0325901	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	7.75	8.83	6.47	9.79
DCRAF8G	DM27D4J	PD-0325901	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	13.35	10.38	1.66	11.51
DCXPSJ8	DM27D4J	PD-0325901	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	2.62	2.86	3.74	6.04
DCB7QI1	DM27D4J	PD-0325901	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	2.09	2.19	0.12	3.53
DCT6FEF	DM27D4J	PD-0325901	Phase 2	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	17.67	26.81	23.88	23.89
DCRH5UX	DM27D4J	PD-0325901	Phase 2	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	0.59	1.73	5.03	8.69
DCVYA37	DM27D4J	PD-0325901	Phase 2	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.24	6.56	0.09	9.13
DCGB5B1	DM27D4J	PD-0325901	Phase 2	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	6.36	7.89	1.15	1.02
DCFAJ09	DM27D4J	PD-0325901	Phase 2	21	DMR5GSB	Tetrahydrouridine	Phase 2	21	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	U-HO1	16.33	15.44	2.41	6.42
DCZYYO1	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	5.92	6.61	2.59	11.12
DCVUZ8I	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.37	3.05	4.61	0.43
DCKZPM3	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.22	3.42	1.91	9.3
DCGRZ01	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	4.51	1.93	0.35	1.26
DC0EYTD	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	13.86	13.24	11.04	15.89
DCL93IW	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.09	2.3	7.08	10.66
DCVZZHJ	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	9.29	10.36	1.27	14.79
DCVME96	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	2.79	3.47	3.96	4.15
DCXVS28	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	7.09	7.44	7.29	12.43
DC982VC	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	7.38	7.19	0.29	10.62
DCN9C8O	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.09	2.83	4.78	9.98
DCD500B	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.06	7.37	0.18	11.19
DCFOM1J	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	12.49	13.94	1.17	13.49
DCSS6RF	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	5.13	6.05	1.83	8.86
DCM1QFD	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.52	8.55	1.41	10.59
DCQ81MS	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	5	5.9	2.66	11.5
DCKN209	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	5.1	5.9	5.08	9.33
DC6PXVD	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.83	0.97	2.5	5.75
DCIPK9X	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	3.52	3.88	0.91	7.21
DC23UHK	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.42	5.42	1.81	7.44
DC3Q403	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	5.88	5.65	4.44	7.87
DC1T7WR	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	7.23	6.07	3.84	8.54
DCGV0DO	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.89	5.3	0.54	10.63
DCSZVM9	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	12.71	12.8	5.17	13.13
DC1FZ7N	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	2.99	1.76	4.1	4.34
DC9BP9V	DM27D4J	PD-0325901	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	3.77	10.52	7.59	8.94
DC7UTM2	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.83	0.71	3.58	10.27
DCFWLG9	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.79	6.43	8.95	12.57
DCLHADZ	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.88	3.39	7.54	10.17
DCDI39N	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	3.25	5.48	2.71	7.26
DCNG2LD	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	2.94	1.67	1.49	5.91
DCLWN16	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.56	4.09	1.63	8.19
DCAMEBC	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	8.78	7.87	7.9	12.61
DCR6BA2	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	10.56	13.87	13.53	17.12
DCH56PU	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.02	2.6	1.46	6.94
DC4ZF58	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	4.55	8.25	7.54	11.85
DCI0R4X	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.18	2.33	3.5	5.42
DCL7I0X	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.96	2.49	3.9	7.41
DC8URF5	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.47	4.66	7.33	9.95
DCR3YSO	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	16.6	14.32	13.39	19.19
DCZ8EPL	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	6.74	5.9	4.43	9.59
DCYSXLR	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	11.1	10.86	9.62	18.76
DC4UPC5	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8.3	6.96	8.21	12.24
DCJUY1E	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	4.27	4.82	2.93	6.22
DC5LJRR	DM27D4J	PD-0325901	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	1.27	0.9	6.58	10.6
DCK6AU9	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	5.9	4.11	5.68	9.99
DCY0MJ5	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	19.26	17.07	17.91	25.22
DCHD19T	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	5.41	4.42	4.99	10.81
DCZONCK	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	3.95	5.21	4.61	10.44
DCWOGKM	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	3.29	3.44	0.09	6.08
DC8H7BV	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.3	1.21	5.59	7.65
DC4NGI9	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	3.64	3.55	3.09	8.56
DCVUXPJ	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.03	1.04	0.8	6.69
DC12CKB	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.46	0.76	1.92	5.23
DCHOPIQ	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.43	2.54	0.27	5.98
DCC3WC6	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.49	5.74	2.42	8.88
DCPSPI8	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.12	4.86	6.93	12.14
DCZK2W6	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	8.65	8.21	5.11	12.19
DCBTV1O	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.38	4.75	4.65	7.93
DC7TOCT	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	5.5	4.89	2.95	8.92
DCMV03R	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	1.42	1.89	1.97	7.35
DCRCHCE	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.05	1.62	3.97	7.66
DCE526N	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	10.66	10.43	3.22	11.85
DCIG20P	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	8.55	8.29	4.68	11.59
DC1QEDH	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.46	7.22	6.77	12.66
DCD4ZT4	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.28	6.83	5.53	9.34
DCOBK02	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	4.75	3.52	2.07	7.01
DCRW4LT	DM27D4J	PD-0325901	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	10.34	11.1	4.08	11.75
DCY0Y4T	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	0.12	0.19	12.62	15.64
DCCGBVS	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.7	2.76	10	13.84
DCUY5X6	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	8.66	3.79	10.52	13.24
DCR365O	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	2.22	2.04	9.39	11.11
DCN6L5Z	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	9.66	7.97	9.44	14.37
DCZDUH8	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	5.24	5.06	10.21	10.9
DCDLIUN	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	5.76	8.3	10.05	13.05
DC2KEXR	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.71	7.88	7.79	12.89
DCPI7BV	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	23.87	23.8	1.08	28.22
DCYNB3X	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	13.75	13.15	4.29	17.34
DCDLC9Z	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	11.05	8.57	10.72	13.33
DCFZES4	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.93	14.19	7.36	16.43
DCHD0AB	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	19.81	19.29	19.46	24.28
DCXU44K	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.39	0.67	6.88	9.13
DCMODXC	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.86	8.57	8.54	9.78
DC9UHQM	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	19.17	16.61	17.41	21.72
DCQPPGN	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	1.61	0.26	1.68	5.42
DC0R5QP	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	17.62	17.39	22.03	27.48
DC4UCVP	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.25	0.16	3.12	7.34
DC54J98	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	8.36	9.5	9.18	21.54
DC9UBBI	DM27D4J	PD-0325901	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	0.36	2.21	0.45	0.47
DCT70TX	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM09NGV	Ribavirin-TP	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.51	3.51	4.47	4.53
DCK6UOP	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM0CEY3	Lefaxin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.42	3.42	3.94	3.95
DC4DSMF	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	8.08	9.63	0.38	0.31
DC618MO	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.39	8.04	2.72	0.78
DCEXCRJ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM0KYI4	Mebutamate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5	5	5.82	5.83
DCH7X6J	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.27	0.63	1	3.39
DCTAH28	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	1.14	4.68	4.02	4
DC7MHKU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM15HL8	Clindamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.05	3.05	3.5	3.51
DCHFIOE	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM1AF5U	Acetazolamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.69	2.69	3.16	3.2
DC8CEBD	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM1TJ8F	Diethylcarbamazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.19	3.19	4.43	4.5
DCDFPDF	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.67	8.15	2.54	9.45
DCC628K	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM29GAD	Lumefantrine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.32	1.32	1.76	1.8
DCYBKN9	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2DMPO	Kanamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.19	1.19	1.96	2.03
DC1Y9WY	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.1	3.01	0.14	3.74
DCWNOWF	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.09	1.42	2.15	4.9
DCUT6JV	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	9.23	10.15	6.26	10.71
DC16ICE	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.15	3.15	3.9	3.93
DCF5SPY	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.85	5.11	4.43	6.08
DC4FM1J	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	4.21	7.22	5.22	8.92
DC91NC8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	5.45	9.73	1.75	8.31
DC9C9JI	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.32	1.42	0.79	0.13
DCOM4T1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.11	8.59	6.05	8.9
DCYNGJ7	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.32	2.1	6.49	5.95
DCQQY90	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3P6V7	Furazolidone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.89	3.89	4.37	4.44
DC7E76W	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3VZJQ	Chlorphenesin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.21	1.21	1.52	1.61
DC2LNBX	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.81	5.53	1.14	7.13
DCBU9MA	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM5J64S	Miglustat	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.1	4.1	4.85	4.86
DC4JO3B	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	9.55	4.72	7.05	9.05
DC2K2PC	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.48	1.17	1.39	3.78
DC8KPP0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	7.26	7.36	6.74	10.9
DCY4RGE	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	9.38	9.64	5.37	11.51
DCFLKXE	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.34	2.53	0.14	0.9
DCY0ADX	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.4	1.4	3.99	4.08
DCE0P88	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.03	0.81	3.49	4.79
DCJ2PEZ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM8BKU9	Acitretin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.2	3.2	4.54	4.57
DCBF0ED	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFI8A7	Tranexamic acid	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.03	2.03	2.37	2.46
DCM7O46	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	3.88	6.39	1.22	8.27
DCRUJLA	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.63	0.7	0.19	3.54
DCDQRMG	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.58	0.4	1.38	1.38
DCMAU46	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	5.66	5.6	7.57	7.57
DCGN201	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	8.07	2.59	3.09	4.36
DCTZC7I	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.49	0.51	0.02	1.29
DCEW4B0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	3.98	5.16	1	7.12
DC6X7JC	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMBEX4O	Methylergonovine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.18	2.18	2.68	2.76
DC6N0QP	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMBHMOX	Palonosetron	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.1	1.1	1.54	1.57
DCCE4GE	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.06	1.06	3.04	3.1
DC1QB52	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMPN5IH	Guanfacine	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.13	5.13	5.72	5.72
DCH2MW4	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	3.49	6.16	0.14	8.66
DC8OXX1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.35	2.4	3.42	3.62
DCZAGC1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DME4RA8	Amodiaquine	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.1	1.1	1.61	1.61
DC8EI2V	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCUT21	Ursodeoxycholic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.37	1.37	1.85	1.85
DCU7KQ4	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMD9WSC	Memantine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.23	1.23	1.74	1.82
DCT8OLQ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMDO279	Phenprocoumon	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5	5	5.56	5.64
DCAU62D	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DME5TUR	LY03004	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.41	1.41	1.9	1.91
DC2XHTR	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DME9QGW	Marizomib	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	9.35	7.65	8.78	12.14
DC2WYCW	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMENSL5	Aminosalicylic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.8	3.8	4.31	4.32
DC61OAT	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMF57DM	Pazopanib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.73	4.73	5.49	5.56
DCVI3GX	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	2.57	6.31	2.09	7.29
DCT4OB4	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	6.19	14.82	6.36	16.05
DC5EYLV	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFO843	Fluspirilene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.35	0.35	0.77	0.84
DCJD0B6	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFQWNI	VR-776	Discontinued in Phase 1	3	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.32	1.32	1.84	1.9
DC3XOUN	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMGC5DB	Ciprofibrate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.09	5.09	5.5	5.58
DC8748I	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMGFV3Z	Nizatidine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.54	2.54	2.95	3.03
DCG2V5U	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	0.1	0.24	1.22	5.45
DCXO8RD	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3	2.74	5.55	7.28
DC24G71	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.2	3.95	0.4	5.12
DCYUD7H	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	7.91	9.76	5.71	9.73
DC3G62T	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	7.25	10.03	3.61	11
DC8VXAD	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMHPWOM	Diphenidol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.21	1.21	1.76	1.77
DCN9YBD	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMIK367	Procarbazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.26	0.26	0.76	0.76
DCOOVOS	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMIWFRL	Tolvaptan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.17	3.17	3.77	3.8
DCD5HXF	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJOQM3	Eflornithine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.49	1.49	1.93	1.99
DC5ROFJ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJPE61	PF-02545920	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.86	0.86	2.52	2.56
DCQXNU0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMKBYWI	Trifluoperazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.07	5.07	5.54	5.6
DCNKW7O	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMGO72P	Oseltamivir	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.36	0.36	1.09	1.16
DC1K3VJ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMKXY2R	Ibutilide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.81	4.81	5.41	5.45
DCFUBAR	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMKZJ7T	GINKGOLIDE A	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.79	3.79	4.4	4.48
DCF1HEO	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DML1538	Diazoxide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.24	1.24	3.86	3.94
DC1UGM8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.74	1.49	1.32	2.1
DCK35XT	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	1.58	2.04	3.87	4.76
DCSFJ79	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMM0HR1	Pargyline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.38	0.38	0.81	0.88
DCG1V7Z	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.44	5.09	0.64	9.18
DCZIN5P	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	14.42	14.42	21.65	21.71
DCX9GWK	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMM4WBX	Methocarbamol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.41	2.41	2.88	2.95
DCKS00M	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMFWOJ	Probenecid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.06	2.06	2.56	2.65
DCP4IKN	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	0.87	0	0.44	5.69
DCLPSEM	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	5.52	6.12	0.92	7.87
DCR7W8B	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.25	1.7	0.99	4.09
DCZ0S4C	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.78	3.2	2.25	4.93
DC5XC11	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.55	1.11	4.91	6.43
DC4O69F	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNMW9R	Pramipexole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.48	1.48	2.13	2.19
DCZDIFO	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.41	5.91	4.64	4.69
DC5CCGF	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.18	4.69	0.72	5.52
DCXBVDO	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	9.35	8.58	5.31	9.38
DCF4JTE	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMO14SG	Mebendazole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.92	4.92	5.4	5.41
DC1I349	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMOMBJW	Moricizine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.5	5.5	5.97	6.04
DCVMLAU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMPFN6Y	Olanzapine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.1	2.1	2.6	2.67
DCUBIUT	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMPGUCF	Dopamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.41	2.41	2.86	2.86
DCY4JCX	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFYAM1	Enalaprilat	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.42	3.42	3.84	3.86
DC4IYNW	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMQEJVU	1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.3	5.3	5.77	5.79
DCIDRCG	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.59	1.95	5.13	6.94
DC372Q5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	6.69	7.39	7.3	11.12
DCYY36L	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.7	6	2.62	4.98
DCAYTFG	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	7.72	14.87	3.12	3.7
DC3S6YS	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.82	6.21	6.71	8.23
DCG2GX4	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.82	2.71	7.41	8.7
DCTOWIS	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.94	7.96	11.24	12.04
DCKZMUA	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.49	4.62	2.58	7.18
DCH1X6Y	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.01	1.01	1.55	1.55
DC017SC	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRM3AW	Acarbose	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.27	3.27	3.71	3.77
DCD9MYA	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS3YE9	Amantadine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.11	3.11	3.64	3.68
DCX89NT	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.01	1.01	1.37	1.4
DCCYEXH	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.67	7.54	1.68	0.86
DCGCDDK	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.78	4.49	1.9	0.86
DCN5I91	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSQZE2	Asenapine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.19	3.19	3.66	3.66
DCD2HPA	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMUL45H	Naltrexone	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.86	3.86	4.34	4.34
DC1V9OJ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSWYF5	Quinine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.6	2.6	3.79	3.87
DCBD2I2	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	9.99	10.26	2.69	0.8
DCSJ6K4	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.75	5.86	4.19	4.19
DCQ7SRQ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.51	1.28	0.76	0.27
DC97MWG	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.2	7.87	8.14	2.89
DCJITA6	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.02	5.82	2.28	5.86
DC0FW2Z	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.79	4.99	0.12	1.38
DCWXINU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMU8JGH	Hydralazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.86	4.86	5.75	5.79
DCM5F1W	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWT905	Mefloquine	Phase 2/3 Trial	24	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.36	1.36	3.96	4.01
DC3993A	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMV74ZH	Pizotyline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.51	2.51	3.01	3.02
DCJFI8V	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMVM6QR	Lacosamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.27	3.27	3.76	3.82
DC4EVUY	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.42	2.42	5.1	5.1
DCR36AC	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMVRIC2	Zileuton	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.13	5.13	5.89	5.96
DCG530C	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMVTHWQ	Silver sulfadiazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.04	2.04	2.43	2.49
DCABBPS	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMVY4GN	Testolactone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.4	0.4	1.06	1.12
DCVDEAR	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWBHRY	Olmesartan medoxomil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.12	5.12	5.5	5.58
DC19W1G	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWE2N4	Auranofin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.24	1.24	3.8	3.82
DCPPF7J	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.58	2.23	2.42	2.75
DC06BQF	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.16	2.16	2.72	2.79
DCVU9VI	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.2	4.79	2.01	1.03
DC3TRZ2	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.19	3.71	0.92	5.9
DCRN6DQ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.64	5.82	4.21	6.87
DC1OKLA	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWSMND	Cevimeline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.2	3.2	3.69	3.72
DC813BO	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMXLZP6	Metaxalone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.51	2.51	2.95	3.01
DCLM74N	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMYLOVR	Aciclovir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.09	4.09	5.21	5.28
DCBWQZE	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMYTE6L	Enoxacin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.03	6.03	6.48	6.54
DCU9VUA	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMYURI6	Raltegravir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.07	4.07	4.5	4.55
DC8H6RP	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMYX7NI	Acetohydroxamic Acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.96	3.96	4.89	4.94
DCUSTLK	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	13.07	13.86	6.77	9.25
DCLHLUJ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMZ2TD9	GSK2194069	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.49	4.49	4.85	4.94
DCA3681	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.64	1.78	4.67	3.21
DCDJKMT	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	5.67	6.23	0.19	3.09
DCVK7WW	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.26	2.28	0.93	1.01
DCI0CN8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMZ9WI4	Nitrosoglutathione	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.22	3.22	3.63	3.63
DCV09VQ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMZA017	Tetracycline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.58	1.58	1.98	2.06
DCKUF8W	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMZI3WO	Etomidate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.77	3.77	4.18	4.21
DCSVZVO	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.1	4	0.51	3
DCU80JT	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	10.07	10.01	8.51	16.58
DC4MUM6	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.58	0.77	3.43	7.91
DC9O9JD	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	0.56	0.45	2.89	4.37
DC7PUHK	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.8	0.62	1.47	5.23
DC1HPL6	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	8.08	7.1	2.51	9.52
DCP3PVI	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.25	0.46	0.81	5.75
DCQFRDT	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.06	2.53	1.89	7.26
DCRJ3EL	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.44	3.24	2.68	7.79
DC45PX4	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.71	0.75	1.54	7.13
DCB7DJV	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.94	2.15	0.8	5.95
DCBHNAG	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.01	10.06	10.27	12.24
DCFPN01	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	6.85	7.48	3.65	10.36
DCCVYNW	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	5.05	4.52	2.63	5.69
DCL1UOM	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.67	1.8	3.06	6.7
DCVDW7A	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.21	3.3	2.83	7.58
DCALFPL	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.62	5.9	0.54	6.12
DCOJV0Z	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.39	1.57	0.49	5.72
DC7A4MJ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.7	3.32	5.34	9.93
DCHEZJU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	0.53	0.13	0.74	4.02
DCYZJ1K	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	6.41	6.58	6.96	10.56
DCC10LP	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	8.48	7.92	9.45	12.49
DCNZ2NH	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.21	4.44	1.72	8.02
DCTOBP7	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.64	2.77	3.61	8.59
DC974QV	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.29	7.27	5.31	8.48
DCEKR1K	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.67	1.34	3.48	9.72
DC5IAPB	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	8.38	7.85	11.77	14.35
DCQT9XT	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.74	12.32	9.43	0.93
DC2YJES	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	5.43	3.75	4.79	7.61
DCBF5N7	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.6	1.33	4.9	8.44
DCO4O3W	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	5.25	5.47	6.77	9.14
DCWDHM4	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	6.16	8.82	7.42	12.03
DCD19FK	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.48	4.1	1.16	6.8
DCPO0RH	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.71	4.07	2.39	6.04
DC8PYMN	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.08	3.44	1.76	0.12
DCOAWB5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.68	2.48	1.57	0.88
DC7A5HC	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.13	1.88	5.73	7.66
DCTM1SU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.35	4.77	0.52	3.19
DC9NBS4	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	8.13	7.8	11.01	14.39
DCGBRNJ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	7.72	7.39	10.28	14.17
DCF4WBW	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	6.35	6.36	6.79	9.89
DCO1LZ2	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.37	0.76	3.43	8.6
DC27CDY	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	7.36	7.06	5.47	10.24
DCXSJP1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	10.29	10.13	11.15	15.37
DCHPJ5X	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	8.66	9.87	9.99	14.32
DCET4HM	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.68	3.8	8.56	10.94
DC83G70	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	4.19	3.5	6.93	9.83
DC87P6H	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.12	3.6	9.19	12.17
DCRE0CW	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	16.51	12.48	10.9	14.73
DCT0WDH	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	9.03	9.02	6.46	11.55
DC4UN7X	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.43	1.5	1.75	5.09
DCM4HHD	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.89	4.24	0.83	6.6
DCRMHVY	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	3.81	3.25	0.5	7.33
DCWZJ86	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.81	1.78	3.9	7.4
DC0J1O2	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	4.98	2.54	2.26	8.14
DC7MIHC	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.83	0.16	1.97	7.65
DCQVA1G	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.04	4.39	1.81	6.38
DCITM4I	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	6.59	6.42	10.47	14.88
DC6EUC5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.62	4.49	10.31	13.47
DCCYV6C	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	15.99	3.29	7.11	8.84
DCSR1WA	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.66	3.33	6.2	10.27
DC2455R	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	15.41	16.07	16.63	19.47
DC9NTB5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.62	1.1	5.15	8.68
DC8I16C	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.69	3.5	7.46	8.92
DC460P9	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.81	5.76	2.53	7.97
DCOHWWV	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.26	4.2	5.56	8.58
DCWDIJD	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.62	3.75	1.09	7.74
DCLOSRF	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.76	2.51	1.47	6.68
DCD0CQT	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.76	1.31	2.04	8.04
DCEAAH5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.98	11.77	10.48	13.46
DCL9ADU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.62	2.81	4.22	5.64
DCQUJ5X	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.9	2.71	2.57	2.47
DC58606	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	10.89	11.3	6.51	12.51
DCQ84DL	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	16.62	13.96	10.46	15.36
DCY53EN	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	7.17	8.3	4.99	9.85
DCZQVGB	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	7.2	4.22	2.13	8.09
DCQRTK9	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	5.39	7.47	8.4	11.42
DCDOSII	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	6.27	3.92	0.71	6.08
DCA832Q	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.83	9.92	6.92	0.38
DC3QFQU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.99	2.93	5.77	10.41
DC4B27N	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.65	2.14	6.89	11.3
DCZRF6F	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.84	1.84	6.68	11.47
DC8YQ64	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.78	2.03	1.49	5.12
DCW5359	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.81	1.92	2.49	7.91
DCBOULC	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.6	0.51	1.53	7.2
DCXIFSU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.62	2.27	0.94	2.88
DCSW69F	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	5.01	5.37	10.17	13.24
DCBUGM8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.94	2.37	8.3	10.97
DCA3FKC	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	6.94	9.83	10.04	13.6
DC6VFZ6	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	7.85	8.86	5.31	10.87
DCZ2IWM	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.69	2.54	4.36	5.87
DC8E2HH	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.53	4.37	2.34	8.37
DC6TT3A	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.75	5.2	6.37	9.5
DCP1SOY	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.15	0.44	4.58	7.46
DC1E4J8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	6.25	6.86	4.1	12.62
DCFHC3U	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	10.83	11.15	8.35	13.35
DCBE809	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	6.94	5.89	5.73	9.53
DCP8ZW9	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.28	1.15	1.07	0.46
DCJ6PVD	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.47	2.64	6.34	9.79
DCLU1ME	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.39	2.77	4.56	9.1
DC66SN3	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.79	4	0.55	7.2
DCB3J1H	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.9	2.72	0.61	6.2
DCFYG5U	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.84	4.96	1.3	6.14
DCZ4S79	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	10.92	14.42	4.56	15.71
DCFZST1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.45	6.74	4.67	9.32
DCH8ERN	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	7.47	7.83	3.57	9.63
DC3GBHK	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.53	6.09	1.13	7.09
DC3V4DR	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.4	2.37	7.08	8.32
DCBUZ7L	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	3.2	2.97	4.47	6.74
DC2GLOV	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	5	5.84	8.38	10.8
DCMSKSS	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.35	2.83	3.75	6.02
DC0A5TS	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	3.59	2.44	7.54	8.89
DCFZW34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	6.24	6.23	8.58	10.86
DCZPHBA	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.33	2.3	6.19	7.68
DC7F46V	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	10.27	13.19	18.57	19.69
DCP0OGN	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	11.09	9.52	9.26	10.99
DC3W140	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.43	3.76	4.09	4.49
DCKK333	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	10.62	11.35	4.89	16.17
DCZKRAH	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.83	5.02	7.49	12.07
DCODSK4	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.61	4.75	8.52	12.59
DCM7GCZ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	1.88	2.68	0.46	6.26
DCLKOEG	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	3.96	4.26	1.13	9.24
DC6SZDS	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.91	2.07	0.79	6.72
DCC75ZS	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.25	4.38	1.4	7.16
DCBQ3P9	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.24	0.15	1.21	5.2
DCX8LG8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	11.99	11.87	9.34	14.82
DCNOIUG	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	7.28	7.17	8.88	11.12
DCBZTAI	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.21	5.15	0.29	5.58
DC6X64P	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.96	5.12	0.4	5.33
DCXO5W9	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	5.82	4.89	3.83	7.65
DCLJSFC	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	5.41	7.09	1.43	7.71
DCB1ZS4	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.29	2.91	0.8	4.49
DCEOETQ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.89	3.93	0.82	4.75
DCPAZD4	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.53	11.86	7.16	12.91
DCKJ95R	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	10.77	10.09	4.92	11.58
DCPK02H	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	10.92	10.59	7.91	11.93
DCA2VQF	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.52	5.68	3.49	5.65
DCGZW09	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.91	7.07	7.13	9.93
DCSVFXU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.24	5.83	1.31	6.34
DCAQKDM	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	4.31	5.78	6.48	7.25
DCAEQ9M	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.96	7.29	5.74	10.88
DC1F4TN	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.18	5.13	4.48	5.47
DCJN4WR	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.95	1.79	2.67	7.55
DCE5V11	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.76	0.83	0.19	6.48
DC1UXEM	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	4.28	1.39	2.03	5.41
DC1HG27	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.44	0.93	2.99	7.6
DCKE4LE	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	8.37	8.61	1.64	13.31
DCDKOU3	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	10.76	11.09	4.9	15.02
DCSVBQG	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSG91J	ER819762	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.32	4.61	3.86	4.15
DCZ0LFZ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3	5.5	7.47	10.48
DCU5OG4	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	8.63	8.59	10.02	13.42
DC8KHWW	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	5.45	5.11	12.04	14.59
DCKQVB2	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.23	1.45	0.2	4.35
DCU9Z3G	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.4	3.83	3.06	9.36
DCQIUTI	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.57	1.2	1.98	6.01
DCHFMBB	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.21	4.65	6.08	8.1
DCXGWFZ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.54	0.89	5.05	7.62
DC4YVWR	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.4	1.93	3.98	8.7
DCONOH9	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.09	4.64	3.64	8.45
DCQHK3S	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.36	2.01	0.03	5.34
DCNQA6J	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.85	7.92	4.58	2.21
DCUUBOT	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.65	6.57	2.16	1.91
DC7TOV4	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	6.1	4.32	6.56	9.57
DCT9K83	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.42	2.23	4.66	9.03
DCOFY89	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	2.61	2.18	2.4	5.88
DCQFOLQ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.92	0.92	6.71	9.4
DCWJ3OH	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.83	1.91	4.47	7.01
DC4UCNN	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.22	3.16	2.92	8.15
DCFTIYM	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	5.22	2.95	2.11	7.42
DCAW2GI	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.44	1.05	2.08	6.76
DCQTTOG	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	7.24	7.45	8.95	14.37
DCTIMBB	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	12.29	13.13	13.23	17.03
DCLFV1G	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	5.71	5.07	5.03	8.82
DC0Z1Y5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.65	3.11	3.67	5.98
DCQKV10	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.13	10.07	6.99	9.79
DCZRIPZ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	3.04	6.55	6.06	9.75
DC3I1JT	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.56	5.44	1.05	6.24
DCIOFBP	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.28	1.01	1	6.61
DCY2NJ2	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.4	6.01	3.02	10.65
DCM3Y64	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.4	4.56	5.89	9.51
DCP1JK7	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.5	8.26	7.48	11.31
DCGP8V9	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	6.16	8	10	12.62
DCW4MFV	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	5.63	9.62	9.72	4.42
DCPE3PC	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.09	5.99	0.98	2.56
DC40EAO	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.31	7.05	6.01	1.5
DC3JE5B	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.41	2.76	1.13	2.19
DC2AM1R	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.6	3.3	0.64	1.14
DC39RQL	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.11	3.15	0.51	1.49
DC87MA5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.05	1.73	1.53	1.33
DCD4C7L	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.79	2.29	2.36	0.95
DCWF791	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	2.85	0.9	1.93	3.72
DCZ946N	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.39	5.97	1.82	9.37
DCJKNKQ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	2.75	3.25	2.73	8.21
DCHGW9T	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	6.32	6.16	1.44	7.76
DC2EB35	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	12.05	11.54	2.61	11.49
DC4QD00	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	6.44	5.43	1.01	7.85
DCV6OLV	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	11.83	13.45	8.04	15.05
DCJZEEU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	4.9	4.09	1.37	6.14
DCQO0SX	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	8.14	6.35	2.53	9.21
DCSU961	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.04	6.65	1.88	9.36
DCEEBYZ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	9.57	9.43	4.54	9.81
DCXHD8X	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	13.04	15.24	7.23	15.3
DC6TGWS	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	8.54	10.36	3.18	10.57
DCN852K	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	9.38	9.84	8.37	13.3
DCQNIUT	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	2.5	4.39	2.53	6.49
DCR5TJH	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	12.05	11.71	9.2	14.85
DCMRYBD	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	13.49	17.5	4.51	15.12
DCRUDNF	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	7.77	9.21	6.31	11.02
DCMRECW	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	28.96	23.95	22.6	28.9
DCV04LU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	15.15	13.86	8.32	16.11
DCE16QG	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	8.86	10.05	5.25	13.44
DCD217R	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	10.61	9.9	7.23	12.71
DCEWLN0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	5.29	6.94	10.39	11.21
DCSVFFU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	7.47	9.96	2.25	10.44
DCTZDSQ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	6.05	6.47	0.14	6.61
DC78IDL	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.06	5.23	1.72	5.74
DCS89N5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.88	6	2.24	4.77
DCILY0B	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	7.5	7.47	3.01	7.41
DCQ6SB3	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	6.52	5.35	2.39	6
DCXS5HM	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	6.47	5.82	1.09	5.63
DC3PKTQ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.94	3.57	0.27	4.57
DCOCAUT	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.63	4.58	4.05	8.24
DC9VINL	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.4	4.48	2.64	7.55
DCMSP5A	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	7.25	13.28	2.31	7.16
DC48LEP	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	0.85	5.39	7.9	10.21
DC2WSKL	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	4.72	4.89	8.65	11.84
DC1RX46	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	5.14	4.71	4.25	8.64
DCTQTDU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.26	4.52	2.29	6.12
DCYNBL8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	9.7	8.53	1.79	7.38
DCOLF6Q	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	8.71	9.29	4.43	10.93
DCOCOSS	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	8.57	7.89	8.93	10.71
DCQRX2B	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.87	7.22	3.17	10.4
DCCMJUN	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	13.77	17.32	10.34	15.38
DCUGMAD	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.42	6.69	0.25	7.27
DC5LB93	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.97	5.27	1.59	6.61
DCCHRV9	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	13.05	13.77	2.21	10.34
DCU6VW2	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.23	8.74	6.82	9.47
DCZALWS	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	11.2	9.42	5.78	16.48
DCI9GSJ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	4.24	4.41	7	9.76
DCVUCST	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	9.57	10.58	4.33	11.48
DCBY00X	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.42	3.06	3.97	8.28
DCVGY0O	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	6.97	5.54	6.69	13.37
DCY3VA2	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	9.91	12.1	4.73	12.59
DCJCM39	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	3.67	5.64	0.04	8.24
DCCXX9J	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	6.9	5.38	0.37	5.9
DCUOYG5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	4.24	6.58	1.06	7.91
DCYFW4R	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	7.38	3.34	2.29	5.46
DCYUU2H	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.81	2.16	0.92	5.8
DCH8KAJ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.4	8.62	3.84	10.63
DCVOJXD	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.72	3.18	0.26	3.6
DCUTYLL	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	6.85	5.65	0.91	7.64
DCEET63	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	3.38	4.69	0.23	5.79
DC3ZEIN	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.95	6.05	5	11.28
DCT2GR0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	8.14	5.48	2.17	9.42
DCE14RQ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	5.22	8.82	4.01	10.15
DCPAH12	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	16.93	11.41	14.53	19.3
DCZCR8K	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	0.25	1.62	0.43	3.71
DCCKWO2	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	8.36	9.04	7.02	12.75
DC7UTW2	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	2.8	2.2	7.43	11.36
DCYXUY0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	3.46	7.12	1.71	8.39
DCVO2X9	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	8.37	6.89	2.62	0.17
DC9X5OP	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.15	1.31	4.74	6.86
DC7H8ZE	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	8.52	8.4	10.47	14.99
DCY62RB	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.21	4.73	3.65	8.13
DCA0S7H	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	9.12	10.03	9.8	14.71
DCMNFOH	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.53	5.07	4.09	8.05
DCUNGWO	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	13.86	13.03	11.05	14.54
DCFO3O6	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	8.64	8.93	7.56	11.87
DCTNFXU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	5.13	5.01	4.46	8.33
DC1BYEF	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.34	4.74	2.93	8.52
DCODHD0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.01	7.56	9.84	13.49
DCHKVPS	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.07	6.79	3.91	7.29
DCIF6M4	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	13.17	13.91	11.42	15.24
DCKNLGD	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	7.47	7.94	5.22	9.2
DCWBW8S	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.64	2.91	3.57	8.57
DCWHOCA	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	4.62	3.22	4.03	7.34
DCP0YTE	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	6.43	6.33	6.68	10.43
DC7LMRI	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	9.91	10.38	11.7	15.05
DCPN52Y	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	10.22	9.97	3.51	9.92
DC7DLXM	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.99	7.84	6.93	11.29
DCNDF03	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	13.87	12.77	17.17	20.77
DCR7062	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	10.84	11.01	7.98	14.58
DCGOPGW	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	11.69	11.51	10.47	14.56
DCS724X	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	12.84	13.22	14.1	17.83
DCYZ3TK	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	5	1.68	5.28	9.53
DCVXLTP	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	10.91	11.87	11.91	15.61
DCQN0PH	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	9.42	10.63	6.78	12.34
DCNKJ52	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.24	2.45	9.67	11.55
DCE0GNZ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	6.31	5.7	4.93	10.09
DCPA4RV	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	10.3	8.7	5.67	11.3
DCS0XKO	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	8.47	5.4	0.95	5.54
DCIZDRR	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	13.36	13.54	12.16	15.5
DCBYLID	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	3.28	5.94	2.84	7.48
DCJZSO1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.05	1.83	1.09	3.87
DCCT50G	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.65	2.75	4.67	8.29
DCYJD69	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	14.28	13.83	8.98	14.27
DCMCMVY	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	5.36	7.2	4.35	8.25
DCV2XN1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.63	0.97	1.9	3.82
DC1W2J7	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	17.05	16.76	14.66	20.47
DCISX8I	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	5.15	6.44	2.94	10.21
DC0SUH2	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	8.03	6.39	4.3	9.9
DCS234W	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	11.43	13.43	4.24	14.12
DCCQFJ0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	10.58	10.5	4.97	12.71
DC176V4	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	23.87	21.39	19.78	23.48
DCFD8U8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	9.35	8.85	4.9	11.56
DCGRXZ7	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.94	9.76	8.25	11.95
DCO81SW	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	12.16	11.64	8.17	13.82
DC852SR	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	7.4	5.48	2.12	13.14
DC2VE9B	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	0.47	6.97	1.8	10.23
DC3OCRL	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.68	6.58	4.4	5.86
DCXKOL1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	4.4	8.27	7.76	6.85
DCFUT49	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.89	3.22	2.31	6.81
DCBW24O	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	9.43	3.07	6.66	9.79
DCB1L1H	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	14.47	14.6	7.39	15.59
DC4REBS	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.38	1.16	2.41	3.31
DCHQ4H9	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	12.08	5.15	4.84	9.09
DC1F439	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	4.85	4.22	1.88	7.07
DCGIZTC	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.65	4.21	2.82	9.51
DCI38YC	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	8.29	8.94	4.75	10.69
DCTON42	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	5.28	5.58	0.12	6.65
DCGW3D1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	3.9	3.33	2.79	4.75
DC4L9J1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	11.03	11.57	11.04	14.9
DC5BU3B	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	11.69	6.23	7.43	10.65
DCTCDG8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	11.51	2.76	1.56	6.47
DCGH59X	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.11	6.24	2.06	8.9
DCDIW81	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	6.43	4.05	3.8	8.92
DCHKB0C	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	6.6	3.85	2.14	6.06
DCLSEFU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.25	1.01	1.96	3.7
DCAV4LI	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.68	9.37	3.06	11.84
DCS6DEY	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.03	2.58	4.92	5.65
DC4NRL0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	7.26	7.33	9.48	13.31
DCPV3OI	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	3.67	6.73	2.5	7.26
DCF0IWR	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	5.44	7.17	2.85	8.63
DCZ2UJD	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.98	5.95	2.17	9.38
DCAUY3D	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	8.73	8.46	4.52	8.37
DC1ME6K	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	9.72	9.91	2.42	9.66
DCBW055	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.1	2.72	6.27	8.03
DCR8CWM	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	4.06	6.34	2.61	9.16
DC72659	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	1.29	1.83	4.41	5.75
DCEK702	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	13.94	16.64	4.1	13.85
DCHFQ77	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	7.3	6.9	4.78	9.2
DC4AMUG	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.33	4.6	1.14	7.17
DC6QI84	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	28.12	24.07	25.58	30.6
DC7UYVF	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	7.5	8.69	7.69	10.63
DCAC6GK	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.95	8.71	6.41	11.31
DC1N3C2	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8.22	8.29	12.65	8.93
DCV5L6E	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	10.56	7.8	10.38	15.04
DCZKO2V	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	7.91	12.83	11.83	12.61
DCF7K84	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.91	5.57	2.42	5.78
DCVP7AR	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.77	4.75	1.82	5.46
DC64O3I	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.98	4.32	7.42	7.42
DCZO0UT	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.29	0.16	0.32	0.32
DC7RX4C	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.19	3.12	1.48	2.66
DC10HXM	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	17.75	6.65	3.75	6.41
DC2TLGN	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	11.37	2.85	1.8	1.8
DCCM0YI	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.95	0.59	1.05	0.96
DCVZO79	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.08	1.5	0.93	0.48
DCHWI4U	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.12	1.79	0.79	1.94
DCFCN7D	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	4.88	1.53	1.95	2.08
DCZZ6Q6	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.08	0.32	0.31	0.39
DCOUYTQ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	7.92	6.63	0.51	6.06
DCTIEAR	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	3.72	2.29	1.28	6.04
DCL86IC	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	8.89	7.67	5.11	8.86
DC002P8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	3.17	2.69	0.45	5.35
DCX2MFC	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	6.62	5.18	1	6.26
DC9EY8M	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	13.28	8.35	10.15	13.63
DCE92B0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	12.87	12.31	9.34	14.34
DCJE60S	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.37	3.64	2.12	6.99
DC56HJ7	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	5.35	5.59	10.2	13.81
DCA40XM	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	6.32	10.43	0.55	11.19
DC6SCLI	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	4.88	9.82	4.86	2.4
DC07T4H	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	0.48	1.92	4.29	9.19
DCL7LAS	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	11.03	11.67	1.93	12.02
DCG7ISF	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	5.34	5.56	0.26	9.01
DC0241Q	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	8.55	7.87	2.61	12.33
DCOM2CA	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.6	3.97	1.76	9.67
DC6946P	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	10.56	11.72	1.88	11.93
DCAMXSP	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.51	5.92	2.19	10.7
DCHXSGR	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	3.23	4.88	0.78	9.84
DC85SEE	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.14	1.75	26.85	2.2
DC38TFX	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.55	8.3	2.19	10.71
DC57ZSV	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	3.23	4.29	0.19	8.28
DC2PVMT	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.83	3.38	4.29	6.93
DCGXVT1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	10.88	11.24	16.34	18.43
DCDU6XE	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	5.25	4.97	7.28	11.07
DCCBOTR	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.55	0.85	6.87	8.42
DC1SFK4	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	5.87	5.58	5.72	10.4
DCO6MI1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	5.27	9.13	3.37	8.29
DCTCT8K	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	19.83	14.81	12.92	17.09
DCMLM62	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	4.54	4.66	2.04	7.57
DCQVJCD	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.7	2.74	1.68	6.18
DCEB0PR	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.22	6.23	26.15	4.67
DCSEJJC	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	16.14	17.31	10.36	16.18
DC2ZD27	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.34	6.88	1.64	7.05
DCS4IR4	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.49	2.24	5.43	6.96
DCPH7R8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	3.52	4.4	2.1	7.17
DCC73Y9	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	16.18	17.59	14	19.55
DCQNOYI	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	6.46	9	1	6.59
DCTKTI1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.72	6.24	4.38	8.57
DC35VQ9	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	9.24	9.37	7.15	12.25
DCGXAW3	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	21.56	19.51	27.66	31.51
DC03OBE	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	8.58	6.62	9.31	11.79
DCCMFAW	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	11.15	13.83	10.24	15.21
DCU4UVO	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.89	2.41	1.67	6.84
DC4QS65	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	5.49	5.32	6.31	11.63
DC4WF60	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	18.21	19.07	11.81	19.64
DCHOUFX	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	6.2	8.3	4.84	4.3
DC8C60L	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.15	11.25	0.98	5.54
DCBM0RO	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.27	3.45	1.54	7.03
DCY6SDD	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.39	4.42	2.44	6.25
DCTOOD7	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	4.12	7.06	7.55	9.84
DC8TY1R	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	5.97	6.08	3.54	9.92
DC6SRZY	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	9.8	9.97	4.87	10.54
DCOQNFA	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	7.2	8.02	2.23	9.96
DCGSBFD	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	8.06	8.81	7.33	11.34
DCV3WK5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.96	4.96	2.09	4.9
DCLEVTS	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	5.91	9.7	0.53	9.59
DCZ1AZF	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.02	4.6	2.36	7.25
DCINR6T	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	11.11	18.07	7.69	15.38
DCB70AW	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.18	4.03	0.39	5.73
DCMDD82	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	15.89	10.8	10.05	17.51
DCD52I9	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.64	1.13	1.17	5.4
DCWAX3M	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.94	4.58	1.91	7.81
DCKA1TH	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	2.23	6.61	2.34	9.12
DCEXDY8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	6.58	3.45	0.15	7.59
DCR08EP	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.14	0.4	0.41	4.66
DCV3EY8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.3	4.19	2.13	2.16
DC820ZC	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.59	7.7	0.06	8.62
DCQXJSA	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.23	6.19	7.07	9.93
DCNS3HY	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	4.66	5.6	0.69	6.78
DCCNT58	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	5.82	4.67	0.29	5.83
DCUFY41	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	17.69	16.4	16.78	19.17
DCOE9PV	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.79	5.94	1.28	6.89
DCIAE4B	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	5.48	4.63	1.52	8.02
DCWS79G	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	1.86	7.69	5.15	4.77
DCN7ZAD	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.99	7.17	12	13.53
DCA8UOM	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.53	2.42	3.3	4.82
DCFAU99	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	0.68	1.28	5.69	6.52
DCST9D1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	6.02	6.6	8.06	8.42
DCUWRZF	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.18	2.71	3.69	5.72
DCKJTAU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	7.37	7.54	5.69	8.02
DC2DMUJ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.94	4.95	4.39	5.04
DCJZOZN	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.53	1.28	2.41	3.3
DCZLHCY	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.96	5.67	6.27	5.94
DC062GC	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.97	3.73	7.54	8.6
DCKOWPP	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.23	3.19	2.15	3.59
DC1DZ16	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	5.04	10	7.76	9.63
DC3KLLY	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	8.03	9.36	8.68	10.33
DC42EX4	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	8.57	10.59	11.65	11.97
DCOLC5B	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.68	3.63	7.77	9.26
DCZ1JTT	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	11.24	17.26	14.24	14.92
DCEFP0M	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	12.04	8.86	13.23	14.04
DCV3LX2	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	3.39	4.59	4.6	6.21
DC2QHWU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	16.4	14.45	15.55	18.51
DCAEXVO	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.07	3.97	7.49	8.94
DC4OTAT	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	7.22	0.47	6.87	9.51
DCJ35LH	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	2.51	4.12	3.32	4.28
DCHJAX8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	3.16	5.57	0.53	6.86
DC3LG5Y	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	15.26	15.03	9.8	16.22
DCWNWOX	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.08	1.29	0.48	4.07
DCY57A0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	11.9	10.69	4.85	11.68
DCN21WR	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	6.9	6.4	1.52	8.84
DC4FWYZ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	16.71	17.3	1.89	18.47
DCWKRN5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	19.41	12.97	11.14	16.65
DCO0S10	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.67	9.24	4.39	9.34
DCG8UMB	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	1.6	1.52	3.52	6.5
DC17M64	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.59	5.7	1.9	8.93
DCV8W9G	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	6.28	4.75	0.08	5.7
DCL3ZIC	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.38	4.71	0.06	8.14
DCENZ49	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.44	4.06	0.3	4.43
DC9XZHG	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	11.73	13.25	2.47	11.46
DCI6W22	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.13	4.39	1.72	7.74
DCM57OR	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.06	1.6	0.61	5.75
DCSMDQB	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	20.55	15.84	9.43	22.98
DCC7IHM	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	6.03	6.68	5.2	9.7
DC006ZU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	11.63	11.71	9.03	15.46
DCR8ABU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.69	8.67	2.69	10.4
DCIWOTK	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	9.35	5.67	7.25	12.42
DCKEAJB	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	10.86	12.1	8.55	15.26
DCXTWRV	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.07	1.99	7.35	9.7
DCEDVB1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.46	4.58	5.96	8.7
DC3XF02	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.71	3.21	6.35	8.19
DCK8TK8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	4.84	5.4	1.47	5.48
DCXCH1H	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	3.92	3.18	2.46	4.87
DCAD5FS	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	6.12	6.56	2.14	8.61
DCCHOZ4	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.5	3.73	2.6	3.28
DC9TEN7	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	10.84	8.54	4.6	8.61
DC9LR0T	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	3.97	5.86	2.02	6.68
DCRCN16	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.36	6.08	3.37	7.33
DCR9Q2H	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.26	5.64	1.81	6.46
DCV23T3	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.27	7.57	4.15	6.96
DCBR8M2	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	5.92	8.02	1.34	5.93
DCR8FZA	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.64	6.86	5.28	9.4
DCEHQ9T	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	7.16	9.42	4.93	10.51
DC7XXQX	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	4.33	3.36	0.04	4.74
DC1L6RJ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.58	5.62	1.08	5.64
DCHK1ZI	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	10.05	13.28	3.06	11.43
DCOM8ID	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.6	4.17	0.98	5.69
DC5WEU6	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.36	6.57	2.25	6.35
DC4XSS1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	16.53	10.16	7.06	13.4
DCKOXR9	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	6.15	5.14	1.77	6.74
DCGV0D7	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	3.12	4.03	0.2	5.67
DCOALUY	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.83	8.77	5.66	11
DCRAVYP	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	7.03	7.02	5.52	9.74
DCIHV3W	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	8.51	8.22	5.07	9.92
DCCA785	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	2.32	5.61	0.09	8.04
DC1XD27	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	17.39	19.9	0.39	16.7
DCCCYGD	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	36.58	31.15	8.13	34.92
DC98IRH	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.32	12.29	0.1	7.01
DCSW50N	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	8.24	10.53	7.73	12.65
DCF5HCZ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.13	6.66	6.56	10.02
DCOALNC	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	9.16	7.75	12.07	13.98
DCQ2VH8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	5.94	8.35	4.93	6.91
DC1D022	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.45	5.24	7.01	8.79
DCSLOTU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.08	3.81	0.51	4.72
DC0ZYLA	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	10.86	7.7	5.56	1.55
DCRJXW5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.6	3.13	3.92	4.34
DCGOUL9	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.49	8.93	6.3	4.38
DCY6FXB	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	15.73	19.89	16.42	19.65
DCGXBLZ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.05	4.11	1.61	1.88
DC0UOZW	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.2	6.3	3.17	1.92
DCACYZQ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	8.51	11.09	6.2	12.54
DCGPFBM	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	10.2	10.08	2.6	11.59
DC2OJ7D	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	8.29	8.85	1.97	9.93
DCVS5FW	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	6.06	7.39	0.72	10.44
DCCHFLA	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.78	5.61	0.1	9.56
DCF8DMH	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.62	10.16	2.22	9.78
DCVHU8M	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	11.63	15.35	1.86	13.12
DC4ZBKH	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.51	6.92	1.43	11.37
DC911I3	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	8.4	10.34	3.89	14.02
DCD0DD2	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	2.75	3.62	1.53	6.92
DCENLB1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	3.98	3.93	6.71	8.77
DCXV32M	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	7.66	8.86	2.78	9.93
DCEH3FL	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	11.55	10.39	0.06	11.08
DC3Q20R	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	1.65	0.88	2.06	8.06
DC87UR8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	9.03	12.96	2.8	12.6
DCC3J90	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.26	5.11	8.82	6.99
DCHW1ZE	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSG91J	ER819762	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.39	9.41	7.05	4.91
DCIYQVI	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSG91J	ER819762	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.22	8.82	4.89	4.39
DCQ68UX	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMSG91J	ER819762	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.83	4.21	2.44	0.78
DCZZW9S	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.51	6.11	6.58	10.01
DCF7663	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.77	1.53	0.92	5.08
DCARI41	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	1.56	4.23	6.97	8.93
DCE4TQF	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.37	4.29	5.19	8.9
DCIWZ4X	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	3.9	3.92	1.89	5.82
DCW65F7	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	6.68	6.55	6.24	9.93
DC9WQT3	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	7.29	9.96	7.73	11.84
DCY2VA5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.21	6.45	9.25	12.24
DC0PTHN	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.8	6.63	0.26	7.53
DC4AV5V	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	3.93	7.37	4.17	6.81
DCL48TT	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	2.86	4.05	1.66	5.1
DCE4472	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.77	5.94	5.17	9.19
DCQ6LJ2	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.36	1.04	2.31	4.8
DCXH2F8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	21.57	19.45	25.49	28.81
DCT6ME8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	8.07	8	9.67	12.25
DCRMZZT	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	3.44	4.27	3.7	8.07
DCUO2D0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.14	6.11	5.17	10.38
DCP68PR	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	3.45	0.89	6.03	9.26
DC3ZDR2	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	6.47	7.52	10.22	13.35
DCHUJDB	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	8.8	19.18	16.87	13.59
DCZYW69	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.92	6.29	3.74	1.66
DCSAGMW	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.72	3.22	4.07	0.35
DC0D1H5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	6.28	13.45	7.31	7.31
DCRRMLZ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.45	8.97	2.2	1.54
DCISRN5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.02	10.86	6.57	8.3
DCJVK5C	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.01	7.19	3.3	8.06
DCL7PVS	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.63	0.67	0.4	0.4
DC7BXZ2	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.55	4.88	5.4	3.82
DCCGCHL	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	13.26	18.89	6.79	4.53
DCJZSID	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.79	9.83	10.64	7.11
DCLJMOU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.98	5.16	2.7	3.17
DC3VCEE	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.41	5.24	3.12	8.49
DC3F4IA	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	1.89	1.72	5.01	8.21
DCG6B9T	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	4.96	5.09	2.95	6.75
DCFGHI0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	0.78	0.24	0.41	4.39
DCBVUQ9	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	7.7	6.2	4.69	9.59
DC3E8R7	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.94	1.57	0.81	5.54
DC09PJX	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.51	3.54	2.77	7.57
DCJZEVI	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.67	5.58	3.31	6.24
DCUN9IP	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	6.55	6.15	3.1	7.91
DCHTWZ6	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.47	4.08	2.45	8.16
DCLLQEW	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	7.85	5.68	2.82	8.42
DCUH97P	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	5.56	6.72	6.59	11.9
DC1MLV2	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	7.66	7.29	5.93	10.55
DCAV7GU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	5.82	5.18	1.2	6.56
DC6TOK0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.21	1.02	2.07	5.69
DCLJVMU	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	9.05	5.79	8.23	12.37
DCT0G8H	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	6.33	7.16	2.7	9
DCG38RJ	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	8.11	6.33	6.09	9.65
DCIS8M7	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.27	9	7.21	12.65
DCQHHEE	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	6.63	7.5	7.14	11.56
DC64I1I	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.47	7	4.88	8.81
DCZGO4H	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	5.69	4.89	7.17	8.44
DC470GH	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.33	4.38	1.53	0.85
DCG9STD	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.72	3.62	4.9	7.55
DCRQPEM	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	14.46	13.5	15.53	15.1
DC45DTY	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.67	5.38	2.22	1.21
DCVCSZX	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.89	1.33	2.57	4.83
DCOQ8ZV	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.9	0.49	5.92	7.19
DCAHMGO	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	0.48	1.18	0.8	2.94
DCJ1IOV	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.24	6.23	1.54	4.57
DCWM64F	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	5.1	6.41	2.06	2.99
DCDKI86	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	15.49	17.48	14.79	17.96
DCGMDEW	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	2.98	2.87	1.75	3.9
DC42CDK	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0	3.14	3.29	3.92
DCWJZ4D	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.71	7.7	2.19	8.74
DCVBFJF	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	19.01	16.74	27.28	31.13
DC7AIQV	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.47	5.79	3.01	3.02
DCJBHD8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	0.21	0.12	1.45	4.84
DCNLMM8	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	0.66	0.89	4.9	6.43
DC5PRQK	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	7.7	12.86	6.97	12.49
DCLVVJ2	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM053KT	Aprepitant	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	40.11	40.11	55.78	55.78
DCTGMPR	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM05FXR	Meclofenamic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	13.67	13.67	26.19	26.19
DCG9CYR	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM0KYI4	Mebutamate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.27	5.27	25.23	25.23
DCICTVU	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.75	8.68	5.12	3.9
DCZ0200	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.03	7.64	7.17	7.17
DCLDDXZ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.15	2.94	0.66	1.53
DCOO1RZ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	13.8	13.8	19.15	19.15
DCA6DQ1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	9.152	15.1	3.492	5.295
DCRDCBN	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	4.925	3.29	2.675	3.77
DCPJ3K3	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	12.75	13.87	5.51	15.58
DCOULIA	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM2B9E0	AT13387	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	9.643	9.41	3.123	6.775
DCAQGOP	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM2DMPO	Kanamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	50.98	50.98	70.87	70.87
DC02FFI	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM2G9AE	Citalopram	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.55	4.55	22.44	22.47
DCUQR3J	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM2NUH3	Imipramine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.16	4.16	17.66	17.69
DCNR31D	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	0.13	3.52	2.46	2.46
DCUNFBK	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.15	2.94	1.3	3.15
DCG3M3L	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM36PKZ	PF-3758309	Phase 1	17	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	12.519	12.052	9.734	12.654
DCQRP13	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	9.28	12.02	8.88	13.12
DCCQ10Q	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM48QOT	Artemether	Approved	34	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	17.085	15.387	1.43	5.533
DCMG1QU	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.34	4.18	5.5	1.43
DCTH1LK	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.57	3.01	1.54	1.33
DCMZXUV	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM5UGDK	Mephenytoin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.49	11.49	26.87	26.9
DCVRVAO	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.87	4.9	2.41	9.71
DCTFAHC	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	7.02	7.75	1.4	9.33
DCETO9M	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM6HXTS	Anamorelin	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	14.38	14.38	32.27	32.27
DCLAQA8	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM6KU93	Alvespimycin hydrochloride	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	7	7.254	4.096	8.002
DCEKY8Z	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM6VOWQ	Fomepizole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.75	5.75	8.65	8.65
DCODDKT	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.01	2.08	2.53	1.7
DCWFVW1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	6.36	3.87	2.36	2.18
DC0YANM	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.23	2.4	2.24	2.24
DCPNE7X	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.66	2.66	3.81	3.81
DCQ0X6B	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.05	4.3	2.57	1.46
DCF59TD	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM93L4X	Dexmedetomidine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	32.95	32.95	45.34	45.35
DCIKU5O	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	0.81	2.93	0.31	5.65
DCIQCPL	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMA8FS5	Dronedarone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	20.38	20.38	32.83	32.85
DC92THY	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.79	0.28	1.39	2.96
DCV86GJ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.94	0.96	1.45	1.45
DCE9E4W	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.18	0.07	1.53	0.83
DCZX4UN	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMAYD7O	IT-141	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.46	2.46	3.43	3.43
DCV8855	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	5.69	6.77	2.75	9.48
DCLX0Z9	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMBLM5H	BHV-0223	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	13.83	13.83	29	29.02
DC7RJH6	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	5.43	9.94	10.64	5.94
DCOYWKC	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	16.21	16.21	23.8	23.8
DC2Y8P6	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.61	11.25	9.23	4.85
DCF38PO	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.17	2.71	2.25	2.22
DCDI8OK	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.79	5.45	4.72	2.88
DCGOUB7	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.07	5.16	4.61	4.02
DC7RZCN	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMPN5IH	Guanfacine	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	19.12	19.12	34.19	34.2
DCHMDHU	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DME4RA8	Amodiaquine	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.84	9.84	22.9	22.91
DCOO2Y4	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	17.67	14.92	10.69	15.69
DCIVDY9	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMDI269	Docetaxel	Approved	34	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	13.19	13.01	0.616	5.05
DCOENNU	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMEITAS	SNS-032	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	32.653	27.648	0.864	2.513
DC6SUCL	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMF3MV1	GDC-0980/RG7422	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	12.96	13.235	11.12	12.578
DCFETI2	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFGLXB	Phensuximide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.44	11.44	31.27	31.27
DCHYKG3	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	2.47	2.58	0	9.08
DCCWBWD	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.23	6.24	1.28	8.27
DC5RF1I	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.62	4.31	1.76	4.26
DC1P13M	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMGYBZI	PHA-739358	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.54	6.54	19.37	19.37
DCH9LDW	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.7	4.16	2.92	2.92
DC86TDM	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOL54H	Clopidogrel	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.07	5.07	16.5	16.53
DC8G3IV	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMHZJCG	Pentamidine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	41.43	41.43	61.1	61.1
DCK1VXN	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMINOX3	Vincristine	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	4.21	4.777	2.952	6.015
DC6K7GW	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMKFQJP	Triflupromazine	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	22.4	22.4	38.56	38.57
DCO6XF4	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJPE61	PF-02545920	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.35	11.35	22.43	22.43
DC1BFOC	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMKXDOI	AS602868	Discontinued in Phase 1	3	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	3.058	3.425	0.061	0.154
DC9TQUL	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMKZJ7T	GINKGOLIDE A	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	33.45	33.45	51.21	51.24
DCIQOY6	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLB0EZ	Tamoxifen	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	17.797	17.671	2.219	6.298
DC0BICP	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	8.36	6.17	1.77	7.62
DCEB8VI	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	6.24	12.55	10.42	6.11
DCO7WUL	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	18.94	18.46	21.42	23.14
DC23P0A	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNE56X	ABT-263	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	16.741	14.477	6.993	6.7
DC8GWAA	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	2.2	6.81	2.89	8.43
DCC8I0G	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOL5IU	Mesalazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	13.96	13.96	27.2	27.21
DC3ECH3	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.22	5.44	0.15	6.05
DC0CBU4	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	11.5	11.91	3.73	8.98
DCC1JXJ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	7.67	7.89	2.13	6.27
DC2Z4XG	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.82	6.17	4.11	7.11
DC7IJ0V	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.57	2.92	2.6	3.31
DCPXMZ9	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	7.44	9.24	3.15	7.7
DC4QHED	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	6.37	7.35	0.83	5.97
DCM1H33	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	6.53	6.42	5.09	6.85
DCCXNR5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.47	3.17	1.5	5.6
DC74M4D	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	6.48	6.75	5.06	5.32
DC7AHQP	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.53	6.93	6.61	8.91
DC52B8U	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	11.95	12.01	1.63	3.29
DCZSYQ0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	9.48	10.47	9.18	9.81
DC3WRRS	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMPAJ41	BIIB-021	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	3.24	2.829	1.722	4.552
DC9SBLG	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMPK32V	BMS-754807	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	8.082	12.864	6.749	7.609
DCEQ2J6	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMPP4DT	Trimethobenzamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.46	1.46	10.86	10.86
DC3F6HG	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMPWB7T	Maprotiline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.66	7.66	20.21	20.21
DCDAXOI	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMR8ONJ	Leflunomide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.36	8.36	11	11
DCXLKYH	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMRJFN9	Theophylline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	10.29	10.29	23.25	23.28
DCS7XAD	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.84	8.7	6.58	6.51
DC2HEMH	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS0PND	Brincidofovir	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.45	6.45	7.88	7.88
DCZE5D5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	9.49	9.4	3.14	14.43
DCZUPN5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMSG91J	ER819762	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.01	7.16	4.82	3.22
DCRS8Z5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMSG91J	ER819762	Investigative	0	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	6.01	12.8	8.51	8.51
DCPORRP	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMSQZE2	Asenapine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	15.29	15.29	33.92	33.95
DCMRY0I	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	9.37	9.02	6.27	11.23
DCUVXGK	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	27.95	27.95	41.3	41.32
DCUJ8PG	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.85	2.38	1.07	0.4
DCRAJ9Q	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	1.95	3	5.89	5.89
DCZMQQG	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.51	8.63	12.53	12.57
DCU1IQH	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	25.18	19.25	0.67	0.67
DCXRM9O	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.47	8.26	6.58	6.58
DCSPKNB	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.9	2.51	1.48	1.35
DCN5DWM	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1	1.61	0.89	0.32
DCR68GN	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	6.85	6.73	5.22	4.65
DCLTBV5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.53	3.37	4.88	1.48
DCLVHUM	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTX8IZ	Endoxifen	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	16.74	16.74	31.99	31.99
DCM1EIT	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMUF0BJ	CYTISINE	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	20.97	21.696	7.948	8.013
DCKEPJA	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMVDYTG	CPG 52364	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	3.323	8.938	1.719	3.586
DCDZG0E	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMVTHWQ	Silver sulfadiazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.88	2.88	14.38	14.41
DCRJJ10	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.28	1.6	1.02	0.01
DC5UH2Y	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.49	2.65	1.72	1.43
DCQ0SM4	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.08	4.08	17.29	17.3
DCPWG1I	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.3	2.3	3.38	3.38
DC7Y3VC	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	0.06	5.07	3.82	4.42
DCCIOMO	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.53	5.47	6.51	6.04
DCCTON2	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.13	5.66	0.44	0.51
DC9F4RA	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMXCM7H	Cerivastatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.6	3.6	4.55	4.61
DCJC7I1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	4.823	4.575	0.347	4.481
DCWNMXN	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	14.14	14.49	6.97	13.59
DCRF3RC	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMZP7YM	L-165041	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.47	8.47	20.08	20.1
DCVW99F	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.73	1.46	1.08	1.08
DCHVDZN	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.17	3.89	3.36	2.17
DCIYVNH	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	5.06	4.81	12.32	12.92
DC8NACR	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.16	4.15	9.38	9.94
DC12B2O	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	4.29	4.48	8.19	11.83
DCGQ8SN	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	7.01	7.23	10.14	16.31
DCGQFR4	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.63	7.85	1.59	9.75
DCTFVFK	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.1	3.34	4.12	11.82
DC0SVTA	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	9.44	9.52	5.5	13.84
DC3QN74	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	24.45	26.63	20.89	24.61
DCIR0UF	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.84	6.22	3.57	7.95
DCQLMYB	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.4	1.37	1.91	8.3
DC4T2R3	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.03	4.39	10.11	14.3
DCM6MY8	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	7.65	7.53	7.12	13.01
DCHMXVX	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	8.77	8.41	17.65	20.38
DCBHIQZ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	17.99	15.25	13.41	17.66
DCRJQLH	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	9.67	9.23	6.9	10.97
DCW8CRT	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.9	2.09	0.75	5.36
DC5WHWD	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.15	0.82	7.86	14.88
DC8FPFW	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.1	1.59	1.6	8.65
DCDP1Q8	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	13.51	18.3	9.25	16.59
DCBIRCZ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	6.48	6.8	15.21	18.1
DCG2B84	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.54	3.58	7.5	12.15
DC7BFLH	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.69	1.92	5.76	9.33
DCZ6Z2X	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	20.26	22.78	18.51	20.85
DC6OAUB	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.5	4.16	10.59	15.19
DC9YP2G	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.38	2.5	1.09	13.72
DC932MB	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	6.33	3.17	11.1	15.31
DCE2309	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.76	2.04	6.19	10.81
DCZPD8J	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	5.3	6.27	1.02	7.49
DCUI5MH	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.83	2.52	11	15
DC1G1GT	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.25	0.23	9.52	12.83
DCFWUUJ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.98	2.49	7.16	11.9
DCIYXJ2	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	7.36	6.72	7.81	14.38
DC9Z8IP	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.38	4.37	2.15	5.61
DCYGQRW	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.18	1.21	5.87	10.56
DC7U843	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.2	0.83	0.84	9.11
DCLL6ON	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	22.93	26.13	19.85	19.85
DCMAAYH	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.56	1.66	1.11	0.86
DCMTEWP	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.66	4.79	0.44	0.44
DCS7S2U	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.62	3.12	9.28	10.12
DCL7Y0G	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.23	4.71	7.52	12.07
DC5ECRN	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	9.68	11.91	4.47	13.52
DCQB9JS	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.35	2.42	2.42	7.6
DC1GXW1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.36	2.98	0.58	10.37
DCVMJQ6	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.06	2.75	8.04	4.95
DCBAY93	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	7.15	9.81	10.49	13.94
DCMBCYK	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	5.76	7.21	3.33	8.48
DCFZ852	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.31	4.53	7.2	11.35
DCUJXOJ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	8.27	4.9	0.56	7.95
DC3VM0G	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	7.26	7.54	3.18	11.06
DC5UA49	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	16.43	19.71	15.19	17.58
DCSP8J2	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.15	1.13	3.29	8.43
DCMLU56	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.49	3.28	0.98	0.98
DC06VGB	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.33	2.25	9.93	15.14
DC93LHY	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.85	2.95	14.55	17.67
DCEDSJE	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	7.82	7.79	8.15	12.7
DCUBHQ4	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	9.65	9.24	11.36	15.3
DCFGRDD	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	5.98	12.87	11.81	15.29
DCR1TJX	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	9.13	10	3.26	11.49
DCTVIH3	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.07	4.05	7.62	11.98
DCA0IUH	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.44	0.42	9.78	13.85
DC17L6R	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	18.04	20.73	3.03	18.85
DCKS52X	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	5	4.78	11.08	15.75
DC5HO05	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.58	1.91	2.55	0.84
DC1J31K	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	13.62	17.67	8.24	15.76
DCQ2OYW	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	5.29	5.17	2.37	7.76
DC72FKC	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.5	3.29	2.26	7.55
DCNDLIW	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.72	0.74	1.74	5.32
DCGKR47	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.85	5.37	4.43	9.29
DCXC8ZA	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	9.61	12.53	4.52	13.21
DCFEANK	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	5.08	4.8	3.05	8
DCH9K1D	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.34	2.4	1.84	7.28
DC14K0D	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	6.74	6.71	2.22	11.94
DCGD6X4	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	6.18	7.59	3.75	11.63
DCN6ED9	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.2	3.44	3.75	0.06
DCVS7TD	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.7	1.38	1.08	0.46
DC7N05K	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	0.43	3.32	12.88	15.04
DCLGDG3	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.82	6.95	15.82	16.25
DCNWV2J	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	10.65	11.13	8.71	21.8
DCA24FU	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	10.4	10.45	15.64	17.85
DC697WH	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.09	4.03	12.36	15.81
DC0HB0P	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	11.45	12.68	10.31	14.5
DCW1ILJ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.22	4.46	13.49	15.04
DCMZKFN	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	5.39	4.49	13.06	14.03
DCXSUXF	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	9.51	9.53	15.28	16.81
DCEGW23	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	23.7	27.78	4.94	25.74
DC80MMZ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.7	2.56	4.33	4.44
DCREPHS	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	32.62	33.93	20.15	20.15
DCJFFUH	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.64	3.33	5.72	10.72
DCB0I7O	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.03	1.12	0.56	2.27
DCS27DN	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.05	0.41	4.82	7.73
DCW3TTW	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.73	3.68	0.78	5.69
DC0ZVQG	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.38	1.46	1.53	1.58
DCBK9UI	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.69	6.15	0.21	6.64
DCSAP4Q	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.77	5.18	2.05	7.27
DCQVGPL	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.23	1.66	0.01	3.53
DCTATCF	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.62	5.67	0.25	6.86
DCI1YZ7	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.33	3.51	5.35	8.69
DCKVWFQ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	5.77	8.22	2.47	6.23
DCTBWQQ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.22	1.24	0.62	4.46
DC6A5AC	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.32	6.65	0.55	5.67
DCZTHPL	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.88	5.5	2.76	6.92
DCCPGB4	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.57	4.15	3.2	7.22
DC4ADUK	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.34	2.33	1.39	2.52
DC5JBBF	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	14.22	16.06	3.28	18.02
DCQCSBE	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.43	5.22	4.83	4.9
DCD3N8V	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.43	6.69	9.05	12.64
DCRQZ86	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	21.84	23.01	20.79	19.75
DCAHTA9	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	11.26	3.5	15.16	16.22
DCPBXNU	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.56	2.66	5.61	12
DCAZVHM	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	26.91	27.56	12.98	25.53
DCOH8VM	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.11	2.89	9.73	12.45
DC7MCBZ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.17	3.18	9.9	10.87
DCWSSCS	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	0.69	0.79	3.83	10.88
DCPJ3OG	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	3.27	3.27	13.53	17.71
DCOHNUZ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.17	5.8	10.36	13.07
DC7A2G3	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.37	2.17	12.57	15.93
DCTQC52	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.94	4.92	7.69	12.37
DCHGWUP	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	18.06	18.89	9.9	17.55
DCUUUJ6	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	0.5	1.42	5.76	11.3
DC7ZE5U	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.36	3.94	2.05	1.2
DC73KW6	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.4	4.21	2.31	1.04
DC50RVI	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.13	2.95	0.98	0.86
DCHOQ4Q	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.89	2.51	2.35	0.07
DCKPV1A	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.95	1.84	10.95	14.06
DCCANFM	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.5	0.81	0.25	8.82
DCTJGVG	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	7.11	8.44	8.31	13.14
DC8OJYT	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	9.16	9.36	12.69	15.46
DCX1IW7	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.07	2.51	3.88	4.86
DC4PD8L	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	9.17	9.11	11.38	16.4
DCIUMCB	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.19	0.08	10.97	14.59
DCK6RS5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	23.46	23.56	24.81	28.78
DC69RU9	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.2	9.55	1.56	7.78
DCO26VC	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.43	2.96	12.73	15.46
DCBF9MY	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	18.35	17.65	3.1	2.37
DCMK4D7	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.54	4.71	1.67	0.81
DCH5W2A	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.37	3.01	2.75	0.39
DC2CA14	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.28	4.21	2.69	3.25
DC8MVO1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.3	3.38	8.57	15.66
DCUKRQG	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3	9.44	10.22	11.88
DC3QC57	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	7.69	8.28	5.55	15.65
DCE4M13	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.71	2.31	7.33	11.4
DCQ41XZ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	18.18	18.59	5.61	21.61
DCEXRB4	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	10.28	10.26	5.51	15.01
DCJ4RB5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	5.37	7.09	10.74	11.15
DCQAE80	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	12.37	12.12	13.83	19.75
DCFJOD3	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	10.46	11.33	3.77	15.5
DCA0Z42	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	11.76	12.43	3.13	15.94
DC3HLFN	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	16.87	18.4	8.43	20.21
DC9NLCP	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.23	10.55	15.91	16.84
DCZYOQU	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	9.35	9.37	9.27	17.46
DC5DGWE	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	9.94	10.31	10.21	14.57
DCJ0NVY	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	11.77	10.09	34.34	11.14
DC1LSTR	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	14.51	16.02	3.95	16.17
DC8GWJW	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	17.81	18.27	15.96	21.44
DCFHDAU	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	10.57	11.24	3.45	16.37
DCOF3G0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	9.55	7.63	0.71	11.43
DCLHZK0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.94	6.92	3.38	14.89
DCZHNC1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.75	4.32	2.67	10.05
DCU9Q32	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	9.2	6.97	5.48	5.78
DCIS5WG	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	7.74	5.92	0.15	6.62
DC9M9GB	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.79	4.78	3.97	5.55
DC949DQ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	10.67	9.65	9.66	10.3
DCFLRLC	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	6.19	4.28	2.2	4.66
DCXWXCM	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.67	4.9	2.52	5.23
DCPSNVX	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	8.38	6.66	7.73	8.56
DCXT9GC	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	8.02	8.23	12.7	15.71
DCRBUTX	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	6.06	2.71	2.69	5.15
DC13YSB	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	11.88	11.29	13.19	17.58
DCL54WA	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	8.45	8.37	13.82	16.97
DCV3M1I	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	23.99	20.71	9.97	22.51
DCLPPZ0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.57	3.6	0.85	8.32
DCXNBQ0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	8.57	12.03	2.55	13.4
DC8NREV	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	9.92	10.59	5.98	14.3
DCAXXR2	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	15.27	14.53	16.38	19.77
DCQMHPI	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	10.02	11.91	1.82	16.19
DCG6KRX	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	14.18	15.16	14.46	20.34
DCN9MKR	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	21.52	22.43	17.06	23.77
DC0F3DB	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	22.08	23.66	10.42	25.67
DCGEUEJ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.36	4.18	8.64	9.8
DCRN70O	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	10.88	12.2	13.74	17.21
DCCR44N	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	7.47	8.32	15.41	8.33
DCMRUVM	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	10.06	10.51	0.99	11.77
DCBK6ZT	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	10.55	13.42	13.05	16.75
DCUR672	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	8.22	8.76	0.65	16.34
DC12UZ6	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	7.2	6.23	7.25	14.12
DC2CN77	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	15.3	15.87	9.23	19.08
DCMEIY5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.71	9.47	13.86	19.32
DC02XQC	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	6.46	10.02	3.02	10.27
DCTHQ0O	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.63	3.17	2.15	8.91
DCRTG0L	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.83	5.85	6.94	7.56
DCKN2J6	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	18.88	18.86	23.39	19.49
DCV83HO	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	5.98	6.84	1.76	11.18
DCAOUYE	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	6.74	8.59	3.05	12.19
DCP2EGW	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	3.45	3.52	1.96	6.68
DCKSW32	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	16.15	16.91	11.52	20.08
DCELXAQ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	10.41	5.71	5.5	12.29
DCELEVY	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	5.19	4.8	6.36	13.33
DC9AJ7L	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	0.77	3.88	6.66	9.7
DCQVUW2	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.43	3.62	11.31	3.75
DC5EHSD	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	7.54	9.67	1.11	11.36
DCN32GL	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	0.57	0.46	4.08	10.12
DC6QENA	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	3.15	11.53	0.21	12.25
DC631BG	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	9.41	15.43	10.02	5.1
DC6IEOO	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.74	5.48	4.5	4.93
DCZPUJP	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.18	2.08	7.85	13.17
DCG8JG3	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	12.49	11.22	19.17	22.27
DCQGR5Z	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	6.04	8.67	11.98	15.79
DCKTMAI	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.71	3.28	3.81	10.68
DCKTV40	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	11.06	10.09	7.95	14.83
DCO4K1X	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	7.85	7.83	9.34	14.82
DCN0FCN	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	7.81	7.11	5.23	14.1
DCTTJO9	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	11.83	10.5	6.83	16.04
DCFPIIA	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	15.48	15.41	20.26	25.29
DCEGMN5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.52	4.04	5.14	11.53
DCWCVOI	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	12.97	12.97	12.55	18.95
DCHBUCT	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	7.85	7.04	5.74	11.53
DCI057A	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	13.69	12.48	7.99	17.97
DC38Q9O	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	4.93	4.59	7.73	13.17
DCZ590L	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	11	10.76	4.97	17.18
DCLY1M6	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	12.11	10.25	53.85	12
DCBBX9G	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	8.29	7.12	4.83	11.84
DCHBIG2	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	7.89	7.72	6.7	13.28
DCDAWN4	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	5.91	5.09	4.6	11.83
DCB2QR9	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	9.04	8.53	6.65	14.6
DCYZG6H	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	11.67	9.42	10.44	16.55
DCNHMMU	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8.94	8.57	10.25	16.42
DCH3S9D	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	9.05	7.52	9.82	15.04
DCRSEZH	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	15.4	15.99	11.76	18.25
DCA6RV1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.78	2.94	12.09	17.28
DCO77CY	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	10.6	10.43	13.07	20.07
DC4V54L	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	4.11	7.34	5.02	11.69
DC7K0MG	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	9.15	9.69	9.19	14.85
DC29FJP	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.79	3.07	2.83	5.87
DCFSSX6	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	9.93	10.32	13.63	18.83
DC4XTCM	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.57	8.07	5.58	11.33
DCJL27L	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	20.17	19.92	19.2	25.58
DCVDCC9	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	13.83	18.45	14.75	21.63
DCMJTED	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.56	12.16	14.06	15.64
DCV9UV4	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	16.39	16.54	19.97	24.5
DCPBTAA	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	5.17	7.4	11.15	14.22
DCDGA0L	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.11	2.78	44.37	3.62
DC7HJMU	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	7.05	7.37	2.7	13.58
DCOXZUA	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	14.7	15.35	13.93	19.88
DCMC99S	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	7.59	9.15	2.48	10.32
DC5VA04	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	12.88	13.02	11.72	18.18
DCMTY2S	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	4.91	10.17	4.04	12.64
DCLXN1R	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.58	2.42	3.9	2.5
DC1JZD7	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.3	3.38	1.48	2.37
DCYONGQ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	114.72	106.451	10.91	15.773
DC7HGEQ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.42	4.22	0.37	2.52
DCRA9IY	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.35	3.71	0.86	1.81
DCEGF2U	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.19	1.04	0.59	0.27
DCC47B5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.14	9.31	7.55	5.63
DC0LXEE	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	9.63	11.83	5.99	4.25
DCSEVUH	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	8.04	9.43	7.26	14
DCPB73B	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.08	5.32	6.41	7.33
DCDZPOW	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	5.1	5.32	2.52	11.23
DCPGCMQ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	2.06	10.43	11.9	12.88
DCKD99J	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	7.72	8.01	1.42	12.37
DCL5PPA	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	8.68	7.6	2.62	12.04
DCGV8E7	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	6.41	7.25	3.41	11.51
DC3P7GW	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	9.98	7.51	3.01	10.73
DCRJ5AZ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	7.28	6.71	0.21	11.85
DCX2HO7	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	8.49	8.17	4.69	13.15
DCLEAIF	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.38	4.2	2.77	9.51
DCYL316	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	7.6	8.59	0.72	11.34
DC4S44I	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	13.77	11.71	4.87	14.53
DC7OTQE	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	15.63	15.99	20.55	21.99
DC92FJ5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	8.22	7.76	4.41	12.89
DCH1QF2	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	16.51	14.35	33.05	14.99
DCNH31A	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	10.86	12.32	1.84	14.48
DCJVISE	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.37	5.4	3.07	9.9
DCAIQR2	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	12.95	12.9	9.02	19.95
DCRAIJC	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	12.3	11.37	10.09	15.64
DCCZBWU	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.64	7.76	7.36	14.9
DC5BUZQ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.63	4.92	11.52	7.08
DCK8T8X	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	9.3	8.99	10.72	17.22
DCJ3JPL	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.7	14.89	13.08	14.35
DC1IQAG	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.66	0.73	0.89	1.24
DCNTZD1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.02	0.36	0.9	1.12
DCM2BSB	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	3.16	1.39	0.05	1.07
DCX8F1X	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	6.03	0.17	1.7	1.7
DCVZK22	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	7.17	7.01	5.19	9.65
DCEJ0I0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	9.92	11.91	2.55	9.75
DC6B7J1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	4.41	4.64	5.38	10.76
DC99D59	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	5.15	4.53	4.43	9.35
DC6EYWZ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	7.86	6.77	4.51	11.45
DC3BZZM	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	9.89	12.86	2.32	12.59
DCJCPPS	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	8.43	7.46	6.37	13.69
DCJDRIR	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	13.36	11.77	8.04	16.06
DC1P9RZ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.56	4.18	3.08	9.23
DCSK9RL	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.33	2.46	0.9	7.42
DCX63AB	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	9.82	9.3	6.5	13.48
DCKIF96	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	13.45	17.07	8.24	18.98
DCM4DWY	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.83	5.32	3.79	7.59
DCMLM2Y	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	9.57	9.34	11.58	16.81
DCRUBB6	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	5.94	3.04	0.47	7.63
DCDX2E6	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.75	0.7	65.48	0.97
DCJW0L0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	0.89	5.41	0.61	7.9
DCW9K9E	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	12.12	11.79	8.94	15.11
DCFCGM5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	9.73	10.22	7.37	13.96
DCUB2MT	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	8.88	7.01	4.51	12.46
DCOFKPH	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.2	6.37	4.72	11.2
DCUZS0S	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.69	3.54	2.44	8.65
DC0L9XJ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	6.09	1.42	5.1	10.04
DC9EN77	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	3.88	4.77	2.31	5.24
DCSMN2R	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.28	5.64	2.03	3.25
DCETV9W	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.5	3.78	2.5	1.81
DC3WBS1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.18	2.5	1.27	1.18
DCBGK5Y	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.1	3.06	10.88	14.66
DCVT3OI	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	14.72	16.61	5.33	19.03
DCK04LM	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	8.06	8.44	10.01	16.04
DCYLYV6	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	3.38	4.47	10.82	12.95
DC9TDN7	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	6.08	6.3	6.58	13.1
DCVUDQ8	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	7.67	13.15	5.98	15.04
DC7WFAI	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	5.04	4.29	3.7	10.32
DCLRN0Z	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	11.05	10.33	7.48	15.87
DC98ZPQ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	15.73	16.5	15.69	21.62
DCX2GQ8	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.51	7.32	26.95	9.19
DC33XGD	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	14.74	15.12	9.46	18.25
DCAMBJA	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	17.91	19.65	10.39	20.9
DCZPDQ3	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	9.24	9	7.75	14.33
DC36TQ7	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	4.39	7.1	5.53	12.06
DCHT28T	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.96	8.79	22.02	9.07
DC2RR4R	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	1.31	8.18	3.05	11.97
DC4J01B	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	16.26	16.21	15.33	21.19
DC2M3XJ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	6.86	6.21	9.59	14.15
DCGASXP	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	11.5	11.8	9.98	16.22
DCGPPPC	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.24	5.21	5.49	13.48
DCHQO4B	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	4.26	1.37	1.82	7.98
DCHM9M2	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.18	8.38	1.44	8.81
DCPA2ZY	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	5.04	4.96	4.35	11.33
DCUW6N3	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	6.07	5.35	6.98	13.97
DCADS4G	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	5.57	5.62	0.45	9.74
DCZBWR7	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	9.38	9.14	7.87	14.42
DCUODBQ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	1.43	1.39	2.57	5.04
DCCAV6I	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	9.58	10.34	4.59	13.05
DCCSGCB	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	9.54	8.89	5.84	14.5
DCU98CA	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	6.76	6.98	1.77	10.93
DCNSBDH	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	9.46	9.94	1.12	10.33
DCN7XPG	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.27	0.41	22.55	1.25
DCYT7CV	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	2.74	7.28	2.94	9.67
DCH18AH	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	8.43	8.22	6.71	12.15
DCVW1WR	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	2.56	1.35	0.26	8.03
DC6TFTC	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	3.15	3.2	4.53	11.76
DC6VI1Z	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.71	7.82	1.93	10.18
DC4XGZM	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.55	5.54	0.49	0.86
DC439XI	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.81	3.47	1.3	0.58
DCHWNMB	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.14	4.3	5.09	4.91
DC0UNBB	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.99	5.59	4.89	3.97
DCDEMPY	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	9.42	9.75	7.99	13.17
DCMTW0E	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	8.09	4.46	2.4	9.63
DCIKHF6	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	13.51	14.43	6.92	16.19
DCMK9Y9	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	11.84	12.1	5.96	15.35
DCP8IOP	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	7.63	9.52	0.98	11.34
DCYFQOS	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	10.82	12.08	7.62	15.56
DC9K291	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	12.44	12.19	8.34	15.08
DCZTKNF	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	8.03	7.73	2.97	9.44
DCHJI10	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.13	4.37	1.31	8.02
DC60NVT	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	9.78	10.55	4.12	13.7
DCCFMW0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	13.82	12.17	2.86	13.05
DCAPBAE	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.7	6.87	5.23	9.25
DCRS76M	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	8.61	9.44	4.29	12.84
DC916VH	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	5.11	2.99	43.82	2.55
DCXCA3V	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	11.62	12.37	7.17	15.99
DC6WQ7G	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	8.28	8.53	7.18	11.96
DC0RRZX	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.27	6.36	0.67	8.08
DCJMWA6	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.66	10.89	1.27	10.43
DCPXSYD	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	8.81	5.07	0.15	8.53
DC3DXJR	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	17.11	19.56	5.34	19.43
DCEYVAK	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.27	7.33	9.59	1.53
DCS8LO1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.82	7.74	6.02	2.29
DC696X1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.98	2.57	10.86	12.51
DC1DDQ1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.48	12.01	10.57	13.7
DCHTTY5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	10.22	12.29	18.66	19.17
DCLPMDM	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	25.81	25.33	28.97	25.53
DCD6ULY	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	17.66	17.62	22.38	24.99
DCQ97H9	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	13.48	14.02	13.78	18.21
DCNYKAI	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	12.41	15.13	16.74	16.97
DCNDJ48	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	17.49	16.61	19.19	20.5
DC4LTRP	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	10.68	12.15	12.54	12.41
DCGV3UZ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	14.79	14.28	20.33	21.98
DC82UBL	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.69	7.41	12.34	13.15
DC9ZVQB	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	19.68	19.91	21.1	23.73
DC9GIIF	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	15.03	18.02	19.49	21.49
DC61CRJ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	9.11	15.58	19.33	19.32
DCBOLHQ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	17.23	17.06	19.2	19.24
DCQBEQC	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	10.89	17.35	21.99	22.93
DCZ1MPD	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	13.31	12.53	46.93	15.74
DCO3GRW	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	15.52	17.33	19.88	20.91
DC2DTRI	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	16.14	20.68	24.77	26.75
DCEFV8W	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	12.4	12.54	14.06	17.03
DC7XKKZ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	6.49	9.56	11.45	12.89
DC8ODSZ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	11.53	11.21	18.56	21.89
DCPQ91K	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	12.29	12.12	19.71	21.31
DC0U3H4	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	7.58	5.26	10.93	15.3
DCSWNY4	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	3.25	10.29	8.37	9.7
DCNFQCE	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	9.78	9.58	7.27	22.12
DC0F6BE	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	14.84	13.03	15.46	13.41
DC6050G	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	5.81	5.28	1.47	15.01
DCIL0Q7	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	4.25	5.15	7.79	12.82
DCUMWSL	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.25	5.24	6.99	7.87
DCMS3G1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	6.97	7.51	1.52	10.88
DCDNCMR	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	15.03	14.15	6.61	16.83
DCNW4H8	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	16.52	16.47	11.54	17.95
DCSWLF6	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.43	0.97	1.02	1.94
DCDEF6R	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.36	1.23	4.41	10.94
DCS1LNE	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	11.28	15.3	7.73	17.27
DC33CRL	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	9.76	9.91	12.24	19.97
DCTL9GX	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	3.47	2.58	1.92	9.55
DCFX1NM	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.31	7.87	3.98	10.31
DCPVDEH	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.44	5.4	5.77	6
DCAPM1C	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	7.49	8.91	2.84	9.38
DCLFJL7	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	5.21	6.09	2.73	7.81
DCF5CU4	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	17.36	15.36	10.74	16.06
DCDJ1T7	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.91	6.11	0.69	7.05
DCEPJYA	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.6	4.67	0.54	6.15
DCXNNM6	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	8.53	10.93	4.12	9.47
DC5OS2F	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.71	2.48	3.79	5.49
DC7D6B0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	5.72	7	2.68	9.24
DCTCMHB	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.55	2.36	50.09	1.47
DCLM3CF	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	9.05	10.3	2.31	10.85
DCL0SP1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	8.26	8.92	4.05	10.75
DCCER6X	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	11.03	10.41	1.2	13.11
DC513GB	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.35	6.33	2.6	10.03
DCW6RCC	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	1.76	2.75	0.26	5.31
DC7BSAB	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	7.08	8.13	0.01	8.76
DC5MKNF	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.64	4.58	3.94	5.54
DC2HNV6	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.49	4.28	3.43	3.7
DCKBY92	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.5	4.27	1.61	2.71
DCYOP9S	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.29	3.89	1.3	4.81
DCW2NC9	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	7	7.62	8.26	9.66
DCR7ES1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	9.71	11.47	7.59	10.7
DC6U5RO	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	9.66	12.45	11.1	11.92
DCDTD20	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	10.96	14.06	6.94	11.67
DCCO3KL	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	2.41	3.49	4.05	5.84
DC4B7EZ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	7.06	8.25	6.07	7.21
DCEMDPV	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	8	12.96	11.87	12.93
DCXET5M	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	9.12	12.09	8	11.45
DCL0QJR	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	9.03	8.8	5.43	5.85
DCJ9X6E	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.85	2.84	0.46	4.2
DCKIRZX	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	6.19	6.43	2.28	5.46
DCRAVKK	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	8.86	12.8	9.83	9.87
DC58857	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.64	3.8	2	2.88
DCK864R	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.78	3.71	0.47	3.21
DCVR6RL	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.88	5.24	6.8	7.3
DCNGAI7	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	4.16	4.68	1.05	3.25
DCI6KVJ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	10.73	9.93	1.91	3.16
DC5DZDR	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	15.51	11.72	17.2	12.16
DC23MYV	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	15.27	16.69	0.39	16.12
DCOO6US	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.76	2.69	2.52	0.97
DCR9QWK	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	15.41	15.23	0.06	17.38
DC1R0WB	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.6	6.35	1.56	4.82
DC3NOJS	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.43	3.13	1.47	0.23
DCWFX3A	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.92	4.44	5.33	2.35
DCDY5MC	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	6.33	3.75	4.25	13.15
DC3SELN	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	11.47	11.76	1.26	16.41
DCQ8OZP	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	6.88	6.73	1.74	12.97
DCMLQA1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	4.95	3.4	0.32	9.8
DCXGQEA	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	12.52	12.24	2.96	18.04
DCT4IYJ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.24	5.21	1.47	11.83
DCHE3LF	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	6.46	7.03	3.36	1.29
DC0O79H	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	14.2	15.92	2.24	15.42
DCOD5RV	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.44	2.2	3.18	3.18
DCW6IVX	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.55	2.15	0.42	5.68
DCHPOEW	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	10.82	10.47	5.63	18.56
DCZ4VSS	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	6.05	8.43	5.02	13.74
DCW6K0Q	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	5.94	5.98	3.95	13.41
DCMSKLL	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	11.27	11.66	1.35	14.63
DC1OGA1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	3.18	3.46	0.2	10.56
DC0OQ7U	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMSG91J	ER819762	Investigative	0	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.33	4.38	5.1	0.62
DCNPW8U	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	5.33	7.37	1.97	13.67
DC56YTG	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	9.43	9.78	14.77	17.88
DCUGO62	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	3.36	7.35	11.19	14.53
DCYDBUS	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	15.6	14.42	1.31	16.62
DC6AW92	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.88	8.13	10.23	14.2
DCDSZ42	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	4.96	4.83	4.12	10.61
DCL6JWO	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	8.06	7.53	10.49	15.97
DCQ6LRR	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	6.57	7.91	8.66	11.45
DCD42TG	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	9.51	8.7	2.8	10.4
DCT14BL	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	15.66	16.02	21.48	25.12
DCCNI9P	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	24.91	23.92	22.49	27.29
DCC43XJ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	15.98	17.98	14.7	20.89
DCJUW32	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.48	12.5	16.93	18.23
DC7OC4J	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	10.74	13.99	1.42	14.76
DCI3ME4	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	10.05	12.91	15.67	18.38
DCJK4ZK	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	14.8	15.9	32.55	17.27
DCLOREQ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	11.55	14.89	10.42	17.95
DCHU4T8	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	14.16	14.25	18.17	21.35
DCCVKHI	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	3.11	1.42	2.98	9.87
DCRZ595	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	10.2	8.99	11.12	16.75
DCVV6L2	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	12.24	12.2	17.03	21.96
DCUEBAO	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.18	4.12	7.02	12.04
DCK5AQU	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	4.46	3.15	6.63	11.16
DCELEML	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	3.78	3.76	1.64	7.61
DC7QV99	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	8.63	18.82	11.77	8.7
DCLUVUO	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.93	14.22	12.39	6.45
DCE0ZJ3	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	12.97	18.6	11.92	11.92
DCLBITW	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	12.98	15.36	7.7	5.4
DCD3313	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	13.36	11.05	6.74	3.84
DC9ISN2	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	3.28	4.48	2.47	0.09
DCC66B5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	9.38	17.05	4.83	9.93
DC3OZ62	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.07	3.58	0.64	0.08
DC1JR95	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.76	2.4	1.02	0.92
DC4MNJ9	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.68	5.01	1.94	0.78
DCRDV2Q	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.7	6.12	3.82	3.82
DCB9XNJ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.55	7.45	4.89	4.48
DC61U85	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.43	2.87	1.36	1.13
DC4TL3L	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.12	1.58	0.46	0.76
DC1P1GU	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.27	2.92	2.77	8.28
DC8AQD0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.76	3.08	8.07	13.17
DCN5SZD	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	3.34	2.38	1.2	7.18
DCF60S1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	0.93	0.62	1.73	6.55
DCTW5RS	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	2.22	1.31	4.93	10.82
DCAE0XS	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.99	1.61	0.24	7.8
DCQGCWH	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.49	0.25	4.23	9.47
DC7PHE7	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	5.48	4.92	2.4	9.9
DCU12K2	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	2.52	1.87	0.37	3.28
DC26REZ	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	2.44	1.97	0.54	7.83
DCCPEB2	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	6.1	2.71	65.47	3.72
DC3EFXI	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	4.22	4.18	5.29	11.49
DCPXP0A	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	4.05	3.49	0.65	8.98
DCTA3FY	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	3.1	2.89	6.15	11.05
DCK2PVR	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	5.61	5.55	0.97	8.24
DC97O66	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.97	11.35	6.47	6.95
DCUMC3M	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.79	1.41	1.43	2.28
DCEW2EM	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	7.21	10.56	9.94	11.15
DCK2BTG	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.85	6.91	0.69	3.67
DCOHUCK	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.25	2.32	5.13	4.97
DCIMAN2	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.77	4.45	1.59	6.13
DCO32AL	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	4.29	4.37	14.13	18.56
DCA99WV	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	3.07	3.02	7.9	9.1
DCFWLRV	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	40.2	30.3	7.43	5.29
DC8HPTY	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	8.07	8.12	12.34	17.31
DC34TGX	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	12.06	5.52	8.45	11.4
DC4W22K	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	15.83	15.55	0.46	13.32
DCBUGNW	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	12.02	11.99	11.69	18.46
DC8RO0I	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	22.72	23.4	6.2	20.28
DCDD10G	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	15.58	15.66	23.48	27.32
DCESF18	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	16.84	16.73	7.78	20.87
DCT8Q1V	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	16.99	17.11	17.76	21.11
DCG06CM	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	9.86	9.72	9.43	14.58
DC92V6B	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	13.79	19.41	23.08	24.38
DCU3RBR	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	14.92	15.02	16.33	22.1
DCNLO3Y	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	14.01	13.83	0.27	5.6
DCC56V2	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.75	3.17	59.29	5.46
DC2AJ5Q	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	11.75	15.41	14.95	18.99
DCS2U0L	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	10.72	10.29	15.51	21.11
DCHH4ZL	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.63	0.31	1.99	7.61
DCL76KL	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	13.35	13.15	17.79	25.16
DCO223Y	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.99	1.03	6.97	10.41
DCKW865	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	5.69	4.55	12.44	15.21
DC36GW4	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	14	17.22	11.19	16.61
DCEDVX5	DMP6G8T	Topotecan	Approved	34	DMP6SC2	Irinotecan	Approved	34	.	.	.	.	Relapsed Small Cell Lung Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCJGINW	DMP6G8T	Topotecan	Approved	34	DMS104F	Temsirolimus	Approved	34	.	.	.	.	"Genital Neoplasms, Female"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCXOVQG	DMP6G8T	Topotecan	Approved	34	DMUNJZB	UCN-01	Phase 2	21	.	.	.	.	Fallopian Tube Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCYHSU1	DMP6G8T	Topotecan	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCQ5WST	DMP6G8T	Topotecan	Approved	34	DMR9PCT	VX-970	Phase 1	17	.	.	.	.	"Carcinoma, Non-Small -Cell Lung"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC96C9E	DMP6G8T	Topotecan	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.38	1.23	15	15.37
DCW2QXV	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.87	3.03	10.85	11.34
DCK95OC	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	12.06	11.68	6.26	18.61
DCFKX6L	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.07	1.58	1.73	1.87
DC21YB4	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.62	3.99	9.76	13.06
DCQH694	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.06	1.91	2.34	8.12
DCL9DWF	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	9.36	9.04	10.15	14.53
DCYVPIH	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.1	7.48	12.32	13.14
DC23Q9V	DMP6G8T	Topotecan	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.23	2.21	0.53	3.26
DC47SHB	DMP6G8T	Topotecan	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.72	7.99	6.31	8.3
DCJY3VL	DMP6G8T	Topotecan	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.73	4.53	6.3	6.32
DCPW21K	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	8.78	15.34	15.05	15.06
DCPC2BJ	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.02	7.48	7.96	7.65
DC2V2LW	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	5.05	5.8	5.5	5.53
DCC54NP	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.35	11.72	11.91	11.59
DCMODTR	DMP6G8T	Topotecan	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.46	6.69	4.67	8.85
DC2PFRZ	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.53	1.14	1.88	7.53
DCRZL02	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.22	3.39	6.04	11.65
DCXVPTH	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.88	3.78	4.5	7.01
DCHTJVO	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.26	5.88	3.89	5.41
DC5IYT7	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	4.59	4.07	10.28	12.52
DCHYCI4	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.84	3.98	9.46	11.88
DCFKOU7	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.94	5.24	3.94	10.52
DCDUA7M	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	8.56	8.47	11.34	13.57
DCTJT6N	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	8.01	7.96	8.94	16.73
DCRUGXC	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.32	11.51	7.68	14.3
DCM5AYI	DMP6G8T	Topotecan	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	5.61	5.43	2.5	5.66
DCCSSED	DMP6G8T	Topotecan	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	11.66	10.75	6.74	7.23
DC5COY2	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.74	2.54	8.14	12.19
DC4UEBS	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.66	3.62	1.27	9.92
DCAF5LU	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	4.1	4.43	2.23	10.56
DCGVQFA	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.84	6.84	8.91	10.87
DCH0I2C	DMP6G8T	Topotecan	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.08	5.37	1.63	4.47
DCWABDW	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	14.24	13.97	21.05	23.1
DC4E407	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.53	4.24	10.78	14.43
DC4AXUJ	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.93	1.23	6.5	8.9
DCXVDME	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.63	2.59	3.39	7.84
DC0K9WT	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.98	11.56	2.61	6.48
DCBV4UX	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	10.35	10.6	10.04	10.1
DCXEPOI	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.96	4.66	5.52	5.24
DCWPAP7	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.19	2.98	3.04	3.19
DCJPO4J	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	11.56	12.7	12.85	12.58
DCW4NJU	DMP6G8T	Topotecan	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.11	4.56	3.61	4.34
DCFQ8Q4	DMP6G8T	Topotecan	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.37	2.14	0.77	3.91
DCQ768P	DMP6G8T	Topotecan	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.84	2.61	6.81	8.39
DCT2YGY	DMP6G8T	Topotecan	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.39	0.46	3.76	4.45
DCKLZH0	DMP6G8T	Topotecan	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.09	2.04	2.66	2.68
DCVP8UA	DMP6G8T	Topotecan	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	6.85	5.39	13.08	6.92
DC2PHNM	DMP6G8T	Topotecan	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	10.19	11.33	5.51	11.69
DCG7HK6	DMP6G8T	Topotecan	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.86	8.97	10.05	10.99
DCB2JJN	DMP6G8T	Topotecan	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	7.8	5.92	0.64	6.43
DCYQDCC	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.39	0.1	6	10.46
DC6TAOE	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.44	4.47	6.18	6.84
DCLKC97	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.58	5.64	3.45	8.02
DCJZP37	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.43	3.5	2.82	3.47
DCBG3SN	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.53	3.21	4.25	9.64
DCIRBI7	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.42	4.21	5.37	14.16
DCMXFXM	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	10.85	9.9	2.23	8.1
DCSYELD	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.2	1.65	2.93	6.36
DCRBDG0	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.38	7.76	4.65	12.76
DCRZ96R	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.05	3.64	2.59	9.75
DCEGDPR	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.29	0.27	6.66	8.83
DCL6352	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.06	2.02	5.89	8.85
DCGE7O7	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.54	6.12	9.5	12.46
DCXHHRF	DMP6G8T	Topotecan	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.66	7.2	4.18	7.29
DCFU837	DMP6G8T	Topotecan	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.63	3	0.62	2.4
DC0B4DZ	DMP6G8T	Topotecan	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.23	3.08	3.23	8.3
DC0A5IB	DMP6G8T	Topotecan	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.36	3.79	7.21	9.97
DCKXV7I	DMP6G8T	Topotecan	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	4.84	4.77	6.15	11.41
DCOMDCG	DMP6G8T	Topotecan	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.94	2.45	2.66	5.5
DC4FWJL	DMP6G8T	Topotecan	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	8.14	9.77	8.32	10.35
DCPAHAH	DMP6G8T	Topotecan	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.2	3.87	1.67	1.54
DC79K4M	DMP6G8T	Topotecan	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.93	4.61	12.5	13.82
DCSQN9W	DMP6G8T	Topotecan	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.06	5.96	9.48	9.95
DCAE7XG	DMP6G8T	Topotecan	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.38	0.08	6.5	7.44
DC8GNGX	DMP6G8T	Topotecan	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.99	1.42	2.9	4.91
DC1X243	DMP6G8T	Topotecan	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.15	3.4	7.48	9.03
DCIPDNP	DMP6G8T	Topotecan	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.92	2.45	1.68	3.43
DC0ZEKI	DMP6G8T	Topotecan	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.4	3.64	0.96	5.69
DCDYH3F	DMP6G8T	Topotecan	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.29	1.87	3.04	5.67
DC7KLBQ	DMP6G8T	Topotecan	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.01	0.34	2.88	6.92
DCWF4HD	DMP6G8T	Topotecan	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.96	4.18	1.61	8.87
DCF2LB2	DMP6G8T	Topotecan	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.83	6.35	5.4	8.24
DCZMDHY	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.56	4.14	13.11	14.83
DCKOUS6	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.72	5.2	12.79	13.98
DCII00O	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.28	0.61	4.49	7
DCZWDU0	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.18	4.3	5.68	12.65
DCVIP3C	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.53	0.5	5.05	7.31
DCNVY2B	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.7	3.53	11.68	12.51
DC7MRWM	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.11	2.13	6.52	8.39
DCDPBVQ	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.29	2.47	7.16	7.69
DC10XIY	DMP6G8T	Topotecan	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	8.49	7.03	1.99	4.82
DC9EVWI	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.84	3	4.11	5.39
DCY4X66	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.17	0.62	0.34	0.36
DCKGA0N	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.29	5.16	1.17	6.37
DCL9W04	DMP6G8T	Topotecan	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.57	6.74	6.72	9.87
DCOTE7T	DMP6G8T	Topotecan	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.5	7.94	6.66	8.17
DC2DTSN	DMP6G8T	Topotecan	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	12.03	15.65	8.11	13.85
DCM7LBD	DMP6G8T	Topotecan	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.62	3.15	0.46	2.76
DC6UKR0	DMP6G8T	Topotecan	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	6.06	7.52	6.11	6.93
DCFYBVP	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	5.8	2.27	10.21	13.62
DC14B5H	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.46	5.43	8.49	10.62
DCEOX6C	DMP6G8T	Topotecan	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.56	2.43	0.38	0.73
DCH2QDH	DMP6G8T	Topotecan	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.91	1.01	0.2	0.15
DC7QZZY	DMP6G8T	Topotecan	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	5.32	3.54	1.32	1.97
DC1CO3X	DMP6G8T	Topotecan	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.21	3.28	10.14	12.31
DCAL1IK	DMP6G8T	Topotecan	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.1	2.85	8.15	9.87
DCDXGKV	DMP6G8T	Topotecan	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.82	1.21	4.02	7.87
DCLQH29	DMP6G8T	Topotecan	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.57	1.66	8.48	10.4
DCG2PT3	DMP6G8T	Topotecan	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.55	2.15	4.02	5.82
DC6NEVT	DMP6G8T	Topotecan	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	5.81	9.03	7.85	10
DC4KCIJ	DMP6G8T	Topotecan	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.55	0.89	1.14	2.24
DCWKEGY	DMP6G8T	Topotecan	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	10.37	7.42	2.82	7
DCSWPZC	DMP6G8T	Topotecan	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.18	0.89	3.91	5.69
DCUQ6GX	DMP6G8T	Topotecan	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.41	0.79	0.3	2.39
DCB2ET0	DMP6G8T	Topotecan	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	9.72	9.75	4.09	4.58
DCMOS7M	DMP6G8T	Topotecan	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.08	1.29	0.1	1.68
DCRXOFP	DMP6G8T	Topotecan	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.78	1.4	7.28	8.04
DCIBCIY	DMP6G8T	Topotecan	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	8.34	6.79	8.2	8.51
DCOUW8V	DMP6G8T	Topotecan	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	7.9	5.9	4.11	4.32
DCWQF21	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.67	1.59	6.45	8.99
DCG14VB	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.15	0.46	5.09	6.14
DCLLXR2	DMP6G8T	Topotecan	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	7.63	0.44	1.32	2.98
DCNJOYT	DMP6G8T	Topotecan	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	5.84	4.44	4.61	5.47
DCDCZCL	DMP6G8T	Topotecan	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	3.27	3.3	1.96	4.15
DCF1X44	DMP6G8T	Topotecan	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	17.11	17.11	26.94	26.98
DCUTNAU	DMP6G8T	Topotecan	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	6.07	5.85	10.46	10.54
DC9IP2A	DMP6G8T	Topotecan	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	8.35	9.83	5.92	9.72
DCGYU9B	DMP6G8T	Topotecan	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	12.02	11.67	5.61	10.79
DCGQPS1	DMP6G8T	Topotecan	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.36	6.4	5.5	8.06
DCHBDZ4	DMP6G8T	Topotecan	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	14.58	13.23	4.66	15.14
DCEPOLH	DMP6G8T	Topotecan	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	7.63	9.13	1.26	7.68
DCAQEQW	DMP6G8T	Topotecan	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	15	21.84	8.59	17.18
DCZN7EW	DMP6G8T	Topotecan	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	10.91	8.14	1.5	6.31
DCUPNPP	DMP6G8T	Topotecan	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.23	10.18	2.07	5.61
DCHQ8IZ	DMP6G8T	Topotecan	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	9.33	10.1	8.43	10.78
DCDIGJD	DMP6G8T	Topotecan	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.06	0.84	0.65	1.41
DCYCKWD	DMP6G8T	Topotecan	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	10.86	7.07	5.02	5.9
DC5AP68	DMP6G8T	Topotecan	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.59	7.09	6.81	7.9
DC7LUGN	DMP6G8T	Topotecan	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	5.63	3.03	1.63	5.5
DCW7HGT	DMP6G8T	Topotecan	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	6.89	7.74	7.11	7.75
DCP4V87	DMP6G8T	Topotecan	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	3.26	6.73	5.84	6.02
DCGO9UQ	DMP6G8T	Topotecan	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.34	1.81	1.52	1.65
DCAP53I	DMP6G8T	Topotecan	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.95	5.66	3.5	6
DC266TN	DMP6G8T	Topotecan	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	6.91	8.49	8.43	8.89
DCJNUDL	DMP6G8T	Topotecan	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	10.9	10.83	10.61	10.98
DC1RAZQ	DMP6G8T	Topotecan	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.58	3.09	3.74	4.49
DC35OJD	DMP6G8T	Topotecan	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	3.25	1.01	1.47	2.97
DC2119F	DMP6G8T	Topotecan	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	8.57	7.54	9.98	10.1
DCRDIFZ	DMP6G8T	Topotecan	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.2	1.63	1.54	2.06
DCSPNZJ	DMP6G8T	Topotecan	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	3.01	2.42	3.4	3.78
DCMSXHM	DMP6G8T	Topotecan	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	9.2	9.2	18.07	18.07
DCPK3JL	DMP6G8T	Topotecan	Approved	34	DM15HL8	Clindamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	9.8	9.8	18.59	18.61
DC5A3IM	DMP6G8T	Topotecan	Approved	34	DM1AGXN	Paromomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	1.64	1.64	10.85	10.85
DC3ZOB0	DMP6G8T	Topotecan	Approved	34	DM1BV7W	Aliskiren	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	6.46	6.46	17.54	17.56
DCT6GKK	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	20.71	20.28	0.92	26.62
DCJQZ42	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	6	5.49	3.3	11.69
DC32I62	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	10.2	7.38	3.4	9.93
DCBPP1W	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	6.18	5.4	5.18	10.83
DCFACZZ	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.37	2.41	2.08	8.24
DC2PNT8	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.95	1.74	3.57	7.48
DCLQDZE	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	7.16	6.25	2.33	9.89
DCN6XJ7	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.51	6.1	0.89	9.65
DCRV22A	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.17	4.92	3.78	9.92
DCQAYUQ	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	12.29	15.77	10.4	18.66
DCOFR51	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	1.22	6.9	3.01	9.27
DC5RN2I	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	10.71	9.8	6.42	13.16
DCKTDYR	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.66	3.59	1.77	6.14
DCELR9H	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	8	9.67	4.72	13.06
DCTYW79	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	0.68	5.56	6.58	9.63
DCO69YY	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.05	3.29	4.77	9.25
DCZ59ZJ	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	7.14	9.07	1.63	8.08
DCJY6CJ	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.71	1.44	3.1	5.87
DCELTWO	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	0.43	1.81	9.94	10.58
DC1GPD7	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	9.36	8.37	6.07	12.39
DCBQYW1	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	8.91	8.21	6.7	14.38
DC4XMU3	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.21	7.21	5.37	9.95
DCO3BOQ	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	5.73	4.07	7.86	13.81
DCDPZM0	DMP6G8T	Topotecan	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.48	12.72	6.76	12.16
DCX9JW2	DMP6G8T	Topotecan	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	6.66	4.55	3.99	5.2
DC6DFEF	DMP6G8T	Topotecan	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	11.24	9.33	0.67	8.82
DC7H56D	DMP6G8T	Topotecan	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	11.01	11.67	10.03	11.95
DCNEHVZ	DMP6G8T	Topotecan	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	11.07	11.41	10.51	12.31
DC25LNG	DMP6G8T	Topotecan	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	1.04	2.08	0.16	3.58
DCXSNH6	DMP6G8T	Topotecan	Approved	34	DM2G9AE	Citalopram	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	0.86	0.86	14.04	14.08
DCDZ77D	DMP6G8T	Topotecan	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	5.61	1.46	1.06	2.42
DC0QH2K	DMP6G8T	Topotecan	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	7.1	0.53	1.85	1.85
DCHI5BJ	DMP6G8T	Topotecan	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.76	4.64	1.62	4.86
DCZLZNS	DMP6G8T	Topotecan	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	6.25	4.78	3.08	2.98
DCPLZSI	DMP6G8T	Topotecan	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	0.93	1.51	0.02	1.51
DC32JCJ	DMP6G8T	Topotecan	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	4.33	3.61	2.92	3.29
DCU2CLV	DMP6G8T	Topotecan	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	4.91	3.62	6.74	7.31
DCF8YDG	DMP6G8T	Topotecan	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.07	4.58	2.48	2.5
DCCDE0U	DMP6G8T	Topotecan	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.8	1.9	1.58	1.54
DCFBBKQ	DMP6G8T	Topotecan	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.89	3.68	0.12	2.87
DC6XIC2	DMP6G8T	Topotecan	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.72	5.11	5.42	5.36
DC7WY5T	DMP6G8T	Topotecan	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.95	10.98	8.25	10.25
DCROCG9	DMP6G8T	Topotecan	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.84	7.64	9.23	9.48
DCJ614K	DMP6G8T	Topotecan	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	5.39	5.57	4.51	4.51
DCC017O	DMP6G8T	Topotecan	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	7.73	8.37	7.26	8.67
DC2IQIG	DMP6G8T	Topotecan	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.33	5.05	5.1	5.06
DCF6SEY	DMP6G8T	Topotecan	Approved	34	DM2TUCU	Crotamiton	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	4.9	4.9	14.85	14.89
DCCBT2M	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.6	2.43	2.88	2.54
DC831ZM	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	7.01	3.8	3.5	3.52
DCUQ0N1	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.7	9.57	9.3	9.3
DC0AM0X	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	25.22	21.79	23.65	23.66
DCTVSQ2	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.69	2.32	2.94	2.99
DCKADZ1	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	6.54	9.36	9.55	9.56
DCZ5RAO	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	4.31	4.1	2.52	2.89
DCJ17RG	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	10.99	12.18	12.91	12.95
DCRYZ7J	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.34	2.24	1.5	4.17
DCU1A8D	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	9.71	13.1	13.33	13.37
DCMWQA4	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.42	3.46	3.13	3.14
DCMD550	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.43	4.93	5.32	5.29
DCYL17A	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.47	4.7	4.25	4.25
DCFHSCL	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	7.56	8.92	8.21	8.15
DC8U0Q0	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	11.05	12.07	12.67	12.68
DCZ8HID	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	8.62	9.06	8.9	8.83
DCDXZTZ	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.94	6.86	6.07	6.02
DCJ0SOA	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	8.05	8.56	5.1	8.54
DC0M8YU	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.56	1.84	1.87	2.13
DCAZFVP	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8.92	9.52	8.28	8.53
DCC5PAB	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	3.48	4.1	3.96	7.19
DC4LZ7Z	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.53	8.47	8.36	8.37
DCJB1IG	DMP6G8T	Topotecan	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	6.66	2.79	3.2	3.16
DCI3FBW	DMP6G8T	Topotecan	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	6.57	2.16	4.46	5.74
DC1U9BW	DMP6G8T	Topotecan	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	10.74	9.57	3.4	8.11
DCQB8NQ	DMP6G8T	Topotecan	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	9.29	7.95	3.51	6.6
DCR9AM2	DMP6G8T	Topotecan	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.36	4.09	3.74	4.68
DCMHL31	DMP6G8T	Topotecan	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.01	6.43	7.12	10
DCY4GRK	DMP6G8T	Topotecan	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.54	8.09	7.84	9.74
DC14MIJ	DMP6G8T	Topotecan	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.18	2.81	0.15	3.69
DCRTPF4	DMP6G8T	Topotecan	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.75	8.09	8.93	9.4
DCNCZFO	DMP6G8T	Topotecan	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.53	3.26	5.28	6.46
DC51OL4	DMP6G8T	Topotecan	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	1.16	1.62	0.17	2.17
DCQ3W5L	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.07	7.1	7.74	11.35
DCJPHFZ	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	5.93	4.39	6.79	10.9
DCQVINH	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	5.09	2.76	5.18	8.36
DCS485X	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.79	1.99	3.29	5.57
DCGB6G4	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	5.44	5.34	1.91	10.3
DCLJRLI	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	4.94	7.86	11.42	13.85
DCXVRJC	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.06	1.41	0.21	5.63
DC8X9XO	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.36	3.06	5.24	7.42
DCT6ZP7	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	5.62	8.67	6.72	10.2
DCCHMAX	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	2.8	4.17	4.03	4.56
DC7EZMP	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	3.39	4.33	9.52	10.22
DCVUTTJ	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.94	5.27	2.18	3.28
DCUCO7M	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	5.91	5.35	4.48	6.78
DC6DQRB	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	6.13	6.61	1.42	8.98
DCJQZTD	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	1.62	8.44	5.55	6.18
DC1O210	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.11	1.36	2.59	3.2
DCYOPYQ	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.52	2.61	2.6	5.62
DCEGB43	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	9.72	12.18	9.23	12.97
DCJ7NF1	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.27	4.37	6.24	8.14
DCYI29S	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.21	4.3	1.33	2.35
DCGJXJA	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.49	5.75	7.46	9.83
DCBEKBF	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.13	3.43	6.29	8.76
DC4MBOD	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	14.14	12.49	8.23	14.64
DCXH2KT	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.05	3.96	6.54	8.03
DCL5U9T	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	3.54	5.02	5.79	7.73
DCMQJ51	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.78	7.02	5.06	5.76
DCQPSNL	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.87	8.03	8.18	8.89
DCQS5F5	DMP6G8T	Topotecan	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.43	0.99	3.3	4.1
DCPM070	DMP6G8T	Topotecan	Approved	34	DM3JCVS	Terazosin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	0.24	0.24	12.25	12.29
DCA3ET4	DMP6G8T	Topotecan	Approved	34	DM3VZJQ	Chlorphenesin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	28.14	28.14	35.72	35.76
DCGY7GB	DMP6G8T	Topotecan	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	1.76	3.59	1.44	7.02
DC7QUPF	DMP6G8T	Topotecan	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	1.33	2.77	4.03	7.67
DCJ8H74	DMP6G8T	Topotecan	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.57	0.99	0.5	4.55
DCC5MCG	DMP6G8T	Topotecan	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.05	3.73	1.73	8.62
DCJZG2O	DMP6G8T	Topotecan	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.62	8.56	5.7	11.43
DCU46KT	DMP6G8T	Topotecan	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.84	0.41	1.29	5.46
DCU12WP	DMP6G8T	Topotecan	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	1.92	0.06	0.72	4.34
DC1LCTT	DMP6G8T	Topotecan	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	3.97	3.62	2.62	8.56
DC3H1AG	DMP6G8T	Topotecan	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	3.74	2.27	0.82	6.08
DCMXLK1	DMP6G8T	Topotecan	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	1.86	6.86	3.68	7.77
DCP5151	DMP6G8T	Topotecan	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	11.07	8.05	10.69	15.53
DC4R94Q	DMP6G8T	Topotecan	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	5.86	8.52	1.97	8.82
DCBZA6T	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	7.59	7.68	5.11	11.47
DC5UB29	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.61	2.33	1.36	6.07
DCAK7U2	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.27	2.24	3.79	6.93
DCR3FXW	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	2.38	2.39	4.38	9.16
DCP3YEZ	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	8.38	9.43	4.47	10.45
DC8IDF9	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	0.44	0.23	1.83	4.97
DCP60ZP	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	5.09	4.34	0.34	7.52
DCG4621	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.38	4.72	1.67	8.52
DC4SPUR	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.69	0.99	0.33	5.76
DCS6M66	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.98	8.45	4.72	8.6
DCRJ8NN	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	7.92	8.09	1.92	12.25
DCRFWGZ	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	6.23	9.06	1.12	8.17
DCCW4QX	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	7.09	7.46	6.97	9.77
DC9PUM8	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	4.35	4.35	6.14	6.15
DCY9SX3	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	2.2	1.1	2.92	3.8
DCR4S4G	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	2.88	1.2	4.55	5.61
DC6TPTV	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	3.94	4.01	8.91	10.21
DC7QPVW	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	9.16	9.53	10.48	13.51
DCSI60C	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	4.2	5.5	3.16	8.63
DC2DIRD	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.16	4.83	0.3	6.06
DCJEDEP	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.51	3.24	0.26	9.09
DC2N8ZF	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	8.68	10.43	3.38	12.83
DCITTM5	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	5.85	7.53	1.07	6.42
DCFFO3D	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.29	0.84	1.4	4.16
DCB1JOA	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.34	5.46	9.5	10.02
DC7X16O	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	5.93	2.81	8.17	12.56
DC2M8Z3	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	9.84	8.97	9.89	10.35
DCNNVRC	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	14.04	13.45	13.88	14.12
DCFQ1GT	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.05	1.19	1.96	5.44
DCO9I00	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.69	5.96	2.23	9.13
DC91P8V	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.05	5.7	0.96	7.98
DCXX779	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	10.32	10.74	9.55	11.2
DC7R11S	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	7.79	11.88	0.33	12.78
DCEXI22	DMP6G8T	Topotecan	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	4.09	5.13	6.75	7.06
DCP3OQ3	DMP6G8T	Topotecan	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.37	1.96	0.44	5.35
DCMWSRY	DMP6G8T	Topotecan	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	2.14	0.36	2.7	5.54
DC55KFV	DMP6G8T	Topotecan	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	6.27	7.25	3.25	5.9
DC5GNKS	DMP6G8T	Topotecan	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.75	3.34	1.23	4.24
DCXV3S8	DMP6G8T	Topotecan	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	13.45	14.84	13.08	13.54
DCJERAI	DMP6G8T	Topotecan	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	9.94	10.05	7.39	10.17
DC520G9	DMP6G8T	Topotecan	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.54	5.73	6.14	6.72
DCBNEED	DMP6G8T	Topotecan	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	4.29	3.38	0.79	4.66
DC0YWBQ	DMP6G8T	Topotecan	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.82	3.26	2.96	5.53
DCTJEDG	DMP6G8T	Topotecan	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	0.41	0.87	2.78	3.34
DCBIC9K	DMP6G8T	Topotecan	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	14.17	14.69	0.11	10.93
DC16Q6Q	DMP6G8T	Topotecan	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	3.83	1.17	5.35	7.38
DCHX2QY	DMP6G8T	Topotecan	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	1.92	3.8	5.27	6.8
DCKX3TO	DMP6G8T	Topotecan	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	5.46	5.76	7.46	11.44
DCNS9I4	DMP6G8T	Topotecan	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.83	6.98	7.68	8.69
DCMP3Y4	DMP6G8T	Topotecan	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	8	9.56	9.04	11.35
DC7ZSWT	DMP6G8T	Topotecan	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.84	3.56	5.41	6.71
DC8BLS3	DMP6G8T	Topotecan	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.91	10.12	12.03	13.02
DCGDFU2	DMP6G8T	Topotecan	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.47	5.96	6.11	8.13
DCPC5NE	DMP6G8T	Topotecan	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	2.63	1.77	5.78	8.22
DCTV79K	DMP6G8T	Topotecan	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	7.69	10.12	10.31	11.21
DCKYX82	DMP6G8T	Topotecan	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.34	6.35	0.12	0.46
DCC7GEC	DMP6G8T	Topotecan	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.88	6.78	3.75	4.27
DCC8052	DMP6G8T	Topotecan	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.48	1.59	1.28	1.73
DCW7EIQ	DMP6G8T	Topotecan	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	11.68	10.05	5.47	8.84
DCR0MEM	DMP6G8T	Topotecan	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	9.94	4.08	2.51	5.61
DC7LO2F	DMP6G8T	Topotecan	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	12.03	13.03	4.93	11.61
DC1T0M7	DMP6G8T	Topotecan	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.26	7.18	2.65	4.95
DCG5BHP	DMP6G8T	Topotecan	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	1.03	3.2	2.16	3.15
DCSL5IX	DMP6G8T	Topotecan	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	5.64	9.7	7.33	9.23
DCS0UWV	DMP6G8T	Topotecan	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.76	5.99	4.67	6.83
DCM67IG	DMP6G8T	Topotecan	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.76	9.74	7.32	9.43
DC92PKD	DMP6G8T	Topotecan	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.29	5.6	2.27	4.94
DC9925I	DMP6G8T	Topotecan	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	8.75	10.45	6.08	7.9
DC3Q2KW	DMP6G8T	Topotecan	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.73	3.25	1.04	3.43
DCT6P7N	DMP6G8T	Topotecan	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.42	4.23	0.69	1.31
DC4ZWNX	DMP6G8T	Topotecan	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	7.05	5.32	2.23	2.41
DCTLM1L	DMP6G8T	Topotecan	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	2.73	3.8	3.4	3.72
DCWPW4N	DMP6G8T	Topotecan	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	6.33	6.3	3.56	3.91
DC4PRS5	DMP6G8T	Topotecan	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.66	3.58	2.99	5.04
DCGTF42	DMP6G8T	Topotecan	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	9.84	10.8	6.98	7.2
DCGAFHX	DMP6G8T	Topotecan	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	15.07	16.05	13.82	16.58
DCILY7K	DMP6G8T	Topotecan	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.13	5.54	2.13	2.67
DC54I6G	DMP6G8T	Topotecan	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	7.35	5.65	4.24	5
DC36Y3O	DMP6G8T	Topotecan	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	7.16	6.49	5.75	7.53
DC02J4O	DMP6G8T	Topotecan	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	5.93	4.72	3.17	3.42
DCU7Y3I	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	0.91	0.98	6.98	9.78
DCIEMLA	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.6	0.3	5.49	7.87
DCJI2P2	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	0.87	0.94	3.48	8.25
DCQH0CC	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	4.4	2.97	5.64	10.17
DCWCK25	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	0.21	0.13	5.1	9.3
DC79END	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	1.71	1.18	5.19	8.92
DCLKIEL	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.19	1.84	6.51	9.9
DCBXQ1R	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.4	2.15	3.76	7.91
DC2OV98	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	4.01	3.38	3.21	7.14
DC6FRQK	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.77	4.55	8.33	12.61
DC9E021	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.94	1.14	6	9.33
DCXRFYS	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	3.87	2.78	0.64	6.24
DCYINVY	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	1.14	0.7	3.08	6.93
DCON7DV	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.14	0.06	1.49	7.42
DC9A2G5	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	2.85	1.42	2.84	7.19
DCG7LEP	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.25	3.72	1.39	7.31
DCF9BZL	DMP6G8T	Topotecan	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	1.91	0.49	4.26	8.6
DCRKMG5	DMP6G8T	Topotecan	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	8.49	6.09	1.01	5.73
DCLHUUJ	DMP6G8T	Topotecan	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	8.4	4.62	0.07	3.06
DCO8824	DMP6G8T	Topotecan	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	5.97	4.18	4.6	6.82
DC6X39I	DMP6G8T	Topotecan	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	3.02	5.84	1.83	3.43
DCWNGKC	DMP6G8T	Topotecan	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	10.32	14.27	7.77	9.65
DCIJ68L	DMP6G8T	Topotecan	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	9.41	9.51	6.08	9.79
DCEWLT9	DMP6G8T	Topotecan	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8.58	8.18	5.28	7.68
DC0I5VV	DMP6G8T	Topotecan	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	6	4.75	2.2	6.16
DCOOYO7	DMP6G8T	Topotecan	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.51	7.13	5.05	6.22
DC70Q7F	DMP6G8T	Topotecan	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	5.73	9.33	6.17	8.26
DCFP594	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	26.86	24.91	30.51	32.91
DCC7FHS	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.91	1.26	5.33	8.96
DCAMOSF	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	6.01	3.42	6.95	10.95
DCI3SHT	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	2.52	2.38	6.35	10.26
DCLSTM8	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	1.46	0.99	5.52	8.45
DCBW31M	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	9.11	8.85	12.34	15.28
DCLR5OW	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.39	3.52	7.49	10.33
DC7M74Y	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	1.42	0.71	0.47	4.04
DC922SZ	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.57	3.04	1.66	6.04
DCETFRA	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.87	0.3	3.86	7.6
DCTUVI2	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.34	7.73	1.31	7.99
DCVZGGG	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	13.44	13.39	16.25	19.04
DC6BGOC	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	3.28	3.49	0.69	5.74
DCS4JPW	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	2.93	2.24	3.12	6.94
DCRYU0H	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.34	6.46	7.28	9.47
DC1UO09	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	7.51	9.86	11.28	13.6
DCM3L9F	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.24	5.21	4.89	9.85
DCV0ROY	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	7.51	7.12	5.82	11.93
DCZYAM4	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.72	6.64	6.31	10.18
DCZM1E2	DMP6G8T	Topotecan	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.12	6.32	2.83	7.83
DC8P7R2	DMP6G8T	Topotecan	Approved	34	DM6BZCV	Sivelestat	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	30.28	30.28	40.99	40.99
DCKL2TE	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.6	0.56	0.3	0.52
DCZFFS0	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.96	3.95	3.18	3.27
DCB69F5	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	23.27	17.07	14.18	14.31
DC27LN9	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.76	2.56	1.3	1.49
DCXTAFG	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	4.47	2.94	2.27	2.41
DCRMB17	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	3.67	3.67	3.16	3.69
DC2P06D	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	10.02	11.42	15.63	15.7
DCMP9R4	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	6.63	7.87	7.46	7.57
DC6FXG1	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	1.66	4.13	5.23	5.14
DC0TOI6	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.92	0.98	1.33	1.45
DCOW38N	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	20.9	19.11	18.9	18.94
DCD8ZT7	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.46	6.26	6.32	6.31
DC72SEM	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.78	0.89	0.14	0.2
DCEHBHL	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.71	3.95	3.61	3.61
DCJWGDK	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.49	4.96	4.4	4.42
DCAAJDR	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	10.33	12.62	13.15	13.12
DCUKVM3	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.71	6.84	6.73	7.05
DCVN2FV	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	8.02	7.68	6.16	8.29
DCBXF00	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.9	6.72	5.31	5.36
DCEFZUE	DMP6G8T	Topotecan	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	5.34	5.91	5.72	5.75
DCQPFO9	DMP6G8T	Topotecan	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6.86	2.31	0.5	1.72
DCCZCSR	DMP6G8T	Topotecan	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.31	1.56	0.1	0.42
DC4Q9SZ	DMP6G8T	Topotecan	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	5.27	3.44	0.26	1.17
DC2II91	DMP6G8T	Topotecan	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	0.53	0.97	0.96	2.16
DCMJ2AB	DMP6G8T	Topotecan	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	8.47	9.8	8.31	8.56
DCOXFIQ	DMP6G8T	Topotecan	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.96	5.53	3.64	3.19
DCQ3D78	DMP6G8T	Topotecan	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	5.49	4.99	3.4	3.72
DCEU2HE	DMP6G8T	Topotecan	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	9.88	8.65	4.04	4.4
DCGHFAU	DMP6G8T	Topotecan	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	10.91	9.92	9.06	9.13
DCAL4DI	DMP6G8T	Topotecan	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.83	8.88	7.21	8.81
DCXA3WI	DMP6G8T	Topotecan	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	7.76	5.69	3.93	5.14
DCYI8YZ	DMP6G8T	Topotecan	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.45	7.96	6.35	6.63
DCT4GC6	DMP6G8T	Topotecan	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.57	0.78	3.61	3.57
DCG1LVW	DMP6G8T	Topotecan	Approved	34	DM7IW9J	Ramelteon	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	12.97	12.97	22.09	22.09
DCUBVJ8	DMP6G8T	Topotecan	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	3.49	2.92	2.02	4.57
DCPK6Z9	DMP6G8T	Topotecan	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	6.09	7.68	4.52	12.73
DCDDHAM	DMP6G8T	Topotecan	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4.08	8.22	0.19	9.76
DCQ8BZU	DMP6G8T	Topotecan	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	1.6	2.15	1.15	6.62
DC56P2N	DMP6G8T	Topotecan	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	6.3	8.55	7.25	9.6
DC09UEV	DMP6G8T	Topotecan	Approved	34	DM8BKU9	Acitretin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	5.85	5.85	29.86	29.86
DCGX9FX	DMP6G8T	Topotecan	Approved	34	DM9S1EA	Pepstatin	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	11	11	31.71	31.75
DCHXXJQ	DMP6G8T	Topotecan	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.55	0.54	1.22	6.05
DCBKJ88	DMP6G8T	Topotecan	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.18	4.33	7.95	9.7
DCBN5IP	DMP6G8T	Topotecan	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.04	4.53	4.85	6.27
DCLMILN	DMP6G8T	Topotecan	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	6.84	6.67	5.99	9.39
DCLNW4U	DMP6G8T	Topotecan	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.41	3.92	5.04	7.49
DCKY0LC	DMP6G8T	Topotecan	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	2.22	2.5	2.57	5.72
DCE2M5F	DMP6G8T	Topotecan	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.35	8.71	11.93	14
DCCYOOW	DMP6G8T	Topotecan	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.58	1.68	0.45	3.7
DCIF5CT	DMP6G8T	Topotecan	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	0.04	3.65	0.33	9.03
DCY5XZM	DMP6G8T	Topotecan	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.46	2.82	0.65	2.92
DCQP5WK	DMP6G8T	Topotecan	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	4.21	3.6	5.23	4.64
DCSFE3Z	DMP6G8T	Topotecan	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	5.43	5.98	5.85	9.13
DC6T63F	DMP6G8T	Topotecan	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.06	6.63	6.21	6.18
DCLDTZS	DMP6G8T	Topotecan	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.34	2.58	4.26	6.17
DCKAVHX	DMP6G8T	Topotecan	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.24	1.42	4.53	5.43
DCT4JUC	DMP6G8T	Topotecan	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	3.17	1.01	0.7	5.04
DCXPEK6	DMP6G8T	Topotecan	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	6.49	9.64	13.36	14.23
DCWMOF2	DMP6G8T	Topotecan	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.46	4.17	4.22	4.22
DC1Y31T	DMP6G8T	Topotecan	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.13	0.76	0.1	3.43
DCFLFBQ	DMP6G8T	Topotecan	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	3.63	1.7	0.8	1.16
DCXDWYI	DMP6G8T	Topotecan	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	6.62	4.68	2.35	5.4
DC2BKCK	DMP6G8T	Topotecan	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.03	1.61	1.76	1.72
DCN8X2Z	DMP6G8T	Topotecan	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.61	1.75	3.62	3.55
DCU4XMG	DMP6G8T	Topotecan	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.52	6.42	6.94	6.88
DCZ0RPR	DMP6G8T	Topotecan	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.16	8.61	8.66	8.62
DCEKO2O	DMP6G8T	Topotecan	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.68	8.07	6.94	9
DCF6CEH	DMP6G8T	Topotecan	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	5.21	3.03	3.17	3.17
DC91QQO	DMP6G8T	Topotecan	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	7.11	6.68	6.19	6.92
DCBEXH8	DMP6G8T	Topotecan	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.99	1.82	4.63	6.89
DCLW2DT	DMP6G8T	Topotecan	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.08	2.31	2.33	7.28
DCMOQ2Z	DMP6G8T	Topotecan	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	1.59	0.49	2.98	6.58
DCNTDK3	DMP6G8T	Topotecan	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	6.41	7.39	1.24	7.13
DCN2AWX	DMP6G8T	Topotecan	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	7.5	8.02	6.33	11.27
DCUSSC4	DMP6G8T	Topotecan	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.24	3.4	0.77	6.58
DC1WGFU	DMP6G8T	Topotecan	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	3.29	4.17	3.05	7.02
DCYLVEJ	DMP6G8T	Topotecan	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	5.3	4.66	1.79	7.59
DCKS4DS	DMP6G8T	Topotecan	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	6.76	5.68	3.92	9.09
DCGVBG2	DMP6G8T	Topotecan	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	3.42	3.47	1.81	7.84
DC9WYKP	DMP6G8T	Topotecan	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	1.68	0.53	0.03	4.43
DCCR2VW	DMP6G8T	Topotecan	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	3.66	2.86	1.2	6.61
DC2S58Q	DMP6G8T	Topotecan	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.23	5.81	3.76	7.81
DC0GNP4	DMP6G8T	Topotecan	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	4.59	4.54	10.05	13.4
DCCVR56	DMP6G8T	Topotecan	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	3.98	6.15	9.3	6.32
DCWXDA2	DMP6G8T	Topotecan	Approved	34	DMBEX4O	Methylergonovine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	25.02	25.02	36.04	36.08
DCB8YN5	DMP6G8T	Topotecan	Approved	34	DMBHMOX	Palonosetron	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	10.87	10.87	19.85	19.88
DCJ2L5I	DMP6G8T	Topotecan	Approved	34	DMBLM5H	BHV-0223	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	17.77	17.77	28.96	28.98
DC3FM9S	DMP6G8T	Topotecan	Approved	34	DMBS632	Buspirone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	1.5	1.5	11.88	11.9
DCZWRHZ	DMP6G8T	Topotecan	Approved	34	DMBYCU0	Metyrosine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	10.64	10.64	17.76	17.76
DCFU6CZ	DMP6G8T	Topotecan	Approved	34	DMC0GSJ	Efavirenz	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	4.13	4.13	17.13	17.17
DCNMUVB	DMP6G8T	Topotecan	Approved	34	DMC1TEV	Testosterone cypionate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	8.93	8.93	25.13	25.16
DCRX4AG	DMP6G8T	Topotecan	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	12.96	13.76	7.51	14.07
DC1B4DJ	DMP6G8T	Topotecan	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	8.38	7.67	1.47	7.69
DCU7FJ5	DMP6G8T	Topotecan	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	7.22	7.22	19.81	19.81
DC7KF4D	DMP6G8T	Topotecan	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	6.16	4.09	0.25	4.81
DCHH52G	DMP6G8T	Topotecan	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	13	14.04	5.75	14.13
DCEN9PL	DMP6G8T	Topotecan	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	6.56	5.58	1.23	5.6
DCZRX3H	DMP6G8T	Topotecan	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.82	9.21	4.15	8.94
DCUYPYL	DMP6G8T	Topotecan	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	10.34	10.58	3.98	10.48
DC1MC3E	DMP6G8T	Topotecan	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.26	5.77	1.54	6.37
DCFL2XL	DMP6G8T	Topotecan	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	6.48	8.47	5.07	8.85
DCO606O	DMP6G8T	Topotecan	Approved	34	DMPN5IH	Guanfacine	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	12.64	12.64	23.77	23.77
DC2ZJGT	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	11.8	12.14	1.99	18.36
DCO87VX	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	8.23	8.39	8.25	16.82
DCAHS37	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.02	2.98	4.76	11.28
DCF61JD	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	9.16	8.87	3.95	14.17
DCX5CN2	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6.93	3.06	1.56	2.64
DCJZT3L	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	5.02	4.96	9.35	15.2
DC7K6DG	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	1.85	1.63	3.3	9.3
DCY7CXC	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	9.95	9.08	3.31	14.81
DCBMX96	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.89	6.77	7.89	14.48
DCRS6XV	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.88	5.33	3.64	11.09
DCBOX84	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	7.78	3.09	4.47	5.11
DCQQV9Z	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	9.95	11.43	8.24	14.44
DCLLM87	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	3.17	4.42	3.43	3.84
DCXH2F4	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	4.72	2.29	3.53	6.59
DC5NJGZ	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	1.53	5.09	3.69	9.93
DC8MIMB	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	11.36	10.48	5.77	14.72
DC7ASKH	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	6.93	8.34	3.28	3.49
DC1KS14	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.09	3.41	4.41	8.11
DCOCEWI	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	7.62	9.73	2.29	14.5
DCH5G31	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	0.82	4.87	7.83	11.62
DCGG4XI	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.17	3.79	25.48	5.73
DCV2M07	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	7.43	7.93	1.95	12.76
DCY69IC	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.91	8.98	5.86	15.35
DC5PDRH	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.74	4.34	1.15	4.5
DC5VN9Q	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	6.5	7.1	5.28	5.6
DC26JD8	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	10.21	10.16	7.49	10.02
DCQ4J2E	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.28	1.92	1.19	9.75
DCSKVHN	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.67	7.46	7.75	15.13
DCP944H	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.85	7.12	2.02	11.78
DCVC1DL	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	6.07	4.17	0.82	4.58
DCPXDTD	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.37	6.79	4.06	4.31
DCELSAL	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	6.24	12.48	1.5	13.13
DC85ZZJ	DMP6G8T	Topotecan	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	4.37	5.4	5.02	5.28
DC8O778	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.06	5.6	4.75	12.01
DCGBFH4	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.47	2.57	12.17	15.2
DCSMBDL	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	10.36	10.16	11.9	16.9
DCZPFC0	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	2.22	1.74	6.35	9.43
DCF8G91	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.61	0.28	5.35	8.81
DC0FIVH	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	4.26	4.62	4.22	8.01
DCPEV27	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.66	2.8	6.44	10.16
DC8CQPP	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	1.56	0.63	3.13	6.8
DC29TC4	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	6.26	4.95	0.87	8.27
DCFNQLC	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.6	7.2	7.58	11.72
DCDWI6U	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	10.9	10.03	22.1	10.18
DCI1ZUN	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	14.49	15.69	15.89	18.45
DCO31CG	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	10.55	8.41	9.82	9.55
DC8DUJ4	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	6.1	4.31	1.78	6.89
DCX3PDX	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.35	2.38	5.71	8.06
DCLCASU	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	1.09	6.96	2.96	10.06
DC54PVX	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	4.38	3.27	1.14	8.12
DC6JX2H	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.77	2.66	5.05	7.32
DCJKQCL	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	2.98	5.51	4.82	8.27
DCDM74B	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.42	6.26	8.29	12.17
DCOCYTO	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	18.87	19.05	18.3	22.6
DC0D2P3	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.08	2.95	1.51	7.22
DCZVHNJ	DMP6G8T	Topotecan	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	6.65	11.09	11.03	12.11
DCZK8SG	DMP6G8T	Topotecan	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	1.14	2.22	0.37	1.68
DCHRY14	DMP6G8T	Topotecan	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.27	3.08	8.82	10.59
DCCB7RC	DMP6G8T	Topotecan	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.62	5.42	6.32	10.8
DCSYJLS	DMP6G8T	Topotecan	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	3.32	2.61	5.87	7.62
DC3QFJ1	DMP6G8T	Topotecan	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.65	2.26	2.07	3.02
DCLJ83O	DMP6G8T	Topotecan	Approved	34	DMF57DM	Pazopanib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	11.54	11.54	27.32	27.36
DCENTX1	DMP6G8T	Topotecan	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	6.95	7.08	10.72	13
DCC8RSG	DMP6G8T	Topotecan	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	1.36	1.31	2.27	7.78
DCN1HHM	DMP6G8T	Topotecan	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	2.69	2.47	3.13	8.27
DCT4ZHB	DMP6G8T	Topotecan	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	0.55	0.38	4.77	9.01
DCCLYBR	DMP6G8T	Topotecan	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	1.27	1.23	5.47	8.48
DC13C5B	DMP6G8T	Topotecan	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	2.98	1.51	3.21	5.53
DCDAJE5	DMP6G8T	Topotecan	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.89	2.36	2.91	7.61
DC4F7K9	DMP6G8T	Topotecan	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.91	7.31	5.26	9.34
DCVI8L7	DMP6G8T	Topotecan	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.57	4.15	5.4	8.6
DC7MB92	DMP6G8T	Topotecan	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	10.06	13.16	5.19	16.09
DCQTLT8	DMP6G8T	Topotecan	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	3.89	7	5.53	9.69
DCX08VO	DMP6G8T	Topotecan	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	5.02	5.1	6.26	11.81
DC7UDJZ	DMP6G8T	Topotecan	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	2.21	6.36	2.82	6.03
DCW552U	DMP6G8T	Topotecan	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	1.85	5.65	4.01	6.96
DCEO6HT	DMP6G8T	Topotecan	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.59	6.84	8.07	13.36
DCRVT2C	DMP6G8T	Topotecan	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.63	6.53	7.44	7.49
DCZ2LET	DMP6G8T	Topotecan	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6.38	5.56	4.41	6.4
DCLE8SJ	DMP6G8T	Topotecan	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.55	3.88	4.16	7.37
DC5GR4B	DMP6G8T	Topotecan	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	12.39	7.8	11.33	12.58
DCAW70D	DMP6G8T	Topotecan	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	1.11	0.47	4.44	5.76
DCN8KK1	DMP6G8T	Topotecan	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	3.89	3.78	8.94	10.62
DCWGMSR	DMP6G8T	Topotecan	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	4.56	6.02	7.3	10.8
DCVIIS9	DMP6G8T	Topotecan	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	10.47	11	11.16	13.77
DCS40FU	DMP6G8T	Topotecan	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	8.91	10.77	11.25	13.35
DC0HVFL	DMP6G8T	Topotecan	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.6	1.41	2.48	5.14
DCVE8UK	DMP6G8T	Topotecan	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	22.16	19.02	18.58	21.37
DCK13UJ	DMP6G8T	Topotecan	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.59	5.25	10.83	11.15
DC4NV8E	DMP6G8T	Topotecan	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	10.5	11.83	9.96	10.91
DCQWJH8	DMP6G8T	Topotecan	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.41	5.34	7.81	8.63
DCUR3GY	DMP6G8T	Topotecan	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.98	6.07	8.31	8.91
DC64CTI	DMP6G8T	Topotecan	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.88	2.93	7.57	8.18
DCOX7RI	DMP6G8T	Topotecan	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	1.67	2.43	1.11	3.5
DCNVYW9	DMP6G8T	Topotecan	Approved	34	DMFO843	Fluspirilene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	20.7	20.7	29.99	30.03
DCR7V6R	DMP6G8T	Topotecan	Approved	34	DMFQWNI	VR-776	Discontinued in Phase 1	3	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	11.06	11.06	22.11	22.15
DC058WK	DMP6G8T	Topotecan	Approved	34	DMGC5DB	Ciprofibrate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	3.58	3.58	12.93	12.97
DC5YI7S	DMP6G8T	Topotecan	Approved	34	DMGQFYB	Mecamylamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	13.39	13.39	22.97	22.98
DCM6UL6	DMP6G8T	Topotecan	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	5.33	4.83	11.98	12.71
DCYKTGD	DMP6G8T	Topotecan	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	1.68	0.76	11.1	12.37
DCWP6H1	DMP6G8T	Topotecan	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	0.8	2.94	9.06	10.04
DCRRPLX	DMP6G8T	Topotecan	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.17	3.83	7.06	8
DCXKQZQ	DMP6G8T	Topotecan	Approved	34	DMGYBZI	PHA-739358	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	30.09	30.09	39.56	39.56
DCK252G	DMP6G8T	Topotecan	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	9.64	4.97	3.44	5.53
DCMPKGZ	DMP6G8T	Topotecan	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	12.03	11.15	6.36	8.81
DCGL4CI	DMP6G8T	Topotecan	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	2.5	2.91	1.52	3.32
DCOUP7U	DMP6G8T	Topotecan	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	6.94	4.72	1.7	7.04
DCZPR1R	DMP6G8T	Topotecan	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	10.67	7.28	4.13	5.6
DCZEQHB	DMP6G8T	Topotecan	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.73	4.42	3.77	4.14
DCNLQVD	DMP6G8T	Topotecan	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.77	3.61	1.51	2.72
DC3SIE5	DMP6G8T	Topotecan	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	9.08	8.49	9.29	10.54
DCVDM0H	DMP6G8T	Topotecan	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	9.42	8.56	9.33	9.98
DCEX7IM	DMP6G8T	Topotecan	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.3	4.99	3.54	5.26
DCHXD9D	DMP6G8T	Topotecan	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.1	8.95	10.02	10.15
DCXYS49	DMP6G8T	Topotecan	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	5.48	5.2	3.48	4.88
DC1H5OJ	DMP6G8T	Topotecan	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.76	1.69	3.03	5.79
DCJQCHB	DMP6G8T	Topotecan	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	9.75	9.6	7.46	15.9
DCFQ85Z	DMP6G8T	Topotecan	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	13.65	14.5	14.01	15.83
DCVA7OL	DMP6G8T	Topotecan	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4	2.71	1.41	2.81
DC0AN9H	DMP6G8T	Topotecan	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	6.25	4.75	3.14	4.58
DCRXU7P	DMP6G8T	Topotecan	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.27	3.29	7.52	8.79
DCHQ2ZU	DMP6G8T	Topotecan	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.82	3.05	1.25	5.28
DCGTBLB	DMP6G8T	Topotecan	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	14.67	15.81	9.43	15.99
DCS46OW	DMP6G8T	Topotecan	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	2.36	1.74	4	7.08
DC1W037	DMP6G8T	Topotecan	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.73	8.73	0.36	7.09
DCGVY8E	DMP6G8T	Topotecan	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	7.89	0.13	0.68	2.22
DCB5EJM	DMP6G8T	Topotecan	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	7.6	8.57	6.57	8.42
DCNFOTE	DMP6G8T	Topotecan	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	3.7	4.81	11.77	12.37
DCSERC3	DMP6G8T	Topotecan	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.02	6.28	2.74	3.84
DCCOIK3	DMP6G8T	Topotecan	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	10.32	12.68	6.69	7.32
DCC740M	DMP6G8T	Topotecan	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.94	0.59	0.77	1.9
DCF9089	DMP6G8T	Topotecan	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	3.43	4.53	2.48	2.25
DCIKAMH	DMP6G8T	Topotecan	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	8.45	6.13	6.71	7.59
DCFMJ7K	DMP6G8T	Topotecan	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	11.12	13.92	15.42	15.89
DCM7VUG	DMP6G8T	Topotecan	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	5.44	5.8	10.55	11.59
DC5ZJES	DMP6G8T	Topotecan	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	10.51	10.33	15.57	16.05
DCF5OWL	DMP6G8T	Topotecan	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	7.94	7.88	8.71	9.16
DCJ614X	DMP6G8T	Topotecan	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.56	2.48	3.13	4.12
DC4JXH6	DMP6G8T	Topotecan	Approved	34	DMHPWOM	Diphenidol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	11.34	11.34	20.37	20.38
DCXIDK5	DMP6G8T	Topotecan	Approved	34	DMI40NL	Tolazoline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	3.76	3.76	11.45	11.48
DC3KEPV	DMP6G8T	Topotecan	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4	2.25	1.32	1.34
DCMQS1X	DMP6G8T	Topotecan	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.83	1.63	0.29	5
DC8SWI7	DMP6G8T	Topotecan	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.93	1.45	0.78	0.82
DCURQ9A	DMP6G8T	Topotecan	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	3.52	3.24	0.61	5.85
DCVU5WW	DMP6G8T	Topotecan	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	2.27	2.45	1.32	1.36
DCLO8Q7	DMP6G8T	Topotecan	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	2.43	3.38	1.64	1.62
DC9J98Q	DMP6G8T	Topotecan	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	1.92	0.84	0.18	0.36
DC9T1VM	DMP6G8T	Topotecan	Approved	34	DMIUYFH	Sulfapyridine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	13.78	13.78	23.76	23.8
DCRCYKT	DMP6G8T	Topotecan	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	3.79	0.03	4.18	6.09
DC2I09O	DMP6G8T	Topotecan	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	6.17	5.28	3.04	11.9
DCZDKN5	DMP6G8T	Topotecan	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	6.33	6.22	8.36	10.11
DCP1NN9	DMP6G8T	Topotecan	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.53	5.13	3.99	10.22
DCNCJ2N	DMP6G8T	Topotecan	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.43	5.21	6.96	10.99
DC8I9Z3	DMP6G8T	Topotecan	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.24	4.73	6.68	8.1
DCTV704	DMP6G8T	Topotecan	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.89	3.19	2.94	8.25
DCFY4BF	DMP6G8T	Topotecan	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.64	4.19	6.65	9.53
DCEKHT3	DMP6G8T	Topotecan	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.33	5	7.71	9.24
DCINZO1	DMP6G8T	Topotecan	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	4.56	4.86	7.22	9.82
DCLFTRL	DMP6G8T	Topotecan	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.48	7.06	9.27	10.36
DCXARTJ	DMP6G8T	Topotecan	Approved	34	DMKFQJP	Triflupromazine	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	32.67	32.67	42.13	42.15
DCH5AQJ	DMP6G8T	Topotecan	Approved	34	DMJTEMW	Lubiprostone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	6.19	6.19	16.18	16.18
DC0TDQD	DMP6G8T	Topotecan	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	8.63	6.23	0.17	4.96
DCS66Z7	DMP6G8T	Topotecan	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	16.1	16.64	7.98	14.48
DCY80MR	DMP6G8T	Topotecan	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.42	7.38	1.2	6.03
DCEKZLV	DMP6G8T	Topotecan	Approved	34	DMKSQG0	Tiagabine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	8.96	8.96	14.77	14.78
DCXK01Z	DMP6G8T	Topotecan	Approved	34	DML1538	Diazoxide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	4.12	4.12	5.69	5.69
DCGPGL1	DMP6G8T	Topotecan	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	4.09	6.36	3.06	8.3
DCMSXNH	DMP6G8T	Topotecan	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	3.54	4.03	3.81	7.7
DCOP16M	DMP6G8T	Topotecan	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.35	4.59	4.72	8.27
DC06EGR	DMP6G8T	Topotecan	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	2.96	3.6	2.46	7.81
DCUALSA	DMP6G8T	Topotecan	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	4.45	4.36	0.64	7.74
DCBYXSE	DMP6G8T	Topotecan	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.99	3.24	1	6.61
DC5MA5R	DMP6G8T	Topotecan	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.17	2.3	0.52	4.27
DCS449Y	DMP6G8T	Topotecan	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	6.06	10.69	9.52	12.69
DCWE12J	DMP6G8T	Topotecan	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.88	4.58	0.05	5.95
DCHHSG7	DMP6G8T	Topotecan	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	2.7	1.18	2.25	4.67
DCXOK60	DMP6G8T	Topotecan	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.16	4.81	0.52	6.32
DCICO6J	DMP6G8T	Topotecan	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	7.29	4.74	1.5	8.32
DCEJYM4	DMP6G8T	Topotecan	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.2	5.03	1.04	7.61
DCZ1FQP	DMP6G8T	Topotecan	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.9	3.99	3.69	6.35
DC271N6	DMP6G8T	Topotecan	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	9.51	3.12	0.76	3.75
DCPCRJ2	DMP6G8T	Topotecan	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	10.3	8.92	4.26	7.59
DCM6HJV	DMP6G8T	Topotecan	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	2.33	3.19	0.11	2.75
DCIX18S	DMP6G8T	Topotecan	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	7.43	6.42	10.17	10.17
DCYJOD3	DMP6G8T	Topotecan	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	10.62	7.82	6.62	8.68
DC9ZREI	DMP6G8T	Topotecan	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.06	0.41	0.78	0.85
DCBO1EW	DMP6G8T	Topotecan	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	5.09	4.96	5.06	6.24
DCVPMNS	DMP6G8T	Topotecan	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.84	4.84	4.94	5.5
DCOHWM3	DMP6G8T	Topotecan	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	14.39	15.9	18.16	19.67
DCHRHF3	DMP6G8T	Topotecan	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	8.7	8.75	9.16	10.38
DCL76XU	DMP6G8T	Topotecan	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.29	4.06	2.48	4.88
DC7HDPD	DMP6G8T	Topotecan	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	0.28	0.01	2.52	3.21
DCR0EXB	DMP6G8T	Topotecan	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.53	7.14	8.49	9.82
DCIWFSG	DMP6G8T	Topotecan	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	12.53	14.21	14.99	17.08
DCT0VAV	DMP6G8T	Topotecan	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	2.79	4.29	1.88	4.32
DCSI8BZ	DMP6G8T	Topotecan	Approved	34	DMLU8NX	Benserazide	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	18.09	18.09	28.05	28.09
DC6HTVH	DMP6G8T	Topotecan	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	3.44	4.12	3.28	5.55
DCHRF8K	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.65	2.24	6.06	8.04
DC70YC5	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.18	3.01	9.62	10.23
DCV6HWC	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.04	4.65	9.91	11.06
DCA3XCY	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	5.39	4.69	6.83	6.91
DC1XNHI	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.17	0.99	9.05	10.35
DCL62JN	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	1.54	0.49	6.54	9.18
DCM6JTJ	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	2.75	4.75	6.6	6.67
DCANWEH	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	4.76	7.58	11.6	12.35
DCZHVBI	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.88	0.4	1.09	0.71
DCMY6O1	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.65	5.24	10.75	11.84
DCC0Y4E	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.66	6.17	9.86	11.33
DC9NSG0	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	10.36	12.43	14.67	16.52
DCDELN2	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	1.03	1.96	6.79	7.69
DCUJ0HD	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	6.24	6.73	11.34	12.15
DCBYEW7	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.38	3.54	6.89	6.22
DCRJ694	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	2.19	2.32	2.57	3.36
DCEXYGY	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	0.32	4.4	5.62	6.56
DCR4J4O	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	0.99	2.25	6.18	7.04
DCZ1MSP	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.67	5.01	9.85	12.6
DCC4PTS	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	10.81	10.05	14.08	15.31
DCEV2HU	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	0.12	0.41	7.26	10.16
DCYF19E	DMP6G8T	Topotecan	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	2.05	12.19	11.39	12.1
DCSWMTA	DMP6G8T	Topotecan	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.67	0.15	1.42	9.96
DCVWMMD	DMP6G8T	Topotecan	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	2.92	2.91	1.01	5.49
DCV9NZM	DMP6G8T	Topotecan	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	2.44	2.21	5.5	8
DCAY5RM	DMP6G8T	Topotecan	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	SYNERGxDB Database	Investigative	T98G	30.88	30.88	12.77	12.77
DCUHP8W	DMP6G8T	Topotecan	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	5.38	11.65	9.01	10.74
DCAKMR3	DMP6G8T	Topotecan	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	8.67	12.61	6.23	8.23
DCPDYKV	DMP6G8T	Topotecan	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	7.06	9.92	0.99	7.05
DCOSH7A	DMP6G8T	Topotecan	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	12.32	11.16	1.56	7.56
DCFCZ6D	DMP6G8T	Topotecan	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	8.03	9.06	5.12	9.81
DCJY2PX	DMP6G8T	Topotecan	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.3	9.52	2.45	8.08
DCHUY55	DMP6G8T	Topotecan	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	13.44	13.29	7.62	12.12
DCIMDQQ	DMP6G8T	Topotecan	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	4.8	5.76	3.48	6.42
DCMJTKE	DMP6G8T	Topotecan	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.37	4.78	0.59	3.92
DC17H1X	DMP6G8T	Topotecan	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	4.19	4.19	8.02	8.03
DCWM19T	DMP6G8T	Topotecan	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	9.59	11.53	8.46	10.06
DCQS371	DMP6G8T	Topotecan	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.65	5.16	1.95	5
DC8LHHK	DMP6G8T	Topotecan	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.18	4.92	1.17	3.04
DC1XXZT	DMP6G8T	Topotecan	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.21	4.36	3.24	6.06
DCGKHKI	DMP6G8T	Topotecan	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.89	8.62	6.01	7.66
DCNKQ3K	DMP6G8T	Topotecan	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.01	11.44	6.41	8.8
DC44Z5Y	DMP6G8T	Topotecan	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.28	7.87	5.09	6.67
DC0JQZK	DMP6G8T	Topotecan	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	5.98	5.23	2.07	4.16
DCAL5YJ	DMP6G8T	Topotecan	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.25	3.74	5.57	6.91
DCC279J	DMP6G8T	Topotecan	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.24	3.48	2.94	3.1
DCJPGGH	DMP6G8T	Topotecan	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.36	3.67	2.46	2.62
DCTGTJQ	DMP6G8T	Topotecan	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.59	3.54	0.53	1
DCU3EH0	DMP6G8T	Topotecan	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	3.1	5.36	1.63	1.4
DCPC055	DMP6G8T	Topotecan	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.75	2.78	2.28	2.26
DCN13MU	DMP6G8T	Topotecan	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.12	5.46	2.76	2.14
DC9PVJH	DMP6G8T	Topotecan	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.4	1.69	1.99	3.23
DC333OW	DMP6G8T	Topotecan	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	4.76	4.29	1.08	1.74
DC0E071	DMP6G8T	Topotecan	Approved	34	DMNMW9R	Pramipexole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	22.52	22.52	31.72	31.72
DCY580X	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	1.67	1.8	0.84	5.47
DCQVTOR	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	1.37	0.57	0.35	2.28
DCF95N8	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	5.89	4.68	6.47	6.48
DCU231E	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	5.61	4.66	2.19	5.37
DCVOLY2	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.05	4.22	0.95	5.44
DCTREM8	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3	3.85	0.13	4.66
DC7F2JG	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.72	1.71	5.29	5.41
DC5P6PH	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.37	4	4.2	4.25
DC9695D	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	0.96	1.78	3.06	2.95
DCXC3DR	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	4.22	3.96	3.07	3.43
DCV009E	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	7.33	7.19	9.16	9.18
DCIE4R7	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.78	2.53	0.15	0.17
DCI6I4M	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	1.68	3.01	1.73	5.03
DCLSJ1J	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.22	2.03	1.91	4.89
DCYFPNC	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	8.24	6.31	1.57	8.98
DCB8ZSS	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.86	7.75	6.28	6.22
DCKCUV2	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.19	5.67	6.33	6.17
DCMF6XI	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	3.03	3.45	0.58	6.4
DCM50XU	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.88	8.49	9.63	9.88
DCH6QET	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	4.85	5.26	4.79	4.79
DCCC5TI	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	6.61	10.9	11.47	11.38
DCPTDDF	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	1.32	2.87	1.42	5.66
DC5JVGV	DMP6G8T	Topotecan	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.94	3.82	4.99	4.95
DCJVT2J	DMP6G8T	Topotecan	Approved	34	DMODJ40	Ethinyl estradiol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	9.01	9.01	18.96	18.96
DCM6913	DMP6G8T	Topotecan	Approved	34	DMOL5IU	Mesalazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	2.69	2.69	12.47	12.47
DCM1JXN	DMP6G8T	Topotecan	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	6.36	1.83	4.11	5.29
DCK1YSB	DMP6G8T	Topotecan	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.27	4.66	6.49	6.45
DCO2L51	DMP6G8T	Topotecan	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	1.5	0.53	2.04	2.27
DC3Q6T6	DMP6G8T	Topotecan	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	1.87	1.4	3.5	3.61
DCOGUIX	DMP6G8T	Topotecan	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	8.4	6.93	10.24	10.26
DCNVAAT	DMP6G8T	Topotecan	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.04	1.81	0.56	0.65
DC7INYL	DMP6G8T	Topotecan	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	2.02	7.01	8.31	8.2
DCKQ60M	DMP6G8T	Topotecan	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.38	2.3	2.25	2.23
DCPKN3I	DMP6G8T	Topotecan	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.65	1.48	4.29	4.29
DCCZJ9E	DMP6G8T	Topotecan	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	7.01	13.53	13.46	14.25
DCGZ4UR	DMP6G8T	Topotecan	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.83	2.32	3.19	3.5
DCPLGVB	DMP6G8T	Topotecan	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	6.56	8.02	9.28	9.22
DC3ERO1	DMP6G8T	Topotecan	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.02	2.46	4.72	4.74
DCKFUQC	DMP6G8T	Topotecan	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.88	6.49	4.03	9.03
DCSHDZ1	DMP6G8T	Topotecan	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	4.23	1	0.02	8.03
DC7X0ZU	DMP6G8T	Topotecan	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	5.88	12.33	3.33	11.61
DCNAE5D	DMP6G8T	Topotecan	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	3.29	11.29	1.27	4.79
DC5D7PT	DMP6G8T	Topotecan	Approved	34	DMPP4DT	Trimethobenzamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	9.87	9.87	25.46	25.46
DCV5BZ5	DMP6G8T	Topotecan	Approved	34	DMPWB7T	Maprotiline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	18.99	18.99	39.79	39.79
DCUIX3F	DMP6G8T	Topotecan	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	9.45	6.69	5.8	8.73
DC1G946	DMP6G8T	Topotecan	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	11.09	9.32	2.98	6.31
DC86GDT	DMP6G8T	Topotecan	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.81	3.63	0.31	1.98
DCV7E7B	DMP6G8T	Topotecan	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	4.93	3.24	0.1	6.41
DCJMFL3	DMP6G8T	Topotecan	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	9.13	9.08	2.41	4.47
DCC8AX9	DMP6G8T	Topotecan	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.89	5.51	2.95	4.83
DC23SIZ	DMP6G8T	Topotecan	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	11.81	14.33	12.53	15.04
DCEKXYK	DMP6G8T	Topotecan	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.25	6.04	4.53	6.92
DCFNGTV	DMP6G8T	Topotecan	Approved	34	DMRJFN9	Theophylline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	15.1	15.1	24.65	24.69
DCGXBMU	DMP6G8T	Topotecan	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	3.41	4.85	1.32	4.53
DCS089T	DMP6G8T	Topotecan	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	5.19	6.58	0.21	4.41
DCUAR0R	DMP6G8T	Topotecan	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	8.52	8.19	0.43	8.48
DCM0ZKX	DMP6G8T	Topotecan	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	8.18	7.93	2.57	6.65
DCZIXZJ	DMP6G8T	Topotecan	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	13.28	12.15	10.15	11.22
DCHCMSY	DMP6G8T	Topotecan	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	7.39	9.77	1.12	5.14
DCK7GDZ	DMP6G8T	Topotecan	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.76	5.05	3.98	6.72
DCIGNLJ	DMP6G8T	Topotecan	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.25	10.55	5.18	9.46
DC6LF8L	DMP6G8T	Topotecan	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	10.94	14.14	12.65	14.56
DCGPFG8	DMP6G8T	Topotecan	Approved	34	DMS3YE9	Amantadine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	1.68	1.68	12.45	12.48
DCVBGAT	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	0.09	0.25	0.51	6.64
DC0OWBE	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	2.79	1.57	4.38	10.41
DCYNBW8	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.56	1.21	2.78	5.65
DCSMTZS	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	4.34	2.96	1.24	9.97
DCA7TT1	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.06	2.45	0.19	7.79
DCS3NH5	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	8.02	8.54	2.86	11.7
DC2T98X	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	20.69	21.44	12.21	20.16
DCAWWMX	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	3.41	4.64	0.63	6.65
DCSBLHZ	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	22.15	22.15	29.55	29.58
DCQHUVS	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	5.38	5.34	4.24	11.19
DCBQ211	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	1.53	0.35	0.05	6.37
DCBUT1Q	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	3.3	4.03	0.87	9.16
DC0B1GW	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	0.16	1.48	0.85	7.34
DC058K8	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.88	4.21	4.89	6.01
DC3K6EY	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	2.77	2.08	4.15	5.58
DC19EV7	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4.13	6.58	2.61	9.06
DCV4MVM	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	5.97	3.34	0.98	6.07
DC8G29P	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	2.34	2.51	0.74	7.98
DCMFU3T	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.57	11.13	3.2	11.26
DCWY8KH	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	3.21	1.48	0.67	5.55
DCX5QKC	DMP6G8T	Topotecan	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	2.5	6.98	1.56	6.02
DCULSLI	DMP6G8T	Topotecan	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	9	3.07	0.99	1.63
DCKR9O8	DMP6G8T	Topotecan	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	8.48	5.71	4.04	4.85
DCFWVSQ	DMP6G8T	Topotecan	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	4.14	4.61	2.6	3.02
DCRWD1J	DMP6G8T	Topotecan	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	3.61	2.09	0.03	1.14
DCIJT1D	DMP6G8T	Topotecan	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	8.56	7.91	5.06	8.34
DCRZCFO	DMP6G8T	Topotecan	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.14	3.14	1.89	2.36
DCRP14I	DMP6G8T	Topotecan	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	2.17	9.22	7.13	7.34
DC9XXVI	DMP6G8T	Topotecan	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.8	1.01	0.81	0.35
DCGKBMX	DMP6G8T	Topotecan	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	13.32	12.04	10.51	10.6
DCL417N	DMP6G8T	Topotecan	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	8.91	8.34	6.88	7.16
DCBGKWO	DMP6G8T	Topotecan	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	8.69	9.4	6.33	6.64
DCGFT0L	DMP6G8T	Topotecan	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4.02	6.38	5.89	6.1
DCMCFY4	DMP6G8T	Topotecan	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	11.47	10.18	8.2	8.86
DC4X5YX	DMP6G8T	Topotecan	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	6.02	3.15	2.67	3.74
DCZWT21	DMP6G8T	Topotecan	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	8.61	7.23	4.51	4.76
DCKE4C0	DMP6G8T	Topotecan	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.29	2.8	2.63	2.99
DCCIXOU	DMP6G8T	Topotecan	Approved	34	DMSIWD0	Hyodeoxycholic acid	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	8.88	8.88	17.76	17.76
DCP0NC2	DMP6G8T	Topotecan	Approved	34	DMSQZE2	Asenapine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	2.76	2.76	16.49	16.53
DC5D6RM	DMP6G8T	Topotecan	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.18	7.38	8.23	10.61
DCNAVCI	DMP6G8T	Topotecan	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	0.38	1.1	5.36	8.41
DC0XMY0	DMP6G8T	Topotecan	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	1.91	1.62	5.6	8.48
DCP2R03	DMP6G8T	Topotecan	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	1.19	0.9	9.47	12.03
DCMKSFO	DMP6G8T	Topotecan	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	5.81	7.24	8.14	11.44
DC594EO	DMP6G8T	Topotecan	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.35	4.03	1.31	5.8
DC64U2C	DMP6G8T	Topotecan	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.07	5.9	10.86	13.49
DC1G82Y	DMP6G8T	Topotecan	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.06	2.66	4.73	7.35
DC6F4NY	DMP6G8T	Topotecan	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	13.29	13.55	14.37	17.38
DC8OH29	DMP6G8T	Topotecan	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	6.22	5.81	6.5	10.08
DCKQZHI	DMP6G8T	Topotecan	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	8.42	9.08	8.29	10.76
DC44EG3	DMP6G8T	Topotecan	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.09	4.92	7.58	11.95
DCOL852	DMP6G8T	Topotecan	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.71	0.75	2.61	5.11
DC1Q4RP	DMP6G8T	Topotecan	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	5.42	2.88	0.87	4.93
DCGX23B	DMP6G8T	Topotecan	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.49	4.57	5.61	7.42
DCTQERC	DMP6G8T	Topotecan	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	1.82	4.43	2.59	7.21
DC2HXKH	DMP6G8T	Topotecan	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	5.76	5.87	6.24	8.44
DCYMPP2	DMP6G8T	Topotecan	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	28.87	24.44	28.36	28.97
DCPTY55	DMP6G8T	Topotecan	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.35	2.59	1.96	4.55
DC6K40J	DMP6G8T	Topotecan	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	4.11	5.83	8.25	9.58
DCIXHNP	DMP6G8T	Topotecan	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	16.95	12.14	12.59	17.41
DCNI3UD	DMP6G8T	Topotecan	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	9.76	10.38	13.63	14.16
DC7B60V	DMP6G8T	Topotecan	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	14.62	13.06	5.62	15.63
DCBIIBK	DMP6G8T	Topotecan	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.65	5.31	5.14	7.3
DCAJ5ZS	DMP6G8T	Topotecan	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	4.14	2.16	5.61	7.34
DC82IOA	DMP6G8T	Topotecan	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	9.22	10.14	4.37	13.06
DCZ1QIP	DMP6G8T	Topotecan	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	4.65	4.12	6.64	7.56
DCY4PJT	DMP6G8T	Topotecan	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.44	1.48	3.4	4.22
DCXTSI9	DMP6G8T	Topotecan	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	6.32	1.08	2.43	2.91
DCGKR0K	DMP6G8T	Topotecan	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	11.22	8.91	5.82	6.43
DC5MLQ6	DMP6G8T	Topotecan	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	6.34	5.44	6.29	6.47
DC9U3DI	DMP6G8T	Topotecan	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	8.32	9.92	6.02	6.37
DCD3AFH	DMP6G8T	Topotecan	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	5.77	6.68	2.93	5.47
DCZKPJS	DMP6G8T	Topotecan	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	7.84	7.07	4.05	4.23
DCBKSJZ	DMP6G8T	Topotecan	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	6.43	6.78	9.67	10.32
DC4ADYF	DMP6G8T	Topotecan	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	14.75	15.93	13.43	15.89
DCDLA69	DMP6G8T	Topotecan	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.06	2.26	1.09	1.63
DCY63GW	DMP6G8T	Topotecan	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	2.57	1.35	5.13	6.34
DC7U3BL	DMP6G8T	Topotecan	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	8.6	9.06	6.71	8.7
DCN1R4Y	DMP6G8T	Topotecan	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	5.86	6.71	2.92	7.63
DCHHIVH	DMP6G8T	Topotecan	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	17.62	18.65	11.21	18.76
DCRFHGF	DMP6G8T	Topotecan	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.02	4.8	1.54	4.63
DCMT127	DMP6G8T	Topotecan	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	0.47	5.58	3.83	5.4
DC6R49Q	DMP6G8T	Topotecan	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	3.59	8.94	6.18	9.12
DCE3HMW	DMP6G8T	Topotecan	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	8.93	9.86	8.9	10.04
DCUTGBS	DMP6G8T	Topotecan	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	3.51	10.09	7.47	8.32
DCOS4WV	DMP6G8T	Topotecan	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	6.71	9.3	6.26	9.36
DCQFJWY	DMP6G8T	Topotecan	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	9.68	9.51	5.68	9.25
DC7EW3X	DMP6G8T	Topotecan	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.56	11.19	8.48	12.02
DC6OD2X	DMP6G8T	Topotecan	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.45	7.19	4.19	6.79
DCMHXOD	DMP6G8T	Topotecan	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.97	3.85	2.37	5.78
DC17JQL	DMP6G8T	Topotecan	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	5.96	11.32	7.67	12.01
DCQBY12	DMP6G8T	Topotecan	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	6.98	2.66	0.56	2.42
DCMMKFW	DMP6G8T	Topotecan	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.61	2.41	5.56	6.3
DCV0J6X	DMP6G8T	Topotecan	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	7.94	8.12	2.94	11.01
DCKQBK8	DMP6G8T	Topotecan	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	0.01	2	2.66	5.85
DCC40FQ	DMP6G8T	Topotecan	Approved	34	DM2AQ5N	Spironolactone	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	28.79	28.79	38.14	38.16
DCGCVGN	DMP6G8T	Topotecan	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	6.46	1.8	1.31	3.41
DC8KV7I	DMP6G8T	Topotecan	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	7.49	6.39	1.04	2.14
DCTF9JG	DMP6G8T	Topotecan	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	0.15	6.33	5.96	6.26
DCGDNB9	DMP6G8T	Topotecan	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	2.15	7.21	5.91	7.73
DC7OOVN	DMP6G8T	Topotecan	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.88	6.64	6.59	9.07
DCJ21PM	DMP6G8T	Topotecan	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.22	5.12	3.29	4.59
DC0H5Z0	DMP6G8T	Topotecan	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	8.09	8.01	4.45	6.39
DCWCWLX	DMP6G8T	Topotecan	Approved	34	DMU8JGH	Hydralazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	18.65	18.65	36.31	36.34
DC84DAM	DMP6G8T	Topotecan	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	6.44	6.88	6.32	10.19
DC72BE4	DMP6G8T	Topotecan	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.34	1.53	4.87	6.74
DCFSTFO	DMP6G8T	Topotecan	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	2.31	0.99	4.45	5.65
DCS8PZ0	DMP6G8T	Topotecan	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	9.43	11.08	9.1	12.65
DCK7TVC	DMP6G8T	Topotecan	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.71	3.71	4.94	6.22
DCRCP4V	DMP6G8T	Topotecan	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	7.59	7.56	6.35	7.48
DCOLQPP	DMP6G8T	Topotecan	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	7.09	7.32	7.85	9.43
DCP8HZJ	DMP6G8T	Topotecan	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	1.78	2.42	0.48	3
DC5LBZC	DMP6G8T	Topotecan	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	1.97	1.99	7.08	9.57
DC4LJ2S	DMP6G8T	Topotecan	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.37	4.85	8.52	10.67
DC68S58	DMP6G8T	Topotecan	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.35	3	6.09	8.86
DCC0WN0	DMP6G8T	Topotecan	Approved	34	DMUZPJ5	Cisatracurium	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	15.82	15.82	34.76	34.79
DC2WBD4	DMP6G8T	Topotecan	Approved	34	DMWT905	Mefloquine	Phase 2/3 Trial	24	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	3.5	3.5	5.86	5.86
DC4R1QU	DMP6G8T	Topotecan	Approved	34	DMVM6QR	Lacosamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	12.64	12.64	23.06	23.1
DCY11HO	DMP6G8T	Topotecan	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	6.99	5.49	7.13	10.44
DCP1CR7	DMP6G8T	Topotecan	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.86	4.18	3.88	6.7
DC6SPDM	DMP6G8T	Topotecan	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.72	3.84	8.84	10.06
DCHMH3D	DMP6G8T	Topotecan	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	1.19	3.07	5.64	5.84
DCI6LN4	DMP6G8T	Topotecan	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	4.56	6.6	9.36	10.58
DCQBQOA	DMP6G8T	Topotecan	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.53	5.19	7.97	8.39
DC8154U	DMP6G8T	Topotecan	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.91	7	6.12	9.56
DC0C227	DMP6G8T	Topotecan	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.45	2.45	4.96	6.91
DCMO7YH	DMP6G8T	Topotecan	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	1.23	1.09	1.49	7.43
DCPR78O	DMP6G8T	Topotecan	Approved	34	DMVYXR8	Sumatriptan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	20.37	20.37	30.06	30.08
DCHZ9D5	DMP6G8T	Topotecan	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	4.16	0.43	1.41	4.21
DCFPUB2	DMP6G8T	Topotecan	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	6.04	3.98	8.21	9.26
DC0B5IC	DMP6G8T	Topotecan	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.23	4.23	2.95	4.6
DCTYCRH	DMP6G8T	Topotecan	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	9.63	5.27	4.9	5.19
DC14WDK	DMP6G8T	Topotecan	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	10.87	9.17	8.04	8.43
DCLDC9L	DMP6G8T	Topotecan	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	0.39	0.25	1.05	1.13
DC4ZZLP	DMP6G8T	Topotecan	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	7.18	4.82	5.21	6.85
DCVM5Y8	DMP6G8T	Topotecan	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	6.09	6.47	6.7	6.93
DCJR6PN	DMP6G8T	Topotecan	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	5.4	4.78	3.75	3.83
DC1C0XW	DMP6G8T	Topotecan	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	7.37	6.52	6.47	7.48
DCT6INL	DMP6G8T	Topotecan	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	10.04	9.22	9.82	10
DC187FX	DMP6G8T	Topotecan	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.9	3.03	3.96	4.39
DCR1TP8	DMP6G8T	Topotecan	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	2.4	1.02	2.27	2.33
DCSX4TJ	DMP6G8T	Topotecan	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.64	7.51	9.4	9.18
DC1EN9T	DMP6G8T	Topotecan	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.86	2.65	2.81	2.94
DC8GRPV	DMP6G8T	Topotecan	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	1.19	2.04	3.07	3.2
DCZG5L8	DMP6G8T	Topotecan	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	7.75	4.51	9.31	12.13
DCKIVSW	DMP6G8T	Topotecan	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	2.21	2.38	7.58	10.88
DC8BUUO	DMP6G8T	Topotecan	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.56	1.08	4.06	6.39
DC5EJRJ	DMP6G8T	Topotecan	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.64	3.82	1.93	5.33
DCNLDCK	DMP6G8T	Topotecan	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	8.69	7.85	11.35	14.22
DCGR9UT	DMP6G8T	Topotecan	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.14	3.21	6.83	7.8
DCSDBKT	DMP6G8T	Topotecan	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	6.85	3.74	3.76	8.21
DC053EN	DMP6G8T	Topotecan	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	7.01	7.47	6.19	6.47
DCDY80T	DMP6G8T	Topotecan	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.05	3.73	1.71	3.8
DC12I92	DMP6G8T	Topotecan	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	3.7	6.69	4.55	4.45
DC120SR	DMP6G8T	Topotecan	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.31	3.06	0.67	0.1
DCS4XV9	DMP6G8T	Topotecan	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.46	3.97	1.35	4.51
DCGRATT	DMP6G8T	Topotecan	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	8.6	7.95	6.74	6.79
DC1770M	DMP6G8T	Topotecan	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	15.15	16.44	14.44	16
DCTUAY5	DMP6G8T	Topotecan	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.36	3.76	3.24	3.61
DCUSFKC	DMP6G8T	Topotecan	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	2.54	2.02	1.37	6.07
DCTHN3V	DMP6G8T	Topotecan	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	9.99	9.55	8.87	8.93
DCF9IOS	DMP6G8T	Topotecan	Approved	34	DMXCM7H	Cerivastatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	4.98	4.98	6.56	6.62
DCL5141	DMP6G8T	Topotecan	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	6.9	3.5	2.75	6.22
DC5PCH6	DMP6G8T	Topotecan	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	15.7	15.7	25.44	25.45
DCFXNOM	DMP6G8T	Topotecan	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	3.31	2.13	0.4	1.95
DCHL8UJ	DMP6G8T	Topotecan	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	2.26	2.2	3.23	7.23
DCVB16S	DMP6G8T	Topotecan	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	2.76	1.55	6.65	8.74
DC8I515	DMP6G8T	Topotecan	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	3.82	7.27	6.2	7.79
DC9H4E9	DMP6G8T	Topotecan	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.51	4.15	1.22	3.83
DC2P3HY	DMP6G8T	Topotecan	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	8.73	8.52	5.92	10.8
DCOBW8T	DMP6G8T	Topotecan	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.23	5.73	4.66	5.78
DC9LRSK	DMP6G8T	Topotecan	Approved	34	DMYLOVR	Aciclovir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	4.49	4.49	26.97	27.01
DC0MZ06	DMP6G8T	Topotecan	Approved	34	DMYTE6L	Enoxacin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	2.75	2.75	12.43	12.47
DCAZKEA	DMP6G8T	Topotecan	Approved	34	DMYZ57N	Albendazole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	18.01	18.01	25.59	25.63
DC5THB3	DMP6G8T	Topotecan	Approved	34	DMZ1OO0	AS-1949490	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	6.8	6.8	16.46	16.48
DCK1CBI	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.99	3.94	6.86	10.89
DCGGTY9	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	1.98	1.69	10.33	12.11
DCMGSXR	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.18	0.26	0.24	5.16
DC665WP	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	4.04	3.44	6.93	10.54
DCQZ368	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.18	3.09	10.14	12.73
DCZX7IT	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.55	8.73	10.27	13.06
DCTEV8J	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	4.82	6.21	3.71	3.84
DC6SF5V	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	1.96	5.71	4.58	4.94
DCHYVVA	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	5.56	9.25	13.31	14.34
DC5KDIG	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.08	6.92	2.99	3.05
DCDIODJ	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	2.08	4.14	5.05	4.62
DCBNJZS	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	3.13	5.06	6.86	7.08
DCTPCTE	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.34	3.62	3.88	4.03
DCKBQ8Y	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	6.82	11.39	7.83	11.13
DCYZ3XQ	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.56	3.49	10.3	12.66
DCJ9IQR	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.58	2.85	5.28	5.89
DCCR1L5	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.12	2.33	1.26	5.91
DCNRRB4	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	6.31	5.9	2.88	9.25
DC70MC4	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.7	0.3	1.06	1.13
DCY20TC	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	4.41	1.85	11.76	13.56
DCUK2AM	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	10.42	10.17	16.89	18.54
DCXPPPJ	DMP6G8T	Topotecan	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	0.56	9.5	8.79	9.42
DCY85TZ	DM3BH1Y	Lapatinib	Approved	34	DMQNWRD	Oxaliplatin	Approved	34	DMTS85L	Capecitabine	.	.	"Neoplasms, Gastrointestinal Tract"	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCJVI8F	DM3BH1Y	Lapatinib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	DMDI269	Docetaxel	DMPDW6T	Epirubicin	Breast Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC06496	DM3BH1Y	Lapatinib	Approved	34	DMHIDCJ	Octreotide	Approved	34	DMTS85L	Capecitabine	.	.	Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCXJ6ZK	DM3BH1Y	Lapatinib	Approved	34	DM8X2EH	Everolimus	Approved	34	DMH07Y3	Letrozole	.	.	Breast Neoplasms	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCHO9NG	DM3BH1Y	Lapatinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Metastatic Breast Cancer With Intracranial Metastases	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC39K68	DM3BH1Y	Lapatinib	Approved	34	DMDI269	Docetaxel	Approved	34	DMF57DM	Pazopanib	.	.	"Neoplasms, Breast"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC8TZKW	DM3BH1Y	Lapatinib	Approved	34	DMSE3I7	Gemcitabine	Preclinical	2.1	DMQNWRD	Oxaliplatin	.	.	Metastatic Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCBG7QK	DM3BH1Y	Lapatinib	Approved	34	DM58WKG	Panobinostat	Approved	34	DMTS85L	Capecitabine	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC19AY7	DM3BH1Y	Lapatinib	Approved	34	DMDASC6	Metformin	Investigative	0	.	.	.	.	Advanced Cancers	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC1JKPH	DM3BH1Y	Lapatinib	Approved	34	DMQCTIH	Digoxin	Approved	34	.	.	.	.	"Neoplasms, Breast"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC3OMTZ	DM3BH1Y	Lapatinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	"Neoplasms, Breast"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC6UAXV	DM3BH1Y	Lapatinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Ovarian Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC73YZZ	DM3BH1Y	Lapatinib	Approved	34	DMKECZD	Temozolomide	Approved	34	.	.	.	.	Brain Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCAHJZ9	DM3BH1Y	Lapatinib	Approved	34	DMHJTR2	XL880	Phase 2	21	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCAUQG4	DM3BH1Y	Lapatinib	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCBGJ59	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCEJ7BH	DM3BH1Y	Lapatinib	Approved	34	DMTS85L	Capecitabine	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCGINTW	DM3BH1Y	Lapatinib	Approved	34	DMS49KH	Valproic Acid	Investigative	0	.	.	.	.	Solid Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCHGDDP	DM3BH1Y	Lapatinib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	"Neoplasms, Breast"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCHUIOX	DM3BH1Y	Lapatinib	Approved	34	DMMX2E6	Pemetrexed	Approved	34	.	.	.	.	"Lung Cancer, Non-Small Cell"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCIZGA3	DM3BH1Y	Lapatinib	Approved	34	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCKK4B7	DM3BH1Y	Lapatinib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Breast Neoplasms	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCMTEK5	DM3BH1Y	Lapatinib	Approved	34	DMXOELT	Midazolam	Approved	34	.	.	.	.	"Neoplasms, Breast"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCR384Z	DM3BH1Y	Lapatinib	Approved	34	DMF57DM	Pazopanib	Approved	34	.	.	.	.	"Carcinoma, Renal Cell"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCSWME9	DM3BH1Y	Lapatinib	Approved	34	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Metastatic Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCZA7XF	DM3BH1Y	Lapatinib	Approved	34	DM9HPW3	Exemestane	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC59A3V	DM3BH1Y	Lapatinib	Approved	34	DMQNWRD	Oxaliplatin	Approved	34	DMTS85L	Capecitabine	.	.	"Neoplasms, Colorectal"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCEXSG5	DM3BH1Y	Lapatinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.94	4.14	0.1	1.09
DCN0E7E	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	14.85	14.21	18.38	19.1
DCL98IZ	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.61	0.83	5.16	5.81
DCZY7TD	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	1.04	3.11	17.49	18.13
DC909I2	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	19.12	18.92	19.88	20.11
DCBGYAK	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	39.72	30.48	30.69	32.13
DCGP215	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	3.44	4.94	0.08	8.75
DCK8EQV	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	7.58	7.35	5.7	7.53
DCMEXFB	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	15.01	14.91	17.93	18.37
DCJSORG	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.61	3.14	15.33	18.28
DCJ5A6D	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	42.87	38.96	45.67	47.24
DCJ3U73	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.75	3.47	4.6	5.12
DCUCGP5	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	6.89	6.89	16.65	19.34
DC1B2O2	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.52	4.49	0	9.72
DCG942Q	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.4	5.37	2.19	9.61
DCBE7MQ	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.47	4.43	1.22	11.45
DCV0LXB	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.84	3.95	0.62	7.19
DCWF90P	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.56	2.4	3.79	5.84
DCXJ4B4	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.4	0.74	10.38	11.63
DCDQG8R	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	15.31	14.46	17.95	20.18
DCVG4BJ	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.95	2.96	10.18	11.82
DCZWKXC	DM3BH1Y	Lapatinib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.28	5.99	3.94	2.61
DCEO6IL	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	7.57	7	10.42	13.21
DCTPC9J	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	11.46	11.41	15.41	18.76
DCARH2D	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	1.13	0.33	3.67	11.85
DCE9R98	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.26	2.01	2.95	6.5
DC8PAWZ	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.41	5.35	11.65	14.24
DCUHRPH	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.03	1.61	1.16	5.28
DCJUEHG	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	6.26	6.47	12.75	15.63
DCK428S	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.79	5.87	7.18	9.12
DCXZFWY	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.22	0.01	6.07	12.96
DC9JWMG	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.01	0.04	4.92	7.15
DCOR7OW	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	12.35	12.14	15.42	16.98
DC0A69K	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	13.3	13.64	16.32	22.3
DCCLPD0	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.41	0.58	4.47	2.06
DCCZ72M	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	3.34	3.7	2.92	8.43
DC3V4IY	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.49	0.42	3.13	9.96
DCVPY1B	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.21	0.22	4.19	11.99
DCXKUTJ	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.44	3.46	2.86	5.84
DCJ6ADC	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.62	0.09	5.97	10.23
DCYN8E6	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	6.63	5.9	9.15	11.63
DCVQ0S3	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.71	3.67	9.94	11.82
DCXWDHL	DM3BH1Y	Lapatinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.28	2.09	1.08	0.34
DCXXWIK	DM3BH1Y	Lapatinib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.4	4.4	2.81	1.66
DCMK5L0	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.03	1.1	4.81	7.78
DCMVN2J	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.6	5.04	9.9	11
DCYY5QV	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	7.15	8.12	9.94	11.26
DCABNXY	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.31	1.12	5.07	8.39
DCMB29X	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.58	0.02	3.8	6.89
DCVV5JB	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.59	4.53	4.61	7.43
DC8PSQC	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.61	2.6	8.47	10.14
DC3G8OR	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	6.74	3.49	8.21	10.79
DCWB95I	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.96	4.35	14.88	15.93
DC5EUV5	DM3BH1Y	Lapatinib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.43	2.93	0.81	2.02
DCNAMUN	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	6.18	1.44	0.04	2.35
DCZM7L6	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.65	5.58	2.6	7.24
DC6WQ5P	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	3.25	3.11	4.49	7.9
DCHQLIL	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.08	7.6	6.73	9.03
DC3BAJ6	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	5.74	4.94	1.17	7.61
DCG8MNS	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	6.58	10.27	11.11	12.67
DC6V0RQ	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.38	4.28	2.82	6.2
DCIHF76	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	0.98	0.6	6.23	8.06
DCD6B4L	DM3BH1Y	Lapatinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	5.69	5.84	8.51	12.58
DCE34OB	DM3BH1Y	Lapatinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.58	3.48	10.52	12.75
DCRZWQR	DM3BH1Y	Lapatinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.16	2.99	5.08	8.71
DCKG5NK	DM3BH1Y	Lapatinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.04	5.48	7.98	9.19
DCMC89G	DM3BH1Y	Lapatinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.85	3.58	8.23	10.8
DCZ60GD	DM3BH1Y	Lapatinib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.17	7.6	2.48	2.08
DCWIP4F	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.43	2.43	5.16	9.06
DC857MR	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.44	1.17	4.46	8.12
DCJ3GIX	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.19	0.8	7.18	9.66
DCDUNLJ	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.88	2.4	3.54	8.82
DCM8K8T	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.08	0.21	10.87	12.91
DCVCROF	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	9.16	12.54	11.89	14.02
DCQUVH4	DM3BH1Y	Lapatinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.07	4.7	6.8	6.24
DCW1S71	DM3BH1Y	Lapatinib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.69	3.86	1.55	0.42
DCWAAUK	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.55	4.03	1.77	6.19
DC8HVA8	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.33	1.08	0.08	4.22
DCY0OS1	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	6.24	5.12	2.51	5.59
DCMP7O2	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.27	3.05	3.92	7.42
DCNGB7O	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.64	2.04	3.62	7.22
DCNJLIT	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	5.49	5.77	1.4	5.67
DCSFJHE	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	12.62	12.78	13.57	17.39
DC67AO2	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.53	3.61	7.66	9.28
DCVLOIM	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.33	3.52	2.11	8
DCG9MUY	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	0.72	3.25	7.36	9.17
DCROE3V	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.19	5.59	11.21	12.29
DCS3PIE	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	10.68	10.88	11.99	13.77
DCMC3RW	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	8.47	7.98	17.59	18.84
DCC07FH	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.63	2.65	6.12	7.28
DCSS3E4	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	6.9	6.63	15.35	16.55
DCZWCW6	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.55	2.72	15.58	16.35
DCQNGK7	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	8.82	7.95	14.15	14.53
DCBFK0L	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.54	3.36	9.71	10.69
DCNZHJ5	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	0.14	0.32	6.69	6.89
DCXQM7K	DM3BH1Y	Lapatinib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	6.07	6.45	6.09	13.01
DCYLA46	DM3BH1Y	Lapatinib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.07	1.59	0.96	8.2
DC656PZ	DM3BH1Y	Lapatinib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.04	1.4	6.01	7.76
DCEKXFJ	DM3BH1Y	Lapatinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.99	3.61	0.88	4.63
DC5BCWW	DM3BH1Y	Lapatinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.11	2.07	1.17	3.66
DCCBYRL	DM3BH1Y	Lapatinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.7	1.69	5.49	7.91
DCPQ4WH	DM3BH1Y	Lapatinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.93	3.95	3.48	5.76
DC868SC	DM3BH1Y	Lapatinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.33	2.17	6.08	7.11
DCZYH53	DM3BH1Y	Lapatinib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.1	2.87	1.3	4.96
DC711JG	DM3BH1Y	Lapatinib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.21	4.87	3.3	4.96
DCLK50I	DM3BH1Y	Lapatinib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.44	6.62	0.64	8.67
DC7ALR8	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.97	3.77	3.25	9.21
DCR4SGU	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	5.79	5.35	5.84	11.51
DC9KZXQ	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	13.01	4.13	14.37	17.89
DCA2IP7	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	5.15	5.22	2.75	9.15
DCUW80A	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.27	4.04	9.08	13.83
DCXPOE3	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.77	5.68	7.21	9.62
DCTI7OA	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.07	2.56	5.03	9.73
DC22NZD	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	9.03	9.16	8.5	11.97
DC4S4KY	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.82	6.99	10.83	13.39
DCG8IDD	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.17	0.96	1.57	5.04
DC3R796	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.82	3.53	4.85	8.82
DCT0I92	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.24	4.52	6.97	9.92
DCAYZK0	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	1.13	2.12	14.81	15.82
DC7IBU4	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	9.32	9.28	10.12	15.2
DCSKIAU	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	12.68	10.84	16.3	19.04
DCP0JBD	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	7.08	6.7	13.08	16.64
DCG52ZA	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.38	11.68	18.01	18.98
DCRMVVH	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.3	3.25	13.92	15.21
DCKY3A1	DM3BH1Y	Lapatinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.86	2.98	1.13	0.57
DCVOF1G	DM3BH1Y	Lapatinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.44	1.89	0.1	0.98
DCA5V4P	DM3BH1Y	Lapatinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.69	5.69	3.98	4
DCYP1TC	DM3BH1Y	Lapatinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.68	5.51	4.03	1.44
DCZXFTC	DM3BH1Y	Lapatinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.43	8.25	4.01	2.84
DC4NCSD	DM3BH1Y	Lapatinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.74	7.73	3.79	3.82
DCXBA8O	DM3BH1Y	Lapatinib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	6.91	10.49	4.15	2.2
DC1AOH0	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	1.04	0.88	12.85	15.31
DCOGIEF	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.31	3.34	5.85	8.07
DC7YAUN	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.56	1.43	12.71	14.36
DCN0EME	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.17	0.9	5.52	9.77
DC256VK	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.5	3.67	6.03	9.63
DCRL7YN	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.33	2.57	6.6	8.96
DCZE45W	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.41	1.81	6.13	8.72
DCDBPDI	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	7.44	9.04	6.76	10.65
DC20MCK	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	18.31	15.16	17.54	20
DC5ZUNQ	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.98	5.71	8.93	10.13
DC3HX6E	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	6.11	9.45	5.27	15.63
DCQW0V2	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.05	9.09	14.3	14.65
DCIXM1A	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	6.02	6.07	19.34	20.33
DCVW9P5	DM3BH1Y	Lapatinib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	12.08	13.19	1.55	0.27
DCL074P	DM3BH1Y	Lapatinib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	3.97	7.34	4.61	3.6
DC9CQAW	DM3BH1Y	Lapatinib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	1.99	5.24	1.69	0.64
DC7YNQ6	DM3BH1Y	Lapatinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.12	1.72	0.23	0.58
DCJLIXT	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.9	5.52	12.12	13.17
DCQDUXE	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.41	10.63	16.71	17.35
DCI4N4J	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	22.55	23.05	29.64	31.09
DCN9156	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.83	2.67	5.8	7.04
DC7Q9B6	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	42.64	36.32	38.65	41.5
DCWPX30	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	7.85	7.21	10.71	13.26
DC078BX	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	4.75	9.37	6.33	6.47
DCQMU7N	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	8.73	7.62	8.79	8.9
DCWGBCD	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	8.59	13.25	17.95	18.33
DCHBSZJ	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.99	3.48	3.65	8.18
DC5OTT4	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	67.34	57.4	57.01	59.56
DCO4MNH	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	1.93	5.18	4.95	6.87
DCZ9V28	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	64.05	55.7	56.45	58.62
DCGNIMN	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	22.34	24.11	26.47	29.97
DCGTD23	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	8.05	8.66	8.61	13.22
DCS4RNP	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.14	0.67	1.63	3.85
DCFVMNF	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.3	4.49	5.5	7.07
DCSAETK	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	11.9	12.09	14.33	15.7
DC0YFC7	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.41	1.55	7.12	7.65
DCAII4H	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	27.55	27.26	32.76	32.92
DCMOFZ7	DM3BH1Y	Lapatinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	5.81	14.17	12.79	12.86
DCQAZJN	DM3BH1Y	Lapatinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	3.84	4.97	5.97	6.65
DCXH0P2	DM3BH1Y	Lapatinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	5.03	5.01	2.33	6.89
DCGWFE4	DM3BH1Y	Lapatinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.03	2.01	4.39	5.54
DCSXWTY	DM3BH1Y	Lapatinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.13	3.37	1.04	4.49
DCWQWWZ	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.01	1.45	2.6	4.95
DCHK8J8	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	1.48	3.85	7.04	10.66
DC1ZD85	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	2.59	7.16	9.82	11.24
DCEILRL	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	4.99	6.31	4.78	8.3
DC2QLEZ	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	1.88	6.03	1.24	7.88
DCY0VCX	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.15	1.18	2.76	4.89
DCHSU4T	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.22	4.09	3.74	7.33
DCTBR5P	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	8.73	12.68	7.21	14.3
DC21Q7Q	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	6.32	5.75	4.02	7.88
DCRLKOF	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	0.26	4.39	2.23	5.05
DCQ06O0	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	6.4	10.69	4.46	12.9
DCDY7WK	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	7.89	8.53	4.18	11.1
DCGE571	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	4.22	5.74	9.74	10.38
DCQJQ3Q	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.89	10.85	7.01	12.11
DCUDG1U	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	14.81	20.63	12.09	19.77
DC79KEQ	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.94	8.18	9.11	11.63
DCYTAS1	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	6.62	6.11	6.88	13.06
DCFHHSE	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	1.17	2.33	4.95	7.17
DCQ4R64	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	11.67	12.52	10.35	15.37
DCDIBWQ	DM3BH1Y	Lapatinib	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	4.98	11.01	7.35	10.94
DCF25SR	DM3BH1Y	Lapatinib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	4.74	10.21	4.9	3.85
DCPQE5Y	DM3BH1Y	Lapatinib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	1.59	7.09	6.19	3.54
DCC2WFR	DM3BH1Y	Lapatinib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	3.33	5.5	1.27	0.63
DCNLHG6	DM3BH1Y	Lapatinib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	2.54	3.23	0.98	1.01
DCXV3R2	DM3BH1Y	Lapatinib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	7.3	11.92	6.04	4.97
DCWDMNV	DM3BH1Y	Lapatinib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.11	2.69	1.33	1.28
DCNKUFW	DM3BH1Y	Lapatinib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	8.27	10.17	6.85	4.64
DCYK6YC	DM3BH1Y	Lapatinib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	7.15	7.34	3.89	7.49
DCVW745	DM3BH1Y	Lapatinib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	1.81	3.63	1.74	0.91
DC97C8S	DM3BH1Y	Lapatinib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.81	7.59	0.89	0.38
DCPODS1	DM3BH1Y	Lapatinib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	0.67	1.69	0.49	0.31
DCJA0GA	DM3BH1Y	Lapatinib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.49	3.34	0.85	0.73
DC6DUR0	DM3BH1Y	Lapatinib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.49	4.62	4.55	5.82
DCR8JFE	DM3BH1Y	Lapatinib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	4.91	7.87	1.35	8.72
DC1QQY0	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.34	2.63	7.64	9.41
DC8UFPF	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.01	2.3	7.3	9.58
DCPPUAI	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	8.45	8.45	8.81	12.46
DCQCC9K	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.74	4.49	5.03	9.24
DCLG5O1	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	8.84	7.9	5.77	9.67
DCU28IT	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	4.81	3.71	3.33	6.85
DCMAOGS	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	4.42	6.83	9.59	11.75
DCJDKCX	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.85	8	11.29	13.27
DCYDYLZ	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	5.81	7.01	5.17	8.97
DCV9EV8	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	0.02	1.37	0.33	2.68
DC7LEZX	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	5.77	5.28	4.43	9.8
DC53J8N	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.83	3.7	2.84	6.12
DCZUYOE	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	5.78	8.17	3.84	9.09
DCBRVXC	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.34	2.65	1.74	5.67
DC5LURT	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	1.22	0.91	4.91	10.29
DCV4HEM	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	14.07	13.67	10.88	15.97
DCEKO7A	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.75	5.21	9.01	13.08
DCVV38E	DM3BH1Y	Lapatinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	7.18	9.24	1.89	10.22
DCPRZL1	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	8.16	9.46	17.08	18.19
DC4UVY1	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.54	2.58	3.6	6.03
DCIJHN8	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	0.85	0.81	5	7.12
DC7NQHO	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	1.02	1.25	0.99	4.97
DC7KLHI	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.29	1.47	0.35	5.33
DCWTFQ8	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	9.93	8.98	4.64	10.95
DCPHQOE	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	10.29	15.76	17.46	19.07
DC7UJ88	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.45	2.98	4.32	5.92
DCV8M0G	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.23	7.29	4.63	11.61
DCYVBUC	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.56	7.41	5.2	4.9
DC34WMZ	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	5.38	3.99	4.42	7.05
DC67BV5	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	17.36	16.9	13.27	16.25
DCROA3T	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	6.35	9.21	8.33	12.12
DCW9V02	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	6.74	7.04	4.13	9.8
DCA7DTL	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	13.52	13.67	9.69	18.18
DC90EQ2	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	6.43	4.77	1.79	6.14
DC0J01A	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	10.19	11.53	5.46	12.6
DCU8MEA	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.79	12.14	12.62	14.23
DCASJ1H	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	8.4	8.26	1.88	8.28
DCG2N6S	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	1.23	0.18	1.4	6.47
DCNC1ZV	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	10.77	14.89	9.72	16.44
DCOCDIM	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.35	2.53	4.79	7.04
DCRWOTM	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	2.59	3.7	9.98	11.09
DCAQIEP	DM3BH1Y	Lapatinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.55	6.25	5.75	7.82
DCTMUHM	DM3BH1Y	Lapatinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.22	7.42	6.54	5.52
DC5U7BN	DM3BH1Y	Lapatinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.1	2.08	0.01	1.24
DCUP5BW	DM3BH1Y	Lapatinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	3.26	8.65	1.41	3.88
DCT25PK	DM3BH1Y	Lapatinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.38	4.63	4.54	0.04
DCBZ3OI	DM3BH1Y	Lapatinib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.22	5.22	1.78	0.03
DCWKW4S	DM3BH1Y	Lapatinib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.86	8.51	3.16	0.37
DCOFI5E	DM3BH1Y	Lapatinib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.91	4.29	4.16	2.8
DCHHBM1	DM3BH1Y	Lapatinib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	0.44	4.02	2.48	1.82
DCBUDLX	DM3BH1Y	Lapatinib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.41	5.73	3.25	2.68
DCUN5DA	DM3BH1Y	Lapatinib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	7.2	9.21	7.22	1.03
DCFSL6P	DM3BH1Y	Lapatinib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	7.28	2.55	0.07	0
DCYQ8UP	DM3BH1Y	Lapatinib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.87	4.93	0.46	1.06
DCMSBHG	DM3BH1Y	Lapatinib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.57	2.62	2.01	1.89
DCKIIYA	DM3BH1Y	Lapatinib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.52	1.3	0.91	0.38
DCEEF8Q	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	10.86	10.86	8.15	13.58
DCK2ECZ	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.07	3.24	9.79	10.27
DCICV7F	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.76	0.88	2.4	5.49
DCBPWTC	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	3.17	6.72	8.82	9.14
DC8UDM5	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	10.24	11.61	14.66	18.3
DCKUWWT	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	14.79	18.79	15.72	22.45
DCTXZ1H	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	2.42	5.97	3.32	7.99
DCMTCJY	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	7.06	7.44	3.89	9.81
DC5RSD2	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	3.26	8.97	10.69	12.79
DC0FXKV	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	13.03	15.42	6.31	20.12
DC5OR6V	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	10.11	11.16	7.24	12.48
DCMYLNI	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	8.72	4.09	1.91	4.87
DC58MBB	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	14.69	16.42	7.51	18.25
DCPANJV	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	24.87	25.33	0.24	31.27
DC9W1EE	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	9.87	9.98	14.64	15.49
DC40JSC	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	13.8	16.3	13.23	18.15
DC2CGAW	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	8.4	12.6	3.66	12.1
DCL4VEE	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.21	1.8	2.08	4.51
DCJCCX4	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	12.91	10.73	1.1	17.3
DC6LWIP	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	10.23	7.94	10.31	12.31
DCICFPV	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	24.4	23.19	18.96	25.38
DC78PYN	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.99	10.17	17.51	12.74
DCSCOXK	DM3BH1Y	Lapatinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	4.35	11.57	10.45	11.11
DCICA2U	DM3BH1Y	Lapatinib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	6.54	3.16	2.24	2.24
DCBA6TH	DM3BH1Y	Lapatinib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	2.87	2.68	0.31	2.64
DCQROGI	DM3BH1Y	Lapatinib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.01	1.14	1.07	1.02
DC5N8P0	DM3BH1Y	Lapatinib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	7.02	1.04	1.7	1.7
DC3AC42	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	4.89	6.55	3.45	6.94
DCUTWQC	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.33	5.69	5.66	6.29
DC3J2XN	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	5.29	4.34	5.32	7.9
DCR3I9B	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	1.31	0.65	4.33	8.4
DC241AL	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	6.93	5.37	3.95	7.54
DCD6UTH	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.28	1.78	0.4	4.64
DCQKABK	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	8	6.95	5.73	8.54
DC7U9YE	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	7.71	9.15	3.73	8.78
DC8XVLW	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	7.05	7.27	9.37	11.22
DCQ4HR0	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	6.28	8.27	1.58	9.9
DCF8Y6M	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.7	3.33	1.8	5.96
DCDSVWU	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	9.07	9.4	6.62	10.81
DCBCI1Q	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	9.34	7.74	5.98	8.45
DCGKHYX	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	0.49	6.41	0.43	8.31
DCKO0EK	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.01	7.11	7.72	9.36
DCAJOI2	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	6.25	5.95	1.95	9.23
DCFDE92	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.43	3.69	1.14	4.44
DCRYVPD	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	5.06	10.3	4.27	9.46
DCI8CQZ	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.84	7.3	7.46	9.32
DC36V6H	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.34	1.36	4.29	9.08
DCH8QSO	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.51	6.25	1.94	7.94
DCVD3V9	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.97	1.37	3.35	5.76
DC6OTA8	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	8.86	2.45	7.87	9.98
DCGOS7K	DM3BH1Y	Lapatinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	2.9	4.95	6.65	4.81
DC6EI9S	DM3BH1Y	Lapatinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.47	4.62	1.18	1.31
DC2QRLQ	DM3BH1Y	Lapatinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.78	1.75	0.93	0.43
DCM0HF2	DM3BH1Y	Lapatinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.72	5.3	0.68	1.17
DCN6P3D	DM3BH1Y	Lapatinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	11.77	16.01	2.93	1.23
DCQM0BR	DM3BH1Y	Lapatinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	1.24	3.83	0.64	2.1
DCXAHNE	DM3BH1Y	Lapatinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	7.56	10.08	2.08	0.71
DC8SBDV	DM3BH1Y	Lapatinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	4.96	1.24	4.69	7.38
DCXXX1P	DM3BH1Y	Lapatinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	0.51	1.2	2.57	6.49
DC81U1C	DM3BH1Y	Lapatinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	7.17	9.16	4.63	9.94
DCYBSA7	DM3BH1Y	Lapatinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	0.31	1.68	1.36	4.84
DC1NGLF	DM3BH1Y	Lapatinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.29	2.52	5.41	7.36
DC8EGOU	DM3BH1Y	Lapatinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.32	5.72	3.37	8.69
DC6R27Z	DM3BH1Y	Lapatinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	5.13	7.69	4.16	9.21
DCHK3Q3	DM3BH1Y	Lapatinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	16.92	19.37	15.44	19.88
DC42OPM	DM3BH1Y	Lapatinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.29	5.17	6.34	8.38
DCC65MV	DM3BH1Y	Lapatinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	11.58	8.73	5.4	9.8
DCSDOD2	DM3BH1Y	Lapatinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	6.23	4.69	7.33	11.48
DCG8XU8	DM3BH1Y	Lapatinib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.13	9.37	6.14	2.27
DC22N8K	DM3BH1Y	Lapatinib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.79	5.32	0.79	0.79
DC5JK9I	DM3BH1Y	Lapatinib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	0.31	0.83	0.17	0.06
DC5NISX	DM3BH1Y	Lapatinib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	4.68	9.19	8.06	3.52
DCX2GME	DM3BH1Y	Lapatinib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.18	3.75	2.74	0.63
DCTHPEN	DM3BH1Y	Lapatinib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.26	2.83	0.06	0.06
DCGBWQ7	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.19	2.89	4	6.8
DCBUJM5	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.3	7.98	11.19	12.41
DC5JDCW	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	1.46	0.95	2.23	5.5
DC74E5U	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.01	0.46	1.85	5.31
DCCA7UO	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.73	2.68	3.15	7.69
DC6IYBF	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.54	4.62	1.34	6.73
DC1YJUD	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	2.15	6.67	10.03	11.3
DCLZLZF	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.28	3.42	6.59	7.1
DCD36I8	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.34	8.59	1.89	9.37
DC3JF88	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	13.32	12.59	8.35	14.19
DC346TM	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	3.63	10.94	8.68	11.45
DC6HQTJ	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	0.05	3.97	3.73	3.74
DCXLBD2	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	0.47	7	4.53	11.6
DCIZ5SN	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.55	4.52	2.46	6.01
DC2LUNB	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	7.65	13.71	7.83	12.54
DCF8N2D	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.9	12.11	12.3	14.39
DC56TEL	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	29.75	25.84	30	31.74
DCZ4ZT5	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	0.96	0.23	7.62	10.66
DCDIUAT	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	10.01	10.72	7.71	13.48
DCYFM9K	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.39	6.39	4.42	9.51
DCC9HJ7	DM3BH1Y	Lapatinib	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	2.67	5.21	0.44	6.39
DCZAGR9	DM3BH1Y	Lapatinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.84	3.66	3.06	0.35
DC4D3WM	DM3BH1Y	Lapatinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.23	4.47	2.19	1.97
DCUYSK5	DM3BH1Y	Lapatinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.93	12.43	11.12	5.67
DC1MNCT	DM3BH1Y	Lapatinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	8.91	9.71	7.07	0.92
DC66HYP	DM3BH1Y	Lapatinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	6.29	10.51	2.92	2.73
DC3U84V	DM3BH1Y	Lapatinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	5.53	8.32	3.45	1.61
DC50YMI	DM3BH1Y	Lapatinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	2.49	4.21	2.18	1.34
DCYKWZG	DM3BH1Y	Lapatinib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	2.95	5.3	2.16	0.23
DCPL6ER	DM3BH1Y	Lapatinib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	2.07	3.73	2.33	2.33
DC6ZUSV	DM3BH1Y	Lapatinib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	5.6	11.47	2.23	2.23
DCSQFXI	DM3BH1Y	Lapatinib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.45	4.37	1.68	1.68
DCR7RQ8	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.01	3.12	1.81	3.51
DCXVROI	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	4.89	4.14	4.17	7.31
DC4XGCD	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	3.38	5.49	2.9	7.22
DCP7287	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	6.11	7.35	3.9	9.18
DC0CIAD	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	0.93	6.37	1.03	6.47
DCWC6LW	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	10.62	11.34	6.28	12.63
DC5O3XS	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	8.18	11.34	9.05	13.4
DC66JPI	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.17	6.39	5.42	8.5
DCNWRA3	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	8.08	9.12	4.99	10.06
DC8NE1P	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	16.85	15.51	12.58	15.3
DC60AWK	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	6.35	7.91	3.61	7.88
DCW8KCC	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	5.05	8.21	1.47	8.13
DCIO4YZ	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.09	5.12	2	6.63
DCBE837	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.67	6.19	0.38	6.58
DCNQ2OQ	DM3BH1Y	Lapatinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	10.71	11.79	0.22	14.75
DC8MRNT	DM3BH1Y	Lapatinib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.21	4.98	3.24	2.51
DCQA4Z4	DM3BH1Y	Lapatinib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.65	3.82	4.01	2.36
DC17218	DM3BH1Y	Lapatinib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	1.01	4.51	0.89	1.36
DCMH100	DM3BH1Y	Lapatinib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.08	6.61	5.98	1.91
DC9AGA4	DM3BH1Y	Lapatinib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.69	5.9	2.41	1.13
DCNMQNC	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	4.32	4.15	10.87	12.12
DCAZA14	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.99	0.85	8.58	9.06
DCLVQU1	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	8.02	10.71	13.36	13.71
DCFKPCB	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.61	3.09	7.37	8.15
DC3IXI9	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	1.95	6.42	5.29	8.28
DCX15U6	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	11.35	14.22	14.76	14.98
DCKUVAX	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	14.18	13.45	17.44	17.89
DC2AQMJ	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.43	7.35	10.13	11.66
DCOWG8P	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	8.84	10.3	11.13	12.76
DC9OV8V	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	2.47	8.71	9.52	10.6
DC6L7M8	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	9.38	10.24	9.26	12.94
DCCY7Y1	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	7.4	15.69	16.29	17.05
DCSTLKF	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	5.43	5.39	7.96	9.35
DCN46IZ	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	8.12	15.99	14.77	15.58
DC73KQ8	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.25	3.43	6.05	7.25
DCBSVGB	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	38.02	37.36	32.11	40.65
DCU36L0	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	0.45	1.14	4.59	5.13
DCAAYO9	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	13.35	13.35	13.91	16.86
DCDMYZK	DM3BH1Y	Lapatinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.62	3.86	14.57	15.46
DC2KT12	DM3BH1Y	Lapatinib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	11.3	17.47	10.1	16.95
DCD3DHX	DM3BH1Y	Lapatinib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	10.19	8.49	8.09	13.1
DC6WTUA	DM3BH1Y	Lapatinib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.76	7.39	4.31	10.46
DCYCMC5	DM3BH1Y	Lapatinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	6.49	9.47	6.78	9.91
DCUT0M0	DM3BH1Y	Lapatinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	7.11	4.32	4.18	6.33
DCAFJA7	DM3BH1Y	Lapatinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.1	5.57	1.99	7.38
DCXV6RZ	DM3BH1Y	Lapatinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	7.75	5.98	3.07	7.43
DCD4WHQ	DM3BH1Y	Lapatinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	23.8	21.02	4.26	21.26
DC9ZHJO	DM3BH1Y	Lapatinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	4.67	5.79	2.65	6.49
DCH6IMR	DM3BH1Y	Lapatinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	3.65	5.48	0.09	2.62
DC9XUBG	DM3BH1Y	Lapatinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.66	3.02	0.6	1.78
DCV7GWY	DM3BH1Y	Lapatinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	5.51	4.24	2.66	4.97
DCYYZKO	DM3BH1Y	Lapatinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.14	6.02	1.71	5.54
DC9C9OZ	DM3BH1Y	Lapatinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	6.96	10.75	3.56	9.52
DCHNND8	DM3BH1Y	Lapatinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	1.23	0.39	1.11	4.48
DCFIHVI	DM3BH1Y	Lapatinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	8.78	7.66	1.84	7.98
DC7L6GU	DM3BH1Y	Lapatinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	3.94	5	1.69	7.58
DCYTO7X	DM3BH1Y	Lapatinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	18.61	14.67	0.85	14.05
DCSLPLM	DM3BH1Y	Lapatinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1	6.1	0.67	3.92
DCCZY1U	DM3BH1Y	Lapatinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	19.47	16.63	2.52	14.09
DCP2ICM	DM3BH1Y	Lapatinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	2.93	6.1	1.36	4.75
DC7T0XN	DM3BH1Y	Lapatinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	7.18	7.81	4.89	8.32
DCAZ1XG	DM3BH1Y	Lapatinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.16	7.17	1.82	5.06
DCCYP4F	DM3BH1Y	Lapatinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	4.53	7.25	0.77	6.28
DCO7KE5	DM3BH1Y	Lapatinib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	1.03	1.94	3.78	6.02
DCNSVNL	DM3BH1Y	Lapatinib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	7.3	11.68	7.05	11.61
DCY0QUU	DM3BH1Y	Lapatinib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	0.05	4.22	0.67	0.67
DCUE4Z7	DM3BH1Y	Lapatinib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	3.5	3.53	3.4	10.36
DCI9Y9Z	DM3BH1Y	Lapatinib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.21	10.12	0.4	10.53
DCC5YCB	DM3BH1Y	Lapatinib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	7.54	13.52	15.81	21.56
DCGF0M5	DM3BH1Y	Lapatinib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.16	3.31	0.76	4
DC3REP7	DM3BH1Y	Lapatinib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.81	7.1	2.9	2.1
DCPB7SG	DM3BH1Y	Lapatinib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.2	4.5	3.92	3.5
DC33JE6	DM3BH1Y	Lapatinib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	1.7	6.68	3.78	3.36
DCIEWFW	DM3BH1Y	Lapatinib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.63	2.51	0.34	0.32
DCMNJS3	DM3BH1Y	Lapatinib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.26	7.71	5.82	5.57
DCYZ2NW	DM3BH1Y	Lapatinib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.38	8.35	6.9	4.84
DC4353L	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	5.7	9.26	5.92	10.94
DC3D362	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	12.56	7.74	10.33	1.44
DCKAO7M	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	5.49	5	6.62	9.18
DCGZYEJ	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	6.02	5.77	7.6	10.64
DC4L6GT	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	6.58	6.22	0.97	8.87
DCR5ONT	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	13.07	13.54	7.16	15.83
DCE1EM8	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	14.85	15.45	16.56	20.81
DCI0SUU	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.44	5.08	2.61	8.47
DCHB97R	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	8.89	10.75	0.93	8.61
DC9X8P0	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	16.08	20.55	10.04	18.8
DC58RBZ	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	4.21	9.5	5.24	3.41
DCY1YKF	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	3.53	9.92	7.76	7.06
DCS5JKS	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	5.66	9.76	7.01	11.35
DC07ROM	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.01	6.46	3.52	9.64
DCAULY8	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	5.04	8.33	4.05	10.51
DCQGBCJ	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	11.35	10.78	1.84	14.6
DC37WZD	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	7.4	7.55	3.58	10.01
DCJMOEQ	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	15.56	15.41	12.91	16.82
DC0LPVS	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	4.19	2.78	2.57	4.76
DCHOLN4	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	6.06	3.64	1.35	6.06
DCFLEC7	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	8	7.86	1.85	9.9
DCMH79C	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	15.04	14.98	12.27	16.64
DCU8GEC	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	3.29	1.05	3.87	7.38
DCU3US1	DM3BH1Y	Lapatinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	7.02	8.46	3.48	7.33
DCLOH8Z	DM3BH1Y	Lapatinib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.76	3.94	3.4	2.32
DC3ESRO	DM3BH1Y	Lapatinib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	8.51	9.38	2.66	0.73
DC7T8PX	DM3BH1Y	Lapatinib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	0.68	3.7	1.14	1.1
DC7RJWB	DM3BH1Y	Lapatinib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	2.12	5.84	4.14	3.17
DCVL6YC	DM3BH1Y	Lapatinib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.22	6.56	5.63	0.41
DCKHH56	DM3BH1Y	Lapatinib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	3.54	5.36	4.38	2.18
DCXS7NZ	DM3BH1Y	Lapatinib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.6	5.35	1.69	1.99
DC7QF2K	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.31	4.82	8.29	10.65
DCW5M62	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.78	2.05	0.78	8
DCP8ZUS	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	3.65	3.48	11.38	12.68
DC9KE08	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	12.72	12.71	15.46	18.78
DC756UX	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.14	5.59	7.87	10.1
DC4DSH3	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	2.55	1.38	0.45	3.52
DC8FGX3	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	9.41	8.75	9.1	12.59
DC02DNR	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	10.36	15.93	19.12	20.03
DCBNHUK	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.65	11.59	13.75	13.97
DC0RBBL	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	10.63	11.46	15.42	16.08
DCP6STQ	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.19	7.88	5.64	6.2
DCXMDRK	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	11.19	17.21	16.39	19.36
DCJZG20	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	7.51	3.77	3.5	4.62
DC1P5B6	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	7.71	15.32	15.95	18.05
DC4CHS1	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	12.28	18.83	20.06	19.7
DCJ3JUF	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	0.05	8.22	5.19	12.69
DCHSPRB	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.65	12	12.13	14.67
DCEUHVI	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	4.98	16.88	10.74	16.14
DCR0WTW	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.57	7.43	9.66	11.31
DCAA2AP	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	14.12	14.57	17.21	21.94
DCSMH6T	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	0.56	0.59	9.95	11.82
DCAL8I7	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	13.56	14.08	13.93	17.37
DCFB2IT	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.13	6.42	13.45	15.73
DC5XC2V	DM3BH1Y	Lapatinib	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	3.69	5.56	0.02	7.92
DCUFEC4	DM3BH1Y	Lapatinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.52	9.91	10.24	6.63
DC5RSJB	DM3BH1Y	Lapatinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.34	4.72	1.4	1.12
DCK3WXV	DM3BH1Y	Lapatinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	6.56	6.12	1.77	0.68
DCHS4T8	DM3BH1Y	Lapatinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	2.38	4.45	0.46	0.36
DCO62JX	DM3BH1Y	Lapatinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.74	2.08	1.32	0.35
DCN5X64	DM3BH1Y	Lapatinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.22	8.1	4.58	2.08
DC6SDWH	DM3BH1Y	Lapatinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.23	8.93	5.83	1.75
DCHWWXX	DM3BH1Y	Lapatinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	2.5	8.54	3.18	1.68
DCPQ4M8	DM3BH1Y	Lapatinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	16.03	26.77	21.96	21.42
DCEXLU4	DM3BH1Y	Lapatinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.87	5.5	4.47	4.97
DCST8LA	DM3BH1Y	Lapatinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	5.24	9.37	5.25	9.07
DCOCAX9	DM3BH1Y	Lapatinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.12	4	0.96	0.99
DCDDUO0	DM3BH1Y	Lapatinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.26	3.95	0.52	0.52
DCUS801	DM3BH1Y	Lapatinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.17	3.72	2.42	2.36
DCW3415	DM3BH1Y	Lapatinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	4.76	8.23	4.95	1.52
DC8OTR9	DM3BH1Y	Lapatinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	16.19	19.44	11.45	11.33
DCJMECB	DM3BH1Y	Lapatinib	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.74	4	4.43	4.83
DCI9OK1	DM3BH1Y	Lapatinib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.58	8.27	4.19	3.22
DC4HN51	DM3BH1Y	Lapatinib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	0.01	6.59	2.54	3.28
DCBH5E1	DM3BH1Y	Lapatinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.39	5.07	3.53	0.69
DCFQ6Q9	DM3BH1Y	Lapatinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.35	3.51	1.83	1.7
DC06ESE	DM3BH1Y	Lapatinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.56	10.66	6.47	3.5
DCX1M57	DM3BH1Y	Lapatinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.1	5.14	4.26	3.74
DCD6CB8	DM3BH1Y	Lapatinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	2.15	6.09	3.08	2.19
DC1Q0F2	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	4.09	3.63	0.53	6.84
DCJ0SXH	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.18	1.34	3.64	5.87
DCZVJHA	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	1.62	1.6	5.47	8.94
DCVHK2C	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	3.68	2.99	5.6	8.16
DCJ78S8	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	12.72	11.13	9.51	14.37
DCU3ID6	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	3.82	1.41	3.87	5.81
DC1IGNI	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	10.8	7.29	4.8	8.67
DCGUPWN	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	2.61	1.66	0.13	2.47
DCRP7OQ	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.14	5.18	0.52	7.61
DC458L1	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	9.92	8.92	6.68	10.42
DCYX2P1	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	3.59	5.33	3.2	7.33
DC6CQ8P	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.49	1.85	1.75	6.37
DCN3NXC	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	9.75	9.5	7.95	11.98
DCT8BQ2	DM3BH1Y	Lapatinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	7.75	8.4	3.46	9.85
DCRGVZS	DM3BH1Y	Lapatinib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.6	9.81	9.02	9.84
DCXRLMR	DM3BH1Y	Lapatinib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.39	9.95	7.44	6.56
DCQ4PUZ	DM3BH1Y	Lapatinib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	0.7	4.04	3.04	5.23
DCGIJQ3	DM3BH1Y	Lapatinib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	10.71	8.79	2.43	9.06
DC92GRQ	DM3BH1Y	Lapatinib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.44	3.31	5.71	6.52
DCDM9XR	DM3BH1Y	Lapatinib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.41	5.54	3.64	2.49
DCZP2KR	DM3BH1Y	Lapatinib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.26	7.27	4.26	3.98
DCSKTZM	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	0.49	1.33	8.02	8.85
DCGGLRL	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	1.68	1.43	8.8	9.72
DC7D1H4	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	2.94	1.09	3.11	3.5
DCD4Q38	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	7.54	12.22	0.89	9.07
DCFHMFN	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	12.79	12.29	15.89	17.65
DCACNCL	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	9.01	8.18	12.32	13.83
DCA4JT6	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.85	4.55	2.85	2.85
DCJ75EP	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	14.67	18.21	18.93	21.18
DCW9ZKO	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	14.21	9.81	1.63	11.62
DCW4F94	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.1	0.51	1.6	3.16
DCFW8OO	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	24.12	29.3	5.92	14.73
DCZES1H	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.95	6.72	8.12	9.22
DCSV0CI	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	13.27	9.69	16.42	18.26
DC5S8N4	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.18	1.83	11.42	13.82
DC2S6AT	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	18.93	19.63	19.29	24.03
DCDCM19	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.2	4.75	3.18	13.49
DCXYWK3	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	1.32	2.66	13.94	14.62
DCTIN0Y	DM3BH1Y	Lapatinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.38	8.32	7.34	7.76
DCC64EG	DMH0ZJE	Mitomycin	Approved	34	DMTS85L	Capecitabine	Approved	34	.	.	.	.	Carcinoma of Anal Canal	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCNB36D	DMH0ZJE	Mitomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.71	1.6	2.17	2.11
DCZ7000	DMH0ZJE	Mitomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.16	4.3	1.77	1.03
DCHBSUW	DMH0ZJE	Mitomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.82	5.46	1.92	0.11
DC912TA	DMH0ZJE	Mitomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	5.91	8.6	2.44	2.02
DCV4WI9	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	10.91	10.64	5.88	12.6
DCQ38N8	DMH0ZJE	Mitomycin	Approved	34	DM2B9E0	AT13387	Phase 1	17	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	22.061	21.787	3.621	7.525
DC49DYI	DMH0ZJE	Mitomycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	3.4	7.22	0	6.61
DCW9A22	DMH0ZJE	Mitomycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	4.54	6.93	4.21	7.4
DC1RR9V	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.39	3.55	1.22	3.89
DCK7635	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.57	5.39	2.39	7.56
DCVU9CT	DMH0ZJE	Mitomycin	Approved	34	DM3XQDH	JQ1	Investigative	0	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	9.947	8.427	1.024	3.232
DC2PDKP	DMH0ZJE	Mitomycin	Approved	34	DM48K0X	Carfilzomib	Approved	34	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	6.478	0.163	13.314	5.94
DCYB5IS	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	12.83	12.95	9.89	15.6
DC3FL0O	DMH0ZJE	Mitomycin	Approved	34	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	10.582	11.087	0.697	4.355
DCIKPT5	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	9.95	8.89	9.46	13.52
DCWWTUZ	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	12.28	11.8	8.91	14.04
DCASEI1	DMH0ZJE	Mitomycin	Approved	34	DM7CLEZ	Eltanexor oral	Phase 1/2	19	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	11.803	11.204	0.141	1.028
DCZG24A	DMH0ZJE	Mitomycin	Approved	34	DM7WFZ8	Formononetin	Investigative	0	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	14.098	12.754	2.35	5.7
DC6YO7H	DMH0ZJE	Mitomycin	Approved	34	DM8X2EH	Everolimus	Approved	34	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	8.556	6.271	6.408	7.606
DC90B5Y	DMH0ZJE	Mitomycin	Approved	34	DM91LGU	Abexinostat	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	18.832	19.84	3.147	3.352
DC3504I	DMH0ZJE	Mitomycin	Approved	34	DMA9SEY	GDC-0084	Phase 2	21	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	5.52	3.941	1.288	3.637
DCQ6FZJ	DMH0ZJE	Mitomycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	10.54	10.09	0.015	3.159
DCGFJPE	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	10.97	8.03	4.87	10.22
DCS0GM9	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	11.11	11.42	6.17	14.43
DC8OY4T	DMH0ZJE	Mitomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.12	6.02	7.27	1.57
DCXSYTV	DMH0ZJE	Mitomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	12.29	16.25	0.6	0.6
DCESEPH	DMH0ZJE	Mitomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.65	5.52	1.73	1.54
DCJN23U	DMH0ZJE	Mitomycin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	8.602	7.05	0.566	2.708
DCHU26C	DMH0ZJE	Mitomycin	Approved	34	DMDMQIE	THAPSIGARGIN	Preclinical	2.1	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	8.944	6.851	0.294	3.255
DC2X4HV	DMH0ZJE	Mitomycin	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	6.761	7.212	0.654	4.432
DCDTMU8	DMH0ZJE	Mitomycin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	3.41	6.96	3.34	8.11
DC8C7LW	DMH0ZJE	Mitomycin	Approved	34	DMH7W9X	SNDX-275	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	12.376	21.467	1.473	8.306
DCZI8HN	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	9.79	9.03	5.43	10.81
DCEJA4Z	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	7.09	9.27	11.36	12.4
DCRS0WL	DMH0ZJE	Mitomycin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.8	5.14	5.11	10.35
DC4KBL7	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	8.91	6.13	3.24	6.99
DCX5TPY	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.38	0.74	1.42	3.21
DCOY1NR	DMH0ZJE	Mitomycin	Approved	34	DMODA2X	Bardoxolone methyl	Phase 3	25	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	11.499	11.549	7.243	10.304
DC35CE8	DMH0ZJE	Mitomycin	Approved	34	DMPH1AG	TG100801	Phase 2	21	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	19.809	17.731	3.504	6.864
DCX8X8P	DMH0ZJE	Mitomycin	Approved	34	DMQ2AIJ	Lestaurtinib	Approved (orphan drug)	34	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	6.013	4.998	3.326	5.222
DCGGFSM	DMH0ZJE	Mitomycin	Approved	34	DMQLODU	Citarinostat	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	16.15	17.01	2.7	2.87
DCU2RBW	DMH0ZJE	Mitomycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.62	2.01	2.59	5.69
DCLBNFX	DMH0ZJE	Mitomycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.3	0.3	0.47	2.79
DC3PNAT	DMH0ZJE	Mitomycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.76	6.32	1.83	2.15
DC1ZN2K	DMH0ZJE	Mitomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.17	4.01	1.17	1.17
DC80WV6	DMH0ZJE	Mitomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.31	5.54	1.06	1.06
DCIVUPO	DMH0ZJE	Mitomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.87	3.88	3.47	3.21
DC3S55C	DMH0ZJE	Mitomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.62	4.54	2.88	2.87
DC5KOVS	DMH0ZJE	Mitomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	6.11	7.98	1.81	1.79
DCYG77E	DMH0ZJE	Mitomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.98	3.55	2.06	1.56
DCN81SM	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.15	7.45	0.1	8.76
DCA85TX	DMH0ZJE	Mitomycin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	8.878	7.263	0.019	3.858
DC5RB6N	DMH0ZJE	Mitomycin	Approved	34	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	2.073	0.975	5.799	7.392
DC8QGOV	DMH0ZJE	Mitomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.98	2.76	0.35	0.35
DCRF46C	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	9.36	10.69	13.1	13.93
DCV7GWW	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	6.4	7.62	6.29	9.14
DCB0N4P	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	14.01	13.75	13.02	19.08
DCVWRZZ	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.4	3.36	10.14	13.31
DC406B7	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	7.93	7.58	9.75	14.54
DC0ZYZJ	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.54	1.3	7.61	10.43
DCYCXYP	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.73	2.25	4.46	10.47
DCFJ2HS	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.55	3.52	1.9	8.09
DCPH4KH	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.99	8.51	8.94	12
DCAJIB6	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.54	1.81	7.92	12.43
DCZY3EK	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.4	4.73	6.86	10.61
DC2S0N8	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	9.1	11.1	12.73	14.98
DC4MJ2N	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.3	1.49	3.36	5.69
DCDSM28	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.75	1.56	7.78	10.24
DCCMRMZ	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.4	0.06	7.63	10.92
DCR61I6	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	6.49	6.11	10.98	16.53
DCAO0MG	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	8.99	8.24	11.14	14.21
DCA3I4L	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.28	4.05	9.31	11.44
DCVIRLG	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	5.45	5.45	15.3	18.5
DC7RKW8	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.94	5.46	6.05	8.84
DCATEAT	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	6.77	6.2	4.58	10.32
DCQ3H1D	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	7.7	7.09	11.89	15.02
DC8QFU0	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.84	0.87	1.9	6.94
DCQRF0C	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.65	3.51	5.64	9.75
DC6240I	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.67	3.61	4.43	7.2
DCNV46K	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	6.8	7.15	5.77	10.12
DC4U0YS	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.68	1.89	2.63	7.48
DC7O2HK	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	6.8	6.61	7.5	11.76
DC6ZF7F	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.35	4.18	4.2	9.99
DCGR8JL	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	14.03	14.06	11.29	16
DCE5KXK	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.03	3.01	2.9	7.08
DCXMJXN	DMH0ZJE	Mitomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.73	1.54	3.25	6.23
DCK8MUW	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	9.06	9.98	6.54	13.73
DCOHUWC	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.32	1.97	0.17	10.06
DCVYJ9L	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.84	1.75	4.09	7.73
DCL4HCM	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	4.63	4.69	8.38	12.17
DCI16HP	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.82	1.67	7.18	10.15
DCSVLFS	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.24	3.33	10.46	13.53
DC55PDF	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	15.83	16.1	16.46	19.69
DCLAQNO	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.76	1.29	7.27	10.02
DCKNSXS	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	6.84	4.64	5.6	9.53
DCQ8SDD	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	9.85	9.47	5.6	9.3
DC3DMYF	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	16.31	16.57	17.72	22.38
DCDC11P	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.06	1.03	12.33	14.12
DCDY965	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	7.08	6.4	7.39	13.68
DCSSTXZ	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	10.46	10.77	16.05	20.17
DCOFTQF	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	18.33	15.14	2.92	17.21
DCXWZ7S	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.87	5.94	1.2	6.36
DCZISN6	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	8.53	9.07	3.26	10.68
DCTKGJ8	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	6.36	6.11	0.35	7.21
DCA41PU	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.69	6.31	3.55	7.35
DC0PRE9	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	0.72	0.55	6.6	9.59
DC4HDUC	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.72	4.24	8.6	9.7
DCUWVQD	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.39	0.36	7.95	11.08
DCNZ0YD	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.26	3.37	6.39	10.72
DCXFKLD	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.45	5.56	0.2	7.09
DCJ3BAG	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.04	2.69	4.85	11.24
DCFNYLH	DMH0ZJE	Mitomycin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.01	7.53	8.39	11.86
DCK82K4	DMH0ZJE	Mitomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.54	5.73	1.11	1
DC7JXP6	DMH0ZJE	Mitomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.91	8.38	0.92	0.42
DCCSSLT	DMH0ZJE	Mitomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.6	5.4	1.48	0.9
DCW5EAA	DMH0ZJE	Mitomycin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	8.38	8.02	9.47	11.93
DCUK3G5	DMH0ZJE	Mitomycin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.89	0.55	5.12	8.86
DCK57KE	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.57	4.21	3.02	7.04
DCLB655	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	5.15	6.63	1.29	7.37
DCALZ0F	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.71	4.25	1.66	6.72
DCMWDDH	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	6.09	6.29	4.99	10.34
DC4K55M	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	8.59	8.65	6.16	11.97
DCROOK2	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.65	2.92	3.01	6.6
DC16S4W	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.35	1.45	3.08	5.91
DCC21YY	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.13	1.28	8.23	9.83
DCGI4KS	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.72	4.16	7.15	8.46
DC6ZSD4	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	9.36	12.83	15.13	19.22
DC5EIKS	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.27	0.07	4.23	6.84
DCNMCS4	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	5.47	5.08	10.65	12.7
DC2KD4U	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.59	2.3	8.83	10.94
DCG9WT3	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.9	3.41	9.1	10.14
DCAN8K3	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.35	4.73	7.05	8.9
DC7FHVJ	DMH0ZJE	Mitomycin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.85	5.42	6.25	9.17
DCEA8TE	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.06	5.57	3.86	6.16
DCHDJ85	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.05	0.83	2.01	5.85
DCW48UB	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	5.86	3.96	1.84	5.74
DCSPHOB	DMH0ZJE	Mitomycin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	7.23	8.73	7.3	11.21
DCET7BG	DMH0ZJE	Mitomycin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	5.53	12.26	10.1	11.87
DC7VVBH	DMH0ZJE	Mitomycin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.78	4.74	2.97	8.6
DCG8LIY	DMH0ZJE	Mitomycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.43	3.22	1.22	4.62
DCIFGGU	DMH0ZJE	Mitomycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.56	9.19	6.5	4.84
DCX0W2S	DMH0ZJE	Mitomycin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.16	2.83	2.53	5.56
DC59EHQ	DMH0ZJE	Mitomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.21	2.8	0.55	0.48
DCOWEUZ	DMH0ZJE	Mitomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.36	4.85	0.92	0.55
DCBIHKE	DMH0ZJE	Mitomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.58	2.66	1.5	0.05
DCYS70R	DMH0ZJE	Mitomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.75	7.83	1.54	2.21
DC2FZ1C	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.22	8	9.67	11.43
DCXG3UA	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	5.75	5.58	13.08	15.6
DCWZZDQ	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.58	0.69	1.89	5.92
DCXZ92M	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.45	0.07	4.35	9.48
DCEREJI	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.34	0.59	5.62	7.28
DCLGC41	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.22	0.2	6.95	9.01
DC8DN2F	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	6.13	5.81	6.83	12.41
DC6RKXO	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.13	3.39	8.72	14.64
DCCIMFE	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.1	1.4	2	4.43
DCUS90H	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	6.14	6.18	9.15	10.83
DCML89V	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.11	5.62	3.79	8.32
DCOZDAB	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	4.48	4.21	8.73	13.66
DCI8ULC	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.96	2.06	1.75	6.51
DC6C71W	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.33	1.31	6.71	8.27
DC6CG1X	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.08	0.84	14.5	16.02
DC8VX4L	DMH0ZJE	Mitomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	5.48	6.46	1.97	0.53
DC6GRZQ	DMH0ZJE	Mitomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.3	1.45	1.52	1.09
DCYW788	DMH0ZJE	Mitomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.59	1.8	0.49	0.02
DC1G2JB	DMH0ZJE	Mitomycin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	16.43	14.41	9.93	9.6
DCHZ431	DMH0ZJE	Mitomycin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	HDLM-2	14.49	14.06	9.62	14.12
DCD5H77	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	5.79	5.65	10.93	14.99
DCSZC0X	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	16.55	15.04	14.68	25.05
DCIHP4O	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	8.86	8.7	5.67	13.47
DCITH2O	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	5.51	6.82	6.56	12.72
DCIP9QH	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	14.9	12.66	10.52	15.08
DCIM1KN	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.93	4.77	4.01	10.15
DCJC6U8	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	2.45	1.83	0.28	6.94
DCK5UUF	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	7.44	6.42	3.83	9.6
DC8YUWU	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	1.62	3.31	3.31	5.57
DC377VW	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.35	2.58	0.65	6.29
DCQEL2Y	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	17.07	15.71	13.96	20.54
DCKZZVJ	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.3	3.4	6.24	11.51
DC7GN09	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	13.5	12.21	11.74	17.97
DCBEYEA	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	14.81	14.9	11.18	18.39
DCSW3WB	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.79	2.78	0.68	4.39
DC7PHVP	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	12.5	12.41	11.64	17.49
DCHLMJ3	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	0.88	2.13	1.25	7.16
DCG5M1V	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.25	2.46	1.61	7.72
DCI10O3	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	12.86	13.91	9.2	15.27
DC6Q4J1	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.89	4.29	5.74	10.14
DCM91WH	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	10.16	8.84	6.18	12.85
DCKJNM7	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.23	5.95	6.83	13.2
DCTT5FO	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8.84	7.65	5.01	13.24
DCFBTOF	DMH0ZJE	Mitomycin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	13.04	13.47	6.88	13.94
DCH1QKG	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	10.73	10.36	11.15	14.93
DCK0DIT	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	9.63	8.44	10.03	13.27
DCDJP44	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	3.67	3.33	4.13	11.08
DC8CVU7	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	12.26	12.18	15.99	18.96
DCIXZ62	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	10.32	7.85	6.42	11.93
DC0NAIU	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	3.79	2.26	0.39	4.78
DCE5MPO	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	4.02	3.22	2.6	6.08
DCT57RP	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	2.86	4.46	5.79	8
DC6LFUS	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.73	5.44	3.57	8.66
DCZ3W8J	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	12.62	10.8	12.13	16.24
DCHLIM0	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	17.1	14.7	13.95	17.29
DCJOSTQ	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.91	1.86	0.31	3.92
DCZEEI2	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	0.59	4.93	3.27	7.18
DC3PMPY	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.15	3.06	3.66	6.56
DCTGAG4	DMH0ZJE	Mitomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	11.62	9.28	7.63	11.86
DCVV9VP	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	11	9.98	10.35	14.64
DC4FJT9	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.06	4.89	3.07	9.84
DCSX5PI	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	11.01	10.84	7.16	14.8
DCNWPVW	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	6.91	6.04	6.42	11.19
DC3O73X	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.52	8.01	7.5	11.29
DCJMD43	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.95	0.27	1.03	5.55
DC9QQIY	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	8.76	8.84	7.67	12.63
DCXJJED	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.72	2.99	7.41	11.83
DCKPEAG	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	1.28	0.42	7.6	10.73
DCNXV16	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	9.33	8.12	7.86	12.96
DCKUQ53	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	8.09	7.79	9.52	13.66
DCIC1O9	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	5.09	4.69	2.35	6.84
DCZNK2N	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	6.8	7.4	6.09	10.1
DCFX2QR	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	8.4	8.03	8.98	14.33
DCONMV4	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	2.28	1.94	8.22	11.68
DC6BYI0	DMH0ZJE	Mitomycin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	0.32	6.24	5.07	8.76
DC3VZIY	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	7.64	7.31	0.74	11.95
DC73SW1	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	0.79	0.42	0.95	5.79
DCWP7N4	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	1.9	1.39	1.34	5.55
DCXHPGU	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	15.22	12.32	15.88	19.48
DCZJOQK	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	7	5.72	3.65	8.52
DCNVTXX	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	5.15	3.93	2.53	5.35
DC1MGNG	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.05	1.47	0.8	3.76
DCMVW3Z	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.6	6.47	8.66	12.94
DCNKTI3	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	9.34	9.47	7.12	10.29
DC5YVPM	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	15.83	15.52	13.72	17.98
DC2154S	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.11	5.03	1.7	6.11
DC7E8OG	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.79	0.38	0.47	4.99
DC8LGAT	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	11.38	8.13	6.03	11.24
DCFMEX6	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	1.44	2	1.2	6.43
DC0PW6Z	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	5.8	5.14	4.62	9.29
DCO7MDT	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	5.43	5.29	1.57	6.59
DCIM5LI	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.16	4.48	4.45	8.66
DCUL2KT	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	17.08	13.74	17.93	22.05
DCW3HUB	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	5.78	3.67	1.15	6.36
DCRSCC2	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.59	6.11	5.36	9.57
DCDJ1Y9	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.1	8.87	8.54	13.5
DCY91BU	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	5.01	6.15	6.31	9.99
DCPBLAJ	DMH0ZJE	Mitomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	9.08	9.11	15.04	18.99
DCSBR41	DMH0ZJE	Mitomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.52	4.12	0.59	2.76
DCHNWI4	DMH0ZJE	Mitomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.54	3.96	3.3	8.08
DCU4W0J	DMH0ZJE	Mitomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.61	2.24	1.71	4.36
DCBQXHJ	DMH0ZJE	Mitomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.06	2.85	2.72	5.23
DCA71W4	DMH0ZJE	Mitomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.19	1.69	5.26	5.77
DC2FQY1	DMH0ZJE	Mitomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.95	0.34	2.14	4.13
DCIQTN2	DMH0ZJE	Mitomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.15	1.15	2.22	2.78
DC9M8WR	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.82	1.36	6.65	9.1
DC3MM4R	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	10.33	9.77	12.7	16.35
DCC5KW4	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	3	1.67	5.02	8.71
DC2PEHD	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	8.96	9.06	13.72	16.75
DC8DCA7	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.33	1.79	5.7	9.35
DCB5VFW	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	1.42	0.36	5.04	8.54
DC3XOTO	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	7.56	5.83	7.47	11
DCXS277	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.92	0.81	1.97	6.15
DCS9G7D	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	10.47	10.3	18.87	21.62
DCVS08X	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.41	2.99	6.85	11.44
DCABD2S	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	2.24	1.84	8.75	11.48
DCI0GIS	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	6.94	6	9.79	13.26
DCU7X6B	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.53	5.43	8.8	11.76
DCKJPKL	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	17.09	16.32	18.13	21.71
DCIU09T	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	4.7	3.73	8.83	12.31
DCFL4Z3	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	2.38	0.57	2.99	6.95
DCBZ04G	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.38	0.27	4.58	8.73
DCI58FG	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	4.05	1.97	4.05	7.83
DC2TQ2W	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	3.5	3.24	4.25	8.43
DCICKB5	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	3.96	3.36	6.38	10.42
DCFB33K	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.9	0.31	5.22	8.88
DC358J9	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	3.33	6.64	9.43	11.97
DCX5RWL	DMH0ZJE	Mitomycin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	0.59	0.26	7.38	10.65
DCM8M9P	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	10.19	10.16	9.26	19.8
DCE6M2R	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	26.91	25.04	29.74	31.84
DC0IWOZ	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	16.58	15.44	13.45	21.23
DCQWTEN	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	14.14	13.6	10.95	19.1
DC0VJFT	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	15.11	10.13	14.59	18.19
DC0WWCS	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	7.19	5.87	8.06	12.83
DCQO1II	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	8.83	8.46	1.35	15.98
DCJZ50T	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	18.75	19.03	19.49	22.88
DCL2REM	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	7.22	7.75	2.5	9.27
DCQJ7FA	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	8.54	9.16	8.71	11.73
DCN3Q4A	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	24.94	23.56	29.67	33.57
DCR563N	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	23.34	21.1	21.81	29.85
DCFAKT0	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	12.04	13.72	15.16	18.14
DCAPUX5	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.9	5.06	5.2	6.82
DCAMYPR	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	13.03	14.83	15.89	19.81
DCY1UT9	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	6.87	6.18	7.18	12.39
DCPZ84A	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	15.63	14.55	17.61	23.2
DC5RXJP	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.8	0.41	0.12	7.08
DCH9SQB	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	12.61	10.17	7.65	11.95
DCFYHRG	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	10.78	10.05	7.66	13.94
DCMRKLU	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	12.52	12.21	12.07	16.78
DCBIECC	DMH0ZJE	Mitomycin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	9.21	9.06	11.12	14.74
DCD8U8A	DMH0ZJE	Mitomycin	Approved	34	DM7CLEZ	Eltanexor oral	Phase 1/2	19	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	U-HO1	11.8	11.2	0.14	1.03
DCTYVU7	DMH0ZJE	Mitomycin	Approved	34	DM7WFZ8	Formononetin	Investigative	0	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	U-HO1	14.1	12.75	2.35	5.7
DCG6AHM	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.06	3.16	2.95	6.67
DCEVAVX	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	7.96	7.81	7.92	12.43
DCMJACE	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	6.33	5.77	5.25	9.85
DC2QPQO	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.88	4.75	7.23	10.93
DCE0BVH	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	6.45	4.95	6.89	10.09
DCXO3HF	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.6	0.71	0.46	4.64
DC5IG6K	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.6	0.61	3.87	6.58
DC97OPA	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.3	1.41	2.33	6.54
DCTY7RB	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	10.8	9.12	12.75	16.12
DCFHKU3	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	10.47	11.84	9.43	14.47
DCTN1BL	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.04	2.3	2.64	5.96
DC0N06K	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	6.4	6.56	7.65	11.55
DCKF2BI	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.77	0.31	0.77	3.94
DC0MIWT	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	8.31	7.77	7.29	11.53
DC5M25J	DMH0ZJE	Mitomycin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	1.48	1.43	2.48	6.09
DCEYV7Z	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	7.83	7.38	10.42	15.91
DCG93NK	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	10.26	10.25	8.59	16.77
DCSM2M7	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	1.34	3.72	2.92	9.24
DCCJBS9	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	3.52	3.77	2.52	9.51
DCI5X3U	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	6.4	5.9	7.04	11.87
DCHW4K6	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	2.25	1.37	0.11	7.16
DCYC2JR	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.71	5.29	4.07	11.57
DCGCYU4	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	10.09	10.21	15.15	20.99
DC0410N	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.28	2.79	6.81	12.65
DCOHRQV	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	7.68	7.26	8.67	14.99
DCNH1Z8	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	10.74	10.8	5.71	14.71
DCPB27R	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.64	1.77	1.19	4.27
DC5UFGA	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	7.86	7.9	9.11	15.32
DC1SP1I	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	1.37	1.68	4.25	9.59
DCOQ9MX	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.37	0.24	1.11	7.31
DC0CSC5	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	3.53	3.85	2.52	11.14
DCWOYSC	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	2.68	2.2	6.52	12.08
DC96PIK	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.26	0.63	1.49	8.59
DCJOLNN	DMH0ZJE	Mitomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	4.16	6.17	3.02	8.98
DCR23NK	DMH0ZJE	Mitomycin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	13.23	10.94	16.09	19.56
DCO5JR1	DMH0ZJE	Mitomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.58	8.14	1.84	0.92
DCPXCMG	DMH0ZJE	Mitomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.16	6.22	2.94	6.62
DCZO39Y	DMH0ZJE	Mitomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	3.73	3.77	1.72	0.82
DCT8WQ6	DMH0ZJE	Mitomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	16.26	12.76	15.67	8.55
DC4RP6V	DMH0ZJE	Mitomycin	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	U-HO1	6.76	7.21	0.65	4.43
DCQ6MIY	DMH0ZJE	Mitomycin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.28	1.53	0.56	6.1
DCS2JLQ	DMH0ZJE	Mitomycin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.53	2.19	2.32	7.52
DCBDO84	DMH0ZJE	Mitomycin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.59	4.21	6.33	10.52
DCBGT33	DMH0ZJE	Mitomycin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.13	3.61	5.08	11.53
DCMWDYE	DMH0ZJE	Mitomycin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	5.19	4.45	5.57	9.92
DCIFDF1	DMH0ZJE	Mitomycin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	5.12	4.73	5.95	11.25
DCVIHQZ	DMH0ZJE	Mitomycin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	0.92	0.52	4.74	8.68
DC7GDHL	DMH0ZJE	Mitomycin	Approved	34	DMIU0VP	SNX-5422	Phase 1/2	19	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	18.14	20.05	6.886	10.079
DCE0MFI	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.04	1.03	2.44	5
DC4W5KV	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	9.8	4.27	2.59	7.9
DC4KMN2	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	13.54	10.73	10.92	14.62
DC8ZW1T	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.31	1.17	0.08	5.16
DCUGYGG	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	1.36	0.71	0.17	4.1
DCTBOPL	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	5.32	5.59	2.53	8.19
DCLKW9U	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.33	6.74	6.67	10.28
DC00GL3	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	9.13	7.32	4.27	8.88
DCXKF2J	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	10.4	8.91	9.3	13.71
DCRWUP5	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	12.26	9.24	5.95	10.6
DC6CJSL	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	12.48	7.49	5.38	10.05
DC7JUBY	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	5.85	5.72	2.31	7.46
DCDVWKF	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.87	1	0.15	6.53
DC2IZB4	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	9.79	9.03	8.85	11.52
DCF9C0D	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.2	3.73	1.28	5.37
DCKSNEG	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	0.63	4.71	1.66	6.01
DCH60UY	DMH0ZJE	Mitomycin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	5.66	2.73	2.17	7.35
DC9DNKB	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	5.62	5.35	10.75	11.39
DCJ9WP9	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	4.37	8.2	11.74	13.16
DCA95HN	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.86	4.18	8.82	9.68
DCW7RTJ	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	11.45	13.25	15.24	15.81
DC03FZE	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.84	3.95	9.12	10.41
DCEAMXD	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	9.79	11.62	12.82	13.28
DCPZS2L	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	2.41	4.6	6.12	7.08
DCQXX3K	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.31	0.56	0.4	0.84
DCAY2F1	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	11.43	10.04	17.99	18.7
DCRWMKZ	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.42	3.37	8.54	9.48
DC1513C	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	2.11	1.67	6.66	7.76
DC336YK	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	9.5	11.36	15.6	16.55
DCT0MHX	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.37	4.31	4.11	5.59
DC2TJSI	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	13.36	19.2	19.82	20.56
DCE7R7O	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	1.21	4.77	9.93	10.44
DC16URR	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	5.21	5.11	8.52	9.23
DC9LH6A	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.74	3.62	10.73	11.7
DC49DOV	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	12.97	8.06	9.95	11.62
DC4PM32	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	1.71	1.5	2.37	3.77
DCA9BSY	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.94	4.57	12.44	14.12
DCWK6BD	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.34	5.95	12.43	13.1
DCTGNT5	DMH0ZJE	Mitomycin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	3.26	5.88	6.72	7.43
DCKYOFW	DMH0ZJE	Mitomycin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	13.5	13.72	12.42	17
DCIMCD1	DMH0ZJE	Mitomycin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.81	4.29	2.38	7.28
DCHS1CN	DMH0ZJE	Mitomycin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	7.51	4.72	8.17	15.77
DCK6OKC	DMH0ZJE	Mitomycin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.71	6.15	4.06	9.22
DC1TXYJ	DMH0ZJE	Mitomycin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	7.96	7.99	4.52	10.02
DCQAWG6	DMH0ZJE	Mitomycin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.73	0.34	0.78	4.73
DCP4XKC	DMH0ZJE	Mitomycin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	7.97	7.52	4.65	10.04
DCWN4I2	DMH0ZJE	Mitomycin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	2.9	2.63	0.35	3.82
DC6Q9FU	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	5.44	4.46	1.41	4.78
DC2I58Y	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.75	0.46	0.45	2.99
DCMU880	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.47	4.44	1.89	6.23
DCQLDQ5	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	5.11	5.86	4.99	10.15
DCDDJFT	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.83	1.64	0.18	4.15
DC4HLHP	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	14.42	12.22	9.11	12.53
DCNT3RI	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.4	2.81	0.4	3.74
DCBCTTI	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.86	5.03	1.7	6.52
DCL649X	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	9	7.07	3.32	6.96
DCOHYQM	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	7.8	7.13	3.5	9.1
DCPVQJS	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	9.26	7.2	0.77	3.26
DC2TSAU	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.13	0.93	0.37	2.89
DCDHLB6	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	2.63	1.68	0.95	3.12
DCNT7UZ	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	10.63	9.55	5.22	11.68
DC3DWSS	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	2.53	2.56	2.08	6.06
DCHZFOG	DMH0ZJE	Mitomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	3.35	0.39	1.21	3.81
DCPDGVH	DMH0ZJE	Mitomycin	Approved	34	DMODA2X	Bardoxolone methyl	Phase 3	25	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	U-HO1	11.47	11.55	7.24	10.3
DCM557O	DMH0ZJE	Mitomycin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.13	3.41	2.95	6.02
DCTT1ID	DMH0ZJE	Mitomycin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	6.1	8.57	2.23	11.61
DC5U31T	DMH0ZJE	Mitomycin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	8.01	8.3	4.53	9.98
DCKFS3O	DMH0ZJE	Mitomycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.6	5.26	1.28	8.49
DCNQNUW	DMH0ZJE	Mitomycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.62	2.4	3.61	4.89
DC0BT85	DMH0ZJE	Mitomycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.47	9.33	1.9	8.39
DCVIH93	DMH0ZJE	Mitomycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.15	4.48	4.67	4.34
DCC3NXO	DMH0ZJE	Mitomycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.29	1.51	1.32	0.3
DCGUZFY	DMH0ZJE	Mitomycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.43	2.73	3.51	1.28
DCWKJPC	DMH0ZJE	Mitomycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.14	6.04	2.59	2.35
DCVRQQ4	DMH0ZJE	Mitomycin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	4.06	3.71	6.18	7.74
DC18QUL	DMH0ZJE	Mitomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.35	4.15	2.35	2.34
DCQUD0M	DMH0ZJE	Mitomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.02	5.48	2.23	0.21
DC13B16	DMH0ZJE	Mitomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.8	10.24	4.66	4.59
DCE8LFJ	DMH0ZJE	Mitomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.54	4.16	1.79	1.16
DCW866Y	DMH0ZJE	Mitomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.27	2.85	0.54	0.45
DCJE4G4	DMH0ZJE	Mitomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.69	2.12	2.13	0.6
DCPXNDZ	DMH0ZJE	Mitomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.21	4.54	4.31	6.41
DC95I8M	DMH0ZJE	Mitomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.09	5.58	0.46	0.87
DC0LPCV	DMH0ZJE	Mitomycin	Approved	34	DMSLE03	PF-562271	Phase 1	17	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	U-HO1	9.95	8.43	1.02	3.23
DC31C93	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	4.95	5.39	8.31	11.01
DCPPYFV	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.65	1.26	0.18	6.99
DCU0QRR	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	9.53	9.36	15	17.52
DCXJ990	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.34	4.28	6.85	9.46
DC6L7D8	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	5.89	5.89	10.29	12.73
DC0VZIX	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	7.05	6.25	2.29	7.67
DCVE92R	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	9.59	9.38	16.39	19.75
DCDXSA7	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	7.27	5.48	8.57	10.6
DC0ZOK0	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	16.77	16	17.08	19.71
DCDGPUI	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.35	5.8	6.54	9.42
DC1LPOS	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	3.49	5.54	0.32	11.02
DCTS4N9	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.35	2.26	4.16	7.22
DCHLQU3	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.84	1.66	8.72	11.24
DCBMWMM	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	15.32	12.15	15.18	18.86
DC49XY5	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.05	5.85	12.09	14.62
DCCHF40	DMH0ZJE	Mitomycin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	2.66	2.57	8.83	11.07
DCZ0LQS	DMH0ZJE	Mitomycin	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	15.982	14.167	1.12	5.108
DCD3J1R	DMH0ZJE	Mitomycin	Approved	34	DMXKDUL	BGT226	Phase 1/2	19	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	113.47	115.37	0.11	6.69
DC9MFFE	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	8.31	6.46	8.58	17.44
DCLK8KQ	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.12	0.04	8.66	12.1
DCG3NVY	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	9.39	9.4	12.35	16.83
DC6Y3U4	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	2.58	2.08	9.01	10.36
DCUOYL9	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.49	0.96	5.55	9.06
DCIDAL9	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	3.39	2.25	4.12	7.18
DCE02N1	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.04	3.84	15.32	17.49
DCZO91F	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	16.53	15.85	0.95	20.47
DCBIVA6	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	14.3	10.78	11.69	17.15
DCAGHXL	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	6.05	5.64	12.06	14.53
DCOTG29	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	16.58	16.23	16.85	20.48
DCIHWXA	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.09	0.01	7.47	10.3
DCCH8F7	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	14.34	12.36	18.16	22.12
DCYA9Q9	DMH0ZJE	Mitomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.78	7.33	11.94	16.18
DCO9Y73	DMNH3PG	Etoposide	Phase 2 Trial	21	DMQUSBT	Daunorubicin	Approved	34	DMZD5QR	Cytarabine	.	.	Acute Myeloid Leukemia	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCSAF8Y	DMNH3PG	Etoposide	Phase 2 Trial	21	DMOLNHF	Melphalan	Phase 2 Trial	21	DMXZRW0	DTI-015	DMZD5QR	Cytarabine	Lymphoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCUIQMZ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMM0XGL	Idarubicin	Approved	34	DMXYJ9C	Busulfan	DMZD5QR	Cytarabine	Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCXEHDI	DMNH3PG	Etoposide	Phase 2 Trial	21	DMM39BF	Mitoxantrone	Approved	34	DMOGGAQ	Sirolimus	DMZD5QR	Cytarabine	Adult Acute Megakaryoblastic Leukemia (M7)	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC0MIZ8	DMNH3PG	Etoposide	Phase 2 Trial	21	DMXZRW0	DTI-015	Approved	34	DMZD5QR	Cytarabine	.	.	Lymphoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCM9986	DMNH3PG	Etoposide	Phase 2 Trial	21	DMNO38U	Bortezomib	Approved	34	DMZD5QR	Cytarabine	.	.	Adult Acute Monoblastic Leukemia (M5a)	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC0F3Y4	DMNH3PG	Etoposide	Phase 2 Trial	21	DMKECZD	Temozolomide	Approved	34	DMZ4Q0B	Dasatinib	.	.	Recurrent Childhood Brain Tumor	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC0OXFQ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMXYJ9C	Busulfan	Approved	34	DMZD5QR	Cytarabine	.	.	Adult Acute Basophilic Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCIGYM6	DMNH3PG	Etoposide	Phase 2 Trial	21	DMG281S	Carboplatin	Approved	34	DMIZKOP	Thiotepa	.	.	Ewing's Family Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCSW9N4	DMNH3PG	Etoposide	Phase 2 Trial	21	DMUPE07	Nicotinamide	Approved	34	DMWMPD4	Vorinostat	.	.	Hodgkin's Disease	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC3JRQM	DMNH3PG	Etoposide	Phase 2 Trial	21	DMG281S	Carboplatin	Approved	34	.	.	.	.	Extensive Stage Small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC68MZD	DMNH3PG	Etoposide	Phase 2 Trial	21	DMZD5QR	Cytarabine	Approved	34	.	.	.	.	Adult Acute Basophilic Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC82FCV	DMNH3PG	Etoposide	Phase 2 Trial	21	DMQNWRD	Oxaliplatin	Approved	34	.	.	.	.	Angioimmunoblastic T-cell Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCGQ0SQ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMF30HL	Zarnestra	Phase 3	25	.	.	.	.	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCGWIHN	DMNH3PG	Etoposide	Phase 2 Trial	21	DMF30HL	Zarnestra	Phase 3	25	.	.	.	.	Adult Acute Megakaryoblastic Leukemia (M7)	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCJH6BL	DMNH3PG	Etoposide	Phase 2 Trial	21	DMJOQM3	Eflornithine	Approved	34	.	.	.	.	Neuroblastoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCPI550	DMNH3PG	Etoposide	Phase 2 Trial	21	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adult Acute Myeloid Leukemia in Remission	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCZYELT	DMNH3PG	Etoposide	Phase 2 Trial	21	DMINOX3	Vincristine	Approved	34	.	.	.	.	Brain Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC0ZE2W	DMNH3PG	Etoposide	Phase 2 Trial	21	DMG281S	Carboplatin	Approved	34	DMNO38U	Bortezomib	.	.	"Unspecified Adult Solid Tumor, Protocol Specific"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCMCVSB	DMNH3PG	Etoposide	Phase 2 Trial	21	DMINOX3	Vincristine	Approved	34	DMUYKBZ	Cyclosporin A	.	.	Brain Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCWKWJ0	DMNH3PG	Etoposide	Phase 2 Trial	21	DMWMPD4	Vorinostat	Approved	34	DMZD5QR	Cytarabine	.	.	Accelerated Phase Chronic Myelogenous Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCFW7M0	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	5.35	5.01	5.3	9.6
DCXEMK1	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	5.97	8.89	9.28	13.15
DCAQBON	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	5.89	6.08	2.09	8.38
DCNUD3H	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	4.47	4.96	2.08	7.6
DCAU6Z7	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	3.05	7.62	3.86	9.52
DCOF1EO	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	1.32	0.33	2.5	3.02
DC84ILQ	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	2.54	5.39	3.01	8.44
DC2TKG0	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	8.96	10.14	5.15	12.35
DCUBUR7	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	9.99	9.4	3.9	12.71
DC4NRYF	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	3.06	2.95	0.33	5.52
DC7CP0F	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	5.31	3.51	0.88	4.87
DC2ZWZ3	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	3.9	3.58	9.03	10.09
DCBXS1W	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	4.2	4.15	5.57	10.28
DC8HEMC	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	4.9	4.23	7.79	9.84
DC72OJJ	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	5.55	5.08	5.04	9.56
DCF6WNH	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	10.57	11.46	5.46	11.06
DCTCPIB	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	0.27	2.06	4.22	7.15
DCWM0RI	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	6.13	2.11	0.42	6.45
DCSTDWN	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	1.95	1.53	0.66	5.87
DCQUX7Z	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	6.85	6.16	6.97	12.27
DCNE4SX	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	7.16	7.11	5.57	9.41
DCYVZVV	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	2.08	1.39	8.72	12.53
DC3X626	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	12.91	13.78	6.61	14.4
DCJKUYN	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	2.92	6.61	6.2	9.41
DC93UNY	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	0.9	0.48	3.14	5.32
DC51YQZ	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	1.92	2.71	7.07	8.79
DCJ2IA8	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	4.09	2.18	4.86	7.95
DC34QBY	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	0.19	4.42	2.95	5.47
DCNDOQJ	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	2.88	4.89	5.04	6.65
DCM03AU	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	8.92	10.95	13.24	15.07
DCJMOCK	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	10.44	11.35	6.39	14.5
DCOR98A	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	5.67	5.36	2.52	8.05
DC7015V	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	4.21	3.34	0.31	4.41
DCREIRF	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	0.35	2.89	5.23	8.71
DCRV7CW	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	5.36	6	4.03	7.67
DCWOZPY	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	1.94	7.6	4.8	8.5
DCX5LG3	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	0.95	0.35	2.48	4.11
DCIOBEW	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	9.91	4.57	2.89	10.73
DCI7RNJ	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	8.45	8.41	6.33	10.48
DCXGS8O	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	3.49	2.68	0.51	5.87
DCE4HR5	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	4.65	2.22	8.11	11.51
DCH65TQ	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	2.33	4.34	0.77	5.71
DCFB4LH	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	8.05	7.25	4.53	9.57
DC3GGQD	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	3.19	2.63	2.93	6.5
DC12MK4	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	9.34	9.81	11.43	13.8
DCG7OO3	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	3.41	6.26	4.97	8.41
DCN9QZH	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	6.76	5.94	4.22	10.23
DCDT878	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	5.93	7.45	4.1	8.9
DC35IR0	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	1.82	0.54	2.53	6.49
DC4TR78	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	5.99	6.26	4.19	9.37
DCV6OVC	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	0.67	0.17	2.58	6.93
DCKLQP1	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	4.22	5.02	2.24	6.75
DCW9MLK	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	3.32	6.58	3.78	7.72
DC0RP68	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	4.57	3.3	5.38	10.16
DCT7T04	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	0.19	0.07	4.45	7.91
DCUDZX1	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	6.38	7.92	5.73	10.22
DCHP7WM	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	0.69	3.19	1.73	5.59
DC8780N	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	0.17	3.52	3.46	6.48
DCOFA9W	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	3	2.7	4.77	8.76
DCC93ZO	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	6.59	5.61	3.27	8.09
DCT3CO6	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	5.4	9.01	4.19	8.48
DCB0VNF	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	1.71	6.45	4.66	7.64
DCP7OIZ	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	7.5	8.52	5.95	10.97
DCS702W	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	4.71	5.47	3.95	8.69
DCTS7WU	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	6.35	7.4	5.86	10.19
DCUJHPK	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	9.01	9.19	1.27	9.3
DCXPD4U	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	9.65	10.17	4.75	11.08
DCNVHSK	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	7.33	8.55	6.2	11.33
DCC42VD	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	2.34	1.54	4.05	7.52
DCTHLGF	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	2.36	2.98	3.74	7.6
DCY96JH	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	10.15	11.07	9.89	14.25
DC2JOGP	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	12.04	14.21	9.12	13.72
DC4YLZB	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	8.43	9.83	9.86	13.47
DCNIL0O	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	11.93	10.62	16	19.63
DC0D9HT	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	8.01	7.06	4.54	10.22
DCQBNIU	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	6.38	6.3	5.2	9.54
DCG9KR8	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	10.07	10.7	5.77	12.35
DC99B7M	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	5.51	2.77	7.4	11.59
DCCFWGO	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	7.01	8.99	8.14	13
DCBTLGX	DMNH3PG	Etoposide	Phase 2 Trial	21	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	9.56	12.89	0.64	6.61
DCLOGBF	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	2.29	1.88	2.48	5.79
DC5URWJ	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	2.04	0.54	5.12	7.66
DCXJ1DI	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	0.78	0.53	3.04	6.96
DCYJTNR	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	1.38	1.61	2.18	4.86
DCRBCPZ	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	1.32	2.54	2.24	5.72
DCRVXQS	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	0.12	3.43	3.03	7.66
DCM0SFR	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	2.66	3.12	5.57	8.37
DC1WX4U	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	1.12	0.81	2.71	6.14
DCS84HW	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	0.41	0.62	2.38	5.89
DC31F8J	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	2.56	1.62	7.72	10.89
DCPU5CQ	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	5.58	5.4	9.18	12.4
DCIPAF8	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	0.93	2.22	7.53	10.7
DCEDP0E	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	6.38	7.03	7.07	11.42
DC0OM8K	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	0.73	0.82	5.6	8.49
DCK46GG	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	3.99	2.48	5.55	8.96
DCUIA73	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	0.79	0.05	3.72	6.63
DCZ19AK	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	7.56	7.51	7.2	10.89
DC7LUNV	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	2.48	1.46	4.35	10.01
DC904B0	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	1.27	2.58	5.18	8.1
DC897PH	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	5.23	5.09	5.18	10.37
DCPJKPX	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	20.79	19.21	13.69	24.65
DCH0785	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	3.64	5.36	6.82	9.72
DCIGISI	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	3.08	2.43	5.79	9.3
DCEKAFX	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	3.35	2.25	4	8.34
DC6DWMH	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	6.23	7.55	9.92	11.73
DCHTPZ9	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	6.23	10.62	9.88	12.79
DC7Z4V3	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	3.38	5.16	2.43	7.28
DC5UOTV	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	3.58	3.77	2.35	6.28
DC8TUFA	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	7.21	7.7	8.56	11.94
DCZHJXN	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	10.62	9.91	4.69	14.68
DCW57HO	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	5.11	3.18	0.21	5.71
DCY2PYG	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	1.76	1.97	3.22	5.09
DCVUKR5	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	0.01	0.91	7.76	9.54
DCPPP23	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	8.85	7.84	8.43	12.53
DCPCXD8	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	15.99	16.23	18.17	22.24
DCZZUXM	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	3.25	4.02	7.85	10.37
DCIEBDC	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	9.88	10.14	8.46	11.85
DCJV1CM	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	7.93	7.16	4.86	10.42
DC9H87F	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	6.72	6.29	1.65	7.16
DCNMLOI	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	4.47	3.45	6.09	12.44
DCEL9DT	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	6.26	7.63	6.91	12.41
DC4S7JQ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMA9SEY	GDC-0084	Phase 2	21	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	4.198	3.321	1.488	4.524
DC3N1UQ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	4.73	6.04	3.07	6.79
DCOCZ91	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	2.46	0.14	2.22	4.96
DCMUJYF	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	2.92	3.66	2.3	7.08
DCI5S6P	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	0.85	0.51	2.54	5.59
DCV4I6T	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	3.1	1.49	2.81	4.79
DC2M15B	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	1.53	6.49	0.57	6.01
DCD2GWJ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	4.65	3.56	2.65	6.42
DCDRA37	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	5.41	1.61	0.46	4.57
DC3IADM	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	5.76	4.24	0.79	8.28
DCPW6OT	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	8.35	7.8	8.89	12.72
DCLA0BK	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	3.76	4.7	2.61	7.58
DCV845B	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	1.84	0.91	3.42	6.67
DCPKW2H	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	1.45	0.26	1.62	6.1
DC73LKV	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	2.54	1.52	1.21	4.36
DCRZX19	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	14.47	14.35	12.67	16.4
DCVJZ30	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	3.68	1.58	2.15	5.51
DCIC1SN	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	1.8	1.09	3.08	6.87
DCIBKK3	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	2.67	2.17	2.97	6.49
DCAZAFO	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	7.4	7.08	4.43	9.46
DCTYPNI	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	5.26	3.4	11.02	13.37
DCB4KDT	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	5.04	8.4	0.98	10.14
DC53VV8	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCE08M	AT7519	Phase 1	17	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	17.096	18.013	6.034	12.94
DCAOOS0	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	4.94	5.65	4.25	10.01
DC4WLKD	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	5.51	4.27	5.38	12.07
DCFVFM4	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	2.18	6.81	6.85	11.07
DCOR5HJ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	10.93	10.09	5.87	12.53
DCP9KO3	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	5.55	5.29	4.2	9.13
DC0X1PD	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	4.74	3.6	0.51	8.47
DC5DB8D	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	3.92	3.98	3.27	9.13
DCPHKDC	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	4.11	3.1	0.03	7.29
DC9SCOV	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	1.64	1.03	0.71	5.58
DC2T2PJ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	4.49	1.35	39.38	2.15
DCLQVXA	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	4.23	3.99	2.43	9.15
DC2MDCN	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	1.97	1.27	3.71	9.37
DCVW22R	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	4.7	6.85	0.21	10.25
DCCIXZ5	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	0.52	0.84	5.67	10.47
DCAP27V	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	6.74	8.32	3.82	10.89
DC3YHKV	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	7.05	6.66	7.55	10.95
DCI6C05	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	6.38	0.61	2.99	6.03
DCSVFBW	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	0.66	1.63	6.85	8.11
DCUC0UZ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	4.11	2.92	7.48	10.26
DC30ZB7	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	9.44	11.69	11.14	13.43
DCB30RD	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	2.51	1.8	2.61	4.86
DC63PYD	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	2.03	1.83	2.44	6.57
DCVHS5C	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	13.33	15.41	5.1	18.4
DCG6CWP	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	9.68	10.15	9.26	12.5
DCTCG3W	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	9.44	5.03	30.61	5.9
DC2YI0K	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	3.72	3.85	0.9	6.28
DCRBX9C	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	6.81	5.21	9.77	11.64
DCQR8F5	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	6.19	5.28	5.91	9.57
DC5KBP3	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	3.98	3.18	7.67	9.39
DC5ECPF	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	2.32	2.16	0.78	5.13
DC86MOO	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	5.46	4.5	3.82	6.9
DCCIMT7	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	6.23	4.78	8.6	11.48
DCWW83N	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	14.43	9.67	15.96	19.15
DC59P1V	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	6.63	5.88	6.7	9.74
DCMZ603	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	5.52	5.67	3.63	8.78
DCF8TUO	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	7.72	5.27	10.03	12.32
DC1O6ES	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	4.97	8.6	5.11	10.15
DCDCQUD	DMNH3PG	Etoposide	Phase 2 Trial	21	DMDMQIE	THAPSIGARGIN	Preclinical	2.1	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	17.999	16.735	2.774	5.403
DCJII5O	DMNH3PG	Etoposide	Phase 2 Trial	21	DMEOS5K	AEE-788	Phase 1/2	19	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	17.153	15.824	0.915	2.258
DCYI0SI	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	7.4	8.51	5.25	10.51
DC73F9R	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	3.89	0.22	1.74	6.04
DCICOME	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	5.75	5.5	7.79	11.96
DCDLKIR	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	3.41	6.06	4.63	8.66
DCBWLK5	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	4.15	3.69	2.06	8.07
DCO31Q7	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	6.62	11.67	6.77	12.27
DCBDCE7	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	8.77	7.85	9.59	11.9
DC8PBXB	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	5.76	6.73	4.71	9.14
DCGFQOX	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	3.14	2.11	1.51	5.43
DCKOU9F	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	11.95	12.04	10.56	16.11
DCSPQFF	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	8.78	11.93	8.97	12.86
DCFSVO3	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	0.58	4.34	6.99	9.6
DCYVDYU	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	18.51	14.72	10.25	20.26
DCARDKE	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	1.11	0.82	1.88	6.96
DCNKB04	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	4.66	4.23	7.21	10.94
DC1R8Q3	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	3.61	9.01	1.9	9.35
DCUX6G9	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	6.09	6.56	3.7	7.24
DC4Y9Z8	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	4.27	4.27	0.23	5.03
DCF0E3Z	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	2.74	2.89	2.68	6.36
DCB8OFC	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	3.32	7	3.32	8.65
DCX1YQ3	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	3.9	4.88	1.65	7.54
DCEHM8Z	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	3.03	2.66	1.51	5.71
DC8JKKI	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	2.8	4.05	1.31	5.04
DC06FJZ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	5.68	5.65	2.01	8.85
DCCKZKO	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	2.81	3.49	0.49	5.63
DCU5033	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	3.93	3.96	1.91	5.96
DC1XQKW	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	3.22	3.92	5.4	8.82
DCGDTSF	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	12.68	13.02	13.5	15.78
DCKZD5R	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	2.81	2.46	0.27	4.05
DC6I0CI	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	9.63	7.47	7.52	11.39
DCI1W22	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	3.41	4.07	0.02	5.56
DCGF74C	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	0.58	5.07	7.75	8.87
DC0U5JR	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	2.35	0.05	5.36	5.36
DCS3W2X	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	0.76	8.67	11.75	12.73
DC3XMI8	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	1.33	3.33	5.71	6.09
DC69KFQ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	3.37	7.83	8.66	8.93
DCJQT6O	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	1.35	3.15	3.69	3.46
DC9JCGH	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	2.88	5.87	8.86	9.72
DCE2H04	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	0.24	0.67	4.14	4.79
DCLBMJY	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	3.3	2.45	4.31	5.38
DC4N4B2	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	0.9	1.19	5.59	6.24
DCV0LOA	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	0.73	0.39	2.58	2.75
DCO8PVZ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	4.3	5.07	6.69	7.02
DCZ9IL7	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	1.05	1.24	7.66	7.99
DCX9256	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	3.82	4.2	4.95	5.99
DCEXRDJ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	1.19	3.15	10.19	11.16
DCHCVDJ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	7.91	5.63	8.04	9.53
DCFDAH9	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	0.78	3.1	5.25	5.89
DCXB48K	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	2.88	2.16	8.04	9.68
DC5HQEH	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	2.83	3.5	5.41	6.37
DCIUIZG	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	2.63	2.07	11.03	13.42
DCEXNVT	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	4.16	6.84	7.1	7.9
DCHXGNQ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	3.35	3.05	1.43	5.63
DCLOVGJ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	1.63	2.79	7.36	8.73
DC06LL9	DMNH3PG	Etoposide	Phase 2 Trial	21	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	3.64	2.44	4.79	8.65
DCG40UT	DMNH3PG	Etoposide	Phase 2 Trial	21	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	3.78	3.5	0.14	8.94
DCBDV3I	DMNH3PG	Etoposide	Phase 2 Trial	21	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	ALMANAC Dataset	Investigative	T98G	30.12	30.12	42.8	42.82
DCVTL32	DMNH3PG	Etoposide	Phase 2 Trial	21	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	1.41	2.7	0.81	7.46
DCNCD8M	DMNH3PG	Etoposide	Phase 2 Trial	21	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	7.6	4.94	2.88	7.7
DCMQP4X	DMNH3PG	Etoposide	Phase 2 Trial	21	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	8.15	7.17	5	8.17
DC8ZHT9	DMNH3PG	Etoposide	Phase 2 Trial	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	5.88	6.1	0.81	5.94
DCXB46N	DMNH3PG	Etoposide	Phase 2 Trial	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	1.99	2.1	1.09	5.32
DCS0R4D	DMNH3PG	Etoposide	Phase 2 Trial	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	12.15	16.79	13.57	16.79
DCHSVVQ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	4.18	4.88	1.31	5.19
DC2L8YX	DMNH3PG	Etoposide	Phase 2 Trial	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	8.17	6.07	0.4	5.93
DC6DFEM	DMNH3PG	Etoposide	Phase 2 Trial	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	2.4	2.25	0.67	4.09
DCOJNE9	DMNH3PG	Etoposide	Phase 2 Trial	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	0.69	0.11	0.63	3.22
DCSOGXX	DMNH3PG	Etoposide	Phase 2 Trial	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	2.01	1.69	0.55	3.62
DC1QAKG	DMNH3PG	Etoposide	Phase 2 Trial	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	4.34	4.26	0.01	4.9
DCQ7V0Y	DMNH3PG	Etoposide	Phase 2 Trial	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	3.09	4.41	0.18	4.31
DCDF7P0	DMNH3PG	Etoposide	Phase 2 Trial	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	9.84	6.83	3.41	9.31
DCQI2L4	DMNH3PG	Etoposide	Phase 2 Trial	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	1.41	1.72	0.49	5
DC0AN1M	DMNH3PG	Etoposide	Phase 2 Trial	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	3.66	3.84	3.56	7.31
DC89GPI	DMNH3PG	Etoposide	Phase 2 Trial	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	2.75	4.36	0.25	7.27
DCKHRTU	DMNH3PG	Etoposide	Phase 2 Trial	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	8.33	11.98	12.59	14.15
DC7SDN6	DMNH3PG	Etoposide	Phase 2 Trial	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	7.17	9.78	4.08	10.07
DCHSM0H	DMNH3PG	Etoposide	Phase 2 Trial	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	8.53	7.5	3.83	8.92
DCQCB6G	DMNH3PG	Etoposide	Phase 2 Trial	21	DMR5GSB	Tetrahydrouridine	Phase 2	21	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	U-HO1	2.86	5.94	1.05	3.48
DCN48PK	DMNH3PG	Etoposide	Phase 2 Trial	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	8.93	8.39	0.38	9.24
DC1HOVO	DMNH3PG	Etoposide	Phase 2 Trial	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	2.6	3.72	3.24	7.65
DCSUHMC	DMNH3PG	Etoposide	Phase 2 Trial	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	1.94	2.31	0.4	5.33
DCCXLM1	DMNH3PG	Etoposide	Phase 2 Trial	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	6.1	5.81	5.14	10.83
DCPUR7D	DMNH3PG	Etoposide	Phase 2 Trial	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	4.39	4.86	1.3	9.16
DCZLJAL	DMNH3PG	Etoposide	Phase 2 Trial	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	2.97	3.7	0.48	7.52
DCSZU8N	DMNH3PG	Etoposide	Phase 2 Trial	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	1.02	0.59	1.88	7.43
DC54RP4	DMNH3PG	Etoposide	Phase 2 Trial	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	3.31	2.92	2.23	9.26
DCQ1D34	DMNH3PG	Etoposide	Phase 2 Trial	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	0.6	0.37	3.58	7.08
DCORPO3	DMNH3PG	Etoposide	Phase 2 Trial	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	2.15	2.44	6.67	9.59
DCI6Q3O	DMNH3PG	Etoposide	Phase 2 Trial	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	3.91	3.58	6.19	7.73
DCV1LMT	DMNH3PG	Etoposide	Phase 2 Trial	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	6.74	6.94	2.5	9.18
DCU2C8U	DMNH3PG	Etoposide	Phase 2 Trial	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	2.34	2.29	3.62	8.43
DC9HFU6	DMNH3PG	Etoposide	Phase 2 Trial	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	10.9	11.4	0.56	11.21
DC8EQSU	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	7.24	8.47	2.72	10.41
DC6JGMK	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	1.99	1.94	5.75	7.82
DCUKA8H	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	1.83	5.55	8.19	10.06
DCAN8JX	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	5.85	5.58	9.73	12.54
DCALRA9	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	2.29	2.18	2.01	5.77
DC6ZPPM	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	5.62	5.97	8.31	10.72
DCIKPGM	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	10.33	12.1	11.76	13.62
DCRSR2C	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	4.15	3.48	5.27	7.97
DCN44PF	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	6.46	5.16	5.15	7.63
DC4C133	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	4.13	8.52	3.83	11.57
DCLLK3A	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	2.43	0.67	0.34	2.22
DCSZ8OK	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	4.26	3.91	6.82	10.01
DC375FU	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	3.27	3.98	8.27	10.44
DCLZB9R	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	1.24	2.7	4.82	6.9
DC5CLGR	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	3.72	5.14	3.93	6.57
DCR5UGT	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	4.14	3.98	10.62	13.28
DCA0PBQ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	19.98	19.04	23.28	26.62
DCRF3Q1	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	3.07	2.42	5.49	9.38
DC9G65A	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	7.33	6.48	8.04	13.45
DCQK074	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.65	2.02	2.08	5
DC1N0ZM	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	1.75	0.43	7.23	10.12
DCY5EJN	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	2.14	2.08	7.78	10.41
DCZJSVE	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	10.092	9.746	0.812	4.064
DCDUJDF	DMNH3PG	Etoposide	Phase 2 Trial	21	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	6.234	7.305	0.231	3.955
DCRC0LT	DMNH3PG	Etoposide	Phase 2 Trial	21	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Diffuse large B cell lymphoma	ALMANAC Dataset	Investigative	TMD8	3.852	2.827	3.075	7.49
DC7OLL9	DMNH3PG	Etoposide	Phase 2 Trial	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	6.01	6.13	9.19	11.3
DCEBIP9	DMNH3PG	Etoposide	Phase 2 Trial	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	1.64	1	7.16	11.09
DCRC013	DMNH3PG	Etoposide	Phase 2 Trial	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	1.3	1.98	6.32	6.88
DCVYUCE	DMNH3PG	Etoposide	Phase 2 Trial	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	2.87	2.06	4.72	6.39
DCB4BJC	DMNH3PG	Etoposide	Phase 2 Trial	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	2.4	3.29	6.3	8.77
DC97VMI	DMNH3PG	Etoposide	Phase 2 Trial	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	4.05	3.13	7.35	9.46
DCS8SNS	DMNH3PG	Etoposide	Phase 2 Trial	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	0.94	0.52	2.65	4.74
DC40SRU	DMNH3PG	Etoposide	Phase 2 Trial	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	6.41	5.55	7.73	11.35
DC8TMBL	DMNH3PG	Etoposide	Phase 2 Trial	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	8.08	1.52	8.87	12.18
DC2E59W	DMNH3PG	Etoposide	Phase 2 Trial	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	8.32	7.86	11.69	15.25
DCTGD8J	DMNH3PG	Etoposide	Phase 2 Trial	21	DMZD5QR	Cytarabine	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	2.857	5.941	1.053	3.477
DC0JL94	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.99	3.62	9.75	10.54
DCP2BVK	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	1	0.77	11.77	12.65
DCYBN4X	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	8.61	9.98	10.89	13.36
DCIBB8E	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.95	6.3	5.7	11.24
DCVOVFB	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.45	1.76	2.6	5.87
DCNU553	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.62	2.44	2.77	7.44
DCF1W5I	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.93	0.76	5.15	9.2
DCXCY8S	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	10.67	10.45	10.39	14.55
DC9XTLY	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.11	0.41	1.4	3
DCANEJ9	DMNH3PG	Etoposide	Phase 2 Trial	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	5.67	9.21	6.74	14.73
DCJUJ4V	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.72	0.82	3.31	6.68
DCWLF6D	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	5.81	7.32	3.02	10.83
DCNL6VW	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	0.93	0.84	11.7	12.87
DC2JMJ4	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.86	0.36	5.66	8.37
DCHC1VS	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.99	0.81	1.29	3.66
DCCXPRB	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.33	0.29	12.99	14.73
DCSKTVU	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.87	2.43	8.6	9.81
DCTEUUY	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.55	9.64	11.13	12.58
DCK7Y1K	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.72	2.67	0.66	7.05
DC4LU4S	DMNH3PG	Etoposide	Phase 2 Trial	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.57	0.61	3.21	6.71
DC3QO8T	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	5.67	5.38	8.05	11.72
DCK6UYC	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	7.38	10.45	6.96	13.6
DCVZIYM	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	2.77	5.43	6.21	9.43
DC7VKRD	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	4.51	6.19	6.5	10.85
DC2LV0Z	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.02	5.1	3.83	8.08
DCTAFPA	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	8.26	9.08	8.65	13.77
DCL5TV9	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.57	4.48	2.68	8.4
DCUPZSV	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.9	1.93	5.35	8.16
DCHU06E	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.53	2.13	5.55	9.4
DCU9IJY	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.61	3.52	7.25	10.76
DCNWTJ8	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	15.19	16.37	12.19	17.94
DCH2VPH	DMNH3PG	Etoposide	Phase 2 Trial	21	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	7.3	12.08	10.52	13.56
DCN1XD8	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	2.76	1.61	7.05	10.66
DCE2347	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.47	0.25	1.95	6.08
DC5MYFX	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.84	0.43	4.39	7.73
DCXW99M	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.65	0.8	1.87	5.73
DC9L6XG	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.47	0.92	7.87	10.32
DC1DBFW	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.74	8.14	9.01	12.09
DCBTNQ3	DMNH3PG	Etoposide	Phase 2 Trial	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.29	5.09	3.69	9.57
DC2ACXA	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.11	0.81	2.03	5.57
DCV1S66	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.01	5.8	12.05	13.2
DCTCQSY	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.43	2.26	3.72	7.42
DCYRD3S	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	7.36	6.97	0.11	11.98
DC0K7YD	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.91	1.63	8.27	11.22
DC6GKKK	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.13	0.75	6.11	9.13
DCU7WG2	DMNH3PG	Etoposide	Phase 2 Trial	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.72	4.35	4.98	8.41
DCH03P7	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	11.17	4.78	3.22	6.79
DCW7QH7	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	2.91	1.35	8.13	10.25
DCIB7PR	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	5.34	2.51	4.18	7.45
DC3EVRX	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.31	0.19	5.88	8.06
DC0Q9PA	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.03	0.9	1.85	4.57
DCDERPE	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	21.52	21.54	19.67	21.85
DCVDVQR	DMNH3PG	Etoposide	Phase 2 Trial	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.31	5.37	6.52	9.13
DCXJFJL	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.84	2.63	4.62	7.81
DCT7JX6	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.14	2.83	3.43	9.59
DC0BLPN	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	0.7	1.76	3.19	7.71
DC6JUJF	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.24	4.63	1.05	8.72
DCDGFJ8	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	3.75	2.99	8.75	14.82
DC7UWCB	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.47	2.3	1.75	6.22
DC5O3FL	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4	1.32	1.79	4.84
DCXQJMS	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.8	1.64	1.08	5.67
DC7U7VY	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.41	0.72	6.23	8.65
DCPIN8K	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.47	0.38	2.15	6.34
DCFOVH8	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.41	1.5	2.54	5.17
DCVGNAZ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	8.07	7.86	12.86	14.73
DC49G70	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.08	1.7	2.2	6.81
DCSP5GN	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.45	6.58	1.47	9.39
DCIYN3G	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	5.47	5.72	6.03	9.4
DCOMNYX	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.99	2.82	2.7	6.3
DCY4I5V	DMNH3PG	Etoposide	Phase 2 Trial	21	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	12.46	17.87	5.42	19.09
DCHQFPY	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.61	4.21	3.3	6.83
DCM531A	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	4.86	2.98	1.91	3.27
DC58AVR	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.18	3.05	0.77	5.57
DCA806E	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.99	2.72	0.45	5.36
DC16211	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.12	0.85	1.55	5.09
DCMOAP9	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.89	2.71	3.13	7.9
DCKMPP2	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.65	7.19	7.7	10.83
DC81M3J	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.36	8.05	8.05	12.2
DCUIRW8	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.75	0.36	4.45	6.88
DCMDRDC	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.04	2.63	5.69	7.82
DCAE54V	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.16	1.66	10.4	11.38
DCRW5SE	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	8.97	8.6	14.31	15.03
DCGWLCK	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.2	6.41	8.44	9.98
DCI4KM8	DMNH3PG	Etoposide	Phase 2 Trial	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.75	7.68	9.73	10.21
DC2SMMZ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	9.47	7.75	12.26	13.58
DCWCPFX	DMNH3PG	Etoposide	Phase 2 Trial	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.01	0.93	0.57	2.75
DCLAO7B	DMNH3PG	Etoposide	Phase 2 Trial	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.91	3.83	3.15	5.97
DCDPMRZ	DMNH3PG	Etoposide	Phase 2 Trial	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	0.44	2.43	1.75	5.12
DCAL2QA	DMNH3PG	Etoposide	Phase 2 Trial	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.94	3.46	6.86	8.85
DC3KZNM	DMNH3PG	Etoposide	Phase 2 Trial	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	4.56	1.58	8.46	13.34
DC878Q7	DMNH3PG	Etoposide	Phase 2 Trial	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.67	0.68	0.88	4.91
DCNMBN0	DMNH3PG	Etoposide	Phase 2 Trial	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.49	2.15	1.3	6.35
DCAR2NP	DMNH3PG	Etoposide	Phase 2 Trial	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.08	1.92	1.47	6.45
DCEB3Y0	DMNH3PG	Etoposide	Phase 2 Trial	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	5.01	4.66	2.18	6.51
DCNIYJU	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.24	6.65	10.08	12.92
DCLALNT	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.29	1.37	3.21	6.97
DCXU2X9	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.94	5.09	9.38	12.41
DCL6W44	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.62	3.14	8.06	9.73
DC53OD0	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.2	4.08	9.53	10.86
DCDH1XN	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.08	0.38	7.44	9.06
DCKSJVK	DMNH3PG	Etoposide	Phase 2 Trial	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.46	5.08	10	11.58
DCMO17I	DMNH3PG	Etoposide	Phase 2 Trial	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.73	8.52	10.37	11.54
DC7G497	DMNH3PG	Etoposide	Phase 2 Trial	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.85	2.87	2.96	5.97
DC2JOG1	DMNH3PG	Etoposide	Phase 2 Trial	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.36	1.37	1.93	7.83
DCUDXNE	DMNH3PG	Etoposide	Phase 2 Trial	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.44	0.24	4.07	5.09
DCNV8U9	DMNH3PG	Etoposide	Phase 2 Trial	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.38	2	8.41	10.39
DCHUH7F	DMUOT9V	Taxol	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.65	4.19	0.3	0.3
DCUOD8R	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.99	6.79	1.44	8.95
DC4ZKX4	DMUOT9V	Taxol	Approved	34	DM2KITF	LY335979	Discontinued in Phase 3	9	.	.	.	.	Human papillomavirus-related cervical adenocarcinoma	DrugCombDB Database	Investigative	KB-ChR-8-5-11	55.792	53.502	8.007	32.688
DCEQJX2	DMUOT9V	Taxol	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	8.71	7.34	8.26	8.73
DC797B8	DMUOT9V	Taxol	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.56	2.44	3.1	6.57
DCFS6SN	DMUOT9V	Taxol	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	9	6.34	6.63	7.71
DCQ3I8Q	DMUOT9V	Taxol	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.95	0.61	2.37	5.08
DC8QC3O	DMUOT9V	Taxol	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	8.67	3.95	3.68	7.15
DCFAQVG	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	37.03	35.5	31.92	30.91
DCV0Q5W	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	5.49	11.8	13.06	12.69
DC44E08	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	17.1	18.44	19.28	21.07
DCNGZEB	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.36	4.43	1.22	7.53
DC5MN3U	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	10.34	16.9	15.53	17.7
DCX0X37	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	9.33	10.63	5.67	12.65
DCFPA2G	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	7.95	11.82	1.35	7.92
DC20JTY	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.77	8.62	7.13	8
DCDM6OT	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.48	5.35	7.19	7.1
DCDCVOV	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	5.24	9.71	9.72	9.65
DCOZ0EB	DMUOT9V	Taxol	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	1.85	3.39	1.74	5.94
DCW0TM4	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	11.02	12.2	10.56	14.92
DC4ZEP4	DMUOT9V	Taxol	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	5.3	7.04	2.44	2.4
DCUH2IK	DMUOT9V	Taxol	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	8.65	7.97	1.93	7.29
DCQ09OO	DMUOT9V	Taxol	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.34	4.04	2.79	4.33
DCVRHE9	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	3.25	0.01	1.55	4.83
DCEW2SX	DMUOT9V	Taxol	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	2.95	3.24	1.28	5.57
DCYHN6O	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	15.42	18.72	9.95	11.74
DCSXTP0	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	9.72	10.71	11.57	12.19
DCDC5O7	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	10.93	4.2	2.07	1.45
DCMJOXQ	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	7.14	6.96	6.04	6.36
DCL4Z7F	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.39	4.97	2.27	5
DCKW2MV	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.06	4.52	3.06	4.33
DCSIN75	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	4.59	4.68	1.85	4.08
DC3XFH5	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.48	4.38	3	4.12
DC9EQTZ	DMUOT9V	Taxol	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.45	7.32	1.39	4.03
DCP1XFT	DMUOT9V	Taxol	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.03	6.72	1.45	5.61
DCA4FNV	DMUOT9V	Taxol	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.62	1.3	1.68	5.75
DCOHVZ3	DMUOT9V	Taxol	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.38	1.42	1.09	2.49
DCL9ER5	DMUOT9V	Taxol	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.59	3.06	0.8	4.94
DCUGUQO	DMUOT9V	Taxol	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.25	0.22	0.26	0.42
DCX7J5N	DMUOT9V	Taxol	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.34	0.05	0.02	0.02
DCR57AE	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	5.96	4.94	3.11	7.47
DC08I6Q	DMUOT9V	Taxol	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.05	0.79	0.28	1.54
DC3PRJN	DMUOT9V	Taxol	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	7.37	11.27	6.9	4.21
DC8CYQJ	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	14.01	11.51	8.04	9
DCZSJPL	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	18.74	16.84	15.81	5.51
DCDGE1S	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	6.78	12.14	0.66	9.27
DC4ICDI	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.77	1.4	1.26	4
DCJQ765	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.53	6.21	4.77	5.5
DC5WLVV	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	11.99	10.88	5.7	14.2
DCRLJPR	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	6.26	6.96	4.79	6.86
DCD02A3	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	8.27	6.62	6.9	6.21
DCYKUK5	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	4.15	8.49	8.4	7.99
DCKU2O8	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.38	2.82	4.06	4.11
DC3X79A	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.51	0.21	0.33	0.06
DC5HIC8	DMUOT9V	Taxol	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	9.36	10.33	10.19	11.12
DCBWEPY	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	7.68	11.52	9.24	13.2
DCDMGYV	DMUOT9V	Taxol	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	6.01	4.75	0.69	4.83
DCLMAVJ	DMUOT9V	Taxol	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	18.46	15.81	17.97	19.61
DC6NW7G	DMUOT9V	Taxol	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	5.6	10.48	7.34	5.03
DCY50IV	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	2.96	2.78	0.34	4.63
DCZKYOP	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	2.55	2.68	3.23	6.43
DCGI7LS	DMUOT9V	Taxol	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	1.74	2.05	1.32	7.45
DC87NUD	DMUOT9V	Taxol	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	3.59	3.59	5.84	5.92
DCBJG0Z	DMUOT9V	Taxol	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.56	0.04	1.06	4.55
DCJ1UTX	DMUOT9V	Taxol	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.23	4.54	5.51	5.08
DCBGIS3	DMUOT9V	Taxol	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.31	1.94	4.78	8.45
DC7SL8S	DMUOT9V	Taxol	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.53	1.01	0.05	2.17
DCE44FL	DMUOT9V	Taxol	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.26	4.94	3.14	6.22
DC0DK6F	DMUOT9V	Taxol	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.28	2.54	1.51	3.81
DCX25X5	DMUOT9V	Taxol	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.1	0.99	1.62	1.02
DCRGN3L	DMUOT9V	Taxol	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.16	0.73	0.68	0.88
DCZ9XZY	DMUOT9V	Taxol	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	9.44	9.97	10.58	10.78
DC3DISG	DMUOT9V	Taxol	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	0.06	1.51	1.83	2.02
DC9T1GO	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	5.11	6.76	3.83	7.04
DCH8VPM	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.57	7.55	8	8
DCE5I64	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	9.62	16.53	14.17	14.57
DCIGAFZ	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	5.03	8.5	4.61	3.87
DC53KDW	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	8.95	17.75	17.42	15.74
DCEIQCH	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	7.1	7.14	5.75	11.55
DCDH3PT	DMUOT9V	Taxol	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	18.88	17.41	2.1	17.26
DCS3FJZ	DMUOT9V	Taxol	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	26.62	26.19	5.46	25.59
DCF24Y5	DMUOT9V	Taxol	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	25.55	20.42	14.96	23.08
DC29MCU	DMUOT9V	Taxol	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.93	4.42	5.6	5.76
DC02A62	DMUOT9V	Taxol	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.7	5.28	3.54	1.48
DCHL2IA	DMUOT9V	Taxol	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	4.18	6.05	4.48	6.08
DC3TDIT	DMUOT9V	Taxol	Approved	34	DMURVE8	Elacridar	Discontinued in Phase 1	3	.	.	.	.	Human papillomavirus-related cervical adenocarcinoma	DrugCombDB Database	Investigative	KB-ChR-8-5-11	52.499	54.105	38.484	39.007
DCI9681	DMUOT9V	Taxol	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.84	4.29	3.87	0.75
DC2O7Y9	DMUOT9V	Taxol	Approved	34	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	33.256	28.782	6.751	28.783
DCZEDLK	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	3.56	9.17	1.16	5.43
DC37VKQ	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	6.91	6.08	6.72	10.39
DCZTZN8	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	3.23	2.21	5.51	8.29
DC4F3FE	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.09	11.62	7.14	4.63
DCESKQH	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.51	7.59	2.65	5.31
DCILOAD	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.65	5.46	3.68	3.07
DC7H8SQ	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	5.71	9.59	10.48	13
DC8TCXZ	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.53	0.49	5.27	7.85
DCSZTH2	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	1.21	2.2	15.57	16.3
DCVU9VW	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.56	1.04	2.18	6.46
DCZIBKS	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	6.64	6.16	11.23	14.28
DCVGPO1	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	4.68	3.92	3.69	7.63
DC3QYU9	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	5.33	4.4	4.42	8.98
DCX4YRG	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.24	0.33	4.71	8.16
DCL4NAN	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.8	4.48	1.75	8.09
DCY0X4L	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.74	4.11	4.19	8.57
DC87P8P	DMUOT9V	Taxol	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.33	3.76	1.88	4.69
DCA2G0N	DMUOT9V	Taxol	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.06	0.42	0.53	3.46
DC5U5XG	DMUOT9V	Taxol	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.75	5.04	1	6.23
DC2SZTT	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.48	6.22	6.46	8.09
DC4BBTZ	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	0.96	0.19	1.16	4.21
DCXHDLC	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.57	0.18	2.61	5.75
DCDKRWE	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.76	0.03	8.03	9.86
DCBU22M	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.71	3.91	2.35	5.16
DCSARDK	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.52	11.18	10.59	11.64
DCVPTT3	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.26	1.87	7.48	10.1
DCRYGIP	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	22.71	24.54	11.41	19.34
DCNNDOA	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.35	14.9	12.42	14.19
DCN7F6I	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.07	4.73	8.18	9.66
DCSMPA8	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.56	1.95	3.49	7.12
DCDJ3X0	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	6.54	4.97	5.94	8.79
DC4JH6Y	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.56	0.39	4.53	5.83
DCXR6S9	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.98	0.12	0.07	3.39
DCFDMBU	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.81	0.95	0.65	4.21
DCHLYER	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.24	2.91	4.58	7.94
DCOL3P4	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	6.57	5.99	8.1	11.98
DC69HGD	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.03	4.93	6.55	8.36
DCCS71X	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.37	5.65	2.48	6.29
DCLNK5Y	DMUOT9V	Taxol	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.08	4.78	2.98	6.92
DC0T5VG	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.8	1.29	5.47	7.82
DC3CIWF	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.77	2.57	7.42	10.42
DCDNK38	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.47	6.98	10.99	12.91
DCTRQ30	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	0.52	0.94	2.19	4.81
DC1ZGE9	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.42	5.96	3.59	3.58
DCU7MOJ	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.23	4.78	1.64	5.09
DCRFWH0	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	13.21	10.44	6.87	9
DC3ONFM	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.52	7.19	4.16	6.07
DCUZACQ	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.07	0.46	0.32	2.08
DCS5AQF	DMUOT9V	Taxol	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	20.23	20.76	7.41	19.36
DCNZ06C	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.53	4.23	4.54	6.54
DCG6GFK	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	29.51	23.11	17.21	25.02
DCF49E1	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	6.1	2.7	5.91	8.11
DCS4BSH	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	5.99	5.51	7.44	10.51
DC9L7NX	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	5.53	4.34	3.66	5.88
DCRIXV0	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	11.77	11.33	11.9	14.74
DCQZ3RL	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.63	1.95	3.03	6.57
DCXUVF3	DMUOT9V	Taxol	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.31	6.89	0.99	0.06
DCX9VG3	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.81	0.73	0.15	2.12
DCBVHW3	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.89	5.49	7.39	7.17
DCTF34Y	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.17	2.83	2.62	7.81
DCX0DJT	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.99	2.45	3.63	6.56
DCRGN7E	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.99	2.38	2.11	5.86
DCJ3IQ2	DMUOT9V	Taxol	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.9	5.14	6.75	7.54
DCY402E	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	5.42	4.57	5.26	9.99
DC7Z562	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	6.76	6.1	6.07	10.97
DCU9KRX	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.72	0.81	4.5	7.93
DCNS58T	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	5.72	5.42	1.41	8
DCLFAOP	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	6.52	6.24	3.35	7.63
DCNN52G	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.71	1.05	5.17	8.45
DCEJTCT	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.25	0.18	0.99	8.11
DCXI2FY	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.06	0.24	0.13	4.1
DCP02CS	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.33	0.85	2.9	6.4
DC54L7L	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.45	3.13	1.13	5.54
DCSWG7D	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.12	1.31	1.46	4.69
DCTHKEL	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.28	2.35	0.69	6.45
DC6ICEC	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.77	3.86	0.2	5.04
DCWCOXW	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.85	1.54	3.26	5.83
DC87280	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.87	2.16	4.04	6.3
DCLGQ69	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.44	1.7	7.19	8.84
DCDQW9D	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.84	0.58	6.45	7.54
DCI4NAJ	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.72	0.11	8.98	11.35
DC7OV6C	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.94	0.62	1.64	4.75
DCDF9YY	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.29	0.05	4.17	6.59
DCXTNRG	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.59	1.56	2.37	6.67
DCYMBDC	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.5	9.45	15.48	16.55
DCKBMZY	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.5	5.22	4.43	6.41
DCLTNYH	DMUOT9V	Taxol	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.53	0.17	0.68	3.82
DC7Q0GR	DMUOT9V	Taxol	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.29	5.12	0.15	1.12
DCC1FD2	DMUOT9V	Taxol	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.52	4.45	8.48	9.48
DCCEEJG	DMUOT9V	Taxol	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.21	2.33	0.29	4.19
DCSRTH4	DMUOT9V	Taxol	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.03	0.78	3.02	4.26
DCUKIE6	DMUOT9V	Taxol	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.85	2.41	2.5	5.94
DCL0P2X	DMUOT9V	Taxol	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.06	1.47	4.6	6.37
DCCEC9C	DMUOT9V	Taxol	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	8.64	5.87	3.79	7.22
DC9T5VT	DMUOT9V	Taxol	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.76	2.79	1	2.68
DC7I2LZ	DMUOT9V	Taxol	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	13.36	10.12	6.57	10.84
DCM6X3U	DMUOT9V	Taxol	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.22	5.02	5.57	7.6
DC45XD8	DMUOT9V	Taxol	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.42	0.56	0.92	2.99
DC54FI1	DMUOT9V	Taxol	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.25	5.34	2.87	5.92
DCPZ4TH	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4	9.82	9.4	9.4
DC37TC3	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	4.06	0.76	10.61	12.63
DCHILCM	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.66	1.11	6.78	9.02
DCQMHOP	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.29	13.97	13.84	12
DCPF3VB	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.47	10.72	9.31	9.28
DCXZ0S6	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.88	2.56	1.03	6.63
DCL5P58	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	26.65	26.86	26.13	24.61
DC3JA3H	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.16	0.62	4.4	7.88
DC69G57	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	18.94	18.18	3.61	14.76
DCLZ4SC	DMUOT9V	Taxol	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	11.73	9.92	0.17	11.5
DCFWXTH	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	0.3	0.83	0.2	4.49
DCPCV4D	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.09	1.9	0.98	5.28
DCB62J1	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.38	1.76	5.44	7.65
DC3R9FT	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.1	2.45	5.23	7.88
DCOD2BL	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.71	2.02	3.51	5.24
DC64ZXE	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.38	1.43	4.64	6.82
DC6KFW5	DMUOT9V	Taxol	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	12.98	10.85	0.2	11.04
DC70TZC	DMUOT9V	Taxol	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.27	4.15	2.87	2.77
DCLDGY4	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	2.88	0.97	5.57	6.29
DCA3ZY0	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.21	3.42	0.78	5.99
DCD6RC8	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.78	0.09	8.42	10
DC79KUD	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.4	2.13	0.17	5.09
DCPTMXU	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	6.78	8.73	3.55	11.58
DCQAFKL	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.93	4.91	7.11	8.84
DCSBLR2	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	15.04	16.76	11.1	14.09
DCGWRIZ	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6	6.98	11.48	17.96
DC6WWTG	DMUOT9V	Taxol	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.47	4.89	9.25	9.26
DCZFB7O	DMUOT9V	Taxol	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.63	5.81	7.47	3.42
DCUELK7	DMUOT9V	Taxol	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.28	4.33	2.15	1.27
DCRIRXM	DMUOT9V	Taxol	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.89	3.3	2.07	1.33
DC13J0J	DMUOT9V	Taxol	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.62	2.68	2.44	0.78
DC2YDC0	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.53	1.29	7.13	10.66
DCRGWPY	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.72	0.55	1.68	6.48
DCF5M8J	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	7.42	6.54	9.12	12.41
DCRYGZ8	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.38	2.92	1.75	7.08
DC2M4GP	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	5.13	4.02	1.28	7.47
DCDRBWT	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	2.11	4.9	2.94	4.6
DC5ZR81	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.21	2.36	3.76	6.73
DCE1B3E	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.28	3.58	0.17	6.22
DC1ZQWU	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.86	2.4	3.67	8.04
DCPTQAX	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	21.22	18.39	18.59	21.2
DCF8UGP	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	14.86	17.68	5.59	19.58
DC5K6WQ	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.63	2.97	0.99	5.28
DCA0AYL	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	3.58	1.71	0.44	6.27
DCEHP32	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	8.39	8.36	1.38	12.51
DC1AEP9	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.24	2.83	0.3	7.48
DCH9330	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	7.29	5.66	2.87	7.69
DCTN1G3	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	13.38	4.6	4.47	9.05
DCJSIOH	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	4.41	2.93	0.31	6.69
DCD2HJL	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.16	5.12	2.77	9.4
DCSPW4C	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.12	5.08	3.88	9.79
DC7KBLO	DMUOT9V	Taxol	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	7.73	7.19	2.28	8.05
DCGXSWR	DMUOT9V	Taxol	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.16	3.01	1.83	3.88
DCY6EV0	DMUOT9V	Taxol	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	7.38	2.66	3.07	5.69
DCR3171	DMUOT9V	Taxol	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.47	2.57	1.41	7.16
DC3HERI	DMUOT9V	Taxol	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.7	1.63	2.17	6.35
DC30OND	DMUOT9V	Taxol	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	7.78	2.99	3.78	7.39
DCSWR1P	DMUOT9V	Taxol	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.27	5.03	5.69	7.33
DCXL5MF	DMUOT9V	Taxol	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	4.69	3.34	3.09	5.05
DC5AT0U	DMUOT9V	Taxol	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.41	0.41	1.53	4.42
DC33HGQ	DMUOT9V	Taxol	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.7	0.61	0.14	4.66
DC386GQ	DMUOT9V	Taxol	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	21.1	19.08	8.95	20.6
DCK6Z93	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	14.63	16.41	17.47	18.18
DC7WQGF	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	4.59	4.82	7.17	9.09
DCYHE5D	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.17	0.8	2.43	4.09
DCT36VT	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	10.18	15.83	14.4	17.91
DC61E9U	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	25.47	27.55	24.08	26.42
DCL01S3	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	21.81	21.93	22	22.25
DCN27YH	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	16.84	16.22	18.23	19.9
DC3HLC1	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	3.7	3.37	0.46	4.72
DCEC35A	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.23	4.66	0.81	3.31
DCPYKCL	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.6	6.93	5.19	8.32
DCJI5XI	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	8.75	12.16	10.78	11.92
DCO2RJ6	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	5.38	6.6	7.33	7.33
DCKOL9M	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.11	7.27	6.66	9.01
DCXSRCN	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	18.64	19.71	21.92	23.37
DC034D1	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	8.25	8.4	9.69	9.99
DCYD78S	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	3.67	5.26	0.7	9.54
DCDAM0L	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.23	3.74	2.06	5.57
DCGWUSA	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	5.84	5.29	3.3	6.87
DCJ75O1	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.03	4.11	3.39	7.27
DCU9IPI	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.53	3.9	3.48	5.41
DCUNO9J	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.98	3.07	3.16	5.06
DCGP6NU	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	4.8	4.46	5.87	12.48
DCPRU66	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.5	3.85	6.96	7.31
DCI4O4J	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	8.03	5.87	2.16	7.37
DCL5X5I	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.35	3.26	3.35	10.46
DCD8P7I	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.22	6.91	3.77	7.64
DCFIFV7	DMUOT9V	Taxol	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	9.46	12.12	4.24	12.58
DC6H2ID	DMUOT9V	Taxol	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	4.25	11.69	11.54	11.85
DC3K8EN	DMUOT9V	Taxol	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.95	4.46	1.77	6.93
DCGYJZA	DMUOT9V	Taxol	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.96	2.89	0.46	4.86
DCD58VV	DMUOT9V	Taxol	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	3.17	0	0.56	5.14
DCKR90C	DMUOT9V	Taxol	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	6.05	5.31	8.11	11.88
DCWQJ5C	DMUOT9V	Taxol	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	2.94	1.28	1.53	6.06
DC7NET9	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.42	3.01	2.24	5.55
DCFA8VH	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.41	0.11	2.29	5.61
DCZ51LI	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	3.52	3.46	0.85	6.27
DCDDWM7	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	4.56	3.58	1.85	4.58
DC8E89A	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.09	4.35	3.4	4.11
DCQBZ1R	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	6.07	7.13	3.58	9.58
DCZT409	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.59	2.26	1.25	5.27
DCIWYIJ	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.76	6.08	5	9.35
DCOUQ43	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.7	6.34	3.79	6.57
DCAMPXH	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.18	11.5	5.47	9.93
DCUBTG4	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	3.81	4.83	0.69	5.31
DCPTIN7	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.28	0.75	0.12	5.56
DCUSRY2	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	0.07	1.8	0.73	5.05
DCVLAIR	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	2.65	4.05	4.65	7.93
DCGB5BW	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.13	1.8	0.99	5.43
DC4ONIJ	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	3.08	4.02	2.12	6.06
DCY28QW	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.65	2.24	2.45	6.04
DCVWL9B	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	9.22	7.15	12.63	15.28
DCIDRVJ	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	8.39	9.09	4.3	12.24
DCE8OUP	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.77	4.6	2.78	7.39
DCLQGG9	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.19	4.47	5.05	7.83
DCAU2F9	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	4.42	1.55	3.61	7.76
DCEXR1W	DMUOT9V	Taxol	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	3.87	4.64	3.25	7.78
DCGM1DV	DMUOT9V	Taxol	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	10.58	12.8	4.02	3.76
DCLDH3Z	DMUOT9V	Taxol	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.05	3.07	4.99	5.28
DCC8CB0	DMUOT9V	Taxol	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.73	2.62	0.4	2.35
DCJMDWK	DMUOT9V	Taxol	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.65	1.39	1.79	0.98
DCP0W50	DMUOT9V	Taxol	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.64	0.33	1.07	2.02
DCEBIK2	DMUOT9V	Taxol	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.14	3.24	3.08	3.92
DCS7NMJ	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	2.68	0.03	2.42	5.5
DC92RGN	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	6.08	4.62	1.92	4.9
DCZV5KI	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	2.23	1.1	2.01	5.51
DCGRRQS	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.95	1.23	4.18	6.93
DCBBQ4W	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	5.26	6.48	5.66	9.95
DCTTLOL	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	2.46	1.69	1.11	4.93
DCZSP5I	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.53	2.77	5.86	9.17
DCZNR2C	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	4.5	3.38	4.55	8.47
DCH19U1	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	3.3	2.71	7.75	10.68
DCZ9I0Z	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.85	0.33	1.99	7.18
DCR11MQ	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	0.78	0.27	3.66	6.27
DCFL9U6	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	10.88	10.23	13.11	16.28
DCFKD6E	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	3.91	3.55	6	9.86
DCB4T7D	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	2.48	1.06	1.16	5.24
DC2GCV1	DMUOT9V	Taxol	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.05	3.07	7.47	9.87
DCAHCR1	DMUOT9V	Taxol	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.66	0.25	0.32	4.55
DCQ1CLF	DMUOT9V	Taxol	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	9.34	7.87	7.02	7.55
DCKA3X6	DMUOT9V	Taxol	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	4.49	5.05	6.72	9.45
DC5I0N9	DMUOT9V	Taxol	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.08	3.08	4.02	8.23
DCBS0X9	DMUOT9V	Taxol	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	9.51	5.13	3.69	6.36
DCNQDIF	DMUOT9V	Taxol	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	1.87	1	0.16	5.32
DCQD7SS	DMUOT9V	Taxol	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.35	4.29	5.08	7.13
DC57ZNT	DMUOT9V	Taxol	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.48	5.38	5.14	8.5
DC7VPE0	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	4.79	9.88	5.17	7.92
DC86HIN	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	7.25	6.66	4.8	4.57
DCLNKO8	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.83	7.03	1.56	4.65
DCAGCHC	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.27	4.02	0.12	2.45
DCX8VYZ	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.7	2.19	1.18	2.57
DCV8S3U	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.99	7.18	4.71	7.03
DCJ1IHX	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.04	6.72	4.78	5.74
DCEAN0G	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.77	2.26	1.45	2.89
DC9SA5G	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.53	5.02	3.23	6.01
DCT1NJN	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.14	7.53	0.15	5.39
DCMKTHX	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.47	1.7	0.01	0.91
DCPCIHF	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.08	3.98	0.05	3.56
DC0ME06	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.5	1.47	3.08	4.36
DC7Q6KU	DMUOT9V	Taxol	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.04	4.49	0.61	4.43
DCBYPD1	DMUOT9V	Taxol	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	12.03	14.73	12.11	16.34
DCPM5VL	DMUOT9V	Taxol	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.85	1.19	1.06	5.31
DCGTBXG	DMUOT9V	Taxol	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.26	2.36	2.17	4.97
DCYRLRO	DMUOT9V	Taxol	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.43	1.68	0.29	0.29
DC8PA5U	DMUOT9V	Taxol	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	6.89	0.19	0.44	0.44
DCO160B	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	1.75	4.86	1.48	3.94
DCBAQG3	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.65	6.74	7.29	10.17
DCAKJ2B	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	12.36	6.15	4.41	9.01
DCXRNYU	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	23.67	18.58	14.81	20.13
DCWVYYX	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.89	0.98	0.25	3.88
DC7F7VA	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	0.66	0.4	0.7	4.77
DC0QXK4	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	4.88	3.94	6.99	9.46
DCDRR2F	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.85	2.26	2.44	5.42
DCJX4O1	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	6.11	5.88	2.47	9.06
DC80HQW	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.92	0.06	2.62	5.51
DCPXR49	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	8.55	5.32	5.62	9.06
DCM1MOO	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	5.25	4.57	6.32	9.89
DCN603S	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	2.4	2.06	1.28	5.05
DCKN6S7	DMUOT9V	Taxol	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.14	0.42	2.51	4.84
DCLGICU	DMUOT9V	Taxol	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.93	3.22	3.37	1.8
DCLOXKP	DMUOT9V	Taxol	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	6.15	8.33	3.8	1.36
DCCO45P	DMUOT9V	Taxol	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	5.58	8.36	2.68	2.57
DCJ0S70	DMUOT9V	Taxol	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.17	3.13	2.41	1.08
DCRX4P6	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.72	1.49	5.09	9.69
DC179M2	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	5.68	4.63	5.78	11.71
DC7V25M	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	5.28	3.77	1.04	7.51
DC0QVLQ	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	10.35	11.46	11.21	10.9
DCYJW5I	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	16	15.87	16.31	16.57
DCYJXV5	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	10.32	8.84	7.35	13.66
DC3W6XM	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.71	4.26	2.6	9.11
DC896L4	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.7	4.03	6.28	10.39
DCS1NLX	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	5.7	5.52	1.29	8.05
DC96IE4	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	6.25	7.8	6.06	7.43
DCIIFVL	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	6.45	4.07	2.88	3.66
DCY64R5	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	8.75	7.62	0.62	9.31
DC5M15X	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	9.25	5.87	6.32	5.91
DCO0H3K	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	6.17	8.63	4.41	1.47
DCOOBWK	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	8.82	8.48	9.01	15
DCOC51Q	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.68	1	1.5	7.18
DCPXMIP	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.08	5.85	7.21	8.58
DC4IGH4	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	3.55	1.61	2.76	9.06
DC7G4M2	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.77	5.34	5.25	7.2
DCELY2Y	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	5.25	3.18	0.53	8.53
DCVKKNJ	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.01	5.5	3.95	10.56
DCXD9BX	DMUOT9V	Taxol	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.21	5.75	8.16	12.84
DC9LWZ4	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	4.36	3.37	8.26	10.31
DCJE5QM	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.51	2.82	6.15	8.86
DCH27YA	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	2.24	2.39	0.68	5.39
DC5VT3P	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	2.15	3.69	2.22	5.57
DCCVPFR	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	6.94	3.14	3.6	3.76
DCIH7G3	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	3.64	4.16	2.93	7.91
DCUDDK0	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.35	5.47	4.34	8.03
DC01B5H	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.1	2.35	14.38	2.57
DCX8RE7	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	5.52	5.61	1.65	6.49
DCF7ZHQ	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.61	6.94	7.05	12.11
DCJA82X	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	9.61	12.08	11.77	15.46
DCUV740	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	4.91	4.72	6.92	10.16
DCCK40Q	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.51	2.12	0.98	5.27
DCAZ60S	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	1.52	1.99	1.79	4.78
DCG0R6M	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.53	3.43	7.03	9.82
DCPWGK0	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	13.34	9.38	15.55	18.05
DC8EXCJ	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.2	1.51	3.02	9.26
DCOGBJH	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	2.99	2.78	1.13	4.86
DCH2AY4	DMUOT9V	Taxol	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.26	1.37	5.58	7.84
DC8FT6I	DMUOT9V	Taxol	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.63	2.51	2.13	1.26
DCU1V9T	DMUOT9V	Taxol	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.76	5	3.63	2.42
DC6EEQ1	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	8.81	6.9	7.37	11.46
DC0U3B1	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.31	2.86	0.7	7.95
DCWJK29	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.52	5.3	3.8	8.88
DC8X8MF	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.17	3.55	0.29	6.09
DCAY37I	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.96	2.02	2.32	7.37
DCLWNDA	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	3.56	1.98	1.55	7.48
DCXOZI7	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	10.65	12.81	12.03	12.69
DCCX2OC	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	9.08	10.97	2.07	13.91
DCAZ0ZG	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.75	4.22	4.41	7.62
DCF7PIV	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	10.18	8.14	4.32	10.35
DC6AI7I	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	8.43	7.66	5.51	10.64
DC6KJ76	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.67	5.5	3.96	10.77
DCW9M6D	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	12.1	11.16	9.64	15.72
DCD8CR0	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	8.94	7.65	3.1	9.11
DC59QWU	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	21.38	18.52	11.48	23.79
DC4ZLGG	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	4.26	2.3	1.01	8.89
DCU846O	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	16.45	13.92	13.12	18.04
DCG0S7C	DMUOT9V	Taxol	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	4.66	3.36	0.7	5.96
DCWC3TT	DMUOT9V	Taxol	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.37	0.06	0.66	4.38
DCH1G4T	DMUOT9V	Taxol	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.17	1.07	2.34	4.05
DCE8EA7	DMUOT9V	Taxol	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.91	2.86	0.79	0.79
DCX80D5	DMUOT9V	Taxol	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.35	7.63	2.29	7.32
DCECDFA	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	1.86	0.94	0.56	4.55
DCWKYC8	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	3.88	4.94	2.47	7.11
DCBII65	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.72	5.41	0.07	6.56
DCXXNHC	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	1.1	1.95	0.47	4.3
DCBIJMR	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	3.94	4.65	0.68	6.18
DCSMZJ0	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.86	0.55	0.53	4.2
DCTGM32	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.61	4.14	2.06	6.26
DCIUV69	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	3.92	4.57	0.14	5.11
DC86OV8	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.96	2.1	0.35	4.69
DCIZ5AX	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	5.47	6.07	3.17	7.98
DCDVY4I	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	1.97	2.89	2.37	6.48
DCD8I9I	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.69	2.83	1.28	5.1
DCZ3QDA	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.34	1.99	2.42	6.86
DCDK86V	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	4.9	5.07	4.47	8.1
DC4HIA9	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.26	4.64	0.94	6.19
DCAV1OH	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	3.8	3.11	1.01	6.14
DCA92X7	DMUOT9V	Taxol	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	5.1	5.9	0.76	7
DCGEMV1	DMUOT9V	Taxol	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.06	9.95	1	6.9
DC59LE0	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.19	2.04	6.21	7.92
DCXKUGN	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	0.62	0.37	1.98	5.55
DCMOP06	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	0.38	7.63	6.94	7.54
DCCZUCO	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	4.53	5.68	6.35	8.44
DCZ8K39	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.29	5.04	1.02	8.3
DCWATTV	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.73	2.02	4.14	5.85
DCFVW72	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.14	4.77	1.9	7.4
DCOZWBI	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	4.46	3.84	6.71	8.61
DCDMG9B	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.16	0.38	6.78	8.5
DCJW27T	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	9.19	8.65	3.02	10.54
DCX9FK0	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	17.43	12.43	12.47	15.75
DCATH9F	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.63	5.62	5.61	8.76
DC1PCTG	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.92	5.44	7.44	10.5
DCT41RY	DMUOT9V	Taxol	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.02	5.99	10.13	12.36
DC68120	DMUOT9V	Taxol	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	2.09	2.44	3.24	3.27
DC1JH8U	DMUOT9V	Taxol	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.14	0.58	2.59	7.65
DCWYFZ8	DMUOT9V	Taxol	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	2.41	2.1	3.64	6.66
DCK9YX7	DMUOT9V	Taxol	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.24	2.71	0.25	6.03
DCU40RS	DMUOT9V	Taxol	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	5.47	8.53	5.45	10.17
DCHYJ17	DMUOT9V	Taxol	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.65	1.96	0.38	5.66
DCPDAZJ	DMUOT9V	Taxol	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	11.17	9.24	8.11	11.91
DCUHPGI	DMUOT9V	Taxol	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.79	3.19	0.17	3.79
DCELB7G	DMUOT9V	Taxol	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.01	4.38	3.08	2.84
DCSVMCC	DMUOT9V	Taxol	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	4.15	3.82	0.5	4.19
DCFL4MV	DMUOT9V	Taxol	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.49	3.54	0.43	4.68
DCBLM1A	DMUOT9V	Taxol	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	15.28	16.08	7.96	15.6
DCOY94A	DMUOT9V	Taxol	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.9	3.74	0.37	4.42
DCZ9NUM	DMUOT9V	Taxol	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	6.15	7.5	0.67	3.77
DCT53UT	DMUOT9V	Taxol	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.65	1.8	0.24	3.62
DCAZMWN	DMUOT9V	Taxol	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	3.95	3.39	0.06	2.62
DCQJP5G	DMUOT9V	Taxol	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.88	4.16	4.06	6.78
DCXTBX5	DMUOT9V	Taxol	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.76	3.92	0.88	4.84
DCRVTXY	DMUOT9V	Taxol	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	14.82	11.32	8.18	13.32
DCCI3IP	DMUOT9V	Taxol	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	1.57	1.7	0.45	4.69
DC1BZHL	DMUOT9V	Taxol	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.73	3.28	1.3	6.09
DC8UHGE	DMUOT9V	Taxol	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	1.32	7.63	4.89	4.75
DCQGXPE	DMUOT9V	Taxol	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.71	5.26	4.19	2.93
DC6PCGW	DMUOT9V	Taxol	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.39	3.69	2.06	1.83
DCCJNQ5	DMUOT9V	Taxol	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.76	3.43	0.54	0.71
DCQVT9F	DMUOT9V	Taxol	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	2.88	8.75	8.05	8.94
DCAT885	DMUOT9V	Taxol	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.55	0.55	0.66	3.12
DCW62WB	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	15.48	18.17	1.03	17.2
DCF6TGX	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.84	2.24	0.38	5.85
DCBMSK6	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	0.26	0.5	2.29	6.47
DCV67M5	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	3.31	2.32	2.3	7.75
DCSF9CV	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	19.6	19.66	18.13	18.13
DC6LD27	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	16.26	18.07	16.42	16.42
DCKQO5S	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.68	3.04	3.5	3.57
DCE90P1	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	9.37	9.71	4.38	13.71
DCBBQ0R	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.45	2.74	0.82	6.1
DCCEK7D	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	27.98	29.53	22.95	24.48
DCO2XCW	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	20.45	18.5	8.02	16.86
DCG1YVV	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	9.27	11.1	0.82	9.86
DC5CII6	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.4	11.91	7.4	13.56
DCGQDLR	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.36	5.23	3.11	9.97
DC5X10G	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	11.22	13.36	13.97	12.04
DCQGULY	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	9.97	7.05	5.71	11.79
DCQANO2	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	3.58	3.36	4.29	9.36
DCWRKYG	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	16.93	15.8	17.66	17.66
DC86565	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	20.63	23.65	21.73	17.9
DC0ON9S	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.13	11.54	7.18	10.62
DCJDXEG	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	5.15	4.92	7.92	8.46
DCF3S7C	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	7.37	6.01	1.36	8.36
DC2Z9B1	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	4.71	9.87	8.7	9.46
DC4YN4B	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	2.46	2	0.33	5.77
DCTD4BC	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	14.18	8.19	4.08	9.13
DC6VYQG	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	5.55	7.59	0.97	7.9
DC0O4S5	DMUOT9V	Taxol	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	7.41	9.8	10.38	10.38
DC0WOTD	DMUOT9V	Taxol	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	26.64	21.09	3.21	20.3
DC3QI2D	DMUOT9V	Taxol	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	5.93	5.6	0.04	4.98
DCYGAN9	DMUOT9V	Taxol	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	21.49	22.93	22.34	22.5
DCHRBXU	DMUOT9V	Taxol	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	18.29	17.41	3.79	17.66
DCSKCEG	DMUOT9V	Taxol	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	6.03	6.58	0.78	6.2
DC7N4W0	DMUOT9V	Taxol	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.04	3.56	0.2	2.57
DCYVHUL	DMUOT9V	Taxol	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.47	7.07	2.18	6.68
DCROJ5R	DMUOT9V	Taxol	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	15.83	14.61	2.11	13.46
DC73SRK	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	7.88	4.7	1.87	8.23
DC1P3ZJ	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.7	2.11	4.59	7.31
DCPRNN5	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.72	0.85	5.23	7.28
DCLZISZ	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	2.07	1.78	0.43	4.37
DC60SO0	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.4	0.29	0.24	4.01
DCO9LA1	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	1.47	1	5.57	8.16
DC27003	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	9.98	10.76	11.14	11.6
DCH6DQ7	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	12.92	12.21	2.72	14.74
DC14W6C	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.29	1.58	1.36	2.76
DC7L7U5	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.2	3.03	4.89	7.36
DCAZM5J	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.6	2.14	4.97	6.1
DCOQ454	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	2.97	2.88	2.13	5.68
DCXUPS5	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	3.31	2.27	1.27	4.28
DC8CKMN	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.03	3.55	4.67	8.67
DCFZXEW	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	4.54	6.53	0.83	11.11
DCU3636	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.31	2.81	2.34	7.39
DC7D1DL	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	9.09	8.37	4.44	9.77
DCO4U0W	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	12.14	7.38	11.44	14.65
DCVF4DG	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	4.38	2.7	4.93	10.59
DCH2R6J	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.12	5.79	7.02	10.5
DCVXZOM	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.14	6.8	10.58	13.01
DCX2VXT	DMUOT9V	Taxol	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	2.46	1.24	4.54	7.06
DCP54G9	DMUOT9V	Taxol	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	22.03	22.41	0.88	17.87
DCIEOUT	DMUOT9V	Taxol	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.74	1.97	1.57	0.27
DC8RK5R	DMUOT9V	Taxol	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.55	6.78	4.01	3.45
DC8JX0C	DMUOT9V	Taxol	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.03	3.23	1.09	0.74
DCHVXR3	DMUOT9V	Taxol	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.08	3.9	2.24	1.15
DCAB71M	DMUOT9V	Taxol	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	6.36	8.26	4.09	3
DCRVG15	DMUOT9V	Taxol	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.27	2.21	1.68	0.88
DCN5H30	DMUOT9V	Taxol	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	8.3	8.81	6.33	5.52
DCQZBRR	DMUOT9V	Taxol	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.51	0.88	0.41	0.75
DCIZYXH	DMUOT9V	Taxol	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.8	4.16	3.87	0.14
DCV75CP	DMUOT9V	Taxol	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	11.13	7.8	6.23	8.21
DCNZRUM	DMUOT9V	Taxol	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.86	5.3	0.79	4.81
DCAW6FH	DMUOT9V	Taxol	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.99	5.28	2.68	1.19
DCSZ8W8	DMUOT9V	Taxol	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.01	8.1	5.78	6.33
DC53G4J	DMUOT9V	Taxol	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.43	8.11	5.32	4.56
DCWPGAQ	DMUOT9V	Taxol	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.71	4.69	4.4	3.57
DCPTPIC	DMUOT9V	Taxol	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.89	1.49	0.57	0.28
DC9EQ9Q	DMUOT9V	Taxol	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.01	3.83	0.65	4.52
DC63YAU	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	7.23	11.55	10.35	10.79
DCZHDHY	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	0.58	0.01	4.07	8.61
DCQZVC2	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	1.46	0.41	2.94	9.17
DCAWGUJ	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	2.83	1.95	3.16	5.7
DCN9Z7Z	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	4.88	6.09	6.88	10.36
DCQ1RSD	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	6.75	8.33	8.17	8.14
DCUZT9R	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	21.74	16.56	24.23	26.68
DC50HLR	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.01	3.52	2.53	2.7
DCBMK0Y	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	5.34	4.5	9.47	11.94
DCXLQ4B	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	12.99	10.98	16.62	17.49
DCREXZQ	DMUOT9V	Taxol	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.74	2.7	10.85	12.01
DCD6IRM	DMWTAOI	Estramustine	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.12	2.98	2.54	3.22
DCYBVPU	DMWTAOI	Estramustine	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.26	7.19	2.7	3.09
DCZPBBD	DMWTAOI	Estramustine	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.14	4.65	2.14	2.39
DCU3HIR	DMWTAOI	Estramustine	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.27	6.2	2.31	2.53
DCFEVOG	DMWTAOI	Estramustine	Approved	34	DM0KYI4	Mebutamate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	48.88	48.88	69.12	69.12
DC5KVCN	DMWTAOI	Estramustine	Approved	34	DM0QV1J	Baclofen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	54.86	54.86	67.78	67.79
DCFWXBJ	DMWTAOI	Estramustine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.17	4.28	2.19	0.19
DC3UA11	DMWTAOI	Estramustine	Approved	34	DM1AF5U	Acetazolamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	45.26	45.26	57.77	57.77
DCD5TK4	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	7.68	8.14	30.38	6.76
DCCIY7T	DMWTAOI	Estramustine	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.47	7.87	5.05	3.71
DCPJA4U	DMWTAOI	Estramustine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	4.06	3.9	0.96	5.09
DCX61F6	DMWTAOI	Estramustine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.27	0.39	0.46	4.08
DC5LW4X	DMWTAOI	Estramustine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.88	3.47	1.59	3.67
DCS78EW	DMWTAOI	Estramustine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.34	2.49	0.39	0.67
DCNYSFQ	DMWTAOI	Estramustine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.41	5.71	0.75	3.86
DCCHZAZ	DMWTAOI	Estramustine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.87	9.26	14.03	6.27
DCXBAE9	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.5	5.92	26.47	4.43
DC8CRC4	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.25	4.51	3.92	5.94
DCKPGOR	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.42	3.82	1.07	5.18
DCTG4KV	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.61	9.16	39.36	8.24
DCABTWY	DMWTAOI	Estramustine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.77	2.72	3.89	3.35
DCG3DU6	DMWTAOI	Estramustine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.41	6.84	4.14	4.36
DCNSOS2	DMWTAOI	Estramustine	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.58	3.58	4.52	4.61
DCLKGTA	DMWTAOI	Estramustine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.46	2.64	0.98	3.71
DCV8NO5	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	9.11	7.04	41.83	7.74
DCKJ8Q5	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.28	7.36	51.22	6.56
DCV86NI	DMWTAOI	Estramustine	Approved	34	DM6BZCV	Sivelestat	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	53.25	53.25	66.99	66.99
DCIBW1D	DMWTAOI	Estramustine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	10.69	17.12	5.14	4.28
DC99KXR	DMWTAOI	Estramustine	Approved	34	DM7HUNW	Testosterone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	45.12	45.12	61.22	61.22
DCP0FVL	DMWTAOI	Estramustine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.77	3.39	1.7	1.14
DCTGKS6	DMWTAOI	Estramustine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.78	4.76	1.38	1.39
DCBOLAN	DMWTAOI	Estramustine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.7	8.08	0.93	4.83
DCA1KTZ	DMWTAOI	Estramustine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.85	4.28	0.15	0.82
DCMB0QF	DMWTAOI	Estramustine	Approved	34	DM8BKU9	Acitretin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.29	1.29	17.66	17.7
DCCK2DZ	DMWTAOI	Estramustine	Approved	34	DMFI8A7	Tranexamic acid	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	59.72	59.72	70.22	70.24
DC36IO0	DMWTAOI	Estramustine	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.04	4.36	0.99	5.61
DCKAG1C	DMWTAOI	Estramustine	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.39	7.46	3.74	8.36
DC0LPMP	DMWTAOI	Estramustine	Approved	34	DMAYD7O	IT-141	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.2	2.2	3.22	3.3
DCFQHPV	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	11.68	6.67	17.79	4.79
DCMLP1E	DMWTAOI	Estramustine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.78	2.78	11.34	11.38
DCLMFEE	DMWTAOI	Estramustine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.18	2.6	1.6	2.17
DCZXSUI	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	12.18	9.05	25.57	8.11
DCZCDJO	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	17.43	6.98	17.58	5.16
DCC26Y9	DMWTAOI	Estramustine	Approved	34	DMDASC6	Metformin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.92	5.92	17.03	17.03
DCU6B3V	DMWTAOI	Estramustine	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.22	1.53	0.9	0.97
DCIGCKR	DMWTAOI	Estramustine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.94	1	2.7	5.61
DCTGWSY	DMWTAOI	Estramustine	Approved	34	DMF57DM	Pazopanib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	47.33	47.33	67.62	67.62
DCTUOIW	DMWTAOI	Estramustine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	7.23	12.31	19.62	9.77
DCQPZO7	DMWTAOI	Estramustine	Approved	34	DMGFV3Z	Nizatidine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	57.69	57.69	69.54	69.55
DCIGSJ6	DMWTAOI	Estramustine	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.28	5.66	4.85	8.73
DC0O9HS	DMWTAOI	Estramustine	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.01	4.88	3.32	3.39
DCFX6C6	DMWTAOI	Estramustine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.09	1.78	0.93	0.93
DCK0YS1	DMWTAOI	Estramustine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.56	1.7	0.18	0.08
DCRX9BN	DMWTAOI	Estramustine	Approved	34	DMIOGBU	Bosentan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	55.33	55.33	68.6	68.6
DCTZKX6	DMWTAOI	Estramustine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.37	9.37	12.63	12.71
DCEUDFM	DMWTAOI	Estramustine	Approved	34	DMK7MEY	Isoproterenol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	45.83	45.83	66.99	66.99
DCR9B85	DMWTAOI	Estramustine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	9.6	12.23	0.73	10.6
DC5CF9U	DMWTAOI	Estramustine	Approved	34	DMGO72P	Oseltamivir	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	16.72	16.72	36.29	36.29
DCCVDSU	DMWTAOI	Estramustine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	7.92	1.21	39.45	0.39
DCCQWD8	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	7.26	7.79	21.71	6.4
DCFPOMS	DMWTAOI	Estramustine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	3.81	3.81	9.29	9.29
DC8K3YP	DMWTAOI	Estramustine	Approved	34	DMNKG1Z	Atenolol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	53.84	53.84	64.6	64.62
DCVWJ03	DMWTAOI	Estramustine	Approved	34	DMNMW9R	Pramipexole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	51.74	51.74	68.92	68.92
DCDPYGA	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.81	2.27	0	3.42
DCWE0M0	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	10.62	8.32	36.24	6.35
DC9MG7S	DMWTAOI	Estramustine	Approved	34	DMO381I	Acamprosate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	55.37	55.37	67.47	67.47
DCET2N6	DMWTAOI	Estramustine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.2	1.4	1.56	1.7
DC7R4IV	DMWTAOI	Estramustine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.58	3.81	2.04	5.14
DCWA0K8	DMWTAOI	Estramustine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.54	0.16	1.81	4.63
DCRRNX6	DMWTAOI	Estramustine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	9.52	11.97	3.73	10.94
DCC43WJ	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	2.34	6.89	7.26	3.1
DCRG7DR	DMWTAOI	Estramustine	Approved	34	DMPP4DT	Trimethobenzamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	30.13	30.13	50.69	50.72
DC6OFX5	DMWTAOI	Estramustine	Approved	34	DMPWB7T	Maprotiline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.22	4.22	5.73	5.78
DCSYN3Z	DMWTAOI	Estramustine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.61	2.99	0.48	5.34
DCY15SS	DMWTAOI	Estramustine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.51	2.14	2.74	3.74
DC44JQF	DMWTAOI	Estramustine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.96	7.15	5.22	9.15
DCMD0I5	DMWTAOI	Estramustine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.67	5.31	3.19	6.98
DC5MRX7	DMWTAOI	Estramustine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.95	7.71	5.25	7.4
DCPA30O	DMWTAOI	Estramustine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.56	5.69	2.89	5.54
DCVZSJD	DMWTAOI	Estramustine	Approved	34	DMRTSGP	Amiloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	55.52	55.52	68.19	68.19
DCNNO3T	DMWTAOI	Estramustine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	0.63	1.17	39.2	1.46
DCM1UFT	DMWTAOI	Estramustine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.31	3.48	3.76	2.1
DCSFDLS	DMWTAOI	Estramustine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.22	2.99	1.73	1
DCTDFON	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	3.28	4.18	9.92	1.37
DCASYSX	DMWTAOI	Estramustine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.17	9.82	0.47	6.11
DCELB2J	DMWTAOI	Estramustine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.44	4.46	3.66	6.02
DCG00ZI	DMWTAOI	Estramustine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.82	3.86	0.33	0.29
DCU8NLB	DMWTAOI	Estramustine	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	9.57	17.63	6.8	6.83
DCKVGBL	DMWTAOI	Estramustine	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.63	9.65	1.45	1.47
DCCJBWK	DMWTAOI	Estramustine	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	4.81	7.92	6.31	2.95
DCLQ3XR	DMWTAOI	Estramustine	Approved	34	DMTX8IZ	Endoxifen	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	35	35	52.25	52.29
DCXPN3V	DMWTAOI	Estramustine	Approved	34	DMWT905	Mefloquine	Phase 2/3 Trial	24	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.23	1.23	2.77	2.84
DC51LQ7	DMWTAOI	Estramustine	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.64	3.64	4.76	4.85
DC3G3H8	DMWTAOI	Estramustine	Approved	34	DMVTHWQ	Silver sulfadiazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	54.88	54.88	65.8	65.8
DCIPOBI	DMWTAOI	Estramustine	Approved	34	DMVY4GN	Testolactone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	47.91	47.91	65.4	65.4
DCUCFOW	DMWTAOI	Estramustine	Approved	34	DMWBHRY	Olmesartan medoxomil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	46.9	46.9	58.04	58.05
DC89TBB	DMWTAOI	Estramustine	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	0.58	3.5	5.5	4.59
DCCJJ8H	DMWTAOI	Estramustine	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.14	5.81	2.51	2.51
DCN4BVK	DMWTAOI	Estramustine	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	1.94	4.36	3.05	6.42
DCIDBD9	DMWTAOI	Estramustine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.44	7.58	4.44	4.81
DCQETTW	DMWTAOI	Estramustine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.46	20	4.6	1.01
DCW6Q0R	DMWTAOI	Estramustine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.82	9.87	3.52	3.52
DCF9JZN	DMWTAOI	Estramustine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.2	1.35	0.15	0.2
DCH0NXT	DMWTAOI	Estramustine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	3.12	5.43	1.98	0.19
DC5GRBC	DMWTAOI	Estramustine	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.67	2.67	3.81	3.89
DCZL1ZQ	DMWTAOI	Estramustine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	0.81	0.49	1.85	4.23
DCA8GKF	DMWTAOI	Estramustine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.41	6.23	5.89	7.72
DCY0QWA	DMWTAOI	Estramustine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.29	2.7	1.88	4.17
DCNVSHS	DMWTAOI	Estramustine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.16	2.12	1.75	4.81
DCFRIED	DMWTAOI	Estramustine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.37	6.54	6.13	8.07
DCYQ06D	DMWTAOI	Estramustine	Approved	34	DMWSMND	Cevimeline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	45.92	45.92	58.65	58.65
DCOHLZX	DMWTAOI	Estramustine	Approved	34	DMYX7NI	Acetohydroxamic Acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	45.06	45.06	65.99	66.01
DC3LBJD	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	5.13	5.08	1.1	1.47
DCX2TI9	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	2.48	2.01	5.46	5.93
DC3NAQ0	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.36	3.69	1.43	0.85
DCL04VR	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	8.98	15.11	18.88	10.94
DCWQG7C	DMWTAOI	Estramustine	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.27	4.79	0.91	0.62
DCPXYQ4	DMWTAOI	Estramustine	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.08	3.78	1.97	2.42
DCIKBP8	DMWTAOI	Estramustine	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	7.87	11	2.55	2.16
DCG92UG	DMWTAOI	Estramustine	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.17	1.77	0.11	0.2
DC4ME60	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	0.38	0.22	4.04	8.26
DC1M5U6	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.64	0.32	1.18	5.86
DC9Y4P6	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	4.78	9.89	2.44	7.15
DCP63WV	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	16.23	15.28	8.16	17.24
DCOY2BX	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	5.07	3.85	3.09	8.2
DCG4CYY	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.53	0.52	4.4	8.59
DC3V8OT	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.65	1.12	4	4.31
DCBLO78	DMWTAOI	Estramustine	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.76	5.1	1.39	1.34
DC53W8K	DMWTAOI	Estramustine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.14	2.61	3.72	8.26
DCSKY5K	DMWTAOI	Estramustine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.13	2.25	2.29	6.71
DC6X31P	DMWTAOI	Estramustine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	6.73	4.55	3.81	8.38
DCPCMFB	DMWTAOI	Estramustine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.36	1.31	7.56	8.96
DC8RIYX	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	0.56	0.33	6.76	9.51
DC05PAU	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.19	1.79	0.2	3.54
DCL04CS	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.04	1.36	2.19	4.07
DCFP73J	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.32	1.23	3.82	7.1
DCCGIN3	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.15	6.21	9.55	10.12
DC7M3ZD	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3	2.31	2.48	4.29
DC09MZ4	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.12	1.58	3.34	7.14
DCUCCCO	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.74	2.91	2.11	6.92
DCIOK9T	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	5.83	5.49	6.6	9.49
DCS9Q84	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	6.24	7.83	1.39	8.12
DC67S5H	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.77	4.7	0.98	8.12
DCPATI4	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.75	0.52	3.53	6.64
DCKXMZI	DMWTAOI	Estramustine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	11.33	12.21	1.36	10.4
DCSNZOI	DMWTAOI	Estramustine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.96	6.99	3.73	3.72
DCR5YEM	DMWTAOI	Estramustine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.36	2.38	0.09	1
DC4XUI4	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	0.39	0.06	5.22	8.34
DC3GT33	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	6.62	6.92	8.06	12.08
DCNYEZ5	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.4	4.25	1.03	6.53
DC29LSD	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.83	2.34	1.61	7.46
DCFL1OS	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.42	3.56	3.4	7.86
DCNC4GN	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.7	0.52	2.83	5.44
DC3CRWQ	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.79	7.87	6.36	9.09
DCZQZ8O	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.69	0.8	1.22	5.25
DC6PA6A	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.1	0.29	2.3	1.5
DCMVT6M	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	13.02	14.45	2.89	13.16
DCTOA3M	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	16.72	17.2	17.66	19.55
DCD8FR0	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1	3.3	5.06	7.23
DCVAV01	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	10.73	10.57	11.46	14.75
DCH7NKT	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.19	1.1	8.64	11.42
DCGL4IA	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	5.8	5.09	5.51	9.35
DCYEI30	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.41	11.67	5.83	5.89
DCPQZK6	DMWTAOI	Estramustine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.02	4.78	2.55	1.39
DCGLHDL	DMWTAOI	Estramustine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.94	7.39	4.38	2.13
DCZVNDY	DMWTAOI	Estramustine	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	7.64	8	9.89	11.26
DCDYNQG	DMWTAOI	Estramustine	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.06	5.51	2.09	6.18
DC2FA0Q	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	9.24	4.9	11.25	6.67
DCHGXC1	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	9.78	11.04	7.93	10.58
DC8ODZZ	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.27	0.72	2.61	5.21
DCUBY2F	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	6.32	9.4	3.5	9.27
DCASG5S	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.49	1.13	2.56	2.77
DC2EM13	DMWTAOI	Estramustine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.94	3.85	0.88	0.77
DCGHEC2	DMWTAOI	Estramustine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.33	3.89	3.74	1.14
DCYZL15	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.3	3.19	9.25	12.84
DCSZM88	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.61	6.2	10.38	12.67
DCQZ08X	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	6.24	7.37	5.6	10.77
DCX96NX	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.89	2.88	3.1	8.19
DCMEIR7	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.74	2.81	2.84	0.29
DCYQXMH	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.29	8.92	6.58	6.87
DCL87OK	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.27	1.15	5.12	7.44
DCSDGM8	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	14.88	14.85	9.68	16.1
DC84A3A	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.9	4.2	2.23	8.05
DCUCEBZ	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.25	0.24	3.22	6
DC1XT6A	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	15.94	14.81	12.97	14.47
DC07Z8U	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.57	7.19	7.76	10.26
DCK59SF	DMWTAOI	Estramustine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.78	5.74	2.75	7.77
DC94B58	DMWTAOI	Estramustine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.08	2.31	2.51	5.61
DC77C9F	DMWTAOI	Estramustine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	21.12	27.11	26.74	26.74
DC97WX0	DMWTAOI	Estramustine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.82	2.06	0.49	5.22
DCL1XI7	DMWTAOI	Estramustine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.34	4.83	3.1	1.78
DC67BLF	DMWTAOI	Estramustine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	10.22	8.04	4.43	8.44
DCCAMEO	DMWTAOI	Estramustine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.57	3.02	1.11	0.31
DCVDU6R	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.92	1.2	7.53	9
DC6QP93	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.17	0.19	2.8	4.17
DCSBN29	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.71	5.86	6.2	8.98
DC5PXLZ	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	5.86	3.1	5.52	7.56
DCHGZDS	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.32	1.16	9.35	10.51
DCMQAS5	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.65	1.95	6.45	8.35
DCBTL6K	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.49	11.76	0.71	11.45
DC44DUE	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	8.19	9.05	1.84	10.73
DCGW8SB	DMWTAOI	Estramustine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	15.64	18.62	10.21	10.55
DCJJK8P	DMWTAOI	Estramustine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.21	11.1	9.45	9.39
DCTUEGY	DMWTAOI	Estramustine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	8.16	7.28	5.47	1.05
DC6Z28G	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.58	3.51	1.74	3.22
DCIQNI2	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	3.57	5.3	0.8	2.39
DCS5JFC	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.96	2.61	0.58	2.8
DCI30V1	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.53	2.79	1.24	5.46
DCQWP0C	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.09	2.26	0.21	3.69
DCN180D	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.73	2.83	4.81	3.91
DCLU3ND	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.37	5.01	2.94	5.78
DCZMVI2	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.95	2.2	2.4	2.47
DCLRTPP	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.15	13.51	10.15	10.67
DCPVF55	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.15	3.56	1.17	3.25
DC2NL91	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	4.01	7.34	0.91	6.06
DCEADE5	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.22	3	5.86	8.07
DCK6ESG	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	19.63	26.31	25.95	25.95
DCCDUD3	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.24	5.92	6.13	7.65
DCTPY3Q	DMWTAOI	Estramustine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	5.88	9.27	3.91	9.3
DCLWALV	DMWTAOI	Estramustine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.61	5.07	3.24	4.48
DCWW1Y3	DMWTAOI	Estramustine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	11	4.92	12.73	14.34
DCDGI9B	DMWTAOI	Estramustine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.4	8.89	5.07	10.08
DCSUTXN	DMWTAOI	Estramustine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.82	3.09	1.18	0.55
DCGIKGG	DMWTAOI	Estramustine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.01	5.56	2.07	1.15
DCCD4HU	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.09	3.96	8.3	10.54
DCG8OD9	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.49	2.79	3.69	5.82
DC1ILR3	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.54	0.55	5.19	6.86
DC42RQI	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	14.01	16.57	1.07	16.25
DCIVBZX	DMWTAOI	Estramustine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.99	6.08	5.86	6.62
DCSQM1O	DMWTAOI	Estramustine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.01	1.61	2.02	0.37
DCCMPTG	DMWTAOI	Estramustine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.35	7.18	4.4	2.14
DCRTG1K	DMWTAOI	Estramustine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.35	8.12	1.95	1.95
DCIA5Y2	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.42	9.8	4.16	7
DCGOVD5	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	6.95	11.84	10.44	12.58
DCL4P5M	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	5.13	7.95	11.56	12.21
DCPNS07	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.84	2.96	7.21	8.93
DCF83WE	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.06	1.04	4.98	6.85
DCIXN5E	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.47	4.12	7.41	8.39
DCJWJ1Y	DMWTAOI	Estramustine	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.85	5.76	6.36	5.48
DCWPTJB	DMWTAOI	Estramustine	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	3.36	7.31	6.04	5.99
DCTRY48	DMWTAOI	Estramustine	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.24	3.26	1.46	1.74
DCUBQ1P	DMWTAOI	Estramustine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.07	7.13	2.12	2.17
DC4NTFJ	DMWTAOI	Estramustine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.84	5.18	2.85	1.23
DC0545T	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.42	2.21	4.35	9.23
DCQ9F0P	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	14.1	14.77	0.39	19.22
DCYDEED	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.62	2.48	3.15	7.29
DCSQQVH	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	6.43	9.47	1.88	9.7
DC44G0T	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	6.49	5.76	2.9	9.89
DCFRU69	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	0.63	7.9	5.05	5.15
DC58FB5	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	0.83	7.21	8.52	8.5
DCPPMJ9	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	1.65	6.38	5.74	5.95
DC81XCM	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.8	8.27	0.48	9.35
DCTSPB4	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	19.6	18.92	14.21	21.34
DCKZ09N	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	3.74	4.89	0.78	6.54
DCIT9L4	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.17	6.88	4.41	9.02
DCZ9WJC	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	3.79	9.21	3.02	10.02
DCV1I7W	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	2.02	8.28	7.28	9.43
DC95CGP	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	5.22	4.65	2.73	8.1
DC14T11	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	17.27	19.56	0.41	14.92
DC13469	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.02	8.23	4.87	8.89
DCHHF1E	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	11.85	13.11	6.48	14.57
DC51QDF	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	3.42	3.4	0.64	5.63
DCCIIBJ	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	9.94	10.2	10.44	16.63
DC2OOVD	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.33	3.73	1.96	5.62
DC68JS8	DMWTAOI	Estramustine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.17	4.7	3.36	0.69
DC788KY	DMWTAOI	Estramustine	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.28	9.75	4.54	1.51
DCITS02	DMWTAOI	Estramustine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.93	0.13	0.56	1.95
DCFVNV7	DMWTAOI	Estramustine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	12.14	11.5	3.58	0.16
DCVT40H	DMWTAOI	Estramustine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	1.24	1.84	5.43	7.82
DCDKD5R	DMWTAOI	Estramustine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.16	1	3.01	5.08
DCWN5Z7	DMWTAOI	Estramustine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	5.27	9.94	2.68	11.58
DCPR9UN	DMWTAOI	Estramustine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	3.91	8.37	4.87	9.33
DCF3OJV	DMWTAOI	Estramustine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	1.27	9.24	7.24	7.76
DCNX1PB	DMWTAOI	Estramustine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.49	6.18	3.01	7.44
DC38H8P	DMWTAOI	Estramustine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.04	9.65	7.1	9.21
DCZSLMU	DMWTAOI	Estramustine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	14.72	16.66	13.68	19
DCO6WCA	DMWTAOI	Estramustine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.34	1.88	2.87	4.52
DC32TT3	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	5.07	3.78	2.18	7.24
DCYRSFL	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	5.67	4.13	9.32	10.35
DCMW6FP	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	5.2	10.8	10.45	11.95
DC5Q9HY	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	0.7	1.9	1.82	5.37
DCSF1LK	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	5.46	9.97	2.05	11.61
DC61LSG	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.26	4.47	0.07	3.97
DCA5QO6	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.93	12.7	1.44	13.19
DCIZKVL	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.46	0.09	0.88	4.76
DCASYQW	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	7.53	4.37	4.56	8.38
DCS0RVF	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	2.92	2.86	0.85	6.13
DCLJNJ2	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	4.34	6.79	3.44	7.86
DCO8IQQ	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	0.27	7.37	8.35	9.87
DCS0WS5	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.08	4.65	0.45	6.05
DCE6FX0	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	6.85	14.77	2.48	10.61
DC9SD03	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	11.82	11.27	7.44	14.11
DC8484L	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	8.18	11.97	13.85	15.9
DCJBZYW	DMWTAOI	Estramustine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.65	7.49	10.57	14.84
DC52W2O	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.4	2.36	3.01	6.25
DCJXN5N	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	6.67	6.81	0.71	6.17
DC7YMCU	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.33	6.67	2.43	6.71
DCI2OZQ	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	11.11	11.71	5.21	11.13
DCXSS62	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.7	4.79	4.86	8.61
DCG8YZN	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	12.02	16.51	9.4	16.11
DCT0BHE	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.92	3.8	0.36	6.17
DCBH5XZ	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	14.41	18.13	5.24	13.41
DCBFHH5	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	9.15	10.6	0.35	10.82
DCYQ2EV	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	6.27	5.31	4.27	9.51
DCUX3UT	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.76	5.96	7.84	7.86
DC6WGLU	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	4.14	3.46	1.38	5.2
DCVCNJG	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	10.85	10.88	7.65	13.83
DCTVVO6	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.93	7.59	1.13	8.66
DCDQNUM	DMWTAOI	Estramustine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	0.25	0.21	3.51	6.66
DCBB37K	DMWTAOI	Estramustine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	8.65	10.7	1.61	1.24
DCX5BFU	DMWTAOI	Estramustine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.04	8.79	6.3	3.31
DC11R6Z	DMWTAOI	Estramustine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	10.98	13.08	4.16	8.81
DCHKN3J	DMWTAOI	Estramustine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.07	9.8	5.98	5.53
DCZISWV	DMWTAOI	Estramustine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.6	6.38	3.58	1.15
DCC99EB	DMWTAOI	Estramustine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.37	1.1	1.1	2.47
DCO6WU8	DMWTAOI	Estramustine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.02	5.04	7.05	6.35
DC0F79J	DMWTAOI	Estramustine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	10.01	8.52	1.8	1.76
DCROPAZ	DMWTAOI	Estramustine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.85	3.83	4.68	5.5
DC64NA8	DMWTAOI	Estramustine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.25	6.62	6.96	9.37
DCMD25L	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.03	0.9	3.69	7.16
DC570BS	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	1.69	0.5	4.8	7.03
DCZS4BT	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	3.94	8.4	5	10.07
DCBUFC7	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	9.18	8.73	10.94	14.78
DCVWAVK	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	7.32	7.86	6.86	10.67
DCVH6SS	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	4.07	3.15	0.35	4.52
DC0T7S2	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.93	8.28	2.76	11.28
DC9S79Y	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.83	2.69	2.71	7.55
DCQ7QFU	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	2.22	1.42	2.03	4.99
DCZYUWT	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	2.41	2.18	3.1	6.52
DCSWDPY	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	11.64	10.66	13.74	16.73
DCSDG9F	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	16.33	16.28	12.73	17.22
DCSC9W4	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	6.41	9.3	0.38	11.78
DCAIK3M	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	5.55	5.69	7.02	10.56
DCK7ZE1	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	12.15	13.38	6.2	11.82
DC1SDJJ	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	9.1	9.8	7.82	12.69
DC862TP	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.25	2.85	3.25	6.92
DC8ZEIC	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	11.92	11.15	12.55	16.12
DC8BFJC	DMWTAOI	Estramustine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.59	6.05	4.45	8.7
DCVOP7Q	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	5.55	6.32	12.09	13.71
DC12K7A	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	16.28	15.62	13.61	18.11
DCGWSD1	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	6.44	4.56	5.05	9.41
DCODMCR	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	2.75	5.47	7.16	8.84
DCASNHG	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	15.73	15.96	8.37	16.98
DC8NXMH	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.32	7.66	4.34	10.35
DC8KCAR	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	10.42	9.47	9.8	12.52
DCHN4GA	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	2.65	3.04	2.36	5.53
DCBXIRD	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.75	6.93	6.9	9.4
DC9MSVH	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	14.6	15.98	14.15	16.88
DCVGC4Q	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	1.05	7.24	7.71	9.63
DCV6X24	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	9.33	8.8	7.74	12.15
DCBSU7P	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	18.1	19.02	13.83	18.27
DCHM2QK	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.95	10.3	8.61	11.42
DC5PIBS	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	7.85	8.23	2.04	7.95
DC47NSK	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	3.78	3.1	1.63	5.21
DCQOYSF	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	12.75	14.86	16.87	19.04
DC1XDU9	DMWTAOI	Estramustine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.76	6.73	0.78	7.24
DCP6UYX	DMWTAOI	Estramustine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.4	6.8	4.7	0.79
DC3RORH	DMWTAOI	Estramustine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.04	4.51	1.69	1.19
DCDOFJM	DMWTAOI	Estramustine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.1	5.5	4.06	1.85
DCDDA2O	DMWTAOI	Estramustine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.42	7.69	6.52	3.1
DCK3APO	DMWTAOI	Estramustine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.18	2.8	2.59	1.8
DCPS3LA	DMWTAOI	Estramustine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.68	8.26	8.93	9.39
DCXLCEY	DMWTAOI	Estramustine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.01	7.18	2.53	0.79
DCDZ98U	DMWTAOI	Estramustine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	13.4	18.81	14.28	8.93
DCBH8D7	DMWTAOI	Estramustine	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.65	4.67	0.52	4.53
DCVJ74G	DMWTAOI	Estramustine	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	11.62	15.42	0.2	9.19
DC475B7	DMWTAOI	Estramustine	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.8	4.89	4.6	6.87
DCHIETW	DMWTAOI	Estramustine	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.1	0.94	1.19	1.19
DCY7NYM	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	6.97	5.12	2.88	6.73
DCWAD34	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.27	3.08	0.51	3.26
DCD6V9Z	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	5.89	4.91	0.9	5.9
DCT8LM1	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	0.97	4.15	3.44	3.72
DCSG1M5	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	2.62	3.33	0.15	3.84
DCP3NN8	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	8.6	7.16	5.72	9.67
DCYVWGR	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	9.18	10.8	7.16	11.5
DCWXPPS	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.3	1.87	0.07	3.88
DC78TZX	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	14.29	16.71	2.94	13.23
DC04W3O	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	4.55	4.79	1.19	5.61
DCUSUS6	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.54	1.04	0.75	4.5
DCLH11P	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.6	5.23	3.7	8.49
DCBLV7H	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.4	3.1	0.71	4.7
DCAGN5S	DMWTAOI	Estramustine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	2.41	6.33	6.31	3.14
DCUFW4U	DMWTAOI	Estramustine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.8	5.41	0.3	2.56
DCEDSWI	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	7.89	8.05	8.49	14.8
DCBJNYB	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.74	5.05	3.58	5.41
DC8LG30	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	6.66	6.07	8.19	11.69
DCSJ2X0	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	8.12	10.33	12.79	10.77
DCLA6Q6	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	14.42	15.76	7.99	17.8
DCFUSYF	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	8.87	10.79	2.18	13.65
DCFHVZY	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.57	5	1.81	9.99
DC69O7A	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	9.72	9.4	5.85	11.96
DC7J14Z	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.79	8.81	10.68	12.16
DC7JIS4	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	7.78	7.85	1.04	10.07
DCVV960	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	1.65	4.62	3.18	7.39
DCWXMJA	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.65	0.94	30.89	1.49
DCCYZOB	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	11.73	12.45	0.95	14.05
DCA3GPR	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	7.5	8.82	5.09	12.17
DCJVNL9	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	4.03	5.91	2.13	10.13
DC3LHTQ	DMWTAOI	Estramustine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	9.09	8.46	9.88	15.94
DC09RVN	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.87	2.17	2.99	7.62
DCNUD6B	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.21	3.66	0.65	6.13
DCTVHIA	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	10.4	11.92	1.96	14.39
DCAODRI	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.43	9.73	1.19	11.01
DC0WVH4	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.82	7.31	15.38	7.07
DC0TU8K	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	11.06	12.42	9.22	14.32
DCFSS8I	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.22	1.78	3.98	6.16
DCRGM44	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	9.53	11.04	5.59	11.04
DC2PCL9	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	2.93	7.62	0.29	9.43
DCN2962	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	5.8	9.05	6.08	11.4
DC1EM91	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	9.69	11.65	7.63	12.93
DCVS3W2	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	16.77	13.2	14.88	17.68
DCXJB7E	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	0.97	0.11	1.8	4.3
DCKQ987	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	13.08	13.9	13.56	17.21
DCI0N3D	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.34	5.79	2.34	8.15
DCMGXD5	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	5.11	4.27	7.35	9.87
DC7HOPS	DMWTAOI	Estramustine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	7.96	13.58	2.77	10.66
DC6RK4Z	DMWTAOI	Estramustine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.07	5.69	3.23	0.96
DCHS51B	DMWTAOI	Estramustine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.9	6.98	5.53	0.68
DCHM2Z4	DMWTAOI	Estramustine	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.73	1.42	1.46	1.11
DCFONZU	DMWTAOI	Estramustine	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.54	5.99	1.39	0.01
DC2057S	DMWTAOI	Estramustine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6.17	7.86	7.76	2.86
DC8H4VR	DMWTAOI	Estramustine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.12	6.73	2.73	1.56
DCOF6VT	DMWTAOI	Estramustine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.74	7	4.03	2.16
DCVCI00	DMWTAOI	Estramustine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.31	3.4	1.64	1.28
DC1K2L3	DMWTAOI	Estramustine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.29	2.94	1.31	0.05
DC38CP7	DMWTAOI	Estramustine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.82	6.26	5.46	1.05
DCROO7R	DMWTAOI	Estramustine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.63	4.82	1.69	0.13
DCROSU1	DMWTAOI	Estramustine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.73	1.27	0.19	4.75
DCFLH11	DMWTAOI	Estramustine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.47	0.88	3.79	7.45
DCR2FV7	DMWTAOI	Estramustine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	2.83	3.64	0.89	4.96
DC1VTGF	DMWTAOI	Estramustine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	1.27	4.28	3.17	3.77
DC2NERJ	DMWTAOI	Estramustine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.83	10.01	7.44	9.95
DCJ70UI	DMWTAOI	Estramustine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	8.64	6.11	1.66	8.66
DCZTFSZ	DMWTAOI	Estramustine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	1.55	1.91	1.33	5.96
DCGMPWJ	DMWTAOI	Estramustine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	10.02	20.26	16.06	17.78
DCD30UN	DMWTAOI	Estramustine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.59	2.71	2.07	6.05
DCRJN2P	DMWTAOI	Estramustine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	6.21	15.76	9.19	11.37
DC6RPZ8	DMWTAOI	Estramustine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.85	10.24	7.61	10.69
DCZU85E	DMWTAOI	Estramustine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	9.77	13.12	12.48	14.93
DCYIFMU	DMWTAOI	Estramustine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	14.24	13.86	15.86	20.33
DCBIT89	DMWTAOI	Estramustine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.91	9.13	9.86	9.08
DCTSBC5	DMWTAOI	Estramustine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.39	1.47	2.32	3.58
DCU55XM	DMWTAOI	Estramustine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.21	1.01	5.55	6.79
DCUJ2DR	DMWTAOI	Estramustine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.35	9	4.27	4.77
DCVM7UZ	DMWTAOI	Estramustine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.94	6.32	3.46	1.96
DC87JSR	DMWTAOI	Estramustine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	6.2	6.79	1.21	5.66
DCLUQWY	DMWTAOI	Estramustine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.87	7.56	2.27	3.45
DCCHNII	DMWTAOI	Estramustine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.03	4.86	4.04	4.33
DC2LB1G	DMWTAOI	Estramustine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.42	5.67	5.34	1.24
DC3NB9F	DMWTAOI	Estramustine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	8.14	8.12	4.52	9.68
DC01IYE	DMWTAOI	Estramustine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.67	4.76	0.99	5.92
DCBQ6A5	DMWTAOI	Estramustine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.08	6.58	3.25	8.13
DCZ9BR2	DMWTAOI	Estramustine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	6.02	4.75	3.65	7.35
DCHPXZP	DMWTAOI	Estramustine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.45	6.56	1.89	2.26
DCFQCRE	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.74	1.98	6.4	7.89
DC5B0CG	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.39	7.36	12.16	13.19
DCGOSKE	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	3.69	5.93	3.7	7.01
DCXQNEO	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	1.32	6.48	6.47	6.99
DC9PTV3	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.33	2.41	6.64	8.1
DCWEHI9	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	0.14	0.89	1.26	4.27
DC3WP0U	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	4.29	9.1	10.43	10.75
DCMEYC8	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	2.67	7.77	7.44	8
DCSUO6D	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.3	8.46	8.88	8.82
DCEJDAW	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.81	5.46	7.69	8.61
DCNCC3T	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.57	3.47	6.51	7.7
DC3CSQQ	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	4.64	8.64	9.1	10.9
DC4R6GG	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.46	4.63	6.29	7.18
DCFNRK6	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.71	2.06	4.23	4.3
DCPS87M	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	1.71	5.84	2.45	4.23
DC806PV	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.97	1.58	6.93	8.09
DCURHSP	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	11.34	16.89	11.69	12.71
DC8KZKY	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.75	5.67	5.77	7.41
DCRQ1ZE	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	21.51	22.62	20.49	23.09
DC3QHQH	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	1.99	5.81	8.06	8.62
DCB5BI2	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	15.96	15	20.67	23.12
DC2EAWX	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.17	5.2	6.62	7.4
DC1VSSS	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	5.87	1.3	6.68	8.85
DCN438M	DMWTAOI	Estramustine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	2.77	13.62	2.48	10.66
DCBDOSY	DMWTAOI	Estramustine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	0.01	2.89	2.67	6.11
DCHB0XM	DMWTAOI	Estramustine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.31	7.54	0.48	3.73
DC0K9PN	DMWTAOI	Estramustine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.45	4.19	1.33	1.88
DC4P7OI	DMWTAOI	Estramustine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	7.29	9.07	2.63	2.12
DCNQNLZ	DMWTAOI	Estramustine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.69	1.94	0.43	4.67
DCUD52V	DMWTAOI	Estramustine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	7.57	8.29	4.79	9.09
DCVUMXN	DMWTAOI	Estramustine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	8.13	9.21	6.22	10.03
DCS8VOP	DMWTAOI	Estramustine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	3.78	6.96	0.88	1.13
DCISVTS	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	13.1	16.28	14.28	16.35
DC9E9NJ	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	5.45	8.12	3.14	7.32
DC97OHD	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.9	4.55	1.3	5.29
DCIO55I	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	11.11	9.1	4.36	7.11
DCI6GEU	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.46	2.01	1.28	4.37
DC4LZS1	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	0.7	6.05	0.98	6.25
DCFSUEA	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	7.58	8.52	4.67	8.71
DCHE1Q2	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	7.21	11.34	2.03	8.62
DCZHRY6	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.93	8	2.67	8.09
DC4YQYC	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	14.11	13.52	1.74	13.8
DCE4P45	DMWTAOI	Estramustine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.51	4.98	2.35	7.22
DCA35HV	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	1.82	9.39	8.17	10.28
DC9QO9X	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.24	3.33	0.6	4.23
DCLJ4OU	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	2.87	8.65	9.68	10.1
DC8ZS1S	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	4.35	9.48	5.91	7.29
DCWDSFA	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.88	11.6	12.47	12.45
DC3V4H5	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.29	5.63	1.54	5.25
DC07ECV	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	0.45	5.19	0.87	4.78
DCRF32H	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	11.14	15.23	8.76	11.37
DCGWT2C	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	10.91	22.09	13.95	16.07
DCFRJSK	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	7.06	8.34	0.14	4.33
DCFMMEG	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	1.27	7.17	6.29	8.67
DCA2HVD	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	17.03	20.43	19.58	22.34
DCB108F	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.9	8.22	2.62	6.03
DC3908F	DMWTAOI	Estramustine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	3.99	8.41	1.27	1.52
DCIFQNM	DMWTAOI	Estramustine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.96	1.63	3.29	5.7
DCJCSS9	DMWTAOI	Estramustine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	5.63	11.77	9.78	5.41
DC3VDT9	DMWTAOI	Estramustine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.74	2.77	1.62	1.31
DCLFIAK	DMWTAOI	Estramustine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.07	0.22	1.26	2.11
DC3MSK9	DMWTAOI	Estramustine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	7.34	7.2	5.86	8.99
DCMQIZM	DMWTAOI	Estramustine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.33	8.5	4.14	3.23
DCS96IZ	DMWTAOI	Estramustine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.14	7.65	7.55	6.66
DCCRKMV	DMWTAOI	Estramustine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.42	3.1	1.22	1.15
DCKCGSQ	DMWTAOI	Estramustine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.95	5.08	4.5	4.61
DCJK8Q2	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.3	3.24	5.92	7.08
DCWKQPN	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	8.92	8.26	12.36	14.68
DCY6YVA	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	7.16	6.91	4.24	7.67
DCW4WHS	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.21	3.47	3.48	6.82
DCB9TCN	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.07	1.86	5.42	6.14
DC2QJTT	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	8.82	6.06	5.66	8.44
DCQ3LJY	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	1.78	3.88	3.23	6.12
DC5BFHA	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.62	0.7	3.68	5.09
DCF1QQ0	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	1.91	6	3.67	4.02
DC6ULTO	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	3.79	9.47	10.99	11.69
DCYR7D4	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.24	0.17	1.03	3.76
DCD96Y6	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	3.03	8.41	2.83	3.67
DCH9ZH2	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.97	6.7	7.44	9.58
DCIJJ1U	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	4	4.21	3.92	7.67
DCT74DR	DMWTAOI	Estramustine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	10.56	10.56	15.47	17.97
DCPEDS3	DMWTAOI	Estramustine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.01	2.59	1	3.02
DC3VT2N	DMWTAOI	Estramustine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.61	6.07	3	6.13
DCNC6I0	DMWTAOI	Estramustine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.08	7.01	3.07	7.8
DCJQ3DP	DMWTAOI	Estramustine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	7.33	12.81	9.7	3.48
DCNEM58	DMWTAOI	Estramustine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.83	3.55	4.42	4.88
DC9C68W	DMWTAOI	Estramustine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.04	7.74	0.17	0.17
DCRXVAT	DMWTAOI	Estramustine	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.36	7.68	2.73	5.86
DCPGLMJ	DMWTAOI	Estramustine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.35	8.9	0	0.93
DCO7QWE	DMWTAOI	Estramustine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.53	7.83	1	0.95
DCQPNAT	DMWTAOI	Estramustine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	9.72	14.29	8.82	5.93
DCDJN9W	DMWTAOI	Estramustine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.63	9.35	1.55	3.33
DCZWKDR	DMWTAOI	Estramustine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	8.37	11.43	4.4	2.77
DCR889E	DMWTAOI	Estramustine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.65	9.02	2.21	4.1
DCF6E51	DMWTAOI	Estramustine	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.55	5.53	2.15	1.44
DCB6SZR	DMWTAOI	Estramustine	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.16	2.1	0.76	0.09
DC7GLWM	DMWTAOI	Estramustine	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.52	7.26	4.07	5.89
DCC5T5D	DMWTAOI	Estramustine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.05	4.28	1.51	1.5
DC461Y6	DMWTAOI	Estramustine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.33	9.29	2.13	2.15
DCAG39G	DMWTAOI	Estramustine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	10.91	9.91	2.61	5.39
DCNDLEH	DMWTAOI	Estramustine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.67	8.74	6.91	11.39
DCIZBFU	DMWTAOI	Estramustine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.22	7.47	8.72	11.45
DCXDHZW	DMWTAOI	Estramustine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.85	3.02	6.58	8.25
DC672CD	DMWTAOI	Estramustine	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.83	5.56	2.34	0.96
DCS1KXW	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.95	2.27	8.33	9.67
DCRVBEL	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.14	1.07	5.79	6.87
DCY0R1C	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.91	2.58	9.04	9.79
DCM3M68	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	8.31	9.75	15.18	16.71
DCKGOPS	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	0.84	3.63	7.51	7.94
DCUFG20	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	3.62	4.67	6.97	7.98
DCCXCA5	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	0.03	0.04	3.11	5.21
DCFPZ5T	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.52	4.8	3.79	0.61
DC3FL79	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.24	0.16	2.26	2.8
DCPYYO0	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	1.19	5.66	1.33	5.95
DCZGYAV	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	13.14	19.98	2.71	5.06
DC5NBBO	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	8.95	9.01	13.51	14.47
DCB5DFX	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	0.98	0.62	2	4.9
DCT3GH5	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.36	5.91	2.91	2.98
DCZXKUI	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	17.35	17.3	26.39	26.77
DC8N67L	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.97	0.38	1.67	4.35
DCTK4D2	DMWTAOI	Estramustine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	4.63	11.49	5.68	8.01
DC1JEAH	DM62UG5	Vemurafenib	Approved	34	DM8BKU9	Acitretin	Approved	34	.	.	.	.	Malignant Melanoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCM00AS	DM62UG5	Vemurafenib	Approved	34	DMX6OE3	Dabrafenib	Approved	34	.	.	.	.	Metastatic Melanoma (Carrying BRAF V600 Mutation)	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC0N038	DM62UG5	Vemurafenib	Approved	34	DMQCTIH	Digoxin	Approved	34	.	.	.	.	"Malignant Melanoma, Neoplasms"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC73N96	DM62UG5	Vemurafenib	Approved	34	DMYISJK	PX-866	Phase 2	21	.	.	.	.	Advanced BRAF-mutant Cancers	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCC3LRD	DM62UG5	Vemurafenib	Approved	34	DM8X2EH	Everolimus	Approved	34	.	.	.	.	Advanced Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCD7H3V	DM62UG5	Vemurafenib	Approved	34	DMF9M57	Cotellic	Phase 3	25	.	.	.	.	Malignant Melanoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCFINOO	DM62UG5	Vemurafenib	Approved	34	DMS104F	Temsirolimus	Approved	34	.	.	.	.	Advanced Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCHDSD2	DM62UG5	Vemurafenib	Approved	34	DMR8ONJ	Leflunomide	Approved	34	.	.	.	.	Melanoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCH54QW	DM62UG5	Vemurafenib	Approved	34	DMDY08K	GDC-0623	Phase 1	17	.	.	.	.	Melanoma	TTD Database	Phase 1	.	.	.	.	.
DC65DSE	DM62UG5	Vemurafenib	Approved	34	DMG281S	Carboplatin	Approved	34	DMLB81S	Paclitaxel	.	.	Advanced Cancers	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC5EY8U	DM62UG5	Vemurafenib	Approved	34	DMH75KV	Acenocoumarol	Approved	34	.	.	.	.	"Malignant Melanoma, Neoplasms"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCBAW91	DM62UG5	Vemurafenib	Approved	34	DMLOS5R	Bay 80-6946	Approved	34	.	.	.	.	Thyroid Carcinoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCNYWZJ	DM62UG5	Vemurafenib	Approved	34	DMR2IQ4	Tizanidine	Approved	34	.	.	.	.	"Malignant Melanoma, Neoplasms"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCYAYKI	DM62UG5	Vemurafenib	Approved	34	DMIYDT4	Cabozantinib	Approved	34	.	.	.	.	Recurrent Melanoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCKBTCJ	DM62UG5	Vemurafenib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.32	7.9	1.5	1.5
DC5GTFG	DM62UG5	Vemurafenib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.73	9.53	6.42	7.29
DCUFP8H	DM62UG5	Vemurafenib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.06	6.44	1.53	5.51
DCDU9UY	DM62UG5	Vemurafenib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.19	5.06	4.38	4.97
DCQNFH2	DM62UG5	Vemurafenib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.39	6.45	4.02	3.82
DC2AACB	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	16.2	18.11	15.2	18.26
DCJ67C0	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.06	7.76	4.85	6.54
DCBQUSX	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	10.6	12.98	2.14	14.31
DCUB1LX	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.11	8.8	6.81	8.52
DCO6NLJ	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.85	9.51	0.65	7.5
DC6U1Y2	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.13	15.7	5.02	9.84
DCM6EEB	DM62UG5	Vemurafenib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.37	6.66	3.28	4.87
DCL6636	DM62UG5	Vemurafenib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.8	8.34	3.64	7.06
DC6WQSH	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	33.94	33.52	33.08	32.96
DCJF6IN	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	18.17	22.07	22.44	22.1
DC8D3U0	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	22.27	27.81	27.34	26.29
DC2W0GH	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	26.52	21.46	20.06	19.9
DCOGS3X	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	42.46	36.35	33.04	33.04
DCYYZEV	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	11.95	17.76	14.42	15.82
DCI3XU9	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	27.66	31.04	28.12	28.58
DCCQAKR	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	16.55	20.14	13.02	13.62
DC41RW6	DM62UG5	Vemurafenib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.46	6.6	1.44	5.22
DC199T7	DM62UG5	Vemurafenib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	9.3	13.03	6.42	6.38
DCFDC2E	DM62UG5	Vemurafenib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.92	2.54	0.21	0.24
DC27MQY	DM62UG5	Vemurafenib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.69	8.32	5.07	6.64
DCYHLFC	DM62UG5	Vemurafenib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.2	7.08	8.32	8.42
DC4NZOD	DM62UG5	Vemurafenib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.63	3	1.86	1.21
DC3BO8Y	DM62UG5	Vemurafenib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	7.18	10.74	4.94	2.59
DCCOLKH	DM62UG5	Vemurafenib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.07	3.1	0.84	0.59
DC0ZUOC	DM62UG5	Vemurafenib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	8.85	13.98	4.3	11.26
DC8B7IC	DM62UG5	Vemurafenib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.4	4.5	0.43	0.57
DC5T96N	DM62UG5	Vemurafenib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.69	5.16	1.99	2.46
DC52GNO	DM62UG5	Vemurafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.49	4.93	3.61	3.61
DCWEDQC	DM62UG5	Vemurafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	16.35	20.77	5.87	4.77
DCYIF6I	DM62UG5	Vemurafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.8	4.98	3.91	2.14
DCSZDO8	DM62UG5	Vemurafenib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.74	3.62	5.47	5.32
DCCZZSN	DM62UG5	Vemurafenib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	6.34	7	5.22	2.89
DCJ5RLZ	DM62UG5	Vemurafenib	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.99	8.01	5.58	5.8
DCYOFFV	DM62UG5	Vemurafenib	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.92	13.4	7.79	6.85
DC05WSL	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	14.89	18.67	20.13	20.11
DCWHHQN	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	21.73	23.87	22.22	22.56
DCH9FDL	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	25.28	25.46	21.42	23.45
DCF9N8A	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	34.78	31.73	28.69	28.41
DCX9W8B	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	32.32	29.56	27.31	27.15
DCNLBE5	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.65	11.45	2.97	5.36
DCZTZ9E	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.04	7.47	2.57	5.97
DCBYKDR	DM62UG5	Vemurafenib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.08	3.87	3.05	3.07
DCTXLW3	DM62UG5	Vemurafenib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.6	7.13	3.99	5.36
DCWLMIQ	DM62UG5	Vemurafenib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.57	6.84	4.35	5.06
DCQR9IC	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	12.64	12.98	12	12.98
DCW8OW1	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.31	6.57	8	9.24
DC5UC31	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.86	6.95	0.59	5.88
DCANGXD	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	10.43	9.86	9.6	13.85
DCJZS8T	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	9.36	9.69	1.78	7.73
DCYSPML	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.44	7.22	3	6.25
DCNPQSN	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	12.92	16.15	6.5	10.3
DCWQ0R0	DM62UG5	Vemurafenib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.03	7.94	4.7	5.45
DCDBSN5	DM62UG5	Vemurafenib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.74	5.26	5.32	8.98
DCAV4PF	DM62UG5	Vemurafenib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.69	6.82	3.37	5.97
DCCYNHW	DM62UG5	Vemurafenib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.11	4.24	3.22	8.39
DC2OBHX	DM62UG5	Vemurafenib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.26	3.04	1.73	1.73
DCF6MI1	DM62UG5	Vemurafenib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.49	4.28	3.23	3.24
DCTWYIE	DM62UG5	Vemurafenib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.02	4.38	2.96	2.99
DC6RUMA	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.33	3.78	2.55	2.41
DC6Y6IU	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.58	11	7.64	7.76
DCY6P8D	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.14	7.04	0.61	0.55
DCX50SK	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.3	4.29	2	1.98
DCSL93U	DM62UG5	Vemurafenib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.82	4.62	3.77	3.41
DCUHWNK	DM62UG5	Vemurafenib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.93	7.58	5.77	6.19
DCNPUVY	DM62UG5	Vemurafenib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.02	3.95	0.26	0.89
DCAY238	DM62UG5	Vemurafenib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.83	9.27	8.71	9.39
DCJNVWT	DM62UG5	Vemurafenib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.54	4.21	3.12	7.61
DCZN75E	DM62UG5	Vemurafenib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.01	9.22	2.68	3.29
DCVGNLV	DM62UG5	Vemurafenib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	11.19	9.73	8.44	9.58
DCFNP6S	DM62UG5	Vemurafenib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	10.32	11.4	5.64	13.84
DCW1E81	DM62UG5	Vemurafenib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	8.27	8.41	2.9	11.58
DCNY104	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.33	7.51	6.32	6.33
DCOMO3U	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.35	4.43	1.1	1.1
DC8II47	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.39	9.86	2.82	1.98
DCIZAED	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.83	12.61	10.28	9.85
DCVO64L	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.42	9.75	9.18	9.64
DCRFXZX	DM62UG5	Vemurafenib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	7.92	6.48	5.05	6.61
DCQ0BEV	DM62UG5	Vemurafenib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.97	7.04	0.93	4.9
DCHC0IA	DM62UG5	Vemurafenib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	18.19	19.37	8.39	15.88
DCYXC1L	DM62UG5	Vemurafenib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	12.52	13.87	4.47	11.85
DC7J3AC	DM62UG5	Vemurafenib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.06	4.07	3.36	3.48
DC3GK5T	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	14.4	13.91	8.73	14.03
DC4EIN7	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.38	5.96	3.31	9.62
DCIUX4O	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.7	12.16	12.71	15.42
DCX6ZOG	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	18.35	17.98	9.34	14.99
DCCKC4S	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.81	8.16	0.84	7.82
DC3FEP3	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	18.18	18.25	2.66	13.41
DC33Y34	DM62UG5	Vemurafenib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0	4.09	3.07	3.6
DCWXLV5	DM62UG5	Vemurafenib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.22	4.18	2.87	2.87
DCB5K45	DM62UG5	Vemurafenib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.14	6.51	5.31	3.78
DCKBSC9	DM62UG5	Vemurafenib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.83	13.27	6.58	6.58
DCX0QTD	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.14	15.09	12.03	12.32
DCZRVZ3	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.98	3.6	2.53	2.2
DC1L4QK	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.2	14.11	7.57	7.57
DCQV4Z3	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.36	7.58	5.45	5.09
DCTCS7T	DM62UG5	Vemurafenib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	18.11	21.38	1.04	21.02
DCMJWFP	DM62UG5	Vemurafenib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.18	11.26	8.27	12.66
DC6G37U	DM62UG5	Vemurafenib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	19.42	18.75	4.72	15.9
DCXXYJ1	DM62UG5	Vemurafenib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.02	10.19	5.69	8.9
DCKABA1	DM62UG5	Vemurafenib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	16.75	15.23	5.25	14.88
DCSRMP7	DM62UG5	Vemurafenib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.35	4.75	3.32	4.86
DCMUG3U	DM62UG5	Vemurafenib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.19	8.37	9.1	10.28
DC14OG4	DM62UG5	Vemurafenib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.33	5.59	4.48	8.92
DCKTQTB	DM62UG5	Vemurafenib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.35	7.75	1.05	1.98
DCAL3G9	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	15.62	16.14	8.89	16.28
DCSDRSI	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	10.45	10.65	7.34	13.85
DC5Y4GA	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	12.09	10.2	10.8	14.58
DCHRESK	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	22.48	19.48	5.84	16.85
DCHAMDM	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.7	12.41	9.62	12
DCMU2P2	DM62UG5	Vemurafenib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.27	3.98	2.48	3.74
DCA74QS	DM62UG5	Vemurafenib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.58	5.85	8.2	8.44
DCFUZDP	DM62UG5	Vemurafenib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.72	6.42	5.38	6.58
DCXR7F8	DM62UG5	Vemurafenib	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.84	8.28	1.7	1.7
DCCP0TS	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.04	5.31	2.96	2.4
DCAVL9N	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.17	4.79	2.19	2.8
DCYGAS3	DM62UG5	Vemurafenib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.33	4.89	1.6	1.38
DC29RC5	DM62UG5	Vemurafenib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.11	6.58	1.75	4.97
DCM93CZ	DM62UG5	Vemurafenib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	7.27	10.27	9.74	10.44
DCH06OI	DM62UG5	Vemurafenib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.27	6.97	0.25	4.16
DCJ4F9G	DM62UG5	Vemurafenib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.05	4.05	4.45	3.65
DCJY4UD	DM62UG5	Vemurafenib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.66	11.1	1.41	11.11
DCJ82I9	DM62UG5	Vemurafenib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.68	4.18	5.45	5.43
DCXDE73	DM62UG5	Vemurafenib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.82	2.33	1.01	0.72
DCJT2HF	DM62UG5	Vemurafenib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.71	9.67	3.11	3.11
DCHN6WG	DM62UG5	Vemurafenib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.18	4.6	2.5	2.4
DCLTIER	DM62UG5	Vemurafenib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.23	4.26	3.39	4.39
DCR89Q5	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	9.24	13.48	11.83	13.07
DCM1TTK	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.92	7.44	4.76	5.58
DC0A2KM	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.77	6.77	1.01	7.8
DC7IVWS	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	6.41	9.52	5.96	7.18
DCQNMCX	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.91	10.15	2.53	8.9
DCT7CY8	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	20.24	21	11.7	15.17
DC357L4	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.42	2.51	2.48	2.7
DC9DTJU	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	8.36	8.8	5.35	7.36
DC1MEII	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.31	4.17	2.73	3.31
DC9PF3Y	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.08	6.81	3.44	4.54
DC39B6D	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.63	13.45	7.02	7.02
DCXQC1R	DM62UG5	Vemurafenib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.68	7.9	6.91	8.05
DCTLIVH	DM62UG5	Vemurafenib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0	3.44	3.9	5.8
DCK8IAJ	DM62UG5	Vemurafenib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	9.58	8.76	5.06	7.86
DCOISCH	DM62UG5	Vemurafenib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	15.89	16.6	10.11	11.57
DCYVVUJ	DM62UG5	Vemurafenib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	10.8	10.34	6.96	13.21
DCUTPGE	DM62UG5	Vemurafenib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.54	4.38	2.02	4.18
DCU854C	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	6.61	11.98	9.19	12
DCB5JAJ	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	7.92	11.29	10.03	13.06
DC7O15X	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	8.95	13.41	10.44	10.41
DCIEB7D	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	11.03	16.79	12.28	13.56
DC7EGAS	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	14.42	20.42	13.77	13.6
DCFAV03	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	12	19.05	16.35	15.79
DCNH9RJ	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	10.27	16.15	2.94	14.85
DCW0AHL	DM62UG5	Vemurafenib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.09	7.06	2.26	2.26
DCO25DO	DM62UG5	Vemurafenib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.64	5.84	0.62	3.8
DC3MIC9	DM62UG5	Vemurafenib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.49	4.83	2.44	1.3
DCHOE5H	DM62UG5	Vemurafenib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	12.53	9.06	2.27	0.68
DC9L0UQ	DM62UG5	Vemurafenib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.93	12.51	11.7	6.86
DCN84QZ	DM62UG5	Vemurafenib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.57	5.43	2.18	2.7
DCDBP0B	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.49	8.43	2.81	7.32
DCVCX4I	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.99	8.51	7.44	7.05
DCZSQYQ	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	6.08	14.89	8.36	6.28
DCI4BRB	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.85	9.67	7.37	7.29
DCNWZ09	DM62UG5	Vemurafenib	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	9.34	10.11	2.99	1.35
DCPWE9V	DM62UG5	Vemurafenib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	4.6	6.26	0.39	8.61
DCDD3N5	DM62UG5	Vemurafenib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.81	2.45	3.11	6.84
DCEW6UB	DM62UG5	Vemurafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.12	5.88	7.01	7.03
DCIIUNJ	DM62UG5	Vemurafenib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.59	3.29	1.02	1.01
DCW842T	DM62UG5	Vemurafenib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.8	8.24	0.51	1.78
DCI5PVZ	DM62UG5	Vemurafenib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.72	5.27	1.49	5.36
DCIJMK0	DM62UG5	Vemurafenib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.38	8.68	0.48	3.07
DCUPXGC	DM62UG5	Vemurafenib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.17	7.95	2.86	5.63
DCJCFJA	DM62UG5	Vemurafenib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.53	8.43	6.2	1.77
DCVDNVK	DM62UG5	Vemurafenib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.34	6.96	3.24	3.87
DCFTERU	DM62UG5	Vemurafenib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	19.3	19.39	16.52	17.16
DCEJWH5	DM62UG5	Vemurafenib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	8.15	12.75	8.1	10.11
DCVYL0Y	DM62UG5	Vemurafenib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.34	4.66	1.03	2.73
DC6992A	DM62UG5	Vemurafenib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.31	3.39	9.9	11.7
DCEPRNE	DM62UG5	Vemurafenib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	3.12	6.87	0.4	0.93
DCATCNW	DM62UG5	Vemurafenib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	0.66	7.4	4.47	5.04
DCK50IU	DM62UG5	Vemurafenib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	8.63	12.55	10.15	10.16
DC6H2BG	DM62UG5	Vemurafenib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	1.16	6.3	3.27	3.4
DCM8DEE	DM62UG5	Vemurafenib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	0.93	8.18	3	6.64
DCXO75Y	DM62UG5	Vemurafenib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	1.41	7.47	4.67	4.15
DCLW2DD	DM62UG5	Vemurafenib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.18	6.57	5.37	5.39
DCV6ASP	DM62UG5	Vemurafenib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.23	5.78	2.32	2.35
DC4PXB7	DM62UG5	Vemurafenib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	7.13	15.13	12.06	10.18
DCL5P1H	DM62UG5	Vemurafenib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	1.82	8.96	1.68	10.67
DC8GDBR	DM62UG5	Vemurafenib	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	4.78	7.15	3.07	2.22
DC8NCOE	DM62UG5	Vemurafenib	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.99	4.86	1.4	1.39
DCQOBZ2	DM62UG5	Vemurafenib	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.98	7.05	6.32	4.76
DCYNGH2	DM62UG5	Vemurafenib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.76	6.96	5.53	4.04
DCI23PE	DM62UG5	Vemurafenib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	8.21	9.08	5.27	10.48
DCNK460	DM62UG5	Vemurafenib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	18.02	17.4	8.21	4.82
DCIUKMQ	DM62UG5	Vemurafenib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	4.44	9.3	6.86	5.11
DCWCHQI	DM62UG5	Vemurafenib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	2.17	7.81	3.59	5.13
DCGYL45	DM62UG5	Vemurafenib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	0.73	7.47	5.85	6.26
DCCMG0L	DM62UG5	Vemurafenib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5	6.97	5.19	5.91
DC8N57J	DM62UG5	Vemurafenib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	1.74	8.18	5.16	4.68
DCOG6IX	DM62UG5	Vemurafenib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.2	7.26	3.51	4.82
DCHTUK6	DM62UG5	Vemurafenib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.06	4.12	2.13	2.13
DCPSFC2	DM62UG5	Vemurafenib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	10.22	10.68	7.39	10.4
DC841VL	DM62UG5	Vemurafenib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.74	7.54	2.51	3.95
DCSJ8CY	DM62UG5	Vemurafenib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.49	7.36	1.38	1.38
DCA0SWB	DM62UG5	Vemurafenib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.05	5.29	2.87	4.68
DCL3TPN	DM62UG5	Vemurafenib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	5.57	15.38	11.35	8.97
DCOPDNR	DM62UG5	Vemurafenib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.36	3.32	1.48	2.29
DCIK7PU	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	8.94	8.39	1.22	7.58
DCCN7H0	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	14.6	18.82	4.87	7.68
DCUJ0WT	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	16.01	15.01	12.59	18.86
DC8WHM2	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	1.98	6.17	4.39	4.11
DC4GFVV	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	1.31	4.81	4.97	6.34
DCXE13I	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	1.19	6.26	2.05	3.52
DCRNDE8	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	13.36	14.69	6.33	12.72
DC6UQFQ	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	5.73	6.27	4.67	7.97
DCMSG5K	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	1.28	6.8	5.72	7.77
DCS8TX6	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	12.62	13.71	13.3	14.8
DCVPJH8	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	1.05	4.51	5.31	6.93
DCM9AA0	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	12.65	13.28	13.65	15.8
DCJ2QV9	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	13.12	13.48	1.91	16.12
DCR45OA	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	2.11	6.86	0.21	5.61
DCBUHGK	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	4.16	8.66	9.51	9.75
DCHL0S4	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	5.1	6.6	6.04	6.98
DCG3YU7	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	2.31	9.16	3.46	6.48
DCTCARF	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.32	10.17	3.55	8.66
DCC43NM	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	8.3	11.08	0.75	14.78
DCNJNUN	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	8.81	9.6	2.62	13.07
DCEFFFB	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	20.62	17.47	6.65	20
DCSAG88	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	7.98	7.21	8.36	10.37
DCDJ46P	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	9.44	9.37	6.76	10.16
DC8BXUS	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.26	9.13	3.67	8.17
DCQZ48G	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8.12	10.66	0.71	10.19
DCT6D29	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	7.45	12.54	1.37	8.27
DCBK2SN	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.8	9.55	7.35	9.01
DCCE4JW	DM62UG5	Vemurafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	0.56	7.94	1.14	6.18
DC0TMPZ	DM62UG5	Vemurafenib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.83	5.63	3.19	2.55
DCJBFTN	DM62UG5	Vemurafenib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.35	4.65	3.55	0.87
DCSDO7V	DM62UG5	Vemurafenib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	0.76	17.66	13.15	15.27
DCEH8YY	DM62UG5	Vemurafenib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	1.97	5.33	2.94	1.64
DCR87HO	DM62UG5	Vemurafenib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	1.25	8.13	9.05	10.19
DCTOM4D	DM62UG5	Vemurafenib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.46	9.09	6.81	6.38
DC0K09C	DM62UG5	Vemurafenib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	9.86	5.48	4.26	2.95
DCJAS3S	DM62UG5	Vemurafenib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	6.91	7.81	4.22	0.5
DCVNXSH	DM62UG5	Vemurafenib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.69	4.21	1.77	2.25
DCEASGV	DM62UG5	Vemurafenib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.64	7.98	4.67	7.04
DCJG9MQ	DM62UG5	Vemurafenib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.75	9.8	3.53	3.48
DC5MKEP	DM62UG5	Vemurafenib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	15.04	14.59	5.38	2.47
DCL49VC	DM62UG5	Vemurafenib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.15	1.45	0.34	0.02
DCJ4QEG	DM62UG5	Vemurafenib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.2	4.89	0.73	1.29
DC5HU3V	DM62UG5	Vemurafenib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.94	4.64	3.22	3.11
DC8KDOL	DM62UG5	Vemurafenib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.13	3.21	0.91	3.61
DC6ORC6	DM62UG5	Vemurafenib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	6.77	4.61	3.05	3.12
DCQH8UY	DM62UG5	Vemurafenib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	3.11	7.34	3.56	2.79
DCAWUXX	DM62UG5	Vemurafenib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	1.84	7.8	5.16	5.19
DCYIIA1	DM62UG5	Vemurafenib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	1.87	2.44	1.83	0.98
DCZ1CO3	DM62UG5	Vemurafenib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	4.3	8.3	10.11	10.19
DC6ANF6	DM62UG5	Vemurafenib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.93	4.88	2.36	2.32
DCBUPXP	DM62UG5	Vemurafenib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.39	3.46	0.89	0.94
DC0CSKK	DM62UG5	Vemurafenib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.27	2.55	0.36	0.36
DCDAF15	DM62UG5	Vemurafenib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	6.43	6.67	4.88	6.33
DC970SC	DM62UG5	Vemurafenib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	0.47	5.23	3	2.74
DC06LVW	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	22.54	26.89	24.38	23.64
DCTSATO	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	22.96	27.62	25.21	25.63
DCPJ0XN	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	22.15	23.82	23.05	21.2
DCJYKYD	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	14.11	16.79	12.49	13.02
DCU71LX	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	61.34	55.4	36.49	36.4
DCZIV2U	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	19.29	19.53	18.83	19.32
DC1759N	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	32.52	30.21	18.03	18.55
DC0JR1W	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	14.41	16.1	13.23	13.22
DCBVANE	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	51.41	49.86	47.9	47.29
DC6PGIV	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	44.43	45.55	33.53	34.25
DCD2XPX	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	66.63	65.68	58.12	63.32
DC9N6KJ	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.21	2.46	1.86	1.96
DCRX5AE	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	7.66	12.32	10.79	11.38
DC418ZG	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	56.96	49.72	45.83	52.59
DCZEUS1	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	14.05	19.1	19.01	18.9
DCZYNAD	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	44.08	37.7	34.64	34.79
DCH0Q6L	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	34.09	36.75	34.48	34.29
DCJ0OT5	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	47.5	48.59	46.07	46.43
DCEIRZE	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	12.03	16.75	14.92	14.96
DCGKDPT	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	33.53	33.26	33.36	33.09
DC4F423	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	13.11	20.72	19.54	19.4
DCJUC4L	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	28.24	27.59	28.27	27.58
DCS9E15	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	5.94	7.28	5.6	5.84
DCHBIXH	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.98	3.33	1.94	2.07
DCF32YH	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	12.75	15.5	14.01	14.01
DCDHD51	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	17.05	20.36	20.7	20.67
DC8B8KR	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	26.99	27.92	24.31	24.91
DC1QIQU	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	10.88	18.23	18.25	18.27
DCQBQHU	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	15.41	18.56	12.68	12.68
DCN2VFE	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	25.36	31.48	28.67	29.26
DC8KH3Z	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.61	5.73	4.14	3.15
DCD0K4Q	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	29.89	29.98	28.43	27.9
DCMHSOQ	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	21.64	25.44	23.38	23.33
DCY3LH0	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	24.88	22.96	21.32	20.61
DCC8BIS	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	20.69	22.02	20	20.78
DCKBA62	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	30.47	33.07	32.75	32.04
DC9XVRI	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	19.06	18.06	18.25	18.41
DCG6ZHM	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	18.64	20.87	21.42	21.57
DCRGZD3	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.29	0.81	0.79	0.69
DCCVCA4	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	26.54	30.22	21.14	25.48
DCCDFJ8	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	9.1	11.02	10.61	10.8
DCHM46W	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	24.51	30.75	24.63	24.63
DCVFE4B	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	13.9	18.4	17.17	16.57
DC15OQ6	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	28.1	27.03	26.01	25.38
DCFUQ92	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	12.62	17.17	15.93	15.77
DCOHQ47	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	20.34	24.34	23.34	23.22
DCQGRQW	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	10.3	12.72	1.4	9.72
DCE65UG	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	22.94	25.23	23	22.84
DCY3WUG	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	19.28	21.62	20.88	20.04
DCRSXZV	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	25.29	27.8	25.76	25.56
DCJ24KS	DM62UG5	Vemurafenib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	1.96	5	3.81	3.54
DCZURZ9	DM62UG5	Vemurafenib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.13	5.61	1.7	3.26
DC5NRVU	DM62UG5	Vemurafenib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	14.97	13.9	4.79	2.45
DCZV3S1	DM62UG5	Vemurafenib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	1	3.91	0.18	1
DCXD3OD	DM62UG5	Vemurafenib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.41	3.91	2.66	2.74
DCWVU15	DM62UG5	Vemurafenib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.13	6.33	0.36	0.36
DCUOS6X	DM62UG5	Vemurafenib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.47	3.48	2.07	2.68
DCB6164	DM62UG5	Vemurafenib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	8.36	11.8	10.35	5.82
DCPNU21	DM62UG5	Vemurafenib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.28	6.6	4.97	4.92
DCK0GUN	DM62UG5	Vemurafenib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	0.01	2.35	5.08	5.35
DCMO8LK	DM62UG5	Vemurafenib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	0.34	5.46	3.24	4.08
DCP3S4G	DM62UG5	Vemurafenib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.24	10.32	8.71	8.13
DCBS3JP	DM62UG5	Vemurafenib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.75	4.53	1.79	0.4
DCK9QOB	DM62UG5	Vemurafenib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.13	5.02	1.43	0.29
DCGY1B4	DM62UG5	Vemurafenib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.21	7.23	3.15	6.99
DC3OUF7	DM62UG5	Vemurafenib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	2.8	8.22	3.44	8.18
DC6IFAS	DM62UG5	Vemurafenib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	11.57	13.35	2.76	2.15
DCFUSYW	DM62UG5	Vemurafenib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.54	4.17	2.82	2.75
DCR41EN	DM62UG5	Vemurafenib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.95	4.73	0.49	6.55
DC68BFA	DM62UG5	Vemurafenib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	16.5	19.64	7.89	17.64
DCGLZVK	DM62UG5	Vemurafenib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	3.19	6.42	5.24	6.06
DCWMLWL	DM62UG5	Vemurafenib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.45	4.5	5.07	7.43
DCG5RMP	DM62UG5	Vemurafenib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	6.77	6.24	2.19	6.11
DCQH5N5	DM62UG5	Vemurafenib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.01	6.44	3.06	3.06
DC43B0S	DM62UG5	Vemurafenib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	1.74	8.44	7.38	8.61
DC1ZJQR	DM62UG5	Vemurafenib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.64	2.03	3.6	6.59
DC32KIC	DM62UG5	Vemurafenib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.41	5.05	9.92	11.57
DCPSUXA	DM62UG5	Vemurafenib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	6.62	8.58	4.52	0.98
DCM6XQW	DM62UG5	Vemurafenib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.9	5	3.1	3.16
DC3FRLD	DM62UG5	Vemurafenib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.1	1.43	1.87	4.93
DCLITKD	DM62UG5	Vemurafenib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	6.99	5.86	2.27	2.9
DCR9YMJ	DM62UG5	Vemurafenib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.47	4.86	1.94	2.38
DCOHY1F	DM62UG5	Vemurafenib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	9.09	12.07	6.05	11.09
DC7RMY6	DM62UG5	Vemurafenib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	12.37	19.51	15.02	16.17
DC537BJ	DM62UG5	Vemurafenib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	2	7.23	2.83	3.94
DCBD8I4	DM62UG5	Vemurafenib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	6.26	14.22	12.03	14.45
DCEXVWL	DM62UG5	Vemurafenib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	2.14	4.25	2.49	1.72
DCSVH93	DM62UG5	Vemurafenib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	12.79	7.34	4.38	2.6
DC154PA	DM62UG5	Vemurafenib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.48	4.34	0.65	1.72
DCWQH8M	DM62UG5	Vemurafenib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.09	3.82	0.2	1.53
DCLRXWJ	DM62UG5	Vemurafenib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.35	3.27	1.05	3.09
DC9DZVO	DM62UG5	Vemurafenib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.39	9.31	4.17	3.75
DCAF0OM	DM62UG5	Vemurafenib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	15.43	11.26	4.13	1.97
DCXB58H	DM62UG5	Vemurafenib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	1.88	6.62	5.23	7.71
DCSWD66	DM62UG5	Vemurafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.72	7.15	4.81	3.83
DCYK8VN	DM62UG5	Vemurafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	6.2	11.9	0.64	0.64
DCQ8L2Z	DM62UG5	Vemurafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	2.23	5.3	3.4	1.75
DCYHZSK	DM62UG5	Vemurafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	2.74	5.54	2.9	2.44
DCI4L74	DM62UG5	Vemurafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	0.84	2.08	0.9	0.51
DCBPQ9F	DM62UG5	Vemurafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	1.75	7.79	7.2	4.49
DCZZTRP	DM62UG5	Vemurafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.88	3.3	0.86	0.86
DC07G84	DM62UG5	Vemurafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	3.58	8.57	3.7	3.63
DC6HNLZ	DM62UG5	Vemurafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.01	3.62	0.52	0.1
DCP8TWE	DM62UG5	Vemurafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.87	3.58	1	0.11
DCQU80E	DM62UG5	Vemurafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.72	4.97	4.14	3.85
DCMRWDA	DM62UG5	Vemurafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.81	5.27	4.96	3.25
DCDOKSM	DM62UG5	Vemurafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	2.52	7.92	5.81	4.4
DC5JA0F	DM62UG5	Vemurafenib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	2.14	7.99	4.91	6.58
DCUSIHG	DM62UG5	Vemurafenib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.46	4.76	2.05	1.6
DCXMVW3	DM62UG5	Vemurafenib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	15.13	15.99	6.82	4.75
DC5RF4H	DM62UG5	Vemurafenib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.59	3.96	2.32	1.61
DC1PFT6	DM62UG5	Vemurafenib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	7.89	17.95	11.64	18
DC9K490	DM62UG5	Vemurafenib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	6.36	5.54	0.57	2.78
DC0M044	DM62UG5	Vemurafenib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.04	3.89	3.61	8.47
DCASCLM	DM62UG5	Vemurafenib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	1.18	2.84	2.2	0.95
DCLO9BA	DM62UG5	Vemurafenib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.51	5.78	3.48	2.47
DC29V3V	DM62UG5	Vemurafenib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.3	5.14	2.54	2.35
DCN85WP	DM62UG5	Vemurafenib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	11.39	11.44	8.61	6.09
DCLV3TU	DM62UG5	Vemurafenib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.96	1.62	3.34	6.25
DCEQ7CB	DM62UG5	Vemurafenib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.22	3.12	0.53	1.16
DC6MVZI	DM62UG5	Vemurafenib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	12.2	11.84	2.43	0.67
DC5175T	DM62UG5	Vemurafenib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	0.74	5.09	1.3	5.97
DC0R7EY	DM62UG5	Vemurafenib	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	0.16	8.45	5.68	5.68
DCGD34V	DM62UG5	Vemurafenib	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	2.06	5.4	1.72	1.97
DCKNOV8	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	18.85	20.61	17.41	17.47
DCWDJ7M	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	24.39	23.13	20.97	21.67
DCX4V28	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	25.48	20.43	16.75	16.75
DC38VHF	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	15.89	13.38	12.63	11.4
DCNPD62	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.82	4.74	2.77	3.94
DCQP8CV	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	22.62	23.89	21.46	22.13
DC75NC1	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	29.38	23.55	4.71	4.71
DC4HP4E	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	24.7	28.56	19.4	16.8
DC9IRHW	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	8.82	10.05	8.55	10
DCPX94P	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	13.07	12.04	9.6	11.1
DCPOKL4	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	17.35	16.75	10.39	18.26
DC6J564	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	25.88	24.14	21.29	21.29
DC4QSK0	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	18.07	20.03	17.76	17.56
DCXI08Y	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	36.39	36.65	34.5	34.43
DCYV3QO	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	27.5	22.86	23.15	23.19
DCA533J	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	15.74	20.17	19.97	20.04
DCCMNUO	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	8.17	13.4	13.31	13.44
DCNYD2H	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	25.43	23.7	25.2	25.27
DCQT4Y1	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	16.98	16.98	13.74	15.57
DCAP0KL	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	0.91	2.36	0.66	0.84
DCS7X3S	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	18.6	17.82	14.95	14.88
DC15OV4	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	10.42	15.2	15.14	15.1
DC011S5	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	15.35	19.14	19.86	19.89
DCQ1ZBC	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	26.38	27.36	25.17	25.17
DCKFN6S	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	24.96	23.49	17.72	17.72
DCCYIUS	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	24.26	26.71	24.95	24.9
DCSKY2I	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	19.12	22.38	20.94	20.38
DCQ8Z73	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	16.3	15.34	13.35	13.35
DCM0TGK	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	5.22	11.1	9.05	9.05
DC9WWA4	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	22.56	24.79	24.69	24.4
DCQ0NHB	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	21.47	22.14	23.25	24.31
DCS9CG3	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	21.83	20.28	20.59	21.09
DCVQHZW	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	8.19	8.69	7.38	9.15
DC82YZ1	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	5.55	8.71	9.23	9.37
DCOO583	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.81	9.62	8.55	5.45
DCRAZRU	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	25.23	29.43	24.29	23.36
DC1IN24	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.25	10.95	9.8	9.42
DCJAPNR	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.95	4.43	3.35	3.35
DCWG8IE	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	11.48	16.82	16.2	16.2
DCT1WMY	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	14.67	17.8	17.02	17.2
DCD3D9F	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	8.52	10.69	6.62	3.32
DCSTHBE	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	20.57	22	19.8	19.87
DCZEDLB	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	4.71	6.59	5.23	5.2
DCSCYQT	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	2.67	7.21	7.39	7.13
DCFAJ2B	DM62UG5	Vemurafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	17.8	18.05	16.05	16.05
DC66S7Q	DM62UG5	Vemurafenib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	1.74	4.46	2.89	3.16
DC973SE	DM62UG5	Vemurafenib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	7.55	11.67	14.21	14.24
DCMXYYK	DM62UG5	Vemurafenib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	2.24	7.39	4.45	3.6
DCQT8DI	DM62UG5	Vemurafenib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	0.9	6.48	6.05	5.74
DCLP7BA	DM62UG5	Vemurafenib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.14	5.41	3.84	2.54
DCBDZTW	DM62UG5	Vemurafenib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.2	3.43	2.34	1.43
DCDOS0P	DM62UG5	Vemurafenib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	9.51	10.19	8.58	7.36
DCGEHZ1	DM62UG5	Vemurafenib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.46	5.57	3.88	4.26
DCYEJHW	DM62UG5	Vemurafenib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	5.87	10.5	8.58	6.5
DCQ3NHP	DM62UG5	Vemurafenib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.28	3.12	2.01	1.38
DCW6GLT	DM62UG5	Vemurafenib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	0.27	9	5.87	6.88
DC4WMD4	DM62UG5	Vemurafenib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	5.31	9.81	3.54	1.72
DCIJWAR	DM62UG5	Vemurafenib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.36	3.85	2.49	1.76
DCB2BQ4	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	7.19	7.17	2.4	4.3
DCVCSDD	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.16	7.15	1.75	6.18
DCVJGOT	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	6.06	7.26	3.72	7.82
DCLL0E6	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	0.73	5.4	1.31	2.98
DC2WI1N	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	21.64	22.02	15	20.29
DC5FT5P	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	14.04	12.89	11.33	13.45
DCPQ4N4	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	10.2	10.59	10.75	12.89
DCMCAMO	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.78	5.33	2.85	7.93
DC5QA30	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	4.73	4.43	1.69	3.07
DC8DZL7	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	2.46	6.3	4.94	6.66
DCJ5CCN	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	4.02	6.51	5.25	7.01
DCGF7QX	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	8.35	9.88	2.82	8.05
DC8T9WI	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	9.18	8.31	3.81	7.23
DCVTBS0	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.64	7.32	4.67	5.36
DCTYLNY	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	6.32	5.51	8.3	13.2
DC2G8CE	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	5.54	7.63	5.98	8.61
DCTIEM3	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.77	8.79	7.28	8.21
DCSHACK	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	6.67	5.98	0.89	7.27
DCKTI38	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	15.83	15.23	2.82	10.99
DCFRRS4	DM62UG5	Vemurafenib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	6.72	11.73	7.36	10.11
DCGWQH0	DM62UG5	Vemurafenib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.77	5.17	1.63	1.86
DC03RU3	DM62UG5	Vemurafenib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	15.25	21.24	11.61	11
DCWSQQK	DM62UG5	Vemurafenib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.67	6.64	0.85	0.8
DCAJTSY	DM62UG5	Vemurafenib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.67	12.57	11.63	8.92
DCV2PB9	DM62UG5	Vemurafenib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	8.52	15.64	2.4	12.52
DC8I94F	DM62UG5	Vemurafenib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.9	10.44	0.48	10.08
DCTYFNK	DM62UG5	Vemurafenib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	8.57	8.47	6.61	8.34
DCYVLAV	DM62UG5	Vemurafenib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	1.51	8.55	4.84	9.03
DCGVOWP	DM62UG5	Vemurafenib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	4.01	10.37	9.78	11.32
DCK3NJS	DM62UG5	Vemurafenib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	9.7	11.77	5.48	10.51
DCO07YW	DM62UG5	Vemurafenib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	9.84	11.39	0.03	9.22
DCENWUQ	DM62UG5	Vemurafenib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	0.83	5	3.42	3.18
DCJV67P	DM62UG5	Vemurafenib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	6.16	4.88	1.78	4.93
DC8L4QU	DM62UG5	Vemurafenib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	8.04	9.17	5.79	9.84
DCUG9EQ	DM62UG5	Vemurafenib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	11.4	12.63	10.77	8.12
DCA6DAM	DM62UG5	Vemurafenib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.57	5.55	3.91	3.67
DCZSFXT	DM62UG5	Vemurafenib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.16	2.49	1.05	1.41
DCU7Y52	DM62UG5	Vemurafenib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	7.58	7.52	1.02	8.16
DCCTHFD	DM62UG5	Vemurafenib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.92	1.04	3.13	6.45
DCJH50E	DM62UG5	Vemurafenib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.24	3.06	7.41	10.22
DCJI54G	DM62UG5	Vemurafenib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.89	2.12	3.94	5.22
DCSW6FS	DM62UG5	Vemurafenib	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	2.92	4.81	0.62	6.73
DCI0LLP	DM62UG5	Vemurafenib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	4.79	9.4	8.04	10.3
DCAJXYV	DM62UG5	Vemurafenib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	5.54	5.79	3.89	8.21
DCU6020	DM62UG5	Vemurafenib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.91	3.3	1.67	6.71
DCSMEQH	DM62UG5	Vemurafenib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	6.12	5.61	13.06	15.08
DC3WVTI	DM62UG5	Vemurafenib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	6.58	7.35	5.9	9.41
DCIBUAX	DM62UG5	Vemurafenib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2	3.28	3.92	6.47
DC91KK3	DM62UG5	Vemurafenib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.79	3.16	1.85	4.39
DCSOI0K	DM62UG5	Vemurafenib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	0.71	10.91	7.41	8.39
DCQN6LK	DM62UG5	Vemurafenib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.34	0.83	0.34	0.35
DC1RVM0	DM62UG5	Vemurafenib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.19	1.93	0.97	0.98
DC8QUQ9	DM62UG5	Vemurafenib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.58	2.63	0.17	0.17
DCXN20E	DM62UG5	Vemurafenib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.27	6.49	4.4	4.32
DC5H598	DM62UG5	Vemurafenib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.39	3.96	3.79	3.3
DCMTEEO	DM62UG5	Vemurafenib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	6.2	5.83	5.89	5.69
DC2DVFT	DM62UG5	Vemurafenib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.19	2.65	3.3	3.42
DCRQR3H	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.61	11.16	8.01	8.01
DCLE032	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	7.99	7.78	6.74	5.35
DCJEAXE	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.48	6.11	2.35	2.38
DCWZDJQ	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.57	4.57	2.2	2.2
DCXMIGI	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.72	11.85	9.89	10.12
DCM9RZ0	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	15.67	13.89	4.08	2.33
DCNXUP5	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	2.21	10.29	7.9	7.78
DCZDZK9	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	0.08	1.82	0.33	0.33
DCIU4WO	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	3.75	8.99	6.44	5.88
DCXHJG4	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.83	6.61	0.61	0.8
DC0UZ9T	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.52	5.52	3.1	3.1
DCIZWUD	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.71	6.74	6.19	5.18
DCQXBOS	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	5.86	3.22	1.16	1.16
DCCANZU	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.29	7.54	5.52	5.46
DCZO15L	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.25	7.98	7.9	7.54
DC3GULW	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.01	6.85	4.43	2.36
DC5YRXJ	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.34	11.15	10.08	9.67
DCUZN1R	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.22	5.2	3.8	3.8
DCRNDL8	DM62UG5	Vemurafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	3.07	7.63	5.54	5.59
DCT012Z	DM62UG5	Vemurafenib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	0.84	1.45	1.19	1.61
DCAP27Y	DM62UG5	Vemurafenib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	5.25	7.89	5.32	4.02
DC6L973	DM62UG5	Vemurafenib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	11.2	14.37	12.11	10.98
DC2K4HS	DM62UG5	Vemurafenib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	1.46	6.15	6.33	7.9
DCEMB2P	DM62UG5	Vemurafenib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	0.67	4.58	2.71	4.58
DC71HE3	DM62UG5	Vemurafenib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.39	4.48	2.28	1.14
DCYO5TT	DM62UG5	Vemurafenib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.52	5.78	3.19	2.97
DC1A7LL	DM62UG5	Vemurafenib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	7.21	6.94	0.98	6.22
DCA3ZM0	DM62UG5	Vemurafenib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.48	6.84	1.52	1.17
DCQNTXV	DM62UG5	Vemurafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.07	7.74	2.3	2.05
DCYS3NL	DM62UG5	Vemurafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.47	10.22	8.71	8.18
DCMBIZX	DM62UG5	Vemurafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.73	8.46	7.05	5.76
DCELYBC	DM62UG5	Vemurafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.8	1.86	0.97	0.7
DC8WZSH	DM62UG5	Vemurafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	11.17	11.76	7.72	7.2
DC9A563	DM62UG5	Vemurafenib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	3.88	5.89	2.49	3.94
DCONYNU	DM62UG5	Vemurafenib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	10.38	13.5	4.6	6.64
DC9JJL8	DM62UG5	Vemurafenib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.46	5.67	1.63	6.83
DCL114G	DM62UG5	Vemurafenib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	2.51	1.92	3.42	4.84
DC57H0M	DM62UG5	Vemurafenib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	3.28	5.43	2.47	6.82
DC01N7V	DM62UG5	Vemurafenib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	5.67	5.78	5.52	6.66
DCEDVQR	DM62UG5	Vemurafenib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	6.23	7.65	11.84	14.3
DCGVF3Z	DM62UG5	Vemurafenib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	9.49	9.82	5.65	10.38
DC19SAM	DM62UG5	Vemurafenib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.29	5.38	2.34	6.62
DCGH6TV	DM62UG5	Vemurafenib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	15.47	13.97	12.08	15.71
DCJG8TE	DM62UG5	Vemurafenib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	26.27	26.85	22.98	27.71
DCLPGLM	DM62UG5	Vemurafenib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	3.73	10.96	7.67	10.8
DCYZA87	DM62UG5	Vemurafenib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	9.56	11.11	4.86	11.81
DC4O27L	DM62UG5	Vemurafenib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.89	2.14	3.2	6.31
DC1AQE5	DM62UG5	Vemurafenib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.48	3.38	6.78	8.91
DCXTZCI	DM62UG5	Vemurafenib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.43	1.38	1.7	4.55
DCMNEM6	DM62UG5	Vemurafenib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.37	1.21	5.32	6.4
DC0OBFN	DM62UG5	Vemurafenib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.42	6.21	0.74	5.14
DC2SQTT	DM62UG5	Vemurafenib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	0.07	6.98	8.23	8.33
DCT21A4	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	6.58	12.94	9.7	8.93
DCMEGOI	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.99	3.23	2.12	1.04
DCSM29I	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.9	5.33	4	2.07
DCU59AE	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.27	5.52	2.84	1.72
DC37E6D	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	2.24	6.68	4.03	3.67
DCP38FI	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	4.45	6.89	3.05	2.36
DCS3DOS	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	4.43	8.1	1	4.87
DCRR70K	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	5.69	6.11	4.17	4.63
DCO73N6	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	0.11	5.96	4.69	6.16
DCSVOSO	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	7.69	9.61	6.65	5.46
DCOKXJM	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.83	5.16	3.1	2.91
DCAPZ67	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.4	3.22	1.24	0.38
DC9RZS7	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.09	4.57	1.37	0.93
DC8FJB0	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.43	10.49	9.47	7.64
DC5ERI8	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	4.27	9.66	7.02	5.92
DCBJ5J9	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	3.42	5.66	3.56	3.26
DC683PV	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.3	3.82	3.73	2.93
DCI6IDY	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	7.17	6.55	1.62	8.29
DCUSHKP	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.04	6.57	3.12	1.26
DC9RYK0	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	9.88	10.82	1.96	9.42
DC6GNXZ	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	9.99	9.44	3.67	9.01
DCGAX2H	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.68	7.83	2.12	1.74
DC6JHES	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.01	4.65	3.54	3.18
DCY95VW	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.56	4	1.5	1.45
DC9QB02	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	4.87	10.17	6.63	8.34
DCEAIH5	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	6.29	22.39	13.88	12.44
DCA7WKK	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.59	11.16	5.36	6.47
DC9SLJS	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.13	6.86	1.95	5.39
DC1Z0UZ	DM62UG5	Vemurafenib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	1.36	7.76	5.71	5.61
DC7GC4Y	DM62UG5	Vemurafenib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	21.16	20.72	7.56	18.58
DC66MDC	DM62UG5	Vemurafenib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.63	3.07	2.5	6.47
DCBG4ID	DM62UG5	Vemurafenib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	19.09	20.28	0.17	18.42
DC7ULW5	DM62UG5	Vemurafenib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	15.26	18.63	2.28	16.91
DCZ7S1A	DM62UG5	Vemurafenib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	10.29	5.59	2.63	6.7
DCXU1JN	DM62UG5	Vemurafenib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	1.69	6.89	4.88	6.73
DCX1M0V	DM62UG5	Vemurafenib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	16.7	15.88	11.22	13.89
DCR3OTO	DM62UG5	Vemurafenib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.39	0.44	3.92	5.16
DCGXDYX	DM62UG5	Vemurafenib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	9.66	10.15	5.96	11.71
DCMLDX1	DM62UG5	Vemurafenib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.87	4.54	2.99	5.29
DCTA3VG	DM62UG5	Vemurafenib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.91	7.25	1.81	5.11
DCHKEHV	DM62UG5	Vemurafenib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	11.71	9.62	3.49	8.34
DCQPX0L	DM62UG5	Vemurafenib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	2.66	5.32	0.81	5.22
DCSIKAE	DM62UG5	Vemurafenib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.47	6.74	0.95	3.05
DCSIW82	DM62UG5	Vemurafenib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	0.6	0.98	0.37	2.13
DC7E5LL	DM62UG5	Vemurafenib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	2.29	2.83	0.26	3.75
DCW2AW3	DM62UG5	Vemurafenib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	0	1.91	3.08	4.23
DCO4E7Q	DM62UG5	Vemurafenib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.25	0.95	0.02	3.98
DC7XHXM	DM62UG5	Vemurafenib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	5.34	4.63	1.83	6.71
DCSOVD1	DM62UG5	Vemurafenib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	6.21	7.95	6.51	10.12
DCI4L77	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	7.07	6.2	8.45	9.47
DC9GAAC	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	13.74	13.93	14.9	15.76
DCTACOE	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	15.37	8.35	6.17	10.34
DC15YFY	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	4.32	8.43	7.84	10
DCB8G8P	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	7.06	10.31	9.91	11.43
DC23FJP	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	6.83	13.42	11.75	14.09
DCCQXLI	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	7.23	10.2	9.66	12.32
DCM492V	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	9.72	13.83	7.06	16.75
DCK6GE5	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	6.38	6.33	11.47	11.93
DC3PF7Z	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	11.78	11.3	11.73	14.18
DCC1N6T	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	13.28	12.6	18.36	19.33
DCNOFM3	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.91	3.77	8.53	9.42
DCOBAGD	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	5.27	5.39	2.52	4.89
DC59RVX	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	10.43	13.4	11.31	14.48
DCUK71T	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	9.05	12.19	11.37	14.54
DCRMUNX	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	7.2	11.8	9.02	10.74
DC8TNUI	DM62UG5	Vemurafenib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	8.91	11.47	11.71	14.06
DC6ZOQW	DM62UG5	Vemurafenib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.74	4.4	3.01	1.51
DC9F4QF	DM62UG5	Vemurafenib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.77	4.51	2.72	2.5
DC0X2RZ	DM62UG5	Vemurafenib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	15.14	13.95	4.56	2.66
DC75W88	DM62UG5	Vemurafenib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	1.17	6.26	3.08	3.34
DCNA32Y	DM62UG5	Vemurafenib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	4.47	5.73	4.27	1.81
DCIVTHE	DM62UG5	Vemurafenib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.73	4.82	2.49	2.16
DCVF3ZJ	DM62UG5	Vemurafenib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.53	6.39	4.36	4.27
DCX3Y5O	DM62UG5	Vemurafenib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.06	6.71	0.69	0.69
DCJ5S5U	DM62UG5	Vemurafenib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	4.69	3.51	1.42	2.42
DCV2FAF	DM62UG5	Vemurafenib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.1	5.12	3.88	4.41
DCM40Y4	DM62UG5	Vemurafenib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	6.61	13.81	10.3	6.91
DC9Z977	DM62UG5	Vemurafenib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.58	6.38	1.23	4.58
DC48YAO	DM62UG5	Vemurafenib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.19	4.98	3.73	3.51
DC7MLZO	DM62UG5	Vemurafenib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	3.09	3.78	1.68	0.38
DCLQZXG	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2	3.47	0.41	0.12
DCXOTWU	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	1.83	6.18	3.16	3.2
DCKKYRH	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	1.92	2.94	0.63	0.63
DCGLLZH	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	2.98	10.51	8.54	6.78
DC9T6FL	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	14.85	15.91	1.43	15.73
DCD245X	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	4.44	10.06	0.2	8.82
DCWQFVC	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	4.79	7.07	3.85	7.95
DCYAYUU	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.96	7.2	4.76	4.97
DC5MOAO	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	4.03	8.88	6.83	6.49
DC1J71B	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.79	4.95	2.76	2.9
DC3NV5J	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.69	3.56	8.91	11.46
DCKBZ4P	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.96	1.93	6.07	8.21
DCOFPPI	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.15	3.43	1.74	0.55
DCPIXIN	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.8	7.66	6.69	6.24
DCZ1YTR	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	5.45	5.1	1.23	0
DCKZNOH	DM62UG5	Vemurafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.39	4.74	3.33	3.3
DCA0WQ6	DM62UG5	Vemurafenib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.03	7.03	4.21	10.77
DCN5NOW	DM62UG5	Vemurafenib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	31.48	31.85	19.31	25.21
DC2MWY3	DM62UG5	Vemurafenib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	1.87	10.85	0.18	7.06
DCOY3XQ	DM62UG5	Vemurafenib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	2.5	10.67	7.82	8.45
DCVKSKH	DM62UG5	Vemurafenib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	6.22	11.63	8.65	9.67
DCHPZ1D	DM62UG5	Vemurafenib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	7.11	5.81	4.17	8.92
DCDACK7	DM62UG5	Vemurafenib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	6.75	6.08	6.89	9.85
DCC61HU	DM62UG5	Vemurafenib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.75	5.46	1.96	1.7
DCZ1ICY	DM62UG5	Vemurafenib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	0.71	6.75	5.02	7.75
DCUH7HV	DM62UG5	Vemurafenib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.04	4.28	4.36	6.86
DCXJWF5	DM62UG5	Vemurafenib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	5.85	9.29	4.61	11.21
DC17ZFO	DM62UG5	Vemurafenib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	27.86	27.72	0.23	25.22
DCDC4JX	DM62UG5	Vemurafenib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	3.7	13.3	3.37	12.79
DC06JX4	DM62UG5	Vemurafenib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	5.82	14.15	5.33	13.47
DCR5GOS	DM62UG5	Vemurafenib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	16.66	18.23	1.07	18.35
DCL97SP	DM62UG5	Vemurafenib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	7.21	9.34	0.1	11.45
DCZC3GG	DM62UG5	Vemurafenib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	24.97	24.29	6.8	23.99
DCKRXJ2	DM62UG5	Vemurafenib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	9.93	9.28	11.02	12.81
DCE15QU	DM62UG5	Vemurafenib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.78	6.51	10.85	12.96
DC6YLPD	DM62UG5	Vemurafenib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	19.47	24.87	5.85	21.54
DCCJA8M	DM62UG5	Vemurafenib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	9.67	11.29	6.26	10.84
DCA6H18	DM62UG5	Vemurafenib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.98	7.87	3.53	9.42
DCDXBUI	DM62UG5	Vemurafenib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	7.28	15.07	7.63	14.68
DCFBDE9	DM62UG5	Vemurafenib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.93	10.95	1.81	8.67
DC5UWF8	DM62UG5	Vemurafenib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.35	3.73	2.43	0.16
DCRNMFJ	DM62UG5	Vemurafenib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	18.16	16.22	9.78	18.55
DC38M64	DM62UG5	Vemurafenib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	18.44	18.49	14.66	20.72
DCI1N4J	DM62UG5	Vemurafenib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	0.96	6.35	3.91	4.08
DCBKY6H	DM62UG5	Vemurafenib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	8.15	9.15	2.81	10.74
DCOAZB9	DM62UG5	Vemurafenib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	6.77	6.55	0.95	7.78
DCG07QS	DM62UG5	Vemurafenib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	5.17	6.14	1.23	6.08
DCL8Y3E	DM62UG5	Vemurafenib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	5.6	10.21	7.83	9.99
DCT1W3L	DM62UG5	Vemurafenib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	2.89	9.13	9.25	8.78
DC2HB7K	DM62UG5	Vemurafenib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	7.1	7.61	4.23	5.09
DCLA43W	DM62UG5	Vemurafenib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	2.99	2.97	1.45	3.92
DCDGYDO	DM62UG5	Vemurafenib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	7.2	9.13	5.27	6.96
DCMENQZ	DM62UG5	Vemurafenib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	2.27	2.93	2.14	3.86
DCR81DC	DM62UG5	Vemurafenib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	4.6	5.08	5.06	7.14
DCW18LO	DM62UG5	Vemurafenib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	6.6	6.94	4.4	5.65
DCOVCSJ	DM62UG5	Vemurafenib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.41	6.06	9.85	12.49
DCMP9CA	DM62UG5	Vemurafenib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	10.67	6.2	0.14	3.27
DC1S73L	DM62UG5	Vemurafenib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	3.74	6.59	2.69	4.81
DCIIZ2R	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.6	6.72	9.12	11.58
DCOKI2P	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	8.61	7.75	3.14	12.02
DCFKYUC	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	12.07	13.15	12.06	14.52
DCK10LF	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	5.47	7.94	5.84	9.59
DCWWEU2	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	13.62	12.11	11.67	12.9
DCPYZC1	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	12.28	12.45	9.9	13.01
DC8S4R5	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	7.38	7.61	6.59	11.57
DCY211K	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	15.24	15.18	13.4	18.46
DCJL4GD	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	10.51	11.25	0.94	11.98
DCO0U6R	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.42	6.03	10.35	12.5
DCE96GM	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.48	3.99	10.66	13.04
DCVFHJ2	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	10.14	11.27	9.26	12.32
DC129IN	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	6.94	5.87	5.23	10.08
DCQJLFT	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4.15	4.92	2.69	6.02
DCXSVR7	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	10.63	11.29	6.87	12.22
DCT015L	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.2	6.48	2.57	6.07
DCR6XPJ	DM62UG5	Vemurafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	1.54	7.85	7.44	10.44
DC3AZUN	DM62UG5	Vemurafenib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.88	5.52	1.37	0.11
DCF32SD	DM62UG5	Vemurafenib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2	4.4	1.27	1.25
DC3QTEN	DM62UG5	Vemurafenib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.34	8.87	4.76	5.3
DCYWUVZ	DM62UG5	Vemurafenib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	4.34	7.48	4.27	8.35
DCN4LMR	DM62UG5	Vemurafenib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	1.19	3.27	3.48	3.65
DCEHE2P	DM62UG5	Vemurafenib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.63	8.08	0.63	2.38
DCE0D6V	DM62UG5	Vemurafenib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.63	3.37	0.85	1.16
DC1N1R7	DM62UG5	Vemurafenib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	4.72	6.26	3.89	3.89
DCUKLVP	DM62UG5	Vemurafenib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.24	5.71	1.98	3.62
DC3T3G5	DM62UG5	Vemurafenib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.22	9.77	1.23	6.63
DCN2CQC	DM62UG5	Vemurafenib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.57	5.83	1.8	2.3
DCPE7K0	DM62UG5	Vemurafenib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.35	11.44	5.01	5.39
DCJL033	DM62UG5	Vemurafenib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	3.41	9.88	7.19	3.45
DCO5CVJ	DM62UG5	Vemurafenib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	0.86	4.52	0.99	2.08
DC69IXT	DM62UG5	Vemurafenib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	2.93	4.51	1.22	5.2
DCA97BY	DM62UG5	Vemurafenib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.5	1.25	2.36	6.26
DC8G7JL	DM62UG5	Vemurafenib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.39	3.21	0.82	6
DCVUFQ5	DM62UG5	Vemurafenib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	12.96	14.93	6.84	13.17
DCKJGUB	DM62UG5	Vemurafenib	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.1	4.73	3.12	1.53
DC5G4R1	DM62UG5	Vemurafenib	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	18.4	15.31	5.12	0.48
DCMOAAC	DM62UG5	Vemurafenib	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	SYNERGxDB Database	Investigative	T98G	45.83	45.83	44.87	44.87
DCCUXPA	DM62UG5	Vemurafenib	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.33	6.05	3.05	3.86
DCGFYPI	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	8.48	13.39	10.55	9.35
DCPFIWU	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.8	5.22	2.02	0.9
DCLR6T2	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.41	7.95	4.17	3.7
DC7CVQJ	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.05	12.85	6.13	11.65
DC4Z0RZ	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	0.4	3.58	2.87	3.13
DCA5Z2U	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	3.14	7.01	5.46	7.24
DC4GPVI	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	0.65	5.17	2.78	3.69
DCCPTFX	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	5.06	5.89	5.94	7
DC4HKRM	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.78	4.28	2.18	1.83
DC9A2DD	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.13	5.25	0.86	2.65
DCEKSSN	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.3	3.81	3.53	2.08
DCJPST8	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.74	8.33	4.49	4.8
DCCXKGE	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	5.1	9.14	1.23	8.61
DC40TN1	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	7.59	11.87	8.36	8.1
DC83W8L	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.96	8.01	7.65	5.38
DCF13QT	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.86	4.03	2.25	2.18
DC4V7SD	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	6.27	12.53	9.57	11.58
DC3W0W3	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	9.91	13.04	7.68	5.49
DCE2FD8	DM62UG5	Vemurafenib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.93	8.22	5.92	5.63
DCG9OM7	DM62UG5	Vemurafenib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	1.22	6.46	2.35	6.67
DCUHGY8	DM62UG5	Vemurafenib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	6.67	15.13	4.12	8.92
DC33FIN	DM62UG5	Vemurafenib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	0.52	3.03	0.35	1.28
DCULXHR	DM62UG5	Vemurafenib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.96	5.07	0.86	2.46
DCV2M2A	DM62UG5	Vemurafenib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.03	20.94	19.17	18.64
DCZS8YW	DM62UG5	Vemurafenib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.63	9.8	8.48	7.66
DCXJYOJ	DM62UG5	Vemurafenib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.9	2.77	2.25	3.13
DCTX8I9	DM62UG5	Vemurafenib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	11.53	13.29	0.96	11.06
DCG9FEZ	DM62UG5	Vemurafenib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	1.27	3.46	1.46	4.18
DCJCMNN	DM62UG5	Vemurafenib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	12.09	12.1	1.58	13.13
DCB9TIJ	DM62UG5	Vemurafenib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	7.1	7.33	7.44	10.03
DCFXYDM	DM62UG5	Vemurafenib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	3.43	7.61	4.48	10.25
DCGJXCB	DM62UG5	Vemurafenib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	6.36	8.95	1.04	7.59
DCLZWWP	DM62UG5	Vemurafenib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	0.82	3.2	2.2	4.06
DCGVNST	DM62UG5	Vemurafenib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	6.81	11.29	0.15	9.6
DCXPCF2	DM62UG5	Vemurafenib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.65	1.84	4.97	7.48
DCA6P5H	DM62UG5	Vemurafenib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	7.14	6.51	14.52	16.56
DCBKHWY	DM62UG5	Vemurafenib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	9.32	9.61	3.29	11.23
DC37G36	DM62UG5	Vemurafenib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.24	5.73	4.94	4.58
DCDKMLJ	DM62UG5	Vemurafenib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	15.72	18.68	5.34	10.07
DC1V05R	DM62UG5	Vemurafenib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	14.79	17.89	12.15	20.55
DCB13M2	DM62UG5	Vemurafenib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	1.16	4.59	5.57	1.42
DCRSKA7	DM62UG5	Vemurafenib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	0.45	1.8	0.31	0.31
DCXOPIA	DM62UG5	Vemurafenib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	8.51	7.77	7.15	7.23
DC2C8W6	DM62UG5	Vemurafenib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.68	3.92	1.9	5.18
DC6BIYS	DM62UG5	Vemurafenib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.52	1.11	3.81	4.77
DCI51X2	DM62UG5	Vemurafenib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.78	5.89	4.06	8.03
DCTB00B	DM62UG5	Vemurafenib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	2.45	1.15	1.21	1.83
DCD00EV	DM62UG5	Vemurafenib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.89	6.14	6.49	8.06
DCJXIE1	DM62UG5	Vemurafenib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.17	2.84	1.56	5.53
DCDOCGY	DM62UG5	Vemurafenib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.58	2.02	0.9	1.07
DCJ146O	DM62UG5	Vemurafenib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.71	6.14	2.02	4.71
DC1IWZQ	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	7.31	7.81	5.01	5.34
DCUS1SA	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	3.66	7.89	3.98	5.49
DC05QQO	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	15.03	18.76	14.52	17.13
DCCCS63	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	5.1	5.07	0.89	5.03
DC36LWS	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	22.06	23.4	16.75	21.13
DCOUX7J	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	6.76	8.52	7.26	9.03
DC2VNAL	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	6.77	7.59	9.02	10
DC9LLTD	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	9.31	8.77	3.83	10.33
DCGURRG	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	1.54	1.56	0.13	2.14
DCBNDYL	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	4.75	7.82	1.71	5.17
DCHO2UV	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	16.1	16.36	12.51	13.77
DC1VBZM	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.65	9.32	6.64	7.56
DCTJ919	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.64	2.14	2.86	6.82
DC3A3M2	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.44	5.48	10.79	13.15
DCLKA7T	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	10.62	12.34	7.29	11.76
DCTWX7M	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	7.93	10.08	5.43	6.8
DCQLPX0	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	7.06	9.83	5.57	10.72
DCOW5VF	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.32	4.47	3.41	3.86
DCR8L8N	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	8.95	8.01	0.78	8.3
DCWAQTC	DM62UG5	Vemurafenib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	14.49	17.27	7.62	13.54
DC58HRN	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.13	4.09	1.5	2.69
DC38X64	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	10.53	14.64	5.41	4.13
DCMQFCW	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.88	6.65	3.78	5
DCHKPDP	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.93	3.71	2.82	4.36
DCB5B60	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	14	15.17	14.26	16.68
DCCOGH2	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	0.84	4.61	2.29	1.96
DCTZ2YQ	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	1.36	6.55	6.32	6.42
DCTU84S	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	0.48	3.5	2.49	3.59
DC7I4O5	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	0.87	2.22	3.87	3.95
DC29OJS	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	7.48	8.53	5.45	6.88
DCE42W4	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.71	6.64	3.32	5.02
DC5QEY2	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	0.92	2.64	1.1	1.15
DCTINME	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.86	3.07	0.45	0.84
DCNUTPF	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.06	2.07	1.15	0.98
DCKP6B0	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.3	7.08	5.7	5.74
DCHVQU8	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.04	1.3	3.75	4.96
DC1XRDQ	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.8	2.6	0.7	2.49
DCN80NH	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.6	6.01	4.87	5.28
DC8KN7T	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.53	11.25	7.84	7.67
DCB1US3	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.69	3.46	1.22	2.37
DCR8A84	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	3.81	5.01	2.9	4.77
DCSXUYR	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	0.84	10.48	6.15	5.75
DCJ45H4	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	6.08	2.95	1.05	1.11
DCSUUFW	DM62UG5	Vemurafenib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	0.11	8.7	10.49	10.58
DC2PPXA	DM62UG5	Vemurafenib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	10.99	8.63	4.08	7.07
DCL88PK	DM62UG5	Vemurafenib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	5.84	5.36	5.76	8.25
DCQ8G3T	DM62UG5	Vemurafenib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	9.43	9.47	9.86	12.1
DCWOCOK	DM62UG5	Vemurafenib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	5.43	10.31	6.3	7.9
DCDAQG5	DM62UG5	Vemurafenib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	6.65	6.04	9.96	11.07
DCBMHRS	DM62UG5	Vemurafenib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.52	6.01	6.04	8.97
DCB91CN	DM62UG5	Vemurafenib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	7.52	10.02	3.47	5.4
DCTOU8B	DM62UG5	Vemurafenib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1	4.27	1.23	4.55
DCD4K9X	DM62UG5	Vemurafenib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.6	11.77	9.02	10.85
DCIULU8	DM62UG5	Vemurafenib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	0.96	1.43	0.74	3.74
DCYX3ND	DM62UG5	Vemurafenib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.91	1.34	3.6	5.56
DCONBC5	DM62UG5	Vemurafenib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	22.18	14.3	9.5	17.63
DCZ4BW0	DM62UG5	Vemurafenib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	7.14	6.41	7.15	12.49
DCB0MS8	DM62UG5	Vemurafenib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	21.79	16.69	6.1	17.48
DC8LDBT	DM62UG5	Vemurafenib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	7.48	7.69	6.38	9.79
DCRTOVS	DM62UG5	Vemurafenib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	11.09	11.39	5.28	13.74
DC48UHP	DM62UG5	Vemurafenib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.7	3.39	7.55	9.68
DCHW3PZ	DM62UG5	Vemurafenib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	10.23	10.17	12.46	15.86
DCTC6C1	DM62UG5	Vemurafenib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.7	7.65	11.73	12.85
DCI7XQ5	DM62UG5	Vemurafenib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	10.83	10.48	12.79	14.17
DCKRTC0	DM62UG5	Vemurafenib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	9.81	9.94	7.42	10.49
DCUB5TH	DM62UG5	Vemurafenib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	16.37	16.57	14.21	17.84
DCFNBPG	DM62UG5	Vemurafenib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	16.61	16.91	12.9	16.04
DCHPWHI	DM62UG5	Vemurafenib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	2.9	4.16	2.01	6.19
DCYHRRL	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	4.42	17.61	14.92	14.05
DCD3UUG	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	7.3	11.81	10.78	9.48
DC6PDQ1	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.07	13.11	8.72	9.26
DCVMAQO	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	8.89	13.2	11.25	10.6
DC8JDUS	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	8.97	12.17	10.36	9.27
DCKEGKZ	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	9.96	10.29	8.53	6.91
DCAFV6K	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	16.54	25.52	8.04	2.04
DC7SNBR	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	38.79	27.89	3.02	1.52
DCA8BQF	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	17.33	20.74	17.79	18.38
DCIUQEC	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	9.72	16.17	16.96	17.66
DCEXFZK	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	2.25	4.08	1.93	0.89
DCZ145J	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	9.49	15.4	12.15	12.62
DCHHSHW	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	10.84	14.71	9.09	12.63
DCYJTYD	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	1.61	10.33	2.27	10.35
DCIXJZ2	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	20.56	21.3	22.69	23.74
DCXU1CI	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	11.9	19.73	16.83	15.2
DCMOTMH	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	11.93	13.75	14.07	14.87
DCR2YYE	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.18	9.14	6.38	6.74
DCMC9C8	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	10.8	16.56	13.72	14.34
DC6X8TI	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	7.75	14.06	8.28	7.96
DC7VHXT	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.13	5.5	4.21	3.31
DCCS9KD	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	12.01	13.98	12.55	10.53
DC77I6D	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	3.5	12.02	10.76	9.45
DC13R21	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	5.86	8.56	5.53	6.55
DCEBSQJ	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	10.73	18.31	14.59	13.65
DCV84ER	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.44	12.01	9.55	10.84
DCYC6FW	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	7.33	11.06	9.49	9.56
DCK3R4I	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.98	8.3	6.38	6.2
DCKORDW	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	11.83	21.45	21.22	21.87
DC939ZS	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	15.35	20.72	12.96	11.62
DCSOMCH	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.67	6.48	4.98	5.08
DCA82QP	DM62UG5	Vemurafenib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	0.22	6.95	4.55	4.93
DCCPS8A	DM62UG5	Vemurafenib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	3.8	11.27	7.74	8.89
DC2AL07	DM62UG5	Vemurafenib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	0.84	5.66	3.15	3.39
DCV5I59	DM62UG5	Vemurafenib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.94	4.2	2.29	1.46
DCDW36K	DM62UG5	Vemurafenib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.72	3.51	0.83	1.39
DC8YIVU	DM62UG5	Vemurafenib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.36	2.37	1.28	0.04
DCD6FFS	DM62UG5	Vemurafenib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	8.7	9.21	3.47	8.87
DCYIFTC	DM62UG5	Vemurafenib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	10.42	15.69	5.97	13.01
DCJ3BCN	DM62UG5	Vemurafenib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	0.26	1.23	0.09	1.74
DCLSUE4	DM62UG5	Vemurafenib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.91	4.85	1.19	3.17
DCY53QY	DM62UG5	Vemurafenib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	6.53	7.03	0.82	7.47
DCDJOXP	DM62UG5	Vemurafenib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.76	7.05	3.52	2.97
DCXTBXS	DM62UG5	Vemurafenib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.38	6.21	2.53	3.61
DCBIXMG	DM62UG5	Vemurafenib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	2.29	8.6	5.24	10.02
DCWJIMM	DM62UG5	Vemurafenib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	0.97	8.66	6.3	9.01
DCHUYJ0	DM62UG5	Vemurafenib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.78	3.52	0.21	1.01
DCGT4W1	DM62UG5	Vemurafenib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.58	4.29	1.39	4.27
DCF0X1E	DM62UG5	Vemurafenib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	11.69	17.76	3.26	13.14
DCOKFP0	DM62UG5	Vemurafenib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.06	2.72	0.82	4.38
DCAES0Z	DM62UG5	Vemurafenib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.56	5.5	3.17	2.82
DCHWMU1	DM62UG5	Vemurafenib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.71	1.63	0.52	0.3
DCSSP5N	DM62UG5	Vemurafenib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.96	3.5	2.09	2.09
DCF9F90	DM62UG5	Vemurafenib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.32	5	0.85	5.66
DCZIW8I	DM62UG5	Vemurafenib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	1.61	5.08	2.01	4.65
DC7UIIZ	DM62UG5	Vemurafenib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.31	3.72	1.62	1.12
DC8NA4Y	DM62UG5	Vemurafenib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.58	6.37	0.57	5.24
DCW1SDN	DM62UG5	Vemurafenib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.71	2.43	1.65	1.18
DC6DU99	DM62UG5	Vemurafenib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	2.24	6.24	4.91	7.59
DCG73CU	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.69	9.47	6.32	6.18
DC3XDZ7	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.75	14.5	4.06	4.06
DCTMQ91	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.67	6.62	2.92	2.92
DCWVDGI	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.47	2.83	0.4	0.22
DCXRMWK	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.77	8.17	6.55	5.86
DCB3R6H	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	3.79	7.12	4.84	3.37
DC3BOXK	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	2.33	4.34	1.48	1.38
DCIXGNL	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	1.15	2.64	0.31	0.05
DCRP6LU	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	4.03	7.06	4.82	3.93
DCU22AG	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	1.81	9.75	0	8.58
DCTD85S	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	0.87	4.76	3.37	3.26
DC1YQQI	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	1.85	6.28	3.46	3.22
DC8VCNR	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.87	6.06	3.57	3.45
DCE64Q2	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.58	4.37	2.47	2.09
DCE8GQX	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	10.51	8.88	3.32	2.99
DCDWLTZ	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.2	10.94	9.51	8.71
DCX7V7X	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	3.12	5.79	4.51	2.83
DCGFLBX	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.21	6.57	4.4	4.5
DCNC9XE	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.38	9.11	8.36	7.76
DCSDY3C	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.31	4.82	1.41	1.41
DCRMPQF	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.11	7.23	1.55	1.18
DC1BPA8	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.07	4.88	3.75	2.47
DC4H6K9	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.3	5.32	4.24	4.66
DC2G4KX	DM62UG5	Vemurafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	0.47	7.21	4.23	4.93
DCX2Y5S	DM62UG5	Vemurafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	13.22	15.36	6.39	12.59
DC1TOTN	DM62UG5	Vemurafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	14.22	14.26	3.33	17.14
DCF9QN6	DM62UG5	Vemurafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	13.09	13.29	6.98	14.97
DC7C2HB	DM62UG5	Vemurafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	7.47	8.2	1.36	9
DCDI7NC	DM62UG5	Vemurafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	5.62	12.62	7.88	12.68
DCM0MMJ	DM62UG5	Vemurafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	6.19	6.85	5.85	10.29
DC7XLUY	DM62UG5	Vemurafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	6.87	8.18	7.51	9.09
DCYXPH7	DM62UG5	Vemurafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.54	4.16	3.25	3.25
DC2A6E2	DM62UG5	Vemurafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	7.37	5.93	5.69	10.22
DC0KTCJ	DM62UG5	Vemurafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.75	5.41	8.81	10.89
DCBIUDG	DM62UG5	Vemurafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	15.13	17.73	9.19	13.23
DC76O3L	DM62UG5	Vemurafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	5.99	10.47	11.64	11.54
DCDXEZB	DM62UG5	Vemurafenib	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	9.05	8.15	1.92	9.76
DCFLPWD	DM62UG5	Vemurafenib	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	0.8	1.96	0.46	0.46
DCR5Y1F	DM62UG5	Vemurafenib	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	7.1	6.55	2.03	6.57
DCHLJYT	DM62UG5	Vemurafenib	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.92	6.08	7.5	10.7
DCDEKE4	DM62UG5	Vemurafenib	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	6.31	8.38	2.86	1.66
DC7QOZ8	DM62UG5	Vemurafenib	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	1.25	3.13	0.25	3.22
DC9FGQA	DM62UG5	Vemurafenib	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.82	4.32	2.91	2.57
DC9WRW5	DM62UG5	Vemurafenib	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	1.66	2.91	1.47	0.98
DCQ92SN	DM62UG5	Vemurafenib	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	3.22	3.49	1.33	1.29
DC1O6RS	DM62UG5	Vemurafenib	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.08	3.39	1.12	0.53
DCQRECU	DM62UG5	Vemurafenib	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.97	1.08	1.54	6.73
DCD1XIQ	DM62UG5	Vemurafenib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	8.31	6.64	7	11.04
DCO6T85	DM62UG5	Vemurafenib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	12.83	12.05	1.53	14.27
DCNGRG9	DM62UG5	Vemurafenib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	16.76	8.6	1.4	5.29
DCUVWMK	DM62UG5	Vemurafenib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	4.58	9.2	2.29	9.01
DCKKJOY	DM62UG5	Vemurafenib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	7.34	10.38	6.32	11.11
DCCTRHC	DM62UG5	Vemurafenib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	2.06	5.72	2.21	7.73
DC50C7F	DM62UG5	Vemurafenib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	9.58	9.47	6.88	12.58
DCP1H2W	DM62UG5	Vemurafenib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.72	2.29	1.48	5.48
DCGJ525	DM62UG5	Vemurafenib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	6.3	8.8	1.57	9.39
DC29LNF	DM62UG5	Vemurafenib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.35	0.99	4.26	6.74
DCQHXP7	DM62UG5	Vemurafenib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	11.52	9.92	16.25	17.66
DC38X4Y	DM62UG5	Vemurafenib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	7.94	7.63	6.85	10.39
DCACTSF	DM62UG5	Vemurafenib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.5	8.66	3.85	7.75
DC53FMX	DM62UG5	Vemurafenib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.38	4.57	3.04	7.78
DCCD25Z	DM62UG5	Vemurafenib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.14	4.09	8.08	9.69
DCYTC3X	DM62UG5	Vemurafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.43	5.03	1.94	1.94
DCYYQIP	DM62UG5	Vemurafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.11	6.54	4.67	4.35
DCXLNHD	DM62UG5	Vemurafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	13.97	14.11	1.8	0.3
DCIV6X2	DM62UG5	Vemurafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	0.65	8.17	5.86	5.74
DCHR1M5	DM62UG5	Vemurafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	0.83	2.03	4.1	4.63
DCY5CM4	DM62UG5	Vemurafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.3	3.77	2.53	2.02
DCUIFWB	DM62UG5	Vemurafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.91	5.24	2.09	1.31
DC5M9UJ	DM62UG5	Vemurafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	7.32	6.23	4.45	6.77
DC9ZH9P	DM62UG5	Vemurafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	8.72	9.17	4.06	14.26
DC2MY3F	DM62UG5	Vemurafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.39	8.78	3.63	3.23
DC5BL7I	DM62UG5	Vemurafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.46	11.19	5.47	4.77
DCFFWPH	DM62UG5	Vemurafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.34	2.54	1.58	1.47
DCQL2TS	DM62UG5	Vemurafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.74	3.62	1.83	1.87
DCJSNKM	DM62UG5	Vemurafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	1.54	2.87	0.78	0.46
DCR1JOD	DM62UG5	Vemurafenib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.27	3.15	0.03	0.03
DCVG1M7	DM62UG5	Vemurafenib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.07	3.83	2.08	1.03
DCMGL39	DM62UG5	Vemurafenib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.79	6.85	1.91	5.98
DCZG6HB	DM62UG5	Vemurafenib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	17.43	14.66	8.39	2.29
DCEBDNR	DM62UG5	Vemurafenib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	1.27	2.73	0.34	0.13
DCAFHRG	DM62UG5	Vemurafenib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	1.53	5.93	3.04	3.04
DC2IBNR	DM62UG5	Vemurafenib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	3.42	6.57	3.71	3.24
DCR1QG2	DM62UG5	Vemurafenib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.83	3.73	1.53	1.53
DCMJLME	DM62UG5	Vemurafenib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.64	2.49	0.43	0.43
DCCF4WH	DM62UG5	Vemurafenib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.87	5.23	0.74	5.66
DCMJ4R1	DM62UG5	Vemurafenib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.73	2.24	1.14	0.98
DCD8VWQ	DM62UG5	Vemurafenib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	5.27	13.48	10.61	6.69
DCDR3JE	DM62UG5	Vemurafenib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.36	2.1	0.69	0.64
DCEA14E	DM62UG5	Vemurafenib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	7.5	7.84	12.06	14.47
DCXVL55	DM62UG5	Vemurafenib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.5	4.36	6.74	9.1
DC8P9EB	DM62UG5	Vemurafenib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.15	9.67	2.9	5.21
DC0PPCF	DM62UG5	Vemurafenib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	9.72	11.24	2.5	5.05
DC6IFFO	DM62UG5	Vemurafenib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	2.77	4.32	0.19	6.44
DCWGRM6	DM62UG5	Vemurafenib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	3.17	3.22	1.1	0.83
DCEAB6Y	DM62UG5	Vemurafenib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	0.14	6.55	1.9	6.31
DCF086C	DM62UG5	Vemurafenib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	1.46	4.5	3.17	5.23
DC8AJB0	DM62UG5	Vemurafenib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.44	3.25	1.77	6.13
DCX63PE	DM62UG5	Vemurafenib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.95	9.79	4.54	7.84
DC1ONYY	DM62UG5	Vemurafenib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	4.16	8.28	2.24	2.91
DC4PPHQ	DM62UG5	Vemurafenib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.1	4.35	1.83	6.02
DCEYPOR	DM62UG5	Vemurafenib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	0	10.06	11.97	12.12
DC6B93R	DM62UG5	Vemurafenib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	1.42	4.63	3.2	2.98
DC81K2X	DM62UG5	Vemurafenib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	5.17	5.49	0.91	3.7
DCNSU76	DM62UG5	Vemurafenib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.1	3.56	0.38	1.67
DCLBAMM	DM62UG5	Vemurafenib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	6.66	13.25	4.19	3.27
DC67E76	DM62UG5	Vemurafenib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.34	3.98	0.47	0.51
DCIXRZ4	DM62UG5	Vemurafenib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	8.1	7.65	7.79	11.26
DCLYQ4F	DM62UG5	Vemurafenib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.56	6.3	2.71	0.61
DC3R18O	DM62UG5	Vemurafenib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.82	8.5	8.25	11.53
DC0X46Y	DM62UG5	Vemurafenib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	8.84	11.99	10.84	10.71
DC6U4PB	DM62UG5	Vemurafenib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	12.95	15.37	12.73	16.49
DCYNB8X	DM62UG5	Vemurafenib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	32.28	31.76	24.46	33.61
DCBYW7P	DM62UG5	Vemurafenib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.43	3.58	2.06	3.74
DCG5R3Y	DM62UG5	Vemurafenib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	2.65	6.79	3.97	7.49
DCPRQRW	DM62UG5	Vemurafenib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.6	1.95	1.68	0.5
DCVHDG9	DM62UG5	Vemurafenib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	12.76	21.69	21.06	19.89
DC3OSEM	DM62UG5	Vemurafenib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.62	12.21	7.32	11.22
DCCLNZH	DM62UG5	Vemurafenib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.21	5.62	5.4	9.07
DCSR88L	DM62UG5	Vemurafenib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	4.1	2.97	3.25	3.76
DC3K01L	DM62UG5	Vemurafenib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	24.26	23.32	19.55	23.1
DC4LVPG	DM62UG5	Vemurafenib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.05	12.11	1.32	11.07
DC78VIG	DM62UG5	Vemurafenib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	6.01	16.45	12.66	17.11
DC6DP2F	DM62UG5	Vemurafenib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.75	9.29	6.63	7.64
DCVX7IQ	DM62UG5	Vemurafenib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	12.28	13.82	1.27	12.54
DCYL2D4	DM5IXKQ	Vismodegib	Approved	34	DMZD5QR	Cytarabine	Approved	34	.	.	.	.	"Myelodysplastic Syndromes, Myelogenous Leukemia, Acute"	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCFZS7M	DM5IXKQ	Vismodegib	Approved	34	DMKECZD	Temozolomide	Approved	34	.	.	.	.	Histologically Confirmed Medulloblastoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCOSQSX	DM5IXKQ	Vismodegib	Approved	34	DMM9F25	LDE225	Phase 2	21	.	.	.	.	Basal Cell Carcinoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCRD9VE	DM5IXKQ	Vismodegib	Approved	34	DMILWZR	Rosiglitazone	Approved	34	.	.	.	.	Solid Cancers	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCTJAD8	DM5IXKQ	Vismodegib	Approved	34	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Pancreatic Adenocarcinoma Resectable	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCVI973	DM5IXKQ	Vismodegib	Approved	34	DM6VZFQ	Pirfenidone	Approved	34	.	.	.	.	Idiopathic Pulmonary Fibrosis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCY63S3	DM5IXKQ	Vismodegib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.6	6.66	0.35	0.26
DCRBK2W	DM5IXKQ	Vismodegib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.15	12.64	5.99	5.99
DC7SOMA	DM5IXKQ	Vismodegib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.61	9.33	7.42	9.02
DCEY6UC	DM5IXKQ	Vismodegib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	7.16	7.7	5.91	10.45
DCJU6QW	DM5IXKQ	Vismodegib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.18	8.38	6.83	6.9
DC23P30	DM5IXKQ	Vismodegib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.05	7.84	1.37	1.37
DC84T73	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	13.21	15.13	12.74	17.39
DCYQXWM	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.13	6.76	7.54	8.04
DCVRA6F	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.59	8.53	8.19	9.82
DCU7JSJ	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	9.83	17.6	3.22	11.51
DCP6Z24	DM5IXKQ	Vismodegib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.01	7.89	5.23	7.05
DCWXU8Z	DM5IXKQ	Vismodegib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.18	4.65	2.15	3.35
DCADQH3	DM5IXKQ	Vismodegib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.08	4.96	0.32	1.74
DCKY9GL	DM5IXKQ	Vismodegib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.68	8.11	6.68	7.88
DC69ALR	DM5IXKQ	Vismodegib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.22	6.77	3.96	5.52
DC15K6E	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	32.94	34.2	33.97	33.87
DCMLK5G	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	11.82	17.24	17.68	17.4
DCFQ58W	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	12.11	20	18.97	18.74
DC05Z1X	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	38.95	38.4	36.44	31.79
DCYEDIZ	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	22.22	27.86	27.83	27.84
DCM3TLS	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.29	12.25	9.49	10.69
DC35MLF	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	20.49	28.34	26.67	27.08
DCLHPX2	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	16.42	18.16	10.8	11.39
DCIQCIK	DM5IXKQ	Vismodegib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.39	9.6	7.82	9.46
DCUC863	DM5IXKQ	Vismodegib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.3	15.74	8.87	8.73
DCKPCB7	DM5IXKQ	Vismodegib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.65	7.43	5.43	6.38
DC6W87Q	DM5IXKQ	Vismodegib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1	7.19	7.58	7.92
DCVAP2O	DM5IXKQ	Vismodegib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.12	4.67	1.75	2.36
DCSMHFG	DM5IXKQ	Vismodegib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.36	4.53	2.34	2.11
DCBNAHU	DM5IXKQ	Vismodegib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.02	7.26	2.53	3.01
DCO4QM3	DM5IXKQ	Vismodegib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.16	3.08	7.63	9.01
DC6C548	DM5IXKQ	Vismodegib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.28	5.88	3.14	4.99
DC9WTP9	DM5IXKQ	Vismodegib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.71	5.53	3.29	3.63
DC9YJEA	DM5IXKQ	Vismodegib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.81	7.59	1.38	0.79
DC2GJ6A	DM5IXKQ	Vismodegib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.46	4.17	1.24	1.88
DCNQ396	DM5IXKQ	Vismodegib	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.41	7.3	1.81	0.49
DCLEA4E	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	28.84	27.33	28.25	28.26
DCBKWNH	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	10.93	14.41	16.27	16.01
DCGGB2G	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	25.56	21.88	20.84	21.06
DCB1RJN	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	43.06	35.21	30.67	28.16
DCIHIS4	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	30.37	30.04	29.75	29.84
DC7MKIN	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	30.49	30.97	23.7	24.22
DC1JVD5	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	31.21	30.75	29.62	29.59
DCMEQRO	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	26.25	25.8	24.62	24.53
DCSR55E	DM5IXKQ	Vismodegib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.2	7.68	5.14	6.34
DCAB494	DM5IXKQ	Vismodegib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	9.51	14.31	7.66	5.69
DCNFSXF	DM5IXKQ	Vismodegib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	8.96	9.52	4.34	11.2
DCXIU5B	DM5IXKQ	Vismodegib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.34	7.82	8.53	10.75
DC83WFG	DM5IXKQ	Vismodegib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	9.68	12.34	5.39	5.36
DC3DQ5U	DM5IXKQ	Vismodegib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	6.23	9.57	1.68	10.08
DCRU67X	DM5IXKQ	Vismodegib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.95	8.08	2.04	0.05
DC45HWA	DM5IXKQ	Vismodegib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.1	4.29	1.93	3.07
DCK9FWS	DM5IXKQ	Vismodegib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.1	8.13	3.83	8.12
DC0EJ4Y	DM5IXKQ	Vismodegib	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.31	7.29	4.83	6.03
DC361XE	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.25	8.2	7.47	7.38
DC9DISQ	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	10.46	12.55	6.93	13.38
DCST5K0	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.54	13.9	7.2	7.15
DC1MEXT	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.88	7.28	6.33	6.33
DCXX37W	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.05	11.34	8.01	10.24
DCQLNHT	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	11.91	12.32	6.53	15
DCLQKAB	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	9.56	11.06	0.57	12.17
DC8ICGX	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	10.62	12.79	11.23	12.68
DCQ8GKZ	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	15.52	16.59	12.22	16.26
DCBCZD3	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.72	11.29	10.48	10.45
DCGGPPD	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.23	9.5	11.17	11.43
DCXMNUW	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.97	12.61	6.38	4.24
DC8B011	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.44	11.5	4.44	2.95
DCTITBA	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.15	8.66	6.89	6.93
DCF5765	DM5IXKQ	Vismodegib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	8.37	9.8	9.52	11.23
DCZKBJW	DM5IXKQ	Vismodegib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.88	4.35	1.84	6.18
DCBS55V	DM5IXKQ	Vismodegib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.89	8.19	9.49	11.19
DC7JN0F	DM5IXKQ	Vismodegib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	12.24	13.62	12.56	13.79
DC54XZG	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	9.29	9.13	9.3	13.2
DCQ7T1L	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	8.06	9.9	2.25	12
DCKFRTB	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.87	2.11	5.51	6.33
DCK8RYW	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.83	12.06	10.78	12.38
DCBRM4Z	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.94	7.79	6.56	7.06
DCDJ3U4	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.1	6.23	4.18	4.42
DCNDIJ8	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.82	15.42	8.47	8.32
DCL0F7X	DM5IXKQ	Vismodegib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.86	6	4.35	5.74
DCFFB62	DM5IXKQ	Vismodegib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	4.93	10.91	8.31	8.16
DCPT422	DM5IXKQ	Vismodegib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.37	5.81	6.8	9.58
DCODQ05	DM5IXKQ	Vismodegib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	13.11	13.08	6.28	6.28
DCYKC69	DM5IXKQ	Vismodegib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.53	4.76	3.26	3.46
DC47ESM	DM5IXKQ	Vismodegib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.51	8.16	8.69	9.21
DCQQHO5	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.09	5.68	9.42	11.1
DCASZAK	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	15.71	16.13	8.67	15.2
DCMM6N2	DM5IXKQ	Vismodegib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	7.23	10.65	6.71	12.65
DCCGQHA	DM5IXKQ	Vismodegib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.71	5.34	3.69	4.94
DCNV8YQ	DM5IXKQ	Vismodegib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.26	7.27	2.9	6.79
DCVMC7M	DM5IXKQ	Vismodegib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.58	2.7	0.56	4.52
DCM7B0F	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	8.05	9.3	4.44	12.96
DCYR7W6	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	12.31	12.29	2.75	13.73
DCABYCK	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	14.45	9.71	14.56	16.44
DC8LSL0	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.94	8.06	5.56	8.03
DC0WA3Y	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	10.43	10.06	0.96	11.71
DC9FO58	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.84	7.69	6.14	7.06
DCSP5KR	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.83	7.86	6.07	6.51
DC3ML9O	DM5IXKQ	Vismodegib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.65	7.08	1.54	9.43
DCOC4UR	DM5IXKQ	Vismodegib	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.04	8.59	1.75	1.75
DCX8AMS	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.13	3.63	4.2	4.26
DCH4TZ4	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.99	15.51	8.92	7.77
DCE4S9Z	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.59	3.69	1.53	1.88
DC4A3U1	DM5IXKQ	Vismodegib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.27	6.49	1.08	3.16
DCQ775X	DM5IXKQ	Vismodegib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	6.55	8.7	9.95	10.22
DCVQM7S	DM5IXKQ	Vismodegib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	6	7	4.86	6.98
DCCXEUP	DM5IXKQ	Vismodegib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.23	5.18	4.08	3.91
DCK9GF2	DM5IXKQ	Vismodegib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.72	9.25	2.44	2.44
DC4RHTW	DM5IXKQ	Vismodegib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.21	3.53	3.25	3.73
DCV2VIA	DM5IXKQ	Vismodegib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0	8.95	4.9	9.43
DC3XAYX	DM5IXKQ	Vismodegib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	17.56	20.96	6.22	14.83
DCZYQB1	DM5IXKQ	Vismodegib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.56	6.87	6.2	6.21
DCIK1TP	DM5IXKQ	Vismodegib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.08	10.12	3.44	3.44
DCXS1RK	DM5IXKQ	Vismodegib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.79	9.82	10.08	11.99
DCG1269	DM5IXKQ	Vismodegib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.51	6.36	7.02	8.72
DC0TA9G	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	8.15	7.99	3.32	9.06
DC4O6V2	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	7.28	7	2.35	8.8
DC8Q18T	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.54	4.42	1	6.07
DC8HJMD	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.36	6.29	3.93	6.52
DC9UWAB	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	11.07	13.05	12.66	13.96
DCX7ZQE	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.14	8.87	8.62	11.03
DCP61QW	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.7	11.95	5.53	9.11
DCOPWL3	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	11.62	17.45	9.15	7.23
DCYJXEP	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	9.14	18.68	11.77	11.43
DC598EZ	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.35	10.29	6.11	7.63
DCNGIQQ	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.46	14.75	10.77	13.82
DCQYW3C	DM5IXKQ	Vismodegib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	10.31	10.03	3.15	3.15
DCITY3O	DM5IXKQ	Vismodegib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.76	5.56	6.62	6.86
DC69VVF	DM5IXKQ	Vismodegib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.21	3.88	1.19	1.2
DC7QMH3	DM5IXKQ	Vismodegib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.61	14.94	8.13	6.16
DCO7MTB	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.03	9.91	5.55	8.62
DCXR1TS	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.41	20.52	13.96	13.75
DC9G3X7	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.45	4.42	2.43	3.39
DCTDBEH	DM5IXKQ	Vismodegib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	12.15	11.65	2.93	12.53
DCS9AY7	DM5IXKQ	Vismodegib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	10.38	12.02	10.84	12.18
DCLJWXW	DM5IXKQ	Vismodegib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	10.23	9.67	6.01	14.41
DCI7B8C	DM5IXKQ	Vismodegib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	14.07	15	11.54	14.79
DCIOAR4	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	10.49	11.13	5.06	13.7
DCG3579	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	9.27	9.99	6.14	9.73
DCT1U19	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.15	8.26	4.83	8.96
DC0057A	DM5IXKQ	Vismodegib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.78	13.11	6.43	4.74
DC807LP	DM5IXKQ	Vismodegib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.01	7.31	0.36	0.26
DCVLV76	DM5IXKQ	Vismodegib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.43	3.34	2.66	2.69
DCSC7DJ	DM5IXKQ	Vismodegib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.25	5.93	2.25	8.23
DCO2RD0	DM5IXKQ	Vismodegib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.82	3.73	3.73	3.94
DCZB6M0	DM5IXKQ	Vismodegib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.18	7.51	2.64	1.56
DCS2BV2	DM5IXKQ	Vismodegib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	13.28	13.52	5.97	10.41
DCP6JLN	DM5IXKQ	Vismodegib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	2.66	3.05	1.29	0.99
DCG69HU	DM5IXKQ	Vismodegib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	1.31	8.54	0.92	7.92
DCJI2PH	DM5IXKQ	Vismodegib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	4.03	8.7	8.27	3.85
DCPITGU	DM5IXKQ	Vismodegib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.02	8.76	4.9	5.16
DCUQZQ8	DM5IXKQ	Vismodegib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	0.63	7.39	7.96	9.05
DCAYH9P	DM5IXKQ	Vismodegib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	3.12	9.84	6.9	5.31
DC5KC75	DM5IXKQ	Vismodegib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.73	7.65	0.87	0.85
DC85SUZ	DM5IXKQ	Vismodegib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	0.1	5.63	3.3	3.51
DC69W7F	DM5IXKQ	Vismodegib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	5.7	6.49	0.79	6.28
DCG79E1	DM5IXKQ	Vismodegib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.95	12.7	12.5	12.89
DCJX3SM	DM5IXKQ	Vismodegib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.74	6.46	4.63	5.34
DCSR8WJ	DM5IXKQ	Vismodegib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	19.01	17.84	16.28	20.04
DCYK8MF	DM5IXKQ	Vismodegib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.19	4.34	2.86	1.3
DCJ3JGJ	DM5IXKQ	Vismodegib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	9.14	11.36	13.32	13.62
DC52921	DM5IXKQ	Vismodegib	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	3.53	8.69	5.56	3.92
DCXBMDM	DM5IXKQ	Vismodegib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.79	6.77	1.28	4.21
DC5954X	DM5IXKQ	Vismodegib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.01	9.24	6.49	6.95
DC0MR8Q	DM5IXKQ	Vismodegib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.05	2.3	0.15	1.93
DCUZU51	DM5IXKQ	Vismodegib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.98	7.27	3.97	3.74
DCDO6DT	DM5IXKQ	Vismodegib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	1.55	11.59	9.68	5.7
DCUZM6F	DM5IXKQ	Vismodegib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	0.05	5.48	2.86	2.22
DCLYHWL	DM5IXKQ	Vismodegib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.91	6.2	2.49	2.14
DCCIA5P	DM5IXKQ	Vismodegib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	2.77	9.14	5.98	5.74
DCBILN2	DM5IXKQ	Vismodegib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	7.33	12.4	11.68	8.9
DC0DAKV	DM5IXKQ	Vismodegib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	3.19	5.57	4.47	4.85
DCA1C2R	DM5IXKQ	Vismodegib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.99	5.88	4.33	4.39
DCZFCER	DM5IXKQ	Vismodegib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.04	5.46	4.1	3.06
DC6Z7NT	DM5IXKQ	Vismodegib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.63	9.21	2.26	4.23
DC9QSPD	DM5IXKQ	Vismodegib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.18	9.02	7.56	7.32
DC3HLOK	DM5IXKQ	Vismodegib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.14	4.29	3.53	3.78
DCKQTIP	DM5IXKQ	Vismodegib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	5.78	11.11	4.09	3.05
DCPIEYX	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.68	5.78	4	5.31
DCB0AQM	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.21	6.5	4.42	7.49
DCW3DJ0	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.53	4.16	3.23	6.25
DC6XU1B	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	14.05	14.66	6.1	15.92
DC7XSIJ	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	5.34	10.74	4.06	10.63
DCQ8RF0	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.81	5.25	1.01	4.56
DCJYDOC	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	11.55	12.99	7.1	11.48
DCYFAUE	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	12.22	16.77	3.83	9.62
DCEH7Q1	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	17.49	19.03	8.95	15.68
DCJT5KW	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	10.23	18.29	13.77	20.64
DC0Z2CM	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	4.16	5.77	5.83	7.56
DCEVQWN	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	5.28	10.54	12.22	13.57
DC4VOZ3	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	7.89	8.03	6.56	8.95
DCBERGZ	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	19.78	21.37	9.25	15.3
DCX2QCI	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.94	7.83	7.75	9.74
DCW8YO7	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.05	7.55	3.76	9.06
DC0PRD4	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	7.88	11.16	10.46	11.31
DC4SDC0	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	4.47	5.59	3.41	6.86
DCT9TTF	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	9.09	15.88	11.14	15.73
DCSU6T8	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.22	7.61	4.66	6.8
DCR6WWE	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	20.87	16.64	6	15.35
DCLCAQD	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.8	4.9	2.6	5.28
DCYN4NG	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	12.57	12.49	9.17	12.82
DC6COBR	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.94	7.8	6.28	8.91
DCUFHDL	DM5IXKQ	Vismodegib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.23	9.81	8.26	10.31
DC0445L	DM5IXKQ	Vismodegib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	12.65	16.63	10.08	15.9
DC2HYA5	DM5IXKQ	Vismodegib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	2.35	9.32	3.69	6.3
DCE8GR2	DM5IXKQ	Vismodegib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	14.59	13.27	10.03	14.63
DCAUL4C	DM5IXKQ	Vismodegib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.95	8.13	1.02	0.31
DC8AOQK	DM5IXKQ	Vismodegib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	12.05	8.3	3.85	2.64
DC0UVI9	DM5IXKQ	Vismodegib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-428	2.36	4.26	1.47	0.68
DCCMW8F	DM5IXKQ	Vismodegib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	9.29	9.91	3.29	10.44
DCZ9I3O	DM5IXKQ	Vismodegib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.59	8.43	2.08	1.98
DCB2NYW	DM5IXKQ	Vismodegib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.73	6.61	2.31	3.98
DCM2XE5	DM5IXKQ	Vismodegib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	6.23	13.2	6.01	4.17
DCHI2FO	DM5IXKQ	Vismodegib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	18.29	17.97	16.06	12.47
DC4D8H1	DM5IXKQ	Vismodegib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.18	5.81	2.14	2.14
DCMJZS3	DM5IXKQ	Vismodegib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	2.62	7.7	2.85	7.57
DC00AT5	DM5IXKQ	Vismodegib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	9.24	5.43	2.74	1.13
DC9RU65	DM5IXKQ	Vismodegib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.98	6.34	3.46	7.94
DC2QW0Y	DM5IXKQ	Vismodegib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	5.8	7.47	0.97	2.57
DC7I6ZD	DM5IXKQ	Vismodegib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.55	2.33	1.13	0.09
DCRZUAK	DM5IXKQ	Vismodegib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.53	2.05	0.01	2.15
DC1QECS	DM5IXKQ	Vismodegib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	1.62	5.84	4.92	4.25
DCK6KHR	DM5IXKQ	Vismodegib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	15.48	20.01	21.54	21.42
DCYNBTR	DM5IXKQ	Vismodegib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.59	7.77	7.46	7.05
DC2NUO9	DM5IXKQ	Vismodegib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.9	12.3	8.04	11.81
DC4E8EW	DM5IXKQ	Vismodegib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.94	4.37	2.42	3.53
DC541O3	DM5IXKQ	Vismodegib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	6.37	4.58	2.04	1.34
DCPQ841	DM5IXKQ	Vismodegib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.13	2.91	1.58	1.74
DCUV44N	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	13.74	20.96	18.06	17.94
DCQ9IH1	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	19.14	25.24	22.81	23.22
DCMBWEC	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	11.53	16.61	15.64	15.22
DCVXOUZ	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	11.9	12.78	11.19	11.31
DCJBPI2	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	29.79	29.6	18.13	26.1
DCGMU49	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	22.64	24.98	23.57	23.61
DC1Y9W8	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	8.99	12.61	11.2	11.01
DCWPEMB	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	42.42	41.01	38.96	38.89
DC80CRP	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	36.86	38.93	36.65	36.32
DCITUNE	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	31.76	26.76	21.81	21.94
DCAUTUK	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	44.24	48.64	45.89	47.76
DCICP5T	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	14.37	17.7	17.03	14.03
DC6I6KL	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	22.22	26.49	17.16	18.81
DCI2M9Z	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	47.46	38.87	38.11	43.72
DC1E5OL	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	14.08	21.57	22.05	21.65
DCIT3JB	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	33.69	34.62	34.62	34.23
DCNHJ9A	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	17.33	22.41	21.51	21.51
DCHDW5M	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	24.16	20.78	21.36	21.37
DCVQFEN	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	21.27	28.6	28.98	28.8
DCXN0W4	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	13.32	18.84	17.84	17.93
DC195Q3	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	14.66	22.18	20.23	20.28
DC3SZTY	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	26.15	27.09	28.24	27.41
DCH5F1Y	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	18.56	20.49	14.31	13.64
DC8AY3E	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	14.61	18.89	14.76	15.43
DCQA92R	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	5.64	14.51	12.36	12.36
DCP58JQ	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	16.38	25.04	21.79	21.92
DCBDPAX	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	11.03	18.18	18.71	18.71
DCE5617	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	12.06	18.79	19.17	19.1
DCG8QV1	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	27.13	27.19	26.79	26.86
DC1UHDX	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.1	4.78	3.91	3.44
DC9PQWF	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	10.31	18.9	17.45	17.45
DCVZLFH	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	21.88	25.02	23.63	23.8
DC6RQVH	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	12.08	14.3	12.67	13.01
DCREC0Q	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	13.67	17.77	17.39	16.97
DCT18DK	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	14.02	19.66	19.31	19.11
DC9X3U8	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	15.3	24.12	23.29	23.05
DCQ42RI	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	11.31	19.44	20.3	19.94
DCGA4NU	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	24.52	28.32	27.26	27.26
DC14YFW	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	15.61	23.39	20.96	21.19
DC0W7LH	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	7.06	12.18	12.22	9.85
DC5W4L5	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	19.65	26.63	16.03	20.91
DCD3QS8	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	18.59	22.94	21.02	20.77
DCGJHXV	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	11.35	17.26	16.41	16.3
DCTCK65	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	17.46	19.61	19.09	18.76
DC5959I	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	11.1	17.02	15.48	15.54
DC2LESS	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	28.91	30.28	28.28	28.28
DC0YQB1	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	44.35	36.38	27.83	29
DC4C2YN	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	12.08	13.83	13.54	13.06
DC3B3KE	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	15.05	17.11	16.75	16.05
DC6FRN6	DM5IXKQ	Vismodegib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	14.35	23.99	23.76	23.57
DC3S44I	DM5IXKQ	Vismodegib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.44	3.52	1	1.64
DCTDW6T	DM5IXKQ	Vismodegib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	3.62	5.65	3.62	0.71
DCEFQ6Y	DM5IXKQ	Vismodegib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.34	7.85	5.03	4.18
DC75BRB	DM5IXKQ	Vismodegib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	1.01	2.33	4.65	4.49
DC76A14	DM5IXKQ	Vismodegib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	10.81	9.96	8.54	5.88
DCDTEGF	DM5IXKQ	Vismodegib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	5.53	6.72	4.24	3.67
DCBOC2N	DM5IXKQ	Vismodegib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.22	7.32	4.57	5.25
DCSXG3M	DM5IXKQ	Vismodegib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.21	4.19	0.35	3.18
DCBMZ11	DM5IXKQ	Vismodegib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.95	4.13	4.44	5.19
DCI6SDA	DM5IXKQ	Vismodegib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	9.27	14.39	11.54	15.63
DCHIKQJ	DM5IXKQ	Vismodegib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.26	5.86	0.1	2.33
DC5GI4U	DM5IXKQ	Vismodegib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.47	2.66	1.37	0.54
DCQT51H	DM5IXKQ	Vismodegib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	0.35	4.43	1.91	2.23
DCDW7MC	DM5IXKQ	Vismodegib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	1.11	10.32	5.22	9.65
DCVRLZX	DM5IXKQ	Vismodegib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	3.73	5.63	6.75	7.08
DCA1HDW	DM5IXKQ	Vismodegib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	9.92	9.61	11.46	9.68
DCWC5KI	DM5IXKQ	Vismodegib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.75	3.65	2.01	1.98
DC7EYTQ	DM5IXKQ	Vismodegib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	8.48	9.35	2.01	9
DCGFDIG	DM5IXKQ	Vismodegib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	1.46	7.25	8.69	8.88
DCABPMJ	DM5IXKQ	Vismodegib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	0.23	6.42	5.05	6.77
DC3XBT2	DM5IXKQ	Vismodegib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	21.43	25.24	23.85	25.26
DCH2D6A	DM5IXKQ	Vismodegib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	9.05	13.37	15.53	16.69
DCN698B	DM5IXKQ	Vismodegib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.78	5.69	3.96	5.25
DCGG5WM	DM5IXKQ	Vismodegib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	11.78	14.9	9.73	13.13
DCNLFSE	DM5IXKQ	Vismodegib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	1.49	4.26	4	4.2
DCSNJEL	DM5IXKQ	Vismodegib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	1.9	8.62	10.36	9.53
DC0JU1G	DM5IXKQ	Vismodegib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.61	3.1	1.76	0.78
DC2Y06I	DM5IXKQ	Vismodegib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	19.2	19.03	16.75	14.94
DCDWTGU	DM5IXKQ	Vismodegib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	1.84	5.97	0.61	0.66
DCZGAUC	DM5IXKQ	Vismodegib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.34	1.43	1.76	1.62
DC72KW7	DM5IXKQ	Vismodegib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	2.3	3.92	2.04	0.15
DC1O3PU	DM5IXKQ	Vismodegib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	1.99	8.41	8.9	10.14
DCZK41B	DM5IXKQ	Vismodegib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.46	8.19	0.39	2.74
DCQF037	DM5IXKQ	Vismodegib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.06	4.06	0.31	4
DC97S3X	DM5IXKQ	Vismodegib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	6.11	8.24	4.72	9.02
DCP3FLI	DM5IXKQ	Vismodegib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.05	5.09	1.09	5.86
DCM43QT	DM5IXKQ	Vismodegib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.48	6.26	6.01	7.53
DCY0MD3	DM5IXKQ	Vismodegib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.86	6.98	1.87	6.37
DCW4C9A	DM5IXKQ	Vismodegib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.49	6.98	4.39	4.1
DCOAJH4	DM5IXKQ	Vismodegib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.14	8.25	1.88	4.45
DCODV48	DM5IXKQ	Vismodegib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	5.38	8.47	6.23	5.15
DC4N0ZV	DM5IXKQ	Vismodegib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	0.73	3.07	1.55	1.5
DCXAORJ	DM5IXKQ	Vismodegib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	1.61	6.54	3.88	5.16
DCXLBQA	DM5IXKQ	Vismodegib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	5.43	9.36	5.24	6.17
DCPA77I	DM5IXKQ	Vismodegib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	1.18	2.27	0.49	0.07
DCBEABS	DM5IXKQ	Vismodegib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	3.18	11.41	0.33	1.53
DCDUGKW	DM5IXKQ	Vismodegib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	2.92	6.07	5.48	2.62
DCO21YI	DM5IXKQ	Vismodegib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.05	4.09	3.3	1.5
DCX0GWS	DM5IXKQ	Vismodegib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.77	6.69	2.2	1.7
DCWVPU4	DM5IXKQ	Vismodegib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.94	7.09	2.89	4.37
DCJZ9SC	DM5IXKQ	Vismodegib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	1.78	7.22	5.53	4.15
DCPGN9E	DM5IXKQ	Vismodegib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	1.11	7.94	4.6	5.11
DCK1SLN	DM5IXKQ	Vismodegib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.93	5.73	0.87	0.98
DC295ES	DM5IXKQ	Vismodegib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	3.28	8.97	5.71	8.95
DCMM3Z1	DM5IXKQ	Vismodegib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.28	6.02	1.92	4.42
DCD4QD2	DM5IXKQ	Vismodegib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	9.01	13.84	10.26	10.3
DCURCEA	DM5IXKQ	Vismodegib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.88	6.14	3.73	2.99
DCOJ520	DM5IXKQ	Vismodegib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	17.44	16.98	15.71	18.98
DC8M0QQ	DM5IXKQ	Vismodegib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.81	5.27	3.15	3.12
DCCCW2M	DM5IXKQ	Vismodegib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	11	17.65	15.7	18
DC41F3Z	DM5IXKQ	Vismodegib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.32	3.73	0.3	0.25
DCC7ST3	DM5IXKQ	Vismodegib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.79	9.94	4.4	9.56
DCQQMZK	DM5IXKQ	Vismodegib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	4.05	11.77	9.23	10.75
DCALHKX	DM5IXKQ	Vismodegib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	1.16	3.44	1.07	1.11
DCT9NHR	DM5IXKQ	Vismodegib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	7.26	3.77	2.5	1.28
DCBVTVZ	DM5IXKQ	Vismodegib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	2.62	8.03	5.36	3.59
DC941DD	DM5IXKQ	Vismodegib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	10.06	10.51	7.74	10.14
DCVMMZV	DM5IXKQ	Vismodegib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.92	7.97	5.11	2.06
DCGFVBM	DM5IXKQ	Vismodegib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	7.92	6.53	2.32	6.45
DCKAR38	DM5IXKQ	Vismodegib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	18.01	16.66	6.98	4.69
DCG8TY6	DM5IXKQ	Vismodegib	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	0.45	3.41	0.94	2.93
DC8PSSX	DM5IXKQ	Vismodegib	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	2.31	3.8	1.2	0.18
DCRPD78	DM5IXKQ	Vismodegib	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.03	6.96	0.32	0.32
DCEW7PW	DM5IXKQ	Vismodegib	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	0.5	5.91	3.5	3.46
DCP0TXY	DM5IXKQ	Vismodegib	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.77	1.95	0.69	0.33
DC347TO	DM5IXKQ	Vismodegib	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	10.25	9.36	8.21	9.12
DCTXME4	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	16.64	21.42	18.8	18.72
DCG2MMK	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	27.82	23.64	22.3	22.33
DCM5SO5	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	7.05	8.57	7.68	7.69
DCVBNR2	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	7.24	10.79	10.35	10.09
DCX2KEU	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	12.94	14.03	11.46	11.46
DCKN4FX	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	10.11	10.68	6.69	6.71
DCCUBBT	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	20.2	24.36	23.12	23.14
DCQV22I	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	11.17	12.4	10.95	10.99
DC1BDZS	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	3.89	3.49	2.7	2.63
DCPXMVW	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	13.83	12.53	12.69	7.32
DCC6DIU	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	31.85	33.25	32.3	31.94
DCCZ9ZH	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	34.26	30.67	27.05	27.03
DCGDOKI	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	34.65	28.11	20.43	20.43
DC7NMBP	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	20.14	19.28	16.27	21.55
DCRJWU1	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	29.66	29.38	30.19	29.95
DCW91Z3	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	28.79	26.14	26.11	26.01
DCS9T4Y	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	2.27	11.78	10.81	10.83
DCZQRX8	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	14.5	21.5	22.17	22.08
DCKN4HV	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	19.81	20.78	20.54	20.55
DCCHRLV	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	22.91	25.11	25.92	25.84
DCHJ0BT	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	19.51	20.79	21.14	21.15
DC73YCW	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	27.5	25.12	26.65	26.63
DCBCLMM	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	33.57	26.13	21.74	22.71
DC9TDZB	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	38.44	32.26	25.34	25.21
DCJWXRD	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	28.48	23.99	21.88	21.88
DCA2JMR	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	24.91	25.45	26.2	26.21
DCO0DKH	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	10.97	15.76	13.25	12.76
DCUO9ZK	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	15.37	18.75	19.16	19.15
DCQMY29	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	30.19	32.13	31.19	31.19
DC4B6II	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	28.84	29.72	29.87	29.89
DCG83A6	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	4.51	11.05	10.95	10.97
DCGOKUU	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	16.87	18.81	18.18	18.2
DC4KTV5	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	6.65	8.03	7.8	7.82
DCY9RJ5	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	7.23	12.87	13.89	13.59
DCB4OVA	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	12.67	15.39	14.16	13.22
DCZQ6NC	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	18.28	21	20.45	20.47
DCSNYNM	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	29.02	27.66	27.02	26.94
DC5RVLC	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	10.99	8.17	9.73	9.71
DCQZCEW	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	37.78	35.63	30.6	30.6
DCFCDEV	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	24.75	23.86	24.13	21.92
DC7AS3H	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	12.15	15.58	13.94	13.96
DC63WZ7	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	18.96	22.9	21.54	21.13
DC3NCKM	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.4	10.88	10.23	10.18
DCWU77T	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	5.63	7.94	8.48	8.36
DCZ20C5	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	11.31	19.69	18.93	18.94
DCKX3NP	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	18.46	22.49	20.54	20.7
DC0B4ID	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	38.16	27.25	21.77	19.92
DCVJQT0	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	7.79	9.95	9.69	9.63
DCV43TU	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	7.79	9.95	9.47	9.09
DCLRXZY	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	0.64	4.68	5.78	5.36
DCL41I9	DM5IXKQ	Vismodegib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	10.87	14.66	14.97	14.82
DC728C4	DM5IXKQ	Vismodegib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.63	5.61	4.03	1.91
DCL8MLL	DM5IXKQ	Vismodegib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	0.71	9.25	3.06	3.9
DCLNAO6	DM5IXKQ	Vismodegib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	22.55	20.85	17.98	23.49
DC468RK	DM5IXKQ	Vismodegib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	0	2.19	0.23	1.52
DCVXWR5	DM5IXKQ	Vismodegib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	13.33	16.32	17.8	17.8
DCCB6K4	DM5IXKQ	Vismodegib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	0.07	4.06	3.82	3.32
DCSLANQ	DM5IXKQ	Vismodegib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	4.11	7.81	5.26	3.91
DCCLL1F	DM5IXKQ	Vismodegib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.37	3.98	0.38	0.43
DC8EZEB	DM5IXKQ	Vismodegib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.73	8.03	9.89	7.42
DCR9NA8	DM5IXKQ	Vismodegib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.32	4.32	1.73	1.72
DCV8TEB	DM5IXKQ	Vismodegib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.4	3.46	2.77	2.7
DCRKQV8	DM5IXKQ	Vismodegib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3	6.59	3.88	3.66
DC18EIQ	DM5IXKQ	Vismodegib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	2.96	4.37	2.52	1.39
DC2PC99	DM5IXKQ	Vismodegib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	7.01	9.5	2.24	0.04
DCBJV5V	DM5IXKQ	Vismodegib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	5.98	7.51	7.24	6.13
DCVA26I	DM5IXKQ	Vismodegib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	6.09	6.23	6.88	6.58
DCO6FXE	DM5IXKQ	Vismodegib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	6	8.71	4.21	6.37
DC6WXT1	DM5IXKQ	Vismodegib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	5.29	8.29	1.75	8.02
DC0ZPHV	DM5IXKQ	Vismodegib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	5.57	6.79	5.64	7.96
DC9QP16	DM5IXKQ	Vismodegib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	0.06	4.91	0.01	5.86
DCXLVZC	DM5IXKQ	Vismodegib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.32	4.44	1.95	2.94
DCJRVQM	DM5IXKQ	Vismodegib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	6.85	10.15	7.93	10.18
DCI7NQA	DM5IXKQ	Vismodegib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	21.64	27.73	19.13	23.16
DC37DG0	DM5IXKQ	Vismodegib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	0.15	4.53	4.5	4.47
DCMDSSI	DM5IXKQ	Vismodegib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.77	9.68	4.59	4.59
DCIWNKI	DM5IXKQ	Vismodegib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.05	11.94	9.69	8.77
DCG7BNI	DM5IXKQ	Vismodegib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	1.16	12.05	1.24	10.6
DCPPUUW	DM5IXKQ	Vismodegib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	14.07	18.59	20.19	19.49
DCYMDM9	DM5IXKQ	Vismodegib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	3.02	5.21	3.73	0.99
DC2DGSI	DM5IXKQ	Vismodegib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	1.16	2.97	0.73	0.53
DCGJQBO	DM5IXKQ	Vismodegib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	13.21	17.1	18.27	19.93
DCA2YEA	DM5IXKQ	Vismodegib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.32	10.59	8.71	5.39
DCJUPNU	DM5IXKQ	Vismodegib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	2.18	6.32	4.45	3.78
DCQLJ9L	DM5IXKQ	Vismodegib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	5.13	7.54	9.5	9.97
DCXAUYL	DM5IXKQ	Vismodegib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.17	7.07	3.84	5.17
DCKNDYW	DM5IXKQ	Vismodegib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	6.03	7.83	2.85	7.66
DC027DB	DM5IXKQ	Vismodegib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	6.8	6.87	2.44	6.54
DC8MK7P	DM5IXKQ	Vismodegib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	4.16	3.83	1.61	6.1
DCM28YV	DM5IXKQ	Vismodegib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	4.74	7.33	2.03	9.79
DCV95W0	DM5IXKQ	Vismodegib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.33	2.53	0.91	3.89
DCILKWW	DM5IXKQ	Vismodegib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	4.13	7.88	4.89	7.88
DC6TR3K	DM5IXKQ	Vismodegib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	8.58	8.97	6.81	7.93
DCXO82B	DM5IXKQ	Vismodegib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	8.08	8.78	7.4	10.4
DCMRW3C	DM5IXKQ	Vismodegib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.47	5.11	1.13	5.91
DCSVXAE	DM5IXKQ	Vismodegib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	4.27	5.84	2.72	5.2
DCO626A	DM5IXKQ	Vismodegib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	5.2	5.38	5.3	7.22
DCT9CQ4	DM5IXKQ	Vismodegib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	5.37	5.91	5.3	8.68
DCQWDAG	DM5IXKQ	Vismodegib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	15.98	20.3	20.39	20.28
DC92X9O	DM5IXKQ	Vismodegib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	0.99	3.78	1.08	0.75
DCXALEE	DM5IXKQ	Vismodegib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.8	11.82	10.99	10.61
DCNVQ9H	DM5IXKQ	Vismodegib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.38	3.31	2.51	2.53
DC3RI20	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.82	9.66	6.07	6.96
DCI42EZ	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.78	17.24	4.49	13.61
DC2PA52	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.73	5.9	3.34	3.34
DCJHU2U	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	12.38	17.88	14.92	12.84
DCH8WYK	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	9.78	13.04	2.58	11.38
DCLDAGO	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	5.81	9.39	1.65	1.63
DCGPJZK	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	2.47	9.47	4.75	9.77
DCFG497	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	3.6	7.86	4.58	7.49
DCFM4TM	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.29	10.28	3.69	3.48
DCG41JT	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.28	6.68	3.18	3.44
DCM136T	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	0.41	4.17	2.03	2.03
DCDEPTQ	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	1.31	7.68	5.72	4.45
DCFKVYS	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.09	10.35	3.17	9.22
DCOXR15	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.77	7.73	7.09	7.1
DC5WSB0	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.8	5.97	3.51	0.47
DC2TNYJ	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.56	9.21	0.76	8.48
DC2XP7I	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.82	8.32	5.59	7.59
DCJC3MQ	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	0.52	5.13	3.31	3.24
DCI2UET	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	14.18	16.17	10.03	8.86
DCUKSWH	DM5IXKQ	Vismodegib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	2.33	9.18	7.32	8.88
DCW0676	DM5IXKQ	Vismodegib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	5.37	8.65	2.67	2.27
DC1OLRD	DM5IXKQ	Vismodegib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.25	6.49	3.49	3.6
DCJDMDY	DM5IXKQ	Vismodegib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.92	2.95	0.35	0.26
DCI0W6P	DM5IXKQ	Vismodegib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.28	4.47	1.37	1.64
DCW5VNX	DM5IXKQ	Vismodegib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	1.57	6.19	3.65	2.73
DCIYZ83	DM5IXKQ	Vismodegib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.44	10.07	6.19	8.96
DCLPQY5	DM5IXKQ	Vismodegib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	24.05	22.88	15.67	16.19
DCDKAJI	DM5IXKQ	Vismodegib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	4.16	5.94	8.13	8.64
DCSVJLJ	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	11.04	9.48	5.01	10.53
DCVXYA5	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	17.26	17.87	14.41	17.6
DCOZX1J	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	16.38	20.92	7.56	19.7
DCGY4EW	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	17.47	17.39	12.42	17.23
DC66ILA	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	20.66	19	12.63	18.31
DCZNE4U	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	21.09	20.21	11.04	17.92
DCHW6JM	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	13.92	15.03	9.54	15.22
DCYH90M	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	12.06	10.47	8.12	12.24
DCTLK1F	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	17.1	15.95	2.14	15.7
DCXL8JF	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	8.22	13.96	11.88	14.35
DCA6VWG	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	10.53	12.19	7	14.72
DCFZZ3B	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	14.3	15.41	12.12	14.52
DCIR1ED	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	10.96	11.35	8.64	12.6
DCOUPO7	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	8.55	6.58	2.97	7.1
DCHQU3I	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	14.52	15.53	10.68	15.13
DC4C60X	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	9.58	11.63	6.13	12.11
DCFWCQC	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	21.76	19.1	1.68	19.1
DCAABUO	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	4.95	7.11	5.57	8.65
DCXUWHF	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.97	11.34	1.97	8.81
DCFXJ95	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	8.34	11.61	7.26	12.42
DCKE3OM	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	10.75	11	7.18	12.07
DCA98VS	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.15	3.75	4.75	5.94
DC12WV4	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	9.5	11.13	7.9	10.52
DC5JCM4	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.18	9.3	7.24	9.35
DCIAZA2	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	8.04	9.56	6.45	10.83
DCDNVZ2	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	17.73	16.49	7.17	15.78
DCJ5J1W	DM5IXKQ	Vismodegib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	19.13	18.84	2.42	19.09
DC8V720	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.86	10.98	7.15	7.28
DCBAFHM	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.47	4.35	2.45	2.41
DCSCZH7	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.54	6.33	2.42	2.88
DCG5V75	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.38	5.33	2.71	1.66
DCKPC7T	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.77	11.17	5.16	5.74
DCV5R1K	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.44	8.08	4.72	5
DCSX4OW	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	5.64	9.48	2.85	8.71
DC960LC	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	5	9.72	4.53	1.19
DCR7X9Q	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	5.24	11.67	4.04	9.74
DC28RZ5	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.64	13.73	8.6	5.6
DCV4KHG	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	7.53	10.24	6.5	6.5
DCPKD6X	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	0.87	0.1	0.78	0.11
DCNP3A0	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	2.7	6.29	2.52	2.57
DCJAZ2Y	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	1.74	10.15	5.61	6.27
DC5ZJIR	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	0.01	3.75	2.1	5.23
DCQXTVS	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	2.86	6.78	5.69	5.69
DCQ3FQ3	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	0.62	6.8	7.06	6.96
DCSMVRE	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	5.53	10.64	4.46	4.04
DCMQF10	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	10.41	13.91	7.09	6.1
DCAXJ0Z	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	0.57	7.43	4.67	5.29
DCPWZBB	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	4.85	5.64	2.09	0.86
DC2HHUV	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.99	2.46	3.2	2.18
DC9PTAM	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.42	12.18	8.34	8.31
DCG6YC0	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	8.52	10.88	3.95	9.28
DC5MM1J	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.46	9.24	7.68	7.74
DCDZG8W	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.32	9.62	6.12	3.66
DC7XWM3	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.04	4.03	2.05	0.67
DC9GDB8	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.94	9.63	7.78	7.75
DCYJ8OD	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.36	5.46	4.91	4.91
DCN2BW1	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	4.14	5.24	3.87	2.73
DCQ8S3Y	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	11.33	22.69	13.94	11.77
DCEEDQU	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	7.06	11.4	7.36	7.64
DC2ZA3T	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.89	7.98	5.35	6.91
DCZ667K	DM5IXKQ	Vismodegib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	1.39	6	5.54	5.59
DCU9ZY3	DM5IXKQ	Vismodegib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	19.75	21.07	15	20.4
DC0M10M	DM5IXKQ	Vismodegib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	28.14	18.56	10.32	15.1
DCW0O6J	DM5IXKQ	Vismodegib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	14.52	16.8	12.44	16.21
DCLTX6X	DM5IXKQ	Vismodegib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	10.73	11.9	9.35	12.32
DCG3C2Q	DM5IXKQ	Vismodegib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	5.83	11.2	11.73	13.49
DCKPWF0	DM5IXKQ	Vismodegib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	0.51	8.52	8.05	7.84
DCJAHVY	DM5IXKQ	Vismodegib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	5.28	8.48	0.36	8.28
DCLODJH	DM5IXKQ	Vismodegib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	6.8	8.62	1.66	7.75
DCTDV4X	DM5IXKQ	Vismodegib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	16.33	17.35	17.71	17.67
DCD8724	DM5IXKQ	Vismodegib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.87	13.58	11.41	12.98
DCIQKZ4	DM5IXKQ	Vismodegib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	12.25	14.72	7.42	13.25
DCPRKTY	DM5IXKQ	Vismodegib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.81	11.06	8.47	11.12
DC96K8F	DM5IXKQ	Vismodegib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.14	8.45	6.89	6.98
DCQ0Y7M	DM5IXKQ	Vismodegib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.07	7.5	4.8	6.33
DC23NG6	DM5IXKQ	Vismodegib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	8.26	9.94	5.68	9.41
DCO8VBN	DM5IXKQ	Vismodegib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	0.31	10.21	6.62	8.02
DCC2QWF	DM5IXKQ	Vismodegib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.72	6.78	5.09	6.02
DCQJJIJ	DM5IXKQ	Vismodegib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.63	3.03	0.37	4.91
DC4B8HQ	DM5IXKQ	Vismodegib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	5.54	6.59	5.95	9.07
DCFWY7S	DM5IXKQ	Vismodegib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	3.24	2.57	0.38	3.5
DCQTNSR	DM5IXKQ	Vismodegib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	11.08	16.86	0.7	10.59
DCYCK8X	DM5IXKQ	Vismodegib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.94	12.52	11.74	12.38
DC24UAO	DM5IXKQ	Vismodegib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.57	7.75	6.39	7.4
DCZZ8U8	DM5IXKQ	Vismodegib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	2.92	2.21	0.82	2.41
DCKKI8L	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	6.4	12.29	10.5	11.68
DCY858Y	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.31	5.51	3.51	5.96
DCXVV9F	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	11.02	11.38	10.62	13.83
DCJ3E0E	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.94	5.23	3.79	5.89
DCQ80U6	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.06	7.14	4.34	7.16
DCMGP08	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	6.59	7.17	5.53	7.57
DCHBN11	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	11.11	11.57	10.93	14.12
DCDINLA	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	8.6	11.29	8.79	12.41
DC6Q4IB	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	6.06	6.91	7.08	9.57
DCP1IG9	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	6.02	9.36	7.55	10.75
DCNCXHY	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	6.58	5.85	6.89	9.51
DCDJ2XD	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	5.7	7.51	6.65	8.62
DCTIV37	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	2.46	3.39	5.93	7.22
DCEP4SG	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	7.98	10.78	10.23	12.1
DCBXAGB	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	1.09	2.57	2.79	4.67
DCOJEUT	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	13.89	14.63	10.28	16.11
DCVM6JY	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.03	3.54	4.31	5.81
DC5FXYJ	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.13	5.89	5.94	7.71
DCSCH37	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	7.4	8.42	7.27	9.6
DC4FU3W	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.47	5.44	5.92	7.9
DC64QRM	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	6.48	8.19	8.18	10.88
DCHIKZE	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	6.53	9.32	8.8	11.09
DC7CIVY	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.98	12.5	11.16	12.46
DCMB6G9	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	15.31	16.02	15.5	19.82
DC4LBG6	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	5.05	6.85	5.01	7.03
DCEYFU3	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.72	10.02	8.05	10.25
DC55ZN6	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	18.89	19.73	18.36	20.18
DCQP4T1	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.34	1.47	0.87	2.8
DCWC4CW	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.46	8.13	7	8.61
DC8Q12C	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.74	8.67	8.67	10.23
DCRO9QQ	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	9.41	12.73	10.75	12.52
DCUP38V	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	12.69	10.41	14.31	15.22
DC4JQNC	DM5IXKQ	Vismodegib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	6.19	8.35	7.48	8.62
DCW4KXY	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.38	4.54	2.36	3.52
DCPR1JI	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.12	3.47	2.31	0.38
DCBNUML	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.29	5.66	0.63	1.27
DCCNPM5	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	3.21	9.08	6.74	4.26
DCQKII7	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	0.13	4.85	2.5	3.25
DCB1BTO	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.36	7.12	4.04	3.44
DCJSSM6	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	5.9	11.07	7.31	3.04
DCAWV0D	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	0.81	6.82	6.52	6.52
DCOQI9I	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	0.25	6.22	4.64	5.59
DCOCUPH	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.86	8.63	1.88	1.56
DCTCPTX	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	3.91	8.44	5.59	3.97
DC5PXRA	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	2.18	9.67	8.22	5.82
DCTTCWH	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	4.16	1.48	0.45	0.5
DC9H3HA	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.5	1.93	0.89	1.32
DC7HWT4	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	7.54	11.75	12.67	13.28
DCLIOJX	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.61	4.63	4.32	2.14
DC95AU0	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.38	7.02	4.16	4.38
DC62KIR	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.28	6.63	5.45	5.95
DC9JE2Y	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	9.2	8.7	5.08	0.3
DC4V1OJ	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.32	4.23	3.31	4.18
DCGZNA5	DM5IXKQ	Vismodegib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	1.01	4.71	1.78	2.06
DCYCD72	DM5IXKQ	Vismodegib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	7.48	7.07	3.72	7.94
DC5CJBR	DM5IXKQ	Vismodegib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	0.08	3.72	3.42	2.8
DCRDVK9	DM5IXKQ	Vismodegib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	11.5	16.32	15.09	17.16
DC8R5CV	DM5IXKQ	Vismodegib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.85	5.59	2.41	2.13
DCCQUY8	DM5IXKQ	Vismodegib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.2	5.77	3.56	5.23
DCJ2LSY	DM5IXKQ	Vismodegib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.22	10.27	7.6	9.48
DCX0VPT	DM5IXKQ	Vismodegib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	20.46	21.52	22.34	22.68
DC8XBGA	DM5IXKQ	Vismodegib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.69	3.19	0.94	3.1
DCVO3HS	DM5IXKQ	Vismodegib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	4	7.99	1.24	0.9
DCOD9UJ	DM5IXKQ	Vismodegib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.62	8.09	4.05	8.79
DC64GFT	DM5IXKQ	Vismodegib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.63	6.77	3.61	4.14
DC3K6RB	DM5IXKQ	Vismodegib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	23.22	23.72	14.05	22.07
DC20KFI	DM5IXKQ	Vismodegib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	1.5	7.87	5.26	4.79
DC9SCRX	DM5IXKQ	Vismodegib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	2.92	3.32	5.2	6.05
DCY4JSZ	DM5IXKQ	Vismodegib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	2.96	12.12	8.97	8.84
DCI34HU	DM5IXKQ	Vismodegib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.19	8.41	8.98	9.45
DCHUDOA	DM5IXKQ	Vismodegib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	23.04	23.97	26	26.08
DCQZPQM	DM5IXKQ	Vismodegib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.71	4.18	2.97	4.37
DC5RESX	DM5IXKQ	Vismodegib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.23	5.66	4.41	4.73
DCSA2CS	DM5IXKQ	Vismodegib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.01	2.14	1.61	1.54
DC8YA03	DM5IXKQ	Vismodegib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	9.84	9.45	11	11.36
DCEOPJO	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	21.51	26.07	21.85	23.79
DCNDGM2	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	7.42	10.68	7.25	10.27
DCHQQU9	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.04	7.63	3.27	7.14
DC6J8Z2	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	24.17	25.79	20.23	25.9
DC1TGRA	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	3.75	6.55	4.13	7.43
DCOZMV2	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	17.1	23.88	9.24	23.57
DC2SEWV	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	7.19	11.66	4.89	11.45
DCF0AQS	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	5.49	13.66	6.98	13.42
DCWXKAG	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	12.57	15.73	15.14	16.92
DCODUXK	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.13	12.42	6.15	12.27
DCF0PR5	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	16.34	16.61	7.71	17.02
DCHBA1X	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	13.09	15.74	8.21	16.49
DCDEN0E	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.16	6.98	1	6.71
DCOY1E8	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	19.14	20.27	11.64	20.48
DC2TZAN	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.37	2.28	3.86	4.87
DCSR5JR	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.67	10.55	5.65	10.03
DCBLFU2	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	22.86	23.92	1.66	19.35
DCN5Q3Y	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	7.75	10.52	8.02	10.68
DCHA8A8	DM5IXKQ	Vismodegib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.66	9.7	7.83	8.99
DCCZZ5C	DM5IXKQ	Vismodegib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	16.19	16.16	11.43	15.31
DCLT2WK	DM5IXKQ	Vismodegib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.2	3.5	2.11	1.13
DCG0237	DM5IXKQ	Vismodegib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	7.47	8.49	6.85	6.56
DC0YRT2	DM5IXKQ	Vismodegib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	10.93	8.21	3.78	3.42
DC4K4JQ	DM5IXKQ	Vismodegib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	10.42	9.73	1.1	8.68
DCV5G6W	DM5IXKQ	Vismodegib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	13.99	12.29	0.24	16.01
DCCWE5A	DM5IXKQ	Vismodegib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	10.03	8.04	4.51	9.06
DCXJLBB	DM5IXKQ	Vismodegib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	5.32	14.58	11.19	15.07
DCCLKQB	DM5IXKQ	Vismodegib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	12.82	12.5	6.95	12.13
DC89N9B	DM5IXKQ	Vismodegib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	11.51	11.08	6.22	11.88
DCU4FVS	DM5IXKQ	Vismodegib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	14.12	14.96	16.24	17.74
DCT3OM2	DM5IXKQ	Vismodegib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.22	11.24	8.44	10.46
DC8BZ7N	DM5IXKQ	Vismodegib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	7.67	10.12	5.19	8.36
DCPL9GS	DM5IXKQ	Vismodegib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	2.82	8.88	2.95	8.91
DCTFV7O	DM5IXKQ	Vismodegib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.49	7.41	4.26	5.92
DC207ZS	DM5IXKQ	Vismodegib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	2.79	6.76	4.06	6.61
DC6K8PZ	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	16.86	14.05	11.89	13.33
DCDRGWC	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	8.71	7.52	3.81	7.52
DCFQ00K	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6.4	5.13	1.53	6.15
DCKP4VP	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	11.7	10.05	5.82	10.62
DCUZR7D	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	8.96	5.78	1.93	6.04
DCSRZBV	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	7.21	9.95	6.4	11.02
DCFAOYW	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	10.46	11.53	7.53	13.34
DCZFKNE	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	16.02	14.16	7.93	13.61
DCPVFKO	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	17.13	12.37	6.5	13.01
DCY8O52	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	6.09	5.5	2.99	6.92
DCK1XRD	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	15.74	12.65	10.56	15.66
DCL2OXC	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	13.02	13.53	13.41	16.03
DCJZYZJ	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	12.78	12.92	11.6	14.02
DCLFOVV	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	6.62	7.17	5.38	7.98
DC0YUE8	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	16.07	16.15	9.82	17.5
DCAMVES	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	11.33	11.12	9.13	12.54
DCNJ83Z	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	11.95	11.5	10.12	12.83
DCWFIGC	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	9.06	9.12	6.22	10.26
DCZ8WGE	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	5.69	8.45	4.05	10.34
DCGAL8F	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	5.15	5.55	2.85	6.73
DCMAU9X	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	13.14	13.66	10.21	14.78
DCE18U0	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	10.37	10.91	8.62	10.79
DCG6N3M	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	6.26	10.19	8	10.23
DCY1OX5	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	7.84	9.28	7.95	9.74
DCETPJ9	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	4.41	3.87	0.4	4.53
DC4TFTA	DM5IXKQ	Vismodegib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	11.31	12.49	10.59	12.27
DC6EGUC	DM5IXKQ	Vismodegib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.39	7.95	2.95	4.35
DC93X87	DM5IXKQ	Vismodegib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	19.73	16	18.42	18.45
DCLIBKC	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.47	9.73	4.49	5.69
DCZXHUL	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	5.01	6.51	4.2	2.22
DCU3ORN	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.64	8.85	4.57	5.21
DC8MFP0	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	5.91	8.35	6.29	0.44
DCRYLTX	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	5.41	9.82	12.93	12.94
DC5G399	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	1.06	4.44	2.54	2.42
DCP4JCI	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	0.66	8.23	5.05	6.47
DCY13ST	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	2.1	6.2	3.6	5.5
DCFHMZB	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.32	9.19	1.09	5.66
DC56XXU	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	3	10.22	1.44	7.64
DCDHEJZ	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.22	5.55	4.75	5.41
DCH1L8R	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.91	10.06	6.62	6.65
DCTSSHO	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.5	2.65	1.22	2.58
DCR1CDH	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	7.03	10.82	9.95	11.99
DC4398N	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.82	6.03	2.76	4.99
DC8OCUF	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.87	3.05	1.77	0.96
DC012X8	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	0.96	7.35	4.79	5.62
DC8IQ00	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	4.95	8.17	2.61	0.09
DCAIRNR	DM5IXKQ	Vismodegib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.02	10.25	3.09	11.03
DCERNR2	DM5IXKQ	Vismodegib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.67	5.68	3.77	5.13
DC5NWZ1	DM5IXKQ	Vismodegib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	1.33	1.41	0.07	2.89
DCVFMUO	DM5IXKQ	Vismodegib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	5.35	7.73	5.25	7.85
DCZLVHK	DM5IXKQ	Vismodegib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.52	6.33	4.5	6.48
DCLPE7N	DM5IXKQ	Vismodegib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	14.41	14.86	11.37	14.93
DCCTDV0	DM5IXKQ	Vismodegib	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	SYNERGxDB Database	Investigative	T98G	6.56	6.56	10.24	10.24
DCV1OJ8	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.88	11.5	7.79	7.85
DCL6BWE	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.2	8.01	6.12	5.82
DCMXN3J	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	7.82	9.85	1.19	9.23
DCQAU75	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.61	8.16	3.95	2.94
DCTK2ZT	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	1.97	4.36	4.8	6.58
DCV4ZSQ	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	0.62	5.87	1.06	5.05
DCA2QGR	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	5.23	11.48	6.21	10.89
DCWRHP8	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	6.3	12.12	5.31	5.06
DC7X3TP	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	15.18	13.05	6.16	5.66
DCV4LX3	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	0.19	5.1	1.7	2.96
DCFK8RC	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.53	6.24	4.71	4.97
DCW3R2D	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	4.45	4.55	0.52	0.7
DCJG3EI	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.26	5.13	4.29	6.14
DCOID1N	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.44	9.21	5.83	5.58
DC97S2G	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.94	4.07	2.77	1.44
DCSW5V8	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	5.09	8.81	3.78	3.78
DC4A9HY	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.21	5.35	3.98	3.74
DC1UX16	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.03	7.62	5.46	5.76
DCN5VQH	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	5.9	12.76	4.04	10.03
DC6UCGN	DM5IXKQ	Vismodegib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	12.09	15.13	8.43	6.02
DC4LEQN	DM5IXKQ	Vismodegib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	11.83	11.19	7.46	12.79
DCOJVF5	DM5IXKQ	Vismodegib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	24.36	25.49	19.11	19.08
DCI8VVO	DM5IXKQ	Vismodegib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	2.76	5.54	3.72	1.5
DCO1G7V	DM5IXKQ	Vismodegib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.32	3.02	0.86	1.46
DC9YZ20	DM5IXKQ	Vismodegib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.66	8.43	0.3	6.32
DCJ48VI	DM5IXKQ	Vismodegib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	9.4	16.12	13.48	14.61
DC3KEJX	DM5IXKQ	Vismodegib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.31	4.09	2.78	2.82
DCOQ025	DM5IXKQ	Vismodegib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.19	12.09	9.62	10.19
DC3J0SJ	DM5IXKQ	Vismodegib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	6.86	6.12	1.03	4.22
DC0WJ4C	DM5IXKQ	Vismodegib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.7	4.86	1.72	6.52
DC7K6Q7	DM5IXKQ	Vismodegib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.86	3.91	0.34	4.95
DC8MVJI	DM5IXKQ	Vismodegib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	6.96	8.25	7.18	7.47
DC00AQK	DM5IXKQ	Vismodegib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	0.84	1.59	0.73	5.02
DC4NY77	DM5IXKQ	Vismodegib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	11.58	11.15	11.89	13.63
DCHSPRT	DM5IXKQ	Vismodegib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	0.59	2.45	1.33	3.66
DCEH0DB	DM5IXKQ	Vismodegib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.27	9.35	1.49	10.23
DCSFDPF	DM5IXKQ	Vismodegib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	4.84	4.88	1.92	6.39
DC1JOBK	DM5IXKQ	Vismodegib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	7.69	6.76	5.61	6.49
DCXJ1ZS	DM5IXKQ	Vismodegib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	7.26	10.46	9.2	12.03
DC5C3R6	DM5IXKQ	Vismodegib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	11.83	11.83	13.75	14.87
DCTLBAW	DM5IXKQ	Vismodegib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.87	7.55	5.39	7.43
DC36EKL	DM5IXKQ	Vismodegib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.17	2.1	0.45	2.45
DCN8IB2	DM5IXKQ	Vismodegib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	4.31	3.64	0.84	4.4
DC8336B	DM5IXKQ	Vismodegib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	8.27	10.96	12.68	13.13
DCHGLVO	DM5IXKQ	Vismodegib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	6.93	9.09	1.98	9.35
DCG27A8	DM5IXKQ	Vismodegib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.14	8.29	4.1	4.21
DCMRP3B	DM5IXKQ	Vismodegib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.51	3.54	2.85	3.06
DCQ9YQD	DM5IXKQ	Vismodegib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	16.35	21.21	3.64	21.52
DCGBEL0	DM5IXKQ	Vismodegib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.11	4.82	1.22	1.22
DC4Z185	DM5IXKQ	Vismodegib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	18.76	17.28	0.71	21.63
DC6V19B	DM5IXKQ	Vismodegib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	6.35	12.57	8.87	12.99
DC8TMOZ	DM5IXKQ	Vismodegib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	1.7	6.78	5.54	5.35
DC6YRE5	DM5IXKQ	Vismodegib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	0.78	2.69	0.53	0.53
DCRZPZ5	DM5IXKQ	Vismodegib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.46	2.02	0.49	0.45
DCN7Q5N	DM5IXKQ	Vismodegib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.43	10.78	6.01	6.01
DCXKG8Z	DM5IXKQ	Vismodegib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.67	3.07	3.06	3.43
DCSX8GQ	DM5IXKQ	Vismodegib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.1	4.35	1.92	3.41
DCLSJHG	DM5IXKQ	Vismodegib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.32	3.75	1.17	4.46
DCK3AHF	DM5IXKQ	Vismodegib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	5.24	5.57	0.07	5.25
DC7IK88	DM5IXKQ	Vismodegib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	9.23	8.62	12.61	12.45
DCE4NUQ	DM5IXKQ	Vismodegib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	8.59	14.31	0.8	6.52
DCT4EJR	DM5IXKQ	Vismodegib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.96	9	2.43	5.41
DC3THBN	DM5IXKQ	Vismodegib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	3.55	5.23	5.39	6.75
DCVKDT0	DM5IXKQ	Vismodegib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	0.07	6.19	2.86	5.99
DCTSAHK	DM5IXKQ	Vismodegib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	17.08	15.38	1.2	9.07
DCGAI45	DM5IXKQ	Vismodegib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	11.26	12.24	5.98	11.34
DCWQXDO	DM5IXKQ	Vismodegib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.67	6.1	1.68	5.83
DC8UAGZ	DM5IXKQ	Vismodegib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.56	10.17	2.4	7.61
DCKVFKJ	DM5IXKQ	Vismodegib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.74	6.22	4.77	6.84
DC42FR3	DM5IXKQ	Vismodegib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.63	7.19	4.23	7.65
DCWY7OQ	DM5IXKQ	Vismodegib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	8.13	8.74	1.52	7.1
DC3VA59	DM5IXKQ	Vismodegib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.29	6.66	4.83	4.76
DCBYU0Y	DM5IXKQ	Vismodegib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	14.18	18.62	16.32	14.45
DCA8YMV	DM5IXKQ	Vismodegib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.55	4.59	1.03	1.03
DCPW869	DM5IXKQ	Vismodegib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	0.6	5.11	6.48	6.63
DCX6DXV	DM5IXKQ	Vismodegib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.3	7.21	0.66	0.3
DCAWDSX	DM5IXKQ	Vismodegib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	2.17	6.61	4.17	3.02
DCR0RRW	DM5IXKQ	Vismodegib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.29	4.35	2.97	3.21
DCNUUMQ	DM5IXKQ	Vismodegib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	5.45	7.04	6.45	6.72
DCXLLZG	DM5IXKQ	Vismodegib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.26	10.53	10.26	10.65
DC098WJ	DM5IXKQ	Vismodegib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.2	5.58	4.27	4.24
DCP8U6R	DM5IXKQ	Vismodegib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	11.37	15.17	16.92	17.24
DCHNJH3	DM5IXKQ	Vismodegib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.2	3.44	2.68	0.76
DCQH126	DM5IXKQ	Vismodegib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	7.78	10.43	5.5	5.42
DCROUAQ	DM5IXKQ	Vismodegib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.05	7.05	5.52	4.97
DC4XX3L	DM5IXKQ	Vismodegib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	7.46	12.05	4.69	4.96
DCT3N2H	DM5IXKQ	Vismodegib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	7.74	10.7	12.78	13.04
DCYGRZG	DM5IXKQ	Vismodegib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.12	3.13	1.53	2.77
DC7ZDZ0	DM5IXKQ	Vismodegib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	8.87	8.51	6.01	9.91
DCVQ0QS	DM5IXKQ	Vismodegib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	7.86	6.89	6.59	8.42
DCJSRHO	DM5IXKQ	Vismodegib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	4.5	1.13	2.24	2.24
DC9DK48	DM5IXKQ	Vismodegib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	5.92	10.91	3.34	8.65
DC2GD3C	DM5IXKQ	Vismodegib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.14	2.48	2.45	4.75
DC2WV4I	DM5IXKQ	Vismodegib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	7.28	7.81	5.08	7.83
DCS5CC3	DM5IXKQ	Vismodegib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	7.75	9.84	7.52	10.35
DCJT144	DM5IXKQ	Vismodegib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.79	5.3	3.1	5.43
DCHAKFK	DM5IXKQ	Vismodegib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.96	1.87	1.45	3.04
DCA0Q62	DM5IXKQ	Vismodegib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.12	4.46	5.18	6.99
DCN1T6T	DM5IXKQ	Vismodegib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	1.23	2.87	1.54	3.03
DCRQROH	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	16.51	16.94	14.66	15.98
DCFFKW4	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	18.02	13.92	9.32	14.46
DCTWHGN	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	18.93	20.09	16.1	20.29
DCYLJFJ	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	11.03	10.97	7.94	12.57
DC1PNEM	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	24.58	21.25	16.97	22.85
DCJS2E2	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	7.3	8.16	4.16	9.48
DCELR9M	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	15.08	11.56	7.75	11.77
DCPLLTU	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	18.98	15.8	10.33	14.96
DC1PLQM	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	8.89	6.79	1.83	6.78
DCGHIOA	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	19.4	14.1	11.76	15.49
DCC2YPB	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	21.08	21.54	14.24	21.73
DC7CSIB	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	15.57	12	8.5	13.55
DC8MTTI	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	8.36	8.55	7.45	9.66
DCABDF7	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	11.08	13.19	10.75	14.63
DCSN2RP	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	12.85	14.49	10.53	15.78
DCFEOLK	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	5.36	8.28	6.07	9.47
DC4GI6Z	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	22.55	15.07	13.42	16.36
DCRZWSL	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	7.86	16.16	11.63	16.59
DCYA89K	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	19.34	15.66	1.46	16.08
DCWQ3IU	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.98	6.88	4.65	8.18
DCSPK1S	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	12.75	14.2	6.58	16.32
DCUSMF0	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	19.54	20.62	12.63	20.78
DCX601H	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	5.85	7.23	3.99	8.25
DCWM7EB	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	13.86	16.24	13.78	15.97
DCQU74P	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	16.42	16.67	13.93	16.26
DCX8XBY	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.48	5.64	2.16	5.8
DCA2CJA	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	12.34	12.24	10.43	12.62
DC7GVQ9	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.61	2.45	0.58	3.61
DCSCQXJ	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.68	9.88	8.08	9.86
DCP2XU8	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	16.88	17.52	15.74	19.45
DC0Z8ZQ	DM5IXKQ	Vismodegib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	4.44	5.58	3	5.39
DCFRAKY	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.58	15.28	10.93	11.91
DCK8UGB	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.93	9.94	6.13	8.65
DCBQVDZ	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.98	8.95	4.1	7.77
DCNEOAT	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	8.12	11.42	5.64	9.16
DCA1NCN	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	8.87	11.55	3.43	7.02
DC7ZX63	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	11.22	15.52	10.84	14.37
DCF6SP6	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	9.25	14.37	7.02	6.31
DCR06DQ	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	6.28	12.28	8.8	8.15
DCH9GNK	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	6.72	12.97	14.88	15.35
DCM43HH	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	1.55	4.19	2.83	2.6
DCQ41NK	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	4.83	10.23	7.96	8.54
DCN8098	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	5.88	11.94	8.41	13.54
DCWXLR7	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	4.01	15.13	12.83	14.39
DCNXPY4	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	2.35	6.8	1.79	3.43
DCKH2YP	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	24.16	25.04	25.87	26.48
DCUF09T	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	6.09	14.17	10.9	9.87
DC5G1HL	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.06	13.88	6.88	6.62
DCV4U5M	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	0.1	9.02	5.97	6.9
DCSGM2H	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	11.92	14.45	16.06	16.78
DCJVC08	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	2.74	15.69	12.8	11.05
DCEPA15	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.88	7.01	1.15	4.93
DCZZ5D3	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.56	8.59	7.62	8.38
DC8LIFS	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.78	5.6	0.56	3.94
DCI07LH	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	9.55	10.87	6.22	7.8
DCYM41D	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.02	7.01	4.08	7.34
DCMTKNG	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	3.33	8.16	5.4	7.1
DCLQ3SG	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.06	11.27	3.51	10.47
DC5YKLH	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.05	5.5	2	4.64
DCW4OB8	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.68	7.18	6.67	8.69
DCY5Y54	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	10.02	18.38	13.23	13.16
DCTXDAR	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	6.07	13.41	12.05	10.88
DCW97TN	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.42	6.9	3.8	6.61
DCZB598	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.4	6.52	3.23	4.35
DCPM68T	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	8.27	18.45	11.53	16.73
DCBVMLB	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	13.06	21.78	13.81	11.74
DCAFIHJ	DM5IXKQ	Vismodegib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.03	8.18	4.41	9.36
DC41FDE	DM5IXKQ	Vismodegib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	3.3	8.29	4.99	3.6
DCHXMKM	DM5IXKQ	Vismodegib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.68	15.23	12.96	13.57
DCONA4R	DM5IXKQ	Vismodegib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	20.73	22.98	24.81	25.03
DCXQDRJ	DM5IXKQ	Vismodegib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.04	3.33	0.59	1.22
DCWE0V2	DM5IXKQ	Vismodegib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	9.47	15.31	4.07	3.65
DC43KDC	DM5IXKQ	Vismodegib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	6.66	7.65	9.43	9.44
DCDJS6F	DM5IXKQ	Vismodegib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	8.01	12.76	10.44	11.71
DCMUGPW	DM5IXKQ	Vismodegib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.37	5.65	2.65	1.77
DCFYUCD	DM5IXKQ	Vismodegib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	0.79	3.29	4.11	4.7
DCAF6KV	DM5IXKQ	Vismodegib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	5.2	6.64	1.33	1
DC969PV	DM5IXKQ	Vismodegib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	4.35	5.56	2.24	0.82
DC50J8E	DM5IXKQ	Vismodegib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.12	4.96	4.11	7.19
DC2MR13	DM5IXKQ	Vismodegib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.45	6.35	8.36	9.15
DCKLXF6	DM5IXKQ	Vismodegib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	4.21	0.64	0.74	0.77
DCXN5DR	DM5IXKQ	Vismodegib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	24	25.37	27.05	26.1
DC8VDBH	DM5IXKQ	Vismodegib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	6.48	7.16	3.08	7.07
DC2IU0X	DM5IXKQ	Vismodegib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.59	3.7	0.78	0.18
DC7G1L2	DM5IXKQ	Vismodegib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	0.41	3.29	1.31	1.55
DCJZ229	DM5IXKQ	Vismodegib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	4.69	8.11	5.78	3.81
DC9P1G5	DM5IXKQ	Vismodegib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.17	2.03	0.01	0.01
DC56ENP	DM5IXKQ	Vismodegib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	3.32	2.72	2.61	2.72
DC1K5A1	DM5IXKQ	Vismodegib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	15.73	16.47	16.45	18.5
DCOF53Q	DM5IXKQ	Vismodegib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	2.86	4.12	7.32	8.73
DCSGMC4	DM5IXKQ	Vismodegib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	0.67	1.1	2.12	4.94
DCUY268	DM5IXKQ	Vismodegib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	5.83	10.7	7.38	5.53
DC97HS8	DM5IXKQ	Vismodegib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.74	5.09	0.52	5.27
DCYTFFQ	DM5IXKQ	Vismodegib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.1	6.73	2.34	1.98
DCWF3NV	DM5IXKQ	Vismodegib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.33	6.61	2.2	2.27
DCVTCLO	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.4	9.89	6.23	6.97
DCN5MRE	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	7.96	11.97	4.77	9.48
DCFNTZB	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	9.69	11.59	9.37	6.36
DCEV29H	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	3.64	10.26	3.5	7.13
DCK7LN7	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	12.05	7.67	0.02	0.02
DCAXEVF	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.21	8.61	4.94	4.94
DC54E06	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	2.17	8.03	0.5	2.94
DCWGK0V	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	0.38	3.53	2.71	2.49
DCZJHTE	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	2.01	6.43	1.5	4.75
DCBVLX5	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	1.96	7.46	1.36	6.3
DC7PIKD	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	0.04	9.97	5.74	7.38
DCXKNXP	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	7.29	14.15	10.69	13.04
DCTOH9O	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.37	8.03	1.57	1.21
DCFLVNZ	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	1.2	5.86	3.83	3.68
DCOLHQ3	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	0.6	11.22	4.42	6.7
DC782Y7	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	1.92	7.69	5.24	4.53
DC3IA4I	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.31	5.63	1.9	3.89
DCW3Z9Z	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.49	10.45	7.44	9.5
DCEEOZN	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.01	7.27	2.09	5.79
DCS08D3	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.85	9.76	4.87	4.87
DC6MH2X	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.5	5.16	3.93	2.95
DC55O9K	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.26	8.68	5.24	7.15
DC3I1US	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	5	9.6	5.49	7.94
DCYINTX	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.38	8.12	6.51	7.49
DCFM1J3	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	5.08	12.04	10.19	9.15
DC39JDZ	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	3.77	7.3	1.37	0.01
DCAYIT3	DM5IXKQ	Vismodegib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.86	7.86	3.36	6.88
DC5C7KL	DM5IXKQ	Vismodegib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	20.03	17.85	12.62	18.11
DCG5KHA	DM5IXKQ	Vismodegib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	15.94	17.23	10.03	16.46
DCXYNF4	DM5IXKQ	Vismodegib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	12.56	16.71	13.47	15.9
DCTLRNQ	DM5IXKQ	Vismodegib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	14.01	15.87	13	16.49
DCXMFOS	DM5IXKQ	Vismodegib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	18.2	20.67	20.28	21.71
DC2EYA6	DM5IXKQ	Vismodegib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	14.32	15.22	10.97	15.39
DC3Y5IP	DM5IXKQ	Vismodegib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	14.47	14.82	12.48	16.12
DCZ3NOA	DM5IXKQ	Vismodegib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	17.27	19.12	12.38	19.19
DCA83I8	DM5IXKQ	Vismodegib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	6.44	12.34	4.83	12.1
DCB9D5B	DM5IXKQ	Vismodegib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	19.2	19.05	2.31	18.03
DC59KFM	DM5IXKQ	Vismodegib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	14.16	13.88	3.1	13.97
DC9TD39	DM5IXKQ	Vismodegib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	17.2	17.85	7.51	17.98
DCY7Q91	DM5IXKQ	Vismodegib	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	0.76	9.89	7.49	11.37
DC54IHC	DM5IXKQ	Vismodegib	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	1.44	6	7.12	8.33
DC3J5K7	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	6.93	11.71	8.84	10.56
DCS85A2	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	6.58	7.33	1.08	7.16
DCZ3JZA	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	14.61	11.45	7.37	12.57
DCD9YXM	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	7.06	8.18	3.41	6.99
DCBWQJV	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	14.21	12.38	7.7	13.42
DCC6WN3	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	17	17.15	10.55	16.18
DC5EE3V	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	34.36	33.69	17.27	30.75
DC8VG2G	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	17.83	18.01	12.19	18.06
DCOGTC0	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	12.73	10.03	3.86	9.87
DCLLGDK	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	4.67	11.66	9.74	12.05
DCB714H	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	12.56	13.53	14.15	15.89
DCGGFT5	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	5.04	10.47	5.79	11.73
DCN12PT	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.36	5.62	0.43	5.57
DC5WHS4	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	8.32	8.58	6.15	10.04
DCJZOYV	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.57	6.34	1.42	7.34
DCLNUVJ	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	28.49	22.86	26.13	26.17
DCZNP4M	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	13.65	14.79	12.3	14.66
DCA0GAZ	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	6.35	11.71	7.98	11.43
DCQYP0A	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	9.86	8.95	6.13	9.24
DCUAIQH	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	8.05	7.64	4.59	9.17
DC67CKO	DM5IXKQ	Vismodegib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	5.68	9.5	7.04	9.24
DCRE8GI	DM5IXKQ	Vismodegib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	0.82	7.55	8.74	9.84
DCGHRL4	DM5IXKQ	Vismodegib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.27	1.79	0.82	3.54
DC3W3U3	DM5IXKQ	Vismodegib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	2.07	9.18	7.99	9.4
DC0CCYZ	DM5IXKQ	Vismodegib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	8.88	15.31	6.42	7.43
DC93O8W	DM5IXKQ	Vismodegib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.38	5.41	1.65	1.79
DCWBNQI	DM5IXKQ	Vismodegib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.63	3.62	0.02	2.42
DCI74S0	DM5IXKQ	Vismodegib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.34	2.94	1.01	0.53
DCRWHKD	DM5IXKQ	Vismodegib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	7.11	8.4	3.17	2.65
DCLQXR6	DM5IXKQ	Vismodegib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	1.5	6.97	5.22	5.26
DC5V53V	DM5IXKQ	Vismodegib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.46	3.76	1.35	1.29
DCC5WEN	DM5IXKQ	Vismodegib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	1.48	9.52	9.12	3.81
DC25GT6	DM5IXKQ	Vismodegib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.97	4.69	2.31	1.02
DC21X2U	DM5IXKQ	Vismodegib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	1.21	3.51	3.49	3.33
DCGN6JN	DM5IXKQ	Vismodegib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	2.77	3.69	3.39	2.91
DCQCZQ2	DM5IXKQ	Vismodegib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.51	6.35	3.2	3.2
DCKB1DP	DM5IXKQ	Vismodegib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	1.22	8.1	5.61	4.87
DC3E17W	DM5IXKQ	Vismodegib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.62	1.51	1.41	1.3
DCD2PE1	DM5IXKQ	Vismodegib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.73	4.1	4.35	1.76
DC8RKR8	DM5IXKQ	Vismodegib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.54	3.85	4.12	4
DCMASTF	DM5IXKQ	Vismodegib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	7.98	10.67	2.76	2.43
DC6CE0F	DM5IXKQ	Vismodegib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	1.54	8.39	0.29	5.91
DCR5E64	DM5IXKQ	Vismodegib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.24	4.53	2.25	3.06
DC1XXHE	DM5IXKQ	Vismodegib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	0.35	2.52	0.84	4.35
DC0G52X	DM5IXKQ	Vismodegib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	12.88	16.28	18.61	19.28
DCGXIJ6	DM5IXKQ	Vismodegib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	3.87	6.12	2.81	2.41
DCB1RWU	DM5IXKQ	Vismodegib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.21	8.14	5.49	5.62
DCFHNRK	DM5IXKQ	Vismodegib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	20.56	22.97	25.11	25.3
DCUHPNB	DM5IXKQ	Vismodegib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.02	3.14	0.62	0.58
DCZGJO1	DM5IXKQ	Vismodegib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	5.76	11.08	6.57	12.07
DCHIVWI	DM5IXKQ	Vismodegib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.72	11.66	5.07	10.22
DC8U39Z	DM5IXKQ	Vismodegib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	5.18	8.39	7.51	7.28
DCEJU5Y	DM5IXKQ	Vismodegib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	21.27	16.05	12.65	18.3
DCBS24R	DM5IXKQ	Vismodegib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	14.76	15.96	13.66	16.59
DCR5F5Q	DM5IXKQ	Vismodegib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	39.89	36.7	26.95	37.74
DCMDG3W	DM5IXKQ	Vismodegib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	6.89	8.32	2.99	5.56
DCL22PL	DM5IXKQ	Vismodegib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.66	8.58	6.57	8.26
DC94Y37	DM5IXKQ	Vismodegib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.27	3.81	3.69	3.9
DCSO9GJ	DM5IXKQ	Vismodegib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	17.73	19.79	18.91	18.99
DCW1ZV0	DM5IXKQ	Vismodegib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	12.47	13.64	11.68	15.11
DC2JJUE	DM5IXKQ	Vismodegib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	6.04	11.96	11.24	12.56
DCZK60U	DM5IXKQ	Vismodegib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.07	5.41	3.41	4.23
DCS3S4V	DM5IXKQ	Vismodegib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	28.88	28.79	26.28	28.73
DCXE00E	DM5IXKQ	Vismodegib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	13.05	13.26	12.85	14.08
DCKPPR1	DM5IXKQ	Vismodegib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.4	9.97	9.11	10.45
DC11Q2V	DM5IXKQ	Vismodegib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	15.66	15.32	8.7	14.94
DCUMDDT	DMT1OZ6	MK-2206	Phase 2	21	DM1WEHC	Buparlisib	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	32.173	31.253	15.202	18.833
DC5I81T	DMT1OZ6	MK-2206	Phase 2	21	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	L-1236	11.39	11.61	6.65	9.02
DCZVZ9P	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	9.53	9.48	12.65	16.26
DCB22JO	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	2.36	2.72	6.03	8.24
DCWFQB4	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	1.59	3.3	11.51	12.9
DCAKRPF	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	0.06	1.04	5.29	5.69
DCIQZ42	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	8.96	7.55	11.1	13.86
DCYF3YD	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	3.07	4.09	10.93	12.67
DC4NDC0	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	3.59	1.69	1.73	2.79
DC4X7RY	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	1.56	9.81	12.77	13
DCPG3V8	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	2.26	1.1	2.59	9.25
DCYYWX6	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	11.59	12.42	14.87	17.08
DCLA14V	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	12.62	13.86	17.22	17.97
DC3OCBP	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	U-HO1	13.27	12.46	2.98	6.24
DC51XGW	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	7.88	9.48	16.04	16.58
DCPUCRG	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	0.69	0.12	6.29	8.05
DCC6Q3J	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	2.3	0.93	1.43	8.54
DCLL49C	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	0.66	0.18	3.71	10.31
DCYE2H2	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	25.09	25.18	33.46	35.03
DCKEM2B	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	8.2	9.41	13.78	14.44
DCCUPDI	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	1.32	3.07	2.9	5.95
DCLYGZ8	DMT1OZ6	MK-2206	Phase 2	21	DM2JGQ3	Trametinib	Approved	34	.	.	.	.	Embryonal rhabdomyosarcoma	ALMANAC Dataset	Investigative	Rh36	20.793	20.647	8.302	10.977
DCJ4851	DMT1OZ6	MK-2206	Phase 2	21	DM2JGQ3	Trametinib	Approved	34	.	.	.	.	Embryonal rhabdomyosarcoma	ALMANAC Dataset	Investigative	CTR	10.133	9.369	4.299	5.616
DCYKNNJ	DMT1OZ6	MK-2206	Phase 2	21	DM2JGQ3	Trametinib	Approved	34	.	.	.	.	Embryonal rhabdomyosarcoma	ALMANAC Dataset	Investigative	RD	15.828	15.897	12.057	14.465
DC90LHD	DMT1OZ6	MK-2206	Phase 2	21	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	13.257	12.463	2.971	6.238
DCBW51D	DMT1OZ6	MK-2206	Phase 2	21	DM3XQDH	JQ1	Investigative	0	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	13.118	14.111	1.166	6.73
DC7FY3J	DMT1OZ6	MK-2206	Phase 2	21	DM3XQDH	JQ1	Investigative	0	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	1.911	2.514	2.684	5.142
DC8RYOL	DMT1OZ6	MK-2206	Phase 2	21	DM48K0X	Carfilzomib	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	11.971	9.493	7.584	11.245
DC60TP7	DMT1OZ6	MK-2206	Phase 2	21	DM48K0X	Carfilzomib	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	10.202	11.102	1.983	5.503
DCV1211	DMT1OZ6	MK-2206	Phase 2	21	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	3.45	3.52	6.67	8.21
DCSRHL6	DMT1OZ6	MK-2206	Phase 2	21	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	4.914	2.955	4.165	6.109
DCFETFN	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	2.33	1.42	9.46	11.91
DC4KVDN	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	2.24	1.11	7.93	10.02
DCAB40L	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	2.48	3.19	9.23	10.84
DC4NSRE	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	7.17	7.76	9.44	12.54
DCD6SBT	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	9.88	9.36	12.29	15.31
DCE19QT	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	7.02	6.78	11.24	14.05
DC7T7DN	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	7.56	6.77	0.96	8.58
DCDSGVS	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	1.85	1.1	8.44	10.37
DCSANPA	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	7.93	9.05	10.5	13.26
DCNMWRF	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	19.75	19.43	18.86	21.24
DCNH6J2	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	8.68	7.69	9.58	12.23
DC5JP4V	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	1.89	0.48	0.87	7.3
DCRGVC8	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	3.38	5.1	2.61	9.74
DCYAJ4Q	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	3.36	4.34	5.55	10.37
DCXF5Q2	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	8.49	9.3	1.82	10.77
DCIHS7F	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	4.43	3.88	1.05	11.25
DCNO56T	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	5.3	3.43	6.63	10.16
DC2TW5C	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	1.68	1.24	5.97	9.95
DCD99YX	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	16.85	11.95	14.36	18.42
DCGCIY5	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	8.4	7.49	11.59	14.29
DC32UPR	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	3.43	2.97	9.37	12.41
DC81SV1	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	3.08	1.97	7.66	9.95
DCK98N5	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	5.48	6.1	8.05	12.4
DCAUUGZ	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	0.43	1.18	2.28	5.88
DCA065B	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	0.83	0.14	2.46	6.28
DCYAN7T	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	6.16	4.07	6.52	9.56
DC9F0DX	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	6.39	5.73	12.41	14.64
DCFG7P7	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	1.7	1.51	5.61	7.67
DCPF62G	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	5.12	11.97	13.65	16.38
DCMCNEN	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	11.14	12.94	5.43	13.85
DCIH705	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	2.4	3.9	7.68	8.56
DCAS7R5	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	0.25	2.65	2.59	6.45
DC1B2QJ	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	5.44	5.5	10.45	12.16
DCDZOHV	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	15.04	12.19	9.91	12.9
DCY2P31	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	6.06	5.48	5.35	9.99
DCG6WL7	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	16.19	16.38	17.76	21.46
DCUY405	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.44	0.65	0.78	4.11
DCOVT6P	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	0.85	2.06	5.22	9.26
DCBUA3G	DMT1OZ6	MK-2206	Phase 2	21	DM7L8SG	AZD8055	Discontinued in Phase 1/2	4	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	0.8	1.06	4.844	6.859
DCNZEIH	DMT1OZ6	MK-2206	Phase 2	21	DM7WFZ8	Formononetin	Investigative	0	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	16.206	13.701	6.093	9.135
DC2JXK7	DMT1OZ6	MK-2206	Phase 2	21	DM7WFZ8	Formononetin	Investigative	0	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	U-HO1	16.21	13.7	6.09	9.14
DCJIVV2	DMT1OZ6	MK-2206	Phase 2	21	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	19.81	21.74	6.41	6.46
DC2BU3S	DMT1OZ6	MK-2206	Phase 2	21	DM8X2EH	Everolimus	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	7.956	8.196	8.219	10.233
DC1ZTB8	DMT1OZ6	MK-2206	Phase 2	21	DM9R0ZL	CA4P	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	4.66	5.96	4.665	7.923
DCLZL4L	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	8.54	7.59	10.23	12.85
DCTFUP0	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	3.75	6.04	10.61	13.95
DCJ20OX	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	4.3	5.66	7.06	10.91
DC4SOSF	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	1.76	8.51	9.7	11.12
DCVCGNT	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	2.16	6.48	8.96	11.4
DCADA1Y	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	2.75	4.67	4.71	7.66
DCF234O	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	9.29	8.56	1.76	11.09
DCTM5N0	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	5.51	7.03	7.23	9.89
DCQWUA1	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	5.62	7.34	12.89	14.1
DCSYJK0	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	0.04	9.96	12.51	16.02
DCHGIVM	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	16.27	17.2	5.62	17.38
DCN64MP	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	1.75	1.03	1.81	6.97
DC3MOV6	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	0.9	4.26	6.44	8.81
DC2A41P	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	8.72	8.58	10.9	15.11
DCCDRUT	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	1.16	0.92	5.16	6.77
DCX8YE0	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	7.18	7.38	7.89	14.19
DC7UJYZ	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	9.41	8.91	15.32	10.92
DCF9UUB	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	1.68	0.2	3.86	6.93
DCU8W8Q	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	8.53	9.21	10.28	10.34
DCI1WR6	DMT1OZ6	MK-2206	Phase 2	21	DMA9SEY	GDC-0084	Phase 2	21	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	51.292	51.2	17.306	22.976
DCXCC6U	DMT1OZ6	MK-2206	Phase 2	21	DMAI95U	PMID25656651-Compound-5	Patented	15.5	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	5.287	8.569	9.478	11.661
DCFK3CS	DMT1OZ6	MK-2206	Phase 2	21	DMB0NVQ	Steroid derivative 1	Patented	15.5	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	4.493	5.253	0.29	1.964
DCBFQUR	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	5.9	5.67	3.4	5.55
DCWV1D9	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	3.28	2.53	4.38	6.58
DCCSU4U	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	3.26	3.35	4.48	8.5
DCB0W6J	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	3.55	2.22	1.9	4.89
DCDROV8	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	3.75	4.08	3.59	6.9
DCDNV8F	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	3.45	2.33	3.61	6.99
DCF7SL7	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	4.93	4.39	4.71	7.46
DCI40S4	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	4.27	2.03	1.48	4.32
DC5KAPJ	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	7.72	10.41	3.17	10.11
DCQP548	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	1.35	1.06	1.27	5.26
DCJXBVU	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	1.85	1.05	1.19	4.57
DC2D8NG	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	1.98	0.51	3.39	7.6
DC0ORDL	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	11.8	11.68	12.79	16.24
DCJMKX8	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	2.56	2.23	3.88	6.36
DCNRH0O	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	0.43	0.15	7.32	9.97
DC83TA1	DMT1OZ6	MK-2206	Phase 2	21	DMC1I56	Exherin	Phase 2	21	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	2.814	3.103	2.35	4.569
DCJGM3N	DMT1OZ6	MK-2206	Phase 2	21	DMCE08M	AT7519	Phase 1	17	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	15.2	12.556	0.791	4.107
DCWDGTF	DMT1OZ6	MK-2206	Phase 2	21	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	4.815	6.155	2.695	5.448
DCJPLDH	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	2.83	3.43	5.27	10.45
DCJB8MD	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	1.64	1.3	10.01	12.3
DCGXAII	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	2.63	3.03	7.66	10.11
DCOCWP7	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	3.4	3.31	12.04	12.66
DCPMTYR	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	14.15	12.91	15.81	18.98
DC4631E	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	5.69	6.37	10.52	12.6
DCEB0J1	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	2.62	2.05	2.14	4.98
DCPM2QW	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	6.42	5.16	8.67	11.53
DC0983O	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	11.33	12.92	9.81	16.29
DC4IT7X	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	0.72	2.41	3.24	4.01
DCW9RYR	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	16.27	15.99	19.34	21.6
DC34EVG	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	2.48	3.92	10.31	3.3
DC81C28	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	2.99	4.76	5.24	8.21
DCVDI8P	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	7.55	9.55	15.89	8.9
DC94AAK	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	5.84	9.32	7.62	10.29
DCJ15YY	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	4.97	5.88	10.79	11.88
DCXEPOG	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	4.84	8.82	1.8	9.69
DC1JTTT	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	6.03	7.48	9.05	11.78
DC8ZOOL	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	1.15	4.83	6.43	8.78
DCIUMOL	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	12.62	14.36	13.3	16.87
DC1VFU2	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	6.56	6.31	10.17	12.73
DCBMMHW	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	27.6	23.97	31.01	33.86
DCQT8AB	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	1.16	0.88	6.53	11.31
DCXSK54	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	14.74	15.1	16.25	19.2
DCEIB1X	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	5.8	6.04	10.72	13.33
DCYJO35	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	3.35	1.86	4.96	8.02
DCI3FI3	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	3.62	7.05	1.6	9.57
DC16NQC	DMT1OZ6	MK-2206	Phase 2	21	DMD7L94	Palbociclib	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	28.88	29.38	10.88	13.76
DCTGOTV	DMT1OZ6	MK-2206	Phase 2	21	DMDI269	Docetaxel	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	20.045	22.496	0.405	5.273
DCADMA4	DMT1OZ6	MK-2206	Phase 2	21	DMDMQIE	THAPSIGARGIN	Preclinical	2.1	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	7.179	7.051	4.663	7.025
DCHUE4W	DMT1OZ6	MK-2206	Phase 2	21	DMDMQIE	THAPSIGARGIN	Preclinical	2.1	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	U-HO1	0.77	4.9	4.57	4.55
DC2ZE9D	DMT1OZ6	MK-2206	Phase 2	21	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	4.237	5.105	1.117	4.158
DCJ5P2H	DMT1OZ6	MK-2206	Phase 2	21	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	U-HO1	4.22	5.11	1.11	4.16
DCLUT9S	DMT1OZ6	MK-2206	Phase 2	21	DMF9M57	Cotellic	Phase 3	25	.	.	.	.	Embryonal rhabdomyosarcoma	ALMANAC Dataset	Investigative	CTR	15.195	15.556	5.645	7.42
DCM9SVR	DMT1OZ6	MK-2206	Phase 2	21	DMF9M57	Cotellic	Phase 3	25	.	.	.	.	Embryonal rhabdomyosarcoma	ALMANAC Dataset	Investigative	RD	18.825	18.725	12.403	13.301
DCTNGZW	DMT1OZ6	MK-2206	Phase 2	21	DMGDA3C	Cycloheximide	Investigative	0	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	14.686	22.848	1.716	3.607
DC5VAJZ	DMT1OZ6	MK-2206	Phase 2	21	DMGDA3C	Cycloheximide	Investigative	0	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	U-HO1	14.69	22.85	1.71	3.61
DCCM5KM	DMT1OZ6	MK-2206	Phase 2	21	DMGHLG5	Withaferin A	Terminated	2	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	3.986	5.599	0.647	2.194
DCUBO0O	DMT1OZ6	MK-2206	Phase 2	21	DMGYBZI	PHA-739358	Phase 2	21	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	8.945	8.906	6.376	8.122
DC9EY3T	DMT1OZ6	MK-2206	Phase 2	21	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Diffuse large B cell lymphoma	ALMANAC Dataset	Investigative	TMD8	9.969	8.286	9.441	14.878
DCZ977D	DMT1OZ6	MK-2206	Phase 2	21	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	9.76	10.045	2.638	5.239
DC8HD2X	DMT1OZ6	MK-2206	Phase 2	21	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	U-HO1	9.74	10.04	2.63	5.24
DCJRS9U	DMT1OZ6	MK-2206	Phase 2	21	DMIU0VP	SNX-5422	Phase 1/2	19	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	1.125	0.824	2.319	3.969
DCCZMX5	DMT1OZ6	MK-2206	Phase 2	21	DMIW453	Pelitinib	Phase 2	21	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	12.955	15.082	3.672	5.065
DC48CAC	DMT1OZ6	MK-2206	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	4.8	6.39	3.47	6.1
DCZXKTY	DMT1OZ6	MK-2206	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	0.82	0.89	1.11	6.11
DCJZV07	DMT1OZ6	MK-2206	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	0.92	4.58	3.15	6.58
DCJ7VZE	DMT1OZ6	MK-2206	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	1.61	5.41	3.92	7.49
DCLXPYZ	DMT1OZ6	MK-2206	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	1.15	2.27	2.54	6.01
DCYDYVJ	DMT1OZ6	MK-2206	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	6.29	6.88	0.86	8.66
DCC0HE3	DMT1OZ6	MK-2206	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	1.38	2.68	1.86	4.93
DCIY1D4	DMT1OZ6	MK-2206	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	1.15	2.46	0.2	3.56
DCRYW61	DMT1OZ6	MK-2206	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	2.21	2.09	0.95	4.64
DCP7TU8	DMT1OZ6	MK-2206	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	9.05	6.73	8.62	10.23
DC29IMA	DMT1OZ6	MK-2206	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	0.94	0.91	1.54	5.69
DCMI7EV	DMT1OZ6	MK-2206	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	3.21	3.78	1.89	5.54
DCI7PGA	DMT1OZ6	MK-2206	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	5.94	7.85	0.96	6.77
DCAXGLU	DMT1OZ6	MK-2206	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	9.01	7.27	6.81	10.94
DCSSUSV	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	11.31	11.32	9.06	18.46
DC6NTIW	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	1.6	0.94	5.91	6.5
DCUOUSC	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	1.79	4.7	10.63	11.74
DCTX7DZ	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	3.09	5.01	11.36	12.16
DCXZNOK	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	8.14	9.78	12.82	13.23
DCRZWRC	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	3.85	5.35	11.29	12.67
DCFLUKF	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	1.02	0.16	6.43	7.75
DCQ5930	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	9.54	4.15	6.25	6.42
DC56Y63	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	12.99	14.25	16.92	17.62
DCLRUJV	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	0.49	6.36	6.84	6.75
DC4V7D6	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	5.68	4.84	12.99	13.9
DC6PSOL	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	0.93	2.39	6.74	8.27
DCLKM9B	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	3.94	8.61	12.42	13.57
DCLU5O8	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	1.34	5.59	4.46	8.72
DC0E0CB	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	11.35	13.51	17.29	18.04
DCMJ6NE	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	0.94	6.54	10.08	10.13
DCVFCWU	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	2.09	18.61	18.13	18.88
DC9IDR0	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	7.75	10.74	16.1	16.55
DCB7NCC	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	2.13	1.95	10.52	11.65
DCSPTQ5	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	10.89	16.84	18.72	19.14
DC9FVKQ	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	0.98	4.88	12.26	13.16
DCGZD4Z	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	16.65	16.78	19.04	20.96
DCJBWKJ	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	11.72	11.43	16.25	16.83
DC26H0N	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	8.84	8.59	17.33	19.44
DC41BAX	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	12.54	12.54	20.2	21.26
DC2RD92	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	1.11	0.04	8.04	9.95
DCN3MHL	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	0.8	2.65	4.89	5.14
DCEQ7W8	DMT1OZ6	MK-2206	Phase 2	21	DMM5SCF	ONC201	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	25.358	29.14	2.635	8.7
DC4QFN8	DMT1OZ6	MK-2206	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	0.9	4.06	1.25	5.09
DCTJLH7	DMT1OZ6	MK-2206	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	16.56	11.65	8.5	17.57
DCPVAWX	DMT1OZ6	MK-2206	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	0.93	1.67	8.88	10.88
DCJHRYM	DMT1OZ6	MK-2206	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	13.27	12.3	18.87	21.61
DCKMHR7	DMT1OZ6	MK-2206	Phase 2	21	DMNE56X	ABT-263	Phase 3	25	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	0.629	2.06	1.536	4.648
DC41UO2	DMT1OZ6	MK-2206	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	4.18	8.21	8.19	8.71
DC86BWE	DMT1OZ6	MK-2206	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	4.96	5.02	3.5	7
DCKLO65	DMT1OZ6	MK-2206	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	4.64	3.63	1.3	5.93
DCAHG6J	DMT1OZ6	MK-2206	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	1.58	4.05	1.4	5.82
DCZ3HNJ	DMT1OZ6	MK-2206	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	6.89	5.47	2.88	5.99
DCQTQTB	DMT1OZ6	MK-2206	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	0.83	3.02	4.85	6.41
DCD0ZHW	DMT1OZ6	MK-2206	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	12.53	8.84	5.67	11.61
DCTT52B	DMT1OZ6	MK-2206	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	9.5	10.07	9.57	13.22
DCX3P0K	DMT1OZ6	MK-2206	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	3.49	3.18	3.62	6.81
DCFBHCN	DMT1OZ6	MK-2206	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	2.77	2.55	4.11	6.16
DCBJVJS	DMT1OZ6	MK-2206	Phase 2	21	DMO14SG	Mebendazole	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	4.08	1.78	8.41	9.51
DC148H3	DMT1OZ6	MK-2206	Phase 2	21	DMODA2X	Bardoxolone methyl	Phase 3	25	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	0.448	2.592	0.386	3.614
DC4LR26	DMT1OZ6	MK-2206	Phase 2	21	DMODA2X	Bardoxolone methyl	Phase 3	25	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	U-HO1	0.43	2.59	0.39	3.61
DC3BKWJ	DMT1OZ6	MK-2206	Phase 2	21	DMP56WJ	CF102	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	19.47	22.32	2.94	7.71
DC7VY89	DMT1OZ6	MK-2206	Phase 2	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	2.03	6.37	4.95	6.81
DC1JPYV	DMT1OZ6	MK-2206	Phase 2	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	3.2	7.71	4.07	4.07
DCSHZ7C	DMT1OZ6	MK-2206	Phase 2	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	1.46	9.88	6.4	8.31
DCO9587	DMT1OZ6	MK-2206	Phase 2	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	24.37	24.41	14.93	26.65
DCYH6XO	DMT1OZ6	MK-2206	Phase 2	21	DMPK32V	BMS-754807	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	6.21	6.64	11.36	13.3
DCA74UX	DMT1OZ6	MK-2206	Phase 2	21	DMPQBWY	(-)-englerin A	Investigative	0	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	2.49	2.55	8.739	10.259
DCH1AHD	DMT1OZ6	MK-2206	Phase 2	21	DMQL8XJ	Decitabine	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	2.967	3.208	3.407	5.384
DCANQGJ	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	7.19	7.63	5.03	8.52
DC3RYYU	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	7.82	3.03	3.06	2.41
DC5KK0G	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	9.94	7.09	10.91	12.58
DCL8H0W	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	3.16	5.12	3.01	6.58
DC3N9N0	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	3.55	3.45	0.79	6.46
DCLKY00	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	2.39	3.2	4.71	8.47
DCBI6JQ	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	3.38	1.82	5.25	10.19
DC51TOX	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	2.97	2.98	4.17	9.17
DC5P51S	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	11.42	14.42	14	18.22
DCKV3TL	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	6.1	5.7	4.13	7.1
DCNQZ6J	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	5.46	5.69	7.86	12.01
DCICSLS	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	5.89	7.09	7.55	9.67
DC89LDE	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	16.26	17.72	11.94	16.72
DC39DE2	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	5.19	5.44	2.62	8.02
DCC1TMT	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	2.37	3.36	3.03	6.43
DCS58TS	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	3.36	4.54	5.04	8.73
DCA9X0X	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	12.89	12.04	7.58	12.81
DCL1JZ3	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	1.22	2.55	1.37	6.53
DCQC497	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	6.3	7.37	3.91	9.27
DCAUNBR	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	0.81	3.58	2.68	7.64
DC6DFTK	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	6.82	6.59	8.72	9.61
DCJYIES	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	5.21	6.64	5.92	9.43
DCT3YMX	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	6.17	6.33	9.44	13.13
DCNBWJS	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	14.09	14.08	8.92	15.33
DCE4GL3	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	7.35	7.99	2.74	8.21
DC8C23A	DMT1OZ6	MK-2206	Phase 2	21	DMSLE03	PF-562271	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	11.41	12.1	1.02	5.77
DC2X9Q8	DMT1OZ6	MK-2206	Phase 2	21	DMSLE03	PF-562271	Phase 1	17	.	.	.	.	Diffuse large B cell lymphoma	ALMANAC Dataset	Investigative	TMD8	16.13	19.59	5.08	11.65
DC87DB0	DMT1OZ6	MK-2206	Phase 2	21	DMSLE03	PF-562271	Phase 1	17	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	U-HO1	1.91	2.51	2.68	5.14
DCW4ARR	DMT1OZ6	MK-2206	Phase 2	21	DMTKD7Q	Afatinib	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	9.297	10.344	5.805	9.181
DCCZCVB	DMT1OZ6	MK-2206	Phase 2	21	DMTYXQF	NVP-AUY922	Phase 2	21	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	5.86	6.25	0.253	4.191
DCK2K3X	DMT1OZ6	MK-2206	Phase 2	21	DMU10FE	THZ1	Investigative	0	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	2.01	1.72	5.4	7.8
DC3BFP4	DMT1OZ6	MK-2206	Phase 2	21	DMU1GX0	Mitotane	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	2.174	3.029	1.534	4.272
DCE1TSM	DMT1OZ6	MK-2206	Phase 2	21	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	5.77	6.02	5.83	8.55
DCB8LB8	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	5	4.52	8.67	10.31
DCXN5UW	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	0.54	2.37	3.95	7.43
DCPJORZ	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	0.9	0.39	4.4	6.65
DCFFDYO	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	4.26	4.02	11.09	14.11
DCPB6ZR	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	7.18	5.88	5.58	7.13
DCYGDQ5	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	1.88	1.44	3.87	7.02
DCFDNXE	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	10.56	7.94	8.61	10.99
DCZD8K8	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	4.05	1.64	2.04	2.33
DCKIYP4	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	7.63	5.24	0.36	8.29
DCMKMM7	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	6.23	5.1	0.83	8.89
DC06HPW	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	12.52	12.12	6.41	14.02
DCR89W6	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	1.91	1.29	3.65	8.97
DCRURKU	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	14.67	11.98	13.54	17.25
DCTZX79	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	4.94	4.96	5.46	9.28
DCS3RIL	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	6.79	6.58	10.13	13.43
DCOEZPT	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.78	2.51	4.17	7.43
DC021WS	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	7.81	7.94	13.67	16.19
DCKXOGA	DMT1OZ6	MK-2206	Phase 2	21	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Diffuse large B cell lymphoma	ALMANAC Dataset	Investigative	TMD8	17.86	15.92	15.57	16.82
DCAWFVY	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	1.64	1.21	11.11	11.83
DCYJM5A	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	4.57	4.51	8.75	11.32
DC5FLF7	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	40.45	39.4	7.33	17.22
DC928TJ	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	0.38	1.6	9.51	10.63
DCTO8H9	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	11.41	15.65	1.66	12.94
DCHVEXL	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	12.18	11.37	12.9	15.21
DCG125Y	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	3.65	7	0.73	2.14
DCPE0CP	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	12.97	12.76	22.24	23.57
DCQ0DTR	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	0.38	9.92	17.51	17.61
DCBIB4Q	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	6.77	9.04	13.9	15.3
DCTJWNV	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	2.55	4.24	2.23	2.46
DCOAIIM	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	1.98	2.18	4.5	5.62
DC0TNZ5	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	3.89	6.89	9.21	11.45
DCTTM22	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	20.25	24.18	7.98	24.98
DC16HZJ	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	13.06	18.78	7.74	9.85
DC4X84Z	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	21.32	27.19	11.19	12.19
DCSZR43	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	0.95	1.81	5.43	6.42
DCM6GNR	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	28.72	21.4	30.99	32.81
DCOULUV	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	1.1	0.51	7.3	10.8
DC9ZKKF	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	20.83	20.81	30.67	32.59
DCI3MDE	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.08	0.76	7.61	8.69
DC9JINO	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	4.75	4.39	8.02	13.09
DCUGL3V	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	8.86	10.64	17.01	17.58
DCEUWNY	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	6.78	9.91	14.06	14.54
DCBUNOQ	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	8.51	9.25	7.81	10.44
DC0ZJLL	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.27	2.89	2.11	11.17
DCSWMN5	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	4.46	3.44	0.54	3.59
DCLOVO9	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.28	5.04	4.18	6.33
DCGKU9V	DMT1OZ6	MK-2206	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.02	1.79	4.52	12.7
DC6F3XI	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	5.02	6.62	11.01	14.03
DCSZ10L	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	8.48	9.68	5.71	14.91
DCLS9YB	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.9	2.76	8.65	14.43
DCC9UXA	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.46	5.54	7.97	11.59
DCK8R0A	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.95	1.28	4.76	9.58
DC362AB	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.28	2.85	6.82	9.77
DC3126A	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.96	1.77	6.81	9.32
DC8SB7C	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.17	2.62	6.48	10.37
DC20UVO	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.81	8.86	15.06	16.78
DCNVYMR	DMT1OZ6	MK-2206	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	6.05	5.83	0.31	13.52
DCP4CVK	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.89	1.87	10.29	13.4
DCAA1QS	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.36	0.38	4.91	6.84
DC1P21L	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.77	0.01	3.46	5.38
DC3KEN4	DMT1OZ6	MK-2206	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	0.06	1.99	5.8	8.71
DCLCL34	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	0.97	0.65	4.3	8.64
DC57IE4	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.81	7.8	11.8	13.05
DC3HCW9	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	12.78	12.72	18.17	19.31
DCN4DCA	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.79	0.9	1.22	6.01
DCLVP7G	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.65	2.6	5.24	9.17
DCTQRCO	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.64	1.71	2.34	6.92
DCP5BJ3	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.58	4.68	5.9	11.12
DCM2FII	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.01	0.03	2.93	5.11
DCLEQFW	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	11.24	10.61	3.19	17.7
DCGI4CV	DMT1OZ6	MK-2206	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.03	3.76	7.78	10.25
DCW1X9R	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	0.51	0.1	5.09	0.85
DCWB37O	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.06	6.98	1.82	7.69
DC9350T	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.96	2.13	4.28	5.82
DCFXQ0T	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.96	4.39	0.15	5.9
DC2LTA6	DMT1OZ6	MK-2206	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.95	4.28	8.33	10.5
DC6VW52	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	6.39	6.11	12.63	14.35
DCIPQGO	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	5.96	5.77	9.96	12
DCAO7P7	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	1.95	1.84	3.17	13.11
DC59C9R	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	6.88	6.6	9.33	11.35
DCHPRV2	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.76	5.7	5.04	9.64
DCOQAG9	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	3.27	6.8	9.82	11.27
DCUXMSD	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	5.07	4.53	5.88	9.71
DCGFZ9N	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.16	7.95	11.69	13.34
DCCTDIE	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	11.4	14.15	19.22	20.91
DCVJTJK	DMT1OZ6	MK-2206	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	8.9	8.85	16.78	19.93
DC6WQZ4	DMT1OZ6	MK-2206	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.77	4.52	1.37	5.91
DCQUG4C	DMT1OZ6	MK-2206	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.47	1.11	3.35	5
DC9Q5VX	DMT1OZ6	MK-2206	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.09	4.47	2.06	5.68
DCOEZ7I	DMT1OZ6	MK-2206	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.54	1.47	6.9	9.23
DCFG80X	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.37	4.24	10.96	12.58
DCPS202	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	13.54	13.51	19.11	20.89
DCADZ15	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	6.83	6.89	11.54	13.78
DCY2WT1	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	8.43	8.2	17.9	19.45
DCEQC76	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.78	3.56	9.43	10.79
DCGHF2G	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.19	2.24	8.62	9.76
DCA6YBG	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.54	1.34	10.24	10.72
DCFLCNU	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.84	7.17	13.82	14.73
DCBWQD3	DMT1OZ6	MK-2206	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.29	2.74	9.18	10.19
DC50KU0	DMT1OZ6	MK-2206	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.41	1.41	0.12	2.19
DCXFISR	DMT1OZ6	MK-2206	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.66	0.75	4.97	8.02
DC47QAM	DMT1OZ6	MK-2206	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.95	1.35	4.5	5.64
DCOW5C5	DMT1OZ6	MK-2206	Phase 2	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.12	5.83	6.02	8.62
DCUT2AW	DMT1OZ6	MK-2206	Phase 2	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.3	8.57	6.96	8.45
DCUP9PM	DMT1OZ6	MK-2206	Phase 2	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	4.01	7.67	8.04	11.2
DCCTZ8X	DMT1OZ6	MK-2206	Phase 2	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.75	9.01	0.09	7.67
DCQXNV2	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.67	3.44	6.77	9.06
DC5A4SM	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.62	3.35	2.64	7.3
DCDFPZ4	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.87	0.35	6.16	10.53
DC1GFJR	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.29	2.48	2.9	9.09
DCADJAL	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.81	3.57	8.13	11.69
DCL0Z7F	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.12	6.31	0.18	4.47
DCISVZJ	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	6.74	6.95	5.32	9.91
DC0YYVS	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.14	6.22	12.07	15.7
DC8GSHI	DMT1OZ6	MK-2206	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.33	5.26	5.34	8.71
DCL1JBR	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	7.35	7.23	6.15	12.39
DCPFMBR	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	5.57	5.33	14.36	16.83
DCIC7RA	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	5.06	4.69	9.29	12.93
DCU5WAS	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.86	0.63	1.59	5.96
DCBK977	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.39	0.12	7.79	10.76
DCRR4D9	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.64	2.01	1.96	8.4
DCTUGNN	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.65	1.64	16.42	18.75
DC3USAG	DMT1OZ6	MK-2206	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.32	1.28	4.47	10.98
DCSZQAV	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.42	1.09	4.8	6.64
DCIJONC	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	5.81	6.33	8.18	10.74
DC4A2UK	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.16	5.76	5.76	9.12
DC23X31	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.67	1	9.23	10.75
DCF05UM	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.29	3.44	1.65	8.41
DCWYYIL	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	11.94	11.74	15.89	17.05
DCKGU6P	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.71	5.39	10.18	11.29
DCEZ0SU	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.9	2.59	12.35	13.53
DCS772R	DMT1OZ6	MK-2206	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.08	1.78	10.32	14.49
DCYV9OC	DMPAZHC	Cabazitaxel	Approved	34	DM2HG4X	Prednisone	Phase 3 Trial	25	.	.	.	.	Hormone-Resistant Prostate Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC2PSQP	DMPAZHC	Cabazitaxel	Approved	34	DMQ8FR2	Prednisolone	Approved	34	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCT13C4	DMPAZHC	Cabazitaxel	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	8.68	8.38	4.43	7.77
DC0CI34	DMPAZHC	Cabazitaxel	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	14.31	14.09	9.29	14.21
DCMJCEP	DMPAZHC	Cabazitaxel	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	3.24	7.36	6.64	8.87
DCTGFVJ	DMPAZHC	Cabazitaxel	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	4.79	2.67	4.45	6.82
DC4W2HW	DMPAZHC	Cabazitaxel	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	2.76	3.28	1.29	3.52
DC8RETM	DMPAZHC	Cabazitaxel	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	18.25	17.27	4.49	19.35
DCIGWFK	DMPAZHC	Cabazitaxel	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	16.84	16.9	14.57	16.78
DC9IVOT	DMPAZHC	Cabazitaxel	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	6.2	5.63	4.6	6.58
DC74TNP	DMPAZHC	Cabazitaxel	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	4.73	7.31	5.18	8.88
DCEPKT6	DMPAZHC	Cabazitaxel	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	2.4	4.23	2.16	3.86
DCJ01ZQ	DMPAZHC	Cabazitaxel	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	24.24	20.45	18.55	22
DCXOE2O	DMPAZHC	Cabazitaxel	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	3.33	6.9	5.23	7.78
DCCWDJR	DMPAZHC	Cabazitaxel	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	22.6	18.29	5.9	18.54
DC280G1	DMPAZHC	Cabazitaxel	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	15.23	11.69	4.84	12.77
DCBX5ZE	DMPAZHC	Cabazitaxel	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	9.18	12.56	8.9	12.79
DCFW7CZ	DMPAZHC	Cabazitaxel	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	2.19	4.32	1.19	4.34
DC2X3L3	DMPAZHC	Cabazitaxel	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	1.18	8.28	5.78	8.28
DC8DEQC	DMPAZHC	Cabazitaxel	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	16.49	17.91	1.81	19.92
DCWORKV	DMPAZHC	Cabazitaxel	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	9.17	9.25	6.99	9.15
DCM13HU	DMPAZHC	Cabazitaxel	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	9.63	9.02	6.35	11.09
DC8SHRR	DMPAZHC	Cabazitaxel	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	21.75	21.54	14.3	22.64
DCKHZGJ	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	7.14	6.05	9.68	11.91
DC30V72	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	11.45	11.36	11.82	18.2
DC86YJI	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	4.34	3.39	3.06	7.29
DCFVIAF	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	21.71	17.52	10.19	20.17
DCOK524	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	33.99	28.27	14.18	32.57
DC0YRQU	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	19.66	18.89	0.8	21.58
DCB92KF	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	34.59	22.97	13.61	26.18
DCTGL4Q	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	16.32	15.9	2.42	16.31
DCROFEW	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	22.92	16.02	9.18	17.33
DCN6MEI	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	18.57	15.18	7.24	17.3
DCTDBH9	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	5.95	6.17	2.37	7.62
DCJMZUT	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	7.15	7.53	2.42	11
DC327BD	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	15.11	11.16	2.63	13.58
DCPN0LU	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	4.94	4.86	12.56	13.35
DCO6BWJ	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	10.77	6.86	6.25	10.76
DCU2FIQ	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	6.75	6.73	13.41	17.45
DCXM38D	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	12.72	9.35	13.51	14.73
DC3HVH3	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	16.14	12.17	12.24	17.26
DC7S5DW	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	5.78	8.8	10.33	13.24
DC4E4H2	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	11.67	10.95	4.68	13.7
DCJDR8G	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	14.54	11.62	11.74	15.77
DC4MND6	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	13.26	10.5	4.17	16.69
DCWYNPL	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	9.46	12.98	14.7	15.16
DCHEX9B	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	26.54	23.01	23.07	26.22
DCE6M9D	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	9.88	9.29	9.52	17.07
DCQ3OAC	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	11.12	10.84	6.25	14.35
DCLS0QG	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	7.12	6.66	4.66	10.04
DCCD0AB	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	13.38	12.51	13.44	20.28
DCF8UHR	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	8.59	9.73	12.38	12.99
DCKJBGE	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	19.42	16.7	19.57	21.88
DCOX7XU	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	12.62	7.99	14.8	17.23
DCPT5IJ	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	7.28	7.28	15.24	16.41
DCD033Y	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	10.94	12.15	18.37	19.47
DCZXY97	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	6.13	5.67	10.21	12.41
DCSZTUH	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	16.78	11.61	7.96	13.7
DCUY2SR	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	2.29	3.49	7.94	8.87
DCO46O5	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	15.63	14.83	16.29	19.68
DCWROO8	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	1.13	4.68	0.92	11.68
DC5X2R8	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	6.73	10.21	14.24	15.43
DC605WF	DMPAZHC	Cabazitaxel	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	11.11	12.65	10.26	14.57
DCB0TLB	DMPAZHC	Cabazitaxel	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	2.5	3.6	0.97	5.65
DCPXRYO	DMPAZHC	Cabazitaxel	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	21.33	17.31	12.51	17.25
DCW5E20	DMPAZHC	Cabazitaxel	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	7.65	7.13	1.17	6.71
DCRKI87	DMPAZHC	Cabazitaxel	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	5.21	6.58	5.21	8.69
DC3YHCX	DMPAZHC	Cabazitaxel	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	8.6	12.44	9.28	11.89
DCUMT7L	DMPAZHC	Cabazitaxel	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	L-1236	3.56	3.387	9.675	11.365
DC5PJAZ	DMPAZHC	Cabazitaxel	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	1.88	4.05	1.12	4.28
DCO0QCI	DMPAZHC	Cabazitaxel	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	14.6	14.78	13	16.76
DCH821U	DMPAZHC	Cabazitaxel	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	17.21	16.44	12.73	16.54
DC9TEAV	DMPAZHC	Cabazitaxel	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	6.42	4.59	0.73	4.2
DCLCGKE	DMPAZHC	Cabazitaxel	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	2.39	2.85	3.16	5.86
DC6H9ME	DMPAZHC	Cabazitaxel	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	27.94	23.99	0.98	24.73
DCXH4PZ	DMPAZHC	Cabazitaxel	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	19.26	18.68	11.14	19.9
DC5O2TG	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	8.34	2.31	0.45	3.31
DCNWZTX	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	15.45	13.56	9.62	13.11
DCFGI2B	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	3.76	4.33	2	5.19
DC3JPVI	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	7.26	7.79	8.6	10.67
DC1W8QH	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	19.46	17.47	14.71	17.27
DCKEMOW	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	12.62	8.16	1.58	8.06
DC6AC0I	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	4.14	6.28	3.61	6.36
DCX0JNZ	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	2.69	4.94	2.69	5.04
DCMEB6E	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	9.47	6.08	4.7	6.57
DCYMFL1	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	0.59	1.88	3.95	5.01
DC1TR7U	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	18.19	17.34	14.15	16.7
DCN2XVL	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	4.06	3.23	1.41	2.76
DCCUZWU	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	9.95	9.81	7.67	9.9
DCYID9A	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	9.68	18.39	15.3	18.05
DCMVSV5	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	2.33	2.89	1.93	3.68
DC173SU	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	6.34	5.12	2.35	6.28
DCL99S5	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	4.97	10.29	6.71	9.05
DCC5NPP	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	3.05	3.46	1.23	3.03
DCZZBOF	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	9.44	12.72	10.95	12.89
DCZDFKK	DMPAZHC	Cabazitaxel	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	17.19	11.99	0.12	12.1
DCXI5TR	DMPAZHC	Cabazitaxel	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	15.42	9.17	9.86	11.24
DCM9BZD	DMPAZHC	Cabazitaxel	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	20.28	15.61	13.95	16.19
DCDSE0O	DMPAZHC	Cabazitaxel	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	12.1	7.43	5.06	8.67
DC7SJIN	DMPAZHC	Cabazitaxel	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	18.41	14.31	5.69	14.94
DCGJT76	DMPAZHC	Cabazitaxel	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	5.91	7.8	0.38	7.42
DCOOWNM	DMPAZHC	Cabazitaxel	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	7.3	9.76	2.54	10.62
DC5PF2D	DMPAZHC	Cabazitaxel	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	9.43	11.97	2.42	12.71
DCIMCFB	DMPAZHC	Cabazitaxel	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	6.22	8.72	1.51	8.34
DCOICG6	DMPAZHC	Cabazitaxel	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	7.43	10.06	1.02	10.44
DCW7OYQ	DMPAZHC	Cabazitaxel	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	5.39	8.13	6.98	8.68
DCO795J	DMPAZHC	Cabazitaxel	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	14.49	10.99	4.46	12.33
DCTHQRR	DMPAZHC	Cabazitaxel	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	10.52	9.87	3.06	11.28
DCERJ69	DMPAZHC	Cabazitaxel	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	26.07	19.91	10.23	20.71
DCHTZYT	DMPAZHC	Cabazitaxel	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	11.95	11.36	9.62	12.31
DCDC5CJ	DMPAZHC	Cabazitaxel	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	18.68	18.67	10.93	19.2
DCLZ1K8	DMPAZHC	Cabazitaxel	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	10.71	12.92	6.8	15.35
DC48JTS	DMPAZHC	Cabazitaxel	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	0.79	7.2	3.28	7.78
DC8H964	DMPAZHC	Cabazitaxel	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	8.69	10.23	6.83	11.7
DC9IW87	DMPAZHC	Cabazitaxel	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	10.93	10.86	2.66	11.81
DCSRCL3	DMPAZHC	Cabazitaxel	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	15.17	14.58	0.1	16.95
DCFZ89L	DMPAZHC	Cabazitaxel	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	23.47	23.4	14.18	23.85
DCTDX8U	DMPAZHC	Cabazitaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	8.62	10.33	6.84	9.64
DC5UDAO	DMPAZHC	Cabazitaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	5.4	5.52	1.36	6.19
DCSWUFZ	DMPAZHC	Cabazitaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	25.77	22.33	14.16	21.63
DC6EHCP	DMPAZHC	Cabazitaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	11.59	8.5	3.5	8.72
DCGN32T	DMPAZHC	Cabazitaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	17.84	16.87	5.46	16.93
DCECAA8	DMPAZHC	Cabazitaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	4.28	4.72	1.66	9.04
DCPME1X	DMPAZHC	Cabazitaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	0.93	3.32	1.5	4.86
DCRRBHJ	DMPAZHC	Cabazitaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	11.93	16.65	14.68	16.63
DCY944Q	DMPAZHC	Cabazitaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	14.41	14.23	1.91	15.72
DC3849A	DMPAZHC	Cabazitaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	16.76	20.32	1.43	23.13
DCQ0XX1	DMPAZHC	Cabazitaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	4.24	3.56	7.35	10.67
DCU1XW9	DMPAZHC	Cabazitaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	2.33	3.27	2.02	4.3
DC02HGE	DMPAZHC	Cabazitaxel	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	2.63	3.48	1.39	4.73
DC1DNH4	DMPAZHC	Cabazitaxel	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	3.38	3.65	2.88	6.57
DCUZN79	DMPAZHC	Cabazitaxel	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	3.19	7.67	4.48	9.41
DCXACSQ	DMPAZHC	Cabazitaxel	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	5.88	7.03	4.46	8.83
DC31BUH	DMPAZHC	Cabazitaxel	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	11.55	10.68	6.25	12.2
DCHCC3J	DMPAZHC	Cabazitaxel	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	0.8	1.78	2.34	4.46
DCK5B70	DMPAZHC	Cabazitaxel	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	8.05	7.01	4.55	9.28
DCC609W	DMPAZHC	Cabazitaxel	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	16.04	16.17	12.9	18.02
DCQUGGX	DMPAZHC	Cabazitaxel	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	7.58	8.22	4.96	12.34
DCF0C0V	DMPAZHC	Cabazitaxel	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	2.63	4.94	8.96	9.73
DC3QM3J	DMPAZHC	Cabazitaxel	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	5.99	6.95	4.53	7.24
DCKNW2V	DMPAZHC	Cabazitaxel	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	13.79	14.8	8	16.26
DCW36EH	DMPAZHC	Cabazitaxel	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	7.73	8.36	8.62	11.36
DC6OC5M	DMPAZHC	Cabazitaxel	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	16.11	15.63	12.2	17.08
DCBMHKB	DMPAZHC	Cabazitaxel	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	8.69	9.24	0.85	8.69
DCWECVX	DMPAZHC	Cabazitaxel	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	4.78	4.54	2.78	5.77
DC1NQG7	DMPAZHC	Cabazitaxel	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	11.54	16.84	12.26	15.91
DCQADUF	DMPAZHC	Cabazitaxel	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	11.17	10.13	7.71	11.74
DCUA0PN	DMPAZHC	Cabazitaxel	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	4.36	9.95	7.89	10.41
DCS5I94	DMPAZHC	Cabazitaxel	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	1.85	2.8	0.61	3.14
DCKZGK6	DMPAZHC	Cabazitaxel	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	13.03	13	10.3	13.78
DC5M76W	DMPAZHC	Cabazitaxel	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	5.46	3.93	4	6.66
DCSTVG0	DMPAZHC	Cabazitaxel	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	7.61	7.33	5.34	9.3
DC10VW1	DMPAZHC	Cabazitaxel	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	0.41	2.52	2.41	6.57
DCRUFQA	DMPAZHC	Cabazitaxel	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	0.76	4.21	0.06	8.43
DC6YIF5	DMPAZHC	Cabazitaxel	Approved	34	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	9.336	5.832	10.831	12.14
DCKENNP	DMPAZHC	Cabazitaxel	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	1.49	1.46	2.17	6.16
DC7EYU0	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	4.03	3.89	0.45	2.92
DCXFYVZ	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	3.65	4.26	1.23	5.86
DCY09N0	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	15.01	13.91	9.99	14.11
DCZS6E1	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	13.68	9.21	4.02	8.37
DCXXRIC	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	14.95	17.05	12.89	18.64
DCOMWT7	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	8.1	7.94	3.98	9.25
DCDDFED	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	7.43	8.21	4.58	8.43
DCEOTGQ	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	5.63	6.74	4.32	8.12
DCQ6C0N	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	15.24	16.14	9.1	16.33
DCNNFDS	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	5.87	5.66	1.87	7.21
DCVSYOE	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	0.89	1.94	0.77	3.05
DC6G64I	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	6.43	4.47	1.98	6.81
DCG4NBR	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	3.3	2.86	0.52	4.31
DCFZ3PE	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	5.35	5.41	1.15	6.69
DCARCNE	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	10.32	5.08	3.44	6.37
DCKE7NB	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	7.31	12.07	9.39	12.51
DC3X3FN	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	15.85	16.75	9.2	18.86
DCVGN0R	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	9.9	13.76	0.06	13.91
DC2SRV3	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	5.8	8.2	6.21	7.93
DC8KGGP	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	5.56	8.53	5.62	8.11
DCTSA5B	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	2.2	4.07	0.73	4.23
DC401DI	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	5.27	7.94	6.12	8.32
DCFPYI1	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	1.94	2.16	0.81	3.32
DCBO1VG	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	5.53	8.07	6.92	8.05
DC2F728	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	14.77	14.6	12.88	16.53
DC9AQM3	DMPAZHC	Cabazitaxel	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	2.54	1.28	4.68	8.02
DCV59G5	DMPAZHC	Cabazitaxel	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	1.97	2.49	1.62	4.62
DC4F363	DMPAZHC	Cabazitaxel	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	0.99	2.54	3.86	7.8
DC7T4IF	DMPAZHC	Cabazitaxel	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	1.91	1.12	3.38	7.69
DC4PG0D	DMPAZHC	Cabazitaxel	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	4.29	3.34	9.25	11.71
DC8KBM5	DMPAZHC	Cabazitaxel	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	3.61	3.95	9.22	10.28
DCSZOBO	DMPAZHC	Cabazitaxel	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	4.01	5.75	3.01	5.91
DCHWQ8Q	DMPAZHC	Cabazitaxel	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	0.38	2.26	2.04	5.47
DCSXHMV	DMPAZHC	Cabazitaxel	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	33.91	24.97	8.92	26.41
DCZFRF4	DMPAZHC	Cabazitaxel	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	14.86	12.65	11.11	14.75
DCI6H51	DMPAZHC	Cabazitaxel	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	7	7.07	3.91	7.42
DCA18F5	DMPAZHC	Cabazitaxel	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	4.67	8.8	4.95	10.77
DCM369C	DMPAZHC	Cabazitaxel	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	19.35	23.97	10.7	25.1
DCEJIQP	DMPAZHC	Cabazitaxel	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	18.75	17.53	3.2	20.28
DC1Z5DE	DMPAZHC	Cabazitaxel	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	8.82	9.89	3.6	12.47
DC6MA2T	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	16.88	16.77	12.4	16.88
DCFKIO7	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	15.08	15.43	9.51	15.62
DCW4KUL	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	8.59	5.42	5.05	5.83
DC7912S	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	15.87	14.97	6.83	16.69
DCBSFP9	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	3.1	6.56	3.92	8.43
DCARKRK	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	4.43	5.09	3.17	6.74
DCQLT1P	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	16.25	15.43	9.67	15.46
DC3APSN	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	5.16	9.04	6.65	8.92
DC88NCY	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	11.69	11.84	9.93	13.85
DCRN3ZN	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	24.56	25.09	11.9	23.99
DCZ6FN5	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	24.86	23.67	5.86	23.9
DCZHY12	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	3.71	3.66	2.08	3.63
DCD4UUV	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	24.72	23.98	1.03	25.46
DCY037T	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	7.66	8.51	5.61	9.79
DCQ2IHU	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	0.05	3.15	2.49	5.73
DC747PX	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	9.27	10.56	3.93	11.38
DCXXD9Y	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	25.06	20.62	11.82	21.57
DCBS5KM	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	0.16	0.57	1.22	4.42
DC4GTW3	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	5.6	6.75	4.46	7.58
DCWODH9	DMPAZHC	Cabazitaxel	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	11.23	9.47	6.25	10.3
DCJ6DE5	DMPAZHC	Cabazitaxel	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	11.6	8.12	9.77	12.18
DC6J9WO	DMPAZHC	Cabazitaxel	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	2.13	4.42	2.74	8.79
DCZCXNY	DMPAZHC	Cabazitaxel	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	1.49	4.97	2.77	4.28
DC5KNCW	DMPAZHC	Cabazitaxel	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	8.37	13.01	4.22	11.61
DC07HF0	DMPAZHC	Cabazitaxel	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	5.26	5.89	4.75	7.72
DCOWUA5	DMPAZHC	Cabazitaxel	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	15.88	15.71	10.41	16.88
DCJ3WTV	DMPAZHC	Cabazitaxel	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	7.83	8.03	6.24	10.52
DC7YHGP	DMPAZHC	Cabazitaxel	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	11	10.35	5.38	13.06
DCXAA9Z	DMPAZHC	Cabazitaxel	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	6.44	4.36	3.1	7.01
DCK7OSQ	DMPAZHC	Cabazitaxel	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	9.63	6.27	6.06	8.36
DCWTKGK	DMPAZHC	Cabazitaxel	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	4.78	5.24	6.92	10.39
DCDU9B9	DMPAZHC	Cabazitaxel	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	6.01	4.48	3.46	7.44
DCSMQXN	DMPAZHC	Cabazitaxel	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	3.16	1.98	4.85	6.77
DCELTPN	DMPAZHC	Cabazitaxel	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	7.61	7.67	6.1	10.13
DCRMT68	DMPAZHC	Cabazitaxel	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	3.47	5.01	3.34	5.91
DC988GF	DMPAZHC	Cabazitaxel	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	13.92	13.52	11.25	16.79
DC3QTF6	DMPAZHC	Cabazitaxel	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	1.01	0.27	1.03	3.53
DC2635Q	DMPAZHC	Cabazitaxel	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	3.53	4.95	4.03	7.75
DCDW7QO	DMPAZHC	Cabazitaxel	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	1.43	0.41	3.75	5.31
DCMSYKF	DMPAZHC	Cabazitaxel	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	5.36	4.16	7.87	9.9
DCYIDLH	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	12.43	12.55	8.55	13.08
DCCB8NU	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	19.36	19.19	15.77	19.14
DCZXGLB	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	16.4	16.05	10.4	16.45
DCT200A	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	7.58	6.39	1.37	6.88
DCXPVJO	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	13.61	9.55	5.35	10.3
DCAZSGX	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	7.28	7.52	6.54	7.37
DCXQMN5	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	6.1	4.64	3.42	6.27
DCDZAKB	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	14.19	13.77	7.57	14.86
DC6ZX9I	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	6.47	8.25	3.79	9.56
DCCI7CX	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	4.65	5.22	3.69	5.49
DCJPYCN	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	2	3.17	0.98	4.9
DC4RJLS	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	2.13	4.01	1.55	3.91
DCI3O6Z	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	3.06	3.03	0.17	5.29
DCPLFKR	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	19.8	20.96	16.89	20.49
DCFEPRS	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	8.79	12.63	10.11	12.83
DCH95OO	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	15.22	15.85	12.64	15.87
DCDP000	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	4.91	1.95	5.05	7.8
DCMEVCL	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	4.05	4.87	3.96	5.97
DCPYRRY	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	9.74	14.09	12.65	14.56
DCC013U	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	5.25	8.25	0.8	9.69
DCDXLIA	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	13.31	13.89	10.73	13.55
DC5XS5B	DMPAZHC	Cabazitaxel	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	7.06	6.92	7	9.17
DCTAA5X	DMPAZHC	Cabazitaxel	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	4.17	3.56	4.38	7.36
DCW15IV	DMPAZHC	Cabazitaxel	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	0.7	0.47	5.56	7.87
DCKG46N	DMPAZHC	Cabazitaxel	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	7.26	4.04	3.11	5.97
DC0C947	DMPAZHC	Cabazitaxel	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	0.79	1.72	4.92	7.66
DCKRGA9	DMPAZHC	Cabazitaxel	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	2.14	2.27	3.26	7.25
DC30GP6	DMPAZHC	Cabazitaxel	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	2	2.01	5.43	7.91
DCDTFRE	DMPAZHC	Cabazitaxel	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	5.18	4.67	8.19	9.67
DCLZGGK	DMPAZHC	Cabazitaxel	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	0.83	1.08	3.33	6.91
DCQDJGG	DMPAZHC	Cabazitaxel	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	6.29	5.76	6.52	10.23
DCXVXTY	DMPAZHC	Cabazitaxel	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	12.18	12.43	10.36	15.82
DC9WA37	DMPAZHC	Cabazitaxel	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	2.18	3.34	1.21	5.57
DCYQGNQ	DMPAZHC	Cabazitaxel	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	3.14	3.26	2.87	5.82
DCWLN41	DMPAZHC	Cabazitaxel	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	3.07	1.54	5.92	8.65
DC9OV79	DMPAZHC	Cabazitaxel	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	4.14	4.31	4.7	10.44
DCYKXXX	DMPAZHC	Cabazitaxel	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	6.59	6.36	5.09	9.41
DCF4972	DMPAZHC	Cabazitaxel	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	1.91	1	0.81	3.3
DCTY7V8	DMPAZHC	Cabazitaxel	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	5.14	5.14	7.93	10.71
DCJMA1J	DMPAZHC	Cabazitaxel	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	2.85	2.44	5.36	7.16
DCLAEHA	DMPAZHC	Cabazitaxel	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	9.7	8.14	6.09	11.16
DCL6TTJ	DMPAZHC	Cabazitaxel	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	2.3	1.17	4.12	5.93
DCO7LU5	DMPAZHC	Cabazitaxel	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	6.61	5.42	7.37	10.75
DCUMU0C	DMPAZHC	Cabazitaxel	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	16.32	11.58	11.42	15.4
DC31FLC	DMPAZHC	Cabazitaxel	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	11.8	9.29	9.04	12.66
DCKR0NL	DMPAZHC	Cabazitaxel	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	5.51	3.2	2.25	6.32
DCCC10S	DMPAZHC	Cabazitaxel	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	9.59	4.1	3.45	6.28
DC3M20K	DMPAZHC	Cabazitaxel	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	1.1	1.82	6.2	8.21
DCVS3YN	DMPAZHC	Cabazitaxel	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	7.14	2.91	1.95	5.67
DCSKOG9	DMPAZHC	Cabazitaxel	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	1.56	0.26	1.01	5.78
DC3OAP6	DMPAZHC	Cabazitaxel	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	9.89	7.13	9.62	13.12
DCRV97B	DMPAZHC	Cabazitaxel	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	8.32	6.02	7.84	10.69
DCANWID	DMPAZHC	Cabazitaxel	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	2.72	1.25	2.13	7.19
DC2AR02	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	15.87	16.68	14.73	15.45
DC1TA7I	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	6.36	5.11	3.18	4.78
DCEBD3A	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	4.64	5.51	5.25	5.73
DC1ZUQH	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	18.06	16.9	15.82	18.93
DC7HSAP	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	5.11	1.76	0.08	2.72
DC1KX21	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	7.29	6.95	6.63	8.3
DCMB0K3	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	4.47	4.64	3.07	4.58
DCPVYO7	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	2.14	8.03	7.3	8.26
DCW1L3K	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	3.48	5.68	3.21	5.29
DC0WX4Q	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	1.54	2.46	1.25	2.68
DCOX79X	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	1.34	1.01	0.05	0.93
DC61SXM	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	2.24	0.59	2.03	3.14
DCNJXT8	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	0.31	4.77	5.09	4.53
DC4EP2I	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	9.9	14.19	14.17	15.15
DC8WWHF	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	14.21	13.2	11.61	15.11
DCR42AQ	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	3.27	3.76	1.96	3.49
DCXXU90	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	1.62	0.14	0.76	0.86
DCFZOG2	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	4.27	5.75	6.85	7.22
DCZTP9V	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	1.71	0.92	0.06	0.96
DCTOH5Z	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	4.36	5.07	3.27	5.31
DCAHHXF	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	12.72	12.31	11.61	12.47
DC5O6S6	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	0.8	4.48	3.8	4.27
DCEQQV9	DMPAZHC	Cabazitaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	10.71	12.13	3.02	12.49
DC9S5J7	DMPAZHC	Cabazitaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	4.24	8.9	5.89	8.62
DCP8EM8	DMPAZHC	Cabazitaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	1.47	2.3	0.08	2.43
DCA2YYS	DMPAZHC	Cabazitaxel	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	6.55	5.85	1.52	6.07
DCDT8JH	DMPAZHC	Cabazitaxel	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	14.49	10.64	12.48	14.11
DCEMBQU	DMPAZHC	Cabazitaxel	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	15.8	15.32	11.53	19.2
DCEAC0O	DMPAZHC	Cabazitaxel	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	13.34	12.3	8.88	14.06
DCJNYGO	DMPAZHC	Cabazitaxel	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	16.76	9.19	8.67	11.22
DCFWOVY	DMPAZHC	Cabazitaxel	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	6.8	5.22	5.56	7.7
DCISSO8	DMPAZHC	Cabazitaxel	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	11.85	10.96	9.41	13.11
DCB64JO	DMPAZHC	Cabazitaxel	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	2.28	3.62	3.01	4.17
DCQ0GGU	DMPAZHC	Cabazitaxel	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	4.63	3.02	2.34	5.61
DCYWEDP	DMPAZHC	Cabazitaxel	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	10.61	10.66	13.25	15.91
DCPL8P6	DMPAZHC	Cabazitaxel	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	3.21	2.33	3.54	5.99
DCGYIK6	DMPAZHC	Cabazitaxel	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	5.19	3.81	5.87	8.87
DCJDSYU	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	12.9	11.76	12.32	15.68
DCZIZDJ	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	3.54	4.82	7.89	10.88
DCQXF0G	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	5.5	5.14	6.72	8.89
DCA23MJ	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	4.97	3.18	5.92	8.97
DC5WZCS	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	9.6	8.51	4.12	10.11
DC0WZ2D	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	18.26	11.47	9.76	13.25
DC9DP82	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	2.8	1.14	0.51	3.02
DC87ETI	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	5.55	5	8.38	10.69
DCIR09L	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	0.38	0.04	0.16	6.43
DCDEMGQ	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	3.24	2.96	1.71	4.7
DCHVO1P	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	3.46	2.6	5.51	8.35
DC5GN0I	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	10.1	9.06	9.43	14.99
DCACUDZ	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	5.15	4.82	5.81	9.91
DCHB6J6	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	9.37	9.82	13.24	15.71
DCE3EJZ	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	1.54	6.59	8.45	11.7
DCJAM65	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	1.64	0.83	1.51	5.58
DCVKQNG	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	26.9	19.73	17.1	22.79
DC2BLMT	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	1.2	2.72	2.47	5.97
DC7XYES	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	7.53	7.04	9.18	11.83
DC1P6X8	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	12.18	11.67	15.25	18.37
DCK61IS	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	0.65	1.04	1.91	5.44
DCPD55X	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	3.14	3.83	7.57	9.39
DCUYWDR	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	11.27	12.15	14.25	16.29
DCPPG61	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	9.36	4.46	1.71	7.27
DC7M91U	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	15.25	15.64	13.39	20.38
DCMD64H	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	13.79	13.77	18.04	20.23
DCH2D3K	DMPAZHC	Cabazitaxel	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	27.53	26.68	21.36	27.19
DC0U27L	DMPAZHC	Cabazitaxel	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	2.9	2.33	2.01	4.43
DC2V581	DMPAZHC	Cabazitaxel	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	2.42	6.37	2.75	8.17
DCQP20D	DMPAZHC	Cabazitaxel	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	16.14	19.31	5.46	19.43
DC2NGKO	DMPAZHC	Cabazitaxel	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	5.19	7.33	3.5	8.24
DC8SHCN	DMPAZHC	Cabazitaxel	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	5.85	5.69	3.69	8.12
DC3L6TL	DMPAZHC	Cabazitaxel	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	2.09	4.51	3.98	6.59
DCE1DZK	DMPAZHC	Cabazitaxel	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	6.79	6.03	4.01	9.13
DCDINHQ	DMPAZHC	Cabazitaxel	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	2.96	4.38	2.68	7.96
DCMRLFA	DMPAZHC	Cabazitaxel	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	9.73	11.79	10.48	12.52
DCHXMTO	DMPAZHC	Cabazitaxel	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	2.85	6.25	5.76	8.04
DCOM78A	DMPAZHC	Cabazitaxel	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	3.1	6.93	5.3	7.67
DCN331L	DMPAZHC	Cabazitaxel	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	7.86	6.3	5.27	11.55
DCS6Y18	DMPAZHC	Cabazitaxel	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	9.49	8.51	5.6	13.95
DC6A9S5	DMPAZHC	Cabazitaxel	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	9.12	8.59	5.86	11.62
DCYZQP6	DMPAZHC	Cabazitaxel	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	12.8	5.99	5.79	7.51
DCS9JV2	DMPAZHC	Cabazitaxel	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	0.26	0.83	6.01	8.35
DC53PNM	DMPAZHC	Cabazitaxel	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	8.31	2.97	2.05	5.29
DCBOB6N	DMPAZHC	Cabazitaxel	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	2.67	1.95	3.56	6.45
DCJKPGS	DMPAZHC	Cabazitaxel	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	5.97	5.53	2.91	9.13
DCSPITM	DMPAZHC	Cabazitaxel	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	8.99	8.16	11.72	13.91
DC5KG9S	DMPAZHC	Cabazitaxel	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	12.48	12.18	13.58	16.2
DCQ7V9R	DMPAZHC	Cabazitaxel	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	6.19	6.29	3.45	9.49
DC1PW5R	DMPAZHC	Cabazitaxel	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	5.78	2.45	1.12	6.18
DCOMNFG	DMPAZHC	Cabazitaxel	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	3.06	1.99	8.56	9.86
DC0THID	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	7.97	7.75	4.86	12.8
DCP73KR	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	2.51	2.95	1	7.93
DCQLNK0	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	11.66	7.32	13.08	16.89
DCNIOBO	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	9.72	9.1	13.79	14.65
DCAJVX3	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	19.33	18.42	21.09	24.82
DC6C03Q	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	25.86	15.88	15.59	21.1
DC4K83U	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	33.37	21.56	19.62	25
DCVCLH7	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	16.28	15.9	7.9	17.9
DCMHW3R	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	11.75	7.98	7.44	10
DC3V8NQ	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	0.46	0.93	1.15	3.03
DCBG2ZH	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	9.15	7.59	6.55	10.08
DC25YED	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	5.6	4.12	3.59	9.57
DCPLH16	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	1.34	0.77	2.4	7.3
DCJ1VVO	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	18.68	15.16	16.66	19.59
DCDWMOT	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	5.91	5.55	9.55	12.79
DCHS59M	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	0.32	3.01	9.1	11.3
DCDEOE4	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	8.57	7.96	7.99	12.98
DC30CXZ	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	1.15	1.86	4.94	5.94
DC33X8K	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	9.09	8.17	5.91	13.66
DCG2KYM	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	6.29	5.63	13.31	15.09
DCC9FTL	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	4.6	4.06	9.2	11.57
DCWQ0Y2	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	28.48	22.62	25.54	25.97
DC3SRH1	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	6.65	6.38	10.16	13.27
DCK7A1Y	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	9.99	8.58	13.18	15.34
DCDAQNU	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	12.68	12.23	16.99	17.69
DCPAUWH	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	4.65	5.2	1.56	11.14
DCEUVHD	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	9.55	12.78	10.75	12.42
DC5M5MZ	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	13.81	12.99	15.3	17.91
DCJMFP4	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	8.47	8.32	16.09	17.65
DC3CG3E	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	4	4.73	12.02	13.22
DCX1O4W	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	6.05	5.5	9.43	14.18
DCZMPRB	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	4.56	4.08	10.96	11.91
DCT4T79	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	12.75	10.15	14.71	16.87
DCHR28Y	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	13.02	11.77	18.02	19.8
DCAFFM9	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	8.02	7.07	11.74	12.33
DCDKG0V	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	11.88	11.34	15.79	18.42
DCT2D84	DMPAZHC	Cabazitaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	14.53	11.67	7.42	12.13
DCF4NFI	DMPAZHC	Cabazitaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	1.71	1.6	6.16	8.43
DCSCYO7	DMPAZHC	Cabazitaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	3.62	2.96	2.37	6.04
DCS00R7	DMPAZHC	Cabazitaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	3.84	4.02	3.86	10.47
DCZLWF6	DMPAZHC	Cabazitaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	3.54	3.8	2.62	7.79
DCHJQGN	DMPAZHC	Cabazitaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	5.07	3.84	1.01	5.4
DC1S6LQ	DMPAZHC	Cabazitaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	1.85	1.54	3.22	7.04
DC7YPMU	DMPAZHC	Cabazitaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	4.18	3.8	4	7.71
DC1GOC3	DMPAZHC	Cabazitaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	8.92	9.38	0.81	9.71
DCC6ACS	DMPAZHC	Cabazitaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	8.49	5.8	0.93	8.85
DCX1XS1	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	25.09	20.64	8.7	21.21
DCF5CKV	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	20.02	14.8	14.13	19.88
DCL69GJ	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	26.6	21.59	16.15	23.77
DCVDJ6Q	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	31.42	24.28	14.88	28.76
DCDXUEZ	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	25.07	24.38	2.41	25.95
DC7P54Z	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	12.55	7.93	0.55	10.46
DC5UWNF	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	5.02	5.39	5.03	12.07
DCSJYHZ	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	12.11	15.31	9.55	16.21
DCUYL3N	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	17.17	17.58	5.23	22.05
DC3JC4U	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	39.04	30.73	17.54	31.81
DC3HIHL	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	20	18.83	0.81	21.28
DCD82CM	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	11.6	11.83	2.87	15.2
DCK05N1	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	11.81	11.59	4.37	14.93
DC8AXGT	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	1	0.61	10.29	11.09
DCLT4H1	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	11.12	13.15	7.55	15.58
DCQS69I	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	6.6	6.36	7.52	12.55
DC0EZ50	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	15.04	11.42	12.39	15.79
DC8VA2B	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	6.43	8.33	0.06	9.31
DC4IIU3	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	12.19	10.55	4.68	13.4
DC92Z5J	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	11.9	6.04	4.83	9.82
DCFR5BZ	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	10.53	8.69	8.38	12.97
DCR3D0Y	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	20.98	21.04	16.67	22.65
DCFN6DO	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	11.01	10.96	6.97	11.71
DC9I1D2	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	19.68	17.23	16.03	18.72
DCOGUGZ	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	19.68	12.42	11.75	14.25
DCHD984	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	14.5	14.16	12.06	18.51
DC0IYWJ	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	3.65	7.92	8	11.5
DCZX6JK	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	8.27	9.58	8.98	12.7
DCA2Y1M	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	3.68	3.89	4.12	7.36
DCU2BY5	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	5.58	6.56	4.97	10.09
DCJG7W0	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	20.44	20.75	15.31	21.88
DCB031S	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	6.68	3.16	4.95	8.27
DC4Q36A	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	12.02	7.05	4.74	9.14
DCD68U0	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	20.44	17.11	16.44	19.89
DC6WSFQ	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	0.79	2.2	1.32	4.71
DC4UFKO	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	1.37	4.9	1.53	6.42
DCK73HK	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	7.87	8.07	6.63	10.99
DCA3GKP	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	15.78	8.65	3.5	10.83
DCDTEVZ	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	8.72	11.68	9.07	12.75
DCG5LSJ	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	0.25	0.84	3.64	6.37
DCSDUI4	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	8.65	8.17	11.72	13.39
DCRR3BY	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	12.01	6.28	1.8	8.63
DC8MI7J	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	10.58	9.46	11.21	13.2
DCMUCUX	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	8.43	7.26	6.73	11.11
DC0X5FB	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	14	12.98	9.74	14.45
DCHR3JP	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	8.99	7.92	9.05	11.9
DCWN328	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	28.69	23.23	5.33	22.29
DCRT3BG	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	11.93	10.85	9.77	14.01
DCV5J7A	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	17.57	14.16	11.52	16.74
DCLJSXB	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	18.44	15.16	12.57	16.98
DCT8VKH	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	22.27	21.15	16.68	20.22
DCKJ4NN	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	14.72	14.01	11.11	14.87
DC35GTA	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	10.65	9.67	9.12	11.76
DCCZ7OK	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	18.83	15.36	10.92	13.85
DC6FJ7Q	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	16.94	12.57	9.7	14.18
DCM8W84	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	7.05	6.93	5.6	10.57
DCNP0PM	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	4.43	4.06	3.28	6.44
DC9ZEF7	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	4.64	6.02	4.45	8.79
DCC7BHU	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	28.37	25.34	19.41	25.71
DCAT2EX	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	6.53	5.22	7.4	9.59
DCVX2JS	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	3.85	7.84	5.85	10.66
DCFQXR9	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	8.43	8.52	9.13	11.44
DCR36OI	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	7.29	7.57	5.65	8.57
DCREWE5	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	8.57	7.28	3.57	7.87
DCP63RT	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	9.56	9.93	7.13	12.16
DCPGT88	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	7.77	6.88	1.62	10.35
DC7QMIR	DMPAZHC	Cabazitaxel	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	10.91	8.7	8.18	12.41
DCKV0ZY	DMPAZHC	Cabazitaxel	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	2.31	1.65	4.46	7.4
DCT7VGF	DMPAZHC	Cabazitaxel	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	15.95	10.96	3.72	12.98
DCUI8FE	DMPAZHC	Cabazitaxel	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	6.55	4.71	5.53	9.12
DCH1I66	DMPAZHC	Cabazitaxel	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	18.16	11.86	7.35	15.06
DCTDRW1	DMPAZHC	Cabazitaxel	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	7.98	5.85	4.61	7.98
DCPTLUM	DMPAZHC	Cabazitaxel	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	12.83	9.39	8.67	11.12
DC4XSF9	DMPAZHC	Cabazitaxel	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	7.68	5.1	3.92	7.81
DC249F9	DMPAZHC	Cabazitaxel	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	1.62	4.16	1.42	6.78
DCO9BB9	DMPAZHC	Cabazitaxel	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	5.59	5.52	3.46	6.12
DCJHVPQ	DMPAZHC	Cabazitaxel	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	19.27	15.94	13.63	18.87
DC8T5SS	DMPAZHC	Cabazitaxel	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	2.11	3.98	4.54	6.48
DCB25EK	DMPAZHC	Cabazitaxel	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	0.6	0.07	2.23	4.42
DCW59RR	DMPAZHC	Cabazitaxel	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	7.1	6.25	8.08	11.35
DCR574I	DMPAZHC	Cabazitaxel	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	6.34	5.18	6.33	10.41
DCDNN52	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	11.92	2.01	8.13	10.36
DCQV82G	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	17.9	13.86	14.82	17.85
DC1HKCV	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	15.06	15.1	16.57	20.86
DCHIS3E	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	10.2	6.5	10.32	12.97
DCQLZ5V	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	7.43	6.17	5.04	8.45
DCLA0DV	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	9.67	7.72	6.51	9.53
DCU2NWH	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	10.71	7.32	6.65	9.26
DCMA8A0	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	2.12	1.87	7.49	10.04
DCDJYHB	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	12.52	10.52	9.24	12.74
DCDJX8Y	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	2.2	2.19	4.55	7.8
DC9ASEF	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	2.04	1.91	10.11	11.64
DC9OHKE	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	0.18	0.47	5.74	8.01
DC2CJHQ	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	12.17	10.91	12.11	15.58
DCDJL2T	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	2.75	1.47	5.98	8.24
DCON9OV	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	6.58	0.83	2.59	6.39
DC2QQQV	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	14.84	9.95	12.7	15.57
DC5913L	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	4.89	2.68	6.31	9.35
DCPGGX9	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	6.43	4.66	9.17	11.65
DCX9UIH	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	1.4	1.56	6.68	9.39
DCE5X1J	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	0.3	3.38	7.86	9.14
DC4VQHH	DMPAZHC	Cabazitaxel	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	9.53	12.67	8.22	12.71
DCMXUMT	DMPAZHC	Cabazitaxel	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	15.03	14.94	6.33	12.9
DCFK40D	DMPAZHC	Cabazitaxel	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	22.36	20.31	14.63	19.77
DC41K76	DMPAZHC	Cabazitaxel	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	5.23	4.32	1.45	5.28
DCVYGMK	DMPAZHC	Cabazitaxel	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	3.58	7.34	5.14	8.36
DCJTBVH	DMPAZHC	Cabazitaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	4.51	5.18	0.46	6.03
DCSJYRS	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	4.14	3.45	7.13	9.52
DCNXMJU	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	5.76	5.87	7.47	11.24
DC5AFQ5	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	9.01	8.21	6.59	13.14
DCJH2E0	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	19.16	15.54	10.84	19.53
DC3NKY4	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	4.08	3.78	7.29	10.08
DCUZ6F8	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	19.37	15.76	12.39	17.87
DC72DKY	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	7.66	4.22	2.94	6.77
DCN7O8T	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	8.37	5.48	5.02	7.51
DC61GXS	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	6.26	5.6	5.35	7.8
DCSRSU9	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	2.35	4.99	3.56	6.29
DC9M25H	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	10.41	6.78	5.75	9.25
DCOIQA9	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	3.12	2.96	4.6	4.86
DC84H27	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	12.42	12.26	12.29	16.78
DCF7B7I	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	13.42	12.63	6.11	17.32
DCD5CIT	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	4.69	5.43	5.21	10.17
DCSQEOL	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	4.16	3.98	7.85	8.6
DCP3KRB	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	11.73	11.66	9.08	15.94
DC3SF5P	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	3.8	6.45	9.26	11.35
DC9PUJM	DMPAZHC	Cabazitaxel	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	ALMANAC Dataset	Investigative	T98G	0.3	0.3	2.29	2.37
DCSTWJ9	DMPAZHC	Cabazitaxel	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	9.65	8.71	4.86	9.15
DC2X9ZS	DMPAZHC	Cabazitaxel	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	14.39	13.81	0.67	15.07
DC1EEQD	DMPAZHC	Cabazitaxel	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	10.94	8.61	4.82	8.25
DCSUMFP	DMPAZHC	Cabazitaxel	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	9	7.42	3.55	7.28
DC6DFCH	DMPAZHC	Cabazitaxel	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	5.75	7.92	2.9	9.18
DCBOHYL	DMPAZHC	Cabazitaxel	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	5.19	4.58	4.68	7.05
DC3TUPD	DMPAZHC	Cabazitaxel	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	13.96	12.97	8.92	12.64
DCDOMVJ	DMPAZHC	Cabazitaxel	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	4.85	6.37	1.45	5.91
DCQPLEC	DMPAZHC	Cabazitaxel	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	2.82	4.47	0.5	5.53
DC19EMB	DMPAZHC	Cabazitaxel	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	23.41	18.63	11.41	18.61
DCI21S6	DMPAZHC	Cabazitaxel	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	7.34	4.1	4.87	8.01
DC65D0X	DMPAZHC	Cabazitaxel	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	4.06	3.28	0.29	3.01
DCMS93T	DMPAZHC	Cabazitaxel	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	1	4.73	2.52	6.05
DC2EBHQ	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	7.53	7.61	7.77	12.15
DCNY6UL	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	5.9	3.96	2.63	9.47
DC0AXJX	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	16.27	15.24	11.61	19.3
DCK0ODQ	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	8.78	6.32	4.81	8.71
DCC69VH	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	3.25	2.83	0.92	4.52
DC440A8	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	1.78	1.27	0.73	3.3
DC5ZSOA	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	5.61	4.83	7.56	11.68
DCNWSRB	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	8.55	8.19	7.7	10.8
DCR346H	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	0.54	0.59	1.35	3.16
DC80NU3	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	4.72	7.77	4.78	10.44
DCGWP4Q	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	3.63	1.94	1.41	5.4
DCIG22T	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	9.44	7.63	11.37	13.3
DCHWI12	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	1.23	0.92	4.34	6.52
DCDVSR9	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	3.38	1.99	4.22	7.11
DCXZSMZ	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	5.11	4.62	2.6	5.14
DCYQKZV	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	6.6	4.96	0.68	5.34
DCVMNBG	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	3.13	3.63	3.54	6.53
DC3G0K1	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	6.33	4.68	4.03	10.63
DCO8EJ4	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	11.44	12.64	10.84	14.2
DCW9WSH	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	3.83	6.62	7.2	9.55
DCKS2LD	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	8.57	7.2	7.92	10.02
DCKL8CZ	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	1.27	3.37	2.31	6.15
DCPMK2F	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	5.97	8.69	8.74	11.19
DCM95NA	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	14.08	13.84	7.51	14.3
DCCTSRL	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	5.96	5.92	4.69	9.41
DC9UF4K	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	11.77	12.32	9.47	12.57
DC74QA3	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	21.52	20.39	16.9	21.25
DC1YKX4	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	6.37	7.82	5.16	9.3
DCA7W4D	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	15.53	17.31	15.48	19.75
DCLCRC4	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	6.57	8.55	1.86	7.95
DC3JDP9	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	11.93	12.58	8.62	12.23
DCKYI5X	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	0.18	1.02	1.25	3.74
DCX2AFJ	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	14.4	17.59	12.75	16.1
DCCCKE5	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	16.53	16	11.52	17
DC0RFJ4	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	20.3	19.66	19.34	21.38
DC7SNW1	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	3.25	2.75	1.77	5.71
DCDDIOA	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	6.03	5.6	8.07	10.64
DCCDYCA	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	7.31	7.93	7.5	11.9
DCS7ILA	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	14.99	14.62	11.89	16.99
DCTVF9E	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	10.44	10.75	11.83	11.95
DC7AE5Q	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	16.88	14.03	15.12	16.46
DCIV2GJ	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	4.2	6.26	6.79	7.04
DCTLWBC	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	3.02	3.16	3.68	3.93
DCWFOHV	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	5.11	4.98	7.99	9.81
DC5UWSG	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	8.65	9.38	1.87	9.93
DCADGPM	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	0.76	0.58	5.3	5.8
DC2WNIY	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	1.52	2.05	5.75	6.84
DCDIB54	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	3.71	3.74	4.63	6.79
DC7XU6O	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	11.9	10.94	10.71	13.41
DCLQMQB	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	11.12	10.47	10.01	13.4
DC3ERWU	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	4.15	6.74	2.36	10.38
DCM4ZUU	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	4.51	4.13	6.22	6.44
DCUFCJQ	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	9.02	6.71	5.54	11.33
DCMZAP2	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	8.85	6.68	10.29	11.82
DCXGTCW	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	13.22	12.64	10.76	13.08
DC2S3IK	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	6.4	5.74	5.44	8.72
DCJYYSM	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	22.48	18.16	14.57	19.99
DCTRNQX	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	9.64	9.45	5.84	10.41
DCM6OFW	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	13.32	12.9	10.58	13.7
DCNP7RV	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	9.45	7.7	4.11	9.4
DCR5F7O	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	18.13	13.9	12.84	15.36
DCGBTQP	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	12.97	5.32	0.28	5.02
DC417S5	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	4.16	3.96	4.03	6.45
DCYUI6W	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	2.76	5.3	6.88	10.91
DC6XWML	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	5.67	6.6	5.67	8.35
DCQB8ZJ	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	4.92	5.14	6.68	9.34
DCOUMMF	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	3.68	4.09	4.8	6.98
DCLIR66	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	2.16	5.4	6.22	8.47
DC44XUQ	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	7.13	6.69	4.11	8.09
DCQGC8I	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	2.11	7.91	4.08	7.45
DCM1NKR	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	31.04	25.98	22.59	27.81
DCEN4IC	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	7.36	6.68	4.02	7.56
DC1UO6U	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	1.89	4.89	2.32	5.89
DC8JHPS	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	2.46	3.21	7.69	9.34
DC69K05	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	5.64	5.95	4.31	7.5
DCB02QZ	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	3.13	1.71	3.09	5.58
DC2DRC2	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	9.32	7.17	2.83	8.78
DC1AUE3	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	12.9	12.09	7.36	15.16
DCKC144	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	9	7.22	5.88	10.11
DCNA33S	DMPAZHC	Cabazitaxel	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	33.34	28.27	0.83	27.31
DCBEPLK	DMPAZHC	Cabazitaxel	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	21.17	17.6	15.23	18.89
DCEMB0C	DMPAZHC	Cabazitaxel	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	12.47	12.23	5.03	13.98
DCMI9BV	DMPAZHC	Cabazitaxel	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	7.25	7.42	1.67	9.73
DCC646R	DMPAZHC	Cabazitaxel	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	32.66	29.28	19.51	29.52
DCOL9W3	DMPAZHC	Cabazitaxel	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	12.68	12.91	10.04	13.19
DCY9GT6	DMPAZHC	Cabazitaxel	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	8.03	8.22	0.3	9.17
DCW3PP9	DMPAZHC	Cabazitaxel	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	8.85	9	4.67	10.02
DCLSBE0	DMPAZHC	Cabazitaxel	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	7.11	7.02	5.31	9.84
DCO3M3B	DMPAZHC	Cabazitaxel	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	9.09	9.37	1.67	11.08
DCETQD7	DMPAZHC	Cabazitaxel	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	5.61	6.89	7.71	10.29
DCW1QAY	DMPAZHC	Cabazitaxel	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	9	8.61	4.35	10.3
DC9XCTQ	DMPAZHC	Cabazitaxel	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	6.68	6.18	10.28	12.66
DC733ZB	DMPAZHC	Cabazitaxel	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	6.39	1.5	9.67	11.65
DCPQSNT	DMPAZHC	Cabazitaxel	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	8.25	7.34	12.2	14.03
DC77QJB	DMPAZHC	Cabazitaxel	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	5.87	3.95	7.96	10.97
DCLPKXU	DMPAZHC	Cabazitaxel	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	10.22	7.89	11.94	14.02
DCJV2VM	DMPAZHC	Cabazitaxel	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	6.56	3.35	6.1	8.93
DCP76E4	DMPAZHC	Cabazitaxel	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	19.54	16.65	15.88	18.74
DCGPTS1	DMPAZHC	Cabazitaxel	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	5.08	3.82	6.11	9.31
DC2KM9B	DMPAZHC	Cabazitaxel	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	3.96	1.76	3.02	4.31
DCU7BHZ	DMPAZHC	Cabazitaxel	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	7.43	2.34	3.96	7.86
DCDBBC9	DMPAZHC	Cabazitaxel	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	16.1	5.77	8.16	10.75
DCPYWZS	DMPAZHC	Cabazitaxel	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	5.44	5.31	6.93	12.23
DC8SDK5	DMPAZHC	Cabazitaxel	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	10.87	9.96	1.92	13.83
DCST11K	DMPAZHC	Cabazitaxel	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	9.65	9.38	4.66	16.9
DCPI208	DMPAZHC	Cabazitaxel	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	2.84	3.26	7.66	9.78
DC7FVCZ	DMPAZHC	Cabazitaxel	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	13.25	13	16.52	20.41
DC3GZX5	DMPAZHC	Cabazitaxel	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	4.52	3.57	9.52	11.1
DCLATA3	DMPAZHC	Cabazitaxel	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	17.25	16.38	13.5	16.98
DCEBTO2	DMPAZHC	Cabazitaxel	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	7.96	10.16	8.32	11.04
DCZV0RR	DMPAZHC	Cabazitaxel	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	16.59	15.53	12.22	16.52
DCNC3SP	DMPAZHC	Cabazitaxel	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	11.17	11.88	7.32	14.77
DCYAJTA	DMPAZHC	Cabazitaxel	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	5.67	5.11	1.71	5.31
DCA098B	DMPAZHC	Cabazitaxel	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	32.16	20.76	17.39	20.97
DC3JOK7	DMPAZHC	Cabazitaxel	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	8.31	11.09	5.46	10.94
DCKCXZR	DMPAZHC	Cabazitaxel	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	6.64	5.5	5.18	7.67
DCUEWSM	DMPAZHC	Cabazitaxel	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	1.02	1.52	3.01	7.14
DCZLW10	DMPAZHC	Cabazitaxel	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	0.93	10.73	8.62	11.06
DCGLL48	DMPAZHC	Cabazitaxel	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	16.08	16.06	13.68	16.27
DCKJTAO	DMPAZHC	Cabazitaxel	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	16.49	15.94	8.73	21.1
DCYGJ0B	DMPAZHC	Cabazitaxel	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	11.73	11.79	9.66	12.06
DCEPSIO	DMPAZHC	Cabazitaxel	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	3.9	3.89	0.21	4.66
DCBQQVP	DMPAZHC	Cabazitaxel	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	2.81	2.73	5.68	7.48
DCOXC4I	DMPAZHC	Cabazitaxel	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	16.49	16.33	14.85	18.39
DCZ4MAF	DMPAZHC	Cabazitaxel	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	8.68	8.01	2.15	7.9
DCJ85Q0	DMPAZHC	Cabazitaxel	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	9.97	9.33	6.63	10.62
DCGXB00	DMPAZHC	Cabazitaxel	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	22.07	19.15	15.57	19.43
DCQQKZY	DMPAZHC	Cabazitaxel	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	3.27	3.69	1.13	4.45
DCM5OYH	DMPAZHC	Cabazitaxel	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	4.44	6.56	2.35	6.62
DCIPKWS	DMPAZHC	Cabazitaxel	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	6.14	5.76	3.56	7.62
DC3IRP0	DMPAZHC	Cabazitaxel	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	2.89	2.14	0.09	1.71
DCYL3S0	DMPAZHC	Cabazitaxel	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	6.11	11.16	8.6	12.41
DCXYHE2	DMPAZHC	Cabazitaxel	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	10.64	10.31	8.89	11.72
DCMHNC7	DMPAZHC	Cabazitaxel	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	11.5	12.94	9.84	13.69
DCD71KK	DMPAZHC	Cabazitaxel	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	22.17	21.28	8.3	22.7
DCAWV7O	DMPAZHC	Cabazitaxel	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	15.98	17.46	12.95	17.61
DCD9AFB	DMPAZHC	Cabazitaxel	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	4.88	7.38	4.55	7.33
DC2X3QA	DMPAZHC	Cabazitaxel	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	10.82	11.3	6.17	10.26
DCRN59A	DMPAZHC	Cabazitaxel	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	15.62	19.68	12.29	21.15
DCQP5SK	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	1.7	3.41	1.2	6.65
DCQJ5AA	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	5.68	4.41	1.58	6.99
DCNFQU8	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	12.28	6.98	8.87	11.44
DCZC7EZ	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	8.59	5.65	5.62	8.81
DCQPRVQ	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	10.17	7.85	4.32	8.78
DC4DX0U	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	16.47	15.66	12.34	17.84
DCEOXW7	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	7.16	5.99	6.49	9.99
DCOQT5K	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	11.13	10.61	8.52	13.03
DC1ZK0O	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	16.46	15.78	11.26	16.31
DCPVBSJ	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	11.68	4.62	0.78	5.3
DCTFCOE	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	4.25	2.42	1.2	5.69
DCZU6X0	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	6.86	5.01	3.58	7.08
DC7XRCZ	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	4.43	2.37	2.46	4.59
DCV2AQD	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	8.03	7.52	7.75	10.53
DCHPFIR	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	1.09	1.86	0.92	4.78
DCQ4NSX	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	18.58	9.02	5.14	9.21
DCXA4PM	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	9.57	6.48	6.14	8.95
DCTEU0Y	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	2.46	1.4	0.13	5.47
DCZ3YNB	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	4.16	3.52	7.27	9.1
DC85T2R	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	14.82	15.68	14.86	19.18
DCH9MFB	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	3.72	2.92	3.88	8.61
DCFHC83	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	4.54	6.85	6.41	10.76
DCI4ZCU	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	1.19	4.54	2.91	6.93
DCHR8XA	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	1.67	0.16	0.68	3.25
DC2LX1O	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	6.14	3.83	3.09	5.34
DCR0OZP	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	11.22	8.97	10.48	13.83
DCMSSTV	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	11.4	11.18	11.82	15.22
DCOP0TA	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	1.01	0.23	2.97	4.8
DCVYSFI	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	4.33	7.33	8.87	9.29
DC7U0UR	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	1.96	1.37	4.42	4.99
DC7ASRW	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	6.55	6.51	9.96	10.56
DCURIWQ	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	2.59	4.12	2.15	6.56
DC1BA35	DMPAZHC	Cabazitaxel	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	17.12	19.39	5.27	19.2
DC5BINF	DMPAZHC	Cabazitaxel	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	3.45	4.79	1.02	4.99
DC8SDAG	DMPAZHC	Cabazitaxel	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	12.8	10.16	9.44	13.72
DC1ZBIS	DMPAZHC	Cabazitaxel	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	4.58	3.74	2.72	4.94
DCU1T2L	DMPAZHC	Cabazitaxel	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	6.02	7.85	6.83	10.72
DC6DW7I	DMPAZHC	Cabazitaxel	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	2.25	2.26	6.05	8.34
DCUMGKX	DMPAZHC	Cabazitaxel	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	19.75	18.75	21.03	22.79
DC7NK7R	DMPAZHC	Cabazitaxel	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	3.65	2.48	2.07	4.52
DCQDAMB	DMPAZHC	Cabazitaxel	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	7.42	7.77	5.7	11.28
DC0IYBW	DMPAZHC	Cabazitaxel	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	3.02	4.08	2.63	5.13
DC63DU3	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	12.38	14.69	3.7	15.29
DCFHJ83	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	9.08	8	4.66	9.49
DCCFR9O	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	16.18	16.2	12.31	16.76
DCUGLYX	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	35.74	31.2	25.39	30.7
DCERVDY	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	28.97	19.48	14.23	22.93
DCY5III	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	36.42	28.93	25.09	29.26
DCIIW1V	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	30.48	24.03	22.22	26.15
DCGUSQ0	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	7.43	5.69	1.06	6.11
DC8605A	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	31.58	27.19	6.83	28.09
DCKMR3Y	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	23.78	14.57	10.02	14.8
DCOOVPT	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	1.76	4.57	3.98	5.93
DCQPUEH	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	2.45	2.19	2.2	8.79
DCGI3EN	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	5.56	4.45	2.53	6.63
DCHCJ6A	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	4.61	4.47	0.09	5.64
DCREI8R	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	29.47	26.02	15.56	29.14
DCQ32W6	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	9.66	9.31	5.88	9.51
DCOT0GT	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	16.78	16.46	13.1	17.44
DCMH380	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	10.22	10.14	2.06	12.77
DCDWZ2M	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	8.06	12.27	10.09	12.5
DCT49HG	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	2.53	2.14	5.97	7.08
DCOBJTF	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	13.68	13.27	11.66	15.04
DCCKODX	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	9.09	9.39	6.93	10.32
DC7UAJB	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	3.68	4.21	0.97	5.47
DCETYZZ	DMPAZHC	Cabazitaxel	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	12.37	11.34	7.55	11.51
DCJ5Z1K	DMPAZHC	Cabazitaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	5.9	4.04	6.07	8.51
DCIZWS0	DMPAZHC	Cabazitaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	6.54	6.04	6.74	9.73
DC8XHIC	DMPAZHC	Cabazitaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	10.4	9.92	10.82	13.57
DC4H26Y	DMPAZHC	Cabazitaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	1.58	0.2	1.14	3.83
DC32MB5	DMPAZHC	Cabazitaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	6.04	7.66	9.51	12.26
DCJA90T	DMPAZHC	Cabazitaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	2.41	0.61	4.13	6.37
DCX39YP	DMPAZHC	Cabazitaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	2.97	4.28	2.21	8.95
DCT07QU	DMPAZHC	Cabazitaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	4.19	5.44	4.58	8.88
DC3YUB8	DMPAZHC	Cabazitaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	5.21	4.72	7.38	10.22
DCHIAAZ	DMPAZHC	Cabazitaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	10.51	10.18	12.15	15.13
DCISXGO	DMPAZHC	Cabazitaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	14.79	10.24	6.87	12.65
DC1VTQ8	DMPAZHC	Cabazitaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	7.75	7.7	5.04	11.14
DC9NVC6	DMPAZHC	Cabazitaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	7.45	7.65	3.87	11.87
DCNJCTT	DMPAZHC	Cabazitaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	4.74	4.03	4	9.22
DC39CLN	DMPAZHC	Cabazitaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	16.21	12.13	10.03	13.73
DCIO655	DMPAZHC	Cabazitaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	4.46	2.3	4.06	7.5
DCDVBEU	DMPAZHC	Cabazitaxel	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	3.72	6.51	0.12	8.37
DCRH15E	DMPAZHC	Cabazitaxel	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	3.5	4.25	1.87	7.3
DCNMWM5	DMPAZHC	Cabazitaxel	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	1.09	1.73	3.34	8.15
DCQEY27	DMPAZHC	Cabazitaxel	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	1.77	3.4	1.65	5.6
DCB4MT3	DMPAZHC	Cabazitaxel	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	11.35	11.91	9.17	13.95
DCB3TXQ	DMPAZHC	Cabazitaxel	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	4.14	6.5	2.21	6.56
DCQ7M2B	DMPAZHC	Cabazitaxel	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	6.04	6.13	2.64	7.25
DCDJ0HN	DMPAZHC	Cabazitaxel	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	5.85	5.95	4.05	7.54
DC10HZE	DMPAZHC	Cabazitaxel	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	3.04	2.37	1.28	5.74
DCIPX8T	DMPAZHC	Cabazitaxel	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	5.19	4.04	2.59	4.35
DCH4KJG	DMPAZHC	Cabazitaxel	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	7.45	6.07	4.73	8.46
DC48R0D	DMPAZHC	Cabazitaxel	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	0.78	1.91	0.86	3.44
DCURPV7	DMPAZHC	Cabazitaxel	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	3.51	5.63	2.7	5.92
DC7A0VU	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	9.18	8.86	9.27	12.2
DCN2YLS	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	3.06	0.76	1.86	4.72
DCDN3AY	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	4.86	5.1	9.83	11.96
DC9YC2R	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	19.46	20.56	18.06	22.58
DCZKB1U	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	13.8	10.29	14.91	17.18
DCC35YQ	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	13.34	11.2	10.28	15.26
DCA7QKW	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	13.92	12	12.96	15.61
DCQLY2Z	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	19.82	19.3	15.3	21.92
DC6EILQ	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	9.6	8.86	7.6	10.4
DCVGJUQ	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	13.32	12.23	12.3	14.92
DCWDW2Q	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	2.12	1.55	3.24	5.85
DC9XKWP	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	4.67	3.65	2.39	9.95
DC6YHW8	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	17.94	18.1	15.2	19.9
DC0EFYW	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	2.97	3.9	5.93	8.46
DCO0RUF	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	8.66	8.74	12.51	14.56
DCDLOIO	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	3.09	3.48	5.49	8.34
DCACEGM	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	5.26	3.96	7.8	8.78
DCO5OWV	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	0.87	0.31	3.14	5.56
DCEXYHR	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	2.46	1.13	1.08	5.38
DCO0VXH	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	23.3	17.08	10.54	20.6
DCZ0FKH	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	8.08	7.63	10.23	12.69
DCHZH8U	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	2.58	1.89	5.64	8.99
DC5D0RI	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	4.22	4.88	8.73	10.87
DCNCX28	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	3.54	3.44	5.63	7.72
DCJQUQ1	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	9.55	8.46	10.86	12.84
DCNJEWA	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	1.4	1.54	5.44	8.84
DC5PWQP	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	11.64	7.07	5.24	8.85
DC2BZCV	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	4.95	6.82	10.05	12.45
DCPHLFE	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	4.83	4.85	9.06	10.81
DCXNZ0K	DMPAZHC	Cabazitaxel	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	0.75	1.56	2.34	5.29
DCCT8L9	DMPAZHC	Cabazitaxel	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	4.25	4.43	3.62	10.67
DC2Z0RR	DMPAZHC	Cabazitaxel	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	7.87	3.07	9.43	10.69
DC9EWEN	DMPAZHC	Cabazitaxel	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	1.7	1.66	0.7	6.72
DC8KAGP	DMPAZHC	Cabazitaxel	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	4.35	3.6	3.91	8.04
DCSXSIU	DMPAZHC	Cabazitaxel	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	0.45	0.87	3.33	6.89
DC1ZIXJ	DMPAZHC	Cabazitaxel	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	10.3	10.3	1	13.64
DCV8N02	DMPAZHC	Cabazitaxel	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	2.04	0.08	3.28	4.43
DCHVUP1	DMPAZHC	Cabazitaxel	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	7.66	4.13	7.4	9.39
DC33GHJ	DMPAZHC	Cabazitaxel	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	7.54	6.73	3.7	7.79
DCW0ECT	DMPAZHC	Cabazitaxel	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	4.7	6.6	3.39	11.1
DC54XH5	DMPAZHC	Cabazitaxel	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	10.68	10.58	6.89	11.6
DCPTE6O	DMPAZHC	Cabazitaxel	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	11.61	11.47	0.2	14.1
DCXLKWU	DMPAZHC	Cabazitaxel	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	10.74	9.59	5.54	10.52
DC51DHZ	DMPAZHC	Cabazitaxel	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	15.01	14.03	1.05	14.97
DCPX0MS	DMPAZHC	Cabazitaxel	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	3.63	4.25	3.97	6.53
DCA4TIZ	DMPAZHC	Cabazitaxel	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	3.37	3.07	5.1	7.83
DC1AXBJ	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	6.66	6.48	7.59	9.22
DCBAZBE	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	4.69	5.27	0.67	11.14
DC4EB3E	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	19.08	15.15	11.27	16.19
DC4IPS9	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	19.34	15.31	8.93	19.41
DCCZXCR	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	18.26	20.81	15.91	21.99
DC3YZ3T	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	10.13	10.14	6.47	11.62
DC86NJ2	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	12.32	12.11	11	13.42
DCUT1KH	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	2.86	3.1	2.92	5
DCF9765	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	10.1	7.88	7.72	9.88
DC6DV3I	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	4.65	3.7	6.44	9
DCNZNXL	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	14.94	11.44	8.74	13.48
DCO913O	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	0.79	3.89	4.8	6.75
DCW4JX3	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	7.92	8.14	11.08	13.89
DCVKE8S	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	4.69	4.76	7.21	10.33
DCQBVFJ	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	4.04	5.55	1.36	10.79
DCNP2JC	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	3.86	2.91	5.04	9.08
DCWAMGC	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	15.26	14.91	16.56	19.55
DCWDWAO	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	1.59	0.91	2.52	4.39
DCCETUR	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	2.12	4.49	2.04	9.29
DCW7XPF	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	3.83	4.23	3.84	9.3
DCPSGGQ	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	1.6	4.75	6.35	8.41
DCU9C20	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	3.19	3.56	0.04	4.67
DCS45O5	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	8.85	7.53	7.29	11.35
DCLL8BU	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	1.34	0.93	4.56	7.29
DC3VZHC	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	8.56	6.1	2.2	8.95
DCQWLDO	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	4.01	5.76	7.52	10.69
DCXY7M1	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	5.45	6.85	1.98	11.22
DC72SEL	DMPAZHC	Cabazitaxel	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	7.42	8.94	7.34	9.65
DCAZH9E	DMPAZHC	Cabazitaxel	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	9.01	7.92	3	8.98
DCE1VZ5	DMPAZHC	Cabazitaxel	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	9.57	6.71	4.88	9.15
DCOZX4K	DMPAZHC	Cabazitaxel	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	19.09	18.31	14.5	20.37
DCTQ49D	DMPAZHC	Cabazitaxel	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	9.82	8.21	3.33	9.22
DCXBWY7	DMPAZHC	Cabazitaxel	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	6.65	6.53	5.54	8.5
DCG3EXU	DMPAZHC	Cabazitaxel	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	5.07	4.47	5.02	6.5
DC22EZS	DMPAZHC	Cabazitaxel	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	11.86	11.44	7.67	12.56
DCFLU7A	DMPAZHC	Cabazitaxel	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	3.22	2.29	0.33	3.01
DCB425F	DMPAZHC	Cabazitaxel	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	10.66	10.48	8.26	12.08
DCHKX4W	DMPAZHC	Cabazitaxel	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	4.8	6.3	3.89	7.69
DC2R6KA	DMPAZHC	Cabazitaxel	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	6.73	6.87	5.24	6.73
DC4NQ9R	DMPAZHC	Cabazitaxel	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	5.7	4.59	1.68	5.96
DCCI6IA	DMPAZHC	Cabazitaxel	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	2.29	3.51	2.39	6.92
DC7HDLB	DMPAZHC	Cabazitaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	6.16	6.42	8.86	10.88
DCFJ2GE	DMPAZHC	Cabazitaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	10.62	11.58	7.53	13.94
DCZ6N1D	DMPAZHC	Cabazitaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	10.79	7.21	7.67	10.52
DC74QVK	DMPAZHC	Cabazitaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	2.31	1.28	4.55	7.63
DC8FY2D	DMPAZHC	Cabazitaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	13.8	11.27	15.12	16.91
DCQ7S2I	DMPAZHC	Cabazitaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	19.08	18.14	6.7	19.31
DCFGUCB	DMPAZHC	Cabazitaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	6.94	6.04	10.1	11.63
DCJC3JS	DMPAZHC	Cabazitaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	14.73	14.16	10.63	15.78
DCOXT3V	DMPAZHC	Cabazitaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	5.98	7.42	6.38	10.46
DCKAL2E	DMPAZHC	Cabazitaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	3.37	6.56	3.95	7.17
DCHDUIK	DMPAZHC	Cabazitaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	15.08	14.16	15.33	17.3
DCU7FYX	DMPAZHC	Cabazitaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	0.84	4.08	7.5	8.61
DCYN7AK	DMPAZHC	Cabazitaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	0.41	2.59	5.62	7.61
DC9D4AD	DMPAZHC	Cabazitaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	17.52	17.29	12.65	18.95
DC0WDTN	DMPAZHC	Cabazitaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	0.89	4.82	4.2	8.06
DC7EWFK	DMPAZHC	Cabazitaxel	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	8.81	8.85	4.65	10.09
DCEPTJR	DMPAZHC	Cabazitaxel	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	8.68	12.1	4.16	15.72
DCO9WU0	DMPAZHC	Cabazitaxel	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	17.64	17.01	11.23	19.82
DCKJ9N4	DMPAZHC	Cabazitaxel	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.48	2.91	8.27	13.87
DCCKGYI	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	15.56	12.79	11.6	17.76
DCM5AKC	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	15.02	14.38	9.13	20.85
DC1VYTV	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	11.55	11.57	9.03	15.67
DCI9ZMO	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	6.99	5.85	8.88	9.77
DC13P7Y	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.82	9.53	13.44	14.52
DC8MW52	DMPAZHC	Cabazitaxel	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	13.49	12.62	7.99	15.07
DCHP5JF	DMPAZHC	Cabazitaxel	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.36	1.98	1.28	5.83
DCMZ1AM	DMPAZHC	Cabazitaxel	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	8.03	8.56	6.35	8.84
DCWFABA	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.59	3.18	2.44	4.7
DC53UXQ	DMPAZHC	Cabazitaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.43	6.8	3.41	7.84
DCV6FZ4	DMPAZHC	Cabazitaxel	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	21.05	16.69	2.64	16.47
DC2A9CL	DMPAZHC	Cabazitaxel	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	19.78	14.73	2.62	14.97
DCE578J	DMPAZHC	Cabazitaxel	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	17.04	13.22	0.45	13.15
DC5MO95	DMPAZHC	Cabazitaxel	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.83	11.24	3.56	11.32
DCB6CNG	DMPAZHC	Cabazitaxel	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.42	9.81	7.57	12.26
DC114U1	DMPAZHC	Cabazitaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	9.55	8.53	3.75	9.57
DCXAW0T	DMPAZHC	Cabazitaxel	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	20.24	19.92	7.71	22.16
DCU4EQ8	DMPAZHC	Cabazitaxel	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.33	5.67	7.14	9.66
DCDWWHY	DMPAZHC	Cabazitaxel	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.68	4.68	3.06	6.27
DCF8CFD	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.87	5.79	1.11	6.86
DC3F1FG	DMPAZHC	Cabazitaxel	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.48	3.14	1.02	3.37
DCPZ4RQ	DMPAZHC	Cabazitaxel	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.26	6.66	3.55	8.54
DCBLV1H	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	21.21	19.78	0.32	20.48
DCASK5E	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	10.34	10.23	6.38	13.49
DC7Z603	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	18.26	20.22	5.91	20.3
DCI8H5T	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	18	13.78	0.32	15.04
DCBZD4E	DMPAZHC	Cabazitaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	11.29	10.29	5.52	11.04
DC9S5AU	DMPAZHC	Cabazitaxel	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.92	4.22	0.21	4.83
DCA3ZES	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.26	2.42	3.83	6.53
DCN7AIM	DMPAZHC	Cabazitaxel	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.68	1.68	0.36	3.65
DCKWBQO	DMPAZHC	Cabazitaxel	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	5.49	6.89	13.28	14.96
DC6F6LJ	DMPAZHC	Cabazitaxel	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	4.2	6.27	5.89	10.57
DCFF6C7	DMPAZHC	Cabazitaxel	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.27	2.82	2.02	5.8
DCJDBPA	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.92	6.39	6.6	7.12
DC9PHCA	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.3	4.01	3.06	4.98
DCDEG3C	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.16	5.24	4.95	6.07
DCSWP76	DMPAZHC	Cabazitaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.37	7.31	7.34	7.77
DCBXQQZ	DMPAZHC	Cabazitaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	12.08	13.5	2.44	14.42
DC1W9N0	DMPAZHC	Cabazitaxel	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	14.98	14.47	1.96	18.88
DCYCZUN	DMPAZHC	Cabazitaxel	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.29	7.91	6.75	9.59
DCZQUB4	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	15.77	15.4	21.08	22.64
DCQBZD2	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	17.61	13.84	15.12	17.71
DCQIW03	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.86	2.35	3.87	7.78
DC0L0N5	DMPAZHC	Cabazitaxel	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.05	3.78	3.08	7.44
DCAT126	DMPAZHC	Cabazitaxel	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	14.39	13.65	2.32	14.52
DC69HUX	DMPAZHC	Cabazitaxel	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	8.46	10.85	10.58	16.2
DCT9NSF	DMPAZHC	Cabazitaxel	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.58	7.25	2.76	5.69
DCBKX6X	DMPAZHC	Cabazitaxel	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.43	4.26	5.49	9.76
DCWMHN9	DMPAZHC	Cabazitaxel	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.44	1.01	1.21	4.8
DC8WTQV	DMPAZHC	Cabazitaxel	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.12	1.56	0.22	3.19
DC6NGHG	DMPAZHC	Cabazitaxel	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.32	1.23	2.5	8.55
DC2G4L9	DMPAZHC	Cabazitaxel	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.16	9.59	6.63	15.74
DCJJI40	DMPAZHC	Cabazitaxel	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.97	3.46	1.64	5.82
DC4JTYP	DMPAZHC	Cabazitaxel	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.85	3.67	1.47	6.99
DCLRIBS	DMPAZHC	Cabazitaxel	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	10.33	9.05	5.16	11.64
DCVHIHW	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	20.48	10.3	14.28	18.41
DC2XSNE	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	11.96	11.6	21.46	22.9
DC3JVOI	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	12.88	12.8	21.76	23.37
DCLAXWG	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.53	3.56	0	6.03
DC8WSO3	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	17.06	13.18	14.08	18.44
DCSWP21	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.08	9.29	9.48	15.76
DCITP4O	DMPAZHC	Cabazitaxel	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	8.71	8.2	10.75	14.68
DC0Z46Q	DMPAZHC	Cabazitaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	15.32	13.96	7.59	13.91
DCBKMGH	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	18.36	17.61	13.62	19.02
DCEOQSM	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	25.07	24.45	1.66	27.2
DCBG3DV	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	17.41	17.16	21.81	23.19
DC7KOX2	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.99	2.8	1.86	6.72
DC5L4VT	DMPAZHC	Cabazitaxel	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	25.7	18.62	15.14	21.96
DCSQJ6O	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	6.36	7.84	3.67	10.49
DCHZFH1	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	7.14	12.23	9.49	16.35
DCKVE2U	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.78	4.8	7.05	9.68
DCY22JJ	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	8.78	6.22	0.89	10.18
DC49E4L	DMPAZHC	Cabazitaxel	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.74	6.26	3.35	8.48
DC414L0	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	6.42	5.36	7.2	9.37
DC8MV6Z	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	14.9	14.39	18.68	19.83
DC84J5F	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.95	2.49	5.41	7.39
DCF7AH2	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.27	6.82	5.07	9.3
DCUVW85	DMPAZHC	Cabazitaxel	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.17	2.76	2.55	7.19
DC573RM	DMPAZHC	Cabazitaxel	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	10.97	11.15	4.18	16.64
DCOOHUB	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.77	2.5	5.4	7.68
DCQ1U2D	DMPAZHC	Cabazitaxel	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	7.92	8.03	14.66	16.83
DC1YCGE	DMPAZHC	Cabazitaxel	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	8.06	8.53	6.92	9.38
DC97TAG	DMPAZHC	Cabazitaxel	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.02	8.35	5.85	8.48
DC7V8Q1	DMPAZHC	Cabazitaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	7.16	7.52	1.34	12.03
DC4F0UC	DMPAZHC	Cabazitaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.97	5.29	1.16	6.54
DCMOWN3	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	10.55	13.05	5.81	17.3
DC7PUL6	DMPAZHC	Cabazitaxel	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.05	1.85	5.11	7.52
DCI2YV5	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	7.7	4.56	1.36	5.63
DCT83ME	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	8.49	11.59	9	14.09
DCXLQQP	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.68	5.63	3.51	8.7
DCX7OK8	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.33	5.93	4.14	8.31
DC1H7AD	DMPAZHC	Cabazitaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.17	5.28	4.46	7.42
DC268OW	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	6.67	7.5	5.91	8.64
DCD1A38	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	19.87	19.37	16.43	21.13
DC6ZMVS	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	9.85	10.29	3.47	10.06
DC2992E	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	11.6	14.05	3.98	14.47
DCKRR3I	DMPAZHC	Cabazitaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	8.22	7.88	5.91	8.57
DCU4J9G	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.69	1.38	2.32	3.61
DCK9WX7	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.54	5.37	7.1	7.87
DC095CB	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	7.43	6.13	8.12	9.43
DC2BU7V	DMPAZHC	Cabazitaxel	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.59	4.19	4.8	7.63
DCNKRT8	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	13.99	13.74	14.48	17.79
DCCJJ4J	DMPAZHC	Cabazitaxel	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.12	2.34	1.89	5.13
DC5CXAR	DMPAZHC	Cabazitaxel	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	11.26	11.47	5.14	11.08
DC5PPI8	DMPAZHC	Cabazitaxel	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.22	8.34	7.07	10.29
DCYDTDK	DMPAZHC	Cabazitaxel	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	10.81	10.39	10.32	17.67
DC3UPMD	DMPAZHC	Cabazitaxel	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	9.57	8.93	6.2	13.79
DCJVPXC	DMPAZHC	Cabazitaxel	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	7.89	6.39	1.62	7.38
DCWAK7L	DMPAZHC	Cabazitaxel	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	18.9	18.27	13.84	18.24
DCSKFB0	DMPAZHC	Cabazitaxel	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.07	5.77	2.55	5.59
DC2TTY7	DMPAZHC	Cabazitaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.73	4.32	2.2	7.27
DC4F5N6	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	10.45	11.84	12.86	15.88
DC8NF0S	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	16.89	16.42	12.5	20.8
DC783TC	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	5.88	11.11	9.31	11.96
DCT983B	DMPAZHC	Cabazitaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	15.16	14.28	2.75	15.72
DCA6B1L	DMPAZHC	Cabazitaxel	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	9.82	7.48	2.73	8.25
DCH0E0R	DMPAZHC	Cabazitaxel	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	9.46	9.1	1.17	9.08
DCRFFYI	DMPAZHC	Cabazitaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	8.34	8.11	5.95	9.28
DCC5HLY	DMPAZHC	Cabazitaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	7.11	5.7	6.8	10.72
DCRZUEE	DMPAZHC	Cabazitaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.36	4.38	5.07	7.29
DC4J9WV	DMPAZHC	Cabazitaxel	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.94	8.06	6.5	8.4
DCU2SXP	DMPAZHC	Cabazitaxel	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.83	0.5	0.64	2.57
DCFU6FC	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	7.57	8.12	11.65	13.87
DCNMEQ2	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	7.36	9.96	15.47	17.17
DCHMBJR	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.78	1.58	9.35	11.13
DCPPW3P	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.49	0.86	4.85	6.99
DCPT8ZY	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.77	3.69	7.15	10.19
DCMWD3I	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	11.81	7.95	10.06	13.59
DCS3GV7	DMPAZHC	Cabazitaxel	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	18.09	12.22	14.9	17.27
DC0DAPH	DMPAZHC	Cabazitaxel	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.95	2.69	0.31	5.87
DCQ1XP7	DMPAZHC	Cabazitaxel	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	5.63	5.78	4.88	7.95
DCX5ASX	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	7.4	7.25	8.33	10.65
DC1STTG	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	10.41	10.77	14.69	16.83
DCJJYTI	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	9.4	9.75	8.36	15.38
DCSP3TQ	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	11.29	10.38	6.05	13.49
DC2BD07	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	8.19	7.59	3.35	9.84
DCB8VWC	DMPAZHC	Cabazitaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.51	6.52	4.16	9.25
DC7SOWI	DMPAZHC	Cabazitaxel	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	15.94	14.97	10.47	16.93
DCY7PWB	DMPAZHC	Cabazitaxel	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	6.1	4.3	1.5	6.51
DCCQEC5	DMCMBHA	Erlotinib	Approved	34	DMDI269	Docetaxel	Approved	34	DMMX2E6	Pemetrexed	.	.	Non-Squamous Non-Small Cell Lung Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC0K3P2	DMCMBHA	Erlotinib	Approved	34	DMDI269	Docetaxel	Approved	34	DMMX2E6	Pemetrexed	.	.	Non Small Cell Lung Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCRJL0M	DMCMBHA	Erlotinib	Approved	34	DMG281S	Carboplatin	Approved	34	DMMX2E6	Pemetrexed	.	.	Lung Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCZQ27L	DMCMBHA	Erlotinib	Approved	34	DMG281S	Carboplatin	Approved	34	DMLB81S	Paclitaxel	.	.	Recurrent Non-small Cell Lung Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC2VT6E	DMCMBHA	Erlotinib	Approved	34	DMIYDT4	Cabozantinib	Approved	34	.	.	.	.	Pancreatic Adenocarcinoma Metastatic	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC9DY4O	DMCMBHA	Erlotinib	Approved	34	DMTKD7Q	Afatinib	Approved	34	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCPFSHH	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Diffuse Intrinsic Pontine Glioma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCPPCPS	DMCMBHA	Erlotinib	Approved	34	DMD9RV3	INCB039110	Phase 2	21	.	.	.	.	Solid Tumors and Hematologic Malignancy	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCU3AFM	DMCMBHA	Erlotinib	Approved	34	DMHJTR2	XL880	Phase 2	21	.	.	.	.	Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCBAO0J	DMCMBHA	Erlotinib	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	DMKECZD	Temozolomide	.	.	Recurrent Childhood Brain Tumor	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCDPJ7J	DMCMBHA	Erlotinib	Approved	34	DMDI269	Docetaxel	Approved	34	DMMX2E6	Pemetrexed	.	.	Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC0OGCP	DMCMBHA	Erlotinib	Approved	34	DMMX2E6	Pemetrexed	Approved	34	.	.	.	.	Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC1W6LW	DMCMBHA	Erlotinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC2MGUV	DMCMBHA	Erlotinib	Approved	34	DMF57DM	Pazopanib	Approved	34	.	.	.	.	"Lung Cancer, Non-Small Cell"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC3P67M	DMCMBHA	Erlotinib	Approved	34	DMTIVEN	Metronidazole	Approved	34	.	.	.	.	Non-Squamous Non-Small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC4YUJT	DMCMBHA	Erlotinib	Approved	34	DMJFRCT	Tasisulam	Phase 3	25	.	.	.	.	Advanced Solid Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC6QIZI	DMCMBHA	Erlotinib	Approved	34	DMOBIKY	Bexarotene	Approved	34	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC6Z0ZX	DMCMBHA	Erlotinib	Approved	34	DMIYDT4	Cabozantinib	Approved	34	.	.	.	.	"Carcinoma, Non-Small-Cell Lung"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC6ZL1I	DMCMBHA	Erlotinib	Approved	34	DMH7W9X	SNDX-275	Phase 3	25	.	.	.	.	Non-Small-Cell Lung Carcinoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC8E5ST	DMCMBHA	Erlotinib	Approved	34	DMSIVND	Hydroxychloroquine	Phase 3 Trial	25	.	.	.	.	Non-small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC9L4H9	DMCMBHA	Erlotinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Metastatic Solid Tumor	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCB80B5	DMCMBHA	Erlotinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	"Unspecified Adult Solid Tumor, Protocol Specific"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCEPOR6	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	"Carcinoma, Non-Small-Cell Lung"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCFLAUJ	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCGAKWQ	DMCMBHA	Erlotinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Recurrent Salivary Gland Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCGQLKX	DMCMBHA	Erlotinib	Approved	34	DMMX2E6	Pemetrexed	Approved	34	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCGVQ8I	DMCMBHA	Erlotinib	Approved	34	DMJSVRL	JM216	Phase 2	21	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCHJAAP	DMCMBHA	Erlotinib	Approved	34	DMS104F	Temsirolimus	Approved	34	.	.	.	.	Adult Anaplastic Astrocytoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCHPW08	DMCMBHA	Erlotinib	Approved	34	DMTS85L	Capecitabine	Approved	34	.	.	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCIHJX7	DMCMBHA	Erlotinib	Approved	34	DMWVCF3	Fusidic acid	Approved	34	.	.	.	.	Non-Small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCJVU80	DMCMBHA	Erlotinib	Approved	34	DMP1I6Y	Alectinib	Approved	34	.	.	.	.	Non-Small-Cell Lung Carcinoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCKNYM9	DMCMBHA	Erlotinib	Approved	34	DMKECZD	Temozolomide	Approved	34	.	.	.	.	"CNS Tumor, Adult"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCL75SK	DMCMBHA	Erlotinib	Approved	34	DMML7BE	Xl147	Phase 2	21	.	.	.	.	Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCMDZO3	DMCMBHA	Erlotinib	Approved	34	DMP6SC2	Irinotecan	Approved	34	.	.	.	.	Colorectal Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCOBMN1	DMCMBHA	Erlotinib	Approved	34	DMNVP8Q	Tivantinib	Phase 3	25	.	.	.	.	Non Small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCPSAAG	DMCMBHA	Erlotinib	Approved	34	DMUKC5L	Tivozanib	Approved	34	.	.	.	.	Non-small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCPTGI4	DMCMBHA	Erlotinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Solid Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCRZOWJ	DMCMBHA	Erlotinib	Approved	34	DMLB81S	Paclitaxel	Approved	34	.	.	.	.	"Unspecified Adult Solid Tumor, Protocol Specific"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCTAY2B	DMCMBHA	Erlotinib	Approved	34	DMKECZD	Temozolomide	Approved	34	.	.	.	.	Adult Giant Cell Glioblastoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCTG9PO	DMCMBHA	Erlotinib	Approved	34	DMMX2E6	Pemetrexed	Approved	34	.	.	.	.	Non-Small-Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCTNWMD	DMCMBHA	Erlotinib	Approved	34	DMDASC6	Metformin	Investigative	0	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCYF1JE	DMCMBHA	Erlotinib	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Non-Small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCZVW5N	DMCMBHA	Erlotinib	Approved	34	DMNE56X	ABT-263	Phase 3	25	.	.	.	.	Solid Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCSEFCM	DMCMBHA	Erlotinib	Approved	34	DMSD1UN	Bevacizumab	Phase 2/3 Trial	24	.	.	.	.	Metastatic colorectal cancer; Non-small-cell lung cancer; Hypopharyngeal squamous cell carcinoma; Hepatocellular carcinoma	TTD Database	Phase 1	.	.	.	.	.
DCGMKYS	DMCMBHA	Erlotinib	Approved	34	DMG281S	Carboplatin	Approved	34	DMLB81S	Paclitaxel	.	.	Adenocarcinoma of the Lung	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC7G46O	DMCMBHA	Erlotinib	Approved	34	DMGVH6N	Axitinib	Approved	34	.	.	.	.	Neoplasms	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCBLDLO	DMCMBHA	Erlotinib	Approved	34	DMYCXKL	Capmatinib	Approved	34	.	.	.	.	Recurrent Non-small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCI05IV	DMCMBHA	Erlotinib	Approved	34	DMTI0ZO	Gilteritinib	Approved	34	.	.	.	.	Non-Small-Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCLIF0U	DMCMBHA	Erlotinib	Approved	34	DMRJFN9	Theophylline	Approved	34	.	.	.	.	Non-small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCNCRCV	DMCMBHA	Erlotinib	Approved	34	DMDI43Y	BGB-324	Phase 2	21	.	.	.	.	Non-Small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCWDWWK	DMCMBHA	Erlotinib	Approved	34	DMF98Q0	Momelotinib	Approved	34	.	.	.	.	EGFR Mutated EGFR TKI Naive Metastatic NSCLC	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCB42SD	DMCMBHA	Erlotinib	Approved	34	DM1WEHC	Buparlisib	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	1.147	5.345	2.425	5.017
DCFF73B	DMCMBHA	Erlotinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	0.39	0.2	9.48	10.39
DCOAHGV	DMCMBHA	Erlotinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	1.76	1.98	4.99	5.7
DCQD2J4	DMCMBHA	Erlotinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	10.09	10.11	13.06	15.71
DCNO82O	DMCMBHA	Erlotinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	0.26	1.88	2.84	3.05
DCHA3MV	DMCMBHA	Erlotinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	3.16	6.71	9.9	10.42
DCZNCV2	DMCMBHA	Erlotinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	3.37	3.87	5.57	7.36
DCMEZXS	DMCMBHA	Erlotinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	1.19	3.57	3.28	4.42
DC7AYRW	DMCMBHA	Erlotinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	0.54	4.67	10.41	11.07
DCA2WUE	DMCMBHA	Erlotinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	1.13	1.31	3.19	5.92
DCSVYUE	DMCMBHA	Erlotinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	1.17	0.94	4.31	7.22
DCXRKRI	DMCMBHA	Erlotinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	0.52	0.96	0.83	4.04
DCV2YIR	DMCMBHA	Erlotinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	1.57	0.2	3.89	6.5
DCM2YFH	DMCMBHA	Erlotinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	13.93	10.78	18.11	19.57
DCRJZCE	DMCMBHA	Erlotinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	11.61	11.84	13.65	15.6
DC48IOQ	DMCMBHA	Erlotinib	Approved	34	DM2B9E0	AT13387	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	15.888	23.074	6.487	11.396
DCNG14S	DMCMBHA	Erlotinib	Approved	34	DM3XQDH	JQ1	Investigative	0	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	0.217	9.28	5.388	8.182
DC57P2N	DMCMBHA	Erlotinib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	1.01	8.75	3.39	4.87
DCE3E7Y	DMCMBHA	Erlotinib	Approved	34	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	5.88	8.7	3.76	6.2
DC2IMRK	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	3.65	3.86	12.09	14.25
DC6KS73	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	3.35	2.77	10.35	12.89
DCQ0O95	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	3.2	2.39	8.69	10.86
DCXHR9O	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	10.19	9.24	10.46	14.29
DCHYUVR	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	4.87	4.35	8.4	11.59
DCCOEML	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	14.21	12.1	11.05	14.67
DCOGT16	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	7.59	4.58	6.62	9.62
DC2C2Z0	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	7.38	7.4	10.4	13.71
DCDQFN6	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	11.51	10.89	13.2	16.07
DCLXXKH	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	8.28	7.55	7.12	11.08
DC15FZK	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	9.12	8.57	8.11	11.34
DC6D0KD	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	4.84	3.55	8.18	10.11
DC8VFMG	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	9.92	8.99	9.37	12.67
DCQ0Q02	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	1.2	2.23	4.38	7.84
DCVYZI7	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	12.55	11.15	11.47	15.28
DC95JR4	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	10.72	12.72	11.23	15
DCAHKIS	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	6.42	6.04	6.87	11.88
DCZ4C4N	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	21.2	20.76	25.43	29
DC6DU05	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	3.29	2.73	6.84	11.91
DC7F52W	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	14.06	13.03	11.64	16.01
DCRQRZX	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	9.49	8.99	13.08	16.39
DC70IJ0	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	6.84	0.87	2.84	6.6
DC6ED4F	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	6.22	10.94	3.69	12.02
DCF8BZU	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	0.47	0.27	4.98	7.91
DCTTDP0	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	7.04	7.24	19.69	21.11
DC2XL6A	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	2.38	0.97	4.6	8.32
DCIKKKF	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	4.95	3.99	4.74	9.26
DCU81XR	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	3.14	1.41	3.29	6.83
DCXFE85	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	12.17	13	14.35	16.18
DCKX7YD	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	20.03	17.97	17.89	21.56
DCX7EJU	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	3.94	5.67	1.14	8.33
DCKOTM9	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	2.03	6.04	8.28	11.16
DCQ2UF3	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	5.77	3.9	5.52	1.53
DC9GKCF	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	4.31	8.01	8.03	10.18
DCVPQTS	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	4.18	3.98	2.95	8.82
DC7UZV4	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	4.74	8.05	5.59	9.13
DCEKLJP	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	0.67	4.85	5.64	9.56
DCXLZSI	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	6.68	7.24	4.96	9.51
DCW6E16	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	4.86	4.33	1.9	6.66
DCA2ZYO	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	2.65	4.34	5.74	8.45
DCP2AOX	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	3.66	9.34	11.83	14.27
DCXZ5EZ	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	15.13	10.54	10.51	12.54
DCTS95G	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	5.26	4.44	9.49	11.36
DC0OQIR	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	22.56	23.23	22.39	25.29
DCXIX79	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	4.63	3.68	2.96	7.54
DCNLBJK	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	4.03	3.97	1.69	9.89
DC6MF6L	DMCMBHA	Erlotinib	Approved	34	DM6KU93	Alvespimycin hydrochloride	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	4.28	6.05	0.93	4.17
DC94UEB	DMCMBHA	Erlotinib	Approved	34	DM93VBZ	LY2835219	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	4	13.94	0.15	6.94
DC1X7QO	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	7.1	7.72	6.35	12.01
DCBVTYP	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	4.97	3.52	3.4	8.6
DCG592S	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	2.55	2.86	4.86	4.92
DCTWYSV	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	9.34	8.72	12.87	16.05
DCOGCDV	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	13.74	12.55	12.77	17.18
DCMDS39	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	2.58	4.23	3.16	7.09
DC6HO3V	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	2.68	4.27	3.85	7.9
DCXKO6O	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	5.89	8.38	7.71	11.3
DC0IQDD	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	15.03	13.85	11.6	17.01
DCDDHWD	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	14.62	11.82	14.05	11.63
DCFG7PH	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	3.85	6.83	3.18	9.21
DCHSL6N	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	11.97	11.4	7.6	12.87
DCZZXKZ	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	13.07	15.59	20.22	21.76
DCEFY8Y	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	9.34	8.87	7.82	12.87
DC3FKYU	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	11.66	12.1	8.84	15.23
DCRJZMI	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	6.01	9.7	4.08	10.52
DCYYXS7	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	5.23	4.68	5.92	9.52
DCK3F2V	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	24.78	20.6	24.74	27.76
DCWQNS1	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	6.22	5.62	7.71	9.4
DCSQ842	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	18.98	19.72	15.76	22.86
DCXU8TY	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	14.24	12.99	19.03	14.93
DCS0I32	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	1.51	12.19	11.27	11.88
DC9NRVW	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	3.94	2.18	0.56	3.88
DC2FZQJ	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	1.25	0.01	1.47	4.54
DCACMZ9	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	5.44	3.34	3.98	7.5
DCRK3B9	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	0.89	0.09	5.16	9.11
DCAAGHB	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	6.55	3.58	3.31	7.07
DCEFHCQ	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	4.82	1.05	0.93	3.34
DCC3SVB	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	2.01	0.68	2.41	5.78
DCXE2VY	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	2.66	1.35	0.92	3.82
DCS7SV7	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	8.61	5.35	10.57	5.93
DC7V5NC	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	7.19	7.02	5.02	9.55
DC8O74J	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	5.07	8.6	3.59	9.17
DCBLMFQ	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	5.46	3.86	2.6	6.19
DCODAF2	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	10.15	9.49	10.01	13.61
DCABR7B	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	6.29	4.82	4.8	8.6
DCE0P5I	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	3.2	9.74	6.86	10.05
DCPWHBW	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	5.25	2.13	3.13	5.72
DC96HYR	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	16.93	16.14	18.66	21.38
DCR1YDL	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	1.6	0.48	6.4	8.63
DC5U26J	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	6.57	5.99	3.73	7.88
DCOQ9YP	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.95	1.58	3.49	6.55
DCLQPRW	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	2.59	5.5	7.44	5.68
DCVY1OQ	DMCMBHA	Erlotinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	2.56	6.44	4.76	6.8
DCWH7NK	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	1.39	2.05	3.16	6.38
DCR179M	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	4.87	4.68	5.14	6.83
DCV6JQ5	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	3.51	2.07	2.31	6.35
DCLTVXF	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	1.96	1.41	2.2	4.91
DCA65YB	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	5.18	4.06	1.61	6.36
DCC1QVD	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	2.58	0.94	0.25	3.84
DCJMJV6	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	2.86	6.78	2.46	7.24
DC8N6CQ	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	24.3	19.53	16.17	22.15
DCFRRB8	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	5.21	2.68	0.05	5.26
DCW7RFA	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	2.83	4.96	1.2	5.32
DCEAV2S	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	2.5	3.13	29.88	1.8
DCB7UL1	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	2.53	4.98	1.12	7.23
DCN4F3B	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	3.8	5.5	0.15	5.64
DCMY13N	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	4.35	4.65	2.76	7.08
DC1W58Z	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	6.22	8.88	6.23	11.38
DC0K92Q	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	9.31	11.68	7.13	12.3
DCFNJJW	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	1.55	5.9	2.24	6.8
DCKGOOX	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	10.55	10.82	8.26	14.13
DCL77IM	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	5.53	5.07	1.07	5.68
DC28KEE	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	15.26	12.5	13.64	15.57
DCDLBFY	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	2.72	0.69	0.24	4.84
DCIP0BL	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	8.53	6.95	3.37	7.78
DCBIK1Y	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	5.43	6.23	1.02	5.58
DC1OSCM	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	13.51	9.57	6.16	11.8
DC03QIJ	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	3.04	3.1	12.63	13.71
DCGH1IE	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	3.23	4.38	10.24	10.96
DCJMO4P	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	1.08	3.04	8.01	9.11
DCUH9VF	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	6.01	7.78	10.1	10.42
DC19XR0	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	6.18	6.17	12.16	13.53
DCG54VV	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	3.27	4.53	4.55	7.31
DC5Y81L	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	8.11	10.7	11.98	12.2
DCL2ANL	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	7.95	9.4	12.47	13.13
DCJTYT7	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	3.27	10.09	10.84	10.48
DC0W83Z	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	4.24	10.13	14.39	15.08
DC5FCN9	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	8.01	11.16	15.16	11.31
DCN9VS2	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	21.11	21.1	23.46	24.43
DCM6AE4	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	15.6	13.11	15.06	13.54
DCH02J5	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	13.45	16.41	16.32	17.36
DC0VV6K	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	8.22	8.65	12.24	12.17
DCHEDY8	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	12.34	15.61	17.08	17.34
DC3POQE	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	1.03	5.94	9.66	10.27
DCG0M5A	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	6.07	6.12	12.01	12.53
DCZ8NAS	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	20.07	20.35	21.71	22.27
DCTFYGE	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	8.7	12.31	16.84	17.93
DC4R5XF	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	3.92	3.3	6.62	6.91
DC011UA	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	14.04	13.86	16.02	18.3
DCVUA20	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	6.57	7.23	14.64	15.52
DC98K69	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	8.6	7.71	13.1	14.77
DCT0J3Z	DMCMBHA	Erlotinib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	25.5	22.08	20.94	29.4
DCQYS1B	DMCMBHA	Erlotinib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	1.61	1.02	1.58	5.44
DCL33KA	DMCMBHA	Erlotinib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	2.61	2.71	0.46	6.18
DCSPRY5	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	3.91	5.2	2.73	5.72
DCIMLCN	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	1.94	2.67	1	5.02
DCCGD91	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	5.7	6.56	3.26	8.93
DCBTI3Z	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	5.66	2.02	0.96	3.98
DC4HGMW	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	11.44	10.72	7.82	11.19
DC7D6OW	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	2.51	2.91	0.19	3.82
DCXJF7D	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	1.27	4.02	0.87	4.62
DCSGIP0	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	3.09	2.44	24.69	1.47
DCAU1WL	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	1.15	1.3	2.23	4.44
DCLZ968	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	0.6	3.13	0.41	3.58
DCGQGN3	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	3.69	4.79	0.22	4.78
DC9ARZ8	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	4.18	9.93	5.11	9.53
DCLK0MH	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	15.21	12.87	11.26	16.12
DC39SCU	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	2.78	3.96	0.55	4.85
DCXGXHG	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.94	1.91	1.71	5.66
DC322MJ	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	3.78	4.33	1.19	4.73
DC3HVR5	DMCMBHA	Erlotinib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	0.7	1.46	3.15	5.12
DCBYE5C	DMCMBHA	Erlotinib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	6.53	4.87	6.07	2.97
DCDRG5H	DMCMBHA	Erlotinib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	38.98	36.01	18.41	40.26
DCXCCYV	DMCMBHA	Erlotinib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	8.68	12.61	11.55	13.65
DCHD8E4	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	5.96	5.62	3.8	9.13
DCUVYY3	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	8.77	5.64	8.98	2.44
DCZKXYH	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	0.33	0.72	2.12	6.2
DC2CJCA	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	7.16	7.43	12.47	14.4
DCMHKXM	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	0.9	0.34	0.79	6.46
DC6BK75	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	4.87	5.11	0.68	8.18
DCF2HRT	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	10.93	10.8	7.98	16.09
DC69K63	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	5	5.56	1.22	8.55
DCLC9MA	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	4.61	5.97	3.36	9.55
DCEQFIW	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	7.82	6.79	30.88	6.63
DCDMVY5	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	16.64	15.53	4.22	14.44
DCRIXT2	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	3.05	1.6	2.6	3.06
DCFA3OR	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	2.44	5.62	5.57	9.75
DC8G4DW	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	6.19	5.16	2.04	9.45
DCQMTUZ	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	4.78	5.45	1.9	9.93
DCOJDYK	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	2.84	2.85	1.45	6.54
DCGUZBS	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	5.74	5.93	3.41	9.14
DCZG27L	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	4.76	4.6	8.2	9.56
DCY0TPR	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	6.99	7.65	5.83	10.7
DCLWIBN	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	9.57	10.13	3.8	11.56
DCSW0VU	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	3.88	6.86	1.73	5.84
DC5Y27B	DMCMBHA	Erlotinib	Approved	34	DMSLE03	PF-562271	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	0.19	7.96	4.62	7.01
DC3D6F3	DMCMBHA	Erlotinib	Approved	34	DMU10FE	THZ1	Investigative	0	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	4.04	8.68	1.29	4.82
DCSCMCP	DMCMBHA	Erlotinib	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	3.157	11.855	1.021	5.987
DCZQ1IB	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	9.55	5.58	3.88	10.52
DCROTWV	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	7.07	6.06	8.88	11.83
DCTV7SH	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	1.6	1.56	6.63	9.93
DCASJFL	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	3.62	3.07	8.18	10.72
DC77GFM	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	11.75	10.98	12.45	15.89
DC3LMA9	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	5.39	4.42	4.46	7.67
DC91M0Q	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	3.58	2.9	6.87	10
DCBYE56	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	1.84	0.84	3.6	7.11
DC3WG5W	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	12.09	10.18	1.66	13.32
DCPZK4L	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	7.2	6.45	5.94	9.52
DCK3GX6	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	10.46	9.34	17.3	10.97
DC9PQ9X	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	10.78	9.83	8.07	12.61
DCHN8GM	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	4.37	3.45	2.6	4.64
DCJZSUN	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	11.78	10.05	10.89	13.35
DCCE5IO	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	13.9	12.88	11.4	15.64
DCR7GSG	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	1.42	1	3.04	7.32
DCAHUD1	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	12.28	11.94	9.97	14.5
DCGSJ0E	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	8.65	8.03	7.97	11.7
DCS9F2B	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	4.45	4.04	7.17	10.15
DCTKC4U	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	12.2	10.77	13.02	17.34
DCI97RR	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	4.54	3.56	3.77	8.05
DCNZ2LQ	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	11.57	11.53	11.38	14.91
DCLQJHW	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.06	0.03	1.12	5.42
DC6KA8K	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	2.82	2.86	5.09	9.54
DCK7BON	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	10.49	10.95	6.1	12.58
DCKHMIR	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	2.71	2.98	15.92	16.64
DCXASAS	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	10.22	10.33	18.4	19.96
DCOKAIN	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	0.56	0.07	7.52	9.35
DCRCUAJ	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	4.63	5.12	8.12	8.49
DC4OIWH	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	14.43	14.25	16.41	19.71
DCW9GXD	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	7.96	7.88	11.7	13.92
DCYM6YE	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	7.58	10.42	16.45	9.6
DCZK3PI	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	1.31	4.52	5.01	8.47
DC1DJ4G	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	8.51	7.58	6.44	4.49
DCSSDPU	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	11.11	8.52	9.49	12.5
DCS0JUU	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	1.11	4.95	5.55	8.84
DC1BPHQ	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	0.39	0.88	3.85	5.9
DCA3XTU	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	3.25	6.43	7.98	9.81
DCOACYM	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	1.25	1.03	11.04	12.93
DCNXZAK	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	10.73	9.85	13.59	14.26
DC64RRG	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.55	1.47	8.69	10.38
DCYZ7TL	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	8.22	8.78	12.42	15.88
DC1GOLX	DMCMBHA	Erlotinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.59	4.29	10.41	11.12
DC8IMPR	DMCMBHA	Erlotinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.31	0.83	4.14	5.81
DCBPRBC	DMCMBHA	Erlotinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.62	0.37	0.69	3.77
DCG00WC	DMCMBHA	Erlotinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.94	6.19	6.17	6.41
DCB04C9	DMCMBHA	Erlotinib	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.88	6.1	8.09	7.91
DC769ZM	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.98	1.67	10.46	12.9
DC099LD	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.27	2.15	8.77	12.72
DC4CYPD	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	5.05	4.1	5.11	7.93
DCE1L58	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	8.35	7.46	7.15	11.73
DC5ZZDC	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	5.18	4.84	6.22	8.12
DCUKLP1	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	8.2	8.32	9	13.19
DC6FV1T	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.46	2.95	9.84	11.77
DCB0DWC	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	11.75	12.18	12.17	15.27
DCC6W02	DMCMBHA	Erlotinib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	0.92	0.72	6.74	9.09
DCMBPBM	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.58	0.26	0.86	2.6
DCK7YBM	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.29	1.59	0.11	7.15
DCE0BDL	DMCMBHA	Erlotinib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.76	2.06	8.08	10.52
DCF5V77	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	1.71	3.8	4.82	18.15
DCNI3YD	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.59	5.81	8.25	9.51
DCDSBTQ	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	7.26	6.28	4.43	10.17
DCM9BX0	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.18	3.82	2.5	8.72
DCBXWUE	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.16	2.74	7.26	10.06
DCZZMOX	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.19	1.82	4.57	7.41
DCPWB4E	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	6.46	8.11	1.37	15.13
DC818JB	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.78	6.04	6.48	9.67
DCTRE1E	DMCMBHA	Erlotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	6.1	6.54	15.91	16.94
DCARUUS	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.55	2.45	3.7	6.46
DCF47VW	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.06	3.81	0.52	4.97
DC1AHT3	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.5	0.79	1.32	2.85
DCQNIBK	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.7	1.47	4	7.36
DCWSOXW	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.36	3.95	6.47	8.93
DCWN5F0	DMCMBHA	Erlotinib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.9	6.36	6.22	8.35
DCHXF6G	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.31	1.38	0.66	5
DCTO9BJ	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.92	1.19	0.66	6.35
DCR9IU3	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	5.61	3.07	0.49	2.93
DCS17XZ	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	5.69	4.18	4.48	6.32
DCKUQFO	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.38	3.57	0.89	6.53
DC8Q3MD	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	5.56	1.93	4.04	6.83
DC9YWTC	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.21	5.08	4.77	7.96
DCVDVPX	DMCMBHA	Erlotinib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.03	2.87	0.74	7.14
DCG60RJ	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.71	2.39	9.29	9.94
DCKE86M	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	8.71	10.87	11.47	13.81
DCWNPQ6	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	11.25	10.43	14.6	16.45
DCXXSJO	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	6.22	5.68	8.51	9.83
DC3VAAH	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	11.31	11.48	15.56	17.26
DCZANBO	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.34	3.26	12.94	13.54
DCGQRYB	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.39	7.69	12.93	13.29
DCLC4QF	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.06	4.77	7.77	8.73
DCNS45Z	DMCMBHA	Erlotinib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	5.13	5.03	10.78	11.06
DCK71ZE	DMCMBHA	Erlotinib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.1	0.59	9.56	12.89
DCOMJPI	DMCMBHA	Erlotinib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.49	1.38	0.49	5.58
DCHPRKQ	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	6.09	6.51	5.02	7.07
DCJSK1Y	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	13.23	8.97	7.52	9.12
DC6XJ6D	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.84	2.29	1.2	5.55
DC4BUJ0	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.28	4.54	0.59	4.68
DCCKS0O	DMCMBHA	Erlotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.6	3.36	7.63	9.08
DCUMHWB	DMCMBHA	Erlotinib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.63	6.84	6.71	9.36
DC2HLXW	DMCMBHA	Erlotinib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.84	4.59	3.71	4.75
DCYH4HT	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.49	1.44	7.22	11.38
DCCHKIG	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.89	2.57	8.01	11.89
DCLS2SF	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	7.43	2.45	18.13	17.53
DCV24P1	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.53	2.03	0.18	5.16
DCEDSMG	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.27	5.99	2.62	10.48
DC956TS	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	3.05	5.19	4.92	8.69
DCLDEZ1	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.35	5.43	0.82	4.53
DCBLIUB	DMCMBHA	Erlotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.15	1.99	1.42	4.34
DCVICYB	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	8.52	8.26	12.26	13.7
DCAS83L	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	7.93	5.62	8.54	10.67
DCMNB4G	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	9.05	8.64	7.84	11.75
DC49T0S	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	5.29	4.59	4.7	9.17
DCSL948	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.17	2.64	7.39	9.55
DCUCT7E	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.18	1.75	9.53	12.3
DC2IX4Q	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	10.37	11.73	0.33	16.65
DC9XEIA	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.47	6.89	11.69	13.8
DC0MJS2	DMCMBHA	Erlotinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1	0.71	10.05	12.47
DC5XSKM	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	6.39	4.91	15.02	16.47
DCPBR00	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.08	2.82	9.94	13.4
DCUMG8Y	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.62	2.4	0.88	5.14
DCJYWIX	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.91	0.42	2.82	4.5
DCZZATX	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.11	4.25	7.03	9.67
DCAF0MC	DMCMBHA	Erlotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.24	4.48	6.83	9.76
DC4AK7R	DMNP60F	Anastrozole	Approved	34	DMTK4LS	Triptorelin	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC3E1BS	DMNP60F	Anastrozole	Approved	34	DMBLHGP	Saracatinib	Investigative	0	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC4R260	DMNP60F	Anastrozole	Approved	34	DMUNTE3	Estradiol	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCJJT6T	DMNP60F	Anastrozole	Approved	34	DMZMSPF	Bicalutamide	Approved	34	.	.	.	.	"Puberty, Precocious"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCSZ9D8	DMNP60F	Anastrozole	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCMJQUH	DMNP60F	Anastrozole	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	14.89	14.58	10.36	15.24
DCD4O0P	DMNP60F	Anastrozole	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.93	5.61	5.89	5.88
DCFGI3X	DMNP60F	Anastrozole	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	3.96	7.28	5.47	5.98
DCK36M3	DMNP60F	Anastrozole	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	4.5	5.64	2.61	5.42
DCR2GLB	DMNP60F	Anastrozole	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	8.09	6.4	8.95	8.89
DCHRSX5	DMNP60F	Anastrozole	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	4.54	2.42	2.4	2.76
DCVI2G8	DMNP60F	Anastrozole	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.06	0.26	2.52	2.44
DC53KU2	DMNP60F	Anastrozole	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	0.91	1.52	3.79	3.12
DCW6IWM	DMNP60F	Anastrozole	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	0.69	3.47	0.63	2.43
DC98D6N	DMNP60F	Anastrozole	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	4.09	4.59	3.96	4.65
DC8YF3F	DMNP60F	Anastrozole	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	0.38	0.83	0.22	1.3
DC9BRGC	DMNP60F	Anastrozole	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	4.8	6.64	4.94	5.47
DCUZKXI	DMNP60F	Anastrozole	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	2.85	4.86	0.4	4.04
DCR18FB	DMNP60F	Anastrozole	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	1.91	4.65	3.39	4.28
DC3U3WB	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	0.44	0.9	1.47	1.41
DCE97OY	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	1.97	2.36	2.38	2.34
DCAGODI	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.18	2.12	0.51	0.77
DCY47NH	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.73	6.26	4.48	3.98
DCPME5Y	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	2.77	4.08	2.46	2.26
DCRNKSL	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	2.14	2.01	2.72	1.81
DCH5Q1Q	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.03	3.81	2.78	2.13
DC7JWCI	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.87	1.09	1.41	1.36
DCK23ZR	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.23	3.6	3.25	3.47
DCY4UYX	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	0.97	2.7	4.21	3.44
DCULV1D	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	2.65	2.87	2.37	2.76
DC12J0K	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.54	4.09	3.87	3.36
DCZ5EI9	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	0.18	0.16	0.98	1.15
DCNTOUE	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	0.47	0.71	0.85	0.46
DCJ71DS	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	1.57	1.16	3.29	2.46
DC8R1GL	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	0.28	0.17	0.89	1.1
DCMHSW8	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	0.47	3.39	1.18	2.11
DCM8N9N	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	1.71	2.8	3.02	2.66
DCAC7FH	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	1.66	6.94	7.47	6.63
DCY4HKY	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	1.41	2.79	3.6	3.22
DCVNJC2	DMNP60F	Anastrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.71	1.88	2.06	3.31
DCCPFYB	DMNP60F	Anastrozole	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	DrugCombDB Database	Investigative	L-1236	31.21	26.756	5.279	9.52
DCIVBVY	DMNP60F	Anastrozole	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.48	4.48	3.55	5.44
DC4PD82	DMNP60F	Anastrozole	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	1.6	1.38	0.7	1.69
DCOXPS5	DMNP60F	Anastrozole	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	0.04	2.61	1.05	2.7
DCUPFA5	DMNP60F	Anastrozole	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.41	2.88	0.39	0.54
DCBQPJ2	DMNP60F	Anastrozole	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	4.33	5.31	3.62	3.35
DCNIHXY	DMNP60F	Anastrozole	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.56	4.05	2.72	3.01
DC1EAFZ	DMNP60F	Anastrozole	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	2.65	3.91	2.05	1.49
DCFHHEZ	DMNP60F	Anastrozole	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	0.23	2.33	1.87	1.84
DC1WG6J	DMNP60F	Anastrozole	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	2.01	1.91	1.48	0.98
DC9364J	DMNP60F	Anastrozole	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	1.35	2.47	2.15	2.77
DCEMP73	DMNP60F	Anastrozole	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	1.81	0.45	1.31	1.33
DC4DR81	DMNP60F	Anastrozole	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	2.11	3.86	3.99	3.92
DCY0MOJ	DMNP60F	Anastrozole	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	1.49	5.02	4.66	4.6
DCERD1A	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	2.23	4.05	3.88	3.71
DCHT8KY	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	0.27	0.34	0.14	0.08
DCI9SJR	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	2.09	2.36	2.56	2.09
DCXX35R	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	1.79	0.31	0.93	0.32
DCBVQFF	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	6.11	13.17	13.06	12.91
DC2R9YV	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	17.96	19.81	19.32	19.22
DCZC27R	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	1.48	2.75	2.26	1.91
DC6RPBF	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	5.18	7.06	7.07	6.81
DC2GX7U	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	3.47	9.02	3.56	8.8
DC8AVFE	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.63	9.57	9.55	9.94
DCNBZ89	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	21.34	21.95	21.48	22.24
DCHW0LI	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	2.77	2.42	2.5	2.33
DCYVK0R	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	5.82	5.87	5.54	5.17
DC42IQJ	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	26.69	25.87	18.21	27.08
DCT2QVV	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.71	2.54	3.26	2.9
DCYWZPX	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	7.59	10.35	11.7	10.96
DCA5LL7	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.57	5.81	6.14	5.94
DCB8GD1	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.22	7.65	8.77	8.76
DC0WT1V	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	3.69	7.03	1.11	7.07
DC87DRU	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.93	7.42	5.88	5.88
DCHPZX2	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	4.06	8.52	8.17	7.66
DCVW2A9	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	6.19	6.2	7.15	6.72
DCPAJ4F	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	4.69	8.05	8.87	8.27
DCJQ3WP	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	12.17	15.09	15	14.64
DCI6ZZ2	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.03	7.22	8.71	8.08
DCH5Y4R	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	5.78	9.06	9.6	9.6
DCL7RX4	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.67	7.8	8.63	7.91
DCKHGX6	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	7.21	12.17	12	11.67
DCAN74L	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	5.99	8.47	7.85	7.81
DC903VE	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	5.52	8.85	10.06	9.19
DC3TRJB	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	7.43	12.88	12.47	12.01
DCZOFNI	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	7.48	9.43	5.08	9.63
DC5WR25	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	2.99	5.66	6.38	5.88
DC7M074	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	2.5	5.6	6.19	6.09
DCCI0RM	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	19.55	20.34	20.6	20.29
DCYB742	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	3.81	2.9	0.82	4.67
DCRQQY4	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	4.64	6.55	7.14	6.75
DCVSM5U	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	2.8	5.76	2.61	2.85
DCB3PFH	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	6.54	8.93	9.4	8.88
DC748SE	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	6.73	13.85	12.81	12.63
DC31K8Z	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	3.15	7.4	6.92	6.92
DC7CJFL	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	3.33	5.13	5.16	4.95
DCYCAHR	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	7.91	11.75	11	10.79
DC723OM	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	5.18	5.08	5.97	4.49
DC3OJL9	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	22.92	23.69	24.26	23.36
DCLZCCG	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	4.54	6.65	7.54	7.02
DCA9OJ6	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.52	10.19	1.29	9.83
DC7195S	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	5.21	9.84	11.43	10.69
DCDF2FP	DMNP60F	Anastrozole	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	0.09	1.44	3.02	2.72
DCNUK7U	DMNP60F	Anastrozole	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	0.43	1.94	0.47	0.67
DC5SZQ9	DMNP60F	Anastrozole	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	3.47	4.27	0.24	2.46
DCPTXDJ	DMNP60F	Anastrozole	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.52	5.19	1.69	3.96
DCNOG3M	DMNP60F	Anastrozole	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	4.44	4.31	2.49	2.76
DCMY5RP	DMNP60F	Anastrozole	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.82	4.69	3.13	4.81
DC610VJ	DMNP60F	Anastrozole	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	0.14	1.07	2.58	2.99
DCP67XG	DMNP60F	Anastrozole	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	1.81	2.7	2.97	3
DC5NFOY	DMNP60F	Anastrozole	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	0.05	4.21	1.59	2.59
DCIPCNR	DMNP60F	Anastrozole	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	1.61	2.27	0.58	3.89
DCBFTCX	DMNP60F	Anastrozole	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	3.51	4.18	1.14	0.41
DCMEEVM	DMNP60F	Anastrozole	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.14	8.66	1.93	2.78
DC0U2PK	DMNP60F	Anastrozole	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.57	7.29	4.73	5.14
DCZFM12	DMNP60F	Anastrozole	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	4.29	6.48	1.91	2.19
DCKHEPY	DMNP60F	Anastrozole	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	3.79	4.62	1.69	1.95
DCDT5GF	DMNP60F	Anastrozole	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.82	4.55	2.68	3.33
DCPNM6K	DMNP60F	Anastrozole	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.95	0.98	0.89	1.11
DCKA679	DMNP60F	Anastrozole	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	1.06	3.08	1.68	2.68
DCPDTOB	DMNP60F	Anastrozole	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	1.98	2.8	0.15	0.46
DCTJ047	DMNP60F	Anastrozole	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	2.38	0.06	0.5	0.63
DCDJOAL	DMNP60F	Anastrozole	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	2.26	3.56	2.65	2.8
DCDAL0F	DMNP60F	Anastrozole	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	2.78	3.85	0.8	0.51
DCW5339	DMNP60F	Anastrozole	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	0.58	3.41	1.76	3.1
DC098K3	DMNP60F	Anastrozole	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	1.65	3.16	1.81	1.9
DCMAH3K	DMNP60F	Anastrozole	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	1.12	3.41	2.26	3.83
DCSOZ8Y	DMNP60F	Anastrozole	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.6	4.27	1.53	4.04
DCNLFYH	DMNP60F	Anastrozole	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.88	3.07	2.27	4
DC9TQKJ	DMNP60F	Anastrozole	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.16	3.59	1.85	3.66
DC9M9EL	DMNP60F	Anastrozole	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.09	3.12	1.18	3.45
DCFMR45	DMNP60F	Anastrozole	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.46	8.83	2.52	9.28
DCGCCYS	DMNP60F	Anastrozole	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	4.68	7.21	4.84	7.46
DC4U7ZX	DMNP60F	Anastrozole	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	3.89	7.13	6.5	7.43
DCKJW7S	DMNP60F	Anastrozole	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	0.76	5.32	0.86	5.47
DC6EVUO	DMNP60F	Anastrozole	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	5.46	7.61	7.66	8.18
DC1R7FC	DMNP60F	Anastrozole	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	0.17	2.21	2.34	2.7
DCPJTAO	DMNP60F	Anastrozole	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	3.79	5.18	2.58	6.44
DC436NK	DMNP60F	Anastrozole	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	0.99	1.25	0.54	1.46
DCFNR71	DMNP60F	Anastrozole	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	5.09	5.8	3.04	3.08
DC6FJ4L	DMNP60F	Anastrozole	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.16	2.44	1.57	1.6
DCNN07Z	DMNP60F	Anastrozole	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	5.55	5.73	6.75	7.26
DCRXW7O	DMNP60F	Anastrozole	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	0.56	4.33	2.34	3.37
DCMUE8J	DMNP60F	Anastrozole	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	1.17	5.01	1.62	5.89
DCN2T05	DMNP60F	Anastrozole	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	0.7	4.38	4.58	5.27
DC1ZZEK	DMNP60F	Anastrozole	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.68	5.14	3.04	4.58
DCWVWC2	DMNP60F	Anastrozole	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	5.51	8.39	6.48	8.95
DCDM54M	DMNP60F	Anastrozole	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	0.85	1.43	0.95	1.81
DC7OTZ9	DMNP60F	Anastrozole	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	2.06	4.12	2.43	4.14
DCURS8Y	DMNP60F	Anastrozole	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	1.54	2.19	2.55	3.66
DCZK7ME	DMNP60F	Anastrozole	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	1.79	4.84	4.99	7.17
DC3ZUUG	DMNP60F	Anastrozole	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	7.98	9.48	9.54	11.13
DCG0XFA	DMNP60F	Anastrozole	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.07	5.6	2.77	7.94
DCE063V	DMNP60F	Anastrozole	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.35	4.6	1.97	6.73
DCL5W1C	DMNP60F	Anastrozole	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	0.35	3.79	5.18	6.25
DCG1ZJB	DMNP60F	Anastrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	3.14	2.21	1.62	2.65
DC9Q7FO	DMNP60F	Anastrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.28	3.14	2.02	2.39
DCQ8LLF	DMNP60F	Anastrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.33	2.44	2.26	3.2
DCHRPOO	DMNP60F	Anastrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	0.16	0.45	1.53	2.61
DCI2IJG	DMNP60F	Anastrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	0.46	1.08	1.33	2.5
DC7UZEJ	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	1.37	5.15	1.18	2.81
DCEXJK3	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.47	6.24	4.77	5.33
DCYQBBK	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	2.81	5.3	1.32	2.38
DCRDS7X	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.45	5.62	2.56	3.16
DCI1VK2	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.87	2.95	1.19	1.79
DCLR88P	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.37	2.63	0.82	1.06
DCCMB1S	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	1.78	2.58	1.49	2.54
DCBBY3T	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	0.36	1.91	2.11	1.48
DCLH5G2	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	1.96	1.99	0.83	1.12
DCYLDPE	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	0.87	3.78	4.16	3.93
DC5CXHB	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	0.77	1.98	1.41	1.4
DCWAO3Q	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	0.24	1.82	0.18	1.53
DCPWRRF	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.07	3.38	0.69	1.72
DCJQUM7	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	3.97	3.79	3.16	3.97
DCSKABH	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	10.52	4.43	2.03	3.13
DCQCPHO	DMNP60F	Anastrozole	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	7.05	3.8	2.26	6.02
DCAZE9H	DMNP60F	Anastrozole	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	2.51	2.86	1.08	0.58
DCXR3GH	DMNP60F	Anastrozole	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	1.54	2.53	0.96	1.4
DCTNCL2	DMNP60F	Anastrozole	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	2.7	2.53	2.17	1.75
DCROAA3	DMNP60F	Anastrozole	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.88	2.54	0.1	0.53
DC69RB4	DMNP60F	Anastrozole	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.39	4.08	1.27	1.42
DCMIKP6	DMNP60F	Anastrozole	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	0.47	1.47	0.43	0.03
DCNI8BE	DMNP60F	Anastrozole	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	1.79	0.54	0.32	0.3
DCYE4A6	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	1.47	1.85	2.15	2.21
DCYXCKT	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	2.45	2.06	2.31	2
DCIYDZ7	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	1.92	2.98	1.89	1.25
DCUXZEP	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	0.45	2.78	2.78	2.03
DC90XQF	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	0.43	1.31	0.74	0.62
DCYY65A	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.42	10.95	10	9.57
DCZ5850	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	11.45	11.95	9.28	9.11
DCGG84H	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	4.02	5.16	4.4	4.07
DCUUUNL	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.11	1.61	1.47	1.08
DCQSU79	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.02	7.43	7.78	7.4
DCH73NY	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	8.48	7.29	8.15	7.31
DCROOSX	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.15	2.52	1.78	1.15
DCX2QXA	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	5.65	5.37	5.4	5.05
DC85V8S	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.96	4.51	4.82	4.79
DCF7GQ8	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	1.09	3.87	4.63	3.77
DCVNK5E	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	3.22	6.26	6.52	6.19
DCNNX8T	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	2.1	2.23	2.62	2.17
DCLLGQC	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	4.2	2.3	2.44	1.93
DC3PUDI	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	1.57	1.48	1.13	0.73
DCKOAP8	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	26.71	22.06	23.03	22.78
DCGXC2H	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	2.97	5.4	6.14	6.19
DCD8ZMI	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	2.9	6.16	5.88	5.03
DCD1H8M	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	3.03	3.12	2.67	2.19
DCM3WX3	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	4.75	1.92	2.04	1.61
DCOI9KK	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	2.07	2.88	3.35	3.32
DC0S7IC	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	2.79	2.99	3.4	3.2
DC3UO3N	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.66	9.2	7.8	7.09
DCJNKPH	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	2.8	0.85	1.19	0.69
DC0Q76N	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	6.56	6.54	6.85	6.82
DCBYWUK	DMNP60F	Anastrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	4.28	4.92	0.65	0.07
DCCEY5Y	DMNP60F	Anastrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	2.15	2.18	0.5	0.35
DCXFXQT	DMNP60F	Anastrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	1.88	2.25	2.03	1.34
DCL1NKJ	DMNP60F	Anastrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	1.29	4.85	2.42	1.59
DC64XCV	DMNP60F	Anastrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.93	8.17	1.18	1.79
DCL25A2	DMNP60F	Anastrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.98	5.24	0.18	0.67
DCOXEL1	DMNP60F	Anastrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	3.38	3.64	2.46	2.42
DC1EQVZ	DMNP60F	Anastrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	2.68	4.29	1.75	1.73
DCDNZM0	DMNP60F	Anastrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.98	4.55	3.27	3.1
DCN1HFI	DMNP60F	Anastrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.2	1.77	2.54	2.68
DCEQFUQ	DMNP60F	Anastrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	1.82	3.66	0.4	3.12
DCZ54DD	DMNP60F	Anastrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	1.77	2.07	1.73	1.31
DC9W2B5	DMNP60F	Anastrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	4.12	4.5	2.45	2.23
DC943AL	DMNP60F	Anastrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	1.76	1.59	2.2	2.11
DCXODC5	DMNP60F	Anastrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	3.29	7.42	5.89	5.63
DCUTPSZ	DMNP60F	Anastrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	3.17	3.58	0.99	0.61
DC0TWNA	DMNP60F	Anastrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	4.22	4.28	3.07	2.97
DCVV1GZ	DMNP60F	Anastrozole	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	2.82	2.51	2.32	4.5
DC8XSQU	DMNP60F	Anastrozole	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	1.23	2.08	1.47	2.59
DCJHPNU	DMNP60F	Anastrozole	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.13	2.01	2.31	3.15
DCH9XBO	DMNP60F	Anastrozole	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	5.16	4.84	5.27	5.64
DCM1K34	DMNP60F	Anastrozole	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.04	0.37	1.81	1.74
DC9S8AM	DMNP60F	Anastrozole	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.17	0.53	1.24	2.1
DCX8A0B	DMNP60F	Anastrozole	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.56	3.42	0.27	5.26
DC1UERH	DMNP60F	Anastrozole	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	4.8	8.42	5.77	8.64
DCACI6P	DMNP60F	Anastrozole	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	4.07	3.15	4.6	5.49
DCR6Q6T	DMNP60F	Anastrozole	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	10.35	9.33	5.2	11.71
DCL9CR5	DMNP60F	Anastrozole	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	1.43	3.73	4.14	4.55
DC8KJ0D	DMNP60F	Anastrozole	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	6.44	7.86	9.02	9.62
DC3GEF4	DMNP60F	Anastrozole	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	3.22	5.97	2.48	8.04
DCU8F7U	DMNP60F	Anastrozole	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.77	10.83	0.46	9.18
DCRFXLO	DMNP60F	Anastrozole	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	1.23	0.42	0.35	1.71
DC1WDME	DMNP60F	Anastrozole	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	10.57	8.37	6.58	8.41
DCUVWOU	DMNP60F	Anastrozole	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	0.88	4.8	0.87	4.77
DCLTBHM	DMNP60F	Anastrozole	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	0.48	0.08	2.46	3.09
DC1OHOC	DMNP60F	Anastrozole	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.35	3.89	1.62	3.62
DC62BEA	DMNP60F	Anastrozole	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.98	2.52	3.01	4.32
DCSER5R	DMNP60F	Anastrozole	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	3.03	3.49	3.17	3
DC4OJYY	DMNP60F	Anastrozole	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	0.27	1.7	1.35	2.44
DCG9A5Z	DMNP60F	Anastrozole	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	7.98	7.55	8.27	8.7
DCTLVEO	DMNP60F	Anastrozole	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.07	3.18	3.9	4.04
DCK4LYX	DMNP60F	Anastrozole	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.83	6.05	6.5	8.76
DC49VKO	DMNP60F	Anastrozole	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	1.82	2.68	3.07	3.17
DC2JGFN	DMNP60F	Anastrozole	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	1.41	2.13	1.52	4.43
DCIIUP3	DMNP60F	Anastrozole	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	1.31	2.4	2.28	2.76
DC72IMQ	DMNP60F	Anastrozole	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	2.97	2.81	3.81	5.75
DCH8FK5	DMNP60F	Anastrozole	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	13.36	13.61	16.14	16.37
DC0KYU7	DMNP60F	Anastrozole	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	0.59	2.4	4.3	4.69
DC5SOBK	DMNP60F	Anastrozole	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	3.04	3.16	5.5	5.59
DCZE5IG	DMNP60F	Anastrozole	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	1.67	3.43	5	6.19
DC0023Y	DMNP60F	Anastrozole	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	0.96	1.11	1.94	1.2
DCXVF96	DMNP60F	Anastrozole	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	1.04	1.51	1.04	0.24
DCXQAWQ	DMNP60F	Anastrozole	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.44	0.08	0.81	0.97
DCBP1B4	DMNP60F	Anastrozole	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	0.56	0.73	1.58	1.05
DCPRABA	DMNP60F	Anastrozole	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	1.09	2.25	2.12	1.85
DCJG4Z7	DMNP60F	Anastrozole	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	1.96	0.64	1.29	1.04
DCS4OW9	DMNP60F	Anastrozole	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	0.37	0.74	1.38	1.18
DCUPT28	DMNP60F	Anastrozole	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	2.45	0.15	0.79	0.55
DCELYJ3	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	1.17	1.5	2.03	1.84
DC7J5TC	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	0.85	3.57	1.36	2.86
DCS3R8H	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	1.24	3.86	1.36	4.39
DCH2JHS	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	0.3	3.22	1.46	3.7
DC8Z5CQ	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	5.23	7.54	1.89	7.43
DCRDJEA	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	0.1	1.02	1.04	2
DCSG078	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	1.02	5.55	2.32	4.77
DC8CZ5V	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.68	7.81	5.67	6.79
DCDJK5O	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.8	3.15	3.76	3.56
DC7H6YQ	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.89	6.72	4.24	5.1
DC7P1ER	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.7	7.29	5.48	6.91
DCVFJ86	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.5	2.47	0.07	1.62
DCFNMNJ	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	1.43	4.39	0.84	4.56
DC5V9MR	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	0.26	2	0.22	2.45
DCYYHHF	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	2.37	3.17	0.18	2.94
DCZN753	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	3.71	5.83	0.47	6.16
DCHV865	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	0.55	2.62	2.27	3.3
DC6F7CB	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	0.11	0.48	0.76	1.46
DC7ZD9Q	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	3.38	6.14	1.35	4.24
DC7D92U	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	7.08	9.51	9.32	9.22
DCE7CT4	DMNP60F	Anastrozole	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	1.09	2.44	1.57	0.99
DCU6K9C	DMNP60F	Anastrozole	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	4.73	8.99	5.77	5.72
DC08EV3	DMNP60F	Anastrozole	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	3.77	6.18	5.42	4.98
DC55ULX	DMNP60F	Anastrozole	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.17	7.18	4.67	4.76
DCW4KX0	DMNP60F	Anastrozole	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.93	3.22	4.3	4.08
DCWOPDO	DMNP60F	Anastrozole	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.17	2.24	0.72	0.92
DCLHXH9	DMNP60F	Anastrozole	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.9	4	1.43	1.75
DCUCQ4B	DMNP60F	Anastrozole	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.95	1.62	1.68	1.62
DCGYR7E	DMNP60F	Anastrozole	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	2.33	2.07	1.49	1.06
DCRKHMP	DMNP60F	Anastrozole	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	0.24	0.65	1.63	0.79
DCNX5Z0	DMNP60F	Anastrozole	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	1.48	1.45	1.79	2.69
DCQLL63	DMNP60F	Anastrozole	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	2.16	3.24	2.71	3.18
DCLLGPZ	DMNP60F	Anastrozole	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	1.69	2.57	2.15	1.77
DC1SI16	DMNP60F	Anastrozole	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	3.41	5.76	1.98	2.19
DCAZ41K	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	1.92	5.88	1.58	5.27
DC4NLZD	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	1.87	1.04	0.04	1.89
DCXCEKO	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	3.38	4.28	3.66	4.99
DCBEBJD	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	1.01	2.06	4.49	4.26
DCXFZFC	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	14.46	15.13	15.59	16.12
DCZ1RMC	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.05	2.08	2.15	2.85
DCUOIUK	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.37	5.12	5.28	5.9
DCPBQJG	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.53	6.28	9.22	9.5
DCXDTIC	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	0.88	5.06	5.14	6.2
DC6LMTT	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.22	2.98	5.03	4.87
DC3IMEK	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	2.91	4.31	1.91	5.07
DCK5U6P	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	1.86	2.74	3.22	4.46
DCN90UU	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	1.44	6.34	3.68	6.21
DCOOP9A	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	2.33	3.01	3.7	5.48
DCB2E45	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	11.6	12.65	15.01	14.62
DC76G7Q	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	1.81	4.61	2.77	4.84
DCFPXEO	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	5.99	6.08	4.67	10.54
DC3U4VG	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	5.94	6.89	8.23	10.09
DCNFXXR	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.54	2.27	5.23	5.25
DCORFDL	DMNP60F	Anastrozole	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	1.69	1.91	0.58	1.64
DCG507U	DMNP60F	Anastrozole	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	0.44	1.32	0.35	2.9
DCC1U6M	DMNP60F	Anastrozole	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	1.2	2.99	2.73	2.23
DCHMNE9	DMNP60F	Anastrozole	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	3.28	4.36	5.49	6.73
DCWX9IM	DMNP60F	Anastrozole	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	4.68	4.78	5.14	5.68
DC77QMP	DMNP60F	Anastrozole	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	5.49	5.36	6.94	9.15
DCYSUA4	DMNP60F	Anastrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	7.87	7.93	0.05	5.42
DCYK3GT	DMNP60F	Anastrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	6.65	9.64	3.59	7.73
DC1GG2N	DMNP60F	Anastrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.57	3.4	0.88	5.19
DC3VLOL	DMNP60F	Anastrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.38	2.76	0.41	3.19
DC1G579	DMNP60F	Anastrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	7.57	9.54	1.64	6.34
DC34YIL	DMNP60F	Anastrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.95	3.1	5.63	5.63
DCQ21UP	DMNP60F	Anastrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	8.94	10.71	0.39	6.73
DCX4TRB	DMNP60F	Anastrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	6.57	7.78	1.49	8.14
DCT57R0	DMNP60F	Anastrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	8.19	10.44	2.38	6.94
DC94JEL	DMNP60F	Anastrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	6.31	5.33	5.09	5.79
DCIB4LG	DMNP60F	Anastrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	4.51	5.95	3.74	6.75
DCGEBHS	DMNP60F	Anastrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	4.76	6.2	0.19	5.18
DCJRZMS	DMNP60F	Anastrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	3.45	2.9	3.36	3.53
DC15ILZ	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	10.63	12.89	10.59	13.5
DCPI3WR	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	6.26	7.98	7.08	8.98
DCQGTDF	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	7.29	7.5	4.46	8.1
DCX1RMQ	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	6.71	6.56	6.29	8.23
DC6N1AK	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	8.53	11.15	11.74	11.77
DCAITIA	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.89	2.04	1.8	2.83
DCRBZ2B	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	11.16	12.24	10.25	12.83
DCDJ78X	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	7.03	7.02	8.61	8.32
DCTDZL4	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.31	9.37	9.64	10.95
DCLNNMV	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	5.28	9.02	5.91	9.6
DCZYXH8	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	3.4	7.23	4.49	7.84
DCHPK19	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	2.39	9.37	8.19	9.33
DC6QGB9	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	5.85	6.82	2.16	6.71
DC5IV5T	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	7.19	8.44	1.55	9.42
DCMQD61	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	14.47	14.65	15.85	15.55
DCUAJAW	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	3.14	7.09	4.3	7.34
DCI34T2	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	21.33	18.3	16.28	17.68
DCJPU3I	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	6.35	8.23	6.75	7.36
DCG4XNP	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	0.73	7.96	8.2	8.69
DC6RAH5	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	5.93	6.88	0.74	8.3
DCE8IGO	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	8.55	7.61	10.37	10.26
DC3HPJB	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.3	4.33	2.99	4.28
DC4AAQ3	DMNP60F	Anastrozole	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	3.65	3.06	3.94	4.1
DCSNXUF	DMNP60F	Anastrozole	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.32	1.22	1.91	1.97
DCQKJHS	DMNP60F	Anastrozole	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.34	3.82	4.36	4.42
DC498MM	DMNP60F	Anastrozole	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.86	1.65	2.24	2.38
DCI0626	DMNP60F	Anastrozole	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.49	3.37	5.02	5.15
DCWAO56	DMNP60F	Anastrozole	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.16	1.8	5.47	5.89
DC8CFQS	DMNP60F	Anastrozole	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.82	0.5	2.71	2.82
DCXFRL9	DMNP60F	Anastrozole	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	0.17	0.31	1.14	2.02
DCOI2Z2	DMNP60F	Anastrozole	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	0.99	0.33	1.68	3.31
DCLL19J	DMNP60F	Anastrozole	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	0.94	5.18	6.5	7.76
DCI0L1B	DMNP60F	Anastrozole	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	9.36	9.2	3.16	12.14
DC63BSC	DMNP60F	Anastrozole	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	0.84	3.14	3.92	4.49
DCONKZC	DMNP60F	Anastrozole	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	1.56	2.14	4.2	4.61
DC06727	DMNP60F	Anastrozole	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	1.28	0.08	4.71	5.34
DC8XJ9R	DMNP60F	Anastrozole	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	1.52	0.02	2.76	5.72
DCTUQZJ	DMNP60F	Anastrozole	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.45	1.3	4.95	5.64
DCPW5WD	DMNP60F	Anastrozole	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	0.74	1.85	2.37	2.74
DCUVMQQ	DMNP60F	Anastrozole	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	0.27	4.02	5.59	5.85
DCOIC40	DMNP60F	Anastrozole	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	0.18	3.76	6.74	7.03
DCH0KTB	DMNP60F	Anastrozole	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	2.54	5.51	9.05	9.39
DCRG1N8	DMNP60F	Anastrozole	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.74	0.47	2.94	3.24
DCSUWIH	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	0.45	1.35	2.21	1.95
DCN6OLV	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	1.42	2.52	1.77	1.14
DCK9491	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.42	2.18	1.13	1.27
DCAO6FX	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	5.48	7.39	4.22	4.72
DCV1MQP	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	2.39	6.03	4.79	5.13
DCZ9WON	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.5	5.98	4.62	5.44
DC2V2BW	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.13	1.45	0.26	1
DCK7FD5	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	3.72	3.49	1.82	1.7
DCRGZHK	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	1.76	2.09	0.6	0.02
DCUQYJ8	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	3.2	3.34	0.23	0.04
DCHQC2J	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	1.36	1.41	2.97	2.1
DC4F8EM	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	1.54	1.07	1.03	1.17
DCME2NV	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	1.14	2.19	2.16	1.79
DC3DAKQ	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	0.92	2.15	0.34	0.57
DC2VUPN	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	2.03	3.44	4.24	4.39
DCKG4AI	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	1.88	2.27	0.61	0.03
DCTM0KX	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	2.01	0.54	0.22	0.22
DCWH7HC	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	3.29	4.37	3.65	5.94
DCBXJI6	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	2.47	2.49	2.68	4.07
DCCKGCE	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	3.67	3.8	4.97	6.44
DCZEDZQ	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	6.65	6.36	6.75	7.58
DCXSS5T	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.3	3.99	2.97	3.91
DC0VBWO	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.21	2.88	1.39	3.35
DCN8360	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.63	1.81	0.91	3.28
DC0TS3E	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.35	2.01	4.52	5.51
DCP9RQP	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.25	4.06	1.37	2.48
DC44FGN	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.11	8.03	7.53	7.98
DCYW5BE	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	6.57	9.02	4.35	8.64
DCKD7HB	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.74	6.43	6.69	8.32
DC3B7IK	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	0.5	2.02	1.35	2.04
DC1TYS6	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	1.03	0.85	1.78	4.22
DC4ZJTA	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	3.27	4.07	1.83	4.65
DCN22JQ	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	3.87	4.16	1.8	5.22
DCW17C4	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	1.53	6.06	3.22	6.56
DCX8WH2	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	4.77	4.97	5.9	6.96
DCW3P9Z	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	6.13	7.7	0.14	9.98
DCMJT67	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	5.63	9.93	10.84	11.33
DC8OCUC	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	1.36	0.91	3.15	4.88
DC0EIYD	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.77	4.19	1.48	5.21
DCZLQU8	DMNP60F	Anastrozole	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	0.13	2.55	4.33	3.46
DC4XPSN	DMNP60F	Anastrozole	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	0.12	1.3	1.34	1.22
DCQ4I6V	DMNP60F	Anastrozole	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	1.77	5.09	8.3	8.32
DCWHTX7	DMNP60F	Anastrozole	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	2.28	3	2.56	2.32
DCT65GT	DMNP60F	Anastrozole	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.07	2.95	3.69	4.02
DCZKAZY	DMNP60F	Anastrozole	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	1.19	4.69	6.63	5.72
DCN11GS	DMNP60F	Anastrozole	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	3.82	7.46	5.05	4.85
DC17PO3	DMNP60F	Anastrozole	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	2	3.49	2.59	2.64
DCDPON6	DMNP60F	Anastrozole	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	1.7	2.76	3.63	4.48
DC4ZRAJ	DMNP60F	Anastrozole	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	3.38	6.39	3.87	4.07
DCNVP75	DMNP60F	Anastrozole	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	0.68	0.77	1.89	1.94
DC2NCOS	DMNP60F	Anastrozole	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	2.39	2.5	3.03	3.83
DCNEI8T	DMNP60F	Anastrozole	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	1.62	2.16	1.13	1.1
DCTHLMQ	DMNP60F	Anastrozole	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	6.25	8.61	9.35	9.49
DCPG4PL	DMNP60F	Anastrozole	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.69	4.39	5.83	6.49
DC3LEMU	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	3.87	3.52	4.5	5.68
DCVQB8O	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	3.29	1.56	0.8	2.9
DC545GU	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	1.87	2.35	3.03	2.98
DCFQTZU	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.63	5.8	5.79	6.53
DCNJL0J	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	12.83	10.05	10.12	10.73
DCHW8YW	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.67	2.32	2.25	3.8
DCZTJRL	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	8.59	9.13	9.65	10.9
DCNSRPB	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	5.7	8.05	8.25	8.49
DCFG5PJ	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	5.47	7.01	1.59	7.45
DCSYQDF	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	3.77	5.63	0.2	6.32
DCNADW8	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	1.48	9.09	5.82	7.64
DC4HPP3	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	5.66	9.12	3.4	8.81
DCDD9JP	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	11.53	13.28	15.37	15.26
DCIFYW7	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	2.69	6.14	4.5	6.6
DCBK06W	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	1.9	3.55	2.35	2.49
DC3K006	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	5.36	7.34	1.73	9.25
DC2OEW9	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	9.2	9.83	7.85	10.8
DCMSRPM	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	7.01	6.71	7.64	8.23
DC9232A	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	6.95	5.51	6.81	7.2
DCX9A1W	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	16.22	15.2	17.55	17.36
DCA47NA	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	6.38	7.49	7.22	8.19
DCHZ344	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	3.25	6.68	1.65	5.99
DCYUYP4	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	9.4	10.37	10.51	11.17
DCYVQW4	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	2.14	4.4	6.2	6.09
DCAMKLC	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	10.34	13.74	13.78	15.21
DCTPS00	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	3.04	9.03	10.22	10.88
DCVJKBU	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	2.18	3.66	6	6.07
DCDE3F9	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	6.14	6.13	5.52	4.79
DC0KO9Y	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	2.08	1.46	1.06	0.48
DCUG9B3	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	3.86	4.48	1.06	5.34
DCFZD1N	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	2.16	6.06	1.95	6.27
DC9O1VM	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	2.46	2.49	0.15	3.78
DC3I1QA	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	3.11	3.48	1.72	1.58
DCUWS8K	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.04	5.73	0.94	7.3
DCCBQ7Y	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.23	4.37	1.93	3.72
DCA8ZI7	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.15	5.37	4.16	3.91
DCINFPH	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	4.98	5.72	3.53	3.69
DCJ9656	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.64	3.11	2.28	1.49
DCSGKBT	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.57	3.56	5.14	5.23
DCMB0CR	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	1.51	2.09	1.36	1.37
DCET9P5	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	3.15	1.02	0.53	0.38
DCGFMQ3	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	5.8	7.7	6.5	5.46
DCIFU9Q	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	3.76	4.51	0.39	4.47
DC2X725	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	1.83	4.06	4	4.25
DC5UJ1M	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	4.88	5.29	4.47	4.55
DCFZP9V	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	3.5	9.08	5.26	7.65
DCA6DL5	DMNP60F	Anastrozole	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2	3.89	3.15	5.83
DCTA4V4	DMNP60F	Anastrozole	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	6.18	7.3	8.7	8.77
DCY7U3V	DMNP60F	Anastrozole	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.89	0.25	2.31	3.8
DCSEYWU	DMNP60F	Anastrozole	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.42	1.67	2.19	4.27
DC6KCT3	DMNP60F	Anastrozole	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	4.98	5.33	6.72	7.58
DCDVTZT	DMNP60F	Anastrozole	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	12.57	12.61	14.36	14.44
DCKV4QU	DMNP60F	Anastrozole	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	10.68	10.64	0.95	11.95
DC2YA88	DMNP60F	Anastrozole	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	4.08	7.76	8.29	9.24
DCGJN2J	DMNP60F	Anastrozole	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.75	1.37	1.98	4.54
DCOYMYI	DMNP60F	Anastrozole	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	5.34	6.73	8.39	9.56
DCW1MKK	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	1.37	1.85	0.79	2.33
DCWD6PD	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	5.45	3.36	4.16	4.3
DCHR4L5	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	3.45	3.57	4.78	6.07
DCBDWPI	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.5	3.92	4.79	5.04
DC9XDVA	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.7	0.48	1.02	1.3
DCXDPNQ	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.92	6.5	7.01	7.3
DCEQNKL	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	2.19	1.26	1.98	4
DC5H0RE	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.38	0.79	1.2	1.59
DCYEZWV	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	10.84	10.97	12.63	12.51
DC9V2O1	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.21	1.08	4.57	4.71
DCNE4OV	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.74	1.24	5.46	6.09
DC0NMKL	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	3.43	2.21	2.8	4.57
DC6WDNA	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	4.09	2.8	4.49	6.46
DC0F0W4	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	6.02	6.11	6.51	8.07
DCUCYMK	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.85	2.89	5.03	5.08
DCY41ZS	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	5.11	3.86	5.69	6.9
DCNNTFC	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	6.72	5.97	8.04	9.82
DC3B8AP	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	0.12	1.55	3.08	2.79
DCJCC1H	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	4.31	3.19	4.64	6.46
DC3524J	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	3.86	3.86	5.14	6.32
DC7402G	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	5.6	4	3.55	7.31
DCHLZYZ	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	3.49	0.71	3.79	4.63
DC9XCKG	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	9.68	11.05	13.96	14.22
DC7VC4P	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	4.81	8.72	7.97	9.42
DCDTAMI	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	5.42	7.24	6.48	8.51
DCO48KT	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	1.42	0.95	2.68	2.89
DCZYORF	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	8.97	7.95	6.64	12.14
DC1A20Y	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.36	3.71	3.07	5.07
DC0HOY3	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	3.34	3.67	2.02	8.32
DC3WP63	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	10.11	9.14	11.73	12.97
DCCZVGJ	DMNP60F	Anastrozole	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	1.68	2.58	1.62	1.45
DCGDJY6	DMNP60F	Anastrozole	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.75	10.36	4.5	4.66
DCUFJS5	DMNP60F	Anastrozole	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	5.33	8.31	5.94	6.15
DCLF8I1	DMNP60F	Anastrozole	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	5.87	7.34	1.35	2.39
DC253LQ	DMNP60F	Anastrozole	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	3.51	4.32	1.54	3.38
DC4XEMF	DMNP60F	Anastrozole	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	2.52	2.04	2.28	4.27
DCW57S5	DMNP60F	Anastrozole	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	2.71	7.48	1.46	4.4
DCK4AZR	DMNP60F	Anastrozole	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	8.27	8.6	5.73	7.23
DCK2KAG	DMNP60F	Anastrozole	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	5.17	7.34	3.64	6.03
DCV3LP9	DMNP60F	Anastrozole	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.39	4.01	1.18	3.81
DCDTU3W	DMNP60F	Anastrozole	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	0.14	2.81	2.28	3.98
DC8YFWW	DMNP60F	Anastrozole	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.28	4.27	0.12	4.3
DCRBX8J	DMNP60F	Anastrozole	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.11	8.11	0.63	3.67
DCOHP4I	DMNP60F	Anastrozole	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.81	10.33	4.21	6.28
DCFNUWN	DMNP60F	Anastrozole	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	6.96	5.68	1.15	3.02
DCVJSE5	DMNP60F	Anastrozole	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.78	5.22	0.97	4.27
DC7BWI7	DMNP60F	Anastrozole	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	7.59	7.61	2.21	3.76
DCSXXU6	DMNP60F	Anastrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	2.67	4.19	2.21	2.04
DCVNGDA	DMNP60F	Anastrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.35	6.78	0.65	1.2
DCSN8I0	DMNP60F	Anastrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.13	3.1	0.37	2.22
DC3ATZK	DMNP60F	Anastrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	3.21	4.06	0.19	0.95
DCSVNE4	DMNP60F	Anastrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.26	2.01	0.71	1.59
DCNLN84	DMNP60F	Anastrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	6.59	4.51	2.89	5.21
DCLY4CC	DMNP60F	Anastrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.63	1.88	0.42	1.65
DCLU836	DMNP60F	Anastrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	1.63	3.11	1.55	1.58
DCB2979	DMNP60F	Anastrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.84	2.59	0.63	1.36
DC2Z2Y7	DMNP60F	Anastrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.74	3.22	1.02	1.94
DCG1TUA	DMNP60F	Anastrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	5.84	8.92	2.96	7.87
DCLKH34	DMNP60F	Anastrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	0.38	1.65	1.11	1.08
DCBM9NN	DMNP60F	Anastrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	3.25	3.06	0.85	1.92
DC598OR	DMNP60F	Anastrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	0.61	0.99	0.68	0.58
DCHK93B	DMNP60F	Anastrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	1.75	5.81	2.44	3.68
DC5VZYY	DMNP60F	Anastrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	2.2	2.98	0.09	0.4
DC36EZF	DMNP60F	Anastrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	2.91	4.19	2.38	3.03
DCL07Y4	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	5.89	7.01	0.71	9.82
DCJPK9M	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	4.42	5.72	4.26	6.06
DCBMWFH	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	4.02	4.19	4.66	8.19
DCP3S2A	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	1.22	3.47	3.3	2.23
DC8Y7M4	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	1.35	0.87	0.5	0.74
DCA229E	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	4.55	5.95	5.92	6.72
DCBKWEC	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.97	7.16	7.87	8.07
DC0E2Y1	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.71	8.97	5.64	5.13
DCLKWT5	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	2.59	3.12	0.38	0.46
DCGDFI6	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	5.02	0.55	0.76	1.58
DCGH2PU	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	8.82	7.09	10.66	10.45
DC36ZL2	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.21	0.06	0.1	0.84
DC9KFJA	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	8.92	7.69	9.14	9.18
DCDYXVD	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.11	4.23	6.39	6.46
DCLI8G8	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	0.21	1.06	0.48	0.43
DCMR319	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	7.3	5.97	5.81	7.34
DCX0LVX	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	3.88	7.07	9.42	10.17
DCJBTUD	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.4	2.93	5.02	5.5
DC47PXH	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.85	1.08	0.61	3.2
DCZ98V0	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.71	0.17	3.94	3.57
DCYZ7UV	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	2.49	5.17	6.87	7.01
DC98VLY	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	3	4.57	4.53	6.54
DC6N2AK	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	2.61	1.38	1.47	1.88
DC1DN9R	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	0.73	0.75	2.84	4.02
DC68RV7	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	2.9	3.15	4.37	5.34
DCNP4GV	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	6.06	7.44	8.21	10.14
DCACRO0	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	7.78	8.62	7.57	11.16
DCKN7LD	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	5.42	5.7	6.81	7.84
DCLRV8D	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	3.17	2.92	5.16	5.75
DCIB7EA	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	16.93	17.46	19.99	20.21
DCENW07	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	4.69	6.34	3.6	2.71
DCQYOCE	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	7.64	7.31	8.29	9.88
DC2M1CK	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	4.57	6.05	3.51	7.11
DC4ZJ08	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	6.52	8.5	9.53	9.92
DCWQ6AD	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	0.36	1.15	3.55	3.63
DC1WGMM	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	9.74	9.37	9.5	11.34
DCY21HT	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	8.63	9.05	6.08	13.59
DCUPAPJ	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	1.47	5.35	3.24	2.42
DCTJ00V	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	0.56	4.16	1.56	6.72
DCULZVW	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	5.3	5.62	4.19	9.4
DCM9YOR	DMNP60F	Anastrozole	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	1.11	2.12	2.61	1.76
DCIJJT0	DMNP60F	Anastrozole	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	1.31	2.27	2.97	2.48
DCJMQTO	DMNP60F	Anastrozole	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	1.92	2.96	0.99	0.39
DCLUUJ5	DMNP60F	Anastrozole	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	3.02	3.14	0.98	0.62
DCWX6KG	DMNP60F	Anastrozole	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	0.73	1.27	1.5	1
DC8BFXL	DMNP60F	Anastrozole	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	2.85	3.91	3.36	3.14
DC9HNXQ	DMNP60F	Anastrozole	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	1.7	2.89	2.98	2.52
DCFY4TL	DMNP60F	Anastrozole	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	3.86	4.76	3.28	3.1
DC90POZ	DMNP60F	Anastrozole	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.17	2.87	2.23	3.29
DC75U61	DMNP60F	Anastrozole	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.39	3.28	3.64	3.68
DCCX41M	DMNP60F	Anastrozole	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	1.48	8.14	4.5	6.04
DCHGAXW	DMNP60F	Anastrozole	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	3.78	8.41	0.79	8.11
DCVZMEB	DMNP60F	Anastrozole	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	4.33	7.24	4.65	7.55
DC6FU5V	DMNP60F	Anastrozole	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	1.11	2.74	3.31	4.12
DCBI9HN	DMNP60F	Anastrozole	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	6.64	7.69	4.88	10.03
DCBWC5Y	DMNP60F	Anastrozole	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	2.1	4.21	4.82	5.14
DCAJZQ5	DMNP60F	Anastrozole	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	5.13	4.95	0.21	5.9
DCLPLRW	DMNP60F	Anastrozole	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.49	5.12	0.51	7.27
DC06M8J	DMNP60F	Anastrozole	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	2.42	3.87	3.82	5
DC1LQBA	DMNP60F	Anastrozole	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	3.55	2.91	5.23	5.01
DCR9XFM	DMNP60F	Anastrozole	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	2.28	3.71	3.15	2.27
DC60X52	DMNP60F	Anastrozole	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	0.93	4.43	4.01	3.26
DC6LPXE	DMNP60F	Anastrozole	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	0.14	0.34	0.89	0.18
DC604E6	DMNP60F	Anastrozole	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	0.43	4.11	4.9	4.79
DCX806B	DMNP60F	Anastrozole	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	2.92	5.37	6.98	6.19
DCIYL3M	DMNP60F	Anastrozole	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	0.39	1.43	3.02	2.33
DC2L1WV	DMNP60F	Anastrozole	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	2.97	4.29	4.12	3.57
DCV02YK	DMNP60F	Anastrozole	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	1.16	2.28	1.99	1.53
DC6D41S	DMNP60F	Anastrozole	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	2.75	2.7	2.41	3.33
DC54G2J	DMNP60F	Anastrozole	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	0.57	0.8	1.83	1.61
DCF18LA	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	2.35	2.95	3.42	4.35
DCPCEKO	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.01	2.13	2.11	2.82
DCOA4AS	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.93	2.5	4.38	5.96
DC5G0RH	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.19	0	1.43	2.27
DCDFIKF	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	3.71	2.9	6.23	7.06
DCMMNUP	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.73	2.9	7.18	7.39
DCJACL5	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	6.74	8.19	9.15	10.52
DC6Q7NE	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	3.43	3.8	4.71	6.43
DCHSSPI	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	4.85	5.34	4.79	8.36
DC4S9BS	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	4.89	4.27	7.28	8.75
DCMM2B4	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	7.89	5.31	6.92	8.23
DCI6WN6	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	3.88	3.82	6.76	7.03
DCHU5QO	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	2.34	3.42	4.56	5.5
DCTNAGA	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	4.72	6.56	8.85	9.58
DCWPWW3	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	0.03	0.43	3.85	4.33
DCFB4IJ	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	4.72	5.07	5.73	6.57
DC2DFV4	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	5.99	5.67	8.02	8.68
DCH7W0W	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.79	4.82	10.15	10.82
DC6GXEZ	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	3.25	2.47	5.42	6.75
DCMMPEX	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.42	0.18	2.91	4.2
DCBAIG1	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	1.11	2.83	4.11	3.41
DCG41Y7	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	0.87	1.08	0.36	0.18
DCZOZWD	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	2.06	2.66	0.6	0.9
DCRXAEX	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	1.99	4.55	4.07	3.71
DCTLDDS	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	4.04	6.2	1.77	2.8
DC0554K	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	3.45	2.82	0.17	1.11
DC07872	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.22	1.93	0.26	1.02
DCSWBNP	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	4.25	5.41	0.47	0.5
DCXERDL	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	1.76	4.07	2.23	1.67
DC6DE0Z	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	2.36	3.66	1.88	2.79
DCQLHAN	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	3.87	6.24	5.37	5.47
DCA7CID	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	0.38	2.31	1.12	2.36
DC5C7XA	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	4.59	6.19	1.32	2.38
DCXDNMD	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	1.78	2.3	2.56	2.7
DCB3TOC	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	0.63	0.75	0.14	1.24
DC7ZEQN	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	4.44	4.93	0.9	2.43
DCNQ9UY	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	5.6	12.28	11.35	11.53
DC3PWCD	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.37	2.9	2.1	2.78
DCE00J5	DMNP60F	Anastrozole	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.84	12.03	6.54	8.98
DCLTU15	DMNP60F	Anastrozole	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.18	3.88	1.43	2.77
DC1IS9I	DMNP60F	Anastrozole	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	3.39	5.46	2.82	4.55
DCJPDRC	DMNP60F	Anastrozole	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	1.73	2.87	0.53	1.36
DCAV8GE	DMNP60F	Anastrozole	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	5.73	5.45	0.17	3.08
DCD5OY8	DMNP60F	Anastrozole	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	2.19	6.03	0.61	5.06
DC1B840	DMNP60F	Anastrozole	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	5.18	6.69	5.55	5.36
DCU0DS0	DMNP60F	Anastrozole	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	3.11	5.6	1.63	3.58
DC87KTP	DMNP60F	Anastrozole	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	8.22	9.52	3.52	4.53
DC1959K	DMNP60F	Anastrozole	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	0.87	2.29	3.14	4.23
DCGIS25	DMNP60F	Anastrozole	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	2.5	1.95	2.68	4.24
DCG4001	DMNP60F	Anastrozole	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	0.69	1.85	1.81	3.28
DCLMTEF	DMNP60F	Anastrozole	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	2.05	2.88	1.02	5.45
DCRCH6Z	DMNP60F	Anastrozole	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.16	0.81	0.97	2.07
DCJDF75	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	1.76	3.67	2.18	1.99
DC8VAV9	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	1.31	1.63	1.25	1.04
DCUB61R	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	1.63	2.89	2.73	2.04
DC90OOZ	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	0.66	2.24	1.58	1.79
DCVHZ1T	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.2	5.1	3.38	3.41
DCQKV2N	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.67	3.79	1.82	2.07
DCOA0S0	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	1.85	3.06	2.13	1.83
DCQUGZE	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	0.94	1.16	0.28	0.13
DC4N68Y	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.75	1.19	0.68	0.09
DCR8CX4	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.75	2.52	0.65	0.89
DCSWWTU	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.77	2.79	1.52	1.4
DC4GOQ4	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.82	1.39	0.36	0.05
DC6DNWM	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.37	2.23	0.84	0.79
DCI8B6Z	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	2.98	2.09	1.57	1.25
DCIX5UB	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.63	2.58	1.32	0.94
DC870JH	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	1.14	1.23	1.51	0.66
DC9ELII	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	1.86	2.76	1.8	1.37
DC9FC9C	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	1.89	0.9	1.2	0.35
DCZPCKS	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	2.16	3.01	2.28	2.06
DC9UTZ7	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	2.08	1.22	1.91	2.11
DCWILOG	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	3.22	5.03	3.23	3.23
DCQW4AN	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	1.05	1.69	1.14	0.86
DC9C17K	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	6.07	6.05	5.17	4.79
DCKUALD	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	5.27	6.43	3.58	3.46
DCDGR3U	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	1.21	1.64	0.49	0.35
DCP65TF	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.25	1.96	0.84	0.16
DCDSU89	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	0.78	0.56	1.17	0.75
DCIP2HI	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.03	1.22	1.77	1.43
DC1ID42	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.63	0.35	0.44	0.21
DCUV14I	DMNP60F	Anastrozole	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	5.22	6.68	3.34	7.61
DCPKFO1	DMNP60F	Anastrozole	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	5.51	5.28	2.84	7.26
DCX20P7	DMNP60F	Anastrozole	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	0.67	0.51	0.07	3.42
DC3KSM8	DMNP60F	Anastrozole	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	4.15	3.07	0.78	6.4
DCK1WCH	DMNP60F	Anastrozole	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	6.65	4.78	1.43	5.75
DCUCTAF	DMNP60F	Anastrozole	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	4.6	4.61	1.39	6.11
DC4RM5R	DMNP60F	Anastrozole	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	9.38	9.66	9.11	10.84
DCY7FBF	DMNP60F	Anastrozole	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	18.45	14.45	11.95	17.11
DCHS7ZE	DMNP60F	Anastrozole	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	10.65	10.95	9.02	13.25
DCOD6KC	DMNP60F	Anastrozole	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	14.77	13.57	11.9	15.01
DC6OPB7	DMNP60F	Anastrozole	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	6.62	7.4	4.11	9.97
DCDMINM	DMNP60F	Anastrozole	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	12.58	12.43	9.74	13.75
DC9IGYM	DMNP60F	Anastrozole	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	3.6	3.84	1.16	6.51
DCE5YJ2	DMNP60F	Anastrozole	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	2.32	3.13	0.89	4.21
DCWLL2V	DMNP60F	Anastrozole	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	8.26	9.23	5.71	11.28
DCV34F4	DMNP60F	Anastrozole	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	2.21	1.6	4.44	4.94
DCHNQ51	DMNP60F	Anastrozole	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	2.72	7.44	7.83	7.61
DCMNJEJ	DMNP60F	Anastrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	2.34	5.74	4.07	6.08
DC7RMWV	DMNP60F	Anastrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	0.72	1.64	1.11	0.41
DCZDQQB	DMNP60F	Anastrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	3.4	5.89	0.85	4.36
DCLTZ89	DMNP60F	Anastrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	1.44	1.52	1.67	1.57
DCONU71	DMNP60F	Anastrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.3	2.63	2.35	2.91
DC7SQPL	DMNP60F	Anastrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.83	2.86	1.24	1.81
DC5TPRB	DMNP60F	Anastrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	6.25	7.71	4.25	3.93
DCA5N55	DMNP60F	Anastrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	5.71	7.73	6.79	8.93
DC75XKT	DMNP60F	Anastrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	3.56	8.96	6.04	5.91
DCWSKM9	DMNP60F	Anastrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	0.88	3.38	0.04	3.39
DCY2VTA	DMNP60F	Anastrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	8.05	9.65	10.17	10.7
DCQQGCV	DMNP60F	Anastrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	0.79	2.96	1.06	2.9
DC1V1AW	DMNP60F	Anastrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	3.36	4.9	4.46	4.29
DCHCHJK	DMNP60F	Anastrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.34	9.59	1.9	8.81
DCPO570	DMNP60F	Anastrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	0.55	1.55	0.02	2.39
DCUCWCT	DMNP60F	Anastrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.54	9.43	7.81	8.27
DC44B5Z	DMNP60F	Anastrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.62	6.71	6.61	6.14
DC7L87U	DMNP60F	Anastrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.87	2.92	1.05	1.78
DCDFF63	DMNP60F	Anastrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	1.93	2.78	2.21	2.59
DCW6G7W	DMNP60F	Anastrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	1.15	4.08	1	3.46
DCOBHUC	DMNP60F	Anastrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	5.98	5	1.74	3.72
DCLP0TM	DMNP60F	Anastrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	15.34	15.73	12.78	16.43
DCDP90O	DMNP60F	Anastrozole	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	0.46	2.84	2.51	2.72
DCJBSUM	DMNP60F	Anastrozole	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.6	7.69	5.02	6.34
DCM6V34	DMNP60F	Anastrozole	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.63	2.82	2.29	3.09
DC0SDLW	DMNP60F	Anastrozole	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	3.44	2.13	2.83	2.82
DCYDNS8	DMNP60F	Anastrozole	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	1.29	6.29	0.65	3.7
DCLEURE	DMNP60F	Anastrozole	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	2.04	2.86	0.14	0.4
DCUNF41	DMNP60F	Anastrozole	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.57	7.51	5.63	6.82
DCQFN5O	DMNP60F	Anastrozole	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	4.79	5.98	1.66	1.46
DCJHLG9	DMNP60F	Anastrozole	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	7.13	9.33	1.6	6.94
DCGPJ9J	DMNP60F	Anastrozole	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	7.65	8.68	7.18	10.31
DCJ4T9R	DMNP60F	Anastrozole	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	4.11	8.26	4.53	4.53
DC2FREV	DMNP60F	Anastrozole	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	0.54	4.51	3.12	5.35
DCL5SVN	DMNP60F	Anastrozole	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	2.53	2.98	2.48	2.37
DC0QMDX	DMNP60F	Anastrozole	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.95	4.61	4.36	4.74
DC9RABQ	DMNP60F	Anastrozole	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.52	2.05	3.11	3
DC1A6JX	DMNP60F	Anastrozole	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	3.86	6.67	1.86	6.75
DCPGUWF	DMNP60F	Anastrozole	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	3.04	4.98	1.53	5.11
DC9VIY0	DMNP60F	Anastrozole	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	1.59	4.79	0.03	5.25
DCNUJMX	DMNP60F	Anastrozole	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	5.17	6.51	3.97	5.49
DC9LK0W	DMNP60F	Anastrozole	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	1.09	2.19	4.09	4.94
DCWLIE6	DMNP60F	Anastrozole	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	5.04	8.75	3.4	8.29
DC3OQNA	DMNP60F	Anastrozole	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	2.02	4.31	0.99	4.76
DC2IHHF	DMNP60F	Anastrozole	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	1.33	1.89	0.49	0
DC3PNQ6	DMNP60F	Anastrozole	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.87	6.44	0.43	5.94
DCOX56R	DMNP60F	Anastrozole	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.1	0.9	0.24	1.24
DCDMWQX	DMNP60F	Anastrozole	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.71	2.19	1.96	2.73
DC1IQXN	DMNP60F	Anastrozole	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	1.64	2.35	0.91	1.88
DCIFRDC	DMNP60F	Anastrozole	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	3.69	4.14	4.69	6.51
DCJYH93	DMNP60F	Anastrozole	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	1.36	1.09	1.96	2.4
DCSU1GS	DMNP60F	Anastrozole	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.72	4.23	2.57	6.97
DCIUSUD	DMNP60F	Anastrozole	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.52	0.38	2.34	2.75
DCOWEUA	DMNP60F	Anastrozole	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	0.19	4.33	3.53	4.8
DCWRDFL	DMNP60F	Anastrozole	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.86	3.59	2.63	3.85
DCJXSUI	DMNP60F	Anastrozole	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.24	3.25	3.62	3.57
DCOTP9S	DMNP60F	Anastrozole	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	5.14	7.96	2.19	7.53
DCPZNOC	DMNP60F	Anastrozole	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	1.74	3.63	2.46	3.75
DCV9CNN	DMNP60F	Anastrozole	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	0.73	3.31	1.65	2.37
DC45NA7	DMNP60F	Anastrozole	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	2.87	3.89	0.66	4.38
DCMIG24	DMNP60F	Anastrozole	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	5.56	4.12	1.87	6.39
DCNIT92	DMNP60F	Anastrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	0.66	1.16	1.03	0.75
DCGAMLA	DMNP60F	Anastrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	0.64	0.99	1.07	0.75
DCMGUX2	DMNP60F	Anastrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	2.53	2.97	2.94	2.07
DC7KDPM	DMNP60F	Anastrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.47	3.17	1.84	1.48
DC3B40U	DMNP60F	Anastrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.94	2.49	1.77	1.63
DCGINAD	DMNP60F	Anastrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	2.27	3.47	3.05	2.6
DC4AAGR	DMNP60F	Anastrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	3.48	2.26	1.58	0.84
DC41T82	DMNP60F	Anastrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.28	1.87	1.42	1.47
DC8ZQ0N	DMNP60F	Anastrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.38	1.29	1.68	2.28
DCL4RZY	DMNP60F	Anastrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	0.91	2.23	3.67	2.81
DCIUPEX	DMNP60F	Anastrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	0.46	0.97	1.4	1.23
DCC1U82	DMNP60F	Anastrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	2.47	2.69	3.3	2.5
DC6I9H3	DMNP60F	Anastrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	1.49	1.92	0.84	0.33
DC4HGYB	DMNP60F	Anastrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	0.54	0.43	1.21	0.73
DCK7IB0	DMNP60F	Anastrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.93	0.12	0.93	1.36
DC83HRV	DMNP60F	Anastrozole	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	1.02	2.38	0.01	0.94
DCQTZ1J	DMNP60F	Anastrozole	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	0.27	3.2	0.96	4.12
DCJ042Z	DMNP60F	Anastrozole	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	0.07	0.62	0.59	2.43
DCQ79CS	DMNP60F	Anastrozole	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	3.34	5.03	2.75	1.79
DCO9RPD	DMNP60F	Anastrozole	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	1.63	1.27	0.39	3.82
DCPEYB2	DMNP60F	Anastrozole	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	0.51	6.15	0.94	6.53
DC36V36	DMNP60F	Anastrozole	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.3	2.12	0.5	2.27
DCU5RSH	DMNP60F	Anastrozole	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.62	2.3	0.35	1.65
DC76UBD	DMNP60F	Anastrozole	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.45	6.77	9.45	9.2
DCLTAJ9	DMNP60F	Anastrozole	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	0.06	2.34	1.63	4.17
DCCN5GI	DMNP60F	Anastrozole	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	4.56	6.81	5.01	8.23
DCWBHKI	DMNP60F	Anastrozole	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	4.37	4.04	2.93	7.59
DCYH82Y	DMNP60F	Anastrozole	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	1.71	2.33	1.6	1.01
DCZ76CW	DMNP60F	Anastrozole	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	2.53	4.7	3.73	2.97
DC1OGW8	DMNP60F	Anastrozole	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.29	2.9	1.72	2.01
DCZ2SH5	DMNP60F	Anastrozole	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	0.7	1.99	2.2	1.61
DCBLDDE	DMNP60F	Anastrozole	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.96	4.12	2.83	2.06
DC2WRDX	DMNP60F	Anastrozole	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	4.91	5.08	3.77	3.33
DC3K4Y3	DMNP60F	Anastrozole	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	7.95	4.82	3.73	3.52
DCHK22O	DMNP60F	Anastrozole	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	0.82	2.7	1.12	2.26
DCNMBQF	DMNP60F	Anastrozole	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	2.44	0.71	0.76	0.3
DC3IK7W	DMNP60F	Anastrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	2.81	6.69	4.88	4.64
DCDMPBB	DMNP60F	Anastrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.4	6.56	3.37	6.19
DCHW3E5	DMNP60F	Anastrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.92	0.78	0.01	0.81
DC7XZ3A	DMNP60F	Anastrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	8.69	11.82	9.14	9.96
DC5ZSWM	DMNP60F	Anastrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.29	7.48	1.09	7.21
DC4RHSZ	DMNP60F	Anastrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	2.26	8.54	5.32	6.72
DCVGKR5	DMNP60F	Anastrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.81	3.63	4.21	3.85
DCXN383	DMNP60F	Anastrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	2.19	3.3	0.41	2.63
DCOS7TZ	DMNP60F	Anastrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	3.66	6.88	1.69	6.75
DCV0OB8	DMNP60F	Anastrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.81	9.24	2.21	4.6
DCDVARM	DMNP60F	Anastrozole	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.01	1.64	0.25	0.61
DCZ9ZDW	DMNP60F	Anastrozole	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	0.76	3.99	5.21	4.39
DCRN6RH	DMNP60F	Anastrozole	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	0.79	0.96	2.77	3.87
DCYXHU9	DMNP60F	Anastrozole	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.7	0.83	2.08	2.46
DCLQ2AB	DMNP60F	Anastrozole	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.36	4.67	3.66	5.59
DCYGQ3V	DMNP60F	Anastrozole	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.58	1.27	0.45	1.07
DCJA5N1	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.48	10.85	11.09	10.61
DCHI90F	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.94	7.49	7.92	7.63
DCF7EU5	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.87	7.03	6.69	5.64
DCEFNPL	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.05	10.01	9.78	9.61
DCZESJD	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.41	3.86	4.14	4.14
DCKXSIF	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	6.19	12.78	13.06	12.6
DCZSLQP	DMNP60F	Anastrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.09	12.39	12.56	12.11
DCEZJFV	DMNP60F	Anastrozole	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.11	5.88	2.12	2.18
DC4PXPN	DMNP60F	Anastrozole	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.87	3.73	2.41	2.46
DC3TC7I	DMNP60F	Anastrozole	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.67	4.62	5.17	5.32
DCCU331	DMNP60F	Anastrozole	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.32	5.89	8.1	9.02
DC82ESU	DMNP60F	Anastrozole	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.83	5.87	4.17	5.95
DCXZ8IB	DMNP60F	Anastrozole	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.41	3.99	1.09	0.99
DCNXHSD	DMNP60F	Anastrozole	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.76	2.7	1.88	3.03
DCJOBPG	DMNP60F	Anastrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.1	1.72	1.39	1.6
DC37Q4X	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.8	2.62	0.27	0.8
DC6V0KB	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.19	2.89	1.54	1.85
DCYX8AP	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	10.65	13.25	0.03	2.9
DC4KJ9Z	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.42	1.26	0.53	1.52
DC0T6OY	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.51	5.72	3.67	4.86
DCNCBGY	DMNP60F	Anastrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.01	4.45	2.58	3.95
DC0L9MR	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.74	6	6.03	5.57
DC2PVBM	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.08	5.43	6.2	5.93
DC6HWDC	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.85	1.87	1.86	0.82
DC2OUMY	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.06	8.29	5.46	5.45
DCKXCM0	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.3	4.13	4.27	3.78
DCK29HU	DMNP60F	Anastrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.57	11.01	10.48	10.13
DCMX5WL	DMNP60F	Anastrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.11	9.25	5.42	5.02
DC56UWD	DMNP60F	Anastrozole	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.86	4.91	4.86	6.52
DCU1GZQ	DMNP60F	Anastrozole	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.84	3.34	4.66	4.99
DCOSP9K	DMNP60F	Anastrozole	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.46	4.79	3.93	5.79
DCPD4AD	DMNP60F	Anastrozole	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.8	4.45	5.48	5.81
DCZIUTK	DMNP60F	Anastrozole	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.78	7.04	0.71	5.78
DCGPV2K	DMNP60F	Anastrozole	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.91	3.91	2.88	3.47
DCNAKNX	DMNP60F	Anastrozole	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.01	1.31	1.63	3.33
DC1ECGU	DMNP60F	Anastrozole	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	11.67	12.47	13.75	14.28
DC8NUM7	DMNP60F	Anastrozole	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.03	5.16	6.27	7.41
DC91VOU	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.38	4.23	0.28	3.93
DCN7U0E	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.33	5.55	1.92	4.16
DCO56FK	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.94	5.5	3.71	5.62
DCL0260	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.01	6.12	2.54	5.96
DCC53BO	DMNP60F	Anastrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.17	3.8	1.42	3.76
DC7CE7O	DMNP60F	Anastrozole	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.14	1.76	1.24	0.55
DCF6OE9	DMNP60F	Anastrozole	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.85	5.54	1.85	2.34
DCYMOIL	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.66	4.36	3.51	5.64
DCF720F	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.56	6.39	7.85	8.41
DCNPD7L	DMNP60F	Anastrozole	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.53	5.72	4.27	6.42
DCD77U9	DMNP60F	Anastrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.32	4.65	2.09	4.59
DCY7NWZ	DMNP60F	Anastrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	8.71	17.37	5.16	11.04
DCV9UA7	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.78	4.89	5.57	6.42
DCI4LEC	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.24	4.55	3.27	5.78
DCPMULY	DMNP60F	Anastrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.9	8.06	7.7	9.02
DCM74A9	DMNP60F	Anastrozole	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.96	3.09	3.99	5.42
DCK29XP	DMNP60F	Anastrozole	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.63	3.41	2.67	3.63
DC6SD5V	DMNP60F	Anastrozole	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.83	6.93	8.33	8.83
DCSAWVU	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.23	0.24	0.17	0.09
DCRQ8KL	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.68	3.46	0.88	1.46
DC8XM9G	DMNP60F	Anastrozole	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.31	2.54	1.26	1.72
DCG086K	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.12	10.29	8.51	8.28
DCG8NEH	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.4	2.94	4.84	5.3
DCTLEKO	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.39	5	4.8	5.48
DCEZDER	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	9.77	10.88	11.37	11.77
DCKBAXG	DMNP60F	Anastrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	9.28	9.14	10.42	10.85
DC90XBP	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.04	4.45	5.19	5.45
DC7NM1L	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	8.96	10.41	11.77	12.15
DC31EML	DMNP60F	Anastrozole	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.97	4.13	3.22	5.89
DCKEV60	DMNP60F	Anastrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.98	3.74	3.79	5.86
DC4J5QL	DMNP60F	Anastrozole	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.79	2.62	3.02	4.5
DCZ9UE2	DMNP60F	Anastrozole	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	4.01	5.66	6.86	7.22
DC0E1I4	DMNP60F	Anastrozole	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.99	3.84	2.2	4.71
DCWRPWF	DMNP60F	Anastrozole	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.14	3.61	4.4	4.87
DCRXEXJ	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.04	3.64	0.49	5.77
DC591OB	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.66	1.88	3.62	4.16
DCSLGFL	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	9.59	7.76	9.08	9.23
DCDI826	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	10.83	10.66	12.4	12.86
DCT6OP4	DMNP60F	Anastrozole	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.77	5.52	7.11	8.61
DCVMBWZ	DMNP60F	Anastrozole	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.67	4.56	1.49	4.05
DCGXZRL	DMNP60F	Anastrozole	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.8	10.08	2.64	6.34
DCFEB0X	DMNP60F	Anastrozole	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.8	4.54	0.31	3.7
DCOC6TY	DMNP60F	Anastrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.88	4.62	0.38	1.41
DCKWBA8	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.51	7.17	7.96	9.12
DC63HP7	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	4.54	5.65	7.5	7.84
DCGVFDE	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.79	7.01	5.94	8.1
DC8RNNV	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	12.55	13.61	14.98	15.44
DCVRVC5	DMNP60F	Anastrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.19	7.85	8.95	10.14
DCLDR8U	DMNP60F	Anastrozole	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.58	3.37	3.06	2
DCFYXDI	DMNP60F	Anastrozole	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.48	1	2.92	3.12
DCWCHDV	DMNP60F	Anastrozole	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.37	1.22	2.16	1.87
DCLK1FS	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.41	2.96	3.78	4.91
DCG08CI	DMNP60F	Anastrozole	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.74	4.01	5.5	6.64
DCDPH1B	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.17	5.87	0.92	2.01
DCFTDY3	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.7	1.76	0.27	0.92
DC9CYNU	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.08	2.38	0.84	1.87
DCKA27G	DMNP60F	Anastrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.92	2.62	0.17	1.36
DC8FQCO	DMNP60F	Anastrozole	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.73	5.54	1.76	4.48
DC7BGM5	DMNP60F	Anastrozole	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.11	0.85	0.45	1.91
DCK1RKY	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.22	1.86	0.78	0.4
DCF8X2J	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.13	4.06	3.29	2.55
DCRTR6D	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.69	4.62	0.15	0.06
DCU6OLM	DMNP60F	Anastrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.1	3.03	1.72	1.53
DCS672W	DMNP60F	Anastrozole	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	9.46	8.67	1.44	10.29
DCEIOY4	DMNP60F	Anastrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.35	2.18	0.12	0.2
DC17HBZ	DMNP60F	Anastrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.49	3.71	2.04	4.09
DC4ABE3	DMNP60F	Anastrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.26	4	1.09	2.52
DCOM3MI	DMNP60F	Anastrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.25	3.54	0.74	2.01
DC8KVYX	DMNP60F	Anastrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.13	3.14	1.08	2.97
DC8QLUO	DMNP60F	Anastrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.38	2.17	0.99	2.3
DC5TSQG	DMNP60F	Anastrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.47	3.16	1.49	3.18
DC0XG9P	DMNP60F	Anastrozole	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.84	1.55	2.43	2.84
DCKHSF7	DMNP60F	Anastrozole	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.26	2.96	0.07	2.69
DC0BGVB	DMNP60F	Anastrozole	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.4	5.59	2.91	4.37
DC7E5SE	DMNP60F	Anastrozole	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.52	3.32	3.15	3.93
DCDGCSY	DMNP60F	Anastrozole	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.58	7.9	4.46	9.03
DCWW216	DMNP60F	Anastrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.64	0.38	0.34	0.25
DC0I3JT	DMNP60F	Anastrozole	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.45	2.32	2.84	2.75
DCEOTIC	DMNP60F	Anastrozole	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.18	5.09	3.19	2.7
DCG3WI5	DMNP60F	Anastrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.69	4.39	1.1	3.64
DCXCXRO	DMNP60F	Anastrozole	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.61	4.34	1.11	1.03
DC7IH5M	DMSE3I7	Gemcitabine	Preclinical	2.1	DMDI269	Docetaxel	Approved	34	DMVXFYE	Vinorelbine	.	.	Advanced Non-Small Cell Lung Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC7N6IM	DMSE3I7	Gemcitabine	Preclinical	2.1	DMDI269	Docetaxel	Approved	34	DMTS85L	Capecitabine	.	.	Nasopharyngeal Neoplasms	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCH3LJR	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	DMVXFYE	Vinorelbine	.	.	Non - Small Cell Lung Cancer NSCLC	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCPAU0W	DMSE3I7	Gemcitabine	Preclinical	2.1	DMAO80I	Pralatrexate	Approved	34	DMT5GNL	Romidepsin	.	.	Relapsed Peripheral T-Cell Lymphoma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCJP1NF	DMSE3I7	Gemcitabine	Preclinical	2.1	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Non-Muscle Invasive Bladder Neoplasms	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCOQO10	DMSE3I7	Gemcitabine	Preclinical	2.1	DMQNWRD	Oxaliplatin	Approved	34	.	.	.	.	Diffuse Large B-Cell Lymphoma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCPJTMZ	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Relapsed Angioimmunoblastic T-Cell Lymphoma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC38QMC	DMSE3I7	Gemcitabine	Preclinical	2.1	DMDI269	Docetaxel	Approved	34	DMG281S	Carboplatin	DMVXFYE	Vinorelbine	"Carcinoma, Non-Small-Cell Lung"	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC3AA12	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	DMQNWRD	Oxaliplatin	.	.	Pancreatic Adenocarcinoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC4EPQ1	DMSE3I7	Gemcitabine	Preclinical	2.1	DMDI269	Docetaxel	Approved	34	DMMX2E6	Pemetrexed	.	.	Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC79PW1	DMSE3I7	Gemcitabine	Preclinical	2.1	DMDI269	Docetaxel	Approved	34	DMTS85L	Capecitabine	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCAEE26	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	DMQNWRD	Oxaliplatin	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCAX0X4	DMSE3I7	Gemcitabine	Preclinical	2.1	DMQNWRD	Oxaliplatin	Approved	34	DMTS85L	Capecitabine	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCC81JT	DMSE3I7	Gemcitabine	Preclinical	2.1	DMDI269	Docetaxel	Approved	34	DMMX2E6	Pemetrexed	.	.	Non-small Cell Lung Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCKBNU3	DMSE3I7	Gemcitabine	Preclinical	2.1	DMDI269	Docetaxel	Approved	34	DMPDW6T	Epirubicin	.	.	Breast Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCNX3HZ	DMSE3I7	Gemcitabine	Preclinical	2.1	DMG281S	Carboplatin	Approved	34	DMLB81S	Paclitaxel	.	.	Lung Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCS5S8P	DMSE3I7	Gemcitabine	Preclinical	2.1	DMG281S	Carboplatin	Approved	34	DMWBZJD	GDC-0068	.	.	Triple Negative Breast Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCSULYL	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	DMDASC6	Metformin	.	.	Locally Advanced Pancreatic Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCZ6U23	DMSE3I7	Gemcitabine	Preclinical	2.1	DMDI269	Docetaxel	Approved	34	DMG281S	Carboplatin	.	.	Lung Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC672F6	DMSE3I7	Gemcitabine	Preclinical	2.1	DMYBV3G	Paricalcitol	Approved	34	.	.	.	.	Advanced Pancreatic Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC7LGYF	DMSE3I7	Gemcitabine	Preclinical	2.1	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Urothelial Carcinoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCIUFM5	DMSE3I7	Gemcitabine	Preclinical	2.1	DMP6SC2	Irinotecan	Approved	34	.	.	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCIZGP5	DMSE3I7	Gemcitabine	Preclinical	2.1	DMRSNEU	Masitinib	Phase 3	25	.	.	.	.	Ovarian Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCPWF2J	DMSE3I7	Gemcitabine	Preclinical	2.1	DMUKC5L	Tivozanib	Approved	34	.	.	.	.	Renal Cell Carcinoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCPZVML	DMSE3I7	Gemcitabine	Preclinical	2.1	DMEFRTZ	Lurbinectedin	Approved	34	.	.	.	.	Non-Small Cell Lung Cancer (NSCLC)	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCRFKER	DMSE3I7	Gemcitabine	Preclinical	2.1	DMMYTRU	RQ-00000007 (oral)	Phase 2	21	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCS4MQD	DMSE3I7	Gemcitabine	Preclinical	2.1	DMTS85L	Capecitabine	Approved	34	.	.	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCSHKOR	DMSE3I7	Gemcitabine	Preclinical	2.1	DMDASC6	Metformin	Investigative	0	.	.	.	.	Stage IA Pancreatic Adenocarcinoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCV773C	DMSE3I7	Gemcitabine	Preclinical	2.1	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	"Mesothelioma, Malignant"	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCXCWIM	DMSE3I7	Gemcitabine	Preclinical	2.1	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Hodgkin's Lymphoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC2DM1F	DMSE3I7	Gemcitabine	Preclinical	2.1	DMDI269	Docetaxel	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC3M780	DMSE3I7	Gemcitabine	Preclinical	2.1	DMY0UEQ	VATALANIB	Phase 2	21	.	.	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC3XER7	DMSE3I7	Gemcitabine	Preclinical	2.1	DMF57DM	Pazopanib	Approved	34	.	.	.	.	"Lung Cancer, Non-Small Cell"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC44Q5V	DMSE3I7	Gemcitabine	Preclinical	2.1	DMAIL4L	Fludeoxyglucose F 18	Approved	34	.	.	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC5ECSE	DMSE3I7	Gemcitabine	Preclinical	2.1	DMQL8XJ	Decitabine	Approved	34	.	.	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC5OPE8	DMSE3I7	Gemcitabine	Preclinical	2.1	DMFU0JY	TH-302	Phase 2	21	.	.	.	.	Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC5UQR8	DMSE3I7	Gemcitabine	Preclinical	2.1	DMTKD7Q	Afatinib	Approved	34	.	.	.	.	Neoplasms	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC67HF0	DMSE3I7	Gemcitabine	Preclinical	2.1	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC6PGA4	DMSE3I7	Gemcitabine	Preclinical	2.1	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCA7QCM	DMSE3I7	Gemcitabine	Preclinical	2.1	DMAS1RB	MK-8776	Phase 1	17	.	.	.	.	Hodgkin Disease	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCAEJWW	DMSE3I7	Gemcitabine	Preclinical	2.1	DMJFRCT	Tasisulam	Phase 3	25	.	.	.	.	Advanced Solid Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCBIZ1V	DMSE3I7	Gemcitabine	Preclinical	2.1	DMRSNEU	Masitinib	Phase 3	25	.	.	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCCKCN9	DMSE3I7	Gemcitabine	Preclinical	2.1	DMQNWRD	Oxaliplatin	Approved	34	.	.	.	.	Cancer of the Head and Neck	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCD6MTR	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLMNFX	Omaveloxolone	Approved	34	.	.	.	.	Pancreatic Neoplasms	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCDDX5Y	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCFE26I	DMSE3I7	Gemcitabine	Preclinical	2.1	DMMX2E6	Pemetrexed	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCGCBSA	DMSE3I7	Gemcitabine	Preclinical	2.1	DMGVH6N	Axitinib	Approved	34	.	.	.	.	Pancreatic Neoplasms	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCHGWKZ	DMSE3I7	Gemcitabine	Preclinical	2.1	DMIYDT4	Cabozantinib	Approved	34	.	.	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCIK2D1	DMSE3I7	Gemcitabine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Refractory Solid Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCIY575	DMSE3I7	Gemcitabine	Preclinical	2.1	DMTBFE4	LY2090314	Phase 2	21	.	.	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCJRJEX	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCKDMR5	DMSE3I7	Gemcitabine	Preclinical	2.1	DMF57DM	Pazopanib	Approved	34	.	.	.	.	Bladder Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCLE5WV	DMSE3I7	Gemcitabine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Ovarian Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCLTKD0	DMSE3I7	Gemcitabine	Preclinical	2.1	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	"Neoplasms, Malignant"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCMELAV	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCXRZF	LY2603618	Phase 2	21	.	.	.	.	Pancreatic Neoplasms	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCMI4GF	DMSE3I7	Gemcitabine	Preclinical	2.1	DMTKD7Q	Afatinib	Approved	34	.	.	.	.	Focus of Study Instead	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCMP46P	DMSE3I7	Gemcitabine	Preclinical	2.1	DMQNWRD	Oxaliplatin	Approved	34	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCOOWI2	DMSE3I7	Gemcitabine	Preclinical	2.1	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Bladder Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCPK6PX	DMSE3I7	Gemcitabine	Preclinical	2.1	DMG281S	Carboplatin	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCPQ42P	DMSE3I7	Gemcitabine	Preclinical	2.1	DMSIVND	Hydroxychloroquine	Phase 3 Trial	25	.	.	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCSFA8P	DMSE3I7	Gemcitabine	Preclinical	2.1	DMMX2E6	Pemetrexed	Approved	34	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCSRX1T	DMSE3I7	Gemcitabine	Preclinical	2.1	DMSI5CB	Chloroquine	Approved	34	.	.	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCTUMXU	DMSE3I7	Gemcitabine	Preclinical	2.1	DMP8HW1	LY2157299	Phase 2/3	24	.	.	.	.	Neoplasms	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCU4K07	DMSE3I7	Gemcitabine	Preclinical	2.1	DMMU6BJ	Sodium bicarbonate	Approved	34	.	.	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCUMAK5	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLB81S	Paclitaxel	Approved	34	.	.	.	.	Head and Neck Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCV7R5U	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCBJSR	Sunitinib	Approved	34	.	.	.	.	Renal Cell Carcinoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCW33WB	DMSE3I7	Gemcitabine	Preclinical	2.1	DMPW5SB	Bay 86-9766	Phase 3	25	.	.	.	.	Neoplasms	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCXPFSI	DMSE3I7	Gemcitabine	Preclinical	2.1	DMOSTXF	Rigosertib	Phase 3	25	.	.	.	.	Malignant Neoplasmas	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCYE274	DMSE3I7	Gemcitabine	Preclinical	2.1	DMP6SC2	Irinotecan	Approved	34	.	.	.	.	"Neoplasms, Unknown Primary"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCYMOOT	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT3D5I	Aflibercept	Approved	34	.	.	.	.	Pancreatic Neoplasm	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCYTOJ2	DMSE3I7	Gemcitabine	Preclinical	2.1	DMTS85L	Capecitabine	Approved	34	.	.	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCRRUX2	DMSE3I7	Gemcitabine	Preclinical	2.1	DMTY4PG	GI-4000	Phase 2	21	.	.	.	.	Pancreatic cancer	TTD Database	Phase 1	.	.	.	.	.
DC4WER4	DMSE3I7	Gemcitabine	Preclinical	2.1	DMHKCIS	Aldoxorubicin	Phase 3	25	DMHKCIS	Aldoxorubicin	DMHKCIS	Aldoxorubicin	Metastatic Solid Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCJIJ1U	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCXRZF	LY2603618	Phase 2	21	DMMX2E6	Pemetrexed	DMT2FDC	Desipramine	Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC0A2KP	DMSE3I7	Gemcitabine	Preclinical	2.1	DMDI269	Docetaxel	Approved	34	DMF57DM	Pazopanib	.	.	Stage III Adult Soft Tissue Sarcoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC4LFVQ	DMSE3I7	Gemcitabine	Preclinical	2.1	DMS2IUH	Valganciclovir	Approved	34	DMS49KH	Valproic Acid	.	.	Nasopharyngeal Carcinoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC6J2FO	DMSE3I7	Gemcitabine	Preclinical	2.1	DM7RJXL	Imatinib	Phase 3 Trial	25	DMQNWRD	Oxaliplatin	.	.	Advanced Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCHRXVN	DMSE3I7	Gemcitabine	Preclinical	2.1	DMRICNP	Vandetanib	Approved	34	DMTS85L	Capecitabine	.	.	Malignant Solid Tumour	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCI5L9F	DMSE3I7	Gemcitabine	Preclinical	2.1	DMQNWRD	Oxaliplatin	Approved	34	DMRICNP	Vandetanib	.	.	Advanced Incurable Solid Malignancy	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCPEA51	DMSE3I7	Gemcitabine	Preclinical	2.1	DMDI269	Docetaxel	Approved	34	DMTS85L	Capecitabine	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCSTD1Q	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	DMTS85L	Capecitabine	.	.	Metastatic Pancreatic Carcinoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCW2ZVG	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCXRZF	LY2603618	Phase 2	21	DMMX2E6	Pemetrexed	.	.	Advanced Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCWSX36	DMSE3I7	Gemcitabine	Preclinical	2.1	DMQNWRD	Oxaliplatin	Approved	34	DMTS85L	Capecitabine	.	.	Advanced Gastrointestinal Malignancies	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC85H4S	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLOS5R	Bay 80-6946	Approved	34	.	.	.	.	Mature T-Cell and NK-Cell Neoplasm	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC995TY	DMSE3I7	Gemcitabine	Preclinical	2.1	DMMX75K	LEE011	Phase 3	25	.	.	.	.	Anaplastic Astrocytoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCH2UVW	DMSE3I7	Gemcitabine	Preclinical	2.1	DMJZHT1	Tadalafil	Approved	34	.	.	.	.	Locally Advanced Malignant Neoplasm	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCP8VKF	DMSE3I7	Gemcitabine	Preclinical	2.1	DMR9PCT	VX-970	Phase 1	17	.	.	.	.	Advanced Solid Tumor	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCVBI4G	DMSE3I7	Gemcitabine	Preclinical	2.1	DMFU0JY	TH-302	Phase 2	21	.	.	.	.	Solid Tumor	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCWQDSF	DMSE3I7	Gemcitabine	Preclinical	2.1	DM93VBZ	LY2835219	Approved	34	.	.	.	.	"Carcinoma, Non-small Cell Lung"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCNWB2P	DMSE3I7	Gemcitabine	Preclinical	2.1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	L-1236	6.127	7.546	1.582	8.293
DCFR80Q	DMSE3I7	Gemcitabine	Preclinical	2.1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	T-cell leukemia/lymphoma	ALMANAC Dataset	Investigative	ED-40515	3.468	1.074	1.206	3.126
DC8IYM5	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	0.98	0.14	2.65	3.33
DCERP08	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	26.32	20.07	23.28	29.69
DC06QZF	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	7.64	2.76	5.95	8.44
DCD4O3Y	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	19.32	14.08	14.55	21.68
DCAKIQH	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	16.47	10.86	9.43	13.58
DCOEZF7	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	3.15	0.35	2.35	3.2
DCA5QDO	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	32.43	24.97	12.31	26.88
DC6HX4S	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	12.6	8.68	9.22	14.49
DCMTFK2	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	19.47	18.32	15.46	21.88
DCPFL52	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	9.76	3.99	0.03	6.12
DC4QGK2	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	32.39	28.63	23.67	32.72
DCBRYAF	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	17.15	12.54	12.31	19.53
DC1VG1L	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	32.24	27.26	22.87	32.34
DCK5EPB	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	5.03	0.01	0.55	3.8
DCS1YO6	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	22.5	17.6	8.63	20.59
DCSZ5YI	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	22.25	18.91	11.17	20.75
DCNLK8Z	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	15.97	17.71	16.78	21.49
DCN0PBY	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	6.36	4.8	4.15	9.97
DCPY9O3	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	14.42	6.98	4.57	10.7
DCUQFUZ	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	20.46	20.22	11.61	23.15
DC6DEPA	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	16.94	12.7	9.54	16.17
DC96ZT4	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	12.89	11.39	6.24	13.64
DCMGWJY	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	7.97	6.04	6.55	9.9
DCX2USE	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	17.25	17.13	3.09	19.84
DCU7I8B	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	11.95	8.43	10.62	12.04
DC0PV2N	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	28.43	21.51	20.99	23.7
DCU3BNY	DMSE3I7	Gemcitabine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	7.06	0.87	2.61	3.74
DC2AP8F	DMSE3I7	Gemcitabine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	15.03	4.21	6.54	9.52
DCOWZBF	DMSE3I7	Gemcitabine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	7.02	0.81	1.04	4.76
DC91KLD	DMSE3I7	Gemcitabine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	9.99	9.26	10.04	14.34
DC8FD8N	DMSE3I7	Gemcitabine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	5.49	8.04	3.61	10.18
DCQ8TLR	DMSE3I7	Gemcitabine	Preclinical	2.1	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	1.81	0.32	1.74	2.66
DCX1ABW	DMSE3I7	Gemcitabine	Preclinical	2.1	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	9.62	1.9	2.76	4.56
DCJSNJA	DMSE3I7	Gemcitabine	Preclinical	2.1	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	8.84	6.15	1.96	8.89
DCTQC6C	DMSE3I7	Gemcitabine	Preclinical	2.1	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	6.88	6.73	1.57	9.61
DCZTHLV	DMSE3I7	Gemcitabine	Preclinical	2.1	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	5.59	5.54	2.67	9.9
DC7TP9G	DMSE3I7	Gemcitabine	Preclinical	2.1	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	7.03	2.16	0.66	3.78
DCMJYJF	DMSE3I7	Gemcitabine	Preclinical	2.1	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	0.47	1.27	0.06	4.26
DCNDQON	DMSE3I7	Gemcitabine	Preclinical	2.1	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	0.02	0.81	1.84	4.95
DCU9J4O	DMSE3I7	Gemcitabine	Preclinical	2.1	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	12.88	11.53	12.07	12.66
DCURN6F	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	8.53	4.46	4.79	11.07
DCOUWPX	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	8.69	1.31	5.95	8.6
DC8C3F2	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	11.07	7.3	3.86	11.41
DC144E2	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	4.53	1.78	6.38	9.85
DCAY25C	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	1.54	2.12	4.56	9.19
DC38ZID	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	2.96	2.64	6.31	12.11
DC9FS1E	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	0.38	0.09	3.47	8.17
DCA74AI	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	5.72	5.42	7.05	13.25
DC05ROP	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	11.02	7.65	6.6	14.12
DC8VR38	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	18.37	14	11.59	18.98
DCIO6IT	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	10.05	9.67	13.45	16.3
DCREE44	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	3.79	0.61	4.71	9.03
DCXEANM	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	9.97	1.67	5.94	9.1
DC16KGZ	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	0.41	0.67	1.27	6.66
DC816D2	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	7.68	4.97	3.99	8.37
DC38TIG	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	8.25	9.06	6.95	13.46
DCJDHAH	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	3.43	1.44	3.95	8.33
DCK6IXC	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	1.05	1.05	8.69	10.51
DCA7BPX	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	2.6	1.05	1.12	3.55
DC6SQEX	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	30.82	23.04	27.12	32.17
DCHNTC2	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	13.83	12	11.21	17.52
DCI40AC	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	31.05	23.96	26.14	31.92
DCRAZV5	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	7.97	4.58	10.21	12.93
DCMDXDY	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	1.7	0.08	1.36	4.61
DCEMQ57	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	30.09	24.31	22.34	26.64
DC7A0NJ	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	17.25	11.54	11.64	16.58
DC7HWO9	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	27.83	26.2	25.03	28.28
DCMEAFV	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	43.08	35.42	33.19	43.28
DCG1H5Y	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	31.56	28	4.89	28.13
DC27FNX	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	12.71	7.06	6.87	8.29
DCMSYLS	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	35.74	33.77	32.23	40.99
DC4C4MK	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	9.37	6.6	5.4	10.63
DCM5CK1	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	28.15	23.83	23.01	27.49
DCXV3MY	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	29.71	22.99	20.45	25.13
DCWTVMY	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	24.18	24.04	26.8	30.01
DC8JB9U	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	9.04	4.89	8.78	11.93
DC8DSR2	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	13.73	9.08	8.15	18.27
DCH60LK	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	18.44	18.26	14.91	21.52
DC99DAI	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	20.11	16.66	6.64	19.69
DC6XN1G	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	10.14	9.41	5.42	10.64
DCKYSBK	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	9.6	7.09	2.8	8.66
DC88RCK	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	32.7	29.41	21.99	30.95
DCOA8LO	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	10.96	9.85	4.97	15.62
DCDT16R	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	30.94	23.23	18.44	29.48
DCS6MFI	DMSE3I7	Gemcitabine	Preclinical	2.1	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	2.95	1.07	5.58	7.48
DCYDDHZ	DMSE3I7	Gemcitabine	Preclinical	2.1	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	11.99	9.54	9.68	15.65
DC1AMZW	DMSE3I7	Gemcitabine	Preclinical	2.1	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	10.36	9.72	4.52	11.87
DCS1WU9	DMSE3I7	Gemcitabine	Preclinical	2.1	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	8.36	6.31	7.46	10.66
DCS6EDV	DMSE3I7	Gemcitabine	Preclinical	2.1	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	3.58	0.13	2.05	4.57
DCZNIMO	DMSE3I7	Gemcitabine	Preclinical	2.1	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	9.82	4.02	1.12	7.97
DC8G2TR	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	2.18	0.52	2.3	3.01
DCV8BP8	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	5.8	2.28	7.84	11.06
DCENKJY	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	3.65	0.04	3.44	9.16
DC4O12U	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	10.36	10.44	9.52	19.47
DCIAKW1	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	3	0.12	1.61	9.05
DC3SIAH	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	7.03	6.42	0.33	12.44
DCCD42H	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	14.45	10.49	1.55	14.04
DC2J54O	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	18.36	13.49	14.73	16.75
DC2OECQ	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	4.38	3.88	4.29	9.48
DC18VO9	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	11.64	4.99	78.68	6.26
DCQB3UW	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	13.29	5.79	6.63	12.63
DCVAHN6	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	7.64	7.18	0.49	11.29
DCBWPY0	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	8.5	1.78	4.2	6.04
DCQH8VI	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	10.49	6.23	11.69	14.18
DC91R2U	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	8.39	9.83	1.72	10.8
DC8HVXM	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	6.86	0.85	3.57	6.97
DCORV6W	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	1.64	2.24	2.4	7.3
DC8IUHE	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	7.9	9.33	8.26	13.91
DC9W669	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	4.26	0.36	28.27	1.97
DCP3927	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	7.35	7.02	3.44	10.84
DCCQU7I	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	12.73	9.36	4.47	11.43
DCG1YHA	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	11.06	7.24	6.53	11.06
DCQ4FWJ	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	2.81	7.24	9.05	11.86
DCZAQPJ	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	8.74	1.23	0.95	4.48
DCRFBS7	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	1.88	1.17	0.43	5.94
DCMXYEZ	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	7.06	4.2	4.06	8.92
DCH6LPN	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	6.51	1.81	2.3	4.61
DCICFF1	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	3.37	4.56	1.14	8.85
DC3RJXF	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	4.97	2.94	3.79	8.65
DCWDZPD	DMSE3I7	Gemcitabine	Preclinical	2.1	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	3.28	1.34	0.28	2.7
DCKORVQ	DMSE3I7	Gemcitabine	Preclinical	2.1	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	7.29	6.53	1.11	9.43
DC5CQA5	DMSE3I7	Gemcitabine	Preclinical	2.1	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	2.35	2.85	3.03	5.57
DCC6CDR	DMSE3I7	Gemcitabine	Preclinical	2.1	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	14.17	12.97	8.91	17.75
DC2N4XJ	DMSE3I7	Gemcitabine	Preclinical	2.1	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	0.11	5.27	7.46	8.96
DCYK8UU	DMSE3I7	Gemcitabine	Preclinical	2.1	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	1.69	0.04	0.07	3.79
DCDM9ZK	DMSE3I7	Gemcitabine	Preclinical	2.1	DMIE1WY	AG-881	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	31.954	37.557	7.712	7.011
DC5EGK9	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	5.01	2.8	2.45	6.9
DCQ2RYH	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	11.91	8.72	0.33	10.36
DCZXMQE	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	8.03	2.5	1.55	6.33
DC7O8DW	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	2.7	3.47	0.68	6.76
DCTN1R0	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	10.78	9.7	5.99	13.49
DC3EAKD	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	9.1	7.36	1.8	8.64
DCAV6P0	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	1.86	0.43	0.37	1.78
DCGURKJ	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	4.01	0.29	0.71	3.92
DCEK73S	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	4.42	1.62	1.72	5.18
DCIO9JF	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	8.48	3.53	2.35	6.55
DC0N87Y	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	15.67	7.74	2.91	9.46
DC3VU2U	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	11.11	10.41	7.36	13.17
DC9DXKQ	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	19.97	8.99	1.6	10.06
DC3W4FP	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	8.69	8.97	1.73	11.93
DCU4H8B	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	2.57	3.54	6.33	10.59
DCUX19P	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	2.19	0.93	1.34	6.08
DCYWJ6D	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	12.89	12.19	8.32	17.49
DCM241T	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	15.88	10.96	3.19	15.27
DCDNWTF	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	5.46	4.1	1.71	4.31
DCJC2GY	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	7.18	8.36	10.57	12.05
DCKPL66	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	8.31	1.63	3.27	9.81
DCSWY0M	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	14.07	5.2	0.16	7.62
DC82FHN	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	4.75	5.72	5.78	9.84
DCJ2V12	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	9.33	6.04	2.4	8.13
DC3D3EC	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	6.91	3.24	2.58	4.17
DCPT2PP	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	4.58	0.46	1.23	5.47
DCNQMX3	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	13.11	12.19	11.97	16.38
DCFBC8F	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	4.19	5.05	1.96	6.82
DC808JH	DMSE3I7	Gemcitabine	Preclinical	2.1	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	5.29	3.4	0.37	2.8
DCELYS8	DMSE3I7	Gemcitabine	Preclinical	2.1	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	13.69	4.86	3.82	7.4
DCFYFDC	DMSE3I7	Gemcitabine	Preclinical	2.1	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	3.15	0.38	0.9	1.93
DC54VPW	DMSE3I7	Gemcitabine	Preclinical	2.1	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	8.88	7.78	9.64	16.49
DC0TRQQ	DMSE3I7	Gemcitabine	Preclinical	2.1	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	9.21	5.85	2.24	8.02
DCEQBXF	DMSE3I7	Gemcitabine	Preclinical	2.1	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	10.21	5.67	1.76	6.94
DCB2M9U	DMSE3I7	Gemcitabine	Preclinical	2.1	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	8.03	2.93	1.56	3.32
DCMJ3WQ	DMSE3I7	Gemcitabine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	1.71	0.57	0.17	0.76
DCJV837	DMSE3I7	Gemcitabine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	5.34	4.49	1.18	6.72
DC0GUCT	DMSE3I7	Gemcitabine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	7.3	2.69	1.21	6.69
DC7CF5G	DMSE3I7	Gemcitabine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	11.09	6.45	0.34	7.69
DC60DXZ	DMSE3I7	Gemcitabine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	15.96	8.66	6.1	9.73
DC4TJVI	DMSE3I7	Gemcitabine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	5.83	6.2	0.89	7.14
DCLNW5T	DMSE3I7	Gemcitabine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	23.21	15.91	10.36	15.46
DC7A53A	DMSE3I7	Gemcitabine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	6.62	2.62	0.97	3.9
DC9SL2P	DMSE3I7	Gemcitabine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	6.89	5.46	0.56	7
DCOWWGT	DMSE3I7	Gemcitabine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	2.86	1.02	3.89	4.52
DC8XO78	DMSE3I7	Gemcitabine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	3.29	0.13	1.66	3.66
DCURWEF	DMSE3I7	Gemcitabine	Preclinical	2.1	DMS2Q9G	PHA848125	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	16.288	17.995	5.67	7.933
DCFSTPX	DMSE3I7	Gemcitabine	Preclinical	2.1	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	5.85	5.46	1.73	10.56
DC3H028	DMSE3I7	Gemcitabine	Preclinical	2.1	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	10.67	11.61	2.07	12.09
DCTGYID	DMSE3I7	Gemcitabine	Preclinical	2.1	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	3.08	2.97	3.18	7.86
DCQW9KD	DMSE3I7	Gemcitabine	Preclinical	2.1	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	0.59	0.06	0.69	2.45
DCY79B5	DMSE3I7	Gemcitabine	Preclinical	2.1	DMSLE03	PF-562271	Phase 1	17	.	.	.	.	Diffuse large B cell lymphoma	ALMANAC Dataset	Investigative	TMD8	10.85	13.81	6.12	9.28
DC7QG7G	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	4.02	2.14	0.38	2.81
DCOLOC8	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	9.19	1.98	5.32	5.75
DC6OSVF	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	12.35	5.49	9.21	11.76
DCVNLWT	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	5.48	2.64	2.66	7.31
DCZ9LSZ	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	11.96	3.94	9.08	12
DCUA1HB	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	0.95	2.24	1.8	4.87
DCJ37TA	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	4.56	4.2	7.85	12.37
DCIUG4I	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	14.05	13.6	13.9	18.27
DCPSN36	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	23.36	14.41	13.48	17.5
DC1RE8W	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	17.23	13.4	15.25	17.49
DCUFLM8	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	5.02	9.74	11.81	13.28
DCTJX70	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	10.68	2.86	3.47	6.67
DC9OA2U	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	9.71	5.68	5.03	9.52
DCUZQPU	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	5	2.35	1.65	5.37
DCANSG1	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	3.3	2.67	1.01	6.48
DCNZLDF	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	5.67	2.19	13.99	16.13
DCERTL1	DMSE3I7	Gemcitabine	Preclinical	2.1	DMY8WDB	CB3304	Phase 1/2	19	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	2.71	10.147	5.823	2.434
DCY768L	DMSE3I7	Gemcitabine	Preclinical	2.1	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Diffuse large B cell lymphoma	ALMANAC Dataset	Investigative	TMD8	6.64	6.01	8.65	12.03
DCHQIT0	DMSE3I7	Gemcitabine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	6.81	3.5	5.59	11.9
DCR050M	DMSE3I7	Gemcitabine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	6.66	3.37	7.23	7.84
DC2FE0G	DMSE3I7	Gemcitabine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	6.69	5.29	6.1	10.91
DCNUBF5	DMSE3I7	Gemcitabine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	5.56	5.47	12.98	16.69
DCS0YL8	DMSE3I7	Gemcitabine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	3.78	3.45	5.48	11.1
DCERVFT	DMSE3I7	Gemcitabine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	17.18	15.19	0.02	17.65
DCEG5PH	DMSE3I7	Gemcitabine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	2.99	1.15	1.74	2.24
DCXI49M	DMSE3I7	Gemcitabine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	6.06	3.81	4.12	9.16
DCBC4H2	DMSE3I7	Gemcitabine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	6.17	2.75	0.91	6.77
DC398ED	DMSE3I7	Gemcitabine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.13	0.25	2.64	5.87
DCK4MOL	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.84	2.55	10.66	14.83
DCE2GMW	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	14.21	10.75	19.96	23.18
DCN8J7R	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	3.19	2.99	1.32	4.22
DCK39BP	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	27.14	22.2	19.73	28.34
DCK8FDZ	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	13.19	6.1	16.23	17.43
DC4C9RD	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	17.51	17	12.64	21.95
DCBMUKR	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	25.8	16.49	19.55	25.12
DC7ZVP8	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	7.45	5.36	1.45	9.38
DCVVQP7	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	20.28	20.25	7.19	25.77
DC0VRBS	DMSE3I7	Gemcitabine	Preclinical	2.1	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	10.79	6.96	18.62	18.83
DCX9C06	DMSE3I7	Gemcitabine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	0.04	1.9	17.2	17.51
DCLSOJT	DMSE3I7	Gemcitabine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.34	0.18	5.69	10.05
DC77MHE	DMSE3I7	Gemcitabine	Preclinical	2.1	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	6.87	5.52	1.52	8.79
DCN53RS	DMSE3I7	Gemcitabine	Preclinical	2.1	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.67	3.61	0.18	11.77
DCW1PJB	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.62	1.31	9.31	12.52
DCR8JM3	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.19	0.01	1.83	6.84
DC4QGMK	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	4.46	4.94	2.11	9.59
DCWSH77	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.87	0.75	12.07	15.26
DC9SRIU	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	11.09	3.51	0.35	9.36
DCJ475K	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.89	6.2	8.91	12.04
DCZFPUN	DMSE3I7	Gemcitabine	Preclinical	2.1	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.02	0.79	10.35	10.57
DC1R3A5	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	9.47	3.62	6.47	9.93
DCJ19QK	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	7.97	8.78	19.25	11.71
DC5U3WA	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	25.25	20.62	14.34	27.47
DCINX8I	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	13.15	10.22	17.93	22.09
DCZIMSV	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	4.82	3.83	7.03	11.68
DCI1KBE	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	10.85	5.17	1.25	10.81
DCIMMMU	DMSE3I7	Gemcitabine	Preclinical	2.1	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	12.48	8.48	20.22	20.38
DC9XM8T	DMSE3I7	Gemcitabine	Preclinical	2.1	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	13.32	13.21	14.11	15.93
DC0CTFQ	DMSE3I7	Gemcitabine	Preclinical	2.1	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	7.28	4.19	14.48	14.6
DC5J4Q9	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	6.72	0.19	0.85	8.77
DCMWEZ8	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.77	0.41	5.51	11.8
DCFGUY8	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	0.86	0.72	11.8	15.85
DC1OXSA	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.06	2.63	7.94	8.91
DCCCRVE	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	12.84	6.58	4.28	11.07
DC7WKBF	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	7.57	7.29	0.98	11.52
DCVGXBU	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.12	1.75	6.54	9.91
DC0RDBN	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.95	4.44	1.01	7.58
DC2CYQX	DMSE3I7	Gemcitabine	Preclinical	2.1	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.14	1.09	15.89	15.99
DCEYB2J	DMSE3I7	Gemcitabine	Preclinical	2.1	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	8.46	8.89	1.75	12.54
DCOI063	DMSE3I7	Gemcitabine	Preclinical	2.1	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.76	8.64	5.47	17.09
DC4W6G2	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.81	4.16	0.42	7.39
DCMXAYU	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.7	9.99	11.86	16.43
DCIO9VN	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.6	4.52	8.65	12.7
DCPM4HL	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	3.47	5.84	13.59	14.72
DCDYA05	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.74	1	5.1	8.99
DCIKB66	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	8.27	7.27	4.92	12.16
DC9ELYV	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.81	1.6	7.18	11.32
DCW9446	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	19.99	11.16	4.87	14.43
DCV2RIU	DMSE3I7	Gemcitabine	Preclinical	2.1	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	14.72	14.98	20.28	22.6
DC1RSSH	DMSE3I7	Gemcitabine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	7.5	5.98	3.76	7.23
DCGQED7	DMSE3I7	Gemcitabine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.48	2.73	0.17	5.24
DC9NM8W	DMSE3I7	Gemcitabine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.47	1.81	2.99	5.23
DC3UJFN	DMSE3I7	Gemcitabine	Preclinical	2.1	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	2.34	0.64	13.67	14.8
DC66O4S	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.71	3.31	7.65	11.61
DCH9HXV	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.59	4.97	7.87	11.68
DCTUPR4	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.41	0.15	1.46	6.62
DCXYQO8	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.74	2.68	0.75	7.7
DCCWN1J	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.74	3.79	7.19	10.26
DCRUE7G	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	9.66	5.52	0.84	8.98
DCCB7TE	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.59	7.48	18.79	21.79
DCIV6TH	DMSE3I7	Gemcitabine	Preclinical	2.1	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.88	1.79	13.78	14.77
DC85HEO	DMSE3I7	Gemcitabine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.48	1.99	2.76	7.46
DC8CLAK	DMSE3I7	Gemcitabine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	14.31	11.06	1.09	14.52
DCUM3F2	DMSE3I7	Gemcitabine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.1	3.41	0.75	9.71
DCHTSP4	DMSE3I7	Gemcitabine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	8.93	5.43	0.03	7.92
DCEWIV9	DMPDW6T	Epirubicin	Approved	34	DMQNWRD	Oxaliplatin	Approved	34	DMTS85L	Capecitabine	.	.	Gastric Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC3EN7P	DMPDW6T	Epirubicin	Approved	34	DMQNWRD	Oxaliplatin	Approved	34	DMTS85L	Capecitabine	.	.	Gastric Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC7PRHQ	DMPDW6T	Epirubicin	Approved	34	DMQNWRD	Oxaliplatin	Approved	34	DMTS85L	Capecitabine	.	.	Esophageal Neoplasms	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCDNBR7	DMPDW6T	Epirubicin	Approved	34	DMQNWRD	Oxaliplatin	Approved	34	DMTS85L	Capecitabine	.	.	CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCRNVB3	DMPDW6T	Epirubicin	Approved	34	DMQNWRD	Oxaliplatin	Approved	34	DMTS85L	Capecitabine	.	.	Gastro Oesophageal Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC7H2DD	DMPDW6T	Epirubicin	Approved	34	DMQNWRD	Oxaliplatin	Approved	34	DMTA5OE	Azacitidine	DMTS85L	Capecitabine	Esophageal Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC6CN26	DMPDW6T	Epirubicin	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	28.94	29.14	4.95	9.64
DC9LSPA	DMPDW6T	Epirubicin	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.45	4.37	4.01	2.78
DCCTR3D	DMPDW6T	Epirubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.01	3.64	2.15	2.33
DCUYAUC	DMPDW6T	Epirubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	9.85	7.87	2.06	4.39
DCXP62Q	DMPDW6T	Epirubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.38	3.4	0.68	0.22
DCCPOOX	DMPDW6T	Epirubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	7.38	11.77	5.29	4.54
DC713GC	DMPDW6T	Epirubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	16.97	16.34	18.42	19.19
DCA3Y4Z	DMPDW6T	Epirubicin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.22	9.82	8.06	7.41
DCCQ53E	DMPDW6T	Epirubicin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.44	3.58	2.1	1.76
DCJNTWP	DMPDW6T	Epirubicin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.36	7.12	5.31	5.75
DCQNNWN	DMPDW6T	Epirubicin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.45	9.03	6.55	5.76
DCQEO3O	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	12.57	17.43	18.81	18.78
DCH6SXM	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.75	2.27	2.91	3.22
DCL30CY	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	2.69	8.56	12.97	13.64
DCH4EDP	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	6.71	7.74	7.93	8.03
DCY6J8K	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	23.28	23.03	23.01	25.82
DCBA2L2	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	13.06	16.07	6.48	13.37
DCHDQX3	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	14.74	18.09	12.68	18.77
DCGOPVG	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	10	11.66	15.09	16.96
DC6Y91Y	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.29	8.26	5.95	9.84
DCGLSN4	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	7.12	10.01	11.65	11.72
DCSE9H5	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	9.25	13.29	17.57	18.14
DCOLS8Y	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.56	10.14	8.29	11.61
DCLKWG5	DMPDW6T	Epirubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	5.55	7.78	4.32	5.67
DC5P7FW	DMPDW6T	Epirubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.09	8.97	12.76	13.7
DCYHN9Z	DMPDW6T	Epirubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.23	8.62	6.89	8.32
DCGT9GO	DMPDW6T	Epirubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.56	12.32	4.49	4.14
DCC555H	DMPDW6T	Epirubicin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.39	7.9	7.03	7.38
DC7ZCA6	DMPDW6T	Epirubicin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.25	6.51	2.6	3.3
DC4GEG7	DMPDW6T	Epirubicin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.07	3.1	4.11	3.86
DCPREJV	DMPDW6T	Epirubicin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.6	9.56	7.05	5.66
DC3SEXX	DMPDW6T	Epirubicin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.27	4.16	3.64	2.37
DCQ7GLF	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	35.49	33.23	8.3	10.92
DCWP350	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	40.95	42.8	43.43	43.58
DC26GXQ	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	41.61	38.42	26.21	41.58
DCDLIAR	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	7.65	12.35	12.85	12.84
DCQAOT7	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	25.42	28.63	27.13	27.19
DCZBEFV	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	11.23	17.56	18.16	17.82
DCBGDTQ	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	26.44	27.66	29.54	29.56
DCKYWVV	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	24.22	25.15	24.89	24.72
DCBR0Z6	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	8.47	12.44	10.05	8.96
DC8TM70	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	7.46	9.47	7.69	7.66
DC2MP86	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	14.04	15.93	17.32	16.92
DC8J7WK	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.39	8.59	9.25	9.25
DCQD6D2	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	8.67	17.78	14.24	14.97
DCNBB97	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	5.1	14.5	15.74	15.56
DCOWLTC	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.46	5.16	6.23	6.28
DCF4VCT	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	13.92	18.08	18.99	18.78
DCY5RT6	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	37.09	36.15	26.99	28.68
DCEOI7Y	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	6.36	13	14.03	13.49
DC8FKKH	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.08	7.04	8.1	8.02
DCT94J0	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.76	6.97	9.67	9.59
DCFY8CM	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.4	7.55	7.02	7.66
DCR5W5M	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	5.11	10.7	7.89	12.26
DC2VOX3	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	3.25	7.74	3.3	4.32
DC130R4	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.09	9.63	9.43	8.17
DC6E1RE	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	5.79	10.06	7.3	7.08
DCHUA1O	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.37	5.73	7.11	7.07
DCWSUIY	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.04	3.13	4.87	5.85
DC3SSV2	DMPDW6T	Epirubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.03	6.35	2.92	2.48
DCDF8EJ	DMPDW6T	Epirubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.1	3.87	2.24	2.81
DCOR3HF	DMPDW6T	Epirubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	10.37	10.73	15.95	16.31
DCN2TNA	DMPDW6T	Epirubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	5.15	9.66	9.97	11.05
DCQ8QQ0	DMPDW6T	Epirubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	10.8	16.17	5.64	4.95
DCGX5L0	DMPDW6T	Epirubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.95	8.75	9.23	9.78
DC57WDH	DMPDW6T	Epirubicin	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.26	4.04	3.99	4.56
DCEUXGM	DMPDW6T	Epirubicin	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	7.27	10.13	13.74	13.89
DCY2O35	DMPDW6T	Epirubicin	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.24	2.98	2.59	4.07
DC68VB0	DMPDW6T	Epirubicin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	8.3	9.33	6.51	8.16
DC3OQEU	DMPDW6T	Epirubicin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.4	5.56	2.25	3.39
DC0JQYI	DMPDW6T	Epirubicin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.21	5.48	1.92	1.31
DCICQPU	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	22.87	25.84	2.06	2.58
DCUDR0G	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.34	10.87	5.54	10.29
DCDFIII	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.93	5.43	7.4	7.81
DC4JXSH	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.7	4.48	3.11	2.89
DCMM5WM	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	5.09	9.62	7.21	7.93
DCACLXV	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.86	12.42	10.07	11.67
DC1T0BM	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.37	3.79	2.11	4.04
DCHM4KR	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	21.06	22.45	23.16	23.89
DCRVR5W	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.1	5.45	2.39	3.32
DC7TQES	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	7.44	9.15	10.75	11.47
DCW1FE0	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	5.44	7.71	0.45	5.98
DCOMZ6X	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	12.16	17.27	9.3	7.24
DCIBMUY	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.85	6.04	6.03	5.97
DC0HA8Q	DMPDW6T	Epirubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.63	7.58	5.1	5.76
DCR3RWS	DMPDW6T	Epirubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.85	5.43	3.08	3.84
DCJVUR0	DMPDW6T	Epirubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.81	11.05	7.48	6.92
DCMHZKG	DMPDW6T	Epirubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.71	7.04	4.79	4.12
DCFVGR5	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	37.44	38.61	16.41	12.7
DCY21CB	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.21	7.91	6.56	8.64
DCV1ZVB	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.41	6.61	7.29	7.31
DCLIIXU	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	14.91	12.97	6.83	10.39
DC5XQX3	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	11.17	11.27	15.89	15.1
DCMDNSH	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	4.91	5.11	3.94	4.42
DC3I2P9	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	6.01	10.18	11.82	12.48
DCMLO4I	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.21	10.03	7.75	5.94
DC23Y76	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	6.55	9.37	0.41	10.68
DCNB1E1	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.92	14.25	5.13	2.22
DC16W88	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.14	7.15	5.73	5.28
DCGSB47	DMPDW6T	Epirubicin	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.15	1.67	0.94	1.36
DCXJMTQ	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	17	22.01	23.42	22.13
DC1XM5T	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	22.4	19.81	18.9	21.96
DCOOD4P	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	24.7	25.64	24.36	24.35
DC6GGW1	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.73	9.02	9.57	9.05
DCTJQJ3	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	12.81	17.18	19.22	18.88
DCGJFPH	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	15.48	16.19	15.58	16
DCZXV64	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	26.05	20.06	20.25	20.02
DCWDMWY	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	17.37	18.34	14.98	14.98
DCQ8BYR	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	17.89	14.16	17.72	17.88
DC3NJFE	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	15.76	18.51	20.2	19.81
DC4HPZP	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.27	7.32	4.52	4.52
DC5STQ8	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	13.5	14.8	15.67	15.62
DCZXQ2Y	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	13.93	15.45	17.22	17.3
DCM5QGF	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	37.77	33.09	26.99	25.62
DCHWXFQ	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.17	3.58	5.18	5.02
DC4WAR4	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	11.69	13.61	16.15	16.37
DCXR942	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.14	9.3	2.43	2.92
DCQ9I1C	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.85	10.26	4.53	4.78
DCRGVK6	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.34	9.14	5.7	7.84
DCSZOHW	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	6.14	8.4	13.36	13.47
DC06YTC	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	10.13	12.71	4.79	4.68
DCVD9SH	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.02	6.47	6.1	5.58
DCJL2RX	DMPDW6T	Epirubicin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	5.41	7.12	2.6	5.93
DCND261	DMPDW6T	Epirubicin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	9.38	8.82	4.08	9.07
DCN1Q9Q	DMPDW6T	Epirubicin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	8.71	7.18	9.71	11.59
DC12B8P	DMPDW6T	Epirubicin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	2.28	3.62	2.02	3.73
DC9OVS2	DMPDW6T	Epirubicin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.94	5.54	3.75	6.97
DCKTWBY	DMPDW6T	Epirubicin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.58	7.15	8.47	9.88
DCDFK7K	DMPDW6T	Epirubicin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	5.81	7.56	5.97	8.59
DCMQ7B1	DMPDW6T	Epirubicin	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.08	8.34	9.03	9.33
DCMPZ0G	DMPDW6T	Epirubicin	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	34.59	31.02	7.86	7.08
DCWPOH4	DMPDW6T	Epirubicin	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	2.34	5.75	8.12	8.41
DCQZQ2S	DMPDW6T	Epirubicin	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	12.59	16.14	18.76	18.94
DC6OOIS	DMPDW6T	Epirubicin	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	5.62	11.07	14.49	14.84
DCSD7GF	DMPDW6T	Epirubicin	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	11.39	15.64	14.8	15.73
DCD3HXM	DMPDW6T	Epirubicin	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	8.85	12.17	5.76	13.62
DC5OBCV	DMPDW6T	Epirubicin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	5.63	6.73	7.05	12.01
DCP6T5N	DMPDW6T	Epirubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.74	1.92	0.47	0.34
DCQ58D9	DMPDW6T	Epirubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.77	6.14	5.39	5.96
DC3GDFQ	DMPDW6T	Epirubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.19	7.51	7.1	6.66
DC54SDH	DMPDW6T	Epirubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.25	8.25	7.9	9.18
DCJNIMS	DMPDW6T	Epirubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	4.03	5.34	6.14	6.15
DC45E43	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	12.77	17.7	17.1	18.03
DCYDRAP	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.82	7.88	7.5	8.33
DCCR3AD	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.45	4.07	2.79	2.65
DCT23YI	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	7.14	11.21	12.92	12.6
DCQ7X6W	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.85	7.6	6.86	7.31
DC698QN	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.6	7.95	4.54	4.54
DC1NSND	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.52	6.9	4.54	4.01
DCK6EEZ	DMPDW6T	Epirubicin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.54	8	5.1	5.1
DCPS529	DMPDW6T	Epirubicin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	8.19	10.21	14.44	14.36
DC681NW	DMPDW6T	Epirubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	13.44	16.04	16.58	17.84
DC5GJ53	DMPDW6T	Epirubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.98	8.3	5.9	7.01
DCOETNI	DMPDW6T	Epirubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.49	2.94	2.31	0.92
DC1YDML	DMPDW6T	Epirubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	43.4	39.7	32.11	32.43
DCTMHOE	DMPDW6T	Epirubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.13	4.29	2.02	3.13
DC6QYDA	DMPDW6T	Epirubicin	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.25	4.05	3.07	4.32
DCRBVMU	DMPDW6T	Epirubicin	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.4	4.65	0.22	1.68
DCO8EMY	DMPDW6T	Epirubicin	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	5.48	6.56	11.56	12.35
DCFMNZ7	DMPDW6T	Epirubicin	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.56	1.98	5.01	5.62
DCUFO0R	DMPDW6T	Epirubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	18.03	16.51	5.4	15.97
DC70BUX	DMPDW6T	Epirubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.89	7.08	3.28	9.49
DC5BLYB	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.69	10.26	9.75	9.9
DCPKQK2	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.5	4.7	4.65	5.22
DCNP7SE	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.58	5.79	4.53	4.08
DCFB4XA	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.75	8.46	4.45	4.73
DC765AH	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	9.19	13.4	12.84	13.11
DCXYC66	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.19	5.39	0.63	0.63
DCFBPQ4	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.65	7.8	6.89	7.24
DCRA6JR	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.47	7.18	6.42	6.34
DC5JB0J	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.41	6.67	7.79	8.36
DCK3QFE	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.63	5.79	2.91	1.94
DCR5BN8	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.17	4.57	4.93	5.51
DCA35T3	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	10.08	17.5	10.55	7.22
DCUZ1XD	DMPDW6T	Epirubicin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	10.7	13.87	14.45	14.83
DC4OY03	DMPDW6T	Epirubicin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	6.47	7.33	1.57	7.15
DC4C3M0	DMPDW6T	Epirubicin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	4.27	9.15	7.22	7.34
DCU3Y8P	DMPDW6T	Epirubicin	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.68	1.14	1.01	5.23
DCEIUUR	DMPDW6T	Epirubicin	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	3.24	3.94	0.54	5.17
DC88J3K	DMPDW6T	Epirubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.35	2.7	2.7	6.69
DCEZF6A	DMPDW6T	Epirubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	25.67	25.15	11.98	27.52
DCTRRTW	DMPDW6T	Epirubicin	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.73	7.07	7.43	7.14
DCXHEYT	DMPDW6T	Epirubicin	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.97	4.44	7.31	6.95
DCGWXTI	DMPDW6T	Epirubicin	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.41	1.64	0.04	0.27
DCVMN6Z	DMPDW6T	Epirubicin	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.06	3.95	0.47	0.47
DC44MPA	DMPDW6T	Epirubicin	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	6.98	9.31	8.13	5.56
DCVXTNE	DMPDW6T	Epirubicin	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.57	3.68	1.12	1.17
DC6L1AF	DMPDW6T	Epirubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.26	2.31	0.76	0.59
DCP4CF9	DMPDW6T	Epirubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	11.3	11.92	12.83	13.42
DC1M0E6	DMPDW6T	Epirubicin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	39.59	41.86	19.24	26.08
DCDVFYZ	DMPDW6T	Epirubicin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.37	5.02	6.6	6.05
DCWBAM2	DMPDW6T	Epirubicin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.25	3.53	4.08	4.24
DCRUQ04	DMPDW6T	Epirubicin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.8	5.57	9.71	9.78
DCWUH8A	DMPDW6T	Epirubicin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.03	4.7	11.24	11.3
DCSTMJI	DMPDW6T	Epirubicin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	4.74	7.85	8.79	9.45
DC33ABV	DMPDW6T	Epirubicin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.81	7.08	0.79	0.37
DCKYM26	DMPDW6T	Epirubicin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	2.53	5.98	8.38	8.45
DCOKQUD	DMPDW6T	Epirubicin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2	6.42	5.34	6.5
DC273K8	DMPDW6T	Epirubicin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	5.83	7.71	10.92	12.55
DCCXO47	DMPDW6T	Epirubicin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	10.48	13.29	9.45	15.09
DCHYXOW	DMPDW6T	Epirubicin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	24.23	23.18	1.76	25.39
DCN0O2C	DMPDW6T	Epirubicin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	16.15	15.37	9.19	11.69
DC8S1V4	DMPDW6T	Epirubicin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	8.55	10.54	14.59	14.64
DC13ZJD	DMPDW6T	Epirubicin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.59	5.29	6.97	7.35
DC1IA7L	DMPDW6T	Epirubicin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	22.21	28.15	28.43	28.56
DCOYF5D	DMPDW6T	Epirubicin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	9.18	8.67	4.69	9.84
DC5A2LG	DMPDW6T	Epirubicin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.75	6.16	5.65	8.05
DCOY9NK	DMPDW6T	Epirubicin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	3.73	3.57	1.04	4.18
DCD41R1	DMPDW6T	Epirubicin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.64	2.81	5.17	6.79
DCL4CJO	DMPDW6T	Epirubicin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.38	2.95	3.85	5.02
DCWPZCF	DMPDW6T	Epirubicin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	3.36	5.31	2.36	5.93
DCTDVGI	DMPDW6T	Epirubicin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.87	6.29	7	8.12
DCE6DIK	DMPDW6T	Epirubicin	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	11.5	10.48	9.16	15.67
DCX6A57	DMPDW6T	Epirubicin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	7.08	11.01	5.24	10.23
DCODT33	DMPDW6T	Epirubicin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	12.6	14.99	14.89	15.68
DCJ3N74	DMPDW6T	Epirubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.38	8	11.78	11.63
DCNCA6D	DMPDW6T	Epirubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.66	4.75	0.78	1.29
DCEB43V	DMPDW6T	Epirubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	6.36	10.94	3.63	8.29
DC86P9G	DMPDW6T	Epirubicin	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	10.88	11.97	7.69	13.16
DCU56D5	DMPDW6T	Epirubicin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	6.45	6.45	10.05	10.12
DCMFL7Y	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.77	1.53	3.62	3.66
DCWPWDO	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.25	3.08	2.41	2.38
DCFXP8Z	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.87	1.58	8.31	8.92
DCXPV6K	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	10.61	11.25	11.89	11.98
DCQ01PE	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.81	9.89	2.55	2.05
DCCUUCL	DMPDW6T	Epirubicin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	9.92	11.53	7.59	7.28
DCBAXMD	DMPDW6T	Epirubicin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	16.42	18.65	9.95	12.79
DCLXZCK	DMPDW6T	Epirubicin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.1	9.45	4	6.28
DC4PGXS	DMPDW6T	Epirubicin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	4.69	9.43	2.77	2.99
DCXR7T1	DMPDW6T	Epirubicin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	16.53	12.21	1.1	11.21
DCC5DAG	DMPDW6T	Epirubicin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	5	5.79	8.39	11.55
DCTQS27	DMPDW6T	Epirubicin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.95	0.8	3.62	4.45
DCHVUCA	DMPDW6T	Epirubicin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.76	3.97	6.19	6.87
DC02C0S	DMPDW6T	Epirubicin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	22.91	22.28	14.83	24.65
DCHXC2I	DMPDW6T	Epirubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	9.3	9.51	0.23	10.94
DCPNIBM	DMPDW6T	Epirubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.27	3.98	1.11	0.46
DC9HD8S	DMPDW6T	Epirubicin	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.54	7.58	7.82	8.05
DCINRQ2	DMPDW6T	Epirubicin	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.32	1.88	3.29	2.92
DCB27HE	DMPDW6T	Epirubicin	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.64	2.19	3.47	3.45
DCWLZVN	DMPDW6T	Epirubicin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	4.88	6.96	4.14	7.14
DCCTSYB	DMPDW6T	Epirubicin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.38	7.55	5.71	6.83
DCC5KYA	DMPDW6T	Epirubicin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.23	6.35	10.91	11.75
DCJ7EDC	DMPDW6T	Epirubicin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	3.11	3.98	2.41	5.86
DCE8M4I	DMPDW6T	Epirubicin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	9.54	8.51	9.11	10.4
DCWTWSB	DMPDW6T	Epirubicin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.7	7.95	5.67	8.01
DCL8ZOM	DMPDW6T	Epirubicin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.6	4.28	3.21	6.06
DC5YUHK	DMPDW6T	Epirubicin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.52	8.42	0.57	1.12
DC0V13Q	DMPDW6T	Epirubicin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	15.44	15.62	13.84	18.5
DCBASI9	DMPDW6T	Epirubicin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	8.68	4.81	1.53	6.11
DC8HZFB	DMPDW6T	Epirubicin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	5.4	4.63	0.81	4.5
DCTRP8V	DMPDW6T	Epirubicin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	7.27	6.33	9.96	11.97
DCWRLF5	DMPDW6T	Epirubicin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.52	3.79	4.74	6.49
DC5YBE5	DMPDW6T	Epirubicin	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	8.24	6.55	3.3	11.26
DCWH56J	DMPDW6T	Epirubicin	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	10.57	9.87	6.83	12.54
DCIDHLH	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.74	2.05	5.06	4.84
DC93PE3	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.97	5.84	3.97	3.13
DCR5054	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.55	5.79	5.52	6.98
DCVU9EX	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	3.65	5.51	2.01	2.01
DCUBM19	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.28	3.4	3	2.82
DCSKAYD	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.71	2.01	4.28	5.81
DCLBAZL	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	7.5	11.64	13.71	13.71
DC98RZE	DMPDW6T	Epirubicin	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	16.4	15.8	18.91	20.56
DC38THL	DMPDW6T	Epirubicin	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.99	6.89	7.97	9.04
DCHSKMU	DMPDW6T	Epirubicin	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	7.05	9.24	1.44	0.57
DC71BO8	DMPDW6T	Epirubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.08	8.57	2.37	8.17
DCTP4FF	DMPDW6T	Epirubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	10.15	11.26	13.72	13.83
DCLXMBZ	DMPDW6T	Epirubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0	3.38	0.1	5.93
DCBCFMO	DMPDW6T	Epirubicin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	5.24	6.42	5.5	5.15
DCKZDSG	DMPDW6T	Epirubicin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.01	2.68	0.59	0.74
DCAHPGN	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.19	6.81	3.82	4.63
DCYT3WH	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.75	5.11	3.82	3.35
DCNZ6XD	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.03	4.58	3.61	4.3
DC4TGFI	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.77	6.02	1.8	5.46
DCWUG1R	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.64	6.61	6.42	6.42
DCHTSZD	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.28	11.47	8.1	7.92
DCPEMOD	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.68	7.8	5.71	6.52
DC29C7Q	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.5	10.73	7.99	7.87
DC19CJ0	DMPDW6T	Epirubicin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.37	10.55	8.14	9.48
DC2GSOI	DMPDW6T	Epirubicin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.79	2.74	3.93	4.07
DCB46RW	DMPDW6T	Epirubicin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	7.31	7.07	10.1	11.04
DCVNP7T	DMPDW6T	Epirubicin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.29	5.68	3.53	7.82
DCFSEOG	DMPDW6T	Epirubicin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	7.63	7.64	4.3	8.88
DCEX5VS	DMPDW6T	Epirubicin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.85	4.81	4.16	4.46
DCAOSPF	DMPDW6T	Epirubicin	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	4.71	7.45	7.23	7.57
DCOO8OO	DMPDW6T	Epirubicin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	7.34	8.23	9.58	10.46
DC5CD0U	DMPDW6T	Epirubicin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	15.19	17.72	16.58	17.79
DCVQ45F	DMPDW6T	Epirubicin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	6	5.94	9.56	10.62
DCYMAWR	DMPDW6T	Epirubicin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	4.2	10.3	12.64	12.28
DC1NAA6	DMPDW6T	Epirubicin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.12	7.28	5.3	9.18
DCZ0740	DMPDW6T	Epirubicin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	12.5	16.44	14.67	19.29
DCHV530	DMPDW6T	Epirubicin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.09	5.92	4.28	3.97
DC7AE2Z	DMPDW6T	Epirubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.44	4.13	4.37	3.96
DC0UCGB	DMPDW6T	Epirubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.66	5.57	2.78	2.37
DCVTSF8	DMPDW6T	Epirubicin	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.77	5.04	5.57	7.2
DCF4PJC	DMPDW6T	Epirubicin	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	10.55	10.29	10.73	12.64
DCXXNIG	DMPDW6T	Epirubicin	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.95	7.22	3.75	7.04
DCFV2CW	DMPDW6T	Epirubicin	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.1	7.79	3.43	4.58
DCUP9H4	DMPDW6T	Epirubicin	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.52	2.2	4.53	5.35
DCKXFLQ	DMPDW6T	Epirubicin	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	18.54	20.34	22.45	23.25
DCHBOX4	DMPDW6T	Epirubicin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	3.94	14.94	14.69	17.07
DCPOUQX	DMPDW6T	Epirubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.07	5.87	4.83	4.93
DCZIXL2	DMPDW6T	Epirubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	37.54	35.16	38.71	39.45
DCTTA88	DMPDW6T	Epirubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	12.17	15.85	7.05	18.39
DC04J7X	DMPDW6T	Epirubicin	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.47	4.01	0.2	0.63
DC9R313	DMPDW6T	Epirubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.32	9.77	5.96	6.92
DCPV0K8	DMPDW6T	Epirubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.97	13.03	10.82	10.52
DCH6ISR	DMPDW6T	Epirubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.22	8.95	8.3	8.83
DC2IGA0	DMPDW6T	Epirubicin	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.89	8.93	5.01	5.83
DCIBMQY	DMPDW6T	Epirubicin	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.94	8.35	0.95	0.87
DC44OOK	DMPDW6T	Epirubicin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.64	2.86	2.02	4.41
DCDGKF3	DMPDW6T	Epirubicin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.56	7.94	5.17	5.22
DCHCHRW	DMPDW6T	Epirubicin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	12.67	14.3	12.14	12.14
DCQRV6O	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	13.51	15.19	6.77	16.87
DCP3ZUK	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.93	9.85	5.67	13.01
DC3SX6G	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	9.46	12.88	7.22	10.18
DC0STK3	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	12.73	14.05	1.43	6.97
DCW54JG	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.3	14.6	10.9	16.1
DC8O5KI	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	10.31	17.93	10.26	15.86
DCGKPSU	DMPDW6T	Epirubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.53	7.31	1.15	0.95
DC4QV1F	DMPDW6T	Epirubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.73	8.35	5.17	4.7
DCQQDH3	DMPDW6T	Epirubicin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.76	6.4	3.11	2.89
DCM4RB6	DMPDW6T	Epirubicin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.47	3.6	0.92	0.81
DC0R8OZ	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	19.26	22.17	21.83	21.82
DCVMQM9	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	8.96	12.69	12.82	12.89
DCMILK1	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	18.27	20.64	18.56	17.7
DCL7GRW	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	31.32	32.61	29.01	24.78
DCYT2JY	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	18.71	20.89	21.05	21.06
DCPRQ28	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.48	12.39	10.78	11.48
DCWLAGV	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	14.23	20.84	17.58	18.2
DCF9HP1	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.13	4.87	2.01	1.81
DC4JW8M	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.53	5.15	3.09	3.93
DCMCWRL	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.13	9.1	9.58	10.3
DCUMOMN	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.25	8.21	0.39	0.36
DCW9DPF	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	9.83	17.33	15.03	13.67
DCID271	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.66	7.77	8.48	8.89
DCTNT0E	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.71	8.92	6.08	6.29
DC32774	DMPDW6T	Epirubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.46	5.82	0.26	6.05
DCU1YK4	DMPDW6T	Epirubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	11.04	8.76	4.81	3.94
DC0X8CP	DMPDW6T	Epirubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.49	7.97	5.29	4.55
DC9F3UD	DMPDW6T	Epirubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	5.05	11.81	11.03	13.32
DCFDQ9I	DMPDW6T	Epirubicin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.01	9.4	5.3	6.11
DCG0369	DMPDW6T	Epirubicin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.49	3.56	0.97	0.9
DCJUC5E	DMPDW6T	Epirubicin	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.61	7.21	7.04	7.83
DC8UW7M	DMPDW6T	Epirubicin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.87	5.07	0.82	1.51
DC6M4RI	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.31	9.18	8.79	10.08
DC1OYZV	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.28	10.1	1.71	11.19
DC0LB7N	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.91	9.59	5.45	6.93
DCR994M	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.47	8.91	1.99	1.65
DC1R0YC	DMPDW6T	Epirubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.74	8.1	4.8	5.56
DCBPK86	DMPDW6T	Epirubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.63	7.59	4.67	4.67
DCE6CTN	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.56	11.36	11.4	11.14
DC84ZWP	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.47	9.22	6.24	5.86
DC1J7S5	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.62	11.73	8.29	9.38
DCGQ9FN	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	12.6	15.35	5.15	5.08
DCZO7BY	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	11.28	11.57	9.81	8.37
DC1UDPO	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.53	11.77	8.54	9.62
DCQVOJZ	DMPDW6T	Epirubicin	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.32	4.85	6.79	6.82
DCO4U18	DMPDW6T	Epirubicin	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.7	3.36	2.62	0.05
DC3MMPT	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	4.62	10.13	12.65	12.04
DCFHZG2	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	24.26	21.13	17.88	18.22
DCS4SOO	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	37.07	32.92	27.1	24.99
DCV7W7E	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	34.23	32.7	30.12	30.06
DC2H8LI	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	22.02	22.72	21.89	21.88
DCBXL01	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.89	8.51	1.93	5.69
DC9VP31	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.28	5.61	4.65	5
DCQPFDR	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.03	6.85	0.24	0.24
DCB1CPE	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.62	6.11	1.24	0.97
DC80TY3	DMPDW6T	Epirubicin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.49	9.18	2.45	10.13
DC2GF04	DMPDW6T	Epirubicin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	7.82	11.59	9.71	13.83
DCV6TKC	DMPDW6T	Epirubicin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	9.26	12.49	4.51	9.93
DC5UHDR	DMPDW6T	Epirubicin	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.21	13.57	6.05	4.78
DC9US4R	DMPDW6T	Epirubicin	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.41	8.65	1.01	7.2
DC0SO6P	DMPDW6T	Epirubicin	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.2	5.42	1.68	2.78
DCUEVC5	DMPDW6T	Epirubicin	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	9.56	13.45	2.49	10.99
DC2CKQQ	DMPDW6T	Epirubicin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.44	15.3	8.71	11.96
DC9WIVA	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.99	9.74	8.51	9.33
DCRIOGO	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.92	10.03	7.2	7.12
DCBCMPC	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.98	9.76	7.57	6.85
DCUYYD8	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.46	5.77	3.14	3.14
DCUB46B	DMPDW6T	Epirubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	9.29	9.35	2.14	1.8
DC3SQX1	DMPDW6T	Epirubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.84	11.2	9.14	7.86
DC1YBDK	DMPDW6T	Epirubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.69	7.39	4.78	4.78
DC851HP	DMPDW6T	Epirubicin	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	4.22	8.75	9.75	11.22
DCNBMU2	DMPDW6T	Epirubicin	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.24	13.18	10.08	10.51
DCZ3HIC	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.7	7.34	6.01	6.42
DC9WT79	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.49	6.96	8.27	8.81
DCJYQ34	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.24	8.13	2.04	2.8
DCZAIG7	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	10.02	15.69	8.93	8.93
DC1KGEM	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.91	6.24	3.62	3.21
DC3MYDU	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.14	10.07	10.14	11.83
DCH94DJ	DMPDW6T	Epirubicin	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	12.78	12.78	10.8	12.64
DCJI1QX	DMPDW6T	Epirubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.76	6.96	5.99	9.18
DC71ZJU	DMPDW6T	Epirubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	16.49	17.85	5.21	16.17
DCPYJ3T	DMPDW6T	Epirubicin	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.12	4.28	3.08	1.48
DC6U98C	DMPDW6T	Epirubicin	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.58	16.42	13.56	12.4
DCQERBC	DMPDW6T	Epirubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.29	2.69	2.35	2.51
DC9WQ4R	DMPDW6T	Epirubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.48	11.43	8.13	8.63
DC2ODP5	DMPDW6T	Epirubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.42	14.34	12.07	11.14
DCSBEIK	DMPDW6T	Epirubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.91	7.67	5.3	5.03
DCHDUAC	DMPDW6T	Epirubicin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.14	10.15	3.16	8.13
DCFTIYS	DMPDW6T	Epirubicin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.83	8.18	3.28	3.28
DCHRSPZ	DMPDW6T	Epirubicin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	7.39	9.94	4.28	11.36
DCQR7YQ	DMPDW6T	Epirubicin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.04	3.96	0.86	5.1
DC7DECE	DMPDW6T	Epirubicin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	10.66	16.79	17.53	18.97
DCO1KGX	DMPDW6T	Epirubicin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	9.93	9.94	6.29	7.84
DCYVVQI	DMPDW6T	Epirubicin	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	14.29	13.8	3.14	15.91
DCPIKW2	DMPDW6T	Epirubicin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.98	10.16	6.54	5.71
DCWP62Q	DMPDW6T	Epirubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	13.17	11.42	7.79	11.54
DCIIE1W	DMPDW6T	Epirubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.65	6.11	3.45	3.45
DCF2WAF	DMPDW6T	Epirubicin	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.26	6.92	1.41	7.73
DC7318N	DMPDW6T	Epirubicin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.24	4.52	2.08	2.9
DCKWUAU	DMPDW6T	Epirubicin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.44	10.45	2.55	1.43
DC62KEV	DMPDW6T	Epirubicin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.74	11.67	9.39	8.26
DC3665Q	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.54	4.95	5.97	5.95
DCW3078	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.82	12.34	4.28	4.03
DCOYKJ6	DMPDW6T	Epirubicin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.97	4.25	0.25	1.6
DC64ZEF	DMPDW6T	Epirubicin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.11	7.2	2.52	1.83
DCX0AH2	DMPDW6T	Epirubicin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	9.24	10.96	0.13	12.48
DCQYJR1	DMPDW6T	Epirubicin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	4.05	8.52	3.07	11.87
DCLSNJB	DMPDW6T	Epirubicin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.62	3.79	1.14	6.03
DCT9VGM	DMPDW6T	Epirubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.11	7.54	5.26	4.25
DCR1AT8	DMPDW6T	Epirubicin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.93	7.45	2.23	5.04
DCO4FUQ	DMPDW6T	Epirubicin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.64	10.21	8.21	10.15
DCH2ZSS	DMPDW6T	Epirubicin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	14.46	18.08	9.57	15.4
DC6CFTQ	DMPDW6T	Epirubicin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.6	3.57	0.7	0.7
DC88HXA	DMPDW6T	Epirubicin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.76	4.8	1.63	5.55
DCK65DA	DMPDW6T	Epirubicin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.34	10.56	8.33	7.87
DC27WT2	DMPDW6T	Epirubicin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.35	4.68	2.61	6.15
DC9YDRI	DMPDW6T	Epirubicin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.49	6.8	4.67	9.36
DCNJM9M	DMPDW6T	Epirubicin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	9.41	11.32	6.67	9.58
DCD3IYU	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.59	2.1	0.85	1.61
DC9Z25M	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	10.71	9.75	7.09	7.09
DC9ED2P	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	9.78	12.34	10.04	8.71
DC4I39Q	DMPDW6T	Epirubicin	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.41	8.56	4.55	5.6
DC46DPE	DMPDW6T	Epirubicin	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.57	7.68	4.94	4.09
DCNDEW8	DMPDW6T	Epirubicin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.81	15.04	8.52	8.25
DCC1U8B	DMPDW6T	Epirubicin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.56	3.58	1.58	0.16
DCIFIFH	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	5.85	10.79	8.87	9.66
DC30ATM	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.94	4.83	2.16	1.88
DC47Z24	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.57	12.99	3.2	4.87
DCEXUTT	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.35	7.08	5	4.06
DCOR888	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.17	4.11	1.48	1.48
DCEQL87	DMPDW6T	Epirubicin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.54	5.77	2.81	2.26
DCYDDCR	DMPDW6T	Epirubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.43	4.19	1.59	1.6
DCOAH4G	DMPDW6T	Epirubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.24	10.04	6.17	7.29
DC9FQ72	DMPDW6T	Epirubicin	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.89	7.25	2.79	4.69
DCDR9DM	DMPDW6T	Epirubicin	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	6.46	8.48	7.59	9
DCM0W2T	DMPDW6T	Epirubicin	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.58	11.05	4.68	8.88
DC28FAJ	DMPDW6T	Epirubicin	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.98	13.63	11.98	13.69
DCF7JPA	DMPDW6T	Epirubicin	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.93	11.46	2.8	9.04
DCXVUKE	DMPDW6T	Epirubicin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.68	5.84	2.85	2.19
DCSZ9UG	DMPDW6T	Epirubicin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.18	7.6	5.46	3.8
DC37TWH	DMPDW6T	Epirubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.67	5.71	5.53	5.46
DCKAVI2	DMPDW6T	Epirubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.15	2.68	3.52	3.9
DCCP669	DMPDW6T	Epirubicin	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.89	3.77	0.16	0.82
DCSRTVC	DMPDW6T	Epirubicin	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.39	4.66	0.81	1.63
DCVQA2X	DMPDW6T	Epirubicin	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.87	3.63	0.57	6.03
DC33YRT	DMPDW6T	Epirubicin	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.48	5.03	2.75	1.77
DCU7G9D	DMPDW6T	Epirubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.61	7.99	4.55	4.01
DCAD8B0	DMPDW6T	Epirubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.24	6.28	3.39	3.36
DCW4260	DMPDW6T	Epirubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	3.74	9.66	6.74	6.02
DCSFQ2N	DMPDW6T	Epirubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.06	5.51	4.89	5.93
DCS772O	DMPDW6T	Epirubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.2	2.41	0.55	0.95
DCOV7T7	DMPDW6T	Epirubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.97	3.68	0.17	0.58
DCBJC6X	DMPDW6T	Epirubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0	5.86	8.21	8.87
DCXURD1	DMPDW6T	Epirubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.94	6.45	4.92	4.5
DC7XJKS	DMPDW6T	Epirubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.83	7.3	6.9	7.59
DCCR3KI	DMPDW6T	Epirubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.5	7.61	5.46	5.9
DCHYX1Q	DMPDW6T	Epirubicin	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.77	4.43	1.07	0.42
DCM4ULB	DMPDW6T	Epirubicin	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.2	2.51	1.47	1.77
DCRM4HG	DMPDW6T	Epirubicin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.42	7.56	6.77	6.77
DCYX838	DMPDW6T	Epirubicin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.81	7.27	3.84	3.35
DC1O3DY	DMPDW6T	Epirubicin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.38	2.8	2.02	2.33
DC56NNV	DMPDW6T	Epirubicin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.25	3.61	3.11	2.62
DCNU8VE	DMPDW6T	Epirubicin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.34	6.27	0.97	2.67
DCTWIRF	DMPDW6T	Epirubicin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.55	6.13	5.84	6
DCC6BHG	DMPDW6T	Epirubicin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.61	2.95	5.13	5.14
DCA93RG	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	8.75	8.88	0.33	8.92
DCEAFVV	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	7.26	7.51	6.35	7.97
DC4AAYP	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.91	6.8	6.48	7.49
DCSNWQ2	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	6.66	8.76	1.78	7.98
DCV0B5O	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	9.57	13.75	6.7	10.1
DC4YVAG	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	12.98	13.12	6.09	10.04
DC9UFD0	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	13.67	12.85	0.56	10.94
DCJXG4I	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	13.21	16.44	8.57	13.84
DCBDT3T	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	11.81	11.77	11.17	12.42
DC76Y0N	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	8.83	14	14.69	15.8
DCCEQMI	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.83	3.12	1.09	4.88
DCBTSLH	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	9.76	12.7	5.79	12.93
DCDBPLA	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	20.42	19.03	12.79	18.64
DCZVB4U	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.71	11.53	1.13	8.33
DC4FQG9	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	14.09	14.65	11.15	14.91
DCTLOEV	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	9.37	14.44	12.72	16.07
DCYBXDG	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	14.12	14.98	0.11	13.56
DCBUDQ1	DMPDW6T	Epirubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	7.44	11.68	10.99	14.76
DCMMTBJ	DMPDW6T	Epirubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.01	5.11	1.05	0.55
DC1GCN6	DMPDW6T	Epirubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.12	5.75	0	4.52
DC6LUMS	DMPDW6T	Epirubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.55	8.82	6.92	6.04
DCMCNP2	DMPDW6T	Epirubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.77	6.27	5.19	3.08
DCTB8V4	DMPDW6T	Epirubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	16.41	16.88	11.19	10.5
DC1X09O	DMPDW6T	Epirubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.83	4.73	0.11	0.08
DCU4U2O	DMPDW6T	Epirubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.85	4.63	1.2	2.72
DC5I6J1	DMPDW6T	Epirubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.83	8.4	2.7	9.11
DC8UW91	DMPDW6T	Epirubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.42	5.96	4.8	5.12
DC8U3OK	DMPDW6T	Epirubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.16	12.37	6.1	6.1
DCT65LB	DMPDW6T	Epirubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.48	6.9	4.28	4.07
DCC67VS	DMPDW6T	Epirubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.84	4.57	2.15	3.32
DC2HZPI	DMPDW6T	Epirubicin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.06	6.46	3.08	3.06
DC21K16	DMPDW6T	Epirubicin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.86	4.72	2.08	1.75
DCFUUU0	DMPDW6T	Epirubicin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.77	12.58	9.77	9.53
DCACU1H	DMPDW6T	Epirubicin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.93	5.49	3.24	1.67
DCB19MS	DMPDW6T	Epirubicin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.46	4	0.03	2.24
DCS4NFC	DMPDW6T	Epirubicin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.56	7.15	2.42	3.6
DC75D1Y	DMPDW6T	Epirubicin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.07	2.14	1.79	1.22
DC8KU8I	DMPDW6T	Epirubicin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.67	4.87	2.94	2.53
DC3UL71	DMPDW6T	Epirubicin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	7.16	4.9	3.92	3.41
DCCKOFG	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	7.5	14.3	13.37	12.7
DCFXN48	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	22.28	24.91	24.44	23.68
DCIDM5C	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	9.58	8.53	7.94	7.1
DC9697Y	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.49	11.89	11.59	11.19
DCXFA05	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	22.86	19.12	7.09	7.61
DCOUTL7	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	4.9	4.28	2.02	1.76
DCUCLXL	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	33.65	32.49	31.62	30.51
DC5O446	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	36.58	32.67	22.95	22.36
DC5J0ER	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	10.79	17.75	17.27	14.37
DCKCDE7	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	8.54	13.82	8.25	9.9
DCPUX87	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	8.81	11.4	8.19	8.99
DC9FHYE	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	9.05	12.08	9.81	9.14
DCXFM4T	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	16.64	21.63	21.52	21.55
DCH7TG6	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	16.14	19.41	17.38	17.36
DCJR6IP	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	14.46	15.91	13.19	12.73
DCBQOER	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	12.79	20.12	19.91	18.52
DC8L40Q	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	6.96	12.02	12.18	12.47
DCS8S1F	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	7.12	12.59	13.69	13.47
DC4GP1E	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	13.02	14.36	14.32	13.98
DC6LXI5	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	6.05	15.22	16.16	16.12
DCXO6JQ	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	12.61	18.44	18.69	18.53
DCGWQC2	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.99	15.3	14.87	14.92
DCNAG66	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.27	4.24	4.22	3.26
DCQIE9K	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	9.06	15.09	5.88	10.3
DCKJM2P	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	7.84	15.6	13.47	13.46
DCYJNC8	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.28	10.3	9.58	9.63
DCXZL50	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	5.56	12.46	12.9	12.41
DC9YGY6	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.83	12.85	11.2	10.57
DC96JS4	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.02	13.68	13.83	13.57
DC6M8HP	DMPDW6T	Epirubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	5.38	11.68	12.14	11.57
DC21SFI	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.49	3.66	3.7	3.11
DCNM0WO	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.48	7.71	4.92	3.51
DCPW6SL	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.35	6.24	3.65	2.85
DC0A5D5	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.58	3.83	1.93	0.28
DC6V772	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.79	6.29	4.88	3.19
DC3UVSE	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.94	5.69	2.96	5.16
DCOOZ90	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.74	5.94	5.53	6.04
DCJYP37	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.79	6.57	4.5	6.88
DCYPERS	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.43	3.71	2.38	2.46
DC7U70M	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.51	9.08	4.8	6.14
DCO5JLC	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.81	5.15	4.71	4.27
DCINDT9	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.32	6.64	7	7.1
DCEGT94	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.17	3.37	4.58	4.61
DCCIA4X	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.61	8.56	5.64	6.6
DCRBIWD	DMPDW6T	Epirubicin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.72	10.15	11.78	11.2
DC88SAQ	DMPDW6T	Epirubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4	2.06	1.66	0.14
DCXI5IP	DMPDW6T	Epirubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.23	6.85	1.5	1.14
DCEOB69	DMPDW6T	Epirubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	7.44	10.15	4.81	4.24
DCP1M5U	DMPDW6T	Epirubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.69	7.32	5.54	6.32
DC6A6EP	DMPDW6T	Epirubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.82	6.26	3.37	3.17
DCHED89	DMPDW6T	Epirubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.41	10.32	9.3	9.28
DC46TBK	DMPDW6T	Epirubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.51	4.69	0.41	0.47
DCYD3FY	DMPDW6T	Epirubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	13.73	12.76	2.99	12.36
DC097BP	DMPDW6T	Epirubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	4.57	8.92	10.21	9.43
DCU33Y2	DMPDW6T	Epirubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	20.44	21.7	21.04	22.25
DC3BTUQ	DMPDW6T	Epirubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.5	10.92	8.49	12.41
DCC20ZT	DMPDW6T	Epirubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.79	4.66	3.51	4.31
DCS8X50	DMPDW6T	Epirubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.44	2.42	0.07	3.73
DCXOM1B	DMPDW6T	Epirubicin	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.25	3.51	3.13	2.68
DCN744Q	DMPDW6T	Epirubicin	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.46	3.32	2.83	2.28
DCJEQRG	DMPDW6T	Epirubicin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.89	2.81	1.02	0.53
DCIAOL6	DMPDW6T	Epirubicin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.95	4.09	0.97	0.72
DC0D43T	DMPDW6T	Epirubicin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	5.22	5.72	3.89	2.72
DC0WB3Q	DMPDW6T	Epirubicin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.09	2.92	3.16	3.09
DCGJEEH	DMPDW6T	Epirubicin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.65	6.27	4.3	2.75
DCPPMLQ	DMPDW6T	Epirubicin	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.57	6.51	2.03	0.97
DCGJT3I	DMPDW6T	Epirubicin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.26	6.32	4.82	5.71
DCZ0JLN	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.34	5.98	0.65	3.67
DCIGY64	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.8	9.14	5.29	6.85
DCFHAE3	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.83	8.15	2.56	5.89
DCNNEMO	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	9.11	15.12	7.41	10.59
DCHJM4G	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.17	11.8	4.45	3.74
DC5EERQ	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.63	6.43	2.95	2.3
DCT77DF	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.07	11.65	8.38	7.35
DCLUXMS	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.83	7.38	0.37	0.12
DC857WK	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	10.25	5.75	1.05	2.68
DC050O3	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.2	10.18	7.38	10.51
DC2DO38	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.14	7.02	4.4	5.97
DC9XHBT	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.56	4.49	0.98	3.64
DCSOR6K	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.13	7.82	7.32	9.33
DC6FE0Q	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.84	10.44	9.08	7.91
DCPMVJ3	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.46	7.77	2.62	2.55
DCH9UHL	DMPDW6T	Epirubicin	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.28	5.66	2.47	3.49
DCOV6KY	DMPDW6T	Epirubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.87	4.36	3.98	2.68
DC90KMW	DMPDW6T	Epirubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.33	2.46	1.63	1.8
DC6QYWN	DMPDW6T	Epirubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.49	2.93	2.22	1.76
DCLLB4H	DMPDW6T	Epirubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	3.91	6.52	1.64	1.5
DCY519Z	DMPDW6T	Epirubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	5.97	1.3	0.57	0.15
DCO0N59	DMPDW6T	Epirubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.27	1.78	1.83	1.62
DC39CLU	DMPDW6T	Epirubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.59	2.58	1.78	1.27
DCT6ZO4	DMPDW6T	Epirubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.36	4.75	3.74	2.61
DCNF5AN	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.34	3.53	2.04	0.7
DCKGOTS	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.56	6.36	5.94	5.6
DC0GSVV	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.71	7.39	0.39	1.05
DCUYKWT	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	5.97	9.44	9.11	8.87
DCGK8GQ	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	10.75	6.76	7.09	3.99
DCZ70G5	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.7	7.74	2.69	1.72
DC292NL	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.65	6.1	2.84	3.46
DC6HE7H	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.48	5.46	4.97	4.79
DCXJOGL	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	9.91	9.91	12.09	3.76
DCM88G8	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	10.31	14.79	16.46	16.54
DCMRG5B	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.24	9.96	7.44	7.44
DCWVMLO	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	13.92	14.23	5.52	16.72
DCMLCJE	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.08	11.54	8.72	6.23
DCQDCZ6	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.85	10.45	4.96	4.33
DC65UAX	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.13	8.68	5.73	7.19
DCNT563	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.95	9.1	7.18	6.91
DC5DQQI	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.92	5.8	1.28	3.77
DCFUFG3	DMPDW6T	Epirubicin	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.68	6.72	3.81	3.9
DCHOGJ6	DMPDW6T	Epirubicin	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.61	3.95	0.09	0.09
DCYYID2	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.7	6.24	4.7	4.75
DCUJ7XR	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	10.38	3.95	1.25	1
DCYEWYY	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.54	3.85	1.18	1.77
DCHEJ7P	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	20.24	22.73	19.41	19.38
DCU9PTZ	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	27.03	26.33	22.41	22.41
DCC58MZ	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	21.51	22.04	20.05	20.05
DCQGSCU	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	25.44	24.44	24.96	24.66
DCN5R9V	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.78	5.6	2.45	2.45
DC8GQNX	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.68	7.19	6.77	6.56
DCMSPFZ	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	5.64	10.61	10	9.89
DCK73UI	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	3.55	9.6	9.93	9.89
DC1OVDB	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	10.21	13.11	13.19	13.21
DCXRK7Y	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	13.09	16.7	19.8	18.52
DCOER6L	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	6.61	13.63	14.45	14.48
DCHXUCR	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.94	5.2	1.65	1.71
DCRYPZD	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	6.79	13.38	12.41	11.41
DC8X13Q	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	11	16.06	14.17	14.17
DCIIJJU	DMPDW6T	Epirubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.89	10.72	11.54	11.33
DCPERFJ	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.15	3.12	1.89	1.44
DCKSHZ3	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	5.29	15.3	11.16	10.92
DCSP3LJ	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.35	3.71	2.27	0.25
DC5HPSB	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.46	7.26	3.38	3.21
DCM3X3V	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	14.78	5.46	2.55	1.79
DCXS4LX	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.78	4.25	2.2	1.16
DC5X111	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	4.49	7.29	4.2	4.07
DC6PCLO	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.12	5.26	1.45	1.52
DCQNE9P	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.07	8.12	6.2	4.37
DC6IPWP	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.14	6.4	1.4	0.52
DCZF40V	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.4	4.12	3.19	2.86
DCERP20	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	5.02	2.91	3.39	3
DCDG5HP	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.81	3.61	1.55	2.15
DCXIFZT	DMPDW6T	Epirubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.6	5.34	6.63	4.97
DCFZ9O2	DMPDW6T	Epirubicin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.89	6.23	0.59	4.53
DC48K9P	DMPDW6T	Epirubicin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.45	2.19	0.13	2.52
DCYAJ2B	DMPDW6T	Epirubicin	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.96	3.39	2.59	2.08
DCMOY52	DMPDW6T	Epirubicin	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.73	3.1	1.52	0.71
DCY16WX	DMPDW6T	Epirubicin	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	5	6.94	3.06	1.95
DCU38LP	DMPDW6T	Epirubicin	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.32	4.02	4.52	1.48
DCSDCOA	DMPDW6T	Epirubicin	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.15	7.67	6.1	5.51
DC0BC7O	DMPDW6T	Epirubicin	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	3.77	8.26	6.79	4.94
DCZCUTV	DMPDW6T	Epirubicin	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.84	6.46	7.58	7.76
DCSCXLM	DMPDW6T	Epirubicin	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.63	2.63	2.29	0.07
DC2T7YQ	DMPDW6T	Epirubicin	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.38	2.96	1.59	3.1
DCZGKK3	DMPDW6T	Epirubicin	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.61	13.18	11.32	8.98
DCPSWIZ	DMPDW6T	Epirubicin	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.47	3.76	1.88	1.6
DC4V8VU	DMPDW6T	Epirubicin	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.78	4.1	0.83	1.99
DCRNGYH	DMPDW6T	Epirubicin	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	9.65	9.98	1.23	12.31
DCE5X13	DMPDW6T	Epirubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.39	2	0.19	0.01
DCA7CN4	DMPDW6T	Epirubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.4	5.99	4.12	4.12
DC6MFOD	DMPDW6T	Epirubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.14	1.35	0.76	0.31
DCDG6SR	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.07	9.85	8.39	8.36
DCZDGFH	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.34	4.8	4.05	2.94
DCDN7IS	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.73	2.9	0.63	2.68
DC122YH	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	11.49	11.35	10.35	10.6
DCV2ALU	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.31	8.73	6.06	6.06
DC0ZUPZ	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.11	1.78	0.65	1.92
DC3IDWP	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.76	6.55	4.13	4.54
DCWETAX	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	6.48	4.45	3.6	2.66
DCGHDII	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.18	3.84	3.23	2.86
DC6RZ6D	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.05	6.8	7.02	7.06
DC32I6O	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.19	3.78	3.42	3.57
DCKC3E6	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.86	7.64	5.21	3.11
DCD8F5I	DMPDW6T	Epirubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.05	4.79	2.84	2.91
DCERQ1P	DMPDW6T	Epirubicin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.31	7.66	3.37	2.38
DC4O45C	DMPDW6T	Epirubicin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.23	3.15	3.21	2.66
DC8Y1MR	DMPDW6T	Epirubicin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	8.52	4.68	1.85	2.09
DCR0O1K	DMPDW6T	Epirubicin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.09	1.65	1	0.53
DCZW7U1	DMPDW6T	Epirubicin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.26	3.84	2.77	2.4
DC6L4YH	DMPDW6T	Epirubicin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.22	3.75	2.4	1.21
DC8W80C	DMPDW6T	Epirubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	7.04	7.83	7.14	6.97
DCXBPVP	DMPDW6T	Epirubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.91	13.6	10.65	10.44
DC8N4FO	DMPDW6T	Epirubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.39	3.2	1.28	1.05
DCK86Q5	DMPDW6T	Epirubicin	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	4.38	6.89	1.61	5.37
DC15D1Q	DMPDW6T	Epirubicin	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.73	6.59	1.85	4.5
DC0JLOQ	DMPDW6T	Epirubicin	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.11	5.54	3.62	3.59
DC02E2A	DMPDW6T	Epirubicin	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.54	9.87	2.98	10.55
DCUL30L	DMPDW6T	Epirubicin	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.15	3.88	2.05	2.4
DCX8DG2	DMPDW6T	Epirubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	16.08	15.22	12.65	15.06
DCJ0Q14	DMPDW6T	Epirubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	7.82	9.23	2.01	9.43
DCD6AAT	DMPDW6T	Epirubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.84	12.67	2.03	11.07
DCFNDE5	DMPDW6T	Epirubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	14.3	12.23	0.97	12.39
DCT5MUT	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.89	5.47	3.33	2.81
DCOYBGJ	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.53	5.66	5.52	4.2
DCTRI17	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.86	5.23	2.04	1.95
DCRN778	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.32	5.8	4.36	2.95
DCKB5F4	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.7	8.75	6.08	5.61
DC8MML8	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.16	5.97	2.05	1.48
DCVLP0T	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.47	10.08	6.64	6.51
DCR0NA6	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.77	10.73	6.12	6.12
DCQ2G7Q	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.47	2.38	0.48	0.37
DC4U5YT	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.53	4.27	1.09	0.51
DCP6HMO	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	4.45	8.66	2.84	5.47
DCQY5WX	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	3.04	5.14	1.34	0.18
DCTTKHL	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	10.56	17.98	14.53	14.84
DC9BX5L	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.88	9.24	9.39	9.11
DC7C8D9	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.5	1.56	0.06	0.19
DCO2Y8M	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	5.22	9	5.55	3.87
DCBJJ7J	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.01	6.37	6.75	7.53
DCB7XBE	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.57	6.7	4.78	4.58
DCX76WP	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.55	8.83	9.27	9.15
DCOGO2L	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.22	3.41	1.75	0.39
DCIGTYZ	DMPDW6T	Epirubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	6.24	10.92	6.47	7.34
DCEZ6GD	DMPDW6T	Epirubicin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	19.99	17.93	14.27	17.03
DCEJXAM	DMPDW6T	Epirubicin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	18.74	14.18	7.93	11.2
DC4UQ6H	DMPDW6T	Epirubicin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.79	8.6	4.58	8.32
DCLII6Z	DMPDW6T	Epirubicin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.11	8.23	1.89	6.65
DCH44GA	DMPDW6T	Epirubicin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.63	8.86	7.35	7.54
DC1C048	DMPDW6T	Epirubicin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	7.98	10.46	6.76	11.26
DCBYC3V	DMPDW6T	Epirubicin	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	9.63	11.62	11.11	13.01
DCY8TBC	DMPDW6T	Epirubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.76	3.84	2.92	4.22
DCYOHV0	DMPDW6T	Epirubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.67	1.7	1.9	3.96
DCZYKOF	DMPDW6T	Epirubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.44	8.59	3.7	10.73
DCQDL57	DMPDW6T	Epirubicin	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.22	8.35	5.53	4.96
DC6X7KU	DMPDW6T	Epirubicin	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.86	7.58	4.45	2.76
DCDHQCI	DMPDW6T	Epirubicin	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	2.63	5.28	2.45	1.81
DCKH9C1	DMPDW6T	Epirubicin	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.17	5.87	5.18	5.46
DC1XUKC	DMPDW6T	Epirubicin	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.72	3.32	2.06	1.71
DCUWSXO	DMPDW6T	Epirubicin	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.53	2.57	2.2	1.23
DCWT86F	DMPDW6T	Epirubicin	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.38	5.43	6.85	6.59
DCT3PPQ	DMPDW6T	Epirubicin	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.72	4.36	1.73	2.44
DC9YIGW	DMPDW6T	Epirubicin	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.67	3.45	2.17	4.65
DCAB0ST	DMPDW6T	Epirubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.04	3.79	2.57	1.61
DCH59H8	DMPDW6T	Epirubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.04	5	3.02	2.46
DCQ8OVP	DMPDW6T	Epirubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.03	8.24	6.91	7.9
DCIMYU7	DMPDW6T	Epirubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.2	2.57	1.95	0.71
DCEZON7	DMPDW6T	Epirubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	13.6	15.62	17.27	17.28
DCA6TRX	DMPDW6T	Epirubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.86	7.8	6.25	5.84
DCACHRW	DMPDW6T	Epirubicin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.22	4.1	0.68	0.39
DCS5CYD	DMPDW6T	Epirubicin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.18	4.58	2.34	2.34
DC5NMBO	DMPDW6T	Epirubicin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.35	2.93	2.13	0.59
DCIQLM3	DMPDW6T	Epirubicin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.97	6.82	4.61	7.14
DCQDMVT	DMPDW6T	Epirubicin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.43	7.13	9.6	10.15
DCRN0KO	DMPDW6T	Epirubicin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.15	6.35	4.99	4.44
DC3GDEX	DMPDW6T	Epirubicin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.99	8.1	8.05	9.25
DCAWD9H	DMPDW6T	Epirubicin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	9.34	12.63	4.49	10.11
DC9JM6C	DMPDW6T	Epirubicin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	22.76	21.79	15.71	21.22
DCK7YDA	DMPDW6T	Epirubicin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.7	4.3	2.4	1.3
DCSTN8L	DMPDW6T	Epirubicin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	8.59	12.77	10.9	11.73
DC6E73P	DMPDW6T	Epirubicin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	7.37	7.63	4.65	6.46
DCRF6HT	DMPDW6T	Epirubicin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.97	4.39	2.06	4.66
DC0JGWX	DMPDW6T	Epirubicin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.36	6.02	3.52	4.28
DCHTFOC	DMPDW6T	Epirubicin	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	8.3	9.45	0.94	9.06
DCUSWYN	DMPDW6T	Epirubicin	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.97	4.65	2.58	4.97
DC8XYPO	DMPDW6T	Epirubicin	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	12.47	13.93	1.32	14.4
DCTTTH1	DMPDW6T	Epirubicin	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	13.59	9.46	7.14	10.64
DC1J7IN	DMPDW6T	Epirubicin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.97	7.26	3.35	2.44
DCYHAKF	DMPDW6T	Epirubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	14.66	5.66	4.67	2.38
DCYB0Z8	DMPDW6T	Epirubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.08	4.79	3.39	1.65
DCBJNFO	DMPDW6T	Epirubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.49	11.01	7.17	7.66
DC70QNA	DMPDW6T	Epirubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.95	5.15	2.52	0.89
DCZO2JV	DMPDW6T	Epirubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.64	6.56	2.35	2.97
DCIYWUD	DMPDW6T	Epirubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0	1.02	0.58	0.23
DCULZI6	DMPDW6T	Epirubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.99	2.64	2.45	3
DC6AP70	DMPDW6T	Epirubicin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.91	5.23	2.25	2.25
DCAVX31	DMPDW6T	Epirubicin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.19	7.28	6.04	7.94
DCBIUQ5	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.63	8.94	7.17	6.23
DC3CAOE	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.71	4.5	1.33	0.56
DCZL9WH	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.59	9.42	8.58	7.96
DCRVIAO	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.1	5.71	3.02	2.37
DC56A9F	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.85	7.77	4.12	2.66
DCMK2TT	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	5.57	8.68	1.93	1.93
DCI7DPI	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.75	2.47	0.67	0.02
DCZWPQ1	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	8.07	13.01	11.61	11.75
DCJ9UNR	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.17	3.06	2.7	1.04
DCBJKIC	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.09	3.83	0.34	0.6
DCZUYZF	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.51	7.55	6.85	6.18
DCNDBC7	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.28	7.96	4.32	4.3
DCGA63F	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.56	2.9	1.68	2.63
DCI5VOA	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.48	4.18	2.25	1.72
DCU5HQA	DMPDW6T	Epirubicin	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.48	7.04	4.63	4.69
DCEDXWV	DMPDW6T	Epirubicin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.17	7.01	5.19	5.51
DCFQQFU	DMPDW6T	Epirubicin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.48	14.54	11.36	11.36
DC0HR48	DMPDW6T	Epirubicin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.06	5.65	5.32	5.37
DCM2QUW	DMPDW6T	Epirubicin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.69	4.64	4.1	3.42
DCUK4GM	DMPDW6T	Epirubicin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.59	5.04	3.23	1.37
DCR1EHD	DMPDW6T	Epirubicin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.35	13.16	11.66	11.76
DCXCF0W	DMPDW6T	Epirubicin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.7	3.61	1.92	4.03
DCH32OK	DMPDW6T	Epirubicin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.77	6.13	5.64	6.63
DCEPBXU	DMPDW6T	Epirubicin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.27	5.19	3.07	6.35
DCNSYU1	DMPDW6T	Epirubicin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	4.34	7.3	4.82	9.53
DCIR627	DMPDW6T	Epirubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.76	4.32	1.25	0.73
DC9DWMV	DMPDW6T	Epirubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.97	4.09	0.77	0.77
DCXAQ0T	DMPDW6T	Epirubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.22	4.56	1.25	0.63
DCL1YI3	DMPDW6T	Epirubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.62	4.24	2.04	2.11
DCSXSW9	DMPDW6T	Epirubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.64	8.31	10.53	10.33
DCT6D8O	DMPDW6T	Epirubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.2	3.39	1.45	1.34
DC5A6FA	DMPDW6T	Epirubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.69	12.35	8.89	8.89
DCY5I4O	DMPDW6T	Epirubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.91	2.6	0.73	0.73
DC8SIII	DMPDW6T	Epirubicin	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.91	3.24	2.3	3.64
DCZU0NJ	DMPDW6T	Epirubicin	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.41	7.4	5.4	8.22
DC413VI	DMPDW6T	Epirubicin	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.81	0.75	1.24	1.14
DC6FVQG	DMPDW6T	Epirubicin	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.25	5.91	6.94	7.5
DCS89RG	DMPDW6T	Epirubicin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	1.52	10.73	3.94	5.31
DC2VB5X	DMPDW6T	Epirubicin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	12.51	7.83	3.32	4.49
DC9JR94	DMPDW6T	Epirubicin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.62	8.74	3.3	5.94
DC0HHDE	DMPDW6T	Epirubicin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	11.45	14.28	10.23	12.67
DC36PYE	DMPDW6T	Epirubicin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.78	12.16	4.6	10.35
DCF7527	DMPDW6T	Epirubicin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.53	5.92	6.32	6.07
DCR9JRU	DMPDW6T	Epirubicin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.24	7.25	1.05	4.05
DC927ZQ	DMPDW6T	Epirubicin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.55	0.21	1.07	0.71
DCM7XTC	DMPDW6T	Epirubicin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.56	3.3	1.08	0.19
DCCJ93M	DMPDW6T	Epirubicin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	7.86	4.58	4.19	0.59
DCJU8PU	DMPDW6T	Epirubicin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.96	8.4	5.8	5.39
DCOWB0E	DMPDW6T	Epirubicin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.91	4.39	1.29	2.33
DCGP8SW	DMPDW6T	Epirubicin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.68	6.06	5.79	6.02
DC79HZD	DMPDW6T	Epirubicin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.53	4.2	3.38	2.6
DCNYBQ9	DMPDW6T	Epirubicin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.44	3.83	3.82	3.66
DCZDZG2	DMPDW6T	Epirubicin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.48	5.36	3.48	3.48
DCJ8V4D	DMPDW6T	Epirubicin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.62	1.37	0.53	1.94
DCR550O	DMPDW6T	Epirubicin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.27	6.13	4.84	7.94
DC4ZRNL	DMPDW6T	Epirubicin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.98	9.83	5.26	8.48
DCH5P6P	DMPDW6T	Epirubicin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.2	2.58	1.75	2.79
DCX26MK	DMPDW6T	Epirubicin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.04	6.46	8.46	9.93
DCITL8F	DMPDW6T	Epirubicin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.62	2.41	0.06	3.42
DCLBW0L	DMPDW6T	Epirubicin	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	16.48	16.14	12.72	16.66
DCRXC65	DMPDW6T	Epirubicin	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	22.4	12.81	10.3	13.14
DCT4R29	DMPDW6T	Epirubicin	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.91	2.95	0.23	4.94
DC4TLNV	DMPDW6T	Epirubicin	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	25.93	19.82	18.4	21.11
DC2JSC2	DMPDW6T	Epirubicin	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	9.13	12.51	4.41	13.91
DC1CZNP	DMPDW6T	Epirubicin	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	16.7	16.78	4.75	19.36
DCSORVJ	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.88	6.24	4.69	3.57
DCIJF0J	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.26	5.42	3.49	1.95
DC2NO9N	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.97	8.08	5.38	5.04
DCGYVGD	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.78	7.08	0.62	0.54
DC9KFLX	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	2.81	6.44	3.17	2.36
DCFQ39F	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.02	7.79	6.49	6.97
DCC0GHK	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.74	2.14	2.37	0.56
DCUVD34	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.73	10.31	12.15	13.34
DCJB4OP	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.56	9.12	6.33	6.07
DCGQUFM	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.35	4.18	2.37	1.92
DC73IMB	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.63	2.91	1.03	1.03
DCZBKF3	DMPDW6T	Epirubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.05	10.17	5.56	8.49
DCVPWWP	DMPDW6T	Epirubicin	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.88	9.4	5.47	4.98
DCP0FZB	DMPDW6T	Epirubicin	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	5.82	9.29	4.03	4.03
DCH07J6	DMPDW6T	Epirubicin	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	6.13	6.12	3.13	1.35
DCHPBXS	DMPDW6T	Epirubicin	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.17	7.62	6.02	6.2
DCNXNVP	DMPDW6T	Epirubicin	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.14	8.59	4.92	4.83
DCA1C69	DMPDW6T	Epirubicin	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.17	4.7	1.01	4.96
DCQNLT3	DMPDW6T	Epirubicin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.25	5.84	2.28	2.28
DC3AIIL	DMPDW6T	Epirubicin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.68	11.06	8.08	7.43
DCWVZBZ	DMPDW6T	Epirubicin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.5	1.51	1.02	0.99
DC5VT37	DMPDW6T	Epirubicin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.34	4.17	2.25	2
DC9C35Q	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.83	8.87	7.41	7.23
DCKYPJT	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.26	10.55	0.22	0.23
DC957Q6	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.18	4.5	5	2.97
DCUL0OE	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	1.69	8.48	4.57	4.57
DCBAKL9	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.06	4.75	1.37	1.37
DCITQRR	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.6	4.95	2.31	2.03
DCLSYCA	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.44	2.77	1.08	0.74
DCU7R6F	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.02	3.85	1.43	2.95
DCXDJWC	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.73	7.86	6.44	5.46
DCRPZ07	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	9.77	3	1.8	0.41
DCDRERE	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.17	8.93	8.25	8.24
DC42R3P	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.02	3.29	3.3	3.03
DCRMTEP	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.9	4.88	1.34	1.34
DCIF9VP	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.04	2.21	1.82	1.42
DCPUDO8	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.67	7.15	7.99	8.02
DCL8Z2Y	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.38	5.44	2.94	3.55
DCQ5X84	DMPDW6T	Epirubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.79	5.08	1.03	4.63
DCT7E1L	DMPDW6T	Epirubicin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.62	6.29	0.05	5.4
DC29B92	DMPDW6T	Epirubicin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.71	3.85	0.83	0.1
DCJNULN	DMPDW6T	Epirubicin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	14.04	11.47	7.74	11.58
DC60EOV	DMPDW6T	Epirubicin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.02	4.5	1.78	1.24
DCH5CY0	DMPDW6T	Epirubicin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.52	5.32	2.02	5.69
DC1PKWK	DMPDW6T	Epirubicin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.18	4.48	2.56	0.61
DC1ESP2	DMPDW6T	Epirubicin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.34	7.98	3.96	3.96
DC1RVHK	DMPDW6T	Epirubicin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	12.23	7.47	3.19	2.37
DCWTG5K	DMPDW6T	Epirubicin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.27	6.59	2.13	2.04
DCVIJ1O	DMPDW6T	Epirubicin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.82	6.51	4.73	3.51
DCIEJ6X	DMPDW6T	Epirubicin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.36	5.47	3.27	3.38
DCO0MF2	DMPDW6T	Epirubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.62	3.1	3.14	2.27
DCOQGMG	DMPDW6T	Epirubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.06	3.19	2.09	0.66
DC80I8E	DMPDW6T	Epirubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.23	5.59	3.5	2.18
DCXXOX8	DMPDW6T	Epirubicin	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.55	4.06	0.18	2.2
DC7F2C1	DMPDW6T	Epirubicin	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.25	5.05	0.74	4.39
DCROF7G	DMPDW6T	Epirubicin	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	1.85	11.21	5.13	7.03
DC2P8OZ	DMPDW6T	Epirubicin	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.43	8.57	7.77	8.9
DCBEFPM	DMPDW6T	Epirubicin	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	9.99	9.01	12.97	11.26
DC2SO2M	DMPDW6T	Epirubicin	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.95	3.45	0.49	0.37
DCOE03I	DMPDW6T	Epirubicin	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.74	5.08	3.17	4.38
DC78QVE	DMPDW6T	Epirubicin	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.97	5.25	7.02	7.95
DCOLIIW	DMPDW6T	Epirubicin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.18	10.05	10.09	13.04
DCGHYLG	DMPDW6T	Epirubicin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.5	6.21	3.52	3.5
DCFZDTX	DMPDW6T	Epirubicin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.54	7.22	6.03	4.6
DCUBK35	DMPDW6T	Epirubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.13	13.4	10.26	13.86
DC5S8Y6	DMPDW6T	Epirubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.88	10.37	9.11	10.3
DCTS2JI	DMPDW6T	Epirubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	10.88	18.43	17.67	15.27
DC3DE2B	DMPDW6T	Epirubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	12.81	18.05	11.4	20.62
DC0UUHW	DMPDW6T	Epirubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.33	7.53	8.5	8.58
DCE6A3K	DMPDW6T	Epirubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.38	9.24	5.43	7.46
DCO2MHQ	DMPDW6T	Epirubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	26.26	25.45	7.67	25.64
DCH4RLX	DMPDW6T	Epirubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	6.1	9.69	8.71	11.24
DCS1CYY	DMPDW6T	Epirubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.68	11.25	10.93	12.86
DCIGDJ3	DMPDW6T	Epirubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	15.99	15.9	5.84	17.08
DC4DCA9	DM5TVS3	Vinblastine	Approved	34	DMS104F	Temsirolimus	Approved	34	.	.	.	.	Recurrent Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCUKT29	DM5TVS3	Vinblastine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Refractory Low-grade Gliomas	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC0D7EV	DM5TVS3	Vinblastine	Approved	34	DM09NGV	Ribavirin-TP	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.51	4.51	5.2	5.3
DCGG3V1	DM5TVS3	Vinblastine	Approved	34	DM0KYI4	Mebutamate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.09	4.09	4.46	4.56
DC7VPAB	DM5TVS3	Vinblastine	Approved	34	DM15HL8	Clindamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.59	0.59	0.86	0.95
DC3FVPV	DM5TVS3	Vinblastine	Approved	34	DM1TJ8F	Diethylcarbamazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.55	3.55	3.88	3.97
DCLW1T3	DM5TVS3	Vinblastine	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	DrugCombDB Database	Investigative	L-1236	11.155	12.705	5.489	10.324
DCBESFT	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	1.57	1.86	3.76	6.91
DC7XOOF	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	2.06	0.32	0.06	5.38
DC2MLE4	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	0.56	0.78	2.16	7.24
DCIR7LK	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	9.33	9.03	4.42	10.32
DCXLDKP	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	2.89	2.55	0.06	6.1
DC5FHXU	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	7.45	5.49	3	9.19
DCA8F80	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	5.75	7.17	3.89	5.32
DC14BLX	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	3.61	3.05	0.26	5
DC48269	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	3.87	3.5	0.26	6.11
DC7DTDF	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.42	7.95	5.9	11.42
DCU4JVU	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	1.32	4.85	4.46	5.71
DCI8O1C	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	1.81	1.43	1.72	6.15
DC2SGMD	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	1.29	4.26	0.02	8.09
DCGJFPT	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	9.36	7.13	4.86	10.44
DC35XVA	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	6.2	6.13	4.91	9.34
DCJ8B3X	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	10.88	9.96	5.49	12
DC0HUZ5	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	7.08	6.14	5.43	11.72
DCRJ392	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	10.56	10.63	4.3	13.27
DCA1TB8	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	6.37	8.07	0.64	6.92
DCDP3MO	DM5TVS3	Vinblastine	Approved	34	DM2DMPO	Kanamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.57	4.57	5.12	5.22
DC0GH52	DM5TVS3	Vinblastine	Approved	34	DM2HU9I	Triamterene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.97	3.97	4.29	4.35
DC4B1XB	DM5TVS3	Vinblastine	Approved	34	DM2NUH3	Imipramine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.98	1.98	2.29	2.39
DCTSVN0	DM5TVS3	Vinblastine	Approved	34	DM2TUCU	Crotamiton	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.4	2.4	2.71	2.81
DCLJZO7	DM5TVS3	Vinblastine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	2.3	4.5	6.79	8.8
DCUE4LH	DM5TVS3	Vinblastine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	4.35	1.75	0.82	4.49
DCKF985	DM5TVS3	Vinblastine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	9.12	9.03	8.5	12.67
DCWQDGU	DM5TVS3	Vinblastine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	2.54	2.06	0.74	0.51
DC5JFX6	DM5TVS3	Vinblastine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	7.47	6.52	9.83	11.55
DC9PHQO	DM5TVS3	Vinblastine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	1.9	3.4	1.01	4.5
DCKQTB3	DM5TVS3	Vinblastine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	7.45	10.93	9.41	11.63
DCPIKUP	DM5TVS3	Vinblastine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	3.26	3.16	0.61	4.17
DCVDV8K	DM5TVS3	Vinblastine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	3.62	6.71	0.45	5.68
DCL4NTC	DM5TVS3	Vinblastine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	5.77	8.48	8.98	10.5
DCX5WYO	DM5TVS3	Vinblastine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	5.94	4.97	1.57	7.22
DCYLRUU	DM5TVS3	Vinblastine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	1.61	1.17	3.25	5.33
DC4EWUY	DM5TVS3	Vinblastine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	5.33	6.78	2.07	5.24
DC4J6UV	DM5TVS3	Vinblastine	Approved	34	DM3OWT4	Tindamax	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.73	0.73	1	1.1
DC7GR6B	DM5TVS3	Vinblastine	Approved	34	DM3P6V7	Furazolidone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.01	3.01	3.34	3.44
DCEHULI	DM5TVS3	Vinblastine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	4	8.18	7.95	10.55
DC08B58	DM5TVS3	Vinblastine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	5.18	9.12	7.46	7.47
DCGGZ6O	DM5TVS3	Vinblastine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	2.43	5.53	3.71	10.18
DCYUD0X	DM5TVS3	Vinblastine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	14.31	15.28	11.89	16.38
DC5IP4V	DM5TVS3	Vinblastine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	3.57	8.1	1.55	7.17
DCHR8L8	DM5TVS3	Vinblastine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	0.09	0.23	0.75	3.13
DCICDHX	DM5TVS3	Vinblastine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	8.13	6.04	4.17	8.62
DCSUA27	DM5TVS3	Vinblastine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	2.11	1.38	2.43	7.63
DCVRA3E	DM5TVS3	Vinblastine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	4.76	8.51	2.54	7.12
DCM80XZ	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	2.7	3.78	2.57	5.87
DCSCOSU	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	3.1	3.09	1.06	5.24
DC3EKY0	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	6.58	2.78	1.03	3.97
DCPMKSQ	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	5.41	5.64	3.95	4.15
DCBHRIN	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	5.41	2.18	0.85	4.06
DCSO9BD	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	7.13	5.91	1.26	5.74
DCO71P8	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	1.57	4.03	0.48	5.73
DC6A2PQ	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	1.39	0.05	0.71	3.72
DCDGKLO	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	4.19	2.96	0.67	5.09
DCAIM7E	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	2.27	0.76	0.3	3.41
DC753KN	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	26.63	24.97	24.47	28.35
DC3Y084	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	6.62	6.1	2.52	8.35
DCTEYFA	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	7.73	4.4	2.3	7.43
DCQD42L	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	9.66	11.39	10.27	13.5
DC2PR2R	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	4.57	6.59	1.93	5.98
DCHC4OI	DM5TVS3	Vinblastine	Approved	34	DM53BDW	Trioxsalen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.23	4.23	4.56	4.59
DC1DC5D	DM5TVS3	Vinblastine	Approved	34	DM5SXUV	Repaglinide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.25	1.25	1.53	1.63
DCD8YOI	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	3.71	1.96	3.65	7.2
DCQRQA1	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	4.62	2.5	0.34	4.68
DCR2765	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	3.4	3.19	3.4	7.86
DCQV4EK	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	2.1	0.43	2.72	5.97
DCBH7TJ	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	9.45	11.02	4.52	9.76
DCT44EB	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	0.43	0.68	2.1	5.57
DCMB3IC	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	2.39	2.79	2.92	7.38
DCWR7S4	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	2.29	0.65	0.54	3.07
DCVRXHH	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	1.49	0.77	2.73	6.53
DCI8MJV	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	7.97	6.13	7.04	9.88
DCPJJL0	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.87	4.41	4.98	7.79
DCQ9HSO	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	2.57	2.76	0.97	3.75
DCB9VNT	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	2.27	2.12	3.46	7.1
DCZTZQK	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	4.74	2.81	5.55	8.52
DC7870Q	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	5.71	4.76	9.71	12.12
DCO8ZXF	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	4.07	3.1	4.62	7.74
DC9RKB6	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	6.74	4.77	2.11	6.44
DCY9CUR	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	1.76	0.53	4.04	6.55
DCLG3CI	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	7.82	6.57	7.34	11.05
DCE8GXP	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	9.02	7.86	8.14	12.91
DCLR091	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	8.74	7.94	9.07	11.97
DCAVNIA	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	5.02	6.29	1.46	5.55
DCU29SX	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	3.76	0.91	5.38	7.82
DCXK3ZS	DM5TVS3	Vinblastine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	0.82	0.37	0.65	3.83
DCZ1N9R	DM5TVS3	Vinblastine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	5.41	3.86	1.75	1.88
DC5FDW4	DM5TVS3	Vinblastine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.34	4.33	0.3	5.54
DCKE7MP	DM5TVS3	Vinblastine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	3.54	1.8	1.09	5.07
DC1DYLJ	DM5TVS3	Vinblastine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	2.58	1.37	1.1	4.77
DC4EV00	DM5TVS3	Vinblastine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	3.15	3	0.78	4.26
DCGRYR0	DM5TVS3	Vinblastine	Approved	34	DM6BZCV	Sivelestat	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.76	3.76	4.15	4.2
DCKU227	DM5TVS3	Vinblastine	Approved	34	DM9S1EA	Pepstatin	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.94	2.94	3.69	3.79
DC3XTYE	DM5TVS3	Vinblastine	Approved	34	DMA8FS5	Dronedarone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.8	0.8	1.09	1.18
DCVNDIE	DM5TVS3	Vinblastine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	3.67	1.19	1.69	4.03
DCF74GB	DM5TVS3	Vinblastine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	3.02	7.71	6.03	5.45
DCBKDRX	DM5TVS3	Vinblastine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	4.1	1.63	0.86	4.26
DCMWS0A	DM5TVS3	Vinblastine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	4.23	1.21	3.2	5.99
DC3I3GE	DM5TVS3	Vinblastine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	2.94	1.1	0.21	3.35
DC5SQVT	DM5TVS3	Vinblastine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	2.84	1.55	1.09	5.15
DC4EGHG	DM5TVS3	Vinblastine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	4.41	3.46	3.46	6.23
DCLD6YY	DM5TVS3	Vinblastine	Approved	34	DMBLM5H	BHV-0223	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.94	4.94	5.31	5.4
DCZBZX0	DM5TVS3	Vinblastine	Approved	34	DMBS632	Buspirone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.18	2.18	2.52	2.61
DCS7GXM	DM5TVS3	Vinblastine	Approved	34	DMC1TEV	Testosterone cypionate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.59	2.59	3.17	3.26
DCOZYC7	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	2.43	1.42	3.83	8.71
DC6V513	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	4.22	2.97	6.99	10.8
DC1ZNLD	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	0.94	2.38	3.46	8.36
DCNGBKB	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	4.31	3.98	1.16	7.9
DCB7TCX	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	15.28	15.09	13.73	13.99
DCYQ565	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	6.94	3.68	0.69	9.47
DC09DPF	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	4.09	3.5	3.18	9.61
DCUPWGZ	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	7.3	6.36	1.39	9.54
DCTKDC7	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.73	1.73	2.25	2.32
DCHQ6F6	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	5.51	6.55	0.49	7.34
DCZ30TQ	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	1.58	0.06	1.68	6.55
DCMR7ON	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	3.7	1.98	4.75	7.95
DCWQJJW	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	12.52	6.01	41.51	6.26
DCMKYGK	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	3.23	3.04	2.37	7.23
DCK7232	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	4.88	3.52	3.9	10.39
DC1UWIK	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	0.73	5.4	5.02	9.67
DCW2GRA	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	4.81	2.75	7.03	9.09
DC7G2ZT	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	4.26	0.69	3.19	5.94
DCZBLQV	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	8.07	5.11	4	8.02
DC5PSCC	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	5.99	3.45	4.82	7.94
DCAZPFL	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	6.56	5.34	4.25	7.34
DCNCXJ5	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	8.99	7.2	5.9	5.79
DCGYEBI	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	6.85	4.99	5.09	9.35
DC20J6W	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	0.51	1.42	0.26	2.86
DCF9XRI	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	7.6	8.29	6.23	10.71
DCTQ92E	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	5.32	5.99	2.59	6.3
DC76Y9J	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	8.47	8.94	5.98	13.32
DC4FDC7	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	7.56	5.34	5.53	8.58
DCHW9OX	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	4.29	2.41	4.99	7.6
DCRKMXS	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	7.14	7.64	5.37	9.78
DCZQ1GF	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	7.17	6.64	2.1	6.61
DC9TKEZ	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	4.48	2.18	4.51	7.02
DCYJQ3Q	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	24.16	22.21	23.63	25.98
DC1IRZJ	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	2.9	1.12	0.52	5.86
DC7G85P	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	9.91	7.73	5.54	10.63
DC1P3J5	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	5.9	5.68	6.99	9.57
DCIVCDH	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	7.89	1.81	4.67	7.93
DCMPB62	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	16.92	17.16	12.56	15.73
DCN8WJC	DM5TVS3	Vinblastine	Approved	34	DMCR1MV	Itraconazole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.31	1.31	1.73	1.82
DCU6PX0	DM5TVS3	Vinblastine	Approved	34	DMCT2YF	Emetine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.84	1.84	3.66	3.76
DCEQEMH	DM5TVS3	Vinblastine	Approved	34	DMCYVDT	Chlorzoxazone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.7	1.7	3.68	3.78
DC1YFAE	DM5TVS3	Vinblastine	Approved	34	DMDO279	Phenprocoumon	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.93	2.93	3.32	3.42
DCLKIA8	DM5TVS3	Vinblastine	Approved	34	DMDXRP1	ETHISTERONE	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.12	2.12	2.51	2.56
DCLRQFQ	DM5TVS3	Vinblastine	Approved	34	DME2H5T	Cilastatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.01	4.01	4.36	4.39
DCT3L69	DM5TVS3	Vinblastine	Approved	34	DMENSL5	Aminosalicylic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.91	3.91	4.23	4.31
DC4NE6C	DM5TVS3	Vinblastine	Approved	34	DMEV954	Sulfinpyrazone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.43	1.43	1.74	1.83
DC0TNYV	DM5TVS3	Vinblastine	Approved	34	DMF57DM	Pazopanib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.32	3.32	3.87	3.97
DCUQHMS	DM5TVS3	Vinblastine	Approved	34	DMFCMPS	Daidzin	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.14	0.14	0.42	0.52
DC032GV	DM5TVS3	Vinblastine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	10.34	4.52	4.53	8.46
DCIO4D9	DM5TVS3	Vinblastine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	4.05	4.05	1.1	6.12
DCF2ND9	DM5TVS3	Vinblastine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	2.73	0.56	0.16	5.43
DCBY7IT	DM5TVS3	Vinblastine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	4.81	5.09	2.92	3.14
DCY4ST9	DM5TVS3	Vinblastine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.86	3.44	0.21	4.66
DC2PVUP	DM5TVS3	Vinblastine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	2.92	3.56	0.84	8.25
DCFO37Z	DM5TVS3	Vinblastine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	8.03	7.74	0.13	10.81
DCFA0MZ	DM5TVS3	Vinblastine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	11.98	12.98	2.67	12.38
DC9ZQEP	DM5TVS3	Vinblastine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	3.6	3.13	1.96	5.97
DCF6HJP	DM5TVS3	Vinblastine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	15.68	14.62	9.15	16.82
DCXOLX5	DM5TVS3	Vinblastine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	4.15	3.22	2.08	8.19
DC2Z0KZ	DM5TVS3	Vinblastine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	8.58	7.43	7.46	13.61
DCZHIW1	DM5TVS3	Vinblastine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	3.39	0.57	5.07	9.11
DC2USGX	DM5TVS3	Vinblastine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	10.66	10.03	4.39	9.24
DCR4WMV	DM5TVS3	Vinblastine	Approved	34	DMFQWNI	VR-776	Discontinued in Phase 1	3	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.15	2.15	2.5	2.6
DCK8IUV	DM5TVS3	Vinblastine	Approved	34	DMGFV3Z	Nizatidine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.87	3.87	4.15	4.25
DCJAHIB	DM5TVS3	Vinblastine	Approved	34	DMHAZLM	Naringenin	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.62	3.62	3.95	4.04
DCXLHRT	DM5TVS3	Vinblastine	Approved	34	DMIOGBU	Bosentan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.67	1.67	2.06	2.09
DCBBVGN	DM5TVS3	Vinblastine	Approved	34	DMIWFRL	Tolvaptan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.99	2.99	3.39	3.48
DCVY65Q	DM5TVS3	Vinblastine	Approved	34	DMK1GBJ	Trazodone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.27	2.27	2.59	2.64
DCXTKO4	DM5TVS3	Vinblastine	Approved	34	DMK7MEY	Isoproterenol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.37	2.37	3.02	3.12
DCVNR53	DM5TVS3	Vinblastine	Approved	34	DMKBYWI	Trifluoperazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.77	1.77	2.08	2.18
DCSEG6U	DM5TVS3	Vinblastine	Approved	34	DML1538	Diazoxide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.18	2.18	4.18	4.28
DCGLAEF	DM5TVS3	Vinblastine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	3.18	2.57	3.08	5.93
DCYHIWJ	DM5TVS3	Vinblastine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	3.99	4.11	0.46	4.96
DCGPPW8	DM5TVS3	Vinblastine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	4.05	4.11	1.52	5.56
DCPIFLS	DM5TVS3	Vinblastine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	3.64	4.22	1.68	7.66
DCIUUH7	DM5TVS3	Vinblastine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	12.6	6.98	6.91	8.37
DCZ58W3	DM5TVS3	Vinblastine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	5.38	3.25	0.22	4.84
DCM6TTJ	DM5TVS3	Vinblastine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	7.73	1.51	0.1	4.14
DCR57DF	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	0.68	4.42	3.08	6.99
DC5922K	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	5.42	8.26	3.84	6.01
DC6P88M	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	0.13	2.38	4.58	5.79
DC8HHT6	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	5.37	5.4	4.08	7.85
DC8VAVU	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	1.82	1.41	0.76	1.99
DCGO38J	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	0.41	1.24	3.62	5.68
DCNDRJA	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	6.24	6.01	7.98	11.27
DC27KSU	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	3.69	9.15	0.47	9.49
DCMVI6G	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	0.28	1.03	3.36	5.23
DC2L8D0	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	23.6	23.22	21.03	23.42
DC2MOXN	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	13.3	11.46	12.27	14.21
DC3J1UQ	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	7.74	5.27	9.87	12.51
DCF5FV4	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	5.29	7.12	9.34	10.88
DCM4K55	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	7.6	2.3	7.84	10.35
DCS4DWM	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	2.62	5.77	1.27	3.72
DCTL9LV	DM5TVS3	Vinblastine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	4.17	6.56	5.22	5.25
DCRBTGR	DM5TVS3	Vinblastine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.06	1.06	2.15	2.25
DCHJ841	DM5TVS3	Vinblastine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	4.04	4.04	7.09	7.17
DCC64U4	DM5TVS3	Vinblastine	Approved	34	DMMN36E	Abacavir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.22	2.22	2.62	2.62
DCHIBNC	DM5TVS3	Vinblastine	Approved	34	DMWFJTR	Linagliptin	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.99	1.99	2.32	2.38
DCTAJ1U	DM5TVS3	Vinblastine	Approved	34	DMNMW9R	Pramipexole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.42	0.42	0.75	0.8
DCADVMS	DM5TVS3	Vinblastine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	5.89	4.62	0.93	4.93
DCGBQVB	DM5TVS3	Vinblastine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	8.12	6.51	1.89	7.36
DC015V8	DM5TVS3	Vinblastine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	2.54	0.72	0.88	2.4
DCXRVKB	DM5TVS3	Vinblastine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	3.54	5.61	2.16	6.31
DC135RB	DM5TVS3	Vinblastine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	7.69	8.31	4.86	7
DCA4DKX	DM5TVS3	Vinblastine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	1.52	3.03	0.65	4.29
DCTJA8M	DM5TVS3	Vinblastine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	2.65	2.98	2.14	5.36
DCJR9F8	DM5TVS3	Vinblastine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	4.22	3.99	0.12	4.2
DCNNFBA	DM5TVS3	Vinblastine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	4.13	4.63	1.73	6.77
DCDFRJK	DM5TVS3	Vinblastine	Approved	34	DMODJ40	Ethinyl estradiol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.69	0.69	1.1	1.1
DCXWVRA	DM5TVS3	Vinblastine	Approved	34	DMOMBJW	Moricizine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.82	3.82	4.14	4.24
DC8QGRK	DM5TVS3	Vinblastine	Approved	34	DMOY7W3	Artemisinin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.04	2.04	3.11	3.2
DCEH2WQ	DM5TVS3	Vinblastine	Approved	34	DMFYAM1	Enalaprilat	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.16	1.16	1.41	1.5
DCQ5T34	DM5TVS3	Vinblastine	Approved	34	DMPWB7T	Maprotiline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.46	1.46	3.42	3.52
DCVEEEV	DM5TVS3	Vinblastine	Approved	34	DMQ2FKJ	Teriflunomide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.88	3.88	4.22	4.31
DCQ6NWU	DM5TVS3	Vinblastine	Approved	34	DMQEJVU	1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.07	3.07	3.36	3.45
DC5EZ5W	DM5TVS3	Vinblastine	Approved	34	DMRFWGK	Novobiocin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.19	5.19	5.58	5.6
DCYFRLB	DM5TVS3	Vinblastine	Approved	34	DMRM3AW	Acarbose	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.26	3.26	3.55	3.65
DCVN2HN	DM5TVS3	Vinblastine	Approved	34	DMRV7H0	Bumetanide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.02	2.02	2.36	2.43
DCSKNRF	DM5TVS3	Vinblastine	Approved	34	DMS3YE9	Amantadine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.5	3.5	3.85	3.94
DCQJ6UE	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	7.48	5.81	2.75	8.33
DC3N6DP	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	1.66	0.62	5.16	7.2
DCDS8AV	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	9.59	7.15	0.7	8.86
DC7P7DY	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	7.93	5.22	2.16	9.48
DC023Z8	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	3.33	2.08	2.21	7.89
DCVE6UB	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	2.05	1.38	0.48	0.55
DCDAOTZ	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	10.81	7.92	4.18	12.98
DCXEWDG	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	8.79	6.69	3.28	11.37
DCH033B	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	10.11	8.86	4.75	12.22
DCXX7ZN	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	15.81	16.85	9.28	16.59
DCKKPBC	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.54	1.54	1.75	1.84
DCL5AVV	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.53	6.46	1.22	9.47
DCFMFIN	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	7.74	5.51	1.98	9.58
DCZMEC9	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	11.44	9.16	8.48	13.47
DCBTUV6	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	6.28	6.14	7.76	11.93
DCNWFPX	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	4.82	4.91	5.22	8.93
DCGW0W9	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	4.16	4.41	4.39	8.42
DCUIOGM	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	6.85	6.75	6.19	8.72
DC1IS6S	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	12.19	7.57	3.85	10.33
DCS903P	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	3.41	4.01	2.96	8.85
DCI2VFY	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	21.28	20.36	15.04	20.56
DCJ9AN9	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	4.03	2.79	3.26	9.48
DCLWKZ0	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	21.11	21.29	12.61	20.23
DCD1FRM	DM5TVS3	Vinblastine	Approved	34	DMSWYF5	Quinine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.28	3.28	4.17	4.27
DC6T62W	DM5TVS3	Vinblastine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	4.99	1.72	2.9	5.85
DCSC8YB	DM5TVS3	Vinblastine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	4.79	6.99	2.09	13.22
DCS340J	DM5TVS3	Vinblastine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	6.3	7.64	5.85	6.31
DCT9ZXJ	DM5TVS3	Vinblastine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	5.96	4.22	1.57	8.64
DCNHL2T	DM5TVS3	Vinblastine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	0.02	3.1	0.29	7.54
DCZT8V9	DM5TVS3	Vinblastine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	1.1	3.29	4.21	6
DC126J3	DM5TVS3	Vinblastine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	1.48	0.65	2.75	6.2
DCWW7C9	DM5TVS3	Vinblastine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	13.67	8.7	8.41	11.62
DCTT4H6	DM5TVS3	Vinblastine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	6.42	6.1	8.39	13.06
DCSK0UP	DM5TVS3	Vinblastine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	7.13	7.7	8.54	11.34
DCU16PG	DM5TVS3	Vinblastine	Approved	34	DMOJZQ9	Loperamide	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.28	2.28	2.54	2.62
DCRJ3WM	DM5TVS3	Vinblastine	Approved	34	DMTL94F	Maraviroc	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.31	1.31	1.61	1.7
DCUDH0C	DM5TVS3	Vinblastine	Approved	34	DMTWUXR	Chlormezanone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.22	2.22	2.52	2.6
DCJMTL3	DM5TVS3	Vinblastine	Approved	34	DMUZPJ5	Cisatracurium	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.71	0.71	1.4	1.49
DC376GF	DM5TVS3	Vinblastine	Approved	34	DMVGPMX	Fosfomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.99	3.99	4.4	4.49
DC0HPIN	DM5TVS3	Vinblastine	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.86	0.86	2.9	2.95
DCE2ZIZ	DM5TVS3	Vinblastine	Approved	34	DMVPZBE	Iloprost	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.49	4.49	4.7	4.8
DCH6L4O	DM5TVS3	Vinblastine	Approved	34	DMVRYT2	Nabilone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.54	4.54	4.89	4.98
DCKZIUT	DM5TVS3	Vinblastine	Approved	34	DMVTHWQ	Silver sulfadiazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.46	0.46	0.71	0.81
DCL136R	DM5TVS3	Vinblastine	Approved	34	DMWBHRY	Olmesartan medoxomil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.35	0.35	0.61	0.71
DC6082E	DM5TVS3	Vinblastine	Approved	34	DMWE2N4	Auranofin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.51	0.51	2.42	2.51
DCWUF4R	DM5TVS3	Vinblastine	Approved	34	DMWSMND	Cevimeline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.65	0.65	0.97	1.06
DCIL6PD	DM5TVS3	Vinblastine	Approved	34	DMY91A3	ML323	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.18	4.18	4.44	4.53
DCCB2QS	DM5TVS3	Vinblastine	Approved	34	DMYTE6L	Enoxacin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.8	4.8	5.1	5.2
DCGBFKP	DM5TVS3	Vinblastine	Approved	34	DMYURI6	Raltegravir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.95	2.95	3.23	3.32
DCIZK5A	DM5TVS3	Vinblastine	Approved	34	DMYZ57N	Albendazole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.14	2.14	2.35	2.45
DC6ZZNT	DM5TVS3	Vinblastine	Approved	34	DMZ2TD9	GSK2194069	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.98	1.98	2.23	2.33
DCK80M5	DM5TVS3	Vinblastine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	5.37	7.49	5.56	2.8
DCLXJV2	DM5TVS3	Vinblastine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	2.44	1.28	3.01	6.1
DCUYJY2	DM5TVS3	Vinblastine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	0.85	0.93	0.41	1.91
DCUAMO9	DM5TVS3	Vinblastine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	1.49	0.42	1.6	4.48
DCU06SH	DM5TVS3	Vinblastine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	0.64	2.06	1.23	4.38
DCKS62T	DM5TVS3	Vinblastine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	17.24	17.89	14.91	22.02
DCNIIED	DM5TVS3	Vinblastine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	10.92	10.21	3.62	18.41
DCMGHD5	DM5TVS3	Vinblastine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	1.29	0.66	5.11	6.03
DC71XEL	DM5TVS3	Vinblastine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	1.41	7.15	2.47	5.34
DC7JSV5	DM5TVS3	Vinblastine	Approved	34	DMZ80SB	Azatadine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3	3	3.35	3.44
DCL14D5	DM5TVS3	Vinblastine	Approved	34	DMZA017	Tetracycline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.12	2.12	2.39	2.49
DCTW9IU	DM5TVS3	Vinblastine	Approved	34	DMZD5QR	Cytarabine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.62	0.62	2.63	2.72
DCAY8UF	DM5TVS3	Vinblastine	Approved	34	DMZI3WO	Etomidate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.84	2.84	3.09	3.18
DCP8CC7	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	8.36	8.43	4.36	11.41
DC35LLF	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.62	2.14	2.71	4.5
DCNS3VG	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	16.85	17.58	3.28	18.33
DCB3I1Z	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	13.3	14.48	9.77	16.26
DC0S9TM	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	3.98	1.72	2.47	6.45
DC6F15U	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.94	6.36	1.59	7.19
DCCP1LE	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	11.02	12.95	8	14.13
DC3VU2V	DM5TVS3	Vinblastine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.24	0.42	25.63	1.71
DC1H99O	DM5TVS3	Vinblastine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.1	2.68	3.54	6.32
DCNYV13	DM5TVS3	Vinblastine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.08	0.05	3.26	5.31
DC93T4L	DM5TVS3	Vinblastine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	5.59	8.16	1.77	8.51
DC87NOS	DM5TVS3	Vinblastine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.62	1.73	1.42	4.78
DCX6XU7	DM5TVS3	Vinblastine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.13	3.17	29.57	4.62
DCIAUA6	DM5TVS3	Vinblastine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	13.06	13.31	8.55	14.77
DCMG4XG	DM5TVS3	Vinblastine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	7.76	8.03	6.76	11.1
DCGOZX7	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.18	1.77	1.73	5.85
DC60FMG	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.3	2.37	4.78	7.42
DC6BNJY	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	6.51	9.32	7.25	10.84
DCQZB9M	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.27	3.52	0.68	7.76
DC5T16C	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.54	1.58	0.23	4.69
DCHUWOJ	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.85	4.79	5.09	7.25
DCLVZQS	DM5TVS3	Vinblastine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	10.16	9.59	36.78	9.08
DCQ722F	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.44	0.84	3.51	6.56
DCOPZRY	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.36	1.07	5.05	7.11
DCLP3K7	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	3.48	3.74	2.36	6.34
DCPLECM	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	6.86	7.2	5.1	9.36
DCWRZ2J	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.19	2.69	3.92	7.39
DCO8N3E	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.03	1.27	3.88	5.97
DC2612B	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.23	5.75	7.04	8.03
DCY95L2	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.56	2.52	0.99	5.71
DCY9A9C	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.63	5.25	5.18	9.06
DCEMH7E	DM5TVS3	Vinblastine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	11.23	2.09	32.05	3.09
DCNGRML	DM5TVS3	Vinblastine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.1	0.05	0.62	3.31
DCT9U5R	DM5TVS3	Vinblastine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.8	6.14	1.68	7.81
DC16DFA	DM5TVS3	Vinblastine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.19	2.33	0.24	5.52
DCK0KWN	DM5TVS3	Vinblastine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.62	3.98	32.32	5.31
DCLM1VT	DM5TVS3	Vinblastine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.96	1.35	2.08	3.44
DCVGN0K	DM5TVS3	Vinblastine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	8.46	9.74	1.27	8.96
DC6RMHM	DM5TVS3	Vinblastine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.84	3.85	0.45	5.64
DCY3WK0	DM5TVS3	Vinblastine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	6.29	3.15	35.04	5.17
DCRN7PM	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	4.59	7.1	3.66	10.45
DC14IKY	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.47	1.79	2.34	3.84
DC1RG4A	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.24	3.98	0.08	7.13
DCAK97G	DM5TVS3	Vinblastine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.54	0.27	27.81	1.88
DC8CMK9	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.73	0.89	4.83	7.78
DCI13R3	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.29	0.42	7.1	8.64
DCDF3KR	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	10.38	12.46	6.71	12.3
DCJU62R	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	17.84	15.61	12.4	17.09
DCQW2AJ	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	5.1	5.5	7.44	8.73
DC9S1R1	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.7	3.89	3.53	4.62
DCU8NRA	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.12	0.05	6.38	8.38
DCBRNJ0	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	12.04	5.55	4.91	8.58
DC7EG8P	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.44	0.63	3.57	6.18
DCYKB6V	DM5TVS3	Vinblastine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	11.44	9.64	39.71	11.59
DCZKNMT	DM5TVS3	Vinblastine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.71	0.9	4.12	7.06
DCG7CLQ	DM5TVS3	Vinblastine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	8.58	8.38	3.57	10.54
DCHGFXN	DM5TVS3	Vinblastine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	7.09	7.7	0.45	7.11
DC12X2E	DM5TVS3	Vinblastine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.5	1.98	0.18	8.4
DCDEM1O	DM5TVS3	Vinblastine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	13.7	13.63	15.99	11.82
DC96QWW	DM5TVS3	Vinblastine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	6.09	7.66	1.62	7.54
DCM6OIV	DM5TVS3	Vinblastine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.04	5.16	0.62	5.81
DCEI53K	DM5TVS3	Vinblastine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.03	2.52	0.62	4.9
DCWGPY1	DM5TVS3	Vinblastine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	6.96	2.03	27.11	1.78
DC08GXQ	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.73	2.5	6.24	7.68
DCXTXTJ	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	17.91	18.36	17.2	19.15
DC2Q86I	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	8.04	8.19	6.87	10.3
DCD635T	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.36	1.46	6.06	7.62
DCF7KOL	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.04	3.24	1.78	8.23
DCGPVX8	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.1	3.12	0.68	3.99
DCVQ6ZG	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.35	2.48	6.05	8.98
DCWYHPM	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.77	4.59	4.84	6.91
DC1M4FQ	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.36	8.31	11.72	13.23
DCBY76X	DM5TVS3	Vinblastine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	6.2	3.55	14.04	2.84
DCWUG6L	DM5TVS3	Vinblastine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.98	4.15	1.67	5.49
DCA1AB7	DM5TVS3	Vinblastine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.2	5.61	0.46	5.3
DC1YHCD	DM5TVS3	Vinblastine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.4	2.04	0.85	3.85
DCS6EZ3	DM5TVS3	Vinblastine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.96	3.93	1.47	4.59
DCNTM39	DM5TVS3	Vinblastine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	11.2	2.71	32.86	4.23
DCZSDDS	DM5TVS3	Vinblastine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.09	7.63	5.34	8.86
DC8LYL2	DM5TVS3	Vinblastine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.49	5.31	3.71	5.25
DC21CRB	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.89	2.68	4.13	7.94
DCA3BEA	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.56	0.65	3.14	6.37
DCCGGN5	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	5.52	5.37	0.61	18.73
DC4DGIL	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	7.94	7.92	2.63	10.14
DCKBARM	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	10.64	9.84	5.66	12.27
DCKWEQ2	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	5.48	5.42	0.07	9.9
DCCQ5LR	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.49	2.73	0.51	6.36
DC2KHHW	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	13.55	12.36	8.06	14.57
DC1MS1D	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.27	4.86	1.39	9.18
DCD7AVE	DM5TVS3	Vinblastine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	13.29	8.23	44.59	9.07
DC19UB9	DM5TVS3	Vinblastine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.96	3.45	5.34	7.59
DCPFRY7	DM5TVS3	Vinblastine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.73	2.56	2.79	5.48
DC1ZDK2	DM5TVS3	Vinblastine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	6.98	7.87	3.99	11.45
DCWRJ2G	DM5TVS3	Vinblastine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.17	2.12	0.11	4.16
DCNAA3S	DM5TVS3	Vinblastine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	9.92	11.26	34.55	12.29
DCTZ56Y	DM5TVS3	Vinblastine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.81	8.08	1.51	8.73
DCXBHET	DM5TVS3	Vinblastine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	5.28	7.48	11.76	13.03
DCNKI39	DM5TVS3	Vinblastine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.69	8.17	0.04	8.29
DCDHJ3P	DM5TVS3	Vinblastine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	7.86	2.68	40.97	5.74
DC51IJ4	DM8V75C	ABIRATERONE	Approved	34	DMGL19D	Enzalutamide	Approved	34	DMQ8FR2	Prednisolone	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCZX54P	DM8V75C	ABIRATERONE	Approved	34	DM8V75C	ABIRATERONE	Approved	34	DMGL19D	Enzalutamide	DMGL19D	Enzalutamide	Metastatic Castration-resistant Prostate Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCDPHIL	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Metastatic Prostate Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCOODJK	DM8V75C	ABIRATERONE	Approved	34	DMGL19D	Enzalutamide	Approved	34	.	.	.	.	Metastatic Castration-resistant Prostate Cancer (mCRPC)	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC4OUBQ	DM8V75C	ABIRATERONE	Approved	34	DMGL19D	Enzalutamide	Approved	34	DMI782S	Erdafitinib	.	.	Castration-Resistant Prostate Carcinoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC6G14H	DM8V75C	ABIRATERONE	Approved	34	DMAT8CG	Goserelin	Approved	34	DMT81LZ	Arn-509	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC7NFUT	DM8V75C	ABIRATERONE	Approved	34	DMNE56X	ABT-263	Phase 3	25	DMXZAL2	Hydroxychloroquine	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC81FZT	DM8V75C	ABIRATERONE	Approved	34	DM2HG4X	Prednisone	Phase 3 Trial	25	DMT81LZ	Arn-509	.	.	Castration Levels of Testosterone	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCMLYR0	DM8V75C	ABIRATERONE	Approved	34	DMGEMB7	Hydrocortisone	Phase 3 Trial	25	DMUDIR8	Fludrocortisone	.	.	Congenital Adrenal Hyperplasia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCQE28F	DM8V75C	ABIRATERONE	Approved	34	DMAT8CG	Goserelin	Approved	34	DMQ8FR2	Prednisolone	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCRFN2Y	DM8V75C	ABIRATERONE	Approved	34	DMJAGXQ	Niclosamide	Approved	34	DMQ7WL7	Prednisone	.	.	Metastatic Prostate Carcinoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC1MW8P	DM8V75C	ABIRATERONE	Approved	34	DMT81LZ	Arn-509	Approved	34	.	.	.	.	"Prostatic Neoplasms, Castration-Resistant"	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC2J02L	DM8V75C	ABIRATERONE	Approved	34	DMNE56X	ABT-263	Phase 3	25	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCECZF8	DM8V75C	ABIRATERONE	Approved	34	DMQ4TJK	Dutasteride	Approved	34	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCH6TA6	DM8V75C	ABIRATERONE	Approved	34	DMGL19D	Enzalutamide	Approved	34	.	.	.	.	Prostate Cancer Metastatic	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCH6TE3	DM8V75C	ABIRATERONE	Approved	34	DMGL19D	Enzalutamide	Approved	34	.	.	.	.	"Prostatic Neoplasms, Castration-Resistant"	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCYXMPV	DM8V75C	ABIRATERONE	Approved	34	DMGL19D	Enzalutamide	Approved	34	.	.	.	.	Metastatic Castration-Resistant Prostatic Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC7GQU9	DM8V75C	ABIRATERONE	Approved	34	DMIYDT4	Cabozantinib	Approved	34	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCIP21R	DM8V75C	ABIRATERONE	Approved	34	DMQ8FR2	Prednisolone	Approved	34	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCTT9F0	DM8V75C	ABIRATERONE	Approved	34	DM2HG4X	Prednisone	Phase 3 Trial	25	.	.	.	.	Hormone-Resistant Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCLEBJ0	DM8V75C	ABIRATERONE	Approved	34	DM93VBZ	LY2835219	Approved	34	DMQ8FR2	Prednisolone	.	.	Advanced Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCHLJ9E	DM8V75C	ABIRATERONE	Approved	34	DMT6E5N	Onapristone	Phase 2	21	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCSEXOP	DM8V75C	ABIRATERONE	Approved	34	DM9SKW8	AZD5363	Approved	34	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCLCQJA	DM8V75C	ABIRATERONE	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	20.28	23.73	15.47	19.1
DCQ7VNL	DM8V75C	ABIRATERONE	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.49	4.01	3.59	4.46
DCGLYYH	DM8V75C	ABIRATERONE	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.1	8.23	4.88	5.82
DCEJEU3	DM8V75C	ABIRATERONE	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	18.6	18.35	20.12	20.39
DC61VMN	DM8V75C	ABIRATERONE	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	22.62	17.77	2.14	16.31
DCDG7U9	DM8V75C	ABIRATERONE	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.41	6.81	3.04	5.36
DCPB63D	DM8V75C	ABIRATERONE	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.34	2.64	2.43	2.41
DCQAS4W	DM8V75C	ABIRATERONE	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	9.39	8.27	5.16	5.64
DCGIKHD	DM8V75C	ABIRATERONE	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.78	5.38	4.71	5.64
DCEJMZ9	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	9.55	15.01	7.69	14.98
DCGQ7V4	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	11.8	15.09	5.76	16.52
DCVQ7MU	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	5.46	6.41	4.36	6.59
DCKKGN5	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	5.36	6.96	0.08	5.29
DCJ0MWD	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.8	12.21	13.26	14.11
DCTX408	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.28	6.66	4.42	9.15
DC8TICB	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	3.8	5.07	6.78	6.82
DCUTS6D	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	4.28	11.85	16.09	16.75
DCDQQQK	DM8V75C	ABIRATERONE	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	5.72	8.48	11.41	10.87
DCT68EA	DM8V75C	ABIRATERONE	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.23	3.46	1.21	2.53
DCHKAU7	DM8V75C	ABIRATERONE	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.61	2.08	0.61	0.12
DC4ZEC1	DM8V75C	ABIRATERONE	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	5.46	8.45	11.17	10.97
DCF80QB	DM8V75C	ABIRATERONE	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.79	3.75	1.88	1.43
DC6E0NN	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	41.58	43.49	35.58	38.2
DC6FL40	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	45.12	48.17	46.46	47.45
DCTRII7	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	34.97	33.23	24.7	36.61
DCRIQX2	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	13.8	17.28	17.98	17.44
DCMW7VW	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	33.85	33.77	34.12	33.92
DCK2AMY	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.12	13.87	14.55	14.41
DCLDUI4	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	17.41	20.79	20.2	20.23
DCUOXHX	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	8.78	16.61	14.44	14.39
DCWLS89	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	25.59	26.6	26	25.88
DC0X85H	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	10.41	19.27	18.13	17.12
DCIYNR7	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	25.27	25.78	26.9	26.38
DCMTQBE	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	9.02	10.53	10.32	9.93
DCOL5LN	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	4.62	12.56	13.65	13.27
DCNCNX8	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	17.73	16.39	13.64	14.11
DC7YJ4P	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	13.06	15.31	16.4	16.21
DCH54R8	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	18.56	19.64	20	19.11
DC8BDXF	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	31.71	30.74	27.09	28.2
DC2I509	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	5.1	12.64	0.38	13.07
DC2P1A6	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	9.79	15.05	15.77	15.2
DCE5BOA	DM8V75C	ABIRATERONE	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.07	5.95	0.25	5.61
DCW2YZA	DM8V75C	ABIRATERONE	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.68	9.74	0.1	7.97
DCA8MEO	DM8V75C	ABIRATERONE	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.5	7.47	6.75	7.54
DCP5II9	DM8V75C	ABIRATERONE	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.19	8.47	1.04	8.04
DC0LRHZ	DM8V75C	ABIRATERONE	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.38	3.8	2.87	3.19
DCSPP88	DM8V75C	ABIRATERONE	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	9.77	9.51	0.02	4.01
DCOP0YV	DM8V75C	ABIRATERONE	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	3.29	6.34	3.78	3.04
DCYM99B	DM8V75C	ABIRATERONE	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.27	8.44	8.43	9.29
DC349BI	DM8V75C	ABIRATERONE	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	6.84	7.05	7.1	7.95
DCX77R9	DM8V75C	ABIRATERONE	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.72	10.73	5.34	3.2
DCSXFJL	DM8V75C	ABIRATERONE	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.39	11.35	2.09	12.12
DCDEYXT	DM8V75C	ABIRATERONE	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	14.26	20.04	21.64	20.94
DC8T25I	DM8V75C	ABIRATERONE	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	4.93	11.77	13.72	14.2
DC66U4C	DM8V75C	ABIRATERONE	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	4.91	1.03	0.74	0.72
DCORH5O	DM8V75C	ABIRATERONE	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.35	11.05	8.06	7.41
DCP0AXY	DM8V75C	ABIRATERONE	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.17	1.26	1.09	0.28
DC477Q5	DM8V75C	ABIRATERONE	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	7.11	10.07	1.39	8.67
DCBSAM3	DM8V75C	ABIRATERONE	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.91	4.67	3.5	2.9
DC9DLT6	DM8V75C	ABIRATERONE	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	13.46	18.35	7.93	6.69
DCCCAT7	DM8V75C	ABIRATERONE	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.11	6.66	7.37	7.69
DCS0YIN	DM8V75C	ABIRATERONE	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	21	15.48	14.08	15.03
DCM3SEG	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	22.58	28.69	23.68	23.34
DCLRX99	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	24.19	23.05	22.27	21.98
DCSSNM4	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	25.53	25.66	26.7	26.44
DCW9DMG	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	20.68	18.63	19.53	19.29
DCG14QT	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.6	6.21	6.73	6.7
DCY8SRU	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	6.45	10.44	9.7	10
DCHM91D	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	8.81	15.96	15.56	15.56
DCM9G39	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	20.63	19.56	17.48	17.48
DCX3VDW	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	18.06	18.73	17.95	17.99
DC15MP5	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	21.45	19.87	22.91	22.43
DCK9BT7	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	18.28	18.77	18.56	18.44
DCWHA60	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	16.85	17.29	18.29	17.96
DCUFL1V	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	26.05	24.2	25.54	25.55
DCC78EE	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	15.43	17.34	17.47	17.58
DCEWB22	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	29.76	26.99	24.71	24.52
DC4YK5L	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	8.35	13.36	14.02	14.1
DCUYOOI	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.8	3.57	4.44	4.42
DCD99J7	DM8V75C	ABIRATERONE	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.3	8.73	2.04	3.47
DCI1LKN	DM8V75C	ABIRATERONE	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	16.6	16.38	12.42	18.81
DC80G3J	DM8V75C	ABIRATERONE	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	5.83	6.95	9.79	9.81
DCFF4RO	DM8V75C	ABIRATERONE	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.37	5.17	1.5	2.12
DCB2Q1K	DM8V75C	ABIRATERONE	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.01	5.89	5.13	4.61
DCWDU0S	DM8V75C	ABIRATERONE	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.94	4.75	1.39	5.69
DC54JZK	DM8V75C	ABIRATERONE	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.97	4.09	1.1	5.79
DC83IWQ	DM8V75C	ABIRATERONE	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	11.11	14.97	13.62	15.32
DCS4UNB	DM8V75C	ABIRATERONE	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	6.29	7.34	6.64	7.77
DC5EU1O	DM8V75C	ABIRATERONE	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.55	4.94	2.01	7.09
DCK2M67	DM8V75C	ABIRATERONE	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	5.92	5	3.66	4.18
DCAA72Z	DM8V75C	ABIRATERONE	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.3	4.03	4.63	5.62
DCF2ABE	DM8V75C	ABIRATERONE	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.61	6.05	5.17	6.66
DC148N2	DM8V75C	ABIRATERONE	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	5.88	5.53	3.05	7.34
DCYUAME	DM8V75C	ABIRATERONE	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.19	3.4	1.84	3.49
DCTIBIN	DM8V75C	ABIRATERONE	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.28	5.44	0.84	6.08
DCVF2O6	DM8V75C	ABIRATERONE	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	7.04	8.7	8.65	9.56
DCUXLGJ	DM8V75C	ABIRATERONE	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	13.31	13.36	12.8	13.23
DCXRKKP	DM8V75C	ABIRATERONE	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.98	5.86	6.26	6.32
DC5446Y	DM8V75C	ABIRATERONE	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	9.44	12.54	6.86	7.21
DCDOT6F	DM8V75C	ABIRATERONE	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.95	6.71	4.62	4.62
DC0XUK7	DM8V75C	ABIRATERONE	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.71	3.97	3.08	3.87
DC03JEG	DM8V75C	ABIRATERONE	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	2.37	6.09	1.41	1.48
DCYANWA	DM8V75C	ABIRATERONE	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.51	8.49	1.18	2.61
DCHTACI	DM8V75C	ABIRATERONE	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	3.83	1.33	1.85	2.12
DCGKXKA	DM8V75C	ABIRATERONE	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	7.34	11.11	11.16	10.93
DC8S5OC	DM8V75C	ABIRATERONE	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	24.65	25.22	11.45	23.11
DC73ZZI	DM8V75C	ABIRATERONE	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.16	3.69	1.49	2.52
DCMP8YH	DM8V75C	ABIRATERONE	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.52	0.62	1.57	3
DCC7WBE	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	20.45	19.33	15.14	19.64
DCW9IYN	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	19.45	16.11	12.58	17.52
DCV7FWX	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	16.13	14.91	9.22	16.97
DCGBDDG	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	16.7	16.61	9.04	17.06
DC1BVQS	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	18.98	17.86	1.34	16.92
DCKSE8K	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.19	13.85	10.19	12.45
DC3LDCZ	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	11.16	12.27	0.59	13.9
DC80HQ5	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	10.05	9.83	6.15	11.99
DCPTGNZ	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	17.79	15.5	8.96	15.18
DCSACHY	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	7.31	8.92	1.67	0.44
DCTM6FL	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.98	5.57	4.58	4.85
DCXQMD7	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.84	6.91	1.52	3.34
DCQ14AB	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.01	7.85	2.64	6.3
DCMR12C	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	3.46	6.17	1.82	1.47
DCV3SQE	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	5.91	5.98	4.06	4.49
DCKNT1B	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.83	3.94	3.27	3.45
DCR5M3A	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.04	4.78	0.56	1.4
DCHCLB1	DM8V75C	ABIRATERONE	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	44.74	45.49	37.94	40.6
DCXSJSM	DM8V75C	ABIRATERONE	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	9.7	13.77	10.53	13.33
DCSHW7D	DM8V75C	ABIRATERONE	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	4.34	5.06	5.71	6.31
DCCXZ32	DM8V75C	ABIRATERONE	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.17	9.37	8.64	9.03
DCMJWP0	DM8V75C	ABIRATERONE	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	11.56	14.36	13.16	14.68
DCVMKL1	DM8V75C	ABIRATERONE	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.08	5.26	2.3	4.86
DC780IS	DM8V75C	ABIRATERONE	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.83	4.95	3	5.77
DCNV2GV	DM8V75C	ABIRATERONE	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	5.85	5.08	2.8	4.95
DCGD64K	DM8V75C	ABIRATERONE	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	4.74	3.89	0.44	6.91
DCISU6Y	DM8V75C	ABIRATERONE	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	4.32	7.01	3.62	7.69
DCRHQMW	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	8.65	9.12	7.47	10.42
DCT44AK	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	9.19	7.69	8.07	11.8
DCLX2FC	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0	0.15	0.85	3.22
DCXJN9I	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	5.38	6.77	5.44	7.73
DCHQEWA	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.02	3.44	2.61	6.02
DCI1M34	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.43	3.28	2.7	6.22
DCHII5R	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.4	5.78	4.12	5.93
DC9MMQT	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.8	1.15	4.13	4.56
DCSXYW4	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	26.55	23.73	26.69	28.99
DCFI89C	DM8V75C	ABIRATERONE	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.39	3.7	1.55	1.55
DC6A079	DM8V75C	ABIRATERONE	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.44	11	3.88	7.96
DC1RVPR	DM8V75C	ABIRATERONE	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.84	5.55	2.78	3.02
DCN7QZN	DM8V75C	ABIRATERONE	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	9.55	7.47	2.43	1.85
DC801YA	DM8V75C	ABIRATERONE	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.76	4.39	2.48	2.24
DCW9X7V	DM8V75C	ABIRATERONE	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	6.67	13.87	0.05	14.2
DCD8GFO	DM8V75C	ABIRATERONE	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	18.34	19.52	3.66	16.99
DCVH9MZ	DM8V75C	ABIRATERONE	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	1.96	4.1	1.61	4.89
DC3L1PF	DM8V75C	ABIRATERONE	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	3.63	8.61	9.7	10.71
DC2HLXJ	DM8V75C	ABIRATERONE	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	58.53	43.62	33.98	39.88
DCN52PI	DM8V75C	ABIRATERONE	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.07	6.34	3.82	7.71
DC26CJX	DM8V75C	ABIRATERONE	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.68	7.66	1.22	9.16
DCUW77F	DM8V75C	ABIRATERONE	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	6.35	7.39	5.63	9.16
DC1XX9N	DM8V75C	ABIRATERONE	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	19.55	17.14	13.77	18.61
DCA9LYN	DM8V75C	ABIRATERONE	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	27.39	27.02	22.77	27.26
DCYTEU1	DM8V75C	ABIRATERONE	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	20.82	20.76	17.17	20.95
DCV7CVY	DM8V75C	ABIRATERONE	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.01	9.12	1.46	9.7
DC1BUQT	DM8V75C	ABIRATERONE	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	10.88	16.89	0.51	17.44
DC9I1OL	DM8V75C	ABIRATERONE	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.44	1.63	0.16	4.2
DCNK2AY	DM8V75C	ABIRATERONE	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	11.83	16.75	4.55	18.95
DC60KCI	DM8V75C	ABIRATERONE	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	19.13	18.55	16.76	19.38
DCSMOYD	DM8V75C	ABIRATERONE	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	11.32	12.66	14.43	14.84
DC9HHV9	DM8V75C	ABIRATERONE	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	9.94	11.44	4.57	10.61
DC95AF7	DM8V75C	ABIRATERONE	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	19.65	17.51	14.26	20.3
DCN8WVN	DM8V75C	ABIRATERONE	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	10.39	11.41	6.45	11.69
DCCR03I	DM8V75C	ABIRATERONE	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.03	8.91	11.5	10.78
DCGKC3Z	DM8V75C	ABIRATERONE	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.9	3.47	0.57	3.38
DCV4KGM	DM8V75C	ABIRATERONE	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	13.42	10.53	11.06	10.9
DCYJ5J5	DM8V75C	ABIRATERONE	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.79	8.65	4.29	9.38
DC1S32L	DM8V75C	ABIRATERONE	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.51	4.94	3.18	5.18
DCJ378D	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	11.74	9.35	4.8	10.08
DCY4M3E	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	11.96	9.73	6.39	12.04
DCY6Z1X	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	5.36	6.11	3.79	6.13
DCDBPMK	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	7.27	6.41	5.28	8.86
DC4LKRS	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	4.34	3.48	1.7	5.39
DCXAJAQ	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	6.87	10.66	11.22	14.77
DC6GVW2	DM8V75C	ABIRATERONE	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	26.83	25.66	12.72	23.05
DCIO3D7	DM8V75C	ABIRATERONE	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	25.63	23.69	12	22.04
DCA0EJG	DM8V75C	ABIRATERONE	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	4.73	11.06	9.95	11.1
DCG0EOS	DM8V75C	ABIRATERONE	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.23	7.6	4.96	7.41
DC8HROL	DM8V75C	ABIRATERONE	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1	5.7	3.07	3.57
DC7UZ0R	DM8V75C	ABIRATERONE	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.91	8.7	8.47	8.96
DCI8DK2	DM8V75C	ABIRATERONE	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	10.13	11.34	8.57	12.03
DC9XTHR	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.02	3.37	4.27	5.95
DCDKTRM	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	6.47	9.56	3.73	9.96
DCVHE9C	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.54	8.53	5.06	8.62
DCND3JP	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.53	6.49	5.42	5.31
DCCC1YP	DM8V75C	ABIRATERONE	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	6.84	8.81	4.05	10.12
DCV4TFS	DM8V75C	ABIRATERONE	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	14.81	17.94	11.06	11.64
DC6O0ZI	DM8V75C	ABIRATERONE	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.78	7.09	0.27	0.6
DCK4ONP	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	13.69	9.68	6.11	10.57
DC3DGW8	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.53	4.33	2.49	4.51
DCJKQE3	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	6.48	12.48	2.04	13.92
DCIUTHU	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	5.66	6.37	2.25	8.69
DCP981X	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	3.92	9.76	3.02	9.47
DCCPTW3	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	12.7	13.26	14.8	15.16
DCGFSHC	DM8V75C	ABIRATERONE	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	13.79	13.92	4.31	9.1
DCEK6SH	DM8V75C	ABIRATERONE	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.52	5.9	2.29	8.95
DC4DUS7	DM8V75C	ABIRATERONE	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.56	8.23	5.64	10.13
DCTOLGT	DM8V75C	ABIRATERONE	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.26	5.52	2.57	2.49
DCH2W42	DM8V75C	ABIRATERONE	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.69	11.31	9.85	10.44
DC19U2O	DM8V75C	ABIRATERONE	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.12	1.43	0.31	2.05
DCMYPEA	DM8V75C	ABIRATERONE	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	18.36	15.3	17.91	17.72
DCCYU60	DM8V75C	ABIRATERONE	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.38	6.08	2.08	5.59
DCLIKY7	DM8V75C	ABIRATERONE	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.33	4.92	4.21	5.66
DCM24A9	DM8V75C	ABIRATERONE	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	3.42	3.91	0.38	1.45
DCN7VVP	DM8V75C	ABIRATERONE	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	5.49	7.86	7.35	8.56
DCE2TI4	DM8V75C	ABIRATERONE	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.09	2.18	5.6	4.9
DCHRAZM	DM8V75C	ABIRATERONE	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	3.44	4.73	5.73	7.14
DCCARHZ	DM8V75C	ABIRATERONE	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	11.31	9.14	8.91	8.94
DCMAUHB	DM8V75C	ABIRATERONE	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	9.24	10.11	4.15	9.88
DCUPUSV	DM8V75C	ABIRATERONE	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.53	7.27	2.07	2.07
DCYC2Y8	DM8V75C	ABIRATERONE	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	10.3	14.12	13.92	16.27
DCIGDOY	DM8V75C	ABIRATERONE	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.78	6.79	4.2	4.62
DCDC5K0	DM8V75C	ABIRATERONE	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	14.14	12.62	14.56	14.79
DC0U7DK	DM8V75C	ABIRATERONE	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	7.1	3.66	2.04	5.23
DCLRNO8	DM8V75C	ABIRATERONE	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.23	4.31	3.41	5.03
DC04AQH	DM8V75C	ABIRATERONE	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	5.14	3.1	1.88	3.48
DC7JS8J	DM8V75C	ABIRATERONE	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	8.36	6.55	8.8	8.8
DCJ0WAD	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	15.11	12.32	8.51	13.64
DCP4TN0	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	7.65	9.21	5.52	10.84
DC159T4	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.2	9.19	0.7	9.94
DCJJ1OH	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	24.75	22.13	15.6	23.21
DC2WGZL	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	23.08	18.76	14.35	20.07
DCNUQHC	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.41	9.1	7.5	9.37
DCY8ZRB	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	38.98	28.58	24.46	28.11
DCZ8LDN	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	7.6	7.04	4.32	9.3
DC0RMWZ	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	15.22	9.63	6.45	10.68
DCOZMKA	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	6.87	8.87	11.18	11.53
DCLYZ88	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.87	4.93	1.75	1.4
DCHAZZT	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	7.3	12.98	1.32	11.68
DCO0OVH	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	14.37	17.55	20.2	20.35
DCSQ42T	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	6.41	11.31	14.74	15.09
DC35RMN	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	6.69	11.05	10.23	11.14
DC8WV02	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	12.6	14.57	8.15	16.02
DCHBVZQ	DM8V75C	ABIRATERONE	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.92	11.35	5.82	5.82
DC7KNOM	DM8V75C	ABIRATERONE	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.54	6.18	0.8	3.74
DCJBSJW	DM8V75C	ABIRATERONE	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.68	3.39	1.23	1.22
DCNMKCN	DM8V75C	ABIRATERONE	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	7.02	6.88	8.14	8.18
DC0K9QA	DM8V75C	ABIRATERONE	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	7.83	11.73	4.45	3.3
DCS8EE7	DM8V75C	ABIRATERONE	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.07	5.89	0.28	5.7
DC44GG2	DM8V75C	ABIRATERONE	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.4	3.54	0.55	4.09
DCBTQCE	DM8V75C	ABIRATERONE	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.92	8.68	2.08	4.72
DCQEXED	DM8V75C	ABIRATERONE	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	9.63	13.16	1.73	7.94
DCKOTAE	DM8V75C	ABIRATERONE	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	18.86	19.76	21.59	21.12
DCA4OS0	DM8V75C	ABIRATERONE	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	17.76	12.21	8.32	11.53
DC8YYWX	DM8V75C	ABIRATERONE	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.11	0.97	1.17	0.62
DCP72Y1	DM8V75C	ABIRATERONE	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	10.06	10.03	13.31	13.3
DCNFJ7G	DM8V75C	ABIRATERONE	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.34	0.09	0.71	3.29
DCI1Z40	DM8V75C	ABIRATERONE	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.26	2.42	0.37	0.24
DCVK77Q	DM8V75C	ABIRATERONE	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	11.32	13.33	8.12	7.97
DC5B0TS	DM8V75C	ABIRATERONE	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.45	10.76	8.4	7.92
DC27L74	DM8V75C	ABIRATERONE	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	4.87	1.92	1.29	1.82
DC7XPEK	DM8V75C	ABIRATERONE	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.19	3.6	3.3	2.63
DCYWOTM	DM8V75C	ABIRATERONE	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.54	6.48	5.09	4.57
DCMNEQS	DM8V75C	ABIRATERONE	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	11.02	11.64	1.39	10.21
DC7X3W0	DM8V75C	ABIRATERONE	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.39	9	4.22	11.03
DCT9L6D	DM8V75C	ABIRATERONE	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.75	9.36	4.94	8.82
DC8N3X4	DM8V75C	ABIRATERONE	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	5.32	10.5	9.33	12.41
DC2J084	DM8V75C	ABIRATERONE	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	11.49	13.56	8.06	12.58
DC3KPRQ	DM8V75C	ABIRATERONE	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	6.69	12.14	13.42	13.69
DCY37RG	DM8V75C	ABIRATERONE	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	6.83	8.64	0.37	9.39
DCBTLGS	DM8V75C	ABIRATERONE	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	12.4	13.09	13.46	13.68
DCA8IQM	DM8V75C	ABIRATERONE	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	22.81	27.5	22.5	22.17
DCFRQJ9	DM8V75C	ABIRATERONE	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	15.19	13.38	10.81	13.21
DCAQ75W	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	22.3	20.98	16.59	21.16
DC8SVDT	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	21.73	18.53	15.24	22.11
DCCC1G3	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	14.22	14.19	3.87	15.24
DCM6LCX	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	19.56	21.03	15.72	21.88
DCKDSR0	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	12.48	14.62	12.3	16.09
DC0P0EW	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	5.3	5.52	8.52	8
DCUH30M	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	6.66	9.4	5.58	11.79
DCMIERP	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	11.4	12.13	5.23	11.68
DCMMSI0	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	9.82	11.08	12.85	13.12
DCESWHV	DM8V75C	ABIRATERONE	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.96	7.08	7.33	8.31
DCH0KFM	DM8V75C	ABIRATERONE	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.89	5.26	0.1	3.26
DCIKH3Q	DM8V75C	ABIRATERONE	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	4	5.62	8.26	9.89
DCJLIM7	DM8V75C	ABIRATERONE	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.71	17.41	8.85	8.45
DCP1NA6	DM8V75C	ABIRATERONE	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.51	5.93	3.82	4.49
DCQKMC8	DM8V75C	ABIRATERONE	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.09	3.22	0.61	0.81
DC0BUPZ	DM8V75C	ABIRATERONE	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.87	4.21	0.74	4.83
DCP5BYH	DM8V75C	ABIRATERONE	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	7.93	9.5	8.21	11.1
DCKIFIE	DM8V75C	ABIRATERONE	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.68	7.59	1.46	4.22
DCRIEW8	DM8V75C	ABIRATERONE	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.55	5.98	5.68	6.88
DCJJWHU	DM8V75C	ABIRATERONE	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	10.15	13.07	15.03	15.38
DCFRJ3A	DM8V75C	ABIRATERONE	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.29	5.35	5.59	8.17
DCP1WD6	DM8V75C	ABIRATERONE	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.87	4.39	0.91	0.55
DCRG75V	DM8V75C	ABIRATERONE	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	10.38	9.09	10.6	10.72
DCADIFJ	DM8V75C	ABIRATERONE	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	12.74	8.06	3.48	9.04
DC2ELHG	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	2.94	4.67	3.81	3.58
DCDE0R2	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	18.97	15.64	11.62	18.12
DCN3LUV	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	10.23	10.53	7.76	10.53
DCS68C2	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	33.74	33.98	27.89	35.99
DC640KB	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.77	3.92	1.12	2.29
DCO9V7V	DM8V75C	ABIRATERONE	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.73	9.83	2.69	10.38
DCFVFCC	DM8V75C	ABIRATERONE	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.45	6.53	2.58	2.58
DC5QPFY	DM8V75C	ABIRATERONE	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.52	2.36	2.99	5.31
DCM8VZG	DM8V75C	ABIRATERONE	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.11	1.43	0.09	0.32
DCOS80J	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.82	6.04	6.81	7.33
DCEVHT9	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	9.56	9.78	1.19	6.16
DCOJGIK	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.95	8.37	9.17	9.97
DCAST26	DM8V75C	ABIRATERONE	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.42	7.83	3.61	4.68
DCXXM9C	DM8V75C	ABIRATERONE	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	6.32	11.98	12.04	12.3
DCQ96LH	DM8V75C	ABIRATERONE	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.85	7.4	6.24	7.18
DC4WZA1	DM8V75C	ABIRATERONE	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.39	5.12	3.87	4.06
DC9FWLL	DM8V75C	ABIRATERONE	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.07	3.81	2.67	3.52
DCBYB1Y	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	27.42	25.57	25.19	25.19
DCTMPDZ	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.96	8.2	8.65	8.36
DCA5BU2	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	23.57	24.81	23.92	23.73
DCRHEV1	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	41.66	41.35	41.1	37.25
DCGFO32	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	30.44	32.62	30.61	30.61
DCTKWRN	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.36	5.97	1.97	2.38
DCUR1QK	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	11.27	18.65	16.63	17.58
DC3FKF9	DM8V75C	ABIRATERONE	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.32	4.85	0.85	0.57
DCKRLRB	DM8V75C	ABIRATERONE	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.26	1.61	0.88	1.21
DCCW3EN	DM8V75C	ABIRATERONE	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.69	5.45	3.05	3.32
DCGA9HM	DM8V75C	ABIRATERONE	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.67	8.72	10.06	10.17
DCM74TX	DM8V75C	ABIRATERONE	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.85	5.81	3.03	5.9
DCKWJHP	DM8V75C	ABIRATERONE	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.24	11.71	6.76	7.45
DCY0J6K	DM8V75C	ABIRATERONE	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.74	10.79	3.09	4.58
DCZ1A85	DM8V75C	ABIRATERONE	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.84	5.25	3.73	4.86
DCRPQ0A	DM8V75C	ABIRATERONE	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.51	5.23	3.02	3.65
DC3A52F	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	26.63	23.76	23.83	24.06
DCC0NXQ	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	21.08	24.06	22.93	23.25
DC20TBS	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	35.37	30.05	27.7	25.74
DCJIWN6	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	26.56	30.91	28.95	28.81
DCBCYQ1	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	31.9	32.03	31.53	31.41
DCKC3D6	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	23.61	26.13	25.12	25.32
DCK3LOJ	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	31.02	29.77	25.85	26.27
DC43POE	DM8V75C	ABIRATERONE	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.94	6.85	3.34	6.31
DCUQZDL	DM8V75C	ABIRATERONE	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	7.65	8.51	1.77	11.34
DC6EH7G	DM8V75C	ABIRATERONE	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.71	9.06	10.87	12.05
DCTCAUC	DM8V75C	ABIRATERONE	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.48	4.05	0.48	7.72
DC53XKB	DM8V75C	ABIRATERONE	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.87	4.06	2.64	5.93
DCNHKCN	DM8V75C	ABIRATERONE	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.38	7.02	2.68	3.08
DC8PN0O	DM8V75C	ABIRATERONE	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	7.48	7.55	4.47	6.72
DC9WBZZ	DM8V75C	ABIRATERONE	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.38	5.64	1.06	1.67
DCQEYRR	DM8V75C	ABIRATERONE	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	9.74	12.49	8.99	8.63
DCP7F16	DM8V75C	ABIRATERONE	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.98	2.03	1.66	1.71
DCKQI2A	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	12.57	10.96	12.2	13.65
DCMCZAW	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	13.85	14.11	8.76	16.84
DCNH026	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	9.42	11.91	2.26	11.97
DC22X7O	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.01	11.39	7.1	11.38
DCELGUC	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.31	6.76	7.5	8.65
DC8S136	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.86	9.18	4.67	2.94
DCK4XNC	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.36	9.5	7.52	8.02
DC03WRB	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.2	6.67	9.27	9.54
DCP5HZ3	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.16	9.12	2.6	3.82
DCO0EXY	DM8V75C	ABIRATERONE	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.75	3.76	0.36	5.42
DC6LR8H	DM8V75C	ABIRATERONE	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.88	6	1.98	5.85
DC15MK8	DM8V75C	ABIRATERONE	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.12	5.19	5.85	9.12
DC1BWT9	DM8V75C	ABIRATERONE	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	7.35	14.64	13.35	14.92
DC2C5DK	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	17.3	15.92	19.61	20.29
DCF33KO	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.94	8.1	7.81	10.45
DC28YHQ	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.51	4.46	4.38	4.84
DCJOVC6	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	12.79	14.41	2.84	13.59
DCAU6LG	DM8V75C	ABIRATERONE	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.99	8.09	0.34	3.59
DC1JVNU	DM8V75C	ABIRATERONE	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.6	2.72	0.62	1.26
DCTVHMW	DM8V75C	ABIRATERONE	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.31	11.23	7.98	8.5
DCFUHPD	DM8V75C	ABIRATERONE	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.36	5.51	5	7.65
DCGTECQ	DM8V75C	ABIRATERONE	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.44	7.58	5.77	6.75
DCWAY8F	DM8V75C	ABIRATERONE	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.35	3.79	0.11	4.44
DC3EVNE	DM8V75C	ABIRATERONE	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	11.5	13.07	6.48	14.32
DCAPZRN	DM8V75C	ABIRATERONE	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	5.68	8.61	1.57	8.48
DCF3SXR	DM8V75C	ABIRATERONE	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.74	11.12	12.16	12.56
DCL1IZW	DM8V75C	ABIRATERONE	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.33	6.04	5.91	7.96
DCFOMSM	DM8V75C	ABIRATERONE	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.89	4.44	0.21	4.14
DCCKRNS	DM8V75C	ABIRATERONE	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	14.43	16.85	17.55	19.12
DCGMH4G	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	10.15	8.3	5.66	11.23
DCVER8D	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	8.25	9.51	6.74	13.33
DCZ7F0H	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	7.59	8.63	7.15	10.33
DCW9574	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	19.68	15.08	16.94	17.83
DCUHHVN	DM8V75C	ABIRATERONE	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.13	4.85	0.18	3.93
DC1BJ6Q	DM8V75C	ABIRATERONE	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.49	6	3.35	4.61
DC5GL54	DM8V75C	ABIRATERONE	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.12	10.34	6.99	5.93
DC7OVII	DM8V75C	ABIRATERONE	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.95	5.94	4.72	5.88
DCFA13W	DM8V75C	ABIRATERONE	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.1	3.52	2.1	2.64
DCQVIOE	DM8V75C	ABIRATERONE	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.54	3.16	3.28	4.8
DCIB03Q	DM8V75C	ABIRATERONE	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	10.44	7.63	3.2	1.23
DC98QNJ	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.54	7.69	4.54	7.82
DC2D5HA	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.32	11.31	7.18	5.95
DCDHIOL	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.88	3.44	1.06	1.71
DCLYH34	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.04	7.32	3.57	6.08
DC0UBUH	DM8V75C	ABIRATERONE	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.23	8.15	3.82	8.16
DCFM2ML	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	7.85	6.57	3.07	8.41
DC6VV7D	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.51	5.7	4.3	7.53
DCC1I2V	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.27	4.87	6.07	6.62
DCUDYJ7	DM8V75C	ABIRATERONE	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.44	5.53	5.64	6.09
DC3NJB8	DM8V75C	ABIRATERONE	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.75	5.33	1.32	0.89
DCSDPPQ	DM8V75C	ABIRATERONE	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.04	8.09	4.88	4.96
DCFECD2	DM8V75C	ABIRATERONE	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	6.86	5.72	4.57	5.58
DCLINMV	DM8V75C	ABIRATERONE	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.85	3.24	3.17	5.82
DCW9G53	DM8V75C	ABIRATERONE	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.75	2.95	1.23	2.91
DCFKCXX	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	9.27	9.06	7.93	11.02
DCMUSL3	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	8.27	15.43	7.91	6.65
DC7YNTK	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.48	7.05	3.29	4.4
DCVSL1A	DM8V75C	ABIRATERONE	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.24	3.83	2.15	2.79
DCK32G8	DM8V75C	ABIRATERONE	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.11	5.72	2.8	3.27
DCRSTKA	DM8V75C	ABIRATERONE	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.07	9.22	1.87	4.94
DCHB4V2	DM8V75C	ABIRATERONE	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.5	4.1	2.62	4.99
DCHLSLV	DM8V75C	ABIRATERONE	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.95	6.04	5.13	7.91
DCLS1BG	DM8V75C	ABIRATERONE	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	8.24	9.45	6.47	9.7
DCYC3JI	DM8V75C	ABIRATERONE	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.98	3.63	3.95	4.63
DCI97DE	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	15.85	13.3	13.23	16.14
DCE9HYZ	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	10.11	10.1	4.61	12.71
DCSCRU4	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	11.3	11.13	9.37	12.56
DCADALD	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	7.99	8.1	3.94	10.19
DCVFY1B	DM8V75C	ABIRATERONE	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.37	2.63	1.34	1.91
DCVL7Z6	DM8V75C	ABIRATERONE	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.48	5.05	2.38	6.78
DCF770Q	DM8V75C	ABIRATERONE	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.18	4.59	4.45	6.92
DCSHYT9	DM8V75C	ABIRATERONE	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.98	8.82	3.65	5.16
DC9Z7UN	DM8V75C	ABIRATERONE	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.99	1.83	0.91	1.72
DCQBY84	DM8V75C	ABIRATERONE	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.88	5.83	1.76	1.57
DCLOC90	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.18	3.76	3.71	4.2
DCHJTLS	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.34	4.88	0.4	7.85
DC809J1	DM8V75C	ABIRATERONE	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	4.53	12.78	1.55	10.36
DC8LYYX	DM8V75C	ABIRATERONE	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.97	3.72	3.15	0.57
DCLNQLX	DM8V75C	ABIRATERONE	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.87	4.46	3.43	3.53
DCC5YWI	DM8V75C	ABIRATERONE	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	2.57	5.2	2.19	1.45
DC9RPSD	DM8V75C	ABIRATERONE	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	24.17	23.03	15.21	26.52
DCKY0FX	DM8V75C	ABIRATERONE	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.51	7.9	6.09	5.35
DC2OKH4	DM8V75C	ABIRATERONE	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.54	5.41	4.46	1.37
DC1KMSQ	DM8V75C	ABIRATERONE	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.66	3.34	1.11	0.91
DCBAHUO	DM8V75C	ABIRATERONE	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.87	4.29	0.54	2.45
DCTQWP7	DM8V75C	ABIRATERONE	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.13	3.63	1.06	1.12
DCF3SE9	DM8V75C	ABIRATERONE	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.31	3.57	2.51	4.03
DCX87AT	DM8V75C	ABIRATERONE	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.36	2.78	1.67	0.44
DCEX7ZN	DM8V75C	ABIRATERONE	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.23	6.18	0.55	4.91
DC6AW0W	DM8V75C	ABIRATERONE	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.1	13.03	9.67	10.09
DCWPFWD	DM8V75C	ABIRATERONE	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.15	5.27	4.72	3.65
DCNA1TR	DM8V75C	ABIRATERONE	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.98	6.37	5.27	6.44
DCJEVY6	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.04	5.85	5.71	8.81
DCIQHVB	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	9.37	6.07	4.72	7.66
DCGZP1S	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.44	9.95	7.91	10.02
DC1SK0I	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	18.29	20.5	13.3	19.23
DCLGJXX	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.3	7.17	3.31	8.94
DCFN0UD	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.66	10.27	8.94	10.36
DC6R5F8	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	4.02	6.53	4.55	7.26
DC8U9XG	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.32	11.34	10.59	12.72
DCHX3QO	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.23	10.64	3.03	8.85
DCV6PPN	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	19.19	15.37	15.85	16.15
DCIM11F	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.99	7.4	6.23	7.26
DC98OUG	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	12.31	12.16	0.32	13.64
DCOAP76	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.01	6.02	5.76	7.5
DCJM37R	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8.68	9.99	0.5	9.98
DCKUPQO	DM8V75C	ABIRATERONE	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.77	8.14	6.79	8.21
DCCLGM8	DM8V75C	ABIRATERONE	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.48	5.04	4.11	3.94
DCU94JH	DM8V75C	ABIRATERONE	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.17	4.73	6.75	8.06
DCSFQ09	DM8V75C	ABIRATERONE	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.87	7.96	6.05	1.79
DCOSCRC	DM8V75C	ABIRATERONE	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.31	2.75	2.04	1.41
DC2D550	DM8V75C	ABIRATERONE	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.01	1.66	1.16	1.26
DCKZJI3	DM8V75C	ABIRATERONE	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.21	4.52	1.11	3.86
DCOHUTU	DM8V75C	ABIRATERONE	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.91	6.91	4.38	4.32
DC8Z9BE	DM8V75C	ABIRATERONE	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.49	5.93	2.48	4.39
DC43MZS	DM8V75C	ABIRATERONE	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	5.14	10.31	6.7	9.02
DCOKC2R	DM8V75C	ABIRATERONE	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	10.77	14.99	9.08	15.27
DCFMMAO	DM8V75C	ABIRATERONE	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.46	8.05	7.47	5.6
DCM5ZTM	DM8V75C	ABIRATERONE	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	11.2	8.42	10.36	9.89
DC4MYSJ	DM8V75C	ABIRATERONE	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.12	2.73	0.5	1.66
DCUKD9J	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	7.56	13.34	12.87	11.65
DCGJI4O	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	28.48	30.19	29.1	29.3
DC0LGI2	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.19	2.8	1.5	1.54
DCT78BH	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6.13	8.26	7.54	6.87
DCPV0S7	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	26.58	30.36	29.06	28.33
DCL3A4R	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	16.37	19.25	10.65	18.1
DCNIHG5	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	8.66	10.29	7.39	7.45
DCYHVKQ	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	5.74	6.96	4.31	4.12
DCZ4D73	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	33.68	36.6	35.79	35.17
DC6BOGP	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	10.01	21.23	20.34	20.18
DC7O488	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	22.9	21.67	19.66	20.47
DC5315A	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	7.78	16.9	14.54	14.63
DC0IG5C	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	19.95	20.37	17.53	17.49
DCSJKVV	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	23	23.47	22.37	22.33
DCF9FPD	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	25.62	29	27.97	28.05
DCI9RNU	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	3.45	6.33	6.33	5.86
DC2I5KN	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	15.99	17.62	15.77	15.77
DC6L32F	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	4.9	10.89	11.55	11.21
DCQ9YQO	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	11.58	17.31	16.99	14.82
DCMCVER	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.77	10.43	8.9	9.33
DCR653U	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	13.29	16.62	15.83	15.68
DCU6QJL	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	21.01	22.58	23	22.88
DC8GMKH	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	6.68	6.54	7.97	7.37
DC03GH5	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	26.51	27.01	19.62	22.96
DCUPW4R	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	12.69	17.45	15.85	16.07
DCPUBNP	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	8.55	17.4	16.29	15.85
DCLC22H	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.72	9.88	9.2	9.23
DCVL6C9	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	6.06	12.43	12.7	11.83
DCFDP4F	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.01	14.78	13.26	13.37
DCNVGJY	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.83	12.57	11.14	10.92
DC34BZI	DM8V75C	ABIRATERONE	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	6.67	11.48	12.07	11.38
DCBTQ1M	DM8V75C	ABIRATERONE	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.26	3.96	2.41	0.93
DCDJILT	DM8V75C	ABIRATERONE	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.74	3.49	4.27	5.2
DC8D2B2	DM8V75C	ABIRATERONE	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	10.52	10.25	0.75	12.17
DCD9UX8	DM8V75C	ABIRATERONE	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.71	0.86	0.16	0.38
DCD936W	DM8V75C	ABIRATERONE	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.53	5.72	3.86	1.43
DCW2DD3	DM8V75C	ABIRATERONE	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	8.47	8.07	0.81	8.65
DCQ3A37	DM8V75C	ABIRATERONE	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.2	7.89	1.21	6.31
DCM0ZNH	DM8V75C	ABIRATERONE	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.42	6.12	3.21	5.17
DCVNKHB	DM8V75C	ABIRATERONE	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	16.21	21.21	20.29	21.49
DCUTYUL	DM8V75C	ABIRATERONE	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	10.85	13.06	15.86	17.22
DCCXXWW	DM8V75C	ABIRATERONE	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.34	11.35	7.95	11.4
DCUDBXQ	DM8V75C	ABIRATERONE	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.83	7.97	8.16	8.25
DCNVG75	DM8V75C	ABIRATERONE	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.43	5.93	2.71	6.39
DC67F7D	DM8V75C	ABIRATERONE	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.55	6.27	8.55	8.93
DC7TM8Q	DM8V75C	ABIRATERONE	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.22	6.33	5.09	5.43
DC9WC0B	DM8V75C	ABIRATERONE	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.62	6.56	1.17	3.2
DC99LKP	DM8V75C	ABIRATERONE	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.97	7.04	1.82	1.76
DCIIVLD	DM8V75C	ABIRATERONE	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.73	6.99	5.83	5.93
DC52YOY	DM8V75C	ABIRATERONE	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	7.18	9.81	5.86	9.77
DC23PNW	DM8V75C	ABIRATERONE	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	8.41	13.56	14.82	16.39
DC2XM01	DM8V75C	ABIRATERONE	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.53	3.72	3.94	2.11
DCU9CBT	DM8V75C	ABIRATERONE	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.02	4.24	2.82	1.2
DC57W56	DM8V75C	ABIRATERONE	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.25	3.76	0.69	1.09
DC8D55B	DM8V75C	ABIRATERONE	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.26	2.42	0.34	1.26
DCEW4WX	DM8V75C	ABIRATERONE	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	13.63	13.07	12.34	16.03
DCOE67G	DM8V75C	ABIRATERONE	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.31	7.1	3.72	8.57
DCJ31D6	DM8V75C	ABIRATERONE	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.01	1.93	0.33	1.91
DCZNZ5H	DM8V75C	ABIRATERONE	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	7.62	6.06	3.3	6.59
DCK5BVU	DM8V75C	ABIRATERONE	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.99	5.24	2.22	0.58
DCBK5JJ	DM8V75C	ABIRATERONE	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.35	4.28	2.11	2.9
DCP4C65	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	6.21	11.69	10.72	10.32
DC08NY5	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	25.39	24.72	24.29	24.49
DCDKMVK	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	7.68	14.93	14.75	14.81
DCKR6JF	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	20.11	21.4	20.75	20.75
DCI5JL6	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	23.29	27.12	25.8	25.92
DCXSE44	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	33.16	34.97	31.69	31.74
DC8I3XG	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	31	27.51	24.88	25.26
DCJ2GEH	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	29.47	30.23	29.68	29.77
DC0TMU8	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.44	9.54	11.42	10.97
DCNIN8Z	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	26.83	26.52	26.05	26.02
DC4ID0K	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.37	4.64	3.04	3.07
DCYA9D8	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.53	3.97	1.67	4.97
DC2QCZE	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.22	8.12	7.6	7.65
DCO7KCZ	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	17.35	16.32	17.12	16.95
DCXANDV	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	24.77	26.27	28.99	30.36
DCO8MWI	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	13.59	12.79	13.64	12.53
DCTAERX	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	34.95	33.48	31.66	30.19
DC2TZ3Q	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.58	16.69	16.36	15.46
DCOORA0	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.93	6.39	6.08	6.15
DC088NU	DM8V75C	ABIRATERONE	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.55	13.82	13.3	13.3
DCXQPZ3	DM8V75C	ABIRATERONE	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.62	3.8	1.81	2.21
DC75MJE	DM8V75C	ABIRATERONE	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.78	7.19	1.97	3.15
DCCFR4Y	DM8V75C	ABIRATERONE	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.8	6.69	6.52	4.77
DCZB1KN	DM8V75C	ABIRATERONE	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.26	6.22	4.74	2.68
DCYOKLV	DM8V75C	ABIRATERONE	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.06	2.54	4.18	2.97
DC3ST12	DM8V75C	ABIRATERONE	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	6.5	7.1	4.09	5.45
DCXRKQV	DM8V75C	ABIRATERONE	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4.64	5.87	6.02	7.52
DCONRXO	DM8V75C	ABIRATERONE	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.67	6.65	5.2	6.17
DCCECF8	DM8V75C	ABIRATERONE	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.53	2.85	1.97	3.88
DCJHL9G	DM8V75C	ABIRATERONE	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	2.14	5.61	4.15	2.22
DCUY7P4	DM8V75C	ABIRATERONE	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.26	4.92	4.18	4.09
DCEFH4Z	DM8V75C	ABIRATERONE	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.73	5.23	4.87	5.07
DCWNJP7	DM8V75C	ABIRATERONE	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.96	4.46	2.62	0.74
DCEAU26	DM8V75C	ABIRATERONE	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.5	5.22	2.59	7.26
DCDE2A9	DM8V75C	ABIRATERONE	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	8.9	8.83	5.23	8.46
DCLHYDX	DM8V75C	ABIRATERONE	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	5.54	2.99	0.53	2.82
DCG530I	DM8V75C	ABIRATERONE	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.04	8.17	6.99	8.14
DCZ6N6G	DM8V75C	ABIRATERONE	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.54	3.61	0.17	4.05
DCHELE6	DM8V75C	ABIRATERONE	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.57	9.49	6.5	8.79
DCD2EUY	DM8V75C	ABIRATERONE	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	10.28	11.25	10.93	12.97
DCO5DU4	DM8V75C	ABIRATERONE	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	8.37	8.1	10.52	12.25
DCQEMCP	DM8V75C	ABIRATERONE	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.13	9.58	2.22	11.04
DC3IP0D	DM8V75C	ABIRATERONE	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.36	7.73	4.36	10.66
DCYN3JC	DM8V75C	ABIRATERONE	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.47	7.43	1.27	8.34
DCEOZP5	DM8V75C	ABIRATERONE	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.45	6.89	6.56	6.29
DCWEQH5	DM8V75C	ABIRATERONE	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.03	3.19	2.51	2.27
DC8Z38C	DM8V75C	ABIRATERONE	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.16	9.91	9	8.54
DCSSIRZ	DM8V75C	ABIRATERONE	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	8.1	11.48	1.6	11.9
DCZQLF8	DM8V75C	ABIRATERONE	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.78	6.47	5.22	5.79
DCNYSY3	DM8V75C	ABIRATERONE	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.45	4.96	0.23	3.57
DC5I5LR	DM8V75C	ABIRATERONE	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	6.27	3.97	3.45	2.13
DC5UWPI	DM8V75C	ABIRATERONE	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.18	4.68	3.57	0.57
DC2VEVL	DM8V75C	ABIRATERONE	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.23	8.03	7.77	7.48
DCTXO9W	DM8V75C	ABIRATERONE	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.55	6.49	5.99	6.01
DCZA38C	DM8V75C	ABIRATERONE	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.59	6.51	3.54	3.9
DCIILG5	DM8V75C	ABIRATERONE	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.41	6.33	4.44	0.98
DCJH1OP	DM8V75C	ABIRATERONE	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.36	3.48	1.49	1.41
DCZCQYT	DM8V75C	ABIRATERONE	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.96	6.9	5.21	4.48
DCH645M	DM8V75C	ABIRATERONE	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	8.24	11.78	1.59	11.56
DCK7QO9	DM8V75C	ABIRATERONE	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	8.55	8.49	5.87	10.02
DC3RUFP	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	9.29	8.18	3.93	9.65
DCKAXAL	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	13.55	14.26	10.89	14.3
DC3VEMX	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	15.89	11.48	7.11	12.03
DCPXSN8	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	20.12	20.26	16.14	20.08
DCFUFSX	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	10.76	18.39	6.01	15.89
DCW6KLK	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	11.24	10.86	4.43	9.58
DCH06JM	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	16.62	17.31	1.15	16.44
DCWZBYF	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	10.21	8.39	2.52	7.94
DCUGHZN	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	6.52	11.17	0.5	10.67
DC3XDCQ	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	9.7	12.26	5.97	12.81
DCI4FQO	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	8.11	10.26	2.04	12.55
DCS8KXH	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	8.04	6.87	0.51	6.04
DC2831Z	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	25.36	25.35	21.88	24.36
DCW5S8S	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	9.88	10.76	8.06	11.26
DCI6EOA	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	9.93	9.79	11.83	13.43
DCI1A9J	DM8V75C	ABIRATERONE	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	8.5	9.25	6.25	9.85
DCLHYLO	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.72	6.6	5.66	3.9
DCJC9CL	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1	5.13	0.32	1.76
DCCLFLB	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.86	9.5	3.34	5.22
DC8A96I	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.29	7.02	2.96	4.22
DC58G3J	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.81	13.51	6.87	8.8
DCNG3B5	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.03	8.18	5.15	5.69
DCKWIP2	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.52	13.84	7.76	9.36
DCAPMSM	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.03	4.65	2.54	3.41
DCLXAAQ	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.42	9.2	6.36	7.86
DC7OCPC	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.75	4.66	1.29	1.99
DCML8JI	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.23	11.94	7.07	8.52
DCXDUSI	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.22	3.95	3.36	1.69
DCNCBQ9	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.05	6.8	5.36	5.93
DCMN4MU	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.22	9.5	6.71	4.73
DCYL1PB	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.06	7.94	3.8	6.53
DCY2CUS	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.63	2.96	2.42	1.6
DC8IZGS	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.87	6.79	7.53	6.63
DCBT4M9	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.37	2.59	1.71	1.87
DCFY0Q5	DM8V75C	ABIRATERONE	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.55	8.42	3.27	4.14
DCKRQU7	DM8V75C	ABIRATERONE	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	18.93	16.61	11.1	16.04
DCDIWR7	DM8V75C	ABIRATERONE	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.63	5.27	3.3	5.58
DCGV9FW	DM8V75C	ABIRATERONE	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.02	8.57	1.08	7.1
DCKV1IP	DM8V75C	ABIRATERONE	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.98	11.35	7.01	10.05
DCCJYNP	DM8V75C	ABIRATERONE	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	9.17	14.93	8.01	13.03
DCKY211	DM8V75C	ABIRATERONE	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	11.22	11.61	2	10.36
DC11VK3	DM8V75C	ABIRATERONE	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	16.83	15.04	13.93	14.11
DCBJCN0	DM8V75C	ABIRATERONE	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	7.66	12.21	12.57	12.89
DC9MRLN	DM8V75C	ABIRATERONE	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	11.77	13.73	8.84	13.15
DCOIL69	DM8V75C	ABIRATERONE	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	7.84	10.22	3.25	9.71
DC4RKBX	DM8V75C	ABIRATERONE	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4.05	6.73	3.64	5.54
DC2YDX0	DM8V75C	ABIRATERONE	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	10.32	8.77	10.24	10.15
DC3H05B	DM8V75C	ABIRATERONE	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.71	5.72	3.7	5.29
DCJSJW1	DM8V75C	ABIRATERONE	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.42	5.67	3.72	4.85
DCADM2T	DM8V75C	ABIRATERONE	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.65	8.6	5.91	8.44
DCQVJIF	DM8V75C	ABIRATERONE	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.94	5.52	2.01	5.35
DCFXF77	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.42	1.03	1.29	3.64
DCB8PHP	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6.34	9.65	8.47	11.24
DCGEUGE	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.16	6.58	6.32	8.97
DCWXSQC	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.18	6.67	6.96	9.1
DCQKCAW	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	7.03	7.69	5.52	8
DC0J3S4	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	8.66	9.35	7.12	10.52
DCCGGT0	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.39	3.76	2.43	3.74
DC1LCIN	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.19	10.15	8.88	10.25
DCZB25I	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.87	5.25	3.7	5.14
DC0GRMS	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.9	8.93	7.82	8.76
DCX7QV2	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.33	5.58	3.63	6.13
DC3E7MM	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.42	6.14	6.99	8.42
DC44BU7	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.72	7.12	6.19	8.03
DCDUCJA	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	14.63	13.6	17.24	18.12
DC2E5H6	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.31	8.27	0.06	10.03
DCEH1XV	DM8V75C	ABIRATERONE	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.12	3.97	3.45	5.2
DCNR2OI	DM8V75C	ABIRATERONE	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.31	6.07	0.54	5.27
DC4ONZ7	DM8V75C	ABIRATERONE	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.18	5.24	2.74	3.99
DCIB9WA	DM8V75C	ABIRATERONE	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.29	5.87	4.97	4.77
DC34FMB	DM8V75C	ABIRATERONE	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.56	4.54	3.77	3.92
DCYIHNX	DM8V75C	ABIRATERONE	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.78	13.46	1.82	10.85
DCLZPEI	DM8V75C	ABIRATERONE	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.37	4	1.15	5.34
DC7DBKG	DM8V75C	ABIRATERONE	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.37	7.12	4.12	6.96
DCODB33	DM8V75C	ABIRATERONE	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.31	5.49	2.02	4.43
DCOO3BK	DM8V75C	ABIRATERONE	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.73	6.6	6.07	3.78
DCL4JVN	DM8V75C	ABIRATERONE	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	26.19	26.82	26.66	28.44
DC6CX8Y	DM8V75C	ABIRATERONE	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.72	11.89	7.75	10.73
DC1M1C9	DM8V75C	ABIRATERONE	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.92	5.32	4.13	7.35
DC6S94P	DM8V75C	ABIRATERONE	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	5.71	4.24	1.43	3.71
DCAEKCR	DM8V75C	ABIRATERONE	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	16.33	18.24	21.1	21.66
DC73WH3	DM8V75C	ABIRATERONE	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.58	2.14	2.18	3.38
DCSCE32	DM8V75C	ABIRATERONE	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.93	4.03	2.22	0.76
DC8K94B	DM8V75C	ABIRATERONE	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.24	12.8	12.13	12.09
DCRFAJW	DM8V75C	ABIRATERONE	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	8.36	15.5	3.44	13.75
DCPOZAB	DM8V75C	ABIRATERONE	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.67	3.45	0.1	4.05
DC3IMSZ	DM8V75C	ABIRATERONE	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	12.72	14.03	5.38	13.35
DCI0YQB	DM8V75C	ABIRATERONE	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	12.88	15.25	8.81	15.13
DCJ34B6	DM8V75C	ABIRATERONE	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	17.54	17.7	0.21	15.14
DCHRFDT	DM8V75C	ABIRATERONE	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	14.64	13.5	0.91	13.22
DCF5WWX	DM8V75C	ABIRATERONE	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	18.65	18.44	14.68	18.89
DC2IF08	DM8V75C	ABIRATERONE	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	3.33	7.13	4.38	3.98
DC5KYNC	DM8V75C	ABIRATERONE	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	23	23.68	8.02	23.54
DC90QTP	DM8V75C	ABIRATERONE	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.29	6.47	2.09	5.39
DCQMPZK	DM8V75C	ABIRATERONE	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	15.4	12.33	7.95	9.16
DC0NX5E	DM8V75C	ABIRATERONE	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	7.89	6.53	3.51	6.86
DCNZ7PF	DM8V75C	ABIRATERONE	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	15.53	15.32	17.84	19.77
DCYA4W8	DM8V75C	ABIRATERONE	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	6.53	6.39	4.8	5.49
DCI8K6N	DM8V75C	ABIRATERONE	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	9.44	7.71	9.63	9.24
DCOJUXG	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	10.49	11.32	9.36	13.34
DCUQOL1	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	6.81	6.57	2.35	7.46
DCEUISK	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	7.06	5.64	2.11	6.47
DC4ROT5	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	12.72	8.75	5.31	8.69
DCH4V7Z	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	6.77	3.81	1.37	5.29
DCX2JO5	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	6.47	6.57	1.64	6.42
DCDLZLP	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	9.49	11.01	5.53	11.59
DCPKYQB	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	11.4	12.23	8.42	13.55
DCBGA2Q	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	11.68	11.17	4.72	11.15
DCBPDWP	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	16.47	17.19	13.58	16.26
DCJDGFG	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	13.68	14.78	10.45	14.07
DCHJHEU	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	6.46	6.23	0.03	7.54
DCT80CC	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	13.55	13.51	10.21	14.05
DCCMCPF	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	6.33	8.42	7.11	9.71
DCSDS32	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	13.81	8.68	3.55	8.73
DC72CT0	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	7.52	11.1	8.55	11.71
DCHOEY1	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	8.38	10.02	3.51	10.15
DCWA9WR	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.01	3.19	0.28	3.25
DCFFW46	DM8V75C	ABIRATERONE	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	9.03	9.28	2.33	11.12
DCMMR10	DM8V75C	ABIRATERONE	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	12.57	13.7	3.42	9.95
DCLT3EP	DM8V75C	ABIRATERONE	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	11.32	15.43	0.13	12.17
DCLS1J1	DM8V75C	ABIRATERONE	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.23	5.64	3.21	4.34
DCAM5NP	DM8V75C	ABIRATERONE	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	17.61	21.06	23.38	24.73
DC8VMH9	DM8V75C	ABIRATERONE	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	7.5	8.81	6.94	3.76
DCDH8D0	DM8V75C	ABIRATERONE	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.05	7.02	4.61	6.41
DCYW02H	DM8V75C	ABIRATERONE	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.19	4.94	0.86	2.72
DCFC1A9	DM8V75C	ABIRATERONE	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.58	6.18	3.81	3.31
DC8AUSH	DM8V75C	ABIRATERONE	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.07	3.02	2.59	2.62
DCJSKRE	DM8V75C	ABIRATERONE	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	9.14	10.25	0.53	9.64
DCDUDM8	DM8V75C	ABIRATERONE	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.16	1.53	0.44	4.21
DCWIRS1	DM8V75C	ABIRATERONE	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.37	8.3	4.62	8.57
DCTIXQL	DM8V75C	ABIRATERONE	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	8.34	7.49	0.04	9.5
DC7QNJW	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.15	10.13	7.92	7.36
DCNNQHL	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.12	5.68	2.99	3.7
DCWLZZW	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.17	7.27	0.78	7.74
DCAOS0W	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.38	6.16	1.56	2.05
DC9F1R4	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.49	7	1.97	3.13
DCHFFFZ	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.48	3.69	0.97	2.61
DCCJLTZ	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.24	4.48	1.39	3.11
DCEWESD	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.71	6.04	1.63	2.65
DC1W04T	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.48	8.27	6.45	4.96
DCI54IX	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.01	4.54	3.36	3.25
DCONUQQ	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.62	1.89	1.22	0.01
DCRUCY9	DM8V75C	ABIRATERONE	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.02	4.69	2.13	2.83
DCXHJKD	DM8V75C	ABIRATERONE	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.05	3.12	0.12	1.28
DCYFODK	DM8V75C	ABIRATERONE	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.93	11.87	7.08	9.85
DC99V1S	DM8V75C	ABIRATERONE	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.15	4.49	0.04	1.21
DCRZQ3K	DM8V75C	ABIRATERONE	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.77	11	8.23	9.58
DC3CFQF	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.86	5.52	2.38	6.76
DCAF16T	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	9.25	6.51	2.66	6.16
DCJYGVE	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	8.08	11.68	1.68	12.48
DC63V5E	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	6.13	9.73	4.59	9.55
DCJG2Q8	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.44	6.91	3.7	7.03
DCXATRV	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	6.64	9.95	9.59	11.61
DC8PP1Y	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.73	6.85	2.29	6.59
DC53PYK	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	7.37	9.12	0.12	8.35
DCROH9S	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	6.02	6.66	4.89	7.21
DCJW50F	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	15.98	17.31	20.89	21.91
DC0V6B6	DM8V75C	ABIRATERONE	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.09	7.22	4.48	8.84
DCEHA35	DM8V75C	ABIRATERONE	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.15	3.25	1.54	0.91
DCXDZ86	DM8V75C	ABIRATERONE	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.26	5.38	1.14	1.33
DCJFX45	DM8V75C	ABIRATERONE	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.58	2.58	1.39	2.42
DCGZT5P	DM8V75C	ABIRATERONE	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.81	0.72	0.91	1.17
DC9SQBW	DM8V75C	ABIRATERONE	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	8.05	5.48	2.6	4.69
DCF214I	DM8V75C	ABIRATERONE	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.11	4.79	0.63	3.65
DCKVJ9J	DM8V75C	ABIRATERONE	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	6	9.24	0.81	6.95
DCTT1ES	DM8V75C	ABIRATERONE	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	10.33	15.36	4.04	14.04
DCT0MSE	DM8V75C	ABIRATERONE	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.78	6.13	2.96	3.44
DCS4PZB	DM8V75C	ABIRATERONE	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.33	2.75	0.88	0.45
DC5C4QB	DM8V75C	ABIRATERONE	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.4	5.67	2.44	2.45
DCJFLO7	DM8V75C	ABIRATERONE	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	6.32	9.1	7.78	8.13
DC9KBDJ	DM8V75C	ABIRATERONE	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	15.9	17.26	20.28	20.65
DCUZ63L	DM8V75C	ABIRATERONE	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.45	5.26	3.52	2.1
DCKU0HV	DM8V75C	ABIRATERONE	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.63	3.13	1.57	4.73
DCQJ5Z7	DM8V75C	ABIRATERONE	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.13	5.14	3.32	5.12
DCSKQUX	DM8V75C	ABIRATERONE	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.7	2.02	1.27	1.57
DCLA0LL	DM8V75C	ABIRATERONE	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	4.4	3.83	3.6	5.44
DCSG4KC	DM8V75C	ABIRATERONE	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	5.87	6.07	4.76	6.99
DC68RAI	DM8V75C	ABIRATERONE	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.86	9.47	7.02	8.95
DCYWTIV	DM8V75C	ABIRATERONE	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.5	3.08	3.18	4.4
DCLU4IU	DM8V75C	ABIRATERONE	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	6.17	5.05	5.14	6.97
DCX8C1Z	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.88	3.88	0.14	5.5
DC51U2B	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	26.24	18.28	15.21	19.51
DCXP0I1	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	14.33	18.21	14.21	18.74
DC00OAE	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	28.68	23.66	17.98	24.05
DCO9NVH	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	23.08	18.89	13.77	19.38
DCPUG5X	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	24.51	17.34	14.29	18.79
DC5CI13	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	27.21	20.13	16.22	20.52
DCG7RRX	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	28.95	28.7	25.31	28.65
DCZZYID	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	28.71	18.49	14.35	19.24
DCV9CDH	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	11.34	10.66	9.16	10.51
DCC2JR4	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	9.96	9.92	7.67	9.82
DC1FWX5	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	17	12.05	8.69	12.92
DCCGPJR	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	8.48	17.07	14.47	17.27
DCUWW58	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	22.25	23.16	19.62	23.18
DCC54ZT	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	10.63	10.64	5.96	12.14
DC0QPLD	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	7.53	6.28	9.42	12.13
DCJUU05	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	15.69	15.71	14.27	16.19
DCP2OCJ	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	4.61	5.04	1.31	6.14
DC4YO2T	DM8V75C	ABIRATERONE	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	16.12	21.38	18.3	21.04
DCRHR4Z	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.42	10.49	8.92	8.33
DCYCF1L	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.13	8.1	3.56	7.1
DCAVXZV	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.37	4.97	1.33	3.88
DCYSTSD	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	5.54	10.4	8.93	7.08
DC9K1UM	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.17	5.35	3.33	4.49
DCLG7D4	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.27	7.53	0.64	6.74
DC8ULBU	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.38	4.55	4.21	2
DCBDAKJ	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	7.37	8.73	4.9	11.38
DCRNCUL	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.72	4.14	2.78	4.28
DCKH16Q	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	5.5	11.56	6.5	10.34
DC99MB4	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.61	11.84	9.97	7.64
DC8TFT4	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.24	5.21	3.42	3.06
DC4J8UD	DM8V75C	ABIRATERONE	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.78	4.37	1.04	2.26
DCRFIB7	DM8V75C	ABIRATERONE	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.28	3.03	2.72	0.58
DCZGJMR	DM8V75C	ABIRATERONE	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.4	1.28	1.69	2.04
DCH5HNF	DM8V75C	ABIRATERONE	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	24.25	23.8	26.1	27.17
DC9LCDA	DM8V75C	ABIRATERONE	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.79	2.25	1.35	0.55
DCCGAO0	DM8V75C	ABIRATERONE	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.95	6.92	1.51	2.6
DCY85DZ	DM8V75C	ABIRATERONE	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.74	5.4	3.57	1.84
DCVMT8A	DM8V75C	ABIRATERONE	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.82	8.71	7.59	8.16
DCLNFHW	DM8V75C	ABIRATERONE	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	14	12.81	14.26	15.75
DCONF5A	DM8V75C	ABIRATERONE	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.03	5.63	3.85	3.1
DCLO1KI	DM8V75C	ABIRATERONE	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.68	10.96	7.37	9.59
DCBILKQ	DM8V75C	ABIRATERONE	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	11.95	9.35	9.92	10.77
DCX1AZ6	DM8V75C	ABIRATERONE	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2	3.99	2.82	0.8
DCR5DNE	DM8V75C	ABIRATERONE	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	4.23	5.38	1.78	5.21
DC5HPJ3	DM8V75C	ABIRATERONE	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	6.02	6.01	6.43	8.19
DC768PH	DM8V75C	ABIRATERONE	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.04	7.58	2.81	3.39
DC7029O	DM8V75C	ABIRATERONE	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.2	2.73	1.98	0.07
DCXOVXN	DM8V75C	ABIRATERONE	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	13.74	13.43	14.51	16.74
DC2R0OY	DM8V75C	ABIRATERONE	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.03	4.33	2.91	2.36
DCY52QI	DM8V75C	ABIRATERONE	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.5	5.24	3.11	1.75
DC3S7MU	DM8V75C	ABIRATERONE	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.76	5.53	3.93	4.02
DCR6EP8	DM8V75C	ABIRATERONE	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	23.36	16.97	12.59	18.4
DCTYQ2D	DM8V75C	ABIRATERONE	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	7.48	10.3	3.17	9.79
DCTG0NG	DM8V75C	ABIRATERONE	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.13	8.67	2	6.57
DCR8ASR	DM8V75C	ABIRATERONE	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	15.24	15.33	10.03	15.56
DCRDCYK	DM8V75C	ABIRATERONE	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.59	8.13	0.58	5.89
DCIJJ5B	DM8V75C	ABIRATERONE	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.55	3.19	0.1	2.72
DC3DT7I	DM8V75C	ABIRATERONE	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.13	4.59	1.04	1.04
DCBXX2Y	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	13.14	11.14	5.7	12.18
DC9AXO9	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	15.48	12.82	8.86	13.56
DC8FO7S	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	10.44	9.19	2.01	7.78
DCTZV6G	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	20.32	16.85	0.37	17.15
DC6X86K	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	12.81	20.14	9.87	19.22
DCGX9OK	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	18.4	15.48	9.46	15.48
DCCLVLM	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	15.38	15.22	10.57	15.92
DCXBDK2	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	13.09	14.69	6.38	14.25
DCSLWNE	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	7.07	8.74	2.8	7.77
DCFKLXA	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.47	5.99	0.86	4.93
DCVPQMO	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.46	5.35	2.56	2.82
DCUM32Y	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	13.23	12.68	9.76	14.28
DCQXIZ0	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	9.03	7.96	5.02	8.38
DCK0Q71	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	27.02	26.01	25.94	31.21
DC0GFIV	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.66	4.84	0.89	4.92
DCLZ8J5	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	9.19	9.34	0.4	10.86
DCJ5QOS	DM8V75C	ABIRATERONE	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.48	7.59	4.01	7.29
DCY28A3	DM8V75C	ABIRATERONE	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.11	2.11	0.1	1.63
DCT73GU	DM8V75C	ABIRATERONE	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.3	2.33	0.69	3.19
DCT94H7	DM8V75C	ABIRATERONE	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	3.72	7.51	6.01	2.43
DCF0FQX	DM8V75C	ABIRATERONE	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.32	7.29	5.4	2.16
DCPJS9Y	DM8V75C	ABIRATERONE	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.51	5.17	3.13	3.55
DC7A5SR	DM8V75C	ABIRATERONE	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.18	2.45	1.08	1.11
DCEUZ17	DM8V75C	ABIRATERONE	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	14.5	15.18	17.53	17.76
DCGUEEI	DM8V75C	ABIRATERONE	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.36	3.26	1.49	1.03
DCU5GH5	DM8V75C	ABIRATERONE	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.62	8.38	7.54	9.68
DCMOKH0	DM8V75C	ABIRATERONE	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.2	4.97	2.16	1.15
DCE28KY	DM8V75C	ABIRATERONE	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.64	1.53	0.28	0.72
DCAYMWR	DM8V75C	ABIRATERONE	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.72	12	1.83	12.46
DC6H2XZ	DM8V75C	ABIRATERONE	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.15	4.36	2.76	4.2
DCNDTJL	DM8V75C	ABIRATERONE	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	19.1	16.88	18.32	21.57
DC135N2	DM8V75C	ABIRATERONE	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.13	3.4	0.93	0.61
DCWWV3F	DM8V75C	ABIRATERONE	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	20.64	21.89	25.19	25.48
DC5OZXB	DM8V75C	ABIRATERONE	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.58	2.88	0.05	0.2
DC4C1TV	DM8V75C	ABIRATERONE	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.05	3.51	1.61	1.3
DC5T2QO	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.52	3.12	2.1	1.47
DCUJ17B	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.1	8.98	5.28	10
DC992H0	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	17.12	18.64	16.94	16.97
DCLRBVI	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.03	12.7	11.81	12.04
DCH4WFX	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	16.02	17.76	17.47	19.69
DCNZLTP	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.94	10.17	9.2	10.34
DC0N8BQ	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.53	11.67	11.74	13.9
DCTM26L	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.01	4.47	5.53	5.86
DC6WEI5	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.84	7.92	5.2	6.98
DCZX0HM	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	24.96	24.34	9.93	25.31
DCKA165	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.14	6.65	3.08	8.02
DCYM2V2	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.59	10.98	2.47	10.91
DCTLQXQ	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	8.72	14.27	12.33	13.25
DCI80OH	DM8V75C	ABIRATERONE	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	9.69	12.5	8.93	14.19
DC6LBVW	DM15F0X	Gefitinib	Approved	34	DM5GFIK	Icotinib hydrochloride	Registered	33	DMCMBHA	Erlotinib	.	.	Non-Small-Cell Lung Cancer	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DC2J8AA	DM15F0X	Gefitinib	Approved	34	DMMX2E6	Pemetrexed	Approved	34	.	.	.	.	Lung Neoplasms	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC8A9UP	DM15F0X	Gefitinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Non-small Cell Lung Cancer (NSCLC)	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCBHRAJ	DM15F0X	Gefitinib	Approved	34	DM3WP0N	Al3818	Phase 3	25	.	.	.	.	"Lung Cancer, Nonsmall Cell"	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCGU6CO	DM15F0X	Gefitinib	Approved	34	DMG281S	Carboplatin	Approved	34	DMLB81S	Paclitaxel	.	.	Adenocarcinoma of the Lung	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC19DHY	DM15F0X	Gefitinib	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Non Small Cell Lung Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC552OD	DM15F0X	Gefitinib	Approved	34	DMHOSCQ	Fruquintinib	Approved	34	.	.	.	.	NSCLC	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC5PKWD	DM15F0X	Gefitinib	Approved	34	DMCMJRA	EGF816	Phase 3	25	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC7ZR22	DM15F0X	Gefitinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Non-small Cell Lung Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCVVUG8	DM15F0X	Gefitinib	Approved	34	DMRJLAT	Osimertinib	Approved	34	.	.	.	.	Non-Small Cell Lung Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCBK20C	DM15F0X	Gefitinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	DMRJLAT	Osimertinib	DMTKD7Q	Afatinib	"Non-squamous, Non-Small Cell Lung Cancer"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCEQAP5	DM15F0X	Gefitinib	Approved	34	DM3WP0N	Al3818	Phase 3	25	DM5GFIK	Icotinib hydrochloride	.	.	Non-Small-Cell Lung	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCEWV4X	DM15F0X	Gefitinib	Approved	34	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMDI269	Docetaxel	.	.	Bladder Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC0QVJU	DM15F0X	Gefitinib	Approved	34	DM8X2EH	Everolimus	Approved	34	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC32TE0	DM15F0X	Gefitinib	Approved	34	DMMX2E6	Pemetrexed	Approved	34	.	.	.	.	"Carcinoma, Non Small Cell Lung"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC4BJ6N	DM15F0X	Gefitinib	Approved	34	DMYCXKL	Capmatinib	Approved	34	.	.	.	.	Non-small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC7BRR3	DM15F0X	Gefitinib	Approved	34	DM6LOQU	Celecoxib	Approved	34	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC7V5UU	DM15F0X	Gefitinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Ovarian Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC9RNOF	DM15F0X	Gefitinib	Approved	34	DMTS85L	Capecitabine	Approved	34	.	.	.	.	"Unspecified Adult Solid Tumor, Protocol Specific"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCDSSKB	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCJCM9J	DM15F0X	Gefitinib	Approved	34	DM8X2EH	Everolimus	Approved	34	.	.	.	.	Brain and Central Nervous System Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCL2W27	DM15F0X	Gefitinib	Approved	34	DMLB0EZ	Tamoxifen	Approved	34	.	.	.	.	Breast Neoplasms	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCMPLO1	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Non-small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCNVKWM	DM15F0X	Gefitinib	Approved	34	DM30SGU	Simvastatin	Approved	34	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCORLUW	DM15F0X	Gefitinib	Approved	34	DM3WP0N	Al3818	Phase 3	25	.	.	.	.	Non-squamous Non-small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCQPDOM	DM15F0X	Gefitinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Estrogen Receptor-positive Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCFP9A7	DM15F0X	Gefitinib	Approved	34	DMCMJRA	EGF816	Phase 3	25	.	.	.	.	EGFR-mutant Non-small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCFXTAY	DM15F0X	Gefitinib	Approved	34	DMALFKX	Savolitinib	Phase 3	25	.	.	.	.	Non-Small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCPELRY	DM15F0X	Gefitinib	Approved	34	DMUQ0E8	Tepotinib	Approved	34	.	.	.	.	Non-small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCXPKLY	DM15F0X	Gefitinib	Approved	34	DMRJLAT	Osimertinib	Approved	34	.	.	.	.	Non-Small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCJMO95	DM15F0X	Gefitinib	Approved	34	DM053KT	Aprepitant	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.93	7.93	15.9	15.92
DCFJEZP	DM15F0X	Gefitinib	Approved	34	DM05FXR	Meclofenamic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	10.28	10.28	13.39	13.39
DCOQQQG	DM15F0X	Gefitinib	Approved	34	DM09NGV	Ribavirin-TP	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	12.33	12.33	18.82	18.85
DCLY3VE	DM15F0X	Gefitinib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	21.1	20.92	21.86	23.6
DCON7X0	DM15F0X	Gefitinib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	7.61	9.88	10.25	10.24
DCZR3YA	DM15F0X	Gefitinib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	0.71	5.63	4.15	4.69
DCXKX59	DM15F0X	Gefitinib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	8.15	6.55	8.28	8.29
DCZ09GC	DM15F0X	Gefitinib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	2.79	8.07	6.88	11.65
DCIT7PM	DM15F0X	Gefitinib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	9.46	9.79	2.46	13.45
DCI0CPI	DM15F0X	Gefitinib	Approved	34	DM0FB1J	Sertraline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	10.15	10.15	13.27	13.27
DCX29Y1	DM15F0X	Gefitinib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.68	1.29	3.11	3.07
DCBTI86	DM15F0X	Gefitinib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	0.05	2.2	3.81	3.23
DCMK15N	DM15F0X	Gefitinib	Approved	34	DM0KYI4	Mebutamate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	14.87	14.87	18.66	18.71
DCG96WT	DM15F0X	Gefitinib	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	26.34	27.32	0.91	22.38
DCGJKOD	DM15F0X	Gefitinib	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.4	6.33	7.01	7.43
DCAU74Z	DM15F0X	Gefitinib	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.97	6.81	0.8	4.38
DC5JMRI	DM15F0X	Gefitinib	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	16.53	13.91	8.3	14.7
DCYN0TA	DM15F0X	Gefitinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	1.13	2.44	2.34	4.54
DCWP914	DM15F0X	Gefitinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.86	7.62	6.48	5.82
DCDWRYK	DM15F0X	Gefitinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	5.63	4.35	0.75	2.28
DCB7IGH	DM15F0X	Gefitinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	0.81	1.53	0.69	2.97
DCX0AGX	DM15F0X	Gefitinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	0.28	0.01	0.74	2.23
DCVRUQ6	DM15F0X	Gefitinib	Approved	34	DM1TJ8F	Diethylcarbamazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.38	9.38	17.68	17.72
DC3W302	DM15F0X	Gefitinib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	1.92	3.54	1.63	4.56
DCZDGYE	DM15F0X	Gefitinib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.5	8	4.61	7.27
DCUMS1E	DM15F0X	Gefitinib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.27	8.85	5.92	7.95
DCOSAYX	DM15F0X	Gefitinib	Approved	34	DM2HU9I	Triamterene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.66	0.66	3.81	3.81
DCHQ3UZ	DM15F0X	Gefitinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	4.66	1.39	0.12	0.13
DCKYLTZ	DM15F0X	Gefitinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	2.96	4.82	3.71	5.44
DCNLLI2	DM15F0X	Gefitinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	0.04	5.01	3.26	2.81
DCVZ4AG	DM15F0X	Gefitinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.1	0.84	0.49	0.5
DCAUBNV	DM15F0X	Gefitinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.69	2.32	5.78	5.81
DC60EXW	DM15F0X	Gefitinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	1.29	4.44	2.45	1.7
DC4BGZX	DM15F0X	Gefitinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	0.41	0.07	0.31	1.08
DC242M6	DM15F0X	Gefitinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.9	2.72	1.55	1.49
DC7N639	DM15F0X	Gefitinib	Approved	34	DM2TUCU	Crotamiton	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	16.91	16.91	20.23	20.27
DCZJYWW	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	4.6	3.75	3.35	3.41
DCDTVQD	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	4.7	10.15	10.53	10.32
DCD6SV0	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	5.62	5.82	5.47	5.53
DC1AVS1	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	1.93	7.21	7.41	7.22
DCSPJG1	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	7.2	11.22	5.82	11.25
DCHSZQ1	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	28.05	29.68	29.36	29.09
DCIH5KN	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	6.18	7.51	7.15	6.54
DCOBCXC	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	9.56	18.25	19.71	19.61
DC23JHU	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	20.89	29.16	28.78	28.79
DCNFDGX	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	18.66	25.36	25.98	26.31
DCNPB7T	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	34.87	38.3	37.09	39.54
DCPQA58	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	3.58	8.5	9.31	9.27
DCD04G4	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	1.78	7.18	7.04	6.59
DCNNHH3	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	44.29	39.12	32.4	41.5
DCXCTN6	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	8.81	12.2	12.83	12.67
DCMP4I7	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	13.73	21.17	22.13	22.12
DCXUN37	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	9.68	18.11	20.28	19.77
DC6JKOJ	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	15.1	18.29	20.29	20.35
DCCA14W	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	10.45	11.34	10.61	10.67
DCHIEML	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	12	18.95	19.26	19.21
DCX0IJY	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	8.98	9.65	8.37	8.46
DCHEKA6	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	4.8	5.5	6.97	6.29
DCWH58V	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	9.85	14.23	14.25	13.72
DCV43UF	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	12.55	15.46	16.08	15.71
DCEVRV0	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	11.61	18.09	19.08	19.1
DCE293G	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	10.51	14.96	15.17	15.27
DCLL7CU	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	16.51	24.04	25.94	25.23
DCNN452	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	10.82	16.03	16.99	16.44
DCVL31D	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	3.56	9.88	9.93	9.45
DCESN2X	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	8.23	11.21	11.47	10.74
DCRH1T7	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	11.43	19.9	19.06	18.82
DC191W0	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	5.57	12	13.71	13.51
DCD9SER	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	8.7	14.81	16.32	15.8
DCVTZLI	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	7.72	11.24	11.13	11.21
DCL9SEI	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	33.76	31.54	31.94	31.96
DCXS3QO	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	5.26	11.54	12.45	12.04
DC40PR3	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	7.85	15.75	16.05	15.53
DCDGENV	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	1.54	6.79	7.57	6.83
DCX00O2	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	6.36	17.84	15.47	16.29
DCD8PRJ	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	4.05	6.65	5.89	6.07
DCR7BXB	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	3.6	5.57	2.65	6.1
DC6E349	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	7.86	15.38	15.94	15.71
DC579FP	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	3.81	1.97	1.15	1.06
DCWVN3U	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	6.66	8.09	8.74	8.67
DCX59FM	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	31.04	34.09	33	32.7
DC46KCT	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	14.27	13.37	14.06	13.27
DCMQDPJ	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	3.85	10.72	11.52	11.15
DCZLV8N	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	2.13	8.41	8.99	10.96
DC100Z8	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.96	11.84	12.98	12.79
DCW48H1	DM15F0X	Gefitinib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	0.52	1.04	0.18	2.78
DCM8F6B	DM15F0X	Gefitinib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.06	2.49	3.32	3.31
DC5AWO7	DM15F0X	Gefitinib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	1.16	5.92	1.55	1.93
DCBVIMM	DM15F0X	Gefitinib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.09	11.55	1.73	3.47
DCJ2DIY	DM15F0X	Gefitinib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.61	12.69	10.67	10.32
DCL2U68	DM15F0X	Gefitinib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	1.59	8.69	5.99	5.55
DCLCMX6	DM15F0X	Gefitinib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.21	6.78	3.41	3.62
DC0UEVY	DM15F0X	Gefitinib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	4.92	8.51	6.37	6.09
DCPAMBN	DM15F0X	Gefitinib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	4.68	6.89	0.77	3.17
DCNR29C	DM15F0X	Gefitinib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	1.25	4.23	1.17	2.94
DCXYQ7P	DM15F0X	Gefitinib	Approved	34	DM3P6V7	Furazolidone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	15.92	15.92	19.42	19.46
DCV32GF	DM15F0X	Gefitinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	6.53	6.13	6.25	9.02
DCQ47T2	DM15F0X	Gefitinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.9	1.06	3.46	3.27
DCR6ZTM	DM15F0X	Gefitinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.78	8.29	6.22	9.45
DCC2Q28	DM15F0X	Gefitinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.82	2.82	5.9	5.95
DCLCECT	DM15F0X	Gefitinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.36	1.92	3.03	4.88
DCR480O	DM15F0X	Gefitinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	0.7	0.42	1.21	3.32
DCFG3I0	DM15F0X	Gefitinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	3.53	3.95	3.26	4.28
DCWZ3QE	DM15F0X	Gefitinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	7.85	11.21	10.35	13
DCTI5ZC	DM15F0X	Gefitinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	3.34	5.8	3.93	7.88
DCRFX41	DM15F0X	Gefitinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.99	2.6	1.81	5.77
DC0H8B2	DM15F0X	Gefitinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	0.46	1.94	5.88	6.52
DC6H23R	DM15F0X	Gefitinib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	2.64	3.77	0.57	3.35
DCJ7MZE	DM15F0X	Gefitinib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	1.33	7.94	5.18	4.73
DCUUSGL	DM15F0X	Gefitinib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.1	6.59	2.89	7.74
DCN8KWT	DM15F0X	Gefitinib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	3.14	3.29	3.5	5.94
DCC9Y4G	DM15F0X	Gefitinib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	3.57	4.27	2.12	4.05
DCV47W2	DM15F0X	Gefitinib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	7.94	10.22	3.74	5.38
DC3TZAV	DM15F0X	Gefitinib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.68	1.89	0.29	2.46
DC6GU4B	DM15F0X	Gefitinib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.82	3.27	3.29	5.76
DCFA9HE	DM15F0X	Gefitinib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	6.59	7.3	4.94	9.06
DCU3BCP	DM15F0X	Gefitinib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	5.62	6.37	7.23	9.84
DCM0S2P	DM15F0X	Gefitinib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.15	4.79	2.15	6.02
DC5EUMN	DM15F0X	Gefitinib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	5.98	12.55	11.91	13.37
DC4VJLX	DM15F0X	Gefitinib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	0.12	3.66	4.98	5.37
DCTN1MI	DM15F0X	Gefitinib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.48	3.51	7.04	9.63
DCX2VUW	DM15F0X	Gefitinib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	3.23	6.03	7.22	8.36
DCK8YK5	DM15F0X	Gefitinib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.4	0.6	3.97	4.9
DCFKUIP	DM15F0X	Gefitinib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	2.3	5.2	7.19	8
DCYSTMC	DM15F0X	Gefitinib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	3.52	4.11	5.81	8.03
DC00TDD	DM15F0X	Gefitinib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	3.19	3.45	4.34	5.97
DCJ6ZRH	DM15F0X	Gefitinib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	0.13	8.47	8.32	8.74
DCQRZBI	DM15F0X	Gefitinib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	6.65	5.29	8.41	10.2
DCMICZA	DM15F0X	Gefitinib	Approved	34	DM5IKUF	Dihydroergotamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	14.22	14.22	17.35	17.35
DCK40AX	DM15F0X	Gefitinib	Approved	34	DM5J64S	Miglustat	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	12.82	12.82	17.69	17.69
DCW3V3U	DM15F0X	Gefitinib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.98	0.52	0.64	0.55
DCKD1Z2	DM15F0X	Gefitinib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.2	9.51	6.54	8.13
DCWV2RS	DM15F0X	Gefitinib	Approved	34	DM5SXUV	Repaglinide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.37	8.37	11.48	11.51
DC4NJ7B	DM15F0X	Gefitinib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.55	5.29	5.04	5.39
DCUBRGA	DM15F0X	Gefitinib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	9.29	9.67	7.55	11.92
DC8QCHK	DM15F0X	Gefitinib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	2.27	2.8	1.91	4.26
DCY7823	DM15F0X	Gefitinib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	5.23	7.09	4.67	10.95
DCRYU44	DM15F0X	Gefitinib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.52	7.42	3.05	5.18
DCSXXIN	DM15F0X	Gefitinib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	1.52	3.94	4.23	6.47
DCVVTAP	DM15F0X	Gefitinib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.05	6.95	1.25	4.27
DCIKFQH	DM15F0X	Gefitinib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	2.67	1.28	2.43	4.44
DCW53LP	DM15F0X	Gefitinib	Approved	34	DM6HXTS	Anamorelin	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.36	11.36	17.94	17.96
DCUFMZ3	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	2.81	2.77	2.42	3.15
DC89OHM	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	5.5	7.43	6.66	7.37
DCTUSDX	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	2.24	5.74	4.42	6.17
DCQ8HXE	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	9.71	15.41	14.38	14.46
DCTOIWA	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	6.89	8.84	8.26	8
DCH8BFJ	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	11.48	16.64	17.08	16.88
DCZOTFR	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	4.76	11.63	12.86	12.92
DC9KDW7	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	11.43	10.07	8.91	8.12
DCSX4NG	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	23.69	26.64	24.85	24.75
DCILU4A	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	24.52	29.71	26.62	26.08
DC4LNBP	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	0.47	3.84	2.88	2.38
DCOYZNF	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	0.62	9.84	9.23	8.78
DCF8J0J	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	14.01	17.3	13.67	17.87
DCF4218	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	6.39	11.43	12.45	12.5
DCKM9JR	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	7.38	11.07	10.63	11.47
DCXQC4R	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	7.97	11.77	11.88	11.38
DC37OR9	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	11.82	22.35	22.63	22.34
DC6IFPI	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.98	4.81	3.73	4.83
DCUU37D	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	8.24	11.02	11.16	11.78
DCEOZLY	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	8.52	9.95	9.06	9.23
DCXZF6G	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	9.39	11.4	11.58	11.05
DCS785L	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	6.51	11.79	11.5	11.18
DC18VHD	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	10.19	17.38	18.49	18.48
DCQH1E7	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	7.06	12.11	12.4	12.59
DC8NLOD	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	7.41	9.93	9.04	9.07
DCHF8ER	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	5.03	9.52	9.55	9.48
DCBR4DH	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	5.06	6.48	7.32	7.12
DCBS1LJ	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	8.79	12.12	12.31	12
DC4XTOW	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	2.34	9.92	9.91	9.85
DCNJBKC	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	6.96	12.35	12.09	11.7
DCGHE8T	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	5.1	9.2	9.23	8.98
DCCPK3P	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	21.59	19.18	18.96	19.99
DCITRJA	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	4.57	7.02	9.13	8.71
DCLOBCE	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	5.73	12.43	12.86	13.08
DCAW2H7	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	5.94	9.57	9.95	9.23
DC4I84G	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	5.94	11.87	11.36	11.02
DCFKP2A	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	7.03	12.16	12.72	12.11
DC0KEXP	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	4.59	6.81	4.46	6.44
DC1G4RC	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	3.07	5.95	4.51	6.49
DCBRGBH	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	5	6.42	5.03	7.13
DCWINL4	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	24.78	25.85	22.94	22.69
DCQSDVR	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	7.12	9.07	8.36	7.68
DCGVS4K	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.69	10.76	9.34	11.66
DCUTD31	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.35	3.43	3.76	4.32
DCP4ZKD	DM15F0X	Gefitinib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	6.13	6.58	3.39	2.76
DCR6NQY	DM15F0X	Gefitinib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.21	7.55	2.24	1.82
DCX7C2V	DM15F0X	Gefitinib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.29	3.21	2.74	3.5
DCF7B1D	DM15F0X	Gefitinib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.25	7.84	3	2.62
DCYAVXK	DM15F0X	Gefitinib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	3.01	6.93	4.66	5.8
DCHXAP9	DM15F0X	Gefitinib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	2.35	3.83	2.97	2.61
DCOS2X4	DM15F0X	Gefitinib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	6.41	8.74	1.78	3.71
DC1O3X0	DM15F0X	Gefitinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	8.18	5.95	2.81	7.82
DCRYUTV	DM15F0X	Gefitinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	9.08	8.7	7.16	11.75
DCHQESV	DM15F0X	Gefitinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.52	5.09	5.18	6.94
DC9IXWR	DM15F0X	Gefitinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.21	5.18	4.61	6.43
DCBHOQS	DM15F0X	Gefitinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	8.11	7.97	10.37	16.03
DCWP8CM	DM15F0X	Gefitinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	3.67	3.16	7	7.96
DCMTH5D	DM15F0X	Gefitinib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	9.27	12.41	8.91	12.24
DC4B246	DM15F0X	Gefitinib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	1.64	1.83	0.27	4.37
DC8DJYE	DM15F0X	Gefitinib	Approved	34	DM8BKU9	Acitretin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.41	9.41	18.13	18.14
DC5IFN1	DM15F0X	Gefitinib	Approved	34	DM9S1EA	Pepstatin	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.22	11.22	18.17	18.21
DCDYPSE	DM15F0X	Gefitinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	10.85	11.6	12.18	14
DC753LI	DM15F0X	Gefitinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	5.85	9.56	5.64	12.04
DCVAFF2	DM15F0X	Gefitinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.95	4.25	2.31	5.52
DCJX5VN	DM15F0X	Gefitinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	16.03	16.03	19.24	19.25
DCUZS45	DM15F0X	Gefitinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.42	2.48	0.9	5.66
DCFLDOU	DM15F0X	Gefitinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.03	1.53	3.94	6.43
DCIJNGE	DM15F0X	Gefitinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	1.39	4.29	4.4	5.82
DCF8CFQ	DM15F0X	Gefitinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	3.55	7.56	1.16	9.9
DCB0UE3	DM15F0X	Gefitinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.52	5.37	0.53	7.65
DC5093V	DM15F0X	Gefitinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	0.53	3.7	3.66	6.38
DC9M17P	DM15F0X	Gefitinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	2.66	4.35	4.15	7.26
DCF7SUR	DM15F0X	Gefitinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	6.7	9.15	8.72	10.22
DC4CPHQ	DM15F0X	Gefitinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	2.74	3.29	0.24	7.03
DC4SS0O	DM15F0X	Gefitinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.61	3.37	3.28	6.29
DCF11XV	DM15F0X	Gefitinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	4.64	8.76	11.8	13.36
DCWKMMC	DM15F0X	Gefitinib	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	4	3.78	6.07	6.96
DCK99LA	DM15F0X	Gefitinib	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.16	4.81	4.46	7.55
DCXSUJF	DM15F0X	Gefitinib	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	1.41	6.12	8.06	10.61
DCZH09I	DM15F0X	Gefitinib	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	2.59	4.58	2.97	5.57
DCIDNER	DM15F0X	Gefitinib	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	1.49	1.47	0.32	1.16
DCA1SJL	DM15F0X	Gefitinib	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.67	1.84	3.68	5.08
DCGF2O8	DM15F0X	Gefitinib	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	9.79	8.76	12.83	13.19
DC47UBC	DM15F0X	Gefitinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	4.47	3.24	0.82	7
DCPHWC7	DM15F0X	Gefitinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	13.32	9.29	6.63	11.31
DCPYZCK	DM15F0X	Gefitinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.61	0.37	2.27	3.95
DCR47PP	DM15F0X	Gefitinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	8.72	9.64	10.77	12.24
DCJY49S	DM15F0X	Gefitinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3	7.28	9.19	10.02
DCPY6AH	DM15F0X	Gefitinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	4.67	5.29	7	9.57
DCMB8GA	DM15F0X	Gefitinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	5.69	6.46	1.37	8.99
DC5GMYZ	DM15F0X	Gefitinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	11.31	10.57	10.18	15.25
DC8QMPE	DM15F0X	Gefitinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	10.1	9.57	11.71	16.88
DC3H1XH	DM15F0X	Gefitinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.25	2.7	8.12	9.95
DCB9USH	DM15F0X	Gefitinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	5	4.42	8.04	9.43
DC85FF2	DM15F0X	Gefitinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.43	3.6	8.26	9.31
DCDI5KT	DM15F0X	Gefitinib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.3	2	1.41	2.74
DCATZVT	DM15F0X	Gefitinib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	0.76	1.06	1.46	1.46
DC3W1C4	DM15F0X	Gefitinib	Approved	34	DMBEX4O	Methylergonovine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	15.28	15.28	18.94	19
DCNMHRC	DM15F0X	Gefitinib	Approved	34	DMBHMOX	Palonosetron	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	15.51	15.51	18.53	18.54
DCR037R	DM15F0X	Gefitinib	Approved	34	DMC0GSJ	Efavirenz	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	14.95	14.95	19.32	19.34
DCKNO50	DM15F0X	Gefitinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	3.96	8.8	8.85	9.83
DC230MQ	DM15F0X	Gefitinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	1.93	6.02	1.02	6.06
DCHNVJK	DM15F0X	Gefitinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.74	6.14	4.39	7.15
DCIW52Z	DM15F0X	Gefitinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.74	6.67	8.56	8.17
DC0SWCW	DM15F0X	Gefitinib	Approved	34	DMPN5IH	Guanfacine	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	14.02	14.02	17.77	17.77
DC8XHCY	DM15F0X	Gefitinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	5.65	5.8	1.55	4.32
DCWJHOH	DM15F0X	Gefitinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	5.74	6.03	0.7	2.47
DCH7U1T	DM15F0X	Gefitinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	2.13	3.08	2.04	2.71
DCRKGEK	DM15F0X	Gefitinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	10.28	13.71	9.08	10.73
DCFFHUQ	DM15F0X	Gefitinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.6	5.4	6.69	7
DC72GHP	DM15F0X	Gefitinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.38	5.7	4.42	4.96
DCYYI8L	DM15F0X	Gefitinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	0.66	6.38	1.55	1.02
DCJDQ21	DM15F0X	Gefitinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	0.74	6.41	6.03	5.52
DCT8XBL	DM15F0X	Gefitinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	0.5	5.53	1.79	4.25
DCSGCJY	DM15F0X	Gefitinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	9.07	10.84	5.08	6.52
DCTR6GQ	DM15F0X	Gefitinib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.39	2.62	0.55	1.69
DC4BZUF	DM15F0X	Gefitinib	Approved	34	DMCY0TI	Carglumic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	16.51	16.51	19.59	19.59
DCAW5MC	DM15F0X	Gefitinib	Approved	34	DMD4OK0	K-134	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	15.27	15.27	18.56	18.62
DCYFIC6	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	18.15	20.16	17.45	22.48
DCN7LI4	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	9.61	7.66	8.82	10.78
DCPFXIQ	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.99	4.72	10.98	12
DCJGKCL	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.16	4.65	2.28	8.43
DCAH5E1	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	6.69	10.48	11.35	12.65
DC5HL48	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.71	10.58	10.63	11.85
DCGE1UM	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	6.43	9.59	12.73	12.89
DCHVN40	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	1.34	3.36	4.71	7.78
DCFKSO2	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	0.86	5.57	6.75	9.58
DCJQMJ0	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	5.61	9.2	7.72	10.21
DCT8NGX	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	6.17	6.02	8.69	11.37
DCF5YHN	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	3.39	4.66	1	9.4
DCLKMA9	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	6.17	9.71	11.47	12.81
DC0GS3G	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	1.09	2.42	4.25	5.54
DCB8VHI	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	0.73	10.76	6.71	11.17
DCFZ1D0	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	10.62	10.32	9.23	15.35
DCTNANE	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	3.93	6.76	2.03	11.58
DCDWB8I	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.84	3.41	7.7	9.52
DCD7TCO	DM15F0X	Gefitinib	Approved	34	DMD9WSC	Memantine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	15.25	15.25	18.93	18.99
DCTAROO	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	5.25	3.38	6.05	9.44
DCQ2E8C	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	1.43	8.58	9.44	11.3
DCDASEZ	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	6.29	4.4	7.79	10.23
DC8ZSCE	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	17.79	16.78	1.64	17.77
DC40O27	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	9.93	13.45	7.14	13.31
DC531EA	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	9.81	9.9	4.55	13.6
DC5PNQN	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	17.5	16.59	14.44	17.91
DCF14U9	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	6.79	6.23	4.52	10.18
DCCPR4O	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.25	8.17	10.84	11.05
DCPCFSN	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	4.11	4.38	1.27	8.04
DCCA201	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.97	5.53	9.51	10.57
DCCAPAF	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.87	3.4	6.05	7.38
DC9H9AF	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.2	2.54	5.42	7.69
DCZ9NHW	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	4.54	7.73	8.34	10.21
DC5CEYN	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	5.61	8.84	8	11.26
DCWFUVY	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	9.68	10.89	10.34	12.28
DCQKRDK	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	10.9	10.35	4.72	13.13
DCAF889	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	10.65	11.14	1.91	12.25
DC5I2KF	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	8.2	7.09	6.08	11.45
DCLF9CG	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	5.68	6.47	5.72	8.96
DCA8H3K	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	6.43	12.13	10.59	11.72
DCNGDNZ	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	2.05	7.89	11.99	13.27
DCDGTNF	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	8.42	9.39	0.39	11.45
DCV04ML	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	6.78	7.63	4.4	10.43
DCLWVGK	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	10.45	9.16	13.75	14.66
DC62LJV	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	3.61	5.91	10.66	11.78
DC8RBHA	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	4.87	4.24	8	10.24
DC1HWTF	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	6.44	6.78	9.82	11.48
DCRFWGG	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	11.18	12.31	14.72	16.21
DCYOPCJ	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	2.14	4.15	5.46	7.71
DC99M1T	DM15F0X	Gefitinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	6.63	9.74	4.21	9.68
DC0JQ6I	DM15F0X	Gefitinib	Approved	34	DME5TUR	LY03004	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.83	0.83	4.02	4.02
DC7N167	DM15F0X	Gefitinib	Approved	34	DMEO794	Galantamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.4	8.4	11.76	11.78
DCA3IET	DM15F0X	Gefitinib	Approved	34	DMEV954	Sulfinpyrazone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	16.02	16.02	19.3	19.3
DCE8HQP	DM15F0X	Gefitinib	Approved	34	DMF57DM	Pazopanib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.84	11.84	17.13	17.17
DCOES54	DM15F0X	Gefitinib	Approved	34	DMFCMPS	Daidzin	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.8	8.8	11.89	11.95
DCNESQ3	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	1.22	4.56	3.83	6.63
DCYF2HB	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	11.28	14.71	13.71	16.03
DCFPASH	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	5.88	9.75	0.27	9.83
DCODQEF	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	7.05	10.45	8.76	12.21
DCAXV1D	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	12.47	16.87	11.93	19.48
DCYDKII	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	9.95	10.9	10.97	11.52
DCZ6CX4	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	9.86	14.73	2.28	15.52
DCLYOL6	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	7.04	12.29	14.66	14.66
DC5SCKR	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	5.49	9.42	10.63	13.24
DC1S8EJ	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	6.65	7.31	11.49	11.94
DCIZTYO	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	5.27	3.55	5.98	7.39
DCVAW8X	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	6.93	9.06	0.73	11.09
DCZK1UO	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	2.77	11.12	11.3	13.02
DCS54LL	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	19.81	19.3	20.89	21.6
DCXTKMZ	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	6.33	7.1	7.06	9.88
DCIKOJR	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	21.89	20.74	19.77	21.42
DCMD2ZI	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	2.14	1.48	0.4	6.67
DCPRFL5	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	13.29	13.13	1.13	12.53
DC8DF14	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	1.7	3.47	8.23	9.38
DC25F07	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.09	2.3	3.64	6.21
DC7VQH9	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	15.33	12.32	5.51	15.93
DCU31IS	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	8.88	11.54	15.59	15.75
DCVS8RN	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	4.57	5.99	5.36	7.14
DC74C1H	DM15F0X	Gefitinib	Approved	34	DMFO843	Fluspirilene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	10.44	10.44	13.53	13.58
DC6J8O4	DM15F0X	Gefitinib	Approved	34	DMFQWNI	VR-776	Discontinued in Phase 1	3	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	15.84	15.84	19.54	19.57
DCQGY3B	DM15F0X	Gefitinib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	4.65	3.26	3.51	4.88
DCTIFG1	DM15F0X	Gefitinib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	8.13	4.28	0.57	5.16
DCP3C5W	DM15F0X	Gefitinib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.21	1.03	2.77	5.14
DCHZ8FH	DM15F0X	Gefitinib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	9.34	8.05	5.98	12.01
DCUE28R	DM15F0X	Gefitinib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.39	1.59	0.21	4.34
DCZNDGQ	DM15F0X	Gefitinib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	0.77	1.46	3.44	5.29
DCAPY99	DM15F0X	Gefitinib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	7.31	6.7	8.94	11.24
DCSRF4B	DM15F0X	Gefitinib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	1.94	1.63	3.87	6.07
DCB4FFJ	DM15F0X	Gefitinib	Approved	34	DMG58FX	WAY-100635	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	12.72	12.72	18.25	18.25
DCTE2UO	DM15F0X	Gefitinib	Approved	34	DMGC5DB	Ciprofibrate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.13	8.13	11.23	11.29
DCD2KPZ	DM15F0X	Gefitinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	0.19	3.14	10.91	12.29
DCVBPGY	DM15F0X	Gefitinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	0.1	0.91	5.3	6.27
DCCIEJ0	DM15F0X	Gefitinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.64	5.45	1.05	8.96
DCV7YR5	DM15F0X	Gefitinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.47	0.8	0.97	6.62
DC0Z9JC	DM15F0X	Gefitinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	6.32	6.6	10.15	10.83
DCOB0HA	DM15F0X	Gefitinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	0.71	1.35	6.54	7.63
DCLJ3AG	DM15F0X	Gefitinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	2.01	1.99	5.07	5.64
DC31ULJ	DM15F0X	Gefitinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	2.66	2.28	9.91	11.67
DCWH9M9	DM15F0X	Gefitinib	Approved	34	DMGZQEF	Mifepristone	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	5.04	11.874	0.611	0.998
DCTOG6H	DM15F0X	Gefitinib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.09	4.01	4.7	4.78
DCON3LT	DM15F0X	Gefitinib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	0.61	7.5	0.2	3.42
DCAGBD3	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	11.8	11.01	2.44	13.49
DCIDF9C	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.02	6.16	6.16	8.73
DCK65BG	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.14	4.74	5.72	7.11
DCM3550	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.88	2.53	4.73	6.05
DCUEVH5	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	4.03	3.65	5.5	8.27
DCQEJUP	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	0.89	4.75	2.74	8.6
DCZATA3	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	13.33	20.34	19.35	20.04
DCKBPEM	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	0.09	4.36	8.85	10.16
DC37BOK	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	1.5	2.61	3.69	4.81
DCTMDD2	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	2.11	8.14	6.35	7.99
DC45TPD	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	1.62	5.1	4.72	7.65
DC7HJX4	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	8.85	8.9	3.96	9.15
DC9DGEC	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	0.3	3.32	5.31	6.5
DCMG1AY	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.01	0.91	2.9	6.2
DC2E9V2	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.59	8.81	3.61	11.41
DC491NZ	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.97	5.52	6.43	9.07
DC47O85	DM15F0X	Gefitinib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	3.72	5.45	1.52	3.35
DCSC8VK	DM15F0X	Gefitinib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	1.38	1.53	8.21	8.86
DC9A8E5	DM15F0X	Gefitinib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	5.37	7.13	10.98	10.99
DCHM3OE	DM15F0X	Gefitinib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	2.4	4.41	3.01	5.54
DCXVL5D	DM15F0X	Gefitinib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	8.16	9.93	11.96	12.7
DCT6Y0B	DM15F0X	Gefitinib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	3.45	3.52	6.61	7.12
DCISVSX	DM15F0X	Gefitinib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.62	2.26	8.69	11.23
DCBC21J	DM15F0X	Gefitinib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.61	10.26	9.22	14.08
DCOMDF3	DM15F0X	Gefitinib	Approved	34	DMOL54H	Clopidogrel	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	16.96	16.96	19.76	19.81
DCO9SRB	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	4.39	3.73	5.53	6.88
DCI12KL	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	1.78	4.71	5.91	7.15
DCKLGJI	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	5.63	5.47	2.12	8.26
DCEJ1BF	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	7.15	7.23	7.87	9.38
DCQVE4Q	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	19.89	19.66	10.6	20.32
DCI332T	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	14.65	15.13	0.64	18.23
DC1VFH2	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	22.13	20.18	18.82	22.13
DCTM0NU	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	2.75	7.39	3.39	9.36
DC6QE7C	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	11.1	16.27	17.14	17.73
DC7L674	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	14.68	15.75	7.05	17.46
DCJW34S	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	8.45	13.7	15.41	15.74
DCELVZB	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.29	4.92	7.59	8.96
DCKUF0S	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	7.84	10.45	10.34	13.49
DC25QYN	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.1	3.64	7.4	9.63
DCU0LI5	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	15.29	16.83	8.36	16.08
DCXEGJW	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	3.83	13.91	12.54	15.74
DCCW0H5	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	13.63	19.58	15.84	21.86
DCMODLL	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	3.39	6.3	9.13	9.02
DCI0C2T	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	2.3	6.97	5.64	5.67
DCCWRUE	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	12.54	12.68	11.49	14.73
DCZXW9K	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	12.78	14.78	15.08	17.05
DC74O69	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	1.35	3.16	7.16	8
DC16VR9	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	14.62	15.01	3.68	17.58
DCZP4HM	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	2.28	9.21	7.97	12.55
DC80C21	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	10.97	13.93	12.53	15.9
DCUFGPA	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	1.71	3.45	1.8	4.55
DC20TOV	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	13.39	13.18	15.31	17.89
DCBY87K	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	6.67	7.91	10.74	11.54
DCZXPS9	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	7.56	9.29	10.6	12.93
DCVJFE0	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	11.24	11.34	12.88	15.75
DCD5MI5	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	11.15	15.62	17.22	17.64
DCIVUF3	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	8.1	12.1	14.42	15.1
DC3YLX6	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.03	8.41	12.51	13.02
DC88D6J	DM15F0X	Gefitinib	Approved	34	DMHZJCG	Pentamidine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	16.39	16.39	19.75	19.75
DCO20M1	DM15F0X	Gefitinib	Approved	34	DMIK367	Procarbazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.7	0.7	3.87	3.87
DCHXHGU	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	10.28	11.85	11.24	12.51
DCBFMM5	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	5.78	5.83	4.28	4.5
DCNUET5	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	7.09	7.37	6.83	6.29
DCWVYE6	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	14.94	17.06	1.63	14.59
DCH78SP	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	13.15	16.85	14.89	17.24
DCJI3VN	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	6.27	6.18	5.13	5.31
DC6QTMH	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	12.99	11.68	2.17	13.51
DCOTSD0	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	8.62	9.89	11.52	11.55
DCVMNUI	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	2.1	7.42	9.4	9.56
DCA6XXA	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	3.61	7.39	3.36	7.15
DCYL7ET	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	14.91	17.16	15.08	14.6
DC5CNPQ	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	0.39	8.71	7.19	9.12
DCC5HEN	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	6.2	10.32	9.75	10.59
DC3GBRB	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	5.3	5.45	0.27	8.67
DCO1YE0	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	2.79	6.98	8.66	9.4
DCMCWM3	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	3.16	2.41	2.42	3.01
DCPVUBY	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	3.71	3.45	2.55	6.92
DC4LX6M	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	2.31	2.79	2.3	2.15
DC3NYG2	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	1	9.07	6.05	8.45
DCRW7R9	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	7.7	13.88	14.03	15.78
DCSTU4J	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.9	5.57	7.3	7.28
DCB4R3K	DM15F0X	Gefitinib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	6.59	6.53	9.03	11.99
DCWX9V1	DM15F0X	Gefitinib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	7.84	8.02	8.63	10.73
DC7ZH06	DM15F0X	Gefitinib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.12	3	4.03	5.37
DCH72KU	DM15F0X	Gefitinib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	4.69	7.22	7.74	8.92
DCUHP9A	DM15F0X	Gefitinib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	4.35	8.43	8.93	10.97
DCQ7HFW	DM15F0X	Gefitinib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	19.7	14.16	12.12	20.88
DCADS4J	DM15F0X	Gefitinib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.98	1.45	3.86	6.49
DC0UHDB	DM15F0X	Gefitinib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	4.52	7.24	11.37	12.44
DCCPUIW	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	5.1	4.12	6.66	9.68
DC8GV4Z	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	0.65	3.96	9.6	11.15
DCALTNT	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	6.92	5.26	2.67	9.73
DCWY00V	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	9.33	8.62	5.69	14.79
DCG5D82	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	8.33	9.93	1.5	12.39
DCJDY0F	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	14.57	14.29	3.44	17.82
DCA0CUN	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	11.61	9.79	0.92	11.99
DC8W0OK	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	23.55	18.94	4.99	20.4
DC20F2D	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	14.15	11.21	5.63	13.19
DCSSCQ8	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	23.63	17.7	15.59	18.91
DCIZR00	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	11.39	11.04	1.52	14.13
DCLKGMZ	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	22.27	22.71	12.78	26.86
DC5A000	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	8.66	7.6	10.15	11.73
DCL1BE3	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.21	3.76	9.96	12.36
DCQN90O	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	11.02	11.5	3.27	15.02
DCZ9K1L	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	15.7	15.74	16.49	18.76
DCLCBOA	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	5.87	6.45	3.67	11.59
DCZQMPC	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	9.95	11.39	1.31	14.31
DCTGW88	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	12.49	13.85	5.39	16.97
DCH93D2	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	7.13	3.73	6.91	9.45
DC2SMR9	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	4.71	7.19	11.52	12.77
DCYL39W	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	7.24	8.27	0.05	13.22
DCYLKKY	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	11.58	10.98	12.48	14.89
DCH1CQ6	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	14.2	16.78	10.28	22.64
DCE962A	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	2.75	2.65	3.66	10.52
DCK5HRR	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	11.95	12.98	0.19	16.04
DCMT5ED	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	5.12	5.71	1.13	8.03
DCWZGAN	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	2.16	13.18	7.66	14.25
DC7UE7G	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	3.32	2.93	7.19	8.44
DCMJD40	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	8.69	8.28	15.23	17.26
DCVRKAH	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	6.62	5.82	9.28	11.43
DCJQMXN	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	1.16	4.35	8.29	10.28
DCKLSEW	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	14.02	10.25	14.27	17.25
DC6LK6K	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	12	11.3	9.41	14.71
DC06CNG	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	7.15	6.57	9.11	13
DC4693A	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	11.65	14.37	19.4	20.68
DCAI3GK	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.92	1.9	4.8	7.41
DCVVQ1V	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	7.29	6.91	14.25	15.49
DCGDRMN	DM15F0X	Gefitinib	Approved	34	DMJPE61	PF-02545920	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.44	9.44	20.28	20.3
DCW76ZK	DM15F0X	Gefitinib	Approved	34	DMKBYWI	Trifluoperazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.34	9.34	12.7	12.73
DCV3Y69	DM15F0X	Gefitinib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	0.03	7.66	2.03	6.35
DCNRP4I	DM15F0X	Gefitinib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.93	4.3	4.34	4.64
DCUR09W	DM15F0X	Gefitinib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	11.21	15.74	7.39	9.6
DC6DH8F	DM15F0X	Gefitinib	Approved	34	DMGO72P	Oseltamivir	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	13.9	13.9	19	19.04
DCWJMKA	DM15F0X	Gefitinib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.04	1.87	2.8	2.68
DCB9KXT	DM15F0X	Gefitinib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	3.18	4.34	0.82	4.59
DCWFS9C	DM15F0X	Gefitinib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	0.33	2.64	3.33	3.9
DC3YGSF	DM15F0X	Gefitinib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.94	4.86	0.94	5.14
DCMIVGE	DM15F0X	Gefitinib	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.49	5.17	4.38	6.11
DCU9MGE	DM15F0X	Gefitinib	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	17.64	17.64	23.56	23.56
DCM1VGD	DM15F0X	Gefitinib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	7.5	12.73	3.15	5.93
DC0I4BT	DM15F0X	Gefitinib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.2	10.09	3.33	10.53
DCDB6PV	DM15F0X	Gefitinib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	5.84	10.55	7.22	9.09
DC77KMM	DM15F0X	Gefitinib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	6.48	8.66	3.15	10.99
DC9K7IM	DM15F0X	Gefitinib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	6.94	8.13	0.73	7.9
DC3RA6K	DM15F0X	Gefitinib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	0.58	1.97	2.41	3.03
DC66PA5	DM15F0X	Gefitinib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	4.87	7.01	1.49	6.59
DCY1E51	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	1.61	3.73	5.69	6.2
DCWI2LB	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	1.76	3.3	8	8.92
DC6W7EY	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	1.84	1.43	1.73	5.6
DCBSMIW	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	1.72	2.84	1.54	1.25
DCU8Q6E	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	6.66	9.47	2.03	12.93
DCGAO0P	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	10.27	8.16	1.24	9.85
DCTQXPG	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	15.17	14.71	9.14	15.77
DCWHCNF	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	10.7	12.74	8.28	8.18
DCV6PJO	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	7.51	3.47	2.22	6.69
DCGLNOF	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	4.84	4.49	6.06	9.07
DCNSAZL	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	14.55	12.69	17.72	16.56
DCOZFXQ	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	11.91	10.64	9.21	15.28
DC9TS89	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.68	3.38	1.96	3.85
DC8V7MP	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.84	2.18	7.09	8.74
DC8XBS0	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.68	1.14	6.53	9.09
DCRXOWO	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	7.01	10.66	11.49	13.63
DCQXVDQ	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	7.98	8.99	9.03	10.74
DC8C33C	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	5.19	5.5	9.19	8.21
DCIKIO7	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.69	7.39	9.85	10.31
DCIRMB9	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	2.17	4.08	6.6	8.09
DCOZPVF	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	1.2	0.94	7.33	8.51
DC1PN9Q	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	9.66	12.02	13.67	14.91
DCLQVQJ	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	13.04	12.12	17.34	17.8
DCUCWZB	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	0.9	5.43	6.31	9.7
DCKUVDE	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	0.81	0.47	6.27	7.96
DCTT71U	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	13.31	13.13	6.46	16.61
DCLTHYZ	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	2.44	6.65	3.41	2.12
DC0UU7L	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	1.47	6.14	3.16	2.04
DCSOTIW	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	2.02	3.1	2.26	3.05
DC7J4C3	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	9.77	9.61	13.09	16.79
DCULSIG	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	2.36	4	7.9	9.73
DCSQXY3	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	0.1	4.93	4.28	9.55
DCY227G	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	6.27	6.06	9.81	12.95
DC4AT0C	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	0.5	5.41	9.83	10.53
DC4I7JE	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.82	4.19	9.38	10.22
DCJSKY7	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	3.96	4.93	7.94	10.43
DCY3Y6T	DM15F0X	Gefitinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	0.03	1.91	1.8	0.81
DCHPNX9	DM15F0X	Gefitinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	0.37	0.49	1.83	1.07
DCDO39L	DM15F0X	Gefitinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	2.23	1.9	0.76	0.86
DCNYG76	DM15F0X	Gefitinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.87	2.68	2.18	2.13
DC31UBG	DM15F0X	Gefitinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	2.91	3.05	2.72	3.73
DCFRGJ3	DM15F0X	Gefitinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.31	0.57	1.21	1.16
DCNCFW6	DM15F0X	Gefitinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.04	0.22	0.78	1.11
DC5ODO0	DM15F0X	Gefitinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.23	1.9	2.36	3.46
DC6WTY6	DM15F0X	Gefitinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	1.36	4.45	5.08	5.58
DCXR1QY	DM15F0X	Gefitinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	2.31	1.25	3.35	4.56
DC0C47R	DM15F0X	Gefitinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	4.39	4.47	6.35	7.44
DCNO6NE	DM15F0X	Gefitinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	9.75	10.83	11.27	11.82
DC05NSZ	DM15F0X	Gefitinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	5.31	7.19	3.85	10.24
DCXZ73Z	DM15F0X	Gefitinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	11.93	11.99	15.31	15.74
DC270YW	DM15F0X	Gefitinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	3.23	3.34	4.95	7.07
DCISCHY	DM15F0X	Gefitinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	0.89	5.65	7.32	8.5
DCQWPKJ	DM15F0X	Gefitinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.47	1.06	5.05	5.54
DC926OV	DM15F0X	Gefitinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	0.68	6.22	1.12	6.17
DCC0ITW	DM15F0X	Gefitinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.42	4.37	3.4	7.63
DCC5GAT	DM15F0X	Gefitinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.27	8.02	8.25	10.2
DC8P9OX	DM15F0X	Gefitinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	1.93	7.67	3.98	5.96
DCR5SK9	DM15F0X	Gefitinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	0.12	2.68	0.03	5.11
DCFOW61	DM15F0X	Gefitinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	0.11	1.6	3.89	5.42
DC7B4JW	DM15F0X	Gefitinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	1.82	6.85	7.31	9.95
DCU9A3U	DM15F0X	Gefitinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	0.62	2.35	0.79	3.49
DCDP5LO	DM15F0X	Gefitinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	10.52	10.23	9.81	15.49
DCF3AHY	DM15F0X	Gefitinib	Approved	34	DMNSJ7V	Tropisetron	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	16.24	16.24	19.97	19.98
DCU6RG3	DM15F0X	Gefitinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	5.56	7.68	6.91	8.45
DCWQBCG	DM15F0X	Gefitinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	2.02	1.57	9.01	10.53
DC28B19	DM15F0X	Gefitinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.16	2	7.1	8.22
DCLL989	DM15F0X	Gefitinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	3.58	5.17	10.34	11.23
DCFC9RK	DM15F0X	Gefitinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	8.44	9.61	11.92	13.02
DC1GVT3	DM15F0X	Gefitinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	2.17	1.75	7.56	8.48
DCLDHBI	DM15F0X	Gefitinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	3.12	4.65	10.9	12.36
DC4A1AD	DM15F0X	Gefitinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	2.57	5.55	8.98	9.49
DCKB3V5	DM15F0X	Gefitinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	7.86	7.53	7.87	14.65
DC4HSLM	DM15F0X	Gefitinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	0.46	0.38	3.13	7.92
DCPRZC4	DM15F0X	Gefitinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.48	1.35	9.36	11.19
DCRQ68K	DM15F0X	Gefitinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	2.73	3.09	7.86	8.76
DCKM2IX	DM15F0X	Gefitinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	3.26	3.56	8.48	9.97
DCP7D58	DM15F0X	Gefitinib	Approved	34	DMPP4DT	Trimethobenzamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.24	11.24	17.65	17.67
DCBMBAR	DM15F0X	Gefitinib	Approved	34	DMPWB7T	Maprotiline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.26	1.26	5.23	5.24
DC6SQKT	DM15F0X	Gefitinib	Approved	34	DMQXTJS	Eptifibatide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	15.92	15.92	19.28	19.28
DC0PSYH	DM15F0X	Gefitinib	Approved	34	DMR6N7H	Acetohexamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.53	11.53	14.08	14.15
DC6SWKQ	DM15F0X	Gefitinib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	9.77	14.07	2.96	13.1
DCEXNCP	DM15F0X	Gefitinib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	0.14	6.51	1.32	1.9
DCK2LBG	DM15F0X	Gefitinib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.99	7.61	3.69	8.81
DC55LDC	DM15F0X	Gefitinib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	2.62	11.83	5.77	10.88
DCVBLTH	DM15F0X	Gefitinib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	6.07	7.87	4.53	8.77
DCQF28F	DM15F0X	Gefitinib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	12.34	13.37	6.61	10.77
DCTQJVO	DM15F0X	Gefitinib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.16	2.59	1.86	4.05
DCWGZHC	DM15F0X	Gefitinib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.98	7.98	11.41	11.41
DCNCODO	DM15F0X	Gefitinib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	2.88	3.86	0.51	4.27
DCILG8G	DM15F0X	Gefitinib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	0.17	5.69	2.66	4.5
DCOGGUP	DM15F0X	Gefitinib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	1.16	8.03	6.86	8.42
DCMBDD9	DM15F0X	Gefitinib	Approved	34	DMRV7H0	Bumetanide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	14.89	14.89	18.22	18.22
DC8WPJF	DM15F0X	Gefitinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	5.48	6.27	1	7.66
DCS5AU4	DM15F0X	Gefitinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.34	8.67	5.02	10.92
DCGQGRK	DM15F0X	Gefitinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.32	3.38	3.96	4.78
DCRCPAI	DM15F0X	Gefitinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	4.08	2.97	3.7	3.9
DCKF6R2	DM15F0X	Gefitinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	0.28	4.94	5.9	6.79
DC1ITE1	DM15F0X	Gefitinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	4.16	6.66	0.81	6.46
DC7FIQJ	DM15F0X	Gefitinib	Approved	34	DMSA4B3	Desoxycorticosterone pivalate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	13.03	13.03	16.02	16.02
DCQY2CK	DM15F0X	Gefitinib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	3.08	4.23	1.23	4.01
DCCBUFD	DM15F0X	Gefitinib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	5.15	6.7	3.19	4.96
DCT99AL	DM15F0X	Gefitinib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	2.62	3.67	0.23	2.76
DC24JUN	DM15F0X	Gefitinib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	0.26	6.15	4.48	4.83
DCDQ6R6	DM15F0X	Gefitinib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.65	6.52	6.51	6.89
DC1YKGF	DM15F0X	Gefitinib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	1.37	1.24	0.5	0.1
DCW96LK	DM15F0X	Gefitinib	Approved	34	DMSIWD0	Hyodeoxycholic acid	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.72	5.72	20.14	20.15
DC9YNPD	DM15F0X	Gefitinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	3.87	4.67	2	5.91
DCK9YBX	DM15F0X	Gefitinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.69	3.74	2.98	5.26
DCWYOXS	DM15F0X	Gefitinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.18	5.46	7.82	7.91
DCE3Q0X	DM15F0X	Gefitinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.85	1.66	0.72	3.86
DC2RU83	DM15F0X	Gefitinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	2.99	5.79	3.7	9.61
DCD03J7	DM15F0X	Gefitinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.66	6.43	10.14	11.35
DC0AV23	DM15F0X	Gefitinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	2.56	1.73	5.13	5.18
DCMTIKZ	DM15F0X	Gefitinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	24.43	22.54	26.89	27.96
DC4SLYK	DM15F0X	Gefitinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	7.4	7.5	1.38	11.01
DC710JB	DM15F0X	Gefitinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	11.92	10.32	8.77	13
DCMAZY7	DM15F0X	Gefitinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	2.93	1.91	5.97	7.78
DCV82W3	DM15F0X	Gefitinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	3.96	2.39	6.07	7.29
DCR7SCQ	DM15F0X	Gefitinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	6.44	3.55	5.81	8.25
DC2OZMM	DM15F0X	Gefitinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	5.71	8.27	2.68	11.14
DC30M0P	DM15F0X	Gefitinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.12	6.7	7.86	7.87
DCI72KH	DM15F0X	Gefitinib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	1.58	2.86	3.87	4.71
DCVOEDM	DM15F0X	Gefitinib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	5.96	6.15	2.81	4.82
DC1I4T3	DM15F0X	Gefitinib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.19	3.62	4.91	5.87
DCUJLM2	DM15F0X	Gefitinib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	10.16	10.81	11.4	13.46
DCI0KUK	DM15F0X	Gefitinib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	7	7.76	5.48	5.03
DCBRMR0	DM15F0X	Gefitinib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	1.86	2.37	0.8	5.37
DC98NHM	DM15F0X	Gefitinib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	7.45	10.67	8.62	10.93
DCTDIUD	DM15F0X	Gefitinib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	2.15	3.31	0.93	2.72
DC83XIY	DM15F0X	Gefitinib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	13.64	15.58	8.53	16.32
DCAMQ24	DM15F0X	Gefitinib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	1.18	5.32	3.27	4.95
DCQ383X	DM15F0X	Gefitinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.93	5.62	1.08	5.83
DCBTDDE	DM15F0X	Gefitinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	0.94	2.69	0.66	4.2
DC6W5CB	DM15F0X	Gefitinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	14.33	18.67	12.06	19.46
DCURV9U	DM15F0X	Gefitinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	8.88	8.98	11.97	12.35
DCQ3UU0	DM15F0X	Gefitinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	13.21	15.03	14.52	15.74
DCHWUK3	DM15F0X	Gefitinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	10.48	10.21	0.4	11.11
DCG45GL	DM15F0X	Gefitinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	14.49	18.44	15.92	17.13
DCG7N1H	DM15F0X	Gefitinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	10.61	6.39	4.81	7.99
DCYXOXJ	DM15F0X	Gefitinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	11.4	12.93	4.69	13.52
DCQC7IE	DM15F0X	Gefitinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	8.88	9.95	5.61	12.19
DCUB0C9	DM15F0X	Gefitinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	8.84	13.07	7.51	13.91
DCMRXB6	DM15F0X	Gefitinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	8.56	7.42	0.5	11.57
DC04003	DM15F0X	Gefitinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	1.22	1.22	2.25	5.86
DCDKD9W	DM15F0X	Gefitinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	5.74	5.35	3.95	9.35
DCD5NRO	DM15F0X	Gefitinib	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	3.75	4.1	1.75	8.05
DC8IOZR	DM15F0X	Gefitinib	Approved	34	DMRBMAU	Mycophenolic acid	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.88	1.88	5.49	5.5
DCOFUUH	DM15F0X	Gefitinib	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	0.89	4.96	2.46	4
DC6MWLG	DM15F0X	Gefitinib	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	0.89	0.82	1.08	2.64
DCPOR6R	DM15F0X	Gefitinib	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	4.46	4.19	2.52	6.22
DCCDHY2	DM15F0X	Gefitinib	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.16	4.37	3.42	4.28
DCPIVTI	DM15F0X	Gefitinib	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	1.46	4.67	5.46	6.38
DCMU31W	DM15F0X	Gefitinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	1.67	1.94	3.1	5.98
DC2LB27	DM15F0X	Gefitinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	6.31	8.41	7.09	8.68
DCXRCQP	DM15F0X	Gefitinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	13.59	15.14	2.62	15.27
DCHSVM0	DM15F0X	Gefitinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.85	4.56	5.54	6.95
DC79M7N	DM15F0X	Gefitinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.81	5.92	5.49	9.68
DC99NY1	DM15F0X	Gefitinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	1.42	4.88	5.08	7.27
DC9MBA7	DM15F0X	Gefitinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	5.75	6.95	6.91	9.38
DCP80Y8	DM15F0X	Gefitinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	4.64	8.26	2.81	9.41
DCJ7GTZ	DM15F0X	Gefitinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	0.62	4.62	0.01	6.75
DC77632	DM15F0X	Gefitinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	1.83	1.06	4.73	6.3
DCRJD8Z	DM15F0X	Gefitinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	3.88	3.15	8.32	10.6
DCGA7HL	DM15F0X	Gefitinib	Approved	34	DMWT905	Mefloquine	Phase 2/3 Trial	24	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.13	0.13	4.22	4.25
DC1NNE9	DM15F0X	Gefitinib	Approved	34	DMVM6QR	Lacosamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	15.55	15.55	19.04	19.07
DCQU312	DM15F0X	Gefitinib	Approved	34	DMVN2E6	Vinpocetine	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	14.672	19.567	2.658	1.441
DCBRZ6V	DM15F0X	Gefitinib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	1.59	1.02	4.39	8.1
DC2FLGY	DM15F0X	Gefitinib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	4.26	4.1	5.55	8.57
DC63JNR	DM15F0X	Gefitinib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	3.03	5.27	6.38	8.71
DC4YBGD	DM15F0X	Gefitinib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	4.1	3.99	3.2	7.06
DCSQZHO	DM15F0X	Gefitinib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.36	7.97	6.37	7.81
DCQ41MF	DM15F0X	Gefitinib	Approved	34	DMVRYT2	Nabilone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.05	11.05	14.62	14.63
DC6PE0F	DM15F0X	Gefitinib	Approved	34	DMVTHWQ	Silver sulfadiazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	12.92	12.92	15.75	15.78
DC6OWOM	DM15F0X	Gefitinib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	1.39	8.44	4.67	6.46
DCFO8IG	DM15F0X	Gefitinib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.19	13.58	3.79	8.48
DCZQD8S	DM15F0X	Gefitinib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.85	10.44	10.53	12.02
DCYYTE9	DM15F0X	Gefitinib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.21	4.06	3	4.97
DC0JPF3	DM15F0X	Gefitinib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.23	5.91	3.68	5.75
DC8LPDO	DM15F0X	Gefitinib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.13	4.08	5.21	5.37
DCR6FBB	DM15F0X	Gefitinib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	2.68	4.73	2.48	6.19
DCZHFAD	DM15F0X	Gefitinib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	1.23	5.91	4.54	6.31
DCKQYT4	DM15F0X	Gefitinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	1.81	1.95	1.61	2.98
DCXM1BM	DM15F0X	Gefitinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	1.28	3.49	3.22	2.45
DCXVOAQ	DM15F0X	Gefitinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	0.39	2.26	2.43	2.42
DC0KV9D	DM15F0X	Gefitinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.77	2.71	3.31	3.44
DCW4RX1	DM15F0X	Gefitinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.8	6.92	8.35	8.64
DCAC4BQ	DM15F0X	Gefitinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.16	1.04	0.96	0.96
DCOZ37C	DM15F0X	Gefitinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.11	1.95	3.09	3.47
DCJJDEO	DM15F0X	Gefitinib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.58	1.58	4.65	4.69
DCQWQCA	DM15F0X	Gefitinib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	3.16	3.87	6.87	7.25
DC2MDAW	DM15F0X	Gefitinib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.97	5.61	0.7	6.82
DCKNKCZ	DM15F0X	Gefitinib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.31	3.32	2.66	5.53
DCZTPS3	DM15F0X	Gefitinib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.01	9.31	10.81	11.53
DC5ZEIT	DM15F0X	Gefitinib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.54	4.72	4.15	6.12
DC42723	DM15F0X	Gefitinib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	0.87	4.52	6.64	7.87
DC2O9UP	DM15F0X	Gefitinib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	3.32	5.16	4.69	9.25
DCIQD73	DM15F0X	Gefitinib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	4.36	4.96	4.58	6.85
DC98M4B	DM15F0X	Gefitinib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.26	4.68	3.52	7.14
DCCCCXW	DM15F0X	Gefitinib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	0.78	7.44	1.11	8.72
DC4AOPY	DM15F0X	Gefitinib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.41	2.34	2.49	6.55
DCOLTAN	DM15F0X	Gefitinib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	4.22	3.23	3.15	12.02
DCQ4BWQ	DM15F0X	Gefitinib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	4.56	4.38	1.55	2.54
DCNN93R	DM15F0X	Gefitinib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	9.71	12.38	5.76	12.2
DCIGSTW	DM15F0X	Gefitinib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	0.39	1.96	1.08	0.26
DC9AVZT	DM15F0X	Gefitinib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.36	3.81	4.09	4.68
DCUV21H	DM15F0X	Gefitinib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	12.45	14.54	14.38	14.1
DCI0YJ1	DM15F0X	Gefitinib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	2.46	3.75	2.93	2.9
DCB1JS7	DM15F0X	Gefitinib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.34	7.65	5.22	5.17
DC53Y8T	DM15F0X	Gefitinib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	1.81	2.25	5.07	7.56
DCHXZL7	DM15F0X	Gefitinib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	12.3	11.65	9.43	9.48
DCX38RK	DM15F0X	Gefitinib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	3.54	7.26	4.45	6.62
DCZB1DC	DM15F0X	Gefitinib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	8.25	9.84	8.57	9.73
DCHNTDG	DM15F0X	Gefitinib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	1.05	1.87	5.52	6.84
DC642D1	DM15F0X	Gefitinib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.16	9.2	1.5	1.93
DCC3XUE	DM15F0X	Gefitinib	Approved	34	DMXCM7H	Cerivastatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.26	2.26	5.1	5.19
DCZ0S12	DM15F0X	Gefitinib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	2.47	4.03	2.08	4.16
DC57FWB	DM15F0X	Gefitinib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	1.86	9.98	7.18	8.54
DCTYGHA	DM15F0X	Gefitinib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	10.66	11.36	4.25	11.43
DCDLXMH	DM15F0X	Gefitinib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.84	6.47	3.2	7.45
DCE1JG3	DM15F0X	Gefitinib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.21	5.73	1.86	6.03
DCUNAAH	DM15F0X	Gefitinib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.39	7.49	4.61	9
DCL223O	DM15F0X	Gefitinib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	5.81	16.54	9.88	15.1
DCWN64S	DM15F0X	Gefitinib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.38	5.17	2.61	4.56
DCSTLD3	DM15F0X	Gefitinib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	1.08	5.3	3.88	6.32
DCZMPAA	DM15F0X	Gefitinib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	3.53	4.69	0.5	4.74
DCFWSYF	DM15F0X	Gefitinib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	3.28	6.58	6.44	8.58
DCPTZA6	DM15F0X	Gefitinib	Approved	34	DMYLOVR	Aciclovir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.87	11.87	19.41	19.45
DC757EH	DM15F0X	Gefitinib	Approved	34	DMYURI6	Raltegravir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	10.67	10.67	13.7	13.72
DCIFGH4	DM15F0X	Gefitinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	3.69	6.08	7.53	7.99
DCNE3EI	DM15F0X	Gefitinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	4.85	4.53	10.07	10.7
DC18K0Q	DM15F0X	Gefitinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	1.81	3.61	8.51	11.43
DCS2DVG	DM15F0X	Gefitinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	1.33	4.46	7.74	7.9
DCR2GD6	DM15F0X	Gefitinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	4.13	7.98	7	11.86
DCZD3G4	DM15F0X	Gefitinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.75	3.32	7.02	10.28
DC17YF1	DM15F0X	Gefitinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.06	5.94	9.57	9.7
DCP1MR2	DM15F0X	Gefitinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	2.64	8.14	2.53	7.25
DC4YOZ1	DM15F0X	Gefitinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	3.91	4.02	7.58	7.96
DC7RZFZ	DM15F0X	Gefitinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	1.25	3.28	2.23	6.38
DCTVMB0	DM15F0X	Gefitinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	7.85	7.41	14.02	15.85
DCD5HNV	DM15F0X	Gefitinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	1.36	4.08	7.75	9.06
DCLCIF6	DM15F0X	Gefitinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	5.08	4.21	8.08	10.19
DC3Q4WL	DM15F0X	Gefitinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	0.51	6.7	7.12	11.04
DCCGZ0O	DM15F0X	Gefitinib	Approved	34	DMZD5QR	Cytarabine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.1	0.1	2.56	2.61
DCWOV5U	DM15F0X	Gefitinib	Approved	34	DMZMSCT	Cilostazol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	13.28	13.28	16.61	16.62
DCWUL9P	DM15F0X	Gefitinib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.51	6.57	3.05	7.15
DCTNAE6	DM15F0X	Gefitinib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.75	8.32	5.64	7.9
DC0TEA4	DM15F0X	Gefitinib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.33	5.55	0.36	8.49
DCOCZA2	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	6.51	13.26	12.93	12.99
DCZVP6W	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	9.01	13.51	14.18	13.69
DCKLLD9	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	7.16	13.42	13.8	13.05
DCJ60LW	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	12.39	19.71	19.72	19.38
DCAIFIO	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	8.94	7.04	11.06	11.96
DCNVGBP	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	11.16	21.19	21.57	21.06
DCGNPVV	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.4	14.87	15.16	14.98
DCP78ZD	DM15F0X	Gefitinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	9.67	17.06	17.36	16.92
DCQKB14	DM15F0X	Gefitinib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.64	7.26	1.46	3.7
DC4S898	DM15F0X	Gefitinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	18.03	16.96	20.67	20.97
DCZDQJK	DM15F0X	Gefitinib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.91	7.56	2.17	2.54
DCU90U8	DM15F0X	Gefitinib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	10.47	12.07	14.66	15.33
DCJT2HC	DM15F0X	Gefitinib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.12	2.36	0.38	6.19
DC5K6ZU	DM15F0X	Gefitinib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.5	10.94	4.12	11.13
DC41P1H	DM15F0X	Gefitinib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.95	6.88	11.04	11.98
DCMTJ4S	DM15F0X	Gefitinib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.93	3.02	1.16	2.79
DCCVA90	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.45	11.28	10.08	10.79
DCXSPF3	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.08	15.4	16.37	16.03
DC24KON	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	7.19	12.68	13.68	12.97
DC0C9PW	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	12.37	19.05	15.68	15.36
DC74WRB	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	18.22	17.95	22.29	20.69
DC0VK6L	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.25	15.44	14.88	14.7
DC85S88	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	23.72	27.06	26.33	25.98
DCD12LA	DM15F0X	Gefitinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.86	15.94	16.2	15.8
DCCUT6E	DM15F0X	Gefitinib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	10.97	12.65	8.64	8.44
DCWTR6F	DM15F0X	Gefitinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.28	4.62	7.59	9.4
DCPUEZY	DM15F0X	Gefitinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.37	1.44	2.94	5.51
DCFZC9V	DM15F0X	Gefitinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.65	1.03	1.47	4.41
DCYZHMV	DM15F0X	Gefitinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.02	10.39	11.72	12.27
DCWA5N2	DM15F0X	Gefitinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.7	2	5.52	7.32
DCAG87I	DM15F0X	Gefitinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	10.48	9.47	15.18	16.53
DC0RAGL	DM15F0X	Gefitinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.16	5.81	8.42	10.51
DCOMPEV	DM15F0X	Gefitinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.19	2.77	4.04	3.45
DC2DBFO	DM15F0X	Gefitinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.71	9.35	7.05	11.18
DCBGK7G	DM15F0X	Gefitinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.15	12.89	9.13	9.11
DC5DTTN	DM15F0X	Gefitinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.11	3.54	0.46	0.46
DCN8F6Y	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	8.53	11.71	15.46	16.51
DC3UO77	DM15F0X	Gefitinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.46	7.89	8.7	10.99
DCAB6VU	DM15F0X	Gefitinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	9.6	7.63	9.57	11.85
DCGCXPP	DM15F0X	Gefitinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.76	13.01	4.51	8.66
DCSHCJQ	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.29	4.38	8.37	9.57
DCNCU2I	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	10.76	13.72	15.11	16.52
DC53Z9K	DM15F0X	Gefitinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.38	9.45	7.17	11.46
DCO30JH	DM15F0X	Gefitinib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.09	1.17	8.53	9.69
DC5ZN0Z	DM15F0X	Gefitinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.12	5.98	2.08	10.4
DCJIAFS	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.24	9.98	7.18	7.44
DCYQ68A	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	12.04	10.6	13.2	15.52
DCKVXLO	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	8.63	8.38	11.06	13.88
DC7C1O3	DM15F0X	Gefitinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.63	13.87	14.45	16.42
DCH3PRA	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.14	7.94	10.69	12.03
DCU3LF0	DM15F0X	Gefitinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	8.08	6.33	13.14	13.88
DCJZ96R	DM15F0X	Gefitinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	10.4	12.89	1.86	12.21
DCRF195	DM15F0X	Gefitinib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.11	3.02	7.84	9.69
DC6ABJR	DM15F0X	Gefitinib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	4	5.3	8.11	9.45
DC8BHAK	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	14.37	12.81	8.92	17.9
DCVRWVX	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.44	3.5	7.38	9.55
DCPGUGI	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.93	7.85	1.87	11.58
DC7Y74W	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	15.18	16.56	7.4	19.68
DCI2DVP	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	18.44	15.72	23.34	23.83
DCBLP2G	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.93	11.08	8.29	15.48
DCU4C5Q	DM15F0X	Gefitinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.09	6.66	6.74	11.36
DCWUWTC	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	9.65	9.76	14.14	15.45
DCJ3Y7H	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.62	8.94	16.14	16.75
DCZ2ZDC	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	10.87	12.52	14.99	17.19
DCRU2CF	DM15F0X	Gefitinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.22	1.75	0.5	6.52
DCYBCDH	DM15F0X	Gefitinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.84	1.39	2.22	3.53
DCQ7SCS	DM15F0X	Gefitinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.02	9.51	10.84	11.25
DCFKQ5B	DM15F0X	Gefitinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.32	2.19	4.74	6.16
DCRRP41	DM15F0X	Gefitinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.2	3.76	10.16	12.16
DC6T4MD	DM15F0X	Gefitinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.97	1.21	5.08	6.21
DC540ZY	DM15F0X	Gefitinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.24	2.26	4.21	6.12
DCWDY5M	DM15F0X	Gefitinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.6	5.91	9.79	10.54
DCK5ED9	DM15F0X	Gefitinib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.58	2.38	1.04	1.97
DCTRSJ5	DM15F0X	Gefitinib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.59	6.7	1.93	5.9
DCTU0AP	DM15F0X	Gefitinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.73	0.71	3.45	3.78
DCD9NY3	DM15F0X	Gefitinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.65	5.64	4.64	6.29
DCIWSJB	DM15F0X	Gefitinib	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	13.99	13.11	17.25	17.8
DCSVF0O	DM15F0X	Gefitinib	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	17.34	15.8	10.05	19.2
DCDB76A	DM15F0X	Gefitinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	5.18	11.21	10.81	13.86
DCWNTDI	DM15F0X	Gefitinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	7.85	6.32	12.87	13.59
DCAWUIS	DM15F0X	Gefitinib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.27	6.9	4.35	9.98
DCVFHGJ	DM15F0X	Gefitinib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	12.6	11.81	14.91	18.22
DC1ATEP	DM15F0X	Gefitinib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.02	5.01	5.38	7.07
DCK35F4	DM15F0X	Gefitinib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.13	4.59	3.14	2.47
DCTNYCT	DM15F0X	Gefitinib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.42	0.93	2.34	2.16
DC7URS0	DM15F0X	Gefitinib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.74	9.07	5.17	9.07
DCRUPJM	DM15F0X	Gefitinib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	6.79	13.12	16.08	18.93
DC5UX58	DM15F0X	Gefitinib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.74	9.69	5.87	7.22
DCM7NBN	DM15F0X	Gefitinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.94	8.29	4.08	4.5
DC4BKE1	DM4F29C	Crizotinib	Approved	34	DMGVH6N	Axitinib	Approved	34	.	.	.	.	Solid Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC6G7W1	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Diffuse Intrinsic Pontine Glioma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCFQJ4P	DM4F29C	Crizotinib	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Non-Small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCMIGX4	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Advanced Cancers	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCXW0I5	DM4F29C	Crizotinib	Approved	34	DMF57DM	Pazopanib	Approved	34	.	.	.	.	Advanced Cancers	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCGQSU9	DM4F29C	Crizotinib	Approved	34	DM5DSFZ	Rifampicin	Approved	34	DMCR1MV	Itraconazole	.	.	Non-Small Cell Lung Cancer ALK-positive	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC59Z33	DM4F29C	Crizotinib	Approved	34	DMICDLV	Lorlatinib	Approved	34	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCOWVBN	DM4F29C	Crizotinib	Approved	34	DMGVH6N	Axitinib	Approved	34	.	.	.	.	Advanced Solid Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCU75S9	DM4F29C	Crizotinib	Approved	34	DMGL19D	Enzalutamide	Approved	34	.	.	.	.	Castration-resistant Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCV0G8A	DM4F29C	Crizotinib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	4.7	8.87	5.68	7.92
DCDI92C	DM4F29C	Crizotinib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	4.18	8.65	2.62	2.29
DCFZYZA	DM4F29C	Crizotinib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	1.29	6.89	3.81	7.16
DC6EG09	DM4F29C	Crizotinib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	0.76	7.46	6.32	6.32
DC5U765	DM4F29C	Crizotinib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	1.02	5.29	1.81	1.84
DCO1Y3A	DM4F29C	Crizotinib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	0.45	4.26	5.02	4.73
DCN64D9	DM4F29C	Crizotinib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	1.79	6.2	2.55	1.92
DCULBIT	DM4F29C	Crizotinib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	0.07	4.58	3.64	3.44
DCDO3VY	DM4F29C	Crizotinib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	1.71	7.64	2.35	7.52
DCVJ0AN	DM4F29C	Crizotinib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	3.59	10.05	6.12	4.46
DCFQILX	DM4F29C	Crizotinib	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	3.48	5.32	1	2.78
DCB5QBZ	DM4F29C	Crizotinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	1.21	7.15	3.04	5.05
DCPHGWL	DM4F29C	Crizotinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	1.99	3.69	1.16	0.35
DCB5W68	DM4F29C	Crizotinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	2.55	9.99	3.17	9.33
DC2HHR3	DM4F29C	Crizotinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	3.99	8.08	4.52	3.99
DCG3XGK	DM4F29C	Crizotinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	5.54	0.89	1	0.72
DC7UOWK	DM4F29C	Crizotinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	3.17	5.98	0.48	5.58
DCWXSRL	DM4F29C	Crizotinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	0.26	6.24	6.48	6.54
DCK2EUS	DM4F29C	Crizotinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	0.26	8.99	6.81	7.73
DC8PGMC	DM4F29C	Crizotinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	5.75	9.15	3.79	3.79
DCAK25M	DM4F29C	Crizotinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	0.93	2.89	1.28	1.85
DC21XTR	DM4F29C	Crizotinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	0.3	4.61	1.64	3.58
DCGSS9M	DM4F29C	Crizotinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	1.75	3.63	2.3	2.13
DCZ9KV1	DM4F29C	Crizotinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	1.68	8.47	8.16	8.25
DC0VGDC	DM4F29C	Crizotinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	1.02	3.63	3.42	2.89
DC4F8LB	DM4F29C	Crizotinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	3.45	9.14	7.56	6.66
DC1TVHU	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	5.32	6.76	3.64	6.35
DC1KF63	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	10.17	9.8	5.39	7.82
DC4JRWH	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	6.72	11.04	12.45	14.65
DCZJIFR	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	0.58	8.91	10.54	11.25
DC6CMQS	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	13.17	15.53	12.51	16.35
DCU6OUW	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	18.26	19.12	16.26	15.92
DCX2I7D	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	11.5	10.79	7.06	11.94
DCARD1Y	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	8.56	10.95	2.07	11.76
DC7304N	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	8.43	9.55	7.72	9.87
DCKNBPZ	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	9.95	14.72	14.56	15.17
DC46KHN	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	3.77	6.78	6.59	9.33
DCT1S18	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	14.09	14.08	8.9	9.55
DCINCQQ	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	21.91	24.31	21.55	20.87
DCDFGF4	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	0.82	7.47	5.81	7.95
DCARPXT	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	0.02	8.24	9.67	9.36
DCG6SKE	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	4.51	10.37	6.43	8.48
DC8M5Y4	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	7.87	11.11	2.41	12.19
DCMD9FS	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	3.33	8.86	8.33	9.36
DC6HL3C	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	1.62	11.29	12.1	12.77
DC3Y7CT	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	8.8	9.74	10.05	12.38
DCVCIPQ	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	6.82	11.24	9.56	10.01
DCFU1L5	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	5.08	7.84	5.24	8.35
DCAMODK	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	17.39	18.48	18.4	18.53
DC3SS31	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	4.79	11.99	0.47	10.41
DCK0PU7	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	3.38	8.51	6.36	8.29
DCEZJP5	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	8.87	8.54	1.28	7.65
DCQHOYY	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	8.6	8.91	6.77	9.45
DCK4SM1	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	12.94	13.06	13.07	15.53
DC00W1P	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	7.65	8.58	8.18	9.6
DCWF6S7	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	8.71	11.92	5.53	7.08
DCO19VA	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	4.12	10.15	10.01	11.79
DCHMTX0	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	0.07	8.39	11.13	11.49
DCUTJVH	DM4F29C	Crizotinib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	0.98	8.51	6.04	7.45
DCIWZ94	DM4F29C	Crizotinib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	1.34	3.08	1.34	0.77
DCS4I3K	DM4F29C	Crizotinib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	2.68	6.74	3.22	3.19
DCYHVUO	DM4F29C	Crizotinib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	3.23	5.68	1.92	4.22
DCBPIA8	DM4F29C	Crizotinib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	0.98	5.22	4.36	4.65
DCQJCZ2	DM4F29C	Crizotinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	3.95	14.12	8.01	8.06
DCO4DKK	DM4F29C	Crizotinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	2.4	6.89	7.15	6.98
DC4Y55I	DM4F29C	Crizotinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	2.99	6.61	5.84	4.89
DCES29K	DM4F29C	Crizotinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	0.04	0.74	3.31	3.36
DCO5XHI	DM4F29C	Crizotinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	0.94	8.38	5.32	8.5
DCGBFJV	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	9.07	14.18	11.6	11.62
DCYXQP3	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	22.23	21.19	17.31	18.56
DCSY44I	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	0.59	4.92	4.46	4.58
DCBJROT	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	3.58	10.6	9.4	9.01
DCICKID	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	3.51	6.07	4.68	4.44
DCV4ED5	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	12.6	16.38	14.79	14.92
DC4CHLC	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	25.1	25.85	24.32	24.26
DC72SVJ	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	14.89	17.38	10.08	15.59
DCTM2VR	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	26.27	24.45	22.78	22.87
DCT7N31	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	22.44	25.8	20.05	20.94
DCJTW71	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	31.99	33.95	32.29	32.88
DCP08BD	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	10.32	18.41	14.53	15.12
DCDWN5V	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	8.12	14.16	13.76	10.65
DCTIF62	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	24.12	21.78	18.91	22.56
DCJ3QW9	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	9.92	12.72	12.7	12.55
DC9UNYK	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	23.46	29.09	29.21	28.98
DCOAPGG	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	12.42	15.95	14.71	14.99
DCTZMB9	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	16.75	15.43	16.14	16.35
DCXXGZ0	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	5.53	12.71	11.61	11.69
DCHCD94	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	25.03	24.7	24.52	24.35
DC6JQU9	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	8.83	14.57	12.63	12.52
DCX161V	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	19.04	20.52	22	21.16
DCYYU14	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	8.75	10.57	7.54	6.05
DCA5OAG	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	7.31	11.12	4.78	5.71
DCLK35J	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	3.96	8.41	7.51	7.54
DCQ8ZM2	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	7.62	12.31	13.37	13.39
DC3LUSM	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	12.16	17.83	14.24	14.72
DCYHDXY	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	4.89	12.16	12.64	12.55
DCC3GF7	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	20.59	25.12	24.19	24.28
DCPFL6Q	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	6.42	15.29	13.43	13.49
DCRVMVX	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	14.19	16.85	15.44	15.64
DCQZ8QM	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	5.37	8.21	5.74	6.7
DCP5VHA	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	6.56	14.43	13.8	13.35
DCWCJKU	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	4.51	9.69	9.74	9.64
DCSOSPE	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	7.03	15.97	14.78	14.6
DCUCW5T	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	4.88	13.48	14.74	14.25
DCH6KZT	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	8.74	18.3	17.7	17.73
DCO3NSG	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	5.28	13.49	11.72	11.99
DCFMXX9	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	3.51	5.83	5.86	5.12
DCV2I0W	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	13.99	18.01	16.28	15.41
DCC6S8H	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	6.39	12.41	11.01	11.04
DC5A4QV	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	3.47	9.96	9.84	9.51
DCC20BU	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	6.21	10.46	8.86	8.99
DCAFED8	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	9.42	18.35	17.44	17.45
DCJYOZB	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	38.92	44.43	37.92	38.33
DCQHMBK	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	6.79	13.39	12.44	12.22
DC3AYBY	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	3.27	9.13	8.76	8.56
DCTCI7X	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	7.61	14.69	15.95	15.45
DC2FXZN	DM4F29C	Crizotinib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	0.51	3.99	0.87	3.03
DCZX3D3	DM4F29C	Crizotinib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	2.51	4.62	1.6	1.1
DCO79DM	DM4F29C	Crizotinib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	3.47	7.77	6.29	2.27
DCF6AZ3	DM4F29C	Crizotinib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	2.97	5.94	4.02	0.94
DCSIWCZ	DM4F29C	Crizotinib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	0.67	5.42	0.82	5.05
DCZ2KMJ	DM4F29C	Crizotinib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	0.23	2.33	1.65	1.22
DC52GI0	DM4F29C	Crizotinib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	1.25	3.58	1.87	1.61
DCKSBSY	DM4F29C	Crizotinib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	3.13	6.95	5.49	0.41
DCO6T67	DM4F29C	Crizotinib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	4.23	4.92	4.89	4.56
DCO2IS8	DM4F29C	Crizotinib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	2.11	5.26	0.62	4.91
DCNGCN0	DM4F29C	Crizotinib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	5.9	8.16	8.28	9.27
DCUT6I6	DM4F29C	Crizotinib	Approved	34	DM48K0X	Carfilzomib	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	15.23	16.519	6.765	10.227
DC5SUC0	DM4F29C	Crizotinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	14.47	17.56	7.87	16.07
DCKXCLC	DM4F29C	Crizotinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	1.84	5.62	2.65	4.9
DCBX6QN	DM4F29C	Crizotinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	0.51	3.24	3.56	3.45
DCR9982	DM4F29C	Crizotinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	4.51	11.35	10.39	12.18
DCARIRI	DM4F29C	Crizotinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	14.43	17.58	16.96	18.44
DCIFMLV	DM4F29C	Crizotinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	1.36	11.2	3.16	10.17
DCK6AHJ	DM4F29C	Crizotinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	2.66	5.43	0.83	4.83
DCD4CK5	DM4F29C	Crizotinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	0.32	4.83	5.91	6.11
DCJT59J	DM4F29C	Crizotinib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	1.04	6.96	5.87	6.75
DCCQIDC	DM4F29C	Crizotinib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	1.74	5.01	2.12	4.32
DCHP0BT	DM4F29C	Crizotinib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	0.12	6.18	2.77	2.47
DCV6TAO	DM4F29C	Crizotinib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	4.44	9.17	3.99	7.4
DCALXY6	DM4F29C	Crizotinib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	0.12	7.35	9.1	8.26
DCBMTU1	DM4F29C	Crizotinib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	0.61	4.22	2.88	1.9
DCFKICD	DM4F29C	Crizotinib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	10.23	11.86	1.35	0.43
DC47XP4	DM4F29C	Crizotinib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	4.12	10.12	0.04	1.17
DCMV6GQ	DM4F29C	Crizotinib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	6.3	12.14	0.7	2.06
DCD0GZR	DM4F29C	Crizotinib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	2.98	9.38	5.34	4.47
DC4YEMQ	DM4F29C	Crizotinib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	0.98	1.82	1.05	0.73
DCTTUJS	DM4F29C	Crizotinib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	4.32	8.47	4.53	1.72
DCZ33RS	DM4F29C	Crizotinib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	4.52	8.54	2.89	4.93
DC5Z19F	DM4F29C	Crizotinib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	11.03	13.67	4.42	2.31
DCMCEI9	DM4F29C	Crizotinib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	0.55	3.99	1.32	1.41
DCBJOQY	DM4F29C	Crizotinib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	1.16	7.74	4.63	6.65
DCDINB7	DM4F29C	Crizotinib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	5.79	6.51	3.57	7.26
DCI8CIP	DM4F29C	Crizotinib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	0.16	5.64	7.08	8.77
DCO945F	DM4F29C	Crizotinib	Approved	34	DM6KU93	Alvespimycin hydrochloride	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	4.8	6.02	0.71	4.15
DCN52D8	DM4F29C	Crizotinib	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	2.23	6.9	2.59	2.7
DCXM143	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	10.01	16.34	13.79	14.1
DCKV3NM	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	25.28	23.88	20.61	21.42
DCPVFAH	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	2.81	6.39	4.18	5.6
DC55L55	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	0.54	5.73	3.26	4.23
DCHPEDV	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	19.22	20.24	18.4	19.05
DCOS0DF	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	15.86	20.32	16.09	17.03
DCR0DAO	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	22.68	23.79	20.33	20.3
DC9WV79	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	11.51	10.14	3.82	9.28
DCUHW44	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	25.51	24.58	24.94	24.63
DCT9OYY	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	20.31	20.86	21.13	21.49
DCG16DE	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	0.72	6.08	2.09	5.1
DCHQMJ6	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	12.87	14.47	11.42	14.98
DC1J8QM	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	9.09	14.37	13.88	14.54
DC8E6WP	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	19.44	21.52	21.54	21.57
DCJUB8I	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	15.85	20.18	19.97	20.15
DC8HPW1	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	17.23	19.58	22.02	21.99
DCIZ3GN	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	34.63	30.69	26.96	25.78
DC1Y6RV	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	27.03	24.26	17.78	18.86
DCVPUYT	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	8.87	15.49	15.02	15.22
DC90BL6	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	9.17	17.42	17.25	18.26
DC8VIJI	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	1.33	7.1	3.58	4.11
DCSUDOW	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	15.08	18.75	19.63	19.65
DC55RQG	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	30.3	27.4	26.88	26.99
DCWC2L6	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	24.18	26.35	24.4	25.11
DCNOP70	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	2.96	8.48	7.57	7.8
DCTCN6L	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	0.91	9.63	9.18	7.64
DCIUPRB	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	3.07	7.08	7	7.35
DCLJEUD	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	14.04	18.75	18.19	18.49
DCLS8EE	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	2.63	5.22	3.78	4.29
DCZUU50	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	10.52	13.89	15.39	13.57
DC9MK6R	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	8.71	16.49	15.64	14.28
DCEX8AR	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	3.39	8.02	6.52	6.79
DC3MRU4	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	3.13	7.2	6.4	6.79
DC85ME0	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	10.71	17.48	16.29	17.03
DC04PH7	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	37.1	35.83	32.38	29.75
DCWMO3L	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	4.38	10.92	9.49	10.08
DCJ3GO6	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	2.19	6.5	7.13	7.32
DC7JS5M	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	0.28	5.12	7.18	7.16
DCQC60I	DM4F29C	Crizotinib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	3.01	5.99	4.29	1.99
DC2MKY0	DM4F29C	Crizotinib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	3.06	4.32	2.89	0.69
DCX41HT	DM4F29C	Crizotinib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	0.71	6.57	3.96	4.34
DCORTTP	DM4F29C	Crizotinib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	11.87	8.65	6.61	9.97
DCY7YMI	DM4F29C	Crizotinib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	1.8	6.01	3.84	4.62
DCEG6Z2	DM4F29C	Crizotinib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	3.86	5.75	1.83	0.04
DCIK2C7	DM4F29C	Crizotinib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	2.61	9.01	9.69	9.57
DC10PJU	DM4F29C	Crizotinib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	0.33	4.72	0.16	3.09
DCDHVW8	DM4F29C	Crizotinib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	3.76	5.62	2.79	5.69
DCSKFN0	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	3.46	8.64	2.99	6.56
DCQXLE6	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	7.54	8.99	6.14	6.89
DC9SG81	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	1.25	2.3	1.98	3.46
DCVF4ZT	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	5.14	5.13	3.91	5.61
DC8M6N5	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	4.76	3.11	1.32	5.47
DCHMUQJ	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	7.65	8.07	6.44	8.01
DCLPWME	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	10.71	9.74	9.52	9.86
DCF6WCE	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	8.77	7.92	10.24	11.33
DC5CVPM	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	6.48	6.51	1.19	2.01
DCRDAA1	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	1.4	3.49	3.75	3.95
DCURH2M	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	0.5	3.09	4.2	5.08
DCEM0EB	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	0.39	4.8	2.42	4.68
DCKA0EQ	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	10.37	10.01	8.6	8.98
DC7L6G7	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	0.64	4.18	2.92	5.2
DC2BNUZ	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	4.13	2.43	0.22	0.58
DCZHL5C	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	1.69	1.52	2.44	4.5
DCWAPW6	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	6.03	4.98	0.9	6.08
DCLEPV3	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	12.26	12.09	5.69	7.4
DCJARS0	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	6.72	8.52	10.31	10.7
DCG38GN	DM4F29C	Crizotinib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	3.07	6.53	6.98	6.86
DC8J5HW	DM4F29C	Crizotinib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	3.9	6.41	0.89	0.72
DCF3O28	DM4F29C	Crizotinib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	3.66	9.94	5.21	7.13
DCQ49CZ	DM4F29C	Crizotinib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	3.96	4.69	2.62	4.36
DCX83L8	DM4F29C	Crizotinib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	5.15	12.26	7.74	10.76
DC18ZQC	DM4F29C	Crizotinib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	1.95	5.38	1.37	1.9
DC3PJU8	DM4F29C	Crizotinib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	1.08	10.3	9.45	10.37
DCDRP14	DM4F29C	Crizotinib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	2.38	4.24	6.43	5.98
DCK5EF4	DM4F29C	Crizotinib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	4.97	6.93	5.39	1.41
DCZKZ2R	DM4F29C	Crizotinib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	1.79	9.73	4.4	4.73
DCWKTT7	DM4F29C	Crizotinib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	9.28	5.01	1.42	4.03
DC05H9W	DM4F29C	Crizotinib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	0.9	3.1	0.59	1.94
DC8DTBE	DM4F29C	Crizotinib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	1.88	7.9	4.89	5.38
DC2N56W	DM4F29C	Crizotinib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	4.88	6.14	8.5	8.8
DCYIZHJ	DM4F29C	Crizotinib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	1.48	2.84	2.14	0.3
DCXPA25	DM4F29C	Crizotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	3.55	2.89	0.42	4.09
DCB4EG6	DM4F29C	Crizotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	3.36	4.41	1.49	5.03
DCB5W32	DM4F29C	Crizotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	2.95	2.96	0.16	4.28
DCIZJHQ	DM4F29C	Crizotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	3.3	4.81	1.87	5.6
DCIJ8CM	DM4F29C	Crizotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	4.29	4.86	0.28	4.78
DCITZAW	DM4F29C	Crizotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	3.23	5.55	4.39	6.47
DCFVWMS	DM4F29C	Crizotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	0	2.34	1.77	4.84
DCIRK7X	DM4F29C	Crizotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	3.42	5.12	0.77	6.66
DC6W1L9	DM4F29C	Crizotinib	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	0.97	4.87	1.35	3.9
DC79UG9	DM4F29C	Crizotinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	3.33	3.47	1.86	4.21
DCYLJ8E	DM4F29C	Crizotinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	4.2	6.23	2.85	7.28
DCV43L8	DM4F29C	Crizotinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	10.23	10.62	2.21	11
DCVM6AV	DM4F29C	Crizotinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	2.78	4.53	2.81	4.78
DCMKZWP	DM4F29C	Crizotinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	4.21	6.4	1.4	7.61
DC7WJ1M	DM4F29C	Crizotinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	0.91	1.89	4.3	4.59
DC4772R	DM4F29C	Crizotinib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	0.6	3.08	1.93	1.94
DCBZ196	DM4F29C	Crizotinib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	0.91	3.44	1.63	2.22
DCMACSR	DM4F29C	Crizotinib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	1.1	1.61	0.69	0.63
DCPWIWK	DM4F29C	Crizotinib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	0.89	1.27	0.62	0
DCWNG5L	DM4F29C	Crizotinib	Approved	34	DMC7W6R	Selumetinib	Investigative	0	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	5.616	13.519	5.821	6.681
DCULP1N	DM4F29C	Crizotinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	4.49	7.97	5.45	5.09
DCETFZJ	DM4F29C	Crizotinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	1.41	6.39	5.72	6.47
DCU95N5	DM4F29C	Crizotinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	0.45	6.65	4.73	6.77
DCD9H67	DM4F29C	Crizotinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	6.88	9.53	6.36	8.34
DCOL92D	DM4F29C	Crizotinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	3.46	4.3	2.87	4.13
DCYXQ80	DM4F29C	Crizotinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	5.38	7.03	3.48	2.73
DC2BCFJ	DM4F29C	Crizotinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	3.62	8.39	2.93	3.01
DCVNHXL	DM4F29C	Crizotinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	0.75	3.34	2.7	2.67
DC88SSR	DM4F29C	Crizotinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	0.75	5.64	5.07	4.14
DCH41TQ	DM4F29C	Crizotinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	0.77	3.52	2.6	1.69
DCBHNKI	DM4F29C	Crizotinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	2.37	3.27	1.62	1.18
DC47GF0	DM4F29C	Crizotinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.37	7.17	6.74	6.79
DCRP2PC	DM4F29C	Crizotinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	11.6	12.53	8.17	6.36
DC39DX3	DM4F29C	Crizotinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	0.03	7.26	4.97	7.61
DC8M3SZ	DM4F29C	Crizotinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	11.42	16.38	2.77	10.59
DCC3WDX	DM4F29C	Crizotinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	0.78	0.96	0.86	0.77
DCNOFQ3	DM4F29C	Crizotinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	3.81	5.19	1.08	4.59
DCKT5HY	DM4F29C	Crizotinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	0.46	2.38	1.34	1.06
DC1171U	DM4F29C	Crizotinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	2.49	5.53	3.52	2.36
DCTT74M	DM4F29C	Crizotinib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	5.57	7.89	3.3	2.02
DC01E1V	DM4F29C	Crizotinib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	4.52	10.77	7.61	9.54
DC12ECP	DM4F29C	Crizotinib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	27.44	28.81	24.06	23.66
DCVD6FO	DM4F29C	Crizotinib	Approved	34	DMD7L48	Plinabulin	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	2.71	5.68	3.22	6.63
DC3ASB1	DM4F29C	Crizotinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	1.91	3.44	3.13	4.01
DC7UPJH	DM4F29C	Crizotinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	11.7	12.65	3.22	10.94
DCOBLDQ	DM4F29C	Crizotinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	7.32	5.47	4.16	8.27
DCYRWO1	DM4F29C	Crizotinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	0.8	5.47	3.99	3.81
DCH5QDR	DM4F29C	Crizotinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	0.67	4.04	5.15	5.73
DCP94OL	DM4F29C	Crizotinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	3.15	5.4	5.69	7.12
DCRNS9U	DM4F29C	Crizotinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	6.29	6.28	2.98	8.04
DCE8M2E	DM4F29C	Crizotinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	8.26	9.27	4.35	9.05
DCQBU14	DM4F29C	Crizotinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	7.38	7.55	1.98	7.81
DCT21SD	DM4F29C	Crizotinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	4.8	5.77	3.43	5.87
DCWV777	DM4F29C	Crizotinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	2.72	3.64	0.07	3.78
DCF7ID4	DM4F29C	Crizotinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	6.07	6.63	3.14	7.55
DCIQ2GK	DM4F29C	Crizotinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	6.54	8.45	4.08	8.26
DCUKMNT	DM4F29C	Crizotinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	4.62	11.08	3.66	9.85
DCFFGBO	DM4F29C	Crizotinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	14.61	15.32	13.55	15.65
DCEJ0U4	DM4F29C	Crizotinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	2.51	6.89	2.96	8.27
DCRDRG4	DM4F29C	Crizotinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	5.54	9.74	6.82	10.87
DCUEETS	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	2.72	12.92	3.23	9.57
DCQGOWQ	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	1.97	6.39	3.81	3.59
DCXA0FE	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	6.2	10.95	1.42	8.06
DCEKFR2	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	4.15	7.11	5.7	6.51
DCDOALC	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	2.76	7.88	4.21	6.56
DC2QJ57	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	7.44	11.58	8	7.81
DCVC52W	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	0.87	2.23	2.12	1.92
DC96UYW	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	1.98	8.71	1.46	7.77
DCJCXRI	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	2.46	3.48	1.89	2.93
DCRYXSH	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	0.05	5.65	0.82	4.43
DCAH9WZ	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	8.02	15.21	10.56	9.24
DCEU09E	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	8.37	13.49	8.82	6.25
DCFBD4P	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	3.18	8.37	3.77	7.63
DCJVX0Z	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	7.93	16.8	3.78	12.69
DC1LJR2	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	1.45	4.54	3.52	2.61
DCY9JKO	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	5.06	7.25	7.16	5.37
DCUUGNF	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	2.43	7.53	3.86	7.03
DCGAYF8	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	8.49	15.04	11.77	11.35
DCWJ2VV	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	1.4	4.75	2.77	2.68
DC3YNED	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	2.68	6.01	4.59	3.73
DC7LWEW	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	0.89	5.66	4.76	4.97
DCX3B2O	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	9.44	19.58	10.99	9.51
DC91RMJ	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	8.22	14.34	0.27	10.35
DCWTTVS	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	1.41	5.07	3.71	5.65
DCQQ424	DM4F29C	Crizotinib	Approved	34	DME9QGW	Marizomib	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	8.85	10.93	2.08	3.55
DCD7E5R	DM4F29C	Crizotinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	13.98	18.4	14.07	17.43
DCARVJR	DM4F29C	Crizotinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	28.66	25.3	9.72	22.29
DC66JG2	DM4F29C	Crizotinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	9.98	11.32	8.46	10.88
DCND7XR	DM4F29C	Crizotinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	11.67	14.19	6.9	10.5
DCYXNP1	DM4F29C	Crizotinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	11.21	14.03	9.09	13.65
DCHSBCF	DM4F29C	Crizotinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	6.98	7.67	7.94	8.59
DCOWTQS	DM4F29C	Crizotinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	7.99	13.52	9.91	13.59
DCQF5F2	DM4F29C	Crizotinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	4.87	6.84	1.03	2.78
DC08QAN	DM4F29C	Crizotinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	7.95	11.13	2.89	9.58
DCC0ASU	DM4F29C	Crizotinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	14.08	14.65	14.13	15.27
DCOV40W	DM4F29C	Crizotinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	8.53	11.96	9.63	11.04
DCALOW4	DM4F29C	Crizotinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	2.49	6.69	2.08	7.92
DCF338K	DM4F29C	Crizotinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	2.31	5.77	6.2	6.26
DCZEN8S	DM4F29C	Crizotinib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	2.63	3.1	1.17	3.57
DC8PW5T	DM4F29C	Crizotinib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	5.4	3.59	3.82	6.92
DC0EVHW	DM4F29C	Crizotinib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	4.16	4.99	3.49	6.27
DCUIVOY	DM4F29C	Crizotinib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	8.16	9.97	3.08	6.59
DC1OZSS	DM4F29C	Crizotinib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	2.83	5.08	1.68	4.62
DCYR0AK	DM4F29C	Crizotinib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	4.4	5.31	4.58	7.8
DCK02G8	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	3.93	5.7	2.83	5.23
DCKE0ZK	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	1.17	5.14	7.45	8.79
DCJJP8W	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	2.11	2.25	0.93	3.73
DCJZPSL	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	3.21	5.48	3.36	3.96
DCXTOM0	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	5.97	11.86	9.7	10.34
DC42DMP	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	10.21	8.03	7.17	11.55
DCG7EWN	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	5.52	6.54	5.82	8.02
DCF3YRN	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	6.08	6.97	6.78	8.63
DCXV5VW	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	1.6	3.37	1.84	3.72
DC3TCN8	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	2.78	4.6	3.74	6.4
DC5KXCY	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	6.2	7.14	4.17	6.47
DCV9LCM	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	6.25	9.81	9	11.04
DCZOFJR	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	5.24	6.72	6.11	8.86
DC8U72H	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	3.6	7.25	5.98	10.28
DCILAWY	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	5.18	5.63	3.19	5.28
DC47MFH	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	7.23	9.36	7.62	10.1
DCQ01A4	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	3.84	3.96	3.07	6.02
DCZ25C4	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	5.58	5.76	4.72	6.41
DCTLRXZ	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	2.92	2.85	3.75	6.08
DC1DFGF	DM4F29C	Crizotinib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	0.78	5.51	1.95	3.41
DC368IF	DM4F29C	Crizotinib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	0.78	3.96	1.48	1.23
DCM5SZN	DM4F29C	Crizotinib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	3.42	6.19	3.05	2.66
DCKDVGI	DM4F29C	Crizotinib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	0.4	3.33	1.64	2.66
DCQ04HM	DM4F29C	Crizotinib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	3.75	5.66	2.09	0.5
DC8WTCI	DM4F29C	Crizotinib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	4.89	7.67	3.27	2.05
DCK25MM	DM4F29C	Crizotinib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	0.64	1.58	1.23	0.45
DCQXS1U	DM4F29C	Crizotinib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	2.71	2.99	1.32	1.32
DCC91IW	DM4F29C	Crizotinib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	0.1	2.35	1.56	1.75
DCA2TEP	DM4F29C	Crizotinib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	10.09	9.9	6.36	2.59
DCZR22K	DM4F29C	Crizotinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	7.75	7.76	5.64	9.75
DCK75OP	DM4F29C	Crizotinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	7.99	9.82	1.13	9.27
DC8MJP2	DM4F29C	Crizotinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	3.52	7.94	3.99	9.12
DCHHZZ1	DM4F29C	Crizotinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	3.22	11.24	9.85	10.97
DCOJHC4	DM4F29C	Crizotinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	11.2	13.06	2.94	12.66
DC8NSZB	DM4F29C	Crizotinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	4.37	8.91	4.09	10.97
DC0KBDX	DM4F29C	Crizotinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	5.4	8.34	5.2	8.49
DCXDJFT	DM4F29C	Crizotinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	19.03	19.39	6.06	16.31
DCVIY00	DM4F29C	Crizotinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	8.3	8.45	6.74	8.47
DCT9KT5	DM4F29C	Crizotinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	0.75	4.12	5.4	5.63
DCQ5A0M	DM4F29C	Crizotinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1	5.84	2.26	4.48
DCVRCEL	DM4F29C	Crizotinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	5.46	8.21	3.46	2.46
DCKX38X	DM4F29C	Crizotinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	4	12.27	8.29	12.04
DCSBEG4	DM4F29C	Crizotinib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	28.6	26.41	28.37	28.69
DCRCFMU	DM4F29C	Crizotinib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	0.46	1.05	0.7	2.34
DC4OIB1	DM4F29C	Crizotinib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	2.08	2.78	4.89	5.71
DCKX5GQ	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	22.75	24.94	18.62	22.96
DCC5PPK	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	1.61	4.55	5.25	6.01
DCJW3D1	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	2.71	7.56	0.52	6.43
DCEXTKY	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	19.78	20.08	17.65	19.97
DCUM9V9	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	13.24	10.29	6.83	11.48
DCPWPDP	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	20.87	21.33	19.33	21.57
DC54TVH	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	4.4	5.79	1.86	6.5
DCRXO5U	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	2.73	5.21	1.72	5.4
DCO90FX	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	16.2	19.04	5.2	18.85
DC4TG70	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	6.39	12.37	2.98	12.34
DCL5XN2	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	20.22	22.97	16.07	22.19
DC9M2Z9	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	7.87	10.68	9.89	13.57
DCPSA9N	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	14.68	15.5	8.74	15.85
DC8Q80N	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	3.88	11.67	7.5	12.01
DCQ0R01	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	15.74	19.41	14.02	18.99
DCDD2C9	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	1.1	6.8	5.66	7.23
DC1O5W0	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	19.42	22.76	18.49	20.47
DC5T1U4	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	6.35	8.9	3.82	10.11
DC966T8	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	9.43	11.44	8.03	11.67
DCY4YAE	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	5.97	8.64	2.08	8.33
DCSE46B	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	12	14.31	0.25	15.09
DCJXL4P	DM4F29C	Crizotinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	8.46	6.12	4.45	4.22
DCDCO2M	DM4F29C	Crizotinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	15.39	13.51	4.02	9.34
DCT3NOA	DM4F29C	Crizotinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	3.45	4.2	1.1	3.49
DC30A64	DM4F29C	Crizotinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	15.15	17.28	9.77	16.15
DC3KQW9	DM4F29C	Crizotinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	13.49	9.25	6.39	10.52
DCAWKQ9	DM4F29C	Crizotinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	0.85	4.88	2.29	2.5
DCSM9MF	DM4F29C	Crizotinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	6.24	7.71	8.8	11.14
DCF3ODJ	DM4F29C	Crizotinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	0.03	3.72	1.53	5.49
DCK5WQK	DM4F29C	Crizotinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	13.56	18.47	15.65	16.45
DCDHGEZ	DM4F29C	Crizotinib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	8.64	8.6	5.36	8.72
DCCEAUR	DM4F29C	Crizotinib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	4.84	6.1	1.19	4.91
DCHACOS	DM4F29C	Crizotinib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	2.72	3.03	0.98	3.14
DCCLCMJ	DM4F29C	Crizotinib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	1.11	2.11	2	2.47
DCC5QYX	DM4F29C	Crizotinib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	0.13	2.49	1.96	5.68
DCAR13R	DM4F29C	Crizotinib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	5.04	9	7.61	7.78
DCJY36M	DM4F29C	Crizotinib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	0.2	3.62	2.09	4.1
DCQWANF	DM4F29C	Crizotinib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	7.26	4.9	1.28	1.48
DC15G1G	DM4F29C	Crizotinib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	4	6.43	7.52	8.19
DC2UY2A	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	24.38	16.58	12.24	16
DC55XAV	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	4.74	4.42	3.69	7.49
DCTW16N	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	3.35	4.95	2.28	7.23
DCMPORQ	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	20.08	17.29	12.87	18.04
DC4V59F	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	9.97	7.75	5.1	10.67
DCEJKQC	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	16.26	15.17	1.7	15.97
DCFHGAX	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	7.05	9.95	6.31	10.85
DCG2HKI	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	13.24	11.99	8.57	13.66
DCU0MO4	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	6.63	6.85	1	6.41
DC2HJEY	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	19.89	17.87	16.02	18.26
DCKFGZV	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	18.33	19.46	15.69	18.16
DC2FQUV	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	5.09	4.55	2.26	5.63
DC20I6M	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	17.48	16.2	14.07	17.3
DC3LFJ7	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	6.62	3.14	0.3	5.14
DCM5ORP	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	14.98	11.52	9.86	12.76
DCP433B	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	12.46	12.78	10.51	14.25
DCPNKBQ	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	9.75	10.79	8.5	11.01
DC0TYGA	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	11.48	13.85	8.11	18.56
DCDSOD6	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	17.28	15.04	9.7	15.38
DCLLCAP	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	12.28	10.76	0.01	14.22
DCLZUQH	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	8.28	7.14	1.99	6.27
DC7TMA8	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	14.39	15.45	6.64	15.58
DCOBCQL	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	10.44	10.65	6.13	11.22
DCFW6RK	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	11.62	10.67	6.26	11.89
DCJIKAE	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	4.73	5.29	3.52	6.65
DCS7K8T	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	8.69	10.26	8.2	12.19
DC61VKX	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	12.18	14.26	11.03	14.68
DCWOHO3	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	5.28	5.05	1.66	7.7
DCW86UA	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	6.13	9.96	7.93	11.08
DCOL6WJ	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	13.73	14.63	9.58	14.72
DCKYTNG	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	14.21	16.72	11.03	15.89
DCMDCNI	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	6.87	9.4	4.12	8.65
DC19Y83	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	7.05	10.26	8.45	11.02
DC1U9IE	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	3.75	5.62	3.33	7.65
DCPXHPK	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	10.19	10.43	6.59	11.24
DCXJ0T3	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	5.83	6.35	3.83	7.64
DCUAY16	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	11.68	14.92	15.12	17.18
DCX4C3V	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	11.37	11.66	8.35	13.91
DCOT1MY	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	8.83	7.99	1.53	10.13
DC8KMQM	DM4F29C	Crizotinib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	11.37	14.48	0.26	0.1
DC6NQLM	DM4F29C	Crizotinib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	0.12	1.52	2.06	2.62
DC1PA03	DM4F29C	Crizotinib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	1.56	5.88	2.27	2.4
DCV9WVR	DM4F29C	Crizotinib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	7.68	10.62	1.78	9.23
DCJV3LJ	DM4F29C	Crizotinib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	1.86	6.98	3.41	3.06
DCICXS9	DM4F29C	Crizotinib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	2.83	7.1	1.16	1.73
DCVH95L	DM4F29C	Crizotinib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	0.34	3.17	2.08	1.84
DC9HA8T	DM4F29C	Crizotinib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	3.36	7.4	4.83	4.18
DCOV9FQ	DM4F29C	Crizotinib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	6.04	14.02	9.77	7.01
DCD1KGQ	DM4F29C	Crizotinib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	5.68	6.34	0.07	5.76
DCVIJOD	DM4F29C	Crizotinib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	2.17	2.93	1.19	3.22
DCBW9HN	DM4F29C	Crizotinib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	8.32	5.86	3.64	7.99
DC9YEW4	DM4F29C	Crizotinib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	1.92	2.03	1.12	2.75
DC51L0G	DM4F29C	Crizotinib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	2.54	4.32	0.02	5.29
DCIRVHW	DM4F29C	Crizotinib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	3.32	1.47	1.18	3.07
DCU5BCZ	DM4F29C	Crizotinib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	2.26	2.23	1.38	2.92
DCIMIR4	DM4F29C	Crizotinib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	6.1	10.12	11.78	12.37
DCMVTQY	DM4F29C	Crizotinib	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	1.16	3.01	2.97	3.04
DC58TE8	DM4F29C	Crizotinib	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	ALMANAC Dataset	Investigative	T98G	6.05	6.05	10.11	10.18
DCRZEHA	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	3.52	14.54	4.93	11.15
DCI1DC0	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	5.17	10.14	7.71	5.51
DC38WSQ	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	0.58	5.06	2.32	3.48
DCHL35T	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	6.51	9.88	7.15	9.19
DC4IAA4	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	5.39	7.72	5.3	2.47
DCOOUNV	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	4.7	8.41	4.19	8.91
DCG74HT	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	6.86	10	4.19	9.19
DCAX511	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	3.15	5.12	2.59	6.01
DCXA1S9	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	2.7	6.16	5.25	5.53
DCZ8P08	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	12.54	11.71	6.62	4.21
DCPTET9	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	3.67	11.88	8.22	6.3
DCM5C8A	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	7.08	14.6	2.07	11.21
DCWX1VA	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	3.29	5.94	3.98	4.61
DCL7C5U	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	1.49	3.17	3.05	1.48
DC6B7XD	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	2.5	8.78	6.06	5.25
DCZXKE7	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	0.2	6.27	2.23	6.07
DCJZ0NI	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	2.92	13.55	1.51	9.86
DCOEOG0	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	0.28	4.77	4.1	3.64
DCAAASU	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	2.66	5.26	3.55	2.58
DC4S565	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	5.94	12.09	6.69	4.11
DCOSU67	DM4F29C	Crizotinib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	3.27	4.92	2.93	1.62
DC2M3GQ	DM4F29C	Crizotinib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	4.17	5.75	5.87	5.85
DCYLG08	DM4F29C	Crizotinib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	5.54	5.49	3.44	6.55
DCCA60I	DM4F29C	Crizotinib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	7.46	13.93	2.35	12.44
DCMAGFQ	DM4F29C	Crizotinib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	0.2	1.23	0.72	0.26
DCZRXRM	DM4F29C	Crizotinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	1.61	3.57	1.38	6.35
DCDZQ3N	DM4F29C	Crizotinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	0.39	4.43	3.04	5.23
DC8WSBE	DM4F29C	Crizotinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	4.1	5.64	1.27	6.33
DCVVSUJ	DM4F29C	Crizotinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	9.81	9.38	5.62	11.09
DC45ZL8	DM4F29C	Crizotinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	4.18	8.37	1.89	3.9
DCVSX93	DM4F29C	Crizotinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	2.68	4.51	1.67	3.28
DCBFKYY	DM4F29C	Crizotinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	14.14	11.76	13.59	13.11
DCXU7ZS	DM4F29C	Crizotinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	15.88	14.39	7.98	14.83
DCIOMT4	DM4F29C	Crizotinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	3.81	3.74	6.28	8.23
DCGE3UK	DM4F29C	Crizotinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	2.74	9.31	2.07	9.07
DCRZPQH	DM4F29C	Crizotinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	3.39	5.91	4.18	5.92
DCJJN7B	DM4F29C	Crizotinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	6.09	7.4	4.77	8.65
DC7RRFS	DM4F29C	Crizotinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	0.76	5.63	2.58	6.69
DC5FAQJ	DM4F29C	Crizotinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	7.17	9.32	8.9	11.8
DCMHFVX	DM4F29C	Crizotinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	4.29	4.04	4.79	7
DCL03YS	DM4F29C	Crizotinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	6.8	7.68	3.15	6.79
DC2W1U9	DM4F29C	Crizotinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	4.71	7.71	9.96	10.48
DCFSMJE	DM4F29C	Crizotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	1.67	5.26	2.83	2.32
DCVHQHI	DM4F29C	Crizotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	13.74	13.53	5.62	12.89
DC016ZH	DM4F29C	Crizotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	1.22	5.98	2.53	2.53
DCRWWH2	DM4F29C	Crizotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	5.16	9.72	5.77	9.48
DC0UFUZ	DM4F29C	Crizotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	3.09	5.35	5.84	4.87
DCLMATY	DM4F29C	Crizotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	1.62	5.59	5.89	5.85
DC70EOU	DM4F29C	Crizotinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	1.13	4.05	0.37	2.97
DC9P94G	DM4F29C	Crizotinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	0.48	2.56	2.26	2.81
DC7NGLJ	DM4F29C	Crizotinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	0.9	1.62	0.35	1.17
DC7XM1F	DM4F29C	Crizotinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	2.76	4.01	0.28	1.3
DCOQN9P	DM4F29C	Crizotinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	8.95	4.44	3.4	3.73
DC8Y4HY	DM4F29C	Crizotinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	2.73	5.57	1.43	2.57
DCM9KEF	DM4F29C	Crizotinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	4.29	5.15	3.14	4.46
DCG3FXC	DM4F29C	Crizotinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	0.79	3.7	2.76	3.92
DC3HEKF	DM4F29C	Crizotinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	1.72	2.84	0.05	1.87
DCGD65T	DM4F29C	Crizotinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	2.18	3.24	1	1.59
DCX70FT	DM4F29C	Crizotinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	0.42	0.53	0.16	0.52
DC8ZGFV	DM4F29C	Crizotinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	1.82	3.6	0.9	3.55
DCY9LYC	DM4F29C	Crizotinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	4.37	7.75	0.21	8.35
DC6R58Y	DM4F29C	Crizotinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	3.88	2.38	4.29	3.96
DCN38FX	DM4F29C	Crizotinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	1.33	1.45	3.01	3.39
DCL9M7T	DM4F29C	Crizotinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	4.9	10.44	7.34	7.5
DCX5802	DM4F29C	Crizotinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	3.53	4.6	1.75	4.45
DCG1NJN	DM4F29C	Crizotinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	0.78	6.02	2.08	2.52
DCB5I5M	DM4F29C	Crizotinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	0.92	1.96	0.26	2.72
DCN4T17	DM4F29C	Crizotinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	6.97	6.91	6.74	7.05
DCH592U	DM4F29C	Crizotinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	0.03	7.38	0.52	1.31
DCWVU4H	DM4F29C	Crizotinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	14.01	8.01	3.93	3.71
DCUVBNZ	DM4F29C	Crizotinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	0.31	1.38	3.63	4.22
DCG31HD	DM4F29C	Crizotinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	8.31	12.77	7.1	11.11
DCL1Y10	DM4F29C	Crizotinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	2.41	5.39	2.19	2.24
DCNAPSN	DM4F29C	Crizotinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	0.98	6.38	4.2	6.37
DC5MSU4	DM4F29C	Crizotinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	2.54	3.62	0.72	0.83
DCHQDY7	DM4F29C	Crizotinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	8.2	7	1.16	7.22
DCH4C6T	DM4F29C	Crizotinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	11.49	13.9	9.05	9.63
DC20SCT	DM4F29C	Crizotinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	0.01	3.45	1.69	2.02
DC8IXZO	DM4F29C	Crizotinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	1.43	2.9	1.31	2.74
DC666Q7	DM4F29C	Crizotinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	7.04	12.92	6.59	8.52
DC6PW5E	DM4F29C	Crizotinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	5	4.81	0.61	3.54
DC9BP4U	DM4F29C	Crizotinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	2.33	5.61	4.3	4.75
DCAD8EQ	DM4F29C	Crizotinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	2.65	8.8	8.33	8.6
DCJDSW2	DM4F29C	Crizotinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	1.24	4.38	3.07	2.91
DCVHG1F	DM4F29C	Crizotinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	0.28	6.12	2.07	2.57
DCG86DP	DM4F29C	Crizotinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	0.59	4.9	3.57	3.53
DC7S6FN	DM4F29C	Crizotinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	0.03	3.12	2.65	2.95
DC6440O	DM4F29C	Crizotinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	1.98	9.15	4.11	3.72
DCRA2OR	DM4F29C	Crizotinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	2.25	2.08	0.14	0.79
DC2POKS	DM4F29C	Crizotinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	7.66	6.16	3.47	6.11
DCR24DS	DM4F29C	Crizotinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	3.08	4.43	4.09	6.58
DCCXT05	DM4F29C	Crizotinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	0.02	1.64	0.08	2.78
DCL15VD	DM4F29C	Crizotinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	5.64	3.87	2.65	4.19
DCWX62J	DM4F29C	Crizotinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	6.05	5.73	8.06	10.92
DCJJVPF	DM4F29C	Crizotinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	3.74	4.02	0.67	1.32
DCM7AAA	DM4F29C	Crizotinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	5.53	9.74	5.63	8.38
DC4XODQ	DM4F29C	Crizotinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	1.94	3.03	0.29	4.18
DCY52EB	DM4F29C	Crizotinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	4.13	4.27	3.88	4.71
DCFSMXP	DM4F29C	Crizotinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	5.49	6.4	4.29	7.3
DCMA5T6	DM4F29C	Crizotinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	5.42	9.08	7.37	7.78
DCLUWW3	DM4F29C	Crizotinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	6.42	5.87	3.21	5.99
DCZASUN	DM4F29C	Crizotinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	3.93	8.78	8.03	9.94
DCM1X4G	DM4F29C	Crizotinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	1.6	3.12	2.87	5.4
DCDHFXM	DM4F29C	Crizotinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	0.3	0.72	2.42	2.74
DCX7HHI	DM4F29C	Crizotinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	3.2	6.7	2.64	5.89
DC82TQR	DM4F29C	Crizotinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	12.31	7.01	5.17	9.59
DCGSJMY	DM4F29C	Crizotinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	5.39	8.92	9.15	11.92
DC9KU1R	DM4F29C	Crizotinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	17.35	16.89	13.47	18.34
DC4JDXB	DM4F29C	Crizotinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	4.15	4.46	0.12	4.44
DCWNGYZ	DM4F29C	Crizotinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	11.17	11.45	3.28	10.91
DCH7H9H	DM4F29C	Crizotinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	24.88	13.18	9.07	13.49
DCCZM0M	DM4F29C	Crizotinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	5.68	4.36	2.34	5.4
DCW68QN	DM4F29C	Crizotinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	4.85	3.78	1.98	5.02
DC36T66	DM4F29C	Crizotinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	7.56	7.33	3.58	7.56
DCLC0XH	DM4F29C	Crizotinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	21.24	21.64	16.88	20.71
DC2RYQZ	DM4F29C	Crizotinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	17.41	12.03	8.7	12.28
DC22VFY	DM4F29C	Crizotinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	4.6	7.86	6	9.47
DCY5JF7	DM4F29C	Crizotinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	2.49	4.55	2.15	5.39
DCMHBPN	DM4F29C	Crizotinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	7.28	10.88	8.82	11.33
DCJ7X3G	DM4F29C	Crizotinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	1.75	3.73	1.54	4.07
DCQ764G	DM4F29C	Crizotinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	10.09	10.11	7.83	11.21
DC3CFH8	DM4F29C	Crizotinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	12.22	12.54	9.92	13.32
DCPCONN	DM4F29C	Crizotinib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	5.61	9.54	7.03	6.32
DC6WDN7	DM4F29C	Crizotinib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	1.66	7.8	4.65	6.7
DC8LF53	DM4F29C	Crizotinib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	4.55	7.53	4.34	3.28
DCFSTQV	DM4F29C	Crizotinib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	7.87	12.75	12.72	13.27
DCD527H	DM4F29C	Crizotinib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	16.95	16.11	19.74	19.87
DCIUO2Y	DM4F29C	Crizotinib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	6.17	14.29	8.74	8.74
DC60HAJ	DM4F29C	Crizotinib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	3.4	11.34	7.56	5.94
DCRSUTD	DM4F29C	Crizotinib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	9.49	9.9	9.51	11
DC4IQB6	DM4F29C	Crizotinib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	1.17	5.28	4.4	3.12
DC4ZNSR	DM4F29C	Crizotinib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	0.53	5.61	4	4.12
DCXIWF3	DM4F29C	Crizotinib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	0.04	6.41	7.7	8.76
DC84ONC	DM4F29C	Crizotinib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	7.14	11.4	10.92	10.37
DCTW6ZC	DM4F29C	Crizotinib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	1.77	4.53	2.73	1.47
DC488S2	DM4F29C	Crizotinib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	10.33	17.77	17.35	18.37
DCO05AN	DM4F29C	Crizotinib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	9.77	12.13	4.31	3.09
DCS7LCF	DM4F29C	Crizotinib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	8.17	12.51	1.49	1.37
DCB2ZQQ	DM4F29C	Crizotinib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	6.15	8.18	4.64	6.99
DCQXPIB	DM4F29C	Crizotinib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	0.69	1.53	1.43	1.66
DCSSBOF	DM4F29C	Crizotinib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	0.95	4.07	2.73	4.48
DC3JXB2	DM4F29C	Crizotinib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	0.44	5.03	2.8	2.49
DCUUUQB	DM4F29C	Crizotinib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	3.78	3.63	1.5	4.06
DCPBKL9	DM4F29C	Crizotinib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	0.12	2.67	2.2	2.61
DCXOUAS	DM4F29C	Crizotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	4.43	4.12	0.12	3.13
DCYCGZ4	DM4F29C	Crizotinib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	2.72	2.91	3.01	5.14
DCLMFB2	DM4F29C	Crizotinib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	0.99	2.01	0.19	1.05
DCK0PBD	DM4F29C	Crizotinib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	3.97	9.99	7.86	9.31
DCU6XJM	DM4F29C	Crizotinib	Approved	34	DMSLE03	PF-562271	Phase 1	17	.	.	.	.	Diffuse large B cell lymphoma	ALMANAC Dataset	Investigative	TMD8	13.87	14.32	2.81	3.32
DCUD41N	DM4F29C	Crizotinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	3.45	7.41	5.73	8.25
DCG82BY	DM4F29C	Crizotinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	14.44	15.27	14.61	16.67
DCQN3JE	DM4F29C	Crizotinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	4.3	5.72	1.99	5.29
DCI75I1	DM4F29C	Crizotinib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	2.02	4.48	5.78	5.4
DCUMX1B	DM4F29C	Crizotinib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	8.43	9.57	1.99	10.15
DCXUT6W	DM4F29C	Crizotinib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	4.48	8.1	2.5	1.92
DCXPVDA	DM4F29C	Crizotinib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	0.03	4.88	0.01	3.76
DCX1HI0	DM4F29C	Crizotinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	9.54	15.46	5.79	4.87
DCFIW61	DM4F29C	Crizotinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	2.93	8.98	5.46	5.45
DCDWVUY	DM4F29C	Crizotinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	2.29	7.78	1.26	2.52
DC2EYVP	DM4F29C	Crizotinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	5.45	12.12	9.4	10.89
DC2JNDW	DM4F29C	Crizotinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	2.23	5.43	0.07	0.07
DC2PKYK	DM4F29C	Crizotinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	3.89	4.62	1.01	0.22
DCVNSKS	DM4F29C	Crizotinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	1.68	7.91	1.58	3.29
DC4XJKH	DM4F29C	Crizotinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	2.89	5.48	4.83	3.61
DC278MO	DM4F29C	Crizotinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	4.17	8.7	7.8	6.55
DC8GE8W	DM4F29C	Crizotinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	1.92	7.82	6.4	5.86
DCEXUHS	DM4F29C	Crizotinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	4.85	8.11	3.84	1.98
DCRH4ZC	DM4F29C	Crizotinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	7.78	5.82	1.97	4.27
DCNBGRL	DM4F29C	Crizotinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	4.83	10.79	0.61	11.78
DCCMSOQ	DM4F29C	Crizotinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	6.98	7.49	3.73	6.59
DC8UAYU	DM4F29C	Crizotinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	2.23	4.54	1.43	3.9
DC98O7V	DM4F29C	Crizotinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	18.53	19.25	13.32	19.71
DCUVA90	DM4F29C	Crizotinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	0.59	4.76	1.2	5.29
DCEKX6D	DM4F29C	Crizotinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	5.76	10.49	4.22	11.24
DC6302U	DM4F29C	Crizotinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	4.65	11.01	7.88	10.91
DCSNX5H	DM4F29C	Crizotinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	3.32	8.08	5.84	10.58
DCXXTJG	DM4F29C	Crizotinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	7.36	11.24	2.68	10.35
DCYVNOM	DM4F29C	Crizotinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	0.22	3.11	2.25	2.25
DCKVOKI	DM4F29C	Crizotinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	4.34	5.88	7.52	7.94
DCI36BQ	DM4F29C	Crizotinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	11.85	10.82	5.62	10.92
DC4MCSE	DM4F29C	Crizotinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	13.16	13.87	7.48	14.04
DC7B59L	DM4F29C	Crizotinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	24.59	24.26	16.37	24.19
DC7Y8TD	DM4F29C	Crizotinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	4.22	7.29	4.91	7.28
DCRBMUZ	DM4F29C	Crizotinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	12.79	10.34	8.41	12.47
DCBTU2H	DM4F29C	Crizotinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	1.08	5.74	0.28	4.54
DC1XZQ3	DM4F29C	Crizotinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	4.51	4.45	2.66	6.66
DCQ2AER	DM4F29C	Crizotinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	12	11.47	13.28	14.85
DCSEUSO	DM4F29C	Crizotinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	5.02	8.21	5.49	9.39
DCT6P38	DM4F29C	Crizotinib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	5.21	5.11	1.77	5.39
DC86RAC	DM4F29C	Crizotinib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	10.28	11.4	4.16	11.13
DCBA85U	DM4F29C	Crizotinib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	6.38	8.54	4.89	9
DCUZQFH	DM4F29C	Crizotinib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	3.48	5.81	3.54	6.16
DC7H8O2	DM4F29C	Crizotinib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	1.22	2.81	1.1	4.97
DCP7GDQ	DM4F29C	Crizotinib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	6.04	9.94	10.41	12.68
DC4IMKZ	DM4F29C	Crizotinib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	3.89	3.87	0.34	0.4
DCU2ZIW	DM4F29C	Crizotinib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	5.48	7.44	2.5	7.65
DCX862G	DM4F29C	Crizotinib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	0.57	4.04	3.02	4.08
DCACNSB	DM4F29C	Crizotinib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	5.55	5.96	1.47	0.04
DC1D8KQ	DM4F29C	Crizotinib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	0.35	2	0.67	0.31
DC93SU9	DM4F29C	Crizotinib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	19.66	23.56	15.01	13.84
DCKC7ZO	DM4F29C	Crizotinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	0.82	4.18	0.76	1.7
DC8T8MD	DM4F29C	Crizotinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	1.03	2.35	0.99	1.16
DCNCQSX	DM4F29C	Crizotinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	6.81	13.17	1.83	7.69
DCMD84O	DM4F29C	Crizotinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	0.48	2.74	2.83	3.02
DCWDIPB	DM4F29C	Crizotinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	1.53	4.27	0.64	0.07
DCC8LTI	DM4F29C	Crizotinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	0.53	2.38	2.6	1.32
DCR9SF4	DM4F29C	Crizotinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	0.6	3.86	1.28	3.98
DC22C4K	DM4F29C	Crizotinib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	9.04	12.67	1.53	10.08
DCWVZFS	DM4F29C	Crizotinib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	0.82	4.9	2.93	3.74
DCVRCDB	DM4F29C	Crizotinib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	1.26	3.38	0.92	1.18
DCLLBME	DM4F29C	Crizotinib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	10.26	12.79	6.21	10.91
DC1T9Y9	DM4F29C	Crizotinib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	6.9	6.26	4.3	7.4
DC72APL	DM4F29C	Crizotinib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	0.18	4.16	4.03	4.38
DCGHMIR	DM4F29C	Crizotinib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	3.61	6.14	0.02	4.76
DCRFUBG	DM4F29C	Crizotinib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	1.15	4.61	5.21	6.18
DC2B108	DM4F29C	Crizotinib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	7.67	8.42	7.24	8.56
DCBLO11	DM4F29C	Crizotinib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	1.79	2.7	1.03	0.96
DC654JN	DM4F29C	Crizotinib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	14.51	21.38	10.44	20.99
DC1V09B	DM4F29C	Crizotinib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	1.25	5.97	2.65	3.48
DCYAASH	DM4F29C	Crizotinib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	11.65	14.61	5.48	4.79
DC7CM9K	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	7.12	3.68	0.77	1.16
DC8GWRW	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	4.56	13.24	12.65	14.4
DC74W5D	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	1.69	7.64	4.11	7.83
DCCILNB	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	8.48	11.78	10.7	10.48
DCEHK4S	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	15.13	10.03	8.22	11.26
DC84GSH	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	10.41	14.73	12.28	14.93
DCRUZA9	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	28.62	28.95	22.2	32.59
DC43WUP	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	3.54	10.69	7.04	8.24
DCUR88V	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	22.1	22.48	21.29	21.65
DC7ZT0X	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	10.16	14.43	13.12	16.52
DCMZ3OV	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	5.67	7.18	6.23	8.51
DCWFOK7	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	11.64	18.67	14.34	17.38
DCYXX70	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	1.58	6.95	5.51	6.81
DC8TRHK	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	4.9	6.56	3.17	4.75
DCJ4FZG	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	22.93	23.33	20.12	22.99
DCY4KUE	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	4.29	12.17	13.33	13.82
DCV3QWN	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.48	6.44	0.4	7.31
DC3H4CV	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	14.53	15.77	12.36	16.37
DCP4R8G	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	7.4	11.66	10.68	11.7
DCDG694	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	15.52	18.35	15.57	19.8
DCGUPUO	DM4F29C	Crizotinib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.47	2.96	0.76	0.95
DCH79MW	DM4F29C	Crizotinib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.55	8.22	3.55	4.08
DCUX2D5	DM4F29C	Crizotinib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.59	2.63	0.63	0.97
DCNGZL8	DM4F29C	Crizotinib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.31	9.98	4.49	4.49
DCZWVLT	DM4F29C	Crizotinib	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.76	7.32	1.21	3.41
DCTOLBG	DM4F29C	Crizotinib	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.94	4.34	1.16	1.16
DCSF0KH	DM4F29C	Crizotinib	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.26	10.64	3	2.48
DC3OYU6	DM4F29C	Crizotinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.12	4.23	4.07	7.15
DCFEHTU	DM4F29C	Crizotinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.32	8.38	3.04	3.04
DCRWNED	DM4F29C	Crizotinib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.14	8.12	4.11	3.8
DCVJKJH	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	14.38	16.21	13.43	17.14
DCJ38L2	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.93	5.11	7.28	9.42
DCI2CTG	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.6	8.76	6.45	7.26
DCIAGZG	DM4F29C	Crizotinib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.6	16.13	10.75	11.11
DC8X7JH	DM4F29C	Crizotinib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.57	8.16	2.8	2.8
DC2GJWD	DM4F29C	Crizotinib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.38	1.85	0.03	0.17
DC9HQAY	DM4F29C	Crizotinib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.96	5.53	1.19	1.13
DCLVNQV	DM4F29C	Crizotinib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.04	7	0.68	1.25
DCGEGDT	DM4F29C	Crizotinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	7.61	3.43	3.93	4.1
DCK8KWX	DM4F29C	Crizotinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.7	8.15	7.2	7.75
DCU7UID	DM4F29C	Crizotinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.57	1.72	2.97	3.2
DCRQ15A	DM4F29C	Crizotinib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.94	6.59	2.82	4.91
DCAWYGN	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	23.68	23.1	22.68	22.67
DC2UWOA	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.32	10.55	10.76	10.58
DCSUD37	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	21.72	19.51	18.22	18.07
DCEHYNT	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	27.69	31.06	28.23	27.1
DCHIZD5	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	20.47	16.41	15.86	16.51
DCM6MKZ	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.73	10.25	4.07	4.66
DCQWVQ7	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.15	6.72	2.68	4.43
DCPJVP9	DM4F29C	Crizotinib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.52	21	16.12	16.73
DC3IJWX	DM4F29C	Crizotinib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.34	6.89	2.68	2.65
DCM0W6A	DM4F29C	Crizotinib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.18	14.94	9.27	9.1
DCV0NB6	DM4F29C	Crizotinib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.49	8.78	4.47	6.56
DCUWTQM	DM4F29C	Crizotinib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.04	5.55	4.46	6.2
DCFU2H6	DM4F29C	Crizotinib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.92	4.44	1.07	1.07
DC72ID3	DM4F29C	Crizotinib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.7	5.9	3.49	1.42
DCDAYMD	DM4F29C	Crizotinib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.71	5.33	3.62	2.54
DCLN28A	DM4F29C	Crizotinib	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.45	8.96	4.12	3.34
DC8RZBD	DM4F29C	Crizotinib	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.96	5.31	1.13	1.23
DCNAOT2	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	18.52	18.32	18.95	18.92
DC8E6GH	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.42	5.38	6.82	6.29
DCIGX4H	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	10.31	17.88	16.05	16.93
DCZ73OY	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	25.8	31.87	27.29	27.53
DCVCNVM	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	22.39	21.4	13.53	21.36
DCQ3VUC	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	14.11	20.43	14.33	14.85
DCTE2BZ	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	29.28	26.98	22.77	22.73
DCBOZI7	DM4F29C	Crizotinib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.85	15.14	13.48	13.45
DC4MB5O	DM4F29C	Crizotinib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.11	6.08	4.06	4.4
DCCS4AU	DM4F29C	Crizotinib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.83	16.55	10.7	10.02
DCXGVBM	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.61	7.95	7.82	8.43
DC1IBTV	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.01	4.97	5.37	6.46
DC9VSKD	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.76	6.86	2.9	7.24
DCFZXYY	DM4F29C	Crizotinib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.5	13.52	7.42	8.5
DCJLE5H	DM4F29C	Crizotinib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.36	5.39	2.63	5.49
DCYD2VV	DM4F29C	Crizotinib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.42	7.48	2.54	3.21
DCTT6ZN	DM4F29C	Crizotinib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.87	8.8	4.6	8.36
DCTOCWO	DM4F29C	Crizotinib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.97	4.29	6.61	8.7
DCPLQIF	DM4F29C	Crizotinib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.59	2.86	3.36	3.41
DC48BWR	DM4F29C	Crizotinib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.62	2.63	0.48	0.97
DCN5UNA	DM4F29C	Crizotinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.46	4.36	4.75	4.84
DC8ZOGD	DM4F29C	Crizotinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.31	3.94	3.52	3.52
DC9MNOY	DM4F29C	Crizotinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3	6.98	5.29	5.31
DCPOP0B	DM4F29C	Crizotinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.18	9.21	4.96	4.96
DC9V8B5	DM4F29C	Crizotinib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.15	13.15	7.64	7.59
DCUBI3M	DM4F29C	Crizotinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.41	2.6	1.17	1.69
DCGLOIU	DM4F29C	Crizotinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.32	1.71	0.66	0.59
DCOVHDZ	DM4F29C	Crizotinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.39	8.02	2.25	1.83
DCKG25Q	DM4F29C	Crizotinib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.4	5.88	3.8	2.97
DCDE5KD	DM4F29C	Crizotinib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.14	6.37	4.69	4.69
DC1HAKJ	DM4F29C	Crizotinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.04	6.81	7.28	7.41
DCRHH5M	DM4F29C	Crizotinib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.78	1.87	0.31	0.24
DC4SAXT	DM4F29C	Crizotinib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	17.48	16.88	10.86	16.63
DCX7FWZ	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.04	7.38	5.39	6.39
DCSQG1M	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	5.61	9	10.42	10.78
DCZROHI	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.89	5.78	1.78	1.16
DCOBTPY	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.5	3.04	1.75	0.96
DCQUF1J	DM4F29C	Crizotinib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	24.53	26.81	20.98	20.41
DC1MKAU	DM4F29C	Crizotinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.65	7.11	6.33	8.15
DC4ZWDW	DM4F29C	Crizotinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	9.06	11.08	4.13	10.76
DCTBIRV	DM4F29C	Crizotinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.18	1.34	0.66	4.8
DC7AFEA	DM4F29C	Crizotinib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.27	7.94	3.2	4
DCV8JU2	DM4F29C	Crizotinib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	14.82	14.93	6.22	11.2
DCFMS3T	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	5.7	6.26	0.99	8.41
DCNNGD5	DM4F29C	Crizotinib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.4	2.97	3.33	6.49
DCXI7U0	DM4F29C	Crizotinib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.96	5.8	4.06	5.49
DCPLZTF	DM4F29C	Crizotinib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.75	12.31	6.58	6.38
DCOUO00	DM4F29C	Crizotinib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.9	5.91	4.24	4.24
DC6ETZH	DM4F29C	Crizotinib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.34	8.76	8.22	4.34
DC0TRBA	DM4F29C	Crizotinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.93	10.07	7.18	7.18
DCWS2KT	DM4F29C	Crizotinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.81	7.6	5.66	9.58
DC2ZPBJ	DM4F29C	Crizotinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	6.88	11.12	6.97	6.85
DC312QD	DM4F29C	Crizotinib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.94	10.97	5.36	5.36
DCHXK0H	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	15.72	18.31	3.71	18.23
DCJIR7Y	DM4F29C	Crizotinib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	11.21	11.75	15.55	16.63
DCX3G02	DM4F29C	Crizotinib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.56	4.25	4.46	4.87
DCGKMDU	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	22.1	22.56	7.37	23.3
DCFUS34	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.11	5.66	0.51	7.15
DC8XAKX	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	8.56	11.43	7.37	11.36
DCXMRUH	DM4F29C	Crizotinib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	18.53	15.45	19.91	21.45
DCSQTGE	DM4F29C	Crizotinib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.49	1.57	0.09	0.09
DCXDRCC	DM4F29C	Crizotinib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.72	17.61	10.66	12.46
DC5URN2	DM4F29C	Crizotinib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.79	9.98	8.04	8.33
DCNXLFV	DM4F29C	Crizotinib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.25	9.7	5.42	5.42
DCH7QAO	DM4F29C	Crizotinib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.93	6.21	6.08	7.13
DC7RM1Y	DM4F29C	Crizotinib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.83	3.55	5.61	9.24
DC4MJ7Z	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	6.44	5.92	4.19	8.65
DCAN6F2	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.17	10.46	0.64	4.49
DCFN9CO	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.12	6	1.67	1.64
DCOVV23	DM4F29C	Crizotinib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.26	3.48	1.68	1.58
DCK6T8D	DM4F29C	Crizotinib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.85	11.34	9.02	9.6
DCNE0AS	DM4F29C	Crizotinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	9.71	9	7.39	9.82
DC81YIX	DM4F29C	Crizotinib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	6.13	5.32	9.76	10.53
DC1H8MO	DM4F29C	Crizotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.87	3.51	2.63	1.34
DCERUMO	DM4F29C	Crizotinib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.24	7.44	1.82	1.82
DCBTJIR	DM4F29C	Crizotinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.16	2.54	2.16	3.19
DCMHV8H	DM4F29C	Crizotinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.09	2.26	3.16	4.86
DC60WHV	DM4F29C	Crizotinib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.67	8.72	3.32	4.77
DCYVJ32	DM4F29C	Crizotinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.42	10.51	10.01	10.37
DCMJPZU	DM4F29C	Crizotinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	19.1	22.49	16.47	17.39
DC6H27Q	DM4F29C	Crizotinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.29	5.84	1.49	2.03
DCFTGI3	DM4F29C	Crizotinib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.73	7.92	6.01	6.3
DCGPB5U	DM4F29C	Crizotinib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.58	10.68	9.67	10.19
DCRK8ZG	DM4F29C	Crizotinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.31	3.2	5.18	5.59
DCHOKHK	DM4F29C	Crizotinib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.51	9.29	5.05	4.97
DCLCKMS	DM4F29C	Crizotinib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	13.26	12.45	7.02	11.68
DCBFSJ0	DM4F29C	Crizotinib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.44	6.77	7.33	7.42
DC3XL78	DM4F29C	Crizotinib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.83	5.97	1.6	1.31
DCADJTY	DM4F29C	Crizotinib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.02	11.33	8.53	9.3
DCJUULH	DM4F29C	Crizotinib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.36	12.84	7.13	6.74
DC8G4T9	DM4F29C	Crizotinib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.68	7.62	6.07	5.89
DC34IJY	DM4F29C	Crizotinib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.32	12.96	6.01	5.38
DCC7UAK	DM4F29C	Crizotinib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.94	3.71	1.31	0.18
DCK2DQD	DM4F29C	Crizotinib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.18	5.77	3.45	3.18
DCQN194	DM4F29C	Crizotinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.41	7.53	5.87	5.87
DC7M9RZ	DM4F29C	Crizotinib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.32	5.67	1.44	1.44
DCNPCUH	DM4F29C	Crizotinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.84	10.74	9.37	10.81
DCZG66G	DM4F29C	Crizotinib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.13	4.09	0.77	9.03
DCTMN14	DM4F29C	Crizotinib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	11.11	10.79	3.63	12.02
DCUOSAK	DM4F29C	Crizotinib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.22	4.57	2.87	2.75
DCMYPYZ	DM4F29C	Crizotinib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.89	5.61	3.94	3.94
DC6KJ1I	DM4F29C	Crizotinib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.85	5.2	4.67	5.66
DC9ONZ0	DM4F29C	Crizotinib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.12	2.61	3.73	3.73
DC0LK47	DM4F29C	Crizotinib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.84	7.98	9.15	9.28
DCITY2M	DM4F29C	Crizotinib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.2	5.93	4.18	4.36
DCN96HJ	DM4F29C	Crizotinib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.7	6.53	4.04	4.92
DCNQ4DB	DMJV2EK	Dasatinib	Investigative	0	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	0.87	4.15	1.91	1.69
DC4J2C0	DMJV2EK	Dasatinib	Investigative	0	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	0.26	2.78	2.05	1.4
DC8J1JR	DMJV2EK	Dasatinib	Investigative	0	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	5.23	7.18	4.52	2.68
DCMJA8Q	DMJV2EK	Dasatinib	Investigative	0	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	4.72	8.69	5.42	5.27
DCTAQOU	DMJV2EK	Dasatinib	Investigative	0	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	2.67	7.87	11.45	10.48
DCWQTIR	DMJV2EK	Dasatinib	Investigative	0	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	1.25	4.05	1.26	1.2
DC96B9K	DMJV2EK	Dasatinib	Investigative	0	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	0.55	2.48	2.08	1.52
DC7S0GY	DMJV2EK	Dasatinib	Investigative	0	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	3.63	13.81	9.88	8.51
DC69PKF	DMJV2EK	Dasatinib	Investigative	0	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	0.22	4.58	4.97	4.14
DCEMG8S	DMJV2EK	Dasatinib	Investigative	0	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	3.49	9.25	5.38	8.07
DCAEY0U	DMJV2EK	Dasatinib	Investigative	0	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	1.21	6.01	4.76	5.2
DCPLXRI	DMJV2EK	Dasatinib	Investigative	0	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	0.78	1.59	0.53	0.44
DCT815U	DMJV2EK	Dasatinib	Investigative	0	DM1WEHC	Buparlisib	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	4.475	9.522	5.116	5.339
DCZ9PFL	DMJV2EK	Dasatinib	Investigative	0	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	3.68	4.21	2.48	5.97
DCUET4E	DMJV2EK	Dasatinib	Investigative	0	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	0.1	1.9	0.76	0.76
DCA7FZO	DMJV2EK	Dasatinib	Investigative	0	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	2.26	3.24	3.89	4.5
DC6X78B	DMJV2EK	Dasatinib	Investigative	0	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	0.84	0.48	4.61	5.7
DCPOG9C	DMJV2EK	Dasatinib	Investigative	0	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	2.81	0.07	3.23	2.17
DCXGD6U	DMJV2EK	Dasatinib	Investigative	0	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	4.21	6.48	6.39	5.46
DCA86OR	DMJV2EK	Dasatinib	Investigative	0	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	4.1	6.15	2.73	2.85
DC7CHFV	DMJV2EK	Dasatinib	Investigative	0	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	3.57	9.12	2.01	2.07
DCHVRP5	DMJV2EK	Dasatinib	Investigative	0	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	1.82	9.56	2.59	2.33
DCAFJY9	DMJV2EK	Dasatinib	Investigative	0	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	3.86	7.73	8.78	8.84
DC0KQEI	DMJV2EK	Dasatinib	Investigative	0	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	3.76	8.78	5.5	6.86
DCY4TSW	DMJV2EK	Dasatinib	Investigative	0	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	1.75	4.27	1.12	1.19
DCF98BX	DMJV2EK	Dasatinib	Investigative	0	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	1.29	3.27	3.33	3.25
DCQBYOJ	DMJV2EK	Dasatinib	Investigative	0	DM3XQDH	JQ1	Investigative	0	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	4.36	11.265	5.716	7.214
DCGPRW4	DMJV2EK	Dasatinib	Investigative	0	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	4.04	10.7	1.78	6.87
DCYQILW	DMJV2EK	Dasatinib	Investigative	0	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	3.84	7.16	3.46	0.81
DCKRR63	DMJV2EK	Dasatinib	Investigative	0	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	3.54	7.51	6.52	2.43
DC39K6V	DMJV2EK	Dasatinib	Investigative	0	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	4.05	8.37	3.98	2.78
DCG6J7C	DMJV2EK	Dasatinib	Investigative	0	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	0.16	2.61	0.01	0.9
DCCBYFQ	DMJV2EK	Dasatinib	Investigative	0	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	2.54	3.33	1.09	0.19
DCHXRLV	DMJV2EK	Dasatinib	Investigative	0	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	4.05	4.69	1.7	3.8
DCOJC57	DMJV2EK	Dasatinib	Investigative	0	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	3.23	3.29	0.19	0.54
DC32A0S	DMJV2EK	Dasatinib	Investigative	0	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	9.89	10.57	2.48	4.98
DCI4O6B	DMJV2EK	Dasatinib	Investigative	0	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	1.11	1.15	0.08	0.51
DCOLGRM	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	0.97	0.07	10.24	12.97
DCSN06J	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	0.59	0.05	9.01	12.42
DCZQMC8	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	2.93	2.54	16.8	17.79
DC9CHXG	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	0.8	0.76	12.14	13.43
DC04LIT	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	1.17	2.16	5.22	11.59
DC6XV2C	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	3.77	1.5	9.19	10.44
DCQEUPS	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	5.71	5.05	8.63	11.59
DCRXVQ6	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	2.01	1.49	11.82	13.78
DCN5S4P	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	6.46	7.73	1.74	12.14
DCAMJ71	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	2.52	2.12	10.08	12.21
DCZVTEJ	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	10.56	9.79	11.59	14.97
DCWNL8S	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	1.74	0.85	11.31	13.06
DCR87GM	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	3.84	5.76	0.47	9.27
DC5I59J	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	9.58	7.97	11.31	17.16
DC7TF78	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	3.14	2.49	8.33	10.93
DCTKV4P	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	14.93	11.75	6.48	19.27
DCC7Q3P	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.44	0.99	10.4	11.9
DC1TH0X	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	8.44	7.15	1.77	15.48
DC83U6D	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	2.9	2.79	13.74	14.44
DCIMXI7	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	10.35	9.71	23.01	23.71
DCZRJON	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	0.46	0.4	6.91	10.06
DCTZJLJ	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	8.08	6.44	11.64	13.85
DC9179G	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	3.98	3.65	9.09	10.9
DCBP533	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	3.98	6.9	3.14	9.82
DCVO5K2	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	8.4	18.8	9.82	14.13
DCAFKRT	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	5.65	5.47	14.25	16.2
DCTDXXY	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	11.29	15.77	16.06	16.06
DC15CBA	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	5.86	6.16	13.07	13.59
DC7YHAC	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	7.73	7.97	10.78	12.13
DC9JYRN	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	4.41	5.59	7.61	8.6
DCKKH4K	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	26.23	25.15	26.33	30.51
DCRLZTX	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	15.92	18	2.67	10.01
DCUPE08	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	2.35	2.06	8.34	10.81
DCRM1ML	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	1.33	7.43	8.91	10.3
DCZNUF7	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	25	19.91	19.63	22.15
DCVZKCG	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	2.07	1.24	4.62	7.29
DCFC4EK	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	18.67	18.64	26.2	26.47
DC1HGCW	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.12	1.38	5	7.37
DCSN5X9	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	5.53	11.67	8.34	11.85
DCJEC96	DMJV2EK	Dasatinib	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	4.48	5.63	3.03	0.03
DC0BMH6	DMJV2EK	Dasatinib	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	2.77	2.98	0.99	2.12
DCNZE1F	DMJV2EK	Dasatinib	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	3.22	6.88	0.03	2.31
DCQPC2M	DMJV2EK	Dasatinib	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	6.17	9.25	1.88	2.43
DC57V5D	DMJV2EK	Dasatinib	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	1.84	5.54	4.64	1.63
DCUE413	DMJV2EK	Dasatinib	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	1.01	1.81	3.97	5.97
DCVK73W	DMJV2EK	Dasatinib	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	1.73	2.37	0.64	1.55
DC4NIEE	DMJV2EK	Dasatinib	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	0.09	1.42	0.12	1.15
DC1CDGN	DMJV2EK	Dasatinib	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	5.07	9.99	2.26	4.94
DCVO3DR	DMJV2EK	Dasatinib	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	0.2	0.92	0.09	1.44
DCUPFG2	DMJV2EK	Dasatinib	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	0.11	0.09	0.04	2.38
DCWPOPN	DMJV2EK	Dasatinib	Investigative	0	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	3.06	7.22	1.28	1.79
DC592YL	DMJV2EK	Dasatinib	Investigative	0	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	5.7	10.35	6.55	3.26
DC2RPVM	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	6.12	6.76	7.68	11.85
DCK7RWP	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	2.68	2.99	9.96	10.21
DCRDUDN	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	1.8	1.59	1.79	8.03
DCLLG0W	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	1.58	2.24	3.57	3.72
DCB2666	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	2.06	1.81	6.72	7.56
DCH8UPR	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	1.57	0.89	8.58	9.08
DCLRNAG	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	3.54	6.67	6.89	9.81
DCKG2HH	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	6.65	6.62	9.56	12.51
DCGR1TG	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	3.53	7.99	6.47	12.11
DCBGU6J	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	4.74	4.57	6.91	9.83
DCNG4C6	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	5.73	8.22	7.66	12
DC06N4Z	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	2.94	2.21	6.92	8.87
DCV91GT	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	1.33	5.55	4.09	8.61
DCE4WD5	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	17.09	12.91	14.46	19.97
DCTC73M	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	17.17	17.28	9.55	24.84
DCE96H4	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.61	0.52	3.81	3.99
DCXB44A	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	1.52	10.51	8.78	9.4
DCE109I	DMJV2EK	Dasatinib	Investigative	0	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	7.1	5.8	4.5	11.18
DCIGJKO	DMJV2EK	Dasatinib	Investigative	0	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	4.41	4.81	4.63	4.63
DCC1WWM	DMJV2EK	Dasatinib	Investigative	0	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	5.25	5.92	2.56	1.81
DCPWIP9	DMJV2EK	Dasatinib	Investigative	0	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	6.85	0.32	1.86	2.12
DC2SIW1	DMJV2EK	Dasatinib	Investigative	0	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	4.26	0.17	0.31	0.48
DCJGEO0	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	4.47	3.51	9.53	12.4
DCGX4EJ	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	3.57	2.27	0.83	6.82
DCVOR4A	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	2.17	3.81	0.59	0.01
DC5R3B7	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	5.1	2.81	5.63	8.62
DC7KPKJ	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	1.75	0.79	3.86	7.09
DCA08EM	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	1.62	1.2	1.53	3.8
DCOQUI3	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	10.53	8.83	10.36	13.37
DCXI0GW	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	1.3	0.68	0.17	5.78
DCWER7T	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	18.07	16.69	22.4	23.49
DCJUVYJ	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	4.39	2.07	6.56	9.46
DCQWO09	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	7.63	7.4	2.3	12.67
DCCG47Z	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	7.25	5.3	12.48	14.72
DCNGCA2	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	3.01	4.53	6.36	3.58
DCIBBV1	DMJV2EK	Dasatinib	Investigative	0	DMC7W6R	Selumetinib	Investigative	0	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	5.414	13.912	3.605	6.062
DCC3DJ7	DMJV2EK	Dasatinib	Investigative	0	DMBP5N3	Cantharidin	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	SU-DIPG-XIII	0.079	7.25	2.357	2.4
DCULAIE	DMJV2EK	Dasatinib	Investigative	0	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	9.5	14.57	9.07	0.25
DCSRMIL	DMJV2EK	Dasatinib	Investigative	0	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	7.65	11.35	5.12	4.74
DCRKBPV	DMJV2EK	Dasatinib	Investigative	0	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	1.91	4.79	2.5	1.97
DCCHPFT	DMJV2EK	Dasatinib	Investigative	0	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	0.93	2.44	0.14	0.14
DCD9B0R	DMJV2EK	Dasatinib	Investigative	0	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	0.88	2.55	2.15	0.88
DCP08WO	DMJV2EK	Dasatinib	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	0.64	4.58	2.31	2.32
DCM3CEV	DMJV2EK	Dasatinib	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	5.67	12.09	4.69	3.23
DCDNYTN	DMJV2EK	Dasatinib	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	0.52	5.02	3.63	3.68
DCEN55L	DMJV2EK	Dasatinib	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	0.61	2.33	0.35	0.42
DCDK1OO	DMJV2EK	Dasatinib	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	3.82	6.69	0.27	0.27
DCPMLYG	DMJV2EK	Dasatinib	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	1.07	7.07	9.4	9.62
DC1H6RN	DMJV2EK	Dasatinib	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	SU-DIPG-XIII	5.773	8.635	2.837	3.114
DC6JOAS	DMJV2EK	Dasatinib	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	0.35	6.41	5.07	6.76
DCM8WNN	DMJV2EK	Dasatinib	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	3.01	5.03	1.06	0.74
DCP9VEV	DMJV2EK	Dasatinib	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	0.39	5.07	2.4	2.54
DCCECJY	DMJV2EK	Dasatinib	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	2.77	4.34	2.27	1.76
DCA4AIV	DMJV2EK	Dasatinib	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	2.2	9.08	9.89	8.3
DCEUMWU	DMJV2EK	Dasatinib	Investigative	0	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	5.05	8.45	6.52	4.83
DCFF413	DMJV2EK	Dasatinib	Investigative	0	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	1.1	1.91	0.17	0.03
DCLARUI	DMJV2EK	Dasatinib	Investigative	0	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	0.54	1	1.5	0.49
DCV75TB	DMJV2EK	Dasatinib	Investigative	0	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	0.01	2.27	0.12	1.25
DCV3AMU	DMJV2EK	Dasatinib	Investigative	0	DMD7L48	Plinabulin	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	6.09	8.24	5.64	8.3
DCYCJ4J	DMJV2EK	Dasatinib	Investigative	0	DMDMQIE	THAPSIGARGIN	Preclinical	2.1	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	SU-DIPG-XIII	14.28	13.859	17.153	18.096
DC091YZ	DMJV2EK	Dasatinib	Investigative	0	DMDMQIE	THAPSIGARGIN	Preclinical	2.1	.	.	.	.	Primitive neuroectodermal tumor	ALMANAC Dataset	Investigative	TC-32	14.27	13.86	17.14	18.1
DCW0PVU	DMJV2EK	Dasatinib	Investigative	0	DMEITAS	SNS-032	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	SU-DIPG-XIII	0.081	7.727	0.936	1.26
DCSKINI	DMJV2EK	Dasatinib	Investigative	0	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	2.95	7.82	9.88	11.07
DC1MHPS	DMJV2EK	Dasatinib	Investigative	0	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	1.54	2.8	2.63	1.79
DC33B4K	DMJV2EK	Dasatinib	Investigative	0	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	2.66	7.02	7.12	8.05
DCWV6AF	DMJV2EK	Dasatinib	Investigative	0	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	13.85	8.48	6.25	11.65
DCCCZMD	DMJV2EK	Dasatinib	Investigative	0	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	2.26	3.02	1.46	2.72
DCIMMNI	DMJV2EK	Dasatinib	Investigative	0	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	2.47	3.13	0.66	7.4
DC0OBOK	DMJV2EK	Dasatinib	Investigative	0	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	1.09	4.22	1.66	2.04
DCXFRCQ	DMJV2EK	Dasatinib	Investigative	0	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	13.56	17.01	5.28	6.69
DCTLEOJ	DMJV2EK	Dasatinib	Investigative	0	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	9.31	10.33	0.06	0.06
DCDXJHZ	DMJV2EK	Dasatinib	Investigative	0	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	3.19	9.2	1.97	2.2
DCJIONV	DMJV2EK	Dasatinib	Investigative	0	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Diffuse large B cell lymphoma	ALMANAC Dataset	Investigative	TMD8	1.127	0.526	2.413	3.911
DCW1CA0	DMJV2EK	Dasatinib	Investigative	0	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	1.89	7.23	5.81	4.35
DCMM61S	DMJV2EK	Dasatinib	Investigative	0	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	3.54	3.31	4.4	6.42
DC8R8VO	DMJV2EK	Dasatinib	Investigative	0	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	3.2	10.71	9.71	8.96
DCJBQ03	DMJV2EK	Dasatinib	Investigative	0	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	1.32	6.06	4.58	2.93
DCD81AO	DMJV2EK	Dasatinib	Investigative	0	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	5.06	6.48	4.64	2.61
DCVF3CU	DMJV2EK	Dasatinib	Investigative	0	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	1.53	2.65	1.09	0.23
DCR799O	DMJV2EK	Dasatinib	Investigative	0	DMKLAYG	Altretamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	10.27	13.62	6	4.98
DCEQYNG	DMJV2EK	Dasatinib	Investigative	0	DMKLAYG	Altretamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	1.34	2.27	0.48	0.11
DCKMPLU	DMJV2EK	Dasatinib	Investigative	0	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	3.43	8.56	0.21	7.56
DCJIRL0	DMJV2EK	Dasatinib	Investigative	0	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	0.17	2.24	1.36	1.2
DC8OYLH	DMJV2EK	Dasatinib	Investigative	0	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	0.7	3.18	0.48	0.48
DCWQB98	DMJV2EK	Dasatinib	Investigative	0	DMKXDOI	AS602868	Discontinued in Phase 1	3	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	SU-DIPG-XIII	2.989	11.812	4.623	4.728
DCVT8JT	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	1.45	1.81	3.87	6.91
DC5RNED	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	1.12	0.92	4.7	7.51
DC6XTB6	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	0.48	0.34	1.51	3.42
DCTSFQZ	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	6.32	6.1	2.75	9.62
DCNQQZ8	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	1.91	2.17	0.14	6.18
DC6RJSL	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	5.74	3.7	2.5	6.46
DCU1O9M	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	2.82	1.21	3.24	5.04
DCA0YNT	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	8.52	9.06	1.81	8.79
DCB3VLK	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	10.5	11.02	1.36	13.45
DCW5L9G	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	1.68	1.97	0.7	3.18
DCPOD3J	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	5.32	9.48	6.36	11.09
DC03VM6	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	21.57	12.58	14.44	15.46
DCZGIYU	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	6.45	6.37	7.69	8.21
DC9JV3I	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	11.65	12.56	1.94	16.47
DCR8B8J	DMJV2EK	Dasatinib	Investigative	0	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	4.66	8.6	4.68	3.65
DC9507V	DMJV2EK	Dasatinib	Investigative	0	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	3.76	4.98	1.63	0.03
DCAANJX	DMJV2EK	Dasatinib	Investigative	0	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	4.06	4.87	0.52	0.07
DCHC0JC	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	0.59	0.25	9.85	10.02
DCA3INL	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	0.43	0.07	5.22	5.62
DC71ZOK	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	4.01	3.83	12.41	12.62
DC2OKE7	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	2.2	2.09	7.42	7.68
DCQZGOQ	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	6.57	6.52	17.17	18.08
DC7IWC1	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	1.73	1.13	12.22	12.36
DCDK6WE	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	7.82	11.23	2.76	7.54
DC6RTRN	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	9.26	9.35	12.93	13.64
DC8BOWZ	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	6.35	12.86	7.89	7.89
DCNGNT5	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	7.24	6.31	14.63	15.09
DCQEH0Q	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	6.81	10.23	13.27	15.66
DCBYIDT	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	14.99	14.71	19.08	21.35
DC4HWYV	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	0.2	5.45	3.72	5.47
DC2ONGT	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	1.46	11.32	15.15	15.16
DC2IELE	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	13.98	15.74	17.08	17.49
DCRYUOU	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	16.26	24.37	2.88	9.81
DCEURGT	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	26.47	19.42	25.4	25.59
DCJ79HU	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	0.27	2.01	5.06	5.78
DC75F21	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	20.33	17.48	27.21	30.31
DC2RTVB	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	2.57	2.39	9.38	9.86
DCGKMMY	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	2.81	3.6	7.85	14.91
DC1JYPP	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	8.08	14.82	11.93	13.25
DCC4HA2	DMJV2EK	Dasatinib	Investigative	0	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	ALMANAC Dataset	Investigative	T98G	9.1	9.1	11.9	11.97
DC0ODQQ	DMJV2EK	Dasatinib	Investigative	0	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	4.29	3.67	4.88	7.38
DCGS4BW	DMJV2EK	Dasatinib	Investigative	0	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	6.96	8.56	8.29	10.09
DC16EWQ	DMJV2EK	Dasatinib	Investigative	0	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	0.34	0.1	4	6.78
DCDB22X	DMJV2EK	Dasatinib	Investigative	0	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	20.67	15.22	22.75	24.8
DCH22YG	DMJV2EK	Dasatinib	Investigative	0	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	5.74	5.77	14.06	16.79
DCNYORB	DMJV2EK	Dasatinib	Investigative	0	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	2.33	0.97	5.53	7.84
DCNQHSF	DMJV2EK	Dasatinib	Investigative	0	DMN5T2A	Ciclopirox	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	SU-DIPG-XIII	16.73	22.379	8.602	11.804
DC39A52	DMJV2EK	Dasatinib	Investigative	0	DMNE56X	ABT-263	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	SU-DIPG-XIII	4.527	11.366	2.586	2.35
DCXDGY5	DMJV2EK	Dasatinib	Investigative	0	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	3.08	4.3	3.12	4.62
DCUK7P2	DMJV2EK	Dasatinib	Investigative	0	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	0.22	0.79	1.75	1.84
DCA252S	DMJV2EK	Dasatinib	Investigative	0	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	1.13	1.76	3.17	5.17
DCL93Y8	DMJV2EK	Dasatinib	Investigative	0	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	0.91	5.95	2.09	3.15
DC03ANZ	DMJV2EK	Dasatinib	Investigative	0	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	9.83	4.9	3.37	4.67
DC43CDY	DMJV2EK	Dasatinib	Investigative	0	DMO14SG	Mebendazole	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	0.13	6.67	4.02	5.52
DCRIUPZ	DMJV2EK	Dasatinib	Investigative	0	DMOFSLE	IMD-0354	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	SU-DIPG-XIII	2.489	6.615	7.886	6.513
DC8J3DO	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	0.49	3.31	2.04	2.82
DCBO70A	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	2.13	3.64	5.76	5.86
DCFDTNK	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	4.97	7.6	3.84	5.45
DCHFNH6	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	1.74	2.59	0.28	0.34
DCR63ZN	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	2.58	2.44	0.42	0.07
DCREQZT	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	4.13	5.49	5.04	5.33
DCN2OIS	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	5.24	4.24	0.49	6.11
DCRAUMN	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	5.27	9.43	6.42	6.89
DCWEKXL	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	3.05	7.37	4.36	4.33
DCF2D26	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	4.84	4.01	1.29	4.38
DCZOGVH	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	0.55	1.91	2.93	3.48
DC41ISQ	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	3.69	7.81	0.23	1.13
DCM7M63	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	7.06	7.13	0.34	0.11
DCO0RKG	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	5.32	5.28	5.54	5.84
DCZ6GRM	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	0.39	2.17	3.53	2.74
DCPJWME	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.38	4.1	4.21	4.6
DCFPLL0	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	2.52	7.42	3.76	6.5
DC44Y0O	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	5.11	7.2	0.18	0.12
DCKG5OU	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	11.37	12.27	11.88	12.76
DC1W56U	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	2.36	2.64	2.52	4.23
DC9PXAC	DMJV2EK	Dasatinib	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	2.55	2.97	0.25	4.78
DC3VYP4	DMJV2EK	Dasatinib	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	1.98	2.38	4.81	10
DC2KXXR	DMJV2EK	Dasatinib	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	2.83	2.99	1.26	3.32
DCEV0T7	DMJV2EK	Dasatinib	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	3.25	7.93	4.21	4.21
DCYLNLW	DMJV2EK	Dasatinib	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	2.94	6.92	6.5	6.5
DCW0S9D	DMJV2EK	Dasatinib	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	0.29	8.44	0.39	3.99
DC69VCG	DMJV2EK	Dasatinib	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	37.92	28.96	27.01	32.92
DC44IC1	DMJV2EK	Dasatinib	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	11.23	12.6	13.78	15.45
DCUAAV3	DMJV2EK	Dasatinib	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	2.6	11.11	0.44	4.37
DCYRJWG	DMJV2EK	Dasatinib	Investigative	0	DMPK32V	BMS-754807	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	16.82	17.21	11.23	18.32
DCIDGK1	DMJV2EK	Dasatinib	Investigative	0	DMPK32V	BMS-754807	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	SU-DIPG-XIII	28.239	27.632	35.448	37.516
DCY1XB7	DMJV2EK	Dasatinib	Investigative	0	DMPK32V	BMS-754807	Phase 1	17	.	.	.	.	Primitive neuroectodermal tumor	ALMANAC Dataset	Investigative	TC-32	28.24	27.63	35.44	37.52
DCJX7ZN	DMJV2EK	Dasatinib	Investigative	0	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	2.52	2.28	5.24	6.17
DCLKOS0	DMJV2EK	Dasatinib	Investigative	0	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	1.22	3.29	2.32	2.47
DCQH03G	DMJV2EK	Dasatinib	Investigative	0	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	1.37	1.91	1.73	1.5
DCJ0RJA	DMJV2EK	Dasatinib	Investigative	0	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	8.31	3.12	0.47	6.51
DCTBFUK	DMJV2EK	Dasatinib	Investigative	0	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	6.33	12.11	6.3	6.51
DCSJS6R	DMJV2EK	Dasatinib	Investigative	0	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	0.56	2.19	2.06	1.62
DCW0Z2P	DMJV2EK	Dasatinib	Investigative	0	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	0.34	3.5	3.32	2.42
DCDV21Q	DMJV2EK	Dasatinib	Investigative	0	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	7.18	10.4	6.11	5.28
DCEIM4L	DMJV2EK	Dasatinib	Investigative	0	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	2.02	2.68	2.58	0
DCN8W2S	DMJV2EK	Dasatinib	Investigative	0	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	10.73	12.8	13.51	12.88
DCASYJS	DMJV2EK	Dasatinib	Investigative	0	DMS610L	PF-04691502	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	SU-DIPG-XIII	8.264	10.565	9.085	11.66
DC3BJQ0	DMJV2EK	Dasatinib	Investigative	0	DMS610L	PF-04691502	Phase 2	21	.	.	.	.	Primitive neuroectodermal tumor	ALMANAC Dataset	Investigative	TC-32	8.27	10.56	9.1	11.66
DCXSWSZ	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	7.3	6.78	8.84	11.64
DC9X8QK	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	0.81	1.72	4.88	2.11
DCCCU9Q	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	0.5	0.05	9.21	11.63
DCQ7GXO	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	2.02	1.34	6.48	10.59
DCO14B8	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	1.78	2.04	7.15	10.34
DCE1S15	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	1.13	1.23	10.96	12.21
DCJEW73	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	6.81	5.69	5.96	11.54
DCVS3H6	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	9.98	10.79	3.15	8.01
DCLLEET	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	4.02	4.26	8.3	12.35
DCQNDQ8	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	5.2	9.41	8.2	11.54
DCMZXQH	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	13.37	14.97	11.96	14.18
DCDEG3K	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	8.24	8.47	5.05	8.96
DC85O0I	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	1.2	0.66	5.12	8.1
DCVHR6B	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	4.61	6.87	5.67	9.65
DCOB7GO	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	15.32	14.02	12.58	19.27
DCY3XRM	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	14.72	11	0.66	5.49
DCSXMBR	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	2.99	3.59	1.6	5.4
DCZRRSL	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	1.39	2.96	0.74	0.55
DCJ8PZK	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	2.9	2.89	6.71	8.23
DCTAHEJ	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	12.32	9.22	13.99	16.75
DCSR4NY	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	7.19	4.98	3.75	7.38
DCXQRCU	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	5.57	10.6	5.39	9.1
DCKC7YL	DMJV2EK	Dasatinib	Investigative	0	DMSG91J	ER819762	Investigative	0	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	6.33	7.68	3.11	0.58
DCMV3ZR	DMJV2EK	Dasatinib	Investigative	0	DMSG91J	ER819762	Investigative	0	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	1.29	2.84	3.26	0.38
DCFYM8W	DMJV2EK	Dasatinib	Investigative	0	DMSG91J	ER819762	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	4.77	5.8	1.88	1.88
DCHT0N0	DMJV2EK	Dasatinib	Investigative	0	DMSG91J	ER819762	Investigative	0	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	2.58	5.28	2.9	2.4
DC08P16	DMJV2EK	Dasatinib	Investigative	0	DMSG91J	ER819762	Investigative	0	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	1.39	6.59	4.16	2.33
DCS1LT2	DMJV2EK	Dasatinib	Investigative	0	DMSLE03	PF-562271	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	3.95	9.66	4.81	6.18
DCEC3HW	DMJV2EK	Dasatinib	Investigative	0	DMSLE03	PF-562271	Phase 1	17	.	.	.	.	Diffuse large B cell lymphoma	ALMANAC Dataset	Investigative	TMD8	8.71	7.67	2.81	8.25
DCKF1EY	DMJV2EK	Dasatinib	Investigative	0	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	1.92	5.94	1.63	0.95
DCRESTH	DMJV2EK	Dasatinib	Investigative	0	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	1.15	4.12	3.77	5.81
DCJHKGS	DMJV2EK	Dasatinib	Investigative	0	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	5.56	9.65	4.75	1.46
DC6JVYA	DMJV2EK	Dasatinib	Investigative	0	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	0.48	4.52	1.21	4.16
DC8EHV9	DMJV2EK	Dasatinib	Investigative	0	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	1.16	3.14	2.43	1.76
DCM2MI9	DMJV2EK	Dasatinib	Investigative	0	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	0.13	1.75	0.48	0.48
DC02XXL	DMJV2EK	Dasatinib	Investigative	0	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	0.58	2.65	0.38	0.38
DCUIZLP	DMJV2EK	Dasatinib	Investigative	0	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	1.31	3.7	1.37	0.55
DC4M7CD	DMJV2EK	Dasatinib	Investigative	0	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	1.3	4.1	1.94	1.68
DC8BNE2	DMJV2EK	Dasatinib	Investigative	0	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	1.58	5.42	1.74	0.65
DC789MI	DMJV2EK	Dasatinib	Investigative	0	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	0.14	2.14	2.87	3.28
DCCUKDN	DMJV2EK	Dasatinib	Investigative	0	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	5.49	3.87	2.77	4.11
DCTBRSQ	DMJV2EK	Dasatinib	Investigative	0	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	0.3	12.26	6.55	3.16
DCKEQQR	DMJV2EK	Dasatinib	Investigative	0	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	0.29	2.6	2.18	2.85
DC9RI75	DMJV2EK	Dasatinib	Investigative	0	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	0.94	0.42	3.58	5.03
DCUM5RK	DMJV2EK	Dasatinib	Investigative	0	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	1.54	6.42	3.81	2.72
DCT72W5	DMJV2EK	Dasatinib	Investigative	0	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	7.59	9.63	1.73	0.91
DC6UPN5	DMJV2EK	Dasatinib	Investigative	0	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	3.17	9	2.45	1.97
DCIFZ70	DMJV2EK	Dasatinib	Investigative	0	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	14.5	16.69	0.54	0.54
DCUENM9	DMJV2EK	Dasatinib	Investigative	0	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	1.98	6.25	1.46	1.73
DCD4O2E	DMJV2EK	Dasatinib	Investigative	0	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	2.02	6.97	2.93	1.6
DCEQ5Y2	DMJV2EK	Dasatinib	Investigative	0	DMUKNQ5	AZD8330	Discontinued in Phase 1	3	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	11.072	14.184	9.242	12.019
DCKSUPG	DMJV2EK	Dasatinib	Investigative	0	DMWT905	Mefloquine	Phase 2/3 Trial	24	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	SU-DIPG-XIII	1.397	8.659	1.641	1.806
DCXF0BX	DMJV2EK	Dasatinib	Investigative	0	DMWT905	Mefloquine	Phase 2/3 Trial	24	.	.	.	.	Primitive neuroectodermal tumor	ALMANAC Dataset	Investigative	TC-32	1.43	8.66	1.64	1.8
DCHQTW2	DMJV2EK	Dasatinib	Investigative	0	DMVDYTG	CPG 52364	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	SU-DIPG-XIII	5.619	12.521	0.062	1.262
DCP8NST	DMJV2EK	Dasatinib	Investigative	0	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	2.2	3.97	5.03	5.03
DC0JCZQ	DMJV2EK	Dasatinib	Investigative	0	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	0.44	2.69	5.07	3.22
DCJI8FC	DMJV2EK	Dasatinib	Investigative	0	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	4.02	5.68	0.24	1.46
DC9CE0O	DMJV2EK	Dasatinib	Investigative	0	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	1.02	0.14	1.93	4.64
DCMM2IJ	DMJV2EK	Dasatinib	Investigative	0	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	2.81	3.44	1.11	1.11
DCMZ5N8	DMJV2EK	Dasatinib	Investigative	0	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	1.35	2.63	1.15	1.15
DCB0QV7	DMJV2EK	Dasatinib	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	6.22	3.09	3.99	9.14
DC99OCZ	DMJV2EK	Dasatinib	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	2.78	2.44	8.4	13.41
DC9RPUC	DMJV2EK	Dasatinib	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	0.5	0.49	14.04	15.97
DC6OMNL	DMJV2EK	Dasatinib	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	1.68	1.03	4.12	7.24
DC90R6W	DMJV2EK	Dasatinib	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	9.3	8.38	6.78	12.09
DCFNNXN	DMJV2EK	Dasatinib	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	1.44	0.64	2.7	4.88
DCRLERA	DMJV2EK	Dasatinib	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	4.2	3.3	2.93	7.04
DCL7511	DMJV2EK	Dasatinib	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	8.36	6.68	12.54	14.61
DC435CN	DMJV2EK	Dasatinib	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	8.44	8.2	3.35	15.73
DCYSDWO	DMJV2EK	Dasatinib	Investigative	0	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	5.53	8.93	6.43	9.06
DCFY9SW	DMJV2EK	Dasatinib	Investigative	0	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	13.28	13.17	15.66	18.46
DCHLBS5	DMJV2EK	Dasatinib	Investigative	0	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	0.7	2.29	4.11	4.84
DCWOWJH	DMJV2EK	Dasatinib	Investigative	0	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	0.86	2.51	2.56	2.91
DC0A8Z6	DMJV2EK	Dasatinib	Investigative	0	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	0.27	5.49	0.9	2.87
DCVNBZN	DMJV2EK	Dasatinib	Investigative	0	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	10.74	10.73	13.03	13.41
DCH62LX	DMJV2EK	Dasatinib	Investigative	0	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	2.53	4.32	1.86	3.71
DCHDRXI	DMJV2EK	Dasatinib	Investigative	0	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	1.73	2.41	6.04	6.06
DCQQQKM	DMJV2EK	Dasatinib	Investigative	0	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	4.74	6	4.63	1.07
DC8PXRI	DMJV2EK	Dasatinib	Investigative	0	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Diffuse large B cell lymphoma	ALMANAC Dataset	Investigative	TMD8	2.16	1.69	2.79	4.53
DCQMI9N	DMJV2EK	Dasatinib	Investigative	0	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.27	5.18	1.93	4.51
DCF80D1	DMJV2EK	Dasatinib	Investigative	0	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.06	2.22	0.67	0.71
DCA11XE	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.97	0.72	7.06	9.41
DC3DWU3	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	8.63	9.43	2.71	13.12
DCAJCZW	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.74	5.69	2.79	9.56
DCG0TK4	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.85	2.01	6.09	10.46
DC3XS8V	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.31	3.44	0.71	10.77
DCZCMLP	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.7	0.44	2.29	5.51
DCT7J7O	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.91	6.81	9.84	11.17
DCCHYFS	DMJV2EK	Dasatinib	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.13	4.27	8.51	13.7
DCIFJUZ	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.39	1.71	5.78	7.05
DCJKEC5	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.86	3.33	6.29	8.57
DC7O2QQ	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.01	1.46	6.4	8.54
DCPLBS2	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	12.73	12.27	16.14	16.78
DCCES8B	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.35	4.37	3.89	9.48
DC18BU6	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.1	0.77	11.43	13
DCTOVGO	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.85	1.19	3.83	5.27
DCO3ZBC	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.01	10.15	0.07	5.15
DC7VTUM	DMJV2EK	Dasatinib	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.4	2.5	11.55	13.13
DCFF6M7	DMJV2EK	Dasatinib	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.64	6.23	1.38	1.6
DC8AJ6K	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.13	0.42	4.75	5.35
DCTLIE8	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.18	6.44	3.01	9.77
DC9D8RI	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.34	0.64	4.23	6.27
DCTA2SC	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.46	10.82	9.74	15.83
DC1RN5U	DMJV2EK	Dasatinib	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.38	3.75	14.06	14.51
DCX1OHC	DMJV2EK	Dasatinib	Investigative	0	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.28	0.59	0.13	0.05
DCWPFTL	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1	2.26	0.44	5.55
DC9VB4W	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.07	10.29	8.04	10.9
DCPRO9Z	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	3.22	2.55	1.57	8.25
DCQCDXX	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.95	5.96	4.19	10.74
DCWPX5E	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.31	0.79	3.5	4.81
DC45XRB	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.43	4.82	2.86	6.81
DCDUC2W	DMJV2EK	Dasatinib	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.28	0.46	8.9	10.15
DCX75RP	DMJV2EK	Dasatinib	Investigative	0	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.84	3.51	0.59	0.21
DCGGW8T	DMJV2EK	Dasatinib	Investigative	0	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.13	4.23	1.89	1.76
DCEU2GZ	DMJV2EK	Dasatinib	Investigative	0	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.17	0.46	2.79	3.96
DCYHA38	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.11	2.05	0.5	1.67
DCZJH7D	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.48	4.15	3.19	5.46
DC3OG0W	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.04	0.51	1.12	6.36
DCK9T9B	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	11.08	12.09	1.07	14.95
DCHBIEM	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	7.06	6.56	4.66	7.45
DCIJZJ6	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.3	0.67	1.78	4.11
DCBWQPK	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.91	4.44	2.59	9.56
DCEDLL2	DMJV2EK	Dasatinib	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	7.41	8.42	7.49	12.85
DCZ42HM	DMJV2EK	Dasatinib	Investigative	0	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.76	7.63	0.33	0.1
DCC61KH	DMJV2EK	Dasatinib	Investigative	0	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.89	4.43	2.56	3.09
DC41GQP	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	9.88	12.96	12.04	15.67
DCHTIDL	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	8.28	8.46	10.53	13.33
DCM8WTD	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.4	0.89	10.68	12.46
DCUFPQ9	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.6	2.81	6.08	9.07
DCTGVJV	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.29	6.7	12.46	14.12
DCRJ9Z6	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	17.62	17.52	21.67	22.61
DCW9IHJ	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.65	6.67	12.11	13.46
DCPHZAA	DMJV2EK	Dasatinib	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.62	0.46	5.51	5.79
DCUS8SY	DMJV2EK	Dasatinib	Investigative	0	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.46	1.49	1.8	4.53
DCZM9PY	DMJV2EK	Dasatinib	Investigative	0	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.49	1.52	1.84	0.32
DCFNP8E	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.78	1.96	0.48	0.62
DC5M2M6	DMJV2EK	Dasatinib	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.37	6.6	7.31	7.55
DCNV16U	DMJV2EK	Dasatinib	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	6.48	2.65	2.6	4.06
DCOUQTD	DMJV2EK	Dasatinib	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.59	1.4	0.53	1.51
DCROVZ0	DMJV2EK	Dasatinib	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.18	6.12	0.63	4.66
DCLKBFY	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	16.83	16.91	23.84	23.61
DC49JME	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.62	0.56	0.37	3.64
DCRJ623	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.84	3.99	4.51	7.88
DC8O8G8	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	5.59	5.41	10.09	13.58
DC7F6YQ	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.72	6.02	5.98	8.56
DC21LDO	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	6.52	7.33	2.32	5.29
DCKS7GZ	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.43	0.29	3.18	6.48
DCNT15U	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.36	5.96	4.26	8.15
DC07SWA	DMJV2EK	Dasatinib	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.4	7.01	11.37	12.77
DCK6O1X	DMJV2EK	Dasatinib	Investigative	0	DMSG91J	ER819762	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.78	2.38	0.72	0.31
DCWB1H2	DMJV2EK	Dasatinib	Investigative	0	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.99	3.29	3.17	0.15
DCNWV78	DMJV2EK	Dasatinib	Investigative	0	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.95	1.42	1.28	0.24
DCM8827	DMJV2EK	Dasatinib	Investigative	0	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.69	1.27	0.57	0.51
DCPKIPN	DMJV2EK	Dasatinib	Investigative	0	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.65	6.03	2.01	0.43
DCFMICY	DMJV2EK	Dasatinib	Investigative	0	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	15.05	6.86	0.8	0.15
DCRJVWA	DMJV2EK	Dasatinib	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.8	1.44	5.33	6.65
DC9U3P4	DMJV2EK	Dasatinib	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.39	2.68	4.97	6.31
DC8QL24	DMJV2EK	Dasatinib	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	7.95	7.01	5.84	11.27
DCZ5KDO	DMJV2EK	Dasatinib	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.23	0.66	7.82	11.12
DCBDMIE	DMJV2EK	Dasatinib	Investigative	0	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.35	5.22	4.93	5.02
DCD4BKP	DM3WDZ5	MK-1775	Phase 2	21	DMDI269	Docetaxel	Approved	34	DMG281S	Carboplatin	.	.	Lung Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC3YX8K	DM3WDZ5	MK-1775	Phase 2	21	DM8QB1D	Olaparib	Approved	34	.	.	.	.	Recurrent Fallopian Tube Carcinoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCKW17N	DM3WDZ5	MK-1775	Phase 2	21	DMLB81S	Paclitaxel	Approved	34	.	.	.	.	"Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation"	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCUBPZK	DM3WDZ5	MK-1775	Phase 2	21	DMG281S	Carboplatin	Approved	34	.	.	.	.	"Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation"	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCENERW	DM3WDZ5	MK-1775	Phase 2	21	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Solid Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC0DPZ7	DM3WDZ5	MK-1775	Phase 2	21	DMCR1MV	Itraconazole	Approved	34	.	.	.	.	Advanced Solid Tumours	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCBRNND	DM3WDZ5	MK-1775	Phase 2	21	DM8QB1D	Olaparib	Approved	34	.	.	.	.	Advanced Malignant Solid Neoplasm	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCCRI37	DM3WDZ5	MK-1775	Phase 2	21	DMG281S	Carboplatin	Approved	34	.	.	.	.	Pediatric Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCCT636	DM3WDZ5	MK-1775	Phase 2	21	DM471KJ	Omeprazole	Approved	34	.	.	.	.	Advanced Solid Tumours	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCO7VD4	DM3WDZ5	MK-1775	Phase 2	21	DM5DSFZ	Rifampicin	Approved	34	.	.	.	.	Advanced Solid Tumours	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCY1LOX	DM3WDZ5	MK-1775	Phase 2	21	DM6OC53	Belinostat	Phase 2	21	.	.	.	.	Acute Myeloid Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCUI7RF	DM3WDZ5	MK-1775	Phase 2	21	DM1WEHC	Buparlisib	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	6.798	7.199	4.729	7.405
DCJ0YKH	DM3WDZ5	MK-1775	Phase 2	21	DM1WEHC	Buparlisib	Phase 3	25	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	11.532	8.189	1.658	4.998
DCE76BJ	DM3WDZ5	MK-1775	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	0.73	0.16	2.95	4.24
DCSX6QD	DM3WDZ5	MK-1775	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	2.61	5.42	4.4	9.21
DCXYLII	DM3WDZ5	MK-1775	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	6.23	6.81	9.87	10.09
DC1558R	DM3WDZ5	MK-1775	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	U-HO1	8.32	9.2	1.17	5.4
DCFOLRX	DM3WDZ5	MK-1775	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	0.07	1.29	8.21	9.08
DCUUTTR	DM3WDZ5	MK-1775	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	12.52	12.14	18.94	20.67
DCDYWYN	DM3WDZ5	MK-1775	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	5.16	8.39	7.04	7.16
DC9US21	DM3WDZ5	MK-1775	Phase 2	21	DM48K0X	Carfilzomib	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	15.896	16.739	0.468	9.874
DCS6Z5Q	DM3WDZ5	MK-1775	Phase 2	21	DM48QOT	Artemether	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	21.811	25.106	2.634	7.179
DCUK2QA	DM3WDZ5	MK-1775	Phase 2	21	DM5ZVLB	Ixazomib	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	4.98	6.358	0.492	2.726
DCYFEOJ	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	6.25	12.45	4.2	15.06
DCYBXH5	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	6.58	5.69	7.33	11.54
DCXSHM2	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	3.86	6.08	4.57	9.22
DCU4EYH	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	1.75	0.64	0.27	3.45
DCWZQV8	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	6.77	6.66	7.87	11.49
DCZXAT9	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	4.04	6.56	5.75	9.86
DC8VZYT	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	2.24	1.96	1.63	8.43
DCR0DKK	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	1.49	0.62	0.46	4.23
DCG0FU7	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	3.86	3.72	5.18	9.01
DCMRDUC	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	10.66	8.9	11.32	15.16
DCFOKO1	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	9.76	11.05	5.97	16.19
DCB5IYJ	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	3.77	5.5	4.02	8.12
DC2TQK3	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	6.26	5.56	1.68	6.6
DCN9LZK	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	5.02	2.39	3.91	8.27
DCVY5FW	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	10.34	8.5	7.45	12.9
DC8BRH3	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	3.89	1.69	3.34	8.4
DCK432M	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	3.53	2.7	8.55	11.61
DCFXWB4	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	6.27	6.08	4.02	8.05
DC48JJX	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	2.65	2.03	3.79	8.62
DC230YQ	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	16.73	16.35	5.82	17.07
DCG16WG	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	2.45	1.47	6.17	7.39
DC7VGCL	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	2.85	5.39	4.76	7.92
DCYVKW7	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	2.87	4.28	8.83	10.84
DCTWTOL	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	13.04	15.37	13.56	17.4
DCIA82B	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	0.77	8.61	9.37	10.76
DCEWOL1	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	2.69	6.33	6.43	8.95
DCSTMED	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	6.29	6.52	5.97	9.81
DCA7ZQN	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	18.01	17.02	17.92	24.66
DCHVP8T	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	11.02	11.66	11.87	15.64
DC8HG4N	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	2.63	6.37	6.82	9.94
DCD281V	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	13.86	13.56	17.11	19.78
DC3ECQB	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	0.06	6.27	9.61	11.41
DC4DUCX	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	6.99	6.5	2.62	7.93
DC34STB	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	10.06	10.13	6.54	11.45
DC7RI9T	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	12.76	12.69	9.1	13.7
DCL0ELV	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	11.48	10.98	12.45	15.65
DCXSBYW	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	3.22	9.6	7.79	11.51
DCR42N8	DM3WDZ5	MK-1775	Phase 2	21	DM6VOWQ	Fomepizole	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	16.241	15.365	0.862	1.346
DCQ1J4M	DM3WDZ5	MK-1775	Phase 2	21	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	6.666	14.077	4.05	6.564
DC16FFF	DM3WDZ5	MK-1775	Phase 2	21	DM7L8SG	AZD8055	Discontinued in Phase 1/2	4	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	32.378	29.853	11.79	13.229
DCZ0WBF	DM3WDZ5	MK-1775	Phase 2	21	DM7WFZ8	Formononetin	Investigative	0	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	21.229	21.644	6.253	10.172
DC6JONG	DM3WDZ5	MK-1775	Phase 2	21	DM93VBZ	LY2835219	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	9.739	11.594	2.665	2.718
DCYAV9W	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	16.67	16.78	13.74	18.98
DCKJVC3	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	3.23	4.18	2.97	9.01
DCJU6CE	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	3.22	12.33	10.01	13.36
DCSFCWT	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	10.23	12.94	13.72	17.62
DCT3STD	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	2.88	5.05	2.81	9.25
DCTACFW	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	7.41	7.96	11.63	14.83
DCFHGLW	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	6.52	13	8.95	15.52
DCE8N91	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	2.43	5.98	5.7	9.18
DCLYDCN	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	11.06	10.05	10.14	14.3
DCNBFSS	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	8.14	10.49	4.48	12.31
DCMYNM0	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	7.11	5.87	2.49	10.8
DCRBVT9	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	9.1	8.06	5.49	12.35
DC7JN0B	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	7.19	5.54	1.78	7.8
DCBUPKM	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	12.51	11.22	9.16	14.46
DCXOCQE	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	11.5	12.17	12.01	16.62
DCOX20A	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	0.76	4.04	9.11	10.48
DCUFHTV	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	25.24	22.62	18.09	24.51
DCL12RU	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	12.08	16.23	7.66	15.52
DC7WTA4	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	13.83	13.86	1.76	17.2
DC7F29S	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	13.33	13.19	12.79	19.65
DCRANYM	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	12.15	15.84	18.51	20.23
DCIPYX0	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	10.94	11.77	14.32	18.44
DCE7JZD	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	12.92	12.91	19.27	12.59
DCS1873	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	2.17	0.76	5.83	9.58
DCW7VLR	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	6.17	13.74	12.11	13.01
DCSYH40	DM3WDZ5	MK-1775	Phase 2	21	DMA9SEY	GDC-0084	Phase 2	21	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	1.605	1.282	1.427	3.943
DCA6MCY	DM3WDZ5	MK-1775	Phase 2	21	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	6.332	5.345	2.564	6.016
DC1OE1P	DM3WDZ5	MK-1775	Phase 2	21	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	U-HO1	8.91	8.12	0.06	3.26
DC9F99K	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	10.72	11.14	2.91	9.44
DCJRSKJ	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	3.45	8.54	6.01	8.11
DCR5JTN	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	2	4.22	3.44	6.42
DCB8F4X	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	4.99	2.39	1.5	5.57
DC0TTTP	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	5.49	2.96	0	6.69
DCNDPZY	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	7.88	6.3	8.16	12.62
DC5488Q	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	8.67	6.27	3.39	7.9
DC3DD90	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	1.5	4.46	1.12	6.72
DCNMHLY	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	9.09	7.29	7.57	9.58
DC1XKAO	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	1.98	3.51	0.08	4.32
DCPFJWS	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	6.11	9.21	4.28	8.61
DCPHBT5	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	8.35	1.29	0.44	4.42
DCRP09O	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	3.91	2.22	0.49	5.74
DCIQ3QC	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	3.83	3.66	3.53	8.1
DCJ2KSI	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	0.58	5.64	6.12	5.85
DCK6Z2R	DM3WDZ5	MK-1775	Phase 2	21	DMC7W6R	Selumetinib	Investigative	0	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	7.727	10.584	3.301	5.055
DC92V49	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	2.48	2.3	4.91	7.65
DCTO1SJ	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	5.22	9.57	2.74	11.57
DCEZJXP	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	2.15	4.72	5.13	8.44
DCK3IEP	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	1.25	0.87	0.53	3.94
DCDA56W	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	5.91	5.22	3.74	8.09
DCMFK7Q	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	2.87	4.24	1.01	7.62
DCJ3FI1	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	5.03	8.32	5.07	10.41
DCHY8DA	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	4.95	2.47	22.21	3.06
DC7CN19	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	0.25	0.48	0.02	4.62
DCVEAFS	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	9.6	7.66	3.49	8.09
DCKPLK7	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	4.89	5.86	1.6	7.33
DC8JI6U	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	0.07	4.71	5.15	10.28
DCOEWRR	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	3.4	5.35	6.2	10.09
DC45ENQ	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	4.97	14.03	8.89	14.56
DCMV16H	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	3.49	9.56	5.94	13.61
DC9QV02	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	19.07	16.52	21.84	24.81
DCEG4FJ	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	5.6	6.43	7.26	10.79
DCWS8F2	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	0.99	4.26	0.77	4.42
DCZ1UOA	DM3WDZ5	MK-1775	Phase 2	21	DMCU74R	Daporinad	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	9.324	8.758	1.404	7.038
DC75EQG	DM3WDZ5	MK-1775	Phase 2	21	DMD7L48	Plinabulin	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	6.912	7.423	7.199	9.657
DCJ5WF6	DM3WDZ5	MK-1775	Phase 2	21	DMDI269	Docetaxel	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	21.541	21.138	10.261	13.833
DCS3FO4	DM3WDZ5	MK-1775	Phase 2	21	DMDMQIE	THAPSIGARGIN	Preclinical	2.1	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	1.785	0.637	1.976	3.981
DCPNVCG	DM3WDZ5	MK-1775	Phase 2	21	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	26.6	23.778	4.245	7.296
DCTV6RJ	DM3WDZ5	MK-1775	Phase 2	21	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	U-HO1	8.77	8.46	0.09	3.22
DCCQCNC	DM3WDZ5	MK-1775	Phase 2	21	DMEOS5K	AEE-788	Phase 1/2	19	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	14.174	14.227	1.037	1.701
DCY6ZZ4	DM3WDZ5	MK-1775	Phase 2	21	DMGDA3C	Cycloheximide	Investigative	0	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	26.987	26.419	0.883	2.902
DC9DB2U	DM3WDZ5	MK-1775	Phase 2	21	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	19.867	21.3	2.407	6.739
DCSUMSL	DM3WDZ5	MK-1775	Phase 2	21	DMHKZLF	OSI-906	Phase 3	25	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	12.198	8.968	2.373	4.803
DC0PERD	DM3WDZ5	MK-1775	Phase 2	21	DMINOX3	Vincristine	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	11.277	9.231	0.422	3.39
DCT7IN2	DM3WDZ5	MK-1775	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	3.68	3.14	0.88	4.83
DCS8YOH	DM3WDZ5	MK-1775	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	7.06	11.69	2.97	12.7
DC52I6V	DM3WDZ5	MK-1775	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	4.1	4.06	1.04	6.95
DCU728B	DM3WDZ5	MK-1775	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	7.96	9.6	2.85	9.09
DCFRRQC	DM3WDZ5	MK-1775	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	4.91	3.49	2.48	7.63
DCJXCKO	DM3WDZ5	MK-1775	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	4.03	6.38	2.93	7.73
DCMVRXJ	DM3WDZ5	MK-1775	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	5.08	6.43	1.92	7.68
DCGA5J7	DM3WDZ5	MK-1775	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	3.07	2.16	0.16	4.25
DCPG0HL	DM3WDZ5	MK-1775	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	8.03	9.79	3.72	9.92
DCZRS2V	DM3WDZ5	MK-1775	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	2.94	0.54	1.32	3.83
DCMF756	DM3WDZ5	MK-1775	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	2.38	7.92	6.32	10.87
DC5YV74	DM3WDZ5	MK-1775	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	4.94	4.73	1.77	6.46
DCX10HL	DM3WDZ5	MK-1775	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	4.91	2.91	1.99	7.06
DCOSCKI	DM3WDZ5	MK-1775	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	7.61	9.98	0.6	9.79
DCS4AFH	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	0.4	7.54	8.22	10.5
DCZJ0WT	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	8.14	9.1	14.2	15.14
DCUOZ58	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	0.13	11.21	13.72	14.29
DCUXGOA	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	1.04	4.85	9.7	11.31
DCIAJFG	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	2.31	2	6.47	9.1
DC1H17C	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	2.58	7.11	7.4	7.87
DCV06I1	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	1.49	2.36	2.95	2.69
DCQH4L2	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	13.24	12.46	15.53	15.72
DCXKP27	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	3.2	1.83	5.07	6.46
DCB756T	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	12.39	8.98	13.11	14.28
DC789LA	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	9.7	9.11	12.09	13.25
DCOT6P6	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	3.35	6.3	10.02	10.02
DC1K916	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	12.48	13.2	15.19	15.35
DCZ0GA3	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	1.23	1.93	4.64	6.15
DCXL4GW	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	17.16	18.2	17.03	18.19
DCSSQGR	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	10.18	13.96	16.34	17.41
DCEX7IO	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	4.51	4.15	11.78	14.1
DC8UK48	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	6.54	8.98	1.63	12.87
DC94MO2	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	3.86	4.12	13.15	15.69
DCP6R64	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	10.45	17.55	15.8	16.63
DC66PPQ	DM3WDZ5	MK-1775	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	3.64	6.38	4.53	8.75
DCVCRTV	DM3WDZ5	MK-1775	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	12.48	12.89	2.53	15.02
DCCR8BU	DM3WDZ5	MK-1775	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	10.53	8.43	7.8	12.59
DCVLUHK	DM3WDZ5	MK-1775	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	1.86	2.39	0.25	5.61
DCPEGKM	DM3WDZ5	MK-1775	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	2.38	1.13	3.41	8.2
DCATC9J	DM3WDZ5	MK-1775	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	6.81	5.35	2.52	8.24
DC3TO8I	DM3WDZ5	MK-1775	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	4.6	4.99	2.89	7.5
DCUFY1O	DM3WDZ5	MK-1775	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	9.1	9.86	6.03	11.08
DC0R7FE	DM3WDZ5	MK-1775	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	19.13	18.69	11.48	23.55
DC68WMK	DM3WDZ5	MK-1775	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	8.93	8.75	13.76	18.31
DC23GGY	DM3WDZ5	MK-1775	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	5.12	1.31	4.73	8.9
DCX8T8L	DM3WDZ5	MK-1775	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	1.35	5.94	4.26	8.05
DC95KVY	DM3WDZ5	MK-1775	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	1.32	1.34	1.27	3.38
DCBLT1Y	DM3WDZ5	MK-1775	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	2.48	5.73	5.72	6.25
DC55GOH	DM3WDZ5	MK-1775	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	7.04	10.76	6.53	10.77
DCJH1GZ	DM3WDZ5	MK-1775	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	7.14	8.72	3.2	8.97
DCZ7HEJ	DM3WDZ5	MK-1775	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	6.3	6.65	2.84	7.89
DCKAAZK	DM3WDZ5	MK-1775	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	4.24	6.9	4.23	8.06
DCF99WB	DM3WDZ5	MK-1775	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	1.11	7.08	1.74	6.61
DCS42M7	DM3WDZ5	MK-1775	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	8.28	11.26	4.49	10.21
DCNOE2F	DM3WDZ5	MK-1775	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	2.53	4.98	4.23	6.69
DCT54QQ	DM3WDZ5	MK-1775	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	7.68	5.26	0.07	7.62
DCI9PTW	DM3WDZ5	MK-1775	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	1.17	2.94	2.46	5.24
DCF09Z3	DM3WDZ5	MK-1775	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	3.05	4.28	2.85	7.66
DC2F2UE	DM3WDZ5	MK-1775	Phase 2	21	DMODA2X	Bardoxolone methyl	Phase 3	25	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	U-HO1	31.48	31.48	7.9	12.09
DC65RBT	DM3WDZ5	MK-1775	Phase 2	21	DMP2BWX	Ispinesib	Phase 2	21	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	20.922	18.48	0.133	3.938
DCZ9JNY	DM3WDZ5	MK-1775	Phase 2	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	4.3	11.96	12.5	13.02
DC7HRPI	DM3WDZ5	MK-1775	Phase 2	21	DMPK32V	BMS-754807	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	14.877	14.372	16.19	18.082
DC0FTSA	DM3WDZ5	MK-1775	Phase 2	21	DMQL8XJ	Decitabine	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	10.338	9.961	3.46	5.44
DCL1V7Z	DM3WDZ5	MK-1775	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	13.39	8.77	15.01	1.26
DCPDEFK	DM3WDZ5	MK-1775	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	4.14	4.55	6.58	11.67
DCIP4TF	DM3WDZ5	MK-1775	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	7.63	9.52	5.42	12.74
DCT8WYP	DM3WDZ5	MK-1775	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	2.43	2.43	0.44	7.32
DCHC4Z3	DM3WDZ5	MK-1775	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	5.58	6.01	1.27	9.19
DCOBIGC	DM3WDZ5	MK-1775	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	3.57	4.13	1.25	8.16
DCXA45N	DM3WDZ5	MK-1775	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	8.79	7.29	5.89	13.39
DCME7R0	DM3WDZ5	MK-1775	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	0.95	3	0.94	7.4
DC9PTZ7	DM3WDZ5	MK-1775	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	2.32	3.9	0.65	6.6
DCWRI9F	DM3WDZ5	MK-1775	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	1.22	3.87	2.29	6.17
DCGCMO5	DM3WDZ5	MK-1775	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	4.99	4.96	5.49	8.02
DC143D3	DM3WDZ5	MK-1775	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	7.2	6.87	4.73	9.33
DCL1G3T	DM3WDZ5	MK-1775	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	1.97	2.25	2.62	8.85
DCUTN1D	DM3WDZ5	MK-1775	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	19.86	16.36	4.65	16.28
DCBFAPA	DM3WDZ5	MK-1775	Phase 2	21	DMSLE03	PF-562271	Phase 1	17	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	U-HO1	5.2	5.07	1.89	4.26
DCFC43W	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	0.68	1.39	0.39	4.27
DCCO6X0	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	16.31	19.06	23.98	26.2
DC7JPOQ	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	12.35	14.23	17.58	19.07
DCPF5PE	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	6.04	6.82	9.88	12.5
DC369HV	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	0.84	0.19	2.09	7.37
DC52IWZ	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	6.66	5.64	5.71	9.81
DCQHCN2	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	6.95	4.94	3.13	6.5
DCQJKT4	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	7.62	8.78	9.29	12.36
DCYS0LN	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	1.65	2.38	6.43	7.12
DCPZ8QH	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	8.21	7.03	8.99	11.65
DC3JZJ4	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	3.53	5.4	2.52	6.8
DC3R8WO	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	14.89	12.04	12.3	15.64
DCB8UL3	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	5.21	8.51	12.26	14.67
DCXGS5G	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	7.54	9.13	0.52	10.04
DCI0AK7	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	2.32	3.17	2.91	5.91
DCAUF9J	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	3.42	10.17	7.97	10.01
DCOP21X	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	13.33	13.33	11.76	18.67
DCK8X1R	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	7.52	6.54	11.8	13.09
DCDJCT3	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	5.37	5	11.46	14.02
DC9S7QC	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	3.58	2.8	2.59	6.45
DC1I7YU	DM3WDZ5	MK-1775	Phase 2	21	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	6.874	6.088	0.866	4.608
DCUMDKR	DM3WDZ5	MK-1775	Phase 2	21	DMTV4L7	CHS-828	Phase 1/2	19	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	5.337	4.358	0.497	4.86
DCWJYMY	DM3WDZ5	MK-1775	Phase 2	21	DMTYXQF	NVP-AUY922	Phase 2	21	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	21.605	18.733	0.867	5.002
DC9EKIB	DM3WDZ5	MK-1775	Phase 2	21	DMUKNQ5	AZD8330	Discontinued in Phase 1	3	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	8.728	11.212	6.163	12.537
DCLAEWE	DM3WDZ5	MK-1775	Phase 2	21	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	9.709	9.873	2.875	5.63
DC2YOAN	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	11.1	9.71	8.25	12.56
DCFOEF8	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	3.68	3.08	1.59	6.09
DCA5L2F	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	10.47	8.73	8.19	12.98
DCLTDUS	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	1.83	1.62	5.31	9.86
DC5QXMU	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	4.66	4.04	4.06	8.33
DC38FI7	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	2.2	1.95	1.01	4.47
DCATNB5	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	10.45	9.22	9.24	14.63
DCUCXMF	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	5.82	5.79	2.03	7.68
DC550KZ	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	5.23	0.3	3.53	7.28
DC2FGVX	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	0.236	6.698	2.451	4.467
DCK35VP	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	7	5.64	3.22	8.01
DCINHCD	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	2.67	1.69	1.78	3.16
DC2XHKH	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	11.24	7.5	2.42	10.16
DCP0V28	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	10.58	8.29	8.21	12.84
DCNALVK	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	11	10.12	6.98	11.7
DCXER2J	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	7.06	5.53	3.39	7.71
DCMC327	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	20.49	16.17	15.87	21.1
DCKQQTA	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	22.59	21.87	19.91	24.39
DCYHZFO	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	3.68	3.63	8.63	11.31
DCI5C9V	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	10.15	9.96	7.87	12.36
DCBK4TC	DM3WDZ5	MK-1775	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	3.55	3.83	1.76	6.18
DC2BAIJ	DM3WDZ5	MK-1775	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	1.99	2.6	4.16	9.14
DCPCIOP	DM3WDZ5	MK-1775	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	2.54	2.05	11.4	12.11
DCI9ORQ	DM3WDZ5	MK-1775	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	5.55	8.12	1.41	4.78
DC4XX4A	DM3WDZ5	MK-1775	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	0.25	3.2	3.4	6.31
DCW3TM8	DM3WDZ5	MK-1775	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	10.64	10.27	10.98	14.25
DCS4H28	DM3WDZ5	MK-1775	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	3.96	2.3	0.69	6.61
DCS1RPI	DM3WDZ5	MK-1775	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	2.87	2.99	5.94	8.58
DCTWNDY	DM3WDZ5	MK-1775	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	6.51	7.05	9.24	12.43
DCLS3W5	DM3WDZ5	MK-1775	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	1.09	1.21	2.14	4.13
DCWU01F	DM3WDZ5	MK-1775	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	18.23	14.79	21.48	23.68
DCN716R	DM3WDZ5	MK-1775	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	11.81	11.57	21.12	22.48
DC42N3Q	DM3WDZ5	MK-1775	Phase 2	21	DMZD5QR	Cytarabine	Approved	34	.	.	.	.	Ewing sarcoma	ALMANAC Dataset	Investigative	TC-71	16.332	15.444	2.409	6.425
DCJNFVQ	DM3WDZ5	MK-1775	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.52	0.87	3.1	3.19
DC0HRUI	DM3WDZ5	MK-1775	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.68	7.56	8.17	7.9
DCYBYGQ	DM3WDZ5	MK-1775	Phase 2	21	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.81	1.36	3.13	3.22
DCXGPKA	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	0.37	0.58	5.71	7.27
DC0HHQV	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	8.9	9.02	5.68	14.18
DCPXFEZ	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	5.33	9.77	5.69	12.45
DCLY0HZ	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.25	1.18	12.58	16.33
DC1BAGP	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.84	0.08	4.11	7.07
DCYH32Q	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.8	0.75	4.48	7.74
DCDU3HX	DM3WDZ5	MK-1775	Phase 2	21	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.43	7.04	8.8	10.05
DCWS3AK	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	6.61	5.74	12.73	14.29
DC4F2BU	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	17.62	17.89	23.08	25.11
DC06G64	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.21	4.89	1.11	7.62
DC3AKDF	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.09	2.82	4.21	8.66
DC89Z74	DM3WDZ5	MK-1775	Phase 2	21	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.45	7.17	0.18	1.71
DCAIH7B	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	5.15	10.81	14.64	16.07
DCQITCE	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	0.85	5.04	13.4	14.42
DCR4NH7	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.17	2.46	8.06	9.55
DCEVLLZ	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	8.55	6.4	1.02	10.96
DCD287V	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	5.54	7	0.5	10.35
DCLK4KW	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	9.67	14.03	4.91	18.23
DCY5C8B	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.11	2.97	5.75	9.17
DC0R11T	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	12.32	10.74	10.3	16.88
DCZOGE0	DM3WDZ5	MK-1775	Phase 2	21	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	13.23	12.77	10.65	16.74
DC1YOJN	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	7.6	3.73	8.41	5.98
DCK7EQI	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	12.98	17.82	11.19	18.43
DCZJPC2	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	11.88	12.73	11.43	14.49
DC58QG1	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.61	0.1	1.68	2.57
DCTN716	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	7.18	5	3.88	5.42
DCUD15Z	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.88	2.63	0.04	5.5
DCRJJBK	DM3WDZ5	MK-1775	Phase 2	21	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.76	0.79	2.03	2.96
DCVTOT1	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.96	2.5	0.9	8.34
DCBHNVH	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.06	2.93	6.17	7.87
DCKLEMV	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.16	3.69	0.38	7.72
DCZLMSY	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.19	6.26	4.29	9.87
DCANMCQ	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.98	2.33	8.37	10.4
DCVL1HK	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	16.24	16.89	19.6	22.45
DCFIU4D	DM3WDZ5	MK-1775	Phase 2	21	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.59	4.12	9.51	12.42
DC0IBEJ	DM3WDZ5	MK-1775	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.46	2.4	2.37	3.75
DCI0DOY	DM3WDZ5	MK-1775	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.59	1.68	1.23	4.32
DCYKCYG	DM3WDZ5	MK-1775	Phase 2	21	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.46	4.24	1.92	8.4
DCMMN8B	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	0.11	2.06	8.29	10.16
DCPCLUJ	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.77	2.07	4.06	8.27
DCBUPX3	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.54	5.04	7.2	12.28
DC0IWEK	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.73	2.73	3.24	6.57
DC6J8HT	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	8.83	7.7	15.18	17.23
DC39R1W	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.7	4.44	8.39	9.46
DCB4CSV	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.41	9.65	13.2	14.26
DC03UAA	DM3WDZ5	MK-1775	Phase 2	21	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.81	6.84	10.91	11.46
DCUP87O	DM3WDZ5	MK-1775	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	4.4	7.87	10.13	12.19
DC496QF	DM3WDZ5	MK-1775	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.43	4.15	5.17	8.92
DCQLKJA	DM3WDZ5	MK-1775	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	4.62	3.78	3.57	6.73
DCDDTV0	DM3WDZ5	MK-1775	Phase 2	21	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.21	6.11	2.84	10.71
DCM5GJK	DM3WDZ5	MK-1775	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	7.83	8.98	7.84	11.55
DC4SF4C	DM3WDZ5	MK-1775	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.32	1.57	0.74	2.35
DCMTJ7X	DM3WDZ5	MK-1775	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	0.66	0.45	3.78	5.72
DCHJWN9	DM3WDZ5	MK-1775	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.44	5.61	3.2	6.79
DCZG84X	DM3WDZ5	MK-1775	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.47	6.62	0.21	8
DCCJ2UW	DM3WDZ5	MK-1775	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.58	3.87	1.48	6.22
DC4JPT4	DM3WDZ5	MK-1775	Phase 2	21	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.11	4.29	0.92	4.83
DCK7PJ9	DM3WDZ5	MK-1775	Phase 2	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.38	12.28	10.89	12.18
DC4CW9F	DM3WDZ5	MK-1775	Phase 2	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	14.01	14.58	8.75	18.91
DC6K20C	DM3WDZ5	MK-1775	Phase 2	21	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.89	9.88	5.41	7.95
DCXTVMS	DM3WDZ5	MK-1775	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.86	2.67	0.37	6.4
DCOB8GX	DM3WDZ5	MK-1775	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	6.62	0.82	7.51	10.14
DCUBPCR	DM3WDZ5	MK-1775	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.91	3.1	0.5	8.66
DCOHX3C	DM3WDZ5	MK-1775	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	12.9	13.21	6.5	16.47
DCK9YXT	DM3WDZ5	MK-1775	Phase 2	21	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.37	6.95	9.6	10.33
DCHT9J8	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.25	4.07	10.92	12.9
DC2MXPD	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.06	1.61	7.85	11.44
DCCFBFL	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	13.31	13.52	7.7	18.19
DCIIOM2	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.88	3.23	9.89	11.19
DCQ1TMN	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	18.64	17.08	19.35	22.82
DCY9QLV	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.62	7.25	13.25	14.23
DCQ8DJH	DM3WDZ5	MK-1775	Phase 2	21	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.39	4.88	10.86	12.69
DCCVQIT	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.78	0.92	3.07	7.41
DCUHNEO	DM3WDZ5	MK-1775	Phase 2	21	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	9.48	8.36	8.21	13.88
DCV6ZA0	DM3WDZ5	MK-1775	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	0.41	1.22	7.41	5.27
DCBAEKF	DM3WDZ5	MK-1775	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.27	3.81	7.12	8.51
DC4HIXA	DM3WDZ5	MK-1775	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.1	3.44	4.92	6.96
DCPQITR	DM3WDZ5	MK-1775	Phase 2	21	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.24	6	7.95	10.57
DC5N9RD	DMRICNP	Vandetanib	Approved	34	DMZMSPF	Bicalutamide	Approved	34	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC5CROC	DMRICNP	Vandetanib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.62	7	8.28	8.56
DCX1ZSJ	DMRICNP	Vandetanib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.52	9.7	2	2
DCKWEFS	DMRICNP	Vandetanib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.33	6.73	0.26	0.26
DCFTW0A	DMRICNP	Vandetanib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.35	10.12	7.35	8.01
DCGUPTC	DMRICNP	Vandetanib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.23	6.58	6.12	9.62
DCDUF6C	DMRICNP	Vandetanib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.7	11.6	3.67	3.27
DC4R0ZO	DMRICNP	Vandetanib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.3	6.63	4.37	3.99
DC3W8NO	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	11.92	16.29	16.46	18.37
DCRSHFK	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.24	8.78	10.61	11.02
DCCIPNM	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.66	11.47	3.42	5.55
DCDELCM	DMRICNP	Vandetanib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.39	12.66	5.68	4.98
DCZR86Y	DMRICNP	Vandetanib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.17	9.93	6.77	5.98
DCD4Z53	DMRICNP	Vandetanib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.17	4.3	2.13	1.26
DC42VOV	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	14.76	21.67	21.33	21.33
DCX8WRY	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.11	10.08	10.23	9.95
DC9YCD1	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	10.22	18.21	17.16	17.16
DCDMK1K	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	43.64	42.92	38.89	35.1
DCKKO1A	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	37.76	37.12	34.09	34.09
DC7CFDY	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.29	6.53	5.26	5.88
DCA4334	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	13.26	21.21	18.46	18.83
DCWRJ3V	DMRICNP	Vandetanib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.24	8.77	0.96	0.78
DCEFF28	DMRICNP	Vandetanib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.33	13.55	6.86	6.84
DC4T004	DMRICNP	Vandetanib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.25	7.69	0.85	0.59
DCQH26D	DMRICNP	Vandetanib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.27	6.29	1.94	1.35
DCHJTZ5	DMRICNP	Vandetanib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.33	2.8	0.71	0.34
DCTE1T1	DMRICNP	Vandetanib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.01	4.14	0.42	2.09
DCJASU7	DMRICNP	Vandetanib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.61	2.74	0.05	0.06
DCSJ5JU	DMRICNP	Vandetanib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.55	10.89	9.82	7.93
DCJSGYE	DMRICNP	Vandetanib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.83	5.43	4.86	0.83
DC8F3HR	DMRICNP	Vandetanib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.69	6.68	4.93	3.45
DCMXU67	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	28.77	28.36	29.25	29.22
DC8EG5B	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.94	7.27	8.13	8.24
DC4MX92	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	14.45	20.64	19.41	20.19
DCFG64T	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	34.33	35.55	28.85	27.54
DC1ZUME	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	34.37	27.09	24.33	24.05
DCXL1JX	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	29.14	25.35	18.25	18.77
DCSVKD2	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	33.3	31.52	29.44	29.17
DC075PN	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	22.8	26.22	25.26	25.79
DCORHX7	DMRICNP	Vandetanib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.39	13.12	5	3.49
DCLTHTB	DMRICNP	Vandetanib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.98	11.09	4.19	3.89
DCH2LA1	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	8.24	10.4	10.74	11.9
DCMRAUT	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.77	4.56	1.47	1.77
DCPCLRE	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	6.43	6.25	2.13	4.36
DCFL2UT	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.4	9.78	2.17	3.87
DC54MHH	DMRICNP	Vandetanib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.5	6.74	5.35	4.82
DCMQLV9	DMRICNP	Vandetanib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.91	8.33	1.56	1.56
DCZBK7S	DMRICNP	Vandetanib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.51	4.8	0.59	5.23
DCMIGPZ	DMRICNP	Vandetanib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.84	10.14	2.57	1.16
DCFLRD3	DMRICNP	Vandetanib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.95	8.78	5.87	6.32
DCCB80Z	DMRICNP	Vandetanib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.22	10.37	0.56	3.46
DCSS1WG	DMRICNP	Vandetanib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.81	2.51	3.89	5.4
DCTMZSR	DMRICNP	Vandetanib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.65	2.1	3.22	3.56
DCTW40Q	DMRICNP	Vandetanib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.24	11.69	3.87	3.99
DC8ZNPZ	DMRICNP	Vandetanib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.37	8.09	5.04	5.11
DCJL25C	DMRICNP	Vandetanib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.3	7.82	1.31	1.25
DCDSV79	DMRICNP	Vandetanib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.9	7.51	5.38	5.27
DC526L0	DMRICNP	Vandetanib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.71	7.25	3.19	2.65
DC7HL3J	DMRICNP	Vandetanib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	9.66	8.68	1.51	1.14
DCMHOXJ	DMRICNP	Vandetanib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.39	2.27	0.16	0.06
DC2Y879	DMRICNP	Vandetanib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.95	8.74	2.36	2.74
DC0J7WF	DMRICNP	Vandetanib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.34	6.62	1.34	7.87
DCC4M9B	DMRICNP	Vandetanib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	8.56	8.41	8.99	10.58
DCVYXDD	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.82	9.59	6.89	8.69
DCEE2LU	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.67	10.75	12.84	13.76
DCKH37N	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.73	10.69	2.98	1.42
DC64N34	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.03	9.09	2.04	1.22
DCNRGWE	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.08	4.68	2.07	1.16
DCGSGJY	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.66	6.27	6.67	7.61
DC8IE6B	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.37	9.05	0.11	8.94
DCTE6CM	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	8.06	10.14	4.37	8.17
DCK8R5H	DMRICNP	Vandetanib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.67	5.75	4.24	7.43
DC8I1CW	DMRICNP	Vandetanib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	15.02	20.62	12.11	17.09
DCXSGZG	DMRICNP	Vandetanib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	10.59	12.63	4.74	10.76
DCSOXXS	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	13.1	12.06	3.94	9.32
DCVBP3C	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.13	6.56	1.27	9.14
DCS7GZF	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.88	15.69	0.49	10.79
DCG2336	DMRICNP	Vandetanib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.36	7.86	6.66	4.99
DCAT2GY	DMRICNP	Vandetanib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.88	11.23	4.46	4.46
DC8G0E4	DMRICNP	Vandetanib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.28	5.82	4.91	5.55
DCKNKR9	DMRICNP	Vandetanib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	10.64	13.35	9.31	10.58
DCYXEL5	DMRICNP	Vandetanib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.62	15.5	8.88	8.88
DCD1CJX	DMRICNP	Vandetanib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	6.04	13.23	11.22	10.78
DC2UXFS	DMRICNP	Vandetanib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.62	7.34	5.86	9.95
DCCO64G	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	14.38	18.08	2.82	18.5
DCI311E	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	14.38	12.28	0.82	9.67
DCQ6T3N	DMRICNP	Vandetanib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.19	4.37	4.13	4.88
DCWMXHC	DMRICNP	Vandetanib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.59	3.93	4.84	5.58
DC73R4L	DMRICNP	Vandetanib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.45	8.3	8.75	10.03
DCRSWT7	DMRICNP	Vandetanib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0	7.26	1.02	1.43
DCGNJEC	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	21.36	20.4	3.16	22.16
DCNZ1HL	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.89	7.88	9.43	10.92
DCJAPOL	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	21.14	20.77	9.67	18.36
DCV6QT3	DMRICNP	Vandetanib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.6	2.54	1.08	1.95
DCYLAS0	DMRICNP	Vandetanib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.3	8.8	2.14	1.86
DCG8RH2	DMRICNP	Vandetanib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.92	8.64	5.83	5.84
DCI3H85	DMRICNP	Vandetanib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.69	3.86	0.64	3.98
DC2ZCZN	DMRICNP	Vandetanib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.68	8.53	1.31	0.44
DCN0F3L	DMRICNP	Vandetanib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.28	7.62	5.48	5.14
DC368YM	DMRICNP	Vandetanib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.19	16.38	6.14	10.3
DCXU3HF	DMRICNP	Vandetanib	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	9.59	13.84	5.9	4.58
DCEBMPJ	DMRICNP	Vandetanib	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.95	7.13	0.47	0.47
DC7W8WD	DMRICNP	Vandetanib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.81	12.55	4.51	3.83
DCYRDDQ	DMRICNP	Vandetanib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.94	8.06	5.89	5.08
DCV78DD	DMRICNP	Vandetanib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.44	7.18	2.52	1.86
DC542BR	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	7.69	10.07	11.24	11.51
DCJO42M	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	11.86	11.82	6.49	9.25
DCWNKD6	DMRICNP	Vandetanib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.75	10.25	3.61	3.61
DC9SKDB	DMRICNP	Vandetanib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.77	2.05	2.76	2.95
DCLMO9T	DMRICNP	Vandetanib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.14	3.42	3.32	4.16
DCABH4F	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	7.21	12.09	11.92	12.47
DCBAVHJ	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	18.54	18.74	11.31	12.84
DCDU964	DMRICNP	Vandetanib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.61	5.87	5.73	6.3
DCPIY83	DMRICNP	Vandetanib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.96	4.27	1.25	2.17
DC0S521	DMRICNP	Vandetanib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.16	10.89	4.38	4.38
DCPZ987	DMRICNP	Vandetanib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	7.06	7.82	9.21	9.8
DCPI7RJ	DMRICNP	Vandetanib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.01	3.42	4.87	6.34
DCB0YTR	DMRICNP	Vandetanib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	12.35	12.94	7.51	7.85
DC8W77D	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	9.42	9.34	4.57	10.32
DCFE45O	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.82	8.45	0.93	10.49
DCDU302	DMRICNP	Vandetanib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.1	4.62	2.58	5.53
DCFJO2Z	DMRICNP	Vandetanib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	12	15.38	6.97	4.47
DCO1IBA	DMRICNP	Vandetanib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.86	7.82	3.81	4.86
DCMSMOY	DMRICNP	Vandetanib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.75	13.61	6.88	6.74
DCACGPO	DMRICNP	Vandetanib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.58	6.77	4.07	3.18
DCYVH5W	DMRICNP	Vandetanib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.88	4.05	1.1	1.1
DCTVBD4	DMRICNP	Vandetanib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.73	5.65	3.5	3.06
DCAYAEY	DMRICNP	Vandetanib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.12	7.95	2.63	7.03
DCR2DP5	DMRICNP	Vandetanib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.86	9.45	9.73	1.68
DCTS8CY	DMRICNP	Vandetanib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.85	9.66	2.86	1.26
DCS4QJT	DMRICNP	Vandetanib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.27	10.46	10.42	4.72
DCFU5G8	DMRICNP	Vandetanib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.43	7.23	2.47	4.97
DCW2YWH	DMRICNP	Vandetanib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	7.49	9.26	6.31	0.57
DC383PG	DMRICNP	Vandetanib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.38	9.77	3.33	3.19
DCHPB47	DMRICNP	Vandetanib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.18	9.55	7.65	9.78
DCIJZTA	DMRICNP	Vandetanib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.16	10.14	8.02	7.81
DCM02ZL	DMRICNP	Vandetanib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	4.64	8.43	8.98	10.52
DCHNYWB	DMRICNP	Vandetanib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.9	4.85	5.03	5.37
DC94MPY	DMRICNP	Vandetanib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.61	3.92	3.2	5.05
DC1T5R1	DMRICNP	Vandetanib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.7	9.39	1.9	2.51
DCC3OQA	DMRICNP	Vandetanib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.94	8.3	1.62	2.63
DCBEG8M	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.92	1.96	3.42	3.65
DCT445E	DMRICNP	Vandetanib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	23.05	21.55	13.87	15.04
DCO73AM	DMRICNP	Vandetanib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.63	5.44	3.41	0.72
DC7OVNJ	DMRICNP	Vandetanib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.44	4.61	7.02	7.79
DCEX87T	DMRICNP	Vandetanib	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	1.32	9.28	3.14	3.22
DCCH70O	DMRICNP	Vandetanib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	2.8	10.07	9.56	10.28
DCMX7CK	DMRICNP	Vandetanib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.8	5.26	3.7	2.38
DCWHKSH	DMRICNP	Vandetanib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.24	3.64	0.73	0.79
DC257UP	DMRICNP	Vandetanib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	0.21	3.41	4.63	4.85
DCPWUJ8	DMRICNP	Vandetanib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.38	9.67	6.85	5.99
DCPKOPK	DMRICNP	Vandetanib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.14	3.62	1.76	1.57
DCDT3XY	DMRICNP	Vandetanib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	3.11	8.89	5.13	3.61
DCB1U7K	DMRICNP	Vandetanib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.61	9.8	2.41	8.55
DCBWOAU	DMRICNP	Vandetanib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.63	6.16	1.67	5.16
DCCBN2E	DMRICNP	Vandetanib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.74	3.63	0.6	1.02
DCEYZ4F	DMRICNP	Vandetanib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	2.48	9.71	3.82	6.9
DCQHW3J	DMRICNP	Vandetanib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.33	6.53	3.59	2.92
DCOL5O1	DMRICNP	Vandetanib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	3.03	6.49	5.18	3.39
DCC073A	DMRICNP	Vandetanib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	0.64	4.52	5.14	5.14
DCOYMGG	DMRICNP	Vandetanib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	3.02	6.09	7.07	7.11
DCS8OS3	DMRICNP	Vandetanib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	3.17	6.08	1	1
DCMGQ0Q	DMRICNP	Vandetanib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	2.75	10.2	7.23	6.83
DCAQW3W	DMRICNP	Vandetanib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.31	3.89	2.38	4.38
DC6WD7X	DMRICNP	Vandetanib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.88	4.2	2.49	3.03
DCZNHES	DMRICNP	Vandetanib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.66	2.75	5.88	5.98
DCE5R9T	DMRICNP	Vandetanib	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	1.32	6.38	8.04	8.18
DCOQSAO	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.71	9.82	14.18	14.67
DC45NA3	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.82	2.64	6.58	7.44
DCE8Y87	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.53	3.29	2.06	4.36
DC1DLR7	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	13.26	14.48	15.1	16.94
DCR65IJ	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	5.14	7.65	8.51	8.88
DCJ3ZN3	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	5.01	9.64	1.64	2.48
DC5VZ1U	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	5.31	8.3	6.63	9.4
DCO6H5B	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	10.02	14.63	11.86	12.72
DCWE7RY	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	17.38	17.72	13.75	15.07
DCUIGWN	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	5.21	8.57	2.91	7.96
DCZPNOM	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	15.94	12.81	5.94	13.84
DC2KYK8	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	6.81	8.54	11.45	13.82
DCQOGJZ	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	6.22	11.75	12.96	14.01
DC7CYH5	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	2.05	3.43	6.93	9.32
DC70PY9	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	13.6	12.97	5.87	8.68
DC4YN9X	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	19.68	20.79	18.54	18.02
DC0HGN8	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	1.01	7.24	9.22	9.33
DCO2FND	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.6	5.56	7.22	9.08
DC4HZS9	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.13	8.19	7.42	8.69
DCRO3MC	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.25	2.87	4.49	7.37
DC7GFTN	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.68	10.62	11.92	12.56
DCK9P0P	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	16.44	17.07	17.54	17.47
DC0II00	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.75	12.07	6.24	10.36
DC8SMH3	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.08	7.55	5.75	7.42
DC1646M	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.84	6.07	6.88	11.96
DCE8WZG	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	8.06	8.21	11.74	12.3
DCID8TQ	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.45	7.97	10.25	12.48
DCD76IS	DMRICNP	Vandetanib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	9.44	12.08	2.98	7.44
DCHMI2M	DMRICNP	Vandetanib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.68	9.76	3.61	10.01
DCX28F1	DMRICNP	Vandetanib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4	7.98	5.9	1.72
DCJD7CA	DMRICNP	Vandetanib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	6.55	11.67	2.32	1.61
DC3GZ6Q	DMRICNP	Vandetanib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	4.75	5.06	3.59	9.72
DCOFCWS	DMRICNP	Vandetanib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.46	5.47	0.85	0.13
DCJZC0C	DMRICNP	Vandetanib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	4.52	8.42	4.64	3.12
DCG7YNV	DMRICNP	Vandetanib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	5.02	8.54	3.37	0.98
DCNBF07	DMRICNP	Vandetanib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	13.69	18.67	11.36	11.09
DCU42TX	DMRICNP	Vandetanib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.22	4.94	2.94	0.9
DCU2R8N	DMRICNP	Vandetanib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.9	5.85	2.94	2.9
DCZLAGD	DMRICNP	Vandetanib	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	3.54	7.87	3.14	2.32
DC6P6VQ	DMRICNP	Vandetanib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.29	7.74	1.22	9
DCB8BLP	DMRICNP	Vandetanib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	1.76	4.02	3.15	3.51
DCHP04P	DMRICNP	Vandetanib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	5.69	7.62	7.75	7.2
DCY6JUY	DMRICNP	Vandetanib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.33	0.88	0.88	0.93
DC2C93N	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	7.08	12.03	10.62	10.7
DCXSMS7	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	16.15	21.02	21.2	21.18
DCLJRPS	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.49	6.55	6.3	6.21
DC7BUP2	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.99	8.84	8.12	8.01
DCP57NJ	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	23.31	27.19	25.7	25.51
DCU33X4	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	4.31	6.29	6.68	6.61
DCSFDQO	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	32.61	30.84	28.83	28.73
DCZNYIF	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	15.77	19.89	10.36	17.44
DCRH0XR	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	39.08	40.57	39.2	40.54
DCIX1VA	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	8.6	12.74	12.22	9.83
DC9FO52	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	13.01	23.51	19.94	21.11
DCPGAXS	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	41.78	38.65	19.89	38.76
DCBCTBV	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	13.9	16.42	17.15	16.71
DCK5ZH6	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	32.04	31.8	31.59	31.41
DCII7EL	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	6.77	14.27	13.96	13.98
DCLD97O	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	14.29	10.5	11.14	11.22
DCNBBO0	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	1.61	12.18	10.49	10.65
DC7OAF4	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	25.37	26.21	26.1	26.09
DC492HV	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	4.17	9.47	8.7	8.69
DCW8WR1	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	21.81	19.6	21.16	20.48
DC33OXX	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	9.33	17.9	11.84	12.77
DC4XZU7	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	15.25	21.33	19.14	17.4
DCV1K6P	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	1.96	8.94	8.81	8.9
DCHAKXK	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	6.02	14.82	15.88	15.61
DCLPHIR	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	7.07	12.37	8.4	9.14
DCRIP4G	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	9.02	16.78	17.22	17.23
DCMOTYB	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	10.26	18.65	18.01	18.06
DCR5LRK	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.98	4.34	4.4	3.87
DCZ1RI8	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	27.87	29.07	28.78	28.87
DCGP1GM	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	11.61	15.43	14.19	14.22
DCIMQWK	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	5	6.03	7.53	6.54
DCEJZSL	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.84	8.42	8.43	7.95
DCDVA5S	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.43	6.05	5.17	5.61
DCZC3NY	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.68	10.82	10.67	10.51
DCEW6R5	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	12.57	17.68	17.89	17.82
DCY1MLK	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.74	14.56	15.69	15.24
DCHUN2Z	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	13.84	21.85	14.35	18.01
DCXKD7A	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	5.56	14.39	12.86	13.03
DCGOXP8	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.66	10.91	9.98	10.06
DCDYUGG	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.41	8.12	7.45	7.67
DCL44UT	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	7.31	11	11.77	11.36
DCO68HR	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	12.63	20.6	21.09	20.99
DCMEG9X	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	36.84	34.61	28.26	28.9
DCHZ4EA	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.64	13.39	13.22	12.7
DCGG4WB	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	7.7	13.66	13.85	13.52
DCAOFKB	DMRICNP	Vandetanib	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	3.45	9.42	10.08	9.97
DCYXQPQ	DMRICNP	Vandetanib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	1.96	5.22	3.76	1.7
DCULRGO	DMRICNP	Vandetanib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	3.12	5.06	1.55	5.38
DCM9ORN	DMRICNP	Vandetanib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	3.75	5.51	1.17	0.3
DCCW9DE	DMRICNP	Vandetanib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	2.89	3.42	0.25	0.19
DCHKH6P	DMRICNP	Vandetanib	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	3.05	10.13	8.67	3.97
DCTHGJS	DMRICNP	Vandetanib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.71	5.53	8.27	6.17
DCJU5LU	DMRICNP	Vandetanib	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4.83	4.52	0.42	8.35
DC0KO67	DMRICNP	Vandetanib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	15.26	19.83	2.24	13.68
DCILISJ	DMRICNP	Vandetanib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	14.98	17.7	18.11	19.11
DCB4HLS	DMRICNP	Vandetanib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.52	0.1	3.73	3.5
DCDABXL	DMRICNP	Vandetanib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.2	6.77	5.4	6.91
DC0BRVR	DMRICNP	Vandetanib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	8.34	13.94	10.39	12.75
DCP4TRJ	DMRICNP	Vandetanib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	2.8	4.8	4.67	4.94
DCSINZ8	DMRICNP	Vandetanib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	3.99	8.34	1.78	6.91
DCW6BTG	DMRICNP	Vandetanib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	2.13	5	3.39	8.65
DC0K812	DMRICNP	Vandetanib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	6.41	5.77	1.99	0.33
DCOI8UN	DMRICNP	Vandetanib	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.93	6.97	5.65	5.78
DCSRJRE	DMRICNP	Vandetanib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	10.41	10.3	3.01	3.01
DCTPAU3	DMRICNP	Vandetanib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	0.16	2.69	2.18	2.04
DCQ01OU	DMRICNP	Vandetanib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	0.63	6.72	5.44	6.68
DCHGR0Z	DMRICNP	Vandetanib	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	1.88	7.56	7.38	8.51
DCR9TFG	DMRICNP	Vandetanib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.17	6.52	1.34	5.93
DCNJQD9	DMRICNP	Vandetanib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.77	6.49	3.19	1.6
DC4S4TJ	DMRICNP	Vandetanib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	4.28	13.69	11.27	12.64
DCCX81Z	DMRICNP	Vandetanib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.84	9.34	7.25	1.43
DCV0LXJ	DMRICNP	Vandetanib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.91	6.58	1.27	0.95
DCIW5GI	DMRICNP	Vandetanib	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.54	7.31	2.24	2.24
DCC47IA	DMRICNP	Vandetanib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.96	6.95	0.74	4.02
DCI23QT	DMRICNP	Vandetanib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	2.56	1.88	2.47	2.66
DCWHA02	DMRICNP	Vandetanib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3	5.85	2.72	1.03
DCPSVSO	DMRICNP	Vandetanib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.34	5.54	0.52	0.52
DCJSPZJ	DMRICNP	Vandetanib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	1.93	5.33	2.54	2.07
DCTTD03	DMRICNP	Vandetanib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.36	4.11	2.54	1.84
DCQRN17	DMRICNP	Vandetanib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	3.54	7.81	4.37	1.45
DC1IZT9	DMRICNP	Vandetanib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.09	5.1	1.28	0.5
DCW52RL	DMRICNP	Vandetanib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	11.24	15.67	6.43	4.47
DC2UZ7X	DMRICNP	Vandetanib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	4.3	11.03	10.51	10.89
DCQ119I	DMRICNP	Vandetanib	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.2	5.02	2.24	0.32
DCTY02U	DMRICNP	Vandetanib	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	1.95	2.69	0.8	0.54
DCCHCUH	DMRICNP	Vandetanib	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.93	5.96	3.19	2.99
DC9FINR	DMRICNP	Vandetanib	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.32	2.51	0.64	0.56
DCC509I	DMRICNP	Vandetanib	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	0.38	4.52	0.3	0.46
DC2KTUU	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	18.51	22.54	23.63	23.64
DC1RR2M	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.44	5.98	6.32	6.25
DC2MQOI	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.04	5.98	4.6	4.71
DC0N9PP	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	6.19	14.23	5.85	7.28
DCYRQMC	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	14.26	20.83	20.77	20.33
DC4A7V8	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	20.48	25.85	23	22.97
DCMGISY	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	23.82	21.28	19.37	18.85
DC4V16Y	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	13.05	16.73	4.22	16.27
DCRV7HJ	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	29.24	28.28	29.42	29.14
DC16JX9	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	26.83	23.95	24.35	24.32
DCTSJJX	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	0.36	4.77	4.22	4.34
DCU3OPO	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	11.67	12.66	12.67	13.06
DCXJP64	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	17.28	18.79	18.67	19.15
DCX5T9P	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	11.39	14.33	15.05	16.12
DC1CX8P	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	9.82	16.31	15.43	16.76
DCESLPW	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	12.66	17.6	19.44	20.93
DC9749A	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	35.87	35.36	32.47	31.06
DCM0HO4	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	30.95	29.22	22.91	24.09
DC5ITWK	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	16.25	19.03	18.52	19.58
DCMCFDA	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	3.22	6.29	3.07	3.07
DC7VTDP	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	17.16	16.69	16.95	17.01
DCL880I	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	23.23	24.29	25.64	25.68
DCWYWBU	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.69	6.1	8.23	7.64
DCLGCPM	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	28.99	27.7	28.11	28.03
DC3CCR0	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	28.53	27.56	27.93	28.2
DC8T1LI	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.11	5.34	4.66	4.94
DCMN2WW	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.67	12.07	12.62	12.5
DCYWALF	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.79	5.09	4.19	4.38
DCPUVQO	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	35.03	32.54	30.6	30.01
DCSJF9W	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	17.84	16.67	16.84	16.13
DCF0Q6H	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	7.66	10.52	9.2	10.17
DCHXIWX	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.26	10.38	8.42	10.16
DCIQWLL	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	10.46	16.5	16.9	17.76
DCFBSJ0	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	34.9	34.21	30.93	28.52
DCAQR6T	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.88	7.26	6.95	7.03
DCFH1B7	DMRICNP	Vandetanib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	2.68	5.68	5.45	6.41
DCA16JD	DMRICNP	Vandetanib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.58	5.31	1.63	1.33
DCCKT5F	DMRICNP	Vandetanib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.5	6.18	4.75	3.16
DCSTYHL	DMRICNP	Vandetanib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	3.28	8.36	0.23	2.91
DCIYXI9	DMRICNP	Vandetanib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	10.6	9.43	8.15	11.12
DC4Y4RW	DMRICNP	Vandetanib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	4.74	6.48	10.79	10.99
DC7YDL2	DMRICNP	Vandetanib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.42	5.16	1.28	0.08
DCGK7UV	DMRICNP	Vandetanib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	2.56	3.79	0.5	0.09
DCKP29A	DMRICNP	Vandetanib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.09	8.03	1.9	4.51
DCLKO24	DMRICNP	Vandetanib	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	9.11	7.14	9.89	7.1
DCUQXKL	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.39	3.99	2.31	3.82
DCFOR1P	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.99	6.16	1.35	6.52
DCJLPP4	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	3.11	3.47	3.32	4.84
DCSDH0C	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.93	6.98	3.88	3.8
DCJBO0K	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	3.68	4.48	2.53	5.46
DCUBY3T	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	7.94	9.89	9.12	9.93
DCINM2H	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	7.51	7.25	7.03	8.05
DC3QS4G	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	7.02	6.9	3.39	12
DC9M9E4	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	2.55	3.59	2.9	4.27
DCSXO09	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	6.21	5.62	0.59	2.9
DC9KJ71	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	5.54	6.28	5.67	7.59
DCV2SS6	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	8.52	9.17	2.92	9.77
DCGRZFS	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.51	8.78	10.48	11.24
DCCZR9X	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.28	4.85	5.85	8.2
DCQIAYL	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.29	3.52	4.06	6.69
DCGC856	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	0.32	1.25	2.63	4.28
DCLKLWO	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	11.89	11.56	3.73	7.07
DCRP00L	DMRICNP	Vandetanib	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	6.93	9.55	11.36	12.33
DCHAGX9	DMRICNP	Vandetanib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	17.62	22.57	15.27	16.19
DCC06QY	DMRICNP	Vandetanib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.73	5.31	3.68	0.85
DCGJLBZ	DMRICNP	Vandetanib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.52	8.96	3.73	3.56
DC1EUX8	DMRICNP	Vandetanib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	1.44	5.8	2.22	2.49
DC9V67R	DMRICNP	Vandetanib	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.17	4.08	1.69	1.08
DC59VPU	DMRICNP	Vandetanib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	6.89	9.53	2.23	1.09
DCJHAV6	DMRICNP	Vandetanib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	0	6.58	4.53	5.91
DCMY0L9	DMRICNP	Vandetanib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	7.63	6.49	0.59	3.55
DCT741H	DMRICNP	Vandetanib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	3.25	6.92	2.51	1.66
DCPBGJP	DMRICNP	Vandetanib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.27	8.23	2.67	3.91
DCRSUFZ	DMRICNP	Vandetanib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.47	7.13	4.52	6.57
DC80HS3	DMRICNP	Vandetanib	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.83	11.18	9.35	7.62
DC7UA8P	DMRICNP	Vandetanib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	8.47	7.12	3.64	7.08
DC8C8K1	DMRICNP	Vandetanib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	2.99	2.02	0.42	3.44
DC1HNBI	DMRICNP	Vandetanib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	5.25	6.23	7.25	9.98
DCVOLQX	DMRICNP	Vandetanib	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	1.05	3.9	4.93	5.53
DC7P5K1	DMRICNP	Vandetanib	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.73	1.34	0.41	0.81
DCWFSCN	DMRICNP	Vandetanib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.52	4.36	0.98	6.22
DCUDB8C	DMRICNP	Vandetanib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	7.92	7.9	2.32	9.29
DCYXNG2	DMRICNP	Vandetanib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	5	4.08	0.41	9.97
DCJOUIH	DMRICNP	Vandetanib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.03	4	0.15	5.48
DCYT4XJ	DMRICNP	Vandetanib	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.11	3.05	3.32	6.45
DC1SNWR	DMRICNP	Vandetanib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.06	4.67	4.71	4.16
DC08761	DMRICNP	Vandetanib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.08	2.6	0.71	4.79
DCPZ87G	DMRICNP	Vandetanib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	5.4	11.74	10.51	10.97
DCINSQ4	DMRICNP	Vandetanib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	1.5	5.98	4.06	3.27
DC2EYRB	DMRICNP	Vandetanib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	3.48	11.1	11.23	10.03
DCFKAGU	DMRICNP	Vandetanib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	4.58	10.19	4.19	10.14
DC66YTU	DMRICNP	Vandetanib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	3.72	8.23	3.02	3.13
DCEH60K	DMRICNP	Vandetanib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.47	8.46	5.76	4.76
DCTGNHR	DMRICNP	Vandetanib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	1.68	5.69	2.66	2.44
DCZ748W	DMRICNP	Vandetanib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.48	5.96	3.57	2.35
DCCXAN8	DMRICNP	Vandetanib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	6.03	7.68	0.82	8.12
DCLO9Y4	DMRICNP	Vandetanib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	10.67	12.01	7.84	6.23
DC8VZ9E	DMRICNP	Vandetanib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.95	5.04	1.29	0.08
DCF8HCF	DMRICNP	Vandetanib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	13.41	19.78	19.91	19.64
DCXA71B	DMRICNP	Vandetanib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	1.94	11.82	8.55	8.55
DCMLQPH	DMRICNP	Vandetanib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.31	8.52	4.24	7.54
DCS3ZJT	DMRICNP	Vandetanib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.41	2.4	0.6	0.37
DCN8ZBY	DMRICNP	Vandetanib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	33.04	35.73	31.09	30.88
DC5T7EG	DMRICNP	Vandetanib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.35	4.99	8.37	9.36
DC73WJG	DMRICNP	Vandetanib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.34	5.17	1.28	5.3
DCXDCG6	DMRICNP	Vandetanib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.37	8.09	3.41	8.22
DC556PR	DMRICNP	Vandetanib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	5.94	7.67	5.79	7.43
DCT9YZV	DMRICNP	Vandetanib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	4.97	7.56	8.05	9.99
DCLEIU3	DMRICNP	Vandetanib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	16.2	16.43	10.8	11.45
DCX5HF4	DMRICNP	Vandetanib	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	6.11	6.86	4.42	6.92
DC2M5NV	DMRICNP	Vandetanib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6.47	5.04	1.71	7.87
DC6G4IM	DMRICNP	Vandetanib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	8.3	8.15	5.54	8.64
DCBEPWP	DMRICNP	Vandetanib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	15.44	14.93	10.94	15.15
DCZZ3FG	DMRICNP	Vandetanib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.03	3.88	1.55	3.22
DCG6T53	DMRICNP	Vandetanib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	9.04	7.53	6.11	8.32
DC9L3NY	DMRICNP	Vandetanib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	2.6	2.79	0.09	3.41
DC7QY1Z	DMRICNP	Vandetanib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	6.94	7.2	6.59	8.99
DCW7LVJ	DMRICNP	Vandetanib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	10.59	9.44	0.55	11.54
DCWFT5F	DMRICNP	Vandetanib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	3.23	7.72	6.76	10.68
DCY7M26	DMRICNP	Vandetanib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.35	3.92	5.25	6.07
DC9PBT3	DMRICNP	Vandetanib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	7.26	8.13	9.36	10.67
DCM6K3Y	DMRICNP	Vandetanib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	9.16	9.84	7.45	11.57
DCPLE49	DMRICNP	Vandetanib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	6.29	11.34	3.12	14.91
DCOZNSN	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.56	8.71	1.99	5.46
DCI11V7	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.79	7.02	1.07	3.93
DCA0K7Q	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	5.65	11.81	10.53	11.78
DCJMAXD	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.21	6.21	4.08	4.23
DC0KNX7	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.9	12.6	1.1	7.9
DCQTURI	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.76	6.35	1.5	3.59
DC2JVUW	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	11.18	16.12	8.44	7.07
DCUHO7R	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	0.56	7.23	5.14	6.14
DCHZQCY	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	5.18	11.32	9.29	6.25
DCSPHPX	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.07	9.72	6.76	6.56
DC8C86D	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	2.04	3.39	3.51	1.99
DCSI7S2	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	4.49	8.22	5.22	7.03
DCDHSZV	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	2.6	10.95	3.8	7.11
DCFS31C	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	5.55	6.59	4.86	5.87
DC8P00M	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	0.85	5.91	4.8	7.34
DCAR30Y	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	7.52	10.08	4.19	3.05
DCSHOF8	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	10.76	16.66	12.06	11.32
DCHTIKL	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	9.79	5.58	2.23	1.25
DC8WOE4	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.01	7.97	4.59	7.25
DCJ2A28	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	6.63	5.27	0.87	3.9
DC87WQD	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	7.24	12.13	6.64	8.85
DCZ3KAU	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.36	8.04	3.18	6.54
DCBQVWI	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.4	3.8	0.72	1.59
DCO1LRA	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	5.18	10.03	7.12	6.82
DCFS4UA	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.17	6.54	4.31	7.53
DCQA3ZR	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	9.17	18.54	9.96	8.72
DC7LA5I	DMRICNP	Vandetanib	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.39	6.52	5.84	6.45
DCLDPIA	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	15.4	15.27	13.85	15.66
DC2A9TW	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	5.2	2.02	4.64	3.68
DCO5G5L	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.01	3.92	1.07	3.24
DC4N2LB	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	29.46	10.6	1.22	3.72
DCGTLX4	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	9.3	12.12	11.73	12.53
DCQHST9	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	12.17	14.79	3.56	11.56
DCXUNAY	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	11.19	13.04	2.76	12.35
DCPF9VR	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	5.44	1.81	2.97	3.34
DC8B37G	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	6.34	7.95	4.91	9.66
DC99CIK	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	1.63	8.54	7.09	10.42
DCYC2Q9	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	9.83	14.45	5.95	11.04
DCG0Y4M	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	6.81	11.08	2.37	10.12
DCKR8FU	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.32	6.49	0.2	7.38
DC50HLW	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	13.98	13.3	14.52	14.23
DCB2I4F	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.69	12.35	13.31	13.31
DC5UAN4	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	6.68	8.87	3.14	8.16
DCKZCIB	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	10.42	14.79	10.65	14.09
DCTMSZ0	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	9.7	10.53	12.3	12.67
DCIM4G6	DMRICNP	Vandetanib	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	0.22	6.63	6.09	6.63
DCZD233	DMRICNP	Vandetanib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.31	3.89	5.32	7.92
DCHVXK8	DMRICNP	Vandetanib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.83	6.07	4.26	6.03
DCHQBUD	DMRICNP	Vandetanib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	2.71	2.67	0.05	4.05
DC1KCWA	DMRICNP	Vandetanib	Approved	34	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.57	6.69	5.03	6.94
DC7OVAO	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6.95	6.41	4.42	11.79
DCEBND3	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.69	2	1.56	3.7
DCX77QR	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.43	5.22	3.59	5.6
DCS4XQS	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	9.46	8.83	9.94	13.19
DCKWWCI	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.69	7.21	4.95	7.96
DCAOUMQ	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.39	1.32	0.42	1.78
DCG3ORA	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	3.11	3.73	1.58	4.56
DCK8P1Y	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	3.41	5.33	5.16	6.94
DC00LIL	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	8.8	8.94	5.07	11.68
DC6KB2Z	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	6.7	6.43	2.48	11.66
DCI4Q9J	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.29	3.93	1.37	7.58
DCUFNZN	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.59	5.28	2.01	6.97
DCR47OI	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.64	9.45	8.22	10.07
DC2VQW4	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.67	1.27	0.67	7.69
DC8NJBS	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.68	2.78	5.77	7.6
DCTJ0H2	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.49	7.66	6.68	11.03
DCZA1WV	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	14.6	14.57	18.18	19.99
DCW08WB	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	4.04	4.97	6.31	9.75
DC7MSHR	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.17	5.25	6.52	11.78
DCJLSD2	DMRICNP	Vandetanib	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.81	3.69	3.9	5.58
DC6OXI1	DMRICNP	Vandetanib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.98	3.98	1.48	1.07
DC1AQT8	DMRICNP	Vandetanib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.27	5.96	4.09	1.61
DCX4X0G	DMRICNP	Vandetanib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	5.25	6.26	2	0.92
DCAAN46	DMRICNP	Vandetanib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.4	6.14	3.44	1.6
DC9GV90	DMRICNP	Vandetanib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	4.17	12	10.39	8.19
DCF5JU8	DMRICNP	Vandetanib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.72	3.57	5.85	5.78
DCA0G8O	DMRICNP	Vandetanib	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	4.97	8.84	5.3	1.92
DCRQ5T8	DMRICNP	Vandetanib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	8.76	11.39	8.57	11.61
DCD55RN	DMRICNP	Vandetanib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	5.33	1.34	1.44	0.52
DCOEEYB	DMRICNP	Vandetanib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	14.92	15.82	2.84	16.16
DCE2509	DMRICNP	Vandetanib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	3.07	9.13	8.97	10.18
DCEDT9V	DMRICNP	Vandetanib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	8.59	8.74	8.3	12.81
DC91YM5	DMRICNP	Vandetanib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	11.86	12.1	6.37	13.73
DC8X83B	DMRICNP	Vandetanib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	4.82	8.21	0.71	7.99
DCYFGQI	DMRICNP	Vandetanib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.1	5.52	6.74	6.93
DCS1OCE	DMRICNP	Vandetanib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.1	7.21	4.98	7.42
DCBI1IW	DMRICNP	Vandetanib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	4	4.27	4.02	6.61
DC8HV0J	DMRICNP	Vandetanib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	10.32	13.48	11.62	14.36
DCZWPA5	DMRICNP	Vandetanib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	27.97	27.6	17.69	22.33
DCHISNA	DMRICNP	Vandetanib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	1.99	8.48	7.48	5.68
DCLZLYI	DMRICNP	Vandetanib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.98	3.45	2.49	0.51
DCV7334	DMRICNP	Vandetanib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	3.02	6.4	2.77	2.23
DCP1B4R	DMRICNP	Vandetanib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	2.15	5.06	5.88	6.19
DCF7QU4	DMRICNP	Vandetanib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.97	5.46	2.04	0.54
DCX9MYL	DMRICNP	Vandetanib	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.09	3.23	1.3	0.72
DCYWWXK	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	13.74	19.36	6.87	20.39
DCLB8JR	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.28	7.93	5.3	8.32
DCUIPM1	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	5.9	10.27	10.02	11.36
DC1JE1J	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.56	7.35	3.15	6.01
DC07BIT	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.51	10.53	4.13	8.92
DC02A63	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	13.03	13.37	4.36	14.03
DCGSUCD	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	16.38	19.42	14.33	19.32
DCX3BCR	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	9.29	13.19	7.48	13.12
DCB2YG3	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	14.9	15.86	1.89	16.42
DCHWOHQ	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	3.41	4.94	7.15	11.19
DCSD4RG	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	18.34	20.03	4.97	20.49
DC6GBZU	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	11.36	11.72	7.85	12.59
DCVM8R0	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.89	8.04	1.89	9.02
DCPP9MD	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.03	6.96	6.38	7.84
DCLY8I5	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	7.88	7.38	0.61	4.37
DCGU6PU	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	10.16	14.1	10.6	15.85
DC4XV0Z	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	10.95	14.43	15.98	16.92
DC81DWQ	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.61	4.36	6.29	6.85
DC7VXIS	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	17.74	18.17	3.38	16.09
DCC2CDD	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	8.06	11.22	8.14	11.71
DCFR8FQ	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	8.3	9.13	8.66	12.14
DCZCZGO	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	8.66	9.87	11.6	12.27
DCPZCFS	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.39	12.29	11.52	14.1
DC2UEFW	DMRICNP	Vandetanib	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	10.89	15.26	1.06	16.94
DC5JWCU	DMRICNP	Vandetanib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	4.78	13.7	4.39	14.55
DCPU3GE	DMRICNP	Vandetanib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	10.1	11.02	3.18	13.11
DCQLVFF	DMRICNP	Vandetanib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	7.13	8.77	6.68	8.2
DCEK1VY	DMRICNP	Vandetanib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	6.47	9.19	0.91	7.32
DC5OBRW	DMRICNP	Vandetanib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.72	4.86	2.19	6.7
DCZ8EAP	DMRICNP	Vandetanib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.69	3.24	5.08	6.09
DCP3NTB	DMRICNP	Vandetanib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	10.32	12.17	6.31	13.05
DC0WMT1	DMRICNP	Vandetanib	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	2.02	8.08	7.83	10.82
DCGOR6M	DMRICNP	Vandetanib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.7	4.18	4.1	5.47
DC3HX3D	DMRICNP	Vandetanib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.65	3.17	4.54	5.54
DC7ZY9E	DMRICNP	Vandetanib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	1.84	3.49	3.05	4.41
DCWB51A	DMRICNP	Vandetanib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	0.8	0.67	1.43	2.21
DCAMKT8	DMRICNP	Vandetanib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	5.46	8.94	8.08	8.84
DC8OHG3	DMRICNP	Vandetanib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.13	4.33	4.34	5.6
DC1T2M6	DMRICNP	Vandetanib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	6.69	4.58	0.31	1.35
DC73HKI	DMRICNP	Vandetanib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	1.58	6.99	7.73	9.26
DCJRHJW	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	11.48	8.21	2.67	10.51
DC5DAFB	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.97	6.32	7.45	10.4
DCQ0TM0	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	5.91	6.71	2.22	9.58
DCJ8PI0	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.23	7.33	2.74	8.67
DCSHWMM	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	14.39	12.73	9.4	12.96
DCFN6A0	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	19.73	19.81	13.82	20.03
DC2II6Y	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	12.17	8.42	5.02	8.69
DC0LBGX	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	15.75	13.95	11.59	17.31
DCLTYCS	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	11.73	10.16	10.72	11.63
DCHCF7A	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	20.91	20.04	2.83	17.48
DC72BDY	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	7.34	5.53	2.01	5.95
DCECMRV	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	11.92	6.63	6.39	8.56
DCHUYWQ	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	4.83	5.67	6.31	10.12
DCMAUR4	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	12.81	14.36	0.8	16.04
DCLX3W4	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	7.89	11.43	4.02	15.77
DCRVM8S	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	11.74	10	1.83	16.21
DC20HZ6	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	15.3	14.17	7.06	16.15
DCRY9UF	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	10.8	9.77	2.08	11.33
DCFOLF4	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	10.36	10.98	8.56	14.4
DCLNSBZ	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	15.83	14.98	6.26	16.25
DCF7P2N	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.55	7.26	3.34	8.76
DCES9SL	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	10.08	9	8.64	11.86
DCTP3ND	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	13.36	10.12	7.38	10.37
DCVEIY9	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	11.34	9.57	4.77	14.03
DC4IQGZ	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	6.76	8.55	8.13	11.99
DC8N42H	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	6	6.49	2.05	9.25
DCQ0HB8	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	9.67	10.77	5.67	10.6
DC4FEHL	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.7	4.77	5.88	7.62
DCSBRCU	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.5	5.7	9.13	11.02
DCWYOQ0	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	8.78	8.63	2.73	11.93
DCXSFAC	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	7.16	8.42	0.75	12.37
DC0ZD4B	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.03	2.32	0.6	4.88
DCDA9VU	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	10.94	11.55	10.34	14.97
DCTKM1J	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	2.95	8.73	13.65	14.94
DC231O1	DMRICNP	Vandetanib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	9.57	8.29	1.03	11.46
DCWDHH1	DMRICNP	Vandetanib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.47	11.65	0.37	8.15
DC0TY8H	DMRICNP	Vandetanib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	25.68	25.63	22.43	23.69
DC08O50	DMRICNP	Vandetanib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.53	8.03	5.72	3.92
DCDE4H5	DMRICNP	Vandetanib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	21.54	21.71	15.08	20.16
DC1KE8G	DMRICNP	Vandetanib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	8.67	7.28	3.53	2.32
DCF087Y	DMRICNP	Vandetanib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	6.91	8.46	1.7	7.4
DCPIJB1	DMRICNP	Vandetanib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.22	6.74	1	3.46
DCTM5G7	DMRICNP	Vandetanib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	7.41	8.9	4.81	4.1
DCFNIAO	DMRICNP	Vandetanib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	2.63	9.04	8.37	9.94
DCGOC9X	DMRICNP	Vandetanib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.16	7.17	4.06	4.29
DC2KGMU	DMRICNP	Vandetanib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.33	7.71	6.37	4.18
DCQXQ1L	DMRICNP	Vandetanib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	2.29	6.67	0.71	1.59
DC8Q0LC	DMRICNP	Vandetanib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	4.29	3.3	5.86	5.43
DCGF3KY	DMRICNP	Vandetanib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.8	3.9	1.45	1.73
DC365KS	DMRICNP	Vandetanib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	5.83	5.05	0.13	6.68
DCW21YQ	DMRICNP	Vandetanib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	2.81	2.47	1.46	4.55
DC86MMQ	DMRICNP	Vandetanib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	0.63	1.9	0.62	3.47
DC9MKHZ	DMRICNP	Vandetanib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.65	2.23	1.29	3.82
DCDHR49	DMRICNP	Vandetanib	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.18	3.33	4.96	5.53
DCBF7MJ	DMRICNP	Vandetanib	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	SYNERGxDB Database	Investigative	T98G	33.11	33.11	37.89	37.89
DCLT53M	DMRICNP	Vandetanib	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	1.5	4.2	0.05	0.34
DCXI2YP	DMRICNP	Vandetanib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.65	6.02	1.61	4.38
DCFO0GG	DMRICNP	Vandetanib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	4.55	8.48	7.51	9.14
DCUA68R	DMRICNP	Vandetanib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	1.7	3.08	3.86	5.28
DC7EDWT	DMRICNP	Vandetanib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	2.16	4.61	2.34	5.99
DCTSQ71	DMRICNP	Vandetanib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	2.27	6.29	4.22	5.76
DCT3457	DMRICNP	Vandetanib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	4.69	8.46	2.53	8.2
DC3FF5C	DMRICNP	Vandetanib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	6.74	12.08	8.55	7.12
DCMMZ1J	DMRICNP	Vandetanib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	7.36	10.67	4.17	3.37
DCQVZNQ	DMRICNP	Vandetanib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.79	4.69	0.52	3.35
DCP31KX	DMRICNP	Vandetanib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.92	7.41	2.46	4.46
DCQVFTK	DMRICNP	Vandetanib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.08	5.13	1.12	3.43
DC1SBKY	DMRICNP	Vandetanib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.58	5.72	3.79	3.17
DC38O51	DMRICNP	Vandetanib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.3	5.26	1.68	4.6
DCXUB7H	DMRICNP	Vandetanib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	7.37	9.83	4.44	2.24
DCSDTIK	DMRICNP	Vandetanib	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.42	5.97	0.98	4.59
DCTWD4W	DMRICNP	Vandetanib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	6.66	6.98	6.28	8.7
DCFVN2Y	DMRICNP	Vandetanib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	2.56	5.38	2.88	1.6
DCXC1NC	DMRICNP	Vandetanib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.56	15.45	12.04	14.02
DCZ6V83	DMRICNP	Vandetanib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	8.56	5.99	4.33	4.59
DC8TVFR	DMRICNP	Vandetanib	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	9.42	11.22	2.86	9.8
DCPLPMI	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6.87	8.54	8.79	12.53
DCEAIMB	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.25	5.66	3.05	3.41
DC0NDF7	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	11.97	9.75	6	9.74
DCKFYR9	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.94	4.93	5.27	7.03
DCPU1BF	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.44	6.15	5.71	7.65
DC1HJYQ	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	1.81	10.99	1.7	3.67
DCDXD6A	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	2.63	5.3	4.54	5.29
DCZ85NY	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	16.89	15.01	16.88	15.89
DCWDW4D	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	1.19	0.74	0.33	2.52
DCLS3QE	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	0.99	2.46	3.29	7.6
DCJNWMV	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	12.23	12.51	2.93	14.43
DCRC964	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	5.38	4.42	8.34	10.89
DCQK4N1	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	0.2	3.16	3.43	4.73
DCV45FC	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	2.5	2.86	4.69	3.73
DCTGAJQ	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.06	8.1	3.81	9.01
DCINPM3	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.47	7.37	4.22	8.84
DCLUJ8N	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	7.45	9.19	10.34	12.84
DCB9YS4	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.79	7.65	11.38	11.64
DCRSRV7	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	6.34	6.63	6.61	9.74
DCQTCJ3	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	7.86	7.73	10.57	10.81
DCREE1I	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	4.68	3.64	3.37	7.64
DCPJUIG	DMRICNP	Vandetanib	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	3.67	8.52	10.3	11.75
DC54JQD	DMRICNP	Vandetanib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.63	4.46	1.35	1.31
DCN1TTG	DMRICNP	Vandetanib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	10.91	13.04	7.24	14.58
DCNCCXB	DMRICNP	Vandetanib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.74	3.79	0.94	0.94
DCF6H71	DMRICNP	Vandetanib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	0.74	1.04	1.56	0.38
DCKOB5V	DMRICNP	Vandetanib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.22	7.47	5.63	5.63
DCAQ05L	DMRICNP	Vandetanib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	0.13	1.82	2.01	1.21
DCI9VH3	DMRICNP	Vandetanib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	3.56	3.85	0.46	4.14
DCWI4UN	DMRICNP	Vandetanib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.59	6.78	0.52	4.34
DC93IKC	DMRICNP	Vandetanib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	1.04	0.36	0.66	0.6
DCWCMHA	DMRICNP	Vandetanib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	6.84	6.06	7.47	7.28
DCC2EL3	DMRICNP	Vandetanib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.83	5.04	3.43	6.47
DC7O41R	DMRICNP	Vandetanib	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	1.1	0.61	1.83	2.77
DCK05L6	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.25	5.45	0.33	4.11
DCR42HV	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	6.16	11.65	7.3	12.34
DC25MHC	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.58	3.99	0.97	2.7
DCO8K02	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	3.54	8.83	7.83	8.87
DCX6OCA	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	5.83	13.11	8.81	8.37
DCUW97J	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	6.01	9.76	6.35	6.85
DCXU8DI	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	8.08	7	1.71	7.06
DCQY3VV	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	6.85	5.87	5.52	6.31
DC6KY4V	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	4.88	7.02	7	7.99
DC2O6XD	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	2.93	5.68	9.59	11.52
DCT3Q09	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	16.43	16.04	12.53	12.35
DCD4HFJ	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	1.57	1.4	1.38	2.33
DCVZ15S	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	12.37	6.01	2.01	3.35
DCPA6IV	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	12.64	17.13	15.35	16.12
DCZO1DM	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.3	2.8	5.24	5.92
DC5ZSPW	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	11.45	12.22	9.69	10.01
DC1K9J6	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4.61	4.82	1.92	8.13
DCLKD0G	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	1.78	3.73	5.2	6.58
DCPICCI	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	12.3	13.8	8	9.73
DCOYBAI	DMRICNP	Vandetanib	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	3.41	9.92	10.97	11.56
DCP7J0N	DMRICNP	Vandetanib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.65	1.93	3.14	2.72
DCM5U40	DMRICNP	Vandetanib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	1.14	9.54	8.67	6.59
DCLI4RA	DMRICNP	Vandetanib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.34	4.53	1.71	1.71
DCPRMVI	DMRICNP	Vandetanib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	0.9	3.74	2.97	3.82
DCJE0Z6	DMRICNP	Vandetanib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.12	7.63	5.1	3.34
DCVB2HM	DMRICNP	Vandetanib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.11	6.91	6.24	6.38
DCWRBIQ	DMRICNP	Vandetanib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.35	5.32	3.47	2.93
DCDIA3C	DMRICNP	Vandetanib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	10.06	10.47	9.8	11.24
DCA0EVL	DMRICNP	Vandetanib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.97	3.2	5.63	5.5
DCEM20J	DMRICNP	Vandetanib	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	6.07	9.45	4.51	4.26
DCLO0F7	DMRICNP	Vandetanib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.82	0.54	3.68	4.52
DCONJA4	DMRICNP	Vandetanib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	8.65	10.13	12.31	12.97
DCMDN70	DMRICNP	Vandetanib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	2.56	3.79	3.49	4.49
DCNG44A	DMRICNP	Vandetanib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	0.07	2.83	7.26	8.69
DC4UJV2	DMRICNP	Vandetanib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	6.06	7.39	8.46	15.21
DCUWYGV	DMRICNP	Vandetanib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.92	4.11	0.92	2.03
DCQHZ5W	DMRICNP	Vandetanib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	8.13	8.61	5.28	5.91
DCDXTRV	DMRICNP	Vandetanib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.96	5	6.22	7.16
DCQT7GZ	DMRICNP	Vandetanib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.93	1.81	5.41	6.65
DCWVQZI	DMRICNP	Vandetanib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	7.35	8.27	6.15	8.98
DCV2CSN	DMRICNP	Vandetanib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.58	5.83	6.96	10.1
DCETUDQ	DMRICNP	Vandetanib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.02	5.63	2.1	9.45
DCID18C	DMRICNP	Vandetanib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.15	0.17	4.6	5.53
DC38EKR	DMRICNP	Vandetanib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.97	4.2	5.07	6.97
DC0X1R9	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	11.58	13.61	10.7	14.6
DC8LN14	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	25.5	15.26	12.59	18.44
DCP50GB	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	11.74	11.77	6.36	11.38
DCTQ1TZ	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	7.53	12.63	8.61	15.52
DCGC051	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	25.2	17.46	13.81	17.67
DC3OJJP	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	27.4	21.63	18.35	21.84
DCAV0YX	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	8.88	12.06	6.11	11.91
DCK8K1I	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	7.94	8.15	7.77	10.33
DCT5RJ0	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	7.11	7.25	8.76	12.87
DCLM8YQ	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	24.14	16.15	6.98	17.48
DCKLBD0	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	5.91	10.99	8.64	11.31
DCYDPAX	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	18.44	19.07	16.73	19.28
DCNUFD8	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	15.52	14.91	7.71	20.06
DC0Z95E	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	4.05	4.02	3.98	6.95
DCV68U6	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	15.22	15.57	13.45	15.84
DC2F8W2	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.75	2.08	5.03	6.83
DCQFZGP	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	0.45	3.14	2.06	8.11
DCSGTS7	DMRICNP	Vandetanib	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	18.18	18.37	16.7	20.44
DCGDF41	DMRICNP	Vandetanib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.88	10.61	6.67	6.18
DC4GD6E	DMRICNP	Vandetanib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	3.15	7.68	9.54	10.01
DCHCBZK	DMRICNP	Vandetanib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	4.03	8.74	6.28	7.6
DC04ZAW	DMRICNP	Vandetanib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	11.16	6.46	1.81	6.51
DC7QPEM	DMRICNP	Vandetanib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	11.19	12.25	15.42	17.02
DCINPL5	DMRICNP	Vandetanib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	6.76	13.23	7.98	7.98
DCVOAU1	DMRICNP	Vandetanib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.96	10.18	7.18	5.41
DCFOMNA	DMRICNP	Vandetanib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	3.12	11.36	8.44	7.04
DC3Z03J	DMRICNP	Vandetanib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.05	4.53	5.29	6.06
DCADFLR	DMRICNP	Vandetanib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.82	8.91	5.24	5.16
DC7XRQC	DMRICNP	Vandetanib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.85	11.66	9.88	10.24
DCEB7K7	DMRICNP	Vandetanib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.98	4.72	1.08	4.98
DCUTNDS	DMRICNP	Vandetanib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	3.87	12.82	13.97	14.98
DCIYBKB	DMRICNP	Vandetanib	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	6.39	12.17	4.37	3.49
DCGEGCV	DMRICNP	Vandetanib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	6.77	10.37	5.06	4.83
DCB2BK0	DMRICNP	Vandetanib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.69	9.01	5.97	7.7
DCCFDTG	DMRICNP	Vandetanib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.29	4.52	0.98	0.88
DC9TM3S	DMRICNP	Vandetanib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	9.9	8.99	4.37	9.62
DCKAF8B	DMRICNP	Vandetanib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	8.07	17.27	6.26	6.26
DCT4X3M	DMRICNP	Vandetanib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	0.79	1.02	4.23	4.62
DC5FXKO	DMRICNP	Vandetanib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	0.17	2.59	1.2	3.29
DC0PRXQ	DMRICNP	Vandetanib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	12.32	13.03	14.39	17.08
DCQ4QTI	DMRICNP	Vandetanib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.49	5	3.62	4.56
DC71CMP	DMRICNP	Vandetanib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	5.12	10.7	8.7	5.94
DCPJN6G	DMRICNP	Vandetanib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	0.61	0.31	0.2	1.94
DCALBWU	DMRICNP	Vandetanib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.97	6.39	1.42	0.78
DCKLVO3	DMRICNP	Vandetanib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.35	6.92	1.62	0.95
DCS4EH7	DMRICNP	Vandetanib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	12.05	11.5	8.51	11.52
DCPY3TK	DMRICNP	Vandetanib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.23	5.87	7.75	8.23
DCUSRBL	DMRICNP	Vandetanib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.43	5.14	0.62	4.07
DCEHVLW	DMRICNP	Vandetanib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	5.62	10.87	3.49	3.34
DCJAZMC	DMRICNP	Vandetanib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.13	8.53	6.62	6.2
DCFPZUE	DMRICNP	Vandetanib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.72	9.85	6.94	6.93
DCQ2KES	DMRICNP	Vandetanib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	0.35	8.79	4.1	7.49
DCGGN3O	DMRICNP	Vandetanib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.93	6.53	1.45	1.45
DCA3M3C	DMRICNP	Vandetanib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.31	11.23	8.52	7.43
DCITFJ3	DMRICNP	Vandetanib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	3.44	11.88	8.71	8.64
DCUUHTW	DMRICNP	Vandetanib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.96	9	2.78	7.97
DC6OCS1	DMRICNP	Vandetanib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.89	8.11	6.23	6.03
DCVVVFV	DMRICNP	Vandetanib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	11.46	15.46	11.44	9.71
DCXIN86	DMRICNP	Vandetanib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.73	4.37	5.4	5.41
DCH11IR	DMRICNP	Vandetanib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.13	4.04	3.38	5.16
DCXY22E	DMRICNP	Vandetanib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	10.66	10.85	7.89	13.34
DC0DTE7	DMRICNP	Vandetanib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.89	6.67	2.86	6.57
DCENWOT	DMRICNP	Vandetanib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	3.09	10.31	7.1	9.18
DCCCZHC	DMRICNP	Vandetanib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	1.52	4.82	2.24	5.55
DCZH8MS	DMRICNP	Vandetanib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	4.11	8.19	2.21	10.36
DCYC4Z7	DMRICNP	Vandetanib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	5.77	6.09	5.21	6.95
DCPXXW7	DMRICNP	Vandetanib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	9.36	10.25	3.67	12
DCC8RNT	DMRICNP	Vandetanib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.36	0.74	2.08	2.89
DC1KZWX	DMRICNP	Vandetanib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	3.67	5	3.04	7.47
DCQJZ2Q	DMRICNP	Vandetanib	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.11	3.7	0.88	0.25
DCK6VJB	DMRICNP	Vandetanib	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	14.44	12.34	8.8	8.55
DCBY7UU	DMRICNP	Vandetanib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	15.85	13.07	8.77	16.62
DC57H7P	DMRICNP	Vandetanib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	22.21	18.16	11.71	17.75
DC0YG8M	DMRICNP	Vandetanib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	3.58	6.49	1.75	7.85
DCTZQ87	DMRICNP	Vandetanib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	18.9	21.44	1.45	22.58
DCSYUU9	DMRICNP	Vandetanib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	11.32	11.69	6.37	11.6
DCSIMA0	DMRICNP	Vandetanib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	2.49	7.08	2.42	8.05
DCFM3T5	DMRICNP	Vandetanib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	6.24	6.54	6.56	9.95
DC7A7SM	DMRICNP	Vandetanib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.41	4.26	1.7	6.41
DC0A5ID	DMRICNP	Vandetanib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	9.21	13.42	12.67	16.7
DCX9SN2	DMRICNP	Vandetanib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	7.92	8.66	9.24	11.22
DCJVN97	DMRICNP	Vandetanib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	10.88	9.93	11.15	14.44
DC4074P	DMRICNP	Vandetanib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	5.15	4.48	3.42	7.05
DCOOKA5	DMRICNP	Vandetanib	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.14	3.77	0.96	5.55
DCAN2EL	DMRICNP	Vandetanib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	2.17	2.6	2.39	4.58
DCXDOKR	DMRICNP	Vandetanib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.3	5.38	5.46	7.3
DCEVXPF	DMRICNP	Vandetanib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.3	2.82	0.24	3.48
DCOC9SG	DMRICNP	Vandetanib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	0.62	8.85	8.94	12.28
DCMKRE2	DMRICNP	Vandetanib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	5.89	10.7	0.52	0.96
DCBCAIJ	DMRICNP	Vandetanib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	0.16	5.25	4.89	5.42
DC3MC67	DMRICNP	Vandetanib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.15	7.28	4.35	4.41
DC5BMXP	DMRICNP	Vandetanib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	6.78	7.14	3.32	7.36
DCGDNQM	DMRICNP	Vandetanib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.71	7.19	2.74	1.87
DC1WCNU	DMRICNP	Vandetanib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.87	7.38	2.02	1.17
DCX2985	DMRICNP	Vandetanib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.64	6.24	1.16	1.16
DCGJ81F	DMRICNP	Vandetanib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.34	5.57	6.27	6.2
DCGTBKX	DMRICNP	Vandetanib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	4.41	7.65	2.88	0.02
DCQCLQA	DMRICNP	Vandetanib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	1.59	3.72	3.65	0.29
DCTH5TV	DMRICNP	Vandetanib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.58	4.49	2.87	1.52
DCAIT8R	DMRICNP	Vandetanib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	1.47	5.83	5.7	5.67
DCIWDOG	DMRICNP	Vandetanib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.12	3.76	0.95	0.23
DCXI4F7	DMRICNP	Vandetanib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	4.89	8.13	4.92	4.69
DCH8EK8	DMRICNP	Vandetanib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.58	2.72	0.42	1.05
DCRGCYH	DMRICNP	Vandetanib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.36	6.79	7.06	8.29
DCY5AKK	DMRICNP	Vandetanib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	3.88	9.54	6.65	2.85
DCR87ST	DMRICNP	Vandetanib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.02	2.08	0.34	2.92
DC3OTLI	DMRICNP	Vandetanib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.71	7.44	4.81	6.45
DCOXLDW	DMRICNP	Vandetanib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.64	7.16	3.68	6.8
DCD282M	DMRICNP	Vandetanib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	8.36	11.66	6.32	6.92
DCCV0ZG	DMRICNP	Vandetanib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.62	10.09	7.43	7
DC4HAKY	DMRICNP	Vandetanib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	5.14	3.68	0.86	3.76
DCLAZXW	DMRICNP	Vandetanib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	0.59	2.22	1.19	2.65
DCU5RJ2	DMRICNP	Vandetanib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.14	8.37	5.52	5.6
DCAA1BJ	DMRICNP	Vandetanib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	3.59	6.69	2.96	4.26
DCHNO8T	DMRICNP	Vandetanib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.3	3.81	4.48	5.52
DC8ETU5	DMRICNP	Vandetanib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.26	3.12	4.83	6.05
DC3DI5Z	DMRICNP	Vandetanib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.31	3.66	2.34	2.02
DCEBV1D	DMRICNP	Vandetanib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.79	1.88	3.55	4.94
DC86089	DMRICNP	Vandetanib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	7.39	11.1	7.59	7.65
DCMNLFS	DMRICNP	Vandetanib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	3.36	3.97	2.13	5.08
DCFDU8Z	DMRICNP	Vandetanib	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	9.4	8.28	6.21	7.97
DCFLYLZ	DMRICNP	Vandetanib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	2.51	3.31	0.93	2.21
DC4PPVB	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.33	3.14	0.82	1.88
DCWF94E	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6.77	13.45	15.59	16.42
DCK78E9	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	3.99	5.66	4.83	4.59
DCPW8MY	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	14.62	11.73	10.16	13.21
DC1TZL7	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	13.33	13.69	14.56	17.33
DC77FDE	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	23.59	19.88	17.24	24.64
DCHVBO8	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	6.87	9.06	3.07	5.89
DC1QVP9	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.94	4.85	4.48	5.06
DC0Z9M2	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	9.16	17.26	16.28	16.56
DCJZ1TI	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.36	16.14	15.65	16.08
DCHFNKX	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	3.92	2.71	5.04	5.99
DCELTOI	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	13.14	13.56	14.09	16.95
DC0FS0P	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.75	4.88	4.44	5.36
DCF61KY	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	21.91	18.35	18.14	20.79
DCMSHIR	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	7.8	10.69	13.54	14.04
DCSGR37	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	7.57	9.56	7.67	13.38
DCNT9ZE	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.71	10.04	9.36	10.77
DC2ARX8	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	13.03	12.29	11.11	14.79
DC0PI67	DMRICNP	Vandetanib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	1.17	7.41	9.69	10.78
DCG0HI7	DMVXFYE	Vinorelbine	Approved	34	DMW7K39	Pyrotinib	Phase 1	17	.	.	.	.	Metastatic Breast Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC1PQR3	DMVXFYE	Vinorelbine	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCI3BRO	DMVXFYE	Vinorelbine	Approved	34	DMY4UMW	Atovaquone	Approved	34	.	.	.	.	Locally Advanced Non-Small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCFPPX1	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.08	3.34	2.1	5.87
DC9MINX	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.18	3.15	8.55	11.08
DC4AAI1	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.25	0.65	3.46	6.47
DCS5WSN	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.8	4.06	2.92	9.11
DCVWMN4	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	3.63	1.41	4.56	7.89
DCFKTH4	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.44	1.93	1.61	5.56
DCDLWTC	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.38	0.23	5.79	9.66
DCTOWK5	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	6.72	6.11	0.57	8.8
DCTQMAM	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.44	3.13	4.35	8
DCVFV0B	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	5.59	4.91	6.11	8.51
DC3WWW9	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.81	4.74	7.87	10.75
DCBRMXP	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.65	0.31	3.3	4.63
DCZT9Y7	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.19	4.08	10.38	13.18
DC7ZA8X	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.58	1.21	5.56	7.81
DCIIS61	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.44	1.32	8.71	12.24
DC32991	DMVXFYE	Vinorelbine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.98	1.54	1.05	5.54
DCBLUPJ	DMVXFYE	Vinorelbine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.21	6.39	10.77	12.18
DCFCKGW	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.38	2.47	2.84	6.39
DCLIF4J	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	6.4	7.07	9.19	12.6
DCTUFZP	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.78	4.72	3.76	7.76
DCACILS	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.28	2.01	5.08	6.47
DCWPF99	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.04	1.03	1.04	4.05
DCRVPWE	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.4	3.86	2.26	5.51
DCOPW7Z	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.09	1.27	1.64	6.04
DC7AKC6	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	10.81	11.99	13.25	14.63
DCLG88F	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	6.36	6.87	4.62	8.25
DCF0T30	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.35	2.87	6.21	8.83
DC7UU2U	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.81	0.91	5.23	7.78
DC65TFK	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	2.53	1.12	9.42	11.07
DCFHG4M	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.65	0.69	6.71	10.04
DCYLZLX	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	6.18	5.15	7.77	11.47
DCL8TSS	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.05	1.96	6.13	8.51
DC113KU	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.22	1.93	3.35	6.54
DCIT7OA	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.83	0.75	4.08	6.39
DCI9FN5	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.93	1.02	3.01	7.04
DCSEJ9R	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	13.47	11.34	13.05	16.05
DCYISEV	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.23	0.66	2.34	4.86
DCVVVT6	DMVXFYE	Vinorelbine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	5.06	3.46	4.6	7.24
DCKAK5O	DMVXFYE	Vinorelbine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.78	0.96	3.01	6.82
DC0T71Q	DMVXFYE	Vinorelbine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.9	1.78	4.83	7.09
DC1NK5R	DMVXFYE	Vinorelbine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.76	2	2.77	7.63
DCP1GTS	DMVXFYE	Vinorelbine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	5.88	6.09	7.92	10.87
DCM1923	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.88	1.7	1.94	3.85
DCRMX0G	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	6.23	5.93	0.78	7.57
DC6RE84	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	5.31	1.43	3.52	5.88
DCJ9F7D	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.36	0.34	0.75	3.76
DCNDT9Q	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.83	1	0.42	3.73
DC63M2O	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.55	3.55	4.99	5.47
DCMTRAE	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.18	1.97	4.49	7.04
DC0O6X1	DMVXFYE	Vinorelbine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.79	0.53	7.27	10.74
DCPRDRI	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	7.92	7.61	7.13	10.86
DCSGBQQ	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.31	2.97	4.6	6.11
DC5YZF4	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.45	1.3	0.94	4.74
DC3OJVK	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.18	3.32	2.97	5.36
DCBQIJI	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.33	0.28	8.77	10.86
DCWQ4ZO	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.95	3.83	7.95	9.99
DCL3MZK	DMVXFYE	Vinorelbine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.81	3.61	4.37	9.22
DC3U39P	DMVXFYE	Vinorelbine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.03	2.65	4.07	8.66
DCVVJGC	DMVXFYE	Vinorelbine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	16.44	14.76	9.3	17.56
DC5NZD6	DMVXFYE	Vinorelbine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	6.09	6.96	2.18	6.55
DCUSTTV	DMVXFYE	Vinorelbine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.39	0.47	3.24	8.8
DCHFE4M	DMVXFYE	Vinorelbine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.61	3.54	7.72	9.52
DCW6M2E	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.19	4.55	2.4	6.82
DCCKIZK	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	6.1	6.39	5.38	10.16
DC6T56A	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	0.63	0.58	4.32	8.15
DCD4RGA	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.16	2.63	3.45	7.22
DC9Z5AZ	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	9.32	8.81	6.76	11.3
DCN47DC	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.98	1.9	2.34	5.95
DCVQRLS	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.18	4.34	3.36	7.82
DCCRYPP	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.1	0.48	2.71	5.04
DCMU92I	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.92	4.51	1.66	6.23
DCSVNM0	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.53	2	3.5	6.29
DC1C3VF	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.96	0.74	3.13	5.14
DCQ6LSR	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.79	1.67	4.8	7.24
DCERZHW	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.07	2.23	5.69	8.8
DCHZQGL	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.32	0.09	7.13	8.84
DCSMI3Q	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.96	1.24	2.04	5.57
DC04C30	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.69	1.2	7.27	9.22
DCVOPC2	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.07	2.22	1.5	6.67
DCMVKO8	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.26	6.02	10.08	11.35
DCFU6XM	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.19	1.68	1.1	3.2
DC1U6MY	DMVXFYE	Vinorelbine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.01	3.93	1.63	5.2
DCQDQNN	DMVXFYE	Vinorelbine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.73	8.32	5.85	8.96
DCL6FMR	DMVXFYE	Vinorelbine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.7	4.71	2.19	6.52
DCTATZU	DMVXFYE	Vinorelbine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.91	5.15	3.44	5.1
DCX7HTN	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.39	4.63	7.05	10.48
DCWTFXV	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.97	1.1	3.58	7.65
DCTEA6G	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	3.4	1.3	9.39	11.98
DCE4GMO	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.44	0.53	2.49	7.42
DCP4D30	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.76	2.72	5.64	8.67
DC4ZUON	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.93	1.06	0.02	5.45
DC3EP5Y	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.94	5.47	2.4	8.83
DCIGE1O	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.15	8.28	10.82	13.47
DCXFCPB	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	7.89	6.56	8.26	9.95
DCHHSCV	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.54	1.84	1.29	5.44
DCQUH50	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.01	1.9	12.78	14.36
DC9N7XZ	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.67	1.22	3.19	6.6
DC666OK	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.18	0.81	3.18	6
DCLL75N	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.33	4.18	4.21	4.96
DCW93CM	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.33	4.79	6.09	9.43
DCI8YHU	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.41	3.42	2.41	8.39
DCT9EID	DMVXFYE	Vinorelbine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.16	0.76	7.09	8.42
DCI8VHA	DMVXFYE	Vinorelbine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.15	2.52	0.92	5.38
DC15FNF	DMVXFYE	Vinorelbine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.39	2.59	2.46	5.14
DC2YWKN	DMVXFYE	Vinorelbine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.96	1.01	6.37	8.42
DCV82VU	DMVXFYE	Vinorelbine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.51	5.47	0.08	5.97
DCRZ6RO	DMVXFYE	Vinorelbine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.64	0.12	0.54	3.49
DCPFQKB	DMVXFYE	Vinorelbine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.94	8.17	14.59	16.06
DC149M7	DMVXFYE	Vinorelbine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	0.74	0.63	7.31	8.84
DC0FTTL	DMVXFYE	Vinorelbine	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	19.88	18.77	10.45	13.15
DC06M2V	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.27	2.57	1.15	5.46
DC9DPI8	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.69	0.93	2.28	6.91
DCJSMXA	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	1.22	0.96	2.58	6.36
DCPR95Y	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	4.4	3.19	0.33	6.76
DC4UAKO	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	8.55	7.47	4.38	5.81
DCPD02U	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	8.71	5.83	3.04	7.73
DCDW8ZZ	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.13	5.58	0.95	7.07
DCFV2QL	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.73	3.08	3.65	8.55
DC425AY	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	12.44	13.37	3.69	14.06
DCPCD2U	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	17.42	16.19	12.99	18.11
DCPYYQ4	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	5.95	6.49	0.16	6.18
DCGCOBV	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	3.76	4.42	1.27	8.48
DCLX6MU	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.21	5.38	2.1	7.9
DC9NEPT	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.1	4.85	2.47	9.44
DC0UMN9	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	7.33	5.58	3.37	7.92
DCHOIT6	DMVXFYE	Vinorelbine	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	6.7	7.15	1.88	7.99
DCDMJGF	DMVXFYE	Vinorelbine	Approved	34	DM2KITF	LY335979	Discontinued in Phase 3	9	.	.	.	.	Human papillomavirus-related cervical adenocarcinoma	SYNERGxDB Database	Investigative	KB-ChR-8-5-11	37.577	33.905	30.605	26.195
DCYY5WT	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	5.59	3.8	4.96	6.65
DCUSXHB	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	0.55	1.97	0.3	3.83
DC7828V	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	2.65	4.88	2.07	6.41
DCRB3JB	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	16.49	16.2	15.1	14.83
DCIKW7T	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	6.88	8.37	9.17	10.73
DCYY3HD	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.36	1.19	1.77	3.37
DCAUFJC	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	1.93	2.8	0.21	3.74
DCJXB51	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	12.4	11.29	8.28	11.18
DCO56IC	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.32	8.2	6.16	12.11
DCUWRSU	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	2.98	2.44	2.18	7.08
DC2978F	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.24	5.31	2.63	6.15
DC96ESD	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	4.7	4.96	0.59	4.35
DCWIPFJ	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.03	4.28	3.59	6.68
DC52WPT	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	4.75	4.09	4.47	10.39
DCP8BDX	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	8.23	6.01	1.6	6.52
DCCL93F	DMVXFYE	Vinorelbine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.91	2.69	0.3	9.65
DC2SARV	DMVXFYE	Vinorelbine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	7.02	7.95	5.62	9.32
DCBZZK5	DMVXFYE	Vinorelbine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	0.78	3.21	1.79	1.57
DCVZ16M	DMVXFYE	Vinorelbine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.24	1.96	0.56	4.77
DC9W253	DMVXFYE	Vinorelbine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.3	4.96	2.93	8.91
DC12MU8	DMVXFYE	Vinorelbine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	5.17	9.66	5.33	9.32
DCHLNHA	DMVXFYE	Vinorelbine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.12	2.21	0.59	6.26
DCAFR89	DMVXFYE	Vinorelbine	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	3.42	2.59	0.07	5.87
DCKCNT7	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.05	5.16	2.75	6.1
DCFLDFX	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	3.94	3.71	4.52	7.41
DC7X7Q5	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.24	4.31	2.07	6.71
DCJT3GX	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	6.45	6.08	4.42	7.36
DCYFCJL	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	5.03	4.36	2.84	3.01
DCW76I7	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.3	1.37	0.16	3.9
DCRPI8B	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.86	8.08	5.62	9.76
DCQCLA9	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.44	3.87	1.2	4.19
DCV6FDS	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	6.97	3.57	0.12	4.21
DCRKDCW	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	6.26	6.97	3.47	8
DCDJYOB	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.39	5.73	3.36	9.98
DCLZ8LY	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.33	2.67	0.43	5.18
DCLDN11	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	3.94	5.5	0.17	5.11
DCTO214	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	17.97	14.09	15.88	18.67
DCT4CVM	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	5.56	6.3	1.9	8.87
DCNUJF6	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.86	7.79	8.34	11.24
DCJ6IKD	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	2.89	2.39	0.37	4.85
DCY6N5M	DMVXFYE	Vinorelbine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	7.37	5.91	6.35	10.51
DCT6JSN	DMVXFYE	Vinorelbine	Approved	34	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	SYNERGxDB Database	Investigative	DIPG25	6.92	5.16	6.72	9.06
DCZEDNJ	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.75	0.12	0.18	3.13
DCXYZPH	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	2.22	1.5	0.16	3.99
DCCBYMY	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	2.91	1.4	4.46	7.82
DCXON7B	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	10.9	11.54	5.2	10.32
DC24MQE	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	4.63	2.91	2.61	6.33
DC7SC5X	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.43	1.8	1.07	4.64
DCXG6YT	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.21	1.74	0.68	4.11
DCH8HUZ	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.06	2.78	5.83	8.75
DCEKEVB	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	1.45	0.66	1.09	4.94
DC5HM33	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	8.55	6.58	5.71	9.22
DCAX45X	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	2.13	1.83	0.36	4.4
DCB8YDX	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.73	4.87	5.69	9.19
DC4YWJ8	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	8.29	6.4	9.2	12.36
DCNUY14	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	5.8	4.6	10.25	13.2
DC90Q7F	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	5.37	5	6.48	9.71
DCWW5WO	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	9.67	10.43	10.71	13.59
DCZ9ZAQ	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.11	2.68	7.58	10.1
DCPHLQ0	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	12.56	11.21	10.96	14.74
DCX16J7	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	4.87	2.07	3.56	7.49
DCL3MY4	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.13	6.65	6.48	9.74
DC9WI8S	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.52	5.48	9.32	12
DCFAH69	DMVXFYE	Vinorelbine	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	7.05	2.57	4.33	7.66
DCZ4121	DMVXFYE	Vinorelbine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	1.37	0.9	1.51	5.83
DCSD1JX	DMVXFYE	Vinorelbine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	7	4.97	3.2	3.16
DC6BBKT	DMVXFYE	Vinorelbine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	4.41	13.47	1.73	14.53
DCKE1HV	DMVXFYE	Vinorelbine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.55	5.77	3.7	7.16
DC2DZNQ	DMVXFYE	Vinorelbine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	8.84	9.53	7.82	11.4
DCYTM57	DMVXFYE	Vinorelbine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	7.72	8.54	0.23	9.17
DC0Q81I	DMVXFYE	Vinorelbine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	5.67	7.21	5.77	9.58
DCJVZLO	DMVXFYE	Vinorelbine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.75	2.49	3.59	5.01
DCQP0GP	DMVXFYE	Vinorelbine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	6.84	4.95	1.77	9.26
DCP90PO	DMVXFYE	Vinorelbine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.77	2.25	1.74	6.13
DCEEAI1	DMVXFYE	Vinorelbine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	6.55	7.48	3.37	12.08
DCC51UK	DMVXFYE	Vinorelbine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	2.26	4.28	0.36	5.49
DCJI7KC	DMVXFYE	Vinorelbine	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.95	3.36	2.94	6.45
DCHMH73	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.96	0.42	1.12	3.83
DC7DKNL	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	1.65	0.69	2.71	5.23
DCXX754	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	1.77	6.93	6.23	4.57
DCARXYR	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.99	2.68	2.2	5.5
DCY7GMF	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	5.53	3.13	3.32	6.57
DCR8TU2	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	3.96	9.09	5.64	9.83
DCDBH1P	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	1.17	4.85	1.05	6.27
DCCXUQ9	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.47	2.01	0.27	4.5
DC6RETK	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	8.32	8.23	10.02	13.02
DCVWSBF	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	1.82	1.03	4.55	6.93
DCCX72M	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.56	4.27	3.58	6.71
DCL8JPD	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	6.08	3.95	1.42	5.26
DCA3GJX	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.31	2.28	3.37	7.25
DCD0RIL	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	1.81	1.83	0.35	3.76
DCTABWZ	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.98	0.06	2.04	4.65
DCDOV5M	DMVXFYE	Vinorelbine	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	6.79	5.08	8.01	10.44
DCCMQQZ	DMVXFYE	Vinorelbine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	7.22	6.57	10.96	15.35
DCNBJRW	DMVXFYE	Vinorelbine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	5.46	6.09	3.57	10.28
DCCUNL4	DMVXFYE	Vinorelbine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	19.95	20.31	19.11	19.37
DCBEWOB	DMVXFYE	Vinorelbine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	11.14	10.87	0.92	14.84
DCOW3J3	DMVXFYE	Vinorelbine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	11.33	7.37	6.22	11.33
DCRSOJG	DMVXFYE	Vinorelbine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.18	4.97	0.99	7.29
DC4LVEK	DMVXFYE	Vinorelbine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.76	7.32	9.05	13.99
DCBCKZS	DMVXFYE	Vinorelbine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	5.51	4.38	0.38	7.77
DC714VI	DMVXFYE	Vinorelbine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	11.18	11.85	6.46	13.22
DC0QSSE	DMVXFYE	Vinorelbine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	10.19	8.4	1.14	10.28
DCGLC5I	DMVXFYE	Vinorelbine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7	4.79	1.59	8.68
DCY8VA3	DMVXFYE	Vinorelbine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	6.03	5.14	7.04	12
DCY06NZ	DMVXFYE	Vinorelbine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.3	0.76	44.31	1.06
DCIPEG6	DMVXFYE	Vinorelbine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	5.95	6.43	4.41	9.95
DC8252D	DMVXFYE	Vinorelbine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	5.84	5.23	1.64	10.34
DCJ5M0G	DMVXFYE	Vinorelbine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.07	6.25	3.83	9.59
DCYZD7L	DMVXFYE	Vinorelbine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8.49	8.45	9.9	15.16
DCT5WTM	DMVXFYE	Vinorelbine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	4.07	1.47	0.23	5.85
DCTPRB4	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.78	0.61	0.55	2.89
DC58OAH	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.25	1.16	4.13	7.15
DCENV0X	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	1.85	2.28	1.03	4.91
DC2950Q	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	3.68	3.98	2.33	6.31
DCH8S40	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	12.73	14.2	13.1	12.99
DC0AD7U	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	14.29	15.43	12.87	18.1
DCOHH5L	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.35	5.68	3.23	6.8
DCWKBQR	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	9.86	6.02	17.28	6.39
DCY3PST	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.37	6.04	2.04	6.65
DCB384L	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.73	7.36	4.29	11.3
DCPGC94	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	12.11	11.25	11.33	14.58
DCJQSYV	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	1.28	0.9	3.51	6.63
DC3A7FA	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	4.53	6.64	4.19	7.35
DCZU8TS	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.57	3.2	6.47	9.02
DCZWOCB	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	3.41	3.35	3.82	9.71
DCY63SQ	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.85	6.05	1.58	7.44
DC4ZE43	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.06	2.14	5.65	8.44
DCQ5QF0	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	3.82	1.85	1.56	5.76
DC3DWQM	DMVXFYE	Vinorelbine	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	3.07	4.68	1.17	5.44
DCKFSNI	DMVXFYE	Vinorelbine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	4.22	4.37	3.38	7.68
DCH5AMG	DMVXFYE	Vinorelbine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.81	4.44	1.59	4.49
DCD2YW4	DMVXFYE	Vinorelbine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	4.41	8.15	1.6	10.4
DCB5MGU	DMVXFYE	Vinorelbine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.51	2.21	3.45	6.82
DCRZVHL	DMVXFYE	Vinorelbine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	11.4	12.94	11.05	11.21
DCPFTOH	DMVXFYE	Vinorelbine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	14.17	14.81	7.38	14.93
DCY3XYC	DMVXFYE	Vinorelbine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	2.56	10.78	6.47	11.1
DCVAL52	DMVXFYE	Vinorelbine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.55	4.93	2.13	7.16
DCRU0NP	DMVXFYE	Vinorelbine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.19	5.78	1.73	9.61
DC9S3I1	DMVXFYE	Vinorelbine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	4.94	8.72	4.03	8.27
DC27QDM	DMVXFYE	Vinorelbine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	13.8	14.34	14.32	17.17
DCL02YT	DMVXFYE	Vinorelbine	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	3.12	0.73	2.24	6.26
DCHYD1R	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.34	1.35	1.75	5.41
DCWLRQN	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	6.7	6.99	3.53	8.35
DCNHA7M	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	7.35	8.23	4.94	9.53
DCRHGHO	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	11.91	12.84	9.15	13.62
DCBLG82	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	2.89	1.76	0.47	4.47
DCFKMUS	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	2.42	7.79	2.82	8.87
DC6FRYG	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.41	3.06	0.24	4.33
DCSN3PF	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	2.96	2.16	0.38	4.71
DCD6DCI	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	8.57	10.98	5.22	11.97
DC5YA49	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.52	7.04	4.12	9.1
DCLJ3AV	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	10.34	11.1	10.96	15.05
DC2UJTM	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.36	4.36	1.9	5.99
DCL7OAL	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	3.58	4.22	1.37	6.48
DCZ44U1	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.04	4.56	4.87	8.99
DCI9GAS	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	11.61	11.35	10.71	12.93
DCZ1Q71	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	3.83	5.51	3.48	8.67
DCP26M4	DMVXFYE	Vinorelbine	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	11.91	8.16	5.13	10.14
DCS41WW	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	2	4.13	5.83	8.24
DCR2ZR4	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	1.03	1.2	3.72	6.77
DCIBRTN	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.59	8.26	3.1	6.23
DCV6A07	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	2.13	6.24	5.81	8.14
DCHGUSB	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	9.73	7.94	8.12	9.89
DCGOMQV	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.01	0.34	2.21	4.41
DCHOXZ7	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	1.21	3.49	3.52	4.99
DCU4KVY	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.85	2.79	3.1	5.93
DCZE4K9	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.42	0.67	3.18	5.28
DCU28TH	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	10.97	14.75	5.06	14.97
DCB5IEW	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	7.85	8.67	6.86	9.86
DCYKNJH	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	1.25	1.94	1.77	5.02
DCVBP23	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	3.66	3.6	3.34	6.57
DCDMU19	DMVXFYE	Vinorelbine	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.41	7.14	10.72	13.25
DCYWDAZ	DMVXFYE	Vinorelbine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	8.47	9.17	4.26	9.45
DCBIS65	DMVXFYE	Vinorelbine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	4.39	3.89	2.73	2.76
DC1G7CM	DMVXFYE	Vinorelbine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	0.35	0.48	0.26	3.53
DCNNKFU	DMVXFYE	Vinorelbine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	11.21	9.73	7.66	11.2
DC72208	DMVXFYE	Vinorelbine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	2.14	4.23	0.56	4.24
DC91ZPZ	DMVXFYE	Vinorelbine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	1.71	0.58	0.2	2.12
DC5Z0QB	DMVXFYE	Vinorelbine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	5.08	5.41	0.15	5.73
DCP2R0W	DMVXFYE	Vinorelbine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.26	3.79	2.7	6.01
DCBGZA4	DMVXFYE	Vinorelbine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.39	3.77	0.01	4.27
DC3BK7R	DMVXFYE	Vinorelbine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	13.32	15.75	9.45	16.63
DC7C8PQ	DMVXFYE	Vinorelbine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.3	5.24	2.26	6.59
DCAB231	DMVXFYE	Vinorelbine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	4.02	4.07	2.42	5.9
DCUHJ11	DMVXFYE	Vinorelbine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	1.52	2.15	0.58	0.47
DCKC13J	DMVXFYE	Vinorelbine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	21.71	22.53	10.38	24.77
DCQLWU8	DMVXFYE	Vinorelbine	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.95	12.69	8.9	13.25
DCOKHRD	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	1.91	1.66	6.47	8.88
DCYERPN	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	2.69	3.39	1.56	5.9
DCAYEX9	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	4.68	3.24	2.47	2.53
DC4K0UJ	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	11.37	11.99	5.13	14.89
DC3KA9X	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.71	4.6	2.13	7.84
DCVFCP7	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.41	5.43	3.29	9.08
DCTB9FB	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	9.86	10.46	6.71	12.68
DCZ55Y7	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.33	5.33	1.65	9.1
DC9B535	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	9	7.09	6.47	11.74
DC5QKDA	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	3.3	2.17	3.68	8.71
DCBGQTG	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	1.79	2.13	6.02	8.75
DCR312L	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	7.1	6.8	8.91	9.06
DCXPPNL	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	16.75	14.03	9.12	16.54
DCJ133U	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	3.46	3.83	1.45	6.35
DC2UFVD	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	15.79	13	8.83	14.03
DC652Z4	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	8.68	8.14	1.74	8.43
DCKBTQW	DMVXFYE	Vinorelbine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	1.78	0.91	0.94	6.15
DCFBD6M	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	1.75	1.91	4.32	6.73
DCLFX4I	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	3.35	3.42	2.68	5.9
DCA6KNQ	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.52	2.56	3.45	5.24
DCRF8H2	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	8.4	9.4	7.8	8.26
DC7QJSS	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	10.7	12.26	1.07	13.82
DCCWDAY	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.35	1.43	0.4	2.44
DCVDUL2	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	9.44	7.68	6.79	9.82
DCR6E3Q	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	SYNERGxDB Database	Investigative	ES2	6.6	8.26	8.87	8.93
DC67KRX	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	6.06	5.53	4.39	7.71
DCNPEC2	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.73	4.76	1.92	8.67
DCZKEM4	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.38	3.37	0.81	6.05
DC8LJQ4	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	2.68	3.93	1.38	3.99
DCLMBSA	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	11.14	5.45	5.64	9.54
DCEMPCB	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.29	1.4	2.68	8.22
DCP1USN	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	2.74	3.06	0.48	5.73
DCEFP9S	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.17	1.51	4.95	7.49
DC1OFV6	DMVXFYE	Vinorelbine	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	1.85	0.92	3.7	6.61
DCBSEK2	DMVXFYE	Vinorelbine	Approved	34	DMURVE8	Elacridar	Discontinued in Phase 1	3	.	.	.	.	Human papillomavirus-related cervical adenocarcinoma	SYNERGxDB Database	Investigative	KB-ChR-8-5-11	39.607	40.69	29.375	29.912
DCU2YWY	DMVXFYE	Vinorelbine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	1.81	0.88	8.47	10.58
DCZN5T7	DMVXFYE	Vinorelbine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.94	5.85	4.19	1.6
DCRP4WH	DMVXFYE	Vinorelbine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	1.59	4.23	3.52	7.37
DCTZI33	DMVXFYE	Vinorelbine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.14	0.67	0.79	3.3
DCKTIIP	DMVXFYE	Vinorelbine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	1.25	1.51	1.6	3.71
DCX8S1N	DMVXFYE	Vinorelbine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	6.66	6	7.21	10.27
DCTCI2U	DMVXFYE	Vinorelbine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	12.38	12.64	16.76	18.03
DCAOOFD	DMVXFYE	Vinorelbine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.02	7.47	6.94	10.19
DCEDYWC	DMVXFYE	Vinorelbine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	7.58	7.19	3.99	11.68
DCK77A1	DMM0XGL	Idarubicin	Approved	34	DMQUSBT	Daunorubicin	Approved	34	DMZ4Q0B	Dasatinib	DMZD5QR	Cytarabine	Acute Myeloid Leukemia (AML)	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC5EV11	DMM0XGL	Idarubicin	Approved	34	DMQUSBT	Daunorubicin	Approved	34	DMZD5QR	Cytarabine	.	.	Acute Myeloid Leukemia (AML)	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCDMZA9	DMM0XGL	Idarubicin	Approved	34	DMTI0ZO	Gilteritinib	Approved	34	DMZD5QR	Cytarabine	.	.	"AML, Adult"	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC9J2VB	DMM0XGL	Idarubicin	Approved	34	DMO8PT9	MLN8237	Phase 3	25	DMQUSBT	Daunorubicin	DMZD5QR	Cytarabine	Acute Myeloid Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC09IXG	DMM0XGL	Idarubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	DMZD5QR	Cytarabine	.	.	Adult Acute Monoblastic Leukemia (M5a)	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC1MYNG	DMM0XGL	Idarubicin	Approved	34	DMQL8XJ	Decitabine	Approved	34	DMZD5QR	Cytarabine	.	.	Adult Acute Megakaryoblastic Leukemia (M7)	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCIQSCF	DMM0XGL	Idarubicin	Approved	34	DMZD5QR	Cytarabine	Approved	34	DMZIM37	CP-868596	.	.	Newly Diagnosed AML With FLT3 Activating Mutations	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCZKNGF	DMM0XGL	Idarubicin	Approved	34	DMZD5QR	Cytarabine	Approved	34	.	.	.	.	Acute Myeloid Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCQ0CWF	DMM0XGL	Idarubicin	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCSJ8O5	DMM0XGL	Idarubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Acute Myelogenous Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCWSJKO	DMM0XGL	Idarubicin	Approved	34	DMZD5QR	Cytarabine	Approved	34	.	.	.	.	Blastic Phase Chronic Myelogenous Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCVBHJ7	DMM0XGL	Idarubicin	Approved	34	DMQUSBT	Daunorubicin	Approved	34	DMWQ4MZ	Gilteritinib	DMZD5QR	Cytarabine	Acute Myeloid Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC679I9	DMM0XGL	Idarubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	DMZD5QR	Cytarabine	.	.	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC7YOJ9	DMM0XGL	Idarubicin	Approved	34	DMTI0ZO	Gilteritinib	Approved	34	DMZD5QR	Cytarabine	.	.	Acute Myeloid Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCK8NZ3	DMM0XGL	Idarubicin	Approved	34	DMO8PT9	MLN8237	Phase 3	25	DMZD5QR	Cytarabine	.	.	Acute Myelogenous Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCGSSUX	DMM0XGL	Idarubicin	Approved	34	DM0FB1J	Sertraline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.19	5.19	12.95	12.95
DCGBYXS	DMM0XGL	Idarubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.26	1.97	1.6	1.47
DCBEDO3	DMM0XGL	Idarubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.09	3.57	2.39	1.78
DCG92RD	DMM0XGL	Idarubicin	Approved	34	DM0KYI4	Mebutamate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.4	11.4	24.59	24.59
DCNXINP	DMM0XGL	Idarubicin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.23	4.81	0.38	0.11
DCCW12N	DMM0XGL	Idarubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.03	6.03	16.5	16.53
DC2C2QK	DMM0XGL	Idarubicin	Approved	34	DM1D8XY	Dantrolene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.94	8.94	20.86	20.88
DCS6DPZ	DMM0XGL	Idarubicin	Approved	34	DM1TJ8F	Diethylcarbamazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	31.05	31.05	39.68	39.68
DCK3QO8	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	2.43	1.75	0.18	5.66
DCK6FH3	DMM0XGL	Idarubicin	Approved	34	DM2G9AE	Citalopram	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.42	1.42	8.98	8.98
DCZCV6I	DMM0XGL	Idarubicin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.3	0.58	1.75	1.47
DCKWOYB	DMM0XGL	Idarubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	5.34	8.34	5.91	0.08
DCLHK45	DMM0XGL	Idarubicin	Approved	34	DM3JCVS	Terazosin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	15.99	15.99	26.04	26.06
DCNCQMG	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	5.34	4.4	3.81	8.24
DCBRGVD	DMM0XGL	Idarubicin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	8.54	10.79	3.34	2.59
DCIA19K	DMM0XGL	Idarubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.08	3.65	2.1	3.25
DCO2NE7	DMM0XGL	Idarubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	4.13	1.79	0.06	1.37
DCJ1V8M	DMM0XGL	Idarubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	7.53	4.53	0.6	0.41
DCJVMU8	DMM0XGL	Idarubicin	Approved	34	DM5SXUV	Repaglinide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	25.73	25.73	33.51	33.52
DCDX0LD	DMM0XGL	Idarubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.53	4.56	7.5	12.11
DC3PZDU	DMM0XGL	Idarubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.2	2.6	2.01	6.38
DCGBX8N	DMM0XGL	Idarubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.38	2.81	0.5	0.19
DCHVWBD	DMM0XGL	Idarubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.13	3.79	2.32	0.59
DCKKCQL	DMM0XGL	Idarubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.33	7.11	2.55	1.15
DCE2SV3	DMM0XGL	Idarubicin	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.59	2.59	4.86	4.86
DCDBFRW	DMM0XGL	Idarubicin	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.1	6.01	2.56	2.14
DCT837I	DMM0XGL	Idarubicin	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2	5.82	3.74	1.1
DC7VH8E	DMM0XGL	Idarubicin	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.91	8.13	7.71	0.69
DCOZ33N	DMM0XGL	Idarubicin	Approved	34	DM8X2EH	Everolimus	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.92	11.92	29.21	29.27
DCEIS06	DMM0XGL	Idarubicin	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.64	2.96	2.62	5.98
DCKCG63	DMM0XGL	Idarubicin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.18	1.1	0.18	4.73
DCABQHO	DMM0XGL	Idarubicin	Approved	34	DMBS632	Buspirone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	22.14	22.14	30.83	30.83
DCM6SX8	DMM0XGL	Idarubicin	Approved	34	DME4RA8	Amodiaquine	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.38	6.38	14.44	14.44
DCYQQBE	DMM0XGL	Idarubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.06	1.65	5.8	4.59
DCGXA64	DMM0XGL	Idarubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	5.06	7.6	1.27	0.93
DCJAKTX	DMM0XGL	Idarubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.85	3.99	2.39	2.32
DCWOVCF	DMM0XGL	Idarubicin	Approved	34	DMCUT21	Ursodeoxycholic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	12.08	12.08	19.73	19.73
DC1GLME	DMM0XGL	Idarubicin	Approved	34	DMCX0K3	Cinacalcet	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.4	3.4	11.37	11.37
DCND3KG	DMM0XGL	Idarubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.94	1	2.7	5.61
DCYZ8QQ	DMM0XGL	Idarubicin	Approved	34	DMDO279	Phenprocoumon	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	18.26	18.26	28.32	28.35
DCLUJ1I	DMM0XGL	Idarubicin	Approved	34	DMEO794	Galantamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.22	11.22	19.6	19.61
DCQTUF9	DMM0XGL	Idarubicin	Approved	34	DMFCMPS	Daidzin	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	13.85	13.85	21.63	21.66
DC9Y11G	DMM0XGL	Idarubicin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.48	4.76	5.84	5.65
DCWO03R	DMM0XGL	Idarubicin	Approved	34	DMFO843	Fluspirilene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.96	7.96	15.74	15.76
DCIOXQ9	DMM0XGL	Idarubicin	Approved	34	DMGB035	Armodafinil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.14	3.14	10.15	10.15
DC9R5FS	DMM0XGL	Idarubicin	Approved	34	DMGC5DB	Ciprofibrate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.15	2.15	9.97	10
DC6GQV9	DMM0XGL	Idarubicin	Approved	34	DMGFV3Z	Nizatidine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	19.87	19.87	27.57	27.6
DCQ095Z	DMM0XGL	Idarubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.28	5.66	4.85	8.73
DCG0JWO	DMM0XGL	Idarubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.79	5.34	3.47	3.35
DCXXANH	DMM0XGL	Idarubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.09	2.09	0.58	0.55
DCXQ3WG	DMM0XGL	Idarubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.71	4.05	2	0.78
DCT05ZM	DMM0XGL	Idarubicin	Approved	34	DMHAZLM	Naringenin	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.08	6.08	14.69	14.69
DCLRKVU	DMM0XGL	Idarubicin	Approved	34	DMOL54H	Clopidogrel	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	14.24	14.24	21.29	21.31
DC4E225	DMM0XGL	Idarubicin	Approved	34	DMHPWOM	Diphenidol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	10.71	10.71	18.27	18.27
DC974PF	DMM0XGL	Idarubicin	Approved	34	DMHZJCG	Pentamidine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.85	9.85	18.19	18.19
DCQA354	DMM0XGL	Idarubicin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	4.42	10.97	5.68	4.67
DC704PO	DMM0XGL	Idarubicin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	6.32	0.13	0.4	0.55
DCU3F4J	DMM0XGL	Idarubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	7.04	9.39	7.81	3.25
DC8OU7E	DMM0XGL	Idarubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.43	5.64	1.39	1.09
DC02AK8	DMM0XGL	Idarubicin	Approved	34	DMLPAOB	Allopurinol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	10.73	10.73	20.7	20.73
DCC2OUV	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	7.07	6.74	11.12	11.62
DCZIMZX	DMM0XGL	Idarubicin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	12.83	12.83	22.25	22.25
DCDX0GB	DMM0XGL	Idarubicin	Approved	34	DMM4WBX	Methocarbamol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	26.12	26.12	34.66	34.68
DCWJW9P	DMM0XGL	Idarubicin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.47	5.14	1.55	1.55
DCH90BO	DMM0XGL	Idarubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	3.67	3.45	2.23	4.97
DCOOR22	DMM0XGL	Idarubicin	Approved	34	DMOL5IU	Mesalazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.48	6.48	14.65	14.65
DCSZ8T3	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.67	6.79	0.9	5.75
DCC5WVO	DMM0XGL	Idarubicin	Approved	34	DMPFN6Y	Olanzapine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.72	3.72	12.69	12.71
DC5EXHI	DMM0XGL	Idarubicin	Approved	34	DMPP4DT	Trimethobenzamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	15.5	15.5	33.92	33.96
DCZEW61	DMM0XGL	Idarubicin	Approved	34	DMPWB7T	Maprotiline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.08	2.08	4.76	4.78
DCBQ8FP	DMM0XGL	Idarubicin	Approved	34	DMQXTJS	Eptifibatide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.62	11.62	19.96	19.96
DCV0KD2	DMM0XGL	Idarubicin	Approved	34	DMR6N7H	Acetohexamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	17.46	17.46	23.91	23.95
DCUZLQS	DMM0XGL	Idarubicin	Approved	34	DMRM3AW	Acarbose	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.44	2.44	10.34	10.35
DCP0UML	DMM0XGL	Idarubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	10.53	14.15	5.03	4.11
DCDDDPJ	DMM0XGL	Idarubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	3.57	3.77	1.22	10.25
DCPXE67	DMM0XGL	Idarubicin	Approved	34	DMSWYF5	Quinine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.49	3.49	23.59	23.62
DC3SRBJ	DMM0XGL	Idarubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.06	5.27	1.34	1.04
DCZNZ2U	DMM0XGL	Idarubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	3.01	7.69	7	2.06
DC6O30T	DMM0XGL	Idarubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.75	3.56	2.71	0.44
DCM0FX8	DMM0XGL	Idarubicin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.05	0.22	4.46	1.86
DCN316N	DMM0XGL	Idarubicin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	23.01	24.66	8.23	8.16
DCCGHVM	DMM0XGL	Idarubicin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.06	2.55	1.43	1.31
DCTSK22	DMM0XGL	Idarubicin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	11.25	5.9	6.11	0.93
DCIEEOX	DMM0XGL	Idarubicin	Approved	34	DM2AQ5N	Spironolactone	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	10.19	10.19	18.02	18.02
DCL1E57	DMM0XGL	Idarubicin	Approved	34	DMRBMAU	Mycophenolic acid	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.22	5.22	7.66	7.68
DCTHSO7	DMM0XGL	Idarubicin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.46	4.81	0.99	0.7
DCE15PL	DMM0XGL	Idarubicin	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4	4	6	6.09
DCQ5AU8	DMM0XGL	Idarubicin	Approved	34	DMVRIC2	Zileuton	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	14.6	14.6	27.68	27.7
DCDPUAR	DMM0XGL	Idarubicin	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	4.49	7.59	3.96	7.45
DCCLUFP	DMM0XGL	Idarubicin	Approved	34	DMXCM7H	Cerivastatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.6	2.6	4.45	4.54
DC6Q1TC	DMM0XGL	Idarubicin	Approved	34	DMYURI6	Raltegravir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	25.44	25.44	32.99	33
DCM41TX	DMM0XGL	Idarubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	4.02	3.42	0.24	0.75
DCK70Y3	DMM0XGL	Idarubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	5.78	4.45	7.38	8.48
DCGPYKQ	DMM0XGL	Idarubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.34	2.56	0.92	0.71
DCUB63Y	DMM0XGL	Idarubicin	Approved	34	DMZA017	Tetracycline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.78	1.78	9.39	9.42
DCMCNBN	DMM0XGL	Idarubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.15	3.24	0.88	0.66
DC7IPU4	DMM0XGL	Idarubicin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.81	10.09	2.03	0.85
DC846KO	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	7.47	10.44	1.41	2.65
DCYIHJS	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	12.14	16.46	6.94	6.94
DCGW9EH	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	3.46	5.76	0.23	7.7
DC02R95	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	6.77	10.07	3.88	2.9
DCMZH25	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	5.52	8.88	10.33	11.58
DCC2Y0H	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	22.09	23.07	9.08	9.86
DCX5ELE	DMM0XGL	Idarubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.83	10.38	1.11	11.01
DCNBZAE	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	9.36	9.37	2.5	18.63
DCESJGB	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.51	6.5	11.84	12.41
DCQXID2	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	33.36	34.03	1.25	25.94
DC1U2QD	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	11.63	14.21	11.8	16.4
DCEK5FD	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	32.05	29.79	12.96	23.06
DCPQH4N	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	14.95	15.16	0.84	17.74
DC1Z1AK	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	21.67	22.93	0.63	24.61
DCVDCXG	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	10.71	22.62	4.86	10.66
DCAWVDV	DMM0XGL	Idarubicin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.53	3.02	2.69	1.79
DCBWOB3	DMM0XGL	Idarubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.51	4.99	3.35	0.84
DCVVTQA	DMM0XGL	Idarubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.27	4.03	1.39	5.74
DCPK21J	DMM0XGL	Idarubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	18.66	22.56	8.24	8.24
DC08HWP	DMM0XGL	Idarubicin	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.12	1.36	0.9	0.02
DCADJ4N	DMM0XGL	Idarubicin	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.27	7.57	1.96	0.64
DCCW4HM	DMM0XGL	Idarubicin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.96	2	11.43	2.68
DC9AU8K	DMM0XGL	Idarubicin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.39	2.77	0.01	3.66
DCT5CKV	DMM0XGL	Idarubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.05	5.21	2.86	1.76
DC5COV0	DMM0XGL	Idarubicin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.22	5.22	3.6	3.6
DC46JGB	DMM0XGL	Idarubicin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	14.32	19.66	13.81	13.87
DC8H1YH	DMM0XGL	Idarubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.67	4.96	2.01	6.59
DC5B4AY	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.64	5.03	2.69	7.7
DCSIZOX	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	9.22	17.98	5.87	16.61
DCZFDFX	DMM0XGL	Idarubicin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.29	5.72	6.01	4.95
DCW5PVP	DMM0XGL	Idarubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.45	1.6	1.12	1.72
DCEPO2U	DMM0XGL	Idarubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	5.88	4.05	0.5	3.97
DC7VQ3D	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.49	5.56	4.1	5.32
DCCPGMW	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	3.21	4.85	0.29	0.29
DCIIOPZ	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	24.81	28.45	18.76	18.83
DCCRAJG	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.13	6.05	5.23	5.74
DCNW3UV	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	12.9	9.89	2.58	2.47
DCUTV2S	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	8.18	13.96	8.81	15.86
DCS0JZU	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	4.6	0.38	2.38	2.39
DCH43ZO	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	24.05	20.5	6.72	6.72
DCUXRBQ	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	8.07	11.75	2.6	6.27
DCBKOJT	DMM0XGL	Idarubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	21.62	12.79	6.26	8.84
DCCGCBM	DMM0XGL	Idarubicin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4	5.48	0.66	0.58
DCFB65P	DMM0XGL	Idarubicin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.09	10.92	7.31	3.36
DCFPNKR	DMM0XGL	Idarubicin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.62	2.52	1.52	0.82
DCHEUVD	DMM0XGL	Idarubicin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.02	1.55	1.96	0.53
DCGV3ON	DMM0XGL	Idarubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.11	6.11	0.65	0.64
DCOIT7G	DMM0XGL	Idarubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.02	4.39	3.38	1.02
DC25U8F	DMM0XGL	Idarubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.02	0.82	0.47	0.39
DCZAIIA	DMM0XGL	Idarubicin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.91	4.79	0.09	0.2
DCIWIFF	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	12.86	11.62	14.74	20.01
DCRFJ4E	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	2.8	5.05	3.03	6.96
DC5KHUQ	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.46	5.44	0.74	7.67
DC36ADM	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	2.26	3.53	0.65	0.67
DCXGARB	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	11.81	11.3	12.73	17.23
DC036XS	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	1.27	6.93	3	3.86
DCT3VG4	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	15.01	14.82	13.17	20.57
DCK7L3P	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	3.68	9.94	4.95	10.54
DC5MMFN	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.88	10.31	1.22	12.15
DC4YD0T	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	9.24	11.01	6.31	13.2
DCS2G1Q	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.48	5.74	5.48	9.58
DC0SIR0	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.67	8.39	8.25	9.91
DCH8R8G	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	21.32	19.05	12.09	20.57
DC52CUG	DMM0XGL	Idarubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	11.19	14.49	9.35	15.67
DCD52ZM	DMM0XGL	Idarubicin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.28	9.75	4.54	1.51
DCQYMZU	DMM0XGL	Idarubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.74	6.55	2.58	3.43
DCV91SU	DMM0XGL	Idarubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	12.77	19.2	5.27	2.85
DCRP3PA	DMM0XGL	Idarubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	6.49	5.37	1.85	6.81
DCD1SOT	DMM0XGL	Idarubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.5	2.17	2.02	4.34
DCDNQBV	DMM0XGL	Idarubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.54	10.37	5.57	8.22
DC00HWL	DMM0XGL	Idarubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.39	3.92	0.2	2.83
DCC4E8I	DMM0XGL	Idarubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	8.13	6.65	7.13	9.6
DCLFQLH	DMM0XGL	Idarubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	16.13	12.05	10.42	11.98
DCFXD31	DMM0XGL	Idarubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.19	3.23	5.59	5.72
DC9A9VD	DMM0XGL	Idarubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	6.16	10.58	10.72	10.83
DCG9MF0	DMM0XGL	Idarubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.25	6.68	5.53	8.33
DCKYM3W	DMM0XGL	Idarubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.6	4.55	5.52	6.77
DCDFID5	DMM0XGL	Idarubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	12.58	14.1	2.66	16.24
DCZZXSM	DMM0XGL	Idarubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.28	15.6	9.23	15.27
DCX6RFQ	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	6.11	8.19	1.39	3.75
DC28HEO	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.78	2.79	9.78	10.41
DCTM16L	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	11.63	15.14	3.75	8.18
DCUD797	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	14.5	19.61	18.88	20.23
DCJGDUJ	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	7.03	7.95	4.58	10.52
DCJH09S	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	4.43	4.28	8.19	9.53
DCTU7Z1	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.42	1.02	5.05	9.93
DCFWILX	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	4.33	2.78	8.54	12.06
DCWEZ0T	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	19.71	19.97	22.38	22.65
DCBGW24	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	29.55	24.79	22.89	27.26
DCHA3Z6	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	17.65	17.91	16.32	19.62
DC4PRQ1	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.37	11.26	14.43	14.61
DCT4OGF	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	27.34	24.16	20.21	26.42
DCPVB08	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	26.34	26.56	13.81	30.7
DCWYB3D	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	31.67	27.62	25.26	28.8
DCK1LH4	DMM0XGL	Idarubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	20.85	21.95	13.64	14.96
DCRKTG1	DMM0XGL	Idarubicin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	6.54	11.18	1.24	1.19
DCIFA5M	DMM0XGL	Idarubicin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.92	4.27	2.22	0.1
DCNPKG5	DMM0XGL	Idarubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.81	6.38	1.73	1.08
DC5SFRT	DMM0XGL	Idarubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	5	11.46	3.56	3.56
DCDAF4M	DMM0XGL	Idarubicin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.04	1.36	3.8	3.83
DC2QYCU	DMM0XGL	Idarubicin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.92	1.6	3.61	3.85
DCFYMW7	DMM0XGL	Idarubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.38	1.82	13.71	15.16
DCJCJWE	DMM0XGL	Idarubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	3.35	4.81	0.84	6.2
DCF1ZZH	DMM0XGL	Idarubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.08	5.83	5.37	9.36
DC206QY	DMM0XGL	Idarubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.79	3.74	9.39	12.28
DCA3W2Z	DMM0XGL	Idarubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	1.03	0.24	5.5	8.78
DCN1NCB	DMM0XGL	Idarubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.35	0.28	1.08	4.15
DCKPVQ7	DMM0XGL	Idarubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	5.77	5.07	2.75	7.19
DCPUDH1	DMM0XGL	Idarubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.8	2.02	1.13	7.03
DC6PVEO	DMM0XGL	Idarubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	12.53	12.8	1.16	16.41
DCZOMB8	DMM0XGL	Idarubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	13.96	11.58	9.33	14.24
DCDHQYZ	DMM0XGL	Idarubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	10.28	8.85	6.37	9.57
DC79XNT	DMM0XGL	Idarubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	13.73	14.25	2.96	8.52
DCZ5OCC	DMM0XGL	Idarubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	15.92	14.05	24.56	26.13
DCZLE36	DMM0XGL	Idarubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.1	5.77	1.55	7.27
DCRV2EX	DMM0XGL	Idarubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	17.01	16.02	20.16	22.81
DCF3RFV	DMM0XGL	Idarubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	13.69	10.53	8.41	10.72
DCOX8DV	DMM0XGL	Idarubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	30.01	27.24	36	37.65
DCL7PM8	DMM0XGL	Idarubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.47	7.46	7.52	9.79
DCW1PG6	DMM0XGL	Idarubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	6.52	11.95	11.9	14.33
DCRNMQK	DMM0XGL	Idarubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	14.89	14.15	11.93	17.37
DCEH6JU	DMM0XGL	Idarubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	14.09	14.94	0.4	16.68
DCR9N5N	DMM0XGL	Idarubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.53	8.18	9.31	11.26
DC3S21B	DMM0XGL	Idarubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	13.67	14.47	9.14	14.27
DCHAX3W	DMM0XGL	Idarubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.72	11.7	9.84	12.33
DCINYI6	DMM0XGL	Idarubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.26	5.54	3.12	1.65
DCW1QWP	DMM0XGL	Idarubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.42	7.69	6.52	3.1
DCDY5E9	DMM0XGL	Idarubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.18	2.8	2.59	1.8
DCQ2IOS	DMM0XGL	Idarubicin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.68	8.26	8.93	9.39
DCAZSAH	DMM0XGL	Idarubicin	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.16	8.72	4.45	0.79
DC8NWEW	DMM0XGL	Idarubicin	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	6.74	10.58	4.37	3.22
DCR4909	DMM0XGL	Idarubicin	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.52	2.47	1.76	1.84
DCTDZRI	DMM0XGL	Idarubicin	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	6.97	9.63	0.46	5.68
DCJYYQA	DMM0XGL	Idarubicin	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	1.98	2.34	0.51	4.89
DCPSQTW	DMM0XGL	Idarubicin	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	4.44	3.47	0.45	7.53
DCTSC9P	DMM0XGL	Idarubicin	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.32	2.64	3.62	6.19
DC3FGF0	DMM0XGL	Idarubicin	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.46	5.45	1.75	6.18
DCVA6GE	DMM0XGL	Idarubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.66	2.44	2.96	2.96
DC9TWWT	DMM0XGL	Idarubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.01	0.03	0.03	0.03
DCCIJ7I	DMM0XGL	Idarubicin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	4.24	1.98	1.64	7.51
DCREE7M	DMM0XGL	Idarubicin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.5	5.32	4.62	5
DCWPKY9	DMM0XGL	Idarubicin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	12.22	10.9	13.97	17.3
DC25FOK	DMM0XGL	Idarubicin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	0.27	2.36	0.16	4.37
DCUGE12	DMM0XGL	Idarubicin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	8.88	7.27	3.49	8.17
DCQF5K6	DMM0XGL	Idarubicin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.61	5.9	2.25	6.16
DCXWIVI	DMM0XGL	Idarubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.16	4.36	0.56	0.56
DCPGEBZ	DMM0XGL	Idarubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.14	3.88	0.84	0.5
DC1ADAR	DMM0XGL	Idarubicin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.34	4.05	2.2	1.73
DCOT79P	DMM0XGL	Idarubicin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.16	4.37	2.43	2.19
DCQA8PI	DMM0XGL	Idarubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.61	1.7	9.59	10.93
DCJ5U1J	DMM0XGL	Idarubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	5.66	6.11	2.35	8.02
DCS3UVL	DMM0XGL	Idarubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	1.08	1.74	5.07	9.24
DCPE80I	DMM0XGL	Idarubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.17	4.2	19.5	6.08
DC2OJIG	DMM0XGL	Idarubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	4.41	3.38	3.9	8.94
DCYJ7YF	DMM0XGL	Idarubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.68	3.86	5.32	7.17
DCHNNUF	DMM0XGL	Idarubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	8.44	11.82	12.13	14.78
DCW4WK8	DMM0XGL	Idarubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.59	3.52	1.36	6.84
DCWAD5N	DMM0XGL	Idarubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	2.91	7.66	3.57	9.21
DCI8GK2	DMM0XGL	Idarubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	7.65	3.65	4.11	7.56
DCPF2BZ	DMM0XGL	Idarubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	19	21.68	18.22	21.84
DCYRPNB	DMM0XGL	Idarubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.32	8.58	3.52	1.35
DCQ5Z2Q	DMM0XGL	Idarubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	11.17	10.52	4.31	1.79
DCSLO6B	DMM0XGL	Idarubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.47	3.49	1.09	1.11
DC6D8CO	DMM0XGL	Idarubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	6.88	10.36	4.57	3.79
DCDGOLB	DMM0XGL	Idarubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.35	3.18	2.36	1.04
DCAL0KN	DMM0XGL	Idarubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.34	4.8	1.35	2.01
DCATEPG	DMM0XGL	Idarubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.12	6.73	2.73	1.56
DCRFYVV	DMM0XGL	Idarubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.74	7	4.03	2.16
DCDVE4U	DMM0XGL	Idarubicin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.31	3.4	1.64	1.28
DCFX184	DMM0XGL	Idarubicin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	4.32	3.55	5.5	12.21
DC70V0L	DMM0XGL	Idarubicin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.2	3.53	3.68	7.38
DC5J8GB	DMM0XGL	Idarubicin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.5	0.9	1.77	4.82
DC5IEVE	DMM0XGL	Idarubicin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	2.87	3.51	0.28	4.64
DCNGA17	DMM0XGL	Idarubicin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.97	8.47	2.56	1.51
DCQP2X6	DMM0XGL	Idarubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	6.33	10.89	3.6	1.72
DCDA8HP	DMM0XGL	Idarubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.41	6.73	0.61	0.49
DCWU8UD	DMM0XGL	Idarubicin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.05	5.21	1.91	2.22
DCQKPE9	DMM0XGL	Idarubicin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	4.48	9.27	1.94	0.27
DCFNPUY	DMM0XGL	Idarubicin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.31	2.43	0.3	0.24
DCOWXNO	DMM0XGL	Idarubicin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.07	2.16	0.28	0.45
DC5RM9J	DMM0XGL	Idarubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	0.73	0.22	0.76	5.99
DCSWFFQ	DMM0XGL	Idarubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	1.17	1.95	2.97	6.84
DCFCXPK	DMM0XGL	Idarubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	5.03	5.59	5.57	10.74
DCZ8RF3	DMM0XGL	Idarubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.12	5.01	1.28	6.61
DC09LTY	DMM0XGL	Idarubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	22.96	19.41	14.96	19.41
DCCNJJX	DMM0XGL	Idarubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	7.49	9.04	4.14	1.13
DCG6FPC	DMM0XGL	Idarubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.25	1.71	0.82	1.09
DCKMWFC	DMM0XGL	Idarubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.06	5.13	0.79	1.08
DCMQESX	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	8.89	8.04	16.91	17.27
DCHWG2F	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	12.35	15.67	15.41	15.77
DCJFV7N	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.52	1	2.58	3.69
DCETASI	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	1.33	1.73	4.04	4.06
DCVCNGI	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	9.03	13.21	10.9	10.9
DCXX7J4	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.73	0.03	4.77	5.66
DC27IAU	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	3.39	3.3	9.7	10.58
DCTGFDP	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	9.79	12.68	11.24	13.92
DCSSAKR	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.51	14.07	16.17	16.21
DCT6D17	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	0.56	7.63	0.9	6.95
DCXL7YD	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.93	2.96	10.13	11.07
DCRACVR	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	4.15	16	17.53	19.35
DCDXBEC	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.89	9.38	13.14	14.18
DC1SS8O	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	9.6	16.65	15.03	16.78
DC6CUKI	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	26.79	28.08	26.89	28.27
DC4SIYG	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	4.51	10.69	6.3	13.84
DC9TFEC	DMM0XGL	Idarubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	9.18	17.55	2.12	12.02
DCN7TMH	DMM0XGL	Idarubicin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.23	1.97	2.27	1.35
DCP0317	DMM0XGL	Idarubicin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.33	4.34	0.43	0.27
DC0UPSE	DMM0XGL	Idarubicin	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	10.65	13.81	6.65	14.52
DCQKNQ3	DMM0XGL	Idarubicin	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.59	3.58	7.8	10.3
DCE08FW	DMM0XGL	Idarubicin	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	8.9	10.97	10.11	13.07
DCG714U	DMM0XGL	Idarubicin	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	20.17	20.54	17.72	21.81
DCDVCWP	DMM0XGL	Idarubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	5.21	2.42	0.67	2.96
DCZ9CR9	DMM0XGL	Idarubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	10.35	8.14	3.71	6.95
DC4N1Y3	DMM0XGL	Idarubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	22.73	21.48	14.23	21.94
DCYVYLR	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	20.39	20.99	9.29	11.83
DCYG5V5	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	8.76	21.62	6.83	17.12
DCA5EWL	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	4.58	4.4	11.49	13.26
DCOMSYM	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	1.1	5.23	4.65	5.63
DCQNS7Y	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.06	4.43	4.51	5.09
DCH09WN	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	5.42	6.03	6.69	6.8
DCCZS5X	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	2.46	3.5	3.24	4.74
DCGINVR	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	2.21	5.4	2.18	2.09
DCYK55D	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	10.65	10.54	8.26	8.26
DCERMII	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	10.92	12.27	9.04	7.26
DCW8JLE	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.66	7.45	2.03	7.19
DC9LAL3	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	14.66	16.37	11.87	16.1
DCNV777	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	24.93	20.09	22.11	19.2
DCGGFG6	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.48	4.52	6.2	6.43
DCQR30U	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	17.87	16.42	12.5	13.06
DCWYY4R	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	1.75	2.36	1.03	1.62
DCCO826	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.16	4.26	1.86	2.97
DCNY6TU	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	1.63	13.3	9.78	11.54
DCTA3XW	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	11.01	12.54	7.95	8.91
DCI2G2Z	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	28.6	28.23	28.96	29.43
DCZG9XK	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	4.34	5.72	5.8	7.14
DCMQI83	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	30.88	32.84	31.71	32.74
DC7RZNG	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.62	7.78	0.24	0.24
DCLLYNA	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	11.56	12.31	13	13
DCKATEH	DMM0XGL	Idarubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	7.66	16.29	9.8	9.02
DCJL8PZ	DMM0XGL	Idarubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.43	2.63	0.34	5.48
DC88A1D	DMM0XGL	Idarubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.21	4.3	3.2	2.91
DCEQ2A0	DMM0XGL	Idarubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	17.35	9.78	7.25	0.68
DC04R1S	DMM0XGL	Idarubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	5.58	4.57	1.39	13.78
DCUS4CO	DMM0XGL	Idarubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	6.3	6.34	0.2	6.34
DCF3IOF	DMM0XGL	Idarubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.41	1.66	2.21	0.53
DCW8ZRK	DMM0XGL	Idarubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.77	6.46	2.25	9.16
DCE72CT	DMM0XGL	Idarubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.54	4.82	0.69	0.51
DC6F0PY	DMM0XGL	Idarubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	10.58	11.86	3.79	14.2
DC4I4UN	DMM0XGL	Idarubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	7.5	7.43	6.14	9.1
DCSVNF5	DMM0XGL	Idarubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	10.65	8.99	4.35	9.92
DCPY550	DMM0XGL	Idarubicin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.47	3.62	0.2	0.05
DCEUCPD	DMM0XGL	Idarubicin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.57	5.39	1.66	1.05
DCXWCT1	DMM0XGL	Idarubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	7.11	12.5	1.99	4.24
DCWGALF	DMM0XGL	Idarubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	1.44	0.2	9.1	10.64
DCZYOC7	DMM0XGL	Idarubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	2.95	5.77	3.49	7.69
DCWLUT3	DMM0XGL	Idarubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	1.46	0.45	4.99	12.14
DCZMHKX	DMM0XGL	Idarubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.91	3.03	6.89	7.43
DCH775J	DMM0XGL	Idarubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	7.16	7.4	11.56	13.78
DC3AL14	DMM0XGL	Idarubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.61	8.44	10.93	11.52
DCKC8RX	DMM0XGL	Idarubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	13.06	16.59	16.38	16.41
DCC6N72	DMM0XGL	Idarubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.11	2.6	5.16	7.3
DCWX89S	DMM0XGL	Idarubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	5.92	12.39	14.76	14.98
DCZF6RN	DMM0XGL	Idarubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.27	5.64	8.72	10.52
DCVLWWC	DMM0XGL	Idarubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	14.17	15.31	13.55	18.32
DCEHZAF	DMM0XGL	Idarubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.13	6.68	5.16	7.95
DCOGQ7O	DMM0XGL	Idarubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	5.59	10.84	5.89	2.47
DCII0GJ	DMM0XGL	Idarubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	9.05	12.84	6.12	4.85
DC6KVPO	DMM0XGL	Idarubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.09	2.65	0.17	0.07
DC821O5	DMM0XGL	Idarubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.77	2.07	0.65	0.29
DCISIAG	DMM0XGL	Idarubicin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.2	2.85	2.03	1.15
DCEFXO1	DMM0XGL	Idarubicin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.46	2.37	1.7	0.47
DC62DA6	DMM0XGL	Idarubicin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.72	6.09	0.98	0.97
DCP1P3N	DMM0XGL	Idarubicin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	7.18	12.02	6.79	2.91
DCNJV4A	DMM0XGL	Idarubicin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.73	2.09	0.96	1.09
DC42BZO	DMM0XGL	Idarubicin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.3	4.95	3.88	3.7
DCLJMAS	DMM0XGL	Idarubicin	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	2.89	2.55	1.35	5.14
DC8BHW5	DMM0XGL	Idarubicin	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	2.26	1.12	0.23	7.52
DCVIIHX	DMM0XGL	Idarubicin	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.46	2.53	0.83	5.12
DCABAXC	DMM0XGL	Idarubicin	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	5.62	5.19	1.08	6.74
DC870WL	DMM0XGL	Idarubicin	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	9.42	9.33	3.25	12.57
DC3FNKP	DMM0XGL	Idarubicin	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.12	3.28	1.01	6.97
DCEFFRL	DMM0XGL	Idarubicin	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	9.08	8	4.66	10.03
DCIGQN8	DMM0XGL	Idarubicin	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	11.97	11.13	9.36	11.86
DC06YGM	DMM0XGL	Idarubicin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.27	7.11	2.81	1.1
DCJP8YU	DMM0XGL	Idarubicin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.43	5.3	5.97	5.35
DCS9P4X	DMM0XGL	Idarubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	0.75	0.83	17.82	18.37
DC59XVX	DMM0XGL	Idarubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	2.59	2.49	8.75	9.48
DCQCDK9	DMM0XGL	Idarubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	8.47	8.63	0.34	11.8
DC3PT24	DMM0XGL	Idarubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.39	3.93	6.17	6.24
DCCRZI5	DMM0XGL	Idarubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.55	0.16	2.63	6.49
DCCYE6G	DMM0XGL	Idarubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	25.19	22.7	26.99	27.65
DC0GWGG	DMM0XGL	Idarubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	13.01	13.16	14.86	15.17
DCVFHMR	DMVP5YE	Doxorubicin	Approved	34	DM053KT	Aprepitant	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.7	1.7	2.84	2.93
DCVR19A	DMVP5YE	Doxorubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.39	3.39	3.81	3.9
DCMYVDO	DMVP5YE	Doxorubicin	Approved	34	DM0KYI4	Mebutamate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.97	1.97	2.46	2.56
DC5IZLH	DMVP5YE	Doxorubicin	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.3	4.3	4.64	4.73
DCI1I0U	DMVP5YE	Doxorubicin	Approved	34	DM0QV1J	Baclofen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.27	4.27	4.69	4.79
DCITJ2L	DMVP5YE	Doxorubicin	Approved	34	DM0RKS4	Bepridil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.73	4.73	5.32	5.41
DCTXMS2	DMVP5YE	Doxorubicin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.75	2.75	4.88	4.97
DC6Z8WD	DMVP5YE	Doxorubicin	Approved	34	DM1AGXN	Paromomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.59	4.59	5.02	5.06
DCKINST	DMVP5YE	Doxorubicin	Approved	34	DM1TJ8F	Diethylcarbamazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.77	0.77	1.96	2.05
DCXCLA6	DMVP5YE	Doxorubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	DrugCombDB Database	Investigative	HDLM-2	2.646	1.096	5.88	9.142
DCTC2FI	DMVP5YE	Doxorubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	DrugCombDB Database	Investigative	L-428	33.724	38.148	8.376	7.011
DCY532Y	DMVP5YE	Doxorubicin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	T-cell leukemia/lymphoma	DrugCombDB Database	Investigative	ED-40515	4.742	4.578	1.564	5.049
DC1PM0F	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	1.46	1.68	5.07	9.87
DC3PZ1F	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	11.16	10.82	9.85	18.52
DC776LG	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	4.33	3.85	1.57	9.46
DCL5V9Y	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	2.48	2.25	0.72	4.81
DCP8ODG	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	3.19	1.37	1.11	6.34
DCB7B5H	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	7.11	6.04	2.92	10.68
DCRMVUE	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	4.25	4.36	3.26	9.78
DCA1USD	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	7.23	5.43	1.97	9.57
DC2FWXV	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	0.71	0.62	2.96	7.6
DCI14QR	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	6.4	5.32	2.15	8.69
DC0YQVQ	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	2.44	1.42	3.05	4.36
DCLHCEX	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.44	4.35	0.53	8.06
DC5047B	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	1.31	1.26	0.12	1.7
DCX5UAT	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	5.01	4.23	1.7	6.68
DCAW1EH	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	0.1	0.34	1.5	6.67
DCWRKUL	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	10.02	10.53	3.29	15.5
DCSXNQO	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	5.08	4.67	0.64	9.33
DCZ4TO4	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	10.79	11.47	6.14	14.13
DC24OIX	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	8.38	8.28	7.31	12.42
DCGH6XJ	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	11.6	7.09	4.53	11.24
DCUQ7IG	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	6.51	4.96	6.45	10.3
DCV5W2P	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	14.27	13.11	2.69	17.21
DC4RR43	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	3.81	2.94	7.71	12.05
DCS45KD	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	8.1	8.94	2.24	10.14
DC2H7SY	DMVP5YE	Doxorubicin	Approved	34	DM2G9AE	Citalopram	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.44	2.44	3.03	3.12
DCO6KBD	DMVP5YE	Doxorubicin	Approved	34	DM2HU9I	Triamterene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.57	1.57	2	2.05
DC3ANR3	DMVP5YE	Doxorubicin	Approved	34	DM2TUCU	Crotamiton	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.7	0.7	1.13	1.22
DC7JI46	DMVP5YE	Doxorubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Hodgkin lymphoma	DrugCombDB Database	Investigative	L-1236	4.472	2.223	3.817	6.725
DCO1WJY	DMVP5YE	Doxorubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	7.74	4.75	6.04	8.92
DCGCV4L	DMVP5YE	Doxorubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	2.21	1.22	2.58	4.4
DCLJEWA	DMVP5YE	Doxorubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	0.13	0.26	4.68	8.23
DCI024N	DMVP5YE	Doxorubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	2.02	1	3.17	6.08
DC4JK9Q	DMVP5YE	Doxorubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	8.33	3.49	0.63	6.31
DCLS5DD	DMVP5YE	Doxorubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	6.12	7.45	4.82	11.3
DCVDI72	DMVP5YE	Doxorubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	1.94	1.45	4.64	6.99
DC5D8I4	DMVP5YE	Doxorubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	3.68	2.21	2.26	2.9
DCS9VHE	DMVP5YE	Doxorubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	2.69	1.34	0.15	2.64
DCJK3HJ	DMVP5YE	Doxorubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	7.6	7.59	3.14	12.4
DCBAT0R	DMVP5YE	Doxorubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	7.84	6.99	4.64	8.59
DC9NE70	DMVP5YE	Doxorubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	5.18	6.89	4.94	10.26
DC1YZXS	DMVP5YE	Doxorubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	8.65	8.49	7.99	10.52
DC8PX6M	DMVP5YE	Doxorubicin	Approved	34	DM3KJBC	Epinephrine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.72	2.72	5.14	5.23
DCM941G	DMVP5YE	Doxorubicin	Approved	34	DM3OWT4	Tindamax	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.76	1.76	2.13	2.23
DCFXIS2	DMVP5YE	Doxorubicin	Approved	34	DM3P6V7	Furazolidone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.48	0.48	0.93	1.02
DCUP72V	DMVP5YE	Doxorubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	3.23	2.53	2.11	6.91
DCHIOXR	DMVP5YE	Doxorubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Hodgkin lymphoma	DrugCombDB Database	Investigative	U-HO1	0.62	1.63	1.58	3.26
DC762VA	DMVP5YE	Doxorubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	5.15	4.11	0.9	5.79
DCNRCTP	DMVP5YE	Doxorubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	1.18	0.62	2.77	7.02
DCGKX71	DMVP5YE	Doxorubicin	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	1.68	1.37	7.54	9.38
DCT3SLV	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	2.44	3.2	0.69	7.51
DCUPEOV	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	1.07	1	3.63	7.42
DCX8PWS	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	4.23	2.31	1.09	4.89
DCDVMLQ	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	7.15	5.89	2.13	6.72
DCUR0JR	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	7.29	7.15	4.82	10.78
DC8BMLM	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	4.84	3.79	2.78	7.1
DC99MEM	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	3.76	1.99	0.37	6.15
DCMCTHN	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	6.07	4.91	4.42	9.95
DC9JU51	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	6.19	5.9	4.08	6.44
DCUKZEY	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	1.91	1.73	2.34	3.73
DC5OZWT	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.41	4.19	2.6	8.24
DCELW3O	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	0.34	0.42	0.41	0.68
DC6K0F3	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	5.3	4.32	3.36	9.7
DCHPJ58	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	3.3	2.54	1.09	6.77
DCO0LAX	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	1.09	2.16	0.44	6.98
DCA4N4N	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	5.75	4.71	3.87	8.51
DCCWVVI	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	2.05	1.96	7.69	11.56
DCLQYZL	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	5.43	4.42	2.79	7.74
DCKH544	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	4.76	5	6.17	8.09
DC5XONO	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	16.49	15.13	12.98	18.79
DCR6OI1	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	7.75	8.74	7.62	13.23
DCF745L	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	9.42	9.05	12.89	16.79
DCBY6TR	DMVP5YE	Doxorubicin	Approved	34	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	8.26	6.17	6.07	8.23
DCVVEH8	DMVP5YE	Doxorubicin	Approved	34	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Hodgkin lymphoma	DrugCombDB Database	Investigative	L-1236	17.867	16.693	0.407	4.383
DCP4S8K	DMVP5YE	Doxorubicin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.18	3.18	5.32	5.37
DCUH6A3	DMVP5YE	Doxorubicin	Approved	34	DM5IKUF	Dihydroergotamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.67	4.67	5.13	5.15
DCO6TN1	DMVP5YE	Doxorubicin	Approved	34	DM5Q1W4	Ym155	Phase 2	21	.	.	.	.	Hodgkin lymphoma	DrugCombDB Database	Investigative	L-1236	5.692	9.484	0.652	4.309
DCRAUAX	DMVP5YE	Doxorubicin	Approved	34	DM5ZVLB	Ixazomib	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	JHH-136	35.762	34.411	2.903	0.255
DCQI8ID	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	0.11	0.08	3.01	8.33
DC8262N	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	1.13	0.84	4.12	7.9
DCVRFRI	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	1.31	0.03	1.93	6.37
DCNCF6R	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	7.57	8.11	12.3	16.19
DCSDBS9	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	1.57	0.01	4.51	8.23
DCSKA1B	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	2.98	1.15	0.31	5.6
DCTJOFS	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	2.04	2.02	7.12	10.58
DCNFOT4	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	4.99	3.97	8.16	12.25
DCCPH1V	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	5.84	5.8	9.82	13.29
DCD1SZV	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	4.66	4.35	7.55	12.81
DCJ0KNW	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	0.43	0.04	3.92	7.4
DC4P4MY	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	1.87	1.62	5.93	10.37
DCVIXM1	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	3.72	3.46	5.38	9.38
DCFFV31	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	2.26	2.24	7.62	9.42
DCLCLIZ	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	7.74	6.4	7.93	12.36
DCFJBQH	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	2.37	0.56	6.15	9.52
DCYP5LL	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	3.25	3.95	6.24	9.97
DCVNOFB	DMVP5YE	Doxorubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	16.58	16.91	13.72	22.72
DC5GYKZ	DMVP5YE	Doxorubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	2.47	1.56	2.33	7.22
DCA04ZC	DMVP5YE	Doxorubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	5.52	4.64	1.48	10.7
DCR3WPD	DMVP5YE	Doxorubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	4.48	2.85	0.48	8.64
DCCPA86	DMVP5YE	Doxorubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	3.38	6.55	1.91	9.73
DCACY3H	DMVP5YE	Doxorubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	5.52	4.97	1.47	12.59
DCY29RX	DMVP5YE	Doxorubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	5.38	3.89	2.05	8.27
DCORGDA	DMVP5YE	Doxorubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	3.24	2.47	3.07	5.14
DCQIN79	DMVP5YE	Doxorubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	8.32	5.59	7.04	11.55
DCMBUCP	DMVP5YE	Doxorubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	6.77	5.24	0.18	13.07
DCEO81I	DMVP5YE	Doxorubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	4.77	3.42	2.59	5.97
DCR5G9Y	DMVP5YE	Doxorubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	5.3	4.44	1.84	7.4
DCOT50J	DMVP5YE	Doxorubicin	Approved	34	DM6BZCV	Sivelestat	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.86	3.86	4.37	4.41
DCQDY59	DMVP5YE	Doxorubicin	Approved	34	DM6VOWQ	Fomepizole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.53	2.53	4.89	4.98
DC0RJQ6	DMVP5YE	Doxorubicin	Approved	34	DM91LGU	Abexinostat	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	24.887	24.515	0.131	16.008
DCCHTXX	DMVP5YE	Doxorubicin	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Hodgkin lymphoma	DrugCombDB Database	Investigative	L-1236	24.125	24.574	4.654	8.261
DC5F51D	DMVP5YE	Doxorubicin	Approved	34	DMA8FS5	Dronedarone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.41	0.41	0.79	0.88
DCSYZRK	DMVP5YE	Doxorubicin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	1.04	0.67	4.02	5.4
DCZF5XW	DMVP5YE	Doxorubicin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	2.71	2.71	0.39	5.87
DC0CBLL	DMVP5YE	Doxorubicin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	3.97	3.28	2.89	6.57
DCNLC38	DMVP5YE	Doxorubicin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	1.45	0.55	2.53	7.11
DCIN1DD	DMVP5YE	Doxorubicin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	2.04	1.59	1.29	5.32
DC5CVLZ	DMVP5YE	Doxorubicin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	0.67	0.17	1.83	5.78
DC9WBO5	DMVP5YE	Doxorubicin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	2.39	2.44	5.25	7.26
DCXJBW3	DMVP5YE	Doxorubicin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	5.06	3.09	2.06	7.5
DCNPERB	DMVP5YE	Doxorubicin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	0.75	1.03	4.98	10.39
DC48HOS	DMVP5YE	Doxorubicin	Approved	34	DMBS632	Buspirone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.41	2.41	2.86	2.95
DCTCMNE	DMVP5YE	Doxorubicin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	1.32	0.41	1.48	7.26
DCK3E2G	DMVP5YE	Doxorubicin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	3.23	3.05	3.53	12.12
DC7ID6U	DMVP5YE	Doxorubicin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.1	0.1	0.79	0.85
DC7AIX7	DMVP5YE	Doxorubicin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	3.12	2.93	1.61	9.69
DCZF6WV	DMVP5YE	Doxorubicin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	0.5	0.42	5.22	8.78
DCXLF43	DMVP5YE	Doxorubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	0.57	0.06	3.47	6.71
DC2XETV	DMVP5YE	Doxorubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	2.04	0.86	4.69	8.08
DCXKCRQ	DMVP5YE	Doxorubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	1.35	1.03	2.8	5.36
DCEK41E	DMVP5YE	Doxorubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	3.93	3.21	1.34	5.95
DCB8VUF	DMVP5YE	Doxorubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	2.35	1.83	2.07	6.22
DCZWI13	DMVP5YE	Doxorubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	4.17	2.61	2.92	4.63
DCDE839	DMVP5YE	Doxorubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	0.48	0.2	0.71	1.63
DCDJWLC	DMVP5YE	Doxorubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	2.49	1.46	3.02	7.03
DCTSRP1	DMVP5YE	Doxorubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	3.09	3.9	4.4	9.81
DCM6Z3B	DMVP5YE	Doxorubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	4.41	4.13	2.29	6.93
DCL9AAL	DMVP5YE	Doxorubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	3.84	4.09	3.98	10.9
DCZU26H	DMVP5YE	Doxorubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	4.45	3.29	10.01	12.93
DCRLMZV	DMVP5YE	Doxorubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	6.58	5.88	7.03	9.52
DCQZUZZ	DMVP5YE	Doxorubicin	Approved	34	DMCMDVR	Triptolide	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	13.172	12.879	6.078	10.785
DC3DAXR	DMVP5YE	Doxorubicin	Approved	34	DMCQP0B	Flavonoid derivative 1	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.25	2.25	2.62	2.7
DCB3S91	DMVP5YE	Doxorubicin	Approved	34	DMD7L48	Plinabulin	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	1.19	3.39	1.75	3.63
DCC04HP	DMVP5YE	Doxorubicin	Approved	34	DMDASC6	Metformin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.7	4.7	5.06	5.15
DCBZMXA	DMVP5YE	Doxorubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.32	3.32	5.86	5.95
DC2GK7Q	DMVP5YE	Doxorubicin	Approved	34	DMDO279	Phenprocoumon	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.28	0.28	0.8	0.9
DCC2PYH	DMVP5YE	Doxorubicin	Approved	34	DME5TUR	LY03004	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.36	4.36	4.78	4.85
DC9ZTS9	DMVP5YE	Doxorubicin	Approved	34	DME9QGW	Marizomib	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	4.58	3.76	0.87	4.02
DCVN2U1	DMVP5YE	Doxorubicin	Approved	34	DMENSL5	Aminosalicylic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.2	4.2	4.63	4.71
DCLQEJA	DMVP5YE	Doxorubicin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	1.41	1	0.47	7.13
DCM5SSN	DMVP5YE	Doxorubicin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	3.32	3.37	0.07	6.98
DC5YECW	DMVP5YE	Doxorubicin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	5.61	4.5	0.71	8.72
DCTWMU4	DMVP5YE	Doxorubicin	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	2.16	2.16	5.54	8.51
DCDZ9V8	DMVP5YE	Doxorubicin	Approved	34	DMFQWNI	VR-776	Discontinued in Phase 1	3	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.53	1.53	2.01	2.1
DC84HE2	DMVP5YE	Doxorubicin	Approved	34	DMG58FX	WAY-100635	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.14	4.14	4.91	4.99
DCBWV85	DMVP5YE	Doxorubicin	Approved	34	DMGB035	Armodafinil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.09	0.09	0.46	0.55
DC1509U	DMVP5YE	Doxorubicin	Approved	34	DMGC5DB	Ciprofibrate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.06	4.06	4.44	4.54
DCKRU0G	DMVP5YE	Doxorubicin	Approved	34	DMGDKXN	Sitagliptin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.39	2.39	2.83	2.91
DCDELK1	DMVP5YE	Doxorubicin	Approved	34	DMGFWSM	Zaleplon	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.04	4.04	4.52	4.56
DCAFB4N	DMVP5YE	Doxorubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	5.075	5.115	6.026	8.404
DCQZLBB	DMVP5YE	Doxorubicin	Approved	34	DMH7W9X	SNDX-275	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	18.387	20.934	3.606	7.949
DCL4R0G	DMVP5YE	Doxorubicin	Approved	34	DMHAZLM	Naringenin	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.75	4.75	5.19	5.28
DCO8EKP	DMVP5YE	Doxorubicin	Approved	34	DMOL54H	Clopidogrel	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.37	3.37	3.8	3.82
DCUTJ7C	DMVP5YE	Doxorubicin	Approved	34	DMIR21F	PFK-158	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.03	1.03	1.44	1.53
DCEFNZE	DMVP5YE	Doxorubicin	Approved	34	DMJSKUI	Norcisapride	Discontinued in Phase 2	5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.53	4.53	4.95	5
DC7V6U8	DMVP5YE	Doxorubicin	Approved	34	DMKSUOI	Flavopiridol	Phase 2	21	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	JHH-136	72.285	72.117	3.657	2.362
DCH066N	DMVP5YE	Doxorubicin	Approved	34	DML1538	Diazoxide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.66	1.66	4.2	4.3
DC9VTGH	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	7.13	6.91	0.63	8.83
DCGXUBO	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	3.88	3.54	2.95	7.01
DCBM264	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	2.69	2.06	0.06	6.04
DCP9YJC	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	9.76	9.45	6.28	12.82
DC089IJ	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	3.12	0.92	0.15	4.88
DC48ALA	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	6.76	5.33	3.8	8.84
DC0DV2Y	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	2.64	2.4	1.13	5.01
DCM3069	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	1.91	0.18	2.2	3.11
DC7AQN9	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.07	2.92	0.34	5.94
DCKBHR7	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	0.54	0.43	0.42	0.66
DCUJSE8	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	3.36	3.11	1.33	5.81
DCY8S0H	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	2.13	2.03	1.51	6.5
DC5PWCB	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	5.08	5.13	4.72	7.16
DC20GV1	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	3.22	2.35	0.77	5.67
DCGK93L	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	3.46	3.36	2.84	4.86
DCWB7QG	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	13.86	12.36	6.78	12.18
DC45DWA	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	9.27	10.23	4.49	12.4
DC4L0BQ	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	1.93	1.4	0.2	5.24
DCTPXL9	DMVP5YE	Doxorubicin	Approved	34	DMLU8NX	Benserazide	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.57	3.57	4	4.09
DCRGB95	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	0.82	0.43	3.85	5.88
DCOMWBQ	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	5.41	1.41	2.58	4.75
DCQQNWT	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	0.9	3.12	6.68	8.07
DC9UG3A	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	0.41	0.17	4.44	7.36
DCI35U2	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	8.97	9.32	10.2	11.32
DCZSZU1	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	4.1	3.24	6.65	7.91
DCATWSC	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	0.07	2.13	7.08	8.69
DCVIH8G	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	0.15	0	2.09	4.3
DCHFJ3S	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	0.75	0.18	0.23	0.47
DCZ15QI	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	1.54	0.6	0.91	2.55
DCRJXWQ	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	4.07	3.69	3.04	5.08
DCMVI08	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	2.86	4.52	9.07	9.98
DCUBP8K	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	2.48	3.13	4.12	6.38
DCZLRWQ	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	7.78	7.19	9.38	10.81
DCU9CZC	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	3.07	2.26	3.58	4.88
DCXDLIS	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	0.83	0.78	8	8.45
DCRH8TS	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	6.36	5.62	9.36	11.14
DCYIV0Q	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	0.71	0.29	8.04	9.48
DC4GMC5	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	4.26	5.92	6.24	7.77
DC3H0I2	DMVP5YE	Doxorubicin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	2.1	2.1	0.2	4.4
DCFAJLH	DMVP5YE	Doxorubicin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	4.37	4.16	2.64	7.27
DCAUCE0	DMVP5YE	Doxorubicin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	6.45	6.84	5.85	7.44
DC7X2OY	DMVP5YE	Doxorubicin	Approved	34	DMM4WBX	Methocarbamol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.58	2.58	3.02	3.11
DCTCJOV	DMVP5YE	Doxorubicin	Approved	34	DMM5SCF	ONC201	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	0.951	10.811	0.227	2.438
DCKEUS7	DMVP5YE	Doxorubicin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.2	1.2	3.62	3.71
DCNX52S	DMVP5YE	Doxorubicin	Approved	34	DMMN36E	Abacavir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.82	0.82	1.32	1.32
DCC9CUP	DMVP5YE	Doxorubicin	Approved	34	DMMQ2OW	Nintedanib	Phase 2 Trial	21	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	1.72	4.22	2.42	2.75
DC8T8XK	DMVP5YE	Doxorubicin	Approved	34	DMN3GCH	Darunavir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.27	4.27	5.18	5.27
DCWB76N	DMVP5YE	Doxorubicin	Approved	34	DMNE1FR	Resminostat	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	7.84	9.31	4.26	6.49
DCHVKYG	DMVP5YE	Doxorubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	9.74	8.37	5.4	9.05
DCQ9KHO	DMVP5YE	Doxorubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	0.71	0.44	1.05	1.84
DCCXR00	DMVP5YE	Doxorubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	0.33	0.15	0.12	0.35
DCEMI5S	DMVP5YE	Doxorubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	1.13	0.52	0.19	3.32
DCD5RVT	DMVP5YE	Doxorubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	0.56	0.97	0.21	4.72
DCP1J99	DMVP5YE	Doxorubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	4.69	4.59	6.28	8.27
DCZWWZ3	DMVP5YE	Doxorubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	2.24	1.71	1.82	4.88
DC7CYV2	DMVP5YE	Doxorubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	1.09	2.14	0.21	4.94
DCWYLQQ	DMVP5YE	Doxorubicin	Approved	34	DMNSJ7V	Tropisetron	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.59	0.59	1.07	1.16
DCZ4SK7	DMVP5YE	Doxorubicin	Approved	34	DMO381I	Acamprosate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.87	2.87	3.27	3.36
DCH1LWA	DMVP5YE	Doxorubicin	Approved	34	DMODJ40	Ethinyl estradiol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.54	3.54	4.05	4.05
DCIMWIU	DMVP5YE	Doxorubicin	Approved	34	DMOY7W3	Artemisinin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.29	1.29	2.67	2.75
DCYVVXM	DMVP5YE	Doxorubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	12.06	9.66	1.95	10.51
DCF9TY1	DMVP5YE	Doxorubicin	Approved	34	DMPFN6Y	Olanzapine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.92	2.92	3.38	3.47
DC3CRDS	DMVP5YE	Doxorubicin	Approved	34	DMPGR1E	Clascoterone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.31	0.31	1.05	1.14
DCU1XD0	DMVP5YE	Doxorubicin	Approved	34	DMPGUCF	Dopamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.56	2.56	2.99	3
DCBBM2L	DMVP5YE	Doxorubicin	Approved	34	DMPK32V	BMS-754807	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	3.84	5.95	6.55	8.66
DCT0B7G	DMVP5YE	Doxorubicin	Approved	34	DMPLY7B	Cefmenoxime	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.35	3.35	3.76	3.85
DCIV7P1	DMVP5YE	Doxorubicin	Approved	34	DMPWB7T	Maprotiline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.28	0.28	2.79	2.88
DCP297X	DMVP5YE	Doxorubicin	Approved	34	DMQLODU	Citarinostat	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	21.25	21.02	0.11	13.72
DC6HOAE	DMVP5YE	Doxorubicin	Approved	34	DMQWS6U	KU-0060648	Investigative	0	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	5.45	6.64	6.7	8.87
DCQ4T5C	DMVP5YE	Doxorubicin	Approved	34	DMR6N7H	Acetohexamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.38	2.38	2.68	2.78
DCHNG8A	DMVP5YE	Doxorubicin	Approved	34	DMR8ONJ	Leflunomide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.85	1.85	4.23	4.33
DCEC0FA	DMVP5YE	Doxorubicin	Approved	34	DMRJFN9	Theophylline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.26	1.26	1.66	1.75
DC45E8S	DMVP5YE	Doxorubicin	Approved	34	DMRV7H0	Bumetanide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.36	3.36	3.8	3.87
DC4TVZN	DMVP5YE	Doxorubicin	Approved	34	DMS2Q9G	PHA848125	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	14.786	15.644	5.437	9.898
DC1CQY2	DMVP5YE	Doxorubicin	Approved	34	DMS3YE9	Amantadine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.35	5.35	5.82	5.91
DCX57WN	DMVP5YE	Doxorubicin	Approved	34	DMS49KH	Valproic Acid	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.46	3.46	3.92	3.93
DC4N4XB	DMVP5YE	Doxorubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	2.44	0.69	0.31	7.5
DCI1TWJ	DMVP5YE	Doxorubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.01	2.01	2.3	2.39
DCLY6OR	DMVP5YE	Doxorubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	2.76	2.63	1.51	9.3
DCBL077	DMVP5YE	Doxorubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	2.3	1.83	5.82	6.93
DCR1VEV	DMVP5YE	Doxorubicin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	0.34	0.5	4.17	7.01
DC0ZS1T	DMVP5YE	Doxorubicin	Approved	34	DMSA4B3	Desoxycorticosterone pivalate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.46	3.46	3.91	3.92
DCXZWVE	DMVP5YE	Doxorubicin	Approved	34	DMSLE03	PF-562271	Phase 1	17	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	5.28	3.89	0.29	4.39
DCH819O	DMVP5YE	Doxorubicin	Approved	34	DMSWYF5	Quinine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.84	3.84	4.98	5.08
DCF0N64	DMVP5YE	Doxorubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	6.44	2.9	4.77	7.07
DC1BCDA	DMVP5YE	Doxorubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	4.7	4.75	6.42	10.12
DC41SZ3	DMVP5YE	Doxorubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	1.24	0.71	4.43	6.84
DCXEBXO	DMVP5YE	Doxorubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	5.66	3.35	1.67	7.09
DCY1TI9	DMVP5YE	Doxorubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	0.42	0.37	6.44	9.93
DCOYPEI	DMVP5YE	Doxorubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	2.99	2.72	0.84	10.61
DCR4WA1	DMVP5YE	Doxorubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	0.2	0.26	0.4	0.47
DCNNII9	DMVP5YE	Doxorubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	7.54	6.81	3.85	12.12
DCFQU9I	DMVP5YE	Doxorubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	3.59	3.76	0.56	7.82
DCNA0DR	DMVP5YE	Doxorubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	7.71	5.61	9.55	12.79
DCFTRBB	DMVP5YE	Doxorubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	5.75	5.81	2.46	12.48
DC4CK76	DMVP5YE	Doxorubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	1.92	2	6.88	8.86
DC30IYX	DMVP5YE	Doxorubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	6.38	5.62	6.84	11.17
DCG3QXK	DMVP5YE	Doxorubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	0.52	0.3	7.26	10.72
DCFN442	DMVP5YE	Doxorubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	1.73	2.29	6.87	11.28
DCB2AJW	DMVP5YE	Doxorubicin	Approved	34	DM2AQ5N	Spironolactone	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.77	5.77	6.17	6.25
DC4CWGL	DMVP5YE	Doxorubicin	Approved	34	DMTV4L7	CHS-828	Phase 1/2	19	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	9.998	11.159	1.13	2.724
DCNS6TN	DMVP5YE	Doxorubicin	Approved	34	DMTX8IZ	Endoxifen	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.4	2.4	3.58	3.67
DC4Q8HB	DMVP5YE	Doxorubicin	Approved	34	DMU8JGH	Hydralazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.98	2.98	3.8	3.89
DCNJHMM	DMVP5YE	Doxorubicin	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	3.849	4.367	1.15	5.79
DCSDV48	DMVP5YE	Doxorubicin	Approved	34	DMVRIC2	Zileuton	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.74	0.74	1.46	1.55
DCTH6YR	DMVP5YE	Doxorubicin	Approved	34	DMVTHWQ	Silver sulfadiazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.25	1.25	1.6	1.69
DCUQ93N	DMVP5YE	Doxorubicin	Approved	34	DMVYXR8	Sumatriptan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.1	0.1	0.52	0.6
DCWS4WS	DMVP5YE	Doxorubicin	Approved	34	DMXCM7H	Cerivastatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.8	2.8	5.38	5.43
DC1TWXV	DMVP5YE	Doxorubicin	Approved	34	DMXLZP6	Metaxalone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.81	3.81	4.29	4.29
DC9SFS4	DMVP5YE	Doxorubicin	Approved	34	DMSIVND	Hydroxychloroquine	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.17	4.17	4.64	4.67
DCCLH0Q	DMVP5YE	Doxorubicin	Approved	34	DMY4UMW	Atovaquone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.2	2.2	2.55	2.64
DCGRKOY	DMVP5YE	Doxorubicin	Approved	34	DMY8WDB	CB3304	Phase 1/2	19	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	0.279	5.418	2.782	1.761
DC2LQNH	DMVP5YE	Doxorubicin	Approved	34	DMYLOVR	Aciclovir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.36	3.36	4.43	4.52
DCF0RX8	DMVP5YE	Doxorubicin	Approved	34	DMYX7NI	Acetohydroxamic Acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.07	3.07	3.94	4.03
DCBZ2BF	DMVP5YE	Doxorubicin	Approved	34	DMYZFNH	Sapanisertib	Investigative	0	.	.	.	.	Hodgkin lymphoma	DrugCombDB Database	Investigative	L-1236	6.806	12.609	0.576	3.468
DC5VD8M	DMVP5YE	Doxorubicin	Approved	34	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	6.05	6.1	6.28	8.76
DCP8SA0	DMVP5YE	Doxorubicin	Approved	34	DMZ2TD9	GSK2194069	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.56	3.56	3.9	4
DCS9EC4	DMVP5YE	Doxorubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	2.77	2.55	3.47	11.62
DC57RVZ	DMVP5YE	Doxorubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	1.36	1.2	5.98	11.19
DCYO57R	DMVP5YE	Doxorubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	2.45	2.42	7.07	10.33
DC14EJC	DMVP5YE	Doxorubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	3.09	3.35	6.69	10.37
DCR7G0R	DMVP5YE	Doxorubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	0.67	0.6	7.29	11.02
DCKQ760	DMVP5YE	Doxorubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	0.56	0.47	0.17	1.81
DCGLAOE	DMVP5YE	Doxorubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	7.05	7.08	10.44	18.37
DCTY93C	DMVP5YE	Doxorubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	3.29	3.36	6.62	10.79
DCD59EM	DMVP5YE	Doxorubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	7.74	6.82	4.9	12.98
DCHAC5B	DMVP5YE	Doxorubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	1.56	1.06	5.86	8.74
DCCPC2K	DMVP5YE	Doxorubicin	Approved	34	DMZI3WO	Etomidate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.43	3.43	3.77	3.86
DC5AMHU	DMVP5YE	Doxorubicin	Approved	34	DMZMSCT	Cilostazol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.28	3.28	3.7	3.79
DCV7V4A	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.58	0.81	1.79	7.23
DCX196W	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.7	4.42	4.66	8.57
DCMVPVF	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	4.95	4.34	4.93	10.29
DC5RDA5	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.03	1.01	6	10.59
DCE0ETS	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.01	0.08	0.77	5.51
DCB7OEP	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	12.25	13.36	1.17	18.13
DC74XPA	DMVP5YE	Doxorubicin	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.39	2.99	5.19	11.11
DCK9UCK	DMVP5YE	Doxorubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.86	4.31	5.14	10.49
DC6ALBR	DMVP5YE	Doxorubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.83	1.24	6.7	9.15
DCEL7MG	DMVP5YE	Doxorubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.63	0.92	0.3	12.43
DCXAKAZ	DMVP5YE	Doxorubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.18	4.04	3.68	8.11
DC3YOS8	DMVP5YE	Doxorubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.15	8.35	3.06	18.89
DCKPCU6	DMVP5YE	Doxorubicin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.09	4.19	3.97	14.01
DCWMFDR	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	8.25	8.56	9.77	15.97
DCV358Y	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	6.83	6.85	6.64	12.5
DCAK5V5	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	7.14	7.74	7.74	11.36
DC1C277	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.43	4.61	4.85	7.88
DCO78OB	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.98	2.67	0.27	7.91
DCKC6T0	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	6.92	5.04	4.03	9.57
DCQGOS7	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.84	0.69	4.96	7.66
DCIU8DF	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.53	0.69	2.56	6.35
DCPGXUR	DMVP5YE	Doxorubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	12.49	9.79	7.15	13.54
DCGY4D1	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	0.68	0.33	7.89	10.95
DC3Z1A5	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	5.42	4.83	6.57	11.32
DCX2CZC	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	0.81	0.2	8.35	11.96
DC54VCW	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.6	0.89	3.77	6.27
DCHMLTV	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.98	3.87	6.2	10.49
DC6EB43	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	10.26	10.09	8.88	16.76
DC5884J	DMVP5YE	Doxorubicin	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.33	3.51	5.96	10.9
DCY6SEL	DMVP5YE	Doxorubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	6.65	4.48	6.29	10.24
DCCVD13	DMVP5YE	Doxorubicin	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.6	2.09	4.32	3.26
DCARSCT	DMVP5YE	Doxorubicin	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	5.55	6.53	1.82	7.97
DCSAXHR	DMVP5YE	Doxorubicin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.89	3.34	0.46	11.6
DC77W5I	DMVP5YE	Doxorubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.15	4.12	3.59	7.21
DCQHT53	DMVP5YE	Doxorubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	12.69	13.09	14.77	19.25
DCL79LZ	DMVP5YE	Doxorubicin	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	0.75	1.04	6.01	10.84
DCDGCGX	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	7.29	5.02	2.08	7.64
DC075OH	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	0.59	0.41	3.6	8.08
DCUKI2Z	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.69	1.45	0.44	4.15
DC5NT18	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.31	3.58	1.03	7.15
DCTTROD	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.78	2.17	2.54	6.42
DCRYRQ4	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.4	0.85	0.02	4.69
DCNMJDD	DMVP5YE	Doxorubicin	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.75	3.4	5.51	9.35
DCTYHPR	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.19	4.22	8.25	9.96
DCVEGLJ	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	1.06	0.77	10.14	12.86
DC8H7CJ	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.92	2.66	7	8.98
DCS0V2H	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.95	0.15	4.63	5.86
DCMJ1DT	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.24	2.11	6.22	8.75
DCT8G89	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.58	2.02	4.59	7.07
DC30CBW	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.07	8.65	13.32	14.82
DCBJWXJ	DMVP5YE	Doxorubicin	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.21	2.15	5.6	6.54
DCI1EJ5	DMVP5YE	Doxorubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	0.11	0.73	2.31	6.96
DCDTAZY	DMVP5YE	Doxorubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.37	1.1	0.43	2.98
DCIUZI6	DMVP5YE	Doxorubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.01	4.23	3.14	7.9
DC9RQWM	DMVP5YE	Doxorubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.46	0.3	3.82	6.29
DCY35CU	DMVP5YE	Doxorubicin	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.05	6.82	4.56	6.83
DCOVF0J	DMVP5YE	Doxorubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.28	4.38	0.78	8.97
DCCNRTQ	DMVP5YE	Doxorubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.36	1.45	0.24	13.39
DC2I0ZU	DMVP5YE	Doxorubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.31	1.47	4.08	6.82
DC23DK1	DMVP5YE	Doxorubicin	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.18	4.31	7.67	17.47
DCM7I0W	DMVP5YE	Doxorubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.96	5.2	3.68	7.51
DCI6EYL	DMVP5YE	Doxorubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.53	0.49	7.9	12.5
DC4LURL	DMVP5YE	Doxorubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.35	8.88	5.71	18.64
DCU46SH	DMVP5YE	Doxorubicin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.32	2.24	5.16	13.84
DC3GRIW	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	24.94	24.44	23.88	27.55
DCMR0AI	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.16	7.32	7.21	9.1
DCDEHKX	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	1.51	10	3.64	4.43
DCLU4B4	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.32	5.6	4.85	6.54
DCPBH2O	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	5.12	4.94	6.88	7.32
DCEP3B2	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	1.34	6.88	2.63	1.88
DCLXGVN	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.24	6	5.69	6.02
DCTIH5X	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.96	0.56	2.64	2.94
DC52X6V	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	12.63	14.76	2.29	12.56
DCPSQT0	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.74	5.53	1.18	5.96
DC9FEG2	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.63	6.31	5.07	4.89
DCLZ6SE	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.93	9.7	6.7	12.85
DCAT4E0	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.36	3.66	3.62	5.54
DCOJU35	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	11.04	12.25	10.34	12.58
DCFAVND	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	7.08	12.26	10.61	11.98
DCFMSEH	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.35	8.64	10.05	12.05
DC6NHLR	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.06	3.26	3.45	5.11
DCNDDDM	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	4.08	6.72	0.05	2.42
DCX3BWJ	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.42	7.05	1.74	6.2
DCPNMGQ	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.3	12.76	7.35	6.09
DC837P2	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.32	2.39	1.45	1.47
DCBNCOE	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.73	6.47	7.08	7.26
DCHH0H3	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.61	2.61	2.96	2.81
DCMPH81	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.26	5.6	3.84	4.7
DCQ38LO	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	30.92	33.42	33.32	34.23
DC3FARW	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	33.64	37.31	37.53	38.07
DCRKZWP	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	25.63	22.68	17.26	25.57
DCVVEFU	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.3	12.02	12.93	12.49
DCBFJAB	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	27.01	26.82	27.1	26.9
DC6GSAV	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	12.04	17.98	18.7	18.61
DCFB407	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	18.66	19.28	20.1	20.35
DCK7RYH	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	8.4	10.46	8.43	8.34
DCPG0FW	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	5.02	10.22	9.01	9.16
DCZF3K2	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	19.88	24.61	24.24	23.97
DC3EJFB	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	15.81	18.76	18.5	17.95
DCBVF5A	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	2.94	7.45	8.11	8.12
DCD062B	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.75	3.13	3.88	4.25
DC1XA3F	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	4.11	8.65	10.05	9.54
DC4Y0M8	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	7.23	14.15	11.5	11.98
DC0AMZY	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	9.96	13.81	13.49	12.98
DCFK81K	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	36.77	30.05	23.2	24.89
DCILQF2	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	3.83	10.24	10.91	10.54
DCH3W3Y	DMM1I8R	Indazole derivative 5	Patented	15.5	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.38	8.66	8.86	10.23
DCGG6OO	DMM1I8R	Indazole derivative 5	Patented	15.5	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.28	4.23	6.53	6.22
DCMO2OW	DMM1I8R	Indazole derivative 5	Patented	15.5	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	5	5.68	1.01	6.99
DCTO5KJ	DMM1I8R	Indazole derivative 5	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.19	10.99	0.78	0.29
DCH0362	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.82	4.68	1.53	6.69
DCB4GB6	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.64	6.05	5.51	7.95
DC8KNJP	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.65	4.82	2.36	5.71
DC99I14	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.78	2.24	1.34	1.61
DCGF7OD	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	9.8	9.73	4.33	1.75
DCV4TI9	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.86	3.91	1.78	1.7
DCOGOBF	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.73	1.66	0.92	0.34
DCMJUPQ	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	10.41	12.54	12.39	14.58
DC7G92S	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	2.99	2.17	2.41	6.01
DC278L1	DMM1I8R	Indazole derivative 5	Patented	15.5	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.85	11.27	6.31	10.67
DC20AVU	DMM1I8R	Indazole derivative 5	Patented	15.5	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	7	10.38	3.67	1.27
DCYL9FS	DMM1I8R	Indazole derivative 5	Patented	15.5	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	2.05	5.1	5.36	5.12
DC9FLTK	DMM1I8R	Indazole derivative 5	Patented	15.5	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	5.09	10.29	1.22	7.13
DC2BWDJ	DMM1I8R	Indazole derivative 5	Patented	15.5	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.5	4.41	2.92	2.77
DC25YBC	DMM1I8R	Indazole derivative 5	Patented	15.5	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.85	2.6	1.53	1.02
DCUMFTB	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	10.95	19.02	19.9	18.98
DCPAJ95	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	8.96	17.02	17.92	17.16
DCRHUXF	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.32	7.05	8.15	8.75
DC9FAPK	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	19.2	19.4	19.99	20.13
DC6VYXF	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	14.6	15.32	12.97	16.57
DCF2XJ0	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	3.16	10.74	10.8	11.64
DC3M1GY	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	12.07	20.16	19.85	19.83
DCB9QWN	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	14.34	17.99	17.46	17.68
DCQBU9J	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	19.38	19.86	20.14	20.55
DCY0AHD	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	6.94	10.47	12.14	11.75
DCHPYBC	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	5.93	13.78	15.01	14.45
DCFJYS8	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	5.17	9.73	9.72	9.78
DCI9O4R	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	35.6	27.04	23.25	21.88
DCFAM6W	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	2.19	4.62	4.37	4.59
DC4TWTR	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	11.88	10.98	10.95	13.98
DCB5KEM	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.86	2.52	1.23	1.05
DC81TEI	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	6.62	8.8	2.93	2.32
DCD5RTQ	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.53	3.87	1.31	2.75
DCCZA55	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.41	6.17	6.95	8.48
DCKFD6H	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	4.16	3.41	5.41	7.14
DCXQ9RK	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	7.88	10.84	9.88	11.2
DC095FR	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	9.46	9.78	9.22	9.47
DC6727M	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	6.61	5.88	4.99	7.53
DC0E3EP	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	6.44	5.62	5.4	5.7
DCVZXXR	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.13	3.02	3.56	4.07
DCHVG4J	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	13.15	13.32	6.67	9.15
DC1T9VM	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	4.07	5.98	7.29	7.64
DCRCGB2	DMM1I8R	Indazole derivative 5	Patented	15.5	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.6	3.38	5.95	7
DCUIF1P	DMM1I8R	Indazole derivative 5	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.89	2.75	1.77	4.12
DCY7MXH	DMM1I8R	Indazole derivative 5	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.78	2.24	0.83	3.8
DCTIQOB	DMM1I8R	Indazole derivative 5	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.69	2.76	1.68	3.19
DCP6MUO	DMM1I8R	Indazole derivative 5	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.87	3.8	3	6.23
DCEP3YJ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.97	7.82	7.99	9.73
DCOF7D1	DMM1I8R	Indazole derivative 5	Patented	15.5	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.43	1.82	1.39	3.56
DCRYF8A	DMM1I8R	Indazole derivative 5	Patented	15.5	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.57	4.06	1	4.84
DCDX1HD	DMM1I8R	Indazole derivative 5	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.35	6.65	6.96	6.93
DC6NUZ6	DMM1I8R	Indazole derivative 5	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	8.51	13.79	13.34	13.77
DCFL9OB	DMM1I8R	Indazole derivative 5	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.5	2.07	1.02	0.73
DCV87W6	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	3.7	8.41	8.1	8.04
DCSUAG1	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	7.44	6.17	1.47	1
DCQNXMZ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.08	3.73	3.76	3.55
DCOM71C	DMM1I8R	Indazole derivative 5	Patented	15.5	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.64	11.68	10.47	10.35
DCCLB8U	DMM1I8R	Indazole derivative 5	Patented	15.5	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	41.72	41.97	36.88	36.94
DCYT7UX	DMM1I8R	Indazole derivative 5	Patented	15.5	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.77	1.13	3.2	3.46
DCR4H8W	DMM1I8R	Indazole derivative 5	Patented	15.5	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.99	2.16	4.5	5.53
DCSM097	DMM1I8R	Indazole derivative 5	Patented	15.5	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.54	1.97	2.86	4.67
DCJSI9A	DMM1I8R	Indazole derivative 5	Patented	15.5	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.73	1.96	2.71	4.24
DCM2RXB	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	23.1	20.17	20.06	23.03
DCOBZIS	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDI269	Docetaxel	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.1	2.08	1.29	4.25
DCM919Y	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	11.17	9.7	9.1	13.94
DCXMRLK	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	12.8	12.42	3.89	13.03
DCVP74X	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDI269	Docetaxel	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	17.5	17.2	11.08	17.09
DCG3HLH	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDI269	Docetaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.18	5.27	2.84	5.87
DC63PSK	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.01	8.97	1.36	7.73
DCFF142	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	2.56	2.1	1.55	0
DCFT565	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.23	9.2	7.22	8.82
DCRORZ5	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.24	7.31	2.28	6.5
DCOYVYF	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	4.32	7.54	6.8	6.9
DCZZLNA	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.26	4.15	4.33	5.08
DCTXNZJ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	10.62	16.13	7.98	6.98
DCX1KYU	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.14	5.58	4.32	5.94
DCNQXAJ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	36.9	37.83	41.44	40.01
DCC2K7K	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	13.28	14.71	15.7	16.96
DCLKMEJ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	6.91	10.59	7.79	10.07
DC5M0M4	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.08	2.34	1.62	3.19
DCPLF0E	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	6.99	7.46	7.26	9.43
DCTVHYH	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.1	4.69	0.85	4.64
DC7GXKQ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.44	8.01	5.23	7.38
DCSHNL2	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	2.96	6.93	5.63	6.51
DCIKOE3	DMM1I8R	Indazole derivative 5	Patented	15.5	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.21	5.47	3.05	6.32
DC2SGLA	DMM1I8R	Indazole derivative 5	Patented	15.5	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.14	4.28	2.63	5.26
DCYYMBG	DMM1I8R	Indazole derivative 5	Patented	15.5	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.9	1.54	2.69	5.89
DC78RPH	DMM1I8R	Indazole derivative 5	Patented	15.5	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	5.31	4.56	3.34	6.31
DCLZRYB	DMM1I8R	Indazole derivative 5	Patented	15.5	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.03	0.8	3.18	5.83
DC2QVWT	DMM1I8R	Indazole derivative 5	Patented	15.5	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	7.63	3.25	5.01	6.33
DC4EHKI	DMM1I8R	Indazole derivative 5	Patented	15.5	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.16	7.63	6.95	8.77
DC8UTUK	DMM1I8R	Indazole derivative 5	Patented	15.5	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.58	5.59	5.25	8.41
DCM7XAP	DMM1I8R	Indazole derivative 5	Patented	15.5	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.25	1.34	2.42	4.27
DCS49OY	DMM1I8R	Indazole derivative 5	Patented	15.5	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.47	3.01	1.4	3.32
DC0N2CW	DMM1I8R	Indazole derivative 5	Patented	15.5	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.29	1.67	0.01	3.19
DCYYZEK	DMM1I8R	Indazole derivative 5	Patented	15.5	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.77	5.87	0.72	8.26
DC3Z56V	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.33	6.5	5.73	6.95
DC5844F	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	5.22	7.09	3.36	7.99
DC7934S	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.35	2.45	1.76	1.53
DCF6APB	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.4	7.39	4.9	7.71
DCPD3PV	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	8.8	18.94	6.54	16.3
DCEVVX6	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	39.17	34.91	35.46	39.21
DCQ3Y10	DMM1I8R	Indazole derivative 5	Patented	15.5	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	25.19	24.77	24.76	27.2
DC5U3NI	DMM1I8R	Indazole derivative 5	Patented	15.5	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	19.81	21.51	19.73	21.73
DCSH966	DMM1I8R	Indazole derivative 5	Patented	15.5	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	5.35	8.35	6.38	9.39
DC5IAIX	DMM1I8R	Indazole derivative 5	Patented	15.5	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	17.3	18.6	4.08	18.47
DCW50SF	DMM1I8R	Indazole derivative 5	Patented	15.5	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	9.79	10.16	0.61	12.52
DC0BF6L	DMM1I8R	Indazole derivative 5	Patented	15.5	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.17	7.58	5.1	7.44
DCXY8WF	DMM1I8R	Indazole derivative 5	Patented	15.5	DMINOX3	Vincristine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	14.5	13.88	13.43	16.18
DCQZN8Y	DMM1I8R	Indazole derivative 5	Patented	15.5	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.5	5.29	6.8	7.99
DC4TXOY	DMM1I8R	Indazole derivative 5	Patented	15.5	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.38	6.16	2.53	6.3
DC6ATLE	DMM1I8R	Indazole derivative 5	Patented	15.5	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.68	2.15	1.71	1.92
DCA4SHD	DMM1I8R	Indazole derivative 5	Patented	15.5	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	4.76	3.02	3.16	3.35
DCNN8TM	DMM1I8R	Indazole derivative 5	Patented	15.5	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.04	4.07	4.13	5.37
DCVXFIO	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	19.52	14.01	13.51	15.56
DCYEWT2	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	8.48	4.43	5.07	7.58
DCKK021	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.17	2.91	0.54	3.1
DC5E3QL	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	5.52	6.24	4.66	8.16
DCPWJ5V	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	16.27	14.28	0.41	15.47
DCNOQ2A	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	7.03	5.94	3.57	11.18
DC7X4TY	DMM1I8R	Indazole derivative 5	Patented	15.5	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	23.26	24.28	19.81	22.59
DCFNHSB	DMM1I8R	Indazole derivative 5	Patented	15.5	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	15.36	15.45	9.05	14.82
DCRWF3X	DMM1I8R	Indazole derivative 5	Patented	15.5	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	11.58	12.92	12.66	13.66
DCVVLQT	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	7.35	7.09	3	1.78
DC0XKUR	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.77	3.38	2.81	6.07
DCRDP1H	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.82	4.67	4.98	7.16
DCOHTNM	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	9.63	10.76	11.72	12.41
DCJEF9Z	DMM1I8R	Indazole derivative 5	Patented	15.5	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	6.12	6.12	9	9.07
DCQZEO2	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	8.12	6.51	5.96	8.83
DC7I8ZO	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.18	4.58	3.92	6.13
DCWN7L4	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	16.81	14.79	16.95	15.84
DC79SRO	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.56	5.07	3.34	5.42
DC3H0SY	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	14.51	12.94	5.83	12.69
DCIL6Y3	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	4.21	3.59	3.83	5.72
DCAFGKS	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	6.35	9.74	10.83	10.96
DCQYM71	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	5.76	7.36	4.7	9.34
DCB1SA7	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.85	12.57	16.17	16.19
DCGUD5Y	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	16.2	16.84	9.08	20.36
DCWKGJI	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.85	6.76	8.11	9.57
DCSGITM	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.4	10.54	8.75	12.65
DCGJ4OW	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.02	1.84	0.52	0.33
DCHKL29	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.79	6.38	6.75	6.83
DCHGU51	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	6.43	6.15	6.77	6.17
DC8YIWZ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.27	0.06	0.41	1.26
DCKAAPE	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.73	9.76	9.28	10.53
DCYF0GR	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.22	3.79	4.5	6.5
DC7GFS4	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	6.12	8.26	7.05	9.01
DCEM3B5	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	7.74	9.24	8.65	8.88
DC6ELHZ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	5.96	5.91	6.01	6.05
DC8UWPL	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	9.73	12.52	7.42	8.77
DCCEUHI	DMM1I8R	Indazole derivative 5	Patented	15.5	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.14	8.89	9.93	10.76
DCOPYPK	DMM1I8R	Indazole derivative 5	Patented	15.5	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.3	5.76	0.39	0.72
DCON5CJ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.69	6.04	10.39	11.43
DC9YGCX	DMM1I8R	Indazole derivative 5	Patented	15.5	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	5.93	4.3	3.11	4.71
DC2BNOM	DMM1I8R	Indazole derivative 5	Patented	15.5	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	7.56	6.58	6.09	8.65
DCMFRR2	DMM1I8R	Indazole derivative 5	Patented	15.5	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.9	6.92	3.7	6.4
DCWJQ5B	DMM1I8R	Indazole derivative 5	Patented	15.5	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.21	0.32	1.03	1.62
DCREQYB	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	8.91	10.93	5.85	12.19
DCO9W0V	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	10.5	10.42	10.53	12.89
DCXYR9G	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	10.14	10.55	6.8	10.85
DCM887N	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	29	24.24	20.16	23.92
DCCOA1H	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.51	3.47	2.8	2.77
DC27J6K	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	4.85	10.22	10.69	11.89
DCFGXUI	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.86	10.88	11.54	11.61
DC8Y5KI	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	7.95	11.88	4.53	4.04
DCDHAU1	DMM1I8R	Indazole derivative 5	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.9	14.56	5.73	12.1
DCN4Z2F	DMM1I8R	Indazole derivative 5	Patented	15.5	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.83	2.94	0.79	4.33
DCSL84C	DMM1I8R	Indazole derivative 5	Patented	15.5	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.59	3.92	0.46	3.67
DCVG7P8	DMM1I8R	Indazole derivative 5	Patented	15.5	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	4.38	6.21	4.14	5.67
DCT79XR	DMM1I8R	Indazole derivative 5	Patented	15.5	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.12	4.17	3.5	5.55
DCRLH3S	DMM1I8R	Indazole derivative 5	Patented	15.5	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.52	10.05	4.66	2.46
DCEB2W6	DMM1I8R	Indazole derivative 5	Patented	15.5	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.71	7.04	5.2	7.38
DC61HV7	DMM1I8R	Indazole derivative 5	Patented	15.5	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.5	9.4	0.81	4.75
DC9JDHO	DMM1I8R	Indazole derivative 5	Patented	15.5	DMSG91J	ER819762	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.53	0.72	2.05	1.89
DCQN2QN	DMM1I8R	Indazole derivative 5	Patented	15.5	DMSG91J	ER819762	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.64	2.59	1.62	1.43
DC933S2	DMM1I8R	Indazole derivative 5	Patented	15.5	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.2	4.75	4.3	5.64
DCSFP7T	DMM1I8R	Indazole derivative 5	Patented	15.5	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.38	3.15	2.32	4.1
DC9XHDF	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.97	6.66	8.76	9.52
DCGMAJD	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.64	4.94	4.91	6.43
DCD4VBU	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	3.02	9.46	8.26	8.14
DCVS791	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.9	11.48	2.39	8.94
DCMAOGC	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.86	4.92	3.88	3.33
DCM44Q2	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.15	5.49	3.05	4.74
DCF5VPL	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.87	2.44	5.23	6.24
DCV7VGO	DMM1I8R	Indazole derivative 5	Patented	15.5	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	20.52	19.49	20.74	18.88
DCHDEOI	DMM1I8R	Indazole derivative 5	Patented	15.5	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	15.71	17.04	17.25	19.85
DC1BPVF	DMM1I8R	Indazole derivative 5	Patented	15.5	DMUOT9V	Taxol	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	15.27	11.53	11.17	14.5
DCBIA53	DMM1I8R	Indazole derivative 5	Patented	15.5	DMUOT9V	Taxol	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	6.27	7.38	8.16	9.83
DC85OCH	DMM1I8R	Indazole derivative 5	Patented	15.5	DMUOT9V	Taxol	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	8.5	10.34	1.87	11.41
DCI2YLE	DMM1I8R	Indazole derivative 5	Patented	15.5	DMUOT9V	Taxol	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	16.26	18.3	9.82	19.24
DCZAYAR	DMM1I8R	Indazole derivative 5	Patented	15.5	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	4.12	1.4	2.58	5.41
DCX82J0	DMM1I8R	Indazole derivative 5	Patented	15.5	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.71	1.49	1.64	3.68
DC0BDS1	DMM1I8R	Indazole derivative 5	Patented	15.5	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.91	0.94	3.14	3.68
DCHD6Q6	DMM1I8R	Indazole derivative 5	Patented	15.5	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.84	6.24	3.46	6.75
DCGSC9Z	DMM1I8R	Indazole derivative 5	Patented	15.5	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	5.13	10.19	7.03	12.07
DCIQWTC	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.97	7.49	3.41	5.04
DC2QDGI	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.3	2.92	4.41	5.97
DCBMN0J	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.83	0.89	0.99	2.99
DCLC8BF	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.66	4.7	6.96	6.94
DCXG41K	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.45	2.33	4.57	5.91
DCQPS6B	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.15	3.01	3.34	5.26
DCNZ6EV	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.84	1.32	4.26	5.32
DCZUDJK	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.42	3.83	3.19	3.59
DCT80CT	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.64	5.51	0.21	4.88
DC1CSVY	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.69	4.27	4.88	5.58
DC3F4SC	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	4.6	6.94	3.65	3.11
DCV001L	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	4.52	5.96	5.79	5.98
DCM306V	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.99	5.55	4.25	7.31
DC90Z56	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.17	3.5	5.22	6.27
DCA1VVG	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	6.17	11.04	1.38	10.21
DCT9XEW	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.58	4.31	0.96	4.33
DCUWP9H	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	14.74	10.55	10.16	12.68
DCTP4CI	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.35	5.28	5.54	6.12
DCAQR7K	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	13.34	13.77	11.13	13.94
DCF0UQD	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	25.17	23.99	18.92	25.13
DCXZ4PK	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.38	3.99	4.54	4.73
DC0PW11	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.98	7.04	4.86	5.39
DC7ELMF	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.31	7.72	3.44	3.54
DC5LOGL	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.58	3.16	3.55	3.95
DC63X0Q	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.45	3.32	2.13	5.22
DC9GJFF	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.08	6.12	2.73	2.08
DCTR96X	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.07	3.78	1.96	1.91
DCVVSC9	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	9.37	10.38	8.07	11.78
DC4F0SZ	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	5.21	8.17	9.62	9.64
DCN312B	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.27	8.2	6.91	7.72
DCO4U0N	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.68	4.74	2.39	3.76
DCAFVBT	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.02	6.64	5.99	8.3
DCPKVRD	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.73	8.91	5.76	5.6
DC4NK4W	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.66	2.63	0.86	0.62
DCKIFQ5	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.91	9.47	10.5	10.38
DCL16MC	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.08	7.97	7.04	8.35
DC6D6X7	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	27.11	26.29	25.82	25.8
DCJ2DBP	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.79	5.31	5.46	4.95
DCF6T15	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	18.37	20.32	19.37	19.46
DCJWUHE	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	28.61	28.3	27.93	24.87
DCGJXS0	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	22.66	20.95	21.22	21.17
DCQTF6F	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.62	4.24	1.03	1.44
DC5WU98	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.83	10.62	7.72	9.09
DC3QNUD	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	18.81	18.7	16.39	17.01
DCYTCR5	DMM1I8R	Indazole derivative 5	Patented	15.5	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.62	6.85	6.4	7.33
DCB7C2C	DMM1I8R	Indazole derivative 5	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.29	3.12	1.4	0.35
DCPHEAQ	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.03	4.05	4.21	4.22
DC7AWS6	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.05	2.28	1.99	5
DC4G1PH	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.14	3.7	2.78	3.51
DCADNYR	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.37	3.9	0.47	0.22
DCDICLN	DMM1I8R	Indazole derivative 5	Patented	15.5	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.06	6.32	5.26	4.06
DCVP7FR	DMM1I8R	Indazole derivative 5	Patented	15.5	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.63	4.19	2.53	1.9
DCC0P93	DMM1I8R	Indazole derivative 5	Patented	15.5	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.39	2.02	1.45	1.44
DC4KB76	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	29.74	27.97	28.76	28.74
DCNT3XE	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	14.42	20.16	18.85	19.9
DCCAG7O	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	29.35	30.7	29.05	27.05
DC62AHJ	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	26.91	29.58	29.1	29.59
DCO8X0V	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	32.31	31.95	30.31	30.26
DCK3F0N	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	24.29	23.24	22.71	22.27
DCDMYCJ	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	19.71	18.65	15.46	15.95
DC49RWB	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.27	2.33	1.45	1.34
DCQ5YCI	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	9.94	11.65	11.78	12.35
DC6E323	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.71	7.31	7.18	8.35
DCBWA7G	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.72	4.02	0.75	1.59
DCKEH6T	DMM1I8R	Indazole derivative 5	Patented	15.5	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.49	5.96	2.8	6.08
DCZLSL4	DMM1I8R	Indazole derivative 5	Patented	15.5	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.79	9.08	4.96	3.72
DC12K85	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.15	10.48	7.92	9.81
DCUX42S	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.81	6.57	3.25	3.29
DC5OXWP	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.83	8.67	8.12	7.92
DC217OB	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.94	4.46	2.77	2.77
DCVZ3BN	DMM1I8R	Indazole derivative 5	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.97	4.03	2.83	3.33
DCUO996	DMM1I8R	Indazole derivative 5	Patented	15.5	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.2	5.77	1.13	2.68
DCSPK7E	DMM1I8R	Indazole derivative 5	Patented	15.5	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.94	13.47	10.64	10.26
DCY8BSD	DMM1I8R	Indazole derivative 5	Patented	15.5	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.53	1.75	1.21	0.77
DCY9FO1	DMM1I8R	Indazole derivative 5	Patented	15.5	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.93	5.15	3.49	3.49
DCRFG0B	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.12	7.51	5.55	6.45
DCNYUWF	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	7.06	10.83	11.58	12.82
DCEJUMO	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.01	9.04	3.13	3.08
DC165T1	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.44	14.36	5.78	9.5
DC49MQF	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.42	10.32	8.61	8.41
DC5FTAJ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.5	5.49	3.84	5.01
DCEELBR	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.28	3.19	0.17	4.2
DCFVNRS	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.49	8.95	1.93	8.57
DC7UVX4	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.05	5.99	3.63	4.42
DCUIGXT	DMM1I8R	Indazole derivative 5	Patented	15.5	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.42	11.21	8.05	12.9
DC3YSO9	DMM1I8R	Indazole derivative 5	Patented	15.5	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.86	4.44	3.4	3.92
DCGWKZT	DMM1I8R	Indazole derivative 5	Patented	15.5	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.39	2.77	4.96	5.34
DC5HXWA	DMM1I8R	Indazole derivative 5	Patented	15.5	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.33	11.41	0.6	10.4
DCBVMI1	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.56	5.27	4.2	1.14
DCA5D92	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.12	3.03	2.49	2.08
DCGHF9E	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.97	3.08	1.89	0.99
DCHOQJS	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	10.35	14.45	11.35	13.94
DCBWL3U	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.2	7.4	8.23	9.78
DCFWBRY	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	6.77	10.57	9	8.88
DCV3P1T	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.91	7.51	6.14	9.41
DC1T48L	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.22	6.14	1.28	1.28
DCTVD7G	DMM1I8R	Indazole derivative 5	Patented	15.5	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.65	8	11.27	11.54
DCUDBPP	DMM1I8R	Indazole derivative 5	Patented	15.5	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.3	2.5	3.05	3.39
DCBPQE0	DMM1I8R	Indazole derivative 5	Patented	15.5	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	13.14	14.45	14.69	14.78
DCYLNE3	DMM1I8R	Indazole derivative 5	Patented	15.5	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.16	1.45	2.25	2.81
DCX77FK	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	13.9	11.14	15.14	15.78
DCLJNXC	DMM1I8R	Indazole derivative 5	Patented	15.5	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.51	3.06	1.89	2.38
DCGX5DQ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.11	2.67	0.42	0.71
DCJ9UAA	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.39	7.97	5.16	4.27
DCXPTRU	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.82	6.81	6	6.07
DCNQZ7E	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.06	4.97	3.27	3.24
DCF3PJU	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	8.38	8.86	8.06	10.28
DCSCXT6	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.85	3.28	5.09	6.65
DCDEVNM	DMM1I8R	Indazole derivative 5	Patented	15.5	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.81	8.27	3.28	2.38
DCE8LJI	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.72	5.51	4.14	4.42
DCVZL2H	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	7.62	9.35	6.75	10.65
DCQIN1C	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.32	3.3	3.15	4.35
DC0X2JR	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.25	6.86	6.98	7.12
DCHTB3L	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	18.69	22.39	2.62	20.06
DCZWCCU	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.3	8.98	8.1	8.15
DCJEEJ2	DMM1I8R	Indazole derivative 5	Patented	15.5	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.75	5.63	1.4	5.05
DCPDFZD	DMM1I8R	Indazole derivative 5	Patented	15.5	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.19	4.26	1.82	2.6
DCYVMRB	DMM1I8R	Indazole derivative 5	Patented	15.5	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.61	4.43	1.95	2.09
DCN3EKC	DMM1I8R	Indazole derivative 5	Patented	15.5	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.99	2.95	3.71	4.15
DCT3KZB	DMM1I8R	Indazole derivative 5	Patented	15.5	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.94	4.46	5.44	6.29
DCZY7A4	DMM1I8R	Indazole derivative 5	Patented	15.5	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.56	2.91	1.1	1.64
DCAJZV9	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	13.92	12.99	0.04	13.58
DC4LL4G	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.82	9.47	1.41	1.16
DC0AQH1	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.35	5.3	2.62	2.57
DC0FGQR	DMM1I8R	Indazole derivative 5	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.21	3.87	2.16	2.16
DCT2WNG	DMM1I8R	Indazole derivative 5	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.62	2.46	1.64	1.22
DCVEXM8	DMM1I8R	Indazole derivative 5	Patented	15.5	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.93	6.4	4.23	3.43
DC8GPUH	DMM1I8R	Indazole derivative 5	Patented	15.5	DMSG91J	ER819762	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.14	5.82	6.09	2.48
DC5MGZS	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1	7.58	4.3	4.24
DCB7BS8	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.24	4.05	3.52	3.44
DCA8X0H	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.23	9.34	7.66	7.66
DC8RCVM	DMM1I8R	Indazole derivative 5	Patented	15.5	DMUOT9V	Taxol	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.35	4.23	7.43	8.15
DCEM46Q	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.7	4.1	1.18	0.99
DCCREDV	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.85	7.61	5.85	3.84
DCNRZ8B	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.04	1.74	1.21	0.98
DCHB54N	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.76	5.42	5.86	6.05
DC6YA5I	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.05	5.82	5.13	5.06
DCASYIT	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.71	4.63	0.08	2.11
DCG4HOI	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.27	3.51	2.91	2.45
DCBZQM5	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.18	5.25	6.85	7.25
DC2E25E	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.21	6.71	4.41	4.47
DCEENUE	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.23	5.66	3.03	3.03
DCTUXBK	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.63	4.63	1.72	1.28
DCIGVM2	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.82	2.87	1.26	0.88
DCQILY4	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.12	6.19	5.04	4.9
DCQ3ZUH	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.82	3.28	2.59	2.75
DCL2UOU	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.83	3.38	2.16	1.68
DC6BKTF	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.43	2.86	3.02	0.93
DCPIDBQ	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.11	5.81	1.81	3.48
DCG9COC	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.91	4.25	1.04	0.14
DCVY30W	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.79	6.52	5.11	4.76
DC3PXBF	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.13	5.32	1.17	0.47
DCT23DT	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.14	3.39	0.55	1.77
DCORU04	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.19	8.54	5.88	5.88
DCRVS3D	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.53	5.64	0.69	0.11
DCJ253K	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	5.12	6.7	0.76	4.77
DC72BWZ	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.33	4.5	3.81	3.43
DCNVEW5	DMM1I8R	Indazole derivative 5	Patented	15.5	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.51	5.41	4.41	5.16
DC2UBFG	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.25	4.04	3.99	6.84
DCGEL7L	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.42	4.65	4.39	3.89
DCIH8W8	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	5.17	11.14	7.75	7.41
DCFGCNS	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	12.33	15.02	12.49	11.96
DC6U6YN	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.1	5.9	3.48	4.84
DC4MJKQ	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.46	8.36	5.45	5.89
DCOZK7B	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.93	3.73	5.46	6.52
DC5K9RP	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	4.88	6.54	5.28	8.69
DCHGM7H	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	14.05	13.35	12.66	12.79
DCANLNT	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.34	3.25	3.25	2.82
DCY4YE5	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	9.62	9.67	8.33	9.74
DCK4N64	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.96	7.66	5.95	7.34
DCIM6GE	DMM1I8R	Indazole derivative 5	Patented	15.5	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.91	10.07	5.52	8.74
DCAJ1J1	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.19	6.64	3.44	0.86
DCA99Z9	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.47	5.96	0.77	0.51
DCGGSSH	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.9	7.79	3.29	3.11
DCZTDP6	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	5.06	3.47	1.69	1.4
DCOCUF1	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.95	4.97	2.26	1.07
DCCS6FG	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.68	4.51	3.26	2.28
DCIGYFX	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.53	3.63	1.02	0.78
DCDNMXF	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.7	7.19	1.06	1.06
DC9ELFW	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.24	2.61	2.04	1.15
DC97U96	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.35	3.03	0.98	1.29
DCY0F38	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.88	5.14	1.04	0.88
DCXLI4K	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.8	4.1	0.74	0.66
DCHGV5M	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.36	2.4	0.98	0.93
DCBOFN4	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.78	1.71	0.42	0.39
DCWX2JC	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.1	1.53	0.85	0.49
DC5Y0IP	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.11	2.34	2.61	1.28
DCHSWIB	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.11	4.89	3.22	3.24
DCZMWMO	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.47	2.95	0.98	0.4
DCNNUUT	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.42	6.6	4.81	4.7
DCUNQTL	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.87	3.84	3.54	3.04
DC67G6T	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.2	3.57	1.47	2.27
DCLTWKM	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.16	2.84	0.67	1.11
DC0BPNY	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.68	11.45	9.78	9.11
DC99BM4	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	17.66	20.68	16.12	17.32
DCXWNW4	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.77	2.38	1.06	0.83
DC31TEY	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.65	0.73	0.25	0.08
DCMH7RS	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	20.96	20.65	18.79	17.96
DCFO0DJ	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	15.92	18.61	11.2	16.62
DC67L8H	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	18.11	19.01	18.98	18.93
DCYFGPB	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	23.19	21.38	20.84	20.34
DCDKGBO	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.2	11.23	8.58	9.42
DCS4TU2	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	10.67	15.43	15.18	11.23
DCFZB3E	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	9.19	11.36	8.58	7.92
DCHH06L	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	8.07	13.19	5.67	6.61
DCXSLSE	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	9.01	14.27	12.83	12.57
DCT3HCW	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	17.61	22.81	20.95	21.54
DCGRP4E	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.54	11.03	9.47	9.59
DC38C9P	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	6.8	7.34	4.1	3.73
DCD97AG	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.59	10.58	6.78	7.94
DCOWYXD	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	5.38	9.72	9.35	8.88
DCVANDD	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	3.79	9.12	8.94	8.57
DC075P0	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	10.14	17.28	17.14	17.11
DC5GDJA	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.4	11.95	12.9	12.7
DCMFSLX	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	7.65	10.87	4.08	7.55
DC36NDK	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	4.32	5.58	5.62	4.49
DCWJCIC	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	7.73	15.73	14.71	14.07
DCAFBC7	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	7.21	14.35	13.24	12.21
DCU4M13	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.68	7.39	6.63	6.65
DCWIU2H	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	7.6	11.77	10.97	10.24
DC36UH4	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.65	9.98	8.48	8.11
DCMVWYH	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	6.2	10.73	10.48	8.58
DCKLOF3	DMM1I8R	Indazole derivative 5	Patented	15.5	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	4.06	7.61	5.44	5.25
DCQI8M3	DMM1I8R	Indazole derivative 5	Patented	15.5	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.62	7.43	4.91	4.86
DCUAPXD	DMM1I8R	Indazole derivative 5	Patented	15.5	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.48	4.2	1.83	0.45
DC8PO7S	DMM1I8R	Indazole derivative 5	Patented	15.5	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.16	2.92	0.52	0.74
DCETGFL	DMM1I8R	Indazole derivative 5	Patented	15.5	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.37	4.87	3.5	3.62
DCGPRM3	DMM1I8R	Indazole derivative 5	Patented	15.5	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.91	2.41	2.33	1.75
DCX0IL5	DMM1I8R	Indazole derivative 5	Patented	15.5	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.7	6.15	3.1	3.3
DCT0GME	DMM1I8R	Indazole derivative 5	Patented	15.5	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	8.68	3.19	2.56	2.15
DC32L2P	DMM1I8R	Indazole derivative 5	Patented	15.5	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.62	5.28	2.12	1.91
DCWW6BL	DMM1I8R	Indazole derivative 5	Patented	15.5	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.65	0.77	0.14	0.1
DC0V8ZE	DMM1I8R	Indazole derivative 5	Patented	15.5	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.24	3.63	1.32	1.88
DC8XI4I	DMM1I8R	Indazole derivative 5	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.79	4.06	2.9	4.1
DCWAL30	DMM1I8R	Indazole derivative 5	Patented	15.5	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.72	3.51	0.86	0.86
DCUMIKE	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.54	8.37	3.55	7.01
DCL4ET4	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	19.64	19.19	10.22	15.55
DCE5MTT	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.48	10.35	8.08	9.79
DC7YJ8R	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.48	7.61	6.99	7.09
DCL67R1	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.25	5.3	1.38	5.09
DCZDG5P	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.28	2.11	1.45	0.99
DC5GSAQ	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.14	3.18	1.47	0.5
DCQ9PLO	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.32	5.77	4.76	4.32
DCZLJBT	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.57	6.09	2.68	2.66
DCIQPJB	DMM1I8R	Indazole derivative 5	Patented	15.5	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.76	5.75	1.62	1.13
DCNHS0X	DMM1I8R	Indazole derivative 5	Patented	15.5	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.24	4.65	0.28	0.28
DCLRBFF	DMM1I8R	Indazole derivative 5	Patented	15.5	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.8	4.52	2.99	3.26
DCBSWML	DMM1I8R	Indazole derivative 5	Patented	15.5	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.69	8.31	4.29	4.46
DCC6PFK	DMM1I8R	Indazole derivative 5	Patented	15.5	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.2	3.17	0.75	0.77
DCZJLI5	DMM1I8R	Indazole derivative 5	Patented	15.5	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.97	4.29	2.99	1.66
DCQSE7N	DMM1I8R	Indazole derivative 5	Patented	15.5	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.1	2.8	0.64	0.93
DC9J0VL	DMM1I8R	Indazole derivative 5	Patented	15.5	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	9.08	12.64	2.84	1.14
DC8NFDA	DMM1I8R	Indazole derivative 5	Patented	15.5	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1	3.21	2.39	1.76
DCUCZ50	DMM1I8R	Indazole derivative 5	Patented	15.5	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	3.51	6.09	2.15	1.23
DC8XQL1	DMM1I8R	Indazole derivative 5	Patented	15.5	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	6.31	3.82	2.92	2.43
DC0AZ5Z	DMM1I8R	Indazole derivative 5	Patented	15.5	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.23	3.43	2.49	1.95
DC6SOKU	DMM1I8R	Indazole derivative 5	Patented	15.5	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.99	5.3	4.46	3.5
DCE6L26	DMM1I8R	Indazole derivative 5	Patented	15.5	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.45	3.77	0.43	0.48
DCS9WPC	DMM1I8R	Indazole derivative 5	Patented	15.5	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	6.27	8.26	5.74	5.36
DCR38V3	DMM1I8R	Indazole derivative 5	Patented	15.5	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.84	8.49	5.37	10.57
DCG1728	DMM1I8R	Indazole derivative 5	Patented	15.5	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.91	3.07	0.55	0.55
DC7OEZS	DMM1I8R	Indazole derivative 5	Patented	15.5	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	5.25	2.86	2.49	1.59
DCZG6WP	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.24	3.82	0.98	0.21
DCCCLGJ	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	24.5	23.05	19.11	19.92
DC4Q8XF	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.12	5.97	5.61	5.84
DC659YG	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.12	6.48	5.88	4.34
DCDCF5O	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	15.29	19.14	16.87	17.33
DC8EKGK	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	8.69	15.54	11.51	11.48
DCW5TKR	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	28.6	27.49	19.84	20.91
DCHTQRX	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.21	5.89	6.28	6.13
DCXFSYB	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	30.79	28.72	27.47	27.47
DCDLKVS	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	23.09	19.87	18.46	18.41
DC1V6R7	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.24	2.93	1.16	0.94
DC4DQKT	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.59	4.52	1.57	1.22
DCKJGRV	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.31	7.17	10.63	9.58
DCU5XVY	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.4	7.54	7.16	6.61
DCEHX1L	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	10.12	12.44	13.34	11.65
DC66JV2	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	33.88	28.78	27.56	26.9
DC3LJKY	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.4	3.72	3.39	2.1
DCUTBHH	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.98	4.58	4.17	4.15
DC32BYX	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.06	6.82	5.06	5.06
DC1XBEP	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.17	4.01	1.69	1.69
DCT2SDA	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.38	6.01	2.25	1.91
DCLADWD	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.4	8.27	4.92	4.22
DCNWOFG	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.65	6	5.82	5.35
DCU11K4	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.54	4.7	1.6	1.77
DC9GOG9	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.77	4.39	2.66	1.28
DCL9UK6	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	6.16	9.05	6.78	6.36
DCAZAEC	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.87	6.09	3.42	3.86
DC5CSZQ	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.41	2.23	0.69	1.15
DCW28K1	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.64	6.05	3.96	5
DC2BG9R	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	8.58	8.25	7.23	7.59
DCMUGY7	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.76	2.8	3.52	4.8
DCR2P4D	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.69	3.79	2.26	1.36
DC7J5U4	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.09	3.7	0.33	0.21
DCF4KKK	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.19	5.51	4.09	3.73
DCPIDXI	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.62	1.41	2.01	2.55
DC2HOH6	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.69	4.82	2.44	2.11
DCIOSIR	DMM1I8R	Indazole derivative 5	Patented	15.5	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.37	6.3	4.09	3.52
DCVUN1Q	DMM1I8R	Indazole derivative 5	Patented	15.5	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.24	5.51	0.43	1.64
DCHXB5F	DMM1I8R	Indazole derivative 5	Patented	15.5	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.49	5.4	1.15	2.02
DCSY3UG	DMM1I8R	Indazole derivative 5	Patented	15.5	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.38	7.11	5.29	3.79
DCJRXF3	DMM1I8R	Indazole derivative 5	Patented	15.5	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.74	3.4	0.9	1.54
DCQJB7F	DMM1I8R	Indazole derivative 5	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	9.48	9.05	4.61	8.36
DC0UAJZ	DMM1I8R	Indazole derivative 5	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.15	7.81	5.44	8.16
DCH4LEY	DMM1I8R	Indazole derivative 5	Patented	15.5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.17	2.03	0.88	4.42
DCEYO90	DMM1I8R	Indazole derivative 5	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.25	1.79	0.3	0.28
DCRLRPD	DMM1I8R	Indazole derivative 5	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.36	4.27	3.52	2.78
DC0CLGE	DMM1I8R	Indazole derivative 5	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.27	2.67	2.3	1.64
DCPTMXH	DMM1I8R	Indazole derivative 5	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.59	2.9	0.26	0.26
DC9TAXZ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.26	1.63	1.09	0.62
DC9SH51	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	4.21	10.36	8.05	8.04
DCIMZ2J	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.01	4.43	3.65	3.27
DCVQ2K0	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.86	8.59	7.67	6.75
DC0RCV4	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.74	3.83	0.53	0.41
DCCD82J	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.74	4.56	3.09	3.11
DCPFLPO	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.5	6.46	6.48	5.21
DCRJ3J5	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.7	6.31	4.05	3.49
DCRTPNL	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.36	8.29	5.92	5.22
DCR8L8L	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.05	3.87	3.51	2.55
DCRHAR1	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.35	4.23	3.91	2.74
DCWZWBU	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.5	3.28	1.5	1.52
DCIHAEI	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.92	4.03	4.21	2.25
DCZHKYJ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.7	5.47	3.11	3.11
DC7BSTO	DMM1I8R	Indazole derivative 5	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.13	3.81	1.28	1.1
DCGJB50	DMM1I8R	Indazole derivative 5	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.23	3.75	1.57	0.45
DCTL4QT	DMM1I8R	Indazole derivative 5	Patented	15.5	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.67	3.1	1.12	0.38
DCJEQF5	DMM1I8R	Indazole derivative 5	Patented	15.5	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	7.14	8.58	4.73	2.08
DCJWLG0	DMM1I8R	Indazole derivative 5	Patented	15.5	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.3	1.83	0.89	0.24
DCW0QXX	DMM1I8R	Indazole derivative 5	Patented	15.5	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.44	6.4	3.16	3.02
DCNTV10	DMM1I8R	Indazole derivative 5	Patented	15.5	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.93	4.25	0.11	1.34
DCRZMV0	DMM1I8R	Indazole derivative 5	Patented	15.5	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2	1.09	0.29	0.06
DCKYPVY	DMM1I8R	Indazole derivative 5	Patented	15.5	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.02	3.62	2.52	2.33
DCK4Z2Z	DMM1I8R	Indazole derivative 5	Patented	15.5	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	4.63	4.49	4.13	2.35
DC051KL	DMM1I8R	Indazole derivative 5	Patented	15.5	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.09	4.49	2.7	2.66
DCQT1SP	DMM1I8R	Indazole derivative 5	Patented	15.5	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.41	0.93	0.29	3.45
DCQJ4NZ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	3.32	6.75	3.39	6.26
DC099RO	DMM1I8R	Indazole derivative 5	Patented	15.5	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.64	6.04	5.1	5.32
DC3I94A	DMM1I8R	Indazole derivative 5	Patented	15.5	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.89	3.15	0.26	0.49
DCEDNOS	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6.52	5.8	2.49	7.5
DC2JHYX	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	11.76	11.46	6.07	10.91
DCC1UPW	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.88	3.72	1.06	4.25
DCGPDQ1	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.56	8.72	0.17	6.65
DCUGV99	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDI269	Docetaxel	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	13.55	16.15	13.23	16.08
DCWEOOZ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	8.31	8.23	3.46	10.2
DCDXGEG	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.26	6.42	4.04	3.28
DCVDV3K	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.2	5.91	2.74	2.32
DCG0SN2	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.76	10.22	6.05	5.49
DC7WU5Z	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	8.38	18.91	5.95	14.1
DCBOEH0	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.98	13.51	9.02	8.87
DCWYMLD	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.54	3.89	2.58	2.47
DCLNSSQ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.35	4.4	3.29	3.02
DCYKGJ7	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	3.67	4.1	4.1	2.46
DC0SEVB	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.43	5.01	2.78	1.44
DC4GZS6	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	4.62	5.51	2.33	0.13
DCYY8VP	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.15	9.67	6.26	7.8
DCVAC2X	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.52	4.53	1.64	1.53
DCUQYGQ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.63	4.23	2.28	2.07
DC6R3W0	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.2	4.39	4.02	3.09
DC8E7KZ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.82	3.57	1.04	0.81
DC1ONYO	DMM1I8R	Indazole derivative 5	Patented	15.5	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.43	5.05	1.09	0.42
DCGIG35	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	17.62	17.9	13.17	17.91
DCW73IU	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	8.96	7.32	1.37	5.92
DC5W7PV	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.61	4.53	3.19	5.52
DC9ABPF	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.26	5.61	0.04	2.32
DCE7U6R	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	8.85	9.84	1.27	7.88
DCAMH45	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	14.89	10.95	8.96	10.95
DCYQKVK	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.93	10.67	10.29	11.06
DCOF4HC	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.4	11.89	9.49	10.55
DCDS81C	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	4.61	11.14	8.61	9.88
DCH3PT9	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.95	7.56	7.4	7.08
DC90OUO	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.98	7.52	2.14	6.14
DCD2BDR	DMM1I8R	Indazole derivative 5	Patented	15.5	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	12.79	11.32	9.52	9.16
DCNC60R	DMM1I8R	Indazole derivative 5	Patented	15.5	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	5.59	9.47	5.04	8.97
DC0WG0B	DMM1I8R	Indazole derivative 5	Patented	15.5	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.51	5.87	0.02	5.63
DCY35VT	DMM1I8R	Indazole derivative 5	Patented	15.5	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.31	3.95	1.71	4.67
DCRCP1F	DMM1I8R	Indazole derivative 5	Patented	15.5	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	7.09	6.66	6.78	9.8
DCMSSP4	DMM1I8R	Indazole derivative 5	Patented	15.5	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	5.23	7.44	5.5	7.28
DC9FMWN	DMM1I8R	Indazole derivative 5	Patented	15.5	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	4.26	6.65	6.86	8.73
DC6RD8W	DMM1I8R	Indazole derivative 5	Patented	15.5	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.93	10.57	8.21	9.74
DCIT16C	DMM1I8R	Indazole derivative 5	Patented	15.5	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.29	5.1	5.16	6.43
DC5JY5X	DMM1I8R	Indazole derivative 5	Patented	15.5	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.7	2.75	3.26	5.65
DC8J74F	DMM1I8R	Indazole derivative 5	Patented	15.5	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.73	6.19	3.69	8.02
DCH9UPD	DMM1I8R	Indazole derivative 5	Patented	15.5	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.03	7.2	6.9	8.58
DCP3KFD	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.25	5.92	2.6	2.35
DC4TFZV	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.87	7.21	1.31	0.36
DC9RXDP	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH07Y3	Letrozole	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.8	7.8	6.9	6.49
DC1KVTG	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.27	3.59	1.87	0.29
DCM8JXE	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.72	6.16	4.88	4.06
DCB2K6O	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.51	3.43	3.12	1.97
DCIYWZX	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.01	2.36	1.31	0.1
DC8FKX1	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.31	8.68	4.89	8.17
DC0HPV2	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.17	7.35	5.46	6.39
DCMQDHF	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.48	5.8	3.19	6.79
DCMVAXI	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.26	2.43	1.6	2.12
DCRMB15	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	8.85	11.74	9.36	9.36
DCDPZ9D	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.71	2.6	0.31	0.31
DC0CYTT	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.65	2.82	1.95	2.01
DCJMRG8	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0	2.63	1.38	1.38
DCR1ZDL	DMM1I8R	Indazole derivative 5	Patented	15.5	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.05	3.14	0.81	0.81
DCQJXKW	DMM1I8R	Indazole derivative 5	Patented	15.5	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.3	13.61	3.76	10.62
DCE9XTK	DMM1I8R	Indazole derivative 5	Patented	15.5	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	13.88	12.7	5.19	12.57
DCXM1F4	DMM1I8R	Indazole derivative 5	Patented	15.5	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	7.7	13.46	8.92	14.2
DCIYHHR	DMM1I8R	Indazole derivative 5	Patented	15.5	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	14.71	16.87	13	17.96
DCSWWEM	DMM1I8R	Indazole derivative 5	Patented	15.5	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	9.18	11.21	7.17	11.75
DCPKADF	DMM1I8R	Indazole derivative 5	Patented	15.5	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	6.09	8.34	3.52	7.91
DC4ZRU5	DMM1I8R	Indazole derivative 5	Patented	15.5	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.58	3.53	1.38	0.78
DCJ7Y6E	DMM1I8R	Indazole derivative 5	Patented	15.5	DMINOX3	Vincristine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	17.02	18.21	11.48	17.42
DCETF9I	DMM1I8R	Indazole derivative 5	Patented	15.5	DMINOX3	Vincristine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.44	12.29	8.16	9.71
DCHA12A	DMM1I8R	Indazole derivative 5	Patented	15.5	DMINOX3	Vincristine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.33	7.36	3.95	6.56
DCLFUE5	DMM1I8R	Indazole derivative 5	Patented	15.5	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	7.08	5.08	3.08	3.23
DCSP1YC	DMM1I8R	Indazole derivative 5	Patented	15.5	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	7.01	6.34	4.54	5.21
DCT9LBC	DMM1I8R	Indazole derivative 5	Patented	15.5	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	5.07	6.63	5.7	5.77
DCQL98S	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	9.06	5.2	0.89	4.82
DCF9LRM	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	8.47	9.86	7.7	10.76
DCO560Z	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	7.58	15.56	11.37	13.92
DC272VJ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.99	6.99	1.69	7.7
DCHNDU0	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	9.77	11.01	7.51	12.95
DCVJNI1	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	7.38	12.29	2.1	11.82
DCM7E7J	DMM1I8R	Indazole derivative 5	Patented	15.5	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.22	5.04	3.77	3.22
DCFVWCF	DMM1I8R	Indazole derivative 5	Patented	15.5	DMKLAYG	Altretamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.5	3.97	1.88	1.76
DCLLH17	DMM1I8R	Indazole derivative 5	Patented	15.5	DMKLAYG	Altretamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.11	5.57	4.55	4.08
DCGEU84	DMM1I8R	Indazole derivative 5	Patented	15.5	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.69	5.73	1.66	1.23
DCV19MO	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.67	6.5	4.2	4.2
DCCB258	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.26	3.42	2.23	0.77
DC7I5VT	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.9	4.45	0.27	0.4
DCIJ9XK	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLNFWU	TEM	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.09	4.76	3.59	3.5
DC39CXQ	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLNFWU	TEM	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	6.89	3.24	2.75	2.36
DCLANZG	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.15	10.24	7.98	6.36
DCRHE85	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.28	4.58	2.92	3.15
DCE56V4	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.61	3.04	2.41	2.16
DCVFD3V	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.06	5.29	3.45	3.53
DCGB05J	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	8.37	9.43	4.28	8.17
DCE4SQR	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.39	3.57	2.81	3.79
DCIUNWV	DMM1I8R	Indazole derivative 5	Patented	15.5	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.31	2.29	1.64	1.45
DC85YZE	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.69	4.9	1.57	1.46
DC0WTD1	DMM1I8R	Indazole derivative 5	Patented	15.5	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	8.56	14.18	12.43	11.58
DCP663P	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	8.72	6.82	2.05	6.15
DC67VHN	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.54	4.23	1.22	3.94
DCNQORV	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.39	7.04	3.48	7.6
DCLJLFK	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	8.16	9.99	2.56	7.31
DC9KK61	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	5.5	6.85	8.47	8.25
DCZ63K7	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	3.95	6.65	5.8	9.08
DCDXJN8	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.77	6.42	1.49	8.3
DCVERL9	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.3	2.75	0.81	0.97
DCQ43FU	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.96	2.15	1.87	0.86
DCT0GMC	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.12	5.52	6.45	6.48
DCONHZO	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.18	4.35	3.29	3.57
DCI14W2	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.6	4.22	0.05	1.07
DCIGAQL	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.29	4.43	0.48	1.76
DCIKO8B	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNP60F	Anastrozole	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.78	2.34	0.7	1.94
DCMF5PD	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.04	2.26	0.39	2.71
DCIR1Q5	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.96	3.06	1.78	2.07
DCGBNKW	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.97	7.17	2.62	2.92
DCXQABI	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	15.77	12.86	9.01	9.7
DCHCWC9	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	15.12	17.27	15.05	15.18
DCBA01I	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.21	9.19	5.38	5.22
DCGBKD3	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.09	1.94	5.74	4.01
DC8UH00	DMM1I8R	Indazole derivative 5	Patented	15.5	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	10.66	8.11	6.44	6.48
DCKID3R	DMM1I8R	Indazole derivative 5	Patented	15.5	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.25	6.26	3.89	3.91
DCZLM7U	DMM1I8R	Indazole derivative 5	Patented	15.5	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	8.29	4.02	0.9	0.54
DCVMIGK	DMM1I8R	Indazole derivative 5	Patented	15.5	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.62	5.66	3.02	3.02
DCNWCV0	DMM1I8R	Indazole derivative 5	Patented	15.5	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.31	2.19	1.06	0.59
DCFJY11	DMM1I8R	Indazole derivative 5	Patented	15.5	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.58	5.83	5.6	4.33
DC96N5K	DMM1I8R	Indazole derivative 5	Patented	15.5	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.84	4.77	3.02	3.02
DCLDV8J	DMM1I8R	Indazole derivative 5	Patented	15.5	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.16	5.57	3.36	5.84
DCMBLB9	DMM1I8R	Indazole derivative 5	Patented	15.5	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	6.29	6.25	3.09	3.73
DC2XWA1	DMM1I8R	Indazole derivative 5	Patented	15.5	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.94	2.44	0.91	1.52
DCD3UP4	DMM1I8R	Indazole derivative 5	Patented	15.5	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	4.09	2.88	1.11	1.91
DCXTOD2	DMM1I8R	Indazole derivative 5	Patented	15.5	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	6.69	3.96	0.83	1.33
DC47JNC	DMM1I8R	Indazole derivative 5	Patented	15.5	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	8.14	7.69	6.98	7.4
DCMC289	DMM1I8R	Indazole derivative 5	Patented	15.5	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.9	2.91	2.26	2.33
DC8FJ3G	DMM1I8R	Indazole derivative 5	Patented	15.5	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	12.62	12.35	11.52	11.93
DCFCJWW	DMM1I8R	Indazole derivative 5	Patented	15.5	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.66	4.19	3.73	4.18
DCY64ET	DMM1I8R	Indazole derivative 5	Patented	15.5	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.42	4.94	4.78	4.71
DCCQXYW	DMM1I8R	Indazole derivative 5	Patented	15.5	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.42	2.75	0.42	0.95
DCKHD9I	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	14.98	8.81	6.86	10.82
DC14B5J	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	11.18	10.08	8.09	11.55
DC0XVOC	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	17.33	18.37	15.18	18.22
DCGIYSY	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	17.55	12.5	10.79	14.57
DC23CXH	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	23.27	22.8	18.57	22.44
DCIPZ72	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	28.41	17.64	12.89	17.8
DC8J6XA	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	4.87	12.03	3.33	11.14
DCACGL6	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.29	7.85	5.68	8.55
DCT048N	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	13.01	14.39	9.47	13.93
DCYZ4RD	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	4.76	8.07	6.31	5.37
DC53D9Y	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.58	5.88	2.71	1.94
DCHLRW4	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.29	3.11	2.27	1.65
DCSFYKM	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	5.39	9.15	2.4	2.4
DCXS0OC	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	8.3	12.34	10.94	11.07
DC7VFRF	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.88	3.53	1.73	1.08
DCB1CTU	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.79	4.65	4.29	2.63
DCM0G4M	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.56	7.25	4.34	4.65
DC86KGD	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.64	11.24	10.54	9.87
DCJB1QB	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.81	10.32	6.68	6.67
DCB81B3	DMM1I8R	Indazole derivative 5	Patented	15.5	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.17	3.14	1.32	0.55
DCHDXSC	DMM1I8R	Indazole derivative 5	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.08	3.32	2.09	0.75
DCYY0P4	DMM1I8R	Indazole derivative 5	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.46	3.42	1.42	0.16
DCICGG6	DMM1I8R	Indazole derivative 5	Patented	15.5	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.58	5.96	3.4	3.62
DC9OKYI	DMM1I8R	Indazole derivative 5	Patented	15.5	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.01	4.06	2.12	1.51
DCXJSG8	DMM1I8R	Indazole derivative 5	Patented	15.5	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.09	5.1	3.67	3.61
DC3RID1	DMM1I8R	Indazole derivative 5	Patented	15.5	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.48	1.86	0.67	0.67
DC2W54V	DMM1I8R	Indazole derivative 5	Patented	15.5	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.52	3.43	2.05	2.18
DCFPTMO	DMM1I8R	Indazole derivative 5	Patented	15.5	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.84	4.72	1.51	2.84
DCX87SK	DMM1I8R	Indazole derivative 5	Patented	15.5	DMSG91J	ER819762	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.63	9.13	6.34	8.21
DCMV28J	DMM1I8R	Indazole derivative 5	Patented	15.5	DMSG91J	ER819762	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.31	3.25	2.54	2.72
DCU13M7	DMM1I8R	Indazole derivative 5	Patented	15.5	DMSG91J	ER819762	Investigative	0	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.09	2.96	2.08	1.23
DCBPA5F	DMM1I8R	Indazole derivative 5	Patented	15.5	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	15.81	12.02	7.8	13.89
DCKQ4GS	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.09	2.64	0.54	1.73
DCAPNDI	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.59	2.97	1.18	0.98
DCC6U60	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	8.9	14.6	5.64	3.81
DC6SVTS	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.92	4.01	3.24	2.9
DCWYOS2	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.2	4.71	3.79	3.2
DCJAPON	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	2.64	6.88	0.35	0.35
DCKPCNO	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.09	4.8	3.66	3.35
DC8USQL	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.14	7.65	6.55	5.88
DC9P78U	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.78	8.19	7.69	6.21
DC3IS2M	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.51	3.97	3.4	3.1
DC8S74I	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.05	5.61	5.23	3.61
DCNP5SI	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.33	2.96	0.89	1.2
DCTYX8C	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.28	6.86	6.16	4.47
DCDRWS3	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.17	8.1	2.82	7.59
DCBBAI9	DMM1I8R	Indazole derivative 5	Patented	15.5	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.28	6.29	0.46	0.02
DCJXFOH	DMM1I8R	Indazole derivative 5	Patented	15.5	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.99	3.99	2.3	1.68
DC1KST3	DMM1I8R	Indazole derivative 5	Patented	15.5	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	12.47	10.79	7.99	12.5
DCUHXAD	DMM1I8R	Indazole derivative 5	Patented	15.5	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	14.33	15.48	13.15	16.62
DC33V27	DMM1I8R	Indazole derivative 5	Patented	15.5	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	8.89	15.43	8.39	14.52
DCRFBF0	DMM1I8R	Indazole derivative 5	Patented	15.5	DMUOT9V	Taxol	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	9.82	12.26	6.34	11.31
DCJJQDP	DMM1I8R	Indazole derivative 5	Patented	15.5	DMUOT9V	Taxol	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	10.43	10.81	2.07	11.79
DC76XZC	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.12	2.41	0.18	0.14
DC3TPS7	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	6.85	8.76	1.88	1.37
DCYCUV5	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.12	6.7	2.36	2.1
DCRREFN	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.43	3.11	1.61	1.68
DC7HC64	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.94	5.73	0.69	0.69
DCJ5GXG	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.9	7.56	5.66	5.01
DCWW2IL	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.08	1.23	0.85	0.26
DCSW4HB	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.27	3.71	2.24	0.59
DCYR31G	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.1	3.89	1.19	1.49
DCZXIPW	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.98	5.31	1.16	2.3
DCTF86O	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.07	3.91	2.65	2.65
DC94PNA	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.87	2.74	0.12	0.12
DCCAOBU	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.28	2.63	2.88	1.21
DC7TVHL	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.74	3.48	2.13	1.42
DCVTF4M	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.65	6.55	1.03	1.82
DCM6GU9	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.09	4.59	1.4	3.27
DCW0NXL	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.06	4.64	3.21	2.98
DCGPPVP	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.17	1.68	0.94	1.12
DC2W91P	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.85	11.29	2.71	9.11
DC53RD4	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWTAOI	Estramustine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.79	4.57	2.85	3.45
DCGJNWU	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.16	6.07	5.41	6.79
DCK45JK	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.32	6.14	3.83	3.93
DCLPJNS	DMM1I8R	Indazole derivative 5	Patented	15.5	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.61	5.18	1.32	2.15
DC2NOC9	DMM1I8R	Indazole derivative 5	Patented	15.5	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.2	3.98	1.01	1.1
DCQO3YR	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.42	9.35	8	11.08
DC89GDM	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.9	9.77	4.92	8.49
DCW8KR7	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	13.16	17.86	16.55	16.69
DCS4O5F	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.26	14.12	8.48	11.51
DCGGPNC	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.13	8.59	8.81	9.85
DC0PNZS	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.89	12.06	9.82	11
DCD7Y8V	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	19.17	22.08	12.42	22.08
DCEI01Y	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.59	11.66	6.19	10.5
DCNYCK2	DMM1I8R	Indazole derivative 5	Patented	15.5	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	15.47	15.38	3.46	13.22
DC62EEG	DMDKF3M	Raloxifene	Approved	34	DMZMSPF	Bicalutamide	Approved	34	.	.	.	.	Stage I Prostate Adenocarcinoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCCG9N8	DMDKF3M	Raloxifene	Approved	34	DMZMSPF	Bicalutamide	Approved	34	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCWN3YJ	DMDKF3M	Raloxifene	Approved	34	DMMC45B	Teriparatide	Approved	34	.	.	.	.	Osteoporosis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC6IJ0N	DMDKF3M	Raloxifene	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.83	7.44	10.88	11.18
DCE8HTJ	DMDKF3M	Raloxifene	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.47	8.3	4.76	5.38
DCZEW1H	DMDKF3M	Raloxifene	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	7.35	13.89	13.19	12.77
DC57131	DMDKF3M	Raloxifene	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	0.7	1.63	2.04	2.38
DCJ5Q8U	DMDKF3M	Raloxifene	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	7.38	19.9	16.08	15.56
DCYVVEQ	DMDKF3M	Raloxifene	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.97	6.05	2.24	2.82
DCOA82U	DMDKF3M	Raloxifene	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.01	7.89	5.34	6.85
DCLQPFO	DMDKF3M	Raloxifene	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	7.79	11.79	1.56	0.96
DCESDYO	DMDKF3M	Raloxifene	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.35	0.22	0.69	0.12
DCP0YXL	DMDKF3M	Raloxifene	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	5.73	4.4	2.32	5.93
DC7BQDC	DMDKF3M	Raloxifene	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.91	10.82	6.01	6.25
DCEA411	DMDKF3M	Raloxifene	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.25	4.89	2.64	0.88
DCHLCJD	DMDKF3M	Raloxifene	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	15.75	20.35	10.97	10.98
DC95LEU	DMDKF3M	Raloxifene	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	8.52	14.07	6.5	5.39
DC4PX4D	DMDKF3M	Raloxifene	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.12	8.38	3.22	7.26
DCVAEOF	DMDKF3M	Raloxifene	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.13	5.08	0.07	0.32
DCXZOFI	DMDKF3M	Raloxifene	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.92	6.26	1.91	2.07
DCV9PSZ	DMDKF3M	Raloxifene	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.51	2.3	0.76	1.3
DC6CLI2	DMDKF3M	Raloxifene	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.94	5.62	2.23	2.33
DCP5VLZ	DMDKF3M	Raloxifene	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.11	3.16	3.09	1.47
DCY86KH	DMDKF3M	Raloxifene	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.95	4.32	3.06	1.94
DCQTDSM	DMDKF3M	Raloxifene	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.83	8.69	5.11	4.25
DCYO0AS	DMDKF3M	Raloxifene	Approved	34	DM48K0X	Carfilzomib	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	20.891	24.796	10.02	10.608
DC3GWBQ	DMDKF3M	Raloxifene	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.37	1.26	2.04	4.98
DCXLBJA	DMDKF3M	Raloxifene	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.81	4.1	3.14	3.28
DCL7YXY	DMDKF3M	Raloxifene	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.57	5.12	2.17	1.94
DC1ORTZ	DMDKF3M	Raloxifene	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.93	5.99	6.58	6.58
DCB3Q0B	DMDKF3M	Raloxifene	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	7.95	12.9	1.52	5.81
DCIXN92	DMDKF3M	Raloxifene	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.75	8.99	2.84	6.43
DCIK2YJ	DMDKF3M	Raloxifene	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	8.51	15.51	15.38	15.36
DCXYRND	DMDKF3M	Raloxifene	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	8	15.6	9.75	10.35
DCI5WC5	DMDKF3M	Raloxifene	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.45	3.8	1.55	1.84
DCHETXK	DMDKF3M	Raloxifene	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.46	5.47	0.93	1.68
DCX7R54	DMDKF3M	Raloxifene	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.32	2.44	1.67	1.56
DCD805I	DMDKF3M	Raloxifene	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.18	12.64	4.27	3.21
DCI4C4X	DMDKF3M	Raloxifene	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.72	2.27	0.98	3.77
DCWX5UO	DMDKF3M	Raloxifene	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	5.63	9.04	8.62	8.02
DCBV35L	DMDKF3M	Raloxifene	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	7.54	12.23	6.8	4.88
DC5AZDU	DMDKF3M	Raloxifene	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.31	6.98	2.39	2.39
DC11K7H	DMDKF3M	Raloxifene	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.38	3.11	1.27	0.74
DC5CH2C	DMDKF3M	Raloxifene	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.34	1.34	0.05	0.24
DCSGGQ3	DMDKF3M	Raloxifene	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.76	4.07	1.25	1.91
DCBDJ6J	DMDKF3M	Raloxifene	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	9.93	7.94	3.96	4.38
DCAQREV	DMDKF3M	Raloxifene	Approved	34	DM6AUHV	Fostamatinib	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	3.041	7.021	2.003	3.899
DCUUWEB	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	19.94	25.77	15.35	14.72
DC0VRBE	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	19.08	19.34	14.83	14.81
DC1HCMI	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	9.45	10.57	3.47	11.27
DC09HHD	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	15.45	11	3.33	3.55
DCC6K8Y	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	20.86	18.23	6.66	20.07
DC22SQP	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.21	2.16	1.1	1.03
DC7TSFW	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	3.27	10.78	9.94	9.92
DCA7TFM	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.27	2.47	1.92	1.52
DCIK646	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.69	5.21	3.3	3.34
DCD9V8Q	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.33	10.35	3.4	3.32
DCYSBJ0	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	17.96	16.09	2.73	2.73
DCOLUJ2	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.74	4.44	3.8	3.38
DCUHZFJ	DMDKF3M	Raloxifene	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.85	2.43	1.36	0.39
DC33ECZ	DMDKF3M	Raloxifene	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.35	3.9	2.95	1.93
DCXECFR	DMDKF3M	Raloxifene	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.54	11.06	7.43	6.68
DC5G1RN	DMDKF3M	Raloxifene	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.49	4.75	1.39	2.24
DC6OSPL	DMDKF3M	Raloxifene	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	16.56	17.8	2.4	2.4
DC2N1P9	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.12	8.02	1.6	3.44
DC2L97W	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	9.17	7.17	4.25	7.14
DCJLQ54	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.27	0.55	1.49	2.2
DCN1GAV	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.6	1.06	0.02	1.12
DCLV1C1	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	7.97	9.24	6.13	7.26
DCBT6UY	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	14.08	13.53	12.61	13.12
DCUJ467	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.57	2.93	1.37	2.77
DC4P03U	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	4.52	2.56	1.6	3.29
DCO82S6	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.31	1.79	1.2	1.7
DCCVYC9	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	3.46	4.84	4.53	4.95
DCVWYMS	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.92	3.4	0.97	2.78
DCC8KZQ	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.99	4.53	6.72	7.5
DCAMQ8S	DMDKF3M	Raloxifene	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.27	4.61	4.54	3.98
DCMXBQZ	DMDKF3M	Raloxifene	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.81	6.24	0.99	0.66
DC912R2	DMDKF3M	Raloxifene	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.42	6.63	0.58	2.03
DCOQX8F	DMDKF3M	Raloxifene	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.16	2.33	0.44	0.44
DCGRV3P	DMDKF3M	Raloxifene	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.61	5.51	1.02	1.79
DC1L666	DMDKF3M	Raloxifene	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.55	5.5	3.62	8.39
DCJH9FQ	DMDKF3M	Raloxifene	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.73	4.14	6.08	8.85
DCJW8CD	DMDKF3M	Raloxifene	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.92	3.87	2.86	7.69
DCIGOI8	DMDKF3M	Raloxifene	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.14	2.37	3.11	1.03
DC0O9B6	DMDKF3M	Raloxifene	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	11.13	13.56	3.09	12.21
DCWDGT5	DMDKF3M	Raloxifene	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.68	3.37	6.81	6.69
DCX5DCW	DMDKF3M	Raloxifene	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.61	1.48	0.41	1.74
DCRV0C0	DMDKF3M	Raloxifene	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.37	11.97	7.86	7.86
DCZ555U	DMDKF3M	Raloxifene	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.08	3.23	6.77	6.63
DCPLY02	DMDKF3M	Raloxifene	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	2.31	4.5	1.76	1.76
DCSN6OH	DMDKF3M	Raloxifene	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.29	0.69	1.6	2.78
DCVYTAP	DMDKF3M	Raloxifene	Approved	34	DMBP5N3	Cantharidin	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	16.958	22.02	3.961	2.369
DCLIIMI	DMDKF3M	Raloxifene	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.56	2.12	1.27	1.49
DC973CU	DMDKF3M	Raloxifene	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.65	7.76	2.21	1.87
DCHAV8B	DMDKF3M	Raloxifene	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	13.89	21.69	12.29	12.29
DCQCVBT	DMDKF3M	Raloxifene	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	5.68	7.11	7.08	0.11
DC9VJH2	DMDKF3M	Raloxifene	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	13.71	20.02	16.31	13.87
DCQN83C	DMDKF3M	Raloxifene	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	6.49	9.69	8.51	9.67
DCAF86N	DMDKF3M	Raloxifene	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.84	3.42	1.29	0.53
DCEZP9H	DMDKF3M	Raloxifene	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.74	3.49	4.77	5.14
DC67GNF	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.38	8.41	5.85	5.72
DCICGSU	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	17.83	15.5	12.91	11.64
DCENSKS	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.87	3.01	1.46	1.39
DCPINZB	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	6.64	9.23	5.68	5.56
DCR1KFH	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.3	9.59	5.29	5.49
DCYHWRT	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.38	6.75	7.25	7.46
DC9Z621	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	6.15	10.64	8.02	7.98
DCP8FIE	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	17.22	21.39	11.46	13.33
DCJSXE4	DMDKF3M	Raloxifene	Approved	34	DMD7L94	Palbociclib	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	28.423	23.41	0.381	1.815
DC602ZD	DMDKF3M	Raloxifene	Approved	34	DMD7L94	Palbociclib	Approved	34	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	28.45	23.41	0.41	1.82
DCNZQ26	DMDKF3M	Raloxifene	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	8.39	9.68	3.6	5.35
DCCI8AC	DMDKF3M	Raloxifene	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.95	1.79	0.02	1.76
DCA0YTG	DMDKF3M	Raloxifene	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	6.71	4.84	7.19	5.04
DCNQHIQ	DMDKF3M	Raloxifene	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.65	2.02	0.91	2.31
DCTK32V	DMDKF3M	Raloxifene	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.26	7.68	0.48	4.41
DC0P8W3	DMDKF3M	Raloxifene	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.7	2.51	2.04	0.97
DCUQ2JS	DMDKF3M	Raloxifene	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.52	7.2	3.47	3.87
DCPZIBS	DMDKF3M	Raloxifene	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.86	2.88	0.8	1.65
DC8B9O3	DMDKF3M	Raloxifene	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	11.28	16.81	5.75	8.89
DCUCIMB	DMDKF3M	Raloxifene	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	10.35	12.25	3.48	11.53
DC2SRB3	DMDKF3M	Raloxifene	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.08	6.76	5.94	5.83
DCZ9IJD	DMDKF3M	Raloxifene	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	10.96	11.71	3.38	8.94
DCG0ONS	DMDKF3M	Raloxifene	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	10.37	17.77	14.21	16.45
DCE7071	DMDKF3M	Raloxifene	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.28	5.66	4.85	8.73
DCFRLP5	DMDKF3M	Raloxifene	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.65	6.63	4.36	4.12
DC0KEEB	DMDKF3M	Raloxifene	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.58	5.92	2.05	2.67
DCGS38Q	DMDKF3M	Raloxifene	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	2.96	6.72	3.13	4.15
DCOKAVQ	DMDKF3M	Raloxifene	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	9.09	14.56	9.55	9.24
DCFTRWW	DMDKF3M	Raloxifene	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.98	3.49	2.15	0.46
DCBZFEP	DMDKF3M	Raloxifene	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.94	0.43	5.66	4
DCL7IJ4	DMDKF3M	Raloxifene	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.35	4.95	1.5	1.35
DC9HMBY	DMDKF3M	Raloxifene	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	9.7	7.78	1.39	2.55
DCDS7E0	DMDKF3M	Raloxifene	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.76	7.96	6.8	7.93
DCE9FO4	DMDKF3M	Raloxifene	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.07	2.99	4.49	4.77
DCW8948	DMDKF3M	Raloxifene	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	9.03	9.12	7.18	6.94
DC106LX	DMDKF3M	Raloxifene	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.52	4.11	1.53	1.76
DCDKTSR	DMDKF3M	Raloxifene	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.93	1.63	2.08	2.32
DCCDVTU	DMDKF3M	Raloxifene	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.45	1.19	0.02	0.87
DCYE7ND	DMDKF3M	Raloxifene	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	15.1	14.02	0.27	14.83
DCLW8SE	DMDKF3M	Raloxifene	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	11.92	14.15	0.45	12.42
DC3CR0N	DMDKF3M	Raloxifene	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	4.8	5.85	0.84	6.83
DCHN6GP	DMDKF3M	Raloxifene	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.72	7.75	6.27	5.89
DCL0S84	DMDKF3M	Raloxifene	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.36	4.32	1.16	0.52
DCV83H2	DMDKF3M	Raloxifene	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.82	3.27	0.78	0.9
DCWXPEI	DMDKF3M	Raloxifene	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	1.84	7.9	4.84	4.24
DC602F8	DMDKF3M	Raloxifene	Approved	34	DMKXDOI	AS602868	Discontinued in Phase 1	3	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	2.107	7.886	0.047	0.037
DC68VCS	DMDKF3M	Raloxifene	Approved	34	DMKYXJW	Dorsomorphin	Investigative	0	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	10.774	14.304	7.575	9.163
DCA8TST	DMDKF3M	Raloxifene	Approved	34	DMKYXJW	Dorsomorphin	Investigative	0	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	11.46	14.3	7.57	9.16
DCG43CY	DMDKF3M	Raloxifene	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.57	9.69	7.04	5.61
DC0KG0L	DMDKF3M	Raloxifene	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.83	3.28	2.34	1.06
DCWDEO8	DMDKF3M	Raloxifene	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.81	2.62	1.65	1.34
DCED6J0	DMDKF3M	Raloxifene	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.15	3.5	3.93	4.02
DCQUMVY	DMDKF3M	Raloxifene	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.34	3.88	1.41	0.26
DCUBDT0	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.28	2.81	1.51	1.5
DCVKR3P	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.64	8.2	5.56	6.99
DCN2L01	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.58	9.29	4.64	6.77
DCRU5WM	DMDKF3M	Raloxifene	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	3.03	4.15	1.09	0.79
DCWKITW	DMDKF3M	Raloxifene	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.37	1.97	1.42	2.19
DCRJCUI	DMDKF3M	Raloxifene	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.49	8.09	3.31	2.1
DCR6AF5	DMDKF3M	Raloxifene	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.03	0.44	0.72	0.56
DCQ31GN	DMDKF3M	Raloxifene	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.07	5.79	4.96	4.43
DC153OU	DMDKF3M	Raloxifene	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3	13.33	15.97	9.41
DCVRITC	DMDKF3M	Raloxifene	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.57	4.35	2.02	0.41
DC4IHSO	DMDKF3M	Raloxifene	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.18	6.01	0.82	0.75
DC2DGBT	DMDKF3M	Raloxifene	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.51	1.37	0.93	0.64
DC1IPYH	DMDKF3M	Raloxifene	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.66	0.22	2.04	1.6
DC56KE5	DMDKF3M	Raloxifene	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.08	8.01	11.16	10.67
DCRDW8Z	DMDKF3M	Raloxifene	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	15.11	17.94	15.84	15.47
DC58BZV	DMDKF3M	Raloxifene	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	18.27	16.92	17.13	16.47
DCX2F4M	DMDKF3M	Raloxifene	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.84	6.18	1.39	2.06
DCOKG4G	DMDKF3M	Raloxifene	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.98	3.58	2.83	3.47
DCG9RGZ	DMDKF3M	Raloxifene	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.57	0.2	0.09	4
DCXV013	DMDKF3M	Raloxifene	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.84	1.73	1.04	3.99
DCPWVVP	DMDKF3M	Raloxifene	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.35	3.97	1.18	5.92
DCKRW8Z	DMDKF3M	Raloxifene	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	5.27	7.4	2.27	10.43
DCBAU5T	DMDKF3M	Raloxifene	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.62	6.06	3.85	7.56
DC1I160	DMDKF3M	Raloxifene	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.09	1.11	1.08	4.65
DC02ERB	DMDKF3M	Raloxifene	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.58	3.32	1.6	2.2
DCJK59J	DMDKF3M	Raloxifene	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.86	2.24	2.43	3.33
DCP10H3	DMDKF3M	Raloxifene	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	10.44	5.55	2.4	6.98
DCISJ8Q	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.21	12.24	7.47	7.62
DCD3WUE	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	5.4	8.74	8.11	8.81
DC8H8MP	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.54	5.17	4.21	3.21
DC19IIG	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.3	5.1	0.79	0.79
DCIXE37	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	5.27	8.09	10.1	10.21
DCABI0R	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.28	6.15	3.84	4.49
DC2GHEO	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.49	4.98	4	3.66
DCNLRXG	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	8.18	6.53	6.56	8.56
DCCUWXC	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	5.4	14.36	11.59	10.29
DC8RR3G	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	15.78	13.66	10.77	11.86
DCM3MWU	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	13.79	20.08	10.82	5.14
DCF05DZ	DMDKF3M	Raloxifene	Approved	34	DMPK32V	BMS-754807	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	4.511	7.933	2.074	9.374
DC9EWAV	DMDKF3M	Raloxifene	Approved	34	DMPK32V	BMS-754807	Phase 1	17	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	4.59	7.93	2.05	9.37
DCCY9RH	DMDKF3M	Raloxifene	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.31	0.33	0.25	5.04
DC1787Y	DMDKF3M	Raloxifene	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2	3.26	0.72	0.19
DCE7HR8	DMDKF3M	Raloxifene	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.52	1.77	2.13	6.52
DCSR8TQ	DMDKF3M	Raloxifene	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	14.32	15.01	0.85	0.56
DCMIG0Z	DMDKF3M	Raloxifene	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	8.93	13.67	4.48	8.69
DCE4KE4	DMDKF3M	Raloxifene	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	5.96	7.6	0.93	3.08
DCB4NKV	DMDKF3M	Raloxifene	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	4.31	7.4	1.84	1.67
DCUKUEO	DMDKF3M	Raloxifene	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.9	6.11	3.21	1.97
DC4CICI	DMDKF3M	Raloxifene	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	13.8	21.9	3.33	5.82
DC3BX2T	DMDKF3M	Raloxifene	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	6.65	14.59	10.11	7.3
DCVAT3M	DMDKF3M	Raloxifene	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.8	9.91	3.32	6.21
DC42FA1	DMDKF3M	Raloxifene	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.76	3.53	3.05	4.95
DC0QXXZ	DMDKF3M	Raloxifene	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.75	5.17	2.31	0.81
DCB590L	DMDKF3M	Raloxifene	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	4.21	7.78	3.87	3.33
DC2VLTK	DMDKF3M	Raloxifene	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.74	2.26	1.82	2.27
DCPN695	DMDKF3M	Raloxifene	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.69	3.56	0.51	1.13
DC8I3LY	DMDKF3M	Raloxifene	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.43	4.28	3.85	0.32
DCSWECQ	DMDKF3M	Raloxifene	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.9	2.56	0.92	0.47
DCAUHFQ	DMDKF3M	Raloxifene	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	14.96	22.75	18.05	16.52
DCRTQSU	DMDKF3M	Raloxifene	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	9.92	10.97	2.2	12.63
DCW41EI	DMDKF3M	Raloxifene	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	3.45	2.24	3.59	4.02
DCJMF9T	DMDKF3M	Raloxifene	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	14.32	12.49	14.34	17.75
DCBSCRL	DMDKF3M	Raloxifene	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	7.31	7.76	5.37	8.99
DCRKKJD	DMDKF3M	Raloxifene	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.42	4.1	2.44	3.15
DC7OJBA	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	2.34	4.91	0.64	0.64
DCA9YHQ	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	6.08	13.7	8.65	6.23
DCTL32V	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	7.12	2.94	1.23	1.57
DCDGBKQ	DMDKF3M	Raloxifene	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	11.12	9.28	0.04	10
DCMLH6X	DMDKF3M	Raloxifene	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.31	1.68	0.92	0.85
DC6GCO8	DMDKF3M	Raloxifene	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.43	8.39	7.52	7.4
DCEU50R	DMDKF3M	Raloxifene	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	12.65	15.05	13.03	12.14
DC6H61X	DMDKF3M	Raloxifene	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	15.23	21.73	21.56	20.25
DCQAS7X	DMDKF3M	Raloxifene	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.37	3.6	2.92	2.33
DCOB3WT	DMDKF3M	Raloxifene	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.65	6.61	3.22	2.55
DCW6XD1	DMDKF3M	Raloxifene	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.92	6.59	0.09	1.06
DCJR79O	DMDKF3M	Raloxifene	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.07	2.23	4.89	4.17
DC7QBKM	DMDKF3M	Raloxifene	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	6.83	9.84	1.19	4.33
DCGAM3P	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	2.74	3.33	1.99	0
DCPA2RR	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	11.56	14.73	2.06	0.59
DCGGABM	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.24	11.22	2.35	1.31
DC9I0W4	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.97	6.48	3.27	3.69
DC7JFKZ	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.15	5.72	6.78	5.91
DCQ7KR7	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.23	3.16	0.94	0.01
DCCLXZU	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.04	2.07	0.55	0.55
DCXEKKP	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0	5.01	4.15	3.34
DCF0PR1	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.47	1.86	0.43	0.39
DCQRD2Y	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.57	7.2	4.79	0.5
DCCGR6B	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	6.09	2.48	4.52	2.65
DC1VX47	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.24	3.22	2.2	2.2
DCUAT12	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.68	6.89	3.41	3.81
DCHHE7F	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	12.78	17.49	11.74	11.35
DCDN2V3	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.79	5.29	0.8	1.37
DCY8LAA	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.72	4.55	2.26	2.63
DCS1PIP	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.44	3.34	2.87	3.28
DCE6P9R	DMDKF3M	Raloxifene	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.74	4.45	4.67	8.11
DC1FRDA	DMDKF3M	Raloxifene	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	7.5	8.83	0.42	0.5
DC8YI17	DMDKF3M	Raloxifene	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.51	2.42	0.3	0.46
DCAP3RV	DMDKF3M	Raloxifene	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.32	3.72	2.96	3.02
DC2CIMU	DMDKF3M	Raloxifene	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	7.54	10.62	6.52	6.67
DC3QR83	DMDKF3M	Raloxifene	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.82	2.23	2.38	1.14
DCFW3Q4	DMDKF3M	Raloxifene	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.44	2.58	0.15	0.2
DC0GBW1	DMDKF3M	Raloxifene	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.06	5.37	1.95	1.99
DCZZYVX	DMDKF3M	Raloxifene	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.34	8.04	0.71	0.54
DCD0FK6	DMDKF3M	Raloxifene	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.79	8.16	3.36	0.65
DCMVMYA	DMDKF3M	Raloxifene	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.81	5.07	2.16	2.85
DCPLRVM	DMDKF3M	Raloxifene	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.01	5.51	1.67	1.67
DCIOFQF	DMDKF3M	Raloxifene	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.3	9.59	4.66	3.25
DCWN5VK	DMDKF3M	Raloxifene	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.49	10.6	2.65	5.72
DCZLP8G	DMDKF3M	Raloxifene	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.35	4.03	0.96	2.76
DCSYOMW	DMDKF3M	Raloxifene	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.03	9.27	3.66	5.58
DCLDZDY	DMDKF3M	Raloxifene	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.45	3.55	1.21	0.75
DCAVXRW	DMDKF3M	Raloxifene	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.68	7.9	1.76	1.14
DCHP3UL	DMDKF3M	Raloxifene	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	10.82	4.09	1.79	1.65
DCGS5ZM	DMDKF3M	Raloxifene	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.76	12.03	5.17	6.17
DCM1H40	DMDKF3M	Raloxifene	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.9	4.68	5.78	6.72
DCG5Y8E	DMDKF3M	Raloxifene	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.25	2.95	0.34	0.26
DCQ9H2O	DMDKF3M	Raloxifene	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.62	4.18	3.25	1.77
DCIITGW	DMDKF3M	Raloxifene	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.13	8.02	6.33	6.81
DC48WL3	DMDKF3M	Raloxifene	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.43	5.2	3.56	3.81
DCKDU9U	DMDKF3M	Raloxifene	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	9.9	10.21	5.57	12.44
DC1691S	DMDKF3M	Raloxifene	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.07	4.18	2.43	0.94
DC60Y8Z	DMDKF3M	Raloxifene	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.2	9.22	4.86	4.05
DCZHEKG	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.93	7.76	4.99	5.06
DC51BBS	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	5.08	5.76	2.5	7.75
DCPFTMU	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	15.99	15.24	7.4	0.77
DCBQOVE	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.06	6.34	0.51	0.61
DCIGNV8	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.97	5.31	0.33	0.84
DCCFFCC	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.78	7.63	5.3	5.44
DCENK9K	DMDKF3M	Raloxifene	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	8.72	11.52	4.74	2
DCAGSU3	DMDKF3M	Raloxifene	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	10.56	12.68	4.09	2.18
DCC2G6W	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.72	1.26	0.71	1.89
DCI8OSF	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.08	5.41	6.5	6.79
DC2NRLP	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	8.9	8.83	3.38	4.78
DCY4SMU	DMDKF3M	Raloxifene	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.82	2.86	2.69	2.72
DCRGI3J	DMDKF3M	Raloxifene	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.54	5.48	2.48	3.05
DCB8E1W	DMDKF3M	Raloxifene	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.49	11.68	3.36	2.34
DCFWK7G	DMDKF3M	Raloxifene	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.49	11.1	3.39	8.96
DCBU4N1	DMDKF3M	Raloxifene	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.23	11.89	5.38	2.59
DCTZ0A3	DMDKF3M	Raloxifene	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.43	8.25	0.73	0.09
DCWB715	DMDKF3M	Raloxifene	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.54	2.21	0.84	0.84
DCHA4GC	DMDKF3M	Raloxifene	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.23	2.84	1.21	0.67
DC4MA4U	DMDKF3M	Raloxifene	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	10.83	11.21	1.57	1.38
DCIMAS1	DMDKF3M	Raloxifene	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.97	4.91	1.17	2.97
DCFE127	DMDKF3M	Raloxifene	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	10.27	10.61	2.22	0.94
DCXDFBZ	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.47	6.07	3.54	3.03
DCLVL4O	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.04	10.36	3.46	4.15
DC9VYK9	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	8.58	12.13	6.46	6.46
DC39VR5	DMDKF3M	Raloxifene	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.03	6.61	0.22	1.24
DCQH3RW	DMDKF3M	Raloxifene	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.27	10.79	1.63	6.66
DCD29OF	DMDKF3M	Raloxifene	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.01	6.8	1.96	3.43
DCZRYFU	DMDKF3M	Raloxifene	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.29	1.49	7.12	9.17
DCRVIM4	DMDKF3M	Raloxifene	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.66	5.75	3.45	3.24
DCGVBQD	DMDKF3M	Raloxifene	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.12	5.55	5.99	0.23
DCK2R7M	DMDKF3M	Raloxifene	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.83	2.71	2.76	3.9
DC382EL	DMDKF3M	Raloxifene	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.47	10.31	4.3	4.3
DCCF5WV	DMDKF3M	Raloxifene	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	9.05	9.7	1.82	2.8
DCXPSUY	DMDKF3M	Raloxifene	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.85	3.81	2.67	3.01
DC1LYHF	DMDKF3M	Raloxifene	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.76	3	4.37	4.33
DCQF9W8	DMDKF3M	Raloxifene	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.54	6.91	0.97	1.81
DCNGM0F	DMDKF3M	Raloxifene	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	10.43	3.94	1.71	1.58
DC6Y397	DMDKF3M	Raloxifene	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.42	7.99	3.03	0.98
DCXFVZT	DMDKF3M	Raloxifene	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.18	1.62	2.72	0.54
DCF6RVK	DMDKF3M	Raloxifene	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.56	3.06	1.27	3.1
DC1VYFU	DMDKF3M	Raloxifene	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.67	5.8	5.01	4.68
DCX877Y	DMDKF3M	Raloxifene	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.02	3.4	4.5	5.68
DCYGTWQ	DMDKF3M	Raloxifene	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.3	10.98	4.92	5.75
DCDAD9A	DMDKF3M	Raloxifene	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.03	10.05	3.95	3.93
DCH740C	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.59	5.25	6.09	6.98
DCAQVAP	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.2	7.4	2.48	2.07
DCUDB90	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.84	6.58	4.38	3.15
DCQ746K	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.15	6.07	3.79	5.63
DC6AENR	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.54	9	0.85	0.22
DCV8AY3	DMDKF3M	Raloxifene	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.61	6.37	0.4	0.4
DC0MM99	DMDKF3M	Raloxifene	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.18	3.36	1.74	2.49
DC0CSRM	DMDKF3M	Raloxifene	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.25	5.26	4.98	5.4
DCAZSPV	DMDKF3M	Raloxifene	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.96	12.64	5.68	6.12
DCJIP3U	DMDKF3M	Raloxifene	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.54	4.21	0.63	1.18
DC3118Q	DMDKF3M	Raloxifene	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.98	5.28	2.18	2.96
DCRCO3H	DMDKF3M	Raloxifene	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.23	4.97	1.38	2.56
DC6ISHY	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.5	3.14	4.19	4
DC5TED2	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	11.9	13.23	6.39	5.41
DC78E56	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.61	14.64	6.47	5.94
DCVG7XP	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	10.89	12.6	11.64	13.52
DCCBAP2	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	6.97	11.75	9.71	8.51
DCGOMH4	DMDKF3M	Raloxifene	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.51	7.3	1.8	0.93
DCPQLY8	DMDKF3M	Raloxifene	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.69	10.37	0.73	0.03
DCVW4AA	DMDKF3M	Raloxifene	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	9.13	11.31	8.47	10.61
DC43O9I	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.53	4.81	2.62	2.99
DCE7BTT	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.34	9.82	2.24	1.65
DCQ0UOT	DMDKF3M	Raloxifene	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.25	1.03	0.07	0.28
DC88PEB	DMDKF3M	Raloxifene	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.02	5.72	4.96	4.93
DCRZ2XR	DMDKF3M	Raloxifene	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.15	2.56	1.86	1.71
DCBD5UM	DMDKF3M	Raloxifene	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.49	5.35	0.51	0.32
DCCHNZ3	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.87	2.33	2.08	1.08
DCPVCOJ	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.81	12.77	8.33	5.07
DC74B30	DMDKF3M	Raloxifene	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.55	3.65	4.08	4.48
DC6L404	DMDKF3M	Raloxifene	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.17	2.35	0.71	0.7
DCCP3EJ	DMDKF3M	Raloxifene	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.4	5.09	3.89	4.91
DC4Q2JL	DMDKF3M	Raloxifene	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	8.06	9.39	0.83	0.83
DCFP32S	DMDKF3M	Raloxifene	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.87	1.18	0.98	1.29
DCONXFB	DMDKF3M	Raloxifene	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.3	9	4.41	2.58
DCR2DUC	DMDKF3M	Raloxifene	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	7.51	9.78	2.16	3.46
DCU8SVH	DMDKF3M	Raloxifene	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.86	5.09	4.04	1.84
DCTJLFC	DMDKF3M	Raloxifene	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	9.91	12.14	3.61	1.49
DCBVE4A	DMDKF3M	Raloxifene	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.11	7.69	1.71	1.56
DCBSK5F	DMDKF3M	Raloxifene	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.69	5.37	0.13	0.13
DCEEDM5	DMDKF3M	Raloxifene	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.7	3.99	2.4	0.5
DC0XB3Q	DMDKF3M	Raloxifene	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.18	4.07	2.36	2.36
DCABBO2	DMDKF3M	Raloxifene	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.27	3.11	0.1	0.03
DCM8G02	DMDKF3M	Raloxifene	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.75	9.78	5.76	3.56
DC37295	DMDKF3M	Raloxifene	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.88	4.07	1.48	5.16
DCMO2A2	DMDKF3M	Raloxifene	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.15	2.58	0.68	0.68
DCFCRPU	DMDKF3M	Raloxifene	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.66	5.77	1.94	0.51
DCEMQKH	DMDKF3M	Raloxifene	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.4	5.65	0.46	0.46
DCCW9KG	DMDKF3M	Raloxifene	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.53	5.17	0.99	2.16
DCIUHHM	DMDKF3M	Raloxifene	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.28	6.89	4.4	3.63
DC857G6	DMDKF3M	Raloxifene	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.41	3.6	2.5	1.69
DCMD1Z4	DMDKF3M	Raloxifene	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.04	4.03	0.33	1.49
DCXLYWH	DMDKF3M	Raloxifene	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.48	2.23	2.11	2.22
DCNNDYI	DMDKF3M	Raloxifene	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.6	3.5	0.18	2.61
DCIK8IH	DMDKF3M	Raloxifene	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	10.28	11.87	3.49	6.64
DC36PBP	DMDKF3M	Raloxifene	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	6.49	7.32	4.56	5.12
DCVE39C	DMDKF3M	Raloxifene	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	16.66	17.65	12.6	13.32
DC7NBH6	DMDKF3M	Raloxifene	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.97	5.39	3.98	2.92
DC8ZEQ8	DMDKF3M	Raloxifene	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.59	5.45	1.99	1.94
DC9DYXW	DMDKF3M	Raloxifene	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.67	1.9	1.78	0.18
DCXJ9RK	DMDKF3M	Raloxifene	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.16	10.02	9.51	5.46
DC65DRT	DMDKF3M	Raloxifene	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.17	3.43	1.35	1.36
DCE6LFB	DMDKF3M	Raloxifene	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.37	5.31	4.31	4.23
DC4SVVR	DMDKF3M	Raloxifene	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.29	3.09	0.85	0.61
DC6Q336	DMDKF3M	Raloxifene	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.57	4.03	0.58	0.18
DCR9SF8	DMDKF3M	Raloxifene	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.28	9.75	4.54	1.51
DC8AUL3	DMDKF3M	Raloxifene	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.25	2.81	0.8	0.9
DC18NZU	DMDKF3M	Raloxifene	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.11	3.3	0.98	0.95
DCZM1JU	DMDKF3M	Raloxifene	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.3	4.54	1.74	1.15
DC1D8QY	DMDKF3M	Raloxifene	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	4.73	9.18	4.4	3.49
DCLCF5E	DMDKF3M	Raloxifene	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.1	4.93	0.17	3.84
DCKR99R	DMDKF3M	Raloxifene	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.23	8.33	1.38	1.68
DC2ILHI	DMDKF3M	Raloxifene	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.62	6.16	5.73	1.12
DCI3H7A	DMDKF3M	Raloxifene	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	9.73	11.45	2.42	2.1
DCJ2DBL	DMDKF3M	Raloxifene	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	4.79	6.03	1.73	0.18
DCHVUNU	DMDKF3M	Raloxifene	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.58	7.15	2.7	1.96
DCZY0QN	DMDKF3M	Raloxifene	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.24	1.68	1.01	2.39
DC1D8VE	DMDKF3M	Raloxifene	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.57	7.59	2.12	1.64
DCUFWXG	DMDKF3M	Raloxifene	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.83	3.75	2.36	1.4
DCFYJ1D	DMDKF3M	Raloxifene	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	8.63	11.86	6.29	2.13
DCEG994	DMDKF3M	Raloxifene	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.67	7.82	3.24	2.24
DCK27DV	DMDKF3M	Raloxifene	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.58	5.97	3.2	1.54
DCAU1OG	DMDKF3M	Raloxifene	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	8.26	9.88	1.57	0.68
DC0GOHU	DMDKF3M	Raloxifene	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.63	5.29	0.37	2.34
DC36NLS	DMDKF3M	Raloxifene	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.3	5.68	3.76	1.48
DCC42OQ	DMDKF3M	Raloxifene	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	10.25	13.39	8.34	7.07
DCXRAX5	DMDKF3M	Raloxifene	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	7.48	15.38	8.71	8.71
DCILEIN	DMDKF3M	Raloxifene	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.94	8.34	2.3	2.29
DCNXCRC	DMDKF3M	Raloxifene	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	8.32	9.11	0.2	0.08
DCGR0VE	DMDKF3M	Raloxifene	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.24	7.28	5.97	2.39
DCM5SJ4	DMDKF3M	Raloxifene	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.02	7.16	3.39	1.87
DCYFULL	DMDKF3M	Raloxifene	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	10.36	13.49	3.59	3.04
DCUOI4U	DMDKF3M	Raloxifene	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	5.65	3.89	1.55	1.55
DCZNZPP	DMDKF3M	Raloxifene	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	10.08	13.45	8.32	7.33
DCEOVE3	DMDKF3M	Raloxifene	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.46	3.34	1.71	1.46
DCJZ3UW	DMDKF3M	Raloxifene	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.09	7.01	4.76	4.41
DCMXE2H	DMDKF3M	Raloxifene	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.15	2.63	0.62	0.17
DC6ZGTO	DMDKF3M	Raloxifene	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.25	4.05	5.29	5.37
DC2MKCB	DMDKF3M	Raloxifene	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.2	4.17	2.41	1.52
DCOBJRG	DMDKF3M	Raloxifene	Approved	34	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.46	1.63	0.59	0.6
DCIPOCD	DMDKF3M	Raloxifene	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.95	1.03	3.86	3.81
DCIR723	DMDKF3M	Raloxifene	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	4.58	6.32	2.84	0.09
DC7B9GT	DMDKF3M	Raloxifene	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	13.77	16.96	11.32	5.88
DCKTUDT	DMDKF3M	Raloxifene	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	7.62	11.75	4.83	3.82
DCM0TW6	DMDKF3M	Raloxifene	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.42	9.08	3.91	1.67
DC365LT	DMDKF3M	Raloxifene	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.42	3.21	1.06	1.06
DCPVJG7	DMDKF3M	Raloxifene	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.4	9.03	2.91	2.91
DC3WPMG	DMDKF3M	Raloxifene	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	4.66	1.43	1.61	1.5
DCJZKW0	DMDKF3M	Raloxifene	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	9.16	7.33	5.02	3.57
DCUKQIJ	DMDKF3M	Raloxifene	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	8.29	11.05	6.39	5.97
DC8NNYZ	DMDKF3M	Raloxifene	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.4	5.78	5.53	7.74
DCDV2YL	DMDKF3M	Raloxifene	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.07	3.1	2.7	6.25
DCHIHXU	DMDKF3M	Raloxifene	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.75	2.56	2.41	4.1
DCIXX9Q	DMDKF3M	Raloxifene	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.98	1.4	1.43	4.89
DCFW2DL	DMDKF3M	Raloxifene	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.85	6.21	3.53	3.39
DCQEVMU	DMDKF3M	Raloxifene	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	6.69	6.66	4.3	5.87
DCACDAU	DMDKF3M	Raloxifene	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.71	1.34	3.73	6.1
DCG5P4O	DMDKF3M	Raloxifene	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.19	3.3	3.1	6.7
DC9G6QX	DMDKF3M	Raloxifene	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.79	3.67	0.76	0.7
DCMGRIM	DMDKF3M	Raloxifene	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.61	3.85	3.14	0.26
DCOXF31	DMDKF3M	Raloxifene	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	6.26	8.26	3.33	0.67
DCNW8WZ	DMDKF3M	Raloxifene	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.76	3.45	4.46	3.44
DCMJ3QO	DMDKF3M	Raloxifene	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.09	1.33	0.83	0.79
DCE8N9U	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.35	4.22	0.75	0.73
DCUM9M6	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	7.64	7.98	5.91	4.78
DCOUZUT	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	15.49	16.06	10.54	14.65
DC1D11H	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.05	8.66	2.17	1.98
DCRYFOB	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	4.37	8.94	2.67	6.13
DC3GRGR	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.58	12.32	4.18	2.71
DCVAQVT	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.67	6.17	2.94	2.9
DCXINQ3	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.64	4.03	2.38	1.7
DC1ABVZ	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.17	9.02	3.77	3.83
DCFPRDH	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.69	7.41	3.45	3.79
DCAUQ1P	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.69	4.64	3.66	1.62
DCDWJ9S	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	9.69	11.41	3.98	3.96
DC544CQ	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.95	10.22	6.3	5.79
DCFK2GI	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	16.58	18.65	2.2	17.12
DCBYAET	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	22.43	17.42	16.64	19.15
DC0E3AZ	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.65	11.68	8.31	7.16
DCXL4SY	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	17.43	16.7	5.39	12.12
DC10ZO1	DMDKF3M	Raloxifene	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.19	5.77	4.87	4.68
DCUA7KH	DMDKF3M	Raloxifene	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.72	6.91	4.39	1.98
DCM5INF	DMDKF3M	Raloxifene	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.54	6.27	2.55	1.04
DC4AXDA	DMDKF3M	Raloxifene	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	8.24	9.74	1.54	1.54
DCCKI2O	DMDKF3M	Raloxifene	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.18	3.85	1.65	1.28
DC90X13	DMDKF3M	Raloxifene	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.8	3.76	3.7	1.81
DC658RO	DMDKF3M	Raloxifene	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.65	5.25	3.35	3.36
DCBYV7G	DMDKF3M	Raloxifene	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.06	8.7	11.04	11.05
DCH5P9V	DMDKF3M	Raloxifene	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.95	6.35	0.74	0.3
DCB9XF2	DMDKF3M	Raloxifene	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.11	6.86	2.1	5.16
DC6JYMM	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.58	4.56	3.72	3.4
DCTC5DH	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.04	6.56	3.68	3.92
DCXU1CP	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.36	6.26	4.13	5.01
DC7FD0B	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	6.24	7.43	0.75	2.11
DC60A57	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.12	7.09	4.24	5.86
DCNYHU0	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.51	2.95	0.22	0.82
DCNIUKH	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.9	0.99	3.28	3.94
DCWHQNU	DMDKF3M	Raloxifene	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.39	1.81	0.01	0.78
DCZ5QOS	DMDKF3M	Raloxifene	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.08	4.12	0.75	0.87
DCUOD3T	DMDKF3M	Raloxifene	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	9.61	10.45	2.73	2.03
DCL7LGQ	DMDKF3M	Raloxifene	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.3	2.32	1.23	0.6
DCV8XZW	DMDKF3M	Raloxifene	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.05	4.61	1.23	0.73
DCC9F9K	DMDKF3M	Raloxifene	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.41	4.36	1.53	1.32
DCE3CBN	DMDKF3M	Raloxifene	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.18	2.48	1.4	2.52
DCD8BQ5	DMDKF3M	Raloxifene	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	10.51	16.92	11.7	12.34
DCMT2AD	DMDKF3M	Raloxifene	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.81	6.71	1.34	1.69
DCRMYLN	DMDKF3M	Raloxifene	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.7	5.36	2.8	2.22
DC984Q1	DMDKF3M	Raloxifene	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.2	6.05	0.44	0.97
DCTLHNA	DMDKF3M	Raloxifene	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.96	14.28	6.09	6.38
DCUFUBS	DMDKF3M	Raloxifene	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	5.6	9.06	0.21	0.21
DC2XQJD	DMDKF3M	Raloxifene	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.78	3.45	0.9	1.95
DC9PAV8	DMDKF3M	Raloxifene	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.66	9.23	6.92	5.07
DCPCYMR	DMDKF3M	Raloxifene	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.78	3.34	1.08	1.47
DC2IW26	DMDKF3M	Raloxifene	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.23	4.67	3.44	1.03
DCM2JTD	DMDKF3M	Raloxifene	Approved	34	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.78	3.53	1.09	1.73
DC8XCYX	DMDKF3M	Raloxifene	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.84	5.21	2.15	0.01
DCG2S95	DMDKF3M	Raloxifene	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.37	9.05	7.35	3.53
DCFD0IA	DMDKF3M	Raloxifene	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.65	4.45	2.88	6.17
DCPSBI7	DMDKF3M	Raloxifene	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	11.3	6.03	1.72	0.33
DC0VXLQ	DMDKF3M	Raloxifene	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.09	5.99	0.23	0.57
DCI0ZVY	DMDKF3M	Raloxifene	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	5.47	6.77	0.38	0.38
DCERFI9	DMDKF3M	Raloxifene	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	8.33	12.64	10.1	8.88
DCGUJFM	DMDKF3M	Raloxifene	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.84	8.61	1.8	1.8
DCI7WU6	DMDKF3M	Raloxifene	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	5.75	9.51	2.27	2.18
DCYKKU3	DMDKF3M	Raloxifene	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.45	3.95	0.31	0.31
DCNVX59	DMDKF3M	Raloxifene	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.69	2.72	0.93	0.93
DCNOVY2	DMDKF3M	Raloxifene	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.16	8.06	5.51	5.13
DCQXSQ5	DMDKF3M	Raloxifene	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	11.65	12.55	7.13	6.45
DCRXJSM	DMDKF3M	Raloxifene	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.24	8.26	2.69	2
DC8ZMXU	DMDKF3M	Raloxifene	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.3	9.83	1.22	0.86
DC61X86	DMDKF3M	Raloxifene	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.42	2.57	0.45	2.12
DCR9X3C	DMDKF3M	Raloxifene	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.42	5.23	3.94	2.86
DCIT81F	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.49	3.38	0.38	0.48
DCG77E4	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.24	8.21	5.48	4.9
DC6RUXR	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	8.36	14.72	12.77	7.55
DCQCYY8	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.24	4.28	2.97	2.99
DCQPU55	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.93	4.99	0.63	0.79
DC1GM88	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.94	7.62	3.18	2.9
DCC63OX	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.3	1.88	1.69	1.15
DCRKYDE	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.28	6.5	1.8	1.21
DCCOR2A	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.38	2.1	0.49	0.49
DC0OWKT	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	8.61	15.41	1.46	1.33
DCHO11L	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.22	14.12	9.76	8.19
DCRLZ4X	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.78	6.07	1.13	0.78
DC14ZJE	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.37	4.49	0.94	0.71
DCQ27RI	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.39	5.22	3.21	2.42
DC5QW4S	DMDKF3M	Raloxifene	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.1	8.04	2.62	3.09
DCHAU3B	DMDKF3M	Raloxifene	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.99	6.77	4.75	3.86
DC7J1JZ	DMDKF3M	Raloxifene	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.64	1.77	0.09	0.19
DCH8K8Z	DMDKF3M	Raloxifene	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.21	5.57	1.97	2.21
DC4K947	DMDKF3M	Raloxifene	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.46	4.22	1.17	0.56
DCZKI1K	DMDKF3M	Raloxifene	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.66	5.57	2.43	0.97
DCD0CAO	DMDKF3M	Raloxifene	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.92	8.87	3.66	3.18
DC9WFCB	DMDKF3M	Raloxifene	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.19	4.09	1.74	1.75
DCFINVX	DMDKF3M	Raloxifene	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.13	8	3.1	3
DCP7VZ5	DMDKF3M	Raloxifene	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	9.28	9.07	1.45	0.75
DCJP7GL	DMDKF3M	Raloxifene	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.42	4.45	2.04	1.42
DCEMHVB	DMDKF3M	Raloxifene	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.63	9.37	5.83	2.76
DCBDMW4	DMDKF3M	Raloxifene	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	5.45	4.88	2.47	1.62
DCY3PYK	DMDKF3M	Raloxifene	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	6.59	8.26	3.42	2.91
DCR6OGU	DMDKF3M	Raloxifene	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.59	8.44	2.63	1.43
DCBQD3B	DMDKF3M	Raloxifene	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.23	3.23	2.68	2.35
DC1PIW8	DMDKF3M	Raloxifene	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.76	3.21	1.52	1.32
DC8EQUV	DMDKF3M	Raloxifene	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.59	3.48	1.38	0.89
DCR64HZ	DMDKF3M	Raloxifene	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	10.41	14.65	9.97	9.92
DC3QMKQ	DMDKF3M	Raloxifene	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	8.89	8.63	0.28	0.09
DCMTRBY	DMDKF3M	Raloxifene	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	7.37	15.11	4.96	4.42
DCWJH3N	DMDKF3M	Raloxifene	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.91	5.13	2.12	2.02
DCT5WSL	DMDKF3M	Raloxifene	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	5.06	6.61	1.75	0.99
DCV14UP	DMDKF3M	Raloxifene	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0	2.72	1.89	1.74
DCDZ9EU	DMDKF3M	Raloxifene	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	6.28	9.46	3.04	2.63
DCEN7W2	DMDKF3M	Raloxifene	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	5.17	5.4	2.49	1.2
DCXG0R5	DMDKF3M	Raloxifene	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.52	2.04	0.49	2.2
DC0NUL5	DMDKF3M	Raloxifene	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	4	2.77	0.53	0.95
DCDB265	DMDKF3M	Raloxifene	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.18	2.81	2.22	2.29
DCW0XVO	DMDKF3M	Raloxifene	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.38	6.4	3.54	4.01
DCZUZOO	DMDKF3M	Raloxifene	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.44	4.06	2.05	1.68
DCN4VHF	DMDKF3M	Raloxifene	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.18	6.99	2.82	3.37
DCCH5NV	DMDKF3M	Raloxifene	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	4.47	2.73	3.37	3.18
DCGXLDC	DMDKF3M	Raloxifene	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.57	0.32	3.6	3.22
DCZXX2S	DMDKF3M	Raloxifene	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	4.53	4.38	1.9	2.22
DCATXS1	DMDKF3M	Raloxifene	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.92	4.62	3.13	4.84
DCPCXR9	DMDKF3M	Raloxifene	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.1	9.81	0.42	6.79
DCGZWYZ	DMDKF3M	Raloxifene	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	8.12	13.17	2.06	1.76
DCZO1BB	DMDKF3M	Raloxifene	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.51	3.36	3.03	2.05
DCBRHJW	DMDKF3M	Raloxifene	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.85	4.6	2.52	1.68
DCIJNIS	DMDKF3M	Raloxifene	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.83	3.51	0.49	0.85
DC4IYD7	DMDKF3M	Raloxifene	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.87	6.95	4.11	4.06
DCIZ8SE	DMDKF3M	Raloxifene	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.77	5.6	2.92	1.41
DC56MDP	DMDKF3M	Raloxifene	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.61	7.81	3.9	1.65
DC7RDYV	DMDKF3M	Raloxifene	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.06	4.34	3.29	2.49
DCPUUVE	DMDKF3M	Raloxifene	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.27	5.95	0.9	0.9
DCLIT6X	DMDKF3M	Raloxifene	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.16	3.23	2.6	2.61
DC40Y6C	DMDKF3M	Raloxifene	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	6.14	7.69	4.73	5.99
DCOV55H	DMDKF3M	Raloxifene	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.54	4.65	2.86	2.86
DC6KGS7	DMDKF3M	Raloxifene	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	13.8	13.95	9.32	3.23
DC5PAP6	DMDKF3M	Raloxifene	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.14	2.27	0.54	0.02
DCUZPTT	DMDKF3M	Raloxifene	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.32	8.61	3.51	2.21
DCPB59K	DMDKF3M	Raloxifene	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.1	4.22	2.3	1.49
DCAZJNZ	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	17.5	19.46	15.12	14.83
DC9LFMS	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.96	7.66	3.39	2.38
DCSWG3U	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.7	5.02	3.6	2.03
DCC5S9O	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.9	7.98	3.8	1.9
DCX3858	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	13.15	14.24	8.77	4.63
DCECULE	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	9.82	13.88	6.12	5.86
DCVZH0V	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.47	8.03	5.89	5.89
DCZJL9V	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.78	4.03	2.58	1.79
DCCO7YX	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.32	8.39	5.73	5.14
DCL3LLH	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.97	3.87	2.97	2.17
DCCMPW8	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.14	6.93	1.79	4.58
DCO0NIJ	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.22	9.4	1.04	5.95
DCO3YTC	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.98	3.69	2.33	1.54
DC850Z8	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.3	6.68	5.86	4.15
DC7E0J9	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.94	3.15	2.93	1.49
DCYNOA7	DMDKF3M	Raloxifene	Approved	34	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.69	6.19	3.77	3.7
DC8KK50	DMDKF3M	Raloxifene	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.55	8.35	6.37	3.82
DCWPU5U	DMDKF3M	Raloxifene	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.61	7.3	0.25	2.76
DCWUYXI	DMDKF3M	Raloxifene	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.18	4.16	4.33	4.39
DCEXMNM	DMDKF3M	Raloxifene	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.62	0.98	2.3	1.96
DC52AQB	DMDKF3M	Raloxifene	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.31	3.8	1.99	1.35
DC7L29B	DMDKF3M	Raloxifene	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.11	2.05	1.59	1.17
DCWOJIR	DMDKF3M	Raloxifene	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.21	1.67	1.71	1.77
DCWTQZX	DMDKF3M	Raloxifene	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.92	3.67	1.39	1.45
DCIZC6T	DMDKF3M	Raloxifene	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.55	1.66	0.51	0.3
DC4IX9A	DMDKF3M	Raloxifene	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.07	3.53	3.2	3.03
DCGSX4G	DMDKF3M	Raloxifene	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.12	5.4	3.2	3.17
DC9JOT9	DMDKF3M	Raloxifene	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	3.98	4.44	5.06	4.17
DCSC5TV	DMDKF3M	Raloxifene	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	10.87	10.26	6.93	2.33
DCDSB2G	DMDKF3M	Raloxifene	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.73	9.37	0.25	0.97
DC89T1V	DMDKF3M	Raloxifene	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.52	6.24	5.97	6.34
DC0YTEI	DMDKF3M	Raloxifene	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.44	2.91	1.62	1.78
DC5C6L8	DMDKF3M	Raloxifene	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	5.95	8.46	3.65	3.75
DCI9COQ	DMDKF3M	Raloxifene	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	5.33	6.51	5.48	1.36
DC4U32T	DMDKF3M	Raloxifene	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.47	1.3	1.55	3.9
DCBH3W9	DMDKF3M	Raloxifene	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.14	4.57	4.15	7.03
DCB9HVG	DMDKF3M	Raloxifene	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.12	4.36	0.25	0.29
DCTXJB4	DMDKF3M	Raloxifene	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.14	3.25	0.17	0.17
DC0ZEVL	DMDKF3M	Raloxifene	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	7.14	9.62	6.4	3.31
DC4I2F5	DMDKF3M	Raloxifene	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.87	4.01	1.3	2.08
DCUI8I6	DMDKF3M	Raloxifene	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	9.92	14.35	2.47	11.7
DCPCSPW	DMDKF3M	Raloxifene	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.59	5.01	2.01	5.66
DC2YD9F	DMDKF3M	Raloxifene	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.62	3.5	3.54	6.89
DC0TDVV	DMDKF3M	Raloxifene	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.23	2.51	1.27	1.16
DCNN0YK	DMDKF3M	Raloxifene	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.77	3.92	0.71	0.71
DCL09U6	DMDKF3M	Raloxifene	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.05	3.33	1.04	1.05
DC1XPJV	DMDKF3M	Raloxifene	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.94	5.71	3.53	4.26
DCFJZN2	DMDKF3M	Raloxifene	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.72	2.96	0.69	0.96
DCY1R5F	DMDKF3M	Raloxifene	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.74	1.57	1.96	2.24
DCMHJ22	DMDKF3M	Raloxifene	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.19	4.99	2.03	2.74
DCULWHT	DMDKF3M	Raloxifene	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	7.27	8.7	1.3	2.66
DC1GRUD	DMDKF3M	Raloxifene	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	4.78	5.74	2.64	3.17
DCF0OTT	DMDKF3M	Raloxifene	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.82	0.08	0.33	0.46
DC7FY87	DMDKF3M	Raloxifene	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.51	2.5	3.12	4.16
DCJYOZ9	DMDKF3M	Raloxifene	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.64	3.55	1.4	1.97
DC2DJBB	DMDKF3M	Raloxifene	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.44	0.42	2.93	3.23
DCCLW61	DMDKF3M	Raloxifene	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.62	2.48	1.6	2.18
DCGILC1	DMDKF3M	Raloxifene	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.99	7.32	6.61	8.43
DCU5FHC	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	13.8	20.1	15.69	15.35
DCTB825	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.59	11.08	10.42	9.33
DCU07RQ	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.62	9.9	4.83	4.83
DC4H0ZR	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.48	3.65	1.65	1.07
DCLHA8D	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.27	4.85	3.12	1.76
DCVFRMR	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.15	6.04	0.86	0.08
DC26C0L	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.93	9.6	4.97	4.23
DC9987P	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.86	10.84	2.87	2.87
DCFCVX6	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	5	11.42	2.5	2.73
DC7OLWZ	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	5.41	9.33	7.94	8.37
DCV3HX5	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.93	6.56	4.02	3.91
DCS0D8A	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.47	3.83	3.05	2.24
DCCVQCF	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.59	11.12	9.02	5.34
DCGQE06	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.21	5.51	2.24	2.29
DCMMPZF	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.3	4.96	4.68	2.84
DC36LNN	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.75	10.43	6.91	6.77
DC11CQ8	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.94	5.84	5.38	5.35
DCL9J1V	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.35	8.18	6.14	6.33
DC721N3	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.11	5.39	4.48	4.58
DCPMI71	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.84	3.37	2.55	2.4
DCDNCIA	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.01	4.17	3.94	1.81
DC6YN7E	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.12	5.68	3.92	4.15
DCVBALQ	DMDKF3M	Raloxifene	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.46	3.09	1.16	1.41
DC39PV6	DMDKF3M	Raloxifene	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.23	9.79	2.37	1.32
DCYFZR8	DMDKF3M	Raloxifene	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.82	6.19	0.61	0.49
DCTDU7A	DMDKF3M	Raloxifene	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.77	4.71	2.28	1.27
DC342XH	DMDKF3M	Raloxifene	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	8.18	5.46	1.91	1.87
DCR6UDU	DMDKF3M	Raloxifene	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.75	6.82	4.46	2.93
DCGVGDH	DMDKF3M	Raloxifene	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	19.21	21.31	11.82	16.36
DCULBK8	DMDKF3M	Raloxifene	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.07	10.19	7.92	7.67
DCE6XO2	DMDKF3M	Raloxifene	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.75	8.8	2.42	6.61
DCD0K7C	DMDKF3M	Raloxifene	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.49	8.04	0.49	0.19
DC5QGL6	DMDKF3M	Raloxifene	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.9	6.94	0.52	2.28
DC3YR8Q	DMDKF3M	Raloxifene	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.3	8.62	2.1	1.35
DC02QSM	DMDKF3M	Raloxifene	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.08	6.5	1.2	0.97
DCFZEGY	DMDKF3M	Raloxifene	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.14	4.87	2.96	3.36
DCBT3W2	DMDKF3M	Raloxifene	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.65	3.79	0.12	0.12
DCC3ITE	DMDKF3M	Raloxifene	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.31	4.77	3.03	1.4
DCLWKIL	DMDKF3M	Raloxifene	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	14.25	14.22	5.64	9.96
DC71ZM8	DMDKF3M	Raloxifene	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.27	3.77	1.02	0.59
DC14E7I	DMDKF3M	Raloxifene	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.76	2.31	1.61	0.84
DC8B5WN	DMDKF3M	Raloxifene	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.76	8.35	1.04	0.86
DCDPQZ9	DMDKF3M	Raloxifene	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.41	2.62	0.91	0.43
DCEIQ1U	DMDKF3M	Raloxifene	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.49	5.92	2.02	1
DCDM6KU	DMDKF3M	Raloxifene	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.44	2.58	0.67	0.87
DC6PWO1	DMDKF3M	Raloxifene	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	7.38	11.18	5.42	3.39
DCW8OF9	DMDKF3M	Raloxifene	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	6.19	13.84	2.1	2.1
DCPX0Q8	DMDKF3M	Raloxifene	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	7.87	7.66	0.19	0.19
DCBVQCK	DMDKF3M	Raloxifene	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.18	4.41	2.1	2.12
DC5X0S0	DMDKF3M	Raloxifene	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.26	4.34	1.53	1.34
DCC30EM	DMDKF3M	Raloxifene	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.13	4.92	3.33	2.51
DCZ9LEM	DMDKF3M	Raloxifene	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.41	3.03	2.49	2.07
DCE7H8N	DMDKF3M	Raloxifene	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.15	7.7	0.02	4.17
DCD0HY4	DMDKF3M	Raloxifene	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.1	4.69	1.45	0.88
DCM4GST	DMDKF3M	Raloxifene	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.44	3.93	0.33	1.43
DCT69HE	DMDKF3M	Raloxifene	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	3.36	4.26	1.3	0.43
DCLXZZV	DMDKF3M	Raloxifene	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.79	6.18	1.84	1.63
DCIAA8I	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.98	11.08	7.66	8.09
DCBV8LG	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.93	3.95	0.97	0.25
DCUFA56	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.66	6.8	3.13	1.97
DC2JEWK	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1	3.65	2.01	3.11
DC9K3KL	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	10.82	22.25	8.6	7.41
DCGLUSG	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.19	10.86	3.88	3.87
DC62DGX	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.43	3.71	1.55	1.6
DCU9DD4	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.92	5.75	2.31	2.16
DCSJ0J0	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.31	4.94	6.25	3
DC9HAYX	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.69	4.97	1.11	1.33
DC13ODB	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.06	3.86	1.89	2.07
DCMNOYL	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.36	0.27	1	1.37
DCED0E0	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.29	4.17	1.26	1.26
DCUBCMP	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.87	5.53	4.55	3.77
DCS8LI1	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	8.36	5.94	3.52	1.73
DCLGWKH	DMDKF3M	Raloxifene	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.86	4.93	6.31	6.16
DCZZVXS	DMDKF3M	Raloxifene	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.24	4.46	4	3.65
DCRRYLO	DMDKF3M	Raloxifene	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.4	2.1	1.28	1.37
DCMXXGM	DMDKF3M	Raloxifene	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.89	4.61	3.26	3.21
DC71EVC	DMDKF3M	Raloxifene	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.8	1.64	1.89	1.24
DC6CVU3	DMDKF3M	Raloxifene	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.14	2.95	1.36	1.43
DCR43SK	DMDKF3M	Raloxifene	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.51	0.84	0.66	0.99
DCH30QU	DMDKF3M	Raloxifene	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.16	8.15	3.82	3.87
DCDBQO2	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.83	4.14	1.3	1.27
DC5XXLL	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.07	5.22	3.76	0.92
DC8EKGD	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.9	5.78	1.6	1.09
DC49KEI	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.04	4.16	1.07	1.08
DCZ01W4	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	9.7	11.83	3.35	2.79
DCYQSKW	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	5.41	6.53	3.13	2.29
DCCBF3W	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.89	2.88	1.63	0.22
DCG7Q5R	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0	8.59	2.04	2.04
DCMZ0DZ	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	5.97	9.04	4.66	3.46
DCRNRGI	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.8	6.16	2.91	2.78
DC8JKDH	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.98	5.04	4.42	3.85
DCKU4G0	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.7	5.04	2.12	2.1
DCMFEXN	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.62	6.02	4.65	4.47
DCYMP1W	DMDKF3M	Raloxifene	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.6	3.34	1.16	2.57
DCXZ1BI	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.08	4.2	2.25	1.28
DCPIVDO	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.59	3.74	2.59	2.83
DC49AGS	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.59	3.95	1.47	0.67
DCYAIBA	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.53	9.01	5.65	2.17
DC1XSPQ	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	8.47	18.14	0.65	0.78
DC2LU63	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	9.76	12.18	4.73	4.5
DCQEQF6	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.61	2.95	2.25	0.73
DC1YPOS	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	1.36	5.62	2.51	2.7
DCT91SE	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.37	8.33	5.36	3.11
DCIUHQJ	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.62	3.8	1.77	1.98
DCD213X	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.57	2.55	2	1.85
DC4IUXQ	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.89	3.01	1.21	1.21
DCYID7W	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.8	9.61	8.17	8.52
DC599BF	DMDKF3M	Raloxifene	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.88	4.72	5.92	1.74
DC3IB8N	DMDKF3M	Raloxifene	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	8.21	10.55	4.62	9.71
DC6GS5L	DMDKF3M	Raloxifene	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	7.82	11.53	1.56	1.37
DCVO5JS	DMDKF3M	Raloxifene	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.1	2.58	0.16	0.11
DCJN0IG	DMDKF3M	Raloxifene	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.13	17.29	2.08	9.12
DCXQTM2	DMDKF3M	Raloxifene	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	4.14	5.92	3.12	2.96
DC7IJC6	DMDKF3M	Raloxifene	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.78	3.9	1.29	1.12
DCL3IAM	DMDKF3M	Raloxifene	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	6.17	7.08	5.39	5.19
DCTL2FL	DMDKF3M	Raloxifene	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.58	5.81	2.53	2.98
DCDGURV	DMDKF3M	Raloxifene	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.97	9.18	4.31	3.58
DCQGH82	DMDKF3M	Raloxifene	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.33	4.64	1.03	0.76
DCIIFU2	DMDKF3M	Raloxifene	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.86	4.28	3.85	3.32
DCHBCJZ	DMDKF3M	Raloxifene	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.04	1.01	0.52	0.06
DCM91KE	DMDKF3M	Raloxifene	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.33	1.91	0.87	0.64
DCMR2M2	DMDKF3M	Raloxifene	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.77	7.37	5.54	5.54
DCCODCF	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMMWZET	Dexamethasone	Phase 3 Trial	25	DME4TH4	Etoposide	.	.	Hemophagocytic Lymphohistiocytoses	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DC49UIQ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMBD4K3	Selinexor	Phase 2 Trial	21	.	.	.	.	Myelofibrosis	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCN3VF4	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTS85L	Capecitabine	Approved	34	.	.	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCUVFNT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	DMLL939	Mycophenolate mofetil	DMZ7XNQ	Tacrolimus	Graft-versus-host Disease	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCPHHE3	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMHSY1I	Regorafenib	Approved	34	DMTS85L	Capecitabine	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC093EF	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTPQ84	"(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE"	Investigative	0	.	.	.	.	Myelofibrosis	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC0WFUR	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMHSY1I	Regorafenib	Approved	34	.	.	.	.	CRC (Colorectal Cancer)	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCB1W4T	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMD9RV3	INCB039110	Phase 2	21	.	.	.	.	MPN (Myeloproliferative Neoplasms)	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCJFU5F	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM8QXOC	Enasidenib	Approved	34	.	.	.	.	Accelerated/Blast-phase Myeloproliferative Neoplasm	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCQ6EM6	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNE56X	ABT-263	Phase 3	25	.	.	.	.	Myelofibrosis (MF)	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCRSIRU	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM6AUHV	Fostamatinib	Approved	34	.	.	.	.	Myelofibrosis	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCTELEY	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM4BDON	Methylprednisolone	Phase 3 Trial	25	.	.	.	.	Acute GVHD	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCYFTUF	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTD7AB	Pracinostat	Phase 3	25	.	.	.	.	Myeloproliferative Diseases	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCG7O1S	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM30SGU	Simvastatin	Approved	34	.	.	.	.	Coronavirus Disease 2019 (COVID-19)	TTD Database	Phase 2	.	.	.	.	.
DC267XW	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM9HPW3	Exemestane	Approved	34	.	.	.	.	Estrogen-receptor Positive Invasive Metastatic Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC5L1H5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMOQVU9	Hydroxyurea	Approved	34	.	.	.	.	Myelofibrosis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC9WR5M	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DML8KTN	Danazol	Approved	34	.	.	.	.	Anemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCAW80U	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	"Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCMAKU9	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMMWZET	Dexamethasone	Phase 3 Trial	25	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCMSI3U	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Steroid Refractory GVHD	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCQHZUU	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTS85L	Capecitabine	Approved	34	.	.	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCQMQCX	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Chronic Phase Chronic Myeloid Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCR6SO6	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Idiopathic Myelofibrosis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC5W7CV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMBD4K3	Selinexor	Phase 2 Trial	21	DMMIU2C	Methylprednisolone	.	.	Multiple Myeloma in Relapse	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC9KQKL	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM20KYR	Ruxolitinib	.	.	"T Cell Leukemia, Adult"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCS3J9P	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM48K0X	Carfilzomib	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCT5MHY	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMZ4Q0B	Dasatinib	.	.	Acute Lymphoblastic Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC0HHXQ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLB81S	Paclitaxel	Approved	34	.	.	.	.	Recurrent Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC0Q6IB	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Solid Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC1GME1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Myelofibrosis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC1P6X3	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM602WT	Idelalisib	Approved	34	.	.	.	.	Myelofibrosis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC22I2A	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMIYHAW	PU-H71	Phase 1	17	.	.	.	.	Myelofibrosis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC2E0H7	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMMX75K	LEE011	Phase 3	25	.	.	.	.	Myelofibrosis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC2JL3F	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMYRBO1	Umbralisib	Approved	34	.	.	.	.	Myelofibrosis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC7E23V	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	"Leukemia, Chronic Myeloid"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC8Q12Q	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Hodgkin's Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC8UIKF	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCB2W4Q	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNE56X	ABT-263	Phase 3	25	.	.	.	.	Myeloproliferative Neoplasm	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCCMQAQ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM6LDI4	BMS-986158	Phase 1/2	19	.	.	.	.	Myelofibrosis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCGV0GY	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2JGQ3	Trametinib	Approved	34	.	.	.	.	Colorectal Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCKV4R4	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM8I94Y	Venetoclax	Approved	34	.	.	.	.	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCLT6AX	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM6AUHV	Fostamatinib	Approved	34	.	.	.	.	Chronic Graft Versus Host Disease	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCMBQ7F	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	"Leukemia, Lymphocytic, Chronic, B-Cell"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCNWTS3	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM4BDON	Methylprednisolone	Phase 3 Trial	25	.	.	.	.	Intestinal GVHD	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCRSJB9	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMQL8XJ	Decitabine	Approved	34	.	.	.	.	Myeloproliferative Neoplasms	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCTQ0GK	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7USVA	Duvelisib	Phase 2 Trial	21	.	.	.	.	T-cell Lymphomas	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCVO76S	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKECZD	Temozolomide	Approved	34	.	.	.	.	Glioma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCXVBR5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM93VBZ	LY2835219	Approved	34	.	.	.	.	Myelofibrosis Due to and Following Polycythemia Vera	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCYRPO5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM6QOVN	HKI-272	Phase 3	25	.	.	.	.	Metastatic Triple-Negative Breast Carcinoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCRCT2J	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	27.72	33.81	19.17	23.87
DCDAAOJ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.57	9.11	10.02	10.8
DC0M3D3	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.51	12.12	3	6.51
DCGJJ9S	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.14	6.39	2.14	1.91
DC82ARE	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	1.24	6.7	2.65	1.78
DCPCZZH	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.7	5.49	3.4	2.88
DCD37IY	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.48	7.88	3.95	3.44
DCRYTUH	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.01	4.4	0.76	2.93
DCQ8WK8	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	8.09	13.82	3.81	12.62
DCQKW7W	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	5.19	10.34	8.92	12.19
DCUX7F9	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	5.95	6.94	5.75	6.87
DCLBMRG	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.69	5.73	4.06	7.33
DCB831U	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.55	9	0.19	4.97
DCQDB17	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.66	7.1	3.35	2.65
DCQ2429	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.36	4.79	1.42	1.41
DC46XTQ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.06	3.75	2.95	3.31
DC25Q0Y	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	4.07	6.16	9.33	9.69
DCY0EDM	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.05	5.2	2.8	2.34
DCUN6X7	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	35.46	41.46	27.47	30.08
DCXPMFW	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	41.06	42.57	42.31	43.34
DCV8TVH	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	39.62	34.88	25.55	34.31
DCHL303	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	10.6	15.65	16.17	15.89
DC5TDR0	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	26.02	27.89	24.77	24.88
DCACAS8	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	21.59	25.81	24.34	24.1
DCAX5P2	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	23.7	30.93	28.11	28.12
DCPWW8O	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	9.44	14.62	13	13
DCGKKD8	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	21.72	26.25	26.33	26.23
DC0ESKV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	5.72	13.52	11.59	11.59
DC3OQMB	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	20.23	17.71	19.43	18.68
DC3HMNO	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.46	8.14	4.5	4.5
DCXEIXA	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	6.91	15.46	16.49	15.97
DCDSKZT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	11.54	13.4	8.33	9.07
DCL8P09	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	4.79	10.96	12.42	11.97
DCIEFCO	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	10.76	18.24	16.92	16.8
DCYGOX2	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	30.25	27.68	21.05	22.42
DCUGW9W	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	3.23	6.86	7.92	7.82
DCVX78B	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.72	9.43	5.17	5.13
DC1CT0U	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.33	12.49	11.03	7.17
DCHG466	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.06	13.96	3.27	3.13
DC36MUF	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.16	1.59	1.63	1.49
DCR5S6Y	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.77	2.28	6.37	6.3
DCYGXLJ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.26	3.52	1.5	1.5
DCKOVJY	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.13	10.12	8.86	10.69
DCOWO9T	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.48	6.7	3.46	8.05
DCW8GW4	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	7.38	11.26	4.07	2.24
DCT2NPX	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	4.03	10.44	1.52	1.52
DCGUYDF	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	5.87	11.79	6.56	8.34
DCKKBVG	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.07	4.13	0.69	2.68
DC15CGY	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.18	12.89	1.95	3.05
DCYHQGZ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.93	7.17	3.63	1.47
DCQO5OD	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.73	5.06	0.03	2.7
DC03VCP	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.19	5.87	1.71	1.71
DCAK2AJ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	13.45	24.31	13.15	12.8
DCVQCXX	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	12.53	16.22	16.94	16.37
DC7I3LT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	18.32	18.5	10.6	16.73
DCMRJUI	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	13.55	16.77	17.56	17.08
DCP0UVE	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	9.41	9.2	6.32	6.32
DCSZ29A	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	5.38	15.18	13.71	13.45
DCT8TVE	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	10.76	22.76	19.99	20.1
DCMGNCV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2	9.17	8.82	8.88
DCYJKW4	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	5.8	13.14	12.69	12.54
DC0MDOV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	5.9	15.95	16.42	16.4
DCN1A5J	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	7.08	10.71	14.23	14.06
DCFUV3H	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	9.35	13.91	15.74	15.63
DCOXTVC	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	5.72	12.6	13.53	12.87
DCFL78I	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.32	7.47	6.53	6.58
DC46V0X	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	33.72	32.88	29.31	27.73
DCKZ839	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.19	5.36	2.16	1.33
DCUKJY9	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	9.93	9.77	4.39	10.35
DCW15JY	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.48	2.28	0.46	0.98
DCERLNP	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	4.04	0.5	0.54	0.22
DCQLJ3S	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.05	7.14	5.64	8.44
DC0UB9C	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	6.91	8.85	2.98	6.35
DCIMAZ1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	15.43	16.04	5.92	15.64
DCWRIIN	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	10.41	10.48	7.91	11.18
DC4O4IJ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	6.83	7.01	2.13	11.23
DCDD9GJ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.38	5.12	2.8	6.28
DC62QJ5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	7	5.59	1.72	5.78
DCPOKV3	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	6.43	7.98	7.63	10.29
DCGV4F8	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.45	5.22	0.05	0.89
DCMRNHR	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.07	2.46	5.41	4.86
DCV4SPO	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.7	2.96	0.21	3.27
DCXZK8U	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	5.19	7.74	2.03	7.4
DCU01CA	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.02	4.65	2.78	6
DCLH1C1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.51	3.64	0.01	4.29
DCGNAYU	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.55	3.75	1.62	4.77
DCTUOO4	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.18	2.7	0.86	2.64
DCG7ZW4	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	6.71	7.25	1.46	8.44
DCNUJLZ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.59	13.69	11.02	11.95
DCRLHHF	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.17	1.19	1.77	1.64
DC05N6P	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.04	7.22	1.99	6.4
DCRBJDD	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.23	8.88	5	4.54
DCDBXVA	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.02	7.07	6.97	7.92
DCPD9RD	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	5.36	9.24	6.7	5.59
DC9YTRL	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	6.53	10.68	5.7	6.49
DCVOMA8	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.83	6.51	1.43	5.34
DC2080A	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.34	4.85	0.48	0.48
DCOWOMQ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	32.9	33.86	28.73	29.04
DCSKAIL	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.13	3.11	1.6	4.38
DCCNYBA	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.43	4.04	2.26	3.83
DCCJ9LQ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	15.51	15.48	13.66	16.49
DCWV2GP	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	11.34	13.81	4.4	11.33
DCH8LKG	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.11	8.83	0.15	8.31
DCOTO11	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	13.24	15.21	4.76	1.19
DCTP4ZN	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.33	6.2	3.32	3.01
DCOBSOR	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.57	7.7	3.89	3.21
DCZROOJ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.19	9.07	3.08	5.56
DCHFQ5Q	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.39	4.16	2.52	3.03
DCH922I	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.28	5.7	4.74	5.44
DCGT9LJ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	8.05	13.25	8.8	8.33
DCR0R09	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	12.21	19.48	10.88	10.09
DCYIXAC	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	36.83	38.72	24.03	28.2
DCV8UUE	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	13.27	16.85	15.52	17.51
DC0MQNV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	6.45	10.95	6.9	9.49
DC72W88	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.8	7.48	6.34	8.36
DCESEXU	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	4.07	5.22	1.93	6.65
DC9ZTDE	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.49	1.63	0.29	1.78
DC1RPQY	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.51	2.77	0.68	5.5
DCJEEHT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.13	5.2	5.09	7.33
DCRF3F9	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	12.41	7.84	8.88	9.44
DC3SOIJ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.03	4.98	2.38	5.68
DCB8TRZ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.3	6.3	4.66	6.24
DC8V49W	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	5.88	7.25	4.93	12.73
DC5KUCO	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.13	3.95	1.92	2.4
DCP2B22	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.2	10.01	7.34	5.16
DCDX6HX	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.47	8.64	5.09	2.61
DCVSZEZ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	7.53	11.03	11.23	11.76
DCUJJJO	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.24	8.41	1.76	11.11
DC1D4YS	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	59.97	42.53	27.64	34.48
DCITECP	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.96	12.92	10.21	12.74
DC84DFM	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	5.98	4.7	5.08	5.66
DCSVVHE	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	30.3	29.41	27.47	30.37
DC01PP6	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	16.81	18.3	5.81	16.45
DCAODFZ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	9.54	10.45	0.75	11.93
DCYIAYN	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.55	2.17	0.33	3.01
DCDC6RB	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.51	0.92	0.53	2.38
DCV6K4T	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.32	5.32	7.11	7.25
DCUIRX3	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	23.92	19.57	16.9	20.56
DC2P74V	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	12.62	8.57	3.15	9
DCVYSSU	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	6.3	8.53	6.5	8.47
DC4PF2V	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.29	2.36	0.16	3.9
DCNOVLZ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	36.73	26.89	6.7	13.99
DC1MHL3	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	26.1	23.87	15.55	21.54
DC2JSB1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	11.28	11.01	7.95	7.74
DCOW5N2	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	18.19	17.15	11.48	9.08
DCR3SZ1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	27.42	27.83	13.79	24.75
DCD6CAV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	10.48	8.82	4.45	2.84
DCBYLK1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	10.4	14.81	0.57	0.57
DC6V8UW	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	10.81	10.54	11.65	11.73
DC4M1QW	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.77	8.73	2.98	7.31
DC75ILE	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.06	11.59	2.85	7.51
DC7PIVX	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	9.77	14.85	11.03	9.04
DCUZNS3	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	8.81	10.01	10.92	12.59
DCYP1IP	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.24	4.23	4.5	4.63
DCQU3EL	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	18.16	18.16	17.77	17.77
DCH6F1J	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.13	7.55	0.04	6.33
DCOCJA0	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.21	4.15	3.12	3.71
DCS9ZF1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	9.08	10.95	5.54	4.28
DCI8JQS	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	6.15	6.82	0.89	6.76
DCT49AZ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.74	5.71	2.28	6.68
DC17J7T	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	15.81	12.78	0.43	10.53
DCMEO4P	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.2	5.18	0.88	5.85
DCZ5XTU	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	6.34	6.93	9.96	10
DCN5ER0	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	16.59	17.16	1.65	6.8
DC7OJX6	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	13.03	14.2	3.46	15.84
DCCJ07B	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.58	7.99	3.51	7.18
DCENKG7	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.98	3.25	0.3	1.2
DC0S84M	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	8.27	11.42	9.53	11.94
DCVU9NV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.89	4.64	1.5	5.73
DCQHXAE	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	18.3	19.64	8.25	18.05
DC5QQ81	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	7.43	9.04	8.15	9.8
DC4NRJC	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	10.94	8.42	2.72	7.77
DCY3FUN	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.09	7.85	6.4	6.87
DCF6CK5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.37	8.87	3.49	3.81
DC1H4NB	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	9.03	7.4	7.3	9.59
DCCFLLS	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	5.15	4.08	6.51	10.32
DCKPPHB	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	10.33	10.01	4.13	9.59
DCU378U	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	9.8	10.45	9.11	12.56
DC6EGAQ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.37	5.69	2.81	5.92
DCJY38I	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.67	6.69	5.67	7.43
DCJBRMD	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.28	4.29	0.88	2.18
DCHFUE6	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	10.62	11.47	15.28	16.2
DCT437T	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.82	6.72	2.42	3.12
DCYURE8	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	8.32	9.94	11.38	12.83
DCY350T	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.7	8.09	4.04	2.74
DCNH4QN	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.04	10.55	9.02	10.25
DCVCP7F	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	6.55	13.18	5.36	5
DC219XZ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	28.78	32.92	21.03	21.03
DC3QMRX	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.09	9.98	6.44	10.79
DCORE6X	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.51	10.27	3.51	8.48
DCON1DE	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.79	6.01	2.97	2.11
DCNAKGS	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.4	3.73	1.14	2
DC6NGA2	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	6.11	7.52	2.78	0.74
DC6GRZ2	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	20.51	22.01	10.97	10.97
DCNYLM3	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.38	7.19	6.22	7.93
DCY451E	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.28	5.69	6.12	6.37
DC25N58	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.6	3.19	1.84	2.28
DCQENQW	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.68	6.52	1.27	1.27
DCOTYOT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.93	6.2	3.27	2.94
DCRZLRV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.34	2.75	1.25	0.89
DC240CF	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.17	13.42	7.05	10.76
DCY9TYY	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.19	8.13	2.09	3.62
DCHD379	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.2	10.15	5.88	5.82
DCQU349	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.87	8.39	4.24	3.27
DCK0KQ8	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	5.22	10.53	7.56	10.09
DCBK5YD	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	7.06	6.1	1.55	5.94
DCZAKE6	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.71	4.24	0.2	3.69
DCAC9SV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	11.01	18.2	8.26	6.74
DCCPZQ0	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.41	4.32	0.73	1.26
DCWQ7X1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	20.05	19.5	17.43	20.38
DCJWWB6	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	14.43	11.34	8.25	12.14
DCY2CPL	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.52	10.97	8.25	10.27
DCJG2ET	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	3.46	5.11	1.24	6.47
DC5GUD4	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.43	6.18	3.28	0.12
DCR1W0G	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	12.03	5.57	3.33	3.16
DCUWJ67	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.91	6.3	5.3	5.21
DCMIKSM	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	22.25	15.73	10.87	16.64
DC9EST0	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	12.25	13.72	10.93	14.62
DCU5R2F	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.1	2.78	0.51	4.24
DCJLVNL	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	29.24	28.39	13.9	32.86
DC2S7YS	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	13.59	13.9	10.11	13.71
DCM5DSN	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.23	7.47	1.54	1.54
DCLJ7V9	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.54	7.55	1.75	2.34
DCZGMOZ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.1	4.99	1.03	1.97
DCJ48VL	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.57	7.66	2.17	1.63
DC81LPK	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.87	1.55	1.1	1.76
DCOI5F1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.79	5.87	2.65	2.65
DCV0SIQ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	11.55	13.09	2.26	12.41
DCX83JW	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.04	13.03	1.98	7.61
DC76S0G	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.53	8.73	7.1	7.88
DCVKFD3	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.7	8.69	6.97	7.99
DCX17DK	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.13	3.15	4.54	4.76
DC0YWUK	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	12.62	21.03	20.16	19.88
DC0YEZJ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	4.51	9.42	8.76	8.42
DCQ4V01	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	12.5	20.23	18.76	18.62
DCPDJUK	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	42.82	42.61	37.93	33.6
DC0FZIV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	20.79	20.93	20.98	21.01
DC3VAF3	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	8.8	15.19	11.47	12.08
DC5BQOZ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.01	6.15	2.12	5.41
DCT455K	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.32	5.2	1.9	2.12
DCTR14O	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.83	11.36	5.24	5.16
DCGN4GG	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.4	5.96	2.53	3.41
DCF8ZA0	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.18	6.72	0.46	0.14
DC8F8M6	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.41	8.08	4.93	4.34
DC4HBSM	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.8	6.05	4.64	6.12
DCW3TCL	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.7	6.83	2.44	1.8
DCG6BZ6	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.41	11.24	4.87	4.07
DCC6H2Y	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.25	8.69	6.03	7.85
DC609OR	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.8	11.07	3.9	2.75
DCZFKMQ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.21	6.96	5.89	3.59
DCJ0OOS	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.52	8.99	9.43	7.07
DC6XBKU	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	9.39	15.89	14.35	14.59
DC4G2QL	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	29.38	30.27	22.83	21.15
DC5BO42	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	10.65	8.94	8.65	8.86
DC29QEU	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	26.56	25.57	20.32	20.31
DCR4RZQ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	34.21	36.28	33.24	33.19
DCDFJDH	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	25.33	22.4	15.86	16.38
DC2B19V	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.45	7.26	6.52	5.96
DCUJF84	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.13	12.21	5.9	5.48
DCDCDMB	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.1	12.68	6.04	6.04
DC1NDMY	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.59	10.71	5.01	5.45
DCIK0CV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	12.4	12.18	3.42	11.48
DCT9FT6	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	13.89	15.46	4.1	10.04
DC6GTPF	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.68	4.49	2.16	1.7
DCZ8OOY	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.7	7.94	1.94	6.72
DC3T7HM	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	10.04	15.09	6.34	5.61
DC210W4	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.43	7.35	3.15	4.2
DCZ0G8B	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.2	3	3.58	3.58
DC25VP5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.21	3.23	2.05	1.99
DCRJM83	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.82	11.6	1.85	2.73
DCTAS8P	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.38	4.14	1.05	1.05
DCFMMP1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6	9.68	4.41	4.47
DCUOLNB	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.72	3.27	2.96	1.53
DCHXZPU	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.62	6.28	2.19	1.63
DCZ4OHV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.55	7.33	1.47	1.25
DCMRCVQ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.41	3.87	0.54	0.98
DCG229J	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	5.67	9.09	6.45	9.79
DC1LQYC	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.97	5.72	1.49	5.21
DCBTCDR	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	7.17	4.48	0.4	7.36
DCXKYX3	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.13	6.61	5.73	4.94
DC0HZ18	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.13	5.6	5.03	5.82
DCT2VYQ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	8.17	11.86	2.9	2.44
DC2G93W	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.3	8.11	1.1	0.55
DCFWM6F	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.57	6.52	0.18	1.87
DCIZZ0L	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.23	9.77	6.63	6.52
DCBJ8PA	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.32	7.65	0.18	6.44
DCIR29V	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	8.28	9.07	6.81	10.32
DC2P348	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.35	11.55	0.49	8.83
DC3Y9K7	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	5.07	7.12	6.47	8.58
DCA2R9L	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	5.94	8.35	6.58	8.56
DCSQ5N2	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	6.6	3.98	5.65	6.58
DCGLT6F	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.37	17.14	1.69	12.65
DCJ0PIC	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.97	2.94	2.38	1.85
DC9SSUQ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.01	5.89	3.93	4.69
DCP7V90	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.13	5.81	4.61	2.5
DC4IWIS	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.58	8.67	2.47	2.45
DCQWGZH	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.31	3.62	2.44	2.41
DCHAROU	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.46	11.77	8.37	8.51
DC34S3N	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.22	3.24	0.41	0.13
DCTGYPT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.69	11.12	5.06	5.06
DCAKPCJ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	6.5	7.19	9.12	10.42
DCN7QXA	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.63	5.77	0.56	5.13
DC8J0WW	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.66	10.27	8.25	10.6
DC4MCGT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.9	6.12	4.69	7.18
DC13ZLD	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.61	6.53	4.05	6.34
DCE6AFQ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	12.36	9.9	12.36	13.78
DCQIMER	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.84	8.62	6.29	6.18
DC2L4XL	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.65	6.01	1.39	4.44
DCS7TW6	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5	12.01	5.97	5.58
DCIIMHD	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	6.06	3.58	2.7	2.59
DC16QFY	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	4.78	7.5	7.9	8.51
DCJEM8R	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.77	6.9	3.79	3.74
DCV8BAK	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.38	4.83	6.07	9.3
DCQWWC4	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.7	5.73	3.4	4.75
DCQ35G4	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.45	14.84	5.56	5.56
DC33N9Z	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.72	9.06	3.66	3.77
DC5DZ62	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.2	7.17	1.59	3.6
DC95FTC	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.74	3.46	1.01	3.27
DCVND6T	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.83	4.2	6.29	7.55
DCVEI9Q	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.09	6.09	1.75	0.77
DCPLPH2	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.47	6.7	0.63	0.63
DC7TMPC	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	6.94	6.88	3.59	5.89
DCTTXKS	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	17.63	17.79	5.9	12.39
DC0PK6Q	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.09	10.23	2.4	5.26
DCEF2E7	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.28	7.49	1.87	4.63
DCUTLJ1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.99	8.02	3.74	4.97
DCYK2KA	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.62	4.67	3.07	4.87
DCGHSW6	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	9.05	11.32	3.75	6.66
DCP9IZW	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	5.73	4.7	2.63	4.88
DCSGQ8A	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.46	1.19	0.47	5.04
DC0MDEV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.02	9.19	7.49	8.28
DC2T6FS	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	9.09	20.3	12.5	9.34
DC4OPDA	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.68	8.25	1.3	3.08
DC61QER	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.95	8.19	5.01	4.53
DCOJOF7	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.33	16.98	10.82	10.61
DC2LP6X	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	9.07	9.28	8.4	8.05
DC0PL2Z	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	7.81	9.09	2.17	4.37
DCDLY8J	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	8.58	10.69	1.84	1.07
DC0R1FD	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.15	17.08	10.95	10.95
DCCTN3M	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3	7.35	2.35	2.04
DCJ7VG5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.19	9.13	6.01	6
DCUO9M9	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.6	7.92	0.94	0.25
DCE0TXG	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.91	9.02	5.82	5.07
DCUQ9XJ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.56	6.33	1.61	0.94
DCO1LKK	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.77	9.94	1.07	1.07
DCIALVE	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.48	10.88	7.8	7.8
DCWTTGN	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.98	7.35	2.14	2.14
DCI9JK1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	5.3	7.71	4.93	8.39
DCUYCP5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.57	6.66	4.12	6.49
DCNI0Q0	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.6	1.04	3.17	5.21
DCFT49J	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.93	4.66	4.33	5.48
DCLP9WG	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.83	6.52	3.33	2.64
DC450B3	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.35	3.28	2.55	2.63
DCCAN5E	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.77	9.75	2.29	4.82
DCMF1XI	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.44	4.55	1.71	1.6
DCOHWJT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.88	4.36	2.43	4.96
DCNEOKG	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.28	1.94	1.56	1.69
DC1RG5H	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.46	10.48	4	5.42
DC0EQCO	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	13	6.77	3.5	4.13
DCIO8UI	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.18	4.5	1.62	3.04
DC4TFIK	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.97	3.62	4.3	7.1
DCO4RBH	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.21	4.02	2.83	2.25
DCXW6O8	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.41	7.69	2.06	1.52
DCVXAI4	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.45	5.71	1.25	1.23
DCLAMZI	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.07	4.7	0.59	0.67
DCR7IDY	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.58	6.13	4.24	4.24
DC6N9PD	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.77	5.98	5.36	5.65
DCFJ4NS	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.5	7.52	1.12	1.52
DCJO7UZ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.21	5.27	3.53	3.69
DC4121G	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.52	4.63	2.37	2.21
DCB2OT2	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.8	4.95	0.84	0.24
DCGZV5Z	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.09	3.13	1.82	1.29
DC5PCPA	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.93	8.28	0.52	2.22
DCHF2HM	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.11	3.56	0.94	0.89
DCD8NGM	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.26	3.9	4.07	2.68
DCJ47YE	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.6	2.41	2.05	2.95
DCY3734	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.82	3.05	2.89	5
DCUUSWP	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.16	4.57	4.74	7.85
DCM0Y09	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	7.28	13.07	0.15	4.1
DCXD1ET	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	8.98	13	3.93	7.34
DCJ1C7F	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	15.52	16.26	6.98	12.25
DCDAV6W	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	4.11	5.42	4.88	7.79
DCXM1VV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	15.13	14.11	6	11.84
DCOVCH8	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	12.08	12.01	4.92	14.67
DC0HVPD	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8.25	8.85	7.93	10.21
DCXTM6D	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	13.68	21.88	20.03	23.29
DCZD8RU	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.19	5.81	3.87	3.88
DC4PYW7	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.63	3.99	3.68	3.12
DCZ7JYX	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.44	0.58	0.76	0.48
DCTUD2U	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.65	12.48	5.33	6.51
DC2O64X	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.37	14.53	1.86	11.63
DCDKK7Z	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	12.36	6.83	2.21	1.48
DCXK5DS	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.37	1.66	1.03	0.64
DC3Z354	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.99	7.48	3.55	7.27
DC8PMKK	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.86	4.66	4.36	3.93
DCA9UBD	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	6.35	14.14	13.62	13.63
DC98BFT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	25.58	26.57	21.14	22.36
DC8UHXB	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.81	3.98	3.55	3.68
DCJKZ68	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.72	9.9	8.89	8.58
DCL0IDF	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	31.58	29.93	29.05	26.86
DCOTGVZ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	12.34	15.43	10.56	11.01
DCNYL1L	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	23.93	27.35	24.81	24.63
DCYGGBT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	9.07	10.46	2.73	4.38
DCHHLZR	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	10.76	17.15	14.16	7.31
DC12SLQ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	9.53	13.12	9.27	8.6
DCJDPZP	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.57	4.97	4.97	3.89
DCS32RC	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	22.69	24.63	22.13	22.72
DCXC3D8	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	19.14	22.24	17.85	17.83
DCHBFZS	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	11.75	14.98	13.45	13.57
DCLKET4	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	7.44	14.57	14.55	13.89
DCODNRV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.75	9.8	7.35	8.11
DC9B6Y7	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	4.09	9.35	9.38	9.14
DCCD784	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	4.14	11.81	11.37	11.22
DCZJA7B	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.58	12.85	13.76	13.77
DCYBU12	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	20.84	19.88	10.23	10.23
DCYXCXJ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	6.46	12.47	9.64	10.58
DCI4XW2	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	9.84	19.33	7.63	12.88
DCTUQZH	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	4.69	5.54	5.61	2.86
DCCWSQD	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	6.96	15.37	14.24	13.79
DCD413Y	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.98	8.12	7.6	7.5
DCFD3KC	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	8.49	16.39	16.67	15.89
DCEYN6C	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.91	7.41	6.11	6.21
DCJ8MEE	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.13	11.11	10.69	10.15
DCD8TH2	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	5.95	8.63	7.69	6.94
DCCMHKS	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.21	4.52	2.33	2.63
DC220Q6	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.67	3.42	3.37	2.27
DCUW3PV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.44	7.4	5.81	5.81
DCHEN2Y	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	14.59	17.58	16.41	17.77
DC6K0LE	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.36	10.91	0.28	9.87
DCYA4EE	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.3	3.03	3.36	3.39
DCYBIBH	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.24	3.05	0.44	0.3
DCW865W	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.98	1.68	1.63	1.33
DCV0BA7	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.4	5.22	0.64	2.59
DCXN6ZR	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM5IXKQ	Vismodegib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	5.81	6.94	0.58	0.49
DCKWN3Z	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.01	8.08	4.19	7.66
DC6IIPI	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.32	8.97	4.17	4.14
DCTM368	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.32	6.87	1.2	0.79
DC17XCP	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.12	3.8	1.7	0.98
DC0HFWB	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.7	6.29	2.77	3.69
DCLZ1FX	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.93	2.63	3.4	0.45
DCZ3UEG	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.05	2.53	2.28	0.14
DCYFTCS	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.57	7.7	4.99	4.57
DCXGXQV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.85	3.57	3.52	7.2
DCL00Y8	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	5.91	7.17	1.19	1.19
DCW24XA	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.8	1.76	0.66	0.13
DCROKN8	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	15.81	17.16	11.87	13.17
DC47ZNK	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.69	3.83	1.46	1.49
DCI2M9Q	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.34	3.46	1.49	1.79
DC0848B	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	11.89	7.99	6.17	5.84
DCL0QDL	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	5.34	7.29	0.62	1.57
DCYYZBV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	9.07	12.99	6.91	6.91
DCD1MDI	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	14.34	18.87	14.3	14.3
DC9YSLR	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	31.16	27.4	7.99	9.19
DCULFUI	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	9.25	8.87	4.8	4.72
DC0QRAK	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	19.31	21.72	19.83	19.83
DCS3AML	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.95	3.06	1.38	0.14
DCFY4S1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.09	2.28	1.43	1.43
DCK0CZ0	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	4.99	6.88	5.91	4.36
DCB9JW5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	27.61	25.95	19.83	19.83
DC2XXRV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.63	7.42	5.68	6.07
DCZSVC1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.03	7.6	7.25	6.54
DC700ZP	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	6.83	0.18	1.49	1.37
DCA079H	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.13	3.7	2.09	2.07
DC1FRQS	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.24	5.7	2.39	0.37
DC6R9D5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	5.47	7.49	1.14	1.14
DC3Z5HI	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.76	5.52	2	1.24
DCQN2Z3	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.45	5.48	5.43	3.64
DC6OL4J	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.26	5.24	3.65	3
DCI2HA0	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.05	7.82	5.6	7.53
DCSWOC4	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.12	7.4	7.34	8.1
DCU5MEN	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.48	2.9	0.48	6.2
DCWCZMJ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.02	7.52	6.51	7.87
DCTVLED	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.23	2.34	1.45	0.41
DCF2K43	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.8	3.02	1.67	0.73
DCQ19CT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.02	7.94	1.75	1.75
DC5Q424	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.84	9.17	5.25	7.91
DCEO8Q7	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.71	9.35	1.98	6.42
DC5RX20	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.87	10.94	9.04	4.78
DCXX68P	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.84	4.64	5.21	5.65
DCOAA3J	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.39	6.42	3.14	6.13
DCO2Z54	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.46	6.14	5.11	7.92
DCKUBMC	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.61	2.92	1.08	0.96
DCG85PZ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.87	2.44	2.44	1.49
DC7M79T	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.04	1.65	1.69	1.16
DC8ALQ1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.04	8.35	3.2	3.2
DCKMO2D	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.21	4.93	0.52	0.23
DCSAVXG	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.38	7.15	1.03	1.01
DCOBX4R	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.04	8.81	4.31	4.66
DCRJZDZ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.57	7.75	7.45	6.59
DCPAFLD	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.76	4.01	3.27	1.78
DCRW50U	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.37	8.21	4.67	1.96
DC17LEH	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.1	2.61	0.09	0.09
DCHJY3R	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.14	2.29	1.2	0.63
DCBBHLK	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.14	3.25	2.87	2.18
DCBFI6S	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.44	8.57	6.09	8.12
DCXFD3Z	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.87	5.27	2.87	5.24
DC8I84W	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.34	2.82	1.18	1.18
DCADPC5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.18	7.89	1.48	1.27
DCWXNBI	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.02	4.56	1.63	2.05
DC8FZV4	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.47	9.35	7.49	8.06
DCXNVGV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.23	1.16	0.07	3.86
DC1GWG6	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	5.99	7.96	3.24	7.01
DC0TT5Q	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	6.76	7.01	5.4	8.24
DCYV93J	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	15.69	15.98	13.15	15.64
DCWGPHR	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.44	3.88	2.84	2.22
DCOT03C	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.97	7.52	4.19	8.54
DCX3SEH	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	4.43	6.19	4.12	8.39
DCKHUR2	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.59	5.44	7.67	8.06
DCNUXYZ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.27	4.08	0.9	5.28
DC11GQL	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.06	10.34	7.42	7.99
DCPJTY0	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	9.21	10.51	6.92	7.52
DC51BJE	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.36	2.57	1.28	0.1
DC69E61	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.75	6.39	5.28	2.38
DCUUP3Q	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.31	6.27	1.63	0.17
DCLF6EQ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	10.17	13.55	3.53	3.53
DCYYI57	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	7.73	17.35	12.61	10.63
DCQPWGD	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.37	10.99	6.31	6.08
DCTGWFL	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.7	6.44	2.47	2.36
DCSY3J1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.56	4.71	2.2	2.76
DCSB9M1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	3.21	4.54	1.39	1.16
DC9E9UT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.29	5.17	2.49	2.84
DCB3RQ8	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	7.24	10.63	7.36	6.38
DCWGVPY	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.91	9.46	6.08	2.77
DCP7V3S	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.23	5.36	3.36	2.16
DCQEJ1M	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.25	7.46	6.89	6.26
DCO22EP	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.59	8.9	4.23	5.08
DC05FN6	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	18.64	21.08	15.89	20.37
DCL08H7	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	19.26	13.9	10.58	13.11
DCD9VLH	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	6.7	8.34	3.62	8.36
DC9QSHE	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.61	4.02	0.83	2.94
DCTR5AW	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	12.61	11.83	5.41	10.32
DCYOGCK	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.64	5.18	3.17	4.9
DCRCWM0	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.33	7.87	9.29	10.96
DC9CBB5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.49	4.07	5.01	7.07
DC9H5GM	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6.73	6.63	6.92	10.38
DC72H01	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	9.15	8.96	9.67	11.59
DCI76Z1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.2	5.02	3.75	8.15
DC7GGFF	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.51	5.57	5.81	7.08
DCLCDII	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3	5.65	5.58	7.06
DCAFCJQ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.49	6.89	2.51	2.29
DCOBDZZ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH07Y3	Letrozole	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.89	6.53	5.67	4.61
DC5BP62	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.69	8.23	1.17	2.33
DC0F35M	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.73	1.04	1.09	0.9
DCCP8DD	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	5.12	4.79	3.51	2.66
DCKS4RL	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	10.53	9.27	6.43	9.28
DCNJSBO	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.68	6.12	6.11	6.83
DC72N8X	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	19.55	22.55	20.31	23.24
DC6K9N1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.03	3.27	1.5	4.31
DCKGV99	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	7.32	14.4	3.31	15.55
DC9WUDT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	19.84	21.43	17.75	22.56
DCTQACX	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8.91	11.93	2.76	12.52
DCMA4JH	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.33	6.39	5.65	7.62
DCLDE8M	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.81	4.55	1.4	3.98
DCS0974	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	12.52	8.48	7.75	10.61
DCCHRGE	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.87	5.23	1.78	5.19
DC3IRXG	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.77	4.82	2.61	6.16
DC6ORWL	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	7.83	14.42	12.68	16.57
DCZ4FBF	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	10.77	12.96	6.9	9.29
DC9WLA6	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	16.06	11.74	6.42	5.88
DCE26VT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	15.15	13.73	4.59	9.83
DCRKJ26	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	14.56	15.14	11.4	8.87
DC20J8R	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	7.16	10.58	8.9	8.57
DCAOAOK	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	10.47	8.19	1.75	3.53
DCTO64E	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.58	5.62	1.72	1.7
DCFROKN	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.56	2.42	1.27	1.79
DCRTI4G	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.89	3.84	8.57	8.34
DCU2QMO	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	9.39	11.41	5.11	4.89
DCD2E8L	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.69	6.26	4.15	7.52
DCTQU0V	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.71	4.51	2.29	1.64
DCKS7CT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.68	7.45	2.66	3.01
DCSCDMH	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.28	6.32	4.09	4.41
DC79ZDF	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	8.08	9.68	7.11	5.9
DCIVVC9	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.54	9.28	2.61	3.23
DCU316K	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.9	4.94	2.4	2.33
DC3FFPC	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.58	0.96	1.6	3.37
DCFJZEF	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.77	4.05	0.04	5.3
DCPVPTA	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.45	1.75	0.48	3.79
DC79PLS	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.87	6.19	3.4	7.23
DCOIAQY	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.22	10.21	7.45	8.02
DC6PNCY	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.82	7.51	6.17	6.27
DCEA6CM	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.47	9.47	4.97	4.79
DCULUAE	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	6.6	10.62	8.84	8.55
DCBPFDP	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.22	6.37	3.65	2.47
DCFCH7V	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.68	5.95	4.71	3.72
DCD7KCW	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.22	3.88	1.27	1.04
DCX8ZCI	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.7	8.69	2.57	2.57
DC39G4B	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.31	2.6	2.03	1.13
DCR3WS5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.01	3.32	2.5	2.08
DCNFVQ5	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.09	3.45	1.41	1.71
DCGFSUI	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMM1I8R	Indazole derivative 5	Patented	15.5	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.42	3.23	1.64	0.74
DCXQL46	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	11.28	13.89	11.76	12.28
DCJNO1V	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.59	13.36	12.25	11.22
DCF5AJ0	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.46	2.2	1.44	3.64
DCP0ZND	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.22	2.86	0.11	5.53
DCK63BX	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	6.13	9.22	11.92	11.12
DCF8CKM	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	7.17	8.33	7.4	10.07
DC8KX8J	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.81	6.04	4.41	9.49
DCWRTNH	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.1	1.62	1.27	0.42
DCPCSS9	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.59	7.59	1.78	1.78
DCKN1TP	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1	2.79	0.76	0.16
DCRL59M	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.73	4.97	4.68	4.44
DC7Z4DT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.37	0.64	1.21	0.82
DCDNLJF	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.75	6.21	1.53	4.47
DCW6KG3	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.58	10.52	1.69	3.91
DCE8NXU	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	14.34	10.19	3.3	6.06
DCB6CFH	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	15.18	18.95	13.99	16.71
DCZ9YTF	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.13	3.39	8.62	7.08
DCUNPKN	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	12.35	9.29	0.91	3.91
DCXFF18	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.96	5.57	3.89	6.08
DCT4SYF	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.66	3.41	4.24	4.26
DCUN36F	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.39	6.83	6.28	0.65
DCYAY5M	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	5.44	12.14	9.83	10.22
DC67DSC	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.57	1.3	0.3	0.97
DCBEKKT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.83	4.17	2.88	2.49
DCDT7J1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	11.82	6.16	0.14	0.06
DCLY8Q7	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.72	4.19	3.92	2.44
DCHDEZU	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.49	5.37	5.54	5.56
DCVCB1S	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.54	3.32	6.13	6.54
DCF52RI	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	8.32	8.53	4.56	7.68
DCXL6TB	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	8.5	10.05	6.87	10.09
DCI2W3U	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4.12	1.75	2.31	4.11
DCQSO68	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.63	5.05	5.83	7.53
DCVB3IC	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.44	4.87	4.15	6.19
DC1X4VJ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	18.21	13.15	10.56	15.2
DCYCGZW	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	16.26	16.17	13.79	18.09
DCN2JM4	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	25.94	26.11	23.38	26.04
DC086JL	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.91	11.44	8.03	10.89
DC1TK6P	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	7.52	8.21	6.41	9.67
DCRQO7V	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	18.98	19.12	17.22	21.1
DC5WXRQ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.46	11.8	4.12	10.38
DCY711Y	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.26	11.48	7.42	6.92
DCQB6TH	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.86	8.65	7.56	5.45
DCFK8Q3	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	5.63	10.25	4.56	3.86
DCM00OP	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.83	12.91	8.28	8.26
DCMB7NV	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.17	9.91	5.86	4.99
DC80N1V	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.74	8.91	5.49	7
DC4OMHK	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.55	3.25	2	1.29
DC84JJZ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.42	8.43	4.62	5.3
DC7YJU6	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.71	11.51	8.88	8.67
DCCYMY0	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	9.84	16.01	9.74	9.74
DCXFBIT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.24	9.25	4.05	3.97
DCXZOX1	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.6	4.69	0.54	0.05
DCOOYLR	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.25	4.01	0.64	0.52
DCAHA17	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.24	8.97	6.89	2.71
DCU8JDM	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.47	6.11	1.49	0.77
DCBVM8V	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.91	3.89	1.78	1.31
DCNL94R	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.23	5.16	1.02	0
DCDZH5S	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.65	4.3	3.44	2.25
DCIWKRJ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	5.71	7.08	1.63	0.97
DC24GQM	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	14.17	12.68	7.68	14.89
DCPBQ5W	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	3.79	4.6	0.29	5.06
DCEIUIT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.62	7.87	1.5	1.32
DCKXHS6	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.8	11.06	4.61	10.68
DCWVBYU	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.84	3.92	2.74	2.15
DC40ZM2	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.7	11.19	5.13	5.13
DCF2KBJ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.52	6.62	2.81	2.15
DC7WGFT	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.82	2.64	2.64	1.31
DCPQNQ7	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.42	5.93	4.54	3.95
DCYUCJW	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.62	8.32	6.92	6.42
DC20Q3N	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.25	1.59	0.13	0.54
DC51DGW	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.17	6.98	4.3	5.01
DC48IRL	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.29	3.27	1.97	1.61
DCKNCPZ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.3	10.11	4.16	4.16
DCC3E43	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0	4.51	3.18	3.16
DCOWHQB	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.91	9.2	5.93	7.81
DC37MAG	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.33	2.43	0.81	0.81
DC5N5QF	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.13	4.4	3.5	5.36
DCAD71Q	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.92	5.84	3.89	3.21
DCNAFFC	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	7.3	10	9.51	11.24
DCB8KTB	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	14.2	12.28	8.47	14.33
DC0I0NI	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	10.32	10.26	8.34	11.87
DCPDN0J	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	5.04	6.45	3.28	7.99
DCTW0K0	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	12.19	12.31	12.69	16.31
DC5AWHY	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	8.82	9.17	1.6	11.99
DCJ554J	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	4.59	5.64	5.97	7.15
DCEIU2G	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.85	9.19	2.96	2.96
DCDIR6C	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.08	5.58	0.89	0.52
DCATM99	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.09	3.93	1.73	1.97
DCQUQR8	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.44	5.58	3.82	2.95
DCT31GG	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.33	10.36	4.01	4.01
DCM0Q9M	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.24	4.08	1.48	1.38
DCYGK2E	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.62	2.47	0.58	0.58
DC21T4O	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	9.54	4.48	3.25	2.29
DCTE6K9	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.74	6.05	0.11	0.11
DC4WBOO	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.63	3.81	2.81	0.97
DCVWSPK	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.18	3.17	3.79	3.93
DCIQSTY	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.08	6.26	5.17	7.09
DC7Q9BN	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.64	9.9	1.7	3.92
DCM2PIN	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.03	7.2	0.52	1.12
DCOAK3V	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.08	6.3	5.86	5.72
DCNWWXK	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6.21	13.93	15.51	15.46
DCAJIC7	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	19	21.22	20.21	20.16
DCPE7WK	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	11.74	15.89	14.46	17.64
DCMLXNI	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	11.04	17.8	11.63	16.36
DCT21D2	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	3.42	6.44	6.85	8.43
DC3NWWE	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	4.34	11.27	11.66	12.26
DC35A7W	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	8.85	10.08	10.02	9.58
DCHDQL0	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	22.66	23.28	5.2	25.09
DCW2O98	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	5.07	12.13	11.62	13.85
DCTLSSZ	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.92	12.54	8.99	13.8
DC85G4X	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.54	16.34	16.54	16.66
DC1FD43	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	9.06	15.75	2.97	14.24
DC0Q87X	DMFGYKS	MK-5108	Phase 1	17	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	1.78	0.85	0.46	3.68
DCDQSUA	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	3.05	5.25	1.76	6.37
DCTOAFZ	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	2.8	6.29	4.57	8.57
DCX3LUQ	DMFGYKS	MK-5108	Phase 1	17	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.19	8.36	3.61	9.76
DCW3GE1	DMFGYKS	MK-5108	Phase 1	17	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	0.7	7.98	4.62	9.38
DCXFU95	DMFGYKS	MK-5108	Phase 1	17	DMIXC7G	Zoledronate	Approved	34	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	2.89	2.07	1.57	3.47
DCJ6CUY	DMFGYKS	MK-5108	Phase 1	17	DMIXC7G	Zoledronate	Approved	34	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	EW-8	4.69	4.44	0.18	4.41
DCZAIVY	DMFGYKS	MK-5108	Phase 1	17	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	16.89	16.89	25	25.05
DCNFA39	DMFGYKS	MK-5108	Phase 1	17	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	2.95	2.65	0.04	3.65
DCG8VQ0	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	3.61	5.6	0.16	8.27
DCR7ZQO	DMFGYKS	MK-5108	Phase 1	17	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	11.35	11.43	8.35	12.71
DC80NPC	DMFGYKS	MK-5108	Phase 1	17	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	0.68	1.61	7.87	9.03
DCGXIRR	DMFGYKS	MK-5108	Phase 1	17	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.55	2.05	5.47	6.8
DC7P8L1	DMFGYKS	MK-5108	Phase 1	17	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.07	0.75	1.07	2.24
DCME9QY	DMFGYKS	MK-5108	Phase 1	17	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.18	1.08	0.72	2.51
DC08PA0	DMFGYKS	MK-5108	Phase 1	17	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.6	1.47	2.8	3.31
DCRX11K	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	14.94	13.38	12.88	17.83
DC56HD2	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.83	3.61	5.08	8
DCABBSQ	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	39.55	35	33.88	36.41
DCYYN7D	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.76	11.97	19.01	19.7
DCUSAYP	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	8.53	9.36	4.56	8.97
DCPWM10	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	0.3	0.26	7.51	11.05
DCI8VGW	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.88	3.38	1.23	10.91
DCJ0R7O	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.44	2.66	0.05	8.85
DC0MBUE	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	4.71	8.91	5.48	13.09
DCJSAE3	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.03	4.29	5.3	8.47
DCG5Z5Q	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.78	0.51	6.66	10.26
DCPB7L4	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	11.72	16.06	17.29	19.11
DC2MX6C	DMFGYKS	MK-5108	Phase 1	17	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.83	3.26	2.39	4.42
DCWYU7K	DMFGYKS	MK-5108	Phase 1	17	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.82	3.38	5.9	8.83
DCGRFMF	DMFGYKS	MK-5108	Phase 1	17	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.56	2.79	3.43	14.67
DCK8NJU	DMFGYKS	MK-5108	Phase 1	17	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.96	3.63	2.4	6.87
DC4KNFP	DMFGYKS	MK-5108	Phase 1	17	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	6.4	3.51	3.67	5.78
DCQI2O1	DMFGYKS	MK-5108	Phase 1	17	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	7.52	7.85	1.54	9.7
DCEW1R4	DMFGYKS	MK-5108	Phase 1	17	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.96	1.22	3.3	6.21
DCIZUBV	DMFGYKS	MK-5108	Phase 1	17	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.24	2.56	0.49	4.24
DC4DE8O	DMFGYKS	MK-5108	Phase 1	17	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.78	2.65	1.28	4.58
DCC6SSF	DMFGYKS	MK-5108	Phase 1	17	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.88	9.72	10	11.86
DCOBHS3	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	6.06	6.11	15.36	18.43
DCS8BJ2	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.97	1	6.51	11.08
DCFUGT7	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.79	7.07	10.54	12.29
DCIC8RS	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.25	0.67	0.01	5.03
DCDD06T	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.73	3.91	3.95	8.1
DCN4N4F	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.42	1.31	9.62	12.29
DC3MKVG	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.71	12.12	13.11	13.68
DCTE8LK	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.42	13.41	16.62	18.86
DCI88SZ	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	13.16	13.22	3.99	12.99
DCC9PAX	DMFGYKS	MK-5108	Phase 1	17	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.83	0.44	0.04	4.2
DCBGGSO	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.34	4.13	9.33	10.85
DC22EC6	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.82	2.4	4.85	9.19
DCOJGWP	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.96	3.76	8.19	10.96
DCSQ5YL	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.68	0.88	4.16	6.78
DCLKJ8Q	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.89	6.4	3.54	7.41
DCDIC8Q	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.67	8.13	11.4	13.04
DC30C6P	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	8.72	10.37	1.91	10.07
DCD6M7Z	DMFGYKS	MK-5108	Phase 1	17	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.72	4.64	4.74	9.35
DC1J1GH	DMFGYKS	MK-5108	Phase 1	17	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.57	0.9	0.52	2.16
DC382MM	DMFGYKS	MK-5108	Phase 1	17	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.22	6.3	2.08	6.09
DC7G1UH	DMFGYKS	MK-5108	Phase 1	17	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.33	9.21	7.75	10.92
DCQVTVP	DMFGYKS	MK-5108	Phase 1	17	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	22.34	25.59	27.22	27.22
DC2V9N0	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.22	0.53	1.66	6.59
DC14Q4A	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	7.86	3.26	11.38	12.17
DCQDCIA	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.56	3.02	6.24	10
DCLJRRL	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.7	0.44	1.35	7.14
DC3WW2U	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.28	1.3	0.35	3.76
DCATF7I	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	5.66	7.91	5.76	10.89
DCQAJFU	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.41	4.56	2.3	5.37
DCA7EXK	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.03	5.36	7.42	9.07
DCEMWQ4	DMFGYKS	MK-5108	Phase 1	17	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	0.37	0.95	7.6	9.79
DC25KX3	DMFGYKS	MK-5108	Phase 1	17	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.11	4.01	7.53	9.66
DCPAM01	DMFGYKS	MK-5108	Phase 1	17	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	1.18	0.68	5.32	9.49
DCF9TP5	DMFGYKS	MK-5108	Phase 1	17	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.3	1.99	9.46	12.58
DCH619Q	DMFGYKS	MK-5108	Phase 1	17	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.46	1.15	1.56	6.53
DC1G6XU	DMFGYKS	MK-5108	Phase 1	17	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.34	2.11	3.65	9.73
DCGZH4N	DMFGYKS	MK-5108	Phase 1	17	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	6.2	5.6	2.75	9.73
DCEY35Z	DMFGYKS	MK-5108	Phase 1	17	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	7.55	2.71	2.87	5.88
DC4Z7Z3	DMFGYKS	MK-5108	Phase 1	17	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.47	1.23	4.35	9.48
DCDZDKF	DMFGYKS	MK-5108	Phase 1	17	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.19	1.76	5.19	8.91
DCLNW2S	DMFGYKS	MK-5108	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	0.98	0.96	8.29	10.69
DC8VII9	DMFGYKS	MK-5108	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.27	0.54	1.5	7.18
DCS08RY	DMFGYKS	MK-5108	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.95	3.01	2.05	6.06
DCIEB0V	DMFGYKS	MK-5108	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.08	8.63	4.34	10.66
DCVDAU3	DMFGYKS	MK-5108	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.92	1.82	11.73	13.51
DCUVADY	DMFGYKS	MK-5108	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.71	4.97	1.77	6.53
DCUM7NG	DMFGYKS	MK-5108	Phase 1	17	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	7.06	8.19	11.63	13.22
DCP5FA4	DMFGYKS	MK-5108	Phase 1	17	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.73	0.27	8.28	10.97
DCR2KEB	DMFGYKS	MK-5108	Phase 1	17	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	2.49	7.06	11.61	11.84
DCZ9FXX	DMFGYKS	MK-5108	Phase 1	17	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	2.93	1.11	2.67	4.85
DCTCC4X	DMFGYKS	MK-5108	Phase 1	17	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.44	1.03	4.2	5.51
DCVMAWB	DMFGYKS	MK-5108	Phase 1	17	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	9.62	9.48	15.64	17.76
DCL07DN	DMFGYKS	MK-5108	Phase 1	17	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.52	11.4	9.82	12.83
DCOXEVO	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.46	3.15	0.83	6.19
DC44MSQ	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.46	4.98	4.69	6.85
DCSO3XW	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	6.84	8.86	9.14	13.28
DCC7BQ6	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	16.16	15.79	8.81	18.33
DCN623R	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.66	1.53	3.45	8.2
DCGQ7NR	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.62	4.85	4.41	7.56
DC2M4QD	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.04	0.78	1.91	6.07
DCUWAYC	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.83	6.55	3.67	6.58
DCBPBOT	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	14.07	13.42	14.59	17.63
DCFA5RP	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	19.28	15.51	14.12	20.51
DCIUM2S	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	10.19	10.12	9.53	15.13
DCFSZYW	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	9.04	9.7	5.68	10.07
DCE0O1S	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.04	6.19	3.64	7.87
DCH60AA	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	3.63	10.14	6.41	9.16
DC45SSS	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.28	10.2	8.18	13.38
DCBDDWF	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.94	6.44	10.18	14.51
DC7SDXK	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.6	5.24	8.94	5.99
DC3W8HM	DMFGYKS	MK-5108	Phase 1	17	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	0.94	7.27	0.53	8.66
DCGX3N2	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	4.62	5.27	7.06	11.05
DC38E6Y	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	1.41	1	5.63	9.01
DC3ZAIZ	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	1.63	1.77	0.42	5.67
DCWSQJO	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	6.04	5.1	6.37	10.84
DCFXDSX	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	8.21	8.99	0.26	11.86
DC2YLWS	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	4.16	4.06	3.04	8.28
DC6RGCD	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	1.87	1.25	4.71	8.42
DCNKF7S	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	1.17	3.2	0.91	8.07
DCJT0W2	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.35	2.52	2.89	8.67
DCHAO2N	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	5.75	11.31	1.46	12.39
DCD44TR	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.2	6.89	0.15	10.89
DCSM853	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	4.23	5.53	2.26	10.49
DCZEFPF	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.87	1.69	2.92	9.29
DCHAJJC	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	8.18	7.08	7.44	12.89
DC9I9LM	DMFGYKS	MK-5108	Phase 1	17	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	3	4.31	4.24	8.1
DCUFS33	DMFGYKS	MK-5108	Phase 1	17	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	0.07	0.34	1.97	7.48
DCBWXWD	DMFGYKS	MK-5108	Phase 1	17	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.97	6.57	6.03	8.81
DCGAT18	DMFGYKS	MK-5108	Phase 1	17	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	0.92	0.13	1.12	7.11
DC8TA85	DMFGYKS	MK-5108	Phase 1	17	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.3	0.4	2.8	7.71
DC7Q4W3	DMFGYKS	MK-5108	Phase 1	17	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.31	1.71	0.9	4.52
DCUJWM8	DMFGYKS	MK-5108	Phase 1	17	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	2.25	1.9	2.45	6
DCDW1MY	DMFGYKS	MK-5108	Phase 1	17	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	5.45	8.06	2.62	8.33
DCSRLNB	DMFGYKS	MK-5108	Phase 1	17	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.95	4.23	3.09	7.95
DCPZPWL	DMFGYKS	MK-5108	Phase 1	17	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	7.65	9.05	3.2	10.58
DCHU1F9	DMFGYKS	MK-5108	Phase 1	17	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	12.1	12.03	9.24	16.44
DCVHLJC	DMFGYKS	MK-5108	Phase 1	17	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.19	1.9	1.67	6.85
DCDSOC2	DMFGYKS	MK-5108	Phase 1	17	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	2.9	6.51	3.13	9.75
DCJE7HQ	DMFGYKS	MK-5108	Phase 1	17	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.47	4.38	6.74	7.7
DCTU3AB	DMFGYKS	MK-5108	Phase 1	17	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	2.7	1.94	0.57	6.05
DCNWGYJ	DMFGYKS	MK-5108	Phase 1	17	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	11.65	11.6	1.43	15.48
DC87YTV	DMFGYKS	MK-5108	Phase 1	17	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	8.09	4.11	2.5	9.44
DCHH7K5	DMFGYKS	MK-5108	Phase 1	17	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.4	6.57	4.62	12.73
DC24S20	DMFGYKS	MK-5108	Phase 1	17	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.63	6.75	13.46	6.49
DCT62Z8	DMFGYKS	MK-5108	Phase 1	17	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	0.89	4.07	3.66	4.29
DCN2TZ2	DMFGYKS	MK-5108	Phase 1	17	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	7.55	10.1	3.54	9.86
DC10PCM	DMFGYKS	MK-5108	Phase 1	17	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	4.59	2.51	3.38	7.6
DCBQ63R	DMFGYKS	MK-5108	Phase 1	17	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	1.81	4.2	3.97	6.81
DCFPC6I	DMFGYKS	MK-5108	Phase 1	17	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.88	4.65	1.06	7.88
DC7OKSR	DMFGYKS	MK-5108	Phase 1	17	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.53	3.52	1.08	6.03
DCTG90W	DMFGYKS	MK-5108	Phase 1	17	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	8.97	13.8	9.06	13.29
DCA3NDS	DMFGYKS	MK-5108	Phase 1	17	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.64	3.86	1.55	6.16
DCEITKI	DMFGYKS	MK-5108	Phase 1	17	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.18	0.84	1.24	6.94
DCXBU3F	DMFGYKS	MK-5108	Phase 1	17	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.58	4.18	3.1	8.2
DCM4Q20	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.07	1.26	3.88	6.6
DC1ZH7A	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	0.36	0.38	3.35	6.39
DCLHP24	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.89	1.24	2.59	7.08
DCG37J1	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	2.35	2.46	1.69	6.82
DCPXROO	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	0.62	1.35	0.25	5.54
DC76B4I	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.3	0.92	4.89	8.81
DC5TJ1Q	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	0.28	5.59	3.91	8.05
DCYSN5X	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	18.79	17.37	18.21	21.32
DCK4QKP	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	2.68	2.74	1.33	6.03
DCS3U2A	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.38	9.07	7.13	10.06
DCKVT7V	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.81	5.14	14.28	5.55
DCXAF9D	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.37	4.79	1.76	8.53
DCIO91C	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	2.09	4.37	0.22	7.82
DCBZQZR	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.14	4.81	1.93	7.12
DC1OL2T	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.93	0.08	1.97	4.62
DCX2EF7	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	0.93	6.69	9.29	11.17
DCKGI43	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.54	6.4	5.52	9.61
DCQV03K	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	7.23	12.98	10.61	13.35
DCVANOK	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.7	4.64	5.47	8.18
DC4KM6B	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	7.29	11.9	9.28	11.91
DCR914L	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	27.26	23.13	23.76	30.2
DC51XGC	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.86	8.24	7.96	12.22
DCA4D1Y	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.86	10.6	2.57	12.71
DC0PT5I	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	2.55	2.81	5.01	10.14
DCEATRI	DMFGYKS	MK-5108	Phase 1	17	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	6.63	10.2	5.32	11.66
DCUBBX3	DMFGYKS	MK-5108	Phase 1	17	DMIXC7G	Zoledronate	Approved	34	.	.	.	.	Embryonal rhabdomyosarcoma	SYNERGxDB Database	Investigative	Rh36	4.18	4.17	1.17	2.16
DCVHUDQ	DMFGYKS	MK-5108	Phase 1	17	DMIXC7G	Zoledronate	Approved	34	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	U-HO1	4.21	6.64	3.07	4.27
DC5W0QB	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	7.48	7.2	10.5	12.34
DCPONMC	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.35	7.65	9.85	11.43
DCR8G24	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	1.11	0.88	4.34	5.79
DCO2W8T	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	1.69	3.8	5.31	5.8
DCNYE0W	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	1.24	0.16	4.16	7.26
DCOTPP6	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.63	7.17	7.13	7.81
DCGZ7WH	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.72	5.91	8.39	9.04
DCE21DR	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.34	1.85	2.29	2.17
DCT21UE	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.62	5.23	6.45	8.36
DCC3F5K	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.31	2.53	6.44	7.74
DC0XA7R	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	6.68	6.41	8.83	10.14
DCQO4VA	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	3.44	13.53	10.7	12.82
DC2QYN9	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.02	3.05	11.18	12.47
DCND5UR	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	2.79	9.85	9.97	10.81
DCXDZ90	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	13.07	15.05	15.7	18.07
DCTRTM1	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	21.39	17.75	23.98	26.86
DCKW65Q	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.46	9.16	2.18	12.17
DCFEYQ1	DMFGYKS	MK-5108	Phase 1	17	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.51	3.46	3.36	3.99
DCTQGNK	DMFGYKS	MK-5108	Phase 1	17	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	0.07	0.35	0.2	4.99
DCLL8FP	DMFGYKS	MK-5108	Phase 1	17	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.34	5.25	7.18	9.41
DCFA2UY	DMFGYKS	MK-5108	Phase 1	17	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.9	0.69	3.52	8.22
DCYIDWC	DMFGYKS	MK-5108	Phase 1	17	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	6.03	8.13	7.41	11.43
DCPJLJD	DMFGYKS	MK-5108	Phase 1	17	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	9.52	7.47	7.47	12.24
DC2FWLJ	DMFGYKS	MK-5108	Phase 1	17	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.25	2.73	1.61	5.61
DCTSM72	DMFGYKS	MK-5108	Phase 1	17	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.66	1.68	2.76	6.22
DCE5G6U	DMFGYKS	MK-5108	Phase 1	17	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	1.42	0.91	1.25	5.81
DC71E68	DMFGYKS	MK-5108	Phase 1	17	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.66	1.2	1.9	5.87
DCXOI1H	DMFGYKS	MK-5108	Phase 1	17	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	0.51	4.31	2.63	5.61
DCLNHEK	DMFGYKS	MK-5108	Phase 1	17	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	16.37	13.13	14.93	17.6
DC1F6QV	DMFGYKS	MK-5108	Phase 1	17	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	12.62	12.8	16.34	21.08
DCGF0MN	DMFGYKS	MK-5108	Phase 1	17	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.78	4.7	5.72	5.21
DCT3SNE	DMFGYKS	MK-5108	Phase 1	17	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	5.73	5.06	7.71	12.84
DCOWOUY	DMFGYKS	MK-5108	Phase 1	17	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	5.83	6.54	0.62	6.5
DCJEJ1U	DMFGYKS	MK-5108	Phase 1	17	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	7.51	6.87	1.92	6.96
DCVRUK2	DMFGYKS	MK-5108	Phase 1	17	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	9.74	11.41	0.83	13.59
DCB43QW	DMFGYKS	MK-5108	Phase 1	17	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	2.78	2.92	0.2	5.55
DCV1ATR	DMFGYKS	MK-5108	Phase 1	17	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.79	9.29	7.04	10.26
DC1SWCL	DMFGYKS	MK-5108	Phase 1	17	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	5.94	10.4	3.56	12.79
DCC5GD9	DMFGYKS	MK-5108	Phase 1	17	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.04	7.07	0.17	6.74
DCCTUH5	DMFGYKS	MK-5108	Phase 1	17	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	4.21	9.61	0.6	5.93
DCLFO5V	DMFGYKS	MK-5108	Phase 1	17	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	1.29	8.31	5.07	8.9
DCP097C	DMFGYKS	MK-5108	Phase 1	17	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	6.57	19.64	9.29	16.74
DCNP5R7	DMFGYKS	MK-5108	Phase 1	17	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.99	10.71	4.48	12.76
DC9X6TN	DMFGYKS	MK-5108	Phase 1	17	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.33	13.15	11.83	10.77
DC9HKGO	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	13.49	7.26	2.7	0.52
DCXCWT9	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	1	0.81	3.82	7.92
DC0AT1A	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	5.35	8.52	5.17	8.01
DCNQV13	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1	1.21	2.22	9.02
DCPWBBG	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	2.55	2.22	3.21	9.24
DCHV1WL	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	1.31	1.44	0.42	5.53
DC5QSRV	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	6.5	8.16	9.12	11.9
DC4SULA	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.83	4.41	3.75	9.83
DCTBZF1	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.44	4.16	0.95	6.01
DCLFUQ3	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.49	6	3.86	8.69
DC6FPGQ	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	1.54	1.43	0.69	7.02
DC1FNH0	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.81	4.04	2.16	9.13
DCQBBFT	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	8.22	9.55	6.72	9.94
DCAZK7P	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	3.13	3.99	4.81	8.19
DCDP2PY	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	4.45	4.61	3.8	7.58
DCPONNG	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	9.07	10.34	7.02	12.48
DCE6I9H	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	7.63	7.47	7.72	9.11
DCFC19C	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	8.28	6.72	2.55	9.4
DCVMSP3	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	3.93	4.22	4.21	10.03
DCIWCUY	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	16.25	15.88	14.12	15.21
DCUITK2	DMFGYKS	MK-5108	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	11.84	13.87	1.1	13.44
DCY265F	DMFGYKS	MK-5108	Phase 1	17	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.65	6.38	1.51	9.61
DCWHZAE	DMFGYKS	MK-5108	Phase 1	17	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	0.53	0.43	0.35	4.57
DCY1299	DMFGYKS	MK-5108	Phase 1	17	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	7.49	6.07	9.5	12.2
DCFKX03	DMFGYKS	MK-5108	Phase 1	17	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	7.68	7.64	8.14	9.31
DC2SRZJ	DMFGYKS	MK-5108	Phase 1	17	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.65	6.2	5.75	9.43
DCK1BZ6	DMFGYKS	MK-5108	Phase 1	17	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	3.11	4.14	4.88	8.03
DCLRBK8	DMFGYKS	MK-5108	Phase 1	17	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	7.36	6.66	7	10.12
DCAS0BF	DMFGYKS	MK-5108	Phase 1	17	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	1.8	5.27	3.39	4.09
DCA845T	DMFGYKS	MK-5108	Phase 1	17	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.46	3.92	7.31	9.43
DCODM2O	DMFGYKS	MK-5108	Phase 1	17	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	26.89	21.02	23.91	27.75
DCYA4FR	DMFGYKS	MK-5108	Phase 1	17	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	1.66	1.05	8.4	10.31
DCY0TYT	DMFGYKS	MK-5108	Phase 1	17	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	10.75	10.8	15.36	19.47
DCI7MAO	DMFGYKS	MK-5108	Phase 1	17	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.64	7.62	1.25	9.85
DCABKON	DMFGYKS	MK-5108	Phase 1	17	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	2.49	2.37	4.32	8.44
DCUXG7L	DMFGYKS	MK-5108	Phase 1	17	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	10.39	9.04	3.95	11.97
DCLQF33	DMFGYKS	MK-5108	Phase 1	17	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	12.69	10.87	4.4	13.62
DCREZHD	DMFGYKS	MK-5108	Phase 1	17	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.86	3.3	2.6	8.25
DCFX8YB	DMFGYKS	MK-5108	Phase 1	17	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	10.49	8.51	5.86	12.57
DCJGOYE	DMFGYKS	MK-5108	Phase 1	17	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	2.03	1.64	2.14	4.24
DCG7Z2J	DMFGYKS	MK-5108	Phase 1	17	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.25	2.32	3.35	7.53
DC2OSVM	DMFGYKS	MK-5108	Phase 1	17	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	11.43	8.93	3.83	12.76
DCVZT9N	DMFGYKS	MK-5108	Phase 1	17	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	10.25	10.77	4.35	13.04
DCN0807	DMFGYKS	MK-5108	Phase 1	17	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.89	2.59	1.09	6.72
DCONO8P	DMFGYKS	MK-5108	Phase 1	17	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	15.36	13.53	4.3	17.32
DC48P5X	DMFGYKS	MK-5108	Phase 1	17	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	4.73	3.2	0.84	6.83
DCSXGZM	DMFGYKS	MK-5108	Phase 1	17	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.3	6.28	8.21	12.62
DCNQT6C	DMFGYKS	MK-5108	Phase 1	17	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	0.62	0.37	0.41	4.65
DCJHT1N	DMFGYKS	MK-5108	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.04	1.78	6.89	9.46
DCDAUVE	DMFGYKS	MK-5108	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.31	2.8	9.43	12.48
DCHTDLJ	DMFGYKS	MK-5108	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	0.72	0.57	11.77	12.37
DCTVEUS	DMFGYKS	MK-5108	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	3.83	6.37	5.26	9.89
DCCS3KO	DMFGYKS	MK-5108	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.3	8.16	3.69	11.55
DCEBA58	DMFGYKS	MK-5108	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.54	4.97	5.01	8.57
DCRYI17	DMFGYKS	MK-5108	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	1.49	2.76	1.82	7.72
DCYYQPZ	DMFGYKS	MK-5108	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.34	4.15	9.36	13.1
DCI223R	DMFGYKS	MK-5108	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	1.17	7.41	0.29	7.4
DCBTCOQ	DMFGYKS	MK-5108	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.72	7.43	8.11	10.08
DC9DXN6	DMFGYKS	MK-5108	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	28.17	22.65	25.21	30.27
DCVGLKA	DMFGYKS	MK-5108	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	14.36	13.75	19.31	23.41
DCGP7KO	DMJ7NVI	BIO-300	Phase 1/2	19	DM053KT	Aprepitant	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.27	0.27	1.16	1.22
DCB6QI2	DMJ7NVI	BIO-300	Phase 1/2	19	DM05FXR	Meclofenamic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.13	3.13	3.5	3.5
DCV7P61	DMJ7NVI	BIO-300	Phase 1/2	19	DM09NGV	Ribavirin-TP	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.19	3.19	3.89	3.97
DCUH89O	DMJ7NVI	BIO-300	Phase 1/2	19	DM0CEY3	Lefaxin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.68	2.68	3.05	3.08
DCVW38R	DMJ7NVI	BIO-300	Phase 1/2	19	DM0FB1J	Sertraline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.48	1.48	1.81	1.85
DCEODI7	DMJ7NVI	BIO-300	Phase 1/2	19	DM0QV1J	Baclofen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.71	2.71	3.02	3.11
DCQMWXJ	DMJ7NVI	BIO-300	Phase 1/2	19	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.17	3.98	1.14	5.11
DC966JR	DMJ7NVI	BIO-300	Phase 1/2	19	DM14NKM	Triiodothyronine	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.09	3.09	3.57	3.64
DC3J7T0	DMJ7NVI	BIO-300	Phase 1/2	19	DM1BV7W	Aliskiren	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.44	2.44	2.85	2.88
DC89H1M	DMJ7NVI	BIO-300	Phase 1/2	19	DM1D8XY	Dantrolene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.58	1.58	3.17	3.25
DC3AR63	DMJ7NVI	BIO-300	Phase 1/2	19	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	5.48	6.24	2.89	6.42
DCYEGWQ	DMJ7NVI	BIO-300	Phase 1/2	19	DM2DMPO	Kanamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.42	1.42	1.98	2.06
DC9DBOO	DMJ7NVI	BIO-300	Phase 1/2	19	DM2HU9I	Triamterene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.47	1.47	1.83	1.84
DCQ87D0	DMJ7NVI	BIO-300	Phase 1/2	19	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.66	1.79	0.56	1.89
DCSNOJB	DMJ7NVI	BIO-300	Phase 1/2	19	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.34	1.41	1.32	1.29
DC5GNW3	DMJ7NVI	BIO-300	Phase 1/2	19	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.52	3.42	1.03	2.77
DC18Y85	DMJ7NVI	BIO-300	Phase 1/2	19	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.25	1.04	1.92	2.51
DC5GVHA	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	9.24	8.72	1.61	9.56
DCPEKXQ	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	14.58	11.28	13.25	14.39
DC3A41W	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.2	1.58	1.6	4.25
DCWU2Y8	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.9	2.81	0.67	4.19
DCWPV81	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	8.05	7.32	8.89	9.46
DCJJIU9	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.4	3.87	1.99	5.29
DCS7HIK	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.64	1.14	0.19	1.32
DC2S7U1	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.18	2.57	3.04	3.06
DCZDUDR	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.11	4.68	3.2	4.89
DCQU237	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	5.58	4.73	4.21	5.59
DCZ9VN6	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	19.4	18.8	16.82	18.36
DCXW4Q8	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.25	3.37	2.15	4.03
DC73DIS	DMJ7NVI	BIO-300	Phase 1/2	19	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	6.77	6.16	5.25	8.38
DCVY6WE	DMJ7NVI	BIO-300	Phase 1/2	19	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	16.52	12.99	7.34	13.93
DCD226Z	DMJ7NVI	BIO-300	Phase 1/2	19	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	5.76	6.29	1.68	8.51
DC5GS4Q	DMJ7NVI	BIO-300	Phase 1/2	19	DM3JCVS	Terazosin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.83	0.83	1.23	1.31
DCL658Z	DMJ7NVI	BIO-300	Phase 1/2	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.36	3.78	1.06	5.17
DCZ5TCP	DMJ7NVI	BIO-300	Phase 1/2	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.8	4.32	4.97	8.03
DCGBWQX	DMJ7NVI	BIO-300	Phase 1/2	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.22	2.74	0.29	3.93
DC3D8JH	DMJ7NVI	BIO-300	Phase 1/2	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.35	4.4	1.51	5.52
DCT8DLT	DMJ7NVI	BIO-300	Phase 1/2	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.99	0.37	0.86	4.5
DCIFI8A	DMJ7NVI	BIO-300	Phase 1/2	19	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.96	2.22	0.62	3.46
DC3SH90	DMJ7NVI	BIO-300	Phase 1/2	19	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	6.35	6.55	1.62	5.68
DC10B8G	DMJ7NVI	BIO-300	Phase 1/2	19	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	6.26	5.35	1.25	6.16
DCKYF3K	DMJ7NVI	BIO-300	Phase 1/2	19	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	7.55	7.29	0.84	9.43
DCWVAMX	DMJ7NVI	BIO-300	Phase 1/2	19	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	5.64	3.96	1.72	5.16
DCSZI8V	DMJ7NVI	BIO-300	Phase 1/2	19	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.48	1.61	1.05	4.11
DCY6SA2	DMJ7NVI	BIO-300	Phase 1/2	19	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.05	5.91	3.18	7.57
DC60GM2	DMJ7NVI	BIO-300	Phase 1/2	19	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.35	2.2	1.97	3.58
DCGNDCP	DMJ7NVI	BIO-300	Phase 1/2	19	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.39	2.39	4.09	4.09
DCH1166	DMJ7NVI	BIO-300	Phase 1/2	19	DM5SXUV	Repaglinide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.63	1.63	1.92	2
DCYRHE1	DMJ7NVI	BIO-300	Phase 1/2	19	DM5UGDK	Mephenytoin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.89	4.89	5.27	5.35
DCVWGS0	DMJ7NVI	BIO-300	Phase 1/2	19	DM6HXTS	Anamorelin	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.2	3.2	3.92	3.99
DCMVO8L	DMJ7NVI	BIO-300	Phase 1/2	19	DM7A8TW	Ezetimibe	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.4	3.4	3.75	3.76
DC8GI8Q	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.94	7.78	2.8	9.25
DCIJ2JR	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	10.03	14.56	6.46	14.55
DC00E21	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.61	6.13	3.49	6.81
DCN032M	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	5.91	8.91	3.76	12.88
DCITZLE	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	11.38	11.48	7.61	12.27
DC2K4L4	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	7.28	9.37	7.34	9.98
DCIA5DZ	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	6.03	5.91	0.38	6.54
DCW6QSP	DMJ7NVI	BIO-300	Phase 1/2	19	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	2.45	5.71	4.49	5.33
DCIV4ST	DMJ7NVI	BIO-300	Phase 1/2	19	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	19.98	13.13	13.57	16.02
DCO6XQY	DMJ7NVI	BIO-300	Phase 1/2	19	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.32	2.64	2.21	5.49
DCMHAKE	DMJ7NVI	BIO-300	Phase 1/2	19	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	12.55	9.88	9.45	12.31
DCPSDD4	DMJ7NVI	BIO-300	Phase 1/2	19	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.5	2.12	2.42	6.44
DCVCO0A	DMJ7NVI	BIO-300	Phase 1/2	19	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.72	1.44	2.14	4.78
DC2YL57	DMJ7NVI	BIO-300	Phase 1/2	19	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	11.01	10.45	0.28	16.58
DCJWGPG	DMJ7NVI	BIO-300	Phase 1/2	19	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	3.02	2.49	2.16	5.36
DCGJMR6	DMJ7NVI	BIO-300	Phase 1/2	19	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	8.43	7.66	6.75	9.91
DCI0RCL	DMJ7NVI	BIO-300	Phase 1/2	19	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	3.8	1.94	1.45	5.87
DC5K75Y	DMJ7NVI	BIO-300	Phase 1/2	19	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.04	3.53	1.55	7.77
DC0EGBI	DMJ7NVI	BIO-300	Phase 1/2	19	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	6.24	5.82	7.87	10.47
DC81IF5	DMJ7NVI	BIO-300	Phase 1/2	19	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	18.97	14.45	7.59	15.6
DCZQF4S	DMJ7NVI	BIO-300	Phase 1/2	19	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	5.62	6.84	3.76	8.02
DCZ0ID1	DMJ7NVI	BIO-300	Phase 1/2	19	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.46	3.86	3.4	8.49
DCVWHZU	DMJ7NVI	BIO-300	Phase 1/2	19	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	7.5	9.71	4.88	13.69
DC3O7AR	DMJ7NVI	BIO-300	Phase 1/2	19	DM8X2EH	Everolimus	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.55	0.55	2	2.01
DCW1HWK	DMJ7NVI	BIO-300	Phase 1/2	19	DM9S1EA	Pepstatin	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.39	4.39	5.14	5.22
DCJTPMR	DMJ7NVI	BIO-300	Phase 1/2	19	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.76	4.3	4.93	7.68
DCCFA7B	DMJ7NVI	BIO-300	Phase 1/2	19	DMA8J1G	Rifampin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.3	1.3	1.77	1.78
DCYNT8X	DMJ7NVI	BIO-300	Phase 1/2	19	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.94	1.67	1.26	4.01
DCPYOCR	DMJ7NVI	BIO-300	Phase 1/2	19	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.1	0.25	1.57	4.65
DCJSQAO	DMJ7NVI	BIO-300	Phase 1/2	19	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.56	2.2	4.66	5.81
DC2XRPS	DMJ7NVI	BIO-300	Phase 1/2	19	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.64	3.56	4.43	7.35
DCFWU2Y	DMJ7NVI	BIO-300	Phase 1/2	19	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.51	3.06	2.89	6.03
DCL4WO5	DMJ7NVI	BIO-300	Phase 1/2	19	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.28	0.38	3.18	5.63
DC36X6W	DMJ7NVI	BIO-300	Phase 1/2	19	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.45	3.14	8.53	11.34
DC1G5G5	DMJ7NVI	BIO-300	Phase 1/2	19	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.32	1.95	2.38	5.49
DCU4X53	DMJ7NVI	BIO-300	Phase 1/2	19	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.49	2.15	6.76	8.52
DCHAS80	DMJ7NVI	BIO-300	Phase 1/2	19	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.68	2.76	4.98	5.79
DCQTJUY	DMJ7NVI	BIO-300	Phase 1/2	19	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.67	4.47	7.27	9.71
DC9W0AH	DMJ7NVI	BIO-300	Phase 1/2	19	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.99	1.73	1.1	1.18
DCWJA87	DMJ7NVI	BIO-300	Phase 1/2	19	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.41	0.21	0.47	0.57
DC51QZQ	DMJ7NVI	BIO-300	Phase 1/2	19	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.39	0.74	1.61	1.74
DCR5RHE	DMJ7NVI	BIO-300	Phase 1/2	19	DMB4AVP	Pamidronate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.21	2.21	2.49	2.58
DCX49I2	DMJ7NVI	BIO-300	Phase 1/2	19	DMBI4JG	Isosorbide dinitrate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.88	1.88	2.16	2.23
DCR2ZIK	DMJ7NVI	BIO-300	Phase 1/2	19	DMBS632	Buspirone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.38	3.38	3.76	3.8
DCY8V8K	DMJ7NVI	BIO-300	Phase 1/2	19	DMBYCU0	Metyrosine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.58	1.58	3.31	3.38
DCH6F46	DMJ7NVI	BIO-300	Phase 1/2	19	DMC0GSJ	Efavirenz	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.36	4.36	4.81	4.88
DCBR77M	DMJ7NVI	BIO-300	Phase 1/2	19	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.05	0.05	1.52	1.6
DCPPZRR	DMJ7NVI	BIO-300	Phase 1/2	19	DMPN5IH	Guanfacine	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.66	1.66	2.11	2.11
DCVI7H4	DMJ7NVI	BIO-300	Phase 1/2	19	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.9	3.9	4.47	4.48
DCKPDTV	DMJ7NVI	BIO-300	Phase 1/2	19	DMCR1MV	Itraconazole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.21	2.21	2.65	2.71
DCL8NCK	DMJ7NVI	BIO-300	Phase 1/2	19	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	11.89	9.57	7.41	11.16
DCT031J	DMJ7NVI	BIO-300	Phase 1/2	19	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.88	6.66	1.51	9.06
DCTKX7Z	DMJ7NVI	BIO-300	Phase 1/2	19	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.75	7.57	4.66	8.37
DCDHL5Z	DMJ7NVI	BIO-300	Phase 1/2	19	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.67	5.35	3.88	5.03
DCJ6PXR	DMJ7NVI	BIO-300	Phase 1/2	19	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	11.81	11.86	1.74	12.48
DC6JD46	DMJ7NVI	BIO-300	Phase 1/2	19	DMCUT21	Ursodeoxycholic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.52	3.52	3.89	3.89
DCH2REF	DMJ7NVI	BIO-300	Phase 1/2	19	DMCYVDT	Chlorzoxazone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.48	0.48	2.43	2.51
DCRZEHO	DMJ7NVI	BIO-300	Phase 1/2	19	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	16.7	14.59	13.17	17.75
DCAL3TM	DMJ7NVI	BIO-300	Phase 1/2	19	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.6	6.33	5.72	9.03
DC037T8	DMJ7NVI	BIO-300	Phase 1/2	19	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	13.2	10.27	10.22	13.37
DCVQQ2W	DMJ7NVI	BIO-300	Phase 1/2	19	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	5.91	7.78	2.33	12.22
DC7EK3W	DMJ7NVI	BIO-300	Phase 1/2	19	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.43	3.49	1.28	6.93
DCTJ6RI	DMJ7NVI	BIO-300	Phase 1/2	19	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	4.19	3.53	3.91	4.63
DCS3S4R	DMJ7NVI	BIO-300	Phase 1/2	19	DMDASC6	Metformin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.16	0.16	0.44	0.51
DC7K5UQ	DMJ7NVI	BIO-300	Phase 1/2	19	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.27	3.32	5.35	7.81
DCH0PXI	DMJ7NVI	BIO-300	Phase 1/2	19	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.86	3.96	4.31	7.58
DCLSGXJ	DMJ7NVI	BIO-300	Phase 1/2	19	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.12	1.58	4.58	6.66
DCE4MOQ	DMJ7NVI	BIO-300	Phase 1/2	19	DMDO279	Phenprocoumon	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.98	1.98	2.37	2.46
DCAZCK5	DMJ7NVI	BIO-300	Phase 1/2	19	DME8FZ9	Methoxsalen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.32	2.32	2.62	2.67
DCZFODJ	DMJ7NVI	BIO-300	Phase 1/2	19	DMEO794	Galantamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.51	2.51	2.84	2.91
DCXHEVW	DMJ7NVI	BIO-300	Phase 1/2	19	DMF70AB	Ginsenoside Rb1	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.32	3.32	3.58	3.66
DCBFOHF	DMJ7NVI	BIO-300	Phase 1/2	19	DMFCMPS	Daidzin	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.79	2.79	3.07	3.16
DCK096I	DMJ7NVI	BIO-300	Phase 1/2	19	DMFGLXB	Phensuximide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.76	3.76	4.31	4.4
DCMYOIZ	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.74	3.02	1.75	4.45
DC8J3L7	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.5	0.43	0.2	1.48
DC03HBQ	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	9.44	9.23	6.02	11.42
DCD71RM	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.93	2	1.83	5.24
DCT6R7A	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	20.82	17.48	18.96	22.11
DC7RL2B	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	7.49	6.9	7.56	10.27
DCPD8LK	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	5.67	4.87	2.15	7.41
DCLWPYT	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.63	4.72	3.79	7.48
DCDD94C	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	7.54	4.21	0.59	9.71
DCZBXNF	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	2.12	7.2	6.17	8.37
DCKNLNA	DMJ7NVI	BIO-300	Phase 1/2	19	DMFO843	Fluspirilene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.24	0.24	0.52	0.61
DCKJB7P	DMJ7NVI	BIO-300	Phase 1/2	19	DMFQWNI	VR-776	Discontinued in Phase 1	3	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.7	1.7	2.06	2.14
DCYIBBK	DMJ7NVI	BIO-300	Phase 1/2	19	DMG58FX	WAY-100635	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.43	0.43	1.06	1.09
DCN88A1	DMJ7NVI	BIO-300	Phase 1/2	19	DMGB035	Armodafinil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.34	2.34	2.63	2.7
DCAAN8M	DMJ7NVI	BIO-300	Phase 1/2	19	DMGC5DB	Ciprofibrate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.36	1.36	1.65	1.74
DCJW6EN	DMJ7NVI	BIO-300	Phase 1/2	19	DMGQFYB	Mecamylamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.47	0.47	0.84	0.85
DCDQTJU	DMJ7NVI	BIO-300	Phase 1/2	19	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.42	0.6	0.87	3.61
DCP6HBX	DMJ7NVI	BIO-300	Phase 1/2	19	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.13	1.75	7.36	8.8
DCH7KTH	DMJ7NVI	BIO-300	Phase 1/2	19	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.56	3.09	8.56	9.23
DCBWTVG	DMJ7NVI	BIO-300	Phase 1/2	19	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	5.97	5.31	11.29	11.85
DC5MFT0	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.47	3.58	1.37	5.45
DCDQZN1	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.77	3.64	6.84	9.33
DC6WZ6L	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.59	1.94	2.74	4.39
DC8BJIW	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.26	2.24	3.44	5.94
DCUVHGO	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	7.41	7.35	3.92	9.71
DCG4VK0	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	4.44	4.59	1.75	9.72
DCK6HFM	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	8.78	8.18	9.47	12.46
DCJC30S	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.63	1.23	2.32	5.88
DCTFWP4	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	10.37	12.78	9.2	14.49
DCDXFGY	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	5.12	4.49	3.77	10.09
DCZQ0AZ	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.79	3.87	3.99	7.67
DCAVQVN	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.23	3.62	0.74	8.14
DCOYE9U	DMJ7NVI	BIO-300	Phase 1/2	19	DMHAZLM	Naringenin	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.3	2.3	2.66	2.71
DCTC2AV	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.49	5.58	3.92	7.33
DCO9IG7	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.96	7.65	5.78	9.83
DCRT120	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	11.01	11.44	10.23	15.56
DCK1Z0P	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.38	1.88	0.08	4.7
DCSM05I	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	5.5	4.72	5.73	8.3
DC2WOTU	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	9.98	10.57	5.17	13.15
DCD36IE	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.17	6.58	5.66	9.28
DCM8K3V	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	9.71	11.91	7.98	13.45
DC69TJ3	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	9.88	9.65	11.25	13.96
DCHX2HL	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	6.12	6.4	4.17	8.72
DCUMYID	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.08	0.67	2.16	4.55
DC8CIB0	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	15.39	15.66	14.79	18.76
DCL9AEF	DMJ7NVI	BIO-300	Phase 1/2	19	DMHPWOM	Diphenidol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.11	4.11	4.5	4.53
DCJQ7HB	DMJ7NVI	BIO-300	Phase 1/2	19	DMHZJCG	Pentamidine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.32	3.32	3.71	3.72
DCFXLB3	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.38	3.22	0.69	3.37
DCREU0P	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.22	2.9	0.26	6.47
DC52PE0	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	4.36	6.66	5.4	10.56
DC0EHOB	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	6.24	3.91	0.48	3.94
DCKXUPC	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	7.19	6.25	6.38	9.34
DCSY7LN	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	6.47	8.83	4.1	7.67
DCXYX9X	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.91	8.17	4.93	7.25
DC5M3DL	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.19	1.62	0.65	3.59
DC4U7HV	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.19	6.89	3.83	7.81
DCYOJTX	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.64	6.68	5.83	10.2
DC3DUFW	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.93	5.62	5.72	8.01
DC6LBV9	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	6.32	6.45	4.79	7.82
DCHLYOQ	DMJ7NVI	BIO-300	Phase 1/2	19	DMIR21F	PFK-158	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.15	1.15	1.49	1.54
DCZN7DH	DMJ7NVI	BIO-300	Phase 1/2	19	DMIUYFH	Sulfapyridine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.31	4.31	4.62	4.71
DCE1XH5	DMJ7NVI	BIO-300	Phase 1/2	19	DMIWFRL	Tolvaptan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.09	4.09	4.52	4.57
DCMPTLK	DMJ7NVI	BIO-300	Phase 1/2	19	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	9.82	7.29	7.62	9.9
DCO6IUI	DMJ7NVI	BIO-300	Phase 1/2	19	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.45	1.98	0.98	4.14
DCALE5O	DMJ7NVI	BIO-300	Phase 1/2	19	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.95	4.73	4.29	7.15
DCMHNI8	DMJ7NVI	BIO-300	Phase 1/2	19	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.29	1.59	3.07	6.54
DC1NA56	DMJ7NVI	BIO-300	Phase 1/2	19	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.09	3.42	3.34	7.22
DCAWLY9	DMJ7NVI	BIO-300	Phase 1/2	19	DMJOQM3	Eflornithine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.94	1.94	2.24	2.32
DC1PWJM	DMJ7NVI	BIO-300	Phase 1/2	19	DMJPE61	PF-02545920	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.35	0.35	1.58	1.64
DCETY41	DMJ7NVI	BIO-300	Phase 1/2	19	DMJSKUI	Norcisapride	Discontinued in Phase 2	5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.97	2.97	3.34	3.34
DC3OVEB	DMJ7NVI	BIO-300	Phase 1/2	19	DMK7MEY	Isoproterenol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.74	1.74	2.38	2.47
DCUUJ5S	DMJ7NVI	BIO-300	Phase 1/2	19	DMKA8J4	Etonogestrel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.13	2.13	2.51	2.58
DC7VVIT	DMJ7NVI	BIO-300	Phase 1/2	19	DMKSQG0	Tiagabine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.41	0.41	2.21	2.27
DCM3OTE	DMJ7NVI	BIO-300	Phase 1/2	19	DMKZJ7T	GINKGOLIDE A	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.16	2.16	2.6	2.69
DCC220X	DMJ7NVI	BIO-300	Phase 1/2	19	DML5VQ0	Fenoprofen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.3	3.3	3.53	3.62
DCP71MR	DMJ7NVI	BIO-300	Phase 1/2	19	DMLB0EZ	Tamoxifen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.24	2.24	2.8	2.84
DCB288A	DMJ7NVI	BIO-300	Phase 1/2	19	DMLBVKQ	Entacapone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.49	2.49	2.81	2.87
DCO4M7Q	DMJ7NVI	BIO-300	Phase 1/2	19	DMLU8NX	Benserazide	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.61	1.61	1.93	2.01
DCFO55S	DMJ7NVI	BIO-300	Phase 1/2	19	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.71	0.39	1.32	2.91
DCJ3CZZ	DMJ7NVI	BIO-300	Phase 1/2	19	DMM0HR1	Pargyline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.16	5.16	5.46	5.54
DCUI1Z5	DMJ7NVI	BIO-300	Phase 1/2	19	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.05	4.07	2.92	5.51
DCZ28OB	DMJ7NVI	BIO-300	Phase 1/2	19	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.41	1.41	2.49	2.57
DC52VLX	DMJ7NVI	BIO-300	Phase 1/2	19	DMM4WBX	Methocarbamol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.15	1.15	1.48	1.56
DCJXURL	DMJ7NVI	BIO-300	Phase 1/2	19	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	15.94	11.83	6.73	12.14
DCRJYA2	DMJ7NVI	BIO-300	Phase 1/2	19	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	7.1	5.32	7.21	10.23
DC61UM6	DMJ7NVI	BIO-300	Phase 1/2	19	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	7.4	9.3	0.44	10.32
DCIY7DF	DMJ7NVI	BIO-300	Phase 1/2	19	DMN3GCH	Darunavir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.35	3.35	4.05	4.13
DCO50A4	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	12.71	8.24	8.47	11.26
DCMV8BE	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.31	4.91	2.6	7.78
DCRJHOG	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.31	7.13	6.14	9.83
DC304HQ	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.27	2.26	5.53	8.2
DC8ZIGX	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	8.71	7.15	6.34	12.86
DCZ6DFM	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.58	0.26	0.83	3.97
DC2YPZ8	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	12	11.15	2.01	7.42
DCNHC16	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	3.72	3.91	5.63	6.95
DC6NHMT	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	3.27	5.24	2.65	5.38
DC354OV	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.77	6.43	10.73	12.42
DCMFEJO	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.14	0.05	4.88	6.92
DCQ8K11	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	12.59	12.42	8.94	15.39
DCCEQYH	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.12	0.76	5.8	8.01
DCGKGRE	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	4.9	5.82	4.87	8.31
DCWDKRP	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	7.31	5.66	6.03	11.1
DCYSK81	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.67	1.19	5.61	8.47
DCUUJ47	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	4.91	6.41	1.9	7.1
DCTHK7J	DMJ7NVI	BIO-300	Phase 1/2	19	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.24	1.24	3.27	3.29
DCFO7CX	DMJ7NVI	BIO-300	Phase 1/2	19	DMNSJ7V	Tropisetron	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.15	4.15	4.54	4.59
DC902K9	DMJ7NVI	BIO-300	Phase 1/2	19	DMO14SG	Mebendazole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.9	2.9	3.25	3.27
DC2O1VV	DMJ7NVI	BIO-300	Phase 1/2	19	DMOMBJW	Moricizine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.68	0.68	1.01	1.09
DC0A1KY	DMJ7NVI	BIO-300	Phase 1/2	19	DMOY7W3	Artemisinin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.4	2.4	3.5	3.53
DCYMMQU	DMJ7NVI	BIO-300	Phase 1/2	19	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	8.81	7.61	11.53	12.82
DCMRLIG	DMJ7NVI	BIO-300	Phase 1/2	19	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.16	2.53	3.52	6.41
DC1TN9I	DMJ7NVI	BIO-300	Phase 1/2	19	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.8	0.9	1.86	3.43
DCMCXOG	DMJ7NVI	BIO-300	Phase 1/2	19	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.22	2.3	10.28	12.21
DCYZTV0	DMJ7NVI	BIO-300	Phase 1/2	19	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	4.15	2.93	5.36	7.35
DCB3UOL	DMJ7NVI	BIO-300	Phase 1/2	19	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.05	2.87	6.42	8.67
DCJE906	DMJ7NVI	BIO-300	Phase 1/2	19	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.16	1.75	5.48	8.8
DCK8TPZ	DMJ7NVI	BIO-300	Phase 1/2	19	DMPGUCF	Dopamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.28	1.28	1.62	1.62
DCS0OW2	DMJ7NVI	BIO-300	Phase 1/2	19	DMPP4DT	Trimethobenzamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.22	2.22	3.58	3.64
DCJLYF2	DMJ7NVI	BIO-300	Phase 1/2	19	DMFYAM1	Enalaprilat	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.74	4.74	5.03	5.08
DCOX4QR	DMJ7NVI	BIO-300	Phase 1/2	19	DMR6N7H	Acetohexamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.02	3.02	3.24	3.33
DC4D01S	DMJ7NVI	BIO-300	Phase 1/2	19	DMRFWGK	Novobiocin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.16	0.16	0.56	0.56
DC3J8HM	DMJ7NVI	BIO-300	Phase 1/2	19	DMRJFN9	Theophylline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.19	1.19	1.49	1.57
DCPI259	DMJ7NVI	BIO-300	Phase 1/2	19	DMRTSGP	Amiloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.99	1.99	2.37	2.39
DC9JKYZ	DMJ7NVI	BIO-300	Phase 1/2	19	DMS0PND	Brincidofovir	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.67	0.67	2.63	2.68
DC53K6M	DMJ7NVI	BIO-300	Phase 1/2	19	DMS49KH	Valproic Acid	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.63	2.63	2.99	2.99
DCJFR48	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.14	3.89	1.75	5.55
DC445KF	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.46	3.34	0.68	4.72
DCBNLMA	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.95	3.74	2.76	5.67
DC9HK7Y	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.54	6.08	3.49	7.93
DCAMJU9	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.67	3.22	2.89	5.63
DCBYK4Q	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.09	2.81	0.89	5.87
DC1SS10	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	5.02	3.54	1.55	8.07
DCM4RJQ	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	4.5	5.07	1.96	7.48
DCSBG7P	DMJ7NVI	BIO-300	Phase 1/2	19	DMSQZE2	Asenapine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.6	1.6	2.07	2.15
DCVMLZ9	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.33	1.75	5.1	5.9
DC49RSL	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	3.13	2.18	4.07	6.95
DC1CWBL	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	6.36	5.89	6.21	7.85
DCKN854	DMJ7NVI	BIO-300	Phase 1/2	19	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	6.47	6.16	0.96	6.88
DCYU5IP	DMJ7NVI	BIO-300	Phase 1/2	19	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	4.63	4.78	2.68	4.96
DC891XI	DMJ7NVI	BIO-300	Phase 1/2	19	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.07	5.56	2.13	6.93
DCXYOWX	DMJ7NVI	BIO-300	Phase 1/2	19	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.31	2.6	5.27	6.58
DCA3HMM	DMJ7NVI	BIO-300	Phase 1/2	19	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	13.53	13.3	7.61	13.46
DCINVKA	DMJ7NVI	BIO-300	Phase 1/2	19	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.31	7.31	5.19	9.9
DCW4QSJ	DMJ7NVI	BIO-300	Phase 1/2	19	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.16	0.32	1.74	4.58
DC1DGTQ	DMJ7NVI	BIO-300	Phase 1/2	19	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.29	3.62	1.16	6.21
DCZGARG	DMJ7NVI	BIO-300	Phase 1/2	19	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.93	2.02	0.52	3.36
DCM5X09	DMJ7NVI	BIO-300	Phase 1/2	19	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	3.88	3.49	5.28	7.02
DCE2RTA	DMJ7NVI	BIO-300	Phase 1/2	19	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	4.05	4.09	6.33	8.54
DCS57CK	DMJ7NVI	BIO-300	Phase 1/2	19	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	4.27	3.37	5.75	7.9
DC0CHQO	DMJ7NVI	BIO-300	Phase 1/2	19	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	6.97	7.13	3.07	9.05
DC9IXGX	DMJ7NVI	BIO-300	Phase 1/2	19	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.71	5.52	3.74	7.88
DC3UUUO	DMJ7NVI	BIO-300	Phase 1/2	19	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.42	1.95	0.82	3.24
DCEA95S	DMJ7NVI	BIO-300	Phase 1/2	19	DMU9MYJ	Oxandrolone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.14	3.14	3.39	3.47
DCL6C1X	DMJ7NVI	BIO-300	Phase 1/2	19	DMUOT9V	Taxol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.49	2.94	0.53	2.53
DCVHWRA	DMJ7NVI	BIO-300	Phase 1/2	19	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.05	0.92	5.32	6.78
DCN4EVW	DMJ7NVI	BIO-300	Phase 1/2	19	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.8	1.47	1.14	3.32
DCMAXIZ	DMJ7NVI	BIO-300	Phase 1/2	19	DMV74ZH	Pizotyline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.33	3.33	3.69	3.72
DCBH2J9	DMJ7NVI	BIO-300	Phase 1/2	19	DMVRIC2	Zileuton	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.26	1.26	1.81	1.89
DC5O3FP	DMJ7NVI	BIO-300	Phase 1/2	19	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.46	2.56	0.03	5.11
DCK1DR3	DMJ7NVI	BIO-300	Phase 1/2	19	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.17	0.01	1.47	3.62
DCAGRIF	DMJ7NVI	BIO-300	Phase 1/2	19	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.31	5.06	4.12	10.39
DC90M3E	DMJ7NVI	BIO-300	Phase 1/2	19	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.01	1.91	3.78	5.69
DC9YLX5	DMJ7NVI	BIO-300	Phase 1/2	19	DMVRYT2	Nabilone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.04	5.04	5.43	5.47
DCERDPV	DMJ7NVI	BIO-300	Phase 1/2	19	DMVTHWQ	Silver sulfadiazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.13	0.13	0.39	0.47
DCVJ7LB	DMJ7NVI	BIO-300	Phase 1/2	19	DMVY4GN	Testolactone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.17	3.17	3.64	3.72
DCMIDE8	DMJ7NVI	BIO-300	Phase 1/2	19	DMVYXR8	Sumatriptan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.08	1.08	1.43	1.47
DC6HG9I	DMJ7NVI	BIO-300	Phase 1/2	19	DMWBHRY	Olmesartan medoxomil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.51	3.51	3.83	3.88
DC1WWR0	DMJ7NVI	BIO-300	Phase 1/2	19	DMWE60C	Rufinamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.22	3.22	3.58	3.6
DCPUK2R	DMJ7NVI	BIO-300	Phase 1/2	19	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	7.18	6.6	4.86	9.29
DCPXFB6	DMJ7NVI	BIO-300	Phase 1/2	19	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	3.86	4.82	2.34	5.28
DC09N3D	DMJ7NVI	BIO-300	Phase 1/2	19	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	4.13	2.58	0.38	3.5
DCHZZYB	DMJ7NVI	BIO-300	Phase 1/2	19	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	8.65	5.85	5.67	9.18
DCQTOKG	DMJ7NVI	BIO-300	Phase 1/2	19	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.95	1.97	0	4.58
DCJ01D6	DMJ7NVI	BIO-300	Phase 1/2	19	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.98	4.14	1.53	4.47
DCR5528	DMJ7NVI	BIO-300	Phase 1/2	19	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.76	2.72	1.64	4.33
DC2TAQD	DMJ7NVI	BIO-300	Phase 1/2	19	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.81	2.9	1.28	5
DC1F7Q2	DMJ7NVI	BIO-300	Phase 1/2	19	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.38	2.58	2.22	6.02
DCARMUM	DMJ7NVI	BIO-300	Phase 1/2	19	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.57	2.34	3.75	7.22
DCQ6HWG	DMJ7NVI	BIO-300	Phase 1/2	19	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.62	4.19	0.84	4.95
DCH70R2	DMJ7NVI	BIO-300	Phase 1/2	19	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	7.46	5.07	0.83	5.36
DC22L0F	DMJ7NVI	BIO-300	Phase 1/2	19	DMXCM7H	Cerivastatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.98	1.98	4.01	4.02
DCODSHF	DMJ7NVI	BIO-300	Phase 1/2	19	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.46	5.53	1.33	7.53
DCJS0XJ	DMJ7NVI	BIO-300	Phase 1/2	19	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.3	0.3	0.67	0.69
DCCCI8P	DMJ7NVI	BIO-300	Phase 1/2	19	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.62	5.24	0.43	5.34
DC0M0DU	DMJ7NVI	BIO-300	Phase 1/2	19	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.36	4.96	2.66	5.94
DC8ZZ0R	DMJ7NVI	BIO-300	Phase 1/2	19	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.77	2.63	0.7	4.17
DCEVCNN	DMJ7NVI	BIO-300	Phase 1/2	19	DMY4UMW	Atovaquone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.37	3.37	3.64	3.71
DCE1261	DMJ7NVI	BIO-300	Phase 1/2	19	DMYLOVR	Aciclovir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.79	2.79	3.61	3.69
DC1GOFQ	DMJ7NVI	BIO-300	Phase 1/2	19	DMYX7NI	Acetohydroxamic Acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.44	0.44	1.11	1.18
DCECV2Q	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	2.39	2.32	5.43	6.34
DCUOQHM	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	1.85	1.52	0.44	5.33
DCL6IUP	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.47	2.19	1	4.95
DCXT5TJ	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	8.47	3.01	5.14	6.92
DCEZ9F5	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	3.78	5.47	3.22	7.31
DCDO1LY	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.96	1.79	6.14	8.28
DCALEWI	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.08	3.58	1.27	5.51
DCV3L83	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.67	2.34	7.96	10.41
DCEQEUY	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	8.43	7.83	8.59	10.09
DC8455S	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	4.94	4.16	7.74	7.68
DCDLAT3	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	7.17	6.97	7.72	8.96
DCTK65S	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.64	4.23	2.5	8.09
DC9R6VG	DMJ7NVI	BIO-300	Phase 1/2	19	DMZ7XNQ	Tacrolimus	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.06	3.06	3.26	3.35
DCC7ZC5	DMJ7NVI	BIO-300	Phase 1/2	19	DMZMSCT	Cilostazol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.71	3.71	4.07	4.11
DCF5WWG	DMJ7NVI	BIO-300	Phase 1/2	19	DMZP7YM	L-165041	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.81	3.81	4.12	4.15
DCGE830	DMJ7NVI	BIO-300	Phase 1/2	19	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	13.87	9.39	7.09	10.16
DCDN1VU	DMJ7NVI	BIO-300	Phase 1/2	19	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.11	2.45	2.3	2.86
DCG8ZY9	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.14	9.28	8.53	9.03
DCIWUPW	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.69	4.09	3.39	4.26
DCFJKRM	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.15	1.25	4.14	5.56
DC2OPYZ	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.97	1.7	1.54	2.02
DCKCSQ9	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.79	4.94	3.47	4.84
DCPICZ9	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.97	4.96	3.04	4.85
DCC1MKW	DMJ7NVI	BIO-300	Phase 1/2	19	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.23	4.84	0.92	6.44
DCRTCWK	DMJ7NVI	BIO-300	Phase 1/2	19	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	9.03	10.07	1.51	9.1
DCYSBB1	DMJ7NVI	BIO-300	Phase 1/2	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	7.93	9.97	7.86	12.11
DC4PYIO	DMJ7NVI	BIO-300	Phase 1/2	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.18	4.52	1.08	6.81
DCGZAU8	DMJ7NVI	BIO-300	Phase 1/2	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.58	5.85	3.7	6.24
DC9462R	DMJ7NVI	BIO-300	Phase 1/2	19	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.96	4.58	7.52	8.94
DCUNFL1	DMJ7NVI	BIO-300	Phase 1/2	19	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.39	2.9	3.34	7.77
DCQXREG	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	13.21	16.14	8.44	15.69
DCFDP2A	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	7.87	17.01	11.38	17.59
DCJK9SP	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	26.42	24.35	10.9	23.52
DCAFHKK	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.79	12.31	4.89	11.66
DCBXG01	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	13.93	15.18	3.31	15.08
DCS6W7D	DMJ7NVI	BIO-300	Phase 1/2	19	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	8.45	5.96	11.17	13.24
DCXEIWM	DMJ7NVI	BIO-300	Phase 1/2	19	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.76	6.7	1.02	8.29
DCUIYU8	DMJ7NVI	BIO-300	Phase 1/2	19	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.27	2.29	1.4	5.38
DCZB2LH	DMJ7NVI	BIO-300	Phase 1/2	19	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.27	5.76	8.15	10.19
DCUI8WP	DMJ7NVI	BIO-300	Phase 1/2	19	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.37	5.18	1.52	6.82
DCQS7U0	DMJ7NVI	BIO-300	Phase 1/2	19	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.59	3.74	9.18	11.15
DC9MV0H	DMJ7NVI	BIO-300	Phase 1/2	19	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.26	2.4	5.3	10.31
DCEOULW	DMJ7NVI	BIO-300	Phase 1/2	19	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.13	4	3.86	3.92
DC4PTVZ	DMJ7NVI	BIO-300	Phase 1/2	19	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.5	3.37	4.64	4.49
DC55UKF	DMJ7NVI	BIO-300	Phase 1/2	19	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	12.84	8.35	1.09	9.04
DCG4RIL	DMJ7NVI	BIO-300	Phase 1/2	19	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.36	4.37	2.17	4.57
DC694XT	DMJ7NVI	BIO-300	Phase 1/2	19	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.79	6.46	3.72	6.47
DCZF9AK	DMJ7NVI	BIO-300	Phase 1/2	19	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	12.71	8.28	11.47	13.2
DC7VOX4	DMJ7NVI	BIO-300	Phase 1/2	19	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.95	2.27	2.34	5.01
DCPT4T2	DMJ7NVI	BIO-300	Phase 1/2	19	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.27	4.68	5.55	8.09
DC6LYSZ	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.19	7.25	3.6	10.4
DCKAVL0	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.47	4.27	6.51	8.49
DC695SI	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	10.88	5.97	4.14	12.93
DCWD8MG	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.99	6.77	6.28	9.22
DCTPF96	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	11.5	13.52	6.95	16.52
DC0LVD6	DMJ7NVI	BIO-300	Phase 1/2	19	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.68	2	6.47	7.24
DCHGMVY	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.55	8.04	13.01	14.66
DC2H6RF	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.94	8.76	7.6	11.98
DCKF2UC	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.24	3.23	6.14	8.07
DCVUWZR	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	6.39	6.46	11.46	12.73
DCMNLLX	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.29	5.67	0.56	7.78
DCNY6M6	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	4.13	5.94	7.79	9.92
DCG3C0E	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	9.47	8.54	4.83	11.31
DC88QBP	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.3	6.8	15.85	16.05
DCQEZGP	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.99	5.37	5.17	8.96
DCHXL81	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.78	1.2	5.04	6.3
DC2X6UN	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2	1.38	2.07	4.22
DCPD3VR	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	8.37	10.04	2.39	10.15
DC1L7KJ	DMJ7NVI	BIO-300	Phase 1/2	19	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.08	5.21	9.5	11.91
DC9EGLF	DMJ7NVI	BIO-300	Phase 1/2	19	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.31	6.18	4.44	6.45
DC0IG6W	DMJ7NVI	BIO-300	Phase 1/2	19	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.84	8.81	6.15	8.66
DCXBE5R	DMJ7NVI	BIO-300	Phase 1/2	19	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.28	6.71	3.91	7.6
DCHB5ZM	DMJ7NVI	BIO-300	Phase 1/2	19	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.02	2.82	1.88	3.54
DCL4XN1	DMJ7NVI	BIO-300	Phase 1/2	19	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.68	9.13	7.32	9.41
DCEC6CR	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	11.81	11.59	7.18	15.13
DC2VSQR	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	13.18	11.66	9.35	13.18
DC3D7EE	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.18	7.4	15.78	17.4
DC01CJE	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.44	1.57	1.03	1.97
DCXWR0K	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.69	5.77	12.66	13.75
DCMOWA4	DMJ7NVI	BIO-300	Phase 1/2	19	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.02	1.71	0.9	1.43
DCTZOEG	DMJ7NVI	BIO-300	Phase 1/2	19	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.15	2.45	4.86	5.07
DC1AWWZ	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.72	0.99	3.51	5.12
DCHFT5A	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.97	4.4	6.29	8.52
DCP5DUS	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.38	3.05	5.48	6.16
DCFK8FY	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.4	6.42	9.14	9.57
DCMTA8T	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.05	5.34	6.78	8.09
DCFJ0X6	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	11.26	9.61	10.37	13.16
DCJ5PU4	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.22	0.12	0.95	4.74
DCB8VR3	DMJ7NVI	BIO-300	Phase 1/2	19	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.26	6.67	8.49	10.57
DC4HJO5	DMJ7NVI	BIO-300	Phase 1/2	19	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.71	2.59	0.42	6.15
DC5NOK7	DMJ7NVI	BIO-300	Phase 1/2	19	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.18	4.59	2.73	6.19
DCV4AKS	DMJ7NVI	BIO-300	Phase 1/2	19	DMUOT9V	Taxol	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.94	3.45	1.57	5.03
DCFH5WA	DMJ7NVI	BIO-300	Phase 1/2	19	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.81	6.19	4.43	7.77
DCPOU65	DMJ7NVI	BIO-300	Phase 1/2	19	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.91	0.66	0.89	3.31
DCLX5S7	DMJ7NVI	BIO-300	Phase 1/2	19	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.35	3.05	1.6	5.04
DCU4095	DMJ7NVI	BIO-300	Phase 1/2	19	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.52	7.01	6.48	10.23
DC2PFJ1	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.71	7.64	0.24	4.01
DCWXCSR	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.81	2.53	1.73	4.54
DC6M8RY	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.02	5.65	2.55	7.38
DCXUHPA	DMJ7NVI	BIO-300	Phase 1/2	19	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.63	2.63	1.22	2.78
DCEKSI9	DMJ7NVI	BIO-300	Phase 1/2	19	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.57	5.46	5.36	6.02
DCCPLYU	DMJ7NVI	BIO-300	Phase 1/2	19	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.32	2.47	4.87	4.91
DCNZHJN	DMJ7NVI	BIO-300	Phase 1/2	19	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	2.83	1.18	1.83	4.17
DCL1PJS	DMJ7NVI	BIO-300	Phase 1/2	19	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.96	2.52	1.87	2.08
DCGSYTI	DMJ7NVI	BIO-300	Phase 1/2	19	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	4.18	4.11	5.78	6.86
DCE8X2P	DMJ7NVI	BIO-300	Phase 1/2	19	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.04	3.43	1.47	1.61
DC77HVF	DMJ7NVI	BIO-300	Phase 1/2	19	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.05	2.23	1.98	2.33
DCRAYZY	DMJ7NVI	BIO-300	Phase 1/2	19	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.47	3.16	3.84	4.19
DCRSA7X	DMJ7NVI	BIO-300	Phase 1/2	19	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.78	1.48	0.76	1.22
DCKN3I1	DMJ7NVI	BIO-300	Phase 1/2	19	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.18	4.06	2.76	4.5
DCA30Q9	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.33	1.23	0.48	0.93
DC3E4W4	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	14.15	12.01	9.74	11.62
DCHJT6E	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	5.33	4.29	2.48	3.49
DCHNQ7W	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.86	5.61	4.62	5.8
DCOJNRP	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.85	8.71	6.78	8.47
DCPJF4L	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	6.75	8.33	7.14	8.66
DCISHQ1	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.12	5.64	4.8	5.11
DCWXY1W	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.57	2.82	2.58	2.37
DCJAVAP	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.68	4.67	1.18	4.04
DCYQ0GZ	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.6	2.2	2.13	3.16
DCM0U34	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	20.05	15.31	14.05	15.29
DCYA10P	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	24.13	20.95	19.7	21.56
DCXKT7Y	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1	6.75	4.51	5.95
DCCPD8T	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.54	7.27	4.87	6.07
DCPL41U	DMJ7NVI	BIO-300	Phase 1/2	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.98	3.47	2.15	3.39
DC2TBK7	DMJ7NVI	BIO-300	Phase 1/2	19	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.22	2.58	0.63	2.65
DCJHVZN	DMJ7NVI	BIO-300	Phase 1/2	19	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	7.21	7.99	5.2	11.18
DCNJEOO	DMJ7NVI	BIO-300	Phase 1/2	19	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	6.51	7.68	3.81	7.42
DCCO1N2	DMJ7NVI	BIO-300	Phase 1/2	19	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	7.09	7.28	4.01	7.67
DCK8ZIQ	DMJ7NVI	BIO-300	Phase 1/2	19	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6.07	8.49	3.27	10.83
DC2X8X2	DMJ7NVI	BIO-300	Phase 1/2	19	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	9.1	11.07	4.29	10.47
DCF4HT3	DMJ7NVI	BIO-300	Phase 1/2	19	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	4.97	6.29	3.88	6.71
DCCTYAE	DMJ7NVI	BIO-300	Phase 1/2	19	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	6.51	10.73	8.14	12.82
DCF7I4X	DMJ7NVI	BIO-300	Phase 1/2	19	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	6.76	6.49	6.46	8.85
DC2VFDK	DMJ7NVI	BIO-300	Phase 1/2	19	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.59	0.72	4.42	8.27
DCJ61CR	DMJ7NVI	BIO-300	Phase 1/2	19	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	4.81	3.26	1.02	3.87
DC5D23N	DMJ7NVI	BIO-300	Phase 1/2	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	8.38	8.36	10.02	11.61
DCUT44M	DMJ7NVI	BIO-300	Phase 1/2	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.02	3.41	1.48	4.93
DCPOR2U	DMJ7NVI	BIO-300	Phase 1/2	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	3.49	4.48	0.14	5.81
DCFVENL	DMJ7NVI	BIO-300	Phase 1/2	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.61	6.67	3.34	8.02
DC092YK	DMJ7NVI	BIO-300	Phase 1/2	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.07	3	2.32	7.53
DCKJA31	DMJ7NVI	BIO-300	Phase 1/2	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	7.6	9.63	5.12	9.96
DCJO46J	DMJ7NVI	BIO-300	Phase 1/2	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	7.21	7.31	6.68	9.63
DC3NJDN	DMJ7NVI	BIO-300	Phase 1/2	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	4.91	8.83	4.14	11.3
DCMYYYV	DMJ7NVI	BIO-300	Phase 1/2	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	3.45	5.19	1.64	7.06
DCMZIJC	DMJ7NVI	BIO-300	Phase 1/2	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.23	4.65	1.83	5.37
DCD6IZY	DMJ7NVI	BIO-300	Phase 1/2	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.96	4.54	7.16	9.95
DC2OKSY	DMJ7NVI	BIO-300	Phase 1/2	19	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.91	3.17	2.59	6.24
DC6HI5B	DMJ7NVI	BIO-300	Phase 1/2	19	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.29	6.12	1.49	6.87
DC0YS05	DMJ7NVI	BIO-300	Phase 1/2	19	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	7.43	6.45	3.74	9.37
DCEH5U0	DMJ7NVI	BIO-300	Phase 1/2	19	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.15	5.9	2.47	7.56
DC3GFBR	DMJ7NVI	BIO-300	Phase 1/2	19	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.83	5.43	3.68	6.55
DCS0PHK	DMJ7NVI	BIO-300	Phase 1/2	19	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	10.27	11.7	6.65	11.8
DCWH348	DMJ7NVI	BIO-300	Phase 1/2	19	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4.01	3.65	1.88	4.41
DCJ3UJW	DMJ7NVI	BIO-300	Phase 1/2	19	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	6.73	4.94	2.3	6.24
DCHBFZJ	DMJ7NVI	BIO-300	Phase 1/2	19	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	8.13	9.1	9.27	11.36
DCKRB3O	DMJ7NVI	BIO-300	Phase 1/2	19	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.02	0.74	2.09	5.54
DC7Q019	DMJ7NVI	BIO-300	Phase 1/2	19	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.77	3.56	1.68	6.27
DCH0KN3	DMJ7NVI	BIO-300	Phase 1/2	19	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.91	1.76	1.65	5.89
DCLN95I	DMJ7NVI	BIO-300	Phase 1/2	19	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.46	5.27	5.3	7.67
DC7NHFT	DMJ7NVI	BIO-300	Phase 1/2	19	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.15	5.12	2.7	8.31
DCKJFKI	DMJ7NVI	BIO-300	Phase 1/2	19	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.64	8.46	1.29	9.74
DCXU6PL	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	8.04	8.61	4.01	9.17
DCZSMOV	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.81	3.02	0.65	3.33
DC40WK2	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	9.88	12.34	7.54	12.36
DCRR8LE	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.14	8.01	3.01	5.97
DCHC6KU	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	8.38	11.96	2.16	10.53
DCZ79WG	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	5.89	17.89	17	18.52
DCCHU7S	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	13.79	15.18	9.91	15.13
DCCSPKE	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	7.55	11.97	0.04	11.47
DC0MTIG	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	28.11	27.89	18	28.67
DC08JHV	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	10.97	13.97	7.5	15.68
DCO83MT	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	16.95	18.06	9.45	17.26
DCC292B	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	11.12	16.26	13.99	15.36
DCD4EFB	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.18	11.29	0.24	10.64
DC0PY6R	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.35	7.84	4.25	7.22
DCHWEXJ	DMJ7NVI	BIO-300	Phase 1/2	19	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.83	6.7	0.21	6.53
DC2NGZC	DMJ7NVI	BIO-300	Phase 1/2	19	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	7.51	9.63	0.48	10.81
DC3681I	DMJ7NVI	BIO-300	Phase 1/2	19	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.61	2.12	2.28	6.85
DC3AQBQ	DMJ7NVI	BIO-300	Phase 1/2	19	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.11	4.8	0.65	5.88
DCVE6FS	DMJ7NVI	BIO-300	Phase 1/2	19	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	4.68	4.22	0.08	4.8
DCPVFSW	DMJ7NVI	BIO-300	Phase 1/2	19	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	8.12	8.07	2.79	8.52
DC2P7ZH	DMJ7NVI	BIO-300	Phase 1/2	19	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	9.17	7.2	2.85	9.31
DCFDNOR	DMJ7NVI	BIO-300	Phase 1/2	19	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.44	6.91	4.27	8.78
DCWJSDT	DMJ7NVI	BIO-300	Phase 1/2	19	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.49	3.19	1.92	4.78
DCRC62Y	DMJ7NVI	BIO-300	Phase 1/2	19	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.79	7.45	3.9	8.71
DCSUQJG	DMJ7NVI	BIO-300	Phase 1/2	19	DMAE6LK	Topetecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.67	5.97	2.14	5.97
DCWUKGQ	DMJ7NVI	BIO-300	Phase 1/2	19	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.25	6.89	5.34	6.37
DCQP1PZ	DMJ7NVI	BIO-300	Phase 1/2	19	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.03	3.15	6.53	8.24
DCKVELM	DMJ7NVI	BIO-300	Phase 1/2	19	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.49	3.93	3.03	8.12
DC8HW9K	DMJ7NVI	BIO-300	Phase 1/2	19	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.31	0.36	7.48	9.31
DCQ9NIE	DMJ7NVI	BIO-300	Phase 1/2	19	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.21	1.48	5.31	7.32
DC3SYXH	DMJ7NVI	BIO-300	Phase 1/2	19	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.82	1.05	0.97	1.11
DC5JUYU	DMJ7NVI	BIO-300	Phase 1/2	19	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.43	4.81	3.7	3.61
DC2KZN3	DMJ7NVI	BIO-300	Phase 1/2	19	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	5.74	6.85	6.32	6.22
DCMF0HK	DMJ7NVI	BIO-300	Phase 1/2	19	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.97	2.63	2.93	2.86
DCUZSPM	DMJ7NVI	BIO-300	Phase 1/2	19	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.05	2.35	1.37	4.53
DC1R7KU	DMJ7NVI	BIO-300	Phase 1/2	19	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.89	1.16	2.66	2.09
DCY20O5	DMJ7NVI	BIO-300	Phase 1/2	19	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.05	2.6	3.38	3.43
DCIG22O	DMJ7NVI	BIO-300	Phase 1/2	19	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.7	3.6	3.32	3.8
DCHLWY2	DMJ7NVI	BIO-300	Phase 1/2	19	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	9.62	10.79	8.28	10.54
DC9HPKT	DMJ7NVI	BIO-300	Phase 1/2	19	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	6.26	9.26	0.11	8.64
DCK9BM9	DMJ7NVI	BIO-300	Phase 1/2	19	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.39	5.42	2.22	6.86
DCY9GGF	DMJ7NVI	BIO-300	Phase 1/2	19	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.78	5.22	1.67	5.89
DCG1HEZ	DMJ7NVI	BIO-300	Phase 1/2	19	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.72	0.77	5.4	7.67
DCP6UZN	DMJ7NVI	BIO-300	Phase 1/2	19	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.26	5.9	6.4	10.67
DCUD45U	DMJ7NVI	BIO-300	Phase 1/2	19	DMDI269	Docetaxel	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.72	0.71	0.81	5.33
DCKA2C3	DMJ7NVI	BIO-300	Phase 1/2	19	DMDI269	Docetaxel	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.17	0.94	2.23	5.37
DC0CIWW	DMJ7NVI	BIO-300	Phase 1/2	19	DMDI269	Docetaxel	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.71	2.09	4.37	7.5
DCHCNQ2	DMJ7NVI	BIO-300	Phase 1/2	19	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.42	5.3	3.24	6
DCUUA2Q	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.89	4.38	0.6	6.01
DCPSVKC	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.1	4.65	2.56	6.47
DCTI5RQ	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.67	0.96	0.6	6.04
DC6BYV9	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	5.15	7.06	0.22	7.79
DCP9C07	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	10.56	9.03	9.98	12.54
DCRXGG7	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	11.35	10.08	11.89	13.99
DCCIQPG	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.24	0.96	4.42	6.89
DC9PG7A	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	11.26	10.72	8.25	13.5
DCYUDI0	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	10.59	11.61	13.29	15.17
DCZGLTG	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	11.72	13.15	10.12	14.98
DCEHGSK	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.29	6.44	3.33	9.01
DC7UDR7	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	11	13.96	11.67	16.01
DCR1YRN	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	8.65	8.7	6.79	11.3
DCBZVS8	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	14.88	9.49	5.19	11.28
DCZIBN3	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	6.99	9.65	8.44	12.17
DCKW0CO	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	26.59	24.98	21.07	26.15
DCIADZT	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.31	8.75	10.69	13.21
DCNSDSE	DMJ7NVI	BIO-300	Phase 1/2	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	7.64	10.22	12.83	15.37
DCT15VG	DMJ7NVI	BIO-300	Phase 1/2	19	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.78	6.19	7.77	10.34
DCF0A6T	DMJ7NVI	BIO-300	Phase 1/2	19	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.61	4.91	7.09	8.23
DC1DK3X	DMJ7NVI	BIO-300	Phase 1/2	19	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.67	2.7	7.48	8.9
DCCAY37	DMJ7NVI	BIO-300	Phase 1/2	19	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.69	1.64	3.3	5.98
DC6UEVU	DMJ7NVI	BIO-300	Phase 1/2	19	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.98	3.09	7.23	8.03
DCJ6TTC	DMJ7NVI	BIO-300	Phase 1/2	19	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.16	2.82	6.64	8.2
DCQ0G4R	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.36	6.73	2.84	6.65
DC8UW9E	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.17	0.05	1.35	5.71
DC99OM9	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.84	4.93	9.6	11.6
DCUMBOY	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	4.25	3.86	5.58	8.43
DC8UR2A	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.6	0.05	5.34	7.75
DCBS2XT	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.86	3.47	6.23	9.04
DCSYNTH	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.33	5.86	7.71	9.95
DCXFEUU	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.36	3.53	7.3	9.06
DC60XUB	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.26	7.77	2.01	5.93
DCJEZ1L	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	5.03	6.34	2.59	8.64
DCV2GF9	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.92	3.67	0.31	3.51
DC1PGU8	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.25	6.26	9.76	11.73
DCO4IBL	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.66	3	1.11	3.39
DCW5TCI	DMJ7NVI	BIO-300	Phase 1/2	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.67	9.08	6.71	13.12
DCJHDKD	DMJ7NVI	BIO-300	Phase 1/2	19	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.98	3.11	8.41	10.24
DCNWRYK	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.41	1.22	1.32	4.02
DCHFU0K	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.97	0.64	2.66	5.06
DCJD0ZV	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.23	7.6	2.97	8.73
DCGOJZY	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.61	7.5	4.54	6.03
DC2XQ4V	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.25	1.35	3.04	5.4
DC02LQJ	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	7.22	7.18	0.82	8.59
DC5UODE	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.75	8.11	6.63	9.62
DCNMFBQ	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.39	5.09	6.36	11.3
DC2V4N8	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.13	6.57	6.97	10.55
DCDRQ84	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.51	5.71	2.18	7.65
DCOL82I	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.59	13.34	4.46	11.88
DC89RYT	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.62	3.35	1.8	4.36
DCFMH6V	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.34	4.77	7.81	10.14
DC5FV8H	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.19	4.88	1.77	7.94
DCPYXFO	DMJ7NVI	BIO-300	Phase 1/2	19	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.35	3.8	2.91	6.91
DCAEIHX	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.19	9.18	7.88	9.48
DCT0YWC	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.8	8.78	8.13	11.01
DCKPBVF	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.86	5.84	0.31	8.08
DC6IXPW	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	9.46	9.58	3.57	8.47
DCA8125	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	13.76	11.75	7.75	10.73
DCNF0QM	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.86	4.15	5.72	8.15
DC6DSUS	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	9.25	11.85	8.68	14.18
DCSUW6Q	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.38	4.51	0.31	3.94
DCVFN7D	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	5.36	9.23	4.5	8.57
DCWMU5H	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	12.34	10.26	2.86	8.22
DC0DFK4	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	7.69	5.5	4.1	5.75
DCP5CBG	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.51	8.42	6.3	9.75
DC3M762	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.94	8.81	9.36	9.66
DCQCZ2Q	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.47	2.33	3.11	7.13
DC7MK4Y	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	4.42	4.46	4.89	7.57
DCX2L4H	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.03	3.94	0.59	3.38
DCGKVQS	DMJ7NVI	BIO-300	Phase 1/2	19	DMINOX3	Vincristine	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	6.26	7.23	3.7	6.75
DCZLHXP	DMJ7NVI	BIO-300	Phase 1/2	19	DMKLAYG	Altretamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	4.86	8.4	5.41	8.09
DC1XWMT	DMJ7NVI	BIO-300	Phase 1/2	19	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	12.57	13.01	6.66	12.99
DCCNCMD	DMJ7NVI	BIO-300	Phase 1/2	19	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	5.04	13.07	8.89	12.52
DC2JRFI	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.3	3.56	0.72	5.36
DC85IU0	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2	3.1	2.25	5.81
DC9OOHQ	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.15	1.82	6.15	8.63
DCSDYQA	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.94	0.06	1.81	7.17
DCSFYUI	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.63	3.81	1.25	3.75
DC13147	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	5.58	7.32	6.74	11.32
DCTO54C	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.46	2.26	5.8	7.2
DC0OCST	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	9.28	10.4	5.82	11.58
DCWPQXH	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	7.76	8.59	7.34	11.63
DC6NCGE	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.67	5.07	1.86	8.08
DCRZPG9	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.7	6.68	2.23	9.67
DC2JP98	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.83	3.08	5.06	7.67
DCS8V89	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.75	1.75	4.11	6.9
DCMXPAB	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.8	4.11	3.16	9.08
DCZSDMS	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	12.08	11.46	8.9	15.84
DC4VNHN	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.49	7.76	11.75	13.72
DCJNYPK	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.42	4.31	11.26	13.73
DC01PE4	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.7	7.05	0.72	2.41
DCWAAN5	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.62	3.98	3	8.38
DCFOYZN	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.47	5.07	3.2	7.91
DC43L41	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.62	1.31	5.07	9.43
DCPTKQN	DMJ7NVI	BIO-300	Phase 1/2	19	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.73	2.28	2.06	3.84
DCU17JE	DMJ7NVI	BIO-300	Phase 1/2	19	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.96	1.1	1.84	1.81
DCXLV26	DMJ7NVI	BIO-300	Phase 1/2	19	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.75	3.19	3.99	5.02
DCRMZIA	DMJ7NVI	BIO-300	Phase 1/2	19	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.21	4.4	3.93	3.57
DCEYLUJ	DMJ7NVI	BIO-300	Phase 1/2	19	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.02	1.18	0.01	0.54
DCAXV8X	DMJ7NVI	BIO-300	Phase 1/2	19	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.73	7.33	7.12	7.79
DC302LL	DMJ7NVI	BIO-300	Phase 1/2	19	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.76	1	0.32	3.52
DCY7NT1	DMJ7NVI	BIO-300	Phase 1/2	19	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	4.34	6.25	9.76	11.14
DCH6ZD9	DMJ7NVI	BIO-300	Phase 1/2	19	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.96	8.77	9.03	10.44
DCIT2P9	DMJ7NVI	BIO-300	Phase 1/2	19	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.85	0.92	4	6.81
DC956IJ	DMJ7NVI	BIO-300	Phase 1/2	19	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.82	3.99	0.73	4.7
DC9X6AJ	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.55	5.34	1.34	7.78
DCR5CSJ	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.8	3.41	3.54	5.28
DCBXWXZ	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	5.57	5.07	5.95	8.81
DCT163G	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.47	5.83	3.9	8.88
DC1CJ3X	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	8.69	5.99	6.88	8.13
DCVZVBH	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.3	3.47	0.57	2.47
DC0LN5S	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	7.09	4.79	1.69	7.67
DCHVCB8	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.54	3.96	1.12	6.37
DCOS77K	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.18	3.13	4.72	6.98
DCB98A5	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.89	1.14	1.28	3.68
DC3RG73	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	7.57	8.1	6.12	11.52
DC2UGGL	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	4.87	5.14	4.83	8.94
DC8Q8IO	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.7	5.47	7.94	9.82
DCX1PHR	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.34	2.1	3.42	6.49
DCZ4X21	DMJ7NVI	BIO-300	Phase 1/2	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.95	4.09	5.2	7.33
DCZ2CU0	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	6.19	5.92	3.32	7.82
DCXULNA	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.59	4.84	2.48	6.72
DCHHI9X	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.32	1.54	0.9	3.98
DCCKDZN	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.44	2.74	2.27	2.95
DCTAMYK	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.55	2.06	1.23	2.35
DCTILGH	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.21	4.33	3.43	7.72
DCAIDTE	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.53	7.32	3.38	7.32
DCBCP7G	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	4.86	7.12	8.75	10.34
DCIQFVP	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.04	0.14	3.84	4.6
DCHOUL0	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.69	4.01	5.36	8.82
DCR6JDE	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	24.17	21.93	23.33	25.31
DCLX41I	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	5.69	6.42	5.63	8.99
DCYRSEC	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	4.37	4.47	4.59	8.18
DC3SKS0	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.03	2.73	3.46	6.16
DCWOBRV	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.82	6.09	3.15	8.49
DCSZ5OY	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	8.1	5.78	8.24	9.05
DC09J6O	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.74	1.16	0.15	3.44
DC5Z8OO	DMJ7NVI	BIO-300	Phase 1/2	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	10.04	10.28	6.45	14.48
DCLRY2X	DMJ7NVI	BIO-300	Phase 1/2	19	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.98	6.78	0.61	8.12
DC3ZGZ4	DMJ7NVI	BIO-300	Phase 1/2	19	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.69	6.25	2.08	5.5
DCT4NGN	DMJ7NVI	BIO-300	Phase 1/2	19	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.22	4.43	1.07	7.71
DC8BIDD	DMJ7NVI	BIO-300	Phase 1/2	19	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.29	4.14	2.62	4.51
DCAJO7H	DMJ7NVI	BIO-300	Phase 1/2	19	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.63	1.83	0.45	2.6
DCFPX4H	DMJ7NVI	BIO-300	Phase 1/2	19	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	6.69	5.2	4.6	8.46
DC4W9SH	DMJ7NVI	BIO-300	Phase 1/2	19	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.24	3.43	1.98	7.53
DC2XE67	DMJ7NVI	BIO-300	Phase 1/2	19	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.83	6.27	1.91	5.23
DC66OAN	DMJ7NVI	BIO-300	Phase 1/2	19	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.64	1.13	1.46	4.36
DCWPD51	DMJ7NVI	BIO-300	Phase 1/2	19	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	7.3	8.7	1.41	10.34
DC8O7QJ	DMJ7NVI	BIO-300	Phase 1/2	19	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.92	4.11	4.83	6.56
DCUNE2M	DMJ7NVI	BIO-300	Phase 1/2	19	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	6.9	5.48	5.27	7.71
DCXZUCT	DMJ7NVI	BIO-300	Phase 1/2	19	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.77	2.91	4.24	6.45
DCN4156	DMJ7NVI	BIO-300	Phase 1/2	19	DMUOT9V	Taxol	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.2	2.89	3.19	7.43
DC8B9L6	DMJ7NVI	BIO-300	Phase 1/2	19	DMUOT9V	Taxol	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	8.31	7.78	3.21	10.07
DCZSWWZ	DMJ7NVI	BIO-300	Phase 1/2	19	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.42	1.51	2.96	4.73
DC4OXY5	DMJ7NVI	BIO-300	Phase 1/2	19	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.7	1.94	2.47	4.31
DCPPIGR	DMJ7NVI	BIO-300	Phase 1/2	19	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.93	5.31	9.02	10.85
DC30VDR	DMJ7NVI	BIO-300	Phase 1/2	19	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.77	4.97	4.71	7.47
DC5PNL2	DMJ7NVI	BIO-300	Phase 1/2	19	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.93	3.33	1.18	4.6
DCHZ7S5	DMJ7NVI	BIO-300	Phase 1/2	19	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.51	5.81	1.6	6.13
DCARRH9	DMJ7NVI	BIO-300	Phase 1/2	19	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2	0.79	2.28	5.35
DCW0C82	DMJ7NVI	BIO-300	Phase 1/2	19	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.8	0.59	1.32	2
DCVKUMI	DMJ7NVI	BIO-300	Phase 1/2	19	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.01	4.19	1	6.24
DCN15US	DMJ7NVI	BIO-300	Phase 1/2	19	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.5	7.86	6.67	7.71
DCPUSEZ	DMJ7NVI	BIO-300	Phase 1/2	19	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.64	3.36	1.46	3.44
DCC9OE8	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1	3.98	3.91	7.26
DCFAFY8	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.06	3.92	2.96	9.15
DCMFWE6	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	6.65	6.67	5.3	8.96
DCE383Q	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	5.92	10.16	1.91	8.52
DCPF31O	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.68	2.38	0.62	4.78
DCRWLX7	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.95	2.4	2.15	6.27
DCG8YBB	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.03	3.35	1.36	5.79
DC9CZZH	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4.27	4.01	8.44	10.99
DCLQJR5	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.24	6.09	8.15	10.42
DCAR7DA	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.53	4.81	1.9	9.16
DCQWASF	DMJ7NVI	BIO-300	Phase 1/2	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.38	3.69	1.49	5.96
DC01Y4T	DMLYGH4	MK-4827	Phase 3	25	DMP6SC2	Irinotecan	Approved	34	.	.	.	.	Metastatic Solid Tumor	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCN401R	DMLYGH4	MK-4827	Phase 3	25	DMP6SC2	Irinotecan	Approved	34	.	.	.	.	Ewing Sarcoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCNCXJ9	DMLYGH4	MK-4827	Phase 3	25	DMRJLAT	Osimertinib	Approved	34	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCD723T	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	16.6	16.31	20.36	21.47
DC386N8	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	13.15	12.57	14.05	14.73
DCQOSV7	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	13.53	17.2	19.75	20.46
DC8BGNB	DMLYGH4	MK-4827	Phase 3	25	DME9QGW	Marizomib	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	1.04	1.06	2.89	4.08
DCFE32M	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	1.19	2.31	0.02	3.64
DC2D9RP	DMLYGH4	MK-4827	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	7.54	7.54	20.69	20.71
DCNCD2R	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.08	3.79	8.6	9.75
DCS4G54	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	0.57	0.76	2.26	3.69
DCU6HS1	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	12.59	12.37	19.55	21.07
DC84CA9	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	18.16	18.1	23.35	24.58
DCN7SGM	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	6.93	6.67	15.89	17.99
DC87O78	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	12.07	11.68	15.62	17.53
DCKIE1M	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	17.6	14.69	20.14	22.3
DCEELWL	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	6.18	6.35	14.68	16.57
DCZIJID	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	16.23	15.98	20.11	22.19
DC2MZW9	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.11	1.07	11.75	12.5
DCK01CR	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	5.4	4.08	11.46	12.88
DCP62QP	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	6.09	5.83	12.27	13.67
DCM5A9G	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	23.26	23.21	23.77	25.9
DC0MC7G	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	17.01	16.17	20.18	20.87
DCUNSD2	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	5.51	2.77	4.66	3.15
DC8BAL5	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.26	3.4	6.54	10.58
DC54IHN	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	0.28	1.01	4.1	10.66
DCU2Y1O	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.19	0.26	6.61	8.59
DCDZ94E	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.11	1.45	8.35	9.61
DCU5P5B	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	11.46	10.17	15.78	16.57
DCQGSFQ	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.73	3.27	5.88	6.27
DC3QOO0	DMLYGH4	MK-4827	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.66	2.59	7.94	9.18
DCSAYP9	DMLYGH4	MK-4827	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	9.44	11.14	13.72	15.64
DCL7X4H	DMLYGH4	MK-4827	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.34	4.28	6.05	10.69
DCSYC51	DMLYGH4	MK-4827	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.81	3.08	2.56	9.34
DC863YI	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	0.46	0.05	7.73	12.34
DC7HYCK	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.91	2.66	6.48	8.47
DCA9DX4	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.02	4.19	0.59	7.66
DCJ44T6	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	5.16	0.97	6.6	7.9
DC6Z2I9	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.49	3.12	9.04	10.97
DCYZGOT	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	7.03	6.83	11.18	12.33
DC2ROHE	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	4.24	3.54	3.62	4.59
DCQIQ79	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2	4.48	5.73	6.92
DC0XGVK	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.56	7.75	4.3	8.53
DCN643W	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.13	1.35	4.16	4.73
DCZDKU8	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.27	1.32	0.24	3.17
DCPRVAD	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.37	2.63	1.8	4.61
DCDUHPX	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	1.47	0.13	4.07	7.98
DCWNYY8	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	5.99	4.47	3.27	5.21
DCD43IB	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.34	2.61	3.75	6.46
DCCLN9V	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.33	0.49	4.9	7.57
DCCLJF5	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.82	2.12	1.77	6.36
DCGQXQR	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.81	0.36	0.64	2.67
DC4ZUBL	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.17	3.23	3.64	7.57
DC42T8R	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.76	8.75	9.94	11.72
DCBPG0V	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	7.57	7.18	8.53	10.33
DCIAR1N	DMLYGH4	MK-4827	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.27	3.64	3.43	6.12
DCJLCYS	DMLYGH4	MK-4827	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	7.77	7.63	11.01	14.31
DCYM93L	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.01	2.79	8.58	9.78
DCPTORE	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.74	4.16	7.62	8.94
DCV7SVS	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	6.35	5.45	4.43	16.67
DCQZ56N	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	4.19	4.14	6.77	8.91
DC9E34I	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.01	3.49	8.44	11.76
DC9P8WI	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	5.96	6.09	12.51	15.62
DCTXXJY	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	4.18	5.07	6.62	10.03
DCHLX3E	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.44	3.28	0.97	2.67
DCULKBQ	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.13	0.37	0.93	4.24
DCF8BJ9	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.62	4.6	5.32	7.34
DC0BHMF	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	10.62	11.14	11.54	14.57
DC6CQGY	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	5.56	4.89	5.52	6.79
DC4CE3X	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	5.69	5.45	10.63	11.64
DC46UW6	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	4.25	3.83	7.07	10.95
DCGZ38Z	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.78	0.63	4.64	6.93
DC9V27I	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.14	0.37	6.32	8
DC8SFSF	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	0.18	0.05	5.4	6.46
DCDU05D	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.75	3.89	9.98	11.02
DC73NTU	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.03	5.02	12.6	13.92
DCRA69Y	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	12.69	12.32	16.89	17.95
DC41PDY	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	13.02	12.66	19.19	20.44
DCDD7TA	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	5.3	5.19	10.89	12.06
DCXJT2O	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	35.27	29.61	30.11	31.31
DCVSPSC	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	10.52	10.1	16.03	17.53
DCFMSGR	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	20.98	18.1	21.5	23.84
DCLO61D	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	16.13	15.19	15.29	16.35
DCP3DTI	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	12.48	12.14	14.24	15.96
DCGIHIB	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.16	2.09	2.15	2.43
DC2I1PQ	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	9.81	9.29	16.04	17.25
DC0SQ46	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	19.34	19.52	23.76	25.01
DCMIY7Q	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	18.23	18.07	20.71	22.87
DCE28IL	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	18.34	17.67	21.99	23.55
DCC4HKB	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.51	5.31	8.47	8.32
DC1SLZC	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	15.69	15.6	19.51	20.46
DC5ENSD	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	18.29	11.68	21.34	22.46
DCVFPMO	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	29.56	29.69	30.49	31.65
DCBT7KV	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	17.63	17.1	22.03	23.24
DCDIM50	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	16.54	15.64	15.6	17.09
DCGNDWF	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	38.66	36.6	37.44	39.61
DCTEKI5	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	19.16	18.51	20.92	22.02
DCICY6D	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	9.66	8.02	12.54	14.96
DCBA8UJ	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	17.13	16.75	22.96	23.97
DCMZVH6	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	15.82	14.89	21.45	23.63
DCCKFAM	DMLYGH4	MK-4827	Phase 3	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	15.04	16.13	15.82	16.93
DCJCNIO	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.45	1.95	12.83	13.51
DC2ECJ4	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.6	6.01	7.62	9
DCTHA6M	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	7.7	7	12.36	13.65
DC4K3HZ	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	1.38	0.31	1.42	2.01
DCIFKNW	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.31	2.02	6.69	8.01
DCLTPD7	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	8.18	9.12	8.96	9.53
DC8OA8H	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	5.31	7.13	9.17	9.97
DCCTRVY	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.48	1.12	7.64	8.59
DCYKMNN	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	2.24	6.91	12.5	14.05
DC1TZ3T	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	2.19	0.44	4.37	5.54
DCB1LP2	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.11	2.74	5.41	5.48
DC1DY7H	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	17.2	16.59	18.5	18.87
DC6MF7R	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	7.76	7.44	11.69	12.35
DCL5VYC	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.11	2.48	8.12	9.59
DCC65TQ	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	14.2	13.97	14.82	15.56
DCPFW2S	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.81	4.58	9.35	10.47
DC5NJSB	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	5.51	9.62	7.02	8.96
DCFLMGE	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	1.64	1.37	2.02	3.25
DC23HDQ	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	26.53	22.72	23.7	28.12
DCPYSTM	DMLYGH4	MK-4827	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	15.95	12.27	15.33	16.16
DCQEWFZ	DMLYGH4	MK-4827	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.07	6.04	6.92	9.88
DCZ9C5V	DMLYGH4	MK-4827	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.05	6.23	11.31	12.56
DCGTHLV	DMLYGH4	MK-4827	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	4.93	6.68	2.05	11.32
DCDYXZW	DMLYGH4	MK-4827	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	5.7	7.54	0.33	10.73
DCFT0CP	DMLYGH4	MK-4827	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.96	2.85	0.06	7.15
DCDVMON	DMLYGH4	MK-4827	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	0.17	3.21	1.16	5.97
DCN7Q9T	DMLYGH4	MK-4827	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	6.38	6	4.5	9.23
DCLCK79	DMLYGH4	MK-4827	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	0.99	4.01	8.35	10.1
DCYXQT0	DMLYGH4	MK-4827	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.47	5.07	7.97	10.38
DCY0W6B	DMLYGH4	MK-4827	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.81	0.54	2.12	7.6
DCB8GMJ	DMLYGH4	MK-4827	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	19.68	17.26	15.08	20.06
DC36PMW	DMLYGH4	MK-4827	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.76	6.87	10.35	14.14
DCMT4I4	DMLYGH4	MK-4827	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.52	4.93	7.25	6.97
DC979RX	DMLYGH4	MK-4827	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	0.73	11.69	9.31	10.46
DCIKDDC	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.17	1.24	0.88	2.07
DC0L2WK	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.71	3.59	3.37	4.02
DCHW25O	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	6.79	4.76	6.68	8.08
DCZZOHN	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	1.58	2.87	6.39	7.24
DCVNSN7	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	7.84	3.44	2.85	3.84
DCNL3AP	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.74	0.89	3.16	4.6
DCFNTKC	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	4.06	2.45	6.65	8.85
DCYAYYW	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	10.03	15.81	11.57	14.86
DCVFKNW	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.13	0.9	3.1	3.98
DCI0IQB	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.61	1.91	2	2.11
DC8VEIK	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.92	0.86	4.32	5.03
DCEKHIK	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.21	0.25	2.66	3.62
DC8ESVA	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	6.07	5.05	7.46	8.65
DCJT3AG	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	7.86	11.73	14.16	14.71
DCFXI48	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.1	6.2	7.82	8.01
DCBPB7L	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	3.3	2.91	5.55	6.21
DCCYUYS	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	10.18	15.45	15.13	15.9
DC96WY2	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.56	0.39	2.58	3.88
DC8Q5PN	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	1.95	3.83	5.06	5.36
DCX2XY6	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	17.55	14.54	13.72	15.45
DCJL92N	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	7.25	6.69	8.66	9.46
DCHMI4S	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	0.82	0.26	2.77	5.13
DCPDGB7	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.65	2.15	4.79	6.14
DCPGJ6F	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	7.14	6.96	15.05	17.2
DCWDV0K	DMLYGH4	MK-4827	Phase 3	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	10.87	16.48	12.37	15.43
DC64MA2	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.05	2	0.91	3
DCNPSKT	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.52	6.73	4.26	8.14
DCFVPZL	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	1.23	7.71	2.83	9.72
DCI85EV	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	2.18	4.97	2.34	5.54
DCTKCSW	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.52	2.21	1.48	4.98
DCW6IX0	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	1.96	6.71	3.23	7.05
DCZX6WL	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	3.36	4.82	0.3	6.38
DCKF7RE	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	1.88	2.07	0.1	4.5
DCFFX4H	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	5.16	5.74	0.54	7.15
DC05ILJ	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.03	2.15	0.94	3.82
DCYI9EL	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	9.11	13.45	3.01	12.9
DCHL0Z9	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.21	3.74	3.1	6.14
DCSZLAH	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	4.02	10.01	0.4	11.1
DCZ89NM	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.35	1.64	1.64	5.47
DCLTYOX	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	4.99	6.76	3.41	7.68
DC02439	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	0.72	1.65	2.03	3.91
DCXZMTP	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	14.95	15.09	13.63	16.87
DCXQHDR	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.81	8.92	5.03	7.92
DCRW6IB	DMLYGH4	MK-4827	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	8.82	8.75	9.52	12.87
DCO4EYL	DMLYGH4	MK-4827	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.71	3.96	3.23	4.44
DCQ2W8I	DMLYGH4	MK-4827	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.73	5.23	5.41	5.72
DCTX38O	DMLYGH4	MK-4827	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.01	1.69	2.43	2.04
DC4N6KT	DMLYGH4	MK-4827	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	0.15	8.43	7.83	9.71
DCFHQT6	DMLYGH4	MK-4827	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	2.42	1.75	2.92	3.96
DCI5OIV	DMLYGH4	MK-4827	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	17.88	17.27	17.53	19.83
DCPHRAI	DMLYGH4	MK-4827	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.54	6.23	14.04	16.38
DCLAI9Q	DMLYGH4	MK-4827	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.29	7.17	9.87	11.13
DCMN5NA	DMLYGH4	MK-4827	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	8.4	7.33	12.09	15.16
DCQYX7M	DMLYGH4	MK-4827	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	0.51	5.32	6.13	6.53
DCKEKRZ	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.68	5.76	6.16	8.68
DCYJPAY	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	11.21	9.65	5.75	3.26
DCHVOJ1	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	4.85	2.91	7.29	7.31
DCIJ729	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	2.95	3.92	2.87	4.75
DC7IGOZ	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	0.64	0.89	1.83	2.57
DCOT7Z5	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.07	3.06	7.6	9.65
DCKHXU2	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	3.2	2.36	6.59	9.65
DC9T68E	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	2.4	2.56	3.77	3.96
DCJXZK1	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	11.86	12	15.54	16.35
DC6N11M	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.6	5.16	5.4	5.39
DC3TKGF	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.75	2.21	6.16	7.29
DC3MNO2	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.37	4.31	5.51	7.23
DCAK7EM	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	6.11	10.98	6.68	9.92
DCBVNRF	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.94	5.44	7.65	7.71
DC7U5LQ	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	7.1	6.21	8.06	8.28
DCMUFUL	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	1.07	2.16	5.67	6.23
DCE5Z8I	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	6.04	9.54	12.51	12.54
DCST48U	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.74	3.08	4.41	6.43
DCHAPDI	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	8.05	7.71	8.96	9.09
DCMHL0J	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	12.42	15.66	15.45	17.33
DCO3GCK	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.85	5.16	10.07	12.44
DCT8R7N	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	16.23	14.74	13.91	16.19
DC5HA32	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	3.22	3.07	8.89	11.59
DCR1ZQO	DMLYGH4	MK-4827	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	5.27	10.16	5.34	8.31
DC2KGL8	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	7.41	5.53	8.52	9.93
DC2KWCJ	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.04	5.48	10.21	10.94
DCXW6ZW	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	4.87	2.82	6.82	8.01
DCAWLWZ	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	5.31	5.23	8.59	9.62
DCC5MW7	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	1.75	1.15	1.92	3.1
DCLDAS5	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	0.74	0.29	7.45	9.07
DC82E4Q	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	1.33	0.98	2.33	2.95
DC9WLZR	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	3.33	1.57	3.79	4.95
DC973KC	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.32	2.55	2.33	2.79
DCMP2NX	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.04	2.04	5.3	6.58
DCWOABF	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.63	0.42	4.67	5.59
DCCVM9I	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.11	5.79	6.29	7.41
DCWBS26	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	10.89	9.6	9.74	10.76
DCBTCDD	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	3.25	3.62	8.96	9.16
DCGG9NF	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	2.35	1.38	6.67	7.93
DC2JYBE	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	3.17	3.03	4.65	5.73
DCO84UU	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.08	0.01	5.91	6.37
DC3HB5O	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	15.16	15.04	15.77	17.65
DCY5P9Z	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	0.21	1.47	2.29	3.5
DC80YXF	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.97	5.7	11.51	13.15
DC6V2DG	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.91	0.78	4.93	6.23
DC7JVX4	DMLYGH4	MK-4827	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	3.46	4.54	4.7	5.49
DC5I8Y5	DMNO38U	Bortezomib	Approved	34	DMZ7XNQ	Tacrolimus	Approved	34	.	.	.	.	Acute Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCLECW6	DMNO38U	Bortezomib	Approved	34	DMYLOVR	Aciclovir	Approved	34	.	.	.	.	Non-Small Cell Lung Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC0H84Q	DMNO38U	Bortezomib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC0P7AH	DMNO38U	Bortezomib	Approved	34	DMP6SC2	Irinotecan	Approved	34	.	.	.	.	Adenocarcinoma of the Gastroesophageal Junction	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC1H6I8	DMNO38U	Bortezomib	Approved	34	DMWCQP4	Interferon alfa-2B	Approved	34	.	.	.	.	Melanoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC2Q6F4	DMNO38U	Bortezomib	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC31YGY	DMNO38U	Bortezomib	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC41Z69	DMNO38U	Bortezomib	Approved	34	DMSIVND	Hydroxychloroquine	Phase 3 Trial	25	.	.	.	.	Multiple Myeloma and Plasma Cell Neoplasm	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC9QK1T	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCA9OFS	DMNO38U	Bortezomib	Approved	34	DMQL8XJ	Decitabine	Approved	34	.	.	.	.	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCCF8S8	DMNO38U	Bortezomib	Approved	34	DMP6SC2	Irinotecan	Approved	34	.	.	.	.	Recurrent Squamous Cell Carcinoma of the Hypopharynx	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCFX0HE	DMNO38U	Bortezomib	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Medullary Thyroid Carcinoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCJ3MVB	DMNO38U	Bortezomib	Approved	34	DMVYRH2	Perifosine	Phase 1	17	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCM5FIW	DMNO38U	Bortezomib	Approved	34	DMS104F	Temsirolimus	Approved	34	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCSEHGD	DMNO38U	Bortezomib	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCTBJYN	DMNO38U	Bortezomib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCTXCEE	DMNO38U	Bortezomib	Approved	34	DMQNWRD	Oxaliplatin	Approved	34	.	.	.	.	"Unspecified Adult Solid Tumor, Protocol Specific"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCVI4CO	DMNO38U	Bortezomib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adult Nasal Type Extranodal NK/T-cell Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCWTM2A	DMNO38U	Bortezomib	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC9EWP3	DMNO38U	Bortezomib	Approved	34	DMGW1ID	Sirolimus	Phase 3	25	DMVRLT7	Fludarabine	DMZ7XNQ	Tacrolimus	Autologous Hematopoietic Stem Cell Transplant Recipient	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCZ3JDZ	DMNO38U	Bortezomib	Approved	34	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Mantle Cell Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCMNO4G	DMNO38U	Bortezomib	Approved	34	DM053KT	Aprepitant	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.47	4.47	5.4	5.48
DC8XXV0	DMNO38U	Bortezomib	Approved	34	DM05FXR	Meclofenamic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.97	2.97	3.36	3.36
DCYGIXH	DMNO38U	Bortezomib	Approved	34	DM09NGV	Ribavirin-TP	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.47	1.47	2.2	2.29
DCD5LYX	DMNO38U	Bortezomib	Approved	34	DM0KYI4	Mebutamate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.86	2.86	3.25	3.34
DCNLYV5	DMNO38U	Bortezomib	Approved	34	DM0QV1J	Baclofen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.67	2.67	3.01	3.1
DC0VEIK	DMNO38U	Bortezomib	Approved	34	DM0RKS4	Bepridil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.38	3.38	3.86	3.94
DCLCBWL	DMNO38U	Bortezomib	Approved	34	DM14NKM	Triiodothyronine	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.31	2.31	2.81	2.89
DCIM3TH	DMNO38U	Bortezomib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.02	1.02	2.76	2.84
DCZCD9Z	DMNO38U	Bortezomib	Approved	34	DM1AF5U	Acetazolamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.14	4.14	4.48	4.55
DC5B671	DMNO38U	Bortezomib	Approved	34	DM1AGXN	Paromomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.77	2.77	3.15	3.16
DCKQGQM	DMNO38U	Bortezomib	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	DrugCombDB Database	Investigative	L-1236	4.81	6.55	0.46	6.91
DCIPQZ2	DMNO38U	Bortezomib	Approved	34	DM2DMPO	Kanamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.76	1.76	2.34	2.43
DCH3HYX	DMNO38U	Bortezomib	Approved	34	DM2NUH3	Imipramine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.68	0.68	1.02	1.1
DCV5C9S	DMNO38U	Bortezomib	Approved	34	DM3P6V7	Furazolidone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.5	2.5	2.85	2.94
DCLL0OS	DMNO38U	Bortezomib	Approved	34	DM3VZJQ	Chlorphenesin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.49	4.49	4.72	4.81
DCUUZEP	DMNO38U	Bortezomib	Approved	34	DM3YG5P	GYKI-52466	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.49	0.49	0.77	0.81
DCZMU2D	DMNO38U	Bortezomib	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.55	1.55	3.63	3.7
DCLSSXO	DMNO38U	Bortezomib	Approved	34	DM51FY6	Tacrine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.94	2.94	3.26	3.33
DCPZNA5	DMNO38U	Bortezomib	Approved	34	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	1.7	0.97	1.92	2.5
DCHMJWR	DMNO38U	Bortezomib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.99	1.99	3.77	3.78
DCG0Y31	DMNO38U	Bortezomib	Approved	34	DM5IKUF	Dihydroergotamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.14	3.14	3.53	3.53
DC4J2HO	DMNO38U	Bortezomib	Approved	34	DM5SXUV	Repaglinide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.21	2.21	2.51	2.6
DCKKHPF	DMNO38U	Bortezomib	Approved	34	DM5UGDK	Mephenytoin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.24	3.24	3.64	3.72
DCOJ7RH	DMNO38U	Bortezomib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	8.54	9.21	4.52	11.13
DC5H25W	DMNO38U	Bortezomib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	2.56	1.38	2.17	3.14
DCTEXTR	DMNO38U	Bortezomib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	2.95	5.43	6.68	6.38
DCFRGCQ	DMNO38U	Bortezomib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.74	1.63	1.82	3.36
DC6DEBR	DMNO38U	Bortezomib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.26	4.78	3.82	6.5
DCCSUTB	DMNO38U	Bortezomib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	11.4	13.71	9.6	13.06
DCWQ15M	DMNO38U	Bortezomib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	1.38	1.77	0.66	2.88
DCKBIU2	DMNO38U	Bortezomib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	6.32	7.19	2.94	5.49
DCA36C5	DMNO38U	Bortezomib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	1.33	7.43	3.97	5.65
DCGHFRL	DMNO38U	Bortezomib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	0.41	0.45	0.44	3.35
DCNQWXX	DMNO38U	Bortezomib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	10.27	12.55	13.58	13.85
DCDJ6SM	DMNO38U	Bortezomib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	6.63	4.06	0.71	6.28
DC0L8U7	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	3.37	5.06	1.66	5.54
DCBK8GA	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	1.09	2.32	0.61	4.47
DCSFTSC	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	2.92	2.26	0.8	4.12
DCLY76B	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	6.17	5.87	2.51	8.05
DC2L65Q	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	8.7	4.87	2.4	7.18
DCPLSK1	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	6.32	5.64	5.71	7.29
DCNM42Y	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	10.57	9.34	6.15	9.76
DCAQPN8	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	4.12	4.3	0.97	5.56
DCQPRDL	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	2.71	3.21	0.8	4.4
DCIAOKW	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	3.42	3.34	1.04	4.28
DC3G3GI	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	5.32	5.55	3.86	6.83
DCT1GE7	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	8.12	6.73	2.3	6.08
DCYDPE0	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.85	5.78	4.33	7.63
DCVWF3Q	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	2.99	3.18	0.65	5.36
DCFFVJJ	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	4.56	1.52	2.38	4.95
DCJNC0Q	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	3.7	2.03	1.95	4.15
DCY31ZI	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	4.65	4.6	0.87	6.59
DCIT67R	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	3.37	4.18	0.82	5.2
DC2CZ8K	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	5.45	5.66	0.99	5.77
DCW0A6Z	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	3.17	3.62	3.22	6.7
DCSZE8Y	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	15.15	13.4	9.45	15.31
DCJL801	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	3.66	2.38	1.4	5.78
DCI62GE	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	9.01	7.66	6.29	10.65
DC04K35	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	4.26	4.4	4.67	8.39
DC01W81	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	6.91	6.43	6.55	9.59
DCDWELD	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	3.67	3.91	0.27	5.88
DC0X7LK	DMNO38U	Bortezomib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	2.47	0.58	1.23	2.02
DCPF8O1	DMNO38U	Bortezomib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	12.69	12.25	8.38	12.01
DCDSJ6X	DMNO38U	Bortezomib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	1.52	3.1	0.58	3.85
DCODT70	DMNO38U	Bortezomib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	7.58	9.2	4.08	7.41
DCB4552	DMNO38U	Bortezomib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	1.73	3.39	3.33	5.78
DC8YRTY	DMNO38U	Bortezomib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	11.67	15.73	14.77	17.03
DC7ZNF3	DMNO38U	Bortezomib	Approved	34	DM6U9CQ	Pazopanib HCl	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.77	2.77	3.08	3.16
DCQJPS1	DMNO38U	Bortezomib	Approved	34	DM7A8TW	Ezetimibe	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.51	3.51	3.87	3.89
DCUDL5E	DMNO38U	Bortezomib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Hodgkin lymphoma	DrugCombDB Database	Investigative	L-1236	148.235	148.159	2.79	8.571
DCYZWG5	DMNO38U	Bortezomib	Approved	34	DM7HUNW	Testosterone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.27	3.27	3.79	3.8
DCCGGLT	DMNO38U	Bortezomib	Approved	34	DM8BKU9	Acitretin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.77	0.77	1.81	1.87
DCAM9DF	DMNO38U	Bortezomib	Approved	34	DM9S1EA	Pepstatin	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.37	3.37	4.16	4.25
DCYXJ5R	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	5.54	6.78	0.76	6.57
DC7OLQ0	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	6.28	7.98	5.11	9.79
DCKSUGC	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	12.1	12.51	11.46	15.73
DCRGVJO	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	16.6	14.01	10.61	14.21
DCPZVWM	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	3.25	5.65	0.21	6.33
DC3BT5J	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	13.29	11.42	9.43	12.3
DCYH91F	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	24.2	20.97	15.32	19.09
DCRON4K	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.06	2.06	2.39	2.46
DC6JFIA	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.02	6.72	3.05	8.07
DCI759X	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	9.9	7.71	2.92	8.48
DC7VHPJ	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	2.75	4.86	6.75	8.23
DCCG7BS	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	1.59	4.27	0.33	4.67
DC6QTWC	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	2.9	8.45	0.91	7.49
DCY0S5J	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	2.56	2.38	0.18	4.18
DCNU0LJ	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	13.63	14.61	8.86	16.29
DCO63PK	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	5.46	2.47	1.28	4.65
DCYE72I	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	3.53	4.17	1.1	4.95
DCT4N3E	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	5	3.23	1.94	5.49
DC13ZO3	DMNO38U	Bortezomib	Approved	34	DMAYD7O	IT-141	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.92	0.92	3.01	3.08
DCPDLA3	DMNO38U	Bortezomib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	5.25	6.38	0.49	5.72
DCYRXX7	DMNO38U	Bortezomib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	3.26	3.38	0.66	4.8
DC23XPG	DMNO38U	Bortezomib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	3.89	5.18	1.75	5.97
DCZ2625	DMNO38U	Bortezomib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	2.53	2.43	0.32	3.61
DC9SKKO	DMNO38U	Bortezomib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	3.96	3.84	1.42	5.2
DCVBWA5	DMNO38U	Bortezomib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	2.12	3.29	1.96	4.81
DC8CTAY	DMNO38U	Bortezomib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	5.46	6.72	1.02	8.18
DCGLYDT	DMNO38U	Bortezomib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	3.76	2.46	1.44	4.73
DCUXD43	DMNO38U	Bortezomib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	3.2	3.56	0.17	4.11
DC2OXO2	DMNO38U	Bortezomib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	8.08	10.98	5.32	10.28
DCLVMI6	DMNO38U	Bortezomib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	12.6	9.76	8.92	12.67
DCNZ0X4	DMNO38U	Bortezomib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	16.21	18.96	7.23	19.42
DC6GD9N	DMNO38U	Bortezomib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	1.35	1.16	0.36	4.49
DCGIMUE	DMNO38U	Bortezomib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	2.96	2.89	0.63	5.08
DC47O1L	DMNO38U	Bortezomib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	2.95	2.51	0.19	5.46
DC5EPS8	DMNO38U	Bortezomib	Approved	34	DMBEX4O	Methylergonovine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.77	3.77	4.15	4.24
DCGCC6T	DMNO38U	Bortezomib	Approved	34	DMBHMOX	Palonosetron	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.86	2.86	3.17	3.24
DC1Y5Y7	DMNO38U	Bortezomib	Approved	34	DMBI4JG	Isosorbide dinitrate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.68	1.68	1.97	2.05
DCH055K	DMNO38U	Bortezomib	Approved	34	DMBS632	Buspirone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.95	2.95	3.33	3.39
DC2D3Y2	DMNO38U	Bortezomib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.1	2.1	3.65	3.74
DCBW8C1	DMNO38U	Bortezomib	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.82	1.82	2.41	2.43
DC7JYHL	DMNO38U	Bortezomib	Approved	34	DMCUT21	Ursodeoxycholic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.47	4.47	4.86	4.86
DCURW11	DMNO38U	Bortezomib	Approved	34	DMDXRP1	ETHISTERONE	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.16	3.16	3.6	3.61
DCOD46I	DMNO38U	Bortezomib	Approved	34	DME2H5T	Cilastatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.65	0.65	1.05	1.05
DCU0C75	DMNO38U	Bortezomib	Approved	34	DME5TUR	LY03004	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.47	3.47	3.84	3.87
DC4RNAU	DMNO38U	Bortezomib	Approved	34	DMENSL5	Aminosalicylic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.97	3.97	4.34	4.38
DC6TP4J	DMNO38U	Bortezomib	Approved	34	DMFNTMY	Fibrates	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.72	2.72	3	3.08
DCSKO89	DMNO38U	Bortezomib	Approved	34	DMFQWNI	VR-776	Discontinued in Phase 1	3	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.7	0.7	1.09	1.17
DCJ7NW5	DMNO38U	Bortezomib	Approved	34	DMGC5DB	Ciprofibrate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.34	3.34	3.65	3.74
DCCFPVO	DMNO38U	Bortezomib	Approved	34	DMGQFYB	Mecamylamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.07	1.07	1.46	1.48
DCUKELO	DMNO38U	Bortezomib	Approved	34	DMGYBZI	PHA-739358	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.74	2.74	3.14	3.14
DC7F94O	DMNO38U	Bortezomib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	0.077	0.404	0.819	0.619
DCZWUFL	DMNO38U	Bortezomib	Approved	34	DMHAZLM	Naringenin	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.17	3.17	3.55	3.61
DCQAPPG	DMNO38U	Bortezomib	Approved	34	DMI40NL	Tolazoline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.18	1.18	1.61	1.61
DCIDSTK	DMNO38U	Bortezomib	Approved	34	DMIK367	Procarbazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.92	4.92	5.3	5.32
DCHFDZO	DMNO38U	Bortezomib	Approved	34	DMIOGBU	Bosentan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.21	3.21	3.65	3.65
DCDQ1QU	DMNO38U	Bortezomib	Approved	34	DMIUYFH	Sulfapyridine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.41	1.41	1.74	1.83
DC886XR	DMNO38U	Bortezomib	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.57	1.57	3.52	3.58
DCW3V27	DMNO38U	Bortezomib	Approved	34	DMJAGXQ	Niclosamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.63	1.63	2.91	2.97
DC0I0BU	DMNO38U	Bortezomib	Approved	34	DMJOQM3	Eflornithine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.88	1.88	2.19	2.28
DC1ZZ4Z	DMNO38U	Bortezomib	Approved	34	DMJSKUI	Norcisapride	Discontinued in Phase 2	5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.38	0.38	0.76	0.77
DCKZLZR	DMNO38U	Bortezomib	Approved	34	DMKA8J4	Etonogestrel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.87	0.87	1.27	1.35
DCNC9RM	DMNO38U	Bortezomib	Approved	34	DMKBYWI	Trifluoperazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.15	4.15	4.49	4.58
DCTIGFF	DMNO38U	Bortezomib	Approved	34	DMGO72P	Oseltamivir	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.03	1.03	1.59	1.68
DCT9VT1	DMNO38U	Bortezomib	Approved	34	DMKXY2R	Ibutilide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.17	2.17	2.61	2.69
DC2S921	DMNO38U	Bortezomib	Approved	34	DML5VQ0	Fenoprofen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.65	2.65	3.16	3.19
DCO8DZL	DMNO38U	Bortezomib	Approved	34	DMLB0EZ	Tamoxifen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.5	3.5	4.07	4.13
DCHNK71	DMNO38U	Bortezomib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	5.81	6.77	0.42	7.56
DC0JJED	DMNO38U	Bortezomib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	9.31	10.68	6.37	10.78
DCLGER4	DMNO38U	Bortezomib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	7.9	5.67	2.06	5.96
DCPHVWI	DMNO38U	Bortezomib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	5.77	2.81	0.63	4.33
DCQPI3W	DMNO38U	Bortezomib	Approved	34	DMLPAOB	Allopurinol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.88	2.88	3.3	3.39
DCZ7PRA	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	2.21	2.51	1.05	3.07
DCBEMGI	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	0.74	0.28	0.02	1.85
DCXG1XH	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	11.49	13.22	7.41	13.3
DC2KTZ8	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	1.75	2.38	1.64	4.23
DCXLGL9	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	4.16	3.84	3.59	5.29
DC9UUY5	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	14.32	13.01	11.11	12.59
DCTG1E3	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	2.54	2.45	0.93	3.17
DCWGFDK	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	1.17	3.49	4.69	6
DCSM0Q6	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	2.8	0.24	0.25	2.49
DC1MOB9	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	0.48	1.05	0.35	2.05
DC7PA1E	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	27.55	31.69	26.91	32.48
DCYID6P	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	1.68	0.62	1.46	2.53
DCM8IQH	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	2.4	3.19	2.6	6.11
DCEJVXK	DMNO38U	Bortezomib	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.74	1.74	2.88	2.97
DC58HZM	DMNO38U	Bortezomib	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	1.17	1.17	1.45	1.54
DC87PC2	DMNO38U	Bortezomib	Approved	34	DMMFWOJ	Probenecid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.78	2.78	3.03	3.12
DCYY4GB	DMNO38U	Bortezomib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	6.2	7.43	0.75	8.63
DCIHAP2	DMNO38U	Bortezomib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	18.24	18.97	5.36	18.95
DCMNL2M	DMNO38U	Bortezomib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	3.21	5.5	1.32	6.68
DCY1X2A	DMNO38U	Bortezomib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	5.17	3.83	0.6	4.95
DC1Y3K4	DMNO38U	Bortezomib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	21.3	21.08	3.95	23.11
DCPMEH5	DMNO38U	Bortezomib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	10.92	10.6	8.8	14.09
DC5CTSE	DMNO38U	Bortezomib	Approved	34	DMNKG1Z	Atenolol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.19	0.19	0.46	0.55
DCZIOAT	DMNO38U	Bortezomib	Approved	34	DMWFJTR	Linagliptin	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.85	3.85	4.25	4.26
DCUUMVA	DMNO38U	Bortezomib	Approved	34	DMNMW9R	Pramipexole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.44	1.44	1.82	1.83
DCV64VI	DMNO38U	Bortezomib	Approved	34	DMJAPE7	Methylene blue	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.31	0.31	2.36	2.45
DCVOZ3F	DMNO38U	Bortezomib	Approved	34	DMO14SG	Mebendazole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.14	2.14	2.5	2.53
DCN6ELX	DMNO38U	Bortezomib	Approved	34	DMODJ40	Ethinyl estradiol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.3	1.3	1.72	1.72
DCC5UL2	DMNO38U	Bortezomib	Approved	34	DMOL5IU	Mesalazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.56	4.56	4.95	4.97
DCZ6324	DMNO38U	Bortezomib	Approved	34	DMOMBJW	Moricizine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.4	0.4	0.74	0.83
DCM27H8	DMNO38U	Bortezomib	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.2	0.2	1.19	1.23
DCDCXUV	DMNO38U	Bortezomib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	2.57	9.37	3.89	6.11
DCE3Q48	DMNO38U	Bortezomib	Approved	34	DMPFN6Y	Olanzapine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.58	3.58	3.95	4.04
DCSP2BU	DMNO38U	Bortezomib	Approved	34	DMPGR1E	Clascoterone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.71	0.71	1.31	1.39
DCN14GT	DMNO38U	Bortezomib	Approved	34	DMPGUCF	Dopamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.6	3.6	3.96	3.96
DCHN9TH	DMNO38U	Bortezomib	Approved	34	DMPLY7B	Cefmenoxime	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.93	0.93	1.28	1.34
DC3J6NS	DMNO38U	Bortezomib	Approved	34	DMPP4DT	Trimethobenzamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.16	1.16	1.89	1.97
DCNTWA5	DMNO38U	Bortezomib	Approved	34	DMPWB7T	Maprotiline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.35	0.35	2.39	2.48
DC8LYOI	DMNO38U	Bortezomib	Approved	34	DMQXTJS	Eptifibatide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.89	0.89	1.31	1.31
DC0UWM6	DMNO38U	Bortezomib	Approved	34	DMR87LC	Ethambutol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.92	1.92	2.32	2.32
DCHBU6I	DMNO38U	Bortezomib	Approved	34	DMR8ONJ	Leflunomide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.38	1.38	3.32	3.41
DC53QUT	DMNO38U	Bortezomib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	3.41	4.58	1.79	3.48
DCDAUYD	DMNO38U	Bortezomib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.79	5.6	0.18	0.57
DCL8YUB	DMNO38U	Bortezomib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	0.94	2.78	2.84	4.11
DCGHCWD	DMNO38U	Bortezomib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	1.52	2.43	0	4.42
DCFORLO	DMNO38U	Bortezomib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.21	1.76	3.3	5.5
DCD9KC6	DMNO38U	Bortezomib	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	0.64	4.18	1.12	5.13
DCCD8ER	DMNO38U	Bortezomib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.79	3.79	4.21	4.22
DCAANGJ	DMNO38U	Bortezomib	Approved	34	DMRTSGP	Amiloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.63	3.63	4.02	4.05
DC851GV	DMNO38U	Bortezomib	Approved	34	DMRV7H0	Bumetanide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.38	0.38	0.78	0.8
DCHWOJS	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	4.93	5.1	2.83	6.41
DC90NR6	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	13.12	12.75	5.36	13.83
DCBKZWF	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	4.13	2.72	0.49	4.38
DC6F7F2	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	6.06	4.81	0.21	5.71
DCYI986	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	16	16.14	9.59	16.58
DCGV1QM	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	36.9	33.84	25.85	31.8
DCBIHT8	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.23	8.01	3.85	10.11
DCZU03K	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	4.8	5.53	0.26	7.26
DC876V3	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	3.7	3.66	0.23	6.01
DCZULYZ	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	8.21	6.92	1.15	8.11
DCSID7E	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	5.7	6.23	1.38	8.04
DC88IIV	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	3.31	4.35	0.22	5.28
DCIKOHY	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	5.42	5.61	0.49	7.81
DCBWRBC	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	10.58	8.79	3.57	10.48
DCZE21S	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	4.53	5.28	2.14	8.21
DCULGX1	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	13.59	10.61	2.57	11.09
DCFMMCE	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	2.44	2.03	0.52	5.14
DC29HJY	DMNO38U	Bortezomib	Approved	34	DMSI5CB	Chloroquine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.99	2.99	3.29	3.34
DCOHDN2	DMNO38U	Bortezomib	Approved	34	DMSIWD0	Hyodeoxycholic acid	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.76	3.76	5.51	5.58
DCVFPWW	DMNO38U	Bortezomib	Approved	34	DMSQZE2	Asenapine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.91	2.91	3.28	3.28
DCYS183	DMNO38U	Bortezomib	Approved	34	DMSWYF5	Quinine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.66	3.66	4.59	4.68
DCFCRRX	DMNO38U	Bortezomib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.18	2.18	2.52	2.6
DCR2TV8	DMNO38U	Bortezomib	Approved	34	DM2AQ5N	Spironolactone	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.87	0.87	1.22	1.27
DCK2432	DMNO38U	Bortezomib	Approved	34	DMTL94F	Maraviroc	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.03	2.03	2.36	2.43
DCXEDNT	DMNO38U	Bortezomib	Approved	34	DMTWUXR	Chlormezanone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.76	4.76	5.13	5.16
DCGN361	DMNO38U	Bortezomib	Approved	34	DMRBMAU	Mycophenolic acid	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.91	1.91	3.96	4.05
DC3L0KT	DMNO38U	Bortezomib	Approved	34	DMUZPJ5	Cisatracurium	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.56	2.56	3.29	3.36
DCOBNMX	DMNO38U	Bortezomib	Approved	34	DMWT905	Mefloquine	Phase 2/3 Trial	24	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.53	2.53	4.58	4.66
DC5BTSJ	DMNO38U	Bortezomib	Approved	34	DMV74ZH	Pizotyline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.14	2.14	2.5	2.55
DCWUB33	DMNO38U	Bortezomib	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.97	2.97	5.11	5.12
DCKO2FD	DMNO38U	Bortezomib	Approved	34	DMVPZBE	Iloprost	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.11	3.11	3.34	3.43
DCPPJG4	DMNO38U	Bortezomib	Approved	34	DMVRIC2	Zileuton	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.98	0.98	1.55	1.64
DCNTIGJ	DMNO38U	Bortezomib	Approved	34	DMVTHWQ	Silver sulfadiazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.06	3.06	3.33	3.42
DC8CNZR	DMNO38U	Bortezomib	Approved	34	DMVY4GN	Testolactone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.45	1.45	1.94	2.03
DC2X710	DMNO38U	Bortezomib	Approved	34	DMVYXR8	Sumatriptan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.78	3.78	4.13	4.19
DCKSPMZ	DMNO38U	Bortezomib	Approved	34	DMWBHRY	Olmesartan medoxomil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.98	1.98	2.26	2.35
DC0V9YI	DMNO38U	Bortezomib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.06	2.06	2.46	2.47
DCACME0	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	3.98	3.88	0.08	4.17
DCF6N18	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	2.22	1.98	0.05	3.57
DC2LOPD	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	1.27	1.23	1.17	4.81
DC2UQYS	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	2.99	1.96	0.13	4.53
DCXCL67	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	7.47	5.39	2.8	6.08
DC68Z2P	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	5.55	4.92	1.21	6.26
DCUCH22	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	3.94	4.15	1.01	5.42
DC5WV1A	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	3.28	3.22	0.25	4.99
DCY53QC	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.31	2.31	4.39	4.46
DCKC8LQ	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	2.71	2.44	0.05	3.64
DC7IVT5	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	4.02	4.2	2.7	5.93
DC9RE1J	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	1.66	2.11	1.09	4.57
DC9SL68	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	4.41	4.08	0.44	5.29
DC7P8CQ	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	1.27	1.1	0.9	5.46
DCPE0YC	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	8.35	7.6	2.88	9.2
DC4I2QW	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	4.78	5.04	5.22	8.82
DCQ44HW	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	3.09	2.52	0.47	5.39
DC220WM	DMNO38U	Bortezomib	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.65	0.65	1.26	1.35
DCECXOV	DMNO38U	Bortezomib	Approved	34	DMXCM7H	Cerivastatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.23	1.23	3.38	3.39
DCPD5QX	DMNO38U	Bortezomib	Approved	34	DMXKDUL	BGT226	Phase 1/2	19	.	.	.	.	Hodgkin lymphoma	DrugCombDB Database	Investigative	L-1236	5.63	6.69	2.38	5.19
DC51WFI	DMNO38U	Bortezomib	Approved	34	DMXLZP6	Metaxalone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.59	3.59	3.92	4
DC6L5B4	DMNO38U	Bortezomib	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.04	4.04	4.42	4.45
DCVVSYB	DMNO38U	Bortezomib	Approved	34	DMY4UMW	Atovaquone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.61	0.61	0.89	0.97
DC1KD22	DMNO38U	Bortezomib	Approved	34	DMYX7NI	Acetohydroxamic Acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.75	4.75	5.45	5.53
DC30PG1	DMNO38U	Bortezomib	Approved	34	DMYZ57N	Albendazole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.48	2.48	2.71	2.8
DCP3W8D	DMNO38U	Bortezomib	Approved	34	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	0.07	0.65	1.1	0.82
DCOZI6D	DMNO38U	Bortezomib	Approved	34	DMZ2TD9	GSK2194069	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.42	2.42	2.69	2.78
DCZUWRL	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	0.61	1.06	0.09	1.47
DCZTWDQ	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	1.75	2.48	2.39	4.26
DCCYDK6	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	1.02	0.61	2.02	2.23
DCY5FDU	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	3.16	4.25	2.53	5.06
DC2WW9S	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	2.4	2.77	1.43	3.71
DCR483O	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	3.28	7.89	3.02	5.47
DCTIYBF	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	11.29	14.85	6.89	13.38
DCAY03H	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	0.17	0.41	0.08	2.57
DCF4AZD	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	0.21	2.45	0.25	3.34
DCUJNZ5	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	3.86	4.65	1.89	5.75
DCXR7TG	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	19.57	15.43	15.05	19.3
DC7F6QB	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	1.71	2	2.13	5.78
DC6B4RU	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	6.24	7.1	11.16	11.85
DCC3B9L	DMNO38U	Bortezomib	Approved	34	DMZD5QR	Cytarabine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.58	0.58	2.68	2.75
DCXQFSQ	DMNO38U	Bortezomib	Approved	34	DMZMSCT	Cilostazol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.93	3.93	4.29	4.35
DCFRY7M	DMNO38U	Bortezomib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.37	0.59	0.22	3.59
DC60SB8	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.37	2.42	0.86	4.86
DCVG3CX	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.11	2.91	0.78	4.11
DCUOTZ1	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	3.72	2.49	3.51	8.38
DCAHAV2	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.4	1.9	5.86	7.93
DCNBMYM	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.01	2.82	0.6	4.4
DC4KIQ9	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	3.18	3.89	1.47	4.26
DC5RG3Q	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.31	0.5	1.4	4.96
DC7M6BR	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.99	2.63	0.55	5.04
DCXXIF4	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.97	1.55	0.5	3.42
DC3U8LH	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.28	5.61	2.02	7.07
DCOQ701	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.7	11.4	1.45	14.11
DCWEEOM	DMNO38U	Bortezomib	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	7.78	6.03	8.46	10.29
DC2CW60	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.03	1.2	0.12	1.98
DC8H1UD	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	0.18	1.13	4.09	6.91
DCVHMJ7	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.07	1.7	1.23	3.02
DCFF5AO	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	18.6	15.01	11	16.35
DC3CWEW	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	3.08	3.68	1.75	5.6
DC5RIIZ	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	15.16	12.89	10.27	13.44
DC97LID	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.07	9.01	7.85	10.38
DC8BQL9	DMNO38U	Bortezomib	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.69	0.41	2.87	3.77
DC6Y2YR	DMNO38U	Bortezomib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	4.32	5.49	0.99	5.09
DC5LXNE	DMNO38U	Bortezomib	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.65	3.23	0.76	3.95
DCU6ET4	DMNO38U	Bortezomib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	5.1	3.25	1.29	8.01
DCP4R3D	DMNO38U	Bortezomib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	3.97	2.4	1.36	4.49
DC2TGAA	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	0.63	1.51	1.33	3.86
DCG57DL	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.03	2.71	2.15	3.54
DC0AGCJ	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	1.59	0.88	4.83	7.41
DC3R9L4	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	4.64	4.29	5.22	6.32
DCFCVHI	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.42	2.53	1	4.16
DCN1GAR	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.78	2.43	0.94	2.75
DCT2OFU	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.19	2.79	3.06	6.71
DC333HS	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.58	3.51	2.96	5.27
DCJL3TB	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.68	8.74	5.81	10.17
DCYVMM0	DMNO38U	Bortezomib	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.64	5.62	6.8	7.21
DCPBG0K	DMNO38U	Bortezomib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.69	0.41	0.06	4.82
DCD3TSX	DMNO38U	Bortezomib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.94	3.18	1.52	4.92
DCJ2T3M	DMNO38U	Bortezomib	Approved	34	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.61	2.56	6.59	8.93
DC4GDPH	DMNO38U	Bortezomib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.49	4.39	1.34	4.08
DCOVNX2	DMNO38U	Bortezomib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.28	2.3	0.5	3.15
DC32K0A	DMNO38U	Bortezomib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	12.55	14.79	10.75	14.75
DCGO5LT	DMNO38U	Bortezomib	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.61	2.79	3.26	3.63
DCF66VG	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	13.5	7.16	2.77	12.92
DC09GZD	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	10.38	8.71	4.01	10.28
DCD7AFQ	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	22.82	17.7	12.49	18.64
DCUCMG9	DMNO38U	Bortezomib	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.21	2.21	2.07	5.95
DCE4KV4	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.18	2.35	2.75	4.67
DCRZZSW	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.8	2.8	0.19	3.25
DCVZZIX	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.55	0.04	0.67	4.56
DC4NZYP	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.76	7.28	5.7	8.96
DCKMBWA	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.28	0.61	6.83	8.59
DC5UFKH	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.09	1.62	1.57	4.01
DCHN51N	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	6.84	8.03	3.36	10.36
DCAK9FB	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	5.13	5.48	2.73	5.74
DC7KDDE	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1	5.22	2.68	6.09
DCJQYPB	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	6.11	8.3	0.7	9.47
DCB2I2X	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.2	2.83	2.25	4.69
DCERSH1	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	8.65	9.9	5.46	10.03
DCXPHMD	DMNO38U	Bortezomib	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	6.29	5.22	11.78	12.67
DCHM289	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM2NLS9	Ciprofloxacin XR	Approved	34	.	.	.	.	Otitis externa; Acute otitis media	TTD Database	Approved	.	.	.	.	.
DC1A7IL	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM70IK5	Marinol	Approved	34	DML53ZJ	Mirtazapine	.	.	Oncologic Complications	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCAIVP1	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM8VCBE	Ibuprofen	Approved	34	DMUIE76	Acetaminophen	.	.	"Pain, Acute"	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCM6UWN	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMZ4Q0B	Dasatinib	.	.	Ph+ Acute Lymphoblastic Leukemia	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCPZ6UH	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMBHMOX	Palonosetron	Approved	34	DMY3VGC	Promethazine	.	.	Postoperative Nausea and Vomiting	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCY5VJE	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMOTQ1I	Ondansetron	Approved	34	DMY3VGC	Promethazine	.	.	Postoperative Nausea and Vomiting (PONV)	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCBHK96	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Hemophagocytic Lymphohistiocytoses	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCGGPCM	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMI4EL5	Ketorolac	Approved	34	.	.	.	.	Obstructive Sleep Apnea	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCO1A3U	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM8VCBE	Ibuprofen	Approved	34	.	.	.	.	"Radiculopathy, Lumbosacral Region"	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCOKMX1	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMUIE76	Acetaminophen	Approved	34	.	.	.	.	Pain Measurement	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCP8O94	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMSVOZT	Nifedipine	Approved	34	.	.	.	.	PreTerm Birth	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCVQF11	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM6LOQU	Celecoxib	Approved	34	.	.	.	.	Stiffness Following Total Knee Arthroplasty	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCVR2IR	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM98IXF	Triamcinolone	Approved	34	.	.	.	.	Total Knee Replacement	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCZCJPP	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMFMRN8	18beta-Glycyrrhetic acid	Investigative	0	.	.	.	.	Immune Thrombocytopenia	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DC83ODJ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMFA5MY	Metoclopramide	Approved	34	DMI4EL5	Ketorolac	DMKQTBA	Diphenhydramine	Headache	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC8V2A3	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM73A5J	Lenalidomide	DMNO38U	Bortezomib	Multiple Myeloma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCEEIW2	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMINOX3	Vincristine	DMTQXS7	Mercaptopurine	Leukemia	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCFH041	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMI6E0R	Midostaurin	Approved	34	DMQUSBT	Daunorubicin	DMZD5QR	Cytarabine	Leukemia	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCJ5PDP	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM48K0X	Carfilzomib	Approved	34	DMNO38U	Bortezomib	DMTGBAX	Pomalidomide	Relapsed or Refractory Multiple Myeloma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCS22UQ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMTA5OE	Azacitidine	Approved	34	DMZD5QR	Cytarabine	DMZKYIV	Amsacrine	Relapsed or Refractory Acute Myeloid Leukemia	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC2V68Y	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM8I94Y	Venetoclax	Approved	34	DMNO38U	Bortezomib	.	.	Relapsed/Refractory Multiple Myeloma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC4DYZA	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	DMRSNEU	Masitinib	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC5OJER	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMQUSBT	Daunorubicin	Approved	34	DMZD5QR	Cytarabine	.	.	Leukemia	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC6EJC6	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMBQYO0	Casopitant	Withdrawn from market	12	DMOTQ1I	Ondansetron	.	.	Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC6T8Z8	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMBFZ6L	Remdesivir	Phase 3 Trial	25	DMBZ27L	Favipiravir	.	.	COVID-19 Infection	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC6ULC1	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMVZL26	"3,4-Dihydroxycinnamic Acid"	.	.	Immune Thrombocytopenia	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC72QL1	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	DMT3D5I	Aflibercept	.	.	Carcinoma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC8SOTE	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	DMVYRH2	Perifosine	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCD4OPJ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM8VCBE	Ibuprofen	Approved	34	DMUIE76	Acetaminophen	.	.	Adenotonsillectomy	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCE49RJ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4M1SG	Clarithromycin	Phase 2 Trial	21	DM73A5J	Lenalidomide	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCESWHA	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNO38U	Bortezomib	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCH6Q4B	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMBQYO0	Casopitant	Withdrawn from market	12	DMOTQ1I	Ondansetron	.	.	"Nausea and Vomiting, Chemotherapy-Induced"	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCJ5K9R	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMBFZ6L	Remdesivir	Phase 3 Trial	25	DM4ONW5	Baricitinib	.	.	Covid19	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCJSXFV	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	DMNO38U	Bortezomib	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCKXV9A	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM48K0X	Carfilzomib	Approved	34	DM73A5J	Lenalidomide	.	.	Relapsed Multiple Myeloma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCLY43W	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMA4MRX	Perphenazine	Approved	34	DMOTQ1I	Ondansetron	.	.	Perioperative Optimization	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCNVEMZ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM471KJ	Omeprazole	Approved	34	DMYZ57N	Albendazole	.	.	Neurocysticercosis	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCPG97F	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	DMTGBAX	Pomalidomide	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCPVNZ9	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	DMTGBAX	Pomalidomide	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCUMJXE	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM58WKG	Panobinostat	Approved	34	DMNO38U	Bortezomib	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC8G8SV	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4ONW5	Baricitinib	Approved	34	.	.	.	.	Covid19	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCCHIYQ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4BDON	Methylprednisolone	Phase 3 Trial	25	.	.	.	.	Dysphasia	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCF7LZU	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMQL8XJ	Decitabine	Approved	34	.	.	.	.	"Purpura, Thrombocytopenic, Idiopathic"	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCHEBQF	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMVEK07	Magnesium Sulfate	Approved	34	.	.	.	.	"Pain, Postoperative"	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCK4H0O	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMQNWRD	Oxaliplatin	Approved	34	.	.	.	.	Metastatic Colorectal Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCOQYDC	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNSJ7V	Tropisetron	Approved	34	.	.	.	.	Cervical Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCPZJ2T	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNE7L3	CC-220	Phase 2	21	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCQKWG1	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM8X2EH	Everolimus	Approved	34	.	.	.	.	Malignant Neoplasm	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC04KK6	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMBFZ6L	Remdesivir	Phase 3 Trial	25	DM6LOQU	Celecoxib	DMWXZH1	Famotidine	COVID-19	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC4BSYP	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	DME4TH4	Etoposide	DMXYJ9C	Busulfan	Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC6QJRO	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM48K0X	Carfilzomib	DM48K0X	Carfilzomib	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC7UILG	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM3X5IV	Dexamethasone	DMNO38U	Bortezomib	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCDCGY8	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM8XP26	Rolapitant	Approved	34	DMBHMOX	Palonosetron	DMPFN6Y	Olanzapine	Germ Cell Tumor	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCHJSF0	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4M1SG	Clarithromycin	Phase 2 Trial	21	DM73A5J	Lenalidomide	DMJZHT1	Tadalafil	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCHZKUV	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMH61ZB	Cimetidine	Approved	34	DMKQTBA	Diphenhydramine	DMLB81S	Paclitaxel	Endometrial Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCIWJEH	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMINOX3	Vincristine	DMTQXS7	Mercaptopurine	Acute Lymphoblastic Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCU91H9	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMKQTBA	Diphenhydramine	Approved	34	DMLB81S	Paclitaxel	DMWXZH1	Famotidine	Gastric Adenocarcinoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC0DQFL	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	DMG281S	Carboplatin	.	.	Nasopharyngeal Carcinoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC1G9ZO	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMBFZ6L	Remdesivir	Phase 3 Trial	25	DMJS42H	Aviptadil	.	.	COVID-19	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC1JU99	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMBFZ6L	Remdesivir	Phase 3 Trial	25	DMQPTOZ	Icatibant	.	.	COVID-19	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC3KY0V	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM48K0X	Carfilzomib	Approved	34	DM8I94Y	Venetoclax	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC4K2CO	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMS4BLQ	Aminolevulinic acid hci	.	.	Stage I Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC51QO5	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	DMYZJGB	Ibrutinib	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC52BGE	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	DMLB81S	Paclitaxel	.	.	Relapse/Refractory Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC57G9K	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM58WKG	Panobinostat	Approved	34	DM73A5J	Lenalidomide	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC5U64N	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM8I94Y	Venetoclax	Approved	34	DMTGBAX	Pomalidomide	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC6IL7L	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	DME4TH4	Etoposide	.	.	Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC7BOG6	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM48K0X	Carfilzomib	Approved	34	DM73A5J	Lenalidomide	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC7ERXM	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM48K0X	Carfilzomib	Approved	34	DMTGBAX	Pomalidomide	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC7KVXW	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	DMNO38U	Bortezomib	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC9U386	DMMWZET	Dexamethasone	Phase 3 Trial	25	DME9QGW	Marizomib	Phase 3	25	DMTGBAX	Pomalidomide	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCA5S4Q	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNO38U	Bortezomib	.	.	Refractory Plasma Cell Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCATDUW	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMBFZ6L	Remdesivir	Phase 3 Trial	25	DMTWS9E	Apremilast	.	.	COVID-19	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCB4LYI	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMDL2OZ	Aspirin	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCCALVA	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMZ4Q0B	Dasatinib	.	.	Acute Lymphoblastic Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCCOQ02	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNO38U	Bortezomib	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCDA2MP	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMBFZ6L	Remdesivir	Phase 3 Trial	25	DM92AH3	Cyproheptadine	.	.	COVID-19	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCDWXYJ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM58WKG	Panobinostat	Approved	34	DMNO38U	Bortezomib	.	.	Relapsed and Bortezomib Refractory Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCFHKM0	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMBHMOX	Palonosetron	Approved	34	DMOTQ1I	Ondansetron	.	.	Chemotherapy-induced Nausea and Vomiting	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCH1LU6	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMFA5MY	Metoclopramide	Approved	34	DMHIDCJ	Octreotide	.	.	Malignant Bowel Obstruction	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCHLP40	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMBFZ6L	Remdesivir	Phase 3 Trial	25	DMUYKBZ	Cyclosporin A	.	.	COVID-19	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCM234Y	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	DMNO38U	Bortezomib	.	.	Primary Systemic Amyloidosis	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCN1PZR	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4M1SG	Clarithromycin	Phase 2 Trial	21	DM73A5J	Lenalidomide	.	.	Relapse/Refractory Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCO2B1U	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM48K0X	Carfilzomib	Approved	34	DMYLOVR	Aciclovir	.	.	Metastatic Castration-resistant Prostate Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCP0GBM	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	DMWMPD4	Vorinostat	.	.	Relapsed or Refractory Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCQEH9V	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMQ8FR2	Prednisolone	Approved	34	DMUIE76	Acetaminophen	.	.	Postoperative Pain	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCQI3SJ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4M1SG	Clarithromycin	Phase 2 Trial	21	DMTGBAX	Pomalidomide	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCRFPHF	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM8I94Y	Venetoclax	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCRGPGW	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMOTQ1I	Ondansetron	Approved	34	DMPFN6Y	Olanzapine	.	.	Emesis	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCRMF2D	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMIXC7G	Zoledronate	Approved	34	DMNO38U	Bortezomib	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCSV7TT	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMBFZ6L	Remdesivir	Phase 3 Trial	25	DM4V8WF	Cenicriviroc	.	.	COVID-19	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCUKT0G	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	DMTGBAX	Pomalidomide	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCXBUN3	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	DMNO38U	Bortezomib	.	.	Stage I Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCY2UDG	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	DMNO38U	Bortezomib	.	.	Stage I Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCYABFL	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	DM73A5J	Lenalidomide	.	.	Amyloidosis	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCYPCFI	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	DMTGBAX	Pomalidomide	.	.	Multiple Myeloma in Relapse	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC1EILQ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM783CH	Levobupivacaine	Approved	34	.	.	.	.	"Effects of; Anesthesia, in Labor and Delivery"	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC1K3VQ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMGO72P	Oseltamivir	Phase 3 Trial	25	.	.	.	.	Thrombocytopenia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC1P7A2	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Lymphoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC2UGER	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC4BZXM	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMBHMOX	Palonosetron	Approved	34	.	.	.	.	Chemotherapy-Induced Nausea and Vomiting	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC4J5GI	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMBFZ6L	Remdesivir	Phase 3 Trial	25	.	.	.	.	COVID-19	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC5OKWD	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMI782S	Erdafitinib	Approved	34	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCBXCFI	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Intrahepatic Cholangiocarcinoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCDTJWS	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMZ7XNQ	Tacrolimus	Approved	34	.	.	.	.	Pharmacological Action	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCFEIUW	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4ONW5	Baricitinib	Approved	34	.	.	.	.	Immune Thrombocytopenia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCGLQE5	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Hodgkin's Lymphoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCJYFWW	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM8V75C	ABIRATERONE	Approved	34	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCQSEGR	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMQ2FKJ	Teriflunomide	Approved	34	.	.	.	.	Immune Thrombocytopenia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCS3KOO	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMOTQ1I	Ondansetron	Approved	34	.	.	.	.	CINV	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCSQJB6	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCUQGVM	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM6T924	Gabapentin	Approved	34	.	.	.	.	Postoperative Nausea and Vomiting	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCPF16C	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMOTQ1I	Ondansetron	Approved	34	DMWXZH1	Famotidine	DMY3VGC	Promethazine	Post-Operative Nausea and Vomiting	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC1SGGR	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	DMVYRH2	Perifosine	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC66OVY	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4M1SG	Clarithromycin	Phase 2 Trial	21	DMTGBAX	Pomalidomide	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC868R0	DMMWZET	Dexamethasone	Phase 3 Trial	25	DML4ZOT	Lidocaine	Approved	34	DMMIU2C	Methylprednisolone	.	.	Sciatica	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCB4TIP	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMCJN1P	Plerixafor	Approved	34	DMNO38U	Bortezomib	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCP9M07	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNH3PG	Etoposide	Phase 2 Trial	21	DMUYKBZ	Cyclosporin A	.	.	Hemophagocytic Syndrome	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC2M2DK	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMUIE76	Acetaminophen	Approved	34	.	.	.	.	Pharyngitis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC2YLYV	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMG3Y89	Trabectedin	Approved	34	.	.	.	.	Ovarian Neoplasms	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC3BFC7	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMGEMB7	Hydrocortisone	Phase 3 Trial	25	.	.	.	.	"Adrenal Hyperplasia, Congenital"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC4D1ZK	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM48K0X	Carfilzomib	Approved	34	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC520RD	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMMX2E6	Pemetrexed	Approved	34	.	.	.	.	Non Small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC6VM8I	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMFA5MY	Metoclopramide	Approved	34	.	.	.	.	Nausea and Vomiting	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC9AEDQ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPZI3Q	Ketoconazole	Approved	34	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC9RQSR	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMKINJO	Gentamicin	Approved	34	.	.	.	.	Vestibular Disorder Preservation	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCA09QP	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCALDB7	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMG3Y89	Trabectedin	Approved	34	.	.	.	.	Endometrial Neoplasms	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCAYJBW	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Bladder Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCBM5AL	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Multiple Myeloma and Plasma Cell Neoplasm	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCC48IL	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMU8V4S	Moxifloxacin	Approved	34	.	.	.	.	Blepharitis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCCAQ4J	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMLS39E	Proparacaine	Approved	34	.	.	.	.	Cataract	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCD8TSN	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCDU4XS	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMOTQ1I	Ondansetron	Approved	34	.	.	.	.	Nausea	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCGHA0E	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMWSXI4	Acetylcysteine	Approved	34	.	.	.	.	Hepatocellular Carcinoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCGNDPC	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMOTQ1I	Ondansetron	Approved	34	.	.	.	.	Chemotherapy-Induced Nausea and Vomiting	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCGPVYT	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCI2Y9F	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMSPJG2	Ropivacaine	Approved	34	.	.	.	.	Total Knee Arthroplasty	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCI70YL	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMQ8FR2	Prednisolone	Approved	34	.	.	.	.	Urticaria	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCI7DR4	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMHWE7P	Ampicillin	Approved	34	.	.	.	.	Preterm Premature Rupture of Membrane	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCIM353	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMVYRH2	Perifosine	Phase 1	17	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCJMJ80	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMUIASK	Cosyntropin	Approved	34	.	.	.	.	Development	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCM59BB	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM8I94Y	Venetoclax	Approved	34	.	.	.	.	Relapsed/Refractory Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCMIO5Q	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMF28YC	Atorvastatin	Phase 3 Trial	25	.	.	.	.	Immune Reconstitution Inflammatory Syndrome	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCNPMP5	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Hemophagocytic Syndrome	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCQ32EK	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMSPJG2	Ropivacaine	Approved	34	.	.	.	.	"Anesthesia, Local"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCRQXDW	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMBHMOX	Palonosetron	Approved	34	.	.	.	.	Chemotherapy-Induced Nausea and Vomiting	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCT9A4G	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM48K0X	Carfilzomib	Approved	34	.	.	.	.	Waldenstrom's Macroglobulinemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCXRLI0	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMS104F	Temsirolimus	Approved	34	.	.	.	.	Refractory Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCZG6E3	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMH2NMY	Mepivacaine	Approved	34	.	.	.	.	Anesthesia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC0Y93T	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNO38U	Bortezomib	DMWMPD4	Vorinostat	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCBMWYN	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM58WKG	Panobinostat	Approved	34	DM73A5J	Lenalidomide	DMNO38U	Bortezomib	Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCHSY3P	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMKQTBA	Diphenhydramine	Approved	34	DMLB81S	Paclitaxel	DMWXZH1	Famotidine	Metastatic Appendiceal Adenocarcinoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCL1WDJ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM58WKG	Panobinostat	Approved	34	DM73A5J	Lenalidomide	DMNO38U	Bortezomib	Multiple Myeloma in Relapse	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCW6FDO	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMINOX3	Vincristine	DMZD5QR	Cytarabine	B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCXNKIO	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM48K0X	Carfilzomib	Approved	34	DM58WKG	Panobinostat	DM73A5J	Lenalidomide	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC03O1X	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM48K0X	Carfilzomib	Approved	34	DMNE7L3	CC-220	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC0T6J6	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM8I94Y	Venetoclax	Approved	34	DMNO38U	Bortezomib	.	.	Relapsed/Refractory Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC18VJ2	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTA5OE	Azacitidine	.	.	Refractory Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC1IKV8	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM8X2EH	Everolimus	Approved	34	DMMX75K	LEE011	.	.	Acute Lymphoblastic Leukemia ALL	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC1K0UI	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMINOX3	Vincristine	Approved	34	DMP6SC2	Irinotecan	.	.	Non-Hodgkins Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC36V79	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMYZJGB	Ibrutinib	.	.	Refractory Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC3A0YB	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	DMYZJGB	Ibrutinib	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC3H4D0	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM48K0X	Carfilzomib	Approved	34	DMYZJGB	Ibrutinib	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC5ITF8	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM48K0X	Carfilzomib	Approved	34	DMTGBAX	Pomalidomide	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC5KSWK	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNO38U	Bortezomib	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC6B7B1	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	DMTGBAX	Pomalidomide	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC7AK5T	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWMPD4	Vorinostat	.	.	Relapsed or Refractory Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC9TIYU	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMX4DQH	Delanzomib	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCE18BM	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM48K0X	Carfilzomib	Approved	34	DM73A5J	Lenalidomide	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCEK6HT	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNE7L3	CC-220	Phase 2	21	DMNO38U	Bortezomib	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCGA61A	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM8X2EH	Everolimus	Approved	34	DMMX75K	LEE011	.	.	Pediatric Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCH2WO3	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM48K0X	Carfilzomib	Approved	34	DM4O2Z7	Cyclophosphamide	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCO0ZYT	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM48K0X	Carfilzomib	Approved	34	DM58WKG	Panobinostat	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCO7BZC	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMSTH01	Rocilinostat	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCQ1M1S	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	DMTGBAX	Pomalidomide	.	.	Refractory Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCTATFC	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM48K0X	Carfilzomib	Approved	34	DM73A5J	Lenalidomide	.	.	Relapsed Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCTGZ6D	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMT5GNL	Romidepsin	Approved	34	DMTGBAX	Pomalidomide	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCVMOZF	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	DMZ4Q0B	Dasatinib	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC19WBF	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMD7L94	Palbociclib	Approved	34	.	.	.	.	Recurrent B Acute Lymphoblastic Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC1NP4F	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	"Relapsed, Refractory, Multiple Myeloma"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC3UGXZ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMDZ6Q3	Napabucasin	Phase 3	25	.	.	.	.	Hematologic Malignancy	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC7ALU7	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC9VLXR	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMC5SAW	LY3039478	Phase 1/2	19	.	.	.	.	T-cell Acute Lymphoblastic Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCF49EV	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMAHJEF	Betamethasone	Approved	34	.	.	.	.	Preterm Birth	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCLMXIE	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMC7W6R	Selumetinib	Investigative	0	.	.	.	.	Acute Lymphoblastic Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCM9R3V	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMI4EL5	Ketorolac	Approved	34	.	.	.	.	Chronic Migraine	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCMDEES	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNE7L3	CC-220	Phase 2	21	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCU26BD	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPRI8G	Buprenorphine	Approved	34	.	.	.	.	Postoperative Pain	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCUH85L	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMMX75K	LEE011	Phase 3	25	.	.	.	.	Acute Lymphoblastic Leukemia ALL	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCXVAYA	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMJ7IKW	PF-4494700	Phase 3	25	.	.	.	.	Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCYE82W	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMABXOZ	Hyaluronic acid	Phase 4	31	.	.	.	.	"Hearing Loss, Sudden"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC0Y025	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	0.04	2.29	3.47	2.85
DCDSBJ6	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	T-cell leukemia/lymphoma	DrugCombDB Database	Investigative	ED-40515	7.726	8	21.053	8
DCD221N	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	4.468	3.51	12.751	14.112
DCNDT5T	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.74	9.05	1.96	8.75
DCK992U	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.21	8.54	1.01	6.17
DCD1NQR	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	5.66	7.52	7.84	13.46
DCWCO3K	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	7.81	8.72	2.91	1.91
DCBP866	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.36	11.77	9.32	9.96
DC6HX86	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.34	0.45	3.15	11.08
DC7JN49	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	5.23	5.01	6.89	12.25
DCQR7NG	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	3.02	4.84	0.73	12.94
DC0VBLG	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	10.45	10.47	19.05	22.41
DC4H5TR	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	10.59	16.33	5.84	16.72
DC1K6QJ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.32	0	0.8	5.64
DCRGPGX	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	12.31	2.28	4.94	1.17
DCIXWLS	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.98	7.18	3.05	5.38
DCNM3Z7	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	9.56	13.08	0.77	12.85
DC85RYX	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	10.01	11.59	4.44	9.91
DC044UG	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.87	8.1	6.2	5.85
DC0M25W	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	10.65	10.67	20.92	22.37
DCZLEFX	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.15	12.77	11.8	11.8
DCDXH5S	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.23	15.25	11.25	11.32
DCIIVTM	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.96	1.12	2.3	2.32
DC1VFXJ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	14.68	14.47	10.83	21.8
DCOFOQN	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	12.75	12.2	18.49	22.56
DCMNRKP	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	6.37	13.26	1.7	12.43
DCNH5AF	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	5.95	14.4	2.14	10.83
DCVI8ZX	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	4.17	7.67	1.24	1.27
DC8O7KB	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	7.08	16.52	6.67	6.67
DCWCWU0	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	8.9	10.23	2.98	0.06
DCAP87Q	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.27	4.09	1.03	1.5
DCSY83A	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.08	1.2	1.03	2.93
DCY4MF9	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	10.98	18.72	17.26	16.85
DC0GJLH	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.79	2.49	3.03	5.27
DCC7VSS	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.67	9.19	2.36	8.86
DC7KVUE	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.15	16.17	9.96	13.5
DC6MTFC	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	0.29	3.17	8.09	8.11
DCUB7T6	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	6.58	10.59	11.05	11.09
DC3BZWQ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	4.36	9.14	2.19	2.19
DC5BFVO	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.71	9.63	1.07	7.51
DCIYX12	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.75	9.18	8.24	8.24
DC10JH8	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	12.44	11.05	9.16	7.96
DCTX4N9	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	8.81	8.53	15.78	18.25
DCY02L5	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.05	1.59	0.45	3.8
DCKCQ3X	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	8.22	8.14	2.33	14.71
DCU4YAP	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	5.93	7.98	13.47	13.93
DCHXVN3	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	6.87	6.79	4.46	14.08
DCT996C	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	54.84	55.95	19.78	23.56
DCVF007	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	HDLM-2	6.05	9.66	10.43	10.86
DC4Q1KC	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-428	33.96	37.44	2.53	1.5
DCR0NRN	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.73	1.47	14.87	14.89
DCLZROW	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	6.74	10.99	2.01	8.71
DCPDRHO	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	5.7	4.26	2.93	6.28
DC8NQEO	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	3.76	5.23	2.28	2.28
DC7QVM9	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	1.19	4.66	3.14	3.31
DCU5QH3	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.4	4.72	2.78	3.64
DC5JZHB	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	5.36	5.85	18.84	18.84
DCLIQLP	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8.71	13.72	9.64	15.69
DCF0VE2	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	4.19	5.46	0.27	0.14
DCXESMF	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.72	6.9	14.87	16.41
DCPU7Z8	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	6.65	11.03	0.68	8.78
DCQ5G9N	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	8.76	10.47	2.09	14.55
DCVPVB3	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	3.76	3.56	7.82	11.85
DCR46IZ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	6.73	12.08	3.23	11.78
DCVSEVB	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.02	6.03	4.52	2.41
DC87ZNB	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	5.87	6.48	8.83	9.27
DCJ9ULG	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.91	12.69	8.23	18.19
DC7JABQ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.88	12.96	9.48	10.52
DCWR38P	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.73	11.87	16.34	16.4
DCGCX8B	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	0.1	1.35	8.85	9.79
DC7EDRT	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	13.29	18.41	1.03	13.19
DCOCK17	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	5.32	5.31	5.81	16.95
DCSWWNX	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	10.2	10.21	7.67	17.54
DCC502R	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	3.52	2.44	3.2	10.76
DCYTC7L	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8.05	12.36	0.03	15.55
DCB6NYP	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.27	3.66	19.38	19.79
DCF3HD1	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	11.52	12.94	2.03	11.69
DCR3GDK	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.74	3.51	1.45	1.7
DCHF3OM	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	12.51	18.31	14.39	22.66
DC26MDL	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.06	17.81	3.39	17.28
DCL6L5N	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	9.4	11.11	0.48	7.03
DCCCOBQ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.57	9.9	9.51	8.48
DCMLR5M	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	1.28	10.36	0.69	12.55
DC2A1LW	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	14.93	19.58	7.39	16.97
DCM0LIA	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.69	4.43	5.59	6.91
DCBPDEA	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	6.88	8.9	5.16	3.96
DCUNTUC	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.44	13.17	5.7	10.69
DCJFQK7	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	6.41	6.8	13.83	10.98
DCDTPGA	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	28.16	25.28	7.24	24.43
DCHTLOE	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	10.78	15.85	2.76	18.65
DC2HRX1	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.3	9.11	10.3	13.35
DCHKMNP	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	7.62	9.41	1.4	0.3
DCXK2VA	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	3.07	2.36	1.16	13.32
DC0KUZK	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	19.82	20.75	0.32	25.2
DC42MB0	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	0.29	1.53	11.04	15.25
DC2NSDB	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	7.55	8.41	2.41	11.88
DCY75BB	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	5.98	5.61	5.7	14.98
DCDCQPD	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.87	3.47	3.1	0.71
DCI2MTQ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	5.78	7.28	2.1	8.02
DCLOB6S	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.52	2.04	5.82	8.76
DC6E1IO	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	17.18	19.65	11.93	18.56
DC1WR3D	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.62	6.35	0.44	4.36
DC1I7LO	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	4.22	10.6	1.14	6.47
DCXVVRM	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	0.5	11.16	0.4	4.4
DC2MSQ5	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	0.01	13.23	7.78	10.29
DCXCT6J	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	14.02	13.77	18.64	14.99
DC41P8S	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	0.79	2.7	2.55	4.83
DCXZFEJ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.25	5.55	0.46	3.75
DC1TL9N	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.31	2.75	14.63	16.02
DCV0P5Q	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	18.21	17.66	21.36	21.36
DCC74UJ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	4.06	9.87	3.73	8.26
DCNBUQE	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	24.7	27.78	17.18	26.74
DC61OFO	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.27	7.1	7.51	7.51
DC8DMA4	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	0.64	11.52	1.76	7.53
DC11AG5	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	11.22	20.44	12.04	18.6
DCTMZKH	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	8.03	13.86	13.22	17.21
DCR9A1J	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.62	5.78	6.35	11.51
DCOS1H7	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.71	4.94	0.14	0.14
DCNFRJ0	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	0.7	4.68	5.02	5.12
DCLVMMX	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.71	4.75	2.28	3.79
DC3096L	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	3.96	3.57	1.35	0.22
DC981EM	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.46	4.77	1.69	0.86
DC1G4GJ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	8.63	13.84	22.43	14.01
DCGC0JJ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.43	5.19	7.21	7.41
DCMWQHM	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	2.13	9.06	4.73	5.29
DCPMA9S	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	6.75	12.31	8.86	10.54
DCZMIT4	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	0.6	5.47	3.4	3.86
DCHJ8ZA	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.49	9.61	2.67	2.79
DCQSRQD	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	9.02	11.77	5.71	5.05
DC1F8BN	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	1.65	6.02	6.29	5.91
DCSECRO	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	0.09	0.4	0.74	0.92
DC3QNW9	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.54	11.24	3.28	8.77
DCL3DNU	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	0.76	8.75	7.61	7.55
DCQXYMX	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.56	7.15	3.39	2.96
DCYXSWN	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.14	7.85	6.02	6.02
DCN7EE4	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	1.56	3.31	3.24	3.24
DCD33X0	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	4.07	15.72	11.53	11.33
DCPEXF1	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	5.58	8.85	1.15	1.45
DCLBMHJ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	1.64	14.9	13.23	12.64
DC51FMU	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	10.1	17.58	13.6	13.6
DCN876R	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	4.53	4.07	5.5	5.5
DCLU22L	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	0.32	6.65	1	5.07
DCNLY9E	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	8.57	7.07	7.36	7.36
DCAQ015	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	6.71	8.8	1.64	1.32
DC37XRR	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	11.32	11.44	14.7	16.36
DCJP280	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	22.77	12.73	12.13	3.98
DCGF6EQ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	14.07	16.26	0.66	15.55
DC9HZNA	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	18.52	23.06	0.55	14.85
DCGXVA6	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	6.31	5.19	4.01	7.9
DCYE5JJ	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	8.17	1.76	3.4	4.89
DCPPRD4	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.14	9.74	1.57	10.28
DC0EA1U	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	7.65	8.67	15.76	15.95
DCSN65F	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	21.83	21.57	28.75	31.78
DCT7LHO	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	45.98	44.7	32.22	43.62
DCJCNU0	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.62	7.42	7.66	8.91
DCRIMCR	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.97	11.12	6.7	15.53
DCEADKP	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	1.9	11.53	7.45	7.45
DCMOB37	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	6.02	15.84	12.41	14.32
DCE03E8	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	9.05	11.9	5.69	17.36
DCG8PIH	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.46	10.74	1.36	15.33
DCI84YB	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	6.55	6.46	12.31	20.43
DCIS814	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	38.81	38.77	20.06	20.11
DCIBUTG	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	1.47	2.55	0.76	2.74
DCUPBVC	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	2.63	8.07	4.31	4.23
DC2DHLD	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.75	4.05	2.39	2.39
DCJ7AB9	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	9.36	11.94	2.53	0.6
DC6PHP7	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	3.19	0.37	7.56	13.01
DCA3K95	DMMWZET	Dexamethasone	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.19	6.92	4.08	5.75
DC8Q8XT	DMMWZET	Dexamethasone	Phase 3 Trial	25	DM7KI4E	Oblimersen	Phase 3	25	.	.	.	.	Multiple myeloma	TTD Database	Investigative	.	.	.	.	.
DC9YJI0	DM62QTW	RTB101	Phase 3	25	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Metastatic Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCQOP4C	DM62QTW	RTB101	Phase 3	25	DM8X2EH	Everolimus	Approved	34	.	.	.	.	Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCZ9GJK	DM62QTW	RTB101	Phase 3	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	4.345	3.537	0.195	2.538
DC6UWIV	DM62QTW	RTB101	Phase 3	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	3.77	3.54	0.14	2.54
DC265RO	DM62QTW	RTB101	Phase 3	25	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	T-cell leukemia/lymphoma	DrugCombDB Database	Investigative	ED-40515	4.474	4.978	5.466	10.186
DCFKO78	DM62QTW	RTB101	Phase 3	25	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	12.478	12.726	17.24	18.861
DCK7WYH	DM62QTW	RTB101	Phase 3	25	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	12.48	12.73	17.24	18.86
DCI41AE	DM62QTW	RTB101	Phase 3	25	DM2JGQ3	Trametinib	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	8.488	8.307	11.715	14.407
DC46MY2	DM62QTW	RTB101	Phase 3	25	DM3XQDH	JQ1	Investigative	0	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	18.908	20.033	9.198	13.213
DCG35RB	DM62QTW	RTB101	Phase 3	25	DM3XQDH	JQ1	Investigative	0	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	25.189	26.403	2.508	9.639
DCN9DEL	DM62QTW	RTB101	Phase 3	25	DM48K0X	Carfilzomib	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	3.449	0.789	4.027	5.645
DCOL24G	DM62QTW	RTB101	Phase 3	25	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	4.36	4.42	7.18	12.83
DCX0FAM	DM62QTW	RTB101	Phase 3	25	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	13.575	12.772	2.406	3.851
DCLJAZU	DM62QTW	RTB101	Phase 3	25	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	9.82	9.85	7.45	15.7
DCLNLE2	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	8.17	6.67	6.14	10.29
DC3LEMX	DM62QTW	RTB101	Phase 3	25	DM7GCVW	Acalabrutinib	Approved	34	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	6.62	5.86	5.26	8.92
DCF3SL2	DM62QTW	RTB101	Phase 3	25	DM91LGU	Abexinostat	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	8.173	5.879	15.748	19.472
DCEI2EO	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	0.16	0.93	0.2	4.72
DCP87VX	DM62QTW	RTB101	Phase 3	25	DM9ZOMD	CUDC-101	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	11.677	10.862	0.919	5.003
DC1DRHZ	DM62QTW	RTB101	Phase 3	25	DM9ZOMD	CUDC-101	Phase 1	17	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	11.67	10.86	0.9	5
DC6C18S	DM62QTW	RTB101	Phase 3	25	DMC56T4	RAF265	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	2.819	5.215	2.323	3.819
DCN7VTJ	DM62QTW	RTB101	Phase 3	25	DMCQBFT	Parthenolide	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	10.395	11.103	0.52	1.524
DCY7G9P	DM62QTW	RTB101	Phase 3	25	DMDMQIE	THAPSIGARGIN	Preclinical	2.1	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	12.176	12.592	11.823	13.146
DC5OWWA	DM62QTW	RTB101	Phase 3	25	DMDMQIE	THAPSIGARGIN	Preclinical	2.1	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	12.17	12.59	11.82	13.15
DC7CCIO	DM62QTW	RTB101	Phase 3	25	DMF3MV1	GDC-0980/RG7422	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	7.88	8.56	3.094	7.141
DCSNU5R	DM62QTW	RTB101	Phase 3	25	DMH7W9X	SNDX-275	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	18.596	18.437	9.075	9.833
DCDBQM3	DM62QTW	RTB101	Phase 3	25	DMH7W9X	SNDX-275	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	6.791	6.274	11.793	13.873
DCSUK3R	DM62QTW	RTB101	Phase 3	25	DMLB0EZ	Tamoxifen	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	5.448	7.963	1.211	2.96
DCB91XB	DM62QTW	RTB101	Phase 3	25	DMLB0EZ	Tamoxifen	Approved	34	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	5.45	7.96	1.19	2.96
DCG1N85	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	3.19	2.09	0.68	4.95
DCV9N5G	DM62QTW	RTB101	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	3.58	3.58	10.29	10.34
DC5B5FF	DM62QTW	RTB101	Phase 3	25	DMN5T2A	Ciclopirox	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	10.537	11.475	8.934	10.221
DCJOA8Z	DM62QTW	RTB101	Phase 3	25	DMNE1FR	Resminostat	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	10.92	12.07	7.12	9.92
DCPY2E2	DM62QTW	RTB101	Phase 3	25	DMNE56X	ABT-263	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	11.275	16.148	3.798	9.233
DCWYMQG	DM62QTW	RTB101	Phase 3	25	DMO8PT9	MLN8237	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	9.884	10.323	1.234	3.18
DC9WTC5	DM62QTW	RTB101	Phase 3	25	DMP56WJ	CF102	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	18.74	18.89	4.49	7.71
DCXD9FC	DM62QTW	RTB101	Phase 3	25	DMPAJ41	BIIB-021	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	2.256	1.837	4.899	6.794
DCCU8JN	DM62QTW	RTB101	Phase 3	25	DMPK32V	BMS-754807	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	13.327	18.552	19.195	19.829
DC4NMG7	DM62QTW	RTB101	Phase 3	25	DMPK32V	BMS-754807	Phase 1	17	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	13.33	18.55	19.19	19.83
DCTB8RL	DM62QTW	RTB101	Phase 3	25	DMQLODU	Citarinostat	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	7.02	5.04	13.67	16.69
DCWSFWI	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	2.6	2.34	2.5	8.48
DCCTQBV	DM62QTW	RTB101	Phase 3	25	DMCD9YG	Prazosin	Phase 2 Trial	21	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	3.729	4.53	1.952	3.475
DCLC3IB	DM62QTW	RTB101	Phase 3	25	DMSI5CB	Chloroquine	Approved	34	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	2.37	4.92	0.6	1.1
DC5X7EN	DM62QTW	RTB101	Phase 3	25	DMSLE03	PF-562271	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	21.6	22.64	2.15	8.26
DCZ6RQ7	DM62QTW	RTB101	Phase 3	25	DMSLE03	PF-562271	Phase 1	17	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	11.75	12.14	6.12	9.98
DCJ4NFR	DM62QTW	RTB101	Phase 3	25	DMSLE03	PF-562271	Phase 1	17	.	.	.	.	Primitive neuroectodermal tumor	DrugCombDB Database	Investigative	TC-32	18.91	20.03	9.2	13.21
DCT9EFX	DM62QTW	RTB101	Phase 3	25	DMTYXQF	NVP-AUY922	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	14.884	15.845	0.153	4.945
DCHFGO8	DM62QTW	RTB101	Phase 3	25	DMU10FE	THZ1	Investigative	0	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	2.18	1.61	1.81	4.74
DC6U2VI	DM62QTW	RTB101	Phase 3	25	DMVN2E6	Vinpocetine	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	SU-DIPG-XIII	9.215	7.846	0.037	0.023
DCXUXOD	DM62QTW	RTB101	Phase 3	25	DMX6PLV	Sodium valproate	Investigative	0	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	2.305	1.466	1.867	0.133
DCZ9Z4K	DM62QTW	RTB101	Phase 3	25	DMY8WDB	CB3304	Phase 1/2	19	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	25.885	25.222	0.001	1.874
DCBDYYO	DM62QTW	RTB101	Phase 3	25	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	2.22	2.32	9.89	12.66
DCJTRP0	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.01	0.21	2.46	5.46
DCMMMHJ	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.53	1.36	8.07	3.94
DCXS7DH	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.8	0.09	1.02	6.6
DCWJIQJ	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.53	1.54	11.18	13.18
DC0AU7S	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	8.77	6.51	14.37	17.24
DC70T79	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.35	5.47	9.95	11.48
DCO7IGG	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.65	3.21	7.24	8.63
DCAQ2G2	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.07	2.95	3.72	8.44
DCANIEV	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.3	1.13	4.58	7.07
DCLV1F4	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.46	3.07	3.07	7.69
DC1OJR8	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.05	0.86	10.2	12.64
DCQF1SQ	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	1.65	1.53	3.59	6.33
DCIUOPX	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.33	4.58	9.29	12.53
DCVV2VP	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.47	6.21	5.45	8.67
DCDS03D	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.43	3.68	3.84	6.77
DCXFJ3A	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.71	2.16	2.51	6.35
DCLQE0M	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.08	1.04	4.06	6.23
DCL12U8	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.13	4.06	2.47	6.91
DCVCHPB	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.75	2.45	6.3	9.29
DC42M44	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	4.42	5.03	3.45	8.34
DCSMB49	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.54	1.13	4.13	5.88
DC32D75	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.88	0.35	2.46	5.26
DCON33B	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.63	2.23	3.94	8.1
DCQBGAY	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.44	7.85	7.52	11.31
DCB3AZD	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	7.13	5.89	4.12	9.51
DCJ9XJF	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	0.86	0.36	5.96	10.99
DCGNUZG	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.32	0.75	3.79	10.09
DCGS356	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.8	4.59	3.17	8.38
DCO1OM9	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	6.37	6.23	0.82	11.02
DCY6OHD	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.43	1.07	2.03	7.43
DC2NKIV	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	15.03	16.08	15.22	19.09
DC5M4WP	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.85	1.7	6.34	10.11
DCVZWY1	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.9	1.19	3.51	8.63
DCF2M9K	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.4	3.88	4.82	11.13
DCOPYPO	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.66	4.47	6.64	11.84
DC4B8MO	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.56	3.89	1.17	8.45
DCSDK7Q	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.9	0.99	0.13	3.15
DCC1WXX	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.12	0.54	1.85	6
DC0LIV0	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.07	1.21	2.36	6.49
DC8COYX	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.15	9.5	10.35	15.74
DCQ7H9K	DM62QTW	RTB101	Phase 3	25	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	1.18	0.17	4.42	6.27
DCMVQXP	DM62QTW	RTB101	Phase 3	25	DM2JGQ3	Trametinib	Approved	34	.	.	.	.	Embryonal rhabdomyosarcoma	SYNERGxDB Database	Investigative	Rh36	21.25	26.028	9.381	10.718
DCZXVQJ	DM62QTW	RTB101	Phase 3	25	DM2JGQ3	Trametinib	Approved	34	.	.	.	.	Embryonal rhabdomyosarcoma	SYNERGxDB Database	Investigative	CTR	15.455	14.06	3.681	4.914
DCZNA62	DM62QTW	RTB101	Phase 3	25	DM2JGQ3	Trametinib	Approved	34	.	.	.	.	Embryonal rhabdomyosarcoma	SYNERGxDB Database	Investigative	RD	22.213	23.407	8.084	8.736
DC2AJYS	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.37	0.27	1.09	7.34
DCAVLNZ	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.3	1.12	9.27	11.71
DCYMZHV	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	1.84	0.46	0.22	5.22
DCN0Q5D	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.96	0.32	3.78	7.57
DCKA5NH	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	4.82	3.86	6.84	9.28
DC2QPIS	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	7.71	5.76	5.81	10.02
DCFO2BC	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.95	3.41	4.28	6.31
DCDEWZD	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.54	0.93	6.53	9.81
DCTFSEU	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	9.73	8.15	10.19	15.11
DCTMSTN	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	3.32	2.64	4.75	7.66
DCVONCU	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	9.54	5.55	7.46	9.16
DCDOI0G	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	18.76	16.69	14.63	22.06
DCY2RQO	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	5.41	4.71	7.94	11.39
DCOS18K	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	10.53	10.93	1.11	15.94
DC4331X	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.13	6.87	0.42	11.76
DCYXLID	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	14.06	9.81	7.72	11.18
DCJJ5G0	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	3.32	0.12	0.2	4.94
DCMI9TQ	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	10.78	13.01	1.23	16.24
DCO053M	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.56	5.31	5.78	9.67
DC8QJPQ	DM62QTW	RTB101	Phase 3	25	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	2.52	4.22	3.82	8.72
DCK4H65	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.62	2.68	3.15	6.95
DCDER3M	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.52	2.99	0.94	8.84
DCU89D9	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	0.56	0.48	1.56	2.51
DCI5ZDI	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.8	4.81	7.83	11.13
DC61SB2	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.4	3.63	3.61	8.18
DCNBLJJ	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	6.63	6.93	8.49	12.47
DCJS2P9	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	6.67	8.65	8.12	12.1
DC195ZG	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	8.14	7.2	6.79	10.02
DC5FL23	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.06	3.18	1.53	7.97
DC1TSGF	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.67	7.89	9.18	13.14
DC25U1I	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.51	2.97	3.44	7.73
DC0QG2Q	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	2.97	2.48	3.4	7.13
DCA4PKC	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.35	7.22	12.66	14.38
DC73RMG	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	8.66	8.77	8.03	12.3
DCGQTR9	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	0.51	2.35	7.64	8.97
DCBB4AQ	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	8.75	9.7	5.86	11.24
DC4VG6Z	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.16	1.84	3.81	7.27
DCVDE1Y	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	5.57	5.39	6.69	10.62
DC78ZRE	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	8.65	7.64	8.4	13.06
DCBLW49	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	5.44	5.27	6.84	9.63
DCUHBEJ	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.43	6.53	7.45	11.72
DCJGGBO	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	10.77	8.65	12.25	10.75
DCQJMLK	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	3.54	2.46	5.36	8.92
DCHJCX9	DM62QTW	RTB101	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	4.39	6.56	6.03	6.72
DCXJOW8	DM62QTW	RTB101	Phase 3	25	DMF9M57	Cotellic	Phase 3	25	.	.	.	.	Embryonal rhabdomyosarcoma	SYNERGxDB Database	Investigative	Rh36	22.053	21.407	10.06	9.121
DCIK6JV	DM62QTW	RTB101	Phase 3	25	DMF9M57	Cotellic	Phase 3	25	.	.	.	.	Embryonal rhabdomyosarcoma	SYNERGxDB Database	Investigative	CTR	19.72	19.153	5.503	6.29
DC9B0VR	DM62QTW	RTB101	Phase 3	25	DMF9M57	Cotellic	Phase 3	25	.	.	.	.	Embryonal rhabdomyosarcoma	SYNERGxDB Database	Investigative	RD	19.866	18.78	7.359	8.071
DCDAC43	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	1.41	0.73	1.14	4.05
DCWQ8GD	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.76	2.86	2.83	7.23
DCNN60Y	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.06	1.81	1.56	6.85
DC633J4	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	1.83	1.83	0.48	4.49
DCK1RN6	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	8.49	9.81	7.19	11.9
DC11JDJ	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.56	2.1	2.12	6.07
DC2FP5T	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	3.88	3.83	2.07	6.69
DCAAG7Z	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	5.71	6.16	3.31	8.9
DCYA1NH	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	3.54	2.79	0.75	6.32
DC1JPKC	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.54	2.12	2.5	5.18
DCI3XU5	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.99	4.65	1.81	5.75
DCVFEF2	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	3.25	1.01	0.17	4.7
DC6B4WV	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.41	3.95	0.81	5.38
DCVYWZH	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.97	6.67	5.68	9.52
DCP24AP	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	4.78	3.06	0.99	5.5
DCWP25P	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	1.85	1.84	0.96	5.66
DC7KTTZ	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	6.38	5.3	5.35	8.28
DCJH8R6	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	2.69	3.17	1.1	5.74
DCGTM6F	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.61	4.71	5	9.09
DCPKBCI	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	5.99	4.91	5.56	7.52
DCH0RMP	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	4.05	3.58	2.55	7.17
DC6P8BI	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	9.16	6.94	4.08	8.61
DCUA4QR	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.02	7.7	1.66	7.75
DC1AMWS	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	2.4	3.8	0.14	5.14
DCD3KOO	DM62QTW	RTB101	Phase 3	25	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	11.72	12.02	10.5	15.55
DCUVNIS	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	0.75	1.03	2.46	9.07
DCJBKUL	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	0.56	0.52	1.39	3.15
DCBGLHP	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	5.15	5.56	3.02	8.86
DC2GJI8	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	6.12	4.93	7.25	11.67
DC94XDY	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	8.07	7.93	3.54	12.27
DCB2JM4	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	2.78	1.29	1.42	6.19
DCYJRRX	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	7.07	5.91	2.84	10.4
DCRYRK1	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.99	0.2	7.17	10.45
DCYYCYP	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	8.49	7.2	4.53	9.51
DCRT4O2	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	9.24	8.28	5.46	11.09
DCVXHTC	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.88	3.82	6.1	10.4
DCOY5B0	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	7.49	7.89	6.64	12.66
DCYT66Q	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.21	0.64	3.03	9.2
DCFN2Z9	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	18.65	19.15	10.41	23.62
DCJSEFX	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	5.61	5.16	7.45	11.66
DC3NJT4	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	7.78	7.06	9.87	14.09
DCEWYXO	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8.49	10.1	8.52	13.34
DC4UA5G	DM62QTW	RTB101	Phase 3	25	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.45	3.79	3.17	8.05
DCWH8ZQ	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	4.16	4.79	2.18	8.38
DC16IMQ	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.54	3.7	10.93	12.31
DCAMME7	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.77	1.99	3.29	9.21
DCER6YV	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	9.65	6.58	7.16	13.1
DCBMABY	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.49	3.58	3.68	8.84
DCGOKWW	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	5.59	5.3	6	11.56
DCY5M0B	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.57	5.47	8.01	12.27
DCV8R3T	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.79	7.74	4.52	12.28
DCI0JA3	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	17.34	15.14	11.03	20.21
DCD1WE6	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	9.65	10.03	4.29	10.19
DCFDGW8	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.66	3.84	2.66	9.53
DCUAEPT	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	4.38	3.44	3.3	9.13
DC9E420	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	4.79	4.8	5.53	11.14
DCBHBJQ	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	4.16	4.31	7.06	11.34
DCH921X	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.98	5.53	2.99	9.8
DC9MEAQ	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	5.09	4.81	7.47	8.53
DCD4HXN	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	8.36	5.16	0.78	7.61
DCMG216	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	3.99	3.77	4.11	8.92
DCRLTY9	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	13.33	13.09	9.08	14.7
DCELGF6	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	3.11	2.96	6.69	11.35
DCD077A	DM62QTW	RTB101	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	8.61	11.34	5.22	10.93
DCSZAA6	DMDI269	Docetaxel	Approved	34	DMPDW6T	Epirubicin	Approved	34	DMY38SB	CATECHIN	.	.	Breast Cancer	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DC11HNK	DMDI269	Docetaxel	Approved	34	DMPDW6T	Epirubicin	Approved	34	DMTS85L	Capecitabine	.	.	Breast Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC4CO7S	DMDI269	Docetaxel	Approved	34	DMG281S	Carboplatin	Approved	34	DMMX2E6	Pemetrexed	.	.	Non-small Cell Lung Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC57S8S	DMDI269	Docetaxel	Approved	34	DMDI269	Docetaxel	Approved	34	DMP6SC2	Irinotecan	.	.	Esophageal Carcinoma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC8P2TD	DMDI269	Docetaxel	Approved	34	DMLB81S	Paclitaxel	Approved	34	DMTJAEP	Vinflunine	.	.	Locally Advanced or Metastatic Unresectable Urothelial Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCFMABY	DMDI269	Docetaxel	Approved	34	DMGL19D	Enzalutamide	Approved	34	DMQ8FR2	Prednisolone	.	.	Metastatic Castration Resistant Prostate Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC2J3QA	DMDI269	Docetaxel	Approved	34	DMMQ2OW	Nintedanib	Phase 2 Trial	21	.	.	.	.	"Carcinoma, Non-Small-Cell Lung"	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCCIJAA	DMDI269	Docetaxel	Approved	34	DMQUSBT	Daunorubicin	Approved	34	.	.	.	.	Endometrial Neoplasms	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCP3FIP	DMDI269	Docetaxel	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Urothelial Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC775W1	DMDI269	Docetaxel	Approved	34	DMDI269	Docetaxel	Approved	34	DMG281S	Carboplatin	.	.	High-grade Serous Ovarian Carcinoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCI3EHU	DMDI269	Docetaxel	Approved	34	DMIXC7G	Zoledronate	Approved	34	DMWTAOI	Estramustine	.	.	Hormone-Refractory Prostate Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCU1KY6	DMDI269	Docetaxel	Approved	34	DMQNWRD	Oxaliplatin	Approved	34	DMQNWRD	Oxaliplatin	.	.	Gastric Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCZA6J2	DMDI269	Docetaxel	Approved	34	DMQNWRD	Oxaliplatin	Approved	34	DMTS85L	Capecitabine	.	.	Gastric Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCMSCEH	DMDI269	Docetaxel	Approved	34	DMGL19D	Enzalutamide	Approved	34	.	.	.	.	Metastatic Castration-Resistant Prostate Cancer (mCRPC)	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCR841C	DMDI269	Docetaxel	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Breast Neoplasms	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCS38PC	DMDI269	Docetaxel	Approved	34	DMPAZHC	Cabazitaxel	Approved	34	.	.	.	.	Prostate Carcinoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCVPMM8	DMDI269	Docetaxel	Approved	34	DMSH4DG	Silibinin	Phase 2/3	24	.	.	.	.	Upper GI Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC6DYV3	DMDI269	Docetaxel	Approved	34	DMF57DM	Pazopanib	Approved	34	DMG281S	Carboplatin	.	.	"Neoplasms, Breast"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCXQDVZ	DMDI269	Docetaxel	Approved	34	DMQNWRD	Oxaliplatin	Approved	34	DMTS85L	Capecitabine	.	.	Esophagus Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC0KSVQ	DMDI269	Docetaxel	Approved	34	DMKSUOI	Flavopiridol	Phase 2	21	.	.	.	.	Adenocarcinoma of the Pancreas	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC15B1A	DMDI269	Docetaxel	Approved	34	DMG281S	Carboplatin	Approved	34	.	.	.	.	Ovarian Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC18SUA	DMDI269	Docetaxel	Approved	34	DMIK6C9	Zibotentan	Discontinued in Phase 3	9	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC1DKCA	DMDI269	Docetaxel	Approved	34	DMY38SB	CATECHIN	Investigative	0	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC27E5H	DMDI269	Docetaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Metastatic Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC4YXHW	DMDI269	Docetaxel	Approved	34	DMMX2E6	Pemetrexed	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC53GGM	DMDI269	Docetaxel	Approved	34	DMP6SC2	Irinotecan	Approved	34	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC68PRA	DMDI269	Docetaxel	Approved	34	DMIQ31Y	Custirsen	Phase 3	25	.	.	.	.	Non-Small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC7M6MW	DMDI269	Docetaxel	Approved	34	DMMX2E6	Pemetrexed	Approved	34	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC7OT9R	DMDI269	Docetaxel	Approved	34	DMVYRH2	Perifosine	Phase 1	17	.	.	.	.	Ovarian Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC7YMDW	DMDI269	Docetaxel	Approved	34	DMYISJK	PX-866	Phase 2	21	.	.	.	.	Non Small Cell Lung Cancer (NSCLC)	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC83PVM	DMDI269	Docetaxel	Approved	34	DMP6SC2	Irinotecan	Approved	34	.	.	.	.	Esophageal Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC8AWAI	DMDI269	Docetaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCB58HH	DMDI269	Docetaxel	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Non-small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCBH0CB	DMDI269	Docetaxel	Approved	34	DMPZI3Q	Ketoconazole	Approved	34	.	.	.	.	Solid Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCBWDP3	DMDI269	Docetaxel	Approved	34	DMMX2E6	Pemetrexed	Approved	34	.	.	.	.	Non Small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCCWXZ6	DMDI269	Docetaxel	Approved	34	DMTS85L	Capecitabine	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCDGRBZ	DMDI269	Docetaxel	Approved	34	DMNLQHK	Tanespimycin	Phase 2	21	.	.	.	.	Recurrent Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCE8F5T	DMDI269	Docetaxel	Approved	34	DMF57DM	Pazopanib	Approved	34	.	.	.	.	"Neoplasms, Breast"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCENAN5	DMDI269	Docetaxel	Approved	34	DMTKD7Q	Afatinib	Approved	34	.	.	.	.	Neoplasms	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCH4ST3	DMDI269	Docetaxel	Approved	34	DM2HG4X	Prednisone	Phase 3 Trial	25	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCHAMMC	DMDI269	Docetaxel	Approved	34	DMVEHI7	[125I]IRL1620	Investigative	0	.	.	.	.	Non Small Cell Lung Cancer (NSCLC)	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCHH8U7	DMDI269	Docetaxel	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCITVH0	DMDI269	Docetaxel	Approved	34	DMTOUY9	Suramin	Investigative	0	.	.	.	.	Recurrent Non-small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCJ5U1O	DMDI269	Docetaxel	Approved	34	DMGL19D	Enzalutamide	Approved	34	.	.	.	.	Metastatic Castration Resistant Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCJLKL8	DMDI269	Docetaxel	Approved	34	DMQNWRD	Oxaliplatin	Approved	34	.	.	.	.	Esophagus Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCKGEJR	DMDI269	Docetaxel	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Non-Small-Cell Lung Carcinoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCKT7LL	DMDI269	Docetaxel	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Metastatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCL2NZG	DMDI269	Docetaxel	Approved	34	DMT3D5I	Aflibercept	Approved	34	.	.	.	.	Neoplasms	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCL9287	DMDI269	Docetaxel	Approved	34	DMGM2Z6	Lonafarnib	Approved	34	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCL9UFM	DMDI269	Docetaxel	Approved	34	DMY0UEQ	VATALANIB	Phase 2	21	.	.	.	.	Ovarian Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCLDWI8	DMDI269	Docetaxel	Approved	34	DMTS85L	Capecitabine	Approved	34	.	.	.	.	Esophageal Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCLJ9PR	DMDI269	Docetaxel	Approved	34	DMMQ2OW	Nintedanib	Phase 2 Trial	21	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCN6FU5	DMDI269	Docetaxel	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCOCHZX	DMDI269	Docetaxel	Approved	34	DMVYRH2	Perifosine	Phase 1	17	.	.	.	.	Neoplasms	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCP7BKB	DMDI269	Docetaxel	Approved	34	DMT3D5I	Aflibercept	Approved	34	.	.	.	.	Neoplasm Malignant	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCPKO3J	DMDI269	Docetaxel	Approved	34	DMSIVND	Hydroxychloroquine	Phase 3 Trial	25	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCPW53G	DMDI269	Docetaxel	Approved	34	DMJG7VP	Tariquidar	Discontinued in Phase 2	5	.	.	.	.	Lung Neoplasms	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCR7L6G	DMDI269	Docetaxel	Approved	34	DMPDW6T	Epirubicin	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCSMSTV	DMDI269	Docetaxel	Approved	34	DMS104F	Temsirolimus	Approved	34	.	.	.	.	Resistant Solid Malignancies	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCSS5OL	DMDI269	Docetaxel	Approved	34	DMO8PT9	MLN8237	Phase 3	25	.	.	.	.	Advanced Solid Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCSTJFP	DMDI269	Docetaxel	Approved	34	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Advanced Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCT6QOI	DMDI269	Docetaxel	Approved	34	DMJFRCT	Tasisulam	Phase 3	25	.	.	.	.	Advanced Solid Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCTHBM7	DMDI269	Docetaxel	Approved	34	DMGVH6N	Axitinib	Approved	34	.	.	.	.	Breast Neoplasms	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCTHM2N	DMDI269	Docetaxel	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCUJT3P	DMDI269	Docetaxel	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma of the Lung	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCVRZZ6	DMDI269	Docetaxel	Approved	34	DMM39BF	Mitoxantrone	Approved	34	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCVU12W	DMDI269	Docetaxel	Approved	34	DMYILBE	Modafinil	Approved	34	.	.	.	.	Prostatic Neoplasms	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCW95ZL	DMDI269	Docetaxel	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCXFBXW	DMDI269	Docetaxel	Approved	34	DMQNWRD	Oxaliplatin	Approved	34	.	.	.	.	Esophageal Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC5VKGA	DMDI269	Docetaxel	Approved	34	DMG281S	Carboplatin	Approved	34	DMLB81S	Paclitaxel	.	.	Brenner Tumor	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCEYJOS	DMDI269	Docetaxel	Approved	34	DMG281S	Carboplatin	Approved	34	DMNO38U	Bortezomib	.	.	Non Small Cell Lung Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCY0HZW	DMDI269	Docetaxel	Approved	34	DMQNWRD	Oxaliplatin	Approved	34	DMRICNP	Vandetanib	.	.	Adenocarcinoma of the Gastroesophageal Junction	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCB1H3B	DMDI269	Docetaxel	Approved	34	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Metastatic Renal Cell Carcinoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCJFMX0	DMDI269	Docetaxel	Approved	34	DMT4QHD	GDC-0032	Phase 3	25	.	.	.	.	"Breast Cancer, Non-small Lung Cancer"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCRSET1	DMDI269	Docetaxel	Approved	34	DMM9F25	LDE225	Phase 2	21	.	.	.	.	Advanced Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCNM6UH	DMDI269	Docetaxel	Approved	34	DM09NGV	Ribavirin-TP	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.95	0.95	1.8	1.85
DC9VDUW	DMDI269	Docetaxel	Approved	34	DM0FB1J	Sertraline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.36	1.36	1.78	1.79
DCUSRS1	DMDI269	Docetaxel	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	1.4	3.35	6	0.96
DCHWXR8	DMDI269	Docetaxel	Approved	34	DM0KYI4	Mebutamate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.57	3.57	4.04	4.1
DCPUKBZ	DMDI269	Docetaxel	Approved	34	DM14NKM	Triiodothyronine	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.88	2.88	3.49	3.52
DCOBUM5	DMDI269	Docetaxel	Approved	34	DM1TJ8F	Diethylcarbamazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.98	2.98	4.09	4.14
DCKQD8K	DMDI269	Docetaxel	Approved	34	DM1YB0R	OZ277	Approved	34	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	2.278	3.893	3.224	3.478
DC24WT2	DMDI269	Docetaxel	Approved	34	DM1YB0R	OZ277	Approved	34	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	1.54	1.291	0.826	3.861
DCEKTQD	DMDI269	Docetaxel	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	T-cell leukemia/lymphoma	DrugCombDB Database	Investigative	ED-40515	6.756	3.161	2.108	4.601
DCZB7S7	DMDI269	Docetaxel	Approved	34	DM29GAD	Lumefantrine	Approved	34	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	3.731	6.076	2.075	3.517
DCIJEGD	DMDI269	Docetaxel	Approved	34	DM29GAD	Lumefantrine	Approved	34	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	1.969	4.773	2.203	5.16
DCY0WF5	DMDI269	Docetaxel	Approved	34	DM2G9AE	Citalopram	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.47	4.47	5.04	5.09
DCCRNZ2	DMDI269	Docetaxel	Approved	34	DM2KITF	LY335979	Discontinued in Phase 3	9	.	.	.	.	Human papillomavirus-related cervical adenocarcinoma	DrugCombDB Database	Investigative	KB-ChR-8-5-11	52.866	52.242	24.33	35.95
DCZ252C	DMDI269	Docetaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	6.17	3.16	6.82	7.78
DC1IBG9	DMDI269	Docetaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.73	0.94	2.5	3.67
DCRV3W5	DMDI269	Docetaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.3	3.08	2.65	8.43
DCCKBY9	DMDI269	Docetaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	4.04	5.14	1.33	5.38
DCM968D	DMDI269	Docetaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	3.51	3.04	10.04	12.24
DC3CPW0	DMDI269	Docetaxel	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	0.67	2.42	2.44	8.3
DCCMS8H	DMDI269	Docetaxel	Approved	34	DM2TUCU	Crotamiton	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.75	3.75	4.17	4.22
DCXP389	DMDI269	Docetaxel	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	7.7	8.95	1.1	5.47
DCYSCNY	DMDI269	Docetaxel	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	7.27	8.97	3.65	5.42
DCFLOGY	DMDI269	Docetaxel	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	10.24	13.73	3.81	8.64
DC4VBJV	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	9.25	14.37	13.67	13.69
DCHM8YK	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	10.01	11.19	14.33	14.41
DCQFXNS	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	20.05	23.4	22.38	21.44
DC0OOEX	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	9.05	15.12	15.79	15.27
DCQ82XX	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	21.37	26.11	20.6	24.61
DCU75ES	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	10.61	13.8	14.14	13.97
DCVZJK5	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	26.08	29.23	18.1	25.82
DCJYPDC	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	22.35	22.04	21.86	19.37
DCJ2DRU	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	41.16	41.59	27.27	24.76
DCG0H0W	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	27.89	28.99	26.61	26.36
DC3SG1L	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	12.6	15.81	15.51	15.68
DCD71JE	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	31.79	30.94	21.74	25.06
DCIDU6D	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	3.68	7.8	8.53	8.78
DCLGGE5	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	5.47	9.8	9.24	11.85
DCVRS9R	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	12.49	11.99	12.92	11.5
DCVYS4Y	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	11.96	16.19	16.08	16.37
DCJUS37	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	5.98	9.44	9.17	8.83
DCUNV1Y	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	29.22	32.05	30.87	30.56
DC39VSH	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	12.37	14.93	13.2	11.97
DCCJ31K	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	13.58	21.01	13.25	15.72
DCZR14Y	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	7.86	10.77	12.27	11.97
DCVSL3V	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	11.61	15.1	16.46	16.53
DCHG9QR	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	7.75	9.69	7.78	7.51
DCTN7WO	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	7.03	11.3	10.82	10.51
DCQMRVP	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	28.7	27.97	27.35	26.6
DC99A6Q	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	19.39	22.14	23.98	20.24
DC7LUF1	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	3.35	9.07	9.28	9.24
DCUQLAC	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	9.71	16.67	17.3	15.18
DCQORSE	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	5.03	9.62	10.04	11.28
DCKQFFA	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	8.33	8.63	10.42	8.83
DCN5A0C	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	5.15	15.39	10.5	11.63
DC9LZY9	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	0.45	4.61	5.35	6.13
DCS5KHY	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	3.95	4.22	6.47	5.89
DCEKZ3B	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	9.91	13.03	12.62	10.61
DC2T3LE	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.08	7.46	5.07	5.29
DC4E33P	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	28.81	30.44	26.03	25.55
DCDWB06	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	2	7.3	3.17	7.78
DC9GMZ1	DMDI269	Docetaxel	Approved	34	DM3JCVS	Terazosin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.8	4.8	5.31	5.36
DC0H4OU	DMDI269	Docetaxel	Approved	34	DM3KJBC	Epinephrine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.37	0.37	2.61	2.64
DC8CUEF	DMDI269	Docetaxel	Approved	34	DM3VZJQ	Chlorphenesin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.23	5.23	5.51	5.59
DC5RWNG	DMDI269	Docetaxel	Approved	34	DM48QOT	Artemether	Approved	34	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	26.745	26.36	8.743	12.453
DCT7IDP	DMDI269	Docetaxel	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	4.02	10.52	11.06	11.02
DCCRMMG	DMDI269	Docetaxel	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	13.38	22.71	16.49	15.31
DCK1WGW	DMDI269	Docetaxel	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	1.69	9.05	3.73	3.05
DC164NC	DMDI269	Docetaxel	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.57	5.77	4.09	4.87
DC0S7OE	DMDI269	Docetaxel	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	16.56	15.02	9.1	9.1
DC57EOD	DMDI269	Docetaxel	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.19	4.23	3.82	3.82
DC1WKXV	DMDI269	Docetaxel	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	14.8	13.98	12.61	12.61
DCAZNFN	DMDI269	Docetaxel	Approved	34	DM51FY6	Tacrine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.92	3.92	4.33	4.35
DCGCQ6D	DMDI269	Docetaxel	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.54	4.78	5.12	5.76
DC5174Y	DMDI269	Docetaxel	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	5.84	3.99	1.07	3.14
DCCHYQF	DMDI269	Docetaxel	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.44	3.05	2.72	2.32
DCXWL3S	DMDI269	Docetaxel	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.37	4.45	1.46	4.07
DCAIR3K	DMDI269	Docetaxel	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.17	0.17	2.15	2.15
DCTK22R	DMDI269	Docetaxel	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	4.57	8.2	8.23	7.67
DCDN1DY	DMDI269	Docetaxel	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.71	8.27	4.48	8.61
DCPKVHG	DMDI269	Docetaxel	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	2.37	5.37	4.29	6.31
DCUUGVL	DMDI269	Docetaxel	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	2.91	6.23	0.79	5.43
DCTVTJ4	DMDI269	Docetaxel	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	3.49	0.23	0.06	0.06
DCSD4VO	DMDI269	Docetaxel	Approved	34	DM5J64S	Miglustat	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.56	4.56	5.24	5.24
DCGZ80E	DMDI269	Docetaxel	Approved	34	DM5UGDK	Mephenytoin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.52	3.52	4.01	4.05
DCD1VX8	DMDI269	Docetaxel	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	5.48	8.09	3.73	4.46
DCPNUZC	DMDI269	Docetaxel	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.9	3.04	2.88	3.54
DCDC4MH	DMDI269	Docetaxel	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	1.43	2.08	0.47	0.92
DC9GRZH	DMDI269	Docetaxel	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	14.68	21.3	3.17	5.73
DC297E4	DMDI269	Docetaxel	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	11.5	12.55	0.87	2.97
DCDNY9P	DMDI269	Docetaxel	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	1.55	3.45	3.21	3.07
DCE6JV4	DMDI269	Docetaxel	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.49	1.85	0.33	1.25
DC6SU3F	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	6.66	14.68	11.2	11.75
DC3K3OK	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	7.52	8.59	7.11	7.52
DCJGROJ	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	8.45	6.97	3.06	4.56
DCITEWQ	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	2.48	3.51	1.17	0.74
DC59IF1	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	8.25	7.37	4.31	6.03
DCLZRTY	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	7.05	9.86	8.09	8.32
DC5UKL1	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	6.38	8.83	1.06	2.62
DCJR3I9	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	20.25	20.92	8.97	11.25
DCUK6B8	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	20.84	20.36	17.91	19.12
DCXJF0J	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	8.05	12.76	9.03	9.91
DCP92YH	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	10.85	11.06	12.2	13.88
DCGROZH	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	10.25	10.75	3.98	9.34
DCHQ5HB	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.34	9.1	7.41	7.49
DCPYOTD	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.01	4.19	0.8	0.43
DCYAIN7	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	13.86	11.93	4.39	7.51
DCFUUTP	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.77	7.83	5.16	4.45
DC23IUN	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.85	6.22	2.02	3.4
DCXD051	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.92	3.81	5.35	7.54
DC4V0EQ	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	5.93	9.39	8.92	9.85
DCNQO0L	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	0.44	4.13	4.45	1.63
DC3QPL1	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.35	3.39	2.13	2.96
DCO7ZX1	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	9.14	10.41	3.68	3.64
DCZC0F8	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	5.23	10.72	8.8	10.65
DC68L6I	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	5.35	8.99	8.15	7.54
DCL04HW	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	1.41	4.63	4.47	4.64
DCARLVQ	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	0.35	2.69	1.11	2.54
DCYVB13	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	12.37	12.02	9.16	8.38
DCT2YK7	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	1.3	3.3	3.04	4.1
DCXLBJ9	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	2.99	4.61	2.8	2.33
DCNS8T1	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	13.33	17.79	12.57	10.6
DCL1LA9	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	8.9	10.63	9.01	9.25
DCT8MBX	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	1.31	4.07	3.39	3.69
DCFKYGM	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	2.91	10.26	6.05	4.64
DCDBA47	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	14.5	14.87	4.37	5.51
DCQCINX	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	2.19	3.63	1.45	1.7
DCLCBMQ	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	1.25	3.63	0.85	0.85
DCLCHDR	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.57	2.62	3.02	3.99
DCOV46H	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	15.87	16.08	14.03	15.73
DCSCY7L	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	0.47	3.44	1.96	2.97
DC6UKJ6	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	6.48	8.78	2.29	3.69
DCKUIMM	DMDI269	Docetaxel	Approved	34	DM7HUNW	Testosterone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.12	0.12	0.71	0.71
DCO4X1U	DMDI269	Docetaxel	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	8.42	14.51	7.49	6.24
DCK9ME9	DMDI269	Docetaxel	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.34	1.97	1.16	2.11
DCKV0GV	DMDI269	Docetaxel	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	9.93	13.12	4.44	5.17
DCO63B7	DMDI269	Docetaxel	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	14.6	14.12	5.07	5.54
DC6DI3U	DMDI269	Docetaxel	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	0.68	6.26	0.78	3.97
DC8R96W	DMDI269	Docetaxel	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	8.45	10.86	6.37	12.38
DC8D1US	DMDI269	Docetaxel	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	0.02	1.92	0.81	0.73
DC6JE2A	DMDI269	Docetaxel	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	1.2	5.37	4.69	3.21
DC65ABI	DMDI269	Docetaxel	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	1.64	3.87	5.79	5.32
DCQBJR7	DMDI269	Docetaxel	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	0.78	4.8	4.61	3.96
DCGZ3XB	DMDI269	Docetaxel	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	2.9	8.04	5.13	3.11
DC1CUMN	DMDI269	Docetaxel	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	1.22	7.27	1.9	5.89
DCXLWKW	DMDI269	Docetaxel	Approved	34	DMFI8A7	Tranexamic acid	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.42	0.42	0.71	0.8
DCR358L	DMDI269	Docetaxel	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	4.01	7.52	2.08	6.17
DCYHD90	DMDI269	Docetaxel	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.1	7.34	8.2	6.75
DC0VIBR	DMDI269	Docetaxel	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.23	4.23	4.66	4.68
DCQSFAL	DMDI269	Docetaxel	Approved	34	DMA8FS5	Dronedarone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.21	3.21	3.63	3.64
DC8O82W	DMDI269	Docetaxel	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	3.88	7.81	3.33	7.82
DCVMUJH	DMDI269	Docetaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	0.76	2.41	3.07	3.07
DCY32ER	DMDI269	Docetaxel	Approved	34	DMB4AVP	Pamidronate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.39	3.39	3.76	3.82
DCN91PG	DMDI269	Docetaxel	Approved	34	DMBHMOX	Palonosetron	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.63	1.63	2.03	2.05
DCLBOPK	DMDI269	Docetaxel	Approved	34	DMBS632	Buspirone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.1	1.1	1.58	1.59
DCZJ21Y	DMDI269	Docetaxel	Approved	34	DMC0GSJ	Efavirenz	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.19	4.19	4.77	4.8
DC3PUJ1	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	5.11	10.6	8.54	8.51
DCHJOKA	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	14.99	19.52	17.99	16.26
DCYQPW3	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	4.34	8.15	1.94	1.8
DCQ5SJ4	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	7.97	10.95	6.41	5.38
DCYRKUS	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	6.16	14.85	10.89	11.8
DCYZQQM	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	12.24	12.65	3.34	13.39
DCR9S6N	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	43.66	44.8	35.76	34.87
DCBF7JA	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	3.32	9.39	1.51	7.11
DCV36WD	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	7.66	9.61	6.57	6.07
DC75FRR	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.74	5.95	2.79	6.66
DCC1AGW	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	13.42	14.85	12.95	12.95
DC42ZJK	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.95	1.95	3.71	3.76
DCMCA3M	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	16.11	17.44	13.96	13.72
DC9SJ8F	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.38	1.19	0.7	1.1
DCUMCW8	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	4.21	6.49	3.42	2.6
DCNSAC0	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	1.4	6.57	1.48	3.08
DCO4RWV	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.86	8.76	0.71	8.22
DCEPCYB	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.18	4.36	3.36	2.97
DC3K2QW	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	6.58	8.34	7.34	8.02
DCEMISO	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	0.62	4.79	1.88	1.03
DCR3BJO	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	17.66	17.8	16.92	16.42
DCX9W8D	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	4.83	11.87	9.94	11.7
DC7R7D0	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	17.59	23.49	13.03	18.56
DCZY8HZ	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	1.31	7.66	3.17	8.26
DCN8G6F	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	3.08	6.72	5.99	6.25
DCGWNRT	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.65	5.57	2.8	4.8
DCW5A1V	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	25.4	25.01	23.8	24.22
DC0NZEH	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	8.91	15.35	13.64	13.45
DCJ3V5J	DMDI269	Docetaxel	Approved	34	DMPN5IH	Guanfacine	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.42	1.42	1.94	1.94
DCQ99OW	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	0.81	5.42	3.15	1.67
DC5VSV2	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	3.92	4.1	3.86	2.69
DCXAQHZ	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	8.61	13.77	15.61	15.35
DC7IKM8	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	6.23	6.27	9.29	6.12
DCURJAN	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	10	12.96	6.87	10.2
DCAVW1C	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	7.65	11.34	9.91	11.81
DCMJ4IR	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	6.33	8.29	7.8	7.55
DC8JR68	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	9.16	8.47	7.64	7.36
DC0RTOW	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	13.87	13.2	7.67	7.81
DCU1BBK	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	10.54	5.85	2.95	2.58
DC0HSVA	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	7.45	10.17	8.01	8.29
DC0ALCE	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	8.64	16.07	9.85	10.21
DCJLFSH	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	9.69	11.37	12.37	9.76
DCTOSZO	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	9.69	14.44	3.31	10.55
DCQ1WGR	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.77	3.77	4.45	4.45
DCIEX6G	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	16.21	17.4	6.65	12.06
DC1G6NX	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.42	0.44	0.41	2.77
DCAPDBS	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.07	1.22	2.64	3.01
DCNYRPX	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	6.95	12.15	12.87	10.07
DC2CF3A	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	6.23	4.61	5.36	3.98
DCUN8VS	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	8.95	11.12	14.84	12.94
DC9ZR80	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	10.73	10.48	7.58	7.28
DCTHI25	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	6.33	7.9	8.02	7.93
DC9QUCR	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	7.15	7.95	3.42	6.64
DCL3IVZ	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	4.38	7.06	4.01	2.23
DCIXC5E	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	9.57	11.83	11.9	11.9
DCS9SWQ	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	15.78	22.4	15.92	14.49
DCOHVON	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	8.03	10.8	9.72	11.24
DCNG8BL	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	4.8	7.39	8.18	8.58
DCMBKDC	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	4.58	3.3	4.01	4.05
DCB189C	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	0.21	3.64	4.35	4.83
DCAEM0D	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	0.03	6.42	3.83	1.38
DC1SD9J	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	5.27	6.8	8.81	8.22
DC2N59F	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	3.08	7.56	8.23	8.07
DCAEI5S	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	11.92	14.41	12.82	12.83
DCLXB39	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	0.07	3.87	3.4	2.05
DCOQA8Q	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	3.91	6.09	8.24	8.24
DCVSPZF	DMDI269	Docetaxel	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	6.87	7.69	13.18	8.53
DCDN1H2	DMDI269	Docetaxel	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	1.2	3.04	1.23	1.23
DC8A0UW	DMDI269	Docetaxel	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	16.92	16.91	17.48	15.38
DC0IA3B	DMDI269	Docetaxel	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	3.13	6.59	0.47	4.93
DCGNNY3	DMDI269	Docetaxel	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	20.37	21.19	19.92	19.92
DCJSI7X	DMDI269	Docetaxel	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	7.23	7.93	3.24	1.87
DCI9AOA	DMDI269	Docetaxel	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.25	5.19	2.01	2.01
DCDHBSR	DMDI269	Docetaxel	Approved	34	DMCUT21	Ursodeoxycholic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.67	4.67	5.1	5.1
DCAT0IY	DMDI269	Docetaxel	Approved	34	DMD9WSC	Memantine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.37	0.37	0.82	0.89
DCR2R75	DMDI269	Docetaxel	Approved	34	DME8FZ9	Methoxsalen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.7	1.7	2.1	2.11
DCUYKVC	DMDI269	Docetaxel	Approved	34	DMEOCKZ	JZL195	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.54	2.54	2.88	2.96
DCBETH2	DMDI269	Docetaxel	Approved	34	DMEV954	Sulfinpyrazone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.59	0.59	1.04	1.04
DCDCQ4G	DMDI269	Docetaxel	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	10.94	13.09	7.81	5.26
DC92KP7	DMDI269	Docetaxel	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	1.43	6.48	8.89	8.85
DCTYL2K	DMDI269	Docetaxel	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.64	6.88	7.62	6.83
DCW1O4S	DMDI269	Docetaxel	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	4.1	7.07	10.36	11.9
DCWJOCV	DMDI269	Docetaxel	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	3.19	4.38	4.63	4.52
DCG3ZX6	DMDI269	Docetaxel	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	1.64	8.08	4.67	4.85
DCC72KU	DMDI269	Docetaxel	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.74	5.5	11.39	11.65
DCRB7KG	DMDI269	Docetaxel	Approved	34	DMGDKXN	Sitagliptin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.79	4.79	5.25	5.26
DC0VNZF	DMDI269	Docetaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	4.63	6.56	4.16	0.83
DCBHTL3	DMDI269	Docetaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	0.59	3.86	2.26	6.59
DCHDXCB	DMDI269	Docetaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.6	4.8	8.74	9.37
DCW1QOU	DMDI269	Docetaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.08	2.77	2.4	3.31
DC51LF1	DMDI269	Docetaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	6.56	7.85	5.9	8.19
DCVK52L	DMDI269	Docetaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	3.005	2.59	9.366	12.492
DCMRKFC	DMDI269	Docetaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.9	2.38	7.45	8.16
DCVBOCT	DMDI269	Docetaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	5.27	5.75	12.33	12.59
DCZMWSC	DMDI269	Docetaxel	Approved	34	DMHAZLM	Naringenin	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.73	4.73	5.2	5.21
DCCV3C0	DMDI269	Docetaxel	Approved	34	DMHZJCG	Pentamidine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.11	4.11	4.58	4.58
DCMJLPF	DMDI269	Docetaxel	Approved	34	DMIOGBU	Bosentan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.43	1.43	1.91	1.91
DCWIRRJ	DMDI269	Docetaxel	Approved	34	DMIYDT4	Cabozantinib	Approved	34	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	20.873	20.271	1.961	5.45
DCE717Y	DMDI269	Docetaxel	Approved	34	DMKFQJP	Triflupromazine	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.61	4.61	5.17	5.17
DCX74JO	DMDI269	Docetaxel	Approved	34	DMJSKUI	Norcisapride	Discontinued in Phase 2	5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.51	5.51	5.94	5.94
DCKTZ2Q	DMDI269	Docetaxel	Approved	34	DMK7MEY	Isoproterenol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.54	4.54	5.31	5.39
DC3XUGS	DMDI269	Docetaxel	Approved	34	DMKBYWI	Trifluoperazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.46	0.46	0.88	0.93
DCT390J	DMDI269	Docetaxel	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	7.88	11.35	10.02	6.26
DCWKW49	DMDI269	Docetaxel	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	4.24	11.72	8.69	10.29
DCO3SYH	DMDI269	Docetaxel	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.72	7.68	4.98	4.98
DCNNIRS	DMDI269	Docetaxel	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.31	1.01	3.29	3.43
DCLOKC7	DMDI269	Docetaxel	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	0.43	5.52	3.21	3.2
DCPN0GK	DMDI269	Docetaxel	Approved	34	DMGO72P	Oseltamivir	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.91	2.91	3.56	3.62
DCLQ7XB	DMDI269	Docetaxel	Approved	34	DMLB0EZ	Tamoxifen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.16	1.16	1.85	1.86
DCR0RU9	DMDI269	Docetaxel	Approved	34	DMLBVKQ	Entacapone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.45	0.45	0.86	0.89
DCVMKQR	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	3.24	7.77	6.77	3.6
DCAYZPH	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	3.79	9.49	5.12	3.57
DCW6D3B	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	2.94	4.6	1.83	1.35
DCBZCY4	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	1.96	7.14	4.54	4.56
DCM63NK	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	5.76	9.48	9.95	10.93
DCTJQ77	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	23.48	18.06	2.62	17.19
DCQ1Z0F	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	17.04	19.78	19.66	21.9
DC0EI81	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	5.05	11.98	1.54	9.08
DC2DWMP	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.18	4.86	2.12	3.78
DCXI9AB	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.43	10.84	5.66	7.65
DC1M1XR	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	1.54	5.61	6.65	6.26
DCIDAJJ	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	0.06	4.97	3.59	3.15
DCMXWFN	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	10.16	16.35	5.95	3.47
DCFHE0D	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	1.11	3.72	2.72	1.92
DCV9UZ2	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	2.83	4.72	4.42	4.25
DC4R28R	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.16	2.64	0.65	0.62
DCUEMAW	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	2.05	2.26	2.17	0.46
DC2GISP	DMDI269	Docetaxel	Approved	34	DMLPAOB	Allopurinol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.84	4.84	5.33	5.4
DC4V7RR	DMDI269	Docetaxel	Approved	34	DMLU8NX	Benserazide	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.92	1.92	2.33	2.39
DC4J4D5	DMDI269	Docetaxel	Approved	34	DMM0HR1	Pargyline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.77	2.77	3.16	3.21
DCCPWO5	DMDI269	Docetaxel	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	0.45	0.45	2.92	3
DCK11BY	DMDI269	Docetaxel	Approved	34	DMM5ZX6	Epothilone B	Discontinued in Phase 3	9	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	3638.629	4330.99	1372.013	168.315
DC9ZTDG	DMDI269	Docetaxel	Approved	34	DMN3GCH	Darunavir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.36	2.36	3.22	3.27
DCD06SR	DMDI269	Docetaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	1.7	3.88	3.76	4.9
DCXL5BZ	DMDI269	Docetaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	0.24	1.94	2.41	3.11
DC3PLSF	DMDI269	Docetaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	7.52	3.21	3.13	7.25
DCWH0L5	DMDI269	Docetaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	7.72	13.24	8.59	8.5
DCGGES7	DMDI269	Docetaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	1.29	14.18	12.59	13.8
DC3YW31	DMDI269	Docetaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.22	1.92	5.31	5.32
DCC3B3P	DMDI269	Docetaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	0.49	5.99	2.9	3.07
DC2UNN7	DMDI269	Docetaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	1.17	0.74	1.16	2.13
DCDX8EM	DMDI269	Docetaxel	Approved	34	DMNMW9R	Pramipexole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.49	3.49	4.08	4.12
DCO37O7	DMDI269	Docetaxel	Approved	34	DMJAPE7	Methylene blue	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.38	2.38	4.69	4.74
DCZ1PAJ	DMDI269	Docetaxel	Approved	34	DMPFN6Y	Olanzapine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.88	2.88	3.33	3.38
DCLX1SQ	DMDI269	Docetaxel	Approved	34	DMPWB7T	Maprotiline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.57	1.57	3.87	3.92
DCT66CO	DMDI269	Docetaxel	Approved	34	DMQEJVU	1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.64	4.64	5.06	5.07
DCYBBV8	DMDI269	Docetaxel	Approved	34	DMQHBSX	NITD609	Phase 2	21	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	4.653	5.486	0.638	2.695
DCND4ZL	DMDI269	Docetaxel	Approved	34	DMR6N7H	Acetohexamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.89	1.89	2.17	2.25
DCQR8O0	DMDI269	Docetaxel	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.05	1.49	2.18	1.1
DCTE5B8	DMDI269	Docetaxel	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.1	1.13	0.5	0.58
DCRPUOU	DMDI269	Docetaxel	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	1.27	2.32	1.23	0.69
DCGH4JH	DMDI269	Docetaxel	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	3.28	4.16	1.86	1.95
DCVIY8A	DMDI269	Docetaxel	Approved	34	DMRJFN9	Theophylline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.71	2.71	3.11	3.16
DCUMRAO	DMDI269	Docetaxel	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.14	2.14	2.62	2.62
DC8CK60	DMDI269	Docetaxel	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	2.65	3.47	4.54	1.19
DCIXFL3	DMDI269	Docetaxel	Approved	34	DMS3YE9	Amantadine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.37	0.37	0.84	0.87
DCA27SC	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	9.16	11.86	8.73	10.54
DCPVH4D	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	18.16	16.43	12.24	10.36
DCMCT2I	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	12.98	13.33	10.71	11.74
DC4N0PP	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	17.26	21.24	14.73	16.97
DC6ZBOE	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	23.77	24.79	25.31	24.69
DCJU6GE	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	22.26	24.12	19.36	19.01
DCWWR06	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	6.4	11.98	5.02	11.3
DCLPU1U	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	23.97	22.81	17.34	24.13
DC3R9M9	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	18.44	21.35	21.75	23.59
DCHNR29	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	41.31	36.31	31.9	31.61
DCWWCJ9	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	7.18	13.19	10.67	10.11
DCBDNZD	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	15.52	22.67	8.17	6.86
DCIZRNG	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.96	8.04	3.37	6.83
DC5NA6P	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	9.51	12.7	9.23	10.43
DCAUVVZ	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	9.26	10.88	11.53	12.61
DC68A2R	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	13.47	18.27	19.31	19.02
DCTQ5I4	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	2.64	6.02	4.67	4.63
DC9CC7Z	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	26.41	31.01	20.68	27.51
DCRFEZA	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	6.86	9.83	6.02	6.03
DCQ323L	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	11.1	14.48	10.41	3.44
DCCCCSE	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	7.73	14.92	13.44	11.98
DCV7DEI	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	4.69	7.23	6.08	6.08
DCNCG98	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	1.89	3.83	2.54	3.11
DC98PFW	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	8.77	12.79	8.77	8.77
DCKG7TD	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	9.73	15.25	12.48	12.25
DCZA5TY	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	26.36	31.66	14.48	15.37
DC8S413	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	1.73	5.74	4.79	4.76
DCSYSYQ	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	3.71	9.94	7.05	7.76
DCZJYXL	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	13.15	15.47	2.81	2.83
DCF6PA8	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	8.61	9.48	1.36	6.55
DC717XR	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	45.99	46.16	31.84	31.79
DCZEY3J	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	0.33	7.52	2.09	5.56
DCEQBV2	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	6.53	7.45	2.42	2.42
DCM7R4M	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	10.87	11.24	7.33	4.66
DC3NRGN	DMDI269	Docetaxel	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	3.22	8.49	7.16	5.59
DCHYKEC	DMDI269	Docetaxel	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.45	1.49	0.81	0.81
DCCAR0E	DMDI269	Docetaxel	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	0.04	2.35	4.79	3.8
DCLJKIM	DMDI269	Docetaxel	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.37	2.57	2.82	2.29
DCWCD63	DMDI269	Docetaxel	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	0.61	0.7	2.06	1.64
DC396D9	DMDI269	Docetaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	1.85	9.14	5.05	6.68
DCT6OHD	DMDI269	Docetaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	1.17	4.11	2.79	0.94
DC8U7BJ	DMDI269	Docetaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	11.1	13.37	7.88	10.97
DC1J5FI	DMDI269	Docetaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.12	2.33	4.21	3.96
DCGJQ6F	DMDI269	Docetaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	0.91	5.33	2.77	3.11
DCLRHKH	DMDI269	Docetaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	2.07	5.69	6.46	6.93
DC0TN6B	DMDI269	Docetaxel	Approved	34	DMOJZQ9	Loperamide	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.19	1.19	1.58	1.58
DC4PD1Z	DMDI269	Docetaxel	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.43	1.97	8.03	6.21
DC7E345	DMDI269	Docetaxel	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.04	5.07	2.81	3.07
DCFB3PK	DMDI269	Docetaxel	Approved	34	DMTL94F	Maraviroc	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.39	1.39	1.81	1.83
DC25QN0	DMDI269	Docetaxel	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.63	2.19	1.16	1.07
DC7RR88	DMDI269	Docetaxel	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.3	2.36	0.36	0.66
DCJH6FR	DMDI269	Docetaxel	Approved	34	DMTWUXR	Chlormezanone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.78	2.78	3.22	3.22
DCY4W67	DMDI269	Docetaxel	Approved	34	DMTX8IZ	Endoxifen	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.28	3.28	4.41	4.42
DCE8N7A	DMDI269	Docetaxel	Approved	34	DMU8JGH	Hydralazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.8	2.8	3.61	3.63
DCV2O7G	DMDI269	Docetaxel	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	5.83	7.11	2.79	2.79
DCPRU6Y	DMDI269	Docetaxel	Approved	34	DMURVE8	Elacridar	Discontinued in Phase 1	3	.	.	.	.	Human papillomavirus-related cervical adenocarcinoma	DrugCombDB Database	Investigative	KB-ChR-8-5-11	45.438	45.462	35.367	33.895
DC2Q3BT	DMDI269	Docetaxel	Approved	34	DMWT905	Mefloquine	Phase 2/3 Trial	24	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	1.151	1.811	0.1	4.433
DCL04PL	DMDI269	Docetaxel	Approved	34	DMV3UN4	JTC-801	Discontinued in Phase 2	5	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	8.052	8.371	2.481	6.671
DCMXP9E	DMDI269	Docetaxel	Approved	34	DMVM6QR	Lacosamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.33	0.33	0.78	0.82
DC2ERZQ	DMDI269	Docetaxel	Approved	34	DMVRIC2	Zileuton	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.12	3.12	3.79	3.85
DC1WME7	DMDI269	Docetaxel	Approved	34	DMVRYT2	Nabilone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.29	3.29	3.78	3.79
DC01LIP	DMDI269	Docetaxel	Approved	34	DMVS9WQ	Nitisinone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.98	1.98	2.38	2.39
DC67I5Z	DMDI269	Docetaxel	Approved	34	DMVTHWQ	Silver sulfadiazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.45	2.45	2.8	2.85
DCAMN8S	DMDI269	Docetaxel	Approved	34	DMWBHRY	Olmesartan medoxomil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.97	4.97	5.31	5.38
DC53AWL	DMDI269	Docetaxel	Approved	34	DMWE60C	Rufinamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.13	4.13	4.57	4.57
DCJG1U3	DMDI269	Docetaxel	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.98	3.98	4.48	4.54
DC87L42	DMDI269	Docetaxel	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	0.73	1.86	0.61	0.42
DCBRSH2	DMDI269	Docetaxel	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.28	2.28	2.73	2.73
DCUCUWK	DMDI269	Docetaxel	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	0.6	2.42	1.76	7.9
DCL10C2	DMDI269	Docetaxel	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.16	2.03	2.56	3.35
DCW4SS0	DMDI269	Docetaxel	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.24	0.14	1.01	1.43
DCI06D4	DMDI269	Docetaxel	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.55	5.23	7.58	8.11
DCJCNUV	DMDI269	Docetaxel	Approved	34	DMXLZP6	Metaxalone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.59	3.59	4	4.04
DCO7GJI	DMDI269	Docetaxel	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	5.55	5.77	2.98	4.97
DCKJSSN	DMDI269	Docetaxel	Approved	34	DMSIVND	Hydroxychloroquine	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.37	2.37	2.82	2.82
DC407GM	DMDI269	Docetaxel	Approved	34	DMY4UMW	Atovaquone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.42	0.42	0.77	0.81
DCWL9L8	DMDI269	Docetaxel	Approved	34	DMY91A3	ML323	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.83	3.83	4.2	4.22
DC360F8	DMDI269	Docetaxel	Approved	34	DMYTE6L	Enoxacin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.13	3.13	3.53	3.58
DCV9D2P	DMDI269	Docetaxel	Approved	34	DMYURI6	Raltegravir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.52	2.52	2.91	2.94
DCRQYWN	DMDI269	Docetaxel	Approved	34	DMYX7NI	Acetohydroxamic Acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1	1	1.83	1.86
DCDM5FX	DMDI269	Docetaxel	Approved	34	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	10.98	11.17	12.54	16.41
DCL2IL6	DMDI269	Docetaxel	Approved	34	DMZ2TD9	GSK2194069	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.37	2.37	2.69	2.77
DCGL0TV	DMDI269	Docetaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	24.94	21.62	4.77	8.07
DCC9SI2	DMDI269	Docetaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	15.22	16.6	15.94	16.19
DCNOYH3	DMDI269	Docetaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.61	7.6	4.1	1.61
DCF61TG	DMDI269	Docetaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	4.17	8.22	6.61	6.91
DCQ6C5G	DMDI269	Docetaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.31	6.22	2.78	3.63
DC5WK6D	DMDI269	Docetaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	1.53	5.35	4.03	2.32
DCPMS0W	DMDI269	Docetaxel	Approved	34	DMZI3WO	Etomidate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.08	2.08	2.45	2.47
DC7U00N	DMDI269	Docetaxel	Approved	34	DMZP7YM	L-165041	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.47	4.47	4.86	4.87
DC4DNP0	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.77	10.82	12.54	12.6
DCRWPMI	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	8.72	15.55	16.25	15.73
DC9IQZD	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.77	7.5	5.97	7.67
DCOD7JZ	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	17.87	21.09	0.66	21.3
DCX0WP7	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	12.84	14.68	12.46	12.93
DCI9H2I	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	15.63	16.74	15.29	17.46
DCUJ54V	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	10.29	16.62	12.66	17.65
DCSIW26	DMDI269	Docetaxel	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	10.13	15.26	10.04	9.93
DC612QV	DMDI269	Docetaxel	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.42	3.53	2.55	1.62
DCFH08P	DMDI269	Docetaxel	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.06	6.1	5.1	2.79
DCUYT17	DMDI269	Docetaxel	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.52	6.3	7.03	3.04
DCX834M	DMDI269	Docetaxel	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.34	3.74	2.61	2.71
DCYUCCS	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.63	4.71	1.96	3.36
DCFZ6J5	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.76	5	1.92	1.57
DCUEJJ1	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.22	3.46	2.86	3.53
DC68T3T	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	9.77	6.93	1.95	3.29
DCWB3PR	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.65	7.07	1.42	3.01
DCTHWH0	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.7	7.03	7.54	8.15
DCXWS4S	DMDI269	Docetaxel	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.85	5.7	4.03	4.58
DCAQ9DV	DMDI269	Docetaxel	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.28	7.97	6.27	4.39
DCJSWTU	DMDI269	Docetaxel	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.25	5.15	4.08	1.25
DC5S2KG	DMDI269	Docetaxel	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.7	2.74	1.42	2.04
DC5MWRB	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.4	5.58	6.73	5.89
DCJSNPD	DMDI269	Docetaxel	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	8.82	9.57	3.69	3.75
DCSS0Y9	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	7.08	10.48	8.09	8.09
DC3D3JO	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	6.21	8.76	5.21	8.17
DC822OJ	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.42	10.8	4.9	7.14
DCSUB8K	DMDI269	Docetaxel	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	13.53	18.5	16.64	15.3
DCCXMUB	DMDI269	Docetaxel	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	8.56	15.3	13.89	13.68
DC9JKE1	DMDI269	Docetaxel	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.81	9.03	6.06	5.72
DC8H4XB	DMDI269	Docetaxel	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4	4.05	5.93	6.21
DCPMIFU	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.63	5.24	4	3.29
DCK0H2X	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.88	2.56	1.25	0.83
DCRE9KD	DMDI269	Docetaxel	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.82	5.01	4.6	1.21
DCPUWUR	DMDI269	Docetaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.61	3.33	2.17	3.52
DCTA56S	DMDI269	Docetaxel	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	8.69	11.55	3.18	3.67
DCI5CAO	DMDI269	Docetaxel	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.52	0.94	0.27	1.17
DCKVT07	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.73	6.03	5.61	5.61
DCB9QEH	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.8	6.37	6.21	5.64
DCIN5IS	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	21.52	19.1	12.98	12.99
DCCFQ6X	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	11.47	15.93	14.44	15.61
DCNOJJD	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	15.76	19.03	17.75	17.75
DCTVFRF	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	15.81	16.37	8.59	12.35
DC6U2KU	DMDI269	Docetaxel	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.02	8.53	0.83	0.83
DCYIUHE	DMDI269	Docetaxel	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.71	2.28	0.32	0.38
DCYJINE	DMDI269	Docetaxel	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.48	7.73	6.54	5.64
DCOECW6	DMDI269	Docetaxel	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.95	1.95	2.13	2.13
DCUV2OZ	DMDI269	Docetaxel	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.72	8.25	4.88	3.69
DCESKZX	DMDI269	Docetaxel	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.94	7.67	6.9	7.81
DC7XTB5	DMDI269	Docetaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.94	4.58	3.43	4.09
DCRUVZS	DMDI269	Docetaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.5	5.47	2.6	2.25
DCUSIID	DMDI269	Docetaxel	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.45	9.5	5.3	4.43
DCGDQWF	DMNER5S	Bleomycin	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	24.7	19.69	5.13	21.47
DCHXEAM	DMNER5S	Bleomycin	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.12	1.27	2.95	3.26
DCE3E1F	DMNER5S	Bleomycin	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	9.92	10.43	6.97	13.41
DCX5DQI	DMNER5S	Bleomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	9.08	9.23	2.04	9.16
DCA9NVF	DMNER5S	Bleomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	9.72	9.04	6.81	9.06
DCR4FH3	DMNER5S	Bleomycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.75	2.3	0.92	0.98
DCI0KMB	DMNER5S	Bleomycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	13.57	7.91	8.09	8.5
DCE9HY5	DMNER5S	Bleomycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	10.18	6.62	3.25	6.71
DCTUSD6	DMNER5S	Bleomycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.77	4.99	3.27	3.35
DCXYOZ9	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.89	0.72	0.84	1.23
DC7ZZAT	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	9.34	9.27	8.68	10.1
DCH479N	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	14.45	10.9	12.99	13.91
DC175PE	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.87	2.82	5.26	3.6
DCA3W4I	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.14	1.11	2.33	2.4
DCQN99X	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.05	3.21	5.38	5.45
DCN9NG6	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.07	6.42	7.84	7.42
DCZZOSY	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	11.72	12.23	11.69	11.98
DCFGECB	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	18.79	17.64	17.26	17.52
DCMAUFX	DMNER5S	Bleomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	10.57	9.04	3.01	9.88
DC956JE	DMNER5S	Bleomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	8.28	6.09	7.39	6.58
DC6MTJH	DMNER5S	Bleomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	7.5	7.19	3.15	8.52
DCNHQWL	DMNER5S	Bleomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.64	4.93	6.42	9.32
DC08EVO	DMNER5S	Bleomycin	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	3.41	5.91	7.68	8.59
DCJSLJ1	DMNER5S	Bleomycin	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.82	3.63	4.4	7.68
DCRX9C9	DMNER5S	Bleomycin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.81	2.01	1.93	3.33
DC5IYQK	DMNER5S	Bleomycin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.21	0.24	1.12	5.89
DCGINLN	DMNER5S	Bleomycin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.42	5.47	1.37	6.75
DC4BJG1	DMNER5S	Bleomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.49	3.25	7.47	7.62
DCM5E68	DMNER5S	Bleomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.22	1.6	0.38	6.15
DCP9OFD	DMNER5S	Bleomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.02	0.37	1.57	2.58
DCRMF3U	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	9.09	6.14	2.01	5.28
DCO9KSY	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.19	4.66	1.2	6.06
DC681BC	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	7.6	5.1	0.59	6.47
DC1ZE0M	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3	6.55	5.37	6.54
DCMVX8Y	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.46	3.72	4.17	4.48
DCK9A4K	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.97	4	7.84	8.4
DC8HR79	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	11.15	12.2	12.53	13.1
DCZH4IP	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	18.84	16.92	12.35	15.21
DCN7V0R	DMNER5S	Bleomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	15.27	9.42	9.42	10.89
DCQRJG7	DMNER5S	Bleomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.19	3.09	2.61	0.95
DCG9PGF	DMNER5S	Bleomycin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	22.32	13.39	13.46	15.95
DCMMBL5	DMNER5S	Bleomycin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.67	5.96	5.69	8.43
DCZPNDG	DMNER5S	Bleomycin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.01	2.05	2.68	5.66
DCEYOBA	DMNER5S	Bleomycin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	10.19	9.67	10.63	16.59
DC93VD1	DMNER5S	Bleomycin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	8.28	11.1	11.43	12.65
DCX3ZNP	DMNER5S	Bleomycin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	8.16	10.03	8.31	12.51
DCNZ7XA	DMNER5S	Bleomycin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.18	4.1	5.29	8.89
DC9YGPN	DMNER5S	Bleomycin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	4.55	3.95	6.52	9.02
DC3KVPI	DMNER5S	Bleomycin	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.31	6.06	6.31	8.89
DCFHTCU	DMNER5S	Bleomycin	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.43	1.08	0.54	3.98
DCKB9OV	DMNER5S	Bleomycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.47	1.54	0.87	3.21
DCEBYTT	DMNER5S	Bleomycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.75	2.78	1.68	3.89
DC5J6R2	DMNER5S	Bleomycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.43	1.54	1.22	5.05
DCAYJG6	DMNER5S	Bleomycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.21	2.14	0.77	4.82
DCKA4P6	DMNER5S	Bleomycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.29	3.75	3.84	3.61
DCMTHP6	DMNER5S	Bleomycin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	9.07	7.43	7.91	10.94
DCRJQHM	DMNER5S	Bleomycin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.77	2.55	0.93	5.54
DC3JTP7	DMNER5S	Bleomycin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	9.56	4.27	4.26	7.24
DCPQ3EJ	DMNER5S	Bleomycin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.8	0.3	3.72	6.9
DCV6R2H	DMNER5S	Bleomycin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.98	4.42	10.7	13.2
DCJ6K17	DMNER5S	Bleomycin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.84	2.71	4.52	6.92
DCN1HIX	DMNER5S	Bleomycin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	9.19	9.51	8.81	13.09
DCVL1A6	DMNER5S	Bleomycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.86	5.61	2.58	2.51
DCF4T63	DMNER5S	Bleomycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.31	4.48	2.55	1.76
DCIPZKS	DMNER5S	Bleomycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.75	0.57	0.44	0.57
DCWD1XL	DMNER5S	Bleomycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	4.18	4.52	6.53	6.55
DCVQY11	DMNER5S	Bleomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	31.02	39.73	0.6	0.6
DC4HIGA	DMNER5S	Bleomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	37.05	41.4	1.56	1.39
DCXA9D0	DMNER5S	Bleomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	20.48	25.88	3.61	3.61
DCTOQ9Z	DMNER5S	Bleomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	21.6	28.48	10.42	7.32
DCK68A0	DMNER5S	Bleomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.82	2.01	3.08	1.41
DCXSGHJ	DMNER5S	Bleomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	10.92	13.35	0.57	13.89
DCD5VB9	DMNER5S	Bleomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	5.72	10.91	8.39	9.44
DC6EZM5	DMNER5S	Bleomycin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.83	2.33	3.99	6.55
DCE02XZ	DMNER5S	Bleomycin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	7.11	4.21	3.51	7.74
DC19TKM	DMNER5S	Bleomycin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.29	0.83	3.61	5.65
DCNSE01	DMNER5S	Bleomycin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.23	1.7	0.04	2.23
DCXU6RU	DMNER5S	Bleomycin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.47	3.25	1.65	4.65
DCPP50J	DMNER5S	Bleomycin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	7.18	5.26	8.73	9.61
DC81S50	DMNER5S	Bleomycin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.05	3.34	0.65	5.87
DCEEO2N	DMNER5S	Bleomycin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.48	3.24	5.01	10.54
DCCT645	DMNER5S	Bleomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.8	4.14	0.99	6.03
DCANU2R	DMNER5S	Bleomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.93	0.5	1.87	2.75
DCQZSLX	DMNER5S	Bleomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.41	1.24	4.41	5.56
DCWYRQA	DMNER5S	Bleomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.56	3.45	6.2	8.79
DCAHJDN	DMNER5S	Bleomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	6.6	7.82	4.43	7.49
DCI41LS	DMNER5S	Bleomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	17.92	19.09	4.14	19.2
DCU1C2A	DMNER5S	Bleomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.75	1.28	3.6	7.05
DCSPRGX	DMNER5S	Bleomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	5.51	7.72	10.32	11.22
DCHM7B0	DMNER5S	Bleomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.83	1.6	6.83	9.18
DCFF1EH	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	10.49	9.85	7.98	11.1
DC2YRC3	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	12.79	8.71	7.52	10.86
DCEZYR5	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	2.68	2.95	4.65	6.62
DC9INEL	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	17.92	17.45	8.62	20.59
DCHCP3N	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.09	3.11	2.32	5.6
DCOP4FF	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	8.33	7.99	10.11	12.1
DC9NJFZ	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	14.93	18.67	9.45	19.41
DC4LYNC	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.09	2.95	0.02	5.81
DCE0ZJZ	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	8.14	8.48	10.77	12.17
DCENRGM	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	16.48	17.2	14.28	19.93
DC6AAQV	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.72	2.85	4.29	7.7
DCESYL9	DMNER5S	Bleomycin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	7.92	7.93	0.38	7.87
DCZJG1H	DMNER5S	Bleomycin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.97	4.92	3.49	8.07
DCDJAI6	DMNER5S	Bleomycin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.74	5.41	3.79	4.1
DCQ26FS	DMNER5S	Bleomycin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.84	5.31	4.55	3.26
DCE1Y75	DMNER5S	Bleomycin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.65	1.59	4.54	4.46
DC7YS0O	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	14.55	12.27	12.26	14.5
DCAN9SJ	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.49	2.38	0.72	4.5
DCRD4G6	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.97	4.63	4.33	7.13
DCCLTVG	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	7.32	6.78	5.18	10.37
DCG72C9	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	8.35	11.39	9.71	16.34
DCE39G3	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.28	2.32	2.28	6.71
DCODVVG	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	6.41	10.3	10.61	12.14
DC1JN3F	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	6.61	6.25	6.54	9.71
DCDS4JL	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.43	4.93	4.96	8.99
DCJWLPN	DMNER5S	Bleomycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.35	5.02	1.32	3.86
DCAXJ33	DMNER5S	Bleomycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.46	1.97	3.11	3.77
DC75KFB	DMNER5S	Bleomycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.63	5.24	2.91	4.91
DCIRIXL	DMNER5S	Bleomycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	8.45	8.63	3.91	4.95
DCWAFUK	DMNER5S	Bleomycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.31	7.97	2.99	5.71
DC77QF1	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	2.41	2.84	3.66	4.76
DCXY3DJ	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.06	3.49	2.61	4.52
DC45MAY	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	3.02	2.53	3.24	5.39
DCIIBTB	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.51	2.49	1.18	2.74
DCMDM00	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	4.66	4.27	6.78	9.35
DCW8IZU	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.45	2.65	0.82	4.91
DC448BD	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	7.64	7.06	6.9	10.19
DC25USS	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.07	1.81	1.73	1.23
DCXRE4P	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	8.19	7.98	6.22	10.61
DCFMEI7	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	7.35	6.31	6.05	8.85
DCV053A	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	9.88	8.76	8.59	13.39
DC6CNZU	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.68	2.03	1.09	6.87
DC0HMTN	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	6.61	8.77	8.16	11.5
DCBJRY2	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	7.68	7.43	6.26	10.36
DCFJ24H	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.46	1.99	1.04	5.36
DCFXNLI	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.21	4.27	2.47	6.62
DCMQPMV	DMNER5S	Bleomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.4	0.51	2.1	3.18
DCP50KX	DMNER5S	Bleomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.98	3	4.07	6.12
DCQIE00	DMNER5S	Bleomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	7.44	10.81	10.17	11
DCFYP01	DMNER5S	Bleomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.05	1.46	2.24	6.14
DCK5S1W	DMNER5S	Bleomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	4.01	9.5	4.02	7.05
DCFPY92	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	10.54	8.46	12.12	13.76
DCP5X77	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.25	4.1	4.9	7.97
DCOFVXM	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.63	2.98	9.24	9.22
DCM19H9	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.51	3.41	8.8	10.75
DCKNJ9O	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	6.29	8.92	11.96	12.78
DC42A3N	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	9.51	9.83	11.21	13.35
DCL7SLT	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.18	4.06	7.97	10.81
DCF17PK	DMNER5S	Bleomycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.83	1.1	6.22	6.31
DC58M1G	DMNER5S	Bleomycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.29	3.82	3.16	7.07
DC91IUL	DMNER5S	Bleomycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	2.04	1.98	2.2	7.03
DCJ6RGM	DMNER5S	Bleomycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	11.57	11.83	5.79	14.91
DCHYL67	DMNER5S	Bleomycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.24	4.19	2.55	5.3
DCYE2HW	DMNER5S	Bleomycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.8	9.27	7.1	10.89
DCFOTZH	DMNER5S	Bleomycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.07	4.4	0.64	8.49
DCZ97Q9	DMNER5S	Bleomycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.75	4.94	1.43	7.37
DC6AVJU	DMNER5S	Bleomycin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	9.43	8.39	5.15	9.73
DCGXRC9	DMNER5S	Bleomycin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.68	5.52	4.76	7.57
DCU07YW	DMNER5S	Bleomycin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	5.62	5.97	1.91	6.91
DCEAPP9	DMNER5S	Bleomycin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.06	3.82	1	5.33
DCJGWCT	DMNER5S	Bleomycin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.94	1.12	0.9	3.39
DCWGF23	DMNER5S	Bleomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.31	7.6	8.69	7.42
DCK7A43	DMNER5S	Bleomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.41	4.96	7.16	6.13
DCXFBWK	DMNER5S	Bleomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.68	3.07	0.07	4.03
DCQFGH5	DMNER5S	Bleomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	3.65	3.87	2.66	5.12
DCYRNCL	DMNER5S	Bleomycin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.3	4.53	5.73	8.18
DCQHN6W	DMNER5S	Bleomycin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.45	1.56	2.77	2.3
DCVOWR8	DMNER5S	Bleomycin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.67	2.77	3.44	7.17
DCD44FN	DMNER5S	Bleomycin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	7.35	7.01	1.33	7.06
DCJO3JA	DMNER5S	Bleomycin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	4.31	7.81	2.39	8
DC7BIU0	DMNER5S	Bleomycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.2	5.17	3.68	5.27
DCDMSX2	DMNER5S	Bleomycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.97	3.74	1.36	4.04
DCCODKO	DMNER5S	Bleomycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	5.69	2.56	0.75	5.08
DCAVH70	DMNER5S	Bleomycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	6.79	15.41	0.87	1.39
DC7K67Y	DMNER5S	Bleomycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.78	1.74	0.72	1.76
DCRMEPZ	DMNER5S	Bleomycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	4.9	6.17	0.25	3.03
DC664XC	DMNER5S	Bleomycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	5.24	7.78	4.39	5.36
DCWYO7E	DMNER5S	Bleomycin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	7.77	5.46	1.92	5.74
DCL8KTM	DMNER5S	Bleomycin	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.11	3.65	2.02	3.45
DCFA0AK	DMNER5S	Bleomycin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.19	4.82	1.89	4.03
DCBPG17	DMNER5S	Bleomycin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.81	5.32	5.08	4.49
DC5Y2BT	DMNER5S	Bleomycin	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.52	5.06	2.62	5.07
DCFI5K5	DMNER5S	Bleomycin	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.46	1.97	1.79	4.37
DCDTT5R	DMNER5S	Bleomycin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.63	2.89	0.24	4.51
DCENO7E	DMNER5S	Bleomycin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.55	0.14	0.91	2.85
DC6805C	DMNER5S	Bleomycin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.92	1.38	1.21	3.52
DC43BFF	DMNER5S	Bleomycin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.45	0.79	3.14	2.94
DCCPUPT	DMNER5S	Bleomycin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.09	3.07	3.04	3.94
DC2ESS0	DMNER5S	Bleomycin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.28	1.66	1.66	1.99
DCG8MX3	DMNER5S	Bleomycin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	9.72	8.77	4.16	10.12
DCNV7MJ	DMNER5S	Bleomycin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.98	4.84	0.22	6.52
DCB8ZXY	DMNER5S	Bleomycin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.66	4.05	0.14	5.97
DCF0SNB	DMNER5S	Bleomycin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.63	4.3	0.13	4.41
DCML76U	DMNER5S	Bleomycin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.2	5.44	5.76	6.2
DCRIJ1K	DMNER5S	Bleomycin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.07	7.68	1.68	6.54
DC32H6Y	DMNER5S	Bleomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	0.5	3.77	0.63	3.29
DCQ98JY	DMNER5S	Bleomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	7.67	6.69	1.67	7.13
DCWATN3	DMNER5S	Bleomycin	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	15.14	15.1	11.77	16.16
DCEFFNL	DMNER5S	Bleomycin	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	10.28	13.6	8.17	13.47
DC9CC3Q	DMNER5S	Bleomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.11	3.96	6.38	7.49
DCHMXYA	DMNER5S	Bleomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	9.72	10.13	6.93	11.18
DCKU75S	DMNER5S	Bleomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.3	4.97	1.67	5.86
DCAHHUO	DMNER5S	Bleomycin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.43	2.69	0.2	2.69
DCSZH1K	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.39	10.86	10.95	10.56
DCPTL03	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.1	4.82	5.13	5
DC8GBTZ	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.03	7.73	7.51	7.47
DCUXFBR	DMNER5S	Bleomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.46	6.42	7.69	8.71
DCDXQZZ	DMNER5S	Bleomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.3	4.37	5.62	8.08
DC8NKNR	DMNER5S	Bleomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.78	5.66	5.77	8.71
DCDJ9YD	DMNER5S	Bleomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.96	9.62	13.83	14.35
DCJ1737	DMNER5S	Bleomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.22	0.29	1.26	3.67
DCBZMB6	DMNER5S	Bleomycin	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.5	4	1.56	6.95
DCJWQBN	DMNER5S	Bleomycin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.11	4.29	0.27	4.03
DCA962R	DMNER5S	Bleomycin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.22	7.09	5.85	6.63
DC1PTL3	DMNER5S	Bleomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.42	0.01	2.11	2.73
DCPUV1O	DMNER5S	Bleomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.65	2.81	6.69	7.71
DCPEC90	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.7	14.56	14.24	14.03
DCN4DUD	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.18	7.38	7.66	8.01
DC1Y5D5	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.35	3.38	2.54	3.62
DC0GGQ5	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.74	4.06	0.35	1.2
DCOCFEY	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.23	12.62	11.35	12.5
DCOTLNI	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	12.16	19.38	17.26	18.43
DC2JPQA	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.51	4.61	5.16	3.94
DCCADC7	DMNER5S	Bleomycin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	8.19	8.48	10.03	11.6
DCC5QOG	DMNER5S	Bleomycin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.67	5.98	3.26	11.7
DCXXL8P	DMNER5S	Bleomycin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.94	4.61	10.26	11.07
DCD6PWO	DMNER5S	Bleomycin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.67	5.67	5.62	9.91
DCB2H67	DMNER5S	Bleomycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.52	0.68	6.22	7.59
DCSYOMZ	DMNER5S	Bleomycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.87	1.22	7.6	9.45
DCERCPN	DMNER5S	Bleomycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.37	1.09	4.8	6.7
DC1OR1P	DMNER5S	Bleomycin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.6	8.39	10.74	12.44
DCW85OZ	DMNER5S	Bleomycin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.28	5.87	9.14	11.8
DC4PW42	DMNER5S	Bleomycin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	9.16	11.95	17.18	19.77
DCGJKZD	DMNER5S	Bleomycin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.61	7.18	13.6	15.14
DC3HVPY	DMNER5S	Bleomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	5.89	11.83	3.25	2.31
DCXS13Y	DMNER5S	Bleomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	14.5	20.69	4.8	1.47
DC1JAA5	DMNER5S	Bleomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	12.92	11.88	10.27	10.27
DCP2SWU	DMNER5S	Bleomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.03	2.51	6.62	7.97
DCR6BEH	DMNER5S	Bleomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.58	2.64	4.57	6.2
DCN9CI2	DMNER5S	Bleomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	4.62	8.86	4.94	6.31
DCUU4OV	DMNER5S	Bleomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.18	3.01	8.09	9.59
DCPLYNB	DMNER5S	Bleomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	10.62	10.35	12.14	13.76
DC1GFS0	DMNER5S	Bleomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.3	3.98	9.24	10.53
DC77FPJ	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	8.46	11.16	0.49	13.83
DCXUUKN	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.38	6.96	9.55	10.43
DC8PPA7	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	8.54	10.04	6.64	11.68
DC430AW	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	9.56	12.26	20.88	21.57
DCEE2QX	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.04	7.89	9.79	11.09
DC28901	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.7	5.12	7.97	9.29
DCUGIYY	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.66	6.21	9.34	11.54
DCTO0WP	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	6.71	5.43	7.3	11.16
DCCSDFP	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.92	6.1	10.25	11.52
DCYQGGX	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.05	2.27	7.29	6.6
DCBEIPQ	DMNER5S	Bleomycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.69	3.81	2.03	2.04
DCFH6U5	DMNER5S	Bleomycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.96	4.1	0.93	5.73
DCMX9TW	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.7	3.86	5.71	5.4
DCCXXHB	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.68	3.89	5.52	7.82
DCROSG4	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.47	1.48	3.07	5.62
DCVB9ZJ	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.58	8.96	10.47	11.46
DCZCOOE	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.01	5.52	7.82	9.06
DC4ZU6Y	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.99	8.74	2.68	11.05
DC30TXJ	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.74	7.05	8.21	10.61
DC72XKQ	DMNER5S	Bleomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.83	4.19	3.53	4.18
DC228VE	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	7.59	6.57	10.56	11.78
DCYT0BA	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.45	4.55	10.97	12.11
DC60D5U	DMNER5S	Bleomycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.73	0.97	3.94	4.8
DCO3W64	DMNER5S	Bleomycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.14	1.66	1.92	1.92
DCCB8IP	DMNER5S	Bleomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.61	3.18	4.1	3.61
DC9NDWA	DMNER5S	Bleomycin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	10.96	10.82	11.25	13.75
DCTMFIG	DMNER5S	Bleomycin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.53	5.01	4.58	7.38
DC9P0DT	DMNER5S	Bleomycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.68	1.79	3.17	5.34
DCM3L9G	DMNER5S	Bleomycin	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.05	4.14	7.49	9.31
DCQKGH3	DMNER5S	Bleomycin	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.81	6.24	3.49	7.81
DCMXZ8H	DMNER5S	Bleomycin	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.85	3.04	2.64	7.01
DCKJNFK	DMNER5S	Bleomycin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.01	6.26	1.62	7.5
DC1ZPSX	DMNER5S	Bleomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.2	5.67	1.17	1.49
DCPOD3N	DMNER5S	Bleomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.46	7.42	1.2	2.23
DC8G39I	DMNER5S	Bleomycin	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	2.83	8.49	3.18	7.44
DCINSSA	DMNER5S	Bleomycin	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	9.56	9.45	5.31	8.68
DCF7I2C	DMNER5S	Bleomycin	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.02	3.46	2.43	2.29
DC788O2	DMNER5S	Bleomycin	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.68	2.47	9.21	10.98
DCO5CGN	DMNER5S	Bleomycin	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	7.13	15.78	4.74	10.21
DC5K7A8	DMNER5S	Bleomycin	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.5	9.42	9.19	13.42
DC6XOP7	DMNER5S	Bleomycin	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.42	3.89	3.5	4.79
DC254CB	DMNER5S	Bleomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	7.03	6.21	2.28	7.69
DCOQR2P	DMNER5S	Bleomycin	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.92	6.87	5.92	7.82
DC1WLTD	DMNER5S	Bleomycin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	HDLM-2	7.795	9.816	7.533	9.655
DCSOI37	DMNER5S	Bleomycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.99	2.59	1.58	3.7
DCINPWK	DMNER5S	Bleomycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.94	1.41	1.3	1.02
DCYBE7C	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.02	10.22	9.86	9.95
DCP9DDC	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	8.5	10.77	10.6	10.33
DCQZ2UE	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.79	2.84	2.39	1.92
DCGIMQP	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	4.38	7.87	7.48	7.27
DCEOE6X	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.97	3.82	3.33	3.35
DCLVSGQ	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.74	5.37	5.95	5.77
DCA5K57	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.84	7.67	6.74	6.93
DC43V2C	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.15	2.73	3.66	3.66
DCGRZJ3	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	13.55	15.81	15.7	15.78
DCSTT63	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	19.53	19.7	20.22	20.38
DCSUD22	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.75	7.89	5.63	6.49
DCUTRBN	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	6.38	11.64	10.96	11.08
DC96W2W	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.96	5.82	3.31	6.04
DCZ87XA	DMNER5S	Bleomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.32	9.02	8.36	7.93
DC72L5X	DMNER5S	Bleomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.3	2.6	1.66	6.24
DCQYRVM	DMNER5S	Bleomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	4.08	6.43	2.16	5.49
DCYLN1L	DMNER5S	Bleomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.83	3.54	5.53	5.44
DCV69QH	DMNER5S	Bleomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.92	8.33	1.88	7.04
DC1L2HG	DMNER5S	Bleomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.75	3.72	2.33	6.11
DCHFSN1	DMNER5S	Bleomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	7.82	10.67	12.53	13.47
DC729RR	DMNER5S	Bleomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.67	7.26	6.55	9.15
DCDWW8I	DMNER5S	Bleomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.8	6.17	6.46	6.32
DC6ELWR	DMNER5S	Bleomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.28	8.98	7.65	11.2
DCHWSQU	DMNER5S	Bleomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.91	9.16	7.63	9.54
DCSBMJV	DMNER5S	Bleomycin	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.31	2.12	1.81	2.81
DCSPDL0	DMNER5S	Bleomycin	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.91	2.9	1.12	2.91
DCMLJY6	DMNER5S	Bleomycin	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.87	1.89	1.55	0.43
DCS4G14	DMNER5S	Bleomycin	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.51	2.23	2.93	5.19
DCUEVX4	DMNER5S	Bleomycin	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.5	7.81	5.16	6.06
DCTB140	DMNER5S	Bleomycin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	9.92	10.96	0.27	8.55
DCVXTF3	DMNER5S	Bleomycin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.88	4.41	3.24	2.23
DCQUTR8	DMNER5S	Bleomycin	Approved	34	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	27.975	23.993	7.957	11.553
DCHKXIU	DMNER5S	Bleomycin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.2	0.15	1.58	5.03
DCT48IM	DMNER5S	Bleomycin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	6.53	8.24	1.32	2.15
DCQQ1N6	DMNER5S	Bleomycin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.28	2.21	0.07	3.03
DCCF0HM	DMNER5S	Bleomycin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	10.75	9.19	6.69	6.69
DCMG8AP	DMNER5S	Bleomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.16	3.85	3.43	4.58
DCWVJNA	DMNER5S	Bleomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.54	0.27	2.34	5.73
DC8LIP4	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.88	6.23	4.13	5.54
DC9G5NU	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5	5.2	5.54	6.36
DCOFS9Q	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.22	4.01	3.93	4.19
DCIVN4X	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.25	7.4	6.56	6.84
DC9DADZ	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.41	13.36	13.51	13.31
DC40M17	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.99	7.57	7.4	7.46
DCDCHY2	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	4.59	9.61	10.1	10.31
DC4P0Z5	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	10.681	8.626	0.853	3.064
DCZHLLY	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.74	2.5	0.05	2.45
DCNFVN7	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.81	3.5	3.03	3.32
DCVHZJL	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	25.1	28.02	28.1	29
DCCLQNA	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	8.97	8.97	7.36	8.23
DC70QHB	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.33	8.69	8.35	8.33
DCSHVG5	DMNER5S	Bleomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.87	13.57	12.75	13.04
DC65PZ9	DMNER5S	Bleomycin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.83	1.95	1.48	6.12
DCOU7CJ	DMNER5S	Bleomycin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.32	3.87	1.79	7.24
DCY2XLW	DMNER5S	Bleomycin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.27	2.05	2.44	6.69
DCU2OEZ	DMNER5S	Bleomycin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	6.79	7.04	3.6	8.83
DC46K49	DMNER5S	Bleomycin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.01	0.02	3.05	7.84
DC9SK92	DMNER5S	Bleomycin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.34	3.09	1.13	4.33
DC1UVZV	DMNER5S	Bleomycin	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.45	2.25	8.73	10.1
DCWQPEP	DMNER5S	Bleomycin	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.02	0.96	1.11	5.72
DC26ZNV	DMNER5S	Bleomycin	Approved	34	DMA9SEY	GDC-0084	Phase 2	21	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	HDLM-2	8.632	8.366	2.428	13.153
DCGTE8M	DMNER5S	Bleomycin	Approved	34	DMA9SEY	GDC-0084	Phase 2	21	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-428	6.801	4.77	11.926	9.314
DC4119G	DMNER5S	Bleomycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.45	2.71	6.03	6.17
DCO3LX6	DMNER5S	Bleomycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.21	5.08	6.32	5.78
DC2TDWU	DMNER5S	Bleomycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	4.15	4.73	6.08	8.36
DCHXMR4	DMNER5S	Bleomycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.68	6.22	5.84	6.76
DCGQ9G7	DMNER5S	Bleomycin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.11	1.85	3.53	5.7
DC5TW0M	DMNER5S	Bleomycin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.41	3.55	5.52	9.32
DCQK5U4	DMNER5S	Bleomycin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	5.31	6.41	4.92	9.95
DCA9RRR	DMNER5S	Bleomycin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.46	3.35	5	7.8
DC5RG33	DMNER5S	Bleomycin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.23	0.66	5.68	8.57
DCE4RS1	DMNER5S	Bleomycin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	7.36	7.78	7.98	11.34
DC6MSQ0	DMNER5S	Bleomycin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.96	5.89	4.57	9.09
DCXNKY5	DMNER5S	Bleomycin	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.23	4.8	12.52	14.4
DCPS5DI	DMNER5S	Bleomycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.07	5.6	3.34	3.38
DC9VMU9	DMNER5S	Bleomycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.53	1.15	1.26	1.23
DCRFQUV	DMNER5S	Bleomycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.86	1.6	1.83	1.22
DCMBGLI	DMNER5S	Bleomycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.81	3.84	2.98	2.99
DCFBLC0	DMNER5S	Bleomycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.02	2.44	4.04	6.2
DCTFCYE	DMNER5S	Bleomycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.17	1.04	1.3	0.2
DCBZ0I3	DMNER5S	Bleomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	17.52	20.41	0.9	0.9
DC7C367	DMNER5S	Bleomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	18	23.42	2.81	1.39
DCQJAN4	DMNER5S	Bleomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	14.77	20.89	11.22	4.33
DCBT0E3	DMNER5S	Bleomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	26.87	29.19	0.86	0.87
DCPK2IF	DMNER5S	Bleomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	10.02	11.68	0.93	0.49
DCTZ4HY	DMNER5S	Bleomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	12.56	13.8	3.82	1.18
DCB60Z8	DMNER5S	Bleomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.75	2.45	2.79	1.51
DCZ17BS	DMNER5S	Bleomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	11.58	14.58	2.28	1.85
DCS0SMZ	DMNER5S	Bleomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	20.52	23.07	3.3	0.49
DCMLMCS	DMNER5S	Bleomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	14.91	17.7	0.21	0.07
DCIDS45	DMNER5S	Bleomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.4	4.33	0.15	3.1
DCZ15IG	DMNER5S	Bleomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	234.699	233.889	7.379	15.488
DC71275	DMNER5S	Bleomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.34	7.53	2.81	2.81
DCZCGWF	DMNER5S	Bleomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	1.04	1.69	0.88	0.47
DCWYGNU	DMNER5S	Bleomycin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	7.41	9.39	7.25	10.41
DC0RFYO	DMNER5S	Bleomycin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.36	2.58	3.24	7
DC5VAYW	DMNER5S	Bleomycin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	7.39	8.8	4.8	10.94
DCQA5VI	DMNER5S	Bleomycin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.45	2.68	0.43	5.85
DCRCCB2	DMNER5S	Bleomycin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	5.61	6.26	0.44	7.35
DCGHJLD	DMNER5S	Bleomycin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.6	9.9	6.5	11.64
DCO8J32	DMNER5S	Bleomycin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	19.32	19.64	12.8	20.53
DCA5BUO	DMNER5S	Bleomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.6	5.32	3.78	7.7
DC42J2M	DMNER5S	Bleomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.62	0.89	5.92	9.62
DCCGTPE	DMNER5S	Bleomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.49	5.37	9.28	11.46
DCADZIL	DMNER5S	Bleomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.05	6.25	7.96	9.21
DCCPH30	DMNER5S	Bleomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.76	5.62	10.48	12.02
DCUUD8W	DMNER5S	Bleomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.05	1.04	0.73	3.69
DCI0RQA	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.16	4.34	6.26	7.66
DCWW4N3	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.12	3.99	6.14	7.67
DCE920K	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.25	1.74	4.05	5.88
DCQZMNA	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.69	4.62	0.14	6.56
DCBJW3T	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.22	4.21	3.06	2.51
DC8MU0O	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.64	4.43	6.66	8.48
DC25QBO	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.03	6.58	8.41	9.6
DCEKZ6G	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	13.97	16.5	15.44	17.77
DCSBNSY	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	11.2	12.87	5.76	12.83
DCWGS9Q	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.6	3.83	6.69	7.46
DCPAVB9	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	8.53	8.84	13.32	15.39
DCKKDUQ	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	10.2	11.25	12.38	13.47
DCPQ7VI	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.35	7.49	1.95	7.83
DCS83AS	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	10.35	10.18	13.59	15.23
DC8FL72	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.72	4.39	7.54	8.58
DCOMKZB	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.39	10.79	9.06	13.53
DCAQUUS	DMNER5S	Bleomycin	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.33	4.22	5.24	6.22
DCWJMN4	DMNER5S	Bleomycin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.3	5	1.66	4.93
DCR7XY0	DMNER5S	Bleomycin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.76	9.84	2.74	10.94
DCWP8O3	DMNER5S	Bleomycin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	5.5	6.01	4.4	4.61
DCQGQYQ	DMNER5S	Bleomycin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	4.03	6.46	5.67	5.38
DCCY0WI	DMNER5S	Bleomycin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.59	4.87	3.84	3.48
DCO1PRX	DMNER5S	Bleomycin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.1	7.09	4.62	5.04
DC6UVDY	DMNER5S	Bleomycin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.23	2.96	6.7	6.64
DCTBBYT	DMNER5S	Bleomycin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.09	5.74	3.69	5.15
DCNJCU6	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	6.07	10.07	5.19	14.08
DCI1SMN	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.35	3.66	4.83	7.18
DC1FW9U	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.52	3.68	2.42	6.9
DCT2Y42	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.39	4.2	5.06	8.42
DC0UOB8	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.82	2.63	6.71	9.24
DC1S50O	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.33	8.21	7.39	10.33
DCBEAE0	DMNER5S	Bleomycin	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.55	6.11	5.31	12.36
DCVDF48	DMNER5S	Bleomycin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.03	4.75	1.86	1.01
DC8K4QW	DMNER5S	Bleomycin	Approved	34	DMKXDOI	AS602868	Discontinued in Phase 1	3	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	24.721	29.247	2.958	4.524
DC107QR	DMNER5S	Bleomycin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.83	6.72	2.87	8.55
DCZI95D	DMNER5S	Bleomycin	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	8.89	8.44	6.97	12.05
DC9KP47	DMNER5S	Bleomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.32	2.41	0.12	2.38
DCW5ILP	DMNER5S	Bleomycin	Approved	34	DMNE56X	ABT-263	Phase 3	25	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	42.568	41.596	5.403	9.678
DCL6CC7	DMNER5S	Bleomycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.35	3.2	3.2	4.7
DC8T3D1	DMNER5S	Bleomycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.75	4.13	3.25	4.01
DCJDSIV	DMNER5S	Bleomycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.93	5.85	0.88	1.28
DCYKZ8B	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.76	4.46	1.35	5.79
DC1VU2P	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.57	4.04	5.76	9.48
DCCYM7P	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	9.32	6.15	3.88	7.19
DCKMGIG	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	8.55	11.52	8.12	8.63
DCDNZ4K	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.13	4.82	7.01	7.14
DCPCBKN	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	5.61	5.01	9.15	10.68
DC3Z9MB	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.68	0.48	1.77	3.17
DCSHPSF	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.15	3.62	6.64	7.28
DCJ68XO	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.52	2.23	1.37	4.51
DC3PU3I	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.13	0.84	3.11	5.58
DCX3AGK	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	6.12	7.66	7.8	9.67
DC9MNK6	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.3	4.6	5.53	8.34
DCZFGUK	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.96	3.45	3.37	6.19
DCOLXRJ	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.08	8.5	8.14	7.95
DCXYPKE	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.12	5.24	6.64	9.42
DCK7YNE	DMNER5S	Bleomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.98	5.67	3.22	7.92
DCUD2DO	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.32	2.31	1.58	5.18
DCGBORJ	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	2.09	9.99	2.53	8.37
DCQA0NB	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.15	5.33	3.68	7.69
DC81E7X	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	3.57	5.72	2.58	7.49
DCHMI6O	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.09	6.11	0.16	5.6
DCGJXC5	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.82	3.63	9.09	11.44
DCKNDPY	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.06	3.66	3.29	5.88
DC2V3QY	DMNER5S	Bleomycin	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.49	8.24	6.3	6.81
DCFZFSK	DMNER5S	Bleomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.16	0.79	1.68	2.55
DCKEXHT	DMNER5S	Bleomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.08	2.31	4.93	5.62
DCALUK5	DMNER5S	Bleomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.56	4.56	4.72	5.32
DCE872L	DMNER5S	Bleomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	6.59	9.28	10.93	11.62
DC3LASI	DMNER5S	Bleomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.5	2.24	0.1	1.25
DC8296C	DMNER5S	Bleomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.94	7.26	9.48	10.68
DCBOV7A	DMNER5S	Bleomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.81	5.42	6.57	7.02
DCR7ZOX	DMNER5S	Bleomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	8.31	6.84	7.8	9.22
DCX23MP	DMNER5S	Bleomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.29	2.64	1.37	2.06
DCWJRFL	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.96	0.03	3.37	6.15
DC5KX0E	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.88	3.17	7.31	9.26
DCU49QO	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.87	4.72	8.58	10.13
DCL44KQ	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.95	2.36	2.3	5
DCJWKKN	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.74	5.06	8.24	9.34
DC9QOMI	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	7.83	9.05	13.24	13.41
DCX29RC	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.48	3.22	6.55	8.15
DCTNIQO	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	4.7	6.72	8.94	9.14
DC7LPGE	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.33	1.79	1.35	4.19
DCT69VW	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.85	3.1	7.16	8.81
DC9S15D	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.69	3.46	7.62	8.81
DCDAAXU	DMNER5S	Bleomycin	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.89	1.48	5.62	7.02
DC2F94E	DMNER5S	Bleomycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.87	8.05	2.54	4.53
DCIY604	DMNER5S	Bleomycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.69	8.05	2.92	2.66
DCYKN2Z	DMNER5S	Bleomycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.72	1.68	4.04	8.47
DCN10V5	DMNER5S	Bleomycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	8.01	10.35	8.1	10.31
DC7R5Y7	DMNER5S	Bleomycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.59	5	0.08	1.18
DC96CWF	DMNER5S	Bleomycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.92	3.11	0.42	0.36
DCJZAVO	DMNER5S	Bleomycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.16	5.62	4.82	6.87
DCJQ6O8	DMNER5S	Bleomycin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1	1.64	2.14	4.9
DCGHSL4	DMNER5S	Bleomycin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.07	6.46	3.19	2.6
DCNA72R	DMNER5S	Bleomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.14	3.15	1.13	3.09
DCDNAPK	DMNER5S	Bleomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.8	5.62	1.21	3.8
DCNXP97	DMNER5S	Bleomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.77	7.66	5.11	7.07
DC3QSPP	DMNER5S	Bleomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	8.6	8.03	4.21	7.76
DCTD2PP	DMNER5S	Bleomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	4.68	9.66	0.87	2.95
DCAX3R0	DMNER5S	Bleomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.12	5.13	1.56	5.34
DC3KHU1	DMNER5S	Bleomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.88	6.9	2.98	6.21
DC9GM9Y	DMNER5S	Bleomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	4.63	5.16	2.4	3.86
DC1ZD9I	DMNER5S	Bleomycin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.64	4.91	2.16	6.33
DCE1A9H	DMNER5S	Bleomycin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.39	1.86	1.39	2.09
DCPRQV3	DMNER5S	Bleomycin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	5.68	7.7	1.5	6.32
DCPTSRN	DMNER5S	Bleomycin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	4.06	7.24	7.24	9.81
DCGZX52	DMNER5S	Bleomycin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	21.46	23.67	23.04	26.57
DCIHGP8	DMNER5S	Bleomycin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	4.15	8.06	0.93	10.57
DCPT2H8	DMNER5S	Bleomycin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	6.49	5.39	5.21	7.49
DC92NRY	DMNER5S	Bleomycin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	12.52	14.39	5.73	17.72
DCJR6ZB	DMNER5S	Bleomycin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.43	8.87	1.62	11.65
DCP69O5	DMNER5S	Bleomycin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	8.57	10.86	4.62	13.6
DCMR0IG	DMNER5S	Bleomycin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.69	1.53	0.41	3.68
DC4FQIO	DMNER5S	Bleomycin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	5.38	6.26	0.58	1.74
DCCV0E6	DMNER5S	Bleomycin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.45	2.84	3.49	6.9
DCOGUXL	DMNER5S	Bleomycin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.44	7.03	6.76	8.25
DCFZB2W	DMNER5S	Bleomycin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.33	4.74	1.84	4.29
DCJXKAW	DMNER5S	Bleomycin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	6.63	9.33	3.72	3.57
DC1MCU3	DMNER5S	Bleomycin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.83	3.78	1.8	2.61
DCRJW5I	DMNER5S	Bleomycin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.87	1.7	1.07	0.24
DCSVCOA	DMNER5S	Bleomycin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	8.04	14.5	3.77	12.79
DCY4TH9	DMNER5S	Bleomycin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.62	10.84	2.35	11.09
DCIENGO	DMNER5S	Bleomycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.18	1.52	1.14	1.57
DCOSJG5	DMNER5S	Bleomycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.55	3.1	5.15	5.32
DCGNC1G	DMNER5S	Bleomycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.9	2.75	1.7	5.84
DCPIVY4	DMNER5S	Bleomycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.35	0.71	1.19	1.66
DCK8GEJ	DMNER5S	Bleomycin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	3.34	3.95	3.23	7.78
DCWRKWX	DMNER5S	Bleomycin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.4	2.13	0.9	2.98
DCV7GP8	DMNER5S	Bleomycin	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.32	2.72	1.52	0.08
DCPP8LW	DMNER5S	Bleomycin	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.6	5.72	4.89	7.65
DCVDB6H	DMNER5S	Bleomycin	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.87	2.44	5.51	7.67
DCD56WJ	DMNER5S	Bleomycin	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.43	1.68	2.64	5.75
DCWSY23	DMNER5S	Bleomycin	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.49	3.01	7.17	8.73
DCUVHC4	DMNER5S	Bleomycin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.47	4.02	4.49	3.92
DCRFX81	DMNER5S	Bleomycin	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.88	2.4	1.03	1.33
DC1GX5D	DMNER5S	Bleomycin	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.65	0.06	1.94	4.83
DCON03K	DMNER5S	Bleomycin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.84	8.55	4.62	5.09
DCP30WW	DMNER5S	Bleomycin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.62	5.92	4.38	5.18
DCFIYB7	DMNER5S	Bleomycin	Approved	34	DMXKDUL	BGT226	Phase 1/2	19	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	129.761	122.849	18.566	20.636
DC6MYBF	DMNER5S	Bleomycin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.57	4.21	3.95	4.22
DCMMNFH	DMNER5S	Bleomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.68	0.96	2.22	3.46
DC92WI4	DMNER5S	Bleomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.32	1.6	6.09	7.68
DCZBFOJ	DM7NKEV	Thioguanine	Preclinical	2.1	DMIK367	Procarbazine	Approved	34	DMINOX3	Vincristine	DMMWSUL	Lomustine	Brain Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCK3BWU	DM7NKEV	Thioguanine	Preclinical	2.1	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.61	2.54	6.57	6.58
DCKQO06	DM7NKEV	Thioguanine	Preclinical	2.1	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.14	5.78	1.76	7.89
DCORW1R	DM7NKEV	Thioguanine	Preclinical	2.1	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	7.21	7.15	2.69	6.45
DCH2DGM	DM7NKEV	Thioguanine	Preclinical	2.1	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1	1.3	1.33	3.31
DCSZAIT	DM7NKEV	Thioguanine	Preclinical	2.1	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.3	10.58	5.83	7.54
DC80W0N	DM7NKEV	Thioguanine	Preclinical	2.1	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.22	3.05	3.83	4.26
DC15IJ3	DM7NKEV	Thioguanine	Preclinical	2.1	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	7.53	7.18	5.36	7.63
DCVDQFH	DM7NKEV	Thioguanine	Preclinical	2.1	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	6.5	7.69	3.2	7.51
DCMA3BL	DM7NKEV	Thioguanine	Preclinical	2.1	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.54	6.56	4.91	4.92
DCZ8G0S	DM7NKEV	Thioguanine	Preclinical	2.1	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.39	2.61	3.38	3.39
DCCVCU9	DM7NKEV	Thioguanine	Preclinical	2.1	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	10.16	10.39	7.37	10.5
DCSVITX	DM7NKEV	Thioguanine	Preclinical	2.1	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	6.99	8.43	0.79	8.15
DCEVC0W	DM7NKEV	Thioguanine	Preclinical	2.1	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.8	8.35	6.39	6.4
DC9R2P9	DM7NKEV	Thioguanine	Preclinical	2.1	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	5.3	4.34	2.7	2.46
DCIN5VQ	DM7NKEV	Thioguanine	Preclinical	2.1	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	3.48	4.35	6.22	6.25
DCL81ZX	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	15.4	14.97	16.04	16.08
DCOLTJZ	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	21.64	17.99	21.64	21.57
DCQGH3A	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	6.52	9.74	8.73	8.97
DCNV1EE	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.78	7.04	7.65	7.65
DCWRHT4	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	28.52	27.22	24.59	25.17
DCG5NEH	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	3.44	6.57	7.34	7.13
DC1N0M2	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.26	2.43	1.64	2.86
DCUNJG8	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	10.82	9.76	1.63	5.2
DC2DDDL	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	11.7	11.53	6.54	12.32
DCMOM38	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.82	3.97	1.29	3.96
DCEDA4O	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	8.89	10.66	9.66	10.82
DCJIZFX	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	8.39	8.44	3.09	6.83
DC578HS	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.24	4.96	3.07	3.89
DC8EFUE	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	5.06	7.66	7.4	7.95
DCJHSZV	DM7NKEV	Thioguanine	Preclinical	2.1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	8.38	8.17	10.91	12.11
DC4ZDZR	DM7NKEV	Thioguanine	Preclinical	2.1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.51	5.03	3.81	8.08
DCS2G4Y	DM7NKEV	Thioguanine	Preclinical	2.1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.79	5.59	4.62	7.82
DCSN017	DM7NKEV	Thioguanine	Preclinical	2.1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	7.48	7.1	7.24	9.76
DCO9HHO	DM7NKEV	Thioguanine	Preclinical	2.1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	10.84	10.88	12.39	12.76
DCU1CBL	DM7NKEV	Thioguanine	Preclinical	2.1	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.27	1.58	0.13	2.06
DCREDHZ	DM7NKEV	Thioguanine	Preclinical	2.1	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	15.31	16.11	17.22	18.1
DCIPJZ4	DM7NKEV	Thioguanine	Preclinical	2.1	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	11.14	10.76	7.44	11.67
DCFSMN2	DM7NKEV	Thioguanine	Preclinical	2.1	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.79	5.31	1.89	4.94
DC375FB	DM7NKEV	Thioguanine	Preclinical	2.1	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.46	7.01	3.95	8.48
DC0AP08	DM7NKEV	Thioguanine	Preclinical	2.1	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.99	2.67	4.05	6.05
DCYLDX2	DM7NKEV	Thioguanine	Preclinical	2.1	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.63	2.72	0.54	5.15
DCK20TQ	DM7NKEV	Thioguanine	Preclinical	2.1	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	6.87	6.12	6.55	10.38
DC0PWKS	DM7NKEV	Thioguanine	Preclinical	2.1	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.08	2.91	4.04	6.97
DC9FVJR	DM7NKEV	Thioguanine	Preclinical	2.1	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.15	6.43	2.3	6.53
DCZV0O7	DM7NKEV	Thioguanine	Preclinical	2.1	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.5	1.86	4	6.89
DC4RAO1	DM7NKEV	Thioguanine	Preclinical	2.1	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.66	2.79	2.22	4.24
DCG4KXC	DM7NKEV	Thioguanine	Preclinical	2.1	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	9.44	6.51	2.29	7.84
DCZ73D6	DM7NKEV	Thioguanine	Preclinical	2.1	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.28	6.93	1.65	4.5
DCJTOB8	DM7NKEV	Thioguanine	Preclinical	2.1	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	6.58	11.6	10.26	11.96
DCYS8YP	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	10.26	13.85	9.77	15.01
DC26IKP	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	7.13	5	1.56	7.88
DCHB204	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	12.99	13.03	9.82	14.33
DCFV82K	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	8	8.28	4.24	9.6
DCQN5TX	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	4.19	3.69	0.65	4.53
DC9G5VL	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.54	5.96	9.6	9.85
DCONS86	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.05	3.51	2.07	2.09
DCVGRT7	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	4.64	8.86	9.05	9.31
DCHE0MO	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	17.25	20.49	16.9	17.13
DCU0MML	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.07	3.31	1.2	3.86
DCLYTBH	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	6.6	4.49	5.29	5.33
DCOQIBF	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	9.12	8.3	1.85	3.35
DCBKKP2	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	12.27	11.59	11.55	12.97
DCXIS0R	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.93	3.31	0.61	1.72
DC7JKYO	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	5.35	7.29	4.76	4.95
DCHVGD4	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	6.8	9.87	5.36	6.96
DCICOQB	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	3.34	5.31	3.32	4.25
DCQ3KIC	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.81	2.33	2.01	2
DCFZD4I	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	4.05	5.78	7.19	7.33
DCMMX0S	DM7NKEV	Thioguanine	Preclinical	2.1	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	10.1	8.45	9.38	12.86
DCZOF2P	DM7NKEV	Thioguanine	Preclinical	2.1	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.08	1.68	0.04	5.37
DC7QO5G	DM7NKEV	Thioguanine	Preclinical	2.1	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.15	6.21	5.61	8.5
DCG7RUR	DM7NKEV	Thioguanine	Preclinical	2.1	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.58	2.5	3.51	6.49
DCYM3LY	DM7NKEV	Thioguanine	Preclinical	2.1	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	2.17	1.61	2.43	5.35
DCX00TP	DM7NKEV	Thioguanine	Preclinical	2.1	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	3.72	4.47	0.96	7.83
DCXG8QG	DM7NKEV	Thioguanine	Preclinical	2.1	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.94	1	1.2	1.21
DCGRHUF	DM7NKEV	Thioguanine	Preclinical	2.1	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.59	1.69	3.79	4.29
DCQAH30	DM7NKEV	Thioguanine	Preclinical	2.1	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.67	0.66	1.18	1.18
DC04OM5	DM7NKEV	Thioguanine	Preclinical	2.1	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.4	2.34	1.32	1.93
DCNCG5S	DM7NKEV	Thioguanine	Preclinical	2.1	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.95	7.77	9.18	9.27
DCPH6YF	DM7NKEV	Thioguanine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.56	3.7	1.32	2.64
DCKITK8	DM7NKEV	Thioguanine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	11.77	11.27	7.48	9.74
DCPIJ2G	DM7NKEV	Thioguanine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.84	1.27	0.75	1.88
DCDHWEJ	DM7NKEV	Thioguanine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.77	7.2	6.42	6.46
DC8LGXH	DM7NKEV	Thioguanine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.42	5.58	2.85	4.26
DCY47EG	DM7NKEV	Thioguanine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.4	2.2	0.51	0.91
DCW6I6D	DM7NKEV	Thioguanine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	6.36	6.36	6.55	6.53
DCNM9OV	DM7NKEV	Thioguanine	Preclinical	2.1	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	10.11	7.33	8.4	11.1
DCF7YZE	DM7NKEV	Thioguanine	Preclinical	2.1	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.09	2.5	2.39	5.85
DCZSRL6	DM7NKEV	Thioguanine	Preclinical	2.1	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	6.67	4.77	7.8	10.39
DCUH0WK	DM7NKEV	Thioguanine	Preclinical	2.1	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	13.8	17.55	0.5	10.18
DCTXREW	DM7NKEV	Thioguanine	Preclinical	2.1	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.98	4.93	8.02	7.52
DCJSRS2	DM7NKEV	Thioguanine	Preclinical	2.1	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.08	0.19	0.63	3.1
DCV92UI	DM7NKEV	Thioguanine	Preclinical	2.1	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.5	1.52	0.16	3.55
DCYQHPS	DM7NKEV	Thioguanine	Preclinical	2.1	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	6.86	4.86	5.76	10.13
DCXEQH0	DM7NKEV	Thioguanine	Preclinical	2.1	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	7.74	7.59	11.18	12.07
DC51ICH	DM7NKEV	Thioguanine	Preclinical	2.1	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.89	3.5	7.2	8.62
DC0ABS5	DM7NKEV	Thioguanine	Preclinical	2.1	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.25	9.08	0.65	5.62
DCTZE9Z	DM7NKEV	Thioguanine	Preclinical	2.1	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.76	0.87	0.2	4.73
DCIZ70H	DM7NKEV	Thioguanine	Preclinical	2.1	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.15	2.3	1.87	4.87
DCNC0JK	DM7NKEV	Thioguanine	Preclinical	2.1	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	2.8	2.64	3.79	8.25
DCQ6ELF	DM7NKEV	Thioguanine	Preclinical	2.1	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.85	1.27	3.06	3.85
DC0BW0W	DM7NKEV	Thioguanine	Preclinical	2.1	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	3.97	5.97	3.22	7.14
DC7NTQT	DM7NKEV	Thioguanine	Preclinical	2.1	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.81	3.59	1.8	7.06
DC2WZZE	DM7NKEV	Thioguanine	Preclinical	2.1	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.07	3.53	4.36	7.48
DC1M0RM	DM7NKEV	Thioguanine	Preclinical	2.1	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.6	5.33	7.64	8.55
DCUQGDE	DM7NKEV	Thioguanine	Preclinical	2.1	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.38	0.55	2.18	2.72
DC6GEYF	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	11.56	11.63	9.04	11.3
DCVBM2B	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	18.27	16.83	14.92	16.62
DCUMSR6	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	14.34	10.53	9.56	13.89
DCV5SNH	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	10.87	11.82	8.47	10.98
DC5QG4P	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	12.19	14.09	12.32	12.03
DC784KE	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.05	13.21	10.73	9.69
DCQ2JU8	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	4.35	7.84	10.69	10.16
DCGHNZD	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.14	5.2	7.03	7.04
DCAEDRB	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	8.99	9.68	9.54	8.99
DC6LHLZ	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	7.01	8.6	8.8	9.3
DC6YOB8	DM7NKEV	Thioguanine	Preclinical	2.1	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	8.2	3.09	3.3	6.92
DCO4YXO	DM7NKEV	Thioguanine	Preclinical	2.1	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.35	0.43	1.06	4.07
DCXXSQ6	DM7NKEV	Thioguanine	Preclinical	2.1	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.03	2.41	5	8.53
DCSJCQR	DM7NKEV	Thioguanine	Preclinical	2.1	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	8.4	9.26	0.02	12.06
DC19546	DM7NKEV	Thioguanine	Preclinical	2.1	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.85	4.12	5.05	7.45
DCWHAAT	DM7NKEV	Thioguanine	Preclinical	2.1	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.35	2.71	2.91	8.3
DCIGQ3S	DM7NKEV	Thioguanine	Preclinical	2.1	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	6.45	6.62	6.19	9.84
DCC366W	DM7NKEV	Thioguanine	Preclinical	2.1	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.09	3.5	2.15	7.11
DCN7H2H	DM7NKEV	Thioguanine	Preclinical	2.1	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.6	4.29	4.74	8.84
DCKREBZ	DM7NKEV	Thioguanine	Preclinical	2.1	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.99	7.63	4.45	9.11
DCZ7POI	DM7NKEV	Thioguanine	Preclinical	2.1	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.22	4.28	3.19	7.59
DCUT1BC	DM7NKEV	Thioguanine	Preclinical	2.1	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.16	1.74	1.51	4.39
DCTIVH8	DM7NKEV	Thioguanine	Preclinical	2.1	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.17	7.58	6.49	9.28
DC0UH06	DM7NKEV	Thioguanine	Preclinical	2.1	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.33	2.51	3.05	6.6
DC1ZTTT	DM7NKEV	Thioguanine	Preclinical	2.1	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.71	0.9	2.05	4.6
DCT8I8Q	DM7NKEV	Thioguanine	Preclinical	2.1	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	5.2	3.89	3.4	5.53
DCYRC59	DM7NKEV	Thioguanine	Preclinical	2.1	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	9.51	10.33	0.07	8.69
DC0OQDF	DM7NKEV	Thioguanine	Preclinical	2.1	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.19	3.06	0.89	3.25
DCS9WXE	DM7NKEV	Thioguanine	Preclinical	2.1	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	6.05	8.01	0.28	9.26
DCF2KQ8	DM7NKEV	Thioguanine	Preclinical	2.1	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	13.74	15.55	4.76	15.28
DC6HRCN	DM7NKEV	Thioguanine	Preclinical	2.1	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	9.04	10.69	5.67	8.52
DCBVO3J	DM7NKEV	Thioguanine	Preclinical	2.1	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	6.41	6.26	4.68	5.87
DCS3RLQ	DM7NKEV	Thioguanine	Preclinical	2.1	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	5.37	8.24	5.24	7.16
DCB1S7W	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	9.99	9.29	7.8	8.05
DCUCX77	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	8.49	8.49	6.03	6.52
DCVG1Y0	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	10.16	11.32	11.34	12.59
DCWXLZZ	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	7.83	9.13	6.27	8.84
DCO497D	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	8.72	8.43	4.86	4.66
DCT7QZS	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	4.84	5.91	4.86	7.8
DCTNR2E	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	3.63	10.05	3.63	6.43
DCXA8OV	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.41	1.94	1.97	6.01
DCNU84W	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.89	1.73	2.33	7.84
DCP66T0	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	7.73	11.27	6.83	7.46
DC5DXG5	DM7NKEV	Thioguanine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	0.72	4.72	8.16	8.29
DCB2TTK	DM7NKEV	Thioguanine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.01	8.62	11.18	11.08
DC1MSFP	DM7NKEV	Thioguanine	Preclinical	2.1	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.42	2.98	6.04	6.08
DC4LO9M	DM7NKEV	Thioguanine	Preclinical	2.1	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	1.65	2.67	1.4	1.58
DCR36KB	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.83	0.85	0.25	6.7
DCUXBB1	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	6.41	6.77	9.84	11.42
DCO6FK3	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.16	4.2	5.96	8.01
DCCCKQN	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	11.27	10.22	3.36	16.95
DCV8MK2	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	5.28	6.99	8.49	9.26
DCLP4SC	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	8.91	10.91	11.35	13.83
DCT8MFN	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.76	3.74	4.85	8.95
DCNM71M	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.24	0.59	3.27	6.28
DCRQCVA	DM7NKEV	Thioguanine	Preclinical	2.1	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	9.84	11.43	5.76	10.41
DCVXYEO	DM7NKEV	Thioguanine	Preclinical	2.1	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.18	3.01	3.53	5.84
DCB2BC4	DM7NKEV	Thioguanine	Preclinical	2.1	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	6.1	6.6	3.38	7.74
DC0I6H1	DM7NKEV	Thioguanine	Preclinical	2.1	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	4.1	8.28	2.56	6.66
DCQZSDF	DM7NKEV	Thioguanine	Preclinical	2.1	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.75	7.01	3.84	8.01
DC0U696	DM7NKEV	Thioguanine	Preclinical	2.1	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.85	4.92	2.01	5.54
DCMEW3I	DM7NKEV	Thioguanine	Preclinical	2.1	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.02	3.05	1.16	6.01
DCHIX5J	DM7NKEV	Thioguanine	Preclinical	2.1	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	7.68	6.54	7.11	9.12
DCU93HQ	DM7NKEV	Thioguanine	Preclinical	2.1	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	10.84	12.09	1.6	12.26
DCNZXDY	DM7NKEV	Thioguanine	Preclinical	2.1	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	5.74	6.89	3.62	7.84
DCSYMXC	DM7NKEV	Thioguanine	Preclinical	2.1	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	4.28	4.46	6.13	8.58
DCXA46J	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	8.84	8.68	6.61	7.93
DCARX4O	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.96	8.25	6.76	9.01
DCSXKS9	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	7.54	8.5	6.14	7.19
DC98MLH	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	5.21	6.73	4.78	4.91
DCRZS5G	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	6.59	5.59	4.29	5.7
DCP72SB	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.14	5.1	3.63	4.03
DCB6SC8	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	3.67	5.19	3.98	4.16
DCR4444	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.55	2.97	0.56	0.82
DC9IUI4	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.62	4.4	4.84	5.03
DCQE367	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.59	3.38	3.19	3.38
DCGXTKB	DM7NKEV	Thioguanine	Preclinical	2.1	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	5.11	3.6	4.16	6.4
DC3BBPT	DM7NKEV	Thioguanine	Preclinical	2.1	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	9.18	10.75	8.12	13.27
DC76X7Q	DM7NKEV	Thioguanine	Preclinical	2.1	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	4.45	4.68	1.4	5.79
DCGN2H9	DM7NKEV	Thioguanine	Preclinical	2.1	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.79	4.78	7.34	8.61
DC04BJA	DM7NKEV	Thioguanine	Preclinical	2.1	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	4.07	2.98	0.96	1.28
DCSFO93	DM7NKEV	Thioguanine	Preclinical	2.1	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.32	0.12	1.17	1.29
DC1ALVA	DM7NKEV	Thioguanine	Preclinical	2.1	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.53	5.06	1.24	6.71
DC2BJHM	DM7NKEV	Thioguanine	Preclinical	2.1	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	8.37	14.45	1.88	14.56
DC9MLLQ	DM7NKEV	Thioguanine	Preclinical	2.1	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	5.82	13.2	10.62	13.34
DCSTFUH	DM7NKEV	Thioguanine	Preclinical	2.1	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	6.36	14.32	10.02	14.75
DC5TQAT	DM7NKEV	Thioguanine	Preclinical	2.1	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	9.64	7.41	6.48	10.15
DC5VWHV	DM7NKEV	Thioguanine	Preclinical	2.1	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	5	4.14	3.34	6.76
DC0KWUB	DM7NKEV	Thioguanine	Preclinical	2.1	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.47	0.13	0.32	3.01
DCC8JF4	DM7NKEV	Thioguanine	Preclinical	2.1	DMUOT9V	Taxol	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.09	0.98	0.56	3.68
DCWKC6K	DM7NKEV	Thioguanine	Preclinical	2.1	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.81	1.79	2.52	4.47
DCB3D4J	DM7NKEV	Thioguanine	Preclinical	2.1	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.74	3.45	5.56	8.18
DCYQZQG	DM7NKEV	Thioguanine	Preclinical	2.1	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.38	1.68	2.97	6.45
DCS06J3	DM7NKEV	Thioguanine	Preclinical	2.1	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.28	4.98	3.69	4.93
DCE3DX4	DM7NKEV	Thioguanine	Preclinical	2.1	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	6.47	7.97	4.38	4.65
DCMJX8A	DM7NKEV	Thioguanine	Preclinical	2.1	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	4	3.67	4.61	4.66
DCF4TXI	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	12.91	11.69	4.44	11.96
DCHBK8K	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.8	5.27	5.45	8.21
DCU4CR1	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	7.15	5.1	4.54	8.1
DCH6X5T	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	7.58	6.56	7.66	10.47
DCWF2K0	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	7.72	8.38	7.34	10.51
DCMSYKV	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	6.1	7.69	5.76	10.03
DCOQM3I	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.14	4.09	7.08	1.73
DC5S5WD	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.5	5.76	6.46	7.79
DCNB60X	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.85	7.21	4.16	7.74
DCB1AY8	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.64	10.21	0.77	8.6
DCH6A5K	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	4	7.7	5.57	8.65
DCKR4G9	DM7NKEV	Thioguanine	Preclinical	2.1	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.19	2.24	3.81	6.2
DCWJ3EG	DM7NKEV	Thioguanine	Preclinical	2.1	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.86	2.32	4.51	5.87
DCJXNV2	DM7NKEV	Thioguanine	Preclinical	2.1	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.9	1.62	3.48	5.08
DC1GAOS	DM7NKEV	Thioguanine	Preclinical	2.1	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.7	1.18	0.05	0.18
DC7Q6R1	DM7NKEV	Thioguanine	Preclinical	2.1	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.54	1.31	2.39	2.39
DCLW6ZP	DM7NKEV	Thioguanine	Preclinical	2.1	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.85	4.3	1.85	6.33
DCH4K6P	DM7NKEV	Thioguanine	Preclinical	2.1	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.05	4.66	1.86	6.25
DC0F938	DM7NKEV	Thioguanine	Preclinical	2.1	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.4	5.39	4.04	6.07
DCIL8G1	DM7NKEV	Thioguanine	Preclinical	2.1	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	8.32	11.84	6.68	11.06
DCBU08O	DM7NKEV	Thioguanine	Preclinical	2.1	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	4.62	8.17	6.19	9.53
DC0L22V	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	8.9	8.55	7.1	7.33
DC265TP	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.54	2.47	2.5	2.97
DCXIK11	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.48	1.96	2.26	3.01
DCRXUFM	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	4.09	3.98	3.98	4.9
DCF9S0G	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.18	6.43	7.96	8.86
DCXTUGZ	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	9.27	9.59	7.82	8.08
DCAO5KS	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	8.84	3.31	7.2	7.96
DC799XW	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	3.47	8.29	2.93	6.74
DC87694	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	4.16	6.16	6.44	6.98
DC5SR7K	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	8.74	10.2	8.14	11.3
DCQBE8A	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.75	3.86	3.81	7.03
DC39CXJ	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.93	5.35	6.88	7.61
DCSV01F	DM7NKEV	Thioguanine	Preclinical	2.1	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.37	4.47	2.16	3.12
DCVM8CM	DM7NKEV	Thioguanine	Preclinical	2.1	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.38	8.53	4.41	7.31
DCI7XAD	DM7NKEV	Thioguanine	Preclinical	2.1	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.79	2.3	3.3	3.44
DCLOTJB	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.79	8.33	8.1	8.07
DCYJFHG	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.77	7.58	4.56	6.36
DCHQDQ5	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.58	5.33	0.76	2.6
DCQ6L6G	DM7NKEV	Thioguanine	Preclinical	2.1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	6.12	9.64	6.34	11.07
DCP60IR	DM7NKEV	Thioguanine	Preclinical	2.1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	10.56	14.75	16.22	16.63
DCWROCZ	DM7NKEV	Thioguanine	Preclinical	2.1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.88	6.09	0.5	9.36
DC2BAY8	DM7NKEV	Thioguanine	Preclinical	2.1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.59	7.45	9	10.62
DCW4E6O	DM7NKEV	Thioguanine	Preclinical	2.1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	9.19	12.99	15.61	16
DCOK7BT	DM7NKEV	Thioguanine	Preclinical	2.1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.71	7.46	3.91	7.53
DCI46MF	DM7NKEV	Thioguanine	Preclinical	2.1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.61	7.57	8.77	9.13
DCZS4C9	DM7NKEV	Thioguanine	Preclinical	2.1	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.29	8.48	1.86	2.23
DC2G2X4	DM7NKEV	Thioguanine	Preclinical	2.1	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	9.49	17.91	3.03	3.73
DC3TE9T	DM7NKEV	Thioguanine	Preclinical	2.1	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.24	6.64	0.36	5.58
DC1VTR3	DM7NKEV	Thioguanine	Preclinical	2.1	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.17	4.35	0.69	1.3
DCRLIJ9	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	13.82	14.82	13.52	13.69
DCH7VUS	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.75	6.52	5.51	5.59
DCXBU7J	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.85	6.62	4.93	6.13
DCNY84B	DM7NKEV	Thioguanine	Preclinical	2.1	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.87	2.39	2.79	2.79
DCUQXFZ	DM7NKEV	Thioguanine	Preclinical	2.1	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.51	3.98	0.06	3.62
DCZBTW6	DM7NKEV	Thioguanine	Preclinical	2.1	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	12	16.06	2.03	13.79
DC14BY5	DM7NKEV	Thioguanine	Preclinical	2.1	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.08	2.59	7.97	9.22
DCOCZU8	DM7NKEV	Thioguanine	Preclinical	2.1	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.76	7.27	2.47	4.6
DC2V2MG	DM7NKEV	Thioguanine	Preclinical	2.1	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.4	6.71	3.96	4.22
DC45A94	DM7NKEV	Thioguanine	Preclinical	2.1	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.37	0.25	7.62	9.26
DCZ99S5	DM7NKEV	Thioguanine	Preclinical	2.1	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.95	8.49	9.1	10.39
DCFKMIK	DM7NKEV	Thioguanine	Preclinical	2.1	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.24	5.26	7.95	10.09
DC51Z44	DM7NKEV	Thioguanine	Preclinical	2.1	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.06	1.4	7.55	8
DCNJXQF	DM7NKEV	Thioguanine	Preclinical	2.1	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.83	6.26	8.86	11.17
DCMUFZB	DM7NKEV	Thioguanine	Preclinical	2.1	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	5.13	9.17	11.98	13.28
DCCTD05	DM7NKEV	Thioguanine	Preclinical	2.1	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	12	11.62	16.13	18.44
DC5XQBZ	DM7NKEV	Thioguanine	Preclinical	2.1	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.13	3.42	4.94	7.05
DCUF4Q1	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.39	6.7	6.55	6.72
DCHY3XY	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.24	5.59	3.69	3.79
DCULA3B	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.28	11.18	9.43	13.09
DCPPBWV	DM7NKEV	Thioguanine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.56	8.34	10.22	9.94
DCCFXHU	DM7NKEV	Thioguanine	Preclinical	2.1	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.06	2.78	2.71	2.77
DCMBPK1	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	6.59	6.41	8.94	10.84
DC8KWT6	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.27	7.26	7.04	11.74
DCHUDB6	DM7NKEV	Thioguanine	Preclinical	2.1	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.65	5.59	3.6	4.81
DCKEV10	DM7NKEV	Thioguanine	Preclinical	2.1	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.23	4.54	1.42	5.65
DCSARWU	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.61	7.23	5.21	5.63
DCDCZTR	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.73	8.08	7.59	8.27
DCYAVA8	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.26	4.28	1.61	2.58
DCURW51	DM7NKEV	Thioguanine	Preclinical	2.1	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.12	5.97	1.18	8.36
DCJ7TST	DM7NKEV	Thioguanine	Preclinical	2.1	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.04	3.01	3.58	4.59
DC7LYF1	DM7NKEV	Thioguanine	Preclinical	2.1	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.41	3.71	0.1	4.49
DCD65N0	DM7NKEV	Thioguanine	Preclinical	2.1	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.42	12.11	3.5	4.46
DCW74HT	DM7NKEV	Thioguanine	Preclinical	2.1	DMUOT9V	Taxol	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.31	4.21	1.45	5.04
DCR3QLE	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.86	10.38	10.26	12.43
DCSP9NQ	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.51	5.27	4.06	7.72
DCT7JA4	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	13.79	17.16	12.6	13.16
DC402Q7	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	7.63	7.95	2.43	2.66
DCA9V3J	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	13.65	15.05	9.31	9.4
DC98CXA	DM7NKEV	Thioguanine	Preclinical	2.1	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	8.22	8.86	7.91	9.89
DC6EYVZ	DM7NKEV	Thioguanine	Preclinical	2.1	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.53	3.91	2.48	3.33
DC0EWZ7	DM7NKEV	Thioguanine	Preclinical	2.1	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.65	5.01	5.27	6.07
DC2FG06	DM7NKEV	Thioguanine	Preclinical	2.1	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.06	1.69	2.34	3.01
DCNH573	DM7NKEV	Thioguanine	Preclinical	2.1	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.43	4.34	3.04	3.52
DCDW6NC	DM7NKEV	Thioguanine	Preclinical	2.1	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1	1.45	0.67	1.34
DCQN45A	DM7NKEV	Thioguanine	Preclinical	2.1	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.17	6.7	1.45	6.34
DCLWMBI	DM7NKEV	Thioguanine	Preclinical	2.1	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.21	3.96	1.53	5.49
DC4M121	DM7NKEV	Thioguanine	Preclinical	2.1	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.83	5.71	3.84	3.73
DCPKXJW	DM7NKEV	Thioguanine	Preclinical	2.1	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.47	2.84	1.37	1.48
DC8FSX8	DM7NKEV	Thioguanine	Preclinical	2.1	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	5.29	3.15	0.73	0.8
DCVQT42	DM7NKEV	Thioguanine	Preclinical	2.1	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	3.58	9.22	7.97	8.04
DC9K1TN	DM7NKEV	Thioguanine	Preclinical	2.1	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.66	3.96	4.65	4.8
DC5KZ95	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.15	8.49	8.02	8.09
DC4UN5P	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.98	2.38	2.88	2.9
DCB51ET	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.35	3.65	2.42	2.47
DCEW6VE	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	22.2	17.01	16.46	16.32
DC8DYIH	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	14.46	16.33	15.39	15.4
DCB1Z4T	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.99	8.73	7.74	7.74
DCMAQIM	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.35	4.33	3.32	5.73
DC8U3NF	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.82	3.77	3.26	3.27
DCLTXRK	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	15.98	18.03	18.05	18
DCR6RXZ	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	22.98	23.49	24.77	24.24
DCFUVNL	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.78	7.11	1.26	4.01
DCX59TO	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	8.17	7.85	7.34	7.35
DCV6AXN	DM7NKEV	Thioguanine	Preclinical	2.1	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.88	3.18	3.09	3.01
DC109BC	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.53	5.06	5.83	7.06
DCCKAJI	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.61	6.35	6.23	8.41
DCBLBID	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.77	7.69	1.95	5.27
DCQ1T2U	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	5.17	6.11	5	7.1
DCNW6AW	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.82	3.07	0.26	2.2
DCUZ7B5	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.44	8.5	1.88	3.87
DC1YRNF	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.44	2.77	0.68	2.16
DC4YFOI	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.89	4.89	0.88	1.98
DC400VD	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	8.96	8.52	0.72	2.33
DCXW1QY	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.37	9.37	8.15	10.11
DCJX6EX	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	10.47	11.96	2.69	12.74
DC1W0WQ	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.83	3.71	2.21	2.98
DC1LKWS	DM7NKEV	Thioguanine	Preclinical	2.1	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	7.55	14.91	12.14	13.31
DC5GMBC	DM7NKEV	Thioguanine	Preclinical	2.1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.94	6.27	6.46	7.08
DCEWF0O	DM7NKEV	Thioguanine	Preclinical	2.1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6.8	7.12	1.57	7.52
DC9OP3Z	DM7NKEV	Thioguanine	Preclinical	2.1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.88	6.01	3.93	7.84
DCSCV8B	DM7NKEV	Thioguanine	Preclinical	2.1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.37	8.69	5.78	8.71
DCP42FB	DM7NKEV	Thioguanine	Preclinical	2.1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.54	5.82	3.32	5.23
DCB02CU	DM7NKEV	Thioguanine	Preclinical	2.1	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	11.53	14.19	15.99	16.96
DCDMVS7	DM7NKEV	Thioguanine	Preclinical	2.1	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	2.71	5.33	0	0.83
DCTQPN0	DM7NKEV	Thioguanine	Preclinical	2.1	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	10.98	19.03	17.3	16.06
DCEEWLZ	DM7NKEV	Thioguanine	Preclinical	2.1	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.06	6.72	6.54	6.54
DCX8SEW	DM7NKEV	Thioguanine	Preclinical	2.1	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.93	3.92	1.31	5.3
DCXL3ML	DM7NKEV	Thioguanine	Preclinical	2.1	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.65	5.85	7.16	9.5
DCRZBJN	DM7NKEV	Thioguanine	Preclinical	2.1	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.3	2.57	1.68	4.83
DCPM9UD	DM7NKEV	Thioguanine	Preclinical	2.1	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.04	7.54	3.49	7.18
DC0741Z	DM7NKEV	Thioguanine	Preclinical	2.1	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	6.22	10.02	2.65	3.35
DC8QBLN	DM7NKEV	Thioguanine	Preclinical	2.1	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.01	6.17	2.02	4.06
DC98DT6	DM7NKEV	Thioguanine	Preclinical	2.1	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.36	5.12	0.32	0.32
DCCWJMX	DM7NKEV	Thioguanine	Preclinical	2.1	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	7.14	7.06	2.29	4.18
DC5OVOO	DM7NKEV	Thioguanine	Preclinical	2.1	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.5	6.62	0.04	4.88
DCDNH67	DM7NKEV	Thioguanine	Preclinical	2.1	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.38	2.97	0.41	5.57
DCHLB1H	DM7NKEV	Thioguanine	Preclinical	2.1	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	7.25	16.9	10.75	10.65
DCSXTZE	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.59	4.27	4.03	4.03
DCCVVD5	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.22	4.29	4.79	4.91
DCBBS3R	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	8.44	7.85	6.53	6.61
DC18PVF	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.1	5.83	5.38	6.31
DCLGJ22	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.21	13.1	12.39	12.44
DCM1C07	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.74	2.15	1.6	1.73
DCX2ICZ	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.92	2.51	1.31	1.25
DC4US7Z	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	23.71	28.03	28.89	28.97
DCWAI88	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	8.88	13.91	15.32	15.39
DCWMPLW	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.18	7.14	7.01	6.67
DCN6AZO	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.81	5.28	3.21	3.22
DCFR43N	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.15	2.64	3.24	3.4
DCL2RVI	DM7NKEV	Thioguanine	Preclinical	2.1	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	5.28	5.88	3.42	8.07
DCEAUH9	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	9.52	9.05	2.9	3.65
DCFX62K	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.64	6.93	4.7	5.27
DCSOV4G	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.51	3.79	2.06	2.58
DCAT66X	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	12.6	10.02	5.06	6.02
DC9HP7E	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	4.63	4.49	1.48	1.86
DCZTW3J	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.18	8.67	2.82	3.19
DC8QC76	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.06	1.11	0.77	0.98
DC7X1S1	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.01	4.08	2.02	2.38
DCW0XYP	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	4.3	9.4	7.92	8.33
DC6OLCN	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.12	3.39	3.99	4.18
DCBNBU1	DM7NKEV	Thioguanine	Preclinical	2.1	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.77	7.66	5.49	5.9
DCHVUET	DM7NKEV	Thioguanine	Preclinical	2.1	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.95	3.94	0.43	4.35
DC1O0NU	DM7NKEV	Thioguanine	Preclinical	2.1	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.83	4.87	2.48	6.55
DCUMTE4	DM7NKEV	Thioguanine	Preclinical	2.1	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.57	3.75	3.17	2.89
DCNPZDN	DM7NKEV	Thioguanine	Preclinical	2.1	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.18	3.85	2.31	2.25
DC76TBJ	DM7NKEV	Thioguanine	Preclinical	2.1	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.15	8.2	3.07	7.94
DCQJ74A	DM7NKEV	Thioguanine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.98	5.58	3.26	3.64
DCLV9NP	DM7NKEV	Thioguanine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.35	3.48	1.65	2.16
DCHA01T	DM7NKEV	Thioguanine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.62	6.75	5.02	5.34
DCODLS4	DM7NKEV	Thioguanine	Preclinical	2.1	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.76	6.62	3.3	3.94
DCHJ131	DM7NKEV	Thioguanine	Preclinical	2.1	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.55	4.09	3.01	8.65
DCV72BJ	DM7NKEV	Thioguanine	Preclinical	2.1	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.06	4.6	3.16	3.79
DCOW43O	DM7NKEV	Thioguanine	Preclinical	2.1	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	6.36	8.84	1.71	8.33
DCVU5CQ	DM7NKEV	Thioguanine	Preclinical	2.1	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	5.92	4.87	0.2	6.84
DC91AMB	DM7NKEV	Thioguanine	Preclinical	2.1	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.24	4.55	1.59	7.19
DCZ6JW7	DM7NKEV	Thioguanine	Preclinical	2.1	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.46	7.18	6.44	6.9
DCI3LKH	DM7NKEV	Thioguanine	Preclinical	2.1	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	10.94	12.72	10.74	14.08
DCL0FQG	DM7NKEV	Thioguanine	Preclinical	2.1	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.53	5.78	6.74	8.97
DC16ATG	DM7NKEV	Thioguanine	Preclinical	2.1	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	14.61	13.19	8.99	13.98
DCV2WBN	DM7NKEV	Thioguanine	Preclinical	2.1	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	7.14	8.87	5.16	8.02
DCTP44V	DM7NKEV	Thioguanine	Preclinical	2.1	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.21	2	2.61	2.84
DCOT3OH	DM7NKEV	Thioguanine	Preclinical	2.1	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.49	3.56	1.04	3.75
DCT9XYE	DM7NKEV	Thioguanine	Preclinical	2.1	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.9	6.03	1.65	5
DCCL7S4	DM7NKEV	Thioguanine	Preclinical	2.1	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.42	4.43	1.8	3.43
DC8R2SI	DM7NKEV	Thioguanine	Preclinical	2.1	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.39	6.72	4.1	6.71
DC1VLTX	DM7NKEV	Thioguanine	Preclinical	2.1	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.65	4.59	2.13	3.95
DC7BKIW	DM7NKEV	Thioguanine	Preclinical	2.1	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.56	7.52	9.03	11.93
DCGJQGZ	DM7NKEV	Thioguanine	Preclinical	2.1	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	4.29	5.44	1.34	8.36
DCM4JO9	DM7NKEV	Thioguanine	Preclinical	2.1	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.85	1.55	5.44	6.77
DCTM2QE	DM7NKEV	Thioguanine	Preclinical	2.1	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.14	0.95	3.01	3.72
DCNZ2PH	DM7NKEV	Thioguanine	Preclinical	2.1	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	9.24	9.17	11.11	11.44
DC2BBEM	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	13.9	16.16	13.05	14.59
DCUUJMY	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	9.46	13.62	5.21	14.72
DC2XM9J	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	9.77	10.48	8.17	8.17
DCL81ZA	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	4.86	5.89	4.55	4.61
DCJJ0K2	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	8.66	15.91	14.4	14.29
DCDZ06U	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	5.05	6.29	3.96	7.12
DCDKOS1	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.67	10.46	8.45	8.14
DCZJBJ8	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	14.91	13.8	11.15	11.3
DCE9Z4Y	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.35	1.92	0.48	5.85
DCMSZFP	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.62	5.51	4.02	4.98
DCBJ9XD	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.55	3.43	3.81	7.07
DC8PHJA	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.83	11.93	14.07	15.05
DCSJBCD	DM7NKEV	Thioguanine	Preclinical	2.1	DMINOX3	Vincristine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	10.14	12.52	12.26	11.72
DCXO112	DM7NKEV	Thioguanine	Preclinical	2.1	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.94	4.86	5.07	8.63
DC5SKCB	DM7NKEV	Thioguanine	Preclinical	2.1	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.99	2.33	0.18	5.16
DCTER85	DM7NKEV	Thioguanine	Preclinical	2.1	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.67	4.92	6.99	10.39
DCKJT66	DM7NKEV	Thioguanine	Preclinical	2.1	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.86	10.77	3.33	10.67
DCX3ZIT	DM7NKEV	Thioguanine	Preclinical	2.1	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4.58	4.35	9.94	11.18
DCIG9X6	DM7NKEV	Thioguanine	Preclinical	2.1	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.63	5.86	4.17	3.41
DC6ZMJP	DM7NKEV	Thioguanine	Preclinical	2.1	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.46	13.16	9.04	11.7
DCOTFBY	DM7NKEV	Thioguanine	Preclinical	2.1	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.86	5.94	4.65	7.61
DCVIEMP	DM7NKEV	Thioguanine	Preclinical	2.1	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.41	5.65	2.52	6.93
DC9ZH7X	DM7NKEV	Thioguanine	Preclinical	2.1	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	7.61	7.25	1	3.03
DCSA1CZ	DM7NKEV	Thioguanine	Preclinical	2.1	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.73	6.84	0.33	5.36
DC3NEL3	DM7NKEV	Thioguanine	Preclinical	2.1	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	4.82	10.9	6.33	10.05
DC7UKFJ	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	4.49	6.28	5.2	5.77
DCDFWO9	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.62	6.19	7.31	8.73
DCSBA0G	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.56	2.46	0.54	0.74
DC1QN5C	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	9.03	8.79	7.72	7.96
DC2ZSQ2	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.73	4.3	3.01	3.11
DCK8G02	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.01	3.54	3.72	6.2
DCRGTTJ	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.91	5.02	0.59	4.58
DCUAXJL	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.25	6.17	1.02	1.57
DCG67TU	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.46	11.48	7.76	7.15
DCD7ES7	DM7NKEV	Thioguanine	Preclinical	2.1	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.65	4.14	6.58	8.13
DC9U5WT	DM7NKEV	Thioguanine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.11	5.51	5.17	5.29
DCMHTLC	DM7NKEV	Thioguanine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.47	9.72	10.56	10.53
DC80N9N	DM7NKEV	Thioguanine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.84	4.08	2.04	0.76
DCIUQ15	DM7NKEV	Thioguanine	Preclinical	2.1	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.55	5.4	5.15	5.15
DCZNRUP	DM7NKEV	Thioguanine	Preclinical	2.1	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.4	0.55	0.54	0.54
DCWL6X1	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.94	3.18	0.18	9.16
DCTCS5J	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.53	0.24	1.3	5.76
DCZ7OV1	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.06	5.79	8.42	10.64
DCW6GEV	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	4.92	6.9	7.85	11.63
DCQE82K	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.41	3.81	7.82	10.46
DCGGG08	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.63	9.72	11.25	12.67
DCSLZDJ	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.27	7.61	8.76	9.2
DCCFPN8	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	5.12	5.53	8.64	10.18
DCYA3PP	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.23	2.95	7.56	9.26
DCO76B7	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.97	6.96	9.81	11.06
DC5W0CI	DM7NKEV	Thioguanine	Preclinical	2.1	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.33	5.03	7.53	9.11
DCEDMIW	DM7NKEV	Thioguanine	Preclinical	2.1	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.73	1.75	0.57	2.78
DCLTOFJ	DM7NKEV	Thioguanine	Preclinical	2.1	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.36	6.45	1.8	6.81
DCECL80	DM7NKEV	Thioguanine	Preclinical	2.1	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.83	7.67	1.51	1.51
DCIHRHJ	DM7NKEV	Thioguanine	Preclinical	2.1	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.65	4.26	2.39	5.89
DCLEJOQ	DM7NKEV	Thioguanine	Preclinical	2.1	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.08	2.25	3.55	5.24
DCKP76Q	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.09	6.56	5.38	5.19
DCFU2M6	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	5.8	8.08	6.02	6.63
DCF6FN2	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.02	8.91	5.85	6.68
DCHNMKL	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.83	3.97	2.93	3.46
DCGS3J6	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.08	3.64	0.1	0.45
DCBFQ9G	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.39	1.67	0.63	0.87
DCJZ45J	DM7NKEV	Thioguanine	Preclinical	2.1	DMSG91J	ER819762	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.94	4.28	0.82	1.4
DCB92I8	DM7NKEV	Thioguanine	Preclinical	2.1	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.12	4.32	0.27	3.24
DCK5N87	DM7NKEV	Thioguanine	Preclinical	2.1	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.68	5.13	3.49	6.43
DCPBU6U	DM7NKEV	Thioguanine	Preclinical	2.1	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	25.83	22.74	23.11	24.57
DCXHW4P	DM7NKEV	Thioguanine	Preclinical	2.1	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	5.46	4.63	4.53	7.02
DCM3QT7	DM7NKEV	Thioguanine	Preclinical	2.1	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	5.77	10.47	3.76	13.21
DCT2N7S	DM7NKEV	Thioguanine	Preclinical	2.1	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.49	1.72	1.77	4.06
DC985B4	DM7NKEV	Thioguanine	Preclinical	2.1	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	11.65	13.12	4.49	16.34
DC8EZ96	DM7NKEV	Thioguanine	Preclinical	2.1	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	9	8.14	1.19	11.24
DCCQ67S	DM7NKEV	Thioguanine	Preclinical	2.1	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.29	4.56	3.96	5.62
DCPFTJX	DM7NKEV	Thioguanine	Preclinical	2.1	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.02	5.27	0.51	0.88
DCULFFL	DM7NKEV	Thioguanine	Preclinical	2.1	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.68	4.68	2.89	6.28
DC8JQT4	DM7NKEV	Thioguanine	Preclinical	2.1	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	7.33	14.64	8.55	14.61
DC4R8AJ	DM7NKEV	Thioguanine	Preclinical	2.1	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.25	3.45	1.63	2.26
DCRFQ2P	DM7NKEV	Thioguanine	Preclinical	2.1	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	6.89	11.97	8.52	10.01
DCHZ699	DM7NKEV	Thioguanine	Preclinical	2.1	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	9.56	13.32	11.1	13.39
DC4N13L	DM7NKEV	Thioguanine	Preclinical	2.1	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	6.07	9.04	4.79	8.21
DC7CYMZ	DM7NKEV	Thioguanine	Preclinical	2.1	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.93	3.93	4.15	6.16
DCE81J7	DM7NKEV	Thioguanine	Preclinical	2.1	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.52	6.23	8.14	10.24
DC8YCHE	DM7NKEV	Thioguanine	Preclinical	2.1	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.15	1.57	1.57	3.26
DCW5UCM	DM7NKEV	Thioguanine	Preclinical	2.1	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.27	8.73	7.88	10.64
DCUN53M	DM7NKEV	Thioguanine	Preclinical	2.1	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.19	3.17	1.23	4.56
DCMSTKR	DM7NKEV	Thioguanine	Preclinical	2.1	DMUOT9V	Taxol	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.69	4.18	6.9	8.65
DCY6EP5	DM7NKEV	Thioguanine	Preclinical	2.1	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.43	2.94	1.27	4.01
DCEFXL0	DM7NKEV	Thioguanine	Preclinical	2.1	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.78	3.22	0.79	3.03
DCWTRQ5	DM7NKEV	Thioguanine	Preclinical	2.1	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.06	2.34	2.56	2.67
DCFJ487	DM7NKEV	Thioguanine	Preclinical	2.1	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.23	1.34	1	0.91
DCM7I9J	DM7NKEV	Thioguanine	Preclinical	2.1	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.04	3.21	2.79	3.01
DCFQOFL	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	4.22	6.99	0.43	6.71
DCMKSER	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.52	4.83	3.28	7.14
DCBR7KS	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.88	12.29	2.02	5.7
DCCBGPY	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.49	3.84	3.06	4.36
DC0PDLZ	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.41	5.05	0.9	7.74
DCO59D2	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	4.44	7.75	5.4	7.34
DCZX7N9	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.53	1.21	0.75	5.95
DC3X18O	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.7	12.44	2.66	7.13
DCXQ3EN	DM7NKEV	Thioguanine	Preclinical	2.1	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.27	2.86	3.55	6.18
DCHNIAX	DM7NKEV	Thioguanine	Preclinical	2.1	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.17	4.69	0.07	5.4
DCXRL8J	DM7NKEV	Thioguanine	Preclinical	2.1	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.92	0.84	0.58	5.02
DCUAHNB	DM7NKEV	Thioguanine	Preclinical	2.1	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.21	1.96	0.05	5.57
DCT7LTX	DM7NKEV	Thioguanine	Preclinical	2.1	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.19	3.04	1.47	2.88
DCAV18O	DM7NKEV	Thioguanine	Preclinical	2.1	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.08	10.12	5.62	10.75
DCQVAJG	DM7NKEV	Thioguanine	Preclinical	2.1	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.91	10.2	1.36	10.39
DC77SEC	DM7NKEV	Thioguanine	Preclinical	2.1	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.44	3.05	3.13	5.1
DCRK05Z	DM7NKEV	Thioguanine	Preclinical	2.1	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.6	7.05	0.21	7
DCCL7UT	DM7NKEV	Thioguanine	Preclinical	2.1	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.86	5.95	4.56	9.92
DCFS8FU	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.73	7.07	4.85	9
DCX5GX1	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.26	5	4.23	5.67
DC5693D	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	4.42	9.65	5.93	5.94
DC5U9YL	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	6.84	7.26	5.7	7.1
DCK83FV	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.87	4.24	4.49	5.74
DCV9LKC	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.65	4.07	2.76	4.79
DCTDHKH	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.67	3.98	9.62	10.84
DCUU397	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.59	1.36	2.63	2.31
DC05SG8	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.25	10.47	7.61	12.88
DCZC05B	DM7NKEV	Thioguanine	Preclinical	2.1	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.2	7.47	6.68	9.43
DCFUMKZ	DMAH59S	Amonafide	Phase 3	25	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	18.65	16.82	0.34	20.04
DCCZ5OK	DMAH59S	Amonafide	Phase 3	25	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	3.32	2.41	8.54	10.42
DCJ7M0D	DMAH59S	Amonafide	Phase 3	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	4.66	4.54	6.23	6.63
DCASZ89	DMAH59S	Amonafide	Phase 3	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	3.74	5.93	0.16	6.55
DCA8HHZ	DMAH59S	Amonafide	Phase 3	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	11.7	9.05	0.99	6.99
DC4VM2A	DMAH59S	Amonafide	Phase 3	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	1.93	2.69	0.48	4.1
DCUTW0G	DMAH59S	Amonafide	Phase 3	25	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	L-1236	3.62	3.72	2.21	1.57
DC8B38X	DMAH59S	Amonafide	Phase 3	25	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	4.85	6.39	1.76	6.28
DC8E8SR	DMAH59S	Amonafide	Phase 3	25	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	3.88	4.46	1.65	4.92
DCN2UHD	DMAH59S	Amonafide	Phase 3	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	1.79	3.23	3.72	2.05
DCI84K8	DMAH59S	Amonafide	Phase 3	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	2.04	1.54	0.58	2.86
DC9MQQL	DMAH59S	Amonafide	Phase 3	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	3.03	3.71	2.86	2.6
DCZ7ZGQ	DMAH59S	Amonafide	Phase 3	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	3.08	4.22	2.4	2.9
DCK9R9T	DMAH59S	Amonafide	Phase 3	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	4.2	4.09	3.48	4.71
DCCLHA8	DMAH59S	Amonafide	Phase 3	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	2.29	2.18	0.28	0.2
DC8V8OK	DMAH59S	Amonafide	Phase 3	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	1.41	3.17	2.91	3.89
DCJ7ZSV	DMAH59S	Amonafide	Phase 3	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	3.38	5.9	4.1	5.84
DC6LHDX	DMAH59S	Amonafide	Phase 3	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	3.71	5.54	3.41	3.87
DCZRZ1C	DMAH59S	Amonafide	Phase 3	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	0.28	0.75	4.05	3.2
DCY13QG	DMAH59S	Amonafide	Phase 3	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	1.56	4.45	5.2	5.47
DCT1CR6	DMAH59S	Amonafide	Phase 3	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	0.82	1.8	2.79	3.01
DCFEH7X	DMAH59S	Amonafide	Phase 3	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	0.55	5.96	4.46	6.28
DCVG6LV	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	1.85	1.29	2.64	0.97
DCAN4GX	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	1.04	2.52	2.15	2.52
DC8TA0U	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	6.57	9.77	8.99	9.5
DCQ10N9	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	18.11	13.89	12.99	13.44
DCKEFOR	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	2.49	3.72	2.94	2.82
DC8MNX1	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	3.4	3.21	5.53	4.48
DCRHZOL	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	8.79	5.97	3.14	8.72
DC0S7HT	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	13.28	13.01	9.98	13.88
DCCIEMO	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	15.93	11.49	14.29	15.3
DCP0NSO	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	1.04	1.91	1.96	2.25
DC6YICW	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	0.65	0.94	0.51	3.46
DC7CL4K	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	1.98	3.48	3.51	5
DC7IGM9	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	2.81	2.97	4.9	5.11
DC533MN	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	2.95	3.22	1.81	4.95
DCFD5XW	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	0.57	1.55	1.99	1.78
DC1I10R	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	2.8	6.09	5.52	5.59
DCCDXZ0	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	4.11	9.12	10.19	10.09
DCZYN9A	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	3.7	7.11	7.31	7.37
DCAJW0U	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	3.32	14.81	14.27	14.24
DCCB2Y2	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	3.9	7.08	6.55	6.6
DCN2W4R	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	3.95	6.47	6.99	6.86
DCG7P9M	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	5.34	6.86	5.11	6.14
DCDA23N	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	1.28	3.37	0.54	3.41
DC64YD8	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	2.35	3.99	4.88	4.92
DCJ21AF	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	16.89	18.04	19.86	18.01
DCKJG6D	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	24.13	24.22	24.21	24.9
DCLY6Y6	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	2.83	4.31	2.66	3.19
DCKQMWB	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	0.02	1.36	1.7	1.4
DC8M1QG	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	0.31	7.99	7.6	7.68
DCSF4EZ	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	0.16	3.7	3.12	3.17
DCAGQK2	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	0.48	6.08	5.43	5.05
DCQJCXY	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	19.05	20.32	19.12	20.21
DC0OJ3B	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	1.16	4.39	5.62	5.25
DCGRDY0	DMAH59S	Amonafide	Phase 3	25	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	6.03	5.24	1.73	6.81
DCY01FH	DMAH59S	Amonafide	Phase 3	25	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	1.62	5.11	2.04	7.97
DCJ0YEY	DMAH59S	Amonafide	Phase 3	25	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	2.36	5	4.3	7.5
DC4UVDX	DMAH59S	Amonafide	Phase 3	25	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	2.12	1.09	2.88	3.34
DCDBEHC	DMAH59S	Amonafide	Phase 3	25	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	4.81	6.64	4.41	6.49
DCBQ1AC	DMAH59S	Amonafide	Phase 3	25	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	3.21	3.03	2.2	3.62
DCJHT1L	DMAH59S	Amonafide	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	6.68	8.57	8.08	7.99
DCOU3Y5	DMAH59S	Amonafide	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	4.97	7.16	2.46	10.83
DCTYQ8W	DMAH59S	Amonafide	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	10.25	12.73	5.58	11.73
DCVU924	DMAH59S	Amonafide	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	7.1	14.4	6.68	12.71
DC5D830	DMAH59S	Amonafide	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	16.89	13.2	8.59	14.62
DC1DJU9	DMAH59S	Amonafide	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	13.22	13.67	0.99	13.98
DC6QN22	DMAH59S	Amonafide	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	4.64	5.97	0.69	6.72
DCN5W34	DMAH59S	Amonafide	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	4.92	6.78	2.27	7.59
DCTAEH4	DMAH59S	Amonafide	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	0.16	8.95	7.4	10.39
DC9TBUN	DMAH59S	Amonafide	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	2.81	2.01	2.59	7.69
DCRFEZ2	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	6.66	8.13	12.13	11.19
DCSOMRN	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	5.77	6.79	5.7	9.25
DC7M7WY	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	17.36	11.97	9.84	13.65
DC47UC4	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	3.54	2.88	2.09	5.34
DC9BEOH	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	1.7	4.67	2.32	7.43
DCPNUF8	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	2.83	3.08	2.96	6.33
DC7WTSX	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	7.26	7.22	8.83	11.55
DCXWR0D	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	3.05	3.92	1.08	5.89
DC63AKQ	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	11.91	12.85	15.99	15.24
DCR1K8Q	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	7.65	8.25	5.87	8.12
DC7YWWR	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	4.73	7.9	7.42	9.45
DCJRNSO	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	4.03	4.18	3.92	9.19
DCI1HPB	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	1.04	9.6	7.78	10.09
DC5Z1LQ	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	1.16	4.83	1.98	6.78
DCERVDN	DMAH59S	Amonafide	Phase 3	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	1.41	3.23	3.25	2.84
DCPQ80J	DMAH59S	Amonafide	Phase 3	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	4.87	6.87	2.83	7.46
DCOEKZ6	DMAH59S	Amonafide	Phase 3	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	1.67	2.01	0.4	2.75
DCSHO14	DMAH59S	Amonafide	Phase 3	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	7.33	8.25	2.6	10.54
DCGHIC2	DMAH59S	Amonafide	Phase 3	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	0.97	2.78	0.15	5.62
DCUE8G0	DMAH59S	Amonafide	Phase 3	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	0.09	8.16	3.65	6.38
DCWIA14	DMAH59S	Amonafide	Phase 3	25	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	2.63	4.65	2.46	7.57
DC1DSBV	DMAH59S	Amonafide	Phase 3	25	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	4.63	2.94	3.03	5.45
DCM61TA	DMAH59S	Amonafide	Phase 3	25	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	4.48	2.64	2	4.82
DCSX2Q5	DMAH59S	Amonafide	Phase 3	25	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	2.48	5.57	2.46	6.52
DCSSTEQ	DMAH59S	Amonafide	Phase 3	25	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	6.44	5.15	6.01	9.01
DCPHLTK	DMAH59S	Amonafide	Phase 3	25	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	4.81	4.64	2.97	5.84
DCVWUQP	DMAH59S	Amonafide	Phase 3	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	1.75	1.69	1.5	3.31
DCIBR7Y	DMAH59S	Amonafide	Phase 3	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	1.65	2.83	1.16	5.24
DCBUSS4	DMAH59S	Amonafide	Phase 3	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	1.89	5.15	3.11	5.13
DCEFFUJ	DMAH59S	Amonafide	Phase 3	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	4.17	4.46	1.35	5.24
DCSX58R	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	1.23	1.65	3.68	2.01
DCQ96Q3	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	4.31	6.74	3.62	7.68
DCPSYXB	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	3.81	5.89	2.83	7.04
DCUZLKL	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	3.92	6.48	7.72	6.69
DCW570H	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	1.37	4.05	0.64	3.28
DCIQJWI	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	8.22	8.1	5.33	9.81
DCGMJVI	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	7.93	7.75	4.82	10.29
DCE0OKI	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	4.08	4.77	0.13	4.76
DC28KVR	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	5.6	7.18	4.92	8.55
DCSOCE0	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	0.48	7.32	5.68	6.97
DCBL8S9	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	6.53	7.4	6.45	8.2
DC46TU2	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	3.59	12.17	5.43	12.12
DC7OLNW	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	2.93	9.85	10.36	10.56
DCQUAIG	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	4.19	5.89	4.21	3.75
DCP5JW3	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	32.99	31.46	34.29	32.43
DCIYBII	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	7.95	7.05	2.61	6.34
DC8FUGO	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	3.16	6.85	6.15	6.49
DCA17FS	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	3.62	11.34	9.74	11.17
DC1QCII	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	4.66	4.88	2.46	7.32
DCENVZI	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	3.64	4.91	2.26	6.14
DCG1MZE	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	12.34	14.44	3.76	12.75
DCAXL1L	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	1.97	4.95	1.89	5.77
DCXMU3U	DMAH59S	Amonafide	Phase 3	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	7.34	11.1	0.36	6.04
DCMQBD1	DMAH59S	Amonafide	Phase 3	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	0.22	5.86	4.62	5.18
DC1JQYC	DMAH59S	Amonafide	Phase 3	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	0.85	1.67	2.84	2.63
DCAL3GW	DMAH59S	Amonafide	Phase 3	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	11.4	9.08	9.94	12.72
DCF0SOI	DMAH59S	Amonafide	Phase 3	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	5.58	4.25	5.22	7.61
DCZNX1J	DMAH59S	Amonafide	Phase 3	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	2.21	7.11	6.16	10.14
DCCFB1M	DMAH59S	Amonafide	Phase 3	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	3.62	5.76	6.94	8.66
DC07G7Z	DMAH59S	Amonafide	Phase 3	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	3.06	3.32	2.9	6.92
DCQE1A8	DMAH59S	Amonafide	Phase 3	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	1.05	0.86	2.69	4.81
DCXKLGV	DMAH59S	Amonafide	Phase 3	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	0.4	2.69	0.13	6.91
DCK63Z7	DMAH59S	Amonafide	Phase 3	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	1.13	3.38	2.07	5.46
DCNPQW0	DMAH59S	Amonafide	Phase 3	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	2.33	3.35	8.45	10.99
DCTNFE1	DMAH59S	Amonafide	Phase 3	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	2.37	3.61	4.65	8.89
DC11F50	DMAH59S	Amonafide	Phase 3	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	8.46	9.38	4.11	9.8
DCYYEQR	DMAH59S	Amonafide	Phase 3	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	3.06	3.79	0.79	5.07
DCWCNLL	DMAH59S	Amonafide	Phase 3	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	2.62	8.2	2.31	8.64
DCDH70M	DMAH59S	Amonafide	Phase 3	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	21.77	14.41	6.7	15.72
DCTJUF2	DMAH59S	Amonafide	Phase 3	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	22.74	14.09	8.47	15.31
DCOHW11	DMAH59S	Amonafide	Phase 3	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	8.02	7.18	1.88	7.2
DC73HSD	DMAH59S	Amonafide	Phase 3	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	2.71	5.69	3.95	7.19
DC3B45C	DMAH59S	Amonafide	Phase 3	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	3.36	4.82	4.53	9.32
DCPG3DT	DMAH59S	Amonafide	Phase 3	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	6.03	8.95	2.59	8.47
DCQOHC3	DMAH59S	Amonafide	Phase 3	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	2.05	2.71	0.08	3.67
DCYW2H2	DMAH59S	Amonafide	Phase 3	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	3.62	6.4	7.54	10.58
DCYPUON	DMAH59S	Amonafide	Phase 3	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	2.1	3.45	0.62	5.41
DC1BP5X	DMAH59S	Amonafide	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	1.22	0.79	2.38	5.72
DCCUDXF	DMAH59S	Amonafide	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	4.16	4.8	6.33	7.53
DCJ4YOB	DMAH59S	Amonafide	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	7.67	6.3	7.73	10.6
DCPT0DJ	DMAH59S	Amonafide	Phase 3	25	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	0.25	3.9	0.45	6.17
DCNIF9N	DMAH59S	Amonafide	Phase 3	25	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	3.13	3.81	3.8	6.33
DC1T41T	DMAH59S	Amonafide	Phase 3	25	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	1.2	0.15	0.4	3.58
DCWIIPI	DMAH59S	Amonafide	Phase 3	25	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	4.17	4.3	6.09	7.92
DCKBJP1	DMAH59S	Amonafide	Phase 3	25	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	0.95	1.25	3.02	4.01
DCSYJZA	DMAH59S	Amonafide	Phase 3	25	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	1.09	2.47	3.56	2.95
DC6MHRH	DMAH59S	Amonafide	Phase 3	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	1.17	2.59	1.4	1.33
DCILAXN	DMAH59S	Amonafide	Phase 3	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	1.91	3.47	3.5	3.55
DCQ09LU	DMAH59S	Amonafide	Phase 3	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	2.86	4.93	5.5	5.18
DCHHYSC	DMAH59S	Amonafide	Phase 3	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	1.15	0.68	0.61	0.85
DCRBCR9	DMAH59S	Amonafide	Phase 3	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	0.49	0.46	1.68	2.02
DCR4QEZ	DMAH59S	Amonafide	Phase 3	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	0.27	2.58	2.48	2.51
DCG9LXW	DMAH59S	Amonafide	Phase 3	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	1.68	0.05	0.4	0.49
DCZMKJY	DMAH59S	Amonafide	Phase 3	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	1.5	3.08	4.72	4.89
DC4GDJ3	DMAH59S	Amonafide	Phase 3	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	3.79	8.92	10.87	10.95
DCQXNK7	DMAH59S	Amonafide	Phase 3	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	5.73	5.66	3.68	5.61
DCGQMYF	DMAH59S	Amonafide	Phase 3	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	3.28	2.98	5.02	7.42
DCLDF6Y	DMAH59S	Amonafide	Phase 3	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	7.11	5.5	4.88	8.93
DC8NB4H	DMAH59S	Amonafide	Phase 3	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	2.02	1.8	5.14	7.23
DCY6XOT	DMAH59S	Amonafide	Phase 3	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	2.63	3.72	4.29	4.32
DCCBITS	DMAH59S	Amonafide	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	6.97	8.27	5.52	9.44
DCTMDM4	DMAH59S	Amonafide	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	3.34	4.6	4.82	8.02
DC57505	DMAH59S	Amonafide	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	7.39	9.3	5.79	11.08
DCMSDM9	DMAH59S	Amonafide	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	0.95	5.21	3.99	8.27
DCNM37B	DMAH59S	Amonafide	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	4.64	4.84	2.53	7.92
DC87KOH	DMAH59S	Amonafide	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	7.28	6.77	5.71	8.48
DC3V0KS	DMAH59S	Amonafide	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	1.21	0.27	0.14	1.36
DCL08FE	DMAH59S	Amonafide	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	3.07	6.26	1.84	7.87
DCW4XC5	DMAH59S	Amonafide	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	4.1	3.62	7.5	8.24
DCIZEEZ	DMAH59S	Amonafide	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	1.72	6.87	2.01	7.64
DCTNOYZ	DMAH59S	Amonafide	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	4.71	5.76	0.71	7.18
DC1GN3O	DMAH59S	Amonafide	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	10.46	10.21	4.55	11.92
DC3KSIT	DMAH59S	Amonafide	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	18.1	22.35	20.43	23.5
DCEBHRJ	DMAH59S	Amonafide	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	6.27	6.6	3.16	13.7
DCU8B96	DMAH59S	Amonafide	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	0.64	5.07	5.72	8.9
DC0JHX0	DMAH59S	Amonafide	Phase 3	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	2.27	2.85	6.85	8.37
DCYI2C6	DMAH59S	Amonafide	Phase 3	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	3.73	3.46	5.65	7.42
DC0G6US	DMAH59S	Amonafide	Phase 3	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	4.17	3.9	5.37	7.73
DCK5Q3A	DMAH59S	Amonafide	Phase 3	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	1.28	1.06	4.9	5.55
DCL29FR	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	0.37	11.07	2.95	9.18
DCRMTHT	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	2.62	2.88	4.09	7.68
DCM7X2S	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	2.08	2.56	2.68	5.93
DC2NR25	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	1.98	1.26	4.83	7.02
DC3SET9	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	4.66	4.91	7.78	10.07
DCA0LIX	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	9.04	8.32	12.02	14.35
DCIG1NZ	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	5.75	5.51	4.78	8.94
DCVZJF9	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	15.2	9.66	8.08	11.72
DCSM3GE	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	4.94	4.14	0.56	4.55
DCE71ML	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	3.52	3.44	3.45	8.99
DCFWKTU	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	0.36	0.68	2.66	5.98
DC3C4QQ	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	2.29	1.84	3.17	4.53
DCYTEHO	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	3.81	3.31	6.13	7.62
DC519TC	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	10.21	9.93	5.06	11.69
DC3I6CC	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	0.71	6.43	6.8	9.3
DC524M3	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	6.31	6.59	7.78	11.21
DCDOOBH	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	1.15	3.43	6.17	7.03
DCHCHYJ	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	19.74	20.29	11.9	20.71
DCWIWGQ	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	3.36	7.27	4.4	6.64
DCSRGZM	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	3.57	2.76	6.42	5.57
DCV0F7I	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	3.93	3.36	5.09	7.22
DCCU0X9	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	6.38	5.85	8.44	10.39
DCA9O4T	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	5.09	6.78	3.46	6.72
DC0NYOH	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	2.09	2.17	2.28	6.57
DC5NFX7	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	3.64	5.16	2.78	10.73
DCGVBCW	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	6.89	11.17	12.57	14.16
DCUTNSP	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	1.44	1.74	1.31	5.89
DC9H3DO	DMAH59S	Amonafide	Phase 3	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	0.63	4.84	6.87	8.35
DC4ULPP	DMAH59S	Amonafide	Phase 3	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	4.1	3.89	9.94	10.56
DC9IN3P	DMAH59S	Amonafide	Phase 3	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	1.53	1.55	5.82	9.07
DCV7YQD	DMAH59S	Amonafide	Phase 3	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	6.22	5.62	10.76	12.99
DC6SA21	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	5.22	10.03	2.81	11.93
DCUF41O	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	5.72	5.32	3.62	7.11
DC8LWD8	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	8.24	6.01	5.68	8.82
DCVUYYC	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	8.95	10.92	11.81	13.6
DCMI4OD	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	1.26	5.26	0.42	7.18
DCHB574	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	1.94	0.94	4.44	6.92
DCM681M	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	12.92	13.46	5.8	13.95
DCDOFHS	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	2.5	6.17	0.03	7.03
DCG8T8J	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	7.87	8.33	4.69	11.66
DCHY6KH	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	0.92	4.77	6.53	6.6
DCS32UT	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	1.94	4.76	3.13	3.23
DCMEXZP	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	0.42	0.85	2.96	4.87
DC2YSTF	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	6.24	8.01	3.73	7.42
DCXPP7O	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	5.98	5.63	9.45	11.76
DCS7NVV	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	0.84	5.81	6.49	7.89
DCQHAWJ	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	4.99	10.04	9.43	10.33
DCZ3N1U	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	8.63	8.07	9.74	11.7
DCDFJ89	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	13.96	14.4	12.68	16.94
DCMX3US	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	0.17	6.2	8.3	9.07
DCOVWI2	DMAH59S	Amonafide	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	4.69	8.04	5.33	8.25
DCFMQZ0	DMAH59S	Amonafide	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	12.19	12.59	10.1	11.23
DCVFX46	DMAH59S	Amonafide	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	1.92	4.41	0.42	7.74
DCZ1STM	DMAH59S	Amonafide	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	3.65	5.7	1	7.32
DCGARNE	DMAH59S	Amonafide	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	2.54	5.07	4.97	4.02
DCDPHB1	DMAH59S	Amonafide	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	11.21	12	9.97	12.06
DCK4QWA	DMAH59S	Amonafide	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	9.91	9.72	4.36	12.03
DC2HR4A	DMAH59S	Amonafide	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	3.83	6.01	4.65	4.04
DCS8I24	DMAH59S	Amonafide	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	7.71	11.37	8.66	10.11
DCHLWSL	DMAH59S	Amonafide	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	3.02	2.91	2.46	4.67
DC4K52B	DMAH59S	Amonafide	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	2.8	8.15	5.34	7.84
DCOE57D	DMAH59S	Amonafide	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	12.77	13.1	8.59	11.01
DCC6WVF	DMAH59S	Amonafide	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	2.99	4.51	3.37	4.68
DCMBB49	DMAH59S	Amonafide	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	2.76	0.76	3.33	3.83
DCY319L	DMAH59S	Amonafide	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	1.79	1.22	0.96	0.56
DC42ODQ	DMAH59S	Amonafide	Phase 3	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	8.96	8.61	9.29	11.83
DCW9VC2	DMAH59S	Amonafide	Phase 3	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	11.2	5.36	6.09	8.7
DCBQIM9	DMAH59S	Amonafide	Phase 3	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	2.47	2.7	4.35	7.27
DCH6E61	DMAH59S	Amonafide	Phase 3	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	1.34	1.71	2.61	5.95
DCE28IS	DMAH59S	Amonafide	Phase 3	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	0.47	2.87	5.09	8.96
DCV9D2B	DMAH59S	Amonafide	Phase 3	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	0.39	4.99	5.03	6.64
DCFIHSQ	DMAH59S	Amonafide	Phase 3	25	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	8.83	5.6	3.63	8.35
DCG8CLU	DMAH59S	Amonafide	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	3.8	2.87	2.44	4.49
DCGCFR4	DMAH59S	Amonafide	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	ALMANAC Dataset	Investigative	T98G	0.02	0.02	7.29	7.35
DCXL79S	DMAH59S	Amonafide	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	6.97	7.75	1.02	7.68
DCXDOOR	DMAH59S	Amonafide	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	10.49	9.91	5.57	10.22
DCBWD1I	DMAH59S	Amonafide	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	6.2	3.43	6.18	8.54
DCTG33Q	DMAH59S	Amonafide	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	1.13	1.53	3.08	3.5
DCT95YY	DMAH59S	Amonafide	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	0.86	3.91	3.77	3.93
DCNIET4	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	6.05	5.87	3.38	7.19
DCUHSSF	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	1.88	3.13	7.11	8.23
DCPJVG8	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	3.7	4.4	2.66	3.78
DCQVOPE	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	7.5	7.7	8.45	10.48
DCPCDL1	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	8.03	9.63	6.37	9.43
DC1BESM	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	1.38	0.71	3.35	6.45
DCG2878	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	3.65	1.23	3.53	5.58
DC43HFW	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	9.01	9.04	8.28	10.7
DCWGFT2	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	5.85	6.47	3.89	6.21
DCGLR48	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	15.75	15.67	8.25	11.88
DCHD8UH	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	0.77	2.16	2.72	4.13
DCJ1UC5	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	2.51	2.36	6.62	8.18
DCDTXIP	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	0.76	1.62	6.53	8.77
DCU0QZB	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	2.41	1.94	7.35	8.39
DC1N2TF	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	4.52	3.67	6.71	7.91
DC1YJ0A	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	6.48	7.12	1.72	4.31
DCQR9XV	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	9.64	10.44	1.39	8.5
DCL05OX	DMAH59S	Amonafide	Phase 3	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	0.71	2.9	5.01	5.41
DCV55EH	DMAH59S	Amonafide	Phase 3	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	1	3.42	3.06	2.54
DCR600T	DMAH59S	Amonafide	Phase 3	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	0	1.68	2.09	0.99
DC0V3X9	DMAH59S	Amonafide	Phase 3	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	0.61	0.14	0.86	0.81
DC9FMER	DMAH59S	Amonafide	Phase 3	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	4.34	4.34	1.7	7.31
DCJQETA	DMAH59S	Amonafide	Phase 3	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	4.32	2.79	3.82	6.22
DCQLPXC	DMAH59S	Amonafide	Phase 3	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	2.61	4.34	4.9	7.8
DC0C4A2	DMAH59S	Amonafide	Phase 3	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	2.36	1.17	3.09	8.45
DCA7UV3	DMAH59S	Amonafide	Phase 3	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	3.19	6.09	3.97	7.77
DCPO364	DMAH59S	Amonafide	Phase 3	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	4.47	5.58	5.83	7.79
DCOF0C0	DMAH59S	Amonafide	Phase 3	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	1.19	2.8	0.95	2.84
DC0ANMH	DMAH59S	Amonafide	Phase 3	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	0.52	1.06	0.62	1.78
DCM8V7Z	DMAH59S	Amonafide	Phase 3	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	0.88	2.03	0.32	3.25
DCP9CX2	DMAH59S	Amonafide	Phase 3	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	1.14	1.67	0.48	2.53
DCL4KW8	DMAH59S	Amonafide	Phase 3	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	6.92	6.85	12.22	13.71
DCUU39C	DMAH59S	Amonafide	Phase 3	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	2.97	2.06	3.19	6.38
DC2DYRD	DMAH59S	Amonafide	Phase 3	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	3.22	4.04	8.22	9.57
DC2ZY93	DMAH59S	Amonafide	Phase 3	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	5.9	5.6	7.86	9.84
DCOTECA	DMAH59S	Amonafide	Phase 3	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	1.63	1.41	5.4	8.03
DCP6CH7	DMAH59S	Amonafide	Phase 3	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	1.66	0.84	2.53	3.35
DCKV1G9	DMAH59S	Amonafide	Phase 3	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	0.7	1.27	4.99	6.74
DCMKMLZ	DMAH59S	Amonafide	Phase 3	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	2.01	3.97	7.22	7.61
DCOLL2U	DMAH59S	Amonafide	Phase 3	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	2.4	1.78	3.57	4.01
DCQPRFV	DMAH59S	Amonafide	Phase 3	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	4.63	5.86	0.96	5.39
DCG08PA	DMAH59S	Amonafide	Phase 3	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	6.03	7.74	4	8.49
DCZIQU8	DMAH59S	Amonafide	Phase 3	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	0.82	8.3	3.8	6.82
DCGOKVL	DMAH59S	Amonafide	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	4.16	4.94	0.12	7.58
DC83V57	DMAH59S	Amonafide	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	2.83	1.99	3.45	5.78
DC0CSP6	DMAH59S	Amonafide	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	1.4	4.38	0.3	5.88
DCH5MCG	DMAH59S	Amonafide	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	8.54	8.31	6.12	9.98
DC5Z1SB	DMAH59S	Amonafide	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	4.17	3.22	3.25	5.76
DCMNXWZ	DMAH59S	Amonafide	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	1.01	1.37	0.84	3.75
DCS0VY3	DMAH59S	Amonafide	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	11.04	11.27	5.91	11.75
DCX83QN	DMAH59S	Amonafide	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	3.09	3.92	1.1	5.44
DCXM4SJ	DMAH59S	Amonafide	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	2.21	1.45	0.35	3.66
DCS4I51	DMAH59S	Amonafide	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	2.87	2.99	4.64	6.38
DCG1JI1	DMAH59S	Amonafide	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	3.61	3.39	7.06	8.5
DC7QCIU	DMAH59S	Amonafide	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	0.97	0.87	0.66	3.15
DCABJLN	DMAH59S	Amonafide	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	1.02	3.26	2.78	5.22
DCG1H8Y	DMAH59S	Amonafide	Phase 3	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	3.25	4.33	0.3	2.5
DCJ3FHF	DMAH59S	Amonafide	Phase 3	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	12.24	7.9	0.42	4.95
DCTJB04	DMAH59S	Amonafide	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	4.58	4.49	1.89	6.03
DCCJ682	DMAH59S	Amonafide	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	0.3	1.13	0.13	1.39
DCE3S4H	DMAH59S	Amonafide	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	1.41	3.04	2.66	3.27
DCZSAB5	DMAH59S	Amonafide	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	7.1	10.07	3.98	8.98
DC76QKE	DMAH59S	Amonafide	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	1.6	1.86	1.58	4.67
DCBEA7M	DMAH59S	Amonafide	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	1.51	0.69	4.25	5.07
DCTE0YA	DMAH59S	Amonafide	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	25.98	24.67	27.23	26.95
DC8RW78	DMAH59S	Amonafide	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	2.07	1.71	2.17	4.67
DCSZNVQ	DMAH59S	Amonafide	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	7.54	7.22	6.85	9.31
DCVLFRL	DMAH59S	Amonafide	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	11.73	13.05	10.94	16.57
DCELCJ2	DMAH59S	Amonafide	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	7.28	7.03	8.64	10.8
DCFVNMP	DMAH59S	Amonafide	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	7.96	12.3	6.36	15.04
DCTUJF0	DMAH59S	Amonafide	Phase 3	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	1.92	4.42	6.57	5.73
DCPL0N2	DMAH59S	Amonafide	Phase 3	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	2.75	4.95	2.02	5.44
DC8SPL8	DMAH59S	Amonafide	Phase 3	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	1.87	3.26	1.51	4.86
DCRQNDO	DMAH59S	Amonafide	Phase 3	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	4.86	6.39	1.71	7.6
DCQ56KW	DMAH59S	Amonafide	Phase 3	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	1.47	3.77	0.61	5.85
DCVK6SX	DMAH59S	Amonafide	Phase 3	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	0.24	3.24	3.66	4.33
DCFSKTZ	DMAH59S	Amonafide	Phase 3	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	2.54	5.05	0.4	9.28
DC5U0PX	DMAH59S	Amonafide	Phase 3	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	0.44	3.23	3.08	3.71
DCNFACN	DMAH59S	Amonafide	Phase 3	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	7.77	6.99	5.68	7.21
DCVMZH2	DMAH59S	Amonafide	Phase 3	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	14.85	9.38	7.88	9.92
DC0YH00	DMAH59S	Amonafide	Phase 3	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	4.59	3.58	2.67	6.81
DC22S8F	DMAH59S	Amonafide	Phase 3	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	1.55	0.76	1.81	3.73
DCB9O8K	DMAH59S	Amonafide	Phase 3	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	3.59	3.54	2.39	6.78
DCSPR9B	DMAH59S	Amonafide	Phase 3	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	1.66	2.37	5.17	6.09
DC9UGZ1	DMAH59S	Amonafide	Phase 3	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	3.49	4.24	2.89	7.32
DCYHYUS	DMAH59S	Amonafide	Phase 3	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	7.69	8.3	5.28	8.68
DCXZTCV	DMAH59S	Amonafide	Phase 3	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	4.78	4.22	1.63	5.35
DCVUMK2	DMAH59S	Amonafide	Phase 3	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	3.11	3.25	2.54	5.88
DCLO539	DMAH59S	Amonafide	Phase 3	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	4.11	3.9	1.71	5.06
DCC3PHH	DMAH59S	Amonafide	Phase 3	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	0.99	2.3	1.08	3.29
DCMUWBC	DMAH59S	Amonafide	Phase 3	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	6.07	8.9	2.51	8.48
DCEXWGY	DMAH59S	Amonafide	Phase 3	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	0.46	2.09	1.33	3.64
DCFVE67	DMAH59S	Amonafide	Phase 3	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	0.68	10.11	3.84	10.41
DC05JUS	DMAH59S	Amonafide	Phase 3	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	3.89	4.35	4.84	6.59
DCXI4FL	DMAH59S	Amonafide	Phase 3	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	1.67	3.55	3.17	5.35
DCQPDNN	DMAH59S	Amonafide	Phase 3	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	4.03	3.82	2.56	6.44
DCJ4EQ2	DMAH59S	Amonafide	Phase 3	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	2.74	2.27	3.34	5.93
DCRYZ9N	DMAH59S	Amonafide	Phase 3	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	2.96	2.71	1.68	2.29
DCA10N3	DMAH59S	Amonafide	Phase 3	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	2.54	5.05	2.86	5.9
DC2B5S0	DMAH59S	Amonafide	Phase 3	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	2.07	3.65	6.98	6.9
DCJ6I7B	DMAH59S	Amonafide	Phase 3	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	1.57	1.65	3.46	5.87
DCICTR4	DMAH59S	Amonafide	Phase 3	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	0.6	0.05	0.95	2.56
DC67NDI	DMAH59S	Amonafide	Phase 3	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	0.19	0.77	2.32	6.12
DCQB2DD	DMAH59S	Amonafide	Phase 3	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	9.16	8.19	2.16	13.31
DCBW7AC	DMAH59S	Amonafide	Phase 3	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	6.95	5.56	3.55	8.25
DCXX0UV	DMAH59S	Amonafide	Phase 3	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	1.59	3.18	4.54	6.65
DCZQQQM	DMAH59S	Amonafide	Phase 3	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	0.86	0.2	5.28	8.13
DCTDNJI	DMAH59S	Amonafide	Phase 3	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	2.21	4.43	5.54	7.56
DCOS106	DMAH59S	Amonafide	Phase 3	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	2.98	2.32	5.36	7.51
DC08O4Q	DMAH59S	Amonafide	Phase 3	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	1.62	0.82	0.88	4.75
DCX2852	DMAH59S	Amonafide	Phase 3	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	2.96	5.61	9	10.92
DCHEUC3	DMAH59S	Amonafide	Phase 3	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	1.08	1.03	3.27	6.45
DCX2CJQ	DMAH59S	Amonafide	Phase 3	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	4.23	3.99	1.3	5.41
DC7QQQ8	DMAH59S	Amonafide	Phase 3	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	1.5	3.56	5.65	4.37
DC54JII	DMAH59S	Amonafide	Phase 3	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	3.75	3.39	2.7	3.69
DCY4Q3B	DMAH59S	Amonafide	Phase 3	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	0.5	1.47	2.92	5.45
DCT354A	DMAH59S	Amonafide	Phase 3	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	2.24	3.13	2.9	5.62
DCUW1HF	DMAH59S	Amonafide	Phase 3	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	5.96	6.43	3.08	7.93
DCOXEXE	DMAH59S	Amonafide	Phase 3	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	6.52	4.26	5.19	7.42
DCWNOS3	DMAH59S	Amonafide	Phase 3	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	6.68	4.8	0.19	7.04
DCI9PV3	DMAH59S	Amonafide	Phase 3	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	0.54	3.28	1.17	3.79
DC1G1MF	DMAH59S	Amonafide	Phase 3	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	2.76	2.29	4.36	7.39
DCN50QR	DMAH59S	Amonafide	Phase 3	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	1.11	3.89	2.57	5.72
DC3WADT	DMAH59S	Amonafide	Phase 3	25	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	5.47	5.36	1.04	10.38
DCTNH1N	DMAH59S	Amonafide	Phase 3	25	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	2.4	7.11	1.22	7.34
DC8XHPU	DMAH59S	Amonafide	Phase 3	25	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	0.87	0.4	1.08	3.71
DCP4Z6G	DMAH59S	Amonafide	Phase 3	25	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	2.79	2.57	3.57	7.31
DCEWGCP	DMAH59S	Amonafide	Phase 3	25	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	0.51	1.34	3.69	5.18
DC0WFRX	DMAH59S	Amonafide	Phase 3	25	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	1.06	1.6	2.55	5.55
DCR2VU7	DMAH59S	Amonafide	Phase 3	25	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	2.38	2.36	3.31	7.75
DCZC6HY	DMAH59S	Amonafide	Phase 3	25	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	1.68	2.65	3.05	1.39
DC84S2B	DMAH59S	Amonafide	Phase 3	25	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	3.34	3.77	1.65	5.49
DC4QVPI	DMAH59S	Amonafide	Phase 3	25	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	1.87	1.77	3.49	5.15
DCKB09K	DMAH59S	Amonafide	Phase 3	25	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	1.68	1.55	4.11	4.24
DC2BSCR	DMAH59S	Amonafide	Phase 3	25	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	0.89	3.51	3.91	6.32
DCBCDZZ	DMAH59S	Amonafide	Phase 3	25	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	2.86	4.18	2.54	5.02
DCZJNIA	DMAH59S	Amonafide	Phase 3	25	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	0.62	1.52	1.33	1.85
DCTD209	DMAH59S	Amonafide	Phase 3	25	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	0.94	5.83	2.51	5.66
DCM75HL	DMAH59S	Amonafide	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	4.91	5.06	1.8	6.8
DCI3K9B	DMAH59S	Amonafide	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	3.67	6.3	3.24	7.69
DCAJTA9	DMAH59S	Amonafide	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	14.9	11.39	7.54	13.56
DCEBNQD	DMAH59S	Amonafide	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	11.52	10.07	7.12	12.05
DC53V0C	DMAH59S	Amonafide	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	6.49	6.65	4.09	8.8
DCVCL3V	DMAH59S	Amonafide	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	0.6	2.22	0.03	5.41
DCQ5NWB	DMAH59S	Amonafide	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	5.34	6.75	2.79	7.12
DCZT9S8	DMAH59S	Amonafide	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	2.6	5.4	2.17	5.1
DCNQ0L0	DMAH59S	Amonafide	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	3.13	6.57	5.63	7.33
DCJAVRL	DMAH59S	Amonafide	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	12.8	14.14	7.72	13.13
DC9TZF1	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	2.11	4.04	7.86	11.06
DC2G669	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	1.83	4.38	6.07	8.98
DC6HI2H	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	0.4	0.43	2.51	3.95
DCMFT99	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	2.97	7.06	1.73	3.71
DC7CD0V	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	0.77	2.18	0.67	3.28
DC3X26U	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	4.71	3.43	4.59	6.78
DCNB84Z	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	8.4	2.78	4.13	7.38
DCB4WQP	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	0.54	2.97	5.7	7.56
DCM1JVF	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	10.96	10.41	5.37	11.88
DCZN612	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	3.93	3.67	7.88	10.79
DCA5WAJ	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	0.7	3.1	1.68	4.44
DCKX3A1	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	0.46	0.49	3.76	4.21
DCOFN3Y	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	4.93	5.39	4.86	7.75
DCE6YPE	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	2.38	4.83	1.95	7.5
DCHFVN5	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	0.24	3.28	5.53	7.91
DC1KS8Y	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	3.87	3.19	4.53	9.17
DCQO2AW	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	3.37	5.77	8.18	9.93
DC2XHX7	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	4.24	7.91	8.91	11.64
DC7QLPE	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	3.22	3.61	4.93	7.92
DCMY4QQ	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	3.81	6.15	4.8	8.12
DC9BCH2	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	2.46	1.95	3.63	4.98
DCEQGUW	DMAH59S	Amonafide	Phase 3	25	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.96	8.05	5.6	9.07
DCFACQZ	DMAH59S	Amonafide	Phase 3	25	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.24	2.63	0.17	2.75
DCTTL43	DMAH59S	Amonafide	Phase 3	25	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.52	4.37	1.49	3.66
DCFVXN1	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.52	10.84	10.82	10.56
DCR86KW	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	4.04	5.1	5.57	5.28
DCUVA0P	DMAH59S	Amonafide	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	8.07	11.83	10.96	11.58
DCHU064	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.16	7.73	7.75	9.77
DC3ATEG	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	5.58	6.45	7.64	10.26
DC37UGO	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	10.82	13.5	14.13	16.42
DCFLRLM	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	9.01	9.89	12.58	13.85
DCO4R24	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.75	3.42	4.5	6.8
DCG7HYI	DMAH59S	Amonafide	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.24	8.4	6.25	8.91
DCDKV2X	DMAH59S	Amonafide	Phase 3	25	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.78	5.98	6	9.86
DCWFD2X	DMAH59S	Amonafide	Phase 3	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.97	1.51	2.36	6.05
DCM04C8	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	8.88	15.43	11.95	14.92
DCHU68A	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	5.88	10.54	7.85	11.18
DCYNTZ4	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.67	11.13	5.98	11.01
DCMONJU	DMAH59S	Amonafide	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	12.59	14.22	7.43	13.32
DCY7DHJ	DMAH59S	Amonafide	Phase 3	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	6.26	6.43	7.75	9.97
DC9HLSK	DMAH59S	Amonafide	Phase 3	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.22	4.91	8.37	9.91
DCBPC48	DMAH59S	Amonafide	Phase 3	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.42	3.77	5.42	10.95
DCMRT5G	DMAH59S	Amonafide	Phase 3	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.47	2.17	4.88	7.07
DCFV8VG	DMAH59S	Amonafide	Phase 3	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.92	4.12	0.39	5.23
DCFVBUO	DMAH59S	Amonafide	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.12	1.74	0.17	2.81
DCIXB1S	DMAH59S	Amonafide	Phase 3	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.57	5.4	3.07	5.33
DC5J4FQ	DMAH59S	Amonafide	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.76	1.7	1.42	8.43
DCXIB87	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.13	9.85	1.1	7.3
DCCMOW0	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.41	5.46	10.49	12.23
DCIOYZD	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.29	2.38	8.85	10.86
DCO3TZV	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.14	6.55	11.45	12.99
DCG34F7	DMAH59S	Amonafide	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	14.77	14.86	15.49	18.26
DCXL28C	DMAH59S	Amonafide	Phase 3	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.52	0.45	4.34	6.21
DCD01T0	DMAH59S	Amonafide	Phase 3	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.49	2.48	9.07	10.95
DCNRE8R	DMAH59S	Amonafide	Phase 3	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.81	2.55	7.56	7.89
DC2OJOQ	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.05	4.67	4.54	6.52
DCYEYNI	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.45	12.36	19.11	19.95
DC4QF8Q	DMAH59S	Amonafide	Phase 3	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.41	6.48	1.67	9.74
DC7EHVI	DMAH59S	Amonafide	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.15	3.37	4.74	6.8
DCGUCD8	DMAH59S	Amonafide	Phase 3	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.47	3.05	5.62	7.27
DC6KQ78	DMAH59S	Amonafide	Phase 3	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.89	1.62	5.71	7.84
DCZLLFO	DMAH59S	Amonafide	Phase 3	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.99	1.72	0.07	6.63
DC2ZDFT	DMAH59S	Amonafide	Phase 3	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.65	8.69	6.21	8.62
DCRZUA9	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	10.38	11.02	5.94	9.28
DCSXEP4	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	8.01	8.25	5.43	10.04
DCJ6STI	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.61	2.1	6.41	8.06
DCLJWK3	DMAH59S	Amonafide	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.21	4.21	3.27	5.27
DCVAIZ1	DMAH59S	Amonafide	Phase 3	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.41	3.3	4.7	4.8
DCXY910	DMAH59S	Amonafide	Phase 3	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.41	3.42	9.87	10.93
DCDKKN3	DMAH59S	Amonafide	Phase 3	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	6.37	6.81	3.43	6.23
DC98MUW	DMAH59S	Amonafide	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.89	2.57	2.56	5.98
DCMY1LU	DMAH59S	Amonafide	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.04	2.16	3.58	6.69
DCHUBHY	DMAH59S	Amonafide	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.04	3.75	3.29	6.26
DC9S0JK	DMAH59S	Amonafide	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	9.91	9.35	9.94	12.66
DCRE1YA	DMAH59S	Amonafide	Phase 3	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.71	2.04	3.79	5.93
DCIG1BM	DMAH59S	Amonafide	Phase 3	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.04	2.57	1.89	3.86
DCW3RNH	DMAH59S	Amonafide	Phase 3	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.99	2.06	1.09	4.66
DC59TQ3	DMAH59S	Amonafide	Phase 3	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.86	4.12	1.37	5.24
DCXOK66	DMAH59S	Amonafide	Phase 3	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.11	3.3	7.3	8.11
DCAX3HC	DMAH59S	Amonafide	Phase 3	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.53	5.74	8.77	10.97
DCTVVZJ	DMAH59S	Amonafide	Phase 3	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.37	6.67	4.6	8.22
DC3MMRI	DMAH59S	Amonafide	Phase 3	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.11	2.74	2.73	5.66
DCKTNFA	DMAH59S	Amonafide	Phase 3	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.75	3.88	6.12	8.62
DC9QZGS	DMAH59S	Amonafide	Phase 3	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.15	2.95	0.84	4.96
DCH4LXP	DMAH59S	Amonafide	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.65	7.78	5.96	9.98
DCIKQMJ	DMAH59S	Amonafide	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	6.03	9.15	5.1	5.17
DCCO9HX	DM2YGNW	Dactinomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	DMINOX3	Vincristine	DMP6SC2	Irinotecan	Rhabdomyosarcoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC62YHJ	DM2YGNW	Dactinomycin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	DMINOX3	Vincristine	.	.	Rhabdomyosarcoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCHFR1L	DM2YGNW	Dactinomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	DMINOX3	Vincristine	.	.	Rhabdomyosarcoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCA235M	DM2YGNW	Dactinomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.81	7.65	7.82	8.61
DCP4LXR	DM2YGNW	Dactinomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.97	8.62	2.72	6.6
DCNELFL	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	17.47	20.23	18.37	18.36
DCDB4F3	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	21.5	22	22.07	19.67
DC7TZBV	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	24.44	22.86	16.41	16.88
DCIGZ9V	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	14.11	19.26	9.73	11.28
DCQ3LWD	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.49	3.62	2.44	1.99
DCEGI6A	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.89	5.19	4.36	7.1
DC72B95	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.93	10.45	10.49	10.64
DCN7ZQY	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	14.24	15.45	12.95	9.91
DC3VS3A	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	11.94	10.87	8.04	7.72
DCB3QBD	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	14.11	17.49	5.86	6.81
DCQEGSN	DM2YGNW	Dactinomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.46	4.05	1.68	2.17
DCDLV9P	DM2YGNW	Dactinomycin	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.36	0.34	0.43	0.26
DCVZZRL	DM2YGNW	Dactinomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.21	0.48	4.76	6.5
DCTOJ02	DM2YGNW	Dactinomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	11.42	15.43	11.37	7.9
DCR9AWM	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	13.87	16.91	15.83	15.17
DCGVLUR	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	12.06	13.93	9.9	9.82
DC7Q41C	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.91	6.04	1.16	1.15
DC67T1X	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	11.35	10.28	8.31	8.07
DCQRWQ2	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	15.7	12.22	6.52	6.22
DCFMU7K	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	18.02	18.94	13.44	11.19
DC967SO	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	12.98	13.26	10.38	10.21
DCQ069U	DM2YGNW	Dactinomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.03	6.45	0.37	0.46
DC2GD9H	DM2YGNW	Dactinomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.54	8.55	5.12	4.24
DCY27HQ	DM2YGNW	Dactinomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.44	10.66	5.88	5.71
DCKDMM7	DM2YGNW	Dactinomycin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.6	0.79	0.93	0.84
DCRKSIR	DM2YGNW	Dactinomycin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.42	3.42	2.85	2.5
DCQYY5T	DM2YGNW	Dactinomycin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.1	8.75	8.59	9.23
DCRP2M5	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	10.73	15.9	14.05	13.84
DC98VC4	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.92	4.05	0.39	1.05
DC0AA85	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.57	4.79	2.37	1.18
DCB7X37	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.82	4.52	7.01	6.83
DCD1VJT	DM2YGNW	Dactinomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.64	6.25	3.44	5.43
DCQGN4V	DM2YGNW	Dactinomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.64	9.12	4.39	4.56
DCIUD4E	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.53	8.31	4.83	11.21
DCNFOEW	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	11.22	11.83	13.58	13.17
DCUXOTV	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.56	2.67	4.29	4.29
DC55DXY	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	13.09	17.18	7.64	13.38
DC7OISJ	DM2YGNW	Dactinomycin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.11	4.79	3.24	2.89
DCWIKOG	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.65	1.04	4.35	4.43
DC23BK7	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.74	6.53	7.72	8.61
DCUA2AU	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	20.82	19.97	18.05	18.28
DCVQPCQ	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	18.99	20.36	15.56	15.7
DCUHEVT	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	12.62	11.29	7.6	8.21
DC27LT6	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	16.51	17.67	14.61	15.37
DC1Z9H1	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	15.59	17.19	15.76	16.12
DCTJVTE	DM2YGNW	Dactinomycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.31	8.91	9.77	12.92
DC5YAUZ	DM2YGNW	Dactinomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.29	4.49	5.35	4.95
DCYAB7K	DM2YGNW	Dactinomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	6.05	10.06	8.21	8.15
DC2A9AN	DM2YGNW	Dactinomycin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.95	9.89	1.27	2.01
DCVPLNX	DM2YGNW	Dactinomycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.04	4.4	1.24	0.79
DCIFR25	DM2YGNW	Dactinomycin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.7	6.24	2.02	4.33
DCCQ3YC	DM2YGNW	Dactinomycin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.46	10.1	2.8	7.93
DC4YCQY	DM2YGNW	Dactinomycin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.01	7.46	4.89	5.74
DCZQ2DI	DM2YGNW	Dactinomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.65	8.31	0.32	2.77
DCXFIZZ	DM2YGNW	Dactinomycin	Approved	34	DM09NGV	Ribavirin-TP	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	29.26	29.26	47.65	47.65
DCSM2J1	DM2YGNW	Dactinomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.72	5.39	5.97	6.25
DC2H9IE	DM2YGNW	Dactinomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	2.68	4.79	2.43	4.69
DC047BC	DM2YGNW	Dactinomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	7.81	12.63	0.16	11.52
DCJI13V	DM2YGNW	Dactinomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.28	9.96	10.34	10.34
DC261QC	DM2YGNW	Dactinomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.24	10.11	5.76	8.23
DCSIKM1	DM2YGNW	Dactinomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	5.18	12.05	3.39	12.66
DCUXXM2	DM2YGNW	Dactinomycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	1.27	6.24	5.64	3.82
DCQO2MH	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	17.9	17.9	17.28	16.25
DC06F6F	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	17.44	15.22	11.86	12.01
DCZN79W	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	7.19	11.17	12.16	11.64
DCVUJ1W	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	28.7	24.49	23.27	22.6
DCCPPW2	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	6.74	12.94	4.72	8.23
DCPHF16	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	29.46	27.24	26.59	27.01
DCDMWZP	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	39.39	34.26	28.29	28.48
DC1PT6C	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	8.86	14.64	12.6	9.77
DC66YDI	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	19.69	19.61	16.47	16.4
DCV1CHT	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	22.59	25.43	25.84	26.29
DCQGRCS	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	16.99	17.68	14.51	16.98
DCAY0TC	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	15.92	24.11	0.24	17.96
DC6DO3W	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	33.61	33.37	25.64	25.64
DC98EL0	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	35.76	35.08	29.22	29.35
DCSHAH4	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	6.21	9.04	5.73	5.36
DC8BHA0	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	10.03	9.46	3.83	9.32
DCYJDX3	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.86	7.49	9.46	8.89
DC0DR0I	DM2YGNW	Dactinomycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	5.55	6.34	5.23	3.72
DCJHP9P	DM2YGNW	Dactinomycin	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	10.26	10.26	15.71	15.72
DCJ9IF0	DM2YGNW	Dactinomycin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	2.104	0.576	0.538	4.369
DCW1KPP	DM2YGNW	Dactinomycin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	T-cell leukemia/lymphoma	SYNERGxDB Database	Investigative	ED-40515	0.231	0.24	0.274	0.28
DCL8G6E	DM2YGNW	Dactinomycin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	5.62	8.35	2.63	2.26
DC6E3CT	DM2YGNW	Dactinomycin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.79	1.01	0.65	0.28
DCZ3YOE	DM2YGNW	Dactinomycin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.27	9.75	4.54	1.51
DC69BZF	DM2YGNW	Dactinomycin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	3.89	7.7	1.95	1.9
DC11S14	DM2YGNW	Dactinomycin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	9.09	13.17	2.56	1.35
DCCH1Y1	DM2YGNW	Dactinomycin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	10.18	8.2	4.32	6.8
DCX8B7Q	DM2YGNW	Dactinomycin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.73	7.58	1.95	1.46
DCSV9A6	DM2YGNW	Dactinomycin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	0.19	2.52	2.56	0.74
DCYOOOM	DM2YGNW	Dactinomycin	Approved	34	DM2G9AE	Citalopram	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	4.39	4.39	22.15	22.17
DCQXK3Y	DM2YGNW	Dactinomycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.41	1.66	0.06	2.92
DCJHAX5	DM2YGNW	Dactinomycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	2	1.63	3.02	3.05
DCJRZHG	DM2YGNW	Dactinomycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	0.38	2.32	0.18	4.1
DCO1EFG	DM2YGNW	Dactinomycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	7.13	5.69	6.39	10.09
DC3WY3W	DM2YGNW	Dactinomycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	9.76	5.49	0.6	6.19
DCRV1QB	DM2YGNW	Dactinomycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.62	4.28	0.18	4.69
DCWHJ0C	DM2YGNW	Dactinomycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	0.08	1.24	0.55	3.05
DC4WOA3	DM2YGNW	Dactinomycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	9.69	8.62	0.26	8.7
DCDZ3V3	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	9.76	10.87	12.71	12.48
DCIZ78Y	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	15.54	12.5	16.04	16.11
DC22D7I	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	8.05	9.09	2.83	9.46
DC8K8PZ	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	1.69	1.24	0.49	1.72
DCZK8VZ	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	9.07	14.06	11.41	11.43
DCQHD50	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	15.22	27.24	20.87	21.05
DCEO2T3	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	0.34	2.96	5.6	5.23
DCGF33H	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	6.95	9.24	6.77	6.29
DCZ3RBW	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	29.07	20.92	5.09	3.55
DCJ6BF1	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	5.09	9.34	7.76	8.24
DCMUUMC	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	3.58	7.18	2.56	2.78
DCLMIZT	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.28	1.94	0.77	0.81
DCTVYFT	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.52	6.35	4.78	3.96
DC6LIVX	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.94	1.17	0.18	0.18
DC2L83M	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.27	3.18	0.17	2.44
DCKDZ5Y	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	10.64	13.95	9.19	9.8
DCF2Z3N	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	5.55	6.01	2.67	4.15
DCCNJGU	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	8.14	10.98	10.07	10.45
DCJ5YL4	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	12.79	14.03	12.99	12.93
DC5T4TN	DM2YGNW	Dactinomycin	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	4.95	6.28	2.06	3.81
DCY0WYS	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	6.56	8.13	6.25	6.19
DC2GC4U	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.09	4.74	6.66	6.49
DCRUBNY	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	7.58	10.53	4.27	4.6
DC01KB0	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	13.21	17.66	17.67	16.99
DC5UK6I	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	19.93	25.24	9.27	9.95
DCVOYJ1	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	12.31	12.76	7.39	7.4
DCLRBC3	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	23.92	27.1	21.17	18.32
DCFSJU5	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	11.02	13.26	2.94	10.49
DCHHRYC	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.25	5.3	4	6.1
DC0I8RR	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	19.72	28.19	11.95	20.33
DC5QKTX	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	16.57	19.05	13.37	13.43
DC53MRX	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	31.66	33.57	8.78	21.69
DCUWY3F	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	17.64	17.57	12.72	12.69
DC18LJG	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	0.25	5.65	3.86	3.69
DCVAOTO	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	22.71	21.51	12.42	12.69
DCYVNN4	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	0.97	5.76	4.93	4
DC30J9C	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	7.58	13.13	15.09	12.33
DCWGTB4	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.13	4.81	1.81	2.11
DCBBQES	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	5.31	8.42	2.76	2.84
DCHPYAH	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	12.6	12.65	7.11	6.79
DCTBK26	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	6.67	7.86	9.82	10.54
DCRW0DN	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	5.02	5.77	3.54	3.85
DCRWWHI	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	5.31	9.58	8.18	9.91
DCP9HY3	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.89	7.91	6.51	6.38
DCCGWYK	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	7.49	11.75	0.1	5.54
DCJA8U8	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	11.29	12.76	8.7	9.01
DCF1S8Z	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.8	11.49	5.36	6.31
DC941RD	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	7.18	9.54	10.58	9.89
DCNO2GN	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	5.29	7.61	5.2	5.71
DCW7SEY	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	9.2	14.18	13.54	13.54
DC9XRW4	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	8.01	7.84	5.26	5.09
DCSTMDQ	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	15.06	18.36	10.94	15.5
DCB6EQB	DM2YGNW	Dactinomycin	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	0.88	4.96	5.56	5.23
DC21R0R	DM2YGNW	Dactinomycin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.1	7.19	1.53	3.02
DCEQJ2S	DM2YGNW	Dactinomycin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	3.88	5.25	4.34	2.89
DC390HX	DM2YGNW	Dactinomycin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	10.53	18.99	15.07	13.18
DCFFQHL	DM2YGNW	Dactinomycin	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.18	8.21	10.79	11.68
DCUCS15	DM2YGNW	Dactinomycin	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.39	5.47	9.67	9.79
DC0JV75	DM2YGNW	Dactinomycin	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.76	11.19	8.56	8.85
DC5I67Y	DM2YGNW	Dactinomycin	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	6.19	8.36	5.28	8.51
DCJMZRJ	DM2YGNW	Dactinomycin	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	3.18	3.13	3.18	4.47
DC6RRAZ	DM2YGNW	Dactinomycin	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	0.95	5.81	2.72	6.42
DCCSUTU	DM2YGNW	Dactinomycin	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	1.32	6.9	5.55	5.73
DCRKIJX	DM2YGNW	Dactinomycin	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	6.66	12.77	9.97	12.26
DCHRG4R	DM2YGNW	Dactinomycin	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.89	6.51	7.24	7.12
DCQPB41	DM2YGNW	Dactinomycin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	13.22	11.91	8.96	11.86
DCXIHTB	DM2YGNW	Dactinomycin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.77	4.95	0.18	0.15
DC5YUT8	DM2YGNW	Dactinomycin	Approved	34	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	3.9	3.9	4.73	4.82
DCTXSGS	DM2YGNW	Dactinomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.21	4.98	0.49	9.35
DCXIH6B	DM2YGNW	Dactinomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	5.56	4.04	4.96	7.77
DCGK5NJ	DM2YGNW	Dactinomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	5.45	6.65	6.33	8.62
DCRZCI3	DM2YGNW	Dactinomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	9.02	7.88	10.19	14.04
DC960VG	DM2YGNW	Dactinomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.28	12.86	7.15	10.26
DC8U2HY	DM2YGNW	Dactinomycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	2.34	1.68	1.81	4.83
DCI8AAU	DM2YGNW	Dactinomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.04	8.36	3.32	6.25
DCJADZW	DM2YGNW	Dactinomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.15	2.39	2.06	0.39
DCT9LCS	DM2YGNW	Dactinomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.81	7.2	4.64	6.2
DCK5ER6	DM2YGNW	Dactinomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.28	5.71	2.16	4.24
DCA5KX7	DM2YGNW	Dactinomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	7.1	8.06	4.83	6.98
DCGV8K4	DM2YGNW	Dactinomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	7.82	8.48	8.25	10.45
DCYC7M5	DM2YGNW	Dactinomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	7.23	5.32	4.47	3.31
DCWUZWC	DM2YGNW	Dactinomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	3.26	9.42	5.03	4.35
DCYJF35	DM2YGNW	Dactinomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	3.95	9.72	7.37	9.97
DC6GLMW	DM2YGNW	Dactinomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	1.56	3.07	2.08	3.74
DCLTRN1	DM2YGNW	Dactinomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.13	6.56	5.93	7.53
DCDP799	DM2YGNW	Dactinomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.7	2.17	0.32	1.53
DC66MUC	DM2YGNW	Dactinomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.87	5.26	5.08	5.76
DCVO1O6	DM2YGNW	Dactinomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.99	1.16	0.75	2.01
DCMYKDW	DM2YGNW	Dactinomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	5.02	4.63	2.38	5.12
DCM98TB	DM2YGNW	Dactinomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	8.66	6.12	2.45	2.45
DCQA9GN	DM2YGNW	Dactinomycin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.35	5.51	2.3	2.27
DC34ODN	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	10.37	7.53	5.91	5.9
DCTG67T	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	15.89	13.68	2.84	2.84
DCH2F7D	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	16.17	18.83	19.33	16.01
DCUMJIM	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	11.08	13.84	10.46	10.1
DC20RVP	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	10.21	14.25	10.29	10.93
DCV4IQJ	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.42	7.69	4.22	3.1
DC3PLKW	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	13.96	14.49	10.2	10.12
DCEJQ6F	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	20.53	21.48	19.47	18.17
DCJMEGJ	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.08	2.8	2.69	1.8
DCXP72L	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.41	2.17	1.28	0.7
DCOZRY5	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	16.33	16.74	16.96	17.39
DCBR369	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	11.54	13.53	10.88	10.58
DCHPRK5	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	5.08	6.64	1.28	3.16
DCX01HA	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	1.31	2.36	1.71	0.45
DCX85EY	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.96	4.96	2.99	2.46
DCPYTQR	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	12.51	15.38	13.66	12.59
DC0M6P8	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	14.96	15.97	13.99	14.14
DCXSIKW	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	3.86	9.66	7.59	0.88
DCPI11Z	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	0.13	1.69	0.44	0.2
DCADYYT	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.96	8.95	7.36	7.01
DCFF2OX	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.97	8.26	8.92	9.39
DCM8FXY	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	8.37	11.61	7.43	8.52
DCZ7MGM	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	9.83	8.18	4.3	4.27
DCK7KFG	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	15.27	16.21	14.22	12.17
DCCPWCM	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	8.23	8.83	1.56	1.38
DCY1C4O	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	20.38	17.36	6.26	5.33
DCKIUNT	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.21	4.57	3.35	2.79
DCNTSG6	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	30.04	32.13	24.08	24.08
DCTK8AR	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	11.66	11.02	5.72	5.72
DCEANAZ	DM2YGNW	Dactinomycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.01	6.69	2.89	2.87
DCX30XK	DM2YGNW	Dactinomycin	Approved	34	DM7IW9J	Ramelteon	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	7.17	7.17	19.43	19.43
DCDEX0D	DM2YGNW	Dactinomycin	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	9.11	8.69	10.22	4.27
DCNY4WB	DM2YGNW	Dactinomycin	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	1.93	1.93	3.11	3.11
DCWHDQQ	DM2YGNW	Dactinomycin	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	3.8	7.01	1.61	1.48
DCZ0BBB	DM2YGNW	Dactinomycin	Approved	34	DMFI8A7	Tranexamic acid	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	10.51	10.51	21.51	21.54
DCNH3XX	DM2YGNW	Dactinomycin	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	11.17	11.61	3.78	10.74
DC7HY5F	DM2YGNW	Dactinomycin	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	6.36	6.76	2.89	8.05
DCJUYVI	DM2YGNW	Dactinomycin	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	20.19	20.19	33.04	33.05
DCDGMM8	DM2YGNW	Dactinomycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.48	0.46	5.6	7.36
DC1EM5L	DM2YGNW	Dactinomycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	0.39	0.34	1.15	2.3
DCQXAYK	DM2YGNW	Dactinomycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	4.76	4.63	2.99	5.02
DCI5I36	DM2YGNW	Dactinomycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	3.84	3.84	6.37	8.13
DCBBPAS	DM2YGNW	Dactinomycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.13	4.54	2.69	6.88
DCQUXW8	DM2YGNW	Dactinomycin	Approved	34	DMAI7ZV	Diltiazem	Approved	34	.	.	.	.	Hepatoblastoma	SYNERGxDB Database	Investigative	HB3	2.287	3.776	0.065	4.97
DCEY1UP	DM2YGNW	Dactinomycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	5.96	4.44	1.22	4.6
DCVOSBQ	DM2YGNW	Dactinomycin	Approved	34	DMBEX4O	Methylergonovine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	12.1	12.1	26.95	26.97
DCWY3EU	DM2YGNW	Dactinomycin	Approved	34	DMC1TEV	Testosterone cypionate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	0.58	0.58	20.68	20.68
DC9O1BS	DM2YGNW	Dactinomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.6	6.11	5.96	5.41
DCHC7JO	DM2YGNW	Dactinomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	25.7	28.72	9.8	21.03
DCO0C0B	DM2YGNW	Dactinomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.5	5.4	3.66	1.84
DCKRPXL	DM2YGNW	Dactinomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	0.78	6.82	5.37	6.62
DC6VOOW	DM2YGNW	Dactinomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.72	5.81	3.89	3.78
DC0C3QY	DM2YGNW	Dactinomycin	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	7.74	11.37	6.88	2.52
DCB4EGL	DM2YGNW	Dactinomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.6	8.23	3.79	3.02
DCDZM84	DM2YGNW	Dactinomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.87	2.46	1.8	0.62
DCODE2L	DM2YGNW	Dactinomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	11.38	19.72	15.98	15.3
DCQFK1O	DM2YGNW	Dactinomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	1.93	5.61	1.05	1.29
DC4QDDX	DM2YGNW	Dactinomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	8.79	10.83	5.92	6.61
DC55M2K	DM2YGNW	Dactinomycin	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.39	7.02	3.47	2.85
DCV1VM2	DM2YGNW	Dactinomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	14.75	20.79	18.05	13.32
DC5OZJ7	DM2YGNW	Dactinomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	22.16	23.49	22.99	22.98
DC38R2A	DM2YGNW	Dactinomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.76	5.98	3.07	2.79
DCNAAPY	DM2YGNW	Dactinomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	8.34	8.36	3.75	6
DC8CCJW	DM2YGNW	Dactinomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	6.4	7.77	5.95	3.85
DCO6L5W	DM2YGNW	Dactinomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.89	3.56	2.74	0.57
DC3G96U	DM2YGNW	Dactinomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	5.25	10.25	11.06	11.09
DCU25M1	DM2YGNW	Dactinomycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	6.7	13.42	12.52	10.21
DCYM82H	DM2YGNW	Dactinomycin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.59	9.14	5.47	6.01
DC9NO07	DM2YGNW	Dactinomycin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.96	5.26	0.3	0.83
DC3HT7O	DM2YGNW	Dactinomycin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	8.64	12.23	0.35	1.99
DC7G4XV	DM2YGNW	Dactinomycin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.05	8.92	5.97	8.25
DCWUGRK	DM2YGNW	Dactinomycin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	3.82	3.82	4.82	4.83
DCBOKW8	DM2YGNW	Dactinomycin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	18.15	18.44	8.78	6.32
DC6V2ZT	DM2YGNW	Dactinomycin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	3.99	6.42	0.51	0.51
DCYJJHH	DM2YGNW	Dactinomycin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	4.13	10.93	0.35	6.87
DC5MI3V	DM2YGNW	Dactinomycin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	11.76	12.11	3.88	4.5
DCWIVTG	DM2YGNW	Dactinomycin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	9.4	10.26	0.58	0.95
DCRM3MR	DM2YGNW	Dactinomycin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.89	5.19	0.18	0.61
DC3J1DE	DM2YGNW	Dactinomycin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.26	7.26	6.33	6.13
DCH2Y6S	DM2YGNW	Dactinomycin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.55	4.33	0.31	2.02
DC2IPJ6	DM2YGNW	Dactinomycin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.71	6.61	5.53	3.56
DCTGOSZ	DM2YGNW	Dactinomycin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	8.74	9.67	7.23	7.23
DCPZOWZ	DM2YGNW	Dactinomycin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	3.69	5.19	2.56	1.27
DCNLRGK	DM2YGNW	Dactinomycin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	1.94	1	2.7	5.61
DC59AEV	DM2YGNW	Dactinomycin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.12	6.73	2.57	1.56
DCAC813	DM2YGNW	Dactinomycin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	4.66	8.72	3.67	1.32
DCJUBME	DM2YGNW	Dactinomycin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	7.78	3.18	0.55	0.19
DCJ19YY	DM2YGNW	Dactinomycin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.6	7	3.71	2.16
DC7CFFA	DM2YGNW	Dactinomycin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.31	3.4	1.4	1.28
DC9YHJ2	DM2YGNW	Dactinomycin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.49	3.84	2.32	1.11
DC9N2UW	DM2YGNW	Dactinomycin	Approved	34	DMENSL5	Aminosalicylic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	1.05	1.05	14.22	14.22
DCPX3M1	DM2YGNW	Dactinomycin	Approved	34	DMEOCKZ	JZL195	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	52.44	52.44	64.65	64.68
DC5WJ0S	DM2YGNW	Dactinomycin	Approved	34	DMFGLXB	Phensuximide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	11.21	11.21	31.43	31.43
DC8SBH8	DM2YGNW	Dactinomycin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	5.89	6.4	4.54	5.77
DCC1TFO	DM2YGNW	Dactinomycin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.94	5.21	2.12	4.74
DC3WWYZ	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.44	3.14	2.16	1.34
DC98HCY	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	10.29	11.11	11.53	9.44
DCFTXZQ	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	9.93	11.57	2.53	7.31
DCLJREL	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	4.65	8.92	4.9	4.42
DCX0XTX	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	3.36	5.66	4.85	8.73
DC23QSG	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	7.63	12.45	0.7	10.68
DCIEM4K	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	6.81	11.88	10.58	10.92
DCGPMZG	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	13.1	13.72	12.35	11.06
DCW9QUD	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	10.15	15.23	7.16	7.15
DC7NYBW	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	2.56	6.28	2.28	2.05
DCNSQPZ	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	3.02	7.92	6.1	6.72
DCSBDX8	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	0.34	6.6	5.79	5.16
DC9KVAF	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	3.09	8.31	0.48	2.82
DCTPPE0	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	7.79	14.62	11.54	7.71
DCB5RLV	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	3.98	8.37	0.26	0.25
DCYSNMT	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	7.17	8.85	1.48	1.34
DCW1JBT	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	10.76	16.08	8.73	10.01
DCW80PX	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	2.68	4.41	1.83	3.92
DC5A3HK	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	18.59	22.71	17.74	16.62
DCNGUIV	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	7.55	7.18	3.33	3.82
DCCRW1K	DM2YGNW	Dactinomycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	0.24	3.83	1.27	1.88
DCQTNPG	DM2YGNW	Dactinomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	4.46	5.03	2.61	5.05
DC9F96B	DM2YGNW	Dactinomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	1.45	1.65	0.73	4.75
DC1QPWS	DM2YGNW	Dactinomycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.34	4.56	5	5.26
DCN21WS	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	21.08	22.7	13.84	11.34
DCKGMRQ	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	16.23	16.65	11.61	10.06
DC168GN	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	23.5	22.77	8.66	25.09
DCQXDJH	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	SNB-19	16.99	21.72	13.69	15.65
DCC5MD4	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	17.7	19.74	19.27	22.44
DC0QJA8	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	21.38	23.33	25.84	25.45
DCQJCIZ	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	12.86	15.02	13.53	12.41
DCKSFV0	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	8.93	12.59	8.25	12.67
DC5Z47D	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.31	8.81	6.97	6.77
DCJ5Y9T	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	11.4	17.37	14.15	14.11
DCYDGNI	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.41	2.77	0.89	0.44
DC6QL1K	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	19.06	18.23	16.93	16.57
DCNDPSH	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	4.63	7.33	1.08	8.73
DCWBDYY	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	14.59	19.12	18.53	17.99
DCEIA8M	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.64	6.24	9.21	9.37
DCDO6FU	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	7.99	11.23	12.03	11.46
DCXME7S	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	11.04	15.07	14.69	15.71
DC9E3D9	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.26	3.64	7.35	7.6
DCS0N1N	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	4.83	6.94	7.29	7.21
DCWMNXP	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	8.15	14.82	12.25	12.5
DCEY2UY	DM2YGNW	Dactinomycin	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	0.62	4.58	5.1	2.15
DCISZLJ	DM2YGNW	Dactinomycin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	4.22	7.53	5.63	7.15
DC21LAN	DM2YGNW	Dactinomycin	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	0.56	1.76	0.63	2.99
DCYEO4D	DM2YGNW	Dactinomycin	Approved	34	DMIUYFH	Sulfapyridine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	1.91	1.91	15.37	15.39
DCW8GI8	DM2YGNW	Dactinomycin	Approved	34	DMIWFRL	Tolvaptan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	22.45	22.45	38.4	38.41
DC575WL	DM2YGNW	Dactinomycin	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	3.76	3.76	4.62	4.67
DC4E6L7	DM2YGNW	Dactinomycin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.22	4.43	3.49	1.25
DCDJRBR	DM2YGNW	Dactinomycin	Approved	34	DMKSQG0	Tiagabine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	9.78	9.78	13.34	13.36
DCZWFSM	DM2YGNW	Dactinomycin	Approved	34	DML5VQ0	Fenoprofen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	8.42	8.42	19.18	19.21
DCT95V5	DM2YGNW	Dactinomycin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	SYNERGxDB Database	Investigative	T98G	4.09	4.09	6.89	6.89
DCMKHVM	DM2YGNW	Dactinomycin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	9.63	10.02	6.91	6.83
DC04UOP	DM2YGNW	Dactinomycin	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.39	5.46	0.79	0.79
DCVYR4R	DM2YGNW	Dactinomycin	Approved	34	DMM4WBX	Methocarbamol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	11.69	11.69	25.44	25.46
DCPNKXG	DM2YGNW	Dactinomycin	Approved	34	DMM5ZX6	Epothilone B	Discontinued in Phase 3	9	.	.	.	.	Hepatoblastoma	SYNERGxDB Database	Investigative	HB3	10463.171	11709.916	1958.917	107.5
DCAVAJ5	DM2YGNW	Dactinomycin	Approved	34	DMM61Y2	BRL-15572	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	12.13	12.13	26.85	26.85
DCWVWLC	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.03	6.77	5.85	6.74
DC4GWDK	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	16.23	18.12	16.72	13.91
DCW9TUY	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	39.12	34.86	18.79	18.82
DC69WGR	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.43	5.79	4.97	6.5
DCQGJKJ	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	6.75	11.06	8.74	8.74
DCJQIPX	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	12.88	15.62	8.21	8.21
DCKEV7X	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	5.02	7.02	14.05	13.36
DC8767S	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	2.36	3.95	0.22	2.97
DCQL3XU	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	5.91	6.81	5.97	6.82
DCSI9D3	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	TK-10	0.31	4.48	3.05	2.65
DCNDJBX	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	6.29	10	7.45	10.69
DC7N931	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	22.82	27.85	24.94	21.83
DCAPP5B	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	7.43	9.57	9.94	9.59
DCEUHMM	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	0.17	3.51	5.98	6.1
DCQALY9	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	16.39	20.82	17.66	17.72
DC89D8U	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	13.4	13.31	9.75	9.75
DC700AJ	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.54	5.64	6.03	6.58
DC4P236	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	11.85	10.47	10.2	9.01
DCMX5PS	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	14.23	16.16	13.7	12.71
DC28TD9	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.59	5.37	7.6	8.57
DCYYWW7	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8.43	15.24	12.09	11.66
DCXFBXJ	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	9.29	13.43	6.27	12.67
DCIWOZM	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	9.82	13.52	11.78	13.36
DCIYZF2	DM2YGNW	Dactinomycin	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.43	7.42	4.39	6.01
DCUAKNQ	DM2YGNW	Dactinomycin	Approved	34	DMMN36E	Abacavir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	28.08	28.08	41.08	41.08
DCM6YZK	DM2YGNW	Dactinomycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.42	3.45	5.14	7.04
DC464T9	DM2YGNW	Dactinomycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	5.08	0.99	2.42	3.37
DCPT5MS	DM2YGNW	Dactinomycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.77	8.04	3.95	4.41
DCYZBXB	DM2YGNW	Dactinomycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.46	5.91	0.24	5.22
DCJ5RJS	DM2YGNW	Dactinomycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-295	3.23	2.7	4.07	7.93
DC3LMKR	DM2YGNW	Dactinomycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.46	7.74	9.36	10.04
DCA91KJ	DM2YGNW	Dactinomycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	10.76	13	14.47	15.53
DCHHPP0	DM2YGNW	Dactinomycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.09	2.36	0.15	3.16
DCE7305	DM2YGNW	Dactinomycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.1	10.05	9.88	11.52
DCAP4WS	DM2YGNW	Dactinomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.73	4.36	0.5	1.69
DC7FO9Z	DM2YGNW	Dactinomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.22	5.86	3.12	5.67
DCH60UF	DM2YGNW	Dactinomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	SYNERGxDB Database	Investigative	HL-60(TB)	7.67	6.72	2.39	5.52
DCAIXZU	DM2YGNW	Dactinomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.96	3.15	2.12	2.79
DCU3LPG	DM2YGNW	Dactinomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	1.69	1.66	0.68	2.95
DCS9Z07	DM2YGNW	Dactinomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	4.38	4.13	0.45	5.45
DCZPBJ2	DM2YGNW	Dactinomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.85	3.58	2.31	3.69
DCDI4SM	DM2YGNW	Dactinomycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.52	5.14	4.03	5.04
DCHYZ2F	DM2YGNW	Dactinomycin	Approved	34	DMOMBJW	Moricizine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	5.49	5.49	19.23	19.25
DCD1SJ4	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	9.74	9.37	8.67	9.07
DCIW72W	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	29.21	26.25	26.73	25.43
DC7E5ZW	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	16.08	16.43	15.86	16.02
DCXRYUQ	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	7.31	7.46	3.83	4.38
DCO4Y07	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.6	2.84	2.35	6.39
DC9TQI6	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	4.34	7.06	10.93	9.93
DCP4CH0	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	9.07	6.94	6.39	5.91
DCMTX67	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	21.47	18.47	14.7	20.64
DC636KQ	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	6.9	9.73	5.49	10.02
DCTPRSV	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	12.32	12.13	13.02	15.96
DC5OQDH	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	17.09	16.2	15.75	16.36
DC9YND8	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	15.98	15.34	9.65	15.75
DCSSN98	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	10.31	8.38	2.83	7.36
DCU46RB	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	15.54	17.21	12.13	12.62
DCDHWLF	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	786-0	10.16	13.32	13.1	14.31
DCF63JA	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	SYNERGxDB Database	Investigative	CAKI-1	6.06	8.92	4.75	7.63
DCFM8Y5	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	15.84	16.06	15.33	15.66
DCGSZ8Q	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	11.45	9.56	7.47	7.93
DCJB0GJ	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Glioblastoma	SYNERGxDB Database	Investigative	SNB-75	24.76	21.04	20.36	20.65
DCF40PD	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	14.79	15.64	7.77	14.9
DCZSDRF	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-268	5.61	5.2	4.08	8.32
DC5O2YU	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	17.17	16.65	17.21	17
DC5SNN2	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	24.46	20.97	19.42	19.81
DCJONMQ	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	14.49	15.78	13.6	14.49
DCE1CM8	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	4.68	8.97	0.05	0.96
DCNKLYM	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	18.04	19.93	16.62	16.96
DCJINAR	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	6.53	11.32	6.95	7.42
DC1JWAE	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	21.82	23.56	23.65	21.87
DCIHFP8	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	11.01	9.56	0.84	9.36
DCF7ZPW	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	27.29	25.25	24.58	24.93
DCYSSA1	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	11.2	9.29	7.28	7.37
DCR9MB7	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	18.42	19.15	9.14	20.33
DCMHWIK	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	7.59	9.27	3.7	9.79
DC9QJBQ	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	SYNERGxDB Database	Investigative	ACHN	2.05	3.75	2.1	4.72
DCK2514	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	23.15	20.85	19.49	18.83
DCX53P5	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	8.22	9.07	8.58	9.05
DC8PW2W	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	10.99	10.47	7.02	7.1
DC89F8U	DM2YGNW	Dactinomycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	SN12C	20.4	20.27	15.5	14.11
DCHOL5K	DM2YGNW	Dactinomycin	Approved	34	DMPWB7T	Maprotiline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	5.63	5.63	7.03	7.03
DCJCLLZ	DM2YGNW	Dactinomycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.99	4.72	4.43	4.97
DC6COCW	DM2YGNW	Dactinomycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	0.98	1.01	1.98	4.93
DCLE5E1	DM2YGNW	Dactinomycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.28	7.8	2.4	6.95
DCHQ0OL	DM2YGNW	Dactinomycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.93	4.88	3.14	8.32
DCBIF7F	DM2YGNW	Dactinomycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.63	5	0.89	5.08
DCSRGUS	DM2YGNW	Dactinomycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.67	6.74	4.94	6.01
DCT1JEK	DM2YGNW	Dactinomycin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	6.94	10.38	11.58	9.93
DCQIOTJ	DM2YGNW	Dactinomycin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	12.56	10.85	10.07	9.49
DC9XNQP	DM2YGNW	Dactinomycin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.9	5.89	1.66	0.74
DCP5V6I	DM2YGNW	Dactinomycin	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.6	4.71	4.9	2.24
DC45J78	DM2YGNW	Dactinomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	19.3	19.91	19.03	19.03
DCEGXH9	DM2YGNW	Dactinomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.81	6.77	4.25	6.35
DCWEH9J	DM2YGNW	Dactinomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	2.69	6.12	1.99	4.86
DCJBK6M	DM2YGNW	Dactinomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	6.53	7.24	6.94	7.6
DCMFUR9	DM2YGNW	Dactinomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	3.06	3.07	1.2	2.67
DCM5ZIC	DM2YGNW	Dactinomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	0.32	4.01	2.44	3.37
DCZSXEG	DM2YGNW	Dactinomycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.47	0.91	0.38	0.35
DCM3VUC	DM2YGNW	Dactinomycin	Approved	34	DMSIWD0	Hyodeoxycholic acid	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	0.27	0.27	5.71	5.73
DC9DMV6	DM2YGNW	Dactinomycin	Approved	34	DMSLE03	PF-562271	Phase 1	17	.	.	.	.	Diffuse large B cell lymphoma	SYNERGxDB Database	Investigative	TMD8	18.49	17.02	4.03	6.61
DCQQ03P	DM2YGNW	Dactinomycin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.27	9.98	2.6	2.22
DC7LK1H	DM2YGNW	Dactinomycin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	6.19	7.22	7.59	8.69
DCO04JA	DM2YGNW	Dactinomycin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	SYNERGxDB Database	Investigative	A498	3.88	7.53	3.86	1.61
DCUBWRH	DM2YGNW	Dactinomycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	9.41	14.87	13.83	13.88
DCX2KLW	DM2YGNW	Dactinomycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Astrocytoma	SYNERGxDB Database	Investigative	U251	0.94	4.6	2.96	1.26
DCEL3SX	DM2YGNW	Dactinomycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	9.11	14.63	12.36	10.58
DCXZAHC	DM2YGNW	Dactinomycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.3	8.53	3.49	4.98
DCN987D	DM2YGNW	Dactinomycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	23.38	17.34	11.99	14.22
DCUQGB6	DM2YGNW	Dactinomycin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	3.18	1.6	1.66	3.17
DCQNU9D	DM2YGNW	Dactinomycin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Renal cell carcinoma	SYNERGxDB Database	Investigative	UO-31	0.81	5.37	0.62	1.23
DCY67U3	DM2YGNW	Dactinomycin	Approved	34	DMTX8IZ	Endoxifen	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	12.61	12.61	28.15	28.17
DC2GRFO	DM2YGNW	Dactinomycin	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	K-562	4.89	5.26	3.73	4.72
DC8T6OR	DM2YGNW	Dactinomycin	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.91	10.35	5.84	10.25
DCPTM2E	DM2YGNW	Dactinomycin	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	8.45	9.62	4.9	13.54
DCDXFL0	DM2YGNW	Dactinomycin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	15.16	16.64	1.94	8.37
DC6KDZN	DM2YGNW	Dactinomycin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	11.17	12.07	0.49	8.69
DC44KJH	DM2YGNW	Dactinomycin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.53	5.96	0.57	5.21
DCL4THS	DM2YGNW	Dactinomycin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	3.1	5.66	4.5	0.61
DC1CQGT	DM2YGNW	Dactinomycin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	7.71	7.63	0.2	7.06
DCZ4V1Z	DM2YGNW	Dactinomycin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioma	SYNERGxDB Database	Investigative	SF-539	7.86	7.89	0.39	3.86
DCK6IXJ	DM2YGNW	Dactinomycin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	9.95	11.46	3.83	6.42
DCDQIF7	DM2YGNW	Dactinomycin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.35	8.23	2.68	7.43
DCLW7D6	DM2YGNW	Dactinomycin	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Plasma cell myeloma	SYNERGxDB Database	Investigative	RPMI-8226	9.6	11.61	6.22	10.2
DCMLEFV	DM2YGNW	Dactinomycin	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	2.93	2.93	3.93	4.02
DC1RM97	DM2YGNW	Dactinomycin	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.02	5.03	2.7	5.48
DC8APIG	DM2YGNW	Dactinomycin	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	0.95	0.42	0.6	0.91
DCYJ8EF	DM2YGNW	Dactinomycin	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.12	7.26	6.65	8.07
DC871P2	DM2YGNW	Dactinomycin	Approved	34	DMVS9WQ	Nitisinone	Approved	34	.	.	.	.	DD2	SYNERGxDB Database	Investigative	DD2	3.424	3.441	2.635	5.824
DCSJ2MI	DM2YGNW	Dactinomycin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	7.33	13.74	2.57	2.3
DC2QZQ5	DM2YGNW	Dactinomycin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.68	0.14	1.37	1.82
DCLTK4I	DM2YGNW	Dactinomycin	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	4.73	4.73	5.81	5.83
DCB2HJ7	DM2YGNW	Dactinomycin	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	12.72	18.61	12.98	11.46
DC1TUN2	DM2YGNW	Dactinomycin	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.97	7.28	3.41	5.64
DCCEGMP	DM2YGNW	Dactinomycin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.53	16.87	2.48	13.53
DCVWY0O	DM2YGNW	Dactinomycin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.54	4.06	1.06	4.45
DCZ9G6M	DM2YGNW	Dactinomycin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.88	9.14	3.94	6.18
DCDM34J	DM2YGNW	Dactinomycin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	MOLT-4	0.65	1.43	0.65	2.88
DCKUHMN	DM2YGNW	Dactinomycin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	3.04	4.04	0.11	4.4
DCP3EK2	DM2YGNW	Dactinomycin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	SYNERGxDB Database	Investigative	CCRF-CEM	2.31	2.11	2.68	5.51
DCJPXFQ	DM2YGNW	Dactinomycin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	2.61	10.85	5.67	6.66
DC0TVVX	DM2YGNW	Dactinomycin	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	7.94	11.92	9.39	9.96
DC8PVM1	DM2YGNW	Dactinomycin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	SYNERGxDB Database	Investigative	SR	2.16	1.12	0.07	3.25
DCRWO02	DM2YGNW	Dactinomycin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.32	10.4	2.49	2.4
DCJF5C7	DM2YGNW	Dactinomycin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.55	3.41	2.95	4.17
DCUZU8E	DM2YGNW	Dactinomycin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.4	5.29	0.21	4.11
DCLO3VT	DM2YGNW	Dactinomycin	Approved	34	DMYURI6	Raltegravir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	0.87	0.87	13.02	13.03
DCDBSB2	DM2YGNW	Dactinomycin	Approved	34	DMYZ57N	Albendazole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	SYNERGxDB Database	Investigative	KBM-7	41.26	41.26	51.47	51.5
DC73NE6	DM2YGNW	Dactinomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.07	1.73	0.36	0.66
DC8GMZP	DM2YGNW	Dactinomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.28	8.81	3.33	2.64
DC84UHM	DM2YGNW	Dactinomycin	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.77	6.71	2.72	0.56
DC02ZGK	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2POTE	Colchicine	Phase 3 Trial	25	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC9Q0YM	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adult Nasal Type Extranodal NK/T-cell Lymphoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCS2BKF	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7GCVW	Acalabrutinib	Approved	34	.	.	.	.	B-cell Lymphoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCRMGBA	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	DMNO38U	Bortezomib	.	.	Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC12TS8	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC1KTN6	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMLB81S	Paclitaxel	Approved	34	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC3HOS0	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMJR9H0	CC-292	Phase 2	21	.	.	.	.	Leukemia Lymphocytic Chronic B-Cell	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC3WOYY	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC7X0IU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMZD5QR	Cytarabine	Approved	34	.	.	.	.	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCAVIXU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM8X2EH	Everolimus	Approved	34	.	.	.	.	Adult Nasal Type Extranodal NK/T-cell Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCB1SLR	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMP6SC2	Irinotecan	Approved	34	.	.	.	.	Malignant Gliomas	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCC5AOW	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCCAFIK	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMSE3I7	Gemcitabine	Preclinical	2.1	.	.	.	.	Metastatic Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCE8HNC	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	"Leukemia, Lymphocytic, Chronic, B-Cell"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCESXKJ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMUYKBZ	Cyclosporin A	Phase 2 Trial	21	.	.	.	.	Myelodysplastic Syndrome	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCI4BXC	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMCBJSR	Sunitinib	Approved	34	.	.	.	.	Renal Cell Carcinoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCJ64A7	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adult Nasal Type Extranodal NK/T-cell Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCNK7LQ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMS104F	Temsirolimus	Approved	34	.	.	.	.	Refractory Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCPAUOT	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Refractory Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCTAJLM	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Acute Myeloid Leukemia (AML)	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCVYV4M	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCYP3D5	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMS49KH	Valproic Acid	Investigative	0	.	.	.	.	Solid Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC6ELTN	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	DMNO38U	Bortezomib	DMNO38U	Bortezomib	Myelodysplasia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCFWOZ6	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNH3PG	Etoposide	Phase 2 Trial	21	DMM39BF	Mitoxantrone	DMZD5QR	Cytarabine	Adult Acute Megakaryoblastic Leukemia (M7)	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCR20ZK	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	DMZD5QR	Cytarabine	.	.	Myelodysplastic Syndrome	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC4DEDR	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM8I94Y	Venetoclax	Approved	34	.	.	.	.	Recurrent B-Cell Non-Hodgkin Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC4F3R9	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMZD5QR	Cytarabine	Approved	34	.	.	.	.	Acute Myeloid Leukemia (AML)	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC6KJNI	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMYRBO1	Umbralisib	Approved	34	.	.	.	.	Chronic Lymphocytic Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC7LCZN	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMM4WAK	Zanubrutinib	Phase 2 Trial	21	.	.	.	.	Relapsed/Refractory Diffuse Large B-Cell Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCDZZ75	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM8I94Y	Venetoclax	Approved	34	.	.	.	.	"B-Cell Lymphoma, Unspecified"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCGJ3NV	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWP1BH	Tazemetostat	Approved	34	.	.	.	.	Relapsed Hematologic Malignancy	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCO2C97	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMYRBO1	Umbralisib	Approved	34	.	.	.	.	Recurrent B-Cell Non-Hodgkin Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCG6O7K	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	33.19	26.71	27.97	31.99
DC948XM	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.84	5.95	7.22	7.27
DCC1CEA	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.77	4.55	0.22	0.47
DC9I9IH	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.59	8.49	2.98	4.5
DCHDW0N	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	0.7	1.55	0.14	0.46
DC3AK70	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.33	3.47	1.14	1.25
DCKLS66	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.24	4.57	6.21	6.73
DC9WX1K	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	14.37	11.24	6.22	11.7
DCZXT06	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.59	2.58	5.72	5.67
DCPKA09	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.49	5.39	2.87	2.87
DCMXKFW	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	33.3	28.61	19.5	24.72
DCFJCJX	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	25.62	26.09	32.99	34.06
DCSTFDF	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	9.76	12.33	13.3	13.3
DCFV25L	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.14	8.84	9.13	9.13
DCUBUPC	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.5	8.61	6.82	6.83
DC513G2	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.64	9.87	10.19	10.19
DC58GSK	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.33	3.85	5.05	5.06
DCJAWCX	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.76	9.16	10.38	10.39
DCNE986	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	5.38	13.58	14.81	14.2
DCL00OL	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	24.8	29.7	29.51	29.51
DCHJ6TG	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.61	3.33	1.76	1.73
DCY13D9	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.13	3.73	4.78	4.78
DCFGF3Z	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	10.1	11.32	3.28	3.67
DCDWRWP	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.54	8.76	6.34	4.1
DCMS4TH	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.78	3.69	6.23	7.24
DC99Q2F	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.56	7.54	3.23	3.34
DCYJA5F	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.57	2.97	1.69	1.69
DCV19Y5	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.63	7.73	0.3	0.96
DCBGQDU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	15.72	21.44	2.38	5.13
DCHUQJD	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0	0.83	3.17	3.18
DC5IXDC	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.9	2.31	0.52	4.11
DCZ64PP	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	13.38	17.69	1.54	4.99
DCW630K	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	8.8	8.08	3.08	9.32
DCOO0YZ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.07	3.38	1.44	1.7
DCJBOQN	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.84	8.38	3.23	2.59
DCFS8BW	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.68	6.66	6.85	6.75
DCKQNUQ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.73	5.26	1.34	1.4
DCSRLWD	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.64	6.74	4.79	4.95
DC4GZ3L	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.82	4.77	5.27	5.29
DCE2F51	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	1.38	10.66	7.86	7.89
DC9TF8U	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.94	7.4	6.05	11.15
DCB9JJ9	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.27	7.4	5.17	7.97
DC8VRJJ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.02	2.19	1.37	1.37
DC6E0BT	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.12	2.63	1.7	1.6
DC5EXVJ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.14	7.82	6.55	7.95
DCL8AGF	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.86	7.3	6.52	6.96
DCUM7RX	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.62	3.33	0.4	0.46
DCJUHQ2	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.51	5.07	0.71	0.79
DCG0K2E	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	9.56	12.79	14.19	14.9
DC11VQS	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.14	1.88	0.41	0.34
DC60882	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	18.58	17.78	5.64	21.94
DCEU6XM	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.24	3.5	4.32	9.14
DCC18RB	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.83	10.54	10.08	10.85
DCJM84P	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	3.13	4.46	5.23	7.25
DCF6XTE	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.06	2.93	5.13	5.49
DCTA3J6	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.99	6.01	6.69	6.69
DCY8LXN	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.91	8.65	2.11	10.95
DCPS20I	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.47	3.57	0.17	0.17
DCAHB7Q	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.07	3.55	0.45	0.45
DCEE145	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	5.7	6.74	2.33	2.33
DCFIXWL	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	17.02	14.8	17.48	19.83
DCUBGTZ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	4.41	5.41	8.49	8.35
DCEWDML	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.28	4.17	12.97	11.39
DCXD5SN	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	4.22	1.49	0.91	1.04
DCTY04F	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.6	7.27	4.7	7.38
DC8RGAV	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.83	8.13	1.97	1.97
DCZQ3QT	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	15.18	14.7	3.23	21.77
DCSWOZQ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.96	3.94	7.04	7.25
DCXMVRX	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	8.89	10.55	6.7	13.67
DCTFX1X	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	7.82	7.33	10.1	11.25
DCYLTM9	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.63	6.13	5.39	5.39
DCWMR29	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.75	4.39	1.01	2.16
DCL1ZGK	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	3.8	7.04	5.56	5.56
DC79AWO	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.64	4.14	0.01	0.01
DCJSPQ4	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.93	6.95	0.58	1.16
DCR7K00	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.51	0.1	1.57	2.1
DCOHY99	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.07	4.61	2.72	2.72
DCVQZDY	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.76	5.82	1.58	1.35
DCSJTMO	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	7.12	7.12	6.02	6.02
DCZ00QE	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMM5SCF	ONC201	Phase 2	21	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	1.225	8.748	0.813	3.659
DCSEEUA	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.72	8.15	1.29	1.75
DCQF6V7	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.72	6.85	2.4	2.64
DCV8IR7	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.17	3.97	1.11	1.58
DCIJ6MU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMMX75K	LEE011	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	3.818	12.768	3.719	4.238
DC3RI4F	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	7.74	7.14	9.52	10.89
DCGPT8C	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	5.73	9.81	7.01	10.39
DCOQUAM	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.54	2.96	5.25	5.4
DC0UG5H	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.6	2.54	4.97	4.74
DCGLJE1	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.81	9.03	9.22	9.22
DC6VD9E	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.05	1.18	2.36	2.65
DCXWW4B	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	5.76	5.28	4.64	4.98
DC2S182	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMO14SG	Mebendazole	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	26.18	27.62	6.5	8.49
DCFOJYB	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	7.13	9.35	8.48	9.82
DCTXHJK	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	13.71	11.64	14.64	14.76
DC7VR2D	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.51	8.04	8	10.4
DCLF64X	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.38	5.72	0.5	0.5
DCKA8CR	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	10.64	11.07	1.64	1.89
DCK13H1	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.19	4.83	0.92	1.69
DC890UZ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.44	3.94	2.07	2.07
DCENO3T	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	12.05	12.34	15.04	15.14
DCV867J	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	8.43	15.37	16.23	16.24
DC0SEMO	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	6.5	6.5	8.06	8.54
DCQZBVG	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMU10FE	THZ1	Investigative	0	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	5.35	7.52	1.59	2.02
DC7F9HT	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	5.34	13.93	10.68	12.74
DCJALP5	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	14.11	16.68	1.38	2.14
DCHA4ZH	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	7.41	6.76	1.35	3.07
DC34IAH	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	5.84	5.4	2.7	5.35
DCPCJCT	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.91	5.42	8.21	8.34
DCAZXDU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.34	7.57	4.02	5.9
DCAM0AS	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.08	7.72	2.99	5.38
DC93A1I	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.31	11.06	3.62	7
DC631RU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	36.954	34.774	27.978	35.964
DCIHZYK	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.43	3.41	0.47	3.56
DCX61BE	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.49	6.44	2.59	2.59
DCATFTA	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.52	5.1	1.68	1.94
DCCB4UD	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.95	10.89	4.22	4.22
DCY9Q6V	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	12.2	18.05	17.71	17.71
DCRTBXU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.7	12.85	13.05	13.06
DCH88KA	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.84	6.68	6.29	6.29
DCA37LB	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.38	5.74	5.39	5.39
DCZ2VYN	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.23	15.09	13.46	13.4
DCM33FD	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	13.65	19.77	19.62	19.64
DCQ9P2O	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.3	5.45	4.79	5.27
DCCPYVP	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.85	10.37	12.65	12.8
DC17OSV	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.94	7.84	3.01	2.22
DCM1CNO	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.61	6.33	2.71	2.98
DC24XPK	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.6	4.63	1.93	2.03
DCDI09W	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.99	6.45	6.78	6.78
DCXQDGW	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	10.26	17.99	3.15	3.43
DCPO80W	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.56	5.13	6.3	6.32
DCZIEXG	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.73	5.67	0.69	0.69
DCGJB2R	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.28	3.66	3.05	3.05
DCOU517	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.18	6.44	7.14	7.15
DC99LBU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	12.57	17.22	16.01	16.04
DCPEW12	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.67	4.55	3.83	2.86
DCM2FO4	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.43	3.42	1.07	0.56
DCSSX18	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.59	7.95	3.75	3.51
DCEY8PY	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.43	3.1	1.19	4.25
DC9HE87	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.3	8.13	6.67	4.89
DCVVVHD	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.2	5.23	3.73	4.02
DCRL0IJ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.87	8.07	7.48	7.65
DC2V8MY	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.3	8.65	8.58	8.95
DCHVSKR	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.65	5.04	4.24	3.48
DC4BQVM	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.83	6.39	2.34	2.34
DCEFOB4	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.76	11.14	12.23	12.55
DCQF1KP	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.42	6.12	7.98	7.9
DCGOKI4	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	10.53	11.89	8.25	13.4
DCMFBU8	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	10.21	11.88	12.87	13.55
DC6HT0C	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.1	4.34	4.55	5.94
DC0DN5V	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.18	10.4	12.21	12.27
DC0LSLF	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.4	1.23	0.79	1.06
DC3C7D9	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	10.75	16.59	8.03	15.59
DCIRBI5	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	15.2	15.03	11.42	17.9
DCWDXGL	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.78	7.09	7.32	7.53
DCN4HFP	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.69	4.88	3.19	6
DCFYGVN	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.93	4.76	3.42	3.55
DCM5HWX	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.19	5.73	4.99	3.69
DCSTUS9	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.14	4.16	0.67	1.1
DCVPC0X	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	6.89	9.6	7.4	11.48
DCD7EFC	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.56	7.58	2.14	9.87
DC3NAN2	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.81	2.44	1	2.63
DCPVG7R	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.58	5.38	7.75	7.45
DCM8S9K	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.08	2.38	2.74	2.82
DCN4KVC	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.68	5.1	5.24	6.95
DCSHYS4	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.07	7.76	0.91	7.2
DC46A7B	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2	2.85	2.11	0.56
DCIC8VD	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.81	3.19	0.75	0.79
DCQBYG3	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.69	0.94	0.62	0.52
DCKUTYG	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.13	2.27	0.15	0.22
DCVOYG0	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.2	6.42	0.63	0
DC1A03H	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.41	10.19	11.34	11.54
DC8525P	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.42	13.43	5.23	5.58
DCOV7X0	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.77	3.51	3.74	3.99
DCPB867	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.82	8.56	2.71	1.83
DCC15YH	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.92	9.52	12.35	12.41
DCWLE1S	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.85	1.07	0.5	0.44
DC3P9MK	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.87	4.8	0.15	0.15
DCKYDBN	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.61	3.34	2.09	2.37
DCGV505	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.48	7.04	5.88	4.01
DCJOFPZ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.09	4.82	4.39	4.77
DC57Z1L	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.39	5.31	0.61	0.61
DCIV1GZ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.16	3.57	2.49	3.09
DC1MYHO	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.11	6.1	4.56	9.57
DC8WAKP	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.21	3.81	3.04	3.04
DC4YOHS	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.53	4.53	5.49	2.9
DCTJEFW	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.94	5.39	3.31	2.38
DC4GAVU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.92	5.95	6.04	6.04
DC9W6JK	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.34	1.68	0.25	0.25
DCDIJSM	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	36.63	43.04	37.17	37.17
DCXT0DU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.67	4.72	0.93	0.04
DCLT4VL	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.97	6.05	1.59	1.59
DCEQKBK	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.25	5.52	1.54	1.97
DCTMBN3	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.68	4.23	0.14	0.94
DC2MICL	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.9	4.47	1.15	1.15
DCLPCQR	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.87	1.37	0.01	0.82
DCJK0B4	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.78	6.74	6.72	6.69
DC08HY7	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.88	5.5	3.54	2.57
DCC0NYI	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.77	3.05	2.89	2.89
DCVOLWR	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	14.44	13.2	16.22	15.94
DCW2EQH	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.58	3.79	1.5	2.79
DCRN2XC	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.3	5.42	5.07	5.32
DCQMM0T	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.47	9.12	6.45	6.45
DC7PCMQ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.47	5.29	5.02	5.07
DCSH414	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.5	2.99	1.19	0.96
DCNCMBS	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.95	3.16	3.42	3.28
DC5I7SL	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.9	2.4	0.93	0.93
DCJHW0J	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.14	4.29	1.52	1.37
DCGKB9U	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.39	5.89	6.1	6.03
DCR0NQ4	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	11.48	19.48	18.84	18.85
DCMVC5K	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	6.04	13.65	12.77	13.17
DCCEGAJ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.62	4.11	2.07	4.28
DCF4X1R	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.99	12.39	12.02	12.02
DCT2BZ9	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	7.32	11.65	11.1	11.1
DC6MD81	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	3.02	7.67	6.55	6.87
DCG0D2Q	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	5.83	9.38	8.65	8.47
DCWRWI7	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	6.02	13.59	14.08	13.91
DCYMGRX	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.47	6.33	5.69	5.69
DCFS87M	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.36	10.49	9.3	9.3
DCRHIKJ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	3.7	11.32	11.75	11.8
DC7YF36	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.22	11.19	12.3	12.09
DC1OZO5	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	15.03	18.71	18.67	18.66
DCUIKS4	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	20.92	24.27	25.19	25.2
DCRLEZS	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.06	3.62	4.16	4.17
DCQ7ETJ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.6	4.88	0.99	0.99
DCAMGW7	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	7.89	12.17	11.66	11.29
DCNSALU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.65	6.72	6.77	6.71
DC2AWMC	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	6.26	10.65	9.58	9.58
DCMWQ10	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.21	6.55	5.92	5.92
DCRKA3N	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.64	10.39	10.76	10.77
DCLFZUM	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.15	8.56	7.36	7.37
DCWYT2E	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.63	6.12	6	6
DCV9SF1	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.02	2.11	3.9	4.19
DCS7LLI	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.86	6.37	0.84	0.84
DCCWAIH	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.77	4.78	2.14	2.14
DCUBJF9	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.84	6.94	3.68	3.82
DCM89ZI	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	12.33	13.55	12.49	13.87
DC6ZZ76	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.38	6.43	7.82	7.89
DCQAHLQ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.36	8.45	0.36	0.36
DCDB4X1	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.21	2.69	2.34	1.84
DCPGZMR	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.61	6.93	4.32	4.32
DCBL3N6	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.81	4.95	1.97	2.59
DCOMM3T	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.42	4.79	0.65	1.53
DCKZHXU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.32	5.5	0.44	0.44
DCU4XEX	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.42	13.04	15.39	16.18
DCMQ8YU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.76	9.05	10.22	10.22
DC2RRS2	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.03	0.14	0.12	2.36
DCIEWHP	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.23	2.29	0.16	2.82
DCNK0XN	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.62	8.08	1.01	1.01
DCDXUXT	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.57	2.66	5.41	5.7
DCSOCMZ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.82	5.19	2.8	2.11
DC3XU0H	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.61	3.85	0.33	0.33
DCO7PX2	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.16	3.52	0.56	0.56
DC3KFLW	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.49	5.63	6.7	6.68
DC8Z4VI	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.91	8.31	5.41	5.41
DCS70VN	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.32	6.67	5.44	5.49
DCTSNP4	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	3.8	5.94	1.73	1.66
DCYH18O	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.69	5.98	0.72	0.79
DCBWSPB	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.34	6.01	2.84	2.84
DC0SHW0	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.82	4.86	1.23	1.23
DC41NZB	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.22	4.46	3.1	3.12
DCDGNVH	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.19	1.25	0.82	0.35
DCTNZPD	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.59	2.79	2.69	1.14
DCSKR1I	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.03	3.04	1.96	1.9
DCJVBK2	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.02	2.88	2.75	2.7
DC4P8S4	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	27.97	24.13	25.28	25.21
DC3HPS3	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.52	5.51	4.57	4.53
DCNQ56B	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.15	5.55	5.61	4.5
DCTOJTU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.63	5.35	1.96	1.96
DCRDTDB	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.66	7.19	6.5	6.5
DCKJFE4	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.03	5.51	3.96	3.96
DCGJOU7	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	1.81	4.4	1.1	1.1
DCAWVV0	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.19	4.38	2.75	2.32
DCB5UGS	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.98	7.75	5.07	3.66
DC4Q1IY	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.53	6.51	6.04	6
DCON37T	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.38	3.27	2.13	2.13
DC5JJ5R	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.18	2.48	1.9	1.9
DCJFWN9	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.44	3.39	1.61	1.61
DCGTDCK	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.51	5.58	7.07	7.07
DCMQG9R	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.25	2.63	1.91	1.91
DCCW4JM	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.72	2.24	2.09	2.09
DC438Y6	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.09	5.05	7.78	7.67
DCHRZGZ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.23	6.61	6.26	5.78
DCQZVT6	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.11	1.09	2.77	2.77
DCQULVA	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.16	6.49	6.53	6.53
DCGXGNC	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.5	3.97	4	4
DCRQPXM	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.44	1.88	1.57	1.57
DCTX2L6	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.72	6.16	6.61	6.61
DCV5ADR	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.03	2.17	2.33	1.76
DC9YTCS	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.08	2.64	0.35	0.3
DCMKAIP	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.66	10.63	10.29	10.3
DCSJKKL	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.77	7.89	4.23	4.23
DC22SL8	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.77	6.99	2.79	2.79
DC5NWBP	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.39	6.2	3.51	3.59
DCE5F5D	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.85	5.28	3.8	3.8
DC1Y8RB	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.71	2.43	1.45	1.45
DCIZQEU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.65	2.48	0.9	4.26
DCFIBK1	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.14	7.56	4.49	7.07
DCNQM85	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.88	2.96	1.8	5.77
DCGSIYS	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.34	2.81	4.52	4.61
DCM4TDK	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	6.15	5.5	9.3	9.38
DCU8GGJ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	8.4	9.02	2.61	8.97
DC5Y9SW	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.63	2.58	0.78	0.78
DC9Q6MU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.25	4.58	0.55	0.55
DCLOB17	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.83	4.88	3.02	3.02
DCT4W2O	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.81	3.03	2.37	2.37
DC8MPZB	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6.83	15.76	16.76	17.14
DCYRR5F	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.61	6.93	4.04	8.41
DC89WLA	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	8.22	12.27	0.16	12.39
DCWJ33M	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.38	7.58	2.08	9.06
DC8R2Z8	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	17	17.66	19.19	19.52
DCSNZJ7	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.57	7.9	1.06	9.81
DC2ISIN	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4.48	12.71	11.5	11.64
DC3JIF7	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMG2YBD	Trifluridine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.44	7.14	6.18	10.49
DCL5LBF	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.31	4.51	4.54	4.75
DCKGHX7	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.38	4.71	1.3	1.3
DCBF2RY	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.85	1.85	1.72	1.72
DC2OZF3	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.11	4.66	3.67	3.67
DCO126F	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.39	1.87	1.5	1.5
DCXSB7H	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.85	11.85	12.34	15.15
DCG2BUY	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.33	4.68	0.62	0.62
DCTM58K	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.52	3.84	7.91	8.01
DCDCI5I	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.51	1.98	1.77	1.55
DC8CHOL	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.53	3.67	0.42	0.42
DC36V8A	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.86	0.69	2.86	3.37
DC49LTE	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.08	2.24	1.19	1.15
DCUSB4P	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.83	1.27	4.35	4.57
DCI74WO	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.02	2.7	2.38	2.35
DCVQV96	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.26	6.49	3.36	3.36
DC6XVG0	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	38.66	35.64	33.54	37.14
DCW548A	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	8.56	7.07	12.29	10.14
DCP5N8V	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.02	3.34	0.64	7.34
DCITGJX	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.13	3.86	2.18	2.35
DC8JNY2	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.04	2.35	1.18	1.61
DCMZFBF	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.3	5.73	1.86	2.05
DCJ18JR	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	6.55	7.8	1.63	1.63
DCILU4U	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.63	11.51	9.34	7.79
DCN6MTD	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.86	5.77	1.84	1.82
DCA1QN2	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.96	3.46	1.59	1.59
DCSHSDR	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2	5.11	0.84	0.84
DCHOGVO	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	5.23	7.92	1	0.38
DCN93SY	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.41	4.49	1.18	1.18
DCBA7MB	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.2	8.33	6.99	6.99
DCIQUWO	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.55	5.22	2	2.41
DCTF6D3	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.17	1.92	0.76	0.67
DCJO2W1	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.63	7.63	6.89	6.91
DC6CGSV	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.04	2.38	0.65	0.88
DCY93FU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.81	5.21	2.79	2.79
DCJFJT0	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.4	2.9	5.4	6.12
DCFJ3CQ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.37	4.56	4.48	4.48
DC994HE	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.32	2.58	0.84	0.84
DCOU0NF	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.9	2.14	1.55	1.48
DCDA98Z	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.64	7.41	0.87	9.62
DCCFM9N	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	4.28	5.38	8.16	7.82
DCMD504	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	6.03	8.28	5.11	11.73
DCNVKN8	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.26	6.45	1.85	1.85
DC7RMS7	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.44	6.37	2.81	1.18
DCFWV0U	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.6	6	2.55	9.38
DC16SJH	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.97	3.81	0.58	0.36
DCAYP7O	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.09	0.88	0.02	0.02
DCO8LF1	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.31	5.43	6.07	5.91
DCHASPZ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNP60F	Anastrozole	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	3.26	2.53	0.28	2.28
DCRSPQM	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNP60F	Anastrozole	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.51	3.4	5.44	5.42
DC1VYMY	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	3.52	5.41	6.32	6.47
DCS2PAQ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.39	5.88	7.25	7.26
DC5L3L7	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.65	2.24	2.82	2.88
DCGTLFM	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.69	2.42	2.41	2.52
DCGJQN1	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.39	0.16	1.08	1.1
DC12DLB	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.09	3.13	3.95	4.11
DCQWWC5	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.75	2.66	2.9	3.77
DCPW71W	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.36	2.02	4.17	4.18
DC1QJGR	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.85	5.06	1.77	4.5
DCQXA45	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.83	2.67	2.31	1.12
DCGECA3	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	9.54	8.76	5.29	10.54
DCJ0OWX	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	4.96	5.56	5.36	8.15
DCDF6RC	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.08	6.28	1.89	8.81
DCNYHA2	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.69	4.65	2.31	4.99
DCPYBLU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	6.56	3.34	5.98	7.03
DCYI24Q	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.46	8.13	8.08	10.16
DCPVLXW	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.1	6.08	0.62	6.68
DCEDB27	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.52	4.11	2.79	6.77
DCI83ZM	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	5.35	8.09	8.84	10.44
DC1RFGE	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.68	0.73	0.49	0.49
DCWDN1W	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.8	4.39	3.23	3.23
DC2QVZR	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	2.39	4.67	1.93	1.2
DCBGT6J	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.78	7.08	0.96	0.96
DC5DDH0	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.8	5.4	3.02	3.02
DC5XPAL	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	8.59	3.82	0.52	0.52
DCSMMVR	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.6	4.7	1.31	1.31
DCD4B2T	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.3	3.1	1.15	1.15
DCEVC42	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	2.62	7.68	3.53	2.25
DCORA7P	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.92	4	2.36	1.52
DCKFN3D	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.84	2.06	1.26	0.36
DC4SZTX	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.34	12.05	6.14	6.14
DC0MN0J	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.77	1.35	2.32	2.37
DC1SWJL	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.64	4.03	0.96	0.56
DCFM2GD	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.39	3.27	2.24	2.24
DCS67DM	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.08	3.58	1.32	1.35
DC02RCR	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.3	9.25	5.74	5.74
DCUDZCU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.85	3.66	1.03	4.46
DC0RN0G	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	19.34	18.95	13.93	22.02
DC8KPAK	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	11.7	10.7	2.93	11.68
DCEPNMK	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	11.83	11.8	13.73	14.25
DC1K15G	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.99	3.15	4.49	5.07
DCG9D4Q	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.11	6.45	3.51	2.52
DCMVDSN	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.24	6.3	1.58	1.58
DCN7M9I	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.74	8.07	4.91	9.03
DC8EK6C	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.91	6.49	2.86	2.7
DC32NWC	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.78	1.86	1.84	0.47
DC1EIU2	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.83	3.92	3.69	3.69
DCZ6DN7	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.28	3.02	1.04	1.74
DCKCUDH	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.09	9.11	8.65	8.65
DCT0CIN	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.39	4.1	1.02	1.02
DCBHU29	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.39	5.57	0.91	0.8
DCVQ6ID	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.78	8.79	5.35	5.35
DCSV8YA	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.72	7.81	8.56	8.75
DCXGNKR	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.89	5.65	3.88	3.88
DCPDJFR	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.02	12.43	11.79	12.86
DC1ANGU	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.35	6.99	4.57	4.34
DCN9YKC	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.86	5.3	2.58	2.98
DCLOLMJ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.42	7.73	4.32	3.27
DC8LM5Q	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.29	4.8	0.57	0.57
DC1C6D8	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.58	5.02	0.15	0.15
DCK9X6X	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.33	6.8	4.31	4.31
DCXKR1G	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.81	6.27	5.17	4.7
DC5J9F0	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.96	5.43	5.08	5.1
DCNRNL7	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.25	2.84	2.32	1.85
DCIL3TN	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.35	0.95	0.28	0.14
DCOPZXG	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.78	2.35	2.6	2.11
DC5WHAG	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.21	1.34	0.13	0
DCZF0L0	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.6	7.67	1.64	1.64
DC3YRWM	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.65	7.17	3.67	2.05
DCAF9V1	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4	4.09	0.91	8.16
DC180UQ	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.44	2.04	1.89	0.86
DCBD02A	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.53	7.43	4.36	3.58
DCZPD7U	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.57	8.83	4.62	6.37
DCZGAV2	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.91	8.14	2.97	2.97
DC519YA	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.15	10.41	5.51	6.79
DCDTC43	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.55	3.18	0.53	0.53
DCK8KQF	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1	3.63	0.29	0.04
DC6KEWD	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	13.39	16.93	12.64	12.64
DCMTAJ9	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.56	8.71	10.09	10.31
DCNYXV0	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.19	5.46	5.26	5.47
DC20WT7	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	4.18	4.27	0.16	0.08
DC08DRK	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMMZSXQ	Azathioprine	Approved	34	DMTQXS7	Mercaptopurine	.	.	Crohn's Disease	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DC3OAEB	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMUYKBZ	Cyclosporin A	.	.	Hematopoietic Stem Cell Transplantation	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DC4YGOL	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMICA9H	Sulfasalazine	Approved	34	DMXZAL2	Hydroxychloroquine	.	.	Rheumatoid Arthritis	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DC5KP7N	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMICA9H	Sulfasalazine	Approved	34	DMXZAL2	Hydroxychloroquine	.	.	"Arthritis, Rheumatoid"	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DC61B0K	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMUYKBZ	Cyclosporin A	.	.	Beta-Thalassemia Major	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DC9EHO7	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMICA9H	Sulfasalazine	Approved	34	DMR8ONJ	Leflunomide	.	.	Psoriatic Arthritis	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCJN91L	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM8BKU9	Acitretin	Approved	34	DMUYKBZ	Cyclosporin A	.	.	Plaque Psoriasis	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCAC3BT	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMR8ONJ	Leflunomide	Approved	34	.	.	.	.	Rheumatoid Arthritis	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCFZS7F	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMBR01X	Brilinta	Approved	34	.	.	.	.	Rheumatoid Arthritis	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCI20T9	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMBS370	Tofacitinib	Phase 2 Trial	21	.	.	.	.	Rheumatoid Arthritis	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCA69PQ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMF28YC	Atorvastatin	Phase 3 Trial	25	DMZ7XNQ	Tacrolimus	.	.	Acute Myeloid Leukemia	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCXC09Y	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMZ7XNQ	Tacrolimus	.	.	Chronic Myelogenous Leukemia	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCPUUM8	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM5PVQE	Paroxetine	Approved	34	.	.	.	.	Rheumatoid Arthritis	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCQK0OU	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMDI269	Docetaxel	Approved	34	.	.	.	.	Head and Neck Squamous Cell Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC04JPN	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMIK367	Procarbazine	Approved	34	DMINOX3	Vincristine	DMZD5QR	Cytarabine	Chemotherapeutic Agent Toxicity	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC7ZS1W	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMDIOAR	Treosulfan	Approved	34	DMVRLT7	Fludarabine	DMZ7XNQ	Tacrolimus	Accelerated Phase Chronic Myelogenous Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCB7FI1	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMUYKBZ	Cyclosporin A	Phase 2 Trial	21	DMWMPD4	Vorinostat	DMZ7XNQ	Tacrolimus	Accelerated Phase Chronic Myelogenous Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCPTTD8	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMVRLT7	Fludarabine	Approved	34	DMXYJ9C	Busulfan	DMZ7XNQ	Tacrolimus	Accelerated Phase Chronic Myelogenous Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCX9VKT	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMUYKBZ	Cyclosporin A	DMZ7XNQ	Tacrolimus	Chronic Myeloproliferative Disorders	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCZMDCP	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMTL94F	Maraviroc	Approved	34	DMUYKBZ	Cyclosporin A	DMZ7XNQ	Tacrolimus	Graft-versus-host Disease	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC31FMS	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMKECZD	Temozolomide	Approved	34	DMYZJGB	Ibrutinib	.	.	Primary Central Nervous System Lymphoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC838W5	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMF28YC	Atorvastatin	Phase 3 Trial	25	DMZ7XNQ	Tacrolimus	.	.	Acute Myelogenous Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCJI1O7	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMNO38U	Bortezomib	Approved	34	DMZ7XNQ	Tacrolimus	.	.	Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCL4PX4	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMMZSXQ	Azathioprine	Approved	34	DMU65NK	Mycophenolic acid	.	.	Mucous Membrane Pemphigoid	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCMHPS9	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMWMPD4	Vorinostat	Approved	34	DMZ7XNQ	Tacrolimus	.	.	Graft vs Host Disease	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCWL1XT	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMTL94F	Maraviroc	Approved	34	DMZ7XNQ	Tacrolimus	.	.	Acute Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCWQ945	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM7NKEV	Thioguanine	Preclinical	2.1	DMUAZWG	Leucovorin	.	.	Hodgkin's Disease	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCG5MN4	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM2POTE	Colchicine	Phase 3 Trial	25	.	.	.	.	Coronary Artery Disease	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCKS8UJ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMUAZWG	Leucovorin	Approved	34	.	.	.	.	Osteosarcoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCNPZIX	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMRBMAU	Mycophenolic acid	Investigative	0	.	.	.	.	Acute Myeloid Leukemia (AML)	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCO4NWS	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMKECZD	Temozolomide	Approved	34	.	.	.	.	Primary CNS Lymphoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCW9ZZE	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMZD5QR	Cytarabine	Approved	34	.	.	.	.	Diffuse Large B Cell Lymphoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCSIJ0Q	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMG281S	Carboplatin	Approved	34	DMUAZWG	Leucovorin	DMVP5YE	Doxorubicin	Osteosarcoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC0GFSX	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMOTQ1I	Ondansetron	Approved	34	DMUAZWG	Leucovorin	.	.	Juvenile Idiopathic Arthritis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC0MTOY	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMNO38U	Bortezomib	Approved	34	DMZ7XNQ	Tacrolimus	.	.	Graft Versus Host Disease	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC1N5HJ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMXZAL2	Hydroxychloroquine	.	.	Recurrence (Disease Attribute)	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC2P00C	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMUYKBZ	Cyclosporin A	.	.	Acute Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCL7YBJ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMICA9H	Sulfasalazine	Approved	34	DMR8ONJ	Leflunomide	.	.	Chronic Nonbacterial Osteomyelitis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCLPML3	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMMZSXQ	Azathioprine	Approved	34	DMTQXS7	Mercaptopurine	.	.	Inflammatory Bowel Disease	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC0YH58	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Recurrent Childhood Acute Lymphoblastic Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC1Q8UQ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMQ8FR2	Prednisolone	Approved	34	.	.	.	.	Polymyositis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC5F8IO	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMZ1UOI	Asp-015K	Phase 3	25	.	.	.	.	"Arthritis, Rheumatoid"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC5IQZT	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMBS370	Tofacitinib	Phase 2 Trial	21	.	.	.	.	Rheumatoid Arthritis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC69XSL	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMZD5QR	Cytarabine	Approved	34	.	.	.	.	Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCA6BWO	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Desmoid Tumor	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCBGXKZ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Neurofibromatosis Type 1	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCBITQN	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMZ7XNQ	Tacrolimus	Approved	34	.	.	.	.	"Leukemia, Myelocytic, Acute"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCERZFR	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMOBIKY	Bexarotene	Approved	34	.	.	.	.	Primary Cutaneous Anaplastic Large Cell Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCF4EMZ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMUAZWG	Leucovorin	Approved	34	.	.	.	.	Brain Tumor	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCJWKYY	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMIZKOP	Thiotepa	Approved	34	.	.	.	.	Brain and Central Nervous System Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCK7VO5	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMUYKBZ	Cyclosporin A	Phase 2 Trial	21	.	.	.	.	Graft vs Host Disease	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCLRI0S	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMQ8FR2	Prednisolone	Approved	34	.	.	.	.	Erythema Nodosum Leprosum	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCMBK7X	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMZ7XNQ	Tacrolimus	Approved	34	.	.	.	.	Graft Versus Host Disease	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCNO2DZ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMUYKBZ	Cyclosporin A	Phase 2 Trial	21	.	.	.	.	Neoplasm Metastasis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCS35QB	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMRP69M	Bucillamine	Approved	34	.	.	.	.	Rheumatoid Arthritis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCZUUZW	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Rheumatoid Arthritis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC123FL	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM8Y4JS	AC220	Approved	34	DME4TH4	Etoposide	DMZD5QR	Cytarabine	"Lymphoblastic Leukemia, Acute, Childhood"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC832YA	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMF3AN7	Loratadine	Approved	34	DMMIU2C	Methylprednisolone	DMUIE76	Acetaminophen	Rheumatoid Arthritis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCSJX87	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMVRLT7	Fludarabine	Approved	34	DMXYJ9C	Busulfan	DMZ7XNQ	Tacrolimus	Acute Myeloid Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC26KNS	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMCVJ86	Clofarabine	Approved	34	DMZD5QR	Cytarabine	.	.	Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCEAFKR	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM5DSFZ	Rifampicin	Approved	34	DMDEXQ0	Febuxostat	.	.	Drug Interaction	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCEQO1B	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMNO38U	Bortezomib	Approved	34	DMZ7XNQ	Tacrolimus	.	.	Hematologic Malignancies	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCRVSCR	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMIZKOP	Thiotepa	Approved	34	DMVRLT7	Fludarabine	.	.	Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC6MNXU	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMDEXQ0	Febuxostat	Approved	34	.	.	.	.	Drug Interaction	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC6YRVT	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM5DSFZ	Rifampicin	Approved	34	.	.	.	.	Drug Interaction	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCBTZ9I	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMSV12M	Isavuconazole	Phase 3	25	.	.	.	.	Pharmacokinetics of Isavuconazole	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCZI61X	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMUAZWG	Leucovorin	Approved	34	.	.	.	.	Rheumatoid Arthritis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCTK72A	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM09NGV	Ribavirin-TP	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.97	1.97	8.8	8.88
DCGV1TC	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM0FB1J	Sertraline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.81	11.81	15.06	15.12
DCU48OJ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.68	2.68	6.12	6.2
DCHHJMJ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM0P729	GSK461364	Phase 1	17	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	11.908	12.231	1.055	3.481
DCWY2O7	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM0QV1J	Baclofen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.61	0.61	4.13	4.21
DCSA7GH	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.14	3.14	18.39	18.39
DCJC8XV	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM15HL8	Clindamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.88	3.88	6.96	7.02
DCNIQOH	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	1.27	3.53	2.73	3.6
DCO0NF3	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	5.4	6.57	2.84	7.84
DCMJV0L	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	8.42	7.08	1.04	9.38
DC6SBDF	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	4	7.26	0.43	7.39
DCFGZ9L	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	1.89	0.33	0.6	1.69
DCQY2DZ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	4.96	10.79	6.17	10.96
DC293HJ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	5.01	3.79	2.65	8.3
DC4E89G	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	3.1	3.45	0.71	5.83
DC5112T	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	8.07	5.01	0.43	6.55
DCB63BB	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	5.49	6.33	2.84	7
DC62WWB	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM29GAD	Lumefantrine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	12.83	12.83	16.03	16.1
DCDV2MP	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	2.07	4.94	3.34	2.58
DC2IR9R	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	7.14	8.13	1.56	7.33
DCXMC2C	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM2G9AE	Citalopram	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	10.64	10.64	13.81	13.87
DCL8TCC	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	5.94	4.04	0.96	6.59
DC8ZZC4	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM2TUCU	Crotamiton	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.09	3.09	6.58	6.66
DCS9ZWJ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	1.22	3.17	1.3	6.1
DC7EC49	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	13.12	13.13	12.32	14.2
DCX04EK	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	10.77	11.78	9.5	11.52
DCWHNE1	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	4.83	2.19	0.08	3.86
DCQT0RH	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	9.51	12.51	6.73	11.7
DCEHH9Q	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	3.41	5.2	1.45	4.95
DCODCV6	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	5.47	3.74	4.48	10.3
DCGBT6I	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM3KJBC	Epinephrine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.32	1.32	7.7	7.7
DCSA3AB	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM3P6V7	Furazolidone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.68	6.68	10.35	10.43
DCZ3885	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM3VZJQ	Chlorphenesin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	14.57	14.57	17.21	17.29
DCHHKH2	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	4.39	3.24	1.77	2.17
DCYGM6J	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	3.38	5.13	0.39	6.89
DCNY1KW	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	7.44	6.73	1.21	6.9
DCMGF04	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	1.86	4.17	5.96	6.21
DC1A101	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	6.58	5.35	1.88	7.24
DCLCKJ2	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	8.8	5.48	5.99	10.49
DCSD5GL	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	2.74	5.26	5.81	6.67
DCPEZDF	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.04	5.72	1.55	5.08
DCWSUTZ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM5IKUF	Dihydroergotamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.54	7.54	10.85	10.86
DCDMMTC	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	3.73	0.61	0.11	0.19
DC6DYTX	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	7.02	5.37	4.41	2.96
DC3VBDK	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM5TVS3	Vinblastine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.31	2.31	4.84	4.9
DCV0GGD	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	3.12	3.25	2.83	4.06
DCM1FC4	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	5.05	2.48	1.02	5.39
DCU92EV	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	4.2	3.9	0.46	5.06
DCPF8VI	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	9.08	10.1	3.95	9.81
DC1IHTV	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	3.68	1.36	0.79	5.26
DCB4GY2	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	3.45	3.68	3.79	7.7
DCRVF6R	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	5.46	4.17	0.48	6.5
DCGCF91	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	24.962	22.736	0.444	12.543
DCPCMK3	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	8.45	7.29	4.63	8.53
DCV3M2S	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	11.94	11.12	9.05	14.35
DCMYLCC	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	2.49	0.33	1.78	6.4
DCKWCI8	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	10.14	7.24	3.61	8.76
DCK3GO4	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	4.74	3.58	0.75	4.18
DCKA44C	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	3.36	4.32	3.18	4.24
DC5ABBC	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM6BZCV	Sivelestat	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.7	5.7	9.51	9.53
DCBKP6M	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM7A8TW	Ezetimibe	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.41	2.41	5.55	5.59
DCQG38B	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM7CLEZ	Eltanexor oral	Phase 1/2	19	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	17.095	13.669	8.502	11.352
DCE9PQP	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM7CLEZ	Eltanexor oral	Phase 1/2	19	.	.	.	.	Hodgkin lymphoma	DrugCombDB Database	Investigative	U-HO1	17.09	13.67	8.51	11.35
DC9EXNL	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.45	2.1	2.93	3.02
DCSQ13N	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	3.95	7.57	3.07	2.35
DCLF9IQ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM93L4X	Dexmedetomidine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	14.68	14.68	17.91	17.95
DCYI1GN	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMFI8A7	Tranexamic acid	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.38	8.38	11.23	11.31
DCG65PG	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM9S1EA	Pepstatin	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.56	6.56	13.89	13.97
DC3Y75U	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMB0NVQ	Steroid derivative 1	Patented	15.5	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	27.458	25.85	4.222	7.768
DCMAX42	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	8.41	8.18	0.2	9.09
DCK7MV6	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	5.86	6.49	0.54	6.2
DCYNUOX	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	3.89	3.7	0.09	6.92
DCWBDCD	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	7.2	6.72	2.25	7.45
DCJOUYL	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	8.27	6.47	1.63	7.52
DCMOIPZ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMBI4JG	Isosorbide dinitrate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	14.77	14.77	17.85	17.93
DCJ4YRG	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	1.62	5.18	2.13	3.84
DCN6B2L	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	9.55	10.76	2.19	11.18
DC2ZPNQ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	1.5	1.84	2.61	3.63
DC2N846	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	5.61	2.53	1.31	5.97
DC82KVI	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	6.48	6.58	9.43	11.35
DCBFOQA	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	7.28	4.74	1.97	6.57
DCBJJZ2	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	3.39	0.1	19.17	1.2
DCDWV4E	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	3.1	5.61	1.39	5.71
DCMIU92	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	11.95	11.2	7.22	13.44
DCIG80N	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	4.82	4.65	3.47	6.85
DCO3XY6	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	2.74	4.07	3.77	5.87
DCPQUG8	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	7.52	4.13	6.45	10.33
DCP0HK8	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	2.67	1.1	0.5	1.85
DCHCKYT	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	5.88	6.32	1.6	3.99
DCG75B3	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMD9WSC	Memantine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.05	4.05	7.94	8.02
DCHIAWM	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMDASC6	Metformin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.71	0.71	3.72	3.8
DCLIDDT	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.54	2.42	0.64	2.7
DC20EJM	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	1.06	2.71	1.09	0.27
DCR6KUC	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	1.39	5.26	3.53	4.63
DCAZI1W	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	4.6	6.13	5.51	5.62
DCYW9SW	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMDO279	Phenprocoumon	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.39	0.39	4.62	4.7
DCXFTM6	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DME2H5T	Cilastatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	10.51	10.51	13.85	13.86
DCI3OON	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMEOCKZ	JZL195	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	14.77	14.77	17.94	18.02
DCGPFVC	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMF70AB	Ginsenoside Rb1	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.69	8.69	11.63	11.71
DCCVTBB	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMFGLXB	Phensuximide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.16	11.16	16.8	16.88
DCE4CEO	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	5.31	4.22	0.68	6.38
DCO8U4X	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	8.74	6.05	2.37	7.98
DCD0OMB	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	4.41	2.99	2.88	7.54
DCPRYQC	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	5.88	4.82	1.55	6.63
DCIP3AB	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	3.35	7.43	10.91	7.73
DCWYH01	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	2.47	3.18	0.3	3.72
DCLWG40	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMFO843	Fluspirilene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.68	4.68	7.93	8.01
DCH04VF	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMGC5DB	Ciprofibrate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.17	4.17	7.44	7.52
DCGRQDU	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMGDKXN	Sitagliptin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.23	2.23	5.76	5.82
DCJLEOI	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMGQFYB	Mecamylamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	14.21	14.21	17.59	17.63
DCJ5VCR	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	4.07	1.06	0.95	0.83
DCOYJV1	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	6.04	13.57	13.14	13.03
DCUTT93	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.65	1.91	0.46	2.21
DCNQZN6	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	7.56	6.54	1.06	5.89
DCKW79H	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	1.16	2.84	2.2	2.13
DCG7VP3	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMH7IDQ	Dichlorphenamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.86	6.86	10.95	11.01
DC9DXF4	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.45	3.61	4.32	9.16
DC5TNHP	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	3.63	8.49	8.07	12.34
DCAEP3X	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMOL54H	Clopidogrel	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	10.83	10.83	13.77	13.85
DCCOR4D	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMIUYFH	Sulfapyridine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.04	1.04	4.54	4.62
DCXJ6F2	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMJOQM3	Eflornithine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.66	6.66	10	10.08
DC1LIIC	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMJPE61	PF-02545920	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.83	6.83	18.28	18.35
DCP58AR	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	1.53	4.29	2.87	3.04
DCME2J3	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMKSQG0	Tiagabine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.7	1.7	11.7	11.7
DCIALHR	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMGO72P	Oseltamivir	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.54	5.54	10.91	10.99
DC8WLAU	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DML5VQ0	Fenoprofen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.75	0.75	3.54	3.62
DCS67P8	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	3.71	3.48	1.54	7
DCWYVAB	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	6.2	3.94	3.32	6.55
DCZPHQM	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	11.33	7.92	2.32	9.44
DCGLFI4	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	12.23	10.36	4.84	11.83
DC8EQVW	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	6.84	3.28	0.42	4.84
DCOUCLT	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	4.76	1.07	0.18	4.54
DC6LZ9N	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	13.57	11.87	5.33	13.15
DCN9KW5	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	12.68	8.85	2.85	10.37
DCORPAT	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	6.8	2.79	0.78	4.52
DCB2VED	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	0.41	1.54	0.53	4.31
DCLG5GR	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	4.75	1.9	1.07	3.66
DCECWHE	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	4.01	4.39	2.81	4.35
DCGPNZR	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	6.26	2.61	3.76	3.87
DC3PP3V	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	7.27	10.62	11.02	11.94
DCXIG3C	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	7.82	12.4	6.58	9.33
DCDUK5H	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	7.97	6.06	5.32	8.14
DCDXDOQ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMM0HR1	Pargyline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.43	8.43	11.71	11.79
DC32ZUJ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	7.11	5.87	0.8	7.03
DCMLDLK	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	4.67	2.34	1.7	2.46
DC61CFB	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	12.56	8.45	4.39	8.37
DCH1QZG	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMM61Y2	BRL-15572	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.44	4.44	8.29	8.35
DCCEQWP	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	26.22	23.63	20.03	20
DCRHP4W	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	36.63	37.83	36.61	36.48
DCKH32D	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	24.13	24.64	18.61	17.2
DC5KNQD	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	7.94	10.19	14.16	10.08
DCQ5I5A	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	20.86	24.19	22.97	24.07
DC0VZ3S	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	31.61	22.46	22.96	20.44
DC6YDJR	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	0.9	6.64	5.59	2.68
DCCJSX1	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	13.54	17.71	15.66	14.96
DC6ZEZS	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMNKG1Z	Atenolol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.81	2.81	5.73	5.81
DCPFKN0	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMNMW9R	Pramipexole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.76	0.76	5.46	5.54
DC8WDIW	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	4.96	6	1.43	7.13
DC20ZB7	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMJAPE7	Methylene blue	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.63	2.63	6.06	6.06
DC4FMV0	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMOMBJW	Moricizine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	12.99	12.99	16.57	16.65
DCP6UNG	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	1.14	2.16	1.45	2.17
DCSD8C3	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	9.59	18.78	6.37	14.25
DCC4E4U	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	1.87	6.33	2.85	3.89
DCY306C	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMFYAM1	Enalaprilat	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.85	4.85	7.79	7.86
DCXRCZM	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMQ2FKJ	Teriflunomide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	15.36	15.36	19.09	19.15
DCE3N9R	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMRFWGK	Novobiocin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	14.78	14.78	18.34	18.34
DCUC9DF	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	1.45	2.79	1.02	3.37
DCIZ233	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	0.11	4.55	1	1.69
DCVHOON	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMS0PND	Brincidofovir	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.33	1.33	5.42	5.42
DCE161Q	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	10.09	7.57	0.41	9.87
DCCHAT4	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	8.64	8.95	1.61	11.97
DCT07KR	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	16.9	15.74	14.54	15.04
DCX9M37	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMSA4B3	Desoxycorticosterone pivalate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.8	11.8	14.97	14.97
DCPUIIV	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMSG91J	ER819762	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.15	3.43	0.77	2.57
DC91J6T	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMSG91J	ER819762	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.02	3.09	2.4	2.59
DC7K4X4	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMSI5CB	Chloroquine	Approved	34	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	1.016	0.111	0.889	4.567
DCIH26S	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	2.79	1.25	1.83	4.67
DCH2SOV	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	10.92	9.28	7.27	10.96
DCAVZFM	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	10.97	10.34	10.57	13.84
DC4MJ31	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	4.78	1.13	1.96	3.74
DCELOTU	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	5.93	6.02	3.09	5.83
DCPHSA2	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	4.06	7.74	8.15	9.01
DCQBJVK	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	7.63	12.72	1.02	9.22
DCVOFG2	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	2	2.1	1.01	4.77
DC2D537	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	9.42	5.55	5.53	9.51
DCUQDE9	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	3.01	2.07	0.11	3.85
DCB6HWV	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	6.82	7.14	8.03	9.11
DCLYAPT	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Ewing sarcoma	DrugCombDB Database	Investigative	TC-71	31.558	32.144	8.673	11.902
DC8KR49	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMT70RC	Piperaquine	Approved	34	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	1.174	0.29	2.163	4.297
DC8EDXT	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMT70RC	Piperaquine	Approved	34	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	0.41	0.487	0.764	0.706
DC1B9WO	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	13.31	13.31	16.77	16.84
DC6TA2Z	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	0.5	2.97	2.22	1.84
DCUBR59	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	1.52	1	2.37	3.36
DCU15GE	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMRBMAU	Mycophenolic acid	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.57	0.57	4.14	4.14
DCS13Z0	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	10.22	10.17	7.24	10.09
DCBV5GL	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	7.46	11.31	12.76	13.24
DCV7XXJ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.56	1.47	0.37	4.5
DC2E97P	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.01	2.33	1.82	2.68
DCVBDIJ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMUWAM2	Pyronaridine	Approved	34	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	0.169	0.253	0.429	0.867
DCXEWHA	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMVM6QR	Lacosamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.67	1.67	5.33	5.41
DCJG7PU	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMVPZBE	Iloprost	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.59	9.59	12.19	12.27
DCAVF4P	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	0.28	3.26	0.65	0.32
DCYSGAO	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMVRYT2	Nabilone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	15.23	15.23	18.95	19.02
DC0FXBF	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMVYXR8	Sumatriptan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.57	2.57	5.99	6.03
DC3J00Z	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	2.84	1.15	2.51	4.7
DCG2ODZ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.77	0.89	1.18	4.25
DC28KA0	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMWSMND	Cevimeline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	10.84	10.84	14.31	14.38
DCLTULE	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMXCM7H	Cerivastatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.42	0.42	3.26	3.31
DCJZ0MU	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.87	1.79	0.26	3.38
DCLQ05L	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMSIVND	Hydroxychloroquine	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.98	5.98	9.4	9.41
DC84L5U	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMY4UMW	Atovaquone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.75	0.75	3.68	3.76
DC5Z6Z3	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMY4UMW	Atovaquone	Approved	34	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	1.216	1.211	1.158	2.396
DCYQK2L	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMY4UMW	Atovaquone	Approved	34	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	4.748	4.999	0.991	5.496
DCWKRYW	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMY8WDB	CB3304	Phase 1/2	19	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	25.287	24.743	2.934	2.012
DCC95JA	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMY91A3	ML323	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.19	11.19	14.15	14.22
DCDU2T1	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMYURI6	Raltegravir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.06	11.06	14.22	14.29
DCAU7HL	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	6.199	5.835	14.225	14.85
DCOSQT0	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMZ1OO0	AS-1949490	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.63	4.63	8.02	8.09
DC4L6AG	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	0.05	0.89	0.91	2.79
DCXU18P	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	4.49	1.07	1.01	3.08
DCKNNR0	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	2.39	0.99	0.84	2.59
DC0NDDZ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	2.85	0.82	0.15	0.71
DC0X6DO	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.24	2.29	3.28	3.28
DC2ZK87	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	8.87	8.22	0.46	7.83
DCWPOB5	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.17	2.43	2.41	7.7
DCXJNA2	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.01	0.74	5.97	9.24
DCWLR3W	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.01	1.94	0.21	2.2
DCA6J41	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7	11.32	4.19	15.71
DCBFJ7U	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	4.14	1.72	1.07	5.25
DCDC13Q	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.18	1.86	0.71	5.09
DCZLHLS	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.11	7.85	5.25	10.5
DC2MVM6	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.73	4.45	1.21	6.36
DCLJKGK	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	5.01	3.95	12.91	15.33
DCNKCUV	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.46	3.32	1.62	7.39
DCEQQJY	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.14	2.45	3.04	7.96
DC5X33B	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.93	0.91	1.88	6.43
DCI2IJ3	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	6.33	5.29	8.32	12.54
DC1QK32	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.18	1.56	3.06	6.61
DCIVNUX	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	5.67	5.19	1.73	3.51
DC7LFYZ	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.64	1.9	4.26	8.23
DCZEAQA	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.74	9.16	3.17	10.45
DC9GQ7B	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	3.15	2.6	1.37	2.77
DC0WXBB	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.39	2.33	3.17	6.35
DCMMTUY	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.45	1.7	0.51	0.24
DCWYJIF	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.02	5.08	2.39	4.65
DCAFQBG	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.59	3.52	4.43	5.34
DCM9TBI	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.52	3.1	2.1	1.35
DCLBVE5	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.68	3.07	0.93	6.72
DCX9LJX	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.04	2.57	0.57	5.13
DCPILFH	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	8.51	7.84	0.75	10.85
DCTM1LT	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.82	1.78	4.31	7.46
DCVUBB0	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.96	6.69	8.7	9.97
DC38RMV	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.06	0.56	0.77	0.71
DC8EJI1	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	12.58	15.44	13.85	12.25
DCMZNJ7	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	15.73	16.92	16.39	16.05
DCYQ089	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.72	2.75	5.68	8.18
DCVXMPX	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.79	6.17	5.02	8.55
DC39P7E	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.33	3.03	0.44	6.01
DCGGCKA	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	5.24	3.41	0.41	7.66
DCSRRDC	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMSG91J	ER819762	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.6	9.55	4.77	6.77
DCRKZ1C	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.19	0.95	2.68	6.61
DCDIEF2	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.8	0.93	1.47	5.65
DCL7TNI	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.04	0.07	2.13	9.72
DC88BRL	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.81	0.42	1.56	6.23
DC1QDKY	DMB5A80	SNX-2112	Investigative	0	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	5.01	3.49	1.95	7.82
DC24OZ1	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	1.79	1.51	0.45	4.69
DC93ESL	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	0.54	4.78	0.51	7
DCW43QB	DMB5A80	SNX-2112	Investigative	0	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	20.08	20.08	32.18	32.21
DCA96UA	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	12.21	12.82	6.79	16.19
DC2P2K0	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	1.82	0	3.66	7.13
DC38ERZ	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	5.43	3.91	0.75	5.68
DC3JG56	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.38	3.13	1.85	5.5
DC2RGU3	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	7.15	8.21	0.86	10.9
DC801JN	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	4.69	1.81	6.12	8.94
DCCLDRK	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	0.14	0.24	7.2	8.88
DCQFSS3	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.68	0.09	0.25	3.19
DCCQX5B	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.55	2.3	4.77	7.07
DC0FJPG	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	17.06	17.22	4.37	17.59
DC4TXJD	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.43	2.85	0.16	8.63
DCSGE3K	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	5.54	1.77	1.11	2.47
DC70BBV	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	4.12	2.69	8.65	9.93
DCS8LTK	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	20.7	21.86	22.48	24.8
DCM5DGZ	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	5.74	5.13	1.67	7.67
DCOS7Z3	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	10.1	10.32	9.79	14.77
DC54AX7	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.56	20.89	13.13	14.89
DCYF5KP	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.21	8.74	8.37	9.58
DCBJ5ZR	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	8.51	6.06	8.29	10.2
DCEL6FF	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.39	2.72	3.03	8.28
DCFTFMH	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	1.02	1.06	5.34	7.96
DC8B6X5	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	3.4	4.94	3.44	7.86
DCP11S1	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	2.67	3.45	7.46	9.2
DCJCHWI	DMB5A80	SNX-2112	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.51	3.1	1.12	7.24
DC2WE6M	DMB5A80	SNX-2112	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	2.05	1.93	0.96	5.2
DCS3TSH	DMB5A80	SNX-2112	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	9.46	10.64	8.26	13.15
DCVBB2F	DMB5A80	SNX-2112	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.52	7.13	0.48	7.23
DC891HL	DMB5A80	SNX-2112	Investigative	0	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	7.51	3.5	10.24	5.91
DCZUIVN	DMB5A80	SNX-2112	Investigative	0	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.33	6.51	4.07	7.82
DCR784D	DMB5A80	SNX-2112	Investigative	0	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.98	2.73	2.7	3.62
DCGTG2C	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	3.51	2.55	4.05	5.11
DC6IMWR	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	5.48	0.17	8.33	9.12
DC2RLZU	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.05	5.45	4.39	8.45
DC30C40	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.61	1.03	0.59	6.5
DC9YYGB	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	12.54	11.8	6.05	14.45
DC4164Z	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.15	9.64	6.48	9.47
DCU7ND2	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.58	4.65	2.33	7.14
DCWB0RC	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.78	4.46	0.69	7.78
DC2W81A	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.04	1.71	1.38	5.58
DCF0Y2J	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.98	8.24	0.36	9.68
DCI70I0	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	3.21	2.95	9.89	12.76
DCLUOV9	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	4.44	4.24	4.39	6.82
DCO48A5	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	2.83	2.05	4.4	7.56
DCKUWNC	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	1.68	1.33	5.28	8.18
DCHYKY9	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.03	2.36	1.85	6.21
DCKCJYE	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	2.21	0.2	1.63	6.74
DCA1EJW	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	2.81	1.74	5.96	8.75
DCBBXWJ	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.61	3.37	2.2	6.34
DC5D886	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.7	0.81	2.85	6.14
DC7KLTO	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.5	4.05	4.43	8.22
DC0OURA	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	6.69	5.9	7.98	11.77
DCXS1QQ	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	2.32	1.09	0.18	4.21
DCQ0USO	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.77	2.03	1.61	4.72
DCPHVNA	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	4.89	2.56	4.7	8.09
DCNOMJ4	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	10.62	9.12	12.13	14.93
DCBJX51	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	0.67	0.32	1.99	4.21
DC7881Q	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	13.82	13.52	8.96	15.32
DC65VHH	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.17	4.28	5.95	9.25
DCASNR4	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	4.39	1.72	1.09	5.09
DCER53Z	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	8.52	5.28	7.61	11.32
DCEC3K1	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.03	5.59	5.78	9.74
DC9HIBF	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.56	1.65	4.78	7.79
DCMSZZQ	DMB5A80	SNX-2112	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	7.06	4.41	7.71	12.77
DCIQW8V	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	9.19	7.85	7.55	10.48
DCVI0RN	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.88	4.33	2.16	7.21
DCZVWLF	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	7.24	5.32	4.41	9.96
DCRA17M	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	2.94	2.18	2.63	7.8
DC6L3R1	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.52	3.92	3.99	7.88
DCH3CLJ	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	0.67	0.83	4.02	6.28
DCCF31U	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	11.41	14.25	3.92	13.35
DCBUEBJ	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	3.26	4.99	3.56	7.07
DCYQVWB	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	8.29	10.73	9.69	12.23
DCZ025U	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	18.99	19.04	19.14	24.46
DCTRQ8I	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	14.95	18.83	17.85	21.73
DCINTEM	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.84	4.58	2.5	6.17
DCE83OL	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	6.65	7.06	9.46	12.31
DCZN7ND	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	3.34	2.59	1.49	5.74
DC2Q7Y0	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	10.71	12.32	10.6	15.07
DCAJULH	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.35	2.72	0.91	5.31
DCUV7VP	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.68	1.21	2.43	6.39
DC2ZD5K	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	12.37	12.21	0.48	14.22
DC0EUZC	DMB5A80	SNX-2112	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	9.58	10.33	9.61	12.19
DC1IIBI	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	8.17	8.04	4.61	9.09
DCANRJR	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	8.43	10.28	11.67	11.83
DCXP2JZ	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	7.39	7.12	5.9	10.87
DCD7R11	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	1.4	3.58	4.22	4.96
DC3Q9HX	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.18	3.58	5.16	7.93
DC9HM8I	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	5.78	7.25	6.49	9.48
DC4NSF8	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.47	6.09	3.73	8.8
DC7SB24	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.13	5.91	4.62	8.79
DCO90PJ	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	10.9	9.21	7.17	12.02
DC3IBVQ	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	3.87	4.65	1.83	6.31
DCMWXGG	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.88	2.46	3.15	4.83
DC5OEZQ	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	5.23	8.05	7.55	12.14
DCGHUWR	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	0.36	0.16	3.71	5.02
DCFUW4Z	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.79	4.19	0.95	6.16
DC6EM8H	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	21.49	22.39	5.28	22.33
DCIG8QC	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	5.15	4.98	5.65	8.43
DCED0WS	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	6.55	7.39	6.27	9.81
DCR3QZ4	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	7.84	7.65	8.44	11.06
DCQCD32	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	5.03	4.06	2.98	7.57
DCHMH0N	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8.14	6.9	10.62	7.89
DCSUVTN	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	5.82	5.61	9.73	12.8
DC7X0HL	DMB5A80	SNX-2112	Investigative	0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.83	2.23	0.43	1.34
DCX1QTU	DMB5A80	SNX-2112	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	2.52	1.45	0.04	3.25
DCMTTD3	DMB5A80	SNX-2112	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	8.32	6.62	0.9	8.46
DCKXLSW	DMB5A80	SNX-2112	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	5.22	3.11	0.03	5.61
DCWM032	DMB5A80	SNX-2112	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.58	6.28	5.06	8.88
DCYPS1H	DMB5A80	SNX-2112	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.63	3.07	0.17	4.48
DCH19O2	DMB5A80	SNX-2112	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	9.7	8.25	6.08	11.28
DCM8Y2J	DMB5A80	SNX-2112	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.87	5.96	1.14	6.46
DCT6FGM	DMB5A80	SNX-2112	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.89	3.9	0.94	5.66
DC1NNPI	DMB5A80	SNX-2112	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	11.13	12.19	9.87	13.85
DCDSY16	DMB5A80	SNX-2112	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	4.4	4.36	1.96	6.96
DCXOV9U	DMB5A80	SNX-2112	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.96	1.91	0.86	5.25
DCT7HLP	DMB5A80	SNX-2112	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	5.11	0.39	0.06	4.03
DC8CCTB	DMB5A80	SNX-2112	Investigative	0	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	7.68	3.64	0.15	5.91
DCSWL8L	DMB5A80	SNX-2112	Investigative	0	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	2.68	0.16	0.15	4.55
DCTGYZ1	DMB5A80	SNX-2112	Investigative	0	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	8.99	6.86	3.6	9.38
DCVRFLD	DMB5A80	SNX-2112	Investigative	0	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	11.35	9.25	4.77	10.77
DCMAJJO	DMB5A80	SNX-2112	Investigative	0	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	2.53	3.78	2.09	6.29
DCS3PQY	DMB5A80	SNX-2112	Investigative	0	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	18.67	17.02	8.28	19.58
DCW9LN8	DMB5A80	SNX-2112	Investigative	0	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.71	0.79	1.88	5.88
DC7DPJ7	DMB5A80	SNX-2112	Investigative	0	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	6.54	6.05	6.58	10.77
DC5POBB	DMB5A80	SNX-2112	Investigative	0	DMMWSUL	Lomustine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.58	3.14	0.39	5.07
DCVB3UT	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	9.68	8.58	2.04	9.12
DCBWJZ0	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	0.28	0.31	2.18	5.67
DCROH76	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	6.65	5.54	2.6	8.39
DCED7WU	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.52	4.22	3.24	9.32
DCS69B1	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	1.64	0.5	2.05	7.18
DCT55JS	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	3.92	4.8	0.21	4.6
DC9A4U8	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	7.05	7	6.53	12.26
DCACM2Y	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.66	4.12	0.39	7.51
DC131Y6	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.36	7.64	2.74	10.52
DCD85H8	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	12.47	11.81	4.86	12.08
DCZF72G	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	3.6	5.65	1.34	7.88
DCX51A2	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.35	4.03	0.38	6.91
DC8PFWG	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	7.19	4.07	2.87	9.11
DCGN6SU	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	4.25	2.08	0.12	6.96
DCLWM6F	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	0.33	1.02	1.91	5.06
DCU5OT6	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	8.84	8.68	5.21	11.95
DCINNS0	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	4.98	1.95	0.09	5.58
DCRU5RJ	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	12.54	11.89	6.43	12.92
DCDQ8J5	DMB5A80	SNX-2112	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.78	2.23	0.22	1.1
DC0MWPH	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	4.03	2.23	0.64	4.56
DCH8KKC	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	3.66	1.73	5.17	8.08
DCGIK92	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	1.27	0.42	1.19	5.78
DC9RMD3	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.65	0.85	0.87	5.06
DCLNQ1K	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.96	2.35	3.53	7.33
DCFH5R0	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	7.98	7.18	9.28	12.6
DC9LRDG	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.36	1	0.2	4.38
DCDU3FX	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	6.44	5.54	5.36	9.37
DCAK19P	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	0.8	0.1	3.24	7.2
DC6P74Q	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	1.82	1.24	1.09	4.57
DCWRB1T	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	11.34	8.09	7.2	11.42
DCXWD0G	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	4.82	3.49	1.54	6.71
DC1KZG4	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	2.18	1.04	0.31	4.61
DCZYVAG	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	3.53	3.56	4.75	8.59
DC2C9Z2	DMB5A80	SNX-2112	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.95	2.68	2.18	7.37
DC0C2N6	DMD7X1O	Dexrazoxane	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	"Sarcoma, Soft Tissue"	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC6DF7D	DMD7X1O	Dexrazoxane	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	34.42	27.13	19.91	30.69
DCWG9CN	DMD7X1O	Dexrazoxane	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.43	7.51	4.93	8.93
DCF6K8B	DMD7X1O	Dexrazoxane	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	7.83	14.04	1.54	9.06
DC5A2ZB	DMD7X1O	Dexrazoxane	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.29	2.88	2.48	4.31
DCQI14E	DMD7X1O	Dexrazoxane	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.99	1.61	1.97	5.43
DCUJ6GH	DMD7X1O	Dexrazoxane	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	27.06	31.98	10.23	29.58
DCT3MUJ	DMD7X1O	Dexrazoxane	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	9.88	14.2	1.03	10.73
DC2NHBR	DMD7X1O	Dexrazoxane	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	5.05	12.57	2.86	8.44
DCSJSQ1	DMD7X1O	Dexrazoxane	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.53	5.37	3.31	4.47
DC6RWLM	DMD7X1O	Dexrazoxane	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	5.78	6.69	4.74	6.09
DCP5SGC	DMD7X1O	Dexrazoxane	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	4.86	6.4	3.45	4.3
DCTCEUM	DMD7X1O	Dexrazoxane	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.79	7.42	5.44	8.46
DC0AG9C	DMD7X1O	Dexrazoxane	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.26	5.56	3.88	4.63
DCERJ1Z	DMD7X1O	Dexrazoxane	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	5.92	6.92	1.24	8.7
DC7DK9Y	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.6	6.3	2.8	7.99
DCQIMP8	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	17.17	17.76	18.84	19.03
DCJVEI6	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	21.09	16.55	21.37	21.72
DCR2GLE	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.2	5.04	6.19	5.67
DCOIWE8	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.22	6.23	7.88	7.67
DCIXDA3	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	5.7	7.8	8.22	8.05
DC0TNEO	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	7.03	11.49	10.53	10.77
DCU1UM1	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.73	3.72	5.21	4.4
DCNK1KQ	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	25.71	24.16	22.56	23.05
DCS4CV5	DMD7X1O	Dexrazoxane	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.4	4.73	1.12	3.35
DCBJZ4P	DMD7X1O	Dexrazoxane	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.71	4.59	0	6.07
DCNJP1G	DMD7X1O	Dexrazoxane	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.91	6.66	5.19	9.31
DC2MOEI	DMD7X1O	Dexrazoxane	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.95	6.11	5.64	8.78
DCVBD8W	DMD7X1O	Dexrazoxane	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	9.56	13.07	14.75	14.78
DCTTHOU	DMD7X1O	Dexrazoxane	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.84	11.13	1.12	12.92
DCBDUYW	DMD7X1O	Dexrazoxane	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.05	1.57	0.78	4.38
DC9MH7O	DMD7X1O	Dexrazoxane	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.85	0.68	1.13	4.79
DCK74MY	DMD7X1O	Dexrazoxane	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.14	0.25	4.05	5.58
DC99003	DMD7X1O	Dexrazoxane	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	10.82	7.85	9.29	10.61
DCAAHOU	DMD7X1O	Dexrazoxane	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.97	7.54	0.9	6.61
DCEBDA6	DMD7X1O	Dexrazoxane	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.68	6.89	3.3	5.38
DCCIOBK	DMD7X1O	Dexrazoxane	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	5.75	9.72	6.96	8.08
DCIFVCJ	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	14.34	13.59	12.37	12.28
DC1CXSU	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	17.16	15.52	13.26	13.41
DCSZUSY	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	13.8	12.75	9.98	14.73
DC3V7JA	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.77	5.72	5.54	5.48
DC6W5PQ	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.2	5.99	6.48	5.99
DCMA5UE	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.22	8.19	9.23	9.03
DCIADZ5	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.59	7.31	7.63	8.27
DCI81IH	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	9.37	11.8	9	9.27
DCFF846	DMD7X1O	Dexrazoxane	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	19.21	16.33	16.24	19.35
DCRZ9QZ	DMD7X1O	Dexrazoxane	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.51	1.07	2.25	4.85
DC3F1DV	DMD7X1O	Dexrazoxane	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.12	5.49	6.94	9.82
DCLVNX3	DMD7X1O	Dexrazoxane	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.57	1.04	0.78	3.92
DCVKRR0	DMD7X1O	Dexrazoxane	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.31	4.26	2.76	8.81
DCHRYH5	DMD7X1O	Dexrazoxane	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.86	0.31	2.96	6.22
DC1QQZG	DMD7X1O	Dexrazoxane	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.29	0.88	0.8	3.24
DCU0PJ7	DMD7X1O	Dexrazoxane	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.54	2.99	4.42	6.98
DC6I5KA	DMD7X1O	Dexrazoxane	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.65	2.75	4.35	7.67
DCTC27D	DMD7X1O	Dexrazoxane	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	10.64	8.82	9.22	12.18
DC2HVG4	DMD7X1O	Dexrazoxane	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1	0.89	0.74	3.99
DCNU4DP	DMD7X1O	Dexrazoxane	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.23	1.55	3.23	6.75
DCXWYM2	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	17.76	15.23	15.53	18.58
DCLU4RL	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.24	3.81	4.09	6.87
DC5WJ3G	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	14.52	7.56	9.1	11.56
DCSOJ0S	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.12	2.3	3.46	6.77
DCEIHBB	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.28	0.84	0.82	3.97
DCGOH7K	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3	4.21	0.49	9.27
DCCYSX6	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.75	0.88	1.86	4.66
DC20PZG	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.54	3.35	4.29	6.14
DCWBM6B	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.78	8.2	4.93	10.07
DCLU9JC	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.85	2.62	3.93	7.12
DCP2C9O	DMD7X1O	Dexrazoxane	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	13.45	12.97	6.66	13.74
DC08A6J	DMD7X1O	Dexrazoxane	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.46	4.56	6.37	5.94
DCXB04T	DMD7X1O	Dexrazoxane	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	11.21	11.86	8.44	11.96
DC97S69	DMD7X1O	Dexrazoxane	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.12	0.47	1.16	1.95
DC4TJDC	DMD7X1O	Dexrazoxane	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.74	6.05	3.42	4.39
DCW1NRL	DMD7X1O	Dexrazoxane	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.64	8.27	6.16	8.38
DC8LFP1	DMD7X1O	Dexrazoxane	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	21.04	21.7	12.71	21.66
DCU4AWS	DMD7X1O	Dexrazoxane	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.22	2.27	2.54	5.69
DCGDUCI	DMD7X1O	Dexrazoxane	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	6.87	12.96	2.01	7.98
DCH5P1U	DMD7X1O	Dexrazoxane	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.71	5.87	3.73	7.47
DCM64IW	DMD7X1O	Dexrazoxane	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	12.39	6.72	9.35	9.51
DCDULKU	DMD7X1O	Dexrazoxane	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.65	7.22	8.35	10.16
DC0V9MD	DMD7X1O	Dexrazoxane	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.48	0.56	5.34	7.24
DCVN9WI	DMD7X1O	Dexrazoxane	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.41	0.52	3.22	4.59
DCQBYNM	DMD7X1O	Dexrazoxane	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.14	2.61	3.44	6.52
DC7WXOS	DMD7X1O	Dexrazoxane	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.43	4.8	3.95	7.95
DCXUJ1P	DMD7X1O	Dexrazoxane	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	15.5	17.66	1.05	17.78
DC57KXY	DMD7X1O	Dexrazoxane	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.45	3.28	3.73	9.49
DCIGWQD	DMD7X1O	Dexrazoxane	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	13.87	14.48	12.67	16.08
DCUH479	DMD7X1O	Dexrazoxane	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	12.34	7.65	8.41	11.36
DCANKH6	DMD7X1O	Dexrazoxane	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	12.05	12.95	1.42	14.55
DCH589E	DMD7X1O	Dexrazoxane	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.74	4.2	4.1	6.84
DC7DS9X	DMD7X1O	Dexrazoxane	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.55	2.5	2.15	4.97
DCRKKXC	DMD7X1O	Dexrazoxane	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	5.32	13.05	11.51	12.88
DCH4UL3	DMD7X1O	Dexrazoxane	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	7.47	11.31	12.57	16.01
DCKSJL9	DMD7X1O	Dexrazoxane	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	17.31	17.29	0.48	20.28
DC9B1RY	DMD7X1O	Dexrazoxane	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.06	5.35	2.38	4.91
DC7BS8N	DMD7X1O	Dexrazoxane	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.46	2.16	1.29	6.1
DCUV444	DMD7X1O	Dexrazoxane	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.85	3.47	2.5	1.99
DCRP2NI	DMD7X1O	Dexrazoxane	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	13.49	8.97	8.79	11.88
DCZ3ARH	DMD7X1O	Dexrazoxane	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.62	5.24	6.38	9
DCW8MHS	DMD7X1O	Dexrazoxane	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.5	8.6	8.03	12.09
DCIMVC4	DMD7X1O	Dexrazoxane	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	7.24	8.5	5.19	4.57
DCUB7X7	DMD7X1O	Dexrazoxane	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.68	4.06	1.51	3.07
DC6SQHE	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.2	4.39	2.66	2.53
DC4RZEE	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.67	4.56	1.82	1.96
DCXJGV9	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	11.83	10.12	10.22	13.24
DCUV45F	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.96	6.17	4.62	11.42
DCMIRRM	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	15.34	14.9	2.44	17.84
DC49UWX	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	7.02	6.75	6.41	9.36
DC0KI6U	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.29	10.58	7.34	6.28
DCQ7AOZ	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.53	4.96	4.32	8.57
DCOQCEH	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	13.72	16.85	16.81	17.59
DCC8N4R	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	4.86	6.48	8.08	9.45
DCIP6XS	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	13.73	13.63	10.27	14.96
DCFOZMF	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	4.1	3.86	5.47	9.03
DC0D80K	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	12.5	11.9	8.18	17.6
DCWG49T	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	9.72	13.75	12.09	12.07
DCV39FT	DMD7X1O	Dexrazoxane	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.4	11.02	7.14	5.54
DCDM3N4	DMD7X1O	Dexrazoxane	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	11.68	11.93	10.11	14.1
DC2MXH6	DMD7X1O	Dexrazoxane	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	9.64	6.66	8.22	11.4
DCLYG85	DMD7X1O	Dexrazoxane	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.83	5.81	3.2	7.03
DCNN62A	DMD7X1O	Dexrazoxane	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	5.61	7.85	6.42	9.9
DCSLDCT	DMD7X1O	Dexrazoxane	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.24	7.04	2.85	8
DCL6CYB	DMD7X1O	Dexrazoxane	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	4.15	7.55	2.39	9.87
DCQO4QW	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	14.47	10.71	14.68	15.96
DC1KJRL	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.14	1.18	5.68	8.12
DCY04EN	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	6.83	5.46	12.23	14.78
DCAIHWX	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	7.25	7.38	7.17	8.54
DCC9ZKZ	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	13.17	13.35	14.61	16.14
DCS8TWL	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.97	2.98	3.82	10.39
DC12OS2	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	8.78	8.92	12.87	14.56
DCV5YMA	DMD7X1O	Dexrazoxane	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.35	2.73	0.24	4
DC0XDXE	DMD7X1O	Dexrazoxane	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.94	4.65	2.58	2.66
DCSAX9E	DMD7X1O	Dexrazoxane	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.78	2.19	2.15	3.73
DCXUJVR	DMD7X1O	Dexrazoxane	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.66	3	0.72	5.75
DCZRTXP	DMD7X1O	Dexrazoxane	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	0	1.61	0.15	3.16
DCH9MEI	DMD7X1O	Dexrazoxane	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	5.17	7.27	6.2	7.44
DCS7L67	DMD7X1O	Dexrazoxane	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	10.64	12.46	10.24	14.64
DC9LPXA	DMD7X1O	Dexrazoxane	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	14.17	12.28	10.76	12.52
DCHIDTE	DMD7X1O	Dexrazoxane	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	8.06	9.84	6.87	10.31
DCYHEMM	DMD7X1O	Dexrazoxane	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	13.15	15.39	13.59	15.52
DCYMWKI	DMD7X1O	Dexrazoxane	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.25	8.62	7.62	8.83
DC0ZC79	DMD7X1O	Dexrazoxane	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.13	7.43	4.56	6.66
DCZSPZL	DMD7X1O	Dexrazoxane	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	13.34	16.62	16.21	17.41
DCNZJN1	DMD7X1O	Dexrazoxane	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	8.69	6	3.6	5.62
DC6OOK0	DMD7X1O	Dexrazoxane	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.41	3.78	1.94	3.89
DCEDXDY	DMD7X1O	Dexrazoxane	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.61	4.82	4.66	8.39
DCNWR2G	DMD7X1O	Dexrazoxane	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.79	5.95	2.14	7.54
DCDWCHN	DMD7X1O	Dexrazoxane	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	8.42	9.67	4.37	9.07
DCHEK5J	DMD7X1O	Dexrazoxane	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.77	1.84	0.21	3.01
DCTYT1Y	DMD7X1O	Dexrazoxane	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.11	0.84	0.71	4.35
DCPHWFA	DMD7X1O	Dexrazoxane	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.17	5.66	4.52	5.55
DC7BZXV	DMD7X1O	Dexrazoxane	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4	3.88	6.19	8.58
DC2PDK2	DMD7X1O	Dexrazoxane	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.95	3.65	9.7	11.18
DCTINBA	DMD7X1O	Dexrazoxane	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.88	2.83	0.22	4.97
DCITZS2	DMD7X1O	Dexrazoxane	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.92	5.77	5.35	5.7
DCFC2AE	DMD7X1O	Dexrazoxane	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.17	5.33	2.7	2.82
DCOX77X	DMD7X1O	Dexrazoxane	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.63	3.14	3.69	7.09
DCRW49A	DMD7X1O	Dexrazoxane	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	4.04	5.29	2.96	8.33
DC28NMA	DMD7X1O	Dexrazoxane	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.29	9.41	2.86	10.62
DCSGCN7	DMD7X1O	Dexrazoxane	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.39	3.6	5.05	8.34
DCENJWA	DMD7X1O	Dexrazoxane	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.61	1.14	2.22	5
DCTCFXE	DMD7X1O	Dexrazoxane	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.27	3.87	2.96	6.87
DCORI0M	DMD7X1O	Dexrazoxane	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.87	5.52	1.88	6.82
DCTCA5J	DMD7X1O	Dexrazoxane	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.37	3.77	3.83	6.74
DCV95FC	DMD7X1O	Dexrazoxane	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.91	4.39	1.62	1.52
DCEJ2T4	DMD7X1O	Dexrazoxane	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	11.74	12.68	8.93	14.75
DCZG2OX	DMD7X1O	Dexrazoxane	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.28	3.48	0.51	5.24
DCMYW3J	DMD7X1O	Dexrazoxane	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.01	7.24	4.64	9.48
DCVWZSG	DMD7X1O	Dexrazoxane	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.6	5.99	0.18	5.19
DC8OLMY	DMD7X1O	Dexrazoxane	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.28	6.24	4.78	4.54
DC3DY1N	DMD7X1O	Dexrazoxane	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.71	6.7	7.28	7.4
DC8I1B8	DMD7X1O	Dexrazoxane	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.43	1.02	2.4	2.56
DCSPNNK	DMD7X1O	Dexrazoxane	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	12.2	11.74	14.16	14.59
DC4E1SJ	DMD7X1O	Dexrazoxane	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.92	3.96	1.79	1.82
DCTE1X3	DMD7X1O	Dexrazoxane	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.87	5.4	2.34	6.21
DCTTHFW	DMD7X1O	Dexrazoxane	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	10.02	12.71	1.78	9.23
DCRD96U	DMD7X1O	Dexrazoxane	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	10.96	19.96	10.51	14.69
DCM2ER6	DMD7X1O	Dexrazoxane	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.35	3.86	2.18	2.67
DCL6KH3	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.29	10.88	10.72	10.58
DCMXSR3	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.66	8.21	8.83	8.4
DCHG8ET	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.38	12.41	12.21	12.18
DC5J18O	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.6	8.33	8.64	8.67
DC3358W	DMD7X1O	Dexrazoxane	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.8	7.98	7.52	9.5
DCEZ8RC	DMD7X1O	Dexrazoxane	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	16.11	15.75	19.98	20.32
DCMMBYZ	DMD7X1O	Dexrazoxane	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.11	6.96	5.67	7.08
DC43YBL	DMD7X1O	Dexrazoxane	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.49	6.75	1.77	6.61
DCDGH62	DMD7X1O	Dexrazoxane	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.29	4.08	4.92	6.77
DCPT2NW	DMD7X1O	Dexrazoxane	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.99	6.15	9.66	10.07
DCI1FKJ	DMD7X1O	Dexrazoxane	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	8.46	17.05	2.76	4.36
DCAFZRW	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.18	4.08	5.16	4.74
DCQQ6D4	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.41	7.4	4.74	4.77
DCE6P1Q	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	8.02	9.27	13.62	12.68
DCMDXSC	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	8.16	13.05	11.99	11.9
DCZE2RW	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.74	0.83	0.12	0.03
DCZBKKJ	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.76	8.55	7.99	7.89
DC5AO6U	DMD7X1O	Dexrazoxane	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.61	8.99	9.72	11.57
DCO7R0J	DMD7X1O	Dexrazoxane	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.82	3.99	3.9	7.53
DCBUHU8	DMD7X1O	Dexrazoxane	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.36	1.7	3.41	6.93
DCST2BW	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.9	9.15	10.76	12.21
DCF2O13	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.43	4.97	7.88	10.12
DCH8JHY	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.08	8.13	10.03	11.64
DC5S9Q2	DMD7X1O	Dexrazoxane	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.29	5.08	4.33	5.35
DC4RZK9	DMD7X1O	Dexrazoxane	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.37	12.09	6.06	10.92
DCSFKJ5	DMD7X1O	Dexrazoxane	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.98	11.61	9.43	11.15
DCDFI7C	DMD7X1O	Dexrazoxane	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.9	15.3	9.81	13.86
DCS9R55	DMD7X1O	Dexrazoxane	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.82	11.91	1.56	5.93
DC77CLZ	DMD7X1O	Dexrazoxane	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.81	11.01	5.05	8.56
DCPYG7F	DMD7X1O	Dexrazoxane	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.42	8.78	10.87	11.15
DC2DQJN	DMD7X1O	Dexrazoxane	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.07	1.88	5.35	6.74
DCBQ881	DMD7X1O	Dexrazoxane	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.32	2.59	0.42	1.76
DCE4OD3	DMD7X1O	Dexrazoxane	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.54	7.3	5.02	4.62
DCGDMHM	DMD7X1O	Dexrazoxane	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.76	10.33	11.09	11.56
DCS7DJ2	DMD7X1O	Dexrazoxane	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.6	4.18	14.35	14.56
DC9ATAS	DMD7X1O	Dexrazoxane	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.11	9.07	9.91	11.24
DCVU73Y	DMD7X1O	Dexrazoxane	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	9.51	10.7	7.7	11.91
DCMMWBR	DMD7X1O	Dexrazoxane	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.79	1.08	0.93	2.07
DCRTHFJ	DMD7X1O	Dexrazoxane	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.59	5.7	7.44	9.36
DCB5S85	DMD7X1O	Dexrazoxane	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.27	4.58	4.23	7.46
DC10U80	DMD7X1O	Dexrazoxane	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.16	4.8	5.24	9.39
DCGDL6W	DMD7X1O	Dexrazoxane	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.35	5.89	7.44	8.33
DCP2XHG	DMD7X1O	Dexrazoxane	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.68	4.66	8.42	11.08
DCKLQOT	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	16.08	16.65	19.02	19.97
DCXM80C	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.62	5.24	0.47	9.38
DCVVOAF	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.54	5.23	3.45	3.25
DCAJEDQ	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	12.64	11.8	11.91	16.29
DCYQULA	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.95	7.07	0.39	9.07
DC1K7Y9	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	6.39	9.48	10.98	12.83
DCS74O3	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.39	11.41	13.17	14.86
DCNZVC7	DMD7X1O	Dexrazoxane	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.37	3.8	5.41	5.07
DC9419N	DMD7X1O	Dexrazoxane	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.12	4.64	3.49	6.65
DCF08EK	DMD7X1O	Dexrazoxane	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.3	3.77	3.75	3.76
DC4YS83	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.79	8.41	12.17	13.26
DCN4OL1	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.2	6.09	7.56	9.35
DC62I8L	DMD7X1O	Dexrazoxane	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.19	6.36	5.58	5.7
DC3Q82R	DMD7X1O	Dexrazoxane	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.36	9.27	7.04	7.57
DC5D4VM	DMD7X1O	Dexrazoxane	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.84	6.73	0.64	0.93
DCOIAZ6	DMD7X1O	Dexrazoxane	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	9.23	8.67	8.27	9.82
DCNSJ27	DMD7X1O	Dexrazoxane	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	9.83	11.93	2.93	5.09
DC2ZA2O	DMD7X1O	Dexrazoxane	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.68	4.17	1.16	4.15
DCWPZBL	DMD7X1O	Dexrazoxane	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.83	0.28	4.98	5.55
DCN3RCX	DMD7X1O	Dexrazoxane	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	13.9	13.21	12.78	17.13
DC5SVAF	DMD7X1O	Dexrazoxane	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.14	5.12	9.03	12.37
DC648R7	DMD7X1O	Dexrazoxane	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.91	4.19	2.96	3.08
DCVSYU5	DMD7X1O	Dexrazoxane	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.49	4.86	4.99	6.12
DCDK6IJ	DMD7X1O	Dexrazoxane	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.24	5.63	3.12	6.31
DCJCNB4	DMD7X1O	Dexrazoxane	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.57	4.03	0	6.12
DCACPAN	DMD7X1O	Dexrazoxane	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.29	8.26	3.89	9.31
DCNASI5	DMD7X1O	Dexrazoxane	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.48	5.43	3.5	5.98
DC9T2KH	DMD7X1O	Dexrazoxane	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.58	8.93	0.12	5.83
DCJ2WJG	DMD7X1O	Dexrazoxane	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.53	9.02	2.57	2.48
DCTYD32	DMD7X1O	Dexrazoxane	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.32	8.83	4.01	8.54
DCPC4UF	DMD7X1O	Dexrazoxane	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.37	8.26	0.43	6.58
DCHWF7E	DMD7X1O	Dexrazoxane	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.98	1.33	0.21	4.48
DCF2FWX	DMD7X1O	Dexrazoxane	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.8	11.4	1.6	5.73
DC6TAXI	DMD7X1O	Dexrazoxane	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.67	7.21	1.08	4.08
DC22OES	DMD7X1O	Dexrazoxane	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.81	9.1	4.37	8.46
DC2WMFP	DMD7X1O	Dexrazoxane	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.25	5.66	5.13	6.8
DCKDUPT	DMD7X1O	Dexrazoxane	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.45	2.64	3.24	3.94
DCYOH6G	DMD7X1O	Dexrazoxane	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.91	0.75	0.07	0.5
DCPAZ43	DMD7X1O	Dexrazoxane	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.53	3.98	0.75	3.78
DCL23F7	DMD7X1O	Dexrazoxane	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.74	7.78	0.22	5.63
DCPHNN9	DMD7X1O	Dexrazoxane	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.89	7.56	4.08	5.27
DCJLD06	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.85	4.21	2.78	3.31
DC0ZVD8	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	11.78	12.93	12.66	12.62
DCLIEL1	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	14.08	14.46	13.99	13.99
DC1Q8V3	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.08	8.56	7.91	7.99
DCNTE3W	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.04	7.52	7.07	6.92
DCFXNGN	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.39	6.63	7.38	6.17
DCDHPM6	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.25	12.39	12.95	12.83
DCYTOWJ	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.3	1.61	3.83	4.65
DCUFIMA	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.51	7.63	7.41	8.07
DCEH0BU	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	12.78	17.14	17.43	17.11
DC8GDJ0	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	14.17	21.58	23.16	22.41
DCV6X67	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.11	4.05	3.71	2.84
DCT0SXY	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.04	6.76	3.73	5.01
DC7DVYH	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	11.26	15.62	14.46	14.64
DCQBX30	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.94	4.61	5.18	4.94
DCCOEVH	DMD7X1O	Dexrazoxane	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.84	9.15	8.34	8
DCEN28C	DMD7X1O	Dexrazoxane	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.62	1.51	2.45	4.34
DCCUOVY	DMD7X1O	Dexrazoxane	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.67	2.46	4.93	6.08
DCI3I53	DMD7X1O	Dexrazoxane	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.22	3.16	1.64	2.8
DC4GDII	DMD7X1O	Dexrazoxane	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.42	7.44	2.57	3.11
DCKTS6Z	DMD7X1O	Dexrazoxane	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.87	5.46	3.44	8.15
DCMKFV2	DMD7X1O	Dexrazoxane	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	9.97	13.61	14.75	15.05
DCTNFW7	DMD7X1O	Dexrazoxane	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.86	4.85	4.38	5.55
DCMH0CE	DMD7X1O	Dexrazoxane	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.09	5.36	6.46	6.61
DCIKNNK	DMD7X1O	Dexrazoxane	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.21	8.4	2	8.24
DCTQVRI	DMD7X1O	Dexrazoxane	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.64	2.34	0.87	0.69
DCZ6J3K	DMD7X1O	Dexrazoxane	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.17	1.96	4.81	4.89
DCZDMBG	DMD7X1O	Dexrazoxane	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.73	8.99	7.33	7.24
DCL1KT5	DMD7X1O	Dexrazoxane	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.61	3.83	0.18	4.81
DC64R63	DMD7X1O	Dexrazoxane	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.73	7.63	1.56	1.24
DCWTX8V	DMD7X1O	Dexrazoxane	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.41	8.84	5.63	7.61
DC3VX0E	DMD7X1O	Dexrazoxane	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	7.46	11.28	0.25	1.11
DCTKJ0P	DMD7X1O	Dexrazoxane	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.76	1.75	2.41	3.21
DCWJVBZ	DMD7X1O	Dexrazoxane	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.44	8.53	5.03	5.67
DCOBXTZ	DMD7X1O	Dexrazoxane	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.08	4.85	4.17	5.42
DC8NYWU	DMD7X1O	Dexrazoxane	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.75	2.2	1.33	2.36
DCM75CL	DMD7X1O	Dexrazoxane	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.44	11.02	5.77	6.25
DC75L66	DMD7X1O	Dexrazoxane	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.42	7.47	2.88	2.86
DCWZY16	DMD7X1O	Dexrazoxane	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.71	6.29	5.17	6.03
DCEJAV2	DMD7X1O	Dexrazoxane	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.05	4.39	0.17	3.89
DC5YFHX	DMD7X1O	Dexrazoxane	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.27	5.67	1.2	4.4
DCJVUY4	DMD7X1O	Dexrazoxane	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.85	10.53	4.55	4.62
DCPYEDW	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.99	1.3	0.51	0.49
DC9GSPC	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.99	3.7	4.57	4.73
DCBKGCV	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.01	6.18	6.27	6.13
DCR9ZVA	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.37	1.71	1.76	1.65
DC2WA1C	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	25.08	28.96	30.29	30.05
DCO661E	DMD7X1O	Dexrazoxane	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.71	11.05	10.47	9.84
DCC8I1V	DMD7X1O	Dexrazoxane	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.89	3.05	1.41	2.23
DCGGIRY	DMD7X1O	Dexrazoxane	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.02	6.71	2.82	2.97
DCZM39Z	DMD7X1O	Dexrazoxane	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.06	5.34	5.59	5.53
DC3RYFP	DMD7X1O	Dexrazoxane	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.51	6.56	5.45	8.5
DCXCT2G	DMD7X1O	Dexrazoxane	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.08	4.35	5.67	7.55
DC60QNN	DMD7X1O	Dexrazoxane	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.5	1.86	2.72	6.29
DCQ6SRQ	DMD7X1O	Dexrazoxane	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.78	6.36	10.72	12.48
DCULCHQ	DMD7X1O	Dexrazoxane	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.03	4.61	3.78	6.3
DC28H93	DMD7X1O	Dexrazoxane	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.12	4.51	0.2	5.44
DCDMOSE	DMD7X1O	Dexrazoxane	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.04	3.51	4.81	6.66
DCWQCOT	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.45	7.62	7.01	9.95
DC8GXLC	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.21	4.65	6.23	8.07
DC0ZC1P	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.25	0.57	3.1	3.26
DCG92IZ	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.64	6.81	4.56	6.21
DC7N1ZO	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.45	1.87	6.26	8.82
DCS11A4	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.97	3.45	6.19	9.83
DCW3T3D	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.45	3.42	6.66	8.91
DCSEE3U	DMD7X1O	Dexrazoxane	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.43	5.48	1.55	8.29
DCPFC9A	DMD7X1O	Dexrazoxane	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.6	1.99	2.07	2.07
DCSVNIF	DMD7X1O	Dexrazoxane	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.25	6.68	3.35	7.4
DCHKJL3	DMD7X1O	Dexrazoxane	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	8.72	9.89	5.13	9.77
DCW9VVX	DMD7X1O	Dexrazoxane	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.54	4.37	3.11	5.96
DCAXL5N	DMD7X1O	Dexrazoxane	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	4.4	10.48	8.54	9.54
DC92L20	DMD7X1O	Dexrazoxane	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.76	3.14	1.84	2.57
DCZGZUU	DMD7X1O	Dexrazoxane	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.02	1.69	1.57	2.04
DC0YMH3	DMD7X1O	Dexrazoxane	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.49	2.32	0.76	0.34
DCDQK9O	DMD7X1O	Dexrazoxane	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	6.69	6.22	5.66	10.62
DCEOD44	DMD7X1O	Dexrazoxane	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.35	4.31	0.16	5.63
DC9QFPU	DMD7X1O	Dexrazoxane	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	6	11.31	7.29	10.92
DCOV65W	DMD7X1O	Dexrazoxane	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.25	2.77	0.51	2.93
DCVYDJP	DMD7X1O	Dexrazoxane	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.43	2	1.12	4.36
DC7TWWJ	DMD7X1O	Dexrazoxane	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	5.42	10.98	8.89	6.78
DCZME8D	DMD7X1O	Dexrazoxane	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	10.16	14.51	4.7	8.56
DCGK6IQ	DMD7X1O	Dexrazoxane	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	4.85	5.03	1.72	1.58
DCTC615	DMD7X1O	Dexrazoxane	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.41	5.37	0.63	5
DC0RMID	DMD7X1O	Dexrazoxane	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6.12	6.34	5	7.5
DCI6IP5	DMD7X1O	Dexrazoxane	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.69	5.91	3.82	8.09
DCC27QL	DMD7X1O	Dexrazoxane	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	11.21	10.61	12.2	12.96
DCMXPMH	DMD7X1O	Dexrazoxane	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.39	4.03	7.31	8.82
DCA0GEN	DMD7X1O	Dexrazoxane	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.24	2.78	6.51	8.28
DCDB3LN	DMD7X1O	Dexrazoxane	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.19	1.44	5.03	7.33
DCUSVS8	DMD7X1O	Dexrazoxane	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.23	6.47	4.45	6.03
DCA03W0	DMD7X1O	Dexrazoxane	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.25	7.59	6.51	6.12
DCW2OML	DMD7X1O	Dexrazoxane	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.31	8.45	12.14	12.14
DCKF60B	DMD7X1O	Dexrazoxane	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.29	6.14	1.62	6.06
DC05J8I	DMD7X1O	Dexrazoxane	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	9.29	12.03	10.27	10.19
DCX9UWS	DMD7X1O	Dexrazoxane	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.75	5.23	6.44	7.08
DCD22N9	DMD7X1O	Dexrazoxane	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	6.53	10.82	1.17	11.01
DCSQAAB	DMD7X1O	Dexrazoxane	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.42	2.36	1.06	1.09
DCM7DXS	DMD7X1O	Dexrazoxane	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.43	4.68	3.67	3.33
DCLY15B	DMD7X1O	Dexrazoxane	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.61	5.12	1.36	4.72
DCGH78C	DMD7X1O	Dexrazoxane	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.69	2.25	3.56	6.48
DCP3DNS	DMD7X1O	Dexrazoxane	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.15	9.18	14.09	13.86
DC1MD7R	DMD7X1O	Dexrazoxane	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.39	7.2	2.6	4.11
DC6J5C7	DMD7X1O	Dexrazoxane	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.5	5.76	1.04	2
DCQZE67	DMD7X1O	Dexrazoxane	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	8.55	9.71	10.17	11.21
DC6HFRD	DMD7X1O	Dexrazoxane	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.53	4.99	0.58	3.76
DC7H860	DMD7X1O	Dexrazoxane	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.38	2.75	1.38	1.69
DCXWL8B	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	7.24	9.94	0.69	13.06
DCHKORY	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.81	7.74	4.56	9.43
DC4T6H2	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	4.97	4.25	2.16	2.38
DCXC9B2	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	8.14	7.4	9.68	12.01
DC5C9SU	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.29	4.46	5.41	8.57
DC4ZGI8	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.32	9.99	0.4	9.82
DC2QFTK	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	10.52	12.19	10.69	13.55
DC8ZDTK	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.75	9.14	8.97	10.66
DCDA8MV	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	11.15	10.21	11.59	13.16
DC7VZKC	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.67	5.88	10.31	12.91
DC1QT8A	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	14.52	17.2	12.42	18.7
DC7U4JQ	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.88	4.51	1.9	8.83
DC75FA9	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.28	6.11	3.88	10.72
DC4PIVY	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	6.6	5.9	10.43	12.71
DCBEI0C	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.64	4.17	1.82	0.6
DCUD8M4	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.46	8.2	7.93	8.24
DC0JXLD	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.62	8.48	7.97	9.9
DC9QT4W	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.03	5.64	10.08	11.21
DCXXT5N	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.56	10.85	5.03	13.38
DCDOJCP	DMD7X1O	Dexrazoxane	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.56	3.36	2.12	7.42
DCLKTMT	DMD7X1O	Dexrazoxane	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.37	3.68	6.15	6.16
DCE4WQQ	DMD7X1O	Dexrazoxane	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.25	4.71	3.96	3.73
DCG5J2E	DMD7X1O	Dexrazoxane	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.29	6.99	4.83	4.81
DCVFRJO	DMD7X1O	Dexrazoxane	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.38	1.01	0.08	4.06
DCQ9JYV	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	7.41	7.44	6.48	11.2
DC3M7N1	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.72	7.06	9.8	11.41
DCRKGAT	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	7.35	6.65	10.63	12.01
DCLM791	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	4.17	6.6	2.68	11.14
DCNK5CW	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.43	4.65	6.63	8.95
DCKALVC	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	7.37	7.4	8.15	11.75
DC23PKH	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.46	4.48	4.7	7.54
DCBVZTH	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	6.48	12.18	11.75	13.18
DC7HPO6	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.61	3.55	6.18	7.77
DCQYNO1	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.25	5.08	3.53	8.5
DC6EQAL	DMD7X1O	Dexrazoxane	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	4.77	6.49	8.25	9.95
DCXNC45	DMD7X1O	Dexrazoxane	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.74	5.36	0.43	1.5
DC6HKBE	DMD7X1O	Dexrazoxane	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.12	5.46	0.54	3.74
DCA6943	DMD7X1O	Dexrazoxane	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.05	10.99	5.95	6.73
DC60ALG	DMD7X1O	Dexrazoxane	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.15	7.72	4.26	4.72
DCGMVCJ	DMD7X1O	Dexrazoxane	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.32	6.93	3.99	4.33
DC2IRLA	DMD7X1O	Dexrazoxane	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.89	6.18	2.72	5.44
DCG7WT1	DMD7X1O	Dexrazoxane	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.1	2.24	1.3	1.27
DCZR9EX	DMD7X1O	Dexrazoxane	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	9.11	8.83	8.04	10
DCKMCNW	DMD7X1O	Dexrazoxane	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.73	8.46	2.08	2.54
DCPR0IP	DMD7X1O	Dexrazoxane	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.71	2.83	0.57	0.67
DCOJB13	DMD7X1O	Dexrazoxane	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.44	5.53	2.02	2
DCYGFAR	DMD7X1O	Dexrazoxane	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	8.11	9.19	5.39	10.28
DC3I8JM	DMD7X1O	Dexrazoxane	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	19.05	18.96	3.41	22.06
DC8OJ6W	DMD7X1O	Dexrazoxane	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.43	1.05	1.41	3.37
DC8510S	DMD7X1O	Dexrazoxane	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	12.76	12.97	9.78	14.75
DCLAEJ3	DMD7X1O	Dexrazoxane	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.66	5.6	6.13	7.28
DC00T5O	DMD7X1O	Dexrazoxane	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.48	6.71	2.71	2.67
DCVCKWF	DMD7X1O	Dexrazoxane	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.46	2.79	4.66	6.51
DCOHOSB	DMD7X1O	Dexrazoxane	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.3	3.04	1.52	3.34
DCPH0UH	DMD7X1O	Dexrazoxane	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.06	4.86	2.61	5.25
DCI22I3	DMD7X1O	Dexrazoxane	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	9.61	12.65	7.3	12.78
DCXTCWJ	DMD7X1O	Dexrazoxane	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.89	0.91	0.5	1.57
DCIYIU1	DMD7X1O	Dexrazoxane	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	15.56	20.6	19.41	18.69
DCZQD0L	DMD7X1O	Dexrazoxane	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	6.16	11.53	11.54	11.8
DCWK2SJ	DMD7X1O	Dexrazoxane	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.93	3.86	2.94	4.3
DCOW8SG	DMD7X1O	Dexrazoxane	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.43	7.27	7.36	9.4
DC577E8	DMD7X1O	Dexrazoxane	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.18	3.86	7.35	9.34
DCD2UVP	DMD7X1O	Dexrazoxane	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.62	1.58	2.3	2.21
DCV5S0E	DMD7X1O	Dexrazoxane	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.92	7.83	1.72	3
DCCJUTA	DMD7X1O	Dexrazoxane	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.3	0.23	4.04	5.54
DCGQWGD	DMD7X1O	Dexrazoxane	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.77	3.2	1.97	0.77
DCAHLF0	DMD7X1O	Dexrazoxane	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.5	6.09	4.75	5.91
DCWQJUJ	DMD7X1O	Dexrazoxane	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.98	1.68	4.16	6.12
DCVWBLZ	DMD7X1O	Dexrazoxane	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.26	1.64	6.7	9.28
DCTVI6F	DMD7X1O	Dexrazoxane	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.4	2.17	4.78	5.19
DC4PVWK	DMD7X1O	Dexrazoxane	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.16	3.19	2.86	2.89
DC576S1	DM4O2Z7	Cyclophosphamide	Approved	34	DM4BDON	Methylprednisolone	Phase 3 Trial	25	DMMZSXQ	Azathioprine	.	.	Lupus Nephritis	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DC2HDW8	DM4O2Z7	Cyclophosphamide	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMIZKOP	Thiotepa	DMZ7XNQ	Tacrolimus	B-cell Childhood Acute Lymphoblastic Leukemia	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCSZO6I	DM4O2Z7	Cyclophosphamide	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	DMG281S	Carboplatin	DMINOX3	Vincristine	Brain Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCEEEZI	DM4O2Z7	Cyclophosphamide	Approved	34	DMINOX3	Vincristine	Approved	34	DMMWSUL	Lomustine	.	.	Untreated Childhood Medulloblastoma	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCSD3XA	DM4O2Z7	Cyclophosphamide	Approved	34	DMDI269	Docetaxel	Approved	34	DMPDW6T	Epirubicin	.	.	Breast Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCW552D	DM4O2Z7	Cyclophosphamide	Approved	34	DMIZKOP	Thiotepa	Approved	34	DMXZRW0	DTI-015	.	.	Breast Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCHN54L	DM4O2Z7	Cyclophosphamide	Approved	34	DM4BDON	Methylprednisolone	Phase 3 Trial	25	.	.	.	.	"Glomerulonephritis, Membranous"	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC66JRG	DM4O2Z7	Cyclophosphamide	Approved	34	DMG281S	Carboplatin	Approved	34	DMLB81S	Paclitaxel	DMPDW6T	Epirubicin	Triple Negative Breast Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC7GMDM	DM4O2Z7	Cyclophosphamide	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	DMINOX3	Vincristine	DMVP5YE	Doxorubicin	Ewing's Sarcoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC9THKQ	DM4O2Z7	Cyclophosphamide	Approved	34	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMVRLT7	Fludarabine	DMZ7XNQ	Tacrolimus	Acute Myeloid Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCACZHQ	DM4O2Z7	Cyclophosphamide	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMUYKBZ	Cyclosporin A	DMXYJ9C	Busulfan	Adult Acute Myeloid Leukemia in Remission	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCAOIHS	DM4O2Z7	Cyclophosphamide	Approved	34	DM4BDON	Methylprednisolone	Phase 3 Trial	25	DMVRLT7	Fludarabine	DMXYJ9C	Busulfan	Fanconi Anemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCB9RDM	DM4O2Z7	Cyclophosphamide	Approved	34	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMVRLT7	Fludarabine	DMZ7XNQ	Tacrolimus	Accelerated Phase Chronic Myelogenous Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCBXO27	DM4O2Z7	Cyclophosphamide	Approved	34	DMG281S	Carboplatin	Approved	34	DMINOX3	Vincristine	DMIZKOP	Thiotepa	Brain and Central Nervous System Tumors	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCCVM27	DM4O2Z7	Cyclophosphamide	Approved	34	DMG281S	Carboplatin	Approved	34	DMXYJ9C	Busulfan	DMXZRW0	DTI-015	Triple-Negative Invasive Breast Carcinoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCIIRP0	DM4O2Z7	Cyclophosphamide	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	DMIK367	Procarbazine	DMMWSUL	Lomustine	AIDS-related Diffuse Large Cell Lymphoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCMFLGF	DM4O2Z7	Cyclophosphamide	Approved	34	DM672AH	Aspirin	Phase 3 Trial	25	DMHSY1I	Regorafenib	DMTS85L	Capecitabine	Colo-rectal Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCPUEJO	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	DME4TH4	Etoposide	DMINOX3	Vincristine	Sarcoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCU9D5P	DM4O2Z7	Cyclophosphamide	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	DMXDHHH	Mesna	DMXZRW0	DTI-015	Lymphoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCUB5EU	DM4O2Z7	Cyclophosphamide	Approved	34	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMUYKBZ	Cyclosporin A	DMVRLT7	Fludarabine	Accelerated Phase Chronic Myelogenous Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCV762J	DM4O2Z7	Cyclophosphamide	Approved	34	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMVRLT7	Fludarabine	DMZ7XNQ	Tacrolimus	Myelodysplastic Syndrome	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCV8IFB	DM4O2Z7	Cyclophosphamide	Approved	34	DMUYKBZ	Cyclosporin A	Phase 2 Trial	21	DMVRLT7	Fludarabine	DMXYJ9C	Busulfan	Chronic Granulomatous Disease	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCZEYXM	DM4O2Z7	Cyclophosphamide	Approved	34	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMUYKBZ	Cyclosporin A	DMVRLT7	Fludarabine	Acute Myeloid Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC3CAQE	DM4O2Z7	Cyclophosphamide	Approved	34	DMGW1ID	Sirolimus	Phase 3	25	DMUYKBZ	Cyclosporin A	.	.	Acute Lymphoblastic Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC3JKQJ	DM4O2Z7	Cyclophosphamide	Approved	34	DMG281S	Carboplatin	Approved	34	DMLB81S	Paclitaxel	.	.	Lung Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC9WCRN	DM4O2Z7	Cyclophosphamide	Approved	34	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMZ7XNQ	Tacrolimus	.	.	Acute Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCBAHA8	DM4O2Z7	Cyclophosphamide	Approved	34	DM4BDON	Methylprednisolone	Phase 3 Trial	25	DMZ7XNQ	Tacrolimus	.	.	Kidney Transplantation	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCCBX4E	DM4O2Z7	Cyclophosphamide	Approved	34	DMCVJ86	Clofarabine	Approved	34	DME4TH4	Etoposide	.	.	Acute Myeloid Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCCFQRU	DM4O2Z7	Cyclophosphamide	Approved	34	DMZ7XNQ	Tacrolimus	Approved	34	DMZ7XNQ	Tacrolimus	.	.	Graft Vs Host Disease	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCCX6PZ	DM4O2Z7	Cyclophosphamide	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	DMXZRW0	DTI-015	.	.	Lymphoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCECI3I	DM4O2Z7	Cyclophosphamide	Approved	34	DM4BDON	Methylprednisolone	Phase 3 Trial	25	DMQ7WL7	Prednisone	.	.	Lymphoproliferative Disorder	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCENLKG	DM4O2Z7	Cyclophosphamide	Approved	34	DMSE3I7	Gemcitabine	Preclinical	2.1	DMXYJ9C	Busulfan	.	.	"Acute Lymphoblastic Leukemia, Adult"	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCI2UFM	DM4O2Z7	Cyclophosphamide	Approved	34	DMUYKBZ	Cyclosporin A	Phase 2 Trial	21	DMVRLT7	Fludarabine	.	.	Chronic Myelogenous Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCJP2JH	DM4O2Z7	Cyclophosphamide	Approved	34	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMZ7XNQ	Tacrolimus	.	.	Hematologic Malignancy	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCKOQ5H	DM4O2Z7	Cyclophosphamide	Approved	34	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMZ7XNQ	Tacrolimus	.	.	Hematological Malignancies	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCN7EZ7	DM4O2Z7	Cyclophosphamide	Approved	34	DMG281S	Carboplatin	Approved	34	DMIZKOP	Thiotepa	.	.	Breast Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCNHQ9W	DM4O2Z7	Cyclophosphamide	Approved	34	DMP6G8T	Topotecan	Approved	34	DMSQLZJ	Nifurtimox	.	.	Neuroblastoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCQG4P0	DM4O2Z7	Cyclophosphamide	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	DMXZRW0	DTI-015	.	.	Non-Hodgkin Lymphoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCQY0XW	DM4O2Z7	Cyclophosphamide	Approved	34	DMIZKOP	Thiotepa	Approved	34	DMVRLT7	Fludarabine	.	.	Lymphoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCR907N	DM4O2Z7	Cyclophosphamide	Approved	34	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMZ7XNQ	Tacrolimus	.	.	Hematopoietic and Lymphoid Cell Neoplasm	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCVLUL9	DM4O2Z7	Cyclophosphamide	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMUYKBZ	Cyclosporin A	.	.	Aplastic Anemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC8LDFD	DM4O2Z7	Cyclophosphamide	Approved	34	DMPQAGE	Mycophenolate mofetil	Investigative	0	.	.	.	.	Hematopoietic/Lymphoid Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCH9LKH	DM4O2Z7	Cyclophosphamide	Approved	34	DMIZKOP	Thiotepa	Approved	34	.	.	.	.	"Leukemia, Myeloid, Acute"	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCHT595	DM4O2Z7	Cyclophosphamide	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adult-onset Immunodeficiency	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCZABKE	DM4O2Z7	Cyclophosphamide	Approved	34	DM9HPW3	Exemestane	Approved	34	.	.	.	.	Metastatic Beast Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC3C2VJ	DM4O2Z7	Cyclophosphamide	Approved	34	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMUYKBZ	Cyclosporin A	DMVRLT7	Fludarabine	Acute Myeloid Leukemia (AML)	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCATK50	DM4O2Z7	Cyclophosphamide	Approved	34	DMDI269	Docetaxel	Approved	34	DMG281S	Carboplatin	DMPDW6T	Epirubicin	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCRBM5R	DM4O2Z7	Cyclophosphamide	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMXYJ9C	Busulfan	DMZ7XNQ	Tacrolimus	Adult Acute Myeloid Leukemia in Remission	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC009BJ	DM4O2Z7	Cyclophosphamide	Approved	34	DMXDHHH	Mesna	Approved	34	DMZD5QR	Cytarabine	.	.	Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC04R48	DM4O2Z7	Cyclophosphamide	Approved	34	DMG281S	Carboplatin	Approved	34	DMIZKOP	Thiotepa	.	.	Adult Acute Lymphoblastic Leukemia in Remission	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCRAUA1	DM4O2Z7	Cyclophosphamide	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	DMXZRW0	DTI-015	.	.	Adult Acute Lymphoblastic Leukemia in Remission	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCU9D0Y	DM4O2Z7	Cyclophosphamide	Approved	34	DMDI269	Docetaxel	Approved	34	DMPDW6T	Epirubicin	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCYPH5P	DM4O2Z7	Cyclophosphamide	Approved	34	DMVRLT7	Fludarabine	Approved	34	DMXYJ9C	Busulfan	.	.	Epidermolysis Bullosa	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC1WBPB	DM4O2Z7	Cyclophosphamide	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Melanoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC2N014	DM4O2Z7	Cyclophosphamide	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	"Leukemia, Myeloid, Chronic"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC4X6FF	DM4O2Z7	Cyclophosphamide	Approved	34	DMLB81S	Paclitaxel	Approved	34	.	.	.	.	Stage IA Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC7TDVR	DM4O2Z7	Cyclophosphamide	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Intraocular Melanoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC9NZXL	DM4O2Z7	Cyclophosphamide	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Anaplastic Large Cell Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCAB5GY	DM4O2Z7	Cyclophosphamide	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Adult Rhabdomyosarcoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCB1Z2I	DM4O2Z7	Cyclophosphamide	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Mucopolysaccharidosis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCCGLTU	DM4O2Z7	Cyclophosphamide	Approved	34	DMZD5QR	Cytarabine	Approved	34	.	.	.	.	Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCD72UI	DM4O2Z7	Cyclophosphamide	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCDSOPX	DM4O2Z7	Cyclophosphamide	Approved	34	DMZD5QR	Cytarabine	Approved	34	.	.	.	.	Acute Lymphoblastic Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCDYWB2	DM4O2Z7	Cyclophosphamide	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma of the Prostate	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCIJ8RT	DM4O2Z7	Cyclophosphamide	Approved	34	DMUYKBZ	Cyclosporin A	Phase 2 Trial	21	.	.	.	.	Aplastic Anemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCIJBVF	DM4O2Z7	Cyclophosphamide	Approved	34	DMQNWRD	Oxaliplatin	Approved	34	.	.	.	.	Pancreatic Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCJJ5CN	DM4O2Z7	Cyclophosphamide	Approved	34	DMCVJ86	Clofarabine	Approved	34	.	.	.	.	Burkitt's Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCM624E	DM4O2Z7	Cyclophosphamide	Approved	34	DMCJN1P	Plerixafor	Approved	34	.	.	.	.	Refractory Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCNF8YP	DM4O2Z7	Cyclophosphamide	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCQ3HNZ	DM4O2Z7	Cyclophosphamide	Approved	34	DMPQAGE	Mycophenolate mofetil	Investigative	0	.	.	.	.	Systemic Scleroderma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCQFTOE	DM4O2Z7	Cyclophosphamide	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Follicular Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCQZLUL	DM4O2Z7	Cyclophosphamide	Approved	34	DMTS85L	Capecitabine	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCUCBNI	DM4O2Z7	Cyclophosphamide	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCWWWEK	DM4O2Z7	Cyclophosphamide	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	.	.	.	.	Recurrent Adult Burkitt Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCY7CF7	DM4O2Z7	Cyclophosphamide	Approved	34	DM6LOQU	Celecoxib	Approved	34	.	.	.	.	Fallopian Tube Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC65XI3	DM4O2Z7	Cyclophosphamide	Approved	34	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMVRLT7	Fludarabine	DMZ7XNQ	Tacrolimus	Cutaneous T-Cell Non-Hodgkin Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC8O9B9	DM4O2Z7	Cyclophosphamide	Approved	34	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMVRLT7	Fludarabine	DMZ7XNQ	Tacrolimus	Hodgkin's Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC8UWX2	DM4O2Z7	Cyclophosphamide	Approved	34	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMUYKBZ	Cyclosporin A	DMVRLT7	Fludarabine	Acute Lymphoblastic Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCDT6YJ	DM4O2Z7	Cyclophosphamide	Approved	34	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMUYKBZ	Cyclosporin A	DMVRLT7	Fludarabine	Graft Versus Host Disease	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCQW1WE	DM4O2Z7	Cyclophosphamide	Approved	34	DM6LOQU	Celecoxib	Approved	34	DMJOQM3	Eflornithine	DMP6G8T	Topotecan	Neuroblastoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCXVJKR	DM4O2Z7	Cyclophosphamide	Approved	34	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMUYKBZ	Cyclosporin A	DMVRLT7	Fludarabine	Accelerated Phase Chronic Myelogenous Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC0J5JV	DM4O2Z7	Cyclophosphamide	Approved	34	DMUYKBZ	Cyclosporin A	Phase 2 Trial	21	DMVRLT7	Fludarabine	.	.	Acute Myelogenous Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC3JOEX	DM4O2Z7	Cyclophosphamide	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMZ7XNQ	Tacrolimus	.	.	Adult Acute Lymphoblastic Leukemia in Remission	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC3YMDJ	DM4O2Z7	Cyclophosphamide	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	DMXYJ9C	Busulfan	.	.	Adult Grade III Lymphomatoid Granulomatosis	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC7F9O2	DM4O2Z7	Cyclophosphamide	Approved	34	DM8X2EH	Everolimus	Approved	34	DMXDHHH	Mesna	.	.	Liver Transplant	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC877LM	DM4O2Z7	Cyclophosphamide	Approved	34	DME8FZ9	Methoxsalen	Approved	34	DMIZKOP	Thiotepa	.	.	Leukemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCC4UBO	DM4O2Z7	Cyclophosphamide	Approved	34	DMNH3PG	Etoposide	Phase 2 Trial	21	DMXZRW0	DTI-015	.	.	Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCDS5IT	DM4O2Z7	Cyclophosphamide	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	DMTS85L	Capecitabine	.	.	Breast Cancer Female	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCHXAOZ	DM4O2Z7	Cyclophosphamide	Approved	34	DMLB81S	Paclitaxel	Approved	34	DMPDW6T	Epirubicin	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCLZQC3	DM4O2Z7	Cyclophosphamide	Approved	34	DMVRLT7	Fludarabine	Approved	34	DMXDHHH	Mesna	.	.	"Acute Lymphoblastic Leukemia, in Relapse"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCQAZQR	DM4O2Z7	Cyclophosphamide	Approved	34	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMZ7XNQ	Tacrolimus	.	.	Hematologic Malignancies	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCQYR1O	DM4O2Z7	Cyclophosphamide	Approved	34	DMPQAGE	Mycophenolate mofetil	Investigative	0	DMUYKBZ	Cyclosporin A	.	.	Aplastic Anemia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCUG6NF	DM4O2Z7	Cyclophosphamide	Approved	34	DM6Q7U4	Lenalidomide	Phase 3 Trial	25	DMU4RVS	Melphalan	.	.	Refractory Multiple Myeloma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCCDWAH	DM4O2Z7	Cyclophosphamide	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Neoplasm	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCESL59	DM4O2Z7	Cyclophosphamide	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCHZGHS	DM4O2Z7	Cyclophosphamide	Approved	34	DM4XMF7	LY2606368	Phase 2	21	.	.	.	.	Brain Tumor	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCO7SQF	DM4O2Z7	Cyclophosphamide	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Neutropenia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCWHYLB	DM4O2Z7	Cyclophosphamide	Approved	34	DMC1TEV	Testosterone cypionate	Approved	34	.	.	.	.	Prostate Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC5FEHQ	DM4O2Z7	Cyclophosphamide	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	0.29	1.93	0.32	0.14
DC7SSQ0	DM4O2Z7	Cyclophosphamide	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	4.49	12.27	1.24	1.54
DCPFA1Y	DM4O2Z7	Cyclophosphamide	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	7.96	8.37	9.63	9.8
DC4ZXCG	DM4O2Z7	Cyclophosphamide	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	13.25	15.78	4.28	2.87
DC1XCHL	DM4O2Z7	Cyclophosphamide	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	6.67	9.74	6.79	4.79
DCUJZ4V	DM4O2Z7	Cyclophosphamide	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	4.09	6.02	2.89	3.06
DCALC5U	DM4O2Z7	Cyclophosphamide	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	6.64	11.9	3.54	3.41
DC6VRXG	DM4O2Z7	Cyclophosphamide	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	5.2	4.08	0.69	5.38
DC0D39J	DM4O2Z7	Cyclophosphamide	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	5.51	4.59	4.85	6.82
DCBIZ4I	DM4O2Z7	Cyclophosphamide	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	3.35	4.75	3.07	5.6
DCYC2XV	DM4O2Z7	Cyclophosphamide	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	0.21	1.63	0.9	6.22
DCGSNI4	DM4O2Z7	Cyclophosphamide	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	6.84	8.39	1.53	6.09
DCG6AF4	DM4O2Z7	Cyclophosphamide	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	2.09	0.53	2.18	2.39
DCCILOS	DM4O2Z7	Cyclophosphamide	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	5.1	7.52	3.72	3.72
DCN4OAO	DM4O2Z7	Cyclophosphamide	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	13.43	17.06	9.45	10.49
DCNEQCX	DM4O2Z7	Cyclophosphamide	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH1650	0.96	7.99	1.1	3.63
DCT3617	DM4O2Z7	Cyclophosphamide	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	3.79	11.95	3.69	9.51
DCM5RPR	DM4O2Z7	Cyclophosphamide	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	20.93	24.13	2.92	18.02
DCESAQK	DM4O2Z7	Cyclophosphamide	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.46	7.84	1.31	2.63
DCOBJOZ	DM4O2Z7	Cyclophosphamide	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	5.55	13.08	6.66	6.73
DC739CL	DM4O2Z7	Cyclophosphamide	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	1.76	9.43	7.36	6.35
DCUCV4G	DM4O2Z7	Cyclophosphamide	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	5.09	10.87	4.18	2.98
DCPP1TD	DM4O2Z7	Cyclophosphamide	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	5.03	19.2	7.54	12.53
DC4XGB7	DM4O2Z7	Cyclophosphamide	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	17.76	16.77	16.52	14.39
DCFVBCO	DM4O2Z7	Cyclophosphamide	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	0.8	5.22	3.45	2.35
DCCZDGF	DM4O2Z7	Cyclophosphamide	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	13.95	14.23	15.58	12.69
DCNXQ72	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	6.04	10.95	2.16	0.69
DC0CBTH	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	0.78	3.04	1.68	1.26
DCO6I23	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	7.92	8.4	3.57	6.06
DCWKYRI	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	2.58	5.76	1.68	2.5
DCKIPGE	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	3.11	3.38	5.98	5.98
DCIPPO8	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	1.63	3.27	1.19	2.35
DCWTZ82	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	0.25	5.28	2.56	2.56
DC3SLXE	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	10.74	12.77	6.28	6.28
DC7S7Z1	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	8.8	4.09	15.82	0.8
DCZ0JUE	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	2.27	5.05	3.44	2.3
DCFNU74	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	15.6	14.87	13.74	0.01
DCY1AFS	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	2.74	3.8	3.7	0.8
DC3KMH5	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	12.65	10.48	9.11	15.53
DCIKZP7	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	10.39	11.11	8.2	8.14
DC2FO8C	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	11	14.15	2.48	1.57
DCW1A6L	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	16.84	25.93	23.01	18.13
DCQVX3U	DM4O2Z7	Cyclophosphamide	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	3.22	9.55	0.29	5.58
DCO7ST1	DM4O2Z7	Cyclophosphamide	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	3.13	8.38	2.94	6.94
DCLZQHY	DM4O2Z7	Cyclophosphamide	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	4.95	15.1	10.97	9.91
DCTJLJN	DM4O2Z7	Cyclophosphamide	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	0.55	3	0.81	0.44
DC8MYKM	DM4O2Z7	Cyclophosphamide	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	3.45	6.06	5.4	1.12
DCA1AUG	DM4O2Z7	Cyclophosphamide	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	1.86	8.94	5.64	6.38
DCEM8KN	DM4O2Z7	Cyclophosphamide	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	0.97	2.63	4	4.76
DC0HWYR	DM4O2Z7	Cyclophosphamide	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	1.96	5.06	1.73	2.55
DC562JO	DM4O2Z7	Cyclophosphamide	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	7.84	11.82	7.77	6.73
DCZH66Q	DM4O2Z7	Cyclophosphamide	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	7.36	3.65	3.38	1.96
DCZ3C7P	DM4O2Z7	Cyclophosphamide	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	8.31	10.36	9.69	11.11
DCBF60V	DM4O2Z7	Cyclophosphamide	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	4.25	13.99	4.18	5.6
DC7FFR6	DM4O2Z7	Cyclophosphamide	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	3.82	12.74	9.34	9.34
DC2Z6AF	DM4O2Z7	Cyclophosphamide	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	4.65	9.24	0.26	6.72
DC0Q2FE	DM4O2Z7	Cyclophosphamide	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	5.22	13.74	6.02	10.65
DCZT0MV	DM4O2Z7	Cyclophosphamide	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	4.47	13.72	3.25	12.81
DCX9SO9	DM4O2Z7	Cyclophosphamide	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	6.33	11.08	11.5	11.3
DCWJRIV	DM4O2Z7	Cyclophosphamide	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	3.34	11.93	2.36	8.13
DCL4QID	DM4O2Z7	Cyclophosphamide	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	8.09	8.99	0.52	7.02
DCSH8PT	DM4O2Z7	Cyclophosphamide	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	11.69	20.4	5.37	12.31
DCOYS1O	DM4O2Z7	Cyclophosphamide	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	12.59	19.94	1.41	17.03
DC1HI6P	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	16.59	16.7	7.25	6.99
DC41ESM	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	8.09	11.15	3.9	3.81
DCKPPQ2	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A427	3.35	3.17	2.78	4.51
DCVFZEH	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH2122	2.11	6.1	2.96	3.65
DCE5ETU	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	0.38	3.94	0.13	0.23
DC5GU7Z	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	3.55	3.85	1.7	0.52
DCWHO5J	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	2.5	5.88	3.58	3.58
DCZ16T5	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	9.72	9.73	3.8	2.11
DCHCUG5	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	11.27	12.25	3.5	7.78
DC7RJ1Y	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	14.45	15.16	15.08	12.99
DCM2OSN	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	ALMANAC Dataset	Investigative	T98G	17.68	17.68	5.82	5.82
DCRJ3K8	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	1.23	6.96	8.55	7.89
DCEO0XD	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	7.5	12.3	8.15	8.71
DCSBJFK	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	2.04	10.8	9.2	9.16
DC8KC3T	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	3.86	16.5	6.44	8.44
DC4B3AX	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	13.29	17.46	11.52	12.48
DCJ4VV8	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	5.57	7.18	3.35	4.63
DCPUSBN	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	14.78	18.26	14.45	15.15
DCPCDLA	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	3.06	11.67	7.5	8.75
DC93USR	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	2.12	9.68	8.1	8.32
DCLRQFN	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	7.32	8.41	1.61	0.44
DCUK17Z	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	LNCAP	7.72	16.33	11.79	11.83
DCE7XAP	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	11.08	12.24	4.04	3.32
DC8N6ML	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	CAOV3	2.5	6.99	1.31	2.78
DCW0HBZ	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	1.48	7.27	3.33	3.49
DCWFR0P	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	0.9	5.66	4.46	4.61
DCDLW1R	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	0.55	8.53	5.58	5.58
DC52LO2	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DLD1	0.71	3.65	2.66	2.48
DCNST3U	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	5.7	9.38	3.33	1.71
DC90KSO	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	6.56	7.66	1.44	1.07
DCHIK3X	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	A2058	3.75	9.81	2.64	2.7
DCP4AFR	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Germ cell tumour	ALMANAC Dataset	Investigative	PA1	1.26	4.84	2.49	2.41
DCRZKG5	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	3.96	4.35	0.38	0.02
DCUG23R	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	HT144	0.95	6.84	4.96	5.26
DC4PABF	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	11.31	17.92	9.43	9.01
DCDEZAZ	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	4.97	8.17	2.73	2.41
DCR68SZ	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	RPMI7951	2.23	5.64	2.56	2.56
DCIBAAN	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Mesothelioma	ALMANAC Dataset	Investigative	MSTO	0.81	6.15	2.78	2.78
DCSTLWI	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	0.76	6.07	2.95	2.95
DCHE0HO	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	0.37	7.85	2.68	6.73
DCKQARG	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	4.13	10.64	5.03	5.03
DCYCQU1	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	8.17	13.66	6.74	4.43
DCEMLR7	DM4O2Z7	Cyclophosphamide	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	10.77	10.87	9.54	13.9
DCE7LFI	DM4O2Z7	Cyclophosphamide	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	14.57	14.62	12.66	14.4
DCRNV0K	DM4O2Z7	Cyclophosphamide	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	11.89	11.84	5.05	12.28
DCLUICT	DM4O2Z7	Cyclophosphamide	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	1.9	5.77	2.09	7.67
DCIK8CD	DM4O2Z7	Cyclophosphamide	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	1.57	6.83	6.7	6.81
DCURLEA	DM4O2Z7	Cyclophosphamide	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	25.35	17.28	12.7	7.82
DCSZ9U7	DM4O2Z7	Cyclophosphamide	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non small cell carcinoma	ALMANAC Dataset	Investigative	SKMES1	13.34	13.64	0.93	11.32
DCZ51HE	DM4O2Z7	Cyclophosphamide	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	18.76	18.34	0.1	14.14
DCK6QPI	DM4O2Z7	Cyclophosphamide	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	0.24	3.57	2.28	0.71
DC7MMDQ	DM4O2Z7	Cyclophosphamide	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	0.3	6.02	2.59	6.58
DCFMVY0	DM4O2Z7	Cyclophosphamide	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	A375	8.1	10.35	6.46	6.46
DCLVZN6	DM4O2Z7	Cyclophosphamide	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	11.81	13.47	3.22	5.13
DCAZ3FI	DM4O2Z7	Cyclophosphamide	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH520	8.59	4.53	0.97	2.94
DCEM6O5	DM4O2Z7	Cyclophosphamide	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	COLO320DM	3.48	9.73	6.61	4.92
DC6VOZT	DM4O2Z7	Cyclophosphamide	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	0.29	5.66	0.01	0.01
DC9NQ49	DM4O2Z7	Cyclophosphamide	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	ALMANAC Dataset	Investigative	ES2	5.41	9.53	1.52	5.16
DC2AFQV	DM4O2Z7	Cyclophosphamide	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	SKMEL30	13.65	19.25	2.1	2.1
DC37J6G	DM4O2Z7	Cyclophosphamide	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	ALMANAC Dataset	Investigative	A2780	5.32	6.41	3.94	5.61
DCD4ZWN	DM4O2Z7	Cyclophosphamide	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	VCAP	3.37	13.22	0.97	4.91
DCM8QX4	DM4O2Z7	Cyclophosphamide	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.19	4.19	3.51	1.34
DCEMF87	DM4O2Z7	Cyclophosphamide	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.97	8.18	6.6	6.81
DCZK2XQ	DM4O2Z7	Cyclophosphamide	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	17.51	17.15	5.88	6.9
DCMMSMM	DM4O2Z7	Cyclophosphamide	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	0.65	1.38	1.14	0.16
DC7NZZJ	DM4O2Z7	Cyclophosphamide	Approved	34	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.83	5.73	3.06	3.69
DC02HYN	DM4O2Z7	Cyclophosphamide	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.15	2.24	1.73	3.71
DC5HF60	DM4O2Z7	Cyclophosphamide	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.35	5.08	1.08	5.34
DC9XN22	DM4O2Z7	Cyclophosphamide	Approved	34	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	6.02	14.75	1.55	8.22
DCK9EJ2	DM4O2Z7	Cyclophosphamide	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.56	12.2	6	5.92
DCQ53M6	DM4O2Z7	Cyclophosphamide	Approved	34	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	10.46	2.09	3.68	0.59
DCNZWET	DM4O2Z7	Cyclophosphamide	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	18.24	17.12	6.92	12.39
DC146CU	DM4O2Z7	Cyclophosphamide	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.69	6.72	7.12	7.2
DCSD09J	DM4O2Z7	Cyclophosphamide	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	10.39	12.64	10.51	10.34
DC2XMT0	DM4O2Z7	Cyclophosphamide	Approved	34	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	0.78	1.88	2.7	2.7
DCMOIEM	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	11.5	15.06	1.44	0.43
DCZAMKO	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.86	5.43	3.06	3.17
DC9IF58	DM4O2Z7	Cyclophosphamide	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	17.07	16.99	1.42	14.75
DC5UPE0	DM4O2Z7	Cyclophosphamide	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.16	7.89	5.99	5.99
DCC43RE	DM4O2Z7	Cyclophosphamide	Approved	34	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.04	3.64	1.9	2.77
DCDK21F	DM4O2Z7	Cyclophosphamide	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.35	4.37	4.24	1.94
DCFMAJ3	DM4O2Z7	Cyclophosphamide	Approved	34	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.22	14.93	2.58	13.22
DCJ36KA	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	2.61	4.35	1.48	3.03
DC1H24L	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	3.91	7.95	3.13	2.73
DCM4YTV	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	11.2	13.91	2.76	2.35
DCQWQHL	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	14	21.51	15.38	9.22
DCWVL11	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	4.64	8.64	2.57	1.28
DC5989Y	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	4.65	9.65	4.41	5.22
DC1GROU	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	6.02	9.54	8.23	7.99
DCSKXS9	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	11.84	21.19	19.56	18.21
DCW2U0C	DM4O2Z7	Cyclophosphamide	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	19.13	14.18	0.73	0.41
DCK0JWJ	DM4O2Z7	Cyclophosphamide	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	7.26	4.73	0.49	4.96
DCNW7PM	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	1.62	7.63	1.35	1.39
DCISQRC	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.41	3.53	2.42	1.69
DCFG1PG	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	0.47	2.24	1.23	1.26
DCWE5TX	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	9.17	16.32	14.5	14.5
DCV3H7K	DM4O2Z7	Cyclophosphamide	Approved	34	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	12.93	14.54	12.41	11.33
DCECI0G	DM4O2Z7	Cyclophosphamide	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.39	3.91	6.45	7.25
DCWQE9R	DM4O2Z7	Cyclophosphamide	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	22.53	8.17	8.15	9.01
DCLP3XA	DM4O2Z7	Cyclophosphamide	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	19.83	19.86	1	13.45
DCPO1W1	DM4O2Z7	Cyclophosphamide	Approved	34	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	8.9	14.99	2.31	13.35
DC5WTCJ	DM4O2Z7	Cyclophosphamide	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	3.25	3.32	4.27	2.98
DC4F547	DM4O2Z7	Cyclophosphamide	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	3.29	8.74	3.91	7.78
DCGI0SS	DMNPZL4	Dacarbazine	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	17.77	17.05	6.49	18.67
DCO2557	DMNPZL4	Dacarbazine	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	0.04	6.81	4.27	5.11
DC7C9ED	DMNPZL4	Dacarbazine	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	5.74	6.26	5.44	5.43
DCZSJLB	DMNPZL4	Dacarbazine	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	2.89	3.7	3.22	5.06
DCKVQKE	DMNPZL4	Dacarbazine	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	4.91	6.3	1.46	8.5
DC3U30K	DMNPZL4	Dacarbazine	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	4.02	9.25	3.19	5.99
DCD3J5E	DMNPZL4	Dacarbazine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	2.07	2.81	3.75	4.48
DCRVJ41	DMNPZL4	Dacarbazine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	5.91	4.76	3.18	3.76
DCEBU71	DMNPZL4	Dacarbazine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	1.86	3.57	2	2.51
DCDV0SJ	DMNPZL4	Dacarbazine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	1.65	5.09	1.88	2.84
DC0MM4Y	DMNPZL4	Dacarbazine	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	4.1	4.32	2.33	4.8
DC4UVM8	DMNPZL4	Dacarbazine	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	2.5	7.86	6.88	7.34
DCTZQ2O	DMNPZL4	Dacarbazine	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	5.02	6.33	1.67	7.39
DCRNWF6	DMNPZL4	Dacarbazine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	9.35	7.69	5.21	5.34
DCRWB6Q	DMNPZL4	Dacarbazine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	1.44	5.61	2.83	2.89
DC5DPAN	DMNPZL4	Dacarbazine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	7.08	4.8	1.75	4.92
DCX8M0X	DMNPZL4	Dacarbazine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	1.13	2	5.07	3.34
DCPTAK1	DMNPZL4	Dacarbazine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	6.28	11.1	0.61	10.58
DC0YESM	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	1.17	6.03	4.07	4.57
DCMR61Q	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	0.35	0.54	1.42	2.57
DC0PE2Q	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	3.6	11.82	10.09	10.14
DCEQV8Y	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	7.25	10.23	10.44	9.73
DCDBR05	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	10	14.38	13.5	13.08
DC5NORO	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	23.86	24.95	25.13	25.58
DC71GFA	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	20.78	16.42	20.41	20.3
DCGHDY1	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	0.59	2.57	3.86	3.62
DCCVZOQ	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	0.87	7.8	3.52	3.69
DCLPZ5P	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	5.48	7.69	7.06	7.18
DC2AVEF	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	7.24	11.35	11.55	11.53
DC0ZZQX	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	1.2	8.5	6.75	6.82
DCH2OBE	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	5.45	11.96	10.27	10.27
DCXPODB	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	5.83	12.78	11.37	11.55
DCSRN6N	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	3.29	3.8	3.33	3.56
DCXD34X	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	16.79	23.69	23.65	23.55
DC7KJY6	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	29.66	23.99	26.48	24.74
DC4918L	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	11.62	14.42	12.31	12.61
DCMB458	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	1.64	4.92	5.25	5.09
DCHDYXO	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.52	6.26	5.17	5.1
DCEJ0V0	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	1.26	6.44	7.04	6.82
DC1IVLW	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	27.46	26.49	24.74	25.28
DCGUWKH	DMNPZL4	Dacarbazine	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	5.07	6.18	8.46	9.08
DCET1CE	DMNPZL4	Dacarbazine	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	3.95	6.55	6.85	6.27
DCB90KT	DMNPZL4	Dacarbazine	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	0.64	7.07	1.15	2.25
DCJWLM2	DMNPZL4	Dacarbazine	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	5.09	11.77	8.43	9.9
DC99E1C	DMNPZL4	Dacarbazine	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	2.53	10.25	10.57	10.63
DCONUCV	DMNPZL4	Dacarbazine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	0.62	4.2	2.9	3.27
DCBPCIF	DMNPZL4	Dacarbazine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	1.12	5.59	0.83	2.02
DC5MQGC	DMNPZL4	Dacarbazine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	0.4	9.3	4.03	7.01
DCHOMR9	DMNPZL4	Dacarbazine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	2.42	4.19	3.18	3.88
DCVTWBH	DMNPZL4	Dacarbazine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	11.95	13.19	5.48	6.84
DCV47KL	DMNPZL4	Dacarbazine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	4.32	12.4	5.12	6.15
DC7GYHU	DMNPZL4	Dacarbazine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	1.42	6.61	2.67	3.23
DC5ZLYQ	DMNPZL4	Dacarbazine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	8.77	9.23	4.21	10.11
DCBZ75X	DMNPZL4	Dacarbazine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	3.5	6.52	6.95	7.02
DCOHM0D	DMNPZL4	Dacarbazine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	6.61	6.55	3.33	4
DCPYPW4	DMNPZL4	Dacarbazine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	3.83	12.68	3.74	5.48
DCBFCH4	DMNPZL4	Dacarbazine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	5.1	5.9	6.38	6.27
DCVBYCQ	DMNPZL4	Dacarbazine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	0.19	4.08	0.34	1.8
DCQKYJG	DMNPZL4	Dacarbazine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	0.22	9.2	5.77	8.03
DCYBKQM	DMNPZL4	Dacarbazine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	1.62	7.61	4.96	5.28
DCHD6O8	DMNPZL4	Dacarbazine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	2.55	0.88	3.72	1.99
DCVAKD7	DMNPZL4	Dacarbazine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	0.65	9.85	7.23	8.13
DCTI1FK	DMNPZL4	Dacarbazine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	0.22	2.47	2.49	4.91
DCJNJOL	DMNPZL4	Dacarbazine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	9.54	8.62	4.67	10.89
DCK89U5	DMNPZL4	Dacarbazine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	2.01	3.09	0.56	4.1
DCIGA1J	DMNPZL4	Dacarbazine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	5.05	4.7	3.77	6.99
DC7GF4K	DMNPZL4	Dacarbazine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	3.87	4.8	4.54	5.95
DCVXDCM	DMNPZL4	Dacarbazine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	1.44	8.08	2.05	7.4
DCFUB75	DMNPZL4	Dacarbazine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	12.23	16.23	16.59	17.97
DCZTOYE	DMNPZL4	Dacarbazine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	1.06	6.27	0.34	5.8
DCVBZUV	DMNPZL4	Dacarbazine	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	2.8	11.58	4.73	5.52
DC5HKLR	DMNPZL4	Dacarbazine	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	7.82	10.53	12.79	13.38
DCXE32D	DMNPZL4	Dacarbazine	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	1.56	8.33	2.54	6.67
DCRGP0C	DMNPZL4	Dacarbazine	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	3.78	6.61	3.4	3.45
DCD171U	DMNPZL4	Dacarbazine	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	5.99	5.39	8.08	8.58
DCHVUDA	DMNPZL4	Dacarbazine	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	5.26	13.51	11.48	11.2
DC1301X	DMNPZL4	Dacarbazine	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	5.59	8.43	3.58	4.17
DC6YV5O	DMNPZL4	Dacarbazine	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	3.85	6.06	6.6	6.73
DC2O3AY	DMNPZL4	Dacarbazine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	3.18	1.95	1.53	1.42
DCD593I	DMNPZL4	Dacarbazine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	1.84	4.57	0.28	4.59
DCLHTKO	DMNPZL4	Dacarbazine	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	2.13	8.77	10.95	11.8
DCB81PD	DMNPZL4	Dacarbazine	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	3.09	2.25	1.69	4.53
DC2Q7AJ	DMNPZL4	Dacarbazine	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	1.1	1.13	1.26	5.64
DCPALH6	DMNPZL4	Dacarbazine	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	3.8	9.47	2.17	2.9
DCG60J0	DMNPZL4	Dacarbazine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	2.26	10.16	5.64	6.7
DCPBK5H	DMNPZL4	Dacarbazine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	3.43	7.42	1.24	2.94
DCJ8VFS	DMNPZL4	Dacarbazine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	2.51	3.28	4.06	2.33
DCP3VKW	DMNPZL4	Dacarbazine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	1.33	6.02	3.45	5.68
DCBC46Y	DMNPZL4	Dacarbazine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	2.5	11.07	4.7	8.18
DC9C5W1	DMNPZL4	Dacarbazine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	1.47	3.42	1.79	1.15
DCMBBNW	DMNPZL4	Dacarbazine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	0.58	8.05	4.12	5.65
DCYGKN6	DMNPZL4	Dacarbazine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	12.47	12.89	1.36	4.45
DC2LEYC	DMNPZL4	Dacarbazine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	2.71	4.17	0.6	1.82
DCOSCZA	DMNPZL4	Dacarbazine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	2.6	4.5	0.21	2.65
DCW0J9I	DMNPZL4	Dacarbazine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	5.77	7.05	5.65	7.64
DCN2DJ3	DMNPZL4	Dacarbazine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	10.98	14.33	10.43	11.74
DCGKNBB	DMNPZL4	Dacarbazine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	1.64	14.5	7.89	8.58
DCBMLTU	DMNPZL4	Dacarbazine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	1.93	2.99	4.92	4.31
DCQMNR5	DMNPZL4	Dacarbazine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	2.63	5.68	4.05	4.09
DCKETFR	DMNPZL4	Dacarbazine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	20.46	20.12	12.75	19.05
DCD005P	DMNPZL4	Dacarbazine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	18.95	15.76	12.88	12.93
DCKQ3SE	DMNPZL4	Dacarbazine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	3.99	10.68	0.72	8.68
DCXXCSW	DMNPZL4	Dacarbazine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	13.02	12.89	9.7	14.28
DCE4SLQ	DMNPZL4	Dacarbazine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	0.83	7.24	11.83	11.54
DCWWH9Z	DMNPZL4	Dacarbazine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	0.38	5.09	6.41	5.53
DCYX5HJ	DMNPZL4	Dacarbazine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	4.31	3.76	2.32	3.83
DCK8LI0	DMNPZL4	Dacarbazine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	1.56	8.04	7.5	6.09
DCAEXU1	DMNPZL4	Dacarbazine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	3.65	9.12	10.42	9.96
DCCNC9T	DMNPZL4	Dacarbazine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	14.73	17.86	14.91	15.16
DCG9T13	DMNPZL4	Dacarbazine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	2.48	5.91	4.78	4.83
DCJ29YG	DMNPZL4	Dacarbazine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	1.7	8.07	4.89	5.11
DCHKNGA	DMNPZL4	Dacarbazine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	5.54	9.37	10.17	9.9
DCPX6GC	DMNPZL4	Dacarbazine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	11.97	10.91	3.44	4.01
DC9XJAN	DMNPZL4	Dacarbazine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	2.92	9.45	4.15	4.22
DC8WE67	DMNPZL4	Dacarbazine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	7.52	5.83	5.89	7.3
DC4K3Y7	DMNPZL4	Dacarbazine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	3	5.01	3.06	2.74
DCQU60M	DMNPZL4	Dacarbazine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	7.18	5.34	0.92	1.35
DCYVAZG	DMNPZL4	Dacarbazine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	9.05	10.74	8.78	9.15
DCP4H2J	DMNPZL4	Dacarbazine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	2.74	3.66	6.3	5.74
DCNBOLW	DMNPZL4	Dacarbazine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	2.32	10.44	6.55	6.67
DCJBE82	DMNPZL4	Dacarbazine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	3.39	8.34	6.23	6.41
DCD5F1K	DMNPZL4	Dacarbazine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	4.09	5.18	6.47	6
DCI1RJL	DMNPZL4	Dacarbazine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	7.64	7.5	6.17	9.71
DCVY9PV	DMNPZL4	Dacarbazine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	6.89	5.77	6.67	10.21
DC3YK7M	DMNPZL4	Dacarbazine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	2.92	4.06	1.03	7.45
DCVB9OC	DMNPZL4	Dacarbazine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	0.07	4.21	2.99	6.3
DC8AF8G	DMNPZL4	Dacarbazine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	2.93	4.93	3.39	7.4
DCZ6ISJ	DMNPZL4	Dacarbazine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	0.77	10.45	3.7	10.65
DCHUKBX	DMNPZL4	Dacarbazine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	2.71	9.32	0.01	9.27
DCHLYVQ	DMNPZL4	Dacarbazine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	0.83	2.9	0.85	5.01
DCZY3A6	DMNPZL4	Dacarbazine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	0.18	4.89	1.05	6.35
DCWZIZX	DMNPZL4	Dacarbazine	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	1.6	3.12	0.92	5.57
DCOWB5D	DMNPZL4	Dacarbazine	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	16.24	14.28	13.04	16.69
DCO6WKI	DMNPZL4	Dacarbazine	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	5.85	6.25	0.94	10.73
DCWSBM9	DMNPZL4	Dacarbazine	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	0.2	5.42	3.63	8.14
DCBEQPY	DMNPZL4	Dacarbazine	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	7.06	6.02	3.31	7.38
DCKS9IC	DMNPZL4	Dacarbazine	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	5.04	4.54	5.63	8.85
DCMTM2L	DMNPZL4	Dacarbazine	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	0.13	2.33	3.62	5.37
DCVPRRZ	DMNPZL4	Dacarbazine	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	5.45	6.05	3.09	10.11
DCPH0NC	DMNPZL4	Dacarbazine	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	0.16	11.07	9.05	13.69
DC9G3I1	DMNPZL4	Dacarbazine	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	2.41	4.64	5	4.57
DC6OGN0	DMNPZL4	Dacarbazine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	8.38	15.21	11.25	13.28
DC3ALZB	DMNPZL4	Dacarbazine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	3.28	8.55	1.38	8.04
DCOH4WS	DMNPZL4	Dacarbazine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	5.78	11.24	5.88	9.15
DCHZOS9	DMNPZL4	Dacarbazine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	0.85	4.58	0.1	6.93
DC9JF62	DMNPZL4	Dacarbazine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	0.03	6.75	0.1	2.68
DCAQ3KU	DMNPZL4	Dacarbazine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	3.51	11.13	3.49	11.24
DCOUKFQ	DMNPZL4	Dacarbazine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	0.29	4.16	0.83	0.91
DCA81BJ	DMNPZL4	Dacarbazine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	7.05	6.06	4.07	4.51
DCQ2N7Y	DMNPZL4	Dacarbazine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	2.17	6.15	0.38	0.46
DCHM4PD	DMNPZL4	Dacarbazine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	13.65	13.35	9.66	11.75
DC1MAF0	DMNPZL4	Dacarbazine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	3.91	5.01	4.71	4.38
DCBAIPH	DMNPZL4	Dacarbazine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	3.36	9.63	0.84	2.04
DCOW67D	DMNPZL4	Dacarbazine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	2.48	1.3	2.28	1.58
DCSSSKZ	DMNPZL4	Dacarbazine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	2.09	7.06	1.64	2.33
DCLZMEF	DMNPZL4	Dacarbazine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	0.51	5.95	6.01	6.2
DCZDFYL	DMNPZL4	Dacarbazine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	1.27	1.1	4.45	3.23
DC3R6OP	DMNPZL4	Dacarbazine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	3.92	5.65	1	1.92
DC8TOX8	DMNPZL4	Dacarbazine	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	3.81	5.37	0.2	4.48
DCHE0CS	DMNPZL4	Dacarbazine	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	2.57	5.75	0.8	5.2
DCF3G10	DMNPZL4	Dacarbazine	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	0.38	0.57	0.58	3.07
DC920PD	DMNPZL4	Dacarbazine	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	0.27	4.81	3.39	6.88
DCFXW50	DMNPZL4	Dacarbazine	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	6.37	6.29	4.49	8.5
DCL5XK7	DMNPZL4	Dacarbazine	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	5.3	4.38	3.04	5.98
DC3MACC	DMNPZL4	Dacarbazine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	3.5	3.22	0.05	6.32
DCUJHZT	DMNPZL4	Dacarbazine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	3	2.19	3.08	6.05
DCD2DXE	DMNPZL4	Dacarbazine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	4.2	7.05	7.99	8.21
DCSHZE8	DMNPZL4	Dacarbazine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	8.59	15.5	2.04	11.44
DC6Z6UB	DMNPZL4	Dacarbazine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	3.9	14.02	10.57	13.28
DCXYPQQ	DMNPZL4	Dacarbazine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	13.48	13.84	7.1	15.45
DCNNBG3	DMNPZL4	Dacarbazine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	7.99	8.76	8.04	9.74
DCP9CLU	DMNPZL4	Dacarbazine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	2.67	5.17	6.45	7.67
DCPV8UY	DMNPZL4	Dacarbazine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	1.39	8.61	0.11	9.38
DCPAPNK	DMNPZL4	Dacarbazine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	0.25	7.02	6.36	7.03
DCM33W2	DMNPZL4	Dacarbazine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	14.55	17.26	15.91	17.48
DCHOSW9	DMNPZL4	Dacarbazine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	1.94	13.57	13.91	15.28
DC2WFLZ	DMNPZL4	Dacarbazine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	21.91	19.41	9.16	18.73
DCH3V3M	DMNPZL4	Dacarbazine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	1.6	11.68	10.12	10.72
DCPJJF8	DMNPZL4	Dacarbazine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	8.39	5.23	4.89	7.77
DCTFXJP	DMNPZL4	Dacarbazine	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	3.12	10.61	10.94	12.82
DCSXRG4	DMNPZL4	Dacarbazine	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	2.2	3.09	0.49	1.65
DC8Q7XJ	DMNPZL4	Dacarbazine	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	3.38	3.66	2.13	3.85
DC9ATT2	DMNPZL4	Dacarbazine	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	3.51	1.56	0.05	1.54
DCIPRA1	DMNPZL4	Dacarbazine	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	0.49	1.32	0.3	1.42
DC3J5P4	DMNPZL4	Dacarbazine	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	2.19	7.26	1.39	1.9
DC9SUZU	DMNPZL4	Dacarbazine	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	0.39	7.01	1.98	2.72
DCI9L71	DMNPZL4	Dacarbazine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	1.31	4.8	5.72	7.69
DCJAUA1	DMNPZL4	Dacarbazine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	1.99	4.7	3.46	6.11
DCFRPVD	DMNPZL4	Dacarbazine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	7.03	7.23	3.34	9.49
DC7XC34	DMNPZL4	Dacarbazine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	5.99	6.06	0.51	8.17
DCCMPVQ	DMNPZL4	Dacarbazine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	12.62	12.23	2.88	12.07
DCP0N3Y	DMNPZL4	Dacarbazine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	0.8	4.61	0.56	2.45
DC619GZ	DMNPZL4	Dacarbazine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	2.43	8.9	11.56	12.7
DCSKSF5	DMNPZL4	Dacarbazine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	7.33	8.61	5.28	10.05
DCZVV6X	DMNPZL4	Dacarbazine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	0.64	1.7	1.43	2.14
DC63T1C	DMNPZL4	Dacarbazine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	1.2	3.5	2.03	1.95
DCG9M0P	DMNPZL4	Dacarbazine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	0.71	9.06	4.94	4.9
DCUX4W7	DMNPZL4	Dacarbazine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	6.71	8.53	4.56	5.47
DCP60R3	DMNPZL4	Dacarbazine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	3.13	7.2	8.5	9.13
DCQW3GW	DMNPZL4	Dacarbazine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	4.7	9.47	12.83	13.04
DC0XDBZ	DMNPZL4	Dacarbazine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	11.93	11.65	14.36	14.56
DCJ1ZIR	DMNPZL4	Dacarbazine	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	8.01	8.04	5.41	5.32
DCPO0CF	DMNPZL4	Dacarbazine	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	7.42	7.23	3.08	6.39
DCQ7ESX	DMNPZL4	Dacarbazine	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	4.68	4.85	1.13	4.22
DCW8CA2	DMNPZL4	Dacarbazine	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	5.44	4.75	4.14	8.89
DCX39CA	DMNPZL4	Dacarbazine	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	10.8	10.21	5.3	8.44
DC5EE5S	DMNPZL4	Dacarbazine	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	1.95	6.54	4.9	4.43
DCYPJFB	DMNPZL4	Dacarbazine	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	0.85	0.69	4.59	3.65
DC7SCZR	DMNPZL4	Dacarbazine	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	3.03	4.81	2.99	2.79
DC54IJ7	DMNPZL4	Dacarbazine	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	9.2	9.69	8.4	4.9
DC3J0XM	DMNPZL4	Dacarbazine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	0.02	10.44	2.16	11.39
DCKYLQ0	DMNPZL4	Dacarbazine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	9.31	11.4	9.92	13.26
DCZHM7A	DMNPZL4	Dacarbazine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	3.8	1.77	2.45	5.35
DC17DYA	DMNPZL4	Dacarbazine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	6.5	8.48	6.53	11.13
DCPNPFJ	DMNPZL4	Dacarbazine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	1.77	4.28	4.74	7.64
DC6GHFW	DMNPZL4	Dacarbazine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	1.27	7.08	5.2	6.49
DC9GYOL	DMNPZL4	Dacarbazine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	3.68	3.57	8.67	9.15
DCCDQ6S	DMNPZL4	Dacarbazine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	3.39	5.01	9.19	9.75
DCSRCL6	DMNPZL4	Dacarbazine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	6.33	13.54	5.05	8.44
DC8N2AJ	DMNPZL4	Dacarbazine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	2.24	2.9	2.58	3.06
DCJML8I	DMNPZL4	Dacarbazine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	9.94	11.79	2.39	9.46
DCZKVSH	DMNPZL4	Dacarbazine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	0.37	7.27	4.88	5.87
DCDDMZD	DMNPZL4	Dacarbazine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	8.19	9.3	8.36	9.51
DC29JEH	DMNPZL4	Dacarbazine	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	0.95	0.18	0.07	2.79
DCD13CQ	DMNPZL4	Dacarbazine	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	1.03	1.02	0.47	3.69
DCRQDCI	DMNPZL4	Dacarbazine	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	3.77	4.28	0.85	5.19
DC8CL5B	DMNPZL4	Dacarbazine	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	3.07	0.32	0.76	2.3
DCRIO9D	DMNPZL4	Dacarbazine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	10.77	9.14	8.63	10.82
DC02IWX	DMNPZL4	Dacarbazine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	ALMANAC Dataset	Investigative	T98G	1.53	1.53	8.37	8.37
DCC3LKH	DMNPZL4	Dacarbazine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	4.78	9.11	4.6	7.83
DC0ISQV	DMNPZL4	Dacarbazine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	4.96	8.15	4.13	9.75
DCYPK0H	DMNPZL4	Dacarbazine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	5.56	15.01	4.23	9.9
DCBXNJ3	DMNPZL4	Dacarbazine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	2.53	12.29	3.28	10.68
DCOZP5K	DMNPZL4	Dacarbazine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	0.33	5.11	0.16	0.18
DCACFOU	DMNPZL4	Dacarbazine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	5.62	8.58	3.2	7.26
DCAJ562	DMNPZL4	Dacarbazine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	6.39	10.22	0.87	4.23
DCZ09SE	DMNPZL4	Dacarbazine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	0.24	9.81	4.81	5.29
DCJ5KRD	DMNPZL4	Dacarbazine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	0.95	6.12	1.46	1.87
DC0XOD5	DMNPZL4	Dacarbazine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	14.75	13.18	2.89	12.9
DC9OEFF	DMNPZL4	Dacarbazine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	3.31	6.41	3.09	4.31
DCBLRNM	DMNPZL4	Dacarbazine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	3.47	5.47	2.37	4.36
DC9YKWC	DMNPZL4	Dacarbazine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	2.62	6.59	0.84	4.84
DCHQAZR	DMNPZL4	Dacarbazine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	6.98	14	6.06	11.74
DCJB1QL	DMNPZL4	Dacarbazine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	1.48	4.57	1.37	3
DCXZ207	DMNPZL4	Dacarbazine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	6.88	7.56	8.06	6.33
DCZS4R8	DMNPZL4	Dacarbazine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.25	4.39	0.82	1.29
DC8DN8V	DMNPZL4	Dacarbazine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	1.44	8.81	4.5	7.19
DC24OFM	DMNPZL4	Dacarbazine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	2.55	9.8	4.62	4.39
DCFZ3K6	DMNPZL4	Dacarbazine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	4.16	0.57	0.48	3.5
DCSAS1E	DMNPZL4	Dacarbazine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	2.63	5.35	4.41	6.74
DCF5LZ6	DMNPZL4	Dacarbazine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	6.25	11.08	8.66	8.62
DC78WCC	DMNPZL4	Dacarbazine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	3.22	8.54	5.56	4.24
DCFUBW8	DMNPZL4	Dacarbazine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	5.16	5.52	1.74	2.26
DCDCVYP	DMNPZL4	Dacarbazine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	3.59	13.02	12.79	12.79
DCNZA6D	DMNPZL4	Dacarbazine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	2.55	2.72	4.6	4.68
DC728RN	DMNPZL4	Dacarbazine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	3.78	3.15	2.06	2.4
DC0L0KP	DMNPZL4	Dacarbazine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	10.69	11.95	13.48	13.83
DCIVMIV	DMNPZL4	Dacarbazine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	5.73	11.18	14.02	14.02
DCH4BJU	DMNPZL4	Dacarbazine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	1.39	3.95	5.65	5.28
DC3VZ50	DMNPZL4	Dacarbazine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	7.53	10.99	15.6	15.16
DCM4D58	DMNPZL4	Dacarbazine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	0.7	2.49	7.22	5.49
DCD9G8Y	DMNPZL4	Dacarbazine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	1.29	9.54	6.7	6.59
DC4QKBZ	DMNPZL4	Dacarbazine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	8.06	7.47	5	4.82
DCL3KMS	DMNPZL4	Dacarbazine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	0.16	1.99	3.39	2.92
DCA79GG	DMNPZL4	Dacarbazine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	1.81	7.52	7.16	7.29
DCRYZMN	DMNPZL4	Dacarbazine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	5.49	8.49	9.55	9.39
DCV88K1	DMNPZL4	Dacarbazine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	2.04	6.56	3.83	2.26
DC9VSKP	DMNPZL4	Dacarbazine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	1.29	1.81	0.99	1.82
DCCODSJ	DMNPZL4	Dacarbazine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	1.63	3.51	4.53	4.82
DCRIEA7	DMNPZL4	Dacarbazine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	0.29	4.33	1.98	1.27
DCJA7ZD	DMNPZL4	Dacarbazine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	7.48	7.36	4.88	10.73
DCLDNDY	DMNPZL4	Dacarbazine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	7.84	5.78	5.7	8.67
DC3UP3T	DMNPZL4	Dacarbazine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	4.29	1.07	0.23	2.86
DC9TE6J	DMNPZL4	Dacarbazine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	2.72	2.71	6.42	7.98
DCO4LVH	DMNPZL4	Dacarbazine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	1.91	4.68	6.55	8.28
DCZPJUH	DMNPZL4	Dacarbazine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	2.52	1.28	5.46	6.99
DCILXJH	DMNPZL4	Dacarbazine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	7.28	7.45	11.5	15.59
DCO7JZH	DMNPZL4	Dacarbazine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	5.87	6.46	7.72	10.28
DCXYK85	DMNPZL4	Dacarbazine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	8.94	9.61	10.52	12.48
DCJK9CT	DMNPZL4	Dacarbazine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	8.29	10.17	8.84	11.98
DCC1LYL	DMNPZL4	Dacarbazine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	4.21	6.12	6.3	9.26
DCQMRJB	DMNPZL4	Dacarbazine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	1.03	2.76	5.98	8.2
DCWTMWY	DMNPZL4	Dacarbazine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	4.34	6	7.73	8.87
DCX2TTK	DMNPZL4	Dacarbazine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	9.25	10.42	8.71	10.01
DC2CK9A	DMNPZL4	Dacarbazine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	3.62	5.29	4.69	7.61
DCSZ3BY	DMNPZL4	Dacarbazine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	6.42	7.29	8.06	10.19
DCIVB3M	DMNPZL4	Dacarbazine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	1.81	4.64	5.7	8.23
DCBSUWB	DMNPZL4	Dacarbazine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	1.45	6.11	8.37	9.63
DCDAK6H	DMNPZL4	Dacarbazine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	4.23	5.59	1.55	3.08
DCW41HM	DMNPZL4	Dacarbazine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	1.77	7.89	1.46	2.27
DC3LWL4	DMNPZL4	Dacarbazine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	6.93	8.79	1.42	3.01
DC0HJRJ	DMNPZL4	Dacarbazine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	1.36	11.22	5.29	6.05
DCZ2GMY	DMNPZL4	Dacarbazine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	2.54	8.38	7.18	9.4
DCD41DO	DMNPZL4	Dacarbazine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	9.85	14.07	6.73	11.67
DCMI0PH	DMNPZL4	Dacarbazine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	2.73	7.83	0.15	2.33
DCXQ7DS	DMNPZL4	Dacarbazine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	7.25	6.52	7.06	9.5
DC5TCGP	DMNPZL4	Dacarbazine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	3.24	6.19	2.26	5.12
DC6TWHU	DMNPZL4	Dacarbazine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	3.67	6.4	1.77	6.46
DCQBTV5	DMNPZL4	Dacarbazine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	4.38	8.09	7.12	9.81
DCRSOT2	DMNPZL4	Dacarbazine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	1.02	8.87	0.3	4.19
DCTKD5H	DMNPZL4	Dacarbazine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	6.21	11.86	6.9	8.64
DC0XGTE	DMNPZL4	Dacarbazine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	3.11	10.43	2.77	4.5
DC121B9	DMNPZL4	Dacarbazine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	0.35	7.15	0.7	6.57
DC7KPL1	DMNPZL4	Dacarbazine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	5.69	5.23	5.82	7.86
DCSFNPL	DMNPZL4	Dacarbazine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	2.82	8.28	0.81	6.05
DC9K1DG	DMNPZL4	Dacarbazine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	2.6	2.5	5.78	7.36
DC43SEZ	DMNPZL4	Dacarbazine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	2.27	6.36	0.15	6.6
DCPW4SU	DMNPZL4	Dacarbazine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	4.33	8.38	4.31	7.53
DC55JWU	DMNPZL4	Dacarbazine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	0.15	5.98	3.3	3.16
DC0TU4K	DMNPZL4	Dacarbazine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	3.93	6.82	6.64	6.31
DC13SG2	DMNPZL4	Dacarbazine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	0.61	5.24	1.07	1.63
DC511QI	DMNPZL4	Dacarbazine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	9.06	9.27	7.71	7.96
DCSJBGF	DMNPZL4	Dacarbazine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	1.12	5.61	1.51	1.09
DCDBIR7	DMNPZL4	Dacarbazine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	8.03	9.03	7.74	9.82
DCWXD2Z	DMNPZL4	Dacarbazine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	3.2	4.71	3.29	2.96
DCNIGPI	DMNPZL4	Dacarbazine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	3.62	4.46	4.21	4.51
DCUQIOF	DMNPZL4	Dacarbazine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	2.08	4.22	5.66	4.96
DCHOFNA	DMNPZL4	Dacarbazine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	2.24	3.91	1.39	1.84
DCXUD63	DMNPZL4	Dacarbazine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	0.07	2.83	1.72	1.79
DC76J9W	DMNPZL4	Dacarbazine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	1.25	7.89	3.31	3.75
DCU8NGR	DMNPZL4	Dacarbazine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	2.57	11.54	8.16	8.22
DCBFT7X	DMNPZL4	Dacarbazine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	0.76	6.53	2.67	2.95
DCR5DCZ	DMNPZL4	Dacarbazine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	4.75	5.39	2.12	2.6
DCBHO58	DMNPZL4	Dacarbazine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	1.93	5.44	2.3	5.33
DCJ8DJO	DMNPZL4	Dacarbazine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	6.79	7.03	0.89	4.68
DC1INYN	DMNPZL4	Dacarbazine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	4.06	2.07	2.82	5.01
DCJI44M	DMNPZL4	Dacarbazine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	1.07	2.38	0.87	3.02
DCHYN2U	DMNPZL4	Dacarbazine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	5.61	6.89	1.3	6.88
DC9C9NT	DMNPZL4	Dacarbazine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	3.67	6.6	2.5	9.43
DC7WSEP	DMNPZL4	Dacarbazine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	3.06	6.53	2.73	7.92
DCC800G	DMNPZL4	Dacarbazine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	0.27	3.51	0.48	3.85
DC8FXOF	DMNPZL4	Dacarbazine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	19.58	22.21	22.92	24.43
DC2SAYU	DMNPZL4	Dacarbazine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	12.15	12.13	7.66	13.58
DCF4233	DMNPZL4	Dacarbazine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	1.38	6.21	0.83	0.72
DCU2T7P	DMNPZL4	Dacarbazine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	3.13	7.59	2.54	3.14
DCEJIRJ	DMNPZL4	Dacarbazine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	3.07	8.25	6.82	9.17
DCJBE8O	DMNPZL4	Dacarbazine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	3.22	6.12	0.65	5.61
DCVFAEC	DMNPZL4	Dacarbazine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	4.73	13.02	0.47	3.5
DCQN1R8	DMNPZL4	Dacarbazine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	0.82	8.69	5.32	6.32
DCV3DR9	DMNPZL4	Dacarbazine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	5.61	11.44	1.91	11.82
DCYOO9G	DMNPZL4	Dacarbazine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	0.72	9.96	7.71	8.4
DC82U5Z	DMNPZL4	Dacarbazine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	1.2	9.44	4.67	5.82
DCZIREI	DMNPZL4	Dacarbazine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	5.95	12.29	7.45	12.49
DCVGH9I	DMNPZL4	Dacarbazine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	4.95	8.43	4.01	7.46
DC2JPD6	DMNPZL4	Dacarbazine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	21.28	20.01	13.57	20.15
DCOLXFO	DMNPZL4	Dacarbazine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	2.17	4.52	1.37	4.34
DCJEP9E	DMNPZL4	Dacarbazine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	14.51	17.19	16.62	17.39
DC6O317	DMNPZL4	Dacarbazine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	0.89	5.52	1.47	3.68
DCL9STY	DMNPZL4	Dacarbazine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	16.55	18.4	15.49	16.47
DCLK467	DMNPZL4	Dacarbazine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	9.48	13.37	13.81	13.46
DCLUQEH	DMNPZL4	Dacarbazine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	6.34	8.48	2.25	7.39
DC4DQYS	DMNPZL4	Dacarbazine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	8.18	18.19	15.33	17.83
DCHOMMW	DMNPZL4	Dacarbazine	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	2.34	4.61	0.09	5.11
DC7RRB2	DMNPZL4	Dacarbazine	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	2.27	1.53	0.78	4.35
DCZN6XX	DMNPZL4	Dacarbazine	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	5.71	9.44	1.16	6.18
DCDWL27	DMNPZL4	Dacarbazine	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	0.83	3.42	2.27	6.91
DCJPO9R	DMNPZL4	Dacarbazine	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	10.11	10.64	10.9	13.35
DCSH27S	DMNPZL4	Dacarbazine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	1.74	9.14	9.02	10.27
DC3ARZ4	DMNPZL4	Dacarbazine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	3.5	11.91	10.97	13.13
DCZVHAE	DMNPZL4	Dacarbazine	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	0.25	5.62	5.35	7.44
DC8H3RO	DMNPZL4	Dacarbazine	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	3.1	4.88	2.54	6.48
DCGD7TN	DMNPZL4	Dacarbazine	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	2.46	3.24	0.87	2.99
DCBHHEL	DMNPZL4	Dacarbazine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	4.05	4.32	5.84	5.28
DCF1W2X	DMNPZL4	Dacarbazine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	4.49	5.17	4.14	4.13
DC5LECO	DMNPZL4	Dacarbazine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	0.37	0.9	0.69	0.68
DC7807B	DMNPZL4	Dacarbazine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	0.62	1.09	0.71	0.37
DCRXU6F	DMNPZL4	Dacarbazine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	2	8.72	2.51	6.49
DCQO9C9	DMNPZL4	Dacarbazine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	13.05	12.96	1.1	11.13
DC0TZAB	DMNPZL4	Dacarbazine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	5.49	5.45	5.17	8.86
DCXE0IH	DMNPZL4	Dacarbazine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	0.55	0.51	3.35	3.4
DCRLXLH	DMNPZL4	Dacarbazine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	0.06	4.57	27.84	5.16
DCT90ZX	DMNPZL4	Dacarbazine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	4.41	4.58	9.11	8.36
DCEG185	DMNPZL4	Dacarbazine	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	3.82	5.04	4.03	6.54
DCRPCWB	DMNPZL4	Dacarbazine	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	6.6	9.51	1.84	8.6
DCJOZSS	DMNPZL4	Dacarbazine	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	0.02	0.48	1.19	2.49
DCLKTXP	DMNPZL4	Dacarbazine	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	3.48	4.2	2.07	7
DCUJADG	DMNPZL4	Dacarbazine	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	1.66	3.4	1.85	3.16
DCWGACP	DMNPZL4	Dacarbazine	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	3.86	8.3	6.89	8.12
DCVB4NL	DMNPZL4	Dacarbazine	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	5.76	8.12	1.06	8.22
DCF9IX2	DMNPZL4	Dacarbazine	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	1.56	7.5	3.35	6.57
DCIVUPG	DMNPZL4	Dacarbazine	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	10.05	12.84	12.15	15.34
DCR0L77	DMNPZL4	Dacarbazine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	1.49	5.18	3.93	9.01
DCL0GMY	DMNPZL4	Dacarbazine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	3.73	6.95	2.59	3.01
DC9PVSV	DMNPZL4	Dacarbazine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	7.96	10.44	4.67	4.75
DCJ9JO4	DMNPZL4	Dacarbazine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	2.51	1.62	2.58	2.84
DCC4KKJ	DMNPZL4	Dacarbazine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	0.14	2.95	4.17	5.31
DCXCQT1	DMNPZL4	Dacarbazine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	4.84	5.64	3.07	3.38
DCY3C1J	DMNPZL4	Dacarbazine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	9.42	3.92	1.22	6.89
DCHEV1I	DMNPZL4	Dacarbazine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	4.23	6.43	1.63	5.4
DCHUSLQ	DMNPZL4	Dacarbazine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	0.25	4.94	3.79	3.84
DC987D4	DMNPZL4	Dacarbazine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	0.48	0.41	2.47	1.35
DCMLU26	DMNPZL4	Dacarbazine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.35	6.92	5.55	5.61
DCN6ELJ	DMNPZL4	Dacarbazine	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.82	5.16	3.84	4.79
DCQTI61	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.76	7.24	6.7	6.67
DC9WCQQ	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.38	9.04	7.9	7.89
DC4CSMW	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.4	11.12	9.71	10.01
DC1LJR5	DMNPZL4	Dacarbazine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.72	11.32	9.82	10.02
DCLU101	DMNPZL4	Dacarbazine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	4.86	11.54	11.6	12.72
DCZ1TVK	DMNPZL4	Dacarbazine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.75	9.66	3.9	10.81
DC78RV3	DMNPZL4	Dacarbazine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	12.71	12.82	16.83	17.27
DC2DBAO	DMNPZL4	Dacarbazine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.4	12.28	9.67	11.39
DCN5G3C	DMNPZL4	Dacarbazine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	10.48	10.32	1.72	9.2
DCYUWMA	DMNPZL4	Dacarbazine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	8.4	20.05	5.47	6.77
DCR4MIM	DMNPZL4	Dacarbazine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.15	5.35	3.83	3.74
DC5LFK0	DMNPZL4	Dacarbazine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.05	5.93	3.02	6.28
DCWUY2H	DMNPZL4	Dacarbazine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.7	5.98	1.59	1.56
DC767LE	DMNPZL4	Dacarbazine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.54	3.23	2.08	5.26
DC32SV2	DMNPZL4	Dacarbazine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.68	4.86	6.87	8.05
DCFJHN5	DMNPZL4	Dacarbazine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.77	5.37	6.68	8.86
DCJQCW2	DMNPZL4	Dacarbazine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0	5.62	4.85	7.45
DCSTZZE	DMNPZL4	Dacarbazine	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.05	4.93	6.08	7.48
DCK1QDY	DMNPZL4	Dacarbazine	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.61	7.14	2.31	4.34
DCNLR2P	DMNPZL4	Dacarbazine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.12	6.26	3.52	3.58
DCF6GX5	DMNPZL4	Dacarbazine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.67	12.2	11.65	13.15
DC8UJDC	DMNPZL4	Dacarbazine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.35	8.09	10.1	10.57
DCXV6UL	DMNPZL4	Dacarbazine	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.15	6.4	1.86	7.34
DCNQTC3	DMNPZL4	Dacarbazine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.82	7.58	8.99	10.13
DCGBQZN	DMNPZL4	Dacarbazine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.48	3.66	4.61	6.96
DCEW8IL	DMNPZL4	Dacarbazine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.8	2.98	3.69	4.66
DCSMQV2	DMNPZL4	Dacarbazine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.91	1.23	5.73	7.93
DC8NZZY	DMNPZL4	Dacarbazine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.66	4.88	0.4	1.58
DCOH6WD	DMNPZL4	Dacarbazine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.5	6.63	3.96	4.28
DCA9FVR	DMNPZL4	Dacarbazine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.85	6.01	3.76	5.13
DCQBXBG	DMNPZL4	Dacarbazine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.13	10.8	10.91	10.7
DC2S5ZO	DMNPZL4	Dacarbazine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.07	6.59	6	6.01
DCYT5IS	DMNPZL4	Dacarbazine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.15	7.32	8.27	10.8
DCDNXHJ	DMNPZL4	Dacarbazine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.45	3.5	0.54	0.71
DCX4ZA6	DMNPZL4	Dacarbazine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.95	10.63	7.45	11.41
DCC250F	DMNPZL4	Dacarbazine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	9.44	11.38	2.44	4.23
DCY3692	DMNPZL4	Dacarbazine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.52	8.21	0.86	6.97
DCTJKER	DMNPZL4	Dacarbazine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.41	10.22	10.61	14.12
DCNGJ88	DMNPZL4	Dacarbazine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.68	1.8	0.63	1.04
DCFHJYG	DMNPZL4	Dacarbazine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	6.13	6.82	3.59	7.6
DCAU19Q	DMNPZL4	Dacarbazine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.54	9.14	3.63	4.44
DCQFE08	DMNPZL4	Dacarbazine	Approved	34	DM7KI4E	Oblimersen	Phase 3	25	.	.	.	.	Melanoma	TTD Database	Investigative	.	.	.	.	.
DCZNS00	DM0CVXA	Mechlorethamine	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	11.76	15.09	17.35	17.61
DCYCJI7	DM0CVXA	Mechlorethamine	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	15.39	13.38	1.77	10.24
DCAG2ZB	DM0CVXA	Mechlorethamine	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.71	3.59	1.85	0.65
DCCTUUE	DM0CVXA	Mechlorethamine	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	5.42	6.98	2.91	4.1
DCMM7V0	DM0CVXA	Mechlorethamine	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	7.42	10.14	4.24	2.48
DCIL5UE	DM0CVXA	Mechlorethamine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	1.26	8.46	4.34	4.52
DCJENEJ	DM0CVXA	Mechlorethamine	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.9	1.84	0.08	0.08
DC50GUQ	DM0CVXA	Mechlorethamine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	6.43	7.98	5.04	5.07
DC1ZO3V	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	14.79	11.13	11.77	11.9
DCM30V3	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	31.35	32.97	34.57	34.71
DC6YS82	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	34.02	29.58	12.42	31.3
DC10ZTP	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.38	3.37	1.43	1.53
DCDM3YB	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.02	1.72	4.34	3.97
DCQEB4V	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	7.31	14.29	8.12	8.85
DCWGE68	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.32	7.78	7.99	7.96
DCAZ2N1	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	31.56	32.81	29.01	29.85
DCQRZMV	DM0CVXA	Mechlorethamine	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.51	9.81	4.04	6.49
DCFOTU7	DM0CVXA	Mechlorethamine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.73	5.83	1.53	3.43
DC6EF8A	DM0CVXA	Mechlorethamine	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	13.71	16.49	18.42	18.56
DCREBIA	DM0CVXA	Mechlorethamine	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	10.98	16.4	10.35	10.03
DC4TSJM	DM0CVXA	Mechlorethamine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	22.98	16.26	15.39	18.13
DCCDJ0Z	DM0CVXA	Mechlorethamine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.17	5.24	0.18	4.13
DCJAH39	DM0CVXA	Mechlorethamine	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.35	3.34	1.09	3.15
DCG78Y9	DM0CVXA	Mechlorethamine	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.28	3.78	1.22	3.77
DC8ZEPY	DM0CVXA	Mechlorethamine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	10.07	8.1	9.62	11.1
DCNL966	DM0CVXA	Mechlorethamine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	15.21	15.34	12.86	13.61
DCO8HC7	DM0CVXA	Mechlorethamine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.27	1.92	0.54	0.12
DCOWU0S	DM0CVXA	Mechlorethamine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.5	3.84	4.61	3.56
DCEIULB	DM0CVXA	Mechlorethamine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.8	2.13	0.4	0.07
DCF4FRF	DM0CVXA	Mechlorethamine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	10.16	13.89	4.05	4.33
DCV5ZB4	DM0CVXA	Mechlorethamine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.67	5.86	0.42	4.01
DCT3Z0O	DM0CVXA	Mechlorethamine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.6	11.61	12.45	12.19
DC4H4OE	DM0CVXA	Mechlorethamine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.98	14.72	8.18	8.79
DCWF584	DM0CVXA	Mechlorethamine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.4	6.43	3.64	4.07
DCRJ2VC	DM0CVXA	Mechlorethamine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	15.86	7.63	5.75	5.87
DCMUMIE	DM0CVXA	Mechlorethamine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	8.92	16.18	9.07	17.99
DC616H4	DM0CVXA	Mechlorethamine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	7.04	8.44	2.77	9.56
DCEMD40	DM0CVXA	Mechlorethamine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	4.81	9.91	14.47	14.37
DCL3K73	DM0CVXA	Mechlorethamine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.13	14.48	10.16	10.11
DCRX4J5	DM0CVXA	Mechlorethamine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	2.35	5.46	6.39	6.46
DCDMAD1	DM0CVXA	Mechlorethamine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	7.81	9.46	4.24	5.12
DCIY505	DM0CVXA	Mechlorethamine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.56	14.4	7.22	8.24
DCEZL9R	DM0CVXA	Mechlorethamine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	19.45	19.97	5.72	23.73
DCRN3XI	DM0CVXA	Mechlorethamine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.74	3.41	7.12	7.59
DC7KHPQ	DM0CVXA	Mechlorethamine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.66	11.36	4.63	12.91
DC3B4H5	DM0CVXA	Mechlorethamine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.49	11.64	11.38	11.96
DCQVOA4	DM0CVXA	Mechlorethamine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	15.27	13.39	9.07	13.87
DCQXBSO	DM0CVXA	Mechlorethamine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	13.29	17.84	16.5	18.27
DCDY0E5	DM0CVXA	Mechlorethamine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.3	4.21	4.28	4.17
DCF57TJ	DM0CVXA	Mechlorethamine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.14	6	4.49	6.56
DC7CKHE	DM0CVXA	Mechlorethamine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.89	3.37	2.12	3.49
DCAS6UE	DM0CVXA	Mechlorethamine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.22	2.25	0.5	0.5
DCIXYTE	DM0CVXA	Mechlorethamine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.6	7.14	0.67	4.34
DCQOJIT	DM0CVXA	Mechlorethamine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	6.83	7.88	5.12	5.9
DC4G4UG	DM0CVXA	Mechlorethamine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.85	16.5	10.44	11.04
DC7ORA7	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.88	4.46	6.76	7.54
DC3TE8X	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.66	8.22	4.31	5.93
DCIFBII	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	12.09	11.41	7.8	10.73
DCDS1DV	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	8.18	11.11	10.55	3.61
DC9XPRB	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.26	2.57	5.91	8.54
DC812A6	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.42	6.38	1.84	5.11
DC7G7RL	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	10.98	15.15	13.56	13.61
DC5S3AR	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	11.68	12	4.93	6.25
DCPIKPQ	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	39.58	40.58	38.43	38.72
DCS6G7J	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	4.67	6.23	3.38	3.38
DCWF65T	DM0CVXA	Mechlorethamine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	6.25	7.67	0.36	0.36
DCRO0KI	DM0CVXA	Mechlorethamine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	8.14	8.04	8.83	9.86
DCTRAXL	DM0CVXA	Mechlorethamine	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.41	8.69	3.11	4.26
DCA2P3L	DM0CVXA	Mechlorethamine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.89	5.59	5.48	6.05
DCH3XCH	DM0CVXA	Mechlorethamine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.22	2.43	0.56	1.67
DCL6Y1W	DM0CVXA	Mechlorethamine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.86	4.58	6.27	6.87
DCFXASA	DM0CVXA	Mechlorethamine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.99	0.3	0.56	0.45
DCP1CG5	DM0CVXA	Mechlorethamine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.15	1.75	0.84	0.2
DCTI2GI	DM0CVXA	Mechlorethamine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	2.29	5.93	6.88	8.15
DCEJEEI	DM0CVXA	Mechlorethamine	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.12	5.74	3.05	0.3
DC0XTF6	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	14.64	12.55	10.84	11.34
DCHVHE5	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.93	7.39	8.03	7.92
DCRH7QH	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	16.99	17.09	5.7	12.44
DCMZGU1	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.14	2.01	0	0.61
DCY3HUV	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.91	10.53	5.6	11.22
DCYPMT1	DM0CVXA	Mechlorethamine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.85	8.39	3.16	4.3
DCQ86L3	DM0CVXA	Mechlorethamine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.55	2.38	1.2	1.63
DCFSNFN	DM0CVXA	Mechlorethamine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.07	4.48	0.67	0.36
DC51QY3	DM0CVXA	Mechlorethamine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.83	4.05	1.23	3.62
DCBQ3R5	DM0CVXA	Mechlorethamine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.65	5.66	11.08	11.1
DCNU1X2	DM0CVXA	Mechlorethamine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	11.62	11.47	14.06	14.06
DC8KB9Q	DM0CVXA	Mechlorethamine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	7.45	12.66	16.25	16.24
DC1IS24	DM0CVXA	Mechlorethamine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1	6.07	5.02	5.04
DCFOFM8	DM0CVXA	Mechlorethamine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.81	13.55	15.86	16.55
DCDS61R	DM0CVXA	Mechlorethamine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.98	4.91	3.48	4.93
DC40A28	DM0CVXA	Mechlorethamine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	1.88	9.63	7.6	7.47
DC4V9VY	DM0CVXA	Mechlorethamine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	8.89	6.49	10.4	11.17
DCMC452	DM0CVXA	Mechlorethamine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	14.44	17.73	5.76	13.19
DCO57HY	DM0CVXA	Mechlorethamine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	6.33	6.29	1.83	9.61
DC4ZT4B	DM0CVXA	Mechlorethamine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.17	6.53	0.48	4.92
DCBOWUV	DM0CVXA	Mechlorethamine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.65	1.99	0.75	0.9
DCAMP0Y	DM0CVXA	Mechlorethamine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	12.82	13.67	9.73	9.11
DC7F3JJ	DM0CVXA	Mechlorethamine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.03	5.14	6.42	7.27
DCFHBBU	DM0CVXA	Mechlorethamine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	19.74	16.54	15.08	16.59
DCMEMC7	DM0CVXA	Mechlorethamine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.37	13.96	10.78	11.89
DCHRAF0	DM0CVXA	Mechlorethamine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	6.61	8.92	4.33	9.55
DCOUD09	DM0CVXA	Mechlorethamine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.48	9.78	7.82	8.5
DCWFYJN	DM0CVXA	Mechlorethamine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	9.99	13.78	12.96	13.93
DCTLYTO	DM0CVXA	Mechlorethamine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1	2.54	0.93	0.76
DCMELCS	DM0CVXA	Mechlorethamine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	16.9	18.64	18.77	18.88
DC1NRWG	DM0CVXA	Mechlorethamine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	4.13	8.22	2.79	5.38
DCR8PC8	DM0CVXA	Mechlorethamine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	10.68	19.31	18.68	18.94
DC1XN3T	DM0CVXA	Mechlorethamine	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.96	6.48	4.06	5.53
DC2GWLW	DM0CVXA	Mechlorethamine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	21.01	14.69	12.5	14.65
DCKHI74	DM0CVXA	Mechlorethamine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.69	6.61	4.7	7.54
DC72ATW	DM0CVXA	Mechlorethamine	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	11.22	9.68	6.28	15.86
DCUK7K1	DM0CVXA	Mechlorethamine	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	20.38	21.3	10.11	17.66
DC284KS	DM0CVXA	Mechlorethamine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.96	6.54	2.47	2.24
DCWAON1	DM0CVXA	Mechlorethamine	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	12.79	13.3	7	16.51
DCMUQV7	DM0CVXA	Mechlorethamine	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.42	2.32	4.68	7.09
DCI6ADI	DM0CVXA	Mechlorethamine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.74	5.05	2.6	2.72
DCWV2WW	DM0CVXA	Mechlorethamine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	1.29	9.17	7.79	8.01
DC9OYR3	DM0CVXA	Mechlorethamine	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.3	5.24	1.26	1.26
DCGOIX9	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	6.8	11.26	10.67	10.36
DC76ZHD	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.73	8.44	8.09	8
DCWEMUW	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.97	15.3	14.79	14.49
DC7ZVPT	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.32	9.54	7.52	7.8
DCOLKZG	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.39	11.57	9.76	10.23
DCAXYS0	DM0CVXA	Mechlorethamine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.88	4.52	1.94	4.54
DCXCBG0	DM0CVXA	Mechlorethamine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	17.13	16.68	20.21	20.67
DCNGPLA	DM0CVXA	Mechlorethamine	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.49	4.05	3.65	3.78
DC4DP9D	DM0CVXA	Mechlorethamine	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.39	7.03	0.41	0.07
DC11IQ8	DM0CVXA	Mechlorethamine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	20.22	21.09	6.29	7.52
DCT8YA3	DM0CVXA	Mechlorethamine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	7.14	7.92	0.03	12.79
DCFD93E	DM0CVXA	Mechlorethamine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.09	2.6	0.8	1.04
DCCU4ZE	DM0CVXA	Mechlorethamine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.35	6.54	4.2	3.8
DC3SGI7	DM0CVXA	Mechlorethamine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.08	7.2	3.06	3.21
DC1R2Z7	DM0CVXA	Mechlorethamine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.01	9.43	14.17	12.61
DC751JV	DM0CVXA	Mechlorethamine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.22	4.34	3.1	2.51
DCONJZR	DM0CVXA	Mechlorethamine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.28	2.8	1.73	1.97
DCX8AHY	DM0CVXA	Mechlorethamine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.99	8.03	6	9.13
DCT2JVH	DM0CVXA	Mechlorethamine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.76	11.51	6.22	10.7
DC34PQ7	DM0CVXA	Mechlorethamine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.33	1.63	0.11	1.5
DCZJOO4	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	10.1	10.91	8.01	8
DCFB62O	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.36	9.54	4.94	5.96
DC3ZJRA	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.01	14.38	13.56	13.56
DCM8BP0	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.36	14.51	7.47	12.52
DCO4KI0	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	8.14	12.58	9.85	11.28
DC1S2M8	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.66	11.73	6.65	9.97
DC0S7RW	DM0CVXA	Mechlorethamine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.44	3.74	3.12	0.83
DCVG2C6	DM0CVXA	Mechlorethamine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.54	3.03	0.67	0.61
DCFOFEJ	DM0CVXA	Mechlorethamine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	5.13	7.31	4.1	4.28
DCGXOAF	DM0CVXA	Mechlorethamine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.66	6.77	5.05	8.08
DCAYDYU	DM0CVXA	Mechlorethamine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	9.28	10.26	6.51	9.85
DCBSYKM	DM0CVXA	Mechlorethamine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.63	8.51	6.46	8.01
DCLN6UZ	DM0CVXA	Mechlorethamine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	10.86	10.57	17.82	19.94
DCBD9F9	DM0CVXA	Mechlorethamine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.36	10.74	4.67	10.96
DCCFOO5	DM0CVXA	Mechlorethamine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.26	8.11	5.68	9.16
DCK6CEH	DM0CVXA	Mechlorethamine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.05	12.77	10.48	12.66
DCEND2Y	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.22	3.7	1.39	2
DCHOB8Y	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	10.04	12.48	17.69	18.94
DC8ZNBG	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.95	4.51	2.33	2.78
DCRSEXV	DM0CVXA	Mechlorethamine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.74	4.76	11.83	12.42
DCRHOZH	DM0CVXA	Mechlorethamine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.15	1.6	0.4	0.2
DCFGY0L	DM0CVXA	Mechlorethamine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.23	10.49	10.83	10.83
DCOX9W2	DM0CVXA	Mechlorethamine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.91	1.76	0.34	0.27
DC6BDYI	DM0CVXA	Mechlorethamine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.06	4.61	4.15	3.46
DCCIUXH	DM0CVXA	Mechlorethamine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.62	3.75	7.39	7.46
DC2Q8TC	DM0CVXA	Mechlorethamine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.55	8.59	5.56	8.92
DCNRX3R	DM0CVXA	Mechlorethamine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.54	1.36	0.76	0.37
DCI233K	DM0CVXA	Mechlorethamine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.96	3.03	1.82	1.64
DCZYUPP	DM0CVXA	Mechlorethamine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.46	2.32	0.18	0.13
DCTAJ57	DM0CVXA	Mechlorethamine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.04	2.75	0.9	1.39
DCCASKI	DM0CVXA	Mechlorethamine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	10.13	11.31	2.45	3.99
DCOPLJL	DM0CVXA	Mechlorethamine	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.63	8.46	0.74	1.66
DCLRTUV	DM0CVXA	Mechlorethamine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	9.15	8.96	11.79	12.89
DCNKQ6P	DM0CVXA	Mechlorethamine	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.37	8.25	15.26	15.15
DCNNYGC	DM0CVXA	Mechlorethamine	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.4	1.31	0.35	0.27
DC6JLZH	DM0CVXA	Mechlorethamine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.15	7.03	1.76	1.41
DCKM10J	DM0CVXA	Mechlorethamine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.81	9.61	1.82	1.33
DCVGN33	DM0CVXA	Mechlorethamine	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.29	3.97	0.37	0.98
DC1LL3V	DM0CVXA	Mechlorethamine	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	67.56	62.18	51.56	56.14
DC46DXK	DM0CVXA	Mechlorethamine	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	4.26	9.74	2.06	5.55
DC4KX7M	DM0CVXA	Mechlorethamine	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.64	7.69	3.2	4.31
DCC6MML	DM0CVXA	Mechlorethamine	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.59	10.35	4.87	4.63
DC2BUNW	DM0CVXA	Mechlorethamine	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.37	7.5	2.41	1.4
DCQZ3UY	DM0CVXA	Mechlorethamine	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.82	12.75	9.25	8.34
DCGIBEJ	DM0CVXA	Mechlorethamine	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	5.72	8.85	2.74	2.35
DC4GSHV	DM0CVXA	Mechlorethamine	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	5.96	7.21	1.1	1.08
DC4SXP8	DM0CVXA	Mechlorethamine	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.46	5.52	4.82	3.81
DCOPGU4	DM0CVXA	Mechlorethamine	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.29	5.87	2.46	2.06
DCZH20J	DM0CVXA	Mechlorethamine	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.19	2.83	0.83	0.6
DC2XZKR	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	6.26	12.59	11.96	11.86
DCYR82L	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	6	9.64	9.37	9.41
DCK9FB2	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	8.99	16.01	10.63	10.5
DCTA2O7	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.97	6.33	5.66	4.74
DCUOX2Z	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	3.13	6.2	5.64	5.26
DCZKOWT	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.95	7.96	5.81	5.4
DCQ6A3F	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	4.93	6.37	4.75	4.73
DCVI4VN	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.63	9.68	8.14	8.18
DCXN3JB	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.81	7.17	1.6	5.41
DCUBZFC	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	14.51	17.88	17.54	17.49
DCO5I5Q	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	17.57	16.97	18.13	17.7
DCUVSSU	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.75	1.52	2.04	1.96
DCWPTDK	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	7.06	12.38	8.24	9.64
DCUNV22	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.26	4.64	4.78	4.62
DC1P9EM	DM0CVXA	Mechlorethamine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.9	8.23	7.08	7.04
DCCP1DU	DM0CVXA	Mechlorethamine	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	7.78	9.73	10.67	11.78
DCIGY58	DM0CVXA	Mechlorethamine	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.32	10.25	4.82	4.82
DC705YT	DM0CVXA	Mechlorethamine	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.26	11.51	5.82	9.6
DC0ACJE	DM0CVXA	Mechlorethamine	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.44	6.74	3.82	3.82
DCH92KF	DM0CVXA	Mechlorethamine	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.49	8.9	8.33	8.4
DCXEZS4	DM0CVXA	Mechlorethamine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	4.42	6.71	3.41	1.96
DC29HB8	DM0CVXA	Mechlorethamine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.09	3.33	1.37	0.49
DC1GW5M	DM0CVXA	Mechlorethamine	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.03	3.8	0.97	1.18
DC27ILS	DM0CVXA	Mechlorethamine	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.38	3.21	1.57	1.45
DC290MY	DM0CVXA	Mechlorethamine	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.73	3.98	6.52	6.97
DC9XG16	DM0CVXA	Mechlorethamine	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	14.58	20.18	17.06	16.26
DCWBMH9	DM0CVXA	Mechlorethamine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	9.65	6.96	3.06	2.84
DCUT1M5	DM0CVXA	Mechlorethamine	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.29	8.1	9.11	10.3
DCW7RQY	DM0CVXA	Mechlorethamine	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	7.81	11.47	4.02	3.99
DCOD4LF	DM0CVXA	Mechlorethamine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.49	4.78	1.43	1.81
DCXM42T	DM0CVXA	Mechlorethamine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.28	7.26	1.43	2.4
DC0QV5A	DM0CVXA	Mechlorethamine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.53	3.24	0.52	0.71
DCE7VNY	DM0CVXA	Mechlorethamine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.5	8.9	6	5.81
DC9JANL	DM0CVXA	Mechlorethamine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	5.62	6.55	2.54	1.95
DCN4O90	DM0CVXA	Mechlorethamine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.98	6.87	2.15	1.93
DCYCN5H	DM0CVXA	Mechlorethamine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.16	7.15	3.86	3.29
DC3WWTN	DM0CVXA	Mechlorethamine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.76	2.18	0.71	0.69
DCEEJFW	DM0CVXA	Mechlorethamine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.06	6.56	1.69	1.68
DCPMI2S	DM0CVXA	Mechlorethamine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.79	5.85	1.52	1.72
DCSNA4K	DM0CVXA	Mechlorethamine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.25	4.7	2.71	1.82
DCW3LT4	DM0CVXA	Mechlorethamine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.34	5.41	1.71	2.33
DCWXGMJ	DM0CVXA	Mechlorethamine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.62	4.41	2.05	0.73
DCV4RGA	DM0CVXA	Mechlorethamine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.79	2.82	0.95	0.21
DC1DGAI	DM0CVXA	Mechlorethamine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	13.22	19.97	13.72	13.45
DC197KT	DM0CVXA	Mechlorethamine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.99	4.83	0.3	2.63
DCU8AR9	DM0CVXA	Mechlorethamine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.47	4.22	0.08	0.01
DCFALYD	DM0CVXA	Mechlorethamine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.22	3.71	2.58	0.92
DCZVFBT	DM0CVXA	Mechlorethamine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.62	5.95	3.33	5.91
DCZ4V9A	DM0CVXA	Mechlorethamine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.67	13.24	13.78	13.84
DCRVZW1	DM0CVXA	Mechlorethamine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.18	9.7	9.76	6.83
DCOQUWW	DM0CVXA	Mechlorethamine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.96	6.65	5.58	2.83
DCEPWMM	DM0CVXA	Mechlorethamine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.68	8.57	1.02	1.9
DCBI7G4	DM0CVXA	Mechlorethamine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.11	4.56	0.56	0.83
DCBTEH5	DM0CVXA	Mechlorethamine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.61	6.88	0.71	0.93
DC30CKD	DM0CVXA	Mechlorethamine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.19	7.47	4.32	8.34
DCGJCCT	DM0CVXA	Mechlorethamine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.6	12.44	9.83	11.57
DC74JFW	DM0CVXA	Mechlorethamine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.43	8.3	7.99	8.25
DC2OVLQ	DM0CVXA	Mechlorethamine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.58	2.33	5.48	9.43
DCPX91S	DM0CVXA	Mechlorethamine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.81	3.46	0.34	0.26
DCXVPGH	DM0CVXA	Mechlorethamine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.75	4.91	5.88	9.49
DCDXMT2	DM0CVXA	Mechlorethamine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.94	3.73	2.14	4.6
DCZEDC2	DM0CVXA	Mechlorethamine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.48	4.25	1.3	3.82
DCE2WAM	DM0CVXA	Mechlorethamine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.39	3.75	0.26	0.19
DCKHV4K	DM0CVXA	Mechlorethamine	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.33	9.48	5.03	7.91
DCHTC06	DM0CVXA	Mechlorethamine	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.13	1.79	0.28	0.28
DCI94RW	DM0CVXA	Mechlorethamine	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.72	2.21	1.29	0.64
DCBU5CK	DM0CVXA	Mechlorethamine	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.93	6.4	3.34	3.34
DCVW9CP	DM0CVXA	Mechlorethamine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.71	2.63	0.84	1.45
DCH9SFP	DM0CVXA	Mechlorethamine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.24	8.25	5.54	6.82
DCOK1FQ	DM0CVXA	Mechlorethamine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.05	3.11	4.93	4.97
DC00D2V	DM0CVXA	Mechlorethamine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	4.37	4.88	1.63	3.48
DCJWEHK	DM0CVXA	Mechlorethamine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.56	2.61	0.73	1.28
DCHK5V5	DM0CVXA	Mechlorethamine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.51	2.16	0.64	0.64
DCUTZLX	DM0CVXA	Mechlorethamine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.78	4.98	2.56	0.79
DCFZWV6	DM0CVXA	Mechlorethamine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.3	4.44	1.28	1.32
DC4J9T9	DM0CVXA	Mechlorethamine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.46	3.65	1.71	1.76
DCOLGI2	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.5	12.62	2.62	6.09
DC9IPPM	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	13.6	14.7	11.58	12.16
DCD0SA6	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.49	9.13	7.69	8.72
DCGWPB6	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	12.28	14.39	15.26	17.45
DCYG3JI	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	11.46	11.23	6.83	7.97
DCQG6VO	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	8.46	10.71	5.73	8.63
DCAIJAZ	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.67	4.83	1.48	2.38
DCO4N2X	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	8.75	6.69	4.5	5.68
DCM3Y5V	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	6.41	8.7	1.95	1.45
DC3YUU8	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.14	7.92	2.95	4.88
DCFMO62	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	6.77	8.75	7.6	8.74
DCKCEYF	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	7.1	9.46	4.64	7.82
DCQ57DE	DM0CVXA	Mechlorethamine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	15.91	14.17	10.14	7.77
DCPHRJA	DM0CVXA	Mechlorethamine	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.79	4.33	1.65	3.51
DCRZLY1	DM0CVXA	Mechlorethamine	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.32	4.14	2	5.66
DCKE2FZ	DM0CVXA	Mechlorethamine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.52	4.18	1.88	0.27
DCFTCEO	DM0CVXA	Mechlorethamine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.19	5.55	0.88	2.29
DCXYBLK	DM0CVXA	Mechlorethamine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.88	8.55	1.28	1.03
DCZ34EO	DM0CVXA	Mechlorethamine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	3.5	8.13	1.87	1.87
DCFQ97O	DM0CVXA	Mechlorethamine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	9.96	15.82	4.06	4.06
DCLEX8Y	DM0CVXA	Mechlorethamine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.38	6.79	0.03	3.51
DC01XLF	DM0CVXA	Mechlorethamine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.87	6.13	5.08	3.93
DC9SI9I	DM0CVXA	Mechlorethamine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.66	12.49	0.68	11.31
DCCAZX6	DM0CVXA	Mechlorethamine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	6.96	9.29	0.73	7.98
DCT31IM	DM0CVXA	Mechlorethamine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.04	9.38	7.8	8.44
DC7YWAM	DM0CVXA	Mechlorethamine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	11.34	15.42	15.71	15.67
DCOT6AK	DM0CVXA	Mechlorethamine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.02	5.73	3.18	4.54
DCH7WLL	DM0CVXA	Mechlorethamine	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.87	8.89	8.59	9.01
DCT1ZPM	DM0CVXA	Mechlorethamine	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.84	2.57	0.25	0.07
DCIRXY8	DM0CVXA	Mechlorethamine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.62	1.99	1.64	0.32
DCZ2EZN	DM0CVXA	Mechlorethamine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.24	7.94	8.63	11.02
DCLI5S9	DM0CVXA	Mechlorethamine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.96	6.34	4.39	3.4
DC4LPQP	DM0CVXA	Mechlorethamine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.01	4.2	5.75	5.86
DC7YHX2	DM0CVXA	Mechlorethamine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.26	2.66	1.27	1.04
DCLGHCC	DM0CVXA	Mechlorethamine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.6	10.23	6.84	5.64
DCH343O	DM0CVXA	Mechlorethamine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.2	4.71	1.34	1.34
DCX8JCU	DM0CVXA	Mechlorethamine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.24	2.45	0.91	0.35
DCJ5RJM	DM0CVXA	Mechlorethamine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.14	4.93	1.35	0.8
DCYVPBH	DM0CVXA	Mechlorethamine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.63	4.59	1.53	1.22
DCT64U7	DM0CVXA	Mechlorethamine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	6.73	12.81	14.11	14.11
DC4FUXX	DM0CVXA	Mechlorethamine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	7.77	12.15	14.98	14.96
DCBFSEB	DM0CVXA	Mechlorethamine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.69	5.11	0.74	3.09
DC7V0TO	DM0CVXA	Mechlorethamine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.7	7.53	3.98	8.17
DC6LLQI	DM0CVXA	Mechlorethamine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	10.59	8.25	7.34	7.27
DCTYLQI	DM0CVXA	Mechlorethamine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.44	9.65	2.56	6.8
DCCSD19	DM0CVXA	Mechlorethamine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.82	5.58	3.09	1.87
DCEEKGA	DM0CVXA	Mechlorethamine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	8.66	11.9	13.96	15.11
DCA8AH8	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.18	7	1.43	2.96
DC05GKH	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.36	3.05	0.68	1.39
DCA06JB	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	4.82	11.46	4.9	6.99
DCDIWH7	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	9.05	13.46	6.96	9.83
DCHWN51	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	5.24	5.31	0.76	0.03
DCUOG4X	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.93	5.9	4.31	0.88
DC1Q378	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	6.9	4.02	2.75	0.97
DCJF02T	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.4	7.09	4.15	3.04
DCNHI9W	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	9.76	8	6.61	4.26
DCLPG98	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.97	1.1	1.33	5.43
DCPDMOX	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.84	10.93	8.41	7.69
DCPX06S	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.61	0.09	0.52	0.76
DC6M66B	DM0CVXA	Mechlorethamine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.82	5.38	1.74	1.44
DC9M383	DM0CVXA	Mechlorethamine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.02	4.53	5.21	5.75
DCU15WO	DM0CVXA	Mechlorethamine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.61	1.69	0.95	0.39
DC7YADA	DM0CVXA	Mechlorethamine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	15.62	18.97	21.97	21.87
DCWCAR0	DM0CVXA	Mechlorethamine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.42	15.1	9.81	9.81
DCL34AP	DM0CVXA	Mechlorethamine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.27	4.8	2.73	0.13
DCUURN3	DM0CVXA	Mechlorethamine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.35	13.45	10.23	11.84
DC5E0U8	DM0CVXA	Mechlorethamine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.54	5.79	3.17	1.89
DC553A3	DM0CVXA	Mechlorethamine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.87	2.15	0.53	3.77
DC6IIXX	DM0CVXA	Mechlorethamine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.9	14.93	9.36	12.02
DCTAFW1	DM0CVXA	Mechlorethamine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	13.42	17.88	16.99	17.17
DC74XL2	DM0CVXA	Mechlorethamine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.41	8.95	0.31	4
DC0GY1C	DM0CVXA	Mechlorethamine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.28	6.95	3.51	3.51
DC8PCAP	DM0CVXA	Mechlorethamine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.1	4.01	1.42	0.37
DCNNYGX	DM0CVXA	Mechlorethamine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	3.66	5.66	2.52	0.39
DCI1QTA	DM0CVXA	Mechlorethamine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.91	5.56	2.57	0.8
DCMCYZC	DM0CVXA	Mechlorethamine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	5.61	9.61	4.57	3.11
DCDGI0O	DM0CVXA	Mechlorethamine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.41	4.91	3.32	1.76
DC0YVIF	DM0CVXA	Mechlorethamine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	3.43	4.77	0.54	2.37
DC8ILC5	DM0CVXA	Mechlorethamine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.9	4.42	2.49	1.67
DC4COPS	DM0CVXA	Mechlorethamine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.48	6.72	5.35	3.48
DCISD7X	DM0CVXA	Mechlorethamine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.18	9.22	5.66	3.76
DCUFOCE	DM0CVXA	Mechlorethamine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	6.66	14.99	14.28	14.46
DC8UOMB	DM0CVXA	Mechlorethamine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	7.7	12.62	12.47	12.16
DCK7ZKL	DM0CVXA	Mechlorethamine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0	0.52	0.78	0.01
DCVET3F	DM0CVXA	Mechlorethamine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.24	11.31	6.19	5.47
DCSRMLV	DM0CVXA	Mechlorethamine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.02	5.81	0.17	0.47
DC221SE	DM0CVXA	Mechlorethamine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.59	6.42	4.81	4.4
DCZ0XK3	DM0CVXA	Mechlorethamine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.06	1.24	4.5	4.88
DCO86ZO	DM0CVXA	Mechlorethamine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.65	3.79	0.81	0.65
DCM81MY	DM0CVXA	Mechlorethamine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.78	3.41	0.34	0.45
DCAMPV2	DM0CVXA	Mechlorethamine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.76	8.53	7.58	7.56
DC7W0Y4	DM0CVXA	Mechlorethamine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	8.48	7.97	3.67	7.83
DCU364D	DM0CVXA	Mechlorethamine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	3.75	7.19	2.1	5.87
DCKI2X6	DM0CVXA	Mechlorethamine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	7.63	12.04	3.93	6.77
DCGL3SR	DM0CVXA	Mechlorethamine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	4.77	3.82	3.79	5.87
DCDAX35	DM0CVXA	Mechlorethamine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.93	7.72	0.65	6.07
DCR5YQQ	DM0CVXA	Mechlorethamine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.26	2.31	0.69	2.63
DCKQCO6	DM0CVXA	Mechlorethamine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.76	1.34	0.83	0.82
DCF0E37	DM0CVXA	Mechlorethamine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.27	4.39	0.38	0.16
DC91RCI	DM0CVXA	Mechlorethamine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.65	12.72	7.94	7.63
DCM77EL	DM0CVXA	Mechlorethamine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.35	6.71	0.35	0.35
DCSLBST	DM0CVXA	Mechlorethamine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.89	6.96	4.99	4.06
DCPKUY2	DM0CVXA	Mechlorethamine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.89	10.33	5.05	6.81
DCVOLGN	DM0CVXA	Mechlorethamine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.98	5.53	1.28	0.5
DC4PQ9E	DM0CVXA	Mechlorethamine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1	3.12	0.41	0.84
DCTLNJB	DM0CVXA	Mechlorethamine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.23	7.9	1.78	1.98
DCRZ6CK	DM0CVXA	Mechlorethamine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.96	8.92	7.39	6.35
DCXZVAL	DM0CVXA	Mechlorethamine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.05	3.48	0.98	1.05
DCVLYWG	DM0CVXA	Mechlorethamine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.49	3.66	2.52	2.54
DCTJK7Q	DM0CVXA	Mechlorethamine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.73	3.15	1.69	1.56
DCX1OE6	DM0CVXA	Mechlorethamine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.72	4.5	2.11	1.28
DC2ZX8K	DM0CVXA	Mechlorethamine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.51	7.63	0.32	5.71
DC0L1G0	DM0CVXA	Mechlorethamine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.72	2.96	2.81	5.13
DCGTR1C	DM0CVXA	Mechlorethamine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.31	8.95	4.21	3.44
DCGVCLQ	DM0CVXA	Mechlorethamine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.02	5.87	0.97	0.97
DCVQDMG	DM0CVXA	Mechlorethamine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.04	7.91	9.06	8.98
DCTEOC1	DM0CVXA	Mechlorethamine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	6.67	19.33	19.16	19.45
DC94RWB	DM0CVXA	Mechlorethamine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.14	4.53	2.99	3.29
DCR9RM2	DM0CVXA	Mechlorethamine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	5.16	8.27	4.09	4.09
DCZD9PK	DM0CVXA	Mechlorethamine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.56	3.64	2.3	2.43
DC39MQT	DM0CVXA	Mechlorethamine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.58	3.94	1.71	2.04
DCKI64Q	DM0CVXA	Mechlorethamine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	8.67	14.86	13.08	12.27
DCASP9E	DM0CVXA	Mechlorethamine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	16.93	19.38	19.72	19.49
DCKSJA8	DM0CVXA	Mechlorethamine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.53	8.02	6.72	7.03
DCNSWNO	DM0CVXA	Mechlorethamine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.89	4.35	5.29	5.84
DCH8RJD	DM0CVXA	Mechlorethamine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	11.32	9.33	4.15	3.78
DC34G8K	DM0CVXA	Mechlorethamine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.02	5.77	6.87	6.81
DCWDEBR	DM0CVXA	Mechlorethamine	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.94	5.33	0.94	0.94
DCKSJRC	DM0CVXA	Mechlorethamine	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.16	1.93	1.7	5.89
DCTZLPY	DM0CVXA	Mechlorethamine	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.17	5.91	0.89	1.26
DCCH36P	DM0CVXA	Mechlorethamine	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.15	6.27	0.9	0.82
DCHPNYE	DM0CVXA	Mechlorethamine	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	5.35	3.49	1.79	2.48
DCSG695	DM0CVXA	Mechlorethamine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.19	6.36	2.14	2.28
DCS2EYR	DMWMPD4	Vorinostat	Approved	34	DMSIVND	Hydroxychloroquine	Phase 3 Trial	25	.	.	.	.	Malignant Solid Tumour	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCG97F6	DMWMPD4	Vorinostat	Approved	34	DM05FXR	Meclofenamic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.51	0.51	0.99	0.99
DCKHQ49	DMWMPD4	Vorinostat	Approved	34	DM0CEY3	Lefaxin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.19	4.19	4.7	4.71
DCBJINY	DMWMPD4	Vorinostat	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.46	0.46	0.83	0.89
DC81YEJ	DMWMPD4	Vorinostat	Approved	34	DM0RKS4	Bepridil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.41	3.41	4.05	4.1
DCCIHH7	DMWMPD4	Vorinostat	Approved	34	DM14NKM	Triiodothyronine	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.03	3.03	3.71	3.75
DC36ADU	DMWMPD4	Vorinostat	Approved	34	DM15HL8	Clindamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.06	1.06	1.51	1.52
DCYOD4H	DMWMPD4	Vorinostat	Approved	34	DM1TJ8F	Diethylcarbamazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.85	0.85	2.09	2.15
DCR76A1	DMWMPD4	Vorinostat	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	DrugCombDB Database	Investigative	L-1236	6.43	9.32	1.75	4.47
DC2WJRV	DMWMPD4	Vorinostat	Approved	34	DM29GAD	Lumefantrine	Approved	34	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	5.484	5.859	0.316	1.561
DCISVDB	DMWMPD4	Vorinostat	Approved	34	DM29GAD	Lumefantrine	Approved	34	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	9.287	11.406	0.287	6.135
DCTMTZ3	DMWMPD4	Vorinostat	Approved	34	DM2DMPO	Kanamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.61	1.61	2.37	2.44
DCDHQWA	DMWMPD4	Vorinostat	Approved	34	DM2NUH3	Imipramine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.08	2.08	2.55	2.6
DCKULRL	DMWMPD4	Vorinostat	Approved	34	DM3P6V7	Furazolidone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.19	3.19	3.68	3.74
DCA4M8G	DMWMPD4	Vorinostat	Approved	34	DM3Q1HL	T-3.5	Investigative	0	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	4.29	6.845	0.17	1.124
DC8MFUN	DMWMPD4	Vorinostat	Approved	34	DM3VZJQ	Chlorphenesin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.54	0.54	0.86	0.94
DCUNWAR	DMWMPD4	Vorinostat	Approved	34	DM5UGDK	Mephenytoin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.13	3.13	3.68	3.73
DCUDC1L	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	3.91	1	3.12	6.05
DCHH9I7	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	4.3	3.61	8.14	12.3
DCLS7CU	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	3.95	3.58	6.96	10.03
DCZJ68N	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	1.02	0.72	4.58	7.76
DCIXRI1	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	2.04	0.6	3.3	7.1
DCSYHTX	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	1.25	0.27	6.17	8.89
DCSL0RP	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	5.51	4.29	9.1	12.63
DC7Y2WT	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	1.64	0.32	5.54	8.97
DCFUPTT	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	6.69	5.17	6.04	10.12
DC555F6	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	3.79	3.8	6.99	10.24
DCAKTPQ	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	0.8	0.18	3.98	8.38
DCR2YJN	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	1.45	0.16	3.42	6.45
DCSI83N	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	3.2	2.07	2.3	6.07
DCIP34M	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	7.57	5.05	6.41	10.29
DCYZC05	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	5.84	2.07	2.72	6.68
DCOJD80	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	7.19	6.88	13.44	16.22
DCNVPAF	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	1.53	1.08	4.19	7.53
DC7ORZ4	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	3.15	1.65	1.04	7.55
DCT11NZ	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	1.2	0.04	5.7	8.9
DC1TKK3	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	7.37	6.18	6.96	10.98
DCIYBHD	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	5.44	5.36	4.57	9.16
DCN1W7B	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	4.96	4.32	8.42	11.62
DC1FXLW	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	1.42	1.06	3.56	7.26
DCUPU3O	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	2.67	1.99	7.73	11.32
DCVDV78	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	3.07	2.95	5.32	8.58
DCPW82Q	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	6.98	4.22	0.72	10.17
DC2W6FY	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	20.29	20.14	21.81	26.51
DC1RCMZ	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	3.14	1.52	2.25	8.85
DCTX1QX	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	1.33	2.13	2.66	7.45
DC8V0B1	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	2.57	2.9	1.28	10.07
DCRPD5O	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	9.62	8.48	11.18	14.61
DCA2TST	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	8.66	8.53	1.18	10.84
DCWFQTN	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	7.05	7.2	5.81	9.62
DCQE95X	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	8.29	7.76	1.07	13.22
DC820TV	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	10.05	9.73	7.38	14.47
DCHNK6M	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.11	3.65	0.18	5.98
DCMWD7E	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	9.59	9.56	0.73	13.21
DCW4CCF	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	2.33	2.99	0.36	11.31
DCIHE7C	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	5.35	4.58	5.16	9.59
DCI75HV	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	11.65	9.42	12.83	18.25
DC02JQN	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	5.11	4.78	1.97	6.23
DCJ6E0E	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	6.22	5.17	3.09	8.35
DCX2BLO	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	4.7	6.45	3.9	11.31
DC8VZKZ	DMWMPD4	Vorinostat	Approved	34	DM6BZCV	Sivelestat	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.71	3.71	4.27	4.27
DCH3UBB	DMWMPD4	Vorinostat	Approved	34	DM8X2EH	Everolimus	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.7	1.7	3.61	3.61
DCSIZSB	DMWMPD4	Vorinostat	Approved	34	DMFI8A7	Tranexamic acid	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.87	2.87	3.21	3.3
DCUYNMH	DMWMPD4	Vorinostat	Approved	34	DMBAWDG	Thiolactomycin	Investigative	0	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	8.752	16.003	2.348	4.739
DCH2RFE	DMWMPD4	Vorinostat	Approved	34	DMBHMOX	Palonosetron	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.87	0.87	1.31	1.34
DCAJQPT	DMWMPD4	Vorinostat	Approved	34	DMBYCU0	Metyrosine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.26	1.26	3.57	3.61
DC0V6ID	DMWMPD4	Vorinostat	Approved	34	DMC0GSJ	Efavirenz	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.6	4.6	5.24	5.28
DCMKVV9	DMWMPD4	Vorinostat	Approved	34	DMC4RNA	TAK-733	Phase 1	17	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	JHH-136	35.49	36.75	14.22	20.77
DCOO77T	DMWMPD4	Vorinostat	Approved	34	DME4RA8	Amodiaquine	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.92	3.92	4.42	4.42
DCKKWN1	DMWMPD4	Vorinostat	Approved	34	DMCR1MV	Itraconazole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.55	2.55	3.18	3.21
DCTJJSI	DMWMPD4	Vorinostat	Approved	34	DMCT2YF	Emetine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.1	3.1	5.5	5.55
DCJH9VU	DMWMPD4	Vorinostat	Approved	34	DMCX0K3	Cinacalcet	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.2	3.2	3.7	3.7
DCUN9TE	DMWMPD4	Vorinostat	Approved	34	DMCYANK	Doxapram	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.88	1.88	2.34	2.36
DCL0CS3	DMWMPD4	Vorinostat	Approved	34	DMDASC6	Metformin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.95	4.95	5.35	5.4
DCNZETV	DMWMPD4	Vorinostat	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	5.877	7.922	0.565	5.933
DC902TK	DMWMPD4	Vorinostat	Approved	34	DMDXRP1	ETHISTERONE	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.94	3.94	4.5	4.5
DCXSFRH	DMWMPD4	Vorinostat	Approved	34	DME8FZ9	Methoxsalen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.16	0.16	0.6	0.62
DC1KXKQ	DMWMPD4	Vorinostat	Approved	34	DMEV954	Sulfinpyrazone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.73	0.73	1.23	1.24
DC0APMM	DMWMPD4	Vorinostat	Approved	34	DMF70AB	Ginsenoside Rb1	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.89	1.89	2.26	2.33
DC6IY47	DMWMPD4	Vorinostat	Approved	34	DMFCMPS	Daidzin	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.54	1.54	1.95	2.03
DCV171R	DMWMPD4	Vorinostat	Approved	34	DMFGLXB	Phensuximide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.37	2.37	3.13	3.21
DC92EGU	DMWMPD4	Vorinostat	Approved	34	DMFQWNI	VR-776	Discontinued in Phase 1	3	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.43	2.43	2.96	3.01
DCTM9KD	DMWMPD4	Vorinostat	Approved	34	DMGB035	Armodafinil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.65	2.65	3.09	3.09
DC0N726	DMWMPD4	Vorinostat	Approved	34	DMGQFYB	Mecamylamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.92	2.92	3.42	3.42
DC1VT2H	DMWMPD4	Vorinostat	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	1.809	2.243	5.239	7.161
DCJ95TB	DMWMPD4	Vorinostat	Approved	34	DMOL54H	Clopidogrel	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.32	3.32	3.77	3.77
DCGYUHX	DMWMPD4	Vorinostat	Approved	34	DMHPWOM	Diphenidol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.55	2.55	3.09	3.1
DCRGT27	DMWMPD4	Vorinostat	Approved	34	DMHZJCG	Pentamidine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.85	4.85	5.68	5.7
DCB7L51	DMWMPD4	Vorinostat	Approved	34	DMI40NL	Tolazoline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.73	3.73	4.26	4.26
DCCYHT2	DMWMPD4	Vorinostat	Approved	34	DMJOQM3	Eflornithine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.23	4.23	4.67	4.73
DC8QV3H	DMWMPD4	Vorinostat	Approved	34	DMJX3O8	OSI-027	Phase 2	21	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	JHH-136	36.04	37.33	4.38	7.62
DCHDM8B	DMWMPD4	Vorinostat	Approved	34	DMK1GBJ	Trazodone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.72	3.72	4.19	4.19
DCQE8MP	DMWMPD4	Vorinostat	Approved	34	DMKSUOI	Flavopiridol	Phase 2	21	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	JHH-136	14.98	21.25	2.65	1.98
DCOPD18	DMWMPD4	Vorinostat	Approved	34	DMKXY2R	Ibutilide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.27	3.27	3.87	3.91
DCZ0UNT	DMWMPD4	Vorinostat	Approved	34	DMKZJ7T	GINKGOLIDE A	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.81	4.81	5.43	5.5
DCIK5I5	DMWMPD4	Vorinostat	Approved	34	DML1538	Diazoxide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.17	0.17	2.77	2.85
DC3VIRN	DMWMPD4	Vorinostat	Approved	34	DML5VQ0	Fenoprofen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.53	2.53	3.19	3.19
DC3HAPB	DMWMPD4	Vorinostat	Approved	34	DMLBVKQ	Entacapone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.4	4.4	4.86	4.89
DCOOD1L	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	6.07	1.53	0.78	4.09
DCX32I8	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	1.08	0.5	1.1	4.39
DCQOVL7	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	0.53	0.93	1.93	4.75
DCL0FQE	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	4.07	3.11	0.24	6.61
DCOEWXJ	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	4.46	2.32	0.64	6.69
DC6S4Q9	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	5.57	4.52	1.54	7.84
DCKAX17	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.06	3.59	0.65	5.91
DC552QL	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	0.81	0.69	0.24	1.07
DCQX0J6	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	6.26	3.83	0.6	6.21
DC11BUH	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	5.37	6.32	2.77	8.63
DCC79U2	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	1.37	2.12	1.58	6.54
DCFDTTV	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	2.95	2.68	0.7	5.16
DC3L5CB	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	2.1	2.2	1.83	7.43
DCNAYYU	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	16.09	15.15	14.7	17.23
DC3TSDM	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	8.8	5.9	3.66	7.42
DC545GZ	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	5.43	5.47	0.39	5.34
DCQFE2D	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	3.61	4.5	0.69	5.95
DCAYKUM	DMWMPD4	Vorinostat	Approved	34	DMLU8NX	Benserazide	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.36	2.36	2.81	2.88
DCYVVIZ	DMWMPD4	Vorinostat	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.29	3.29	4.75	4.81
DC01ROC	DMWMPD4	Vorinostat	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	23.47	23.47	8.11	8.11
DCMEOHK	DMWMPD4	Vorinostat	Approved	34	DMM4WBX	Methocarbamol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.84	1.84	2.31	2.38
DC9U8MY	DMWMPD4	Vorinostat	Approved	34	DMM5ZX6	Epothilone B	Discontinued in Phase 3	9	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	1051.203	1543.165	953.877	146.166
DCVIZOY	DMWMPD4	Vorinostat	Approved	34	DMMFWOJ	Probenecid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.68	4.68	5.19	5.27
DC9I2EG	DMWMPD4	Vorinostat	Approved	34	DMNKG1Z	Atenolol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.59	1.59	1.94	2.03
DCM78W5	DMWMPD4	Vorinostat	Approved	34	DMO381I	Acamprosate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.57	3.57	4.05	4.06
DCEIVAF	DMWMPD4	Vorinostat	Approved	34	DMOL5IU	Mesalazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.1	1.1	1.61	1.61
DCA6731	DMWMPD4	Vorinostat	Approved	34	DMOMBJW	Moricizine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.19	2.19	2.67	2.73
DCM217X	DMWMPD4	Vorinostat	Approved	34	DMPFN6Y	Olanzapine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.01	4.01	4.51	4.57
DCE2UVH	DMWMPD4	Vorinostat	Approved	34	DMPGR1E	Clascoterone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.87	1.87	2.68	2.72
DCOANG2	DMWMPD4	Vorinostat	Approved	34	DMPP4DT	Trimethobenzamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.72	4.72	5.68	5.72
DCJQAN5	DMWMPD4	Vorinostat	Approved	34	DMPZS7U	Oxyphenbutazone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.41	1.41	3.21	3.28
DC2YGUE	DMWMPD4	Vorinostat	Approved	34	DMQ2FKJ	Teriflunomide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.32	0.32	0.87	0.88
DCOV7LO	DMWMPD4	Vorinostat	Approved	34	DMR87LC	Ethambutol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.35	2.35	2.85	2.85
DCV3BT9	DMWMPD4	Vorinostat	Approved	34	DMRD5SP	Fenretinide	Phase 3	25	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	JHH-136	40.93	45.54	2.75	2.73
DCBSXYM	DMWMPD4	Vorinostat	Approved	34	DMRJFN9	Theophylline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.4	4.4	4.84	4.9
DCHM4YV	DMWMPD4	Vorinostat	Approved	34	DMS0PND	Brincidofovir	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.94	1.94	4.55	4.57
DCVF73F	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	8.93	6.77	1.64	9.27
DCLW1PF	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	0.65	0.55	5.65	9.31
DCZEEM7	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	7.63	6.6	5.45	12.27
DCUVTUA	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	3.78	3.83	7.65	13.02
DCONX1V	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	8.01	7.55	7.29	13.94
DCLPY5N	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	2.88	1.88	0.52	7.39
DCMWJOK	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	2.97	2.48	2.25	7.92
DCICK1X	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	13.72	10.77	4.66	11.67
DCCZW7G	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	8.19	7.74	3.51	11.46
DCU1ZUQ	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	1.53	1.35	1.9	3.49
DCWSQVK	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	8.97	7.97	6.07	13.16
DCL6RJ0	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	11.28	9.13	5.75	13.61
DC2TJG1	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	2.03	2.54	1.85	9.88
DCL7YF6	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	9.06	6.59	3.28	10.95
DCZS2WJ	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	5.19	5.69	6.1	11.43
DCUQKM3	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	1.28	0.97	2.82	4.28
DCYNPD1	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	13.13	12.31	6.21	14.1
DCKCA7V	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	3.3	3.45	5.8	9.54
DCOFHUY	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	9.52	9.01	2.14	10.43
DCNNDQ9	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	6	8.07	1.2	7.92
DC9T3ZW	DMWMPD4	Vorinostat	Approved	34	DMSA4B3	Desoxycorticosterone pivalate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.85	3.85	4.32	4.32
DC202LF	DMWMPD4	Vorinostat	Approved	34	DMSI5CB	Chloroquine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.73	0.73	1.15	1.16
DC4996Y	DMWMPD4	Vorinostat	Approved	34	DMSQZE2	Asenapine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.91	3.91	4.57	4.63
DCUFWGL	DMWMPD4	Vorinostat	Approved	34	DMSWYF5	Quinine	Approved	34	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	2.961	9.428	4.043	6.304
DCLZHNN	DMWMPD4	Vorinostat	Approved	34	DMSWYF5	Quinine	Approved	34	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	3.424	9.516	1.532	4.365
DCTISXK	DMWMPD4	Vorinostat	Approved	34	DMT9K74	MK-4815	Investigative	0	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	9.14	15.115	4.631	5.079
DC305TY	DMWMPD4	Vorinostat	Approved	34	DMT9K74	MK-4815	Investigative	0	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	8.921	12.617	2.614	4.348
DC760E6	DMWMPD4	Vorinostat	Approved	34	DMTX8IZ	Endoxifen	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.87	1.87	3.13	3.15
DCIAF7U	DMWMPD4	Vorinostat	Approved	34	DMRBMAU	Mycophenolic acid	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.34	1.34	3.93	3.99
DC5Z4BH	DMWMPD4	Vorinostat	Approved	34	DMUWAM2	Pyronaridine	Approved	34	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	5.777	6.271	0.927	4.58
DC5BVRR	DMWMPD4	Vorinostat	Approved	34	DMUZPJ5	Cisatracurium	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.57	0.57	1.53	1.56
DCXRP99	DMWMPD4	Vorinostat	Approved	34	DMWT905	Mefloquine	Phase 2/3 Trial	24	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.83	1.83	4.42	4.46
DCTPO49	DMWMPD4	Vorinostat	Approved	34	DMWT905	Mefloquine	Phase 2/3 Trial	24	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	3.763	5.503	0.501	5.636
DCSREJ2	DMWMPD4	Vorinostat	Approved	34	DMV3UN4	JTC-801	Discontinued in Phase 2	5	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	5.606	7.961	0.81	1.98
DCE33CL	DMWMPD4	Vorinostat	Approved	34	DMV74ZH	Pizotyline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.73	1.73	2.23	2.24
DCO8UTY	DMWMPD4	Vorinostat	Approved	34	DMVM6QR	Lacosamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.76	2.76	3.26	3.31
DCLKZUN	DMWMPD4	Vorinostat	Approved	34	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.39	1.39	4.05	4.05
DCRG9OA	DMWMPD4	Vorinostat	Approved	34	DMVPZBE	Iloprost	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.2	2.2	2.53	2.59
DCEH6YX	DMWMPD4	Vorinostat	Approved	34	DMVRIC2	Zileuton	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.34	4.34	5.1	5.16
DC5C1TX	DMWMPD4	Vorinostat	Approved	34	DMWBHRY	Olmesartan medoxomil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.91	3.91	4.37	4.39
DCFEJUW	DMWMPD4	Vorinostat	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.49	1.49	2.05	2.12
DCJTYPF	DMWMPD4	Vorinostat	Approved	34	DMXCM7H	Cerivastatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.04	0.04	2.71	2.71
DC0EVEW	DMWMPD4	Vorinostat	Approved	34	DMSIVND	Hydroxychloroquine	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.24	1.24	1.74	1.74
DCSPEJ3	DMWMPD4	Vorinostat	Approved	34	DMY4UMW	Atovaquone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.52	3.52	3.91	3.96
DC21Z53	DMWMPD4	Vorinostat	Approved	34	DMYZ57N	Albendazole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.27	0.27	0.59	0.67
DCGA4T4	DMWMPD4	Vorinostat	Approved	34	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	10.52	10.25	8.84	11.46
DCLYWF6	DMWMPD4	Vorinostat	Approved	34	DMZ9WI4	Nitrosoglutathione	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.7	1.7	2.1	2.1
DCU0A7M	DMWMPD4	Vorinostat	Approved	34	DMZI3WO	Etomidate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.71	0.71	1.13	1.15
DC84FD2	DMWMPD4	Vorinostat	Approved	34	DMZMSCT	Cilostazol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.73	1.73	2.24	2.25
DC0MVM5	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.76	2.59	7.62	10.97
DC00MOZ	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	1.36	0.96	0.35	10.18
DC4UG94	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	1.19	0.28	2.98	6.8
DCJ73XG	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	5.18	5.27	12.03	14.9
DCC6D78	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	9.37	8.49	14.92	16.92
DCBTML2	DMWMPD4	Vorinostat	Approved	34	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	1.39	1.34	4.22	9.76
DCT0KO1	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.83	1.19	7.54	4.91
DCRFVOR	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	7.58	4.93	3.76	11.72
DCUQR9S	DMWMPD4	Vorinostat	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.17	3.96	9.8	13.42
DC076PV	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.66	2.88	3.7	7.67
DCHG02S	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.09	0.44	1.05	2.4
DCNG9WV	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	LOVO	2.97	1.06	0.64	5.04
DCK6GAX	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.89	2.75	3	7.67
DCNXBZX	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.59	3.62	9.05	11.52
DC2HYD7	DMWMPD4	Vorinostat	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Rectal adenocarcinoma	JAAKS Dataset	Investigative	SW837	4.4	3.25	0.71	7.49
DCFZD6I	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	0.6	1	2.49	8.95
DCLHFAG	DMWMPD4	Vorinostat	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	4.9	5.2	1.79	9.72
DCQKB2S	DMG2YBD	Trifluridine	Approved	34	DMOJV2N	TAS-102	Phase 3	25	.	.	.	.	Metastatic Colorectal Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC4J5ED	DMG2YBD	Trifluridine	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	18.05	13.35	3.78	15.42
DCS7ZQE	DMG2YBD	Trifluridine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.95	2.94	3.21	5.11
DC4F8X6	DMG2YBD	Trifluridine	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.56	6.56	4.26	7.8
DCXR9I8	DMG2YBD	Trifluridine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.34	0.31	0.07	0.38
DCSZHBA	DMG2YBD	Trifluridine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.96	3.38	1.81	3.45
DC8EUKD	DMG2YBD	Trifluridine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.72	2.44	0.37	0.64
DC85KBL	DMG2YBD	Trifluridine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.47	2.39	2.05	2.24
DCE232J	DMG2YBD	Trifluridine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.93	1.75	0.17	0.49
DC16VQP	DMG2YBD	Trifluridine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	3.93	3.01	4.03	4.19
DC3ES2Q	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.99	3.7	0.84	6.42
DCD6CY1	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	13.26	11.81	11.25	11.93
DC3AY1B	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	12.83	7.99	10.33	13.17
DCQP057	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.36	7.12	7.71	7.86
DCRWKV8	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	4.71	5.24	4.89	5.47
DCAH70N	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.67	3.06	1.14	2.1
DCDSXB3	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.11	0.69	0.15	1.22
DCKYSRL	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.02	0.54	0.42	0.95
DC7E7NX	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.89	7.48	7.98	7.77
DCT7RAJ	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	18.44	18.14	18.1	18.02
DCY56W5	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.15	7.31	6.4	9.16
DC0NF83	DMG2YBD	Trifluridine	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.65	4.64	3.15	6.06
DCLFBO8	DMG2YBD	Trifluridine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.01	6.4	5.43	7.82
DCRTG64	DMG2YBD	Trifluridine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.6	2.4	3.21	5.54
DC170GS	DMG2YBD	Trifluridine	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.85	4.12	2.39	5.39
DCRMQDE	DMG2YBD	Trifluridine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	7.44	7.32	3.54	7.94
DC41ZAI	DMG2YBD	Trifluridine	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.08	6.38	6.28	8.17
DC8PSS5	DMG2YBD	Trifluridine	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.25	2.29	1.33	4.98
DCUP182	DMG2YBD	Trifluridine	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.5	8.33	7.72	9.85
DCQNV1Z	DMG2YBD	Trifluridine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	12.67	7.92	4.84	8.89
DC7H53D	DMG2YBD	Trifluridine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	5.11	4.09	0.75	4.98
DC7730D	DMG2YBD	Trifluridine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	2.52	3.61	0.66	3.2
DC4TN6I	DMG2YBD	Trifluridine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.23	0.58	0.01	1.72
DCS6CND	DMG2YBD	Trifluridine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.16	4.57	2.34	4.9
DCQF591	DMG2YBD	Trifluridine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	5.21	4.36	0.56	5.29
DCNOB48	DMG2YBD	Trifluridine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.62	6.32	7.4	9.28
DCSK2FP	DMG2YBD	Trifluridine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.93	1.73	4.68	6.98
DCKNRZ6	DMG2YBD	Trifluridine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.21	0.67	2.13	4.37
DC17SMO	DMG2YBD	Trifluridine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	9.79	9.41	0.81	11.3
DCFGQVO	DMG2YBD	Trifluridine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.67	4.99	1.7	5.72
DCJ7SY2	DMG2YBD	Trifluridine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0	1.87	0.28	3.67
DC3XMGX	DMG2YBD	Trifluridine	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	7.4	4.72	1.76	8.02
DCCNZFQ	DMG2YBD	Trifluridine	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.34	0.33	0.93	2.28
DCG12SZ	DMG2YBD	Trifluridine	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.31	0.28	2.75	4.71
DC1I83B	DMG2YBD	Trifluridine	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.73	5.29	4.59	9.67
DCY946Z	DMG2YBD	Trifluridine	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	7.19	6.89	6.78	6.81
DCZ0K1O	DMG2YBD	Trifluridine	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.72	4	3.18	4.49
DCLCJVI	DMG2YBD	Trifluridine	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.04	1.85	2.64	2.7
DCNVBID	DMG2YBD	Trifluridine	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.84	2.33	3.24	3.42
DCSRRE1	DMG2YBD	Trifluridine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.52	2.49	0.42	3.2
DC818ZI	DMG2YBD	Trifluridine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.42	3.37	1.3	2.61
DC3NSWC	DMG2YBD	Trifluridine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	13.74	7.82	4.71	9.13
DCE2197	DMG2YBD	Trifluridine	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	17.13	12.28	13.45	15.68
DCC416F	DMG2YBD	Trifluridine	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.03	3.16	3.34	4.96
DCEL3FW	DMG2YBD	Trifluridine	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.76	0.71	4.19	6.92
DCSZA1A	DMG2YBD	Trifluridine	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	11.56	11.11	12.79	16.45
DCGC7EZ	DMG2YBD	Trifluridine	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	5.63	9.76	9.77	12.37
DCFB0W6	DMG2YBD	Trifluridine	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.21	0.66	5.87	8.02
DCTS7ZO	DMG2YBD	Trifluridine	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.18	0.25	0.03	5.42
DC8OY5Q	DMG2YBD	Trifluridine	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.22	3.01	4.26	6
DCIY7BJ	DMG2YBD	Trifluridine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.1	0.17	2.49	4.37
DCEL76M	DMG2YBD	Trifluridine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.75	0.49	0.35	2.01
DCG6NWS	DMG2YBD	Trifluridine	Approved	34	DME9QGW	Marizomib	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	6.78	5.19	3.63	4.75
DCXYEUB	DMG2YBD	Trifluridine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.11	3.56	1.17	4.89
DCHL8DC	DMG2YBD	Trifluridine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	7.2	8.67	7.08	11.21
DC29K16	DMG2YBD	Trifluridine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.89	3.42	6.89	9.4
DCLBH0L	DMG2YBD	Trifluridine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	6.68	4.35	7.76	11.56
DCZK81K	DMG2YBD	Trifluridine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.82	5.33	2.35	7.71
DC1EBH0	DMG2YBD	Trifluridine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	13.42	11.49	1.51	12.18
DCRS6P7	DMG2YBD	Trifluridine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.29	2.2	4.07	4.49
DCBZ0F8	DMG2YBD	Trifluridine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	13.2	15.52	14.37	16.56
DC9QPVJ	DMG2YBD	Trifluridine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.26	1.87	3.45	5.71
DCDT531	DMG2YBD	Trifluridine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	8.29	5.53	5.88	9.33
DCPGK7B	DMG2YBD	Trifluridine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.39	1.83	6.96	9.32
DC39HU4	DMG2YBD	Trifluridine	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	7.21	7.74	5.28	9.31
DCNHSY6	DMG2YBD	Trifluridine	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	7.7	6.3	7.07	10.31
DCADJ6I	DMG2YBD	Trifluridine	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.91	0.78	1.22	3.98
DCKJWN7	DMG2YBD	Trifluridine	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	6.93	7.43	9.79	12.12
DC2YTOB	DMG2YBD	Trifluridine	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.64	3.96	0.74	2.66
DCI7Y1Y	DMG2YBD	Trifluridine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.76	1.77	2.53	4.2
DCY7ZHX	DMG2YBD	Trifluridine	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.96	4.65	4.06	8.59
DCL6AJQ	DMG2YBD	Trifluridine	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	7.22	6.87	6.78	15.71
DC0OHGJ	DMG2YBD	Trifluridine	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.61	4.4	7.53	9.14
DCLMY4A	DMG2YBD	Trifluridine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.53	3.98	3.93	5.84
DC4YQ6A	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	9.74	7.18	7.1	11.28
DCN0IS6	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.5	1.28	0.04	2.65
DCY29QR	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.55	1.73	1.43	3.5
DCJ7TKD	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.79	4.97	4.65	11.11
DCCO7R5	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.87	5.9	10.05	14.13
DCTA1ML	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.39	1.85	1.53	3.68
DC74FDF	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.05	6.53	7.51	9.59
DC3EYMP	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.17	4.2	7.62	9.73
DCLHEGY	DMG2YBD	Trifluridine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.85	1.24	0.39	0.82
DC4DYWC	DMG2YBD	Trifluridine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.71	3.49	4.86	4.92
DCMMI8M	DMG2YBD	Trifluridine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.91	1.81	0.93	1.12
DCIS98T	DMG2YBD	Trifluridine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.54	0.67	6.28	7.71
DCX7OOH	DMG2YBD	Trifluridine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.73	2.65	0.35	4.72
DCQU7QP	DMG2YBD	Trifluridine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	4.33	2.48	7.92	9.57
DCNGG9H	DMG2YBD	Trifluridine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1	1.66	7.7	8.8
DCS7Q57	DMG2YBD	Trifluridine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.37	2.42	0.47	3.35
DC91VF2	DMG2YBD	Trifluridine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.34	4.71	0.31	3.29
DC7BWXB	DMG2YBD	Trifluridine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.5	5.38	4.47	6.94
DCNZSLT	DMG2YBD	Trifluridine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.65	5.07	1.4	6.06
DCSL234	DMG2YBD	Trifluridine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.54	4.46	0.43	4.93
DCTB1ZI	DMG2YBD	Trifluridine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.26	7.3	7.66	12.28
DC3HP20	DMG2YBD	Trifluridine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.03	4.17	2.08	4.61
DCJ3FUC	DMG2YBD	Trifluridine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	9.72	10.1	8.16	10.77
DCHEQNK	DMG2YBD	Trifluridine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	7.26	6.55	3.53	10.28
DCRX58I	DMG2YBD	Trifluridine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	13.4	11.92	7.92	11.81
DCPCD6O	DMG2YBD	Trifluridine	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	8.6	9.38	4.24	9.25
DCIGPG9	DMG2YBD	Trifluridine	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.75	4.45	1.86	5.63
DC11KOG	DMG2YBD	Trifluridine	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.99	4.56	4.9	6.58
DCTJAN8	DMG2YBD	Trifluridine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.1	5.27	1.21	4.88
DCHME68	DMG2YBD	Trifluridine	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.7	3.35	6.5	8.99
DCH9A6F	DMG2YBD	Trifluridine	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.86	3.83	2.32	4.39
DC79BFX	DMG2YBD	Trifluridine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	4.3	6.86	7.44	8.63
DCBWM3I	DMG2YBD	Trifluridine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.35	0.84	0.79	4.92
DCPUWBB	DMG2YBD	Trifluridine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.97	0.77	2.58	4.05
DCIKBT9	DMG2YBD	Trifluridine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.05	3.79	3.61	3.72
DCCJVVR	DMG2YBD	Trifluridine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.05	2.56	4.43	8.13
DCSKDFL	DMG2YBD	Trifluridine	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.35	2.94	3.19	4.51
DCL14JJ	DMG2YBD	Trifluridine	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.73	1.09	2.82	5.23
DC1GDUM	DMG2YBD	Trifluridine	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.65	1.76	2.19	4.55
DC99OBA	DMG2YBD	Trifluridine	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	7.98	5.35	8.37	9.73
DCLGIQG	DMG2YBD	Trifluridine	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.72	1.62	1.11	4.11
DCVX6T8	DMG2YBD	Trifluridine	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.41	3.88	5.07	6.06
DCTUQAX	DMG2YBD	Trifluridine	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	8.15	8.28	7.12	10.42
DCTUEWS	DMG2YBD	Trifluridine	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	4.1	7.75	3.01	6.02
DCE1YBQ	DMG2YBD	Trifluridine	Approved	34	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	17.63	14.96	2.41	6.41
DCY9KQ0	DMG2YBD	Trifluridine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.32	2.43	4.02	5.11
DCR2CVS	DMG2YBD	Trifluridine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.05	0.95	2.08	3.51
DC6V8F3	DMG2YBD	Trifluridine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.22	0.6	2.43	2.59
DC23Y6S	DMG2YBD	Trifluridine	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.87	8.06	1.74	7.63
DC5W2G7	DMG2YBD	Trifluridine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.81	2.77	3.9	4.43
DCQJUG9	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.09	2.95	1.72	2.72
DC9YU1L	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.74	6.47	6.36	6.66
DCAL5N9	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.75	1.7	0.01	1.44
DC6WOMM	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.1	6.69	4.84	6.48
DC3V6J8	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.11	7.8	7.87	7.92
DCFB3MA	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.63	8.89	8.44	8.76
DC9K1EX	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.01	10.68	11.05	10.54
DCA1R0Q	DMG2YBD	Trifluridine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.1	3.78	3.76	6.15
DCGI3NO	DMG2YBD	Trifluridine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.89	12.88	0.84	12.41
DCU9BM4	DMG2YBD	Trifluridine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.54	4.06	4.38	7.61
DCPKJZ0	DMG2YBD	Trifluridine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.14	7.35	5.31	8
DCWDGZ2	DMG2YBD	Trifluridine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.69	11.09	7.46	10.01
DCU0WIH	DMG2YBD	Trifluridine	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.95	4.11	8.16	9.88
DC5VSL8	DMG2YBD	Trifluridine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	6.45	6.15	3.72	7.7
DCGTZSX	DMG2YBD	Trifluridine	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.25	0.65	4.68	7.1
DCUIT46	DMG2YBD	Trifluridine	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.89	8.61	9.18	12.93
DC1CX9H	DMG2YBD	Trifluridine	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.12	4.56	5.03	5.14
DCRYNG8	DMG2YBD	Trifluridine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.02	3.29	0.21	4.15
DCVL2L2	DMG2YBD	Trifluridine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.51	2.72	1.02	3.39
DC8MD73	DMG2YBD	Trifluridine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.44	7.88	2	7.39
DCKSNCW	DMG2YBD	Trifluridine	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.73	4.82	4.53	9.47
DC5QVSI	DMG2YBD	Trifluridine	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.83	3.08	6.43	8.06
DCOJ6RO	DMG2YBD	Trifluridine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.04	5.33	8.67	9.15
DC54LBB	DMG2YBD	Trifluridine	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.1	0.56	4.38	5.84
DC6KEXL	DMG2YBD	Trifluridine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	14.34	14.37	7.64	11.79
DC3SDQU	DMG2YBD	Trifluridine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.02	8.52	10.47	10.98
DCSBDF5	DMG2YBD	Trifluridine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	5.23	4.76	11.35	12.26
DCM7XQ4	DMG2YBD	Trifluridine	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.07	3.34	5.99	8.76
DC65JCJ	DMG2YBD	Trifluridine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.76	0.67	6.62	8.1
DC0ZR6E	DMG2YBD	Trifluridine	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.77	1.2	1.45	6.98
DCINT2H	DMG2YBD	Trifluridine	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.45	6.62	3.21	11.38
DCWI7AF	DMG2YBD	Trifluridine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.7	7.87	8.03	8.22
DCI1SOY	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.31	6.83	8.6	12.84
DCTCRIR	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.34	0.01	3.9	6.37
DCNYE51	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.9	9.11	14.82	14.97
DCUF5SM	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.48	4.78	8.63	7.25
DC36LMH	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.22	1.12	6.11	6.88
DCGRARS	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.13	6.36	10.06	11.17
DC9YYLJ	DMG2YBD	Trifluridine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.22	1.35	0.28	1.11
DC9DMAX	DMG2YBD	Trifluridine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.74	4.16	8.59	8.9
DCCJAHI	DMG2YBD	Trifluridine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.46	3.91	0.46	1.63
DC1M1LW	DMG2YBD	Trifluridine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.64	8.6	9.53	11
DCISMCW	DMG2YBD	Trifluridine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.84	1.13	2.31	4.94
DCSRHJU	DMG2YBD	Trifluridine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.29	4.71	3.05	5.91
DCWOS7C	DMG2YBD	Trifluridine	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.66	3.92	1.09	2.96
DC81FC0	DMG2YBD	Trifluridine	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.24	4.3	1.04	2.73
DCKMRID	DMG2YBD	Trifluridine	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.56	1.83	5.74	7.07
DCL0Y3D	DMG2YBD	Trifluridine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.86	10.37	8.82	9.8
DC8E2VG	DMG2YBD	Trifluridine	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.16	4.77	4.06	5.79
DCNY7N1	DMG2YBD	Trifluridine	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	5.86	4.83	3.73	5.04
DCWXHKQ	DMG2YBD	Trifluridine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.05	1.83	0.26	0.36
DC52AQ9	DMG2YBD	Trifluridine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.45	3.42	1.7	3.9
DCPBLNE	DMG2YBD	Trifluridine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.16	0.37	3.55	4.5
DCM2DXB	DMG2YBD	Trifluridine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.3	2.1	1.05	2.37
DCKYIN9	DMG2YBD	Trifluridine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	11.92	12.96	10.34	10.35
DCAXZPN	DMG2YBD	Trifluridine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.46	1.54	1.26	1.55
DCH44JL	DMG2YBD	Trifluridine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.8	6.48	4.03	5.37
DC6P14Y	DMG2YBD	Trifluridine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	7.27	9.97	10.36	10.27
DCJ5Y1O	DMG2YBD	Trifluridine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.58	1.78	2.3	2.49
DCX07QI	DMG2YBD	Trifluridine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	7.38	2.53	1.69	2.54
DCVJV33	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2	2.06	0.47	1.3
DC9X8UX	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	10.57	8.95	7.87	8.59
DCD21RC	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	3.99	5.89	5.29	5.58
DC8028I	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.68	5.29	4.66	4.77
DCCUA30	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.64	6.47	6.57	6.29
DCE2PZ4	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.12	7.13	6.59	6.54
DCOCGKP	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.86	7.04	5.14	6.34
DCGQBLD	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.18	2.73	2.53	0.25
DCEVL8U	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	4.94	7.66	7.83	7.53
DCKV2VV	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	8.38	7.84	6.95	7.69
DCH8RBI	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.91	8.08	0.62	4.47
DCM8FUJ	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.28	9.9	9.48	9.63
DC1GULX	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.61	3.18	2.28	2.14
DCBG6V2	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.76	4.19	5.05	4.53
DC1HPMR	DMG2YBD	Trifluridine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.7	3.61	1.11	3.85
DCJ4OZA	DMG2YBD	Trifluridine	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.87	1.64	0.81	1.86
DCG6GEQ	DMG2YBD	Trifluridine	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.41	8.05	6.93	7.92
DCEZ8HA	DMG2YBD	Trifluridine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.25	5.66	2.72	4.6
DCUD2AQ	DMG2YBD	Trifluridine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.62	9.08	1.88	6.59
DCGCSIS	DMG2YBD	Trifluridine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	9.74	9.91	9.63	10.99
DC88WBS	DMG2YBD	Trifluridine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.4	7.77	4.02	6.41
DCOXTAZ	DMG2YBD	Trifluridine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.57	2.83	1.66	5.48
DC3BV00	DMG2YBD	Trifluridine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.03	2.42	0.99	4.74
DC9JSC2	DMG2YBD	Trifluridine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.5	2.72	0.36	3.03
DCQEXR0	DMG2YBD	Trifluridine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.62	6.76	3.61	4.92
DCODEF4	DMG2YBD	Trifluridine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	1.79	9.32	10.54	11.68
DCDG12V	DMG2YBD	Trifluridine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.16	4.2	5.02	5.69
DCHJ2N5	DMG2YBD	Trifluridine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.82	6.92	6.78	8.03
DCE320E	DMG2YBD	Trifluridine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.02	8.3	6.11	9.17
DCPP7OF	DMG2YBD	Trifluridine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.74	7.7	7.77	8.45
DCHQUAN	DMG2YBD	Trifluridine	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.99	7.32	0.43	3.94
DCWR8TX	DMG2YBD	Trifluridine	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	7.88	11.67	6.94	10.05
DCV1VWJ	DMG2YBD	Trifluridine	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.55	1.57	0.13	1.85
DC0HAA7	DMG2YBD	Trifluridine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	7.27	4.11	3.74	0.17
DCLWDFF	DMG2YBD	Trifluridine	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.64	2.88	0.79	4.39
DC51K0G	DMG2YBD	Trifluridine	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.15	2.97	5.04	6.54
DC2CKS0	DMG2YBD	Trifluridine	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	7.68	9.81	11.51	12.54
DCR3KYR	DMG2YBD	Trifluridine	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.66	4.93	1.61	1.61
DC8O6DY	DMG2YBD	Trifluridine	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	5.65	2.57	2.26	0.6
DCAUCJW	DMG2YBD	Trifluridine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.77	9.97	6.99	11.01
DCLXNOC	DMG2YBD	Trifluridine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.75	7.99	2.5	5
DCUMLUM	DMG2YBD	Trifluridine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.27	13.57	0.79	11.11
DCI1Q3F	DMG2YBD	Trifluridine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4.51	12.1	0.45	12.01
DCH516M	DMG2YBD	Trifluridine	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	14.55	15.45	2.92	9.74
DCR8NCW	DMG2YBD	Trifluridine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.76	6.72	3.71	5.67
DCUGX7I	DMG2YBD	Trifluridine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	11.98	9.37	8.13	10.94
DCMO0HP	DMG2YBD	Trifluridine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	16.48	16.07	16.06	16.77
DCI9HBW	DMG2YBD	Trifluridine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.06	6.04	3.46	4.69
DCQ4K7G	DMG2YBD	Trifluridine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.47	10.99	4.35	7.51
DCQ7S7H	DMG2YBD	Trifluridine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.11	10.46	6.17	8.96
DCVU9SI	DMG2YBD	Trifluridine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	13.32	15.63	7.69	10.39
DCPP4UR	DMG2YBD	Trifluridine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.57	9.39	6.04	7.95
DCJ1ZEV	DMG2YBD	Trifluridine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.47	5.66	2.8	6.86
DCVE9FB	DMG2YBD	Trifluridine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	7.74	11.54	9.91	14.16
DCSSGRY	DMG2YBD	Trifluridine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.38	4.61	5.97	8.29
DCPHD7Z	DMG2YBD	Trifluridine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.93	5.05	4.68	1.01
DCLA67N	DMG2YBD	Trifluridine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.82	4.6	3.75	6.09
DC2ZJRH	DMG2YBD	Trifluridine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	6.44	6.32	3.87	8.37
DC9OA40	DMG2YBD	Trifluridine	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.11	2.14	4.95	6.77
DCVF2XT	DMG2YBD	Trifluridine	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.14	2.39	2.46	5.31
DCO39F1	DMG2YBD	Trifluridine	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.43	2.73	2.37	1.42
DCNAZV1	DMG2YBD	Trifluridine	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.74	8.17	7.5	7.61
DCRA8JJ	DMG2YBD	Trifluridine	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0	4.34	2.58	7.3
DC2MBPY	DMG2YBD	Trifluridine	Approved	34	DMAH59S	Amonafide	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.56	1.16	5.49	7.32
DC45BCD	DMG2YBD	Trifluridine	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.59	0.22	0.02	0.07
DCS7MZU	DMG2YBD	Trifluridine	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.07	7	5.07	5.18
DCPEG4L	DMG2YBD	Trifluridine	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	3.4	0.88	1.04	1.09
DCB01JO	DMG2YBD	Trifluridine	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.3	2.03	1.8	1.83
DCMUZ35	DMG2YBD	Trifluridine	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.9	9.71	10.48	10.28
DCHPKY9	DMG2YBD	Trifluridine	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.58	4.26	2.98	4.42
DCCRGN6	DMG2YBD	Trifluridine	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.36	5.41	5.22	5.67
DCJ8K5K	DMG2YBD	Trifluridine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.4	9.12	9.38	9.38
DCA4DR4	DMG2YBD	Trifluridine	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.33	4.55	1.46	5.4
DC7BLDV	DMG2YBD	Trifluridine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.76	6.84	1.77	3.11
DCZZPXZ	DMG2YBD	Trifluridine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	11.1	12.92	4.41	7.37
DCVI7EK	DMG2YBD	Trifluridine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.83	5.56	4.06	5.2
DC9E70U	DMG2YBD	Trifluridine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	11.62	10.83	6.51	8.97
DCH6AF7	DMG2YBD	Trifluridine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.44	3.76	3.09	4.55
DCARRL4	DMG2YBD	Trifluridine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.02	6.24	1.72	3.57
DCYCJI4	DMG2YBD	Trifluridine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.44	0.95	0.06	0.22
DCMPP1M	DMG2YBD	Trifluridine	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.22	1.48	6.85	7.47
DCXHZOM	DMG2YBD	Trifluridine	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	8.88	8.82	6.75	10.86
DCGDW6F	DMG2YBD	Trifluridine	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.48	6.11	1.31	9.22
DCLDLZW	DMG2YBD	Trifluridine	Approved	34	DMD7X1O	Dexrazoxane	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.59	4.73	6.55	7.11
DCC6KO4	DMG2YBD	Trifluridine	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.71	3.87	2.37	5.75
DCCEOWY	DMG2YBD	Trifluridine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	7.27	9.99	8.63	11.13
DC5VYZV	DMG2YBD	Trifluridine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.82	2.83	0.86	6.23
DC35VZ3	DMG2YBD	Trifluridine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	7.46	8.6	8.21	12
DCWKKVY	DMG2YBD	Trifluridine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.14	2.35	4.82	6.64
DCJZG1Q	DMG2YBD	Trifluridine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.85	4.75	6.47	9.5
DCNCPRC	DMG2YBD	Trifluridine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	9.53	8.82	8.16	10.24
DCZTP1U	DMG2YBD	Trifluridine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	21.46	21.11	22.24	23.26
DC3B0OR	DMG2YBD	Trifluridine	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.13	0.66	0.24	1.44
DCOABR4	DMG2YBD	Trifluridine	Approved	34	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.39	2.47	1.37	3.97
DC34HSL	DMG2YBD	Trifluridine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.65	5.67	2.77	5.28
DCZV2AZ	DMG2YBD	Trifluridine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.71	4.94	4.58	2.14
DC96THB	DMG2YBD	Trifluridine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.96	4.6	7.64	8.61
DCFV1SP	DMG2YBD	Trifluridine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4.6	6.51	8.74	10.02
DCETKAR	DMG2YBD	Trifluridine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	5.72	7.39	0.81	6.51
DCCR74V	DMG2YBD	Trifluridine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.82	3.57	5.33	9.22
DC906SI	DMG2YBD	Trifluridine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.1	5.9	4.28	2.02
DCT7NR5	DMG2YBD	Trifluridine	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.27	5.1	4.83	5.82
DC1I0MX	DMG2YBD	Trifluridine	Approved	34	DMHL7OB	Uracil mustard	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.37	0.45	0.08	4.34
DCRD3AF	DMG2YBD	Trifluridine	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.23	4.63	2.03	3.33
DC0FFX2	DMG2YBD	Trifluridine	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	4.06	6.47	3.14	5.64
DCWEY7M	DMG2YBD	Trifluridine	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.42	5.12	0.88	9.27
DCSM3DO	DMG2YBD	Trifluridine	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.9	2.24	5.26	6.84
DC1O710	DMG2YBD	Trifluridine	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.74	3.8	6.04	7.04
DCJZWC5	DMG2YBD	Trifluridine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.67	0.68	0.9	2.1
DC1VCKH	DMG2YBD	Trifluridine	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.48	3.46	7.4	9.6
DCUYPYZ	DMG2YBD	Trifluridine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	5.31	6.43	3.35	0.92
DCBWAJ9	DMG2YBD	Trifluridine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.05	5.16	0.37	3.9
DC9FKWD	DMG2YBD	Trifluridine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.59	9.48	1.18	7.68
DC83XHG	DMG2YBD	Trifluridine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.3	8.32	0.59	6.09
DC4O7TX	DMG2YBD	Trifluridine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	7.21	9.91	9.73	10.97
DCQTG1I	DMG2YBD	Trifluridine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	7.07	8.75	4.61	7.45
DCHIW65	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.32	1.23	0.21	1.17
DCAKXNZ	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.22	1.83	4.35	8.55
DCVR5FD	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	6.73	7.77	7.7	7.1
DCOJW22	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	8.97	9.93	11.93	13.53
DCPS8H3	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.13	2.78	8.21	9.06
DCQV08B	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.71	8.42	3.29	4.15
DCZ8SM2	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.97	2.51	2.87	6.06
DC4ZWJU	DMG2YBD	Trifluridine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.38	4.81	8.3	9.75
DC8DYUM	DMG2YBD	Trifluridine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.61	1.23	2.6	2.62
DCVP6WQ	DMG2YBD	Trifluridine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.51	3.9	2.61	3.21
DC1W423	DMG2YBD	Trifluridine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.9	0.49	0.55	0.96
DCSGO5M	DMG2YBD	Trifluridine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.57	1.49	0.22	1.02
DCARFOE	DMG2YBD	Trifluridine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.28	2.5	3.14	3.5
DC4PO0Q	DMG2YBD	Trifluridine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.48	0.33	0.23	0.38
DCQWZY4	DMG2YBD	Trifluridine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.74	0.04	0.14	0.53
DCH1QH3	DMG2YBD	Trifluridine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	9.65	10.66	8.94	8.77
DCR0TWN	DMG2YBD	Trifluridine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.88	1.23	1.71	1.8
DCZLFMU	DMG2YBD	Trifluridine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	19.21	15.71	10.17	16
DCTHFAA	DMG2YBD	Trifluridine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	4.24	5.83	4.84	5.81
DC4QXY6	DMG2YBD	Trifluridine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.55	3.03	2.03	2.94
DCFZHPF	DMG2YBD	Trifluridine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	7.28	6.77	11.68	12.16
DC908FG	DMG2YBD	Trifluridine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.34	1.9	6.45	7.48
DCV3TA5	DMG2YBD	Trifluridine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.27	9.91	9.93	9.6
DC78DT8	DMG2YBD	Trifluridine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.46	3.72	6.67	7.54
DCTIP5W	DMG2YBD	Trifluridine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.16	2.53	7.43	7.89
DCGHFEW	DMG2YBD	Trifluridine	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.31	3.23	6.43	6.88
DCPNE5D	DMG2YBD	Trifluridine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.18	2.69	1.73	2.17
DCOIIXF	DMG2YBD	Trifluridine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.61	3.9	2.66	3.01
DCYI9HA	DMG2YBD	Trifluridine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.76	3.76	1.26	4.1
DCGX37L	DMG2YBD	Trifluridine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	7.45	5.95	5.58	1.6
DCRAJGJ	DMG2YBD	Trifluridine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	6.93	15.42	0	9.7
DCBC0SW	DMG2YBD	Trifluridine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.11	1.91	2.81	4.3
DCSELCY	DMG2YBD	Trifluridine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.77	2.45	1.04	2.63
DCNTPHG	DMG2YBD	Trifluridine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.85	8.06	5.67	7.51
DCHTTTK	DMG2YBD	Trifluridine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.1	4.93	2.51	4.22
DCK1CRX	DMG2YBD	Trifluridine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.66	2.04	1.12	3.33
DCV5LYB	DMG2YBD	Trifluridine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.13	6.92	2.05	6.65
DCB86EY	DMG2YBD	Trifluridine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.89	4.24	2.09	3.4
DCV9ELQ	DMG2YBD	Trifluridine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	15.49	16.43	10.56	13.02
DC8C7Z3	DMG2YBD	Trifluridine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	6.02	7.21	0.64	8.58
DC4T9TN	DMG2YBD	Trifluridine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	10.16	9.11	3.19	9.89
DC04BQG	DMG2YBD	Trifluridine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.24	2.69	2.62	5.52
DCT6LU1	DMG2YBD	Trifluridine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	9.82	13.09	9.06	14.51
DCT65RS	DMG2YBD	Trifluridine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.73	5.6	0.73	8.37
DCGK85U	DMG2YBD	Trifluridine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.09	4.58	3.37	6.58
DC24YO8	DMG2YBD	Trifluridine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.47	1.84	0.58	2.02
DCUZG5I	DMG2YBD	Trifluridine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.8	3.02	0.85	4.35
DC6D3FC	DMG2YBD	Trifluridine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	3.03	5.94	5.31	3.39
DCPICLB	DMG2YBD	Trifluridine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.93	2.13	0.41	4.23
DCTPR02	DMG2YBD	Trifluridine	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.86	1.18	0.38	1.58
DCSCJV3	DMG2YBD	Trifluridine	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.94	2.89	1.74	1.11
DCOYKAI	DMG2YBD	Trifluridine	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.64	6.51	5.93	8.48
DCF8RT0	DMG2YBD	Trifluridine	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.42	0.9	0.18	2.73
DCROBD9	DMG2YBD	Trifluridine	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	10.25	8.54	3.69	10.71
DC6IUIG	DMG2YBD	Trifluridine	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.36	1.09	2.82	3.94
DCNZ4BD	DMG2YBD	Trifluridine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.26	3.56	4.67	4.85
DCDPMU3	DMG2YBD	Trifluridine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.56	2.44	0.92	2.72
DC579RX	DMG2YBD	Trifluridine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	15.69	13.15	5.27	14.16
DCRRNG7	DMG2YBD	Trifluridine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.41	7.81	4.12	9.39
DCR9XCI	DMG2YBD	Trifluridine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.74	6.75	5.89	3.93
DCT39BZ	DMG2YBD	Trifluridine	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.4	2.75	2.43	8.17
DCLXTJS	DMG2YBD	Trifluridine	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.02	2.04	2.12	6.78
DCUB1XH	DMG2YBD	Trifluridine	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	4.53	6.08	2.66	1.67
DCQB2JN	DMG2YBD	Trifluridine	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.58	6.2	3.53	2.23
DC34YQM	DMG2YBD	Trifluridine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.33	0.51	2.41	3.61
DCM71OI	DM0PIY6	Picoplatin	Phase 3	25	DM053KT	Aprepitant	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	24.71	24.71	33.89	33.92
DC0GHA7	DM0PIY6	Picoplatin	Phase 3	25	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	12.9	12.9	16	16.04
DCLRTBY	DM0PIY6	Picoplatin	Phase 3	25	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.05	6.6	4.04	6.37
DCW5EV8	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	33.71	32.95	23.14	28.36
DCZZLFC	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	35.16	31.94	23.64	35.68
DCOSZCO	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.01	3.94	1.31	1.43
DCUU2BG	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	6.36	9.77	7.87	8
DCHNLIR	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	9.38	7.72	3.24	3.64
DC23F9K	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	6.53	8.84	5.88	5.98
DCCRE02	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	6.62	6.75	2.12	2.07
DCP6HF4	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.26	2.48	3.55	3.53
DC1AYM3	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.47	3.92	2.26	2.26
DCNW97Z	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	12.16	16.21	9.89	10.63
DCNF0EC	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	7.58	9.48	6.91	6.91
DCVCALY	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	9.59	12.67	8.38	8.6
DCJRCE6	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	35.09	31.85	20.47	22.16
DCVXBTM	DM0PIY6	Picoplatin	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.47	7.42	1.67	0.94
DCFPP4M	DM0PIY6	Picoplatin	Phase 3	25	DM3VZJQ	Chlorphenesin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	13.87	13.87	25.88	25.89
DCI8WCL	DM0PIY6	Picoplatin	Phase 3	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	8	11.61	13.02	12.9
DCLWEKW	DM0PIY6	Picoplatin	Phase 3	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	9.87	12.22	2.08	1.88
DCI9S2C	DM0PIY6	Picoplatin	Phase 3	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	2.91	3.06	0.97	0.1
DCJLIZ1	DM0PIY6	Picoplatin	Phase 3	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	5.03	5.73	0.49	0.49
DC7ESHP	DM0PIY6	Picoplatin	Phase 3	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	7.45	13.08	3.86	3.86
DC5X0MU	DM0PIY6	Picoplatin	Phase 3	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	5.79	5.6	3.15	1.82
DCC74TI	DM0PIY6	Picoplatin	Phase 3	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1	4.11	2.13	2.13
DCVXE2B	DM0PIY6	Picoplatin	Phase 3	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	2.43	4.88	3.6	3.04
DCWFV3R	DM0PIY6	Picoplatin	Phase 3	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.43	6.85	3.31	4.45
DCECBAP	DM0PIY6	Picoplatin	Phase 3	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	2.35	3.45	1.08	0.5
DC08QGV	DM0PIY6	Picoplatin	Phase 3	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.61	3.27	1.96	1.98
DCTBULJ	DM0PIY6	Picoplatin	Phase 3	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	13.92	13.56	3.04	0.51
DCD0EN1	DM0PIY6	Picoplatin	Phase 3	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.83	9.19	4.88	4
DCVJRQD	DM0PIY6	Picoplatin	Phase 3	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.78	3.29	3.7	3.58
DC1OUAV	DM0PIY6	Picoplatin	Phase 3	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	8.04	11.68	5.91	5
DCZPBLW	DM0PIY6	Picoplatin	Phase 3	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	4.59	5.48	3.93	2.79
DC6M03M	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.9	4.02	1.31	0.08
DC53QTP	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	23.94	16.15	11.71	9.07
DCQAGLB	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4	5.81	1.22	1.26
DCJHH9Q	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.76	8.42	9.28	10.98
DC9U4H5	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	15.91	13.26	3.28	3.28
DCYPID5	DM0PIY6	Picoplatin	Phase 3	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.93	12.95	7.27	6.86
DC7B0LF	DM0PIY6	Picoplatin	Phase 3	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.1	4.1	4.78	4.78
DCIW6L0	DM0PIY6	Picoplatin	Phase 3	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.64	3.39	1.74	1.74
DCDHM2T	DM0PIY6	Picoplatin	Phase 3	25	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	3.17	3.58	4.97	4.85
DCGOHH1	DM0PIY6	Picoplatin	Phase 3	25	DMAYD7O	IT-141	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.61	3.61	4.12	4.18
DCE7ZE0	DM0PIY6	Picoplatin	Phase 3	25	DMB4AVP	Pamidronate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.76	6.76	20.56	20.56
DCET8R2	DM0PIY6	Picoplatin	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	10.51	8.03	3.32	3.33
DC78L8J	DM0PIY6	Picoplatin	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.83	5.53	5.52	5.98
DCK58TP	DM0PIY6	Picoplatin	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.74	5.22	2.49	2.73
DC84PJ5	DM0PIY6	Picoplatin	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.57	4.34	2.73	2.59
DCS640N	DM0PIY6	Picoplatin	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.28	4.76	1.94	1.94
DCAYZNM	DM0PIY6	Picoplatin	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	6.82	8.43	8.56	8.56
DCTWTFF	DM0PIY6	Picoplatin	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.17	3.79	2.13	2.13
DC9T9IU	DM0PIY6	Picoplatin	Phase 3	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	6.04	12.92	6.76	5.22
DCE83Z6	DM0PIY6	Picoplatin	Phase 3	25	DMCR1MV	Itraconazole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.89	0.89	13.65	13.66
DCPIP5S	DM0PIY6	Picoplatin	Phase 3	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	12.44	13.42	3.14	3.98
DCBGDCF	DM0PIY6	Picoplatin	Phase 3	25	DMCYVDT	Chlorzoxazone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.57	5.57	6.24	6.28
DCR8WJ5	DM0PIY6	Picoplatin	Phase 3	25	DMD9WSC	Memantine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	15.63	15.63	28.84	28.84
DC9MCRQ	DM0PIY6	Picoplatin	Phase 3	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.42	4.42	4.95	5
DC75UHE	DM0PIY6	Picoplatin	Phase 3	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.64	5.87	3.39	3.39
DC2REMC	DM0PIY6	Picoplatin	Phase 3	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	6.65	12.05	3.95	3.4
DC4M2UO	DM0PIY6	Picoplatin	Phase 3	25	DMF57DM	Pazopanib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	58.96	58.96	70.68	70.68
DCUT0O8	DM0PIY6	Picoplatin	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.3	6.43	3.53	2.4
DCZHTYU	DM0PIY6	Picoplatin	Phase 3	25	DMHZJCG	Pentamidine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.38	1.38	14.93	14.95
DC1HRDP	DM0PIY6	Picoplatin	Phase 3	25	DMI40NL	Tolazoline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	12.91	12.91	25.08	25.08
DCZ51V3	DM0PIY6	Picoplatin	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	4.93	4.55	0.85	0.08
DCZWP3D	DM0PIY6	Picoplatin	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.14	6.89	0.36	2.94
DCK9OW7	DM0PIY6	Picoplatin	Phase 3	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.22	3.36	1.7	1.12
DCAWMHB	DM0PIY6	Picoplatin	Phase 3	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.65	4.65	1.77	1.54
DCO7VJ3	DM0PIY6	Picoplatin	Phase 3	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.19	5.4	0.37	1.36
DCCLIA0	DM0PIY6	Picoplatin	Phase 3	25	DMKSQG0	Tiagabine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.6	8.6	10.6	10.66
DCVOMH1	DM0PIY6	Picoplatin	Phase 3	25	DML5VQ0	Fenoprofen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	25.17	25.17	37.86	37.88
DCEKTE2	DM0PIY6	Picoplatin	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.85	4.58	2.56	1.74
DCXA09B	DM0PIY6	Picoplatin	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.97	4.46	2.24	1.58
DCR5PN8	DM0PIY6	Picoplatin	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	19.06	19.06	21.48	21.48
DCX3TV5	DM0PIY6	Picoplatin	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0	4.05	5.46	5.34
DCXEOXT	DM0PIY6	Picoplatin	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.05	3.54	2.76	2.37
DC4IGC9	DM0PIY6	Picoplatin	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.37	6.02	3.13	2.09
DC6TG2I	DM0PIY6	Picoplatin	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.07	8.07	9.37	9.43
DCTEOHU	DM0PIY6	Picoplatin	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	7.79	13.97	12.1	7.83
DCMI3GJ	DM0PIY6	Picoplatin	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	3.41	4.7	3.03	2.06
DCMWDVM	DM0PIY6	Picoplatin	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	5.16	6.87	3.14	0.26
DCN1DBM	DM0PIY6	Picoplatin	Phase 3	25	DMMN36E	Abacavir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.28	7.28	20.93	20.95
DCTR4HZ	DM0PIY6	Picoplatin	Phase 3	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.47	10.58	8.25	8.25
DCOB0KV	DM0PIY6	Picoplatin	Phase 3	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.27	3.26	1.64	1.64
DC6GYWM	DM0PIY6	Picoplatin	Phase 3	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.42	2.42	2.87	2.96
DC9W9JD	DM0PIY6	Picoplatin	Phase 3	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.38	4	2.33	2.31
DC709NT	DM0PIY6	Picoplatin	Phase 3	25	DMQXTJS	Eptifibatide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.3	1.3	14.85	14.87
DCUOFVP	DM0PIY6	Picoplatin	Phase 3	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.23	6.84	3.09	2.89
DC50IM8	DM0PIY6	Picoplatin	Phase 3	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.88	4.4	2.34	1.66
DC8OJJG	DM0PIY6	Picoplatin	Phase 3	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.5	3.55	1.85	0.77
DC01GS5	DM0PIY6	Picoplatin	Phase 3	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.12	7.36	4.97	1.06
DCD6SZ6	DM0PIY6	Picoplatin	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.05	4.48	2.07	2.82
DCIJ7RC	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	4.39	8.57	3.15	3.12
DC1ZPM9	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	9.96	11.94	9.11	9.1
DCKSW38	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.05	7.61	5.11	4.59
DC0KFPH	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	9.96	14.96	15.12	15.12
DCDGOP1	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.95	7.49	5.99	5.69
DC2FD0V	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.76	5.15	0.46	0.17
DCZ71RP	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	6.56	19.17	19.29	19.24
DCNPNEF	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	7.78	17.21	15.49	16
DCQ0HJ6	DM0PIY6	Picoplatin	Phase 3	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.86	2.65	0.97	0.89
DCIRRFB	DM0PIY6	Picoplatin	Phase 3	25	DMRBMAU	Mycophenolic acid	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.12	6.12	7.51	7.54
DC3NCVL	DM0PIY6	Picoplatin	Phase 3	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.95	7.69	2.02	5.8
DCDXB0F	DM0PIY6	Picoplatin	Phase 3	25	DMWT905	Mefloquine	Phase 2/3 Trial	24	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.02	5.02	5.81	5.86
DCFJKXP	DM0PIY6	Picoplatin	Phase 3	25	DMVRIC2	Zileuton	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	13.88	13.88	25.64	25.65
DCK23YY	DM0PIY6	Picoplatin	Phase 3	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.11	2.43	0.42	0.79
DCCY238	DM0PIY6	Picoplatin	Phase 3	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	10.61	12.6	2.14	1.46
DCJREB3	DM0PIY6	Picoplatin	Phase 3	25	DMXCM7H	Cerivastatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.96	2.96	3.46	3.55
DCZ8EV2	DM0PIY6	Picoplatin	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	7.32	7.24	0.92	0.3
DCDGB7C	DM0PIY6	Picoplatin	Phase 3	25	DMZMSCT	Cilostazol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.84	2.84	16.42	16.43
DCLS6IZ	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	22.98	25.04	21.07	21.07
DCEQ9HP	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	14.12	19.12	16.63	15.89
DCUM2FV	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.99	8.98	6.45	5.6
DC5UQ23	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	14.15	12.6	10.21	5.72
DC56C4Q	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	26.16	33.01	26.73	27.34
DCMOVO8	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	10.8	12.22	5.7	7.97
DC8Y1IU	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	14.43	22.11	14.27	14.86
DCD3GLE	DM0PIY6	Picoplatin	Phase 3	25	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.12	3.47	12.16	11.76
DCKGTFE	DM0PIY6	Picoplatin	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	17.29	17.11	21.31	21.5
DCSB0VS	DM0PIY6	Picoplatin	Phase 3	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.96	8.72	4.22	2.18
DCC3OKL	DM0PIY6	Picoplatin	Phase 3	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	15.22	15.41	1.72	2.1
DCL9DJ7	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	12.65	13.95	10.81	9.88
DC9VOU3	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	11.69	13.62	10.41	10.41
DCJHSDT	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.66	4.05	9.46	7.69
DCCJY7Y	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	30.42	29.28	23.85	23.55
DC1HP05	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.49	8.57	4.37	4.37
DCGGMYY	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	14.06	15.63	8.39	8.38
DCA9WTM	DM0PIY6	Picoplatin	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.99	4.72	5.88	6.55
DCV2428	DM0PIY6	Picoplatin	Phase 3	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.26	4.85	2.93	1.52
DCFP548	DM0PIY6	Picoplatin	Phase 3	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.81	9.16	2.02	1.82
DC3R2ND	DM0PIY6	Picoplatin	Phase 3	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.07	3	0.84	0.36
DC6KRY1	DM0PIY6	Picoplatin	Phase 3	25	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.95	5.09	0.93	0.93
DCTXP4B	DM0PIY6	Picoplatin	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.49	9.58	6.56	5.17
DC5XI9G	DM0PIY6	Picoplatin	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.91	5.6	3.95	5.2
DCUQD9C	DM0PIY6	Picoplatin	Phase 3	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.94	3.23	13.36	13.62
DCO1OFG	DM0PIY6	Picoplatin	Phase 3	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.74	3.85	1.35	0.46
DC6SBUM	DM0PIY6	Picoplatin	Phase 3	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.93	4.46	10.53	11.19
DCV4OQB	DM0PIY6	Picoplatin	Phase 3	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.02	9	1.72	1.44
DC92JF2	DM0PIY6	Picoplatin	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.8	6.04	2.45	2.32
DCGKAGZ	DM0PIY6	Picoplatin	Phase 3	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.55	11.72	5.03	5.03
DCDUSIR	DM0PIY6	Picoplatin	Phase 3	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.57	7.16	0.29	0.31
DC9OD1Y	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.65	9.3	1.63	2.12
DCBV4IS	DM0PIY6	Picoplatin	Phase 3	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.44	10.27	2.55	1.06
DCMKCNU	DM0PIY6	Picoplatin	Phase 3	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	9.75	11.28	14.38	15.35
DCQZXRE	DM0PIY6	Picoplatin	Phase 3	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.91	8.21	0.77	0.77
DC5RRUJ	DM0PIY6	Picoplatin	Phase 3	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	10.93	8.48	2.66	2.66
DCZAIUK	DM0PIY6	Picoplatin	Phase 3	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.96	1.97	5.34	5.4
DCNJ472	DM0PIY6	Picoplatin	Phase 3	25	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.23	5.87	0.98	0.22
DCOKANG	DM0PIY6	Picoplatin	Phase 3	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.2	6.13	3.16	4.5
DC32TH9	DM0PIY6	Picoplatin	Phase 3	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.15	6.73	4	2.94
DCD6H56	DM0PIY6	Picoplatin	Phase 3	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.47	1.87	1.36	0.59
DCGKM2M	DM0PIY6	Picoplatin	Phase 3	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.32	4.28	1.92	3.1
DC6M62L	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.11	7.58	3.67	4.89
DCAKE5Q	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.05	1.8	0.88	0.78
DC1ZRKV	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	21.9	18.91	18.31	17.35
DCLW8XW	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	17.6	18.35	13.24	13.76
DCTCZRS	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	12.65	17.15	14.11	13.74
DCWQB6D	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	9.3	18.36	14.43	13.76
DC9CMZZ	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	6.72	10.39	4.31	5.1
DCXGF5K	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	7.22	8.75	6.28	5.35
DCR7VTS	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	8.17	15.2	9.24	9.83
DCC0BXJ	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	7.62	9.62	5.9	5.65
DC0MQOM	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	13.85	16.46	14.85	13.42
DCRO1QE	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	6.19	13.28	6.45	11.11
DCH59RS	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.14	6.99	0.99	2.12
DCY85D5	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	11.17	14.99	11.37	11.37
DCDBOV0	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	30.05	24.6	21.87	21.22
DCGP60J	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	32.35	28.19	29.13	29.07
DCO3MBC	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.07	4.44	3.73	3.73
DC9GYP9	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	8.52	14.83	7.13	8.86
DCR1N4B	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	6.55	7.5	7.55	2.46
DCHAYHO	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	7.21	13.62	4.61	8.97
DC51IYF	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.03	8.21	3.45	7.16
DCNC0G8	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	7.31	11.68	11.06	10.62
DCG6KWX	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.35	11.53	10.62	10.06
DCYDXGA	DM0PIY6	Picoplatin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.59	8.34	6.08	5.83
DCTGZ41	DM0PIY6	Picoplatin	Phase 3	25	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.54	10.29	8.18	7.06
DCUBD3C	DM0PIY6	Picoplatin	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.69	8.99	8.62	7.49
DCSP3XK	DM0PIY6	Picoplatin	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	10.1	8.81	2.32	1.87
DCNQDVP	DM0PIY6	Picoplatin	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.76	12.35	6.4	6.06
DCDL04R	DM0PIY6	Picoplatin	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.56	5.9	2.31	1.59
DCM72ID	DM0PIY6	Picoplatin	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.56	8.6	3.9	3.5
DC4CYLK	DM0PIY6	Picoplatin	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.8	8.83	3.97	3.97
DCE3AOX	DM0PIY6	Picoplatin	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.88	5.24	4.19	5.25
DCPFGPH	DM0PIY6	Picoplatin	Phase 3	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.09	9.2	4.21	3.74
DC0JB3A	DM0PIY6	Picoplatin	Phase 3	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.14	12.01	9.76	8.67
DC1N6ZE	DM0PIY6	Picoplatin	Phase 3	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.99	4.77	1.23	0.86
DC17OXT	DM0PIY6	Picoplatin	Phase 3	25	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	15.98	16	15.66	16.95
DC2Y6NQ	DM0PIY6	Picoplatin	Phase 3	25	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.63	6.66	2.32	4.19
DCRR2TN	DM0PIY6	Picoplatin	Phase 3	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	7.73	11.71	4.21	4.13
DC1U53U	DM0PIY6	Picoplatin	Phase 3	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.39	10.55	7.99	3.31
DCGKUYA	DM0PIY6	Picoplatin	Phase 3	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.54	6.07	5.42	4.92
DCNXCJL	DM0PIY6	Picoplatin	Phase 3	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	4.63	8.69	3.94	3.77
DC9P4L2	DM0PIY6	Picoplatin	Phase 3	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.53	3.28	1.09	1.09
DC8HXMK	DM0PIY6	Picoplatin	Phase 3	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.03	4.33	3.77	3.86
DC4GUNG	DM0PIY6	Picoplatin	Phase 3	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.62	3.22	2.48	0.54
DCEMKB3	DM0PIY6	Picoplatin	Phase 3	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.82	8.6	5.54	4.9
DC25N5H	DM0PIY6	Picoplatin	Phase 3	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.64	6.53	2.53	2.23
DCIHX1F	DM0PIY6	Picoplatin	Phase 3	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	5.03	7.46	2.56	1.86
DCYR6CU	DM0PIY6	Picoplatin	Phase 3	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.57	5.95	1.93	1.4
DCG8NCE	DM0PIY6	Picoplatin	Phase 3	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.4	7.51	2.79	1.97
DCB538R	DM0PIY6	Picoplatin	Phase 3	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.4	3.95	2.44	2.01
DC9191G	DM0PIY6	Picoplatin	Phase 3	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	5.85	6.45	1.25	0.14
DCQSXAM	DM0PIY6	Picoplatin	Phase 3	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.98	5.27	1.19	0.34
DCX4UTX	DM0PIY6	Picoplatin	Phase 3	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.03	8.53	4.9	4.61
DC16W9R	DM0PIY6	Picoplatin	Phase 3	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.17	4.24	2.51	1.65
DCR423I	DM0PIY6	Picoplatin	Phase 3	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	3.84	11.5	9.01	7.07
DCAEBFF	DM0PIY6	Picoplatin	Phase 3	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	7.9	8.74	3.2	2.41
DCHRUWV	DM0PIY6	Picoplatin	Phase 3	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	6.93	12.21	10.78	10.44
DCTUAWX	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	2.97	6.24	5.47	0.61
DCM9JS5	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	5.34	8.41	0.84	5.06
DC5PE0N	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.87	3.96	0.25	0.2
DCWUXXB	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.63	4.1	2.49	2.21
DCCDCJ4	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	5.05	7.16	3.01	3.13
DCGJ8U1	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	34.03	31.74	28.4	28.4
DC624CF	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.51	11.18	8.82	10.49
DCOUT8S	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	7.46	10.01	4.08	4.06
DCK5TKT	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	8.03	11.8	6.87	6.74
DCCYYQB	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.97	4.1	3.04	0.22
DCB85J3	DM0PIY6	Picoplatin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.28	9.3	9.61	9.48
DC4JSYO	DM0PIY6	Picoplatin	Phase 3	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.25	5.29	2	0.81
DCVUP12	DM0PIY6	Picoplatin	Phase 3	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.75	7.41	7.05	5.5
DCBW7SB	DM0PIY6	Picoplatin	Phase 3	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.84	7	7.73	6.2
DCCUKQ2	DM0PIY6	Picoplatin	Phase 3	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	5.44	12.41	9.27	7.53
DCQTPUP	DM0PIY6	Picoplatin	Phase 3	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.35	5.37	0.63	0.12
DC2F68Y	DM0PIY6	Picoplatin	Phase 3	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.91	7.34	1.3	2.34
DCXCL3G	DM0PIY6	Picoplatin	Phase 3	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.96	5.87	3.95	2.08
DCZ132G	DM0PIY6	Picoplatin	Phase 3	25	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.26	4.33	3.81	1.9
DC7LUCW	DM0PIY6	Picoplatin	Phase 3	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.85	4.73	1.48	0.65
DC8F6TI	DM0PIY6	Picoplatin	Phase 3	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.03	7.5	5.57	5.44
DC2DJEG	DM0PIY6	Picoplatin	Phase 3	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.16	5.99	3.31	2.96
DCL9YUA	DM0PIY6	Picoplatin	Phase 3	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.68	5.2	0.59	0.51
DC693S8	DM0PIY6	Picoplatin	Phase 3	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.71	2.89	0.81	0.46
DCYB8EO	DM0PIY6	Picoplatin	Phase 3	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.28	8.18	3.34	3.34
DC4KVYE	DM0PIY6	Picoplatin	Phase 3	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.07	4.73	1.05	1.05
DC06LX9	DM0PIY6	Picoplatin	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	9.91	15.39	9.23	9.23
DC8HATX	DM0PIY6	Picoplatin	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.64	3.97	1.33	1.26
DCSNOBC	DM0PIY6	Picoplatin	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.34	5.34	4.3	3.45
DCL4GX3	DM0PIY6	Picoplatin	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.13	5.2	1.6	1.87
DC7V87N	DM0PIY6	Picoplatin	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.37	1.58	0.86	0.8
DCSZ3FB	DM0PIY6	Picoplatin	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.7	2.71	0.62	0.49
DCOCPP3	DM0PIY6	Picoplatin	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.62	5.04	2.55	2.55
DCCZVZ5	DM0PIY6	Picoplatin	Phase 3	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.92	6.06	1.94	1.84
DCC1NRT	DM0PIY6	Picoplatin	Phase 3	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.05	6.98	3.11	3.12
DC720PE	DM0PIY6	Picoplatin	Phase 3	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	8.2	8.71	0.8	0.17
DCR2ESQ	DM0PIY6	Picoplatin	Phase 3	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.07	5.1	2.98	1.82
DCSP3L4	DM0PIY6	Picoplatin	Phase 3	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.78	4.73	2.27	0.39
DC5N9FC	DM0PIY6	Picoplatin	Phase 3	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.42	7.69	3.24	2.31
DCNJD3T	DM0PIY6	Picoplatin	Phase 3	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	3.08	4.12	0.96	0.42
DCUV9BR	DM0PIY6	Picoplatin	Phase 3	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	6.77	7.57	0.72	0.15
DC1I9XN	DM0PIY6	Picoplatin	Phase 3	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.94	6.58	4.35	2.9
DCAJ4I8	DM0PIY6	Picoplatin	Phase 3	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.69	6.54	3.09	2.95
DCNEOM9	DM0PIY6	Picoplatin	Phase 3	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.03	2.52	2.12	0.97
DCIN20I	DM0PIY6	Picoplatin	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	20.5	18.97	10.71	16.56
DCDKYNK	DM0PIY6	Picoplatin	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	9.05	16.58	15.39	15.32
DC2K7ZN	DM0PIY6	Picoplatin	Phase 3	25	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.41	9.14	4.36	4.3
DCJEUQ9	DM0PIY6	Picoplatin	Phase 3	25	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.31	4.07	3.39	2.91
DCDSF4J	DM0PIY6	Picoplatin	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3	3.97	1.08	0.18
DCKT9YT	DM0PIY6	Picoplatin	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.4	4.44	3.66	2.18
DCTC2RS	DM0PIY6	Picoplatin	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.35	9.35	8.6	9.29
DCHYBMQ	DM0PIY6	Picoplatin	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.7	5.9	5.16	3.71
DCLIWEX	DM0PIY6	Picoplatin	Phase 3	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.39	6.47	0.88	0.99
DCSARLZ	DM0PIY6	Picoplatin	Phase 3	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.22	5.57	0.84	0.53
DC9ZSYU	DM0PIY6	Picoplatin	Phase 3	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.6	4.53	1.11	0.91
DC4CTNN	DM0PIY6	Picoplatin	Phase 3	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	4.95	12.89	12.23	12.23
DCOUEIR	DM0PIY6	Picoplatin	Phase 3	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.17	12.6	12.09	12.09
DCF8N8W	DM0PIY6	Picoplatin	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	13.7	10.42	1.67	1.67
DC6SABW	DM0PIY6	Picoplatin	Phase 3	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.56	5.37	1.85	1.88
DC4KZR8	DM0PIY6	Picoplatin	Phase 3	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.92	11.08	13.23	11.92
DC6VC4X	DM0PIY6	Picoplatin	Phase 3	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.64	7.19	0.83	0.73
DCKH8ME	DM0PIY6	Picoplatin	Phase 3	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.32	5.32	0.31	0.08
DCVMQB8	DM0PIY6	Picoplatin	Phase 3	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.74	7.13	0.73	0.21
DC96QT0	DM0PIY6	Picoplatin	Phase 3	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	10.86	14.57	9.26	8.1
DCYH84J	DM0PIY6	Picoplatin	Phase 3	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.94	6.85	3.26	2.87
DC956K3	DM0PIY6	Picoplatin	Phase 3	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.46	4.41	0.97	0.31
DCP0EUQ	DM0PIY6	Picoplatin	Phase 3	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.92	2.11	0.9	0.33
DCYXGCE	DM0PIY6	Picoplatin	Phase 3	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	5.56	6.39	2.24	1.1
DC7IGR3	DM0PIY6	Picoplatin	Phase 3	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.47	9.35	6.02	6.64
DC0898C	DM0PIY6	Picoplatin	Phase 3	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.47	4.79	0.87	0.87
DCVY6C4	DM0PIY6	Picoplatin	Phase 3	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	9.67	13.33	14.14	14.03
DCG8LNV	DM0PIY6	Picoplatin	Phase 3	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	9.01	18.3	16.18	15.2
DCTBUB2	DM0PIY6	Picoplatin	Phase 3	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.67	11.46	6.6	9.36
DCN37EB	DM0PIY6	Picoplatin	Phase 3	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.38	15.52	14.62	14.62
DCLC14G	DM0PIY6	Picoplatin	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.47	5.32	3.64	3.05
DCFADXK	DM0PIY6	Picoplatin	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.23	5.32	3.83	1.39
DCRIPRT	DM0PIY6	Picoplatin	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.59	8.93	2.97	2.42
DC283XI	DM0PIY6	Picoplatin	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	8.12	8.85	0.94	0.52
DCLWFWN	DM0PIY6	Picoplatin	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.6	6.74	2.01	1.67
DC0CNKO	DM0PIY6	Picoplatin	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	8.16	12.21	5.15	3.74
DC40G82	DM0PIY6	Picoplatin	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	5.05	7.05	1.93	0.66
DC0WOVR	DM0PIY6	Picoplatin	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.8	12.08	9.54	9.11
DCJI9IV	DM0PIY6	Picoplatin	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.84	4.53	4.01	3.19
DCXV09H	DM0PIY6	Picoplatin	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.31	2.56	0.9	0.22
DC12QCA	DM0PIY6	Picoplatin	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.12	6.9	2.97	2.08
DCZQCOY	DM0PIY6	Picoplatin	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	5.35	7.71	2.26	2.26
DCDPG1W	DM0PIY6	Picoplatin	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.19	3.37	1.25	0.25
DCF48G5	DM0PIY6	Picoplatin	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	4.22	9.44	7.91	7.91
DCVK28V	DM0PIY6	Picoplatin	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.96	4.06	0.12	0.68
DCAIS0Y	DM0PIY6	Picoplatin	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.35	3.01	0.5	0.11
DCBIPJN	DM0PIY6	Picoplatin	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	2.16	2.81	1.37	0.94
DCIJ03W	DM0PIY6	Picoplatin	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	5.8	10.04	6.53	3.14
DCA78QD	DM0PIY6	Picoplatin	Phase 3	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.57	11.35	5.62	11.02
DCIGGUE	DM0PIY6	Picoplatin	Phase 3	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.93	9.06	5.14	5.14
DCES19B	DM0PIY6	Picoplatin	Phase 3	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.84	7.65	4.26	4.76
DCHF2EG	DM0PIY6	Picoplatin	Phase 3	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.9	3.36	4.27	3.87
DCQLIRL	DM0PIY6	Picoplatin	Phase 3	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.62	8.45	4.66	2.8
DC1XI6L	DM0PIY6	Picoplatin	Phase 3	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	7.79	6.8	4.83	3.1
DCWL1MF	DM0PIY6	Picoplatin	Phase 3	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.43	10.44	7.95	7.82
DC416PV	DM0PIY6	Picoplatin	Phase 3	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.72	5.14	1.01	0.81
DC6UNMO	DM0PIY6	Picoplatin	Phase 3	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.91	5.24	1.92	1.53
DC91C3A	DM0PIY6	Picoplatin	Phase 3	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.71	10.18	3.79	3.06
DCI0TJQ	DM0PIY6	Picoplatin	Phase 3	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.76	3.14	0.73	0.26
DCBGGAO	DM0PIY6	Picoplatin	Phase 3	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	3.55	7.9	4.31	3.66
DCJ9C67	DM0PIY6	Picoplatin	Phase 3	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.46	8.92	5.98	9.03
DC0NJI9	DM0PIY6	Picoplatin	Phase 3	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.31	4.57	3.83	3.66
DCSIK94	DM0PIY6	Picoplatin	Phase 3	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.25	3.41	2.84	2.74
DC4NIDK	DM0PIY6	Picoplatin	Phase 3	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	4.25	6.49	2.41	2.23
DCHYQ41	DM0PIY6	Picoplatin	Phase 3	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.26	10.28	4	4
DCSJHG6	DM0PIY6	Picoplatin	Phase 3	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.9	6.3	2.05	0.81
DC4HK60	DM0PIY6	Picoplatin	Phase 3	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	7	13.02	8.09	6.45
DCF36ES	DM0PIY6	Picoplatin	Phase 3	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.15	3.41	0.05	0.05
DCJAVM4	DM0PIY6	Picoplatin	Phase 3	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.88	9.47	3.81	3.27
DCT728J	DM0PIY6	Picoplatin	Phase 3	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	6.11	10.78	8.2	7.02
DC0DRA3	DM0PIY6	Picoplatin	Phase 3	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.48	5.66	5.28	4.32
DC6UT62	DM0PIY6	Picoplatin	Phase 3	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.69	5.34	2.87	1.95
DCPTV8N	DM0PIY6	Picoplatin	Phase 3	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	3.09	3.44	0.03	0.03
DCKU36B	DM0PIY6	Picoplatin	Phase 3	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.49	10.85	7.49	4.85
DCPYCTU	DM0PIY6	Picoplatin	Phase 3	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.83	5.81	2.58	1.58
DCIKLYZ	DM0PIY6	Picoplatin	Phase 3	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.93	1.63	0.7	0.66
DCU0F3W	DM0PIY6	Picoplatin	Phase 3	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	6.29	6.9	1.94	0.92
DCF432A	DM0PIY6	Picoplatin	Phase 3	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.78	9.05	0.23	8.38
DC4RO2Q	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	10.57	12.28	1.69	1.69
DCKIOHH	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.29	2.7	2.34	2.02
DCX9MAV	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	9.87	13.73	14.26	12.81
DCKKTIO	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.79	6.63	0.51	0.51
DC9HBXB	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.21	7.56	4.07	4.04
DCX110E	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.1	5.07	0.38	0.38
DCMC1M7	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.53	5.29	3.67	3.18
DCZHC1T	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	8.37	14.52	12.75	11.68
DCBTK9L	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.05	3.65	0.25	0.25
DCD72RJ	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	7.97	15.12	14.4	14.22
DCK1I2O	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.85	9.29	7.61	7.08
DCZ2YL3	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.02	3.69	3.08	3.27
DCENK0E	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.83	3.39	2.66	1.91
DCDY8F1	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.6	9.12	7.71	8.42
DC40SUG	DM0PIY6	Picoplatin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.21	5.89	3.53	3.31
DCP1F07	DM0PIY6	Picoplatin	Phase 3	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	9.76	6.92	3.56	2.83
DCIDCIW	DM0PIY6	Picoplatin	Phase 3	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	7.68	12.86	4.36	11.84
DCRBW3J	DM0PIY6	Picoplatin	Phase 3	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	4.24	6.43	1.6	1.59
DCXZ7JE	DM0PIY6	Picoplatin	Phase 3	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.73	4.9	3.29	2.8
DC6V5TV	DM0PIY6	Picoplatin	Phase 3	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.72	2.88	2.19	2.19
DCTR5FC	DM0PIY6	Picoplatin	Phase 3	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.51	9.43	5.99	9.25
DC3OTNN	DM0PIY6	Picoplatin	Phase 3	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.77	6.94	2.21	1.65
DCF3H6N	DM0PIY6	Picoplatin	Phase 3	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	6.82	7.79	1.48	1.06
DCZKQ6D	DM0PIY6	Picoplatin	Phase 3	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.51	4.07	0.24	0.63
DCKLUM4	DM0PIY6	Picoplatin	Phase 3	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.88	9.1	3.72	2.35
DC6NKK8	DM0PIY6	Picoplatin	Phase 3	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.04	8.78	4.01	3.18
DCTZYIH	DM0PIY6	Picoplatin	Phase 3	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.77	4.9	1.16	0.44
DC6D82M	DM0PIY6	Picoplatin	Phase 3	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.35	3.53	0.78	1.48
DCUBEL0	DM0PIY6	Picoplatin	Phase 3	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.17	0.85	2	4.02
DCSTD5I	DM0PIY6	Picoplatin	Phase 3	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.76	1.93	1.15	1.02
DCAQ091	DM0PIY6	Picoplatin	Phase 3	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.73	4.52	3.35	1.05
DCJK7CA	DM0PIY6	Picoplatin	Phase 3	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.61	2.36	1.43	1.31
DCJSWMU	DM0PIY6	Picoplatin	Phase 3	25	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.22	4.61	3.64	5.7
DC69D64	DM0PIY6	Picoplatin	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	5.57	6.96	1.73	1.23
DC00P7P	DM0PIY6	Picoplatin	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	7.33	6.79	1.49	0.15
DCYVD5V	DM0PIY6	Picoplatin	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.85	6.74	0.09	4.82
DCXXZBO	DM0PIY6	Picoplatin	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.03	5.7	1.9	1.01
DC7NCXD	DM0PIY6	Picoplatin	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4.73	14.02	10.87	13.85
DCX2HND	DM0PIY6	Picoplatin	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.63	7.54	1.54	0.45
DCBEIHD	DM89QE1	Metformin	Investigative	0	DMRF9YK	Empagliflozin	Approved	34	.	.	.	.	Type-2 diabetes	TTD Database	Approved	.	.	.	.	.
DC3BI0L	DM89QE1	Metformin	Investigative	0	DMGDKXN	Sitagliptin	Approved	34	DMRM3AW	Acarbose	.	.	Type 2 Diabetes Mellitus	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DC47MWP	DM89QE1	Metformin	Investigative	0	DM28UJG	Dapagliflozin	Phase 3 Trial	25	.	.	.	.	Diabetes Mellitus Type 2	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DC4KY92	DM89QE1	Metformin	Investigative	0	DMYHBKN	Exenatide	Approved	34	.	.	.	.	Polycystic Ovary Syndrome	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DC7NJPF	DM89QE1	Metformin	Investigative	0	DMUBP9O	Voglibose	Approved	34	.	.	.	.	Type 2 Diabetes Mellitus	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCKZ2K3	DM89QE1	Metformin	Investigative	0	DMYN59P	Vildagliptin	Approved	34	.	.	.	.	Coronary Artery Disease	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCL0PNL	DM89QE1	Metformin	Investigative	0	DMGQ1TV	ASP1941	Phase 3	25	.	.	.	.	Type 2 Diabetes Mellitus	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCRY3FB	DM89QE1	Metformin	Investigative	0	DMFRM1I	Canagliflozin	Approved	34	.	.	.	.	Polycystic Ovary Syndrome	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCTKP2Y	DM89QE1	Metformin	Investigative	0	DMKI7RB	Clomifene	Approved	34	.	.	.	.	PCOS	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DC8L29B	DM89QE1	Metformin	Investigative	0	DM28UJG	Dapagliflozin	Phase 3 Trial	25	DMGXENV	Saxagliptin	.	.	Type 2 Diabetes	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCCBRXW	DM89QE1	Metformin	Investigative	0	DMDBX5F	Ivermectin	Phase 2/3 Trial	24	.	.	.	.	Covid19	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCFG5WZ	DM89QE1	Metformin	Investigative	0	DMQTJSX	Fluvoxamine	Phase 2 Trial	21	.	.	.	.	Covid19	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC04PHO	DM89QE1	Metformin	Investigative	0	DM672AH	Aspirin	Phase 3 Trial	25	.	.	.	.	Preeclampsia	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCDEZAK	DM89QE1	Metformin	Investigative	0	DMGDKXN	Sitagliptin	Approved	34	.	.	.	.	Type 2 Diabetes	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCDS4EB	DM89QE1	Metformin	Investigative	0	DMZA5PQ	Glipizide	Approved	34	.	.	.	.	Type 2 Diabetes Mellitus	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCI79H1	DM89QE1	Metformin	Investigative	0	DMMUFKM	Colesevelam	Approved	34	.	.	.	.	Type 2 Diabetes	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCJZJ9F	DM89QE1	Metformin	Investigative	0	DMGXENV	Saxagliptin	Approved	34	.	.	.	.	Type 2 Diabetes	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCLUX8K	DM89QE1	Metformin	Investigative	0	DMZA5PQ	Glipizide	Approved	34	.	.	.	.	Type 2 Diabetes	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCMSNPO	DM89QE1	Metformin	Investigative	0	DM28UJG	Dapagliflozin	Phase 3 Trial	25	.	.	.	.	Type 2 Diabetes Mellitus	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCP3JVE	DM89QE1	Metformin	Investigative	0	DMRM3AW	Acarbose	Approved	34	.	.	.	.	"Diabetes, Type 2"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCRRXIM	DM89QE1	Metformin	Investigative	0	DMGDKXN	Sitagliptin	Approved	34	.	.	.	.	Type 2 Diabetes Mellitus	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCSEBNV	DM89QE1	Metformin	Investigative	0	DM28UJG	Dapagliflozin	Phase 3 Trial	25	.	.	.	.	Type 2 Diabetes	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCVSQJL	DM89QE1	Metformin	Investigative	0	DMREUZV	Eslicarbazepine acetate	Approved	34	.	.	.	.	Neuropathic Pain	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCY4K9C	DM89QE1	Metformin	Investigative	0	DMGXENV	Saxagliptin	Approved	34	.	.	.	.	Type 2 Diabetes Mellitus	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCHU4XJ	DM89QE1	Metformin	Investigative	0	DMWFJTR	Linagliptin	Phase 3 Trial	25	DMRF9YK	Empagliflozin	.	.	Diabetic complication	TTD Database	Phase 1	.	.	.	.	.
DCDFXP5	DM89QE1	Metformin	Investigative	0	DMILWZR	Rosiglitazone	Approved	34	.	.	.	.	Advanced solid tumour; Diabetic complication	TTD Database	Phase 1	.	.	.	.	.
DCDZWCY	DM89QE1	Metformin	Investigative	0	DMFRM1I	Canagliflozin	Approved	34	.	.	.	.	Type-2 diabetes	TTD Database	Phase 1	.	.	.	.	.
DCH96ME	DM89QE1	Metformin	Investigative	0	DM28UJG	Dapagliflozin	Phase 3 Trial	25	.	.	.	.	Type-2 diabetes	TTD Database	Phase 1	.	.	.	.	.
DCL18FJ	DM89QE1	Metformin	Investigative	0	DMQHN7I	L-leucine	Investigative	0	.	.	.	.	Type-2 diabetes	TTD Database	Phase 1	.	.	.	.	.
DCRTDAX	DM89QE1	Metformin	Investigative	0	DMGDKXN	Sitagliptin	Approved	34	.	.	.	.	Type-2 diabetes	TTD Database	Phase 1	.	.	.	.	.
DCULQ98	DM89QE1	Metformin	Investigative	0	DMYN59P	Vildagliptin	Approved	34	.	.	.	.	Type-2 diabetes	TTD Database	Phase 1	.	.	.	.	.
DCHDW34	DM89QE1	Metformin	Investigative	0	DMINOX3	Vincristine	Approved	34	DMKECZD	Temozolomide	DMP6SC2	Irinotecan	Solid Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC3UILR	DM89QE1	Metformin	Investigative	0	DMG281S	Carboplatin	Approved	34	DMLB81S	Paclitaxel	.	.	Ovarian Papillary Serous Carcinoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC8RR3V	DM89QE1	Metformin	Investigative	0	DMSV12M	Isavuconazole	Phase 3	25	.	.	.	.	Pharmacokinetics of Isavuconazole	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCFIG8O	DM89QE1	Metformin	Investigative	0	DMZD5QR	Cytarabine	Approved	34	.	.	.	.	Adult Acute Megakaryoblastic Leukemia (M7)	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCPCRU5	DM89QE1	Metformin	Investigative	0	DMRICNP	Vandetanib	Approved	34	.	.	.	.	Renal Cell Carcinoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCYY28M	DM89QE1	Metformin	Investigative	0	DMH61ZB	Cimetidine	Approved	34	.	.	.	.	Interaction	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC1TQFZ	DM89QE1	Metformin	Investigative	0	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	18.06	18.06	21.31	21.33
DCP2IQW	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	3.94	5.97	1.14	6.32
DC4Z6O0	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	0.16	9.64	1.53	8.29
DCXB88W	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	0.92	3.96	1.17	4.46
DCZ6PF2	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	7.63	11.91	4.99	12.91
DCDA23D	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	2.36	1.55	0.2	0.39
DC0WLO5	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	5.58	5.71	3.2	4.05
DCABTUY	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	10.69	14.06	10.06	13.46
DCQO4R7	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	39.07	40.69	2.34	37.91
DCFGBHV	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	9.91	11.73	5.6	10.89
DC0GG3I	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	15.59	17.38	2.06	16.46
DCR0WZX	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	6.41	9.6	4.31	9.77
DC3M1J1	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	18.08	25.23	4.99	19.05
DCBBVT2	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	12.82	15.76	10.12	14.25
DCG259W	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	4.58	5.42	2.23	5.89
DCNBUPU	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	4.42	4.99	2.97	6.8
DCWKVP3	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	7.61	9.79	4.3	10.78
DCSJBBW	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	6.7	7.74	11.83	12.79
DCSC265	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	2.88	1.69	0.61	0.42
DC2Z0KO	DM89QE1	Metformin	Investigative	0	DM2DMPO	Kanamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	42.06	42.06	54.23	54.23
DCF6E8R	DM89QE1	Metformin	Investigative	0	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	7.09	8.02	5.08	8.59
DCQJ959	DM89QE1	Metformin	Investigative	0	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	11.19	6.87	5.01	3.89
DCP0YQP	DM89QE1	Metformin	Investigative	0	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	13.97	16.77	2.3	15.81
DCHG1K0	DM89QE1	Metformin	Investigative	0	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	0.29	5.54	1.41	4.1
DC5KMKA	DM89QE1	Metformin	Investigative	0	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	1.27	5.13	5.05	5.8
DC82WND	DM89QE1	Metformin	Investigative	0	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	0.37	5.54	3.75	5.93
DCP2M11	DM89QE1	Metformin	Investigative	0	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	2.64	2.87	0.75	4.15
DC80V1O	DM89QE1	Metformin	Investigative	0	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	8.74	11.44	7.56	10.34
DCKMZT6	DM89QE1	Metformin	Investigative	0	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	1.42	4.46	0.84	4.47
DCQUVN3	DM89QE1	Metformin	Investigative	0	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	5.88	7.55	9.69	10.32
DC8XTED	DM89QE1	Metformin	Investigative	0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	4.14	5.77	1.32	6.11
DCDWI3U	DM89QE1	Metformin	Investigative	0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	12.23	9.16	2.82	7.98
DCJW8DM	DM89QE1	Metformin	Investigative	0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	5.34	5.25	2.54	5.09
DC4RKRJ	DM89QE1	Metformin	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	5.5	6.74	2.97	7.01
DCU8GWO	DM89QE1	Metformin	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	9.6	8.09	5.87	9.11
DCB3ONA	DM89QE1	Metformin	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	5.77	5.72	4.14	5.82
DCTXG0P	DM89QE1	Metformin	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.22	6.93	4.78	7.83
DCKRSR0	DM89QE1	Metformin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	5.99	5.34	1.27	5.67
DCJLVOI	DM89QE1	Metformin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	1.74	1.83	0.54	3.25
DCJLXTZ	DM89QE1	Metformin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	2.04	2.28	0.23	2.15
DCFSJ95	DM89QE1	Metformin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	6.58	1.13	0.17	0.55
DCF0XTR	DM89QE1	Metformin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	3.47	8.32	3.33	9.19
DC3R3TU	DM89QE1	Metformin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	5.26	7.22	11.07	11.36
DCGUW3M	DM89QE1	Metformin	Investigative	0	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.95	4.95	5.65	5.65
DCK74S0	DM89QE1	Metformin	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	2.98	3.35	1.16	6.56
DCYNWVJ	DM89QE1	Metformin	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	5.3	2.68	1.32	4.04
DCEAP73	DM89QE1	Metformin	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	1.58	3.9	3.44	2.62
DCQQU9I	DM89QE1	Metformin	Investigative	0	DMBLM5H	BHV-0223	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.81	6.81	20.52	20.53
DC0LAAI	DM89QE1	Metformin	Investigative	0	DMBYCU0	Metyrosine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	12.2	12.2	14.79	14.82
DCXI6UM	DM89QE1	Metformin	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	14.16	10.21	13.01	9.18
DCWMK6B	DM89QE1	Metformin	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	7.74	11.26	2.89	12.16
DCAJO7N	DM89QE1	Metformin	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	9.49	12.29	9.04	12.39
DCJNORO	DM89QE1	Metformin	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	9.4	12.37	7.33	12.93
DCAPSCC	DM89QE1	Metformin	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	1.93	2.35	5.96	1.64
DCA2XMW	DM89QE1	Metformin	Investigative	0	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	4.36	3.44	0.18	4.14
DCJ5SO7	DM89QE1	Metformin	Investigative	0	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	2.62	6.29	3.81	5.75
DCFEU8Q	DM89QE1	Metformin	Investigative	0	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	3.53	3.84	4.62	1.3
DCKFJPG	DM89QE1	Metformin	Investigative	0	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	4.93	1.42	5.52	0.13
DC81PQ0	DM89QE1	Metformin	Investigative	0	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	43.49	41.9	7.93	42.18
DCJ3U7J	DM89QE1	Metformin	Investigative	0	DMFCMPS	Daidzin	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.74	1.74	16.07	16.07
DCGTMIK	DM89QE1	Metformin	Investigative	0	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	4.74	5.52	2.08	6.59
DCW7HH5	DM89QE1	Metformin	Investigative	0	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	0.73	6.94	2.6	5.34
DC0BD5V	DM89QE1	Metformin	Investigative	0	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	3.86	11.27	7.51	11.08
DCU9YJG	DM89QE1	Metformin	Investigative	0	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	0.25	4.2	1.59	2.91
DCGBX6L	DM89QE1	Metformin	Investigative	0	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	5.9	5.54	1.34	6.27
DC57WKU	DM89QE1	Metformin	Investigative	0	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	2.78	8.23	0.27	7.88
DC1OVJ5	DM89QE1	Metformin	Investigative	0	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	0.43	7.9	11.94	8.43
DCH4ZOP	DM89QE1	Metformin	Investigative	0	DMFNTMY	Fibrates	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.82	5.82	19.06	19.06
DC65ENX	DM89QE1	Metformin	Investigative	0	DMOL54H	Clopidogrel	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	16.96	16.96	30.19	30.2
DCZ7C5H	DM89QE1	Metformin	Investigative	0	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.9	6.9	8.65	8.7
DC2XSPE	DM89QE1	Metformin	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	5.01	7.06	1.87	6.6
DCEZXSM	DM89QE1	Metformin	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	4.41	5.24	0.58	3.38
DC3QMWE	DM89QE1	Metformin	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	4.51	5.48	3.21	6.71
DCJHU0K	DM89QE1	Metformin	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	2.86	3.44	1.55	4.66
DCIB4EE	DM89QE1	Metformin	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	6.05	9.52	3.57	8.05
DC4RJJL	DM89QE1	Metformin	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	2.41	4.49	4.91	4.83
DC5NYRE	DM89QE1	Metformin	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	2.6	5.68	5.15	5.84
DCVX14L	DM89QE1	Metformin	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	21.13	24.33	4.9	21.59
DCV0NPE	DM89QE1	Metformin	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	6.27	13.35	1.45	8.39
DC0Y88K	DM89QE1	Metformin	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	5.12	9.08	7.5	11.5
DCFXORH	DM89QE1	Metformin	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	3.82	8.88	0.6	11.87
DCC1ZVH	DM89QE1	Metformin	Investigative	0	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	5.51	5.84	1.09	0.99
DC5XSYW	DM89QE1	Metformin	Investigative	0	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH2122	4.58	11.6	5.06	10.51
DC2J9YO	DM89QE1	Metformin	Investigative	0	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	7.69	7.15	4.35	3.78
DCLTB88	DM89QE1	Metformin	Investigative	0	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	9.42	11.86	9.57	9.57
DCWCFGH	DM89QE1	Metformin	Investigative	0	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	6.82	9.36	1.66	5.34
DC7KSAM	DM89QE1	Metformin	Investigative	0	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	3.93	4.62	5.8	3.44
DCQLAMW	DM89QE1	Metformin	Investigative	0	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	1.8	3.37	1.79	2.64
DCYI5XV	DM89QE1	Metformin	Investigative	0	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	6.69	18.46	9.96	13.52
DCJH73L	DM89QE1	Metformin	Investigative	0	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	3.29	6.43	2.05	5.83
DCITYQF	DM89QE1	Metformin	Investigative	0	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	0.4	5.21	0.61	4.26
DC2A9T6	DM89QE1	Metformin	Investigative	0	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	4.16	6.3	0.5	0.5
DCASK83	DM89QE1	Metformin	Investigative	0	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	1.23	5.03	5.35	5.75
DC3M76V	DM89QE1	Metformin	Investigative	0	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	8.78	10.02	4.51	6.61
DCI23PH	DM89QE1	Metformin	Investigative	0	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	7.18	7.23	4.45	7.39
DCHVV7T	DM89QE1	Metformin	Investigative	0	DMJAPE7	Methylene blue	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.56	2.56	3.27	3.29
DCSDAEM	DM89QE1	Metformin	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	0.35	6.7	5.04	5.49
DC4T3HR	DM89QE1	Metformin	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	2.98	2.82	3.79	3.95
DCBQNDW	DM89QE1	Metformin	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	2.44	5.46	4.3	4.3
DC19W0D	DM89QE1	Metformin	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	1.07	4.96	3.28	3.17
DCEH086	DM89QE1	Metformin	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	2.43	5.11	0.24	0.96
DC0QJTE	DM89QE1	Metformin	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	40.33	40.42	37.07	37.11
DCT69VE	DM89QE1	Metformin	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	2.19	6.69	5.84	5.67
DCLJ2R2	DM89QE1	Metformin	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	RPMI7951	1.53	2.31	0.9	1.01
DCKY3DH	DM89QE1	Metformin	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	3.93	5.91	1.59	0.44
DC7OTOE	DM89QE1	Metformin	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	4.73	7.06	2.77	3.05
DC7AINK	DM89QE1	Metformin	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	8.37	7.4	8.87	8.87
DCVIDGB	DM89QE1	Metformin	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	0.93	13.56	18.69	18.69
DCXO3F2	DM89QE1	Metformin	Investigative	0	DMPWB7T	Maprotiline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.58	6.58	7.41	7.42
DCEFXU3	DM89QE1	Metformin	Investigative	0	DMR8ONJ	Leflunomide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.85	9.85	11.46	11.46
DC1G3PU	DM89QE1	Metformin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	17.44	9.59	9.95	1.01
DCC0DKT	DM89QE1	Metformin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	5.76	5.31	1.58	3.47
DCO2CUH	DM89QE1	Metformin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	6.57	6.28	0.37	7.52
DCRYCN7	DM89QE1	Metformin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	10.15	13.43	8.8	14.7
DC0ZHL4	DM89QE1	Metformin	Investigative	0	DMSWYF5	Quinine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	46.6	46.6	56.07	56.07
DCE0TF5	DM89QE1	Metformin	Investigative	0	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	0.54	1.9	0.68	2.09
DCPMMW1	DM89QE1	Metformin	Investigative	0	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	6.56	9.16	9.24	9.41
DCAZPCM	DM89QE1	Metformin	Investigative	0	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	8.79	13.87	14.52	14.04
DCJ05B9	DM89QE1	Metformin	Investigative	0	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	9.45	15.67	6.88	10.56
DC6RZD7	DM89QE1	Metformin	Investigative	0	DMRBMAU	Mycophenolic acid	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.04	6.04	7.51	7.52
DC9XMMZ	DM89QE1	Metformin	Investigative	0	DMUZPJ5	Cisatracurium	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.64	4.64	15.79	15.8
DCCVZ4F	DM89QE1	Metformin	Investigative	0	DMWT905	Mefloquine	Phase 2/3 Trial	24	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.1	4.1	4.93	4.97
DCS9MZ0	DM89QE1	Metformin	Investigative	0	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.94	3.94	17.4	17.4
DCX7199	DM89QE1	Metformin	Investigative	0	DMSIVND	Hydroxychloroquine	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.97	6.97	21.2	21.22
DC34BDD	DM89QE1	Metformin	Investigative	0	DMYLOVR	Aciclovir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	21.36	21.36	31.35	31.35
DC9MOMA	DM89QE1	Metformin	Investigative	0	DMZ2TD9	GSK2194069	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.27	2.27	15.61	15.62
DCT27YV	DM89QE1	Metformin	Investigative	0	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	0.35	1.04	0.04	6.38
DC37316	DM89QE1	Metformin	Investigative	0	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	2.96	2.88	3.56	3.87
DCIJ7VA	DM89QE1	Metformin	Investigative	0	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	2.53	7.16	3.33	3.33
DCIEWQP	DM89QE1	Metformin	Investigative	0	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	2.14	2.54	1.72	2.69
DCJ0PGD	DM89QE1	Metformin	Investigative	0	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	2.06	3.39	2.87	2.87
DCJ5T1P	DM89QE1	Metformin	Investigative	0	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	15.29	18.22	1.6	1.6
DCFEFV6	DM89QE1	Metformin	Investigative	0	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	38.23	33.54	28.26	33.8
DC2N4QX	DM89QE1	Metformin	Investigative	0	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	15.26	15.27	13.24	15.38
DCJJNHX	DM89QE1	Metformin	Investigative	0	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	1.21	7.93	2.11	6.28
DCOK0MR	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.64	9.09	12.1	12.82
DCEGQNG	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	3.27	6.62	4.21	5.5
DC2CL7X	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	8.17	12.58	5.62	13.82
DC9DG9K	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.35	4.01	4.33	3.79
DC28IMT	DM89QE1	Metformin	Investigative	0	DM27D4J	PD-0325901	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.05	11.44	11.64	11.7
DCJ8FKK	DM89QE1	Metformin	Investigative	0	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.4	3.49	2.3	4.19
DCICXT3	DM89QE1	Metformin	Investigative	0	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.83	4.07	2.49	5.75
DCL3ITK	DM89QE1	Metformin	Investigative	0	DM3WDZ5	MK-1775	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.8	7.95	5.33	8.94
DCKNIBB	DM89QE1	Metformin	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	8.96	8.7	1.38	11.87
DCEU735	DM89QE1	Metformin	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	7.79	7.18	5.99	7.83
DCNDSDS	DM89QE1	Metformin	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.17	6.59	3.05	7.92
DCOJWZS	DM89QE1	Metformin	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.88	2.03	0.97	4.58
DCE25JH	DM89QE1	Metformin	Investigative	0	DM62QTW	RTB101	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	14.77	16.43	1.6	15.98
DCTDXPS	DM89QE1	Metformin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.11	5.06	4.44	7.11
DCOJW2C	DM89QE1	Metformin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	4.37	2.66	2.42	2.59
DC1M9HC	DM89QE1	Metformin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.78	7.38	1	1.27
DCWMKUK	DM89QE1	Metformin	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	6.21	5.21	11.7	4.67
DC3C2G8	DM89QE1	Metformin	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.72	5.38	2.04	4.69
DCT0SNM	DM89QE1	Metformin	Investigative	0	DMB5A80	SNX-2112	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.79	9.4	8.81	9.54
DC97D1X	DM89QE1	Metformin	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	2.19	2.44	2.08	3.26
DCZC4LL	DM89QE1	Metformin	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	8.48	10.17	6.97	12.66
DCKCT4P	DM89QE1	Metformin	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.59	4.9	6.59	6.71
DCDLBW8	DM89QE1	Metformin	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	19.23	20.76	18.3	18.57
DC1GB5N	DM89QE1	Metformin	Investigative	0	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	0.81	0.47	0.04	1.18
DCTBIHC	DM89QE1	Metformin	Investigative	0	DMCMBHA	Erlotinib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	5.24	6.11	0.81	6.59
DC4U3XU	DM89QE1	Metformin	Investigative	0	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.15	2.5	0.82	2.97
DC4NZTV	DM89QE1	Metformin	Investigative	0	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	4.59	7.93	2.84	8.79
DCTDOCN	DM89QE1	Metformin	Investigative	0	DMFGYKS	MK-5108	Phase 1	17	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	1.15	8.51	8.08	8.08
DCTVLJB	DM89QE1	Metformin	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	7.13	2.34	0.65	0.62
DCX0YG6	DM89QE1	Metformin	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	7.4	8.65	6.64	10.37
DCBNXOO	DM89QE1	Metformin	Investigative	0	DMLYGH4	MK-4827	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.42	2.45	3.21	5.76
DCLODDC	DM89QE1	Metformin	Investigative	0	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	12.59	11.71	3.68	3.68
DC5MXH3	DM89QE1	Metformin	Investigative	0	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	7.94	9.12	7.71	8.75
DC3YCMC	DM89QE1	Metformin	Investigative	0	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	2.2	2.64	1.92	0.79
DCQYMFP	DM89QE1	Metformin	Investigative	0	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	13.99	16.5	1.83	3.08
DCLFJ1U	DM89QE1	Metformin	Investigative	0	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	9.08	6.07	2.44	6.22
DCJQN3R	DM89QE1	Metformin	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.59	7.11	6.42	8.4
DCIAPS8	DM89QE1	Metformin	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.15	5.02	2	3.8
DCS1LBA	DM89QE1	Metformin	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	7.08	7.09	6.84	6.79
DCPCAEQ	DM89QE1	Metformin	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	2.3	5.54	3.86	3.9
DCA19FU	DM89QE1	Metformin	Investigative	0	DMPAWBN	GSK525762	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	11.6	15.3	12.82	12.81
DCYXW5Q	DM89QE1	Metformin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	3.2	4.2	1.77	4.72
DCTGDZU	DM89QE1	Metformin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	10.77	0.56	3.92	6.97
DC4KSKC	DM89QE1	Metformin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	12.45	12.91	5.9	14.36
DCVIC7S	DM89QE1	Metformin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	8.11	9.01	3.33	11.78
DCM7QXP	DM89QE1	Metformin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	18.61	19.68	7.12	18.74
DCVV3DN	DM89QE1	Metformin	Investigative	0	DMT1OZ6	MK-2206	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	3.25	3.85	0.09	4.92
DCTKKFG	DM89QE1	Metformin	Investigative	0	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	5.36	4.22	3.57	4.66
DC8GAY2	DM89QE1	Metformin	Investigative	0	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	EFM192B	5.79	8.39	4.55	9.24
DC6FWMW	DM89QE1	Metformin	Investigative	0	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MDAMB436	5.08	9.75	7.49	10.13
DCE2E52	DMS8IFC	Sorafenib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	2.22	6.91	5.04	2.66
DC4LZ9A	DMS8IFC	Sorafenib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.48	7.26	7.08	7.08
DCTPGIV	DMS8IFC	Sorafenib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.21	1.71	1.03	0.63
DC157DE	DMS8IFC	Sorafenib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.26	2.75	0.57	0.55
DCUGY1G	DMS8IFC	Sorafenib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	0.65	4.39	0.5	1.04
DCCO1XX	DMS8IFC	Sorafenib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	2.09	2.62	0.52	0.02
DCUXLNC	DMS8IFC	Sorafenib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	4.99	13.84	7.05	6.08
DCS5NYQ	DMS8IFC	Sorafenib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	4.54	9.53	5.92	5.92
DCASRLQ	DMS8IFC	Sorafenib	Approved	34	DM15F0X	Gefitinib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	18.25	18.25	21.07	21.08
DCAQKW5	DMS8IFC	Sorafenib	Approved	34	DM1D8XY	Dantrolene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.51	7.51	10.73	10.73
DC3I0MT	DMS8IFC	Sorafenib	Approved	34	DM29GAD	Lumefantrine	Approved	34	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	5.391	5.453	1.072	6.516
DCYRMY6	DMS8IFC	Sorafenib	Approved	34	DM2DMPO	Kanamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	58.21	58.21	68.75	68.75
DC5BJI2	DMS8IFC	Sorafenib	Approved	34	DM2G9AE	Citalopram	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.54	1.54	14.03	14.04
DCG4VRS	DMS8IFC	Sorafenib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	7.92	6.88	2.6	6.71
DCYZDIE	DMS8IFC	Sorafenib	Approved	34	DM3KJBC	Epinephrine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.44	4.44	5.62	5.63
DCOVVS7	DMS8IFC	Sorafenib	Approved	34	DM3Q1HL	T-3.5	Investigative	0	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	2.99	9.89	3.147	3.081
DCZP6W7	DMS8IFC	Sorafenib	Approved	34	DM3Q1HL	T-3.5	Investigative	0	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	6.747	8.479	1.782	1.317
DCUA28B	DMS8IFC	Sorafenib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	3.36	6.56	1.91	1.51
DC9BEQ7	DMS8IFC	Sorafenib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.17	3.72	3.6	3.6
DC7CLZH	DMS8IFC	Sorafenib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	0.79	6.85	4.07	4.07
DCE8MPN	DMS8IFC	Sorafenib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	6.87	10.71	5.48	5.48
DCRS75B	DMS8IFC	Sorafenib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	1.71	4.2	0.63	0.63
DC9VKEC	DMS8IFC	Sorafenib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	4.46	10.6	8.4	10.48
DCTNH56	DMS8IFC	Sorafenib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	0.65	3.25	0.9	1.75
DCDJNX0	DMS8IFC	Sorafenib	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	2.12	4.83	0.15	2.1
DCN3DOA	DMS8IFC	Sorafenib	Approved	34	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	3.62	6.14	3.1	6.02
DCP9A5I	DMS8IFC	Sorafenib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	13.77	13.77	16.7	16.77
DCYUIFX	DMS8IFC	Sorafenib	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	3.02	9.33	7.14	5.26
DCHOGHQ	DMS8IFC	Sorafenib	Approved	34	DM5IKUF	Dihydroergotamine	Approved	34	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	3.034	6.706	1.129	1.436
DCL6B9G	DMS8IFC	Sorafenib	Approved	34	DM5J64S	Miglustat	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1	1	11.94	11.95
DCOV6ET	DMS8IFC	Sorafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	10.5	13.23	8.82	12.41
DC839OR	DMS8IFC	Sorafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	2.12	6.64	5.95	1.65
DCKYYI7	DMS8IFC	Sorafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	4.38	9.15	8.39	8.18
DCTD5KG	DMS8IFC	Sorafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	6.06	11.42	8.65	5.71
DCEQJBH	DMS8IFC	Sorafenib	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.1	4.54	2.1	1.68
DC6X059	DMS8IFC	Sorafenib	Approved	34	DM5X7VY	Pyrimethamine	Approved	34	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	1.756	5.255	0.473	0.742
DCL6MGI	DMS8IFC	Sorafenib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	9.71	14.88	10.06	14.01
DCQLZR0	DMS8IFC	Sorafenib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	0.38	0.15	1.64	1.98
DC910AU	DMS8IFC	Sorafenib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	2.41	2.9	2.37	6.47
DCYS81C	DMS8IFC	Sorafenib	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	4.9	6.61	2.3	6.64
DC81EMZ	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	4.96	4.52	5.41	9.17
DCBMWF4	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	5.92	2.98	5.86	10.51
DCZNKAK	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH1650	5.95	7.17	5.06	10.15
DCLK3FG	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH520	7.04	5.5	7.95	12.27
DCAW05E	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	COLO320DM	3.06	2.99	1.1	6.5
DCKWV87	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	7.32	9.7	8.28	12.84
DCRFD5W	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	2.67	2.62	1.12	5.33
DC38072	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	1.28	1.55	3	7.59
DCKIVXQ	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	9.69	10.24	2.87	9.05
DC4S540	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	5.21	11.61	5.46	11.03
DCQ8Q6M	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	DrugCombDB Database	Investigative	PA1	2.37	4.03	3.56	7.59
DCHJ5YR	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	4.86	6.04	4.02	8.51
DC9W6P1	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	4.25	6.26	7.99	12.49
DCHNOJL	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	3.17	3.45	2.8	8.68
DCK7WSQ	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	1.58	3.29	0.24	5.71
DC0RPBP	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	4.66	4.56	4.87	6.75
DCVRF8M	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian endometrioid adenocarcinoma	DrugCombDB Database	Investigative	A2780	6.37	6.77	5.03	9.97
DCIAKHZ	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	11.04	9.63	0.91	9.66
DCEX2RA	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	LNCAP	1	1.47	1.35	7.69
DCO6N32	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	VCAP	0.73	8.02	2.09	7.4
DCX49U2	DMS8IFC	Sorafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	8.5	8.61	4.93	2.44
DCV986K	DMS8IFC	Sorafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	9.99	8.21	6.23	6.36
DC60YUW	DMS8IFC	Sorafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	3.81	3.94	0.25	1.49
DCTTPOF	DMS8IFC	Sorafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	6.8	7.98	1.97	1.97
DCHVR3U	DMS8IFC	Sorafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	7.36	5.11	2.91	2.81
DCKFCN0	DMS8IFC	Sorafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	8.61	4.31	0.39	0.65
DCLUYBJ	DMS8IFC	Sorafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	6.49	2.54	1.41	0.91
DCKZ8EG	DMS8IFC	Sorafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	2.93	7.59	5.47	3.54
DCQF6W1	DMS8IFC	Sorafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	5.44	5.6	2.72	2.16
DCLHQIT	DMS8IFC	Sorafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	8.82	2.54	1.68	1.31
DCJ9B5W	DMS8IFC	Sorafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	6.1	5.76	5.99	5.88
DCQJL04	DMS8IFC	Sorafenib	Approved	34	DMA7PEW	Verapamil	Approved	34	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	3.309	10.755	0.769	1.983
DCTGKDH	DMS8IFC	Sorafenib	Approved	34	DMAI7ZV	Diltiazem	Approved	34	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	4.47	6.427	4.586	7.35
DCGQCQJ	DMS8IFC	Sorafenib	Approved	34	DMAI7ZV	Diltiazem	Approved	34	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	7.402	8.809	4.068	9.566
DCVSUQX	DMS8IFC	Sorafenib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	1.7	3.7	0.71	0.71
DCJWQ3V	DMS8IFC	Sorafenib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	4.74	7.82	2.59	1.38
DCIMXCX	DMS8IFC	Sorafenib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.38	4.48	2.94	2.59
DC3MMDC	DMS8IFC	Sorafenib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	8.14	3.75	0.57	0.68
DCU2BBC	DMS8IFC	Sorafenib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.06	2.29	0.57	0.34
DCIOR5Z	DMS8IFC	Sorafenib	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	26.46	27.21	24.07	22.55
DC4D1D1	DMS8IFC	Sorafenib	Approved	34	DMBAWDG	Thiolactomycin	Investigative	0	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	5.269	9.286	2.108	6.339
DC4XF86	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	3.62	6.4	5.14	2.03
DC1KTHH	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	5.94	11.68	5.58	3.7
DCSB4NZ	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	9.55	14.37	9.9	9.92
DCNWDQS	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	13.97	16.78	11.88	11.44
DCVFYS1	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	5.58	6.41	3.37	0.27
DCN6UR2	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	8.32	8.16	6.9	5.71
DCE3M8A	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.18	5.78	5.28	2.85
DC6EQIF	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	10.01	6	3.18	2.47
DCKTFWM	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	13.25	13.97	9.88	6.43
DCV41I2	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.58	6.22	4.12	2.68
DCXG3M2	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.76	2.76	6.78	6.78
DCW77OV	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	15.78	18.27	10.49	9.5
DCB8D5I	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	6.02	7.28	3.07	3.13
DCFG5MD	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	10.34	8.74	6.78	5.91
DC6X7XF	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	9.34	8.8	3.34	4.47
DC3WRMZ	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	8.75	7.54	6.58	4.81
DCX4ZVB	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	6.6	9.99	7.66	5.72
DCDJ7CF	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	5.96	8.59	5.53	0.64
DCZD0EF	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	10.1	11.79	10.89	7.87
DCP2ZIJ	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	5.15	5.26	6.11	6.11
DCXBOGY	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	7.19	4.38	0.75	2.18
DCTGWDG	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	3.11	7.31	5.65	3.83
DCR8OR5	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	5.77	9	7.14	5.69
DCIXI1K	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	7.97	8.27	7.65	6.69
DCU8S0N	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	2.88	6.59	10.59	4.24
DCIRYWP	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	7.48	9.82	10.12	9.94
DCQ2WQS	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	14.61	10.39	6.97	8.08
DCRU7SD	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	2.47	6.81	4.39	6.12
DCEWZPX	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	6.98	9.99	4.47	2.08
DCNVRVQ	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	4.47	6.61	4.3	6.96
DCRL79O	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	5.72	6.37	4.83	5.39
DCJ61SL	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	25.13	29.3	19.71	17.97
DC4YX6G	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	11.22	11.51	10.05	10.26
DCJV308	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	21.86	15.76	10.25	9.47
DCTCJA5	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	10.03	8.04	6.87	2.52
DCQUZ1P	DMS8IFC	Sorafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	0.71	4.46	1.81	1.92
DCW119E	DMS8IFC	Sorafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	4.79	9.54	7.27	4.21
DCGAWOL	DMS8IFC	Sorafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.18	6.3	3.35	0.46
DC1YYXO	DMS8IFC	Sorafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	1.71	5.31	5.02	5.02
DCQHG9I	DMS8IFC	Sorafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	5.8	11.35	8.03	2.86
DC54GUG	DMS8IFC	Sorafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.62	5.9	3.65	2.11
DCMPMMC	DMS8IFC	Sorafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	7.77	9.34	4.22	0.93
DCRY6KV	DMS8IFC	Sorafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	2.44	6.24	5.31	1.2
DC2YBAY	DMS8IFC	Sorafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	3.7	11.47	10.07	10.04
DCUWO09	DMS8IFC	Sorafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	3.98	6.17	4.55	1.98
DCAU2GZ	DMS8IFC	Sorafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	2.37	4.33	1.3	0
DCS1GO4	DMS8IFC	Sorafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	5.13	14.27	11.24	6.54
DC4YAVH	DMS8IFC	Sorafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	3.37	3.76	0.41	0.02
DCY7Y44	DMS8IFC	Sorafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	DrugCombDB Database	Investigative	NCI-H322M	0.12	3.79	2.48	2.93
DCNUSBV	DMS8IFC	Sorafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	2.48	4.21	2.23	1.89
DCF0MYT	DMS8IFC	Sorafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	4.39	7.65	4.67	4.67
DCRB4S1	DMS8IFC	Sorafenib	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	1.531	3.18	1.124	1.536
DC72YME	DMS8IFC	Sorafenib	Approved	34	DMFGLXB	Phensuximide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	42.75	42.75	53.26	53.26
DCEW953	DMS8IFC	Sorafenib	Approved	34	DMFO843	Fluspirilene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.32	3.32	15.74	15.74
DC8KSBK	DMS8IFC	Sorafenib	Approved	34	DMFP8WE	ZM-447439	Investigative	0	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	2.885	5.191	4.723	7.926
DCOOENN	DMS8IFC	Sorafenib	Approved	34	DMGLP6S	Sarpogrelate	Approved	34	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	0.177	3.898	1.43	3.765
DC3ZELQ	DMS8IFC	Sorafenib	Approved	34	DMGLP6S	Sarpogrelate	Approved	34	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	1.458	4.131	0.39	6.213
DCQ8RK3	DMS8IFC	Sorafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	1.72	5.97	3.1	1.98
DCSIX1F	DMS8IFC	Sorafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	1.02	3.39	0.57	0.55
DCRETGN	DMS8IFC	Sorafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	0.72	3.75	1.03	2.54
DCPT2GS	DMS8IFC	Sorafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	1.97	4.54	3.98	3.6
DCSIZTH	DMS8IFC	Sorafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	3.67	6.85	5.29	1.9
DCSWNWO	DMS8IFC	Sorafenib	Approved	34	DMDBX5F	Ivermectin	Phase 2/3 Trial	24	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	2.821	10.538	2.309	3.131
DCC1WC7	DMS8IFC	Sorafenib	Approved	34	DMIK367	Procarbazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.74	7.74	20.13	20.14
DCCP6Q0	DMS8IFC	Sorafenib	Approved	34	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.21	5.21	5.63	5.68
DCE2MLJ	DMS8IFC	Sorafenib	Approved	34	DMKA8R4	SB 228357	Investigative	0	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	5.275	8.931	4.083	8.969
DC1ZLS5	DMS8IFC	Sorafenib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	0.37	6.44	2.86	1.38
DCQNSWG	DMS8IFC	Sorafenib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	5.34	9.57	3.78	0.52
DCLLKDX	DMS8IFC	Sorafenib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	2.06	6.5	5.48	5.46
DCC493Q	DMS8IFC	Sorafenib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	10	16.29	2.67	2.67
DCT7AO5	DMS8IFC	Sorafenib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	NCI\\/ADR-RES	3.4	8.78	3.86	2.24
DC2LD79	DMS8IFC	Sorafenib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	1.87	4.55	3.84	1.6
DCT3BX2	DMS8IFC	Sorafenib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	1.61	3.52	1.99	1.05
DCEYVGI	DMS8IFC	Sorafenib	Approved	34	DML1538	Diazoxide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.4	2.4	2.9	2.9
DCRZFHB	DMS8IFC	Sorafenib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	CAOV3	8.9	8.99	2.9	9.66
DCUSMD8	DMS8IFC	Sorafenib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A427	1.98	1.41	0.37	5.2
DCTC7VP	DMS8IFC	Sorafenib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DLD1	6.46	7.36	0.89	10.5
DCG5WD0	DMS8IFC	Sorafenib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	8.63	8.46	0.39	8.98
DCPVBPO	DMS8IFC	Sorafenib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	A2058	10.23	10.43	1.01	9.89
DCBLHZW	DMS8IFC	Sorafenib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	7.57	7.38	1.32	9.74
DC9GBXS	DMS8IFC	Sorafenib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	6.93	7.63	1.73	10.05
DCBS4D2	DMS8IFC	Sorafenib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	A375	7.7	8.03	1.05	10.05
DC78PJK	DMS8IFC	Sorafenib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	HT144	5.44	7.08	0.73	10.11
DCP6H8I	DMS8IFC	Sorafenib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	SKMEL30	0.35	1.41	0.45	6.44
DCSBPF8	DMS8IFC	Sorafenib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	5.43	7.56	0.77	10.22
DCOW676	DMS8IFC	Sorafenib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	DrugCombDB Database	Investigative	MSTO	6.05	5.57	5.04	6.42
DCS3ZW4	DMS8IFC	Sorafenib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Non small cell carcinoma	DrugCombDB Database	Investigative	SKMES1	8.18	7.66	0.99	9.48
DCB1JHR	DMS8IFC	Sorafenib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	13.19	14.35	1.71	12.14
DC82QZF	DMS8IFC	Sorafenib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	0.96	6.25	5.17	5.54
DCZ78P3	DMS8IFC	Sorafenib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	1.4	3.75	1.04	0.4
DCYWNXI	DMS8IFC	Sorafenib	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	20.06	20.06	26.87	26.87
DC7YWQF	DMS8IFC	Sorafenib	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	37.62	37.62	33.26	33.26
DCNGUZO	DMS8IFC	Sorafenib	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.64	3.64	4.06	4.13
DC2EZUS	DMS8IFC	Sorafenib	Approved	34	DMPMYE8	Miconazole	Approved	34	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	2.617	6.835	2.322	2.232
DCTK2LJ	DMS8IFC	Sorafenib	Approved	34	DMPU2WX	Omacetaxine mepesuccinate	Approved	34	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	6.905	12.8	3.556	5.645
DCVYS9Q	DMS8IFC	Sorafenib	Approved	34	DMPU2WX	Omacetaxine mepesuccinate	Approved	34	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	7.263	7.717	2.199	7.367
DCP7QF6	DMS8IFC	Sorafenib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	22.52	22.52	34.67	34.69
DCIHDZV	DMS8IFC	Sorafenib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.59	5.18	5.02	5.02
DCFX6AO	DMS8IFC	Sorafenib	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	9.74	16.96	11.91	11.68
DCY8IWL	DMS8IFC	Sorafenib	Approved	34	DMS0PND	Brincidofovir	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.82	5.82	6.55	6.58
DCQGG2W	DMS8IFC	Sorafenib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	1.16	8.05	4.85	5.41
DCTN08E	DMS8IFC	Sorafenib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	3.38	10.47	4.49	4.49
DCYJ8RM	DMS8IFC	Sorafenib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	1.73	2.68	0.95	0.24
DC97YW9	DMS8IFC	Sorafenib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.33	4.81	3.15	3.2
DCEX2CV	DMS8IFC	Sorafenib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	3.07	5.29	3.17	2.53
DCB3ZOS	DMS8IFC	Sorafenib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	18.32	17.75	13.28	13.28
DCC488L	DMS8IFC	Sorafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	3.2	5.65	3.47	1.16
DCKC03S	DMS8IFC	Sorafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	1.28	6.14	7.46	7.73
DCAQ3ZT	DMS8IFC	Sorafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.19	3.76	3.08	0.82
DC11K7N	DMS8IFC	Sorafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	6.42	8.42	4.07	1.05
DC60TDJ	DMS8IFC	Sorafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	0.52	1.97	2.15	1.13
DCF2CZ8	DMS8IFC	Sorafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.88	1.8	0.63	0.15
DC8NNXY	DMS8IFC	Sorafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	1.62	3.02	1.78	1.33
DCUB5Z4	DMS8IFC	Sorafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	1.29	4.4	3.63	3.5
DCZILKF	DMS8IFC	Sorafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	0.14	2.03	1.34	0.75
DCOLMT8	DMS8IFC	Sorafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.42	7.22	4.99	4.51
DCRAW0Y	DMS8IFC	Sorafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	15.2	13.12	11.83	11.64
DC4URY3	DMS8IFC	Sorafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	1.6	3.35	3.28	0.05
DC5N3ZZ	DMS8IFC	Sorafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	5.44	5.35	2.84	0.25
DC33W85	DMS8IFC	Sorafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	7.83	9.16	1.28	0.06
DCQB30S	DMS8IFC	Sorafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	1.23	5.2	2.02	2.02
DCYC8QO	DMS8IFC	Sorafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	1.26	4.43	3.76	2.57
DCDA4D4	DMS8IFC	Sorafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	3.54	6.72	0.23	0.23
DC8FH0K	DMS8IFC	Sorafenib	Approved	34	DMRBMAU	Mycophenolic acid	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.02	2.02	2.68	2.68
DC3OSQR	DMS8IFC	Sorafenib	Approved	34	DMU73F0	Bifemelane	Terminated	2	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	10.279	16.623	2.888	2.948
DCH0OM5	DMS8IFC	Sorafenib	Approved	34	DMU764S	Ritonavir	Approved	34	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	3.268	8.967	3.957	7.457
DCEX5VI	DMS8IFC	Sorafenib	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	4.01	8.68	0.21	2.87
DCM7YVZ	DMS8IFC	Sorafenib	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	2.78	3.6	0.49	0.05
DCCPH48	DMS8IFC	Sorafenib	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.33	5.38	0.63	0.63
DC3JRV6	DMS8IFC	Sorafenib	Approved	34	DMUWAM2	Pyronaridine	Approved	34	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	3.127	9.506	0.645	4.898
DCU9GQS	DMS8IFC	Sorafenib	Approved	34	DMWT905	Mefloquine	Phase 2/3 Trial	24	.	.	.	.	DD2	DrugCombDB Database	Investigative	DD2	6.718	9.94	1.952	4.978
DCXVF3T	DMS8IFC	Sorafenib	Approved	34	DMWT905	Mefloquine	Phase 2/3 Trial	24	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	10.127	12.443	5.802	10.914
DC8SBN1	DMS8IFC	Sorafenib	Approved	34	DMWBHRY	Olmesartan medoxomil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	11.95	11.95	24.55	24.55
DC8QJHU	DMS8IFC	Sorafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	0.65	6.58	0.26	2.84
DCGJ345	DMS8IFC	Sorafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	11.18	12.64	4.54	4.54
DCTJYGY	DMS8IFC	Sorafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.26	2.8	0.32	0.32
DCKMH8S	DMS8IFC	Sorafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	2.85	4.43	1.03	0.77
DCUOVPS	DMS8IFC	Sorafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	3.27	9.62	5.53	5.14
DCRVOCK	DMS8IFC	Sorafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.09	2.47	1.21	1.03
DCPZNGM	DMS8IFC	Sorafenib	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	11.38	12.54	7.24	6.33
DCTGXWT	DMS8IFC	Sorafenib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	6.3	9.87	5.48	5.38
DCZVTT8	DMS8IFC	Sorafenib	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	2.27	5.19	3.36	2.16
DC22E23	DMS8IFC	Sorafenib	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.54	0.54	1.09	1.11
DCQ8SUW	DMS8IFC	Sorafenib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.48	3.6	5.85	4.91
DCL1VUT	DMS8IFC	Sorafenib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	0.88	9.13	1.65	7.46
DC0EA7F	DMS8IFC	Sorafenib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	12.97	13.07	12.7	13.49
DCJZL7O	DMS8IFC	Sorafenib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	9.76	11	3.15	6.1
DCLNZWG	DMS8IFC	Sorafenib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	13.18	19.88	6.01	14.85
DCEI834	DMS8IFC	Sorafenib	Approved	34	DMY4UMW	Atovaquone	Approved	34	.	.	.	.	Hepatoblastoma	DrugCombDB Database	Investigative	HB3	5.201	7.521	3.475	3.59
DCTXLMT	DMS8IFC	Sorafenib	Approved	34	DMYLOVR	Aciclovir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.39	3.39	12.04	12.04
DCAWCKJ	DMS8IFC	Sorafenib	Approved	34	DMZD5QR	Cytarabine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.21	2.21	2.64	2.67
DCU3A13	DMS8IFC	Sorafenib	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	8.17	10.11	0.68	2.64
DCYC52A	DMS8IFC	Sorafenib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.09	3.24	1.97	3.4
DCECKT2	DMS8IFC	Sorafenib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.64	2.85	2.45	7.18
DC94IV1	DMS8IFC	Sorafenib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	5.41	3.48	2.99	8.57
DC4I4PL	DMS8IFC	Sorafenib	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.96	6.7	2.99	8.08
DCZ568W	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	6.43	0.7	11.33	11.78
DCI85JI	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.8	2.45	4.7	9.85
DCMAZTI	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	3.67	3.39	3.07	8.94
DC5PK6D	DMS8IFC	Sorafenib	Approved	34	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	16.54	21.74	9.22	17.74
DCP2I4Z	DMS8IFC	Sorafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	13.23	10.51	3.39	3.39
DCGPLRG	DMS8IFC	Sorafenib	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.85	2.4	4.02	4.06
DCXZ74U	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	11.49	8.6	3.98	3.54
DC59M98	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	12.33	17.09	6.04	11.83
DCPWVIL	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.28	8.12	4.82	5.1
DC67Q5H	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.97	5.96	0.75	0.75
DCK8ZC0	DMS8IFC	Sorafenib	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.54	7.66	1.99	4.04
DCUI0XG	DMS8IFC	Sorafenib	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.17	13.62	5.65	3.82
DCW6RIO	DMS8IFC	Sorafenib	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.82	9.56	2.54	2.53
DCR4YCQ	DMS8IFC	Sorafenib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.49	3.16	2.36	0.92
DCEO53Q	DMS8IFC	Sorafenib	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.61	4.1	3.85	0.91
DC1NRHB	DMS8IFC	Sorafenib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	1.72	1.41	0.52	5.43
DCRP8UX	DMS8IFC	Sorafenib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	8.24	8.28	3.83	11.41
DCQR502	DMS8IFC	Sorafenib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	2.48	1.69	1.18	6.64
DC45XJ5	DMS8IFC	Sorafenib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	13.03	13.73	7.11	16.51
DC371OS	DMS8IFC	Sorafenib	Approved	34	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.59	7.66	5.99	11.67
DCSJ9RU	DMS8IFC	Sorafenib	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.01	4.72	2.67	1.58
DCYWLLK	DMS8IFC	Sorafenib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.89	3.25	1.14	0.59
DCSKKAY	DMS8IFC	Sorafenib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.37	3.84	2.31	1.62
DCD5D0T	DMS8IFC	Sorafenib	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.43	2.32	0.68	0.41
DC47SGR	DMS8IFC	Sorafenib	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.44	3.89	2.45	1.27
DCN1JC4	DMS8IFC	Sorafenib	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	11	9.34	6.25	5.53
DCYKREL	DMS8IFC	Sorafenib	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.86	8.56	9.17	9.38
DCYBKX0	DMH8UF0	SY-1425	Phase 1	17	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.93	7.46	3.63	4.93
DCMRBUI	DMH8UF0	SY-1425	Phase 1	17	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	10.08	20.44	10.42	4.89
DCMBB1M	DMH8UF0	SY-1425	Phase 1	17	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	13.24	17.13	11.46	4.6
DCS2ZVS	DMH8UF0	SY-1425	Phase 1	17	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	4.08	5.87	2.42	1
DC9NP7P	DMH8UF0	SY-1425	Phase 1	17	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.51	6.21	4.14	3.89
DCR298D	DMH8UF0	SY-1425	Phase 1	17	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.82	4.52	1.18	1.18
DCGMUOJ	DMH8UF0	SY-1425	Phase 1	17	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.66	6.55	5.9	4.41
DCKB2OG	DMH8UF0	SY-1425	Phase 1	17	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.34	1.63	0.86	3.55
DCOFH0H	DMH8UF0	SY-1425	Phase 1	17	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	5.54	6.27	6.19	7.17
DCI4Y6E	DMH8UF0	SY-1425	Phase 1	17	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	7.22	8.23	7.15	7.02
DCGXGTN	DMH8UF0	SY-1425	Phase 1	17	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	5.05	10.02	1.22	1.22
DCVA73C	DMH8UF0	SY-1425	Phase 1	17	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	7.12	6.09	5.16	4.06
DCUZ9FI	DMH8UF0	SY-1425	Phase 1	17	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.25	4.75	7.12	9.65
DCS9RMN	DMH8UF0	SY-1425	Phase 1	17	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.02	9.45	0.62	0.74
DC798ED	DMH8UF0	SY-1425	Phase 1	17	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	5.96	7.4	1.26	5.63
DCJGGDS	DMH8UF0	SY-1425	Phase 1	17	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.35	1.58	2.7	3.14
DC9U88D	DMH8UF0	SY-1425	Phase 1	17	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	6.26	6.38	2.21	5.09
DCS19JV	DMH8UF0	SY-1425	Phase 1	17	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.68	7.47	0.15	0.69
DCB5W11	DMH8UF0	SY-1425	Phase 1	17	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	5.74	9.64	5.91	5.54
DCQ8PEN	DMH8UF0	SY-1425	Phase 1	17	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.9	6.72	3.78	1.18
DCOCTM7	DMH8UF0	SY-1425	Phase 1	17	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.74	6.31	6.4	10.2
DCXM5N3	DMH8UF0	SY-1425	Phase 1	17	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.29	4.84	0.5	3.92
DCWD7J7	DMH8UF0	SY-1425	Phase 1	17	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	0.08	0.8	0.81	2.6
DCAVXNM	DMH8UF0	SY-1425	Phase 1	17	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	5.48	5.32	0.01	5.96
DCW8OER	DMH8UF0	SY-1425	Phase 1	17	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.91	3.47	4.87	6.96
DCUU5KG	DMH8UF0	SY-1425	Phase 1	17	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.34	2.16	0.54	0.53
DCUQWIC	DMH8UF0	SY-1425	Phase 1	17	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.96	6.84	3.28	5.03
DCHTK01	DMH8UF0	SY-1425	Phase 1	17	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	7.13	8.86	0.06	6.05
DCWDG2S	DMH8UF0	SY-1425	Phase 1	17	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.67	4.2	3.17	1.19
DC3O9QK	DMH8UF0	SY-1425	Phase 1	17	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.64	9.28	2.34	4.25
DCI4FN3	DMH8UF0	SY-1425	Phase 1	17	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.4	3.07	1.91	2.06
DCEN33R	DMH8UF0	SY-1425	Phase 1	17	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.51	3.5	2.11	2.22
DCWCQ26	DMH8UF0	SY-1425	Phase 1	17	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.64	6.94	0.59	4.77
DC97CPL	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.77	6.09	8.37	9.05
DCS4I3S	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	33.81	34.24	0.11	26.7
DCABU9S	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	18.79	14.58	13.76	13.72
DC4ODWE	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	19.64	22.31	11.7	16.79
DCKKJVP	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	12.27	11.5	1.83	3.11
DC9JMBK	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	13.91	12.64	12.27	12.28
DC5FDQ7	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	32.2	34.01	23.66	23.43
DCA2NMN	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	11.4	11.06	6.51	5.56
DCG1TG7	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	22.92	16.9	11.71	3.48
DC6LL9E	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	13.62	16.99	12.57	12.6
DCTEX0N	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	10	12.8	8.23	10.72
DCWFJ67	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	7.47	3.99	1	2.88
DCJ4UFM	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.98	7.13	5.36	5.98
DCIEM4V	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	15.37	16.88	18.2	19.51
DC1F8HA	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.31	5.99	5.18	5.52
DCG235K	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.7	9.19	7.7	7.36
DCUKN23	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.42	2.11	1.78	1.76
DC3LJXB	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	11.72	14.08	11.77	12.03
DC8PN8V	DMH8UF0	SY-1425	Phase 1	17	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.94	1	2.7	5.61
DCCHBKU	DMH8UF0	SY-1425	Phase 1	17	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.01	4.12	3.56	2.83
DCJY3UW	DMH8UF0	SY-1425	Phase 1	17	DME9QGW	Marizomib	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	6.5	4.52	4.41	6.25
DCVYDUM	DMH8UF0	SY-1425	Phase 1	17	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.65	5.66	4.85	8.73
DCBCE1A	DMH8UF0	SY-1425	Phase 1	17	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.21	4.94	4.86	5.01
DCND9UY	DMH8UF0	SY-1425	Phase 1	17	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.03	8.17	6.38	5.91
DC3IJWZ	DMH8UF0	SY-1425	Phase 1	17	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.58	8.85	5.83	5.43
DC8E3D4	DMH8UF0	SY-1425	Phase 1	17	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	11.56	15.01	1.75	1.61
DC06STC	DMH8UF0	SY-1425	Phase 1	17	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	9.68	10.22	7.99	8.95
DC12XZ9	DMH8UF0	SY-1425	Phase 1	17	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	3.59	6.19	1.93	3.96
DCKFP0G	DMH8UF0	SY-1425	Phase 1	17	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	10.93	10.53	7.34	14.67
DC0CYUV	DMH8UF0	SY-1425	Phase 1	17	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.25	6.17	3.96	2.81
DCJ8C9O	DMH8UF0	SY-1425	Phase 1	17	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.13	1.66	1.3	0.34
DC3HT32	DMH8UF0	SY-1425	Phase 1	17	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.51	9.76	4.87	2.8
DC2M5RT	DMH8UF0	SY-1425	Phase 1	17	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.34	3.16	4.83	5.27
DCSSUD1	DMH8UF0	SY-1425	Phase 1	17	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.85	17.36	12.06	10.32
DC8FGGC	DMH8UF0	SY-1425	Phase 1	17	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.4	2.23	0.31	0.24
DCBFXXZ	DMH8UF0	SY-1425	Phase 1	17	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	22.4	22.4	25.92	25.92
DC4IB4Y	DMH8UF0	SY-1425	Phase 1	17	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	12.08	22.81	6.37	4.06
DCC5LYY	DMH8UF0	SY-1425	Phase 1	17	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.49	3.28	2.04	4.15
DC188M0	DMH8UF0	SY-1425	Phase 1	17	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.61	3.74	2.44	3.16
DC0CDNZ	DMH8UF0	SY-1425	Phase 1	17	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3	3.4	9.67	9.91
DCBQJVD	DMH8UF0	SY-1425	Phase 1	17	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	1.75	2.45	4.14	7.07
DC2JDXA	DMH8UF0	SY-1425	Phase 1	17	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	7.9	8.92	3.87	7.83
DCM66MY	DMH8UF0	SY-1425	Phase 1	17	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	7.01	9.85	7.19	12.51
DCDIHX5	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	12.74	15.8	13.09	7.36
DCNEIOK	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	14.73	11.55	7.61	4.51
DCYS24P	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	7.46	2.12	1.24	0.6
DC8OJG7	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	34.72	34.88	11.35	8.72
DCWU39R	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	15.71	19.64	8.25	10.93
DCXTLIK	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	10.6	11.37	6.67	6.15
DCBTQSW	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	15.28	14.1	6.83	6.48
DCIIU4G	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	10.53	9.29	7.38	6.98
DCZWBTS	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	4.96	2.52	6.07	3.64
DCNTFMT	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	10.66	8.83	7.83	6.06
DCVYY74	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	5.34	8.93	5.88	5.59
DCSWX52	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.41	7.73	3.6	3.25
DC5K1UA	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	9.47	8.45	9.04	7.94
DCOHKL2	DMH8UF0	SY-1425	Phase 1	17	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.78	4.31	1.88	0.27
DCMNJGV	DMH8UF0	SY-1425	Phase 1	17	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.64	2.21	1.12	0.01
DCMXQGT	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.85	5.55	7.61	7.81
DCNMWLG	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	10.66	11.57	5.59	5.6
DC0ZOL9	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	12.92	14.78	7.71	7.46
DC475S3	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	8.05	7.5	5.19	5.21
DCA69Z7	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	13.58	14.86	9.75	9.89
DCIM8MA	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.79	8.45	7.01	7.01
DCKH99K	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.78	4.51	3.72	2.02
DCSXPKQ	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.45	5.89	4.98	4.82
DCZ4DXJ	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.94	4.81	4.28	4.51
DCUHV1X	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.22	0.73	0.74	1.82
DC46IBE	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	15.45	15.36	13.93	15.99
DCEUG0B	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	3.25	8.32	5.61	7.63
DCTY9JT	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	10.5	12.18	4.54	8.35
DCK4XFJ	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	4.79	9.5	5.72	9.46
DCDPXWY	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	10.45	16.94	8.29	15.17
DCIJ8WD	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	8.94	12.44	11.63	11.49
DC9FD1U	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	16.49	17.95	7.45	13.1
DCGF0X1	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.83	5.48	5.91	7.06
DCJMAX6	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	12.06	13.2	6.23	13.91
DCB5EZV	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.28	5.28	2.11	3.16
DCNCTYE	DMH8UF0	SY-1425	Phase 1	17	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.3	13.22	9.69	10
DCYO3LA	DMH8UF0	SY-1425	Phase 1	17	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	5.6	14.81	13.52	9.34
DCWZGUJ	DMH8UF0	SY-1425	Phase 1	17	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.22	4.7	0.61	0.1
DCZZBPH	DMH8UF0	SY-1425	Phase 1	17	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	6.84	9.98	2	1.88
DC65S4M	DMH8UF0	SY-1425	Phase 1	17	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	25.14	30.81	5.46	3.05
DCG5IXA	DMH8UF0	SY-1425	Phase 1	17	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.15	6.36	5.82	3.72
DC7AK94	DMH8UF0	SY-1425	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	9.6	14.87	4.9	12.66
DCN7ATE	DMH8UF0	SY-1425	Phase 1	17	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.08	4.44	6.89	0.1
DCHQMHM	DMH8UF0	SY-1425	Phase 1	17	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	9.03	9.05	3.83	3.51
DCG1BA6	DMH8UF0	SY-1425	Phase 1	17	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.29	6.98	2.37	7.37
DCHP05W	DMH8UF0	SY-1425	Phase 1	17	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.12	3.65	2.5	1.62
DCNXQAW	DMH8UF0	SY-1425	Phase 1	17	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.39	4.5	5.09	8.39
DCIHNRU	DMH8UF0	SY-1425	Phase 1	17	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.59	7.27	6.19	6.57
DCOINMX	DMH8UF0	SY-1425	Phase 1	17	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.88	5.62	5.93	7.99
DCPCYTY	DMH8UF0	SY-1425	Phase 1	17	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.29	6.79	3.1	1.6
DCX8AJH	DMH8UF0	SY-1425	Phase 1	17	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.01	4.73	2.5	3.35
DC8I02X	DMH8UF0	SY-1425	Phase 1	17	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.46	1.43	0.42	1.04
DCKS5JY	DMH8UF0	SY-1425	Phase 1	17	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.79	6.61	7.01	8.44
DC6Y8EZ	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	9.55	14.44	14.03	14.12
DCEY78C	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.77	10.09	8.77	8.89
DCVPKK3	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	17.96	16.54	16.08	16.34
DC9GUBY	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	16.22	14.17	10.21	11.5
DCLEGSI	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	9.86	11.45	14.34	14.53
DCSOMJB	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.47	9.32	8.16	8.65
DC23Z7Y	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	11.57	15.28	12.43	14.37
DCV2VN6	DMH8UF0	SY-1425	Phase 1	17	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	8.28	10.8	10.67	10.57
DCCRUIC	DMH8UF0	SY-1425	Phase 1	17	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.88	4.47	7.06	7.25
DCU3MGL	DMH8UF0	SY-1425	Phase 1	17	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.08	8.35	1.49	1.53
DCQEAK4	DMH8UF0	SY-1425	Phase 1	17	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.41	2.44	5.91	6.89
DC2X2FE	DMH8UF0	SY-1425	Phase 1	17	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.86	3.69	2.68	2.09
DCUPKHT	DMH8UF0	SY-1425	Phase 1	17	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.85	7.04	7.39	6.16
DC1R6F0	DMH8UF0	SY-1425	Phase 1	17	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.61	2.14	2.59	2.59
DC7MNHT	DMH8UF0	SY-1425	Phase 1	17	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.34	10.57	0.61	0.61
DCJ8WMW	DMH8UF0	SY-1425	Phase 1	17	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.53	6.44	4.43	5.16
DCFKA4U	DMH8UF0	SY-1425	Phase 1	17	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.15	5.94	3.31	7.12
DCCJL8D	DMH8UF0	SY-1425	Phase 1	17	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	3.21	7.38	1.67	9.65
DCV57AF	DMH8UF0	SY-1425	Phase 1	17	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.21	5.94	6.8	5.72
DCSYR34	DMH8UF0	SY-1425	Phase 1	17	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.45	1.63	2.11	2.92
DCDRAJT	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.35	4.22	3.39	4.01
DCT06GQ	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.7	6.31	5.48	5.48
DC8LVNY	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	11.55	10.79	5.75	5.87
DCKHLWP	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	8.76	5.51	1.89	1.88
DC8N5UQ	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.36	6.71	5.93	5.9
DCGHHUF	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	11.57	12.72	9.9	7.52
DCWKSPV	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	6.25	5.67	5.77	4.62
DC4WN0A	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	15.35	17.19	19.27	19.49
DC60YAW	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.06	5.32	7.22	8.09
DCSZ8BO	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	13.05	13.91	11.76	12.23
DCQP3LK	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	19.77	21.77	14.48	21.73
DCAMS9D	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	18.63	20.53	7.76	20.94
DCK989Q	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.37	6.73	4.13	5.96
DCQ2LX2	DMH8UF0	SY-1425	Phase 1	17	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.75	4.36	4.57	3.51
DCOIA4L	DMH8UF0	SY-1425	Phase 1	17	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.51	1.79	1.57	0.26
DCAL07K	DMH8UF0	SY-1425	Phase 1	17	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.2	7.48	7.14	6.77
DC1WTFM	DMH8UF0	SY-1425	Phase 1	17	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	5.34	11.04	6.79	0.84
DCIMQH4	DMH8UF0	SY-1425	Phase 1	17	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.66	0.91	1.61	0.04
DCV5FVJ	DMH8UF0	SY-1425	Phase 1	17	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.94	8.37	8.15	7.78
DCHJG58	DMH8UF0	SY-1425	Phase 1	17	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.94	6.01	0.06	2.81
DC2VJ7T	DMH8UF0	SY-1425	Phase 1	17	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.58	5.52	3.37	1.47
DC4BELG	DMH8UF0	SY-1425	Phase 1	17	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	7.28	9.75	4.54	1.51
DC1R8H9	DMH8UF0	SY-1425	Phase 1	17	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	6.81	4.43	1.07	5.14
DC6BDLS	DMH8UF0	SY-1425	Phase 1	17	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.92	1.03	4.26	5.47
DCS7K5U	DMH8UF0	SY-1425	Phase 1	17	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	1.35	1.01	1.49	2.09
DCBE2A9	DMH8UF0	SY-1425	Phase 1	17	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.26	3.42	0.5	4.23
DC3ZNQG	DMH8UF0	SY-1425	Phase 1	17	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	4.97	5.1	2.02	5.28
DCDX2SK	DMH8UF0	SY-1425	Phase 1	17	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.35	1.5	6.05	10.1
DC5ZACX	DMH8UF0	SY-1425	Phase 1	17	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.18	6.01	3.6	3.6
DCL2VO0	DMH8UF0	SY-1425	Phase 1	17	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	4.83	7.18	2.71	0.1
DCBCB0P	DMH8UF0	SY-1425	Phase 1	17	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.05	1.88	2.01	0.13
DCDSMTI	DMH8UF0	SY-1425	Phase 1	17	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.05	1.53	1.48	1.48
DCM3Q7F	DMH8UF0	SY-1425	Phase 1	17	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.06	2.55	0.56	0.52
DCBZ8GW	DMH8UF0	SY-1425	Phase 1	17	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.89	5.16	1.04	1.61
DCCPNH1	DMH8UF0	SY-1425	Phase 1	17	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.79	2.01	0.28	0.41
DCGWJE7	DMH8UF0	SY-1425	Phase 1	17	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.58	1.39	2.39	4.3
DC0GGED	DMH8UF0	SY-1425	Phase 1	17	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.97	4.32	2.35	2.49
DCBE4ES	DMH8UF0	SY-1425	Phase 1	17	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.31	4.39	0.62	5.27
DC4JOOX	DMH8UF0	SY-1425	Phase 1	17	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.58	6.6	3.81	2.06
DCYBDGA	DMH8UF0	SY-1425	Phase 1	17	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.75	3.48	0.49	0.37
DCGOD7P	DMH8UF0	SY-1425	Phase 1	17	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	1.62	4.69	2.39	2.99
DCZYG5N	DMH8UF0	SY-1425	Phase 1	17	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	2.65	5.33	5.28	4.15
DC7IXDX	DMH8UF0	SY-1425	Phase 1	17	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	11.43	10.81	6.68	10.32
DC3C4I0	DMH8UF0	SY-1425	Phase 1	17	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.88	2.83	2.28	3.78
DCD05FH	DMH8UF0	SY-1425	Phase 1	17	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.48	3.2	1.23	1.35
DCYI6L3	DMH8UF0	SY-1425	Phase 1	17	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.96	3.4	0.94	0.11
DC35SRQ	DMH8UF0	SY-1425	Phase 1	17	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.42	7.69	5.49	3.1
DCMY8DR	DMH8UF0	SY-1425	Phase 1	17	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.08	2.8	2.65	1.8
DCXIA2A	DMH8UF0	SY-1425	Phase 1	17	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.97	8.26	8.92	9.39
DC9P5VQ	DMH8UF0	SY-1425	Phase 1	17	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.78	17.64	5.85	5.1
DCT082D	DMH8UF0	SY-1425	Phase 1	17	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	12.57	7.96	2.67	0.77
DCEYXXH	DMH8UF0	SY-1425	Phase 1	17	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.92	3.8	1.56	1.34
DC5S843	DMH8UF0	SY-1425	Phase 1	17	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	9.91	18.44	11.51	11.16
DCZZVM5	DMH8UF0	SY-1425	Phase 1	17	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.39	6.73	6.03	4.53
DCL7S6G	DMH8UF0	SY-1425	Phase 1	17	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.48	4.07	6.36	7.92
DC0HM0C	DMH8UF0	SY-1425	Phase 1	17	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.39	2.43	5.17	6.43
DCK07QP	DMH8UF0	SY-1425	Phase 1	17	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.82	3.48	1.58	1.58
DCG4YN6	DMH8UF0	SY-1425	Phase 1	17	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.34	1.07	0.61	0.61
DCSN8T0	DMH8UF0	SY-1425	Phase 1	17	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.69	6.46	2.88	2.14
DCE49JO	DMH8UF0	SY-1425	Phase 1	17	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.18	7.51	3.83	3.7
DCAYAR2	DMH8UF0	SY-1425	Phase 1	17	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	7.53	11.27	10.29	6.61
DC9OIZJ	DMH8UF0	SY-1425	Phase 1	17	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.88	5.4	5.06	5.06
DCK9XX9	DMH8UF0	SY-1425	Phase 1	17	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.41	6.36	3.02	2.89
DCSFEFK	DMH8UF0	SY-1425	Phase 1	17	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.63	3.59	2.87	1.39
DC9AKQ7	DMH8UF0	SY-1425	Phase 1	17	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.11	1.51	0.92	0.57
DCTGDSH	DMH8UF0	SY-1425	Phase 1	17	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.05	4.3	1.35	0.78
DCN4GSL	DMH8UF0	SY-1425	Phase 1	17	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.24	5.19	5.86	2.79
DC97LFY	DMH8UF0	SY-1425	Phase 1	17	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.29	4.18	5.53	3.75
DC8XE4Z	DMH8UF0	SY-1425	Phase 1	17	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.06	12.95	6.5	6
DC98KZP	DMH8UF0	SY-1425	Phase 1	17	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.23	2.48	2.02	1.59
DCJ12EK	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	9.3	13.45	12.6	12.6
DCC2YML	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	19.3	22.24	7.33	8.56
DCHYXGA	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	10.15	9.92	9.55	9.41
DC52BTU	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	8.9	12.07	10.93	11.13
DCJYFB2	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	26.49	24.52	22.44	18.37
DCHC3PZ	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	10.98	14.22	12.05	12.74
DCQK6JZ	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	19.8	19.38	19.94	20.14
DCKU98Z	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	10.12	10.75	17.79	17.37
DCR78CI	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	15.46	16.45	19.13	19.29
DCOF830	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	17.46	20.71	2.23	6.45
DCAH8VO	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	7.63	13.54	9.59	8.7
DCE1G93	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	12.05	16.84	12.81	13.14
DCKMF5J	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	17.2	17.9	10.24	10.61
DCNMOSH	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	25.86	30.69	10.65	15.2
DCGMGB5	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	11.86	12.42	9.92	7.87
DC4MXNY	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	19.8	17	14.47	14.08
DCYNU9Q	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	4.82	9.76	5.3	5.41
DCAAULM	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	5.24	11.27	11.75	10.7
DCF5W8G	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	11.5	15.26	12.5	12.38
DCOOYOU	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	11.51	13.32	10.92	10.92
DC6ZQYH	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.27	9.05	7.51	7.6
DCUN3GK	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.67	11.82	9.42	8.9
DC5XVFL	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8	10.68	11.75	12.01
DCMQZOQ	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.85	7.37	7.21	7.16
DCPK13U	DMH8UF0	SY-1425	Phase 1	17	DMDI269	Docetaxel	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	14.28	13.92	7.6	5.65
DCRQ2L8	DMH8UF0	SY-1425	Phase 1	17	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.12	6.73	2.65	1.56
DCW9GMN	DMH8UF0	SY-1425	Phase 1	17	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.74	7	3.95	2.16
DCPVXJ6	DMH8UF0	SY-1425	Phase 1	17	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	1.31	3.4	1.58	1.28
DCY694H	DMH8UF0	SY-1425	Phase 1	17	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.41	6.54	4.93	5.05
DCD2356	DMH8UF0	SY-1425	Phase 1	17	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.29	3.38	0.36	0.18
DCQU3BW	DMH8UF0	SY-1425	Phase 1	17	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.71	4.29	1.27	1.06
DC1UB77	DMH8UF0	SY-1425	Phase 1	17	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.62	5.06	2.77	0.73
DCHHGA9	DMH8UF0	SY-1425	Phase 1	17	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	7.8	14.13	10.65	14.09
DC7BZYP	DMH8UF0	SY-1425	Phase 1	17	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.18	12.48	5.64	7.36
DCCWQME	DMH8UF0	SY-1425	Phase 1	17	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.49	8.36	0.8	4.08
DCE1IJV	DMH8UF0	SY-1425	Phase 1	17	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.4	2.59	0.35	0.43
DC8L00U	DMH8UF0	SY-1425	Phase 1	17	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.31	5.51	3.02	0.6
DC2BP0F	DMH8UF0	SY-1425	Phase 1	17	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.39	2.78	1.63	0.52
DCAKM5M	DMH8UF0	SY-1425	Phase 1	17	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.7	4.27	3.26	3.28
DCR954W	DMH8UF0	SY-1425	Phase 1	17	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.62	5.4	2.56	2.47
DC80FIE	DMH8UF0	SY-1425	Phase 1	17	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.44	2.72	0.22	0.56
DCYFHO6	DMH8UF0	SY-1425	Phase 1	17	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.5	7.94	3.5	2.48
DCV2PN5	DMH8UF0	SY-1425	Phase 1	17	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.67	3.84	1.75	1.75
DCNNJKT	DMH8UF0	SY-1425	Phase 1	17	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.7	6.03	1.6	1.6
DCD6OLK	DMH8UF0	SY-1425	Phase 1	17	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.7	2.63	0.67	0.48
DCZKTVJ	DMH8UF0	SY-1425	Phase 1	17	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	3.09	7.31	2.95	5.4
DCZ5SCR	DMH8UF0	SY-1425	Phase 1	17	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.84	6.5	2.95	2.3
DCC9Y88	DMH8UF0	SY-1425	Phase 1	17	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.9	0.54	0.81	0.82
DCO10C3	DMH8UF0	SY-1425	Phase 1	17	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.82	5.06	1.96	7.39
DC7Y7N0	DMH8UF0	SY-1425	Phase 1	17	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	6.98	10.74	0.15	9.48
DCMT95V	DMH8UF0	SY-1425	Phase 1	17	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.31	1.71	3.05	4.18
DC6TIZ8	DMH8UF0	SY-1425	Phase 1	17	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.8	8.1	0.58	1.3
DCOW8BR	DMH8UF0	SY-1425	Phase 1	17	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.67	5.13	1.09	0.61
DCH409P	DMH8UF0	SY-1425	Phase 1	17	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.48	6.4	2.47	7.45
DCKM2K1	DMH8UF0	SY-1425	Phase 1	17	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	4.9	10.26	6.64	8.46
DCW1X1L	DMH8UF0	SY-1425	Phase 1	17	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	5.2	8.21	1.51	0.23
DCOY7KB	DMH8UF0	SY-1425	Phase 1	17	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.8	4.11	1.32	0.64
DCFQI14	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	9.61	11.66	10.58	10.41
DCQ879E	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	12.32	9.92	8.26	2.86
DCNXRGP	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	7.7	4.88	3.33	3.33
DCUT485	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.87	3.25	1.36	3.54
DCJ3MW0	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	9.4	3.75	0.08	0.08
DCOAYAL	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	13.81	10.62	6.45	3.28
DCPY8OD	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.81	1.19	0.49	0.49
DCDB5Z9	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	7.01	5.56	7.23	6.89
DCQR7BS	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	13.47	17.01	11.17	12.05
DC7PDZ1	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	7.57	5.33	5.32	5.03
DCDZB03	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	12.87	10.41	5.6	4.84
DCZNQ9H	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	7.96	3.37	2.83	1.29
DCQT1RP	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	5.2	6.75	8.1	7.79
DCTGDMW	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	9.5	14.68	10	8.68
DCMQMV2	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	4.31	2.61	3.62	4.16
DC2YUPY	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.79	5.58	2	4.64
DCID5RW	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	11.95	9.66	5.49	5.49
DC2GSRR	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	7.16	9.84	8.92	8.92
DCNJIUK	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	7.81	8.37	5.64	5.87
DCIWW5M	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	8.77	10.53	9.56	7.46
DCF7PLC	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	10.19	8.53	6.21	6.67
DCH20XY	DMH8UF0	SY-1425	Phase 1	17	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	7.32	5.8	5.51	4.04
DCT8LGX	DMH8UF0	SY-1425	Phase 1	17	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.04	5.28	3.22	3.44
DCHQY7Z	DMH8UF0	SY-1425	Phase 1	17	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.18	3.82	3.28	3.02
DCXGV22	DMH8UF0	SY-1425	Phase 1	17	DMSG91J	ER819762	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.46	2.79	0.63	0.13
DCUO7VZ	DMH8UF0	SY-1425	Phase 1	17	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.51	8.42	8.3	10.5
DCCC91R	DMH8UF0	SY-1425	Phase 1	17	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.7	4.89	0.71	0.47
DC1OP75	DMH8UF0	SY-1425	Phase 1	17	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.12	5.35	1.43	1.43
DC7IB28	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	10.82	12.05	11.28	9.5
DC5X5PH	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.38	2.76	4.56	4.75
DCGHP7R	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	5.79	7.55	6.93	6.72
DCUJYGX	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.12	2.09	0.02	0.1
DC934VJ	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.68	5.18	2.27	0.08
DC5FO64	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.02	9.62	6.35	5.95
DCED3UH	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.55	5.24	4.69	4.72
DCVQRWN	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.21	7.44	3.56	3.82
DCE77KE	DMH8UF0	SY-1425	Phase 1	17	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.1	6.49	6.64	6.59
DCAA956	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	17.34	15.46	1.57	14.58
DCCN6KQ	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	18.77	20.2	6.27	22.35
DCA89CV	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	14.07	14.88	1.54	14.91
DCG9FXT	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	25.41	24.63	20.29	23.04
DCS6OK2	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	9.14	12.46	11.5	14.77
DCX9A17	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	3.52	12.21	10.68	12.18
DCDX22C	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.79	10.79	3.61	9.65
DCKS9T0	DMH8UF0	SY-1425	Phase 1	17	DMUOT9V	Taxol	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	14.34	17.85	7.61	11.85
DCSASP4	DMH8UF0	SY-1425	Phase 1	17	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	8.05	12.33	1.27	1.27
DCTA11M	DMH8UF0	SY-1425	Phase 1	17	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.18	6.55	8	10.17
DC55UYM	DMH8UF0	SY-1425	Phase 1	17	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	5.39	7.11	2.44	4.83
DCIAIFB	DMH8UF0	SY-1425	Phase 1	17	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	6.08	7.76	10.99	11.35
DC9NX6I	DMH8UF0	SY-1425	Phase 1	17	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	0.49	3.89	3.43	2.59
DCDZJPP	DMH8UF0	SY-1425	Phase 1	17	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	1.29	4.62	3.88	2
DCPKWER	DMH8UF0	SY-1425	Phase 1	17	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.76	4.08	0.39	1.03
DC9XWF4	DMH8UF0	SY-1425	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.18	2.79	2.43	1.38
DCO4BQW	DMH8UF0	SY-1425	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.58	8.27	3.97	6.15
DCJS7RU	DMH8UF0	SY-1425	Phase 1	17	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.22	5.06	1.9	7.66
DC9VZIB	DMIXMYK	Arfolitixorin	Phase 3	25	DMMX2E6	Pemetrexed	Approved	34	.	.	.	.	Rectal Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCHX15Z	DMIXMYK	Arfolitixorin	Phase 3	25	DMUAZWG	Leucovorin	Approved	34	.	.	.	.	Osteosarcoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCHZCKO	DMIXMYK	Arfolitixorin	Phase 3	25	DM05FXR	Meclofenamic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9	9	10.63	10.63
DCM0WFE	DMIXMYK	Arfolitixorin	Phase 3	25	DM0KYI4	Mebutamate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.4	2.4	4.35	4.42
DC8UVBE	DMIXMYK	Arfolitixorin	Phase 3	25	DM0QV1J	Baclofen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.72	6.72	8.42	8.5
DCKYWT5	DMIXMYK	Arfolitixorin	Phase 3	25	DM0RKS4	Bepridil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.91	6.91	9.18	9.23
DCSFLOT	DMIXMYK	Arfolitixorin	Phase 3	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.75	4.84	2.78	3.95
DC8MJYR	DMIXMYK	Arfolitixorin	Phase 3	25	DM15HL8	Clindamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.63	8.63	10.17	10.18
DC94ZD1	DMIXMYK	Arfolitixorin	Phase 3	25	DM1TJ8F	Diethylcarbamazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.12	5.12	6.92	6.94
DC0TZN8	DMIXMYK	Arfolitixorin	Phase 3	25	DM29GAD	Lumefantrine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.92	3.92	5.5	5.54
DCYBTC5	DMIXMYK	Arfolitixorin	Phase 3	25	DM2HU9I	Triamterene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.58	0.58	2.23	2.23
DCU70KY	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	20.9	19.82	20.28	20.68
DCQH0KC	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	11.08	7.48	10.54	10.78
DCH007H	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.93	6.36	7.46	7.47
DCK87Q7	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.55	7.37	7.7	7.64
DCD78ZN	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.69	0.75	1.29	1.3
DCW681V	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.86	0.3	0.66	0.56
DCJOHFU	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	24.59	21.99	22.21	21.81
DCX3AP6	DMIXMYK	Arfolitixorin	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.1	2.9	2.12	2.65
DC49AOR	DMIXMYK	Arfolitixorin	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.97	1.16	1.08	1.36
DCQPRM1	DMIXMYK	Arfolitixorin	Phase 3	25	DM3JCVS	Terazosin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.42	7.42	9.49	9.55
DC1L1HF	DMIXMYK	Arfolitixorin	Phase 3	25	DM3OWT4	Tindamax	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	10.62	10.62	12.14	12.22
DCR40PI	DMIXMYK	Arfolitixorin	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.67	4.54	2.64	7.23
DC4BDNY	DMIXMYK	Arfolitixorin	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.96	1.42	0.42	3.7
DCPHICQ	DMIXMYK	Arfolitixorin	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.2	1.2	4.63	4.65
DCVUV71	DMIXMYK	Arfolitixorin	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.5	3.33	3.1	4.67
DCS2V86	DMIXMYK	Arfolitixorin	Phase 3	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	11.2	12.53	13.69	14.58
DC62O44	DMIXMYK	Arfolitixorin	Phase 3	25	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.97	6.93	4.04	7.67
DC2WA76	DMIXMYK	Arfolitixorin	Phase 3	25	DM51FY6	Tacrine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.71	1.71	3.31	3.34
DC5DTTR	DMIXMYK	Arfolitixorin	Phase 3	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	6.09	7.97	3.69	6.45
DCRX3Q9	DMIXMYK	Arfolitixorin	Phase 3	25	DM5UGDK	Mephenytoin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.87	9.87	11.82	11.88
DCULCVT	DMIXMYK	Arfolitixorin	Phase 3	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.32	7.74	7.13	7.96
DCCR9R8	DMIXMYK	Arfolitixorin	Phase 3	25	DM7A8TW	Ezetimibe	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.94	5.94	7.51	7.51
DCNUH3W	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	8.2	6.89	2.9	7.8
DCHQNJA	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	17.94	15.55	13.39	13.53
DCAX9WE	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.02	0.65	1.37	1.48
DCJIOHM	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	5.79	4.81	4.34	4.32
DCXGX2G	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.71	4.62	5.51	5.43
DCE48U2	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	9.54	10.74	14.01	14.19
DCU3RMA	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.29	1.37	1.47	1.49
DC0BYLO	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	6.16	2.26	1.71	1.52
DCBTP00	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	7.35	5.11	4.6	5.51
DCPNN7J	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	15.72	12.39	10.55	10.21
DC0SXWN	DMIXMYK	Arfolitixorin	Phase 3	25	DM7HUNW	Testosterone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.08	5.08	7.3	7.3
DC7K86Y	DMIXMYK	Arfolitixorin	Phase 3	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.99	1.7	1.9	3.08
DCQ37CQ	DMIXMYK	Arfolitixorin	Phase 3	25	DM93L4X	Dexmedetomidine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.2	4.2	5.82	5.82
DCCH5UE	DMIXMYK	Arfolitixorin	Phase 3	25	DMFI8A7	Tranexamic acid	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.63	9.63	11	11.08
DC38HUR	DMIXMYK	Arfolitixorin	Phase 3	25	DM9S1EA	Pepstatin	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.84	1.84	5.44	5.51
DC75YUX	DMIXMYK	Arfolitixorin	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	9.26	8.15	8.87	11.99
DC7LKBI	DMIXMYK	Arfolitixorin	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.07	1.07	2.72	2.76
DCSSQ3V	DMIXMYK	Arfolitixorin	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.43	1.97	0.81	5.62
DCCPRC4	DMIXMYK	Arfolitixorin	Phase 3	25	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.19	1.55	2.29	4.96
DC5N9CK	DMIXMYK	Arfolitixorin	Phase 3	25	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.03	1.26	1.14	3.4
DCTLVAJ	DMIXMYK	Arfolitixorin	Phase 3	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.23	2.26	1.63	1.64
DCSORQM	DMIXMYK	Arfolitixorin	Phase 3	25	DMAYD7O	IT-141	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.11	0.11	3.2	3.22
DCW425L	DMIXMYK	Arfolitixorin	Phase 3	25	DMB4AVP	Pamidronate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	10.8	10.8	12.36	12.43
DCB687U	DMIXMYK	Arfolitixorin	Phase 3	25	DMBHMOX	Palonosetron	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.3	5.3	6.85	6.89
DCGB4W8	DMIXMYK	Arfolitixorin	Phase 3	25	DMBLM5H	BHV-0223	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.86	5.86	7.82	7.84
DCEAQNF	DMIXMYK	Arfolitixorin	Phase 3	25	DMC0GSJ	Efavirenz	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.67	3.67	5.92	5.97
DCHWH9R	DMIXMYK	Arfolitixorin	Phase 3	25	DMC1TEV	Testosterone cypionate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.99	2.99	5.81	5.86
DCWZ0A8	DMIXMYK	Arfolitixorin	Phase 3	25	DMPN5IH	Guanfacine	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.46	9.46	11.43	11.43
DCRXCTX	DMIXMYK	Arfolitixorin	Phase 3	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	5.34	2.89	0.12	1.51
DCLQPU6	DMIXMYK	Arfolitixorin	Phase 3	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.58	1.58	4.14	4.14
DC42NR2	DMIXMYK	Arfolitixorin	Phase 3	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	3.06	1.06	1.19	1.13
DC8LOFX	DMIXMYK	Arfolitixorin	Phase 3	25	DMCQP0B	Flavonoid derivative 1	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.5	6.5	8.04	8.05
DCNBTUB	DMIXMYK	Arfolitixorin	Phase 3	25	DMCR1MV	Itraconazole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.63	1.63	3.8	3.84
DCYTVLV	DMIXMYK	Arfolitixorin	Phase 3	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	11.63	10.81	1.4	12.3
DCZXNSN	DMIXMYK	Arfolitixorin	Phase 3	25	DMCUT21	Ursodeoxycholic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.19	6.19	7.81	7.81
DCLGL5D	DMIXMYK	Arfolitixorin	Phase 3	25	DMCYANK	Doxapram	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	10.1	10.1	11.7	11.73
DCMGRSW	DMIXMYK	Arfolitixorin	Phase 3	25	DMD4OK0	K-134	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.3	9.3	10.98	11.06
DCGAN6Z	DMIXMYK	Arfolitixorin	Phase 3	25	DMD9WSC	Memantine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.39	6.39	8.27	8.35
DCAWOQO	DMIXMYK	Arfolitixorin	Phase 3	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.8	1.8	4.95	4.96
DCQGL2D	DMIXMYK	Arfolitixorin	Phase 3	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	7.9	4.46	0.88	5.73
DCHLXKK	DMIXMYK	Arfolitixorin	Phase 3	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.8	2.97	1.34	4.34
DCIS3Q7	DMIXMYK	Arfolitixorin	Phase 3	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.5	3.8	1.2	6.13
DCMN3N2	DMIXMYK	Arfolitixorin	Phase 3	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.59	4.22	0.53	4.21
DCGKST6	DMIXMYK	Arfolitixorin	Phase 3	25	DMDXRP1	ETHISTERONE	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.48	2.48	4.37	4.37
DCFH555	DMIXMYK	Arfolitixorin	Phase 3	25	DME5TUR	LY03004	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.59	7.59	9.26	9.27
DCABOGD	DMIXMYK	Arfolitixorin	Phase 3	25	DME9QGW	Marizomib	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	6.53	7.72	3.32	5.87
DCTWV3V	DMIXMYK	Arfolitixorin	Phase 3	25	DMFGLXB	Phensuximide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.48	7.48	10.23	10.31
DCLRDGH	DMIXMYK	Arfolitixorin	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	7.1	6.22	7.44	9.24
DC8D5ED	DMIXMYK	Arfolitixorin	Phase 3	25	DMFQWNI	VR-776	Discontinued in Phase 1	3	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.09	5.09	6.99	7.05
DC5591P	DMIXMYK	Arfolitixorin	Phase 3	25	DMG58FX	WAY-100635	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.73	3.73	6.62	6.63
DCS4DW4	DMIXMYK	Arfolitixorin	Phase 3	25	DMGC5DB	Ciprofibrate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.58	6.58	8.16	8.24
DCD8PD8	DMIXMYK	Arfolitixorin	Phase 3	25	DMGQFYB	Mecamylamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.17	3.17	4.86	4.86
DCSSKQE	DMIXMYK	Arfolitixorin	Phase 3	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.05	0.49	4.59	5.81
DC71KSZ	DMIXMYK	Arfolitixorin	Phase 3	25	DMGYBZI	PHA-739358	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.53	6.53	8.2	8.2
DCYODNY	DMIXMYK	Arfolitixorin	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.45	0.53	3.88	6.86
DCL4UT1	DMIXMYK	Arfolitixorin	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.01	0.3	1.89	2.73
DCTOIPO	DMIXMYK	Arfolitixorin	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.11	3.38	2.85	7.23
DCSSYX2	DMIXMYK	Arfolitixorin	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	12.85	12.92	4.56	13.15
DCRVOMS	DMIXMYK	Arfolitixorin	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.69	3.56	3.39	8.15
DCMX0MB	DMIXMYK	Arfolitixorin	Phase 3	25	DMOL54H	Clopidogrel	Phase 2 Trial	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.87	7.87	9.29	9.36
DCAJZEO	DMIXMYK	Arfolitixorin	Phase 3	25	DMHPWOM	Diphenidol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.97	7.97	9.56	9.57
DCRP1S1	DMIXMYK	Arfolitixorin	Phase 3	25	DMI40NL	Tolazoline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	10.56	10.56	11.87	11.92
DCAAKQB	DMIXMYK	Arfolitixorin	Phase 3	25	DMIK367	Procarbazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.19	9.19	10.85	10.85
DCTONSL	DMIXMYK	Arfolitixorin	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	7.64	9.35	4.27	8.26
DC19SOM	DMIXMYK	Arfolitixorin	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.28	3.73	1.85	6.38
DCEL0Y8	DMIXMYK	Arfolitixorin	Phase 3	25	DMINOX3	Vincristine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	5.42	5.23	3.84	3.21
DCHAKYC	DMIXMYK	Arfolitixorin	Phase 3	25	DMIR21F	PFK-158	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.94	6.94	8.62	8.65
DCN31UQ	DMIXMYK	Arfolitixorin	Phase 3	25	DMIUYFH	Sulfapyridine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.08	4.08	5.77	5.85
DCT3Z69	DMIXMYK	Arfolitixorin	Phase 3	25	DMKFQJP	Triflupromazine	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.09	9.09	10.74	10.76
DCPVK5R	DMIXMYK	Arfolitixorin	Phase 3	25	DMJTEMW	Lubiprostone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.51	1.51	3.27	3.27
DCXFD33	DMIXMYK	Arfolitixorin	Phase 3	25	DMKA8J4	Etonogestrel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.32	2.32	4.26	4.32
DCGKAS5	DMIXMYK	Arfolitixorin	Phase 3	25	DMKBYWI	Trifluoperazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.14	4.14	5.86	5.92
DCEABHT	DMIXMYK	Arfolitixorin	Phase 3	25	DML1538	Diazoxide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.15	2.15	5.18	5.18
DC3TQZ2	DMIXMYK	Arfolitixorin	Phase 3	25	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.97	2.19	0.52	3.64
DC4372C	DMIXMYK	Arfolitixorin	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.72	6.72	11.78	11.84
DCSR56E	DMIXMYK	Arfolitixorin	Phase 3	25	DMM4WBX	Methocarbamol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.46	7.46	9.2	9.27
DCWVIVX	DMIXMYK	Arfolitixorin	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.44	5.45	1.52	3.21
DCS9PQU	DMIXMYK	Arfolitixorin	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	4.41	2.8	0.55	1.67
DCU21JE	DMIXMYK	Arfolitixorin	Phase 3	25	DMMFWOJ	Probenecid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.46	7.46	8.81	8.87
DC6B175	DMIXMYK	Arfolitixorin	Phase 3	25	DMN3GCH	Darunavir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.25	3.25	6.61	6.67
DCIIVWO	DMIXMYK	Arfolitixorin	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.49	4	1.35	1.3
DCOZBS4	DMIXMYK	Arfolitixorin	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.19	4.43	0.69	0.97
DC3S00T	DMIXMYK	Arfolitixorin	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.03	0.05	1.46	2.77
DC0RDVT	DMIXMYK	Arfolitixorin	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2	8.87	4.21	4.26
DCXMYSW	DMIXMYK	Arfolitixorin	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.01	5.77	0.34	0.27
DCQ3E1X	DMIXMYK	Arfolitixorin	Phase 3	25	DMNMW9R	Pramipexole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.84	0.84	2.46	2.46
DCOUXMY	DMIXMYK	Arfolitixorin	Phase 3	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	5.52	7.11	9.91	9.89
DCW7REH	DMIXMYK	Arfolitixorin	Phase 3	25	DMNSJ7V	Tropisetron	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.93	5.93	7.86	7.89
DCOBP9P	DMIXMYK	Arfolitixorin	Phase 3	25	DMO14SG	Mebendazole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.18	8.18	9.8	9.81
DCK8IY5	DMIXMYK	Arfolitixorin	Phase 3	25	DMOL5IU	Mesalazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.57	5.57	7.3	7.3
DCAYIF7	DMIXMYK	Arfolitixorin	Phase 3	25	DMOMBJW	Moricizine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.96	8.96	10.71	10.77
DCJTB36	DMIXMYK	Arfolitixorin	Phase 3	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.91	0.35	0.79	1.91
DCJ3336	DMIXMYK	Arfolitixorin	Phase 3	25	DMPGUCF	Dopamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.97	4.97	6.49	6.49
DCTVDC3	DMIXMYK	Arfolitixorin	Phase 3	25	DMPP4DT	Trimethobenzamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.84	8.84	12.16	12.21
DC130EH	DMIXMYK	Arfolitixorin	Phase 3	25	DMFYAM1	Enalaprilat	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.41	4.41	5.87	5.9
DC4J6U6	DMIXMYK	Arfolitixorin	Phase 3	25	DMR87LC	Ethambutol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.97	9.97	11.65	11.65
DCVDCRG	DMIXMYK	Arfolitixorin	Phase 3	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.35	0.1	0.24	2.77
DCEKV6C	DMIXMYK	Arfolitixorin	Phase 3	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.1	6.1	7.9	7.9
DCL69VX	DMIXMYK	Arfolitixorin	Phase 3	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.75	2.02	0.4	3.19
DC0OG8W	DMIXMYK	Arfolitixorin	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.29	2.69	0.08	5.49
DCDT43Y	DMIXMYK	Arfolitixorin	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.56	0.62	1.17	3.07
DCUQRT9	DMIXMYK	Arfolitixorin	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.53	2.53	3.81	3.84
DCVZP2M	DMIXMYK	Arfolitixorin	Phase 3	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.6	2	1.29	2.68
DC7DUMN	DMIXMYK	Arfolitixorin	Phase 3	25	DMSQZE2	Asenapine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.31	6.31	7.87	7.87
DC8U28S	DMIXMYK	Arfolitixorin	Phase 3	25	DMSWYF5	Quinine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.11	7.11	11.29	11.36
DCTZYAJ	DMIXMYK	Arfolitixorin	Phase 3	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.09	5.31	3.19	7.85
DCK3IJ0	DMIXMYK	Arfolitixorin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	10.23	10.23	11.93	11.97
DCZNPY6	DMIXMYK	Arfolitixorin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	8.65	16.07	10.76	16.17
DCV1398	DMIXMYK	Arfolitixorin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	3.29	5.31	3.74	5.36
DCD8V0J	DMIXMYK	Arfolitixorin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	6.51	13.86	8.95	14.01
DCHOR2M	DMIXMYK	Arfolitixorin	Phase 3	25	DMTL94F	Maraviroc	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.04	8.04	9.67	9.7
DCUQLAH	DMIXMYK	Arfolitixorin	Phase 3	25	DMU9MYJ	Oxandrolone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.53	5.53	6.94	7
DCXMA1O	DMIXMYK	Arfolitixorin	Phase 3	25	DMWT905	Mefloquine	Phase 2/3 Trial	24	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.43	0.43	4.96	4.97
DC42SA1	DMIXMYK	Arfolitixorin	Phase 3	25	DMVRIC2	Zileuton	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.9	7.9	10.6	10.67
DCIJTTX	DMIXMYK	Arfolitixorin	Phase 3	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.13	2	0.06	4.53
DC0CFCH	DMIXMYK	Arfolitixorin	Phase 3	25	DMVRYT2	Nabilone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.27	0.27	2.13	2.15
DCC48AP	DMIXMYK	Arfolitixorin	Phase 3	25	DMVY4GN	Testolactone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.95	4.95	7.3	7.36
DCC1IIS	DMIXMYK	Arfolitixorin	Phase 3	25	DMVYXR8	Sumatriptan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.46	6.46	8.15	8.17
DCJIHTV	DMIXMYK	Arfolitixorin	Phase 3	25	DMWE60C	Rufinamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.84	4.84	6.49	6.5
DCJ4P5U	DMIXMYK	Arfolitixorin	Phase 3	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.77	3.2	2.8	3.14
DCPHE52	DMIXMYK	Arfolitixorin	Phase 3	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.27	1.27	4.68	4.7
DC4XK0M	DMIXMYK	Arfolitixorin	Phase 3	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.74	4.34	3.72	6.41
DCD3VLZ	DMIXMYK	Arfolitixorin	Phase 3	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.72	2.17	1.19	5.09
DCBLXEK	DMIXMYK	Arfolitixorin	Phase 3	25	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.7	3.35	4.13	7
DCOBR4C	DMIXMYK	Arfolitixorin	Phase 3	25	DMXCM7H	Cerivastatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.37	2.37	5.51	5.6
DCACQOC	DMIXMYK	Arfolitixorin	Phase 3	25	DMSIVND	Hydroxychloroquine	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.67	5.67	7.37	7.37
DCB4046	DMIXMYK	Arfolitixorin	Phase 3	25	DMY4UMW	Atovaquone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.26	8.26	9.7	9.75
DC3EBFZ	DMIXMYK	Arfolitixorin	Phase 3	25	DMYTE6L	Enoxacin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.59	0.59	2.25	2.31
DCYXKHL	DMIXMYK	Arfolitixorin	Phase 3	25	DMYURI6	Raltegravir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.83	3.83	5.38	5.43
DCSG7KY	DMIXMYK	Arfolitixorin	Phase 3	25	DMYZ57N	Albendazole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.47	9.47	10.73	10.81
DCRE89H	DMIXMYK	Arfolitixorin	Phase 3	25	DMZ1OO0	AS-1949490	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.99	4.99	6.68	6.7
DCXLB21	DMIXMYK	Arfolitixorin	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.97	5.1	2.51	2.61
DCWCPXH	DMIXMYK	Arfolitixorin	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.08	5.65	3.38	3.91
DCXJF1L	DMIXMYK	Arfolitixorin	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.85	1.19	3.34	2.33
DCMYLZU	DMIXMYK	Arfolitixorin	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.42	6.01	2.26	2.36
DCYO92B	DMIXMYK	Arfolitixorin	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	10.83	5.06	0.78	6.64
DCMHGZV	DMIXMYK	Arfolitixorin	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.44	6.04	3.86	5.91
DCGWUAV	DMIXMYK	Arfolitixorin	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.9	2.19	1.48	1.75
DCDMIZ3	DMIXMYK	Arfolitixorin	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.98	7.15	0.89	5.09
DC4BGBN	DMIXMYK	Arfolitixorin	Phase 3	25	DMZ7XNQ	Tacrolimus	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.9	3.9	5.1	5.17
DCMYY9I	DMIXMYK	Arfolitixorin	Phase 3	25	DMZMSCT	Cilostazol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.69	5.69	7.42	7.44
DCFR36Z	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.17	6.05	6.23	6.04
DC70EMT	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.25	6.98	6.7	6.7
DCD8YBF	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.06	12.3	11.83	11.96
DCB3610	DMIXMYK	Arfolitixorin	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.75	3.35	1.84	2.28
DC1YFUY	DMIXMYK	Arfolitixorin	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	7.5	14.87	14.81	16.23
DC9KZH2	DMIXMYK	Arfolitixorin	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	9.79	11.95	14.1	14.63
DC4OCJ0	DMIXMYK	Arfolitixorin	Phase 3	25	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.05	9.2	1.1	1.47
DCGIO1W	DMIXMYK	Arfolitixorin	Phase 3	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	8.39	18.28	3.21	3.88
DCLVOLC	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.85	2.91	2.41	2.45
DCLR5YE	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	11.87	15.56	15.94	15.95
DC114D2	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	6.78	6.25	9.57	7.99
DC9HH1T	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	27.56	23.09	21.92	21.99
DCQ0CNF	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	9.5	14.17	14.01	14.03
DCKKQHE	DMIXMYK	Arfolitixorin	Phase 3	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.61	0.62	1.37	1.37
DCCHWZ7	DMIXMYK	Arfolitixorin	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.7	1.06	6.15	7.64
DCBW0FH	DMIXMYK	Arfolitixorin	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.24	6.69	9.05	9.8
DCS5ZJH	DMIXMYK	Arfolitixorin	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.2	1.62	4.93	6.92
DCIQDHL	DMIXMYK	Arfolitixorin	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.17	4.3	0.06	1.66
DC3680L	DMIXMYK	Arfolitixorin	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	7.49	7.99	2.81	10.32
DC9E4GC	DMIXMYK	Arfolitixorin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.12	11.85	3.19	4.09
DC8RCNR	DMIXMYK	Arfolitixorin	Phase 3	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	6.77	7.13	10.05	10.23
DCN8QZU	DMIXMYK	Arfolitixorin	Phase 3	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.63	6.36	6.01	7.5
DCE1C68	DMIXMYK	Arfolitixorin	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	9.56	11.53	6.05	6.58
DCXEF8U	DMIXMYK	Arfolitixorin	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.98	6.15	0.08	0.41
DCIW70F	DMIXMYK	Arfolitixorin	Phase 3	25	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	2.5	3.28	7.86	9.49
DC9KF45	DMIXMYK	Arfolitixorin	Phase 3	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.49	2.05	0.74	0.8
DC4P0SR	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.59	0.77	0.49	0.48
DCGAASF	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.51	5	2.37	4.53
DCS5T4A	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	22.76	17.6	17.13	17.06
DCPKEBE	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.08	11.05	10.71	10.67
DCGYUN5	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	5.61	10.11	9.92	9.96
DCX5Q8H	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.51	8.43	7.81	7.01
DC57SHU	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	5.4	11.6	11.48	10.99
DC7A851	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	6.84	10.47	9.29	9.46
DC22WTU	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.57	3.25	3.48	3.52
DC1B93N	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	8.3	16.31	16.18	16.28
DCBP5DV	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	26.65	27.79	28.28	28.27
DC0O6GF	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	9.96	12.68	11.85	11.97
DCL9XZK	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.39	7.12	2.66	4.84
DCRURO6	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	14.62	13.43	14.38	12.89
DCEABY8	DMIXMYK	Arfolitixorin	Phase 3	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.64	6.54	5.42	5.42
DCP04RL	DMIXMYK	Arfolitixorin	Phase 3	25	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.62	5.54	6.52	7.44
DCSFGNA	DMIXMYK	Arfolitixorin	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.36	1.46	0.81	0.99
DCZZO7K	DMIXMYK	Arfolitixorin	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	2.11	5.87	3.36	6.72
DCURU0A	DMIXMYK	Arfolitixorin	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	4.11	9.94	12.33	13
DCJJDFZ	DMIXMYK	Arfolitixorin	Phase 3	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.43	7.89	1.49	7.58
DCVT61R	DMIXMYK	Arfolitixorin	Phase 3	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.03	1.29	0.04	1.46
DCXRZZ6	DMIXMYK	Arfolitixorin	Phase 3	25	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	10.77	15.43	12.98	11.92
DCOEAZ9	DMIXMYK	Arfolitixorin	Phase 3	25	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	10.23	8.29	11.18	11.47
DCO5NPC	DMIXMYK	Arfolitixorin	Phase 3	25	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.48	11.82	1.33	10.45
DC02Y2S	DMIXMYK	Arfolitixorin	Phase 3	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.64	1.34	1.11	4.34
DCLKCPE	DMIXMYK	Arfolitixorin	Phase 3	25	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.8	14.6	9.12	8.09
DC9CFYG	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.92	6.49	0.72	6.6
DCCUG75	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.38	0.53	0.45	0.46
DCGN1ZC	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.86	5.27	6.13	6.22
DCPVDE6	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.21	4.98	4.14	5.2
DCW0WOI	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.57	5.31	2.89	2.89
DCVIR4L	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	11.76	6.02	3.89	3.72
DCD67ZE	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	5.72	9.46	9.08	9.09
DC2CMWL	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	7.56	7.35	6.71	6.63
DCXY2YC	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	13.64	14.82	10.18	14.19
DCVHNT7	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	5.12	5.48	5.1	5.02
DCKVOC5	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	10.89	14.78	15.13	14.64
DCO9KER	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.36	3.9	3.35	3.39
DCZ136F	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	4.73	1.12	0.59	0.57
DCJOF1H	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	5.43	5.87	8.92	8.53
DCOMOI5	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.95	6.24	5.5	5.65
DC5FKCX	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	27.26	30.19	30.97	31.14
DC1WPAR	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.59	4.91	5.55	5.58
DC9EYB0	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	9.01	13.91	15.43	15.71
DCSEYSD	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	15.58	17.27	16.82	16.59
DC8GC5Q	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	10.6	11.57	11	10.95
DC893YD	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	8.64	9.44	8.38	8.34
DCC5SVQ	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	13.23	5.65	5.3	2.98
DCJ5WHD	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.9	8.06	10.37	8.68
DCN8VSD	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.28	3.86	3.96	4.05
DCUAZVC	DMIXMYK	Arfolitixorin	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.46	4.28	4.06	4.1
DCS6CSH	DMIXMYK	Arfolitixorin	Phase 3	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.57	1.91	0.77	0.93
DCP7GPH	DMIXMYK	Arfolitixorin	Phase 3	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.2	3.9	2.12	2.18
DCGX3AR	DMIXMYK	Arfolitixorin	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.43	6.39	1.84	5.74
DCZ6SRE	DMIXMYK	Arfolitixorin	Phase 3	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.73	5.95	2.93	3.24
DCQDZYY	DMIXMYK	Arfolitixorin	Phase 3	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.97	4.11	6.67	7.59
DCHIIDS	DMIXMYK	Arfolitixorin	Phase 3	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.63	6.88	1.01	5.25
DC3NP2P	DMIXMYK	Arfolitixorin	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.72	8.88	7.25	9.57
DCAI1LB	DMIXMYK	Arfolitixorin	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.24	1.41	0.25	4.07
DCUGH33	DMIXMYK	Arfolitixorin	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.26	3.93	5.26	7.13
DCJWKVZ	DMIXMYK	Arfolitixorin	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	12.57	11.65	0.6	12.68
DCZ8CMJ	DMIXMYK	Arfolitixorin	Phase 3	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4.77	5.43	6.01	4.52
DC73MHN	DMIXMYK	Arfolitixorin	Phase 3	25	DMH07Y3	Letrozole	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.27	1.93	1.58	2.06
DC9KAIA	DMIXMYK	Arfolitixorin	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.76	3.75	6.92	9.68
DCOEOYA	DMIXMYK	Arfolitixorin	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.17	4.37	2.66	7.54
DCHF99G	DMIXMYK	Arfolitixorin	Phase 3	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.33	0.05	2.18	5.02
DCFHK26	DMIXMYK	Arfolitixorin	Phase 3	25	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.46	3.38	7.43	5.73
DCOGLR8	DMIXMYK	Arfolitixorin	Phase 3	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.46	6.62	4.37	3.52
DC5FXUA	DMIXMYK	Arfolitixorin	Phase 3	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	10.87	8.95	8.22	6.73
DCRJT9G	DMIXMYK	Arfolitixorin	Phase 3	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.99	6.78	8.83	9.12
DC7FGX9	DMIXMYK	Arfolitixorin	Phase 3	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	4.62	6.05	5.24	7.58
DCS7SA7	DMIXMYK	Arfolitixorin	Phase 3	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.11	4.26	0.71	3.1
DCLUYI5	DMIXMYK	Arfolitixorin	Phase 3	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	5.1	10.08	4.47	7.8
DCZSVYG	DMIXMYK	Arfolitixorin	Phase 3	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	5.91	11.32	13.24	13.97
DC6CIXM	DMIXMYK	Arfolitixorin	Phase 3	25	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.16	6.47	4.19	5.05
DC0PW1H	DMIXMYK	Arfolitixorin	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	2.23	4.12	0.82	1.51
DCEJI56	DMIXMYK	Arfolitixorin	Phase 3	25	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.55	8.26	4.33	2.95
DCDV9LV	DMIXMYK	Arfolitixorin	Phase 3	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.44	5.9	7.74	7.75
DC894W7	DMIXMYK	Arfolitixorin	Phase 3	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	2.16	4.54	1.96	2.84
DCMR4BG	DMIXMYK	Arfolitixorin	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	4.85	0.38	1.13	3.34
DCILTIC	DMIXMYK	Arfolitixorin	Phase 3	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	1.8	2.03	0.83	0.35
DCOKBT5	DMIXMYK	Arfolitixorin	Phase 3	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.18	2.48	0.72	0.99
DC7AXSR	DMIXMYK	Arfolitixorin	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.84	3.75	2.54	4.9
DCFT49Y	DMIXMYK	Arfolitixorin	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	22.34	20.63	2.92	24.97
DC4Q928	DMIXMYK	Arfolitixorin	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	4.66	5.22	5.95	8.05
DC62PTK	DMIXMYK	Arfolitixorin	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	10.37	9.05	2.16	11.68
DCBYT0Q	DMIXMYK	Arfolitixorin	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	10.38	13.46	12.59	14.88
DC8WV6U	DMIXMYK	Arfolitixorin	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	10.79	11.89	4.35	13.15
DCMOULR	DMIXMYK	Arfolitixorin	Phase 3	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	0.47	2.09	3.76	4.5
DC4QYTR	DMIXMYK	Arfolitixorin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	7.69	10.03	8.39	10.11
DCL9328	DMIXMYK	Arfolitixorin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.76	9.66	8.62	9.91
DC9Y6TL	DMIXMYK	Arfolitixorin	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.41	7.2	7.19	7.76
DC3ZZEY	DMIXMYK	Arfolitixorin	Phase 3	25	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	6.09	8.25	3.74	11.05
DCRQUQN	DMIXMYK	Arfolitixorin	Phase 3	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4.9	7.8	6.26	9.46
DC0OI8E	DMIXMYK	Arfolitixorin	Phase 3	25	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.29	3	0.37	6.48
DCE6T05	DMIXMYK	Arfolitixorin	Phase 3	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.6	3.34	4.14	4.22
DCLPFO0	DMIXMYK	Arfolitixorin	Phase 3	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.93	5.88	4.09	7.83
DCBRZMT	DMIXMYK	Arfolitixorin	Phase 3	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	8.31	12.6	6.06	6.31
DC9JCO0	DMIXMYK	Arfolitixorin	Phase 3	25	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.56	7.41	6.45	6.28
DCRBXKR	DMIXMYK	Arfolitixorin	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	5.56	7.15	8.21	9.72
DC7JD92	DMIXMYK	Arfolitixorin	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.25	1.46	0.05	1.17
DC829YZ	DMIXMYK	Arfolitixorin	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	4.65	4.37	9.76	11.06
DC1EV9V	DMIXMYK	Arfolitixorin	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.82	5.72	4.55	7.27
DCHWBTR	DMINOX3	Vincristine	Approved	34	DMZD5QR	Cytarabine	Approved	34	.	.	.	.	Hodgkin Disease	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCKW02P	DMINOX3	Vincristine	Approved	34	DMP6SC2	Irinotecan	Approved	34	.	.	.	.	Neuroblastoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCMOCWO	DMINOX3	Vincristine	Approved	34	DMKECZD	Temozolomide	Approved	34	.	.	.	.	Ewing Sarcoma	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCSJ186	DMINOX3	Vincristine	Approved	34	DMP6SC2	Irinotecan	Approved	34	.	.	.	.	"Unspecified Childhood Solid Tumor, Protocol Specific"	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC5P04O	DMINOX3	Vincristine	Approved	34	DMKECZD	Temozolomide	Approved	34	DMP6SC2	Irinotecan	.	.	Brain and Central Nervous System Tumors	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCU3LWE	DMINOX3	Vincristine	Approved	34	DMKECZD	Temozolomide	Approved	34	DMP6SC2	Irinotecan	.	.	Rhabdomyosarcoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCPLEEH	DMINOX3	Vincristine	Approved	34	DMKWCTR	GS-9973	Phase 2	21	.	.	.	.	Non-Hodgkin Lymphoma	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCS15D5	DMINOX3	Vincristine	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	3.3	7.13	6.19	5.6
DC8N57C	DMINOX3	Vincristine	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	3.32	5.71	2.31	1.93
DCGCB29	DMINOX3	Vincristine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	11.45	15.61	2.94	13.97
DCGPNNU	DMINOX3	Vincristine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	1.13	0.71	2.08	2.38
DC27QD6	DMINOX3	Vincristine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	3.57	5.01	5.48	5.72
DC8PSXB	DMINOX3	Vincristine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	2.01	5.69	5.64	6.25
DC5SR63	DMINOX3	Vincristine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	0.78	4.49	1.87	0.08
DCHSV6O	DMINOX3	Vincristine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	19.16	19.14	2.42	15.84
DCH82IB	DMINOX3	Vincristine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	16.65	15.96	11.36	15.53
DC981IX	DMINOX3	Vincristine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	18.3	18.99	15.69	15.53
DCML5Q0	DMINOX3	Vincristine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	1.28	4.8	6.54	6.5
DCWU5YO	DMINOX3	Vincristine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	1.72	3.28	1.41	0.83
DCJPCMX	DMINOX3	Vincristine	Approved	34	DM1WEHC	Buparlisib	Phase 3	25	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	5.559	5.824	4.482	7.497
DCHRZ67	DMINOX3	Vincristine	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	L-1236	1.706	0.765	6.806	7.697
DCI91NL	DMINOX3	Vincristine	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	T-cell leukemia/lymphoma	ALMANAC Dataset	Investigative	ED-40515	4.226	2.331	1.508	3.317
DC6WFJ3	DMINOX3	Vincristine	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	7.27	9.75	4.54	1.51
DCMEXVD	DMINOX3	Vincristine	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	1.5	4.28	1.96	1.79
DCJ9PL8	DMINOX3	Vincristine	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	16.74	19.71	16.87	15.34
DCFHBPF	DMINOX3	Vincristine	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	3.28	7.63	1.95	0.95
DCPCT0Z	DMINOX3	Vincristine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	0.78	0.14	0.58	1.92
DCLLJVH	DMINOX3	Vincristine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	2.04	3.29	1.19	4.52
DCF6WH8	DMINOX3	Vincristine	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	6.34	6.23	2.96	6.88
DCCAJ6U	DMINOX3	Vincristine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	1.38	7.44	5.58	6.32
DC51P9V	DMINOX3	Vincristine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	6.33	6.59	0.26	5.21
DC3FAQY	DMINOX3	Vincristine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	2.14	4.1	3.13	2.19
DCFXCFV	DMINOX3	Vincristine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	1.54	2.52	3.18	4.02
DC1RUAO	DMINOX3	Vincristine	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	1.26	1.55	1.69	3.64
DC3CSL3	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	14.48	19.71	13.36	13.85
DCS6AOK	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	1.38	3.65	4	5.43
DC2CW35	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	6	10.14	6.57	6.86
DC7F25A	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	10.74	13.88	4.88	15.85
DC9E34Q	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	9.65	10.72	4.52	4.65
DCAXEWF	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	17.79	20.35	13.23	12.77
DC7SW5S	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	5.71	10.94	6.72	6.61
DCFX50Q	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	6.18	9.65	9.24	9.99
DCV4YT8	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	7.49	10.7	7.99	8.56
DCFVIES	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	7.71	11.9	4.96	9.91
DCWICSW	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	15.18	16.94	12.56	13.92
DC0FN9T	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	6.84	7.41	3.29	6.59
DCYF3AJ	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	7.6	9	7.95	8.59
DC63BGT	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	3.67	6.78	6.05	6.28
DCLQ3GA	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	3.31	4.26	5.81	4.25
DC1YV4Y	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	8.08	10.21	12.9	12.55
DCMWEFA	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	1.97	4.25	5.09	5.16
DC7EVSN	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	1.62	9.06	7.33	7.37
DCD56FH	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	1.91	3.01	3.53	5.7
DCKPCHI	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	2.27	6.93	9.89	8.92
DCO5VI5	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	7.14	10.1	8.07	8.82
DCRQUU8	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	6.8	9.74	12.93	11.99
DCNDTI5	DMINOX3	Vincristine	Approved	34	DM48K0X	Carfilzomib	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	9.785	9.638	5.046	8.432
DCLUOLM	DMINOX3	Vincristine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	1.68	3.94	0.18	4.05
DCH4AQF	DMINOX3	Vincristine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	0.88	1.2	3.18	4.15
DCS2Y27	DMINOX3	Vincristine	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	5.05	10.55	4.19	0.87
DCLBKHS	DMINOX3	Vincristine	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	3.73	6	4.09	6.77
DCARX9G	DMINOX3	Vincristine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	4.83	13	6.36	4.73
DCTOLNK	DMINOX3	Vincristine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	4.6	5.96	1.62	0.74
DCVLHCS	DMINOX3	Vincristine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	5.97	12.19	3.25	3.25
DCETRM8	DMINOX3	Vincristine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	1.41	3.21	0.21	0.28
DCTYQLK	DMINOX3	Vincristine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	0.56	3.54	0.95	1.93
DCSAYUD	DMINOX3	Vincristine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	0.56	1.54	0.32	0.08
DCCDF0A	DMINOX3	Vincristine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	0.29	2.95	1.44	1.44
DCF5JOK	DMINOX3	Vincristine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	1.78	2.23	0.49	0.04
DC0CPV6	DMINOX3	Vincristine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	9.84	11.84	3.68	0.49
DC55VAW	DMINOX3	Vincristine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	0	2.66	1.95	1.58
DC9WFXA	DMINOX3	Vincristine	Approved	34	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	4.44	3.74	9.84	11.13
DC12Y56	DMINOX3	Vincristine	Approved	34	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	L-1236	8.706	9.188	4.191	7.034
DCNELSS	DMINOX3	Vincristine	Approved	34	DM5Q1W4	Ym155	Phase 2	21	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	L-1236	106.904	109.815	18.201	23.219
DC3ZWFB	DMINOX3	Vincristine	Approved	34	DM5ZVLB	Ixazomib	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	6.294	5.583	2.823	6.365
DCF2KPR	DMINOX3	Vincristine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	5.28	2.78	3.34	5.75
DC12ASV	DMINOX3	Vincristine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	1.45	1.17	0.94	3.82
DCI6HVH	DMINOX3	Vincristine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	3.31	3.33	3.75	5.02
DCW1JNP	DMINOX3	Vincristine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	3.88	5.59	3.87	4.53
DCGJVZQ	DMINOX3	Vincristine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	1.4	2.13	2.39	2.53
DCWFCOF	DMINOX3	Vincristine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	1.74	3.37	1.11	4.34
DCT6DR5	DMINOX3	Vincristine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	2.67	2.65	2.8	5.31
DC9HTM1	DMINOX3	Vincristine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	0.25	0.37	0.85	3.01
DCOZKVM	DMINOX3	Vincristine	Approved	34	DM6VOWQ	Fomepizole	Approved	34	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	L-1236	73.267	73.122	5.78	8.75
DCM71N1	DMINOX3	Vincristine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	3.53	8.19	3.6	2.68
DCVT1HB	DMINOX3	Vincristine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	1.7	5.04	2.54	0.74
DCDGWBY	DMINOX3	Vincristine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	2.14	3.22	2.16	1.64
DC5B7NS	DMINOX3	Vincristine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	L-1236	2.377	2.349	2.553	4.535
DC9KQ2L	DMINOX3	Vincristine	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	1.39	2.91	0.99	0.88
DC65CHW	DMINOX3	Vincristine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	19.59	18.79	13.44	12.62
DCZU3PS	DMINOX3	Vincristine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	3.43	6.24	3.07	4.58
DCQ33B9	DMINOX3	Vincristine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	3.42	7.69	4.22	3.1
DC92QTD	DMINOX3	Vincristine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	0.08	2.8	2.69	1.8
DCG9468	DMINOX3	Vincristine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	0.41	2.17	1.28	0.7
DCL0QSR	DMINOX3	Vincristine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	2.85	3.44	1.5	5.17
DC0INED	DMINOX3	Vincristine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	0.25	3.4	2.3	1.81
DCRAEEJ	DMINOX3	Vincristine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	0.96	4.96	2.99	2.46
DCAZJNA	DMINOX3	Vincristine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	1.49	2.27	5.59	4.36
DCZPGXX	DMINOX3	Vincristine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	8.62	8.03	7.9	5.55
DC248P8	DMINOX3	Vincristine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	3.97	8.26	8.92	9.39
DC6Z1A6	DMINOX3	Vincristine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	2.83	6.6	5.57	4.57
DCMDZ0G	DMINOX3	Vincristine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	7.2	6.96	5.58	5.58
DCVCB0R	DMINOX3	Vincristine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	7.31	8.81	2.57	4.73
DC7X4AM	DMINOX3	Vincristine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	2.36	5.32	1.1	1.07
DCVR0VB	DMINOX3	Vincristine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	2.63	4.05	0.22	0.12
DCTJOY9	DMINOX3	Vincristine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	0.89	2.92	2.56	1.6
DCN11HC	DMINOX3	Vincristine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	2.7	4.99	2.28	1.73
DCPY5U0	DMINOX3	Vincristine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.95	3.27	1.05	0.99
DCGE2HJ	DMINOX3	Vincristine	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	0.23	4.27	0.39	6.42
DCQRUSU	DMINOX3	Vincristine	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	1.61	1.5	0.57	3.22
DCM2ANZ	DMINOX3	Vincristine	Approved	34	DMA9SEY	GDC-0084	Phase 2	21	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	L-1236	2.68	2.137	11.386	11.227
DC89OAP	DMINOX3	Vincristine	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	9.59	6.75	4.47	7.68
DCRHYS0	DMINOX3	Vincristine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	10.62	12.16	6.04	6.27
DC8VKYN	DMINOX3	Vincristine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	11.18	14.97	2.67	10.91
DCX1KBN	DMINOX3	Vincristine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	6.74	8.98	5.36	7.69
DCT67TD	DMINOX3	Vincristine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	2.67	3.01	1.6	3.86
DCDMNLJ	DMINOX3	Vincristine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	3.47	5.16	5.83	6.59
DCFHPS8	DMINOX3	Vincristine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	6.92	12.61	8.01	9.04
DC8W0W6	DMINOX3	Vincristine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	6.41	7.41	0.97	0.97
DCQ8VNF	DMINOX3	Vincristine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	0.58	3.93	2.91	2.13
DCW6MGX	DMINOX3	Vincristine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	L-1236	76.656	75.226	2.371	7.772
DC9DARY	DMINOX3	Vincristine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	14.51	14.19	2.1	12.83
DC500M2	DMINOX3	Vincristine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	10.29	14.43	6.45	10.73
DCJFCXB	DMINOX3	Vincristine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	0.18	8.85	6.92	9.03
DCP09B4	DMINOX3	Vincristine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	0.3	4.43	1.78	1.77
DCCRP1I	DMINOX3	Vincristine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	2.01	3.88	6.13	7.01
DC1ZOB1	DMINOX3	Vincristine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	2.83	4.97	2.31	1.32
DCL1W2O	DMINOX3	Vincristine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	1.26	4.16	2.71	2.41
DCVZY9D	DMINOX3	Vincristine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	12.18	15.99	14.14	13.77
DCUCR0P	DMINOX3	Vincristine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	5.1	6.41	5.26	2.66
DCX9H0R	DMINOX3	Vincristine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	1.26	6.88	1.07	8.32
DC7055V	DMINOX3	Vincristine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	1.6	6.31	2.41	2.05
DCJ8PRV	DMINOX3	Vincristine	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	4.57	14.23	4.85	10.25
DCLQ2VV	DMINOX3	Vincristine	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	2.76	6.63	1.67	3
DCNUIL6	DMINOX3	Vincristine	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	2.31	8.45	2.3	7.45
DCQ0DUX	DMINOX3	Vincristine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	4.31	5.58	4.25	2.79
DCOR1JK	DMINOX3	Vincristine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	1.14	3.9	6.39	3.86
DC2179Q	DMINOX3	Vincristine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	1.94	1	2.7	5.61
DCFRF7E	DMINOX3	Vincristine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	4.12	6.73	2.57	1.56
DCPLM1E	DMINOX3	Vincristine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	3.6	7	3.71	2.16
DC8AY3T	DMINOX3	Vincristine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	1.31	3.4	1.4	1.28
DCNUL93	DMINOX3	Vincristine	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	0.05	1.95	0.77	0.82
DCU3AEL	DMINOX3	Vincristine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	5.3	1.83	3.15	0.86
DCS8RZT	DMINOX3	Vincristine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	5.05	8.93	3.82	3.9
DC23VSG	DMINOX3	Vincristine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	0.65	3.24	0.46	0.86
DC0DVLK	DMINOX3	Vincristine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	1.65	6.91	3.6	2.56
DC9EDSH	DMINOX3	Vincristine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	1.51	2.94	1.08	1.61
DC5U7HT	DMINOX3	Vincristine	Approved	34	DMGHLG5	Withaferin A	Terminated	2	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	L-1236	3.424	4.229	2.133	6.469
DCD5549	DMINOX3	Vincristine	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	3.36	5.66	4.85	8.73
DCAJF42	DMINOX3	Vincristine	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	3.89	10.6	2.42	4.55
DCLJEGR	DMINOX3	Vincristine	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	2.17	6.72	4.4	4.39
DCKKAGG	DMINOX3	Vincristine	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	5.2	13.67	8.08	12.65
DCCGXGX	DMINOX3	Vincristine	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	0.22	9.16	6.89	8.42
DC876GI	DMINOX3	Vincristine	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	0.42	6.97	4.76	4.86
DCY7N4B	DMINOX3	Vincristine	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	0.13	2.76	0.58	1.32
DC9GK7C	DMINOX3	Vincristine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	1.52	3.95	1.94	1.92
DCOWIJD	DMINOX3	Vincristine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	19.49	24.76	15.41	10.78
DCR7QYK	DMINOX3	Vincristine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	4.11	4.82	2.02	1.43
DCBYMPU	DMINOX3	Vincristine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Diffuse large B cell lymphoma	ALMANAC Dataset	Investigative	TMD8	1.55	1.339	5.002	5.683
DCU4LNB	DMINOX3	Vincristine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	6.42	6.6	3.3	7.85
DCD77GR	DMINOX3	Vincristine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	10.7	12.77	3.06	1.58
DCU3B5Z	DMINOX3	Vincristine	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	2.98	4.37	2.35	1.52
DC1ETZF	DMINOX3	Vincristine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	0.51	3.24	0.6	1.78
DCA6IDN	DMINOX3	Vincristine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	1.57	4.98	3.67	4.17
DCP883V	DMINOX3	Vincristine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	1.46	1.57	0.76	5.33
DCU630R	DMINOX3	Vincristine	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	0.81	1.5	1.25	3.28
DC72IAJ	DMINOX3	Vincristine	Approved	34	DMIW453	Pelitinib	Phase 2	21	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	U-HO1	7.326	6.067	5.743	8.285
DCBQREG	DMINOX3	Vincristine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	3.1	5.77	3.01	4.82
DCBGQZE	DMINOX3	Vincristine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	10.47	14.35	13.35	13.34
DCZ4W1R	DMINOX3	Vincristine	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	1.05	5.89	5.3	4
DCJO0F3	DMINOX3	Vincristine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	2.26	4.78	1.23	1.23
DCFZMBV	DMINOX3	Vincristine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	3.12	5.38	2.67	1.74
DCA5AHJ	DMINOX3	Vincristine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	1.49	2.51	1.68	0.24
DCK3Q4L	DMINOX3	Vincristine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	8.67	16.17	5.99	12.64
DC8U37M	DMINOX3	Vincristine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	7.94	17.61	14.72	4.27
DCTPOLX	DMINOX3	Vincristine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	0.4	6.94	3.92	4
DCWKI9T	DMINOX3	Vincristine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	3.58	6.14	3.47	1.09
DCYDFDL	DMINOX3	Vincristine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	26.66	26.93	24.2	25.94
DCKVGQF	DMINOX3	Vincristine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	2.31	9.42	10.37	10.45
DCR53AX	DMINOX3	Vincristine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	1.05	6.07	6.3	3.61
DCYRGFI	DMINOX3	Vincristine	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	4.43	9.56	8.67	8.84
DCNR7FT	DMINOX3	Vincristine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	17.89	18.09	9.23	18.7
DCR1N8B	DMINOX3	Vincristine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	1.79	3.96	0.52	0.36
DCSCR2C	DMINOX3	Vincristine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	0.1	4.6	3.87	4.42
DC1KNM0	DMINOX3	Vincristine	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	1.86	4.54	2.67	0.49
DCVT8AY	DMINOX3	Vincristine	Approved	34	DMMZSXQ	Azathioprine	Approved	34	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	L-1236	1.661	2.367	3.08	5.014
DCX1278	DMINOX3	Vincristine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	5.63	9.6	5.55	4.22
DC3N3C9	DMINOX3	Vincristine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	2.4	12.73	4.92	8.04
DCKWMCP	DMINOX3	Vincristine	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-28	0.68	2.7	0.12	0.22
DC0C2CN	DMINOX3	Vincristine	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	L-1236	1.905	0.204	3.834	6.158
DCFBWD1	DMINOX3	Vincristine	Approved	34	DMOFSLE	IMD-0354	Phase 1	17	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	L-1236	21.099	23.263	4.797	11.886
DCJH7AX	DMINOX3	Vincristine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	3.36	2.3	2	3.95
DC2J0T4	DMINOX3	Vincristine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	2.32	3.78	2.84	3.33
DCBJBGH	DMINOX3	Vincristine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	4.34	2.42	0.43	1.26
DCVZTJK	DMINOX3	Vincristine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	10.26	8.01	8.96	11
DCZIMGV	DMINOX3	Vincristine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	4.39	6.23	4.92	6.72
DC5RDFH	DMINOX3	Vincristine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	1.19	2.43	0.21	2.03
DCW89YX	DMINOX3	Vincristine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	7.63	8.89	1.33	6.18
DCPONKH	DMINOX3	Vincristine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	1.87	3.82	2.72	3.98
DCGU2LS	DMINOX3	Vincristine	Approved	34	DMPK32V	BMS-754807	Phase 1	17	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	4.72	5.5	10.56	12.64
DCCRXR3	DMINOX3	Vincristine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	7.72	9.71	5.18	4.01
DCKVWOK	DMINOX3	Vincristine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	4.13	4.43	3.58	6.17
DCC4PY0	DMINOX3	Vincristine	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	0.27	1.82	0.92	1.48
DCR58C2	DMINOX3	Vincristine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	1.47	3.82	5.97	8.79
DCQW9RN	DMINOX3	Vincristine	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	1.66	4.25	0.31	0.56
DCBRIBM	DMINOX3	Vincristine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	1.51	5.03	3.72	1.22
DC144DL	DMINOX3	Vincristine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	1.86	4.6	2.36	2.57
DCES7ZH	DMINOX3	Vincristine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	3.52	8.29	5.13	3.95
DC9IFTA	DMINOX3	Vincristine	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	2.2	4.76	2.5	0.59
DC94QAO	DMINOX3	Vincristine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	1.5	1.64	0.26	0.09
DC906PJ	DMINOX3	Vincristine	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	2.16	3.56	0.9	0.87
DCD4MG3	DMINOX3	Vincristine	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	2.6	2.7	1.83	4.95
DC9ZNKG	DMINOX3	Vincristine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	0.95	8.52	4.91	6.64
DC5EVUQ	DMINOX3	Vincristine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	0.52	3.01	2.12	2.9
DCSBI2I	DMINOX3	Vincristine	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	0.98	1.21	3.54	6.8
DCXF21V	DMINOX3	Vincristine	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	5.65	11.2	3.04	8.99
DCCRSV8	DMINOX3	Vincristine	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	1.66	0.37	0.07	0.55
DC4MVMM	DMINOX3	Vincristine	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	6.85	5.33	7.92	6.94
DCDUCO8	DMINOX3	Vincristine	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	6.91	11.24	1.35	2.04
DCRPUT5	DMINOX3	Vincristine	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	8.09	8.9	0.4	6.14
DCBNH10	DMINOX3	Vincristine	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	10.07	6.82	1.49	6.76
DCTLEGV	DMINOX3	Vincristine	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	10.88	15.77	13.56	11.76
DCJEA27	DMINOX3	Vincristine	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	13.71	17.23	15.06	14.94
DCFOF9R	DMINOX3	Vincristine	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	4.55	4.19	4.27	4.18
DCSSU4K	DMINOX3	Vincristine	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	6.43	10.51	9.73	9.86
DC0HUQV	DMINOX3	Vincristine	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	1.17	6.78	5.62	5.2
DCYJZJZ	DMINOX3	Vincristine	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	1.51	3.7	3.35	3.57
DCSA5T9	DMINOX3	Vincristine	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	1.53	12.62	2.06	2.9
DCB1Y9I	DMINOX3	Vincristine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	5.29	5.24	1.85	1.95
DC0DQAH	DMINOX3	Vincristine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	12.88	13.79	4.73	11.57
DCDJAJE	DMINOX3	Vincristine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	1.2	3.21	0.95	3.55
DCGM7D1	DMINOX3	Vincristine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	4.05	9.69	2.61	3.16
DCGDJPX	DMINOX3	Vincristine	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	2.79	5.62	3.54	2.07
DC3XR9R	DMINOX3	Vincristine	Approved	34	DMUKNQ5	AZD8330	Discontinued in Phase 1	3	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	11.227	11.519	13.357	15.61
DCHO5GA	DMINOX3	Vincristine	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	1.91	0.98	1.59	2.57
DCWJ3V3	DMINOX3	Vincristine	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	10.08	13.37	0.52	10.26
DC8XQFZ	DMINOX3	Vincristine	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	7.1	6.18	1.33	5.45
DCI4B2L	DMINOX3	Vincristine	Approved	34	DMVBPRO	CP-673451	Investigative	0	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	L-1236	14.61	13.529	5.252	8.328
DCC5XD0	DMINOX3	Vincristine	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	4.28	11.07	6.1	5.51
DCBMTOP	DMINOX3	Vincristine	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	0.36	2.83	2.89	2.5
DCE1HPY	DMINOX3	Vincristine	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	1.15	6.65	1.51	6.01
DCAJ727	DMINOX3	Vincristine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	2.44	3.79	0.74	0.81
DC51J33	DMINOX3	Vincristine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	7.96	10.67	8.42	3.38
DCVB7CL	DMINOX3	Vincristine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	3.8	4.54	0.48	0.02
DCFCG7U	DMINOX3	Vincristine	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	2.02	6.59	3.72	3.09
DCH0OXD	DMINOX3	Vincristine	Approved	34	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	ALMANAC Dataset	Investigative	DIPG25	1.03	1.397	3.596	4.84
DCPN8RS	DMINOX3	Vincristine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	2.17	3.7	1.79	0.83
DC0RZWD	DMINOX3	Vincristine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	1.98	4.76	5.69	5.17
DCN2IO6	DMINOX3	Vincristine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	0.76	1.33	2.81	2.99
DCY0DOR	DMINOX3	Vincristine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	3.28	6.47	4.61	4.18
DC5IFWU	DMINOX3	Vincristine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	SNB-19	2.9	7.2	3.49	3.71
DC25TPK	DMINOX3	Vincristine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	2.68	3.66	8.7	8.92
DCSWF49	DMINOX3	Vincristine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	0.84	3.7	0.73	1.95
DCNTO37	DMINOX3	Vincristine	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	0.13	1.93	1.07	0.98
DCNRRYO	DMINOX3	Vincristine	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	1.94	4.07	2.2	7.87
DCKVDRT	DMINOX3	Vincristine	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	3.11	6.41	5.01	2.72
DCBK8UV	DMINOX3	Vincristine	Approved	34	DMXKDUL	BGT226	Phase 1/2	19	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	L-1236	74.159	74.807	9.947	13.017
DC3OSUX	DMINOX3	Vincristine	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	3.1	9.71	6.5	4.31
DC3JP64	DMINOX3	Vincristine	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	2.14	4.33	2.83	1.69
DCPG5VL	DMINOX3	Vincristine	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	2.14	2.52	1.81	1.29
DCCTJCR	DMINOX3	Vincristine	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	1.09	6.56	6.33	4.65
DC43Y43	DMINOX3	Vincristine	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	2.76	4.52	0.06	0.27
DC0JPIL	DMINOX3	Vincristine	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	0.23	3.34	2.19	1.31
DCEKV5U	DMINOX3	Vincristine	Approved	34	DMHZCPO	Ibrutinib	Phase 2 Trial	21	.	.	.	.	Diffuse large B cell lymphoma	ALMANAC Dataset	Investigative	TMD8	1.733	1.451	2.336	7.455
DCPE3KK	DMINOX3	Vincristine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	0.26	5.66	2.37	3.13
DC7IQKZ	DMINOX3	Vincristine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	0.59	1.01	1.79	1.79
DCYI0WG	DMINOX3	Vincristine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	1.91	5.76	2.93	2.37
DCJRRCC	DMINOX3	Vincristine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	1.02	8.97	1.8	5.77
DCAQ79Y	DMINOX3	Vincristine	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	1.35	5.97	9.37	4.77
DCSRH1T	DMINOX3	Vincristine	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	8.54	8.93	0.95	10.12
DCRU2DN	DMINOX3	Vincristine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	11.8	10.6	8.69	12.77
DCTSG8L	DMINOX3	Vincristine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	23.61	22.42	21.52	20.46
DCYWNEF	DMINOX3	Vincristine	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.24	11.04	6.93	8.47
DC64KAM	DMINOX3	Vincristine	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.92	4.83	5.08	5.13
DCSJ0U9	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.82	4.77	1.68	6.19
DC7AJIN	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	12.71	15.62	1.56	14.73
DC2OUYJ	DMINOX3	Vincristine	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	12.36	20.31	10.16	9.17
DCPM983	DMINOX3	Vincristine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.19	3.97	1.21	0.44
DCI7N9N	DMINOX3	Vincristine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.03	3.46	2.77	1.87
DCPITCI	DMINOX3	Vincristine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.86	4.46	3.37	2.58
DCG082W	DMINOX3	Vincristine	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.34	1.85	1.59	1.28
DCMATW5	DMINOX3	Vincristine	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.7	5.99	7.24	9.2
DC81L1L	DMINOX3	Vincristine	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	8.09	15.25	1.32	9.25
DC3YUU2	DMINOX3	Vincristine	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.94	2.83	2.46	0.51
DCWATS7	DMINOX3	Vincristine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	11.35	13.85	2.2	11.33
DC23Z3M	DMINOX3	Vincristine	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	8.94	12.88	4.97	8
DCFJLDU	DMINOX3	Vincristine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	15.81	16.79	2.12	13.95
DCFUQXN	DMINOX3	Vincristine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.36	12.52	1.27	12.29
DC38UEZ	DMINOX3	Vincristine	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	11.07	14.82	4.33	14.11
DCW3TZH	DMINOX3	Vincristine	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.1	8.25	0.61	2.12
DCR1861	DMINOX3	Vincristine	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.99	4.34	1.96	1.96
DCQYGMV	DMINOX3	Vincristine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.8	4.29	2.54	5.11
DCM5MBC	DMINOX3	Vincristine	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.07	3.7	2.88	3.72
DCEDT1D	DMINOX3	Vincristine	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.11	2.07	2.64	3.84
DCXU1EC	DMINOX3	Vincristine	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.56	6.68	4.19	2.33
DCFEL8F	DMHL7OB	Uracil mustard	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	18.58	19.84	4.49	20.9
DCOCD0V	DMHL7OB	Uracil mustard	Approved	34	DM0PIY6	Picoplatin	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	23.74	22.47	1.48	24.55
DCCGCYQ	DMHL7OB	Uracil mustard	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	5.32	6.67	3.52	6.95
DCY8KG7	DMHL7OB	Uracil mustard	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.1	5.67	0.11	4.3
DCE8RHF	DMHL7OB	Uracil mustard	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	1.91	4.41	1.06	4.32
DCMCOYR	DMHL7OB	Uracil mustard	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.37	3.99	0.79	1.43
DC8KJHD	DMHL7OB	Uracil mustard	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.42	5.75	3.92	4.21
DCI7ARI	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	23.5	24.51	23.35	25.43
DCKH97W	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	26.85	23.25	26.66	27.83
DCI7VB8	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.34	1.25	1.59	1.64
DCBA8TF	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.83	3.81	2.63	4.94
DCZ1XFD	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.36	4.95	5.47	5.51
DCI7MT7	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	25.05	25.84	20.69	24.58
DCLDPII	DMHL7OB	Uracil mustard	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	20.06	18.37	12.98	19.33
DCQ01OJ	DMHL7OB	Uracil mustard	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	9.38	13.4	13.05	13.39
DC4UM7Y	DMHL7OB	Uracil mustard	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	3.26	5.42	9.87	10.44
DCN9XFT	DMHL7OB	Uracil mustard	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	8.1	8.64	6.56	10.56
DCJQ56D	DMHL7OB	Uracil mustard	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.59	5.87	3.86	7.72
DCMVI9G	DMHL7OB	Uracil mustard	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	1.95	2.82	1.83	6.25
DCHM14G	DMHL7OB	Uracil mustard	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.74	7.7	2	4.19
DCL7JUM	DMHL7OB	Uracil mustard	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.24	1.6	4.01	3.82
DCV8F0H	DMHL7OB	Uracil mustard	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.78	0.36	1.77	2.79
DC2CEIV	DMHL7OB	Uracil mustard	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	6.16	7.09	1.48	6.78
DCY7QVY	DMHL7OB	Uracil mustard	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.48	7.18	2.67	9.1
DCCL81S	DMHL7OB	Uracil mustard	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	11.76	14.25	7.5	12.79
DCY670S	DMHL7OB	Uracil mustard	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	7.9	5.68	0.75	7.67
DCIBA6X	DMHL7OB	Uracil mustard	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	16.15	16.55	13.04	18
DCG17VQ	DMHL7OB	Uracil mustard	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.55	5.88	0.46	5.42
DCDFZ8Q	DMHL7OB	Uracil mustard	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	13.48	14.82	1.13	16.21
DC1ZCOW	DMHL7OB	Uracil mustard	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	6.05	9.89	6.59	8.63
DCPBSRF	DMHL7OB	Uracil mustard	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	5.73	11.3	9.26	13.21
DCU0BGK	DMHL7OB	Uracil mustard	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	8.86	9.33	7.38	10.87
DCJ7O5G	DMHL7OB	Uracil mustard	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	12.32	9.63	9.88	12.43
DC5XSIZ	DMHL7OB	Uracil mustard	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	8.82	10.73	12.55	13.33
DCFIUMX	DMHL7OB	Uracil mustard	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	3.24	6.03	2.62	7.36
DCQ1OP1	DMHL7OB	Uracil mustard	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	6.48	5.67	7.08	8.47
DC3OHS7	DMHL7OB	Uracil mustard	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.78	4.46	2.15	6.47
DC5TFG6	DMHL7OB	Uracil mustard	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	16.27	16.87	10.66	18.07
DCRTOH8	DMHL7OB	Uracil mustard	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	7.93	8.72	9.03	9.18
DCTENRU	DMHL7OB	Uracil mustard	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	13.73	15.23	5.45	17.28
DC9E5ES	DMHL7OB	Uracil mustard	Approved	34	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	10.53	9.02	6.56	10.65
DC7WOYW	DMHL7OB	Uracil mustard	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.85	1	2.68	4.25
DCWAR28	DMHL7OB	Uracil mustard	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.41	3.08	4.22	5.01
DCIVJE4	DMHL7OB	Uracil mustard	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.8	4.1	4.1	4.38
DCQ4LCN	DMHL7OB	Uracil mustard	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.56	3.1	1.81	2.19
DCXYF3U	DMHL7OB	Uracil mustard	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.24	11.39	11.54	11.73
DC583VM	DMHL7OB	Uracil mustard	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.54	5.34	5.35	5.46
DCA1T71	DMHL7OB	Uracil mustard	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.21	8.67	4.65	8.22
DCL68E1	DMHL7OB	Uracil mustard	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.93	1.43	0.56	3.31
DCZPGXL	DMHL7OB	Uracil mustard	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.45	2.23	1.9	4.93
DCG71XR	DMHL7OB	Uracil mustard	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.78	4.27	4.43	7.04
DCBQOMW	DMHL7OB	Uracil mustard	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.36	1.44	2.26	5.46
DCUDGLH	DMHL7OB	Uracil mustard	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	14.4	13.5	12.6	15.52
DCL4PCO	DMHL7OB	Uracil mustard	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.1	4.34	4.44	5.57
DCL956D	DMHL7OB	Uracil mustard	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	5.57	6.5	6.38	8.65
DCNWNJG	DMHL7OB	Uracil mustard	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	9.08	7.09	2.62	11.87
DCF6J1C	DMHL7OB	Uracil mustard	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.6	3.2	2.65	4.78
DCBIUTL	DMHL7OB	Uracil mustard	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	8.28	9.31	5.54	10.68
DC8KSSZ	DMHL7OB	Uracil mustard	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.36	4.13	3.12	6.8
DCJNE40	DMHL7OB	Uracil mustard	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.81	2.69	1.92	4.83
DC8HNEY	DMHL7OB	Uracil mustard	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	5.35	4.44	5.53	7.58
DCYUYKH	DMHL7OB	Uracil mustard	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.82	4.13	5.19	6.26
DC1JAME	DMHL7OB	Uracil mustard	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	3.28	8.75	0.27	9.73
DCMAMZ9	DMHL7OB	Uracil mustard	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	4.27	4.09	4.12	7.55
DCOZUJY	DMHL7OB	Uracil mustard	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	10.02	15.99	5.26	14.97
DCD0YFY	DMHL7OB	Uracil mustard	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.92	5.67	1.6	7.71
DCKWADS	DMHL7OB	Uracil mustard	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	6.36	7.7	2.89	11.11
DCNBPTD	DMHL7OB	Uracil mustard	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	7.59	9.72	5.18	8.74
DC3BBSK	DMHL7OB	Uracil mustard	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.37	7.09	3.86	6.63
DCUU940	DMHL7OB	Uracil mustard	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.98	6.57	5.08	10.19
DCRYGZ5	DMHL7OB	Uracil mustard	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	9.43	11.33	5.99	9.96
DC8X84L	DMHL7OB	Uracil mustard	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	3.49	4.59	1.18	6.76
DCYSEXO	DMHL7OB	Uracil mustard	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	8.36	10.15	0.25	5.94
DC74Y0Y	DMHL7OB	Uracil mustard	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	8.85	11.08	9.12	12.44
DCRNPF2	DMHL7OB	Uracil mustard	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.05	4.29	4.15	6.77
DCS4HAJ	DMHL7OB	Uracil mustard	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	6.53	7.06	4.52	9.13
DCUMO9B	DMHL7OB	Uracil mustard	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	4.8	0.2	1.49	3.03
DCAQSPC	DMHL7OB	Uracil mustard	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.55	5.1	3.77	7.01
DCMZT8V	DMHL7OB	Uracil mustard	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.27	4.95	1.84	5.83
DCNJL0X	DMHL7OB	Uracil mustard	Approved	34	DMLWYJB	JNK-IN-8	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	5.03	3.04	2.39	4.81
DCZDDB2	DMHL7OB	Uracil mustard	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.08	6.86	5.48	8.41
DCZML17	DMHL7OB	Uracil mustard	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	19.08	18.71	14.2	18.97
DCESBZG	DMHL7OB	Uracil mustard	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.49	5.71	5.31	8.22
DCH6FYD	DMHL7OB	Uracil mustard	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.93	0.83	1.59	2.32
DC914BL	DMHL7OB	Uracil mustard	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	5.7	8.8	4.24	7.91
DC558DV	DMHL7OB	Uracil mustard	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.3	1.19	0.29	2.82
DCWS3JF	DMHL7OB	Uracil mustard	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.2	2.05	3.16	6.84
DC1HU3P	DMHL7OB	Uracil mustard	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.8	6.61	7.88	8.33
DCF7AQT	DMHL7OB	Uracil mustard	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	7.11	7.86	9.55	9.63
DC1KJMN	DMHL7OB	Uracil mustard	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.14	2.07	1.72	1.17
DCTFFLN	DMHL7OB	Uracil mustard	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.1	5.81	4.54	4.81
DCHCIFA	DMHL7OB	Uracil mustard	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	6.18	6.26	6.54	9.27
DCFQZ6O	DMHL7OB	Uracil mustard	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	5.96	7.57	9.29	10.26
DCM75OP	DMHL7OB	Uracil mustard	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	9.12	11.47	4.64	11.91
DCMHXKW	DMHL7OB	Uracil mustard	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	4.99	2.99	5.53	7.08
DCIYXU0	DMHL7OB	Uracil mustard	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	6.77	8.41	3.74	9.81
DCLEZ56	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.04	3.55	5.45	8.78
DCM689G	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.75	6.45	9.35	10.66
DCW9PTO	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	5.86	5.64	7.85	10.61
DCSI7U2	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	7.04	7.19	8.22	15.04
DCS3P7O	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	3.06	8.95	7.69	10.46
DCRJFVO	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.31	1.56	4.58	6.65
DCWEVZI	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	4.71	5.15	8.05	10.12
DCERK8S	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.88	1.87	4.03	5.92
DCO121Y	DMHL7OB	Uracil mustard	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.9	9.64	1.47	7.48
DCVW1T6	DMHL7OB	Uracil mustard	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.26	1.84	1.84	4.54
DCQ5MS8	DMHL7OB	Uracil mustard	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.86	5.84	0.9	6.21
DCMW6YH	DMHL7OB	Uracil mustard	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.25	5.52	1.98	5.25
DCNMTF5	DMHL7OB	Uracil mustard	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	19.37	16.24	13.34	18.01
DCTOVCX	DMHL7OB	Uracil mustard	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	14.64	12.86	12.51	14.93
DCFBDNO	DMHL7OB	Uracil mustard	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	9.51	10.99	9.97	10.67
DCW1Y1K	DMHL7OB	Uracil mustard	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	7.4	7.04	5.44	7.67
DC0K17X	DMHL7OB	Uracil mustard	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	6.24	6.4	6.43	9.74
DCH0I78	DMHL7OB	Uracil mustard	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.82	2.89	0.89	3.39
DCYC81L	DMHL7OB	Uracil mustard	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.72	5.1	0.93	5.51
DCNJZ9P	DMHL7OB	Uracil mustard	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	3.15	6.37	1.65	7.62
DC2DEA8	DMHL7OB	Uracil mustard	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	13.03	18.68	14	18.91
DCUWWPU	DMHL7OB	Uracil mustard	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.5	4.48	2.39	4.34
DCM83QA	DMHL7OB	Uracil mustard	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	17.29	15.25	13.85	18.19
DCWDOI2	DMHL7OB	Uracil mustard	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	7.34	9.94	6.63	11.43
DC604FK	DMHL7OB	Uracil mustard	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.17	4.85	2.31	5.43
DCPV76R	DMHL7OB	Uracil mustard	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.39	5.96	7.43	9.62
DC7X7SD	DMHL7OB	Uracil mustard	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	12.26	13.45	3.34	14.02
DC24NW2	DMHL7OB	Uracil mustard	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.25	10.13	1.54	8.53
DCGQUQJ	DMHL7OB	Uracil mustard	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.66	3.19	1.13	4.9
DCVUIOD	DMHL7OB	Uracil mustard	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	11.66	11.46	4.1	11.85
DC893PP	DMHL7OB	Uracil mustard	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.02	4.05	1.04	7.19
DC7WPAR	DMHL7OB	Uracil mustard	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	6.76	8.44	7.91	11.57
DCA6BXQ	DMHL7OB	Uracil mustard	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.95	2.88	1.32	5.53
DC6U40G	DMHL7OB	Uracil mustard	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.54	2.42	2.64	4.86
DCCJRH2	DMHL7OB	Uracil mustard	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.61	3.82	2.87	6.89
DCKNE5Q	DMHL7OB	Uracil mustard	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.06	0.69	1.07	4.33
DC3SHRL	DMHL7OB	Uracil mustard	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.16	6.94	0.23	7.25
DCYXYP5	DMHL7OB	Uracil mustard	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.34	6.7	2.45	8
DCUF607	DMHL7OB	Uracil mustard	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	7.01	8.42	4.4	9.67
DCDNVUW	DMHL7OB	Uracil mustard	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	9.3	14.99	4.93	11.05
DCPBKJE	DMHL7OB	Uracil mustard	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4	8.01	5.64	9.46
DCYTCOL	DMHL7OB	Uracil mustard	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.39	1.58	4.12	7.27
DCNGRAU	DMHL7OB	Uracil mustard	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	3.32	11.36	10.15	11.75
DCYBCXO	DMHL7OB	Uracil mustard	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	8.44	11.51	4.57	12.36
DCHF70E	DMHL7OB	Uracil mustard	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	4.4	4.21	8.36	8.24
DC8E3SE	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	9.9	9.54	8.03	9.02
DCAM18M	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.48	6.13	5.09	5.85
DC9MHVZ	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.05	9.69	7.54	8.09
DCZEBJD	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.41	7.49	5.49	6.5
DCT7N5L	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	12.91	15.66	13.98	14.85
DCK9SI5	DMHL7OB	Uracil mustard	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.72	8.44	6.98	9.23
DC0WEDU	DMHL7OB	Uracil mustard	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.17	5.94	1.57	7.09
DC9MY9F	DMHL7OB	Uracil mustard	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	6.71	13.68	17.27	18.1
DCI9L3V	DMHL7OB	Uracil mustard	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.06	15.13	2.66	14.03
DCASNPD	DMHL7OB	Uracil mustard	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	4.7	11.94	2.96	11.95
DCYH7VL	DMHL7OB	Uracil mustard	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.71	13.1	2.32	12.04
DCMISZF	DMHL7OB	Uracil mustard	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.34	3.67	5.45	6.71
DCUS4D5	DMHL7OB	Uracil mustard	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.67	3.18	1.94	1.85
DCUNJI5	DMHL7OB	Uracil mustard	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	5.48	5.83	2.83	6.14
DC4SN0C	DMHL7OB	Uracil mustard	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	8.07	11.45	13.36	14.55
DCIDK4A	DMHL7OB	Uracil mustard	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.96	6.23	1.24	3.23
DCQNSVR	DMHL7OB	Uracil mustard	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.63	6.89	3.53	5.85
DCQHQN1	DMHL7OB	Uracil mustard	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.21	5.78	2.51	6.65
DCW71UK	DMHL7OB	Uracil mustard	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.46	10.53	9.2	9.48
DCKJQDA	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.19	1.31	5.14	5.84
DCQRC15	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	4.8	7.99	8.82	10.97
DCB2HBL	DMHL7OB	Uracil mustard	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.1	6.68	2.55	7.8
DCZYDGE	DMHL7OB	Uracil mustard	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	11.9	14.16	12.7	15.13
DCAUJSW	DMHL7OB	Uracil mustard	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	4.16	7.69	6.74	8.5
DC12MFM	DMHL7OB	Uracil mustard	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.27	9.99	3.29	9.33
DCMGPF4	DMHL7OB	Uracil mustard	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.97	4.49	2.5	2.51
DCZWWHF	DMHL7OB	Uracil mustard	Approved	34	DM0CVXA	Mechlorethamine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.78	0.41	4.24	6.18
DCYPXGR	DMHL7OB	Uracil mustard	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.78	7.2	1.47	6.59
DC03GN0	DMHL7OB	Uracil mustard	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.71	6.24	2.22	5.95
DCJG6SL	DMHL7OB	Uracil mustard	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.68	1.54	0.74	0.94
DCNWC8U	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	7.85	11.03	9.76	10.54
DCKOI33	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.14	11.94	10.75	11.09
DCX8GI8	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.83	11.58	9.88	10.51
DCUCD9K	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.18	12.13	10.15	11.36
DCK9RTT	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	3.66	7.02	6.78	6.47
DC07LA1	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.94	7.12	5.38	6.19
DC67VL9	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.83	3.87	3.52	3.3
DCLG0FN	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	23.89	26.56	26.63	26.49
DC6MVUN	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	32.31	28.26	28.12	29.05
DCFR0SO	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.22	4.07	0.7	1.69
DCJ94X4	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	7.32	13.55	9.12	11.15
DC8V3X9	DMHL7OB	Uracil mustard	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.68	2.53	0.98	0.29
DCCCMD1	DMHL7OB	Uracil mustard	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	5.81	7.93	4	9.2
DC8DKVH	DMHL7OB	Uracil mustard	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.59	10.01	3.85	7.88
DC1GCYU	DMHL7OB	Uracil mustard	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6	7.01	2.5	7.63
DCH99M6	DMHL7OB	Uracil mustard	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	7.95	16.69	6.38	14.12
DCKHEBU	DMHL7OB	Uracil mustard	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.49	6.04	1.29	6.89
DCZKZPT	DMHL7OB	Uracil mustard	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	5.46	8.21	5.3	7.88
DCAOGE9	DMHL7OB	Uracil mustard	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	9.07	15.26	14.77	15.87
DCGOE32	DMHL7OB	Uracil mustard	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.11	10.12	6.05	10.95
DC3CF5F	DMHL7OB	Uracil mustard	Approved	34	DM4F29C	Crizotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.27	5.64	4.74	3.45
DCRYSCZ	DMHL7OB	Uracil mustard	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	3.53	7.37	3.59	3.51
DCESSVD	DMHL7OB	Uracil mustard	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	13.11	10.73	1.55	9.75
DCGPQSZ	DMHL7OB	Uracil mustard	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	6.93	9.62	11.72	12.37
DCNFE0J	DMHL7OB	Uracil mustard	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	4.82	12.52	7.61	7.61
DCGJD01	DMHL7OB	Uracil mustard	Approved	34	DM62UG5	Vemurafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.01	1.92	1.88	4.49
DCVW42Y	DMHL7OB	Uracil mustard	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.95	11.33	7.69	10.12
DCW3EXO	DMHL7OB	Uracil mustard	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.87	10.64	11	11.24
DCGRHM2	DMHL7OB	Uracil mustard	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	35.37	36.39	30.03	37.25
DC6AP8P	DMHL7OB	Uracil mustard	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.62	5.64	0.54	6.94
DCP7GNH	DMHL7OB	Uracil mustard	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	4.97	10.86	4.25	8.48
DCFUZG3	DMHL7OB	Uracil mustard	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.47	3.14	3.8	3.42
DCHDI0F	DMHL7OB	Uracil mustard	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	1.63	2.52	1.42	0.43
DCYZHEC	DMHL7OB	Uracil mustard	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.6	11.13	2.47	11.59
DCB126I	DMHL7OB	Uracil mustard	Approved	34	DM7NKEV	Thioguanine	Preclinical	2.1	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.61	10.05	6.93	10.36
DCT1FMA	DMHL7OB	Uracil mustard	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.75	9.32	1.22	10.06
DCZGJNX	DMHL7OB	Uracil mustard	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.57	3.1	1.84	1.62
DCYZ219	DMHL7OB	Uracil mustard	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	0.21	1.29	1.57	1.54
DC9H470	DMHL7OB	Uracil mustard	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.06	3.27	2.92	2.93
DCI1P6F	DMHL7OB	Uracil mustard	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.04	2.18	3.72	3.95
DCGYGWT	DMHL7OB	Uracil mustard	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	0.98	8.3	6.96	6.53
DC3C5E3	DMHL7OB	Uracil mustard	Approved	34	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.24	5.88	1.72	4.6
DCB50L8	DMHL7OB	Uracil mustard	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.55	1.63	0.92	6.48
DCSHQB6	DMHL7OB	Uracil mustard	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	6.86	13.32	9.58	12.75
DCNFXFN	DMHL7OB	Uracil mustard	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.6	4.65	3.53	6.19
DC5MI9A	DMHL7OB	Uracil mustard	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.88	3.95	4.63	6.96
DCYP0H1	DMHL7OB	Uracil mustard	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	8.87	9.99	2	9.9
DCT0K8M	DMHL7OB	Uracil mustard	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	12.18	11.09	4.22	11.65
DCW04KT	DMHL7OB	Uracil mustard	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	11.8	14	14.14	15.27
DC8529N	DMHL7OB	Uracil mustard	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	12.43	20.08	14.97	18.7
DCHN0M2	DMHL7OB	Uracil mustard	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.57	4.67	7.31	8.32
DCQKXVO	DMHL7OB	Uracil mustard	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.45	5.14	0.15	7.29
DCKNJVJ	DMHL7OB	Uracil mustard	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.91	3.1	3.7	6.1
DC4GJRW	DMHL7OB	Uracil mustard	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	3.89	5.28	0.65	6
DC6YRI9	DMHL7OB	Uracil mustard	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.62	0.48	2.95	5.34
DCTS7RH	DMHL7OB	Uracil mustard	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.76	8.57	0.91	5.02
DCJCHMD	DMHL7OB	Uracil mustard	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	1.11	5.8	5.34	6.38
DCMS331	DMHL7OB	Uracil mustard	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	2.1	5.36	0.14	4.35
DCI34Z6	DMHL7OB	Uracil mustard	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	6.27	13.93	4.67	14.98
DCG571P	DMHL7OB	Uracil mustard	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.19	4.26	7.13	7.59
DC6TTV8	DMHL7OB	Uracil mustard	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0	8.87	3.87	7.79
DCO5YRY	DMHL7OB	Uracil mustard	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.81	10.18	6.03	7.49
DCL5TJG	DMHL7OB	Uracil mustard	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.39	3.67	0.43	3.21
DCBX6XL	DMHL7OB	Uracil mustard	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.76	10.3	2.13	5.36
DCDJ2MM	DMHL7OB	Uracil mustard	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.88	7.83	5.3	4.75
DC4C1XF	DMHL7OB	Uracil mustard	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.58	4.83	7.11	9.45
DCRVOWM	DMHL7OB	Uracil mustard	Approved	34	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	2.17	9.82	9.64	10.68
DC5KJX6	DMHL7OB	Uracil mustard	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.27	5.58	6.89	6.64
DCRS2CH	DMHL7OB	Uracil mustard	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.1	5.1	6.04	6.46
DC4DIOX	DMHL7OB	Uracil mustard	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	6.71	13.59	8.52	12.01
DCKIPAO	DMHL7OB	Uracil mustard	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.23	2.67	1.85	0.77
DC3C860	DMHL7OB	Uracil mustard	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	0.57	8.09	0.59	8.99
DCZ872N	DMHL7OB	Uracil mustard	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.64	3.33	3.88	5.78
DC1T8BQ	DMHL7OB	Uracil mustard	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.81	6.04	7.14	9.39
DC6R9GE	DMHL7OB	Uracil mustard	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	5.48	7.41	7.45	7.46
DCINXZL	DMHL7OB	Uracil mustard	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	1.55	10.46	7.32	7.46
DCHD6KO	DMHL7OB	Uracil mustard	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.37	4.76	2.49	2.32
DCOG94U	DMHL7OB	Uracil mustard	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.11	2.82	2.87	4.28
DC2MUIH	DMHL7OB	Uracil mustard	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	3.18	7.58	0.02	8.38
DCQYK7O	DMHL7OB	Uracil mustard	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	0.53	6	6.12	6.61
DCB9CYN	DMHL7OB	Uracil mustard	Approved	34	DMNPZL4	Dacarbazine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.35	5.33	8.07	8.97
DCQQA7A	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	6.04	5.63	3.05	10.03
DCOR628	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.06	2.41	6.07	6.87
DCKR08Y	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	7.44	7.95	9.55	11.64
DCB2HQT	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	8.3	7.86	10.51	10.71
DCAQWNQ	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.12	3.88	5.22	7.87
DCLVV4D	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	5.41	7.9	6.65	10.93
DCROFWZ	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	16.67	17.48	17.77	19.77
DCFLULP	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.91	1.47	5.27	7.44
DC5ZTKW	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	2.92	6.43	6.58	8.8
DC1PNPK	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	6.79	10.99	9.24	10.84
DCTU1V8	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	4.09	5.42	4.1	6.86
DC0VX0V	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.32	6.57	8.29	10.35
DCR72TA	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.19	11.25	13.17	15.42
DCAE3ZW	DMHL7OB	Uracil mustard	Approved	34	DMP6G8T	Topotecan	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.82	5.97	7.97	8.54
DCBX4CU	DMHL7OB	Uracil mustard	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.28	4.37	0.83	4.51
DCTEA79	DMHL7OB	Uracil mustard	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	6.33	7.57	0.35	8.31
DCBTE3Q	DMHL7OB	Uracil mustard	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.83	3.69	5.75	6.38
DCP7Y8S	DMHL7OB	Uracil mustard	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.16	5.07	5.43	6.45
DCKY54S	DMHL7OB	Uracil mustard	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	5.01	5.03	4.4	5.71
DCJO529	DMHL7OB	Uracil mustard	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.85	2.23	3.93	5.38
DCF26R2	DMHL7OB	Uracil mustard	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	3.16	6.01	2.94	6.77
DCRWHDH	DMHL7OB	Uracil mustard	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.98	4	0.49	4.28
DC0NKSI	DMHL7OB	Uracil mustard	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.57	3.19	1.29	2.73
DCQENWB	DMHL7OB	Uracil mustard	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	7.68	6.27	0.61	7.41
DCN35B3	DMHL7OB	Uracil mustard	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.23	0.77	3.01	3.47
DCUEQ7P	DMHL7OB	Uracil mustard	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	24.21	25.04	24.67	26.51
DCSTN2D	DMHL7OB	Uracil mustard	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	7.06	8.24	2.04	9.78
DCZXJT6	DMHL7OB	Uracil mustard	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	13.08	15.72	10.81	16.89
DC1DYYS	DMHL7OB	Uracil mustard	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	3.66	5.98	0.67	5.74
DCO84QV	DMHL7OB	Uracil mustard	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.92	5.29	2.78	7.47
DCSYUEO	DMHL7OB	Uracil mustard	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.37	8.09	4.08	8.74
DCQGJCG	DMHL7OB	Uracil mustard	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	2.16	8.17	6.66	6.15
DCE8ASK	DMHL7OB	Uracil mustard	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.23	1.25	0.12	2.14
DCU32DV	DMHL7OB	Uracil mustard	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	7.63	11.11	2.82	11.11
DCFSZLE	DMHL7OB	Uracil mustard	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	7.6	10.42	3.36	11.13
DCJGFHW	DMHL7OB	Uracil mustard	Approved	34	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	9.57	9.39	8.99	10.57
DCDRTJ3	DMHL7OB	Uracil mustard	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.64	9.4	9.29	10.87
DCD1JEF	DMHL7OB	Uracil mustard	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.98	3.1	2.51	5.64
DCHDG9Q	DMHL7OB	Uracil mustard	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	4.89	5.54	6.35	8.52
DCEOXYO	DMHL7OB	Uracil mustard	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.14	4.19	6.03	8.43
DCSYT2Y	DMHL7OB	Uracil mustard	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.47	3.27	1.95	4.69
DCPVMEB	DMHL7OB	Uracil mustard	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	3.64	3.23	4.67	6.87
DCPR6CS	DMHL7OB	Uracil mustard	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	3.29	4.84	3.08	3
DCXN5AA	DMHL7OB	Uracil mustard	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	0.15	1.54	1.62	4.18
DCRSSI7	DMHL7OB	Uracil mustard	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.89	9.63	1.49	6.81
DCTAU5X	DMHL7OB	Uracil mustard	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	5.89	15.67	2.98	13.05
DCT7MUE	DMHL7OB	Uracil mustard	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.76	8.62	1.06	8.98
DC1UK7Y	DMHL7OB	Uracil mustard	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.41	6.86	7.54	9.43
DCBBDX5	DMHL7OB	Uracil mustard	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.14	4.18	4.84	8.82
DC8O86G	DMHL7OB	Uracil mustard	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.99	5.93	2.26	8.46
DCI18X3	DM7RJXL	Imatinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Chronic Myeloid Leukemia	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCRZ7C5	DM7RJXL	Imatinib	Phase 3 Trial	25	DMYGJQO	Ponatinib	Approved	34	.	.	.	.	Philadelphia Chromosome Positive CML	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC6LV9E	DM7RJXL	Imatinib	Phase 3 Trial	25	DMTS85L	Capecitabine	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCQYTC7	DM7RJXL	Imatinib	Phase 3 Trial	25	DMOQVU9	Hydroxyurea	Approved	34	.	.	.	.	Glioblastoma Multiforme	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCBVQP7	DM7RJXL	Imatinib	Phase 3 Trial	25	DM053KT	Aprepitant	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.02	0.02	3.19	3.22
DCAB5G1	DM7RJXL	Imatinib	Phase 3 Trial	25	DM09NGV	Ribavirin-TP	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.12	5.12	7.67	7.73
DCTIW5C	DM7RJXL	Imatinib	Phase 3 Trial	25	DM0CEY3	Lefaxin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.93	4.93	6.27	6.28
DCXS0JO	DM7RJXL	Imatinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	0.22	2.15	1.85	1.78
DCI3SMD	DM7RJXL	Imatinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	18.48	20.46	1.83	1.83
DCWYYA1	DM7RJXL	Imatinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	1.61	4.48	2.16	1.9
DC16VE6	DM7RJXL	Imatinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	9.11	4.76	1.69	0.66
DC14D51	DM7RJXL	Imatinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.3	6.4	1.95	1.99
DCY39V2	DM7RJXL	Imatinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	1.05	3.46	0.6	0.56
DCIK2TG	DM7RJXL	Imatinib	Phase 3 Trial	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	1.06	8.33	6.41	5.56
DC9F7EV	DM7RJXL	Imatinib	Phase 3 Trial	25	DM0QV1J	Baclofen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.05	6.05	7.33	7.41
DCQIBBF	DM7RJXL	Imatinib	Phase 3 Trial	25	DM0RKS4	Bepridil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.13	3.13	4.85	4.9
DC51RE0	DM7RJXL	Imatinib	Phase 3 Trial	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.21	5.56	1.52	0.77
DCLLOA8	DM7RJXL	Imatinib	Phase 3 Trial	25	DM29GAD	Lumefantrine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.37	7.37	8.57	8.6
DCXUSJ2	DM7RJXL	Imatinib	Phase 3 Trial	25	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	7.28	9.75	4.54	1.51
DCX74MH	DM7RJXL	Imatinib	Phase 3 Trial	25	DM2G9AE	Citalopram	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.57	6.57	7.78	7.79
DCHPALV	DM7RJXL	Imatinib	Phase 3 Trial	25	DM2NUH3	Imipramine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.42	8.42	9.72	9.77
DCW8SFD	DM7RJXL	Imatinib	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	9.19	6.6	6.59	7.55
DCYUYEK	DM7RJXL	Imatinib	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	7.88	7.78	7.57	7.73
DC2HUE5	DM7RJXL	Imatinib	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	2.65	1.48	3.81	5.91
DC9SLFG	DM7RJXL	Imatinib	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	1.93	8.1	1.49	9.08
DCLE6M3	DM7RJXL	Imatinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.5	2.16	0.04	2.72
DCEHDKO	DM7RJXL	Imatinib	Phase 3 Trial	25	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	28.38	32	12.19	1.53
DC5WBUY	DM7RJXL	Imatinib	Phase 3 Trial	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.83	12.3	7.06	3.98
DCXU1D4	DM7RJXL	Imatinib	Phase 3 Trial	25	DM3KJBC	Epinephrine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.57	3.57	10.09	10.13
DCTJ1R2	DM7RJXL	Imatinib	Phase 3 Trial	25	DM3OWT4	Tindamax	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.7	7.7	8.84	8.92
DCO1RV9	DM7RJXL	Imatinib	Phase 3 Trial	25	DM3P6V7	Furazolidone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.35	4.35	5.71	5.77
DC006PC	DM7RJXL	Imatinib	Phase 3 Trial	25	DM3VZJQ	Chlorphenesin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.42	8.42	9.37	9.45
DCUM7JJ	DM7RJXL	Imatinib	Phase 3 Trial	25	DM3YG5P	GYKI-52466	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.19	1.19	2.19	2.2
DCPV0ZY	DM7RJXL	Imatinib	Phase 3 Trial	25	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	9.11	8.4	4.53	10.45
DCX0419	DM7RJXL	Imatinib	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	8.67	10.99	2.19	1.74
DCT4V4E	DM7RJXL	Imatinib	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	2.79	6.9	3.44	0.06
DC4H7IS	DM7RJXL	Imatinib	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	4.67	8.5	5.55	4.01
DCOKVMI	DM7RJXL	Imatinib	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.15	8.84	4.15	3.34
DCWTDXQ	DM7RJXL	Imatinib	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.75	4.45	2.46	1.88
DC6P32I	DM7RJXL	Imatinib	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	0.76	2.6	0.1	0.32
DCRQQ91	DM7RJXL	Imatinib	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	6.21	4.74	5.8	3.6
DCVEFNH	DM7RJXL	Imatinib	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	0.96	2.17	0.68	0.46
DCHENJJ	DM7RJXL	Imatinib	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	2.19	4.19	1.74	1.1
DC0B1RF	DM7RJXL	Imatinib	Phase 3 Trial	25	DM51FY6	Tacrine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.35	5.35	6.57	6.59
DCCKTMP	DM7RJXL	Imatinib	Phase 3 Trial	25	DM53BDW	Trioxsalen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.22	6.22	7.41	7.41
DCGIUQ3	DM7RJXL	Imatinib	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	14.9	17.15	8.45	3.59
DCRCBSS	DM7RJXL	Imatinib	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	5.43	11.94	5.57	4.7
DCN1IEK	DM7RJXL	Imatinib	Phase 3 Trial	25	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	4.53	4.44	3.01	5.43
DC4G760	DM7RJXL	Imatinib	Phase 3 Trial	25	DM6U9CQ	Pazopanib HCl	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.89	8.89	10.07	10.12
DCIQ66Z	DM7RJXL	Imatinib	Phase 3 Trial	25	DM7A8TW	Ezetimibe	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.15	8.15	9.35	9.35
DC8TOXE	DM7RJXL	Imatinib	Phase 3 Trial	25	DM7HUNW	Testosterone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.91	4.91	6.6	6.6
DCW2V47	DM7RJXL	Imatinib	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	3.42	7.69	5.58	3.1
DCTTI1G	DM7RJXL	Imatinib	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	0.08	2.8	2.62	1.8
DCVCH18	DM7RJXL	Imatinib	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	0.06	1.61	0.85	0.3
DCU1J46	DM7RJXL	Imatinib	Phase 3 Trial	25	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	3.97	8.26	8.92	9.39
DC9I9P4	DM7RJXL	Imatinib	Phase 3 Trial	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	5.2	11.12	5.68	1.54
DCU0JBH	DM7RJXL	Imatinib	Phase 3 Trial	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	0.98	1.85	2.7	0.07
DC7XODB	DM7RJXL	Imatinib	Phase 3 Trial	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	1.02	1.86	1.73	0.27
DCSZVMJ	DM7RJXL	Imatinib	Phase 3 Trial	25	DM8X2EH	Everolimus	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.05	0.05	4.96	4.96
DCNQ8ID	DM7RJXL	Imatinib	Phase 3 Trial	25	DM93L4X	Dexmedetomidine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.63	6.63	7.86	7.86
DCNNTKC	DM7RJXL	Imatinib	Phase 3 Trial	25	DM9S1EA	Pepstatin	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.71	1.71	4.45	4.51
DC5ADTT	DM7RJXL	Imatinib	Phase 3 Trial	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.42	5.42	6.68	6.71
DC4GYC9	DM7RJXL	Imatinib	Phase 3 Trial	25	DMA8FS5	Dronedarone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.64	7.64	8.86	8.88
DCMANX9	DM7RJXL	Imatinib	Phase 3 Trial	25	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	5.93	5.84	6.8	9.42
DCWGM0O	DM7RJXL	Imatinib	Phase 3 Trial	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	7.38	1.55	1.8	1.8
DCC079E	DM7RJXL	Imatinib	Phase 3 Trial	25	DMBEX4O	Methylergonovine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.52	5.52	6.93	7.01
DCPDEH8	DM7RJXL	Imatinib	Phase 3 Trial	25	DMBS632	Buspirone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.72	6.72	8.11	8.12
DCIU24C	DM7RJXL	Imatinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	1.21	4.6	4.09	2.4
DCM8K3N	DM7RJXL	Imatinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	0.4	4.8	5.68	5.68
DCAL5PJ	DM7RJXL	Imatinib	Phase 3 Trial	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	12.32	12.42	2.01	1.94
DCT0BSR	DM7RJXL	Imatinib	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.15	8.15	10.1	10.1
DC9C39J	DM7RJXL	Imatinib	Phase 3 Trial	25	DMCT2YF	Emetine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.94	2.94	9.19	9.24
DC8VT0U	DM7RJXL	Imatinib	Phase 3 Trial	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	5.36	8.22	3.72	2.95
DC5K5Y7	DM7RJXL	Imatinib	Phase 3 Trial	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	1.8	8.15	5.76	4.58
DC70N9C	DM7RJXL	Imatinib	Phase 3 Trial	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	3.99	2.63	1.11	0.67
DCCNPLA	DM7RJXL	Imatinib	Phase 3 Trial	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	0.2	4.84	2.62	3.12
DCO2LBS	DM7RJXL	Imatinib	Phase 3 Trial	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	4.61	7.66	4.03	4.01
DCRH5IK	DM7RJXL	Imatinib	Phase 3 Trial	25	DMCUT21	Ursodeoxycholic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.48	6.48	7.71	7.71
DCKVUKN	DM7RJXL	Imatinib	Phase 3 Trial	25	DMCYANK	Doxapram	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.82	6.82	8.04	8.06
DCXWHIJ	DM7RJXL	Imatinib	Phase 3 Trial	25	DMCYVDT	Chlorzoxazone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.48	2.48	6.42	6.43
DCJKQKV	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDASC6	Metformin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.68	5.68	6.8	6.85
DCHZEE0	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	DU-145	14.55	16.37	11.46	10.34
DCCE2O9	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	4.88	3.12	2.91	3.01
DC4P5OX	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	15.6	17.24	14.96	14.8
DCAQJG2	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	15.88	17.93	7.73	8.26
DC4KV1C	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	10.5	7.79	1.57	1.67
DCQBI4Q	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	SW-620	14.4	16.88	7.54	9.3
DCWE1YG	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	31.44	31.5	22.06	18.63
DC9ICQZ	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	21.63	28.34	21.92	22.44
DCPVNGG	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	12.83	11.48	16.47	13.39
DCR6DKU	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	17.76	18.78	9.46	9.46
DC5LVK0	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	36.42	38.62	5.98	31.28
DCX0ONH	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	15.7	19.56	14.99	16.48
DCPG3T0	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	14	15.13	14.1	13.34
DCYOOYJ	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	19.46	18.89	20.31	18.1
DCZYRT1	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	9.61	9.41	4.94	6.15
DC7RAUQ	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	8.66	11.29	7.43	7.49
DC08XQ7	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.13	1.13	4.35	4.37
DCSVNRK	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	15.4	19.22	8.24	9.33
DCTFEYU	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	10.23	8.39	8.68	7.8
DCOZ6KM	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	17.51	21.07	10.94	10.94
DCM446X	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	17.98	19.38	10.21	10.21
DC6WTW8	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-28	12.73	15.17	1.4	0.94
DCKNOVI	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	10.84	11.31	7.13	5.26
DCAWVQ1	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	3.77	7.92	4.06	6.64
DCG9YJ5	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	11.43	17.3	17.34	17.31
DCQCQ04	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	11.23	10.2	6.92	7.53
DCCIO5D	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	18.78	22.9	5.77	8.84
DCHMED2	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	13.99	17.55	13.61	13.98
DC28NQ7	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-4	13.14	13.32	8.43	8.12
DC3TX6Q	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	14.37	15.12	10.62	11.22
DCJPF23	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	6.43	11.26	0.4	0.4
DCJ0M16	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	1.04	5.25	1.72	1.09
DCM930N	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	13.17	15.14	13.26	12.03
DC2RFXJ	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	4.01	7.34	6.6	5.82
DCZS5WD	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	DrugCombDB Database	Investigative	SK-OV-3	4.1	6.42	3.54	4.82
DCLEPQO	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	11.43	7.95	2.8	4.1
DC974EG	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	20.09	22.01	18.71	18.15
DCU59V1	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	15.98	10.7	5.33	1.03
DCHA01E	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	10.52	12.42	7.54	7.52
DCVE4C7	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.09	4.01	0.15	0.15
DCG2X15	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.94	1	2.7	5.61
DCCTOMT	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	M14	4.12	6.73	2.66	1.56
DCPINYN	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	2.74	7	3.96	2.16
DCL5ORZ	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	1.31	3.4	1.59	1.28
DC2QPLY	DM7RJXL	Imatinib	Phase 3 Trial	25	DME2H5T	Cilastatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.53	4.53	5.79	5.79
DCZSD7R	DM7RJXL	Imatinib	Phase 3 Trial	25	DMF57DM	Pazopanib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.58	0.58	2.64	2.71
DCYVC45	DM7RJXL	Imatinib	Phase 3 Trial	25	DMFCMPS	Daidzin	Terminated	2	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.02	9.02	10.21	10.28
DCHPPU0	DM7RJXL	Imatinib	Phase 3 Trial	25	DMFGLXB	Phensuximide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.59	3.59	5.67	5.75
DCXUJ3Q	DM7RJXL	Imatinib	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	1.79	4.65	5.25	6.36
DCT11YQ	DM7RJXL	Imatinib	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	1.61	4.3	2.64	0.88
DCWPPOE	DM7RJXL	Imatinib	Phase 3 Trial	25	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	0.85	3.23	5.93	6.39
DCKW3K5	DM7RJXL	Imatinib	Phase 3 Trial	25	DMFNTMY	Fibrates	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.41	6.41	7.52	7.55
DC6STGW	DM7RJXL	Imatinib	Phase 3 Trial	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.65	5.66	4.85	8.73
DCXDO0X	DM7RJXL	Imatinib	Phase 3 Trial	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	3.73	8.59	5.24	3.71
DCHJ6FX	DM7RJXL	Imatinib	Phase 3 Trial	25	DMGYBZI	PHA-739358	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.74	6.74	8.02	8.02
DC266VA	DM7RJXL	Imatinib	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	3.14	4.28	1.24	0.72
DCF0GDQ	DM7RJXL	Imatinib	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	EKVX	5.36	3.39	0.46	2.21
DC556D3	DM7RJXL	Imatinib	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	2.29	4.58	3.98	3.28
DC9K5Q8	DM7RJXL	Imatinib	Phase 3 Trial	25	DMHAZLM	Naringenin	Phase 1	17	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.09	8.09	9.46	9.48
DCKVL9R	DM7RJXL	Imatinib	Phase 3 Trial	25	DMHPWOM	Diphenidol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.76	7.76	9.17	9.18
DCNMK0N	DM7RJXL	Imatinib	Phase 3 Trial	25	DMIWFRL	Tolvaptan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.23	8.23	9.81	9.83
DCMGJ0H	DM7RJXL	Imatinib	Phase 3 Trial	25	DMIXMYK	Arfolitixorin	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.15	3.15	9.51	9.53
DCFGCIX	DM7RJXL	Imatinib	Phase 3 Trial	25	DMKFQJP	Triflupromazine	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.37	7.37	8.98	8.98
DCC85V2	DM7RJXL	Imatinib	Phase 3 Trial	25	DMJ7NVI	BIO-300	Phase 1/2	19	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.53	1.53	4.38	4.44
DC7YRFB	DM7RJXL	Imatinib	Phase 3 Trial	25	DMJOQM3	Eflornithine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.82	4.82	6.05	6.11
DCO9PLT	DM7RJXL	Imatinib	Phase 3 Trial	25	DMJSKUI	Norcisapride	Discontinued in Phase 2	5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.95	0.95	2.19	2.19
DC5MP5E	DM7RJXL	Imatinib	Phase 3 Trial	25	DMK1GBJ	Trazodone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.17	6.17	7.39	7.39
DCQRZVJ	DM7RJXL	Imatinib	Phase 3 Trial	25	DMKBYWI	Trifluoperazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.51	7.51	8.82	8.87
DC15OEU	DM7RJXL	Imatinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	7.5	4.69	5.02	1.93
DC6LIM1	DM7RJXL	Imatinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Amelanotic melanoma	DrugCombDB Database	Investigative	MDA-MB-435	5.9	13.04	11.6	2.61
DC2QQ95	DM7RJXL	Imatinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.06	2.55	2.59	0.09
DCKWT04	DM7RJXL	Imatinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	11.65	10.62	5.6	11.07
DCEFQBB	DM7RJXL	Imatinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	2.03	3.07	1.42	0.61
DCGDMO4	DM7RJXL	Imatinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	0	2.26	1.34	1.55
DCJBEL7	DM7RJXL	Imatinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	DrugCombDB Database	Investigative	IGROV1	2.47	3.62	1.1	0.52
DCP7WMI	DM7RJXL	Imatinib	Phase 3 Trial	25	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Prostate carcinoma	DrugCombDB Database	Investigative	PC-3	1.28	2.79	1.34	0.5
DCQTGF0	DM7RJXL	Imatinib	Phase 3 Trial	25	DMKXY2R	Ibutilide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.37	5.37	6.97	7.01
DCOZPH5	DM7RJXL	Imatinib	Phase 3 Trial	25	DMKZJ7T	GINKGOLIDE A	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.21	1.21	2.91	2.98
DCSZOMQ	DM7RJXL	Imatinib	Phase 3 Trial	25	DML1538	Diazoxide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.22	1.22	4.32	4.32
DCNJ99Z	DM7RJXL	Imatinib	Phase 3 Trial	25	DML5VQ0	Fenoprofen	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.78	5.78	7.49	7.49
DCFY60I	DM7RJXL	Imatinib	Phase 3 Trial	25	DMLBVKQ	Entacapone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.34	0.34	1.58	1.61
DCQ5ZKZ	DM7RJXL	Imatinib	Phase 3 Trial	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	4.76	9.56	2.75	1.24
DCN1B66	DM7RJXL	Imatinib	Phase 3 Trial	25	DMLU8NX	Benserazide	Phase 3	25	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.29	6.29	7.58	7.64
DCJB979	DM7RJXL	Imatinib	Phase 3 Trial	25	DMM0HR1	Pargyline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.76	3.76	4.97	5.03
DC6CELA	DM7RJXL	Imatinib	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.25	3.25	7.09	7.15
DC3ASTQ	DM7RJXL	Imatinib	Phase 3 Trial	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	DrugCombDB Database	Investigative	T98G	33.53	33.53	26.19	26.19
DC1BCWG	DM7RJXL	Imatinib	Phase 3 Trial	25	DMM61Y2	BRL-15572	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.09	5.09	6.56	6.57
DC7J2KK	DM7RJXL	Imatinib	Phase 3 Trial	25	DMMFWOJ	Probenecid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.45	5.45	6.88	6.96
DC7F50U	DM7RJXL	Imatinib	Phase 3 Trial	25	DMMN36E	Abacavir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.23	7.23	8.53	8.53
DCWX3Y0	DM7RJXL	Imatinib	Phase 3 Trial	25	DMNMW9R	Pramipexole	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.31	0.31	1.55	1.55
DCD10L7	DM7RJXL	Imatinib	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.37	1.79	1.68	2.63
DCFH5TB	DM7RJXL	Imatinib	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	6.22	6.71	4.36	5.75
DCKTGXB	DM7RJXL	Imatinib	Phase 3 Trial	25	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	4.84	11.97	1.3	5.14
DCTT768	DM7RJXL	Imatinib	Phase 3 Trial	25	DMO381I	Acamprosate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.96	4.96	6.22	6.23
DCHEGET	DM7RJXL	Imatinib	Phase 3 Trial	25	DMOL5IU	Mesalazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.26	5.26	6.58	6.58
DC6WOL7	DM7RJXL	Imatinib	Phase 3 Trial	25	DMOMBJW	Moricizine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.65	1.65	2.97	3.03
DC4I4BW	DM7RJXL	Imatinib	Phase 3 Trial	25	DMOY7W3	Artemisinin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.11	5.11	8.91	8.92
DCPWWQS	DM7RJXL	Imatinib	Phase 3 Trial	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	8.28	9.66	1.02	9.24
DCFWURP	DM7RJXL	Imatinib	Phase 3 Trial	25	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	12.01	11.77	6.15	11.2
DC3LGXG	DM7RJXL	Imatinib	Phase 3 Trial	25	DMPGR1E	Clascoterone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.87	6.87	9.01	9.05
DC1UVE8	DM7RJXL	Imatinib	Phase 3 Trial	25	DMPGUCF	Dopamine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.17	3.17	4.33	4.33
DCR4L39	DM7RJXL	Imatinib	Phase 3 Trial	25	DMPP4DT	Trimethobenzamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.25	7.25	9.78	9.82
DC6M9YI	DM7RJXL	Imatinib	Phase 3 Trial	25	DMPZS7U	Oxyphenbutazone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.15	3.15	7.89	7.96
DCK4C6E	DM7RJXL	Imatinib	Phase 3 Trial	25	DMR87LC	Ethambutol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.37	2.37	3.65	3.65
DCTF1CZ	DM7RJXL	Imatinib	Phase 3 Trial	25	DMRFWGK	Novobiocin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.48	7.48	8.82	8.82
DCVCKAO	DM7RJXL	Imatinib	Phase 3 Trial	25	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.92	0.47	0.65	4.23
DCNU9RF	DM7RJXL	Imatinib	Phase 3 Trial	25	DMRJFN9	Theophylline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.35	0.35	1.58	1.64
DC3HYT7	DM7RJXL	Imatinib	Phase 3 Trial	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.76	6.76	8.13	8.13
DCH41QO	DM7RJXL	Imatinib	Phase 3 Trial	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-5	5.52	9.89	3.69	3.69
DC138M0	DM7RJXL	Imatinib	Phase 3 Trial	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	0.34	5.32	0.57	2.29
DCFXGLG	DM7RJXL	Imatinib	Phase 3 Trial	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	DrugCombDB Database	Investigative	NCI-H226	3.58	7.9	5.94	4.07
DCO7ML9	DM7RJXL	Imatinib	Phase 3 Trial	25	DMRTSGP	Amiloride	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.98	4.98	6.31	6.31
DCJU5Z0	DM7RJXL	Imatinib	Phase 3 Trial	25	DMS0PND	Brincidofovir	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.69	1.69	6.33	6.37
DCILVC4	DM7RJXL	Imatinib	Phase 3 Trial	25	DMS3YE9	Amantadine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.72	5.72	7.15	7.18
DCUX9ZY	DM7RJXL	Imatinib	Phase 3 Trial	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.06	9.06	10.04	10.06
DCL7X3D	DM7RJXL	Imatinib	Phase 3 Trial	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	1.71	2.54	3.31	0.09
DCR8IUS	DM7RJXL	Imatinib	Phase 3 Trial	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	15.08	15.48	11.01	12.89
DC6KZ46	DM7RJXL	Imatinib	Phase 3 Trial	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.93	2.9	0.16	0.39
DCJQM66	DM7RJXL	Imatinib	Phase 3 Trial	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	3.9	5.33	3.76	0.26
DCUMA1J	DM7RJXL	Imatinib	Phase 3 Trial	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	HOP-62	7.61	9.64	5.57	1.74
DCAW4F7	DM7RJXL	Imatinib	Phase 3 Trial	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Lung adenocarcinoma 	DrugCombDB Database	Investigative	NCI-H522	2.17	5.81	4.7	3.18
DCQTIM8	DM7RJXL	Imatinib	Phase 3 Trial	25	DMSG91J	ER819762	Investigative	0	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	UACC-257	0.47	0.61	0.26	0.08
DCM2R3D	DM7RJXL	Imatinib	Phase 3 Trial	25	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	6.27	3.76	0.98	1.18
DCY7Y1B	DM7RJXL	Imatinib	Phase 3 Trial	25	DMOJZQ9	Loperamide	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.87	5.87	6.99	6.99
DCUE5BD	DM7RJXL	Imatinib	Phase 3 Trial	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	2.71	12.12	5.97	5.97
DC0X5TT	DM7RJXL	Imatinib	Phase 3 Trial	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	OVCAR3	13.09	14.8	14.58	12.63
DCO0VCA	DM7RJXL	Imatinib	Phase 3 Trial	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	7.96	13.79	12.93	5.12
DC4ZITY	DM7RJXL	Imatinib	Phase 3 Trial	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	5.25	3.93	5.18	4.45
DC4YGAD	DM7RJXL	Imatinib	Phase 3 Trial	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.84	3.99	3.73	0.94
DCJP1DG	DM7RJXL	Imatinib	Phase 3 Trial	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	20.63	25.2	17.91	14.94
DCK7PAN	DM7RJXL	Imatinib	Phase 3 Trial	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	6.68	10.58	10.32	9.2
DCE0TXJ	DM7RJXL	Imatinib	Phase 3 Trial	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	14.95	12.71	7.01	4
DCZETHP	DM7RJXL	Imatinib	Phase 3 Trial	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.52	6.62	0.55	0.55
DCP8WFA	DM7RJXL	Imatinib	Phase 3 Trial	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Cutaneous melanoma	DrugCombDB Database	Investigative	SK-MEL-5	7.35	8.5	8.05	7.92
DC7PBS1	DM7RJXL	Imatinib	Phase 3 Trial	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.42	3.74	1.66	1.3
DCSI4ZI	DM7RJXL	Imatinib	Phase 3 Trial	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	0.97	3.15	0.55	0.66
DCLO24B	DM7RJXL	Imatinib	Phase 3 Trial	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	LOX IMVI	5.94	9.6	1.83	0.37
DCGL4GC	DM7RJXL	Imatinib	Phase 3 Trial	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Malignant melanoma	DrugCombDB Database	Investigative	UACC62	0.98	7.23	5.65	5.42
DC5XFOC	DM7RJXL	Imatinib	Phase 3 Trial	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	3.91	7.32	4.49	2.13
DCXYLU7	DM7RJXL	Imatinib	Phase 3 Trial	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	12.23	11.79	10.26	8.36
DCHIRP2	DM7RJXL	Imatinib	Phase 3 Trial	25	DMRBMAU	Mycophenolic acid	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.63	2.63	9.08	9.14
DCYXFJT	DM7RJXL	Imatinib	Phase 3 Trial	25	DMU8JGH	Hydralazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.13	4.13	5.4	5.4
DCJC5DA	DM7RJXL	Imatinib	Phase 3 Trial	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.7	4.24	0.43	0.99
DCDBY4F	DM7RJXL	Imatinib	Phase 3 Trial	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	SK-MEL-2	3.84	11.42	9.7	9.24
DCE619O	DM7RJXL	Imatinib	Phase 3 Trial	25	DMU9MYJ	Oxandrolone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.71	6.71	7.78	7.83
DCLF0MP	DM7RJXL	Imatinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	12.32	8.64	13.01	9.37
DCO5HTD	DM7RJXL	Imatinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	1.48	5.31	3.69	3.25
DCFXXLX	DM7RJXL	Imatinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCC-2998	12.18	14.89	0.37	11.76
DCLFN0G	DM7RJXL	Imatinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	10.14	11.87	7.95	11.83
DC4CQKF	DM7RJXL	Imatinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	8.64	12.81	13.64	13.57
DCW3XFA	DM7RJXL	Imatinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	8.16	10.36	0.01	7.28
DCXYNHW	DM7RJXL	Imatinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	12.17	13.59	12.43	12.11
DC0BH3K	DM7RJXL	Imatinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	DrugCombDB Database	Investigative	OVCAR-8	13.43	17.96	12.98	16.66
DC08OS5	DM7RJXL	Imatinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Large cell lung carcinoma	DrugCombDB Database	Investigative	NCI-H460	10	9.26	0.82	7.45
DCMVKBW	DM7RJXL	Imatinib	Phase 3 Trial	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	4.56	5.97	1.55	2.63
DCY3ZNI	DM7RJXL	Imatinib	Phase 3 Trial	25	DMV74ZH	Pizotyline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.15	0.15	1.44	1.45
DCHXBH5	DM7RJXL	Imatinib	Phase 3 Trial	25	DMVGPMX	Fosfomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.93	5.93	7.57	7.58
DCL90KB	DM7RJXL	Imatinib	Phase 3 Trial	25	DMVM6QR	Lacosamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.5	5.5	7.01	7.07
DCAYRJW	DM7RJXL	Imatinib	Phase 3 Trial	25	DMVTHWQ	Silver sulfadiazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.5	5.5	6.6	6.65
DCDD0QH	DM7RJXL	Imatinib	Phase 3 Trial	25	DMVY4GN	Testolactone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.21	4.21	5.99	6.05
DCVS8HP	DM7RJXL	Imatinib	Phase 3 Trial	25	DMWBHRY	Olmesartan medoxomil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.8	7.8	8.9	8.97
DCM257B	DM7RJXL	Imatinib	Phase 3 Trial	25	DMWE2N4	Auranofin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.76	2.76	9.32	9.34
DCE4F45	DM7RJXL	Imatinib	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HT29	1.75	3.99	2.65	0.29
DC5LOFH	DM7RJXL	Imatinib	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT116	1.12	2.9	2.2	0.57
DC90U5G	DM7RJXL	Imatinib	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	2.43	3.87	1.29	1
DCDFGGC	DM7RJXL	Imatinib	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Melanoma	DrugCombDB Database	Investigative	MALME-3M	0.3	2.22	1.58	1.83
DCTI1B9	DM7RJXL	Imatinib	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	5.21	6.29	0.75	0.53
DCVW9TL	DM7RJXL	Imatinib	Phase 3 Trial	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.22	5	4.4	1.89
DCS2KSP	DM7RJXL	Imatinib	Phase 3 Trial	25	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.58	2.58	6.07	6.1
DCKV33H	DM7RJXL	Imatinib	Phase 3 Trial	25	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	A549	2.29	7.17	2.23	5.54
DCT3KFD	DM7RJXL	Imatinib	Phase 3 Trial	25	DMWSMND	Cevimeline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.92	3.92	5.24	5.26
DCPQG6F	DM7RJXL	Imatinib	Phase 3 Trial	25	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.02	6.02	8.16	8.24
DCWHF4O	DM7RJXL	Imatinib	Phase 3 Trial	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	HCT-15	2.46	6.2	2.59	2.47
DCJDBPT	DM7RJXL	Imatinib	Phase 3 Trial	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.92	4.35	2.01	0.94
DCX15FU	DM7RJXL	Imatinib	Phase 3 Trial	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Lung adenocarcinoma	DrugCombDB Database	Investigative	MDA-MB-231	2.56	4.8	2.84	0.95
DCSMTCW	DM7RJXL	Imatinib	Phase 3 Trial	25	DMY4UMW	Atovaquone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.99	5.99	7.08	7.13
DCPVEX6	DM7RJXL	Imatinib	Phase 3 Trial	25	DMY91A3	ML323	Preclinical	2.1	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.68	7.68	8.79	8.82
DC9BYKU	DM7RJXL	Imatinib	Phase 3 Trial	25	DMYLOVR	Aciclovir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.17	4.17	7.15	7.21
DC8RZDU	DM7RJXL	Imatinib	Phase 3 Trial	25	DMYTE6L	Enoxacin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.72	5.72	6.98	7.03
DCLKJAH	DM7RJXL	Imatinib	Phase 3 Trial	25	DMYURI6	Raltegravir	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	6.97	6.97	8.15	8.19
DCMDWBF	DM7RJXL	Imatinib	Phase 3 Trial	25	DMYX7NI	Acetohydroxamic Acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	1.07	1.07	3.52	3.56
DC0LHK2	DM7RJXL	Imatinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adenocarcinoma	DrugCombDB Database	Investigative	NCIH23	4.33	10.4	0.17	6.34
DC2C06F	DM7RJXL	Imatinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	9.07	10.69	4.89	7.68
DC7CO1D	DM7RJXL	Imatinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	5.2	10.93	1.81	1.81
DCUYI7M	DM7RJXL	Imatinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	13.17	16.08	3.46	8.15
DCMG8HW	DM7RJXL	Imatinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.2	7.31	6.36	4.28
DCF3DYK	DM7RJXL	Imatinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.17	5.91	0.52	0.42
DCCQZ9Z	DM7RJXL	Imatinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	DrugCombDB Database	Investigative	HOP-92	3.2	4.95	1.58	1.27
DCHN09A	DM7RJXL	Imatinib	Phase 3 Trial	25	DMZ80SB	Azatadine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	7.45	7.45	8.9	8.91
DCH8MID	DM7RJXL	Imatinib	Phase 3 Trial	25	DMZA017	Tetracycline	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.98	2.98	4.14	4.21
DCBWQ7V	DM7RJXL	Imatinib	Phase 3 Trial	25	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.44	5.59	1.48	5.7
DCHPNQP	DM7RJXL	Imatinib	Phase 3 Trial	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.59	4.3	0.18	0.63
DC156UT	DM7RJXL	Imatinib	Phase 3 Trial	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.47	3.18	1.27	0.75
DCU1J2Q	DM7RJXL	Imatinib	Phase 3 Trial	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	3.48	3.7	0.64	3.61
DCC6UGL	DM7RJXL	Imatinib	Phase 3 Trial	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.6	0.44	0.36	0.99
DC3ND2K	DM7RJXL	Imatinib	Phase 3 Trial	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.15	4.58	2.65	4
DCK244C	DM7RJXL	Imatinib	Phase 3 Trial	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.38	2.66	1.36	0.85
DCZU18J	DM7RJXL	Imatinib	Phase 3 Trial	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	2.19	8.52	2.22	3.54
DCUT1KL	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	11.1	15.1	11.89	11.6
DCZKSNZ	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	5.22	6.13	6.07	6.21
DCODCOM	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.85	5.88	0.62	0.62
DCKJ0MM	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	14.81	15.68	17.37	16.62
DC23644	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	17.52	24.71	13.84	18.05
DCZJP6T	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	16.99	19.25	5.82	6.8
DC4WO2Q	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	11.78	15.83	15.57	15.57
DC978KK	DM7RJXL	Imatinib	Phase 3 Trial	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	14.42	18.56	8.94	10.93
DCBJA9T	DM7RJXL	Imatinib	Phase 3 Trial	25	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.64	8.45	3.42	2.76
DCLNJXQ	DM7RJXL	Imatinib	Phase 3 Trial	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.18	5.64	2.78	2.97
DCNRFBN	DM7RJXL	Imatinib	Phase 3 Trial	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.98	9.73	6.7	6.35
DCYCXD6	DM7RJXL	Imatinib	Phase 3 Trial	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	15.24	18.89	10.62	9.49
DC3C6Y5	DM7RJXL	Imatinib	Phase 3 Trial	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.38	2.23	1.45	0.61
DCVFY9G	DM7RJXL	Imatinib	Phase 3 Trial	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.61	7.83	3.39	2.9
DCP5S58	DM7RJXL	Imatinib	Phase 3 Trial	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.18	1.08	0.39	0.2
DCN8Y7Y	DM7RJXL	Imatinib	Phase 3 Trial	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.46	4.02	1.92	1.73
DCOYCNT	DM7RJXL	Imatinib	Phase 3 Trial	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	9.52	14.63	4.8	11.58
DCY5M5K	DMOYJFK	Valrubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	5.91	7.54	1.97	6.65
DCKPWPI	DMOYJFK	Valrubicin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	4.53	3.8	4.94	6.39
DCZDB1U	DMOYJFK	Valrubicin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.51	1.15	0.02	3.33
DC3WVW0	DMOYJFK	Valrubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.52	4.23	3.44	7.21
DCTHQJ4	DMOYJFK	Valrubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	7.66	8.65	1.93	9.95
DCXSFGU	DMOYJFK	Valrubicin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.23	3.14	1.58	2.59
DCL0PD6	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	5.28	5.39	2.74	4.49
DC89CII	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	7.53	6.66	7.5	9.12
DC48Y0V	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	7.13	7.93	4.91	6.14
DCE6B9E	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.07	6.8	5.92	8.98
DCKVQQN	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	7.52	10.79	11.37	12.6
DCM62E8	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	15.28	17.5	8.28	11.06
DCCZXFO	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	16.77	17.98	17.6	19.45
DC2VPZ8	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	14.64	14.35	14.33	16.76
DC6HGXP	DMOYJFK	Valrubicin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.67	3.03	4.13	4.89
DCJ5T07	DMOYJFK	Valrubicin	Approved	34	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	4.41	3.78	2.58	6.56
DCLAEIE	DMOYJFK	Valrubicin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.11	0.9	0.6	2.27
DC0AXBY	DMOYJFK	Valrubicin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	4.24	4.53	1.51	6.38
DCDEUSY	DMOYJFK	Valrubicin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.02	0.72	0.96	2.89
DCHLG0S	DMOYJFK	Valrubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	10.49	9.84	8.59	10.68
DCA743E	DMOYJFK	Valrubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	14.52	12.6	10.26	12.25
DC7UX2B	DMOYJFK	Valrubicin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.5	1.54	1.6	5.51
DCBJ7DW	DMOYJFK	Valrubicin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.19	0.25	0.54	2.03
DCVS9DD	DMOYJFK	Valrubicin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.84	1.9	1.2	4.77
DCC87YF	DMOYJFK	Valrubicin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.11	2.69	2.61	5.24
DCPB8OE	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	13.86	14	7.8	7.85
DCSMY4W	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	17.63	16.3	10.99	7.71
DCW1ARM	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	7.9	6.48	2.82	4.33
DCY1GF4	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	3.42	3.67	4.53	4.57
DCS7F2R	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	21.33	22.39	13.72	19.73
DCRXOVT	DMOYJFK	Valrubicin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	5.92	5.65	4.48	6.65
DCJ0W9Z	DMOYJFK	Valrubicin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.65	4.09	3.17	5.29
DCR2ZGS	DMOYJFK	Valrubicin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.53	1.41	1.99	4.84
DCI4FS6	DMOYJFK	Valrubicin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.8	0.21	0.96	3.24
DC691R1	DMOYJFK	Valrubicin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.86	1.4	0.88	2.01
DC352PG	DMOYJFK	Valrubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.95	2.27	1.86	1.8
DCS6ETS	DMOYJFK	Valrubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	4.43	4.99	5.29	4.57
DC4FMOM	DMOYJFK	Valrubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.97	1.61	2.01	1.98
DC3TLTL	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	17.12	14.38	10.18	10.72
DC5YD22	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	17	19.37	14.54	15.04
DCFI7YN	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.63	5.77	1.12	0.44
DC6P828	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.02	4.28	1.51	1.56
DCGES92	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.84	9.16	7.9	7.99
DCZVILY	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	9.91	10.15	6.16	6.4
DC7DHCD	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	6.99	11.03	5.8	5.87
DCEVP90	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	8.59	9.04	9.5	9.61
DC5ET3S	DMOYJFK	Valrubicin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	3.14	4.42	3.61	4.77
DCJWEPB	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.17	6.17	9.48	8.47
DCQF0G8	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.74	8.64	1.89	9.91
DCIWRID	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	17.47	18.06	15.01	16.02
DCS9QAP	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	13.68	18.95	16.56	17.29
DC3N680	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	15.5	21.19	14.44	14.63
DC3O4D8	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.67	3.35	2.92	3.39
DCI7BXW	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	7.14	13.97	10.71	10.98
DCOM3TF	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	6.92	4.15	8.03	8.33
DCKN7DO	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	8.6	11.3	11.54	11.78
DCY1J5O	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	18.78	19.61	9.4	9.22
DCSZQOU	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	13.75	15.68	15.52	15.86
DCEICOV	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	16.76	21.86	20.63	20.72
DC3P4R2	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	14.04	16.97	16.32	17.21
DCBRRDQ	DMOYJFK	Valrubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	17.15	13.57	7.57	15.2
DC00XFK	DMOYJFK	Valrubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	7.87	8.46	3.74	9.26
DCBDDQV	DMOYJFK	Valrubicin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	15.18	14.67	13.46	17.11
DCYKNJB	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	8.78	5.17	4.55	6.03
DCBDV81	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.23	3.51	1.74	3.22
DCE9L0Y	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	5.35	4.61	4.13	6.29
DC6M9NP	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.29	3.52	0.48	4.19
DC7U5GE	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	11.09	9.9	8.36	10.05
DCU9JQ7	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	15.12	13.58	14.85	16.41
DC05GWW	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	6.45	5.73	1.28	6.12
DCJ40VR	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.07	3.62	2.3	5.91
DCRF5GE	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	7.07	8.68	3.04	7.94
DCO0O2Y	DMOYJFK	Valrubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	6.45	5.47	1.51	8.3
DCFPZ4K	DMOYJFK	Valrubicin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.29	5.21	2.51	5.64
DCXICHQ	DMOYJFK	Valrubicin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.23	2.84	1.91	2.23
DCGLG7V	DMOYJFK	Valrubicin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.57	0.45	0.89	0.94
DCJUTXH	DMOYJFK	Valrubicin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	1.46	2.27	1.36	2.25
DCOTCEX	DMOYJFK	Valrubicin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	8.36	11.2	0.83	9.55
DCRI0Y6	DMOYJFK	Valrubicin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	7.71	8.44	0.55	8.7
DCEDMIP	DMOYJFK	Valrubicin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	1.64	6.55	5.88	5.89
DCDE07Y	DMOYJFK	Valrubicin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	8.97	6.57	2.88	6.69
DCLSDBU	DMOYJFK	Valrubicin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	9.09	7.54	5.21	10.58
DCBECHH	DMOYJFK	Valrubicin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	12.08	9.08	10.94	10.16
DCAQJI9	DMOYJFK	Valrubicin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.62	5.67	5.51	8.58
DCV1Z5J	DMOYJFK	Valrubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	6.39	1.72	0.76	3.15
DCE07FB	DMOYJFK	Valrubicin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	7.78	5.86	0.43	8.4
DC02EAY	DMOYJFK	Valrubicin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	9.49	7.62	8.02	8.3
DCX81CX	DMOYJFK	Valrubicin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	4.2	6.1	5.14	7.96
DC15RGP	DMOYJFK	Valrubicin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.29	5.45	1.18	4.83
DCADVZJ	DMOYJFK	Valrubicin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.63	2.14	1.7	5.69
DCIMSG7	DMOYJFK	Valrubicin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.33	2.06	2.7	2.31
DC8JU71	DMOYJFK	Valrubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.14	0.73	0.24	0.68
DCBDP2O	DMOYJFK	Valrubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	17.06	15.75	18.38	18.4
DCWMNIP	DMOYJFK	Valrubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	17.42	19.24	17.47	18.4
DCEA479	DMOYJFK	Valrubicin	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.25	4.07	9.42	10.8
DCIHR2J	DMOYJFK	Valrubicin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	8.18	13.34	3.73	4.54
DCVQ11N	DMOYJFK	Valrubicin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.9	1.11	1.7	3.49
DCR8Y4W	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	14.43	14.14	15	15.49
DCQFYGI	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	10.37	14.65	13.02	13.91
DCWT5M6	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	2.33	6.59	3.28	11.2
DCGXQ8F	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	17.67	19.58	14.61	18.99
DCM767B	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	16.44	16.37	19.45	20.11
DC70L1L	DMOYJFK	Valrubicin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	10.41	5.64	7.2	6.72
DC9538N	DMOYJFK	Valrubicin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	3.57	1.6	0.6	5.21
DCZREZV	DMOYJFK	Valrubicin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.21	4.98	5.17	6.99
DCCDS9D	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	4.04	2.32	0.72	1.46
DC1LPRA	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.55	1.61	0.6	0.04
DCFEDRA	DMOYJFK	Valrubicin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.22	2.17	4.53	8.01
DCH1DQI	DMOYJFK	Valrubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.12	2.97	1.31	1.43
DC1T0V2	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	13.25	5.69	5.45	5.1
DC4GFQ0	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.02	3.09	3.63	3.38
DCQ5SSA	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	7.81	8.07	9.48	9.51
DCRVRX4	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	13.13	13.28	11.81	13.24
DCNY2DY	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	14.68	11.65	15.78	14.08
DC89KJB	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	7.44	8.95	9.16	9.37
DCS3D6C	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	12.91	8.35	9.23	9.37
DCBG1ER	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	9.29	18.74	15.46	15.78
DCGUWQ6	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	6.06	11.21	10.79	11.04
DCBI0E8	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	10.87	12.81	13.43	13.37
DCMSPH5	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.29	4.5	3.12	3.3
DC9XMNP	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.32	7.61	5.21	5.08
DCOHGQX	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	8.87	14.71	14.85	14.86
DCMLDUA	DMOYJFK	Valrubicin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	10.27	8.03	3.01	7.26
DCXAYO8	DMOYJFK	Valrubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.46	7.13	4.87	5.95
DCBRJRH	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	13.44	14.82	5.38	13.15
DC85PNM	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	8.79	8.68	7.23	9.22
DC6BO7J	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	6.18	7.34	8.8	11.25
DC95D20	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.68	6.54	8.89	10.03
DCEU9ID	DMOYJFK	Valrubicin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.11	3.74	1.46	6.01
DC6L0N4	DMOYJFK	Valrubicin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	5.54	6.21	7.17	9.43
DCH906O	DMOYJFK	Valrubicin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	6.6	7.73	13.9	9.73
DCNO3M0	DMOYJFK	Valrubicin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.29	5.86	7.84	8.84
DCP6XU7	DMOYJFK	Valrubicin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3	3.83	0.6	4.22
DCUU13L	DMOYJFK	Valrubicin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	9.19	8.92	10.49	11.83
DCE1K9D	DMOYJFK	Valrubicin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.65	4.56	3.95	6.5
DCQBZDC	DMOYJFK	Valrubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.95	6.32	5.78	5.82
DCPIJEX	DMOYJFK	Valrubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.68	10.65	13.92	13.06
DCS9BPS	DMOYJFK	Valrubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.26	3.53	0.98	3.79
DCYJDR4	DMOYJFK	Valrubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.56	2.96	0.59	2.37
DCFZ5TA	DMOYJFK	Valrubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.22	2.31	0.51	2.6
DC50Y2J	DMOYJFK	Valrubicin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.51	2.37	0.21	2.31
DC5K6H1	DMOYJFK	Valrubicin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.39	0.25	0.09	2.12
DCLN0OZ	DMOYJFK	Valrubicin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	3.92	3.24	3.48	6.93
DCO7P2R	DMOYJFK	Valrubicin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	2.37	0.96	1.16	3.52
DCTUY6E	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	18.09	19.69	18.5	20.73
DCWC1R9	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.92	2.19	0.3	4.03
DCBXCDR	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	20.86	22.89	19.58	25.51
DCV4XC2	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	20.34	25.82	15.64	20.63
DCERJVY	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	44.76	43.58	20.42	20.63
DC2F89B	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.82	4.64	1.5	2.96
DCR02UW	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	5.14	5.78	3.97	6.72
DCAXVBH	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	13.97	14.23	7.92	8.58
DCQOMVD	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	3.4	3.05	2.17	5.08
DCIWNBO	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	13.01	12.84	8.24	14.34
DC5ELG1	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	8.4	10	0.27	7.56
DCBZUSG	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	7.77	7.91	5.28	6.64
DC1HZBM	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	15.35	17.64	16.42	20.29
DCZNYL2	DMOYJFK	Valrubicin	Approved	34	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	10.22	12.19	13.76	14.54
DC46UX5	DMOYJFK	Valrubicin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	0.73	2.92	2.09	2.7
DCY5MTH	DMOYJFK	Valrubicin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	6.33	4.52	4.69	7.68
DCLFSO1	DMOYJFK	Valrubicin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	8.22	5.51	3.18	5.44
DCMOP29	DMOYJFK	Valrubicin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	2.97	5.63	1.44	1.67
DC7I1KT	DMOYJFK	Valrubicin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	7.41	6.81	6	6.78
DC3S835	DMOYJFK	Valrubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.52	3.94	1.02	2.97
DCNP9JU	DMOYJFK	Valrubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	9.49	8.86	5.55	6.34
DC6QVKX	DMOYJFK	Valrubicin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	3.5	6.18	4.1	4.16
DCGV3EZ	DMOYJFK	Valrubicin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.22	0.85	0.15	3.92
DCEYHC9	DMOYJFK	Valrubicin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.72	1.31	1.84	5.26
DCSTK81	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.75	5.88	4.39	2.66
DCGQPVA	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	3.19	3.33	1.55	2.98
DCNDQIQ	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.87	10.16	7.77	7.75
DC4I2CK	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	3.37	4.6	3.49	1.52
DCN27KX	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	17.38	14.76	5.88	3.59
DC6OBD5	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	9.97	8.76	8.77	6.31
DCXPKWA	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.95	9.98	4.22	7.64
DCQKAVO	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	7.65	11.76	7.76	10.12
DCQWWIG	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	0.6	6.4	4.96	4.97
DCR54V6	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	4.11	8.58	3.13	2.49
DCPRQX4	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.05	6.23	5.83	5.83
DCQQIZB	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.79	8.79	10.47	7.89
DCW04JH	DMOYJFK	Valrubicin	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.14	5.06	5.83	5.47
DCK7RJA	DMOYJFK	Valrubicin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.5	0.21	0.71	4.35
DCQJ14A	DMOYJFK	Valrubicin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2	2.86	0.05	4.96
DCM5MW2	DMOYJFK	Valrubicin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	0.95	2.08	3.25	6.55
DCBKJYY	DMOYJFK	Valrubicin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.22	0.36	0.29	3.52
DC0ZOCC	DMOYJFK	Valrubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.83	7	7.68	6.98
DC3GAL2	DMOYJFK	Valrubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.44	7.26	2.14	1.52
DCD2U6I	DMOYJFK	Valrubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	11.87	10.74	7.53	7.49
DCNJJ65	DMOYJFK	Valrubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.81	2.56	2.2	2.2
DCOHMQX	DMOYJFK	Valrubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.83	4.85	5.22	5.22
DC2MPRA	DMOYJFK	Valrubicin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.31	3.84	3.67	3.14
DC4G6IK	DMOYJFK	Valrubicin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	6.8	8.26	1.88	9.16
DCWQV1B	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	24.18	19.95	21.44	21.31
DCN7UQ5	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	18.21	14.99	16.95	16.02
DC1EW9E	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	18.33	15.35	13.49	13.72
DCVGAQS	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	17.04	20.45	19.43	19.55
DCG5QWK	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	33.31	29.83	27.16	26.82
DCYTFLY	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	13	15.87	15.14	15.19
DCSLWUS	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	15.2	9.39	5.92	6.42
DCWKNLO	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	17.45	19.18	19.59	19.69
DCNO35O	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	20.8	21.94	21.2	20.78
DCHONCJ	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	23.62	21.74	4.24	19.25
DCSV7GE	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	8.94	7.49	6.96	7
DCGWB2J	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.76	4.51	3.31	3.36
DCF9D8Y	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8.64	8.81	11.04	10.06
DC5WFCN	DMOYJFK	Valrubicin	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	6.4	6.88	5.28	5.29
DC6PF4D	DMOYJFK	Valrubicin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	13.7	14.53	8.06	10.76
DCYO7OA	DMOYJFK	Valrubicin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	3.39	5.97	4.14	5.33
DCNIUN0	DMOYJFK	Valrubicin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.34	5.59	3.34	5.98
DCDYF6O	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.91	4.99	8.09	8.12
DCS96QI	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	9.84	13.83	4.46	6.95
DCA8N5T	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	9.34	8.65	6.83	8.68
DCCCKIU	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	9.16	7.77	5.73	5.2
DCJHR1L	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	7.08	7.23	7.91	10.3
DCF5UMD	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	8.96	8.85	5.29	9.17
DCNOQ8V	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	9.61	12.9	12.77	13.17
DCZFIAV	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	13.02	12.53	11.07	12.04
DCCFT8Y	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	10.84	6.41	6.01	7.08
DCIY6XO	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.3	7.35	5.63	5.75
DC7SH0M	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	9.56	16.06	13.39	13.55
DC2MWYO	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	18.43	16.73	6.27	15.36
DCLHAUO	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	13.66	18.79	12.3	12.21
DCG68W3	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.71	3.38	0.65	4.39
DCVSLZL	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	8.11	11.72	5.34	8.69
DC2QUWK	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	13.33	15.67	12.43	12.76
DC164G2	DMOYJFK	Valrubicin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	1.02	14.21	2.52	10.02
DCW58RH	DMOYJFK	Valrubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.2	2.04	5.01	5.15
DC2N1S7	DMOYJFK	Valrubicin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.13	1.74	5.36	6.06
DCJKJPZ	DMOYJFK	Valrubicin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	7.2	8.61	6.26	7.06
DC6I2AN	DMOYJFK	Valrubicin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	5.12	5.1	4.63	5.11
DCQ64WQ	DMOYJFK	Valrubicin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	8.9	9.07	4.27	9.65
DC4OKV4	DMOYJFK	Valrubicin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	6.15	5.76	4.5	5.85
DCP3OS1	DMOYJFK	Valrubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	5.77	2.45	2.91	1.76
DC1M76E	DMOYJFK	Valrubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.28	5.4	4.2	5.17
DCKC3O4	DMOYJFK	Valrubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.9	3.88	2.59	1.8
DC1H6AQ	DMOYJFK	Valrubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.3	2.49	2.32	2.63
DCPM4DH	DMOYJFK	Valrubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	6.81	9.57	5.16	5.74
DCK6V9D	DMOYJFK	Valrubicin	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	16.64	15.87	14.16	15.67
DCLKRKP	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.06	2.37	0.85	5.25
DC1P0TM	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	9.12	7.18	6.63	10.44
DCZ8VF0	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	4.24	5.88	1.83	3.68
DCOHIZJ	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	7.47	5.12	0.46	3.56
DCHCI3A	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	11.15	12.82	8.4	14.56
DCHMNKR	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	6.21	6.82	0.17	6.71
DCWVYIA	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	11.88	12.6	12.74	15.64
DC3AL94	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	8.78	7.21	3.95	9.37
DCFJLST	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	13.11	10.21	7.34	11.36
DCGHSXL	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	5.15	4.25	2.25	5.36
DC7NKYE	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	5.58	4.04	2.96	5.65
DCUI03M	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	7.67	7.15	3.84	8.42
DCIJG5N	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	9.76	7.47	6.04	10.53
DCEZVDT	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	16.31	15.78	16.87	18.04
DCR8B0L	DMOYJFK	Valrubicin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	8.43	9.11	7.1	8.69
DCKM6M8	DMOYJFK	Valrubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.9	2.58	0.11	5.24
DC2RL3P	DMOYJFK	Valrubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.13	2.26	2.26	5.24
DC2GPF1	DMOYJFK	Valrubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.49	1.54	1.97	4.51
DCCUGVG	DMOYJFK	Valrubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	8.86	11.1	5	9.72
DCPVUYQ	DMOYJFK	Valrubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.81	8.35	2.35	8.44
DCNTJ4P	DMOYJFK	Valrubicin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.4	0.24	1.61	4.01
DC5K2QA	DMOYJFK	Valrubicin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	0.65	0.84	1.26	0.83
DCNAYAP	DMOYJFK	Valrubicin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	0.83	3.86	2.92	3.08
DCCCEQY	DMOYJFK	Valrubicin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	2.85	1.53	0.76	1.09
DCNDOX1	DMOYJFK	Valrubicin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	5.19	3.48	0.11	4.59
DC4CR6E	DMOYJFK	Valrubicin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	6.97	5.81	5.92	8.22
DCS9LBR	DMOYJFK	Valrubicin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.95	5.82	5.23	4.33
DCCUY18	DMOYJFK	Valrubicin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.31	5.99	4.29	7.81
DCVYI6K	DMOYJFK	Valrubicin	Approved	34	DMT5GNL	Romidepsin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	13.33	14.78	2.35	15.64
DCNF2OB	DMOYJFK	Valrubicin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	15.99	9.46	13.57	8.04
DC04PYA	DMOYJFK	Valrubicin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	10.21	12	0.39	10.87
DCSBY8V	DMOYJFK	Valrubicin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	6.58	5.34	4.2	9.42
DC3VVEO	DMOYJFK	Valrubicin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	3.09	6.86	3.64	8.27
DCFEXWJ	DMOYJFK	Valrubicin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	8.14	11.48	7.12	10.98
DCLULQ6	DMOYJFK	Valrubicin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	18.92	19.24	20.76	19.66
DCLMZR1	DMOYJFK	Valrubicin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.15	3.45	5.56	8.2
DCD9LAI	DMOYJFK	Valrubicin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.9	3.77	4.39	6.5
DCXL2RZ	DMOYJFK	Valrubicin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	15.76	13.94	2.89	14.13
DCEQUQ8	DMOYJFK	Valrubicin	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.51	2.9	1.9	4.65
DC0CP77	DMOYJFK	Valrubicin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	5.1	3.37	4.81	5.95
DCS5OY9	DMOYJFK	Valrubicin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	7.97	8.25	6.09	8.88
DCQLUHJ	DMOYJFK	Valrubicin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	8.64	8.12	8.08	9.39
DCNKDTJ	DMOYJFK	Valrubicin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	11.54	14.47	11.43	12.91
DCI8R7J	DMOYJFK	Valrubicin	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	2.79	3.79	2.13	5.36
DCLLJ2V	DMOYJFK	Valrubicin	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	2.47	5.49	1.31	4.7
DCBI8JR	DMOYJFK	Valrubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	27.38	26.79	26.14	26.19
DCLX43N	DMOYJFK	Valrubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	19.86	19.83	18.91	19.7
DCEDY43	DMOYJFK	Valrubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	11.09	11.09	9.3	9.39
DCITBN0	DMOYJFK	Valrubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	24.35	25.93	19.47	23.05
DCSXK71	DMOYJFK	Valrubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	1.47	4.24	3.84	3.88
DC0DDIK	DMOYJFK	Valrubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	18.84	17.73	19.11	19.33
DC0IM15	DMOYJFK	Valrubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	0.67	20.86	15.24	15.41
DCGI67H	DMOYJFK	Valrubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.52	7.15	4	4.12
DCIBCYP	DMOYJFK	Valrubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.76	3.12	2.34	2.72
DCPIC89	DMOYJFK	Valrubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	1.47	1.54	1.25	1.55
DCUZ8D1	DMOYJFK	Valrubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	3.7	3.55	1.95	2.17
DC3PN0D	DMOYJFK	Valrubicin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	6.41	10.08	8.84	8.84
DCMFV1O	DMOYJFK	Valrubicin	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.62	2.14	0.73	4.39
DC8WJGM	DMOYJFK	Valrubicin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.32	4.59	0.16	0.44
DCBTF8M	DM7C8YV	Plicamycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.82	1.24	2.5	1.79
DCRXY29	DM7C8YV	Plicamycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	1.84	7.68	7.19	4.27
DC7YUH9	DM7C8YV	Plicamycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0	4.36	3.03	3.78
DCAMIDT	DM7C8YV	Plicamycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.22	1.91	1.9	1.48
DCTQUY7	DM7C8YV	Plicamycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.13	3.54	0.28	0.28
DCJU590	DM7C8YV	Plicamycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	2.68	3.95	2.93	0.66
DCIOVC4	DM7C8YV	Plicamycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	6.88	8.07	5.8	1.7
DCOZ38Q	DM7C8YV	Plicamycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.44	3.48	3.81	3.65
DCXNNAO	DM7C8YV	Plicamycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.25	6.81	3.96	4.01
DCITX3Q	DM7C8YV	Plicamycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.3	6.07	0.69	1.03
DCQYCF5	DM7C8YV	Plicamycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	2.38	3.44	0.62	0.2
DC3L44V	DM7C8YV	Plicamycin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.4	3.76	5.04	2.59
DC24MUM	DM7C8YV	Plicamycin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	4.85	11.56	6.46	4.64
DC8K20L	DM7C8YV	Plicamycin	Approved	34	DM2KITF	LY335979	Discontinued in Phase 3	9	.	.	.	.	Human papillomavirus-related cervical adenocarcinoma	DrugCombDB Database	Investigative	KB-ChR-8-5-11	43.402	39.326	26.116	23.969
DCMRQDO	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	5.43	6.72	3.95	7.81
DCVKP7D	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	2.87	3.2	1.13	5
DCNF2QI	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	7.09	7.41	10.59	10.39
DCN9R62	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.54	0	0.55	3.66
DCBZQE6	DM7C8YV	Plicamycin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.14	2.84	2.05	0.95
DCI7H98	DM7C8YV	Plicamycin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.39	1.11	1.11	1.16
DCYV5BK	DM7C8YV	Plicamycin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.33	1.42	0.12	0.97
DC0QRDW	DM7C8YV	Plicamycin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.71	3.23	0.25	3.84
DCJWH6E	DM7C8YV	Plicamycin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.41	7.56	1.86	0.81
DCD0DFD	DM7C8YV	Plicamycin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.04	8.38	2.34	4.15
DC5U3GI	DM7C8YV	Plicamycin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	1.81	6.51	1.26	1.26
DCP4KP2	DM7C8YV	Plicamycin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.6	3.21	1.4	1.85
DCQQJH1	DM7C8YV	Plicamycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	8.5	8.75	2.25	6.24
DCRA9VD	DM7C8YV	Plicamycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.35	4.56	1.45	4.73
DCSFW72	DM7C8YV	Plicamycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.51	3.99	1.38	6.27
DCUK2X3	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.49	4.74	0.53	0.24
DC033E3	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.08	3.47	0.98	0.89
DCQD70K	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.48	1.57	2.2	2.51
DC0AKF2	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	5.64	6.71	4.17	1.41
DCMEZ0Y	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	4.61	8.68	3	0.64
DCRK1WT	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.31	2.01	1	0.59
DCTJ5C9	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.97	0.88	1.3	0.87
DCLOLGG	DM7C8YV	Plicamycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	7.93	4.87	3.06	1.39
DC9M83Y	DM7C8YV	Plicamycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.04	3.79	2.14	1.48
DCK3J4F	DM7C8YV	Plicamycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.39	5.08	2.46	3.21
DC293BQ	DM7C8YV	Plicamycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	3.89	7.95	5.56	6.91
DC4JTGU	DM7C8YV	Plicamycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.32	4.56	3.91	1.75
DC3CFFS	DM7C8YV	Plicamycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.61	1.58	1.5	1.44
DCCBX8F	DM7C8YV	Plicamycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2	3.14	1.74	1.68
DCX7L08	DM7C8YV	Plicamycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	3.29	3.91	2.41	4.83
DCUSXDA	DM7C8YV	Plicamycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.2	3.15	0.99	2.1
DC3IUFS	DM7C8YV	Plicamycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.59	2.47	0.14	0.15
DC0FTIQ	DM7C8YV	Plicamycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	1.94	3.96	3.53	0.83
DCDQCEN	DM7C8YV	Plicamycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Diffuse large B cell lymphoma	DrugCombDB Database	Investigative	TMD8	3.384	3.777	3.897	6.268
DCWCX1A	DM7C8YV	Plicamycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	3.91	3.92	1.08	0.13
DCVY2PO	DM7C8YV	Plicamycin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	5.69	8.37	1.82	1.82
DC77FHG	DM7C8YV	Plicamycin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	10.62	3.43	1.33	0.45
DCNY327	DM7C8YV	Plicamycin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	2.78	7.29	5.52	3.37
DCT6KQL	DM7C8YV	Plicamycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	1.14	2.07	1.32	5.03
DCEXPQS	DM7C8YV	Plicamycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.02	5.04	0.39	1.72
DCR6T9R	DM7C8YV	Plicamycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	7.42	7.19	3.89	7.26
DCN8E08	DM7C8YV	Plicamycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	4.76	4.36	1.7	4.84
DCU67JC	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	3.58	1.64	0.74	1.48
DC1GRLT	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	8.55	8.55	8.12	9.02
DCOS4XC	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	10.43	9.9	7.76	11.51
DC5ABT0	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	12.82	9.9	2.78	11.74
DCNYQJF	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	9.21	9.37	7.61	9.43
DCBJ9PH	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	9.56	6.19	4.63	8.21
DC3I9VJ	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	6.58	3.21	2.92	6.11
DC5KT1B	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	6.52	5.76	3.57	6.06
DC1MZN6	DM7C8YV	Plicamycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	2.09	2.63	0.34	1.67
DCODKCZ	DM7C8YV	Plicamycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	0.47	0.96	0.18	1.86
DCA6SSH	DM7C8YV	Plicamycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.47	2.38	3.1	5.68
DCFMYUH	DM7C8YV	Plicamycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	7.75	12.43	9.64	16.08
DCY9LX0	DM7C8YV	Plicamycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	8.46	12.58	9.72	11.15
DCBPG8U	DM7C8YV	Plicamycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	3.99	5.15	6.67	6.38
DC4T49Z	DM7C8YV	Plicamycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.66	4.03	1.11	2.04
DCDQ2K1	DM7C8YV	Plicamycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	0.35	4.29	1.43	1.81
DCTPEU1	DM7C8YV	Plicamycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.7	2.38	2.69	2.15
DCBR7Q1	DM7C8YV	Plicamycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.55	1.25	1.5	1.83
DCC0EA9	DM7C8YV	Plicamycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	3.52	5.05	1.32	0.5
DC4RBVG	DM7C8YV	Plicamycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.08	1.95	1.03	0.89
DCNA6L8	DM7C8YV	Plicamycin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.93	7.46	4.09	2.58
DCT1OX5	DM7C8YV	Plicamycin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	6.78	14.2	10.77	7.39
DC5LIHY	DM7C8YV	Plicamycin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.54	2.21	0.42	0.42
DCMEW3W	DM7C8YV	Plicamycin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.88	3.21	2.54	0.07
DCDUY2I	DM7C8YV	Plicamycin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.18	5.31	3.31	3.1
DCDPZ6C	DM7C8YV	Plicamycin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	0.64	6	6.16	3.9
DCK7XUO	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.38	6.09	3.84	4.17
DCTVI56	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	0.61	3.56	4.81	4.41
DC5QJYU	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	12.69	15.94	6.26	6.79
DCV44QE	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	2.54	4.68	1.48	2.07
DCF54TO	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	2.21	5.18	3.21	3.7
DCZSK1P	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	1.17	1.18	0.54	0.34
DCCPXCZ	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	4.72	5.27	1.93	2.17
DCTY2VI	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.52	3.29	0.85	0.38
DC8JR4M	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	7.39	6.4	4.87	7.35
DCUETR3	DM7C8YV	Plicamycin	Approved	34	DMURVE8	Elacridar	Discontinued in Phase 1	3	.	.	.	.	Human papillomavirus-related cervical adenocarcinoma	DrugCombDB Database	Investigative	KB-ChR-8-5-11	49.624	54.32	37.729	37.711
DCPDQDC	DM7C8YV	Plicamycin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	2.74	4.58	1.84	1.7
DC1ABFG	DM7C8YV	Plicamycin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.01	4.13	0.8	2.51
DCHRD21	DM7C8YV	Plicamycin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.55	2.32	0.56	0.42
DCFFY0F	DM7C8YV	Plicamycin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.16	4.64	0.03	1.04
DCIB3Z3	DM7C8YV	Plicamycin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	8.59	15.59	4.42	3.29
DCXVJIA	DM7C8YV	Plicamycin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.08	4.98	3.2	4.14
DCUX9QA	DM7C8YV	Plicamycin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.15	1.38	0.69	0.65
DC46Z5A	DM7C8YV	Plicamycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.71	5.6	2.81	7.57
DCUHPXN	DM7C8YV	Plicamycin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.7	2.98	2.47	1.46
DC257F1	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.71	6.9	4.07	5.51
DC06B03	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.54	4.57	3.27	5.75
DCG4HAM	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.16	4.35	2.01	7.57
DCNX3GE	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	1.54	1.02	0.79	2.6
DCEVVEF	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	2.73	2.24	2.05	3.21
DCP9OCU	DM7C8YV	Plicamycin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.48	2.1	0.61	0.09
DCAWGPP	DM7C8YV	Plicamycin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	1.07	3.39	1.42	0.76
DCZOLEL	DM7C8YV	Plicamycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.58	1.15	1.62	0.27
DC203AP	DM7C8YV	Plicamycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.47	2.23	0.08	5.24
DCEBT01	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.69	1.08	1.25	0.78
DCEYG1D	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	0.3	1.3	0.17	0.65
DCQO5SY	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.42	1.88	0.74	0.67
DCHPQKH	DM7C8YV	Plicamycin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	1.96	4.19	5.45	0.53
DC733JO	DM7C8YV	Plicamycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.05	3.87	4.92	3.3
DCYV58A	DM7C8YV	Plicamycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.47	5.46	2.77	2.79
DCQBOUK	DM7C8YV	Plicamycin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.71	2.6	2.35	0.6
DC14RT2	DM7C8YV	Plicamycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.8	6.11	0.14	6.02
DCQL7G7	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	12.8	11.33	7.45	10.57
DC16DQ9	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	6.1	5.55	3.98	6.18
DCV0MWR	DM7C8YV	Plicamycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.78	4.13	0.95	5.08
DC8UGUM	DM7C8YV	Plicamycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.78	6.61	6.82	7.71
DCIC01Q	DM7C8YV	Plicamycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.6	3.03	2.12	1.48
DCMQNUW	DM7C8YV	Plicamycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.22	5.15	2.37	2.12
DCCVGXZ	DM7C8YV	Plicamycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	0.65	1.3	2.87	2.99
DCEUW9P	DM7C8YV	Plicamycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.96	5.55	3.28	3.23
DCJ4BTN	DM7C8YV	Plicamycin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.46	1.46	0.37	0.78
DCGM0IW	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	4.67	4.27	1.76	1.76
DCVZHW0	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	2.84	3.68	0.08	1.22
DC96ZF6	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.26	2.89	2.51	2.24
DCM7U8E	DM7C8YV	Plicamycin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	0.07	2.78	0.32	0.38
DC7332H	DM7C8YV	Plicamycin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.47	3.76	2.8	1.76
DCLEK33	DM7C8YV	Plicamycin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	4.73	6.47	2.97	2.27
DCQNE4V	DM7C8YV	Plicamycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.21	4.3	2.09	2.29
DCQBMCZ	DM7C8YV	Plicamycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	0.27	3.48	3.51	1.25
DCVBEG5	DM7C8YV	Plicamycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	7.03	7.83	6.19	6.42
DCRPL76	DM7C8YV	Plicamycin	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.21	1.87	2.11	0.91
DCQDC2O	DM7C8YV	Plicamycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.18	4.89	5.12	3.88
DCZM37A	DM7C8YV	Plicamycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	1.33	2.24	0.75	0.66
DCIQAMR	DM7C8YV	Plicamycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.33	7.74	1.82	1.7
DCI5DU6	DM7C8YV	Plicamycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.89	6.2	0.41	0.41
DCETH02	DM7C8YV	Plicamycin	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.65	7.14	1.14	1.14
DCZ3T7Z	DM7C8YV	Plicamycin	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	6.609	3.769	1.075	3.51
DC5HJKC	DM7C8YV	Plicamycin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.7	6.86	3.91	1.86
DC2QELG	DM7C8YV	Plicamycin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.21	7.1	0.71	3.03
DCQJSYS	DM7C8YV	Plicamycin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.28	9.14	2.3	0.72
DC8YEFP	DM7C8YV	Plicamycin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.31	4.64	0.06	1.34
DCM1NQA	DM7C8YV	Plicamycin	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	0.17	3.07	1.83	2.23
DCRM5LV	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.67	0.82	1.21	3.42
DCSYXRO	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.07	5.32	3.92	4.96
DCMB17E	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.53	1.14	0.14	1.64
DCLCRGC	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	4.07	4.42	3.71	6.32
DC220KC	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	8.87	2.43	3.31	7.39
DC4EGJ1	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.31	0.48	1.4	4.36
DCI1QY8	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	10.25	6.9	5.2	8.06
DCZVGX2	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	2.79	2.79	0.45	2.78
DCJH2AX	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.9	4.67	2.77	4.13
DCDGJQL	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	3.93	3.17	0.22	2.21
DC56Y86	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	11.87	6.4	3.55	8.03
DC42R4B	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	5.16	4.53	5.43	7.58
DCZ6HFA	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	2.41	1.71	0.61	3.5
DCQZJWA	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.51	4.25	3.13	4.86
DCIP6J5	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.26	1.74	0.31	1.53
DCC50IM	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.15	3.22	1.09	4.92
DCDCH3X	DM7C8YV	Plicamycin	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.77	1.45	0.07	4.32
DCKBWA4	DM7C8YV	Plicamycin	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	0.09	2.85	0.22	1.93
DCHBCI0	DM7C8YV	Plicamycin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	7.3	13.35	5.84	4.51
DCFWY0B	DM7C8YV	Plicamycin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.46	2.92	2.07	0.61
DCSSWTS	DM7C8YV	Plicamycin	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.87	1.45	1.51	1.36
DC723RF	DM7C8YV	Plicamycin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	1.43	4.48	0.29	2.99
DCMDXO2	DM7C8YV	Plicamycin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	10.13	7.95	4.61	7.01
DC7LI96	DM7C8YV	Plicamycin	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.06	3.11	0	1.42
DCVNW9W	DM7C8YV	Plicamycin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.2	8.25	2.45	1.8
DCR0ITM	DM7C8YV	Plicamycin	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.75	6.6	4.42	1.21
DC4SB25	DM7C8YV	Plicamycin	Approved	34	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	1.14	2.33	0.32	1.97
DC6OIAY	DM7C8YV	Plicamycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.69	4.49	2.98	1.23
DCV481J	DM7C8YV	Plicamycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.78	9.86	8.4	4.69
DCP6EAN	DM7C8YV	Plicamycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.87	1.57	0.28	1.65
DCMEW1Z	DM7C8YV	Plicamycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.2	4.43	3.45	4.93
DCFD8Y1	DM7C8YV	Plicamycin	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.83	0.99	0.64	0.15
DC5W4O1	DM7C8YV	Plicamycin	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.27	4.91	2.29	1.84
DCO6O80	DM7C8YV	Plicamycin	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	2.67	5.77	1.25	2.65
DCXS0RS	DM7C8YV	Plicamycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.56	2.46	2.56	6.54
DCAAIY5	DM7C8YV	Plicamycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1.51	2.47	0.46	4.36
DCQKMMP	DM7C8YV	Plicamycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	5.3	5.69	1.6	4.77
DC8KDA5	DM7C8YV	Plicamycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	0.66	2.1	0.47	1.57
DCPV4SI	DM7C8YV	Plicamycin	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	0.84	1.83	2	4.21
DCM42IN	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	1.34	3.73	4.57	0.25
DCUGH5K	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.25	7.89	5.59	5.68
DC2K0G8	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	0.95	3.71	3.08	1.87
DCIHV63	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.7	3.55	0.84	0.86
DC42RNM	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.8	4.83	3.67	3.69
DCLZK63	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	EKVX	1.74	3.48	1.72	1.03
DC7Y3R0	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.27	0.43	0.95	0.18
DCMZ2ZO	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	4.06	9.55	5.55	3.4
DCOX30U	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.7	2.61	0.59	0.75
DC2N53J	DM7C8YV	Plicamycin	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.25	2.26	1.79	0.45
DC0ZAZG	DM7C8YV	Plicamycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	1.88	3.41	0.14	0.18
DC9ERDN	DM7C8YV	Plicamycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	2.31	2.83	0.14	0.75
DCYWSSY	DM7C8YV	Plicamycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	10.57	12.18	10.13	7.6
DCK1VQW	DM7C8YV	Plicamycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.07	2.45	1.44	1.7
DC1N3G8	DM7C8YV	Plicamycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.13	3.31	0.51	1.22
DCAWZ68	DM7C8YV	Plicamycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.78	1.92	1.19	0.41
DC7JI7Q	DM7C8YV	Plicamycin	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	3.09	3.88	1.52	1.23
DCHVZO7	DM7C8YV	Plicamycin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	0.11	0.58	2.65	1.91
DCQ3KTO	DM7C8YV	Plicamycin	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.61	2.73	1.42	1.26
DCL01FG	DM7C8YV	Plicamycin	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.75	1.96	1.6	0.55
DCR5UCP	DM7C8YV	Plicamycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	8.61	10.7	6.14	8.78
DCOGK6P	DM7C8YV	Plicamycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.27	0.41	3	3.01
DCE2WCT	DM7C8YV	Plicamycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	5.3	6.72	4.26	6.31
DCG4464	DM7C8YV	Plicamycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	NCI\\/ADR-RES	3.96	4.99	0.12	1.36
DCPGRHR	DM7C8YV	Plicamycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	0.24	0.69	0.1	0.79
DCLSJIB	DM7C8YV	Plicamycin	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	5.98	4.13	2.28	3.45
DCLIJ97	DM7C8YV	Plicamycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.65	4.34	0.91	0.53
DC7TU2V	DM7C8YV	Plicamycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.79	3.21	1.65	1.32
DCJRTRC	DM7C8YV	Plicamycin	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.36	2.42	1.88	0.35
DC9QBPB	DM7C8YV	Plicamycin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.95	2.91	1.82	1.73
DCPIOP1	DM7C8YV	Plicamycin	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.1	9.41	1.6	5.67
DCRA84O	DM7C8YV	Plicamycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.16	2.9	0.36	4.05
DCD4IIN	DM7C8YV	Plicamycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	4.06	8.48	5.71	7.35
DC9765K	DM7C8YV	Plicamycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	0.01	2.18	0.29	0.57
DCHK17X	DM7C8YV	Plicamycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	0.37	3.76	1.44	2.97
DCFLHKX	DM7C8YV	Plicamycin	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.38	4.79	4.38	4.11
DCG1USW	DM7C8YV	Plicamycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	5.15	6.26	1.03	5.27
DCHR9MN	DM7C8YV	Plicamycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.8	4.24	2.49	5.87
DCE5Z6G	DM7C8YV	Plicamycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	5.85	6.08	0.01	5.33
DCLC10A	DM7C8YV	Plicamycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	4.79	4.85	4.15	5.85
DC0VHMX	DM7C8YV	Plicamycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.84	3.57	2.1	4.68
DC7SM9T	DM7C8YV	Plicamycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	14.89	13.43	15.04	15.42
DCKF1FL	DM7C8YV	Plicamycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	7.55	7.53	5.26	7.76
DC7M49C	DM7C8YV	Plicamycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	2.08	3.03	1.93	3.6
DC5H5T1	DM7C8YV	Plicamycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	2.2	2.18	0.91	1.89
DCEIC9S	DM7C8YV	Plicamycin	Approved	34	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	4.45	5.68	0.11	4.99
DCR95X5	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	6.27	3.35	3.87	5.28
DCVQWJQ	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	11.36	9.16	4.84	7.85
DCCPQAN	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	3.14	0.87	2.8	3.6
DCA3LMJ	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	3.34	5.91	4.24	4.93
DCBDBVE	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	14.65	12.83	10.38	13.7
DCSVIGW	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	18.43	17.57	15.5	16.89
DCR5EDM	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	4.34	3.41	0.82	3.35
DCV02ZH	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	9.19	9.69	5.9	7.49
DC62ZF2	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	3.36	1.62	0.22	3.2
DC5MYCQ	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	19.25	17.84	17.62	19.38
DCKNM6V	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	8.22	8.53	3.12	8.11
DC69ARK	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	11.37	10.54	8.42	9.4
DC2RBJA	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	7.69	6.9	0.82	3.58
DCSJVDW	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	10.17	12.34	10.44	11.79
DCKG4T6	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	6.91	9.09	3.25	8.76
DCQ1BPG	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	3.88	2.32	1.51	3.78
DC4O861	DM7C8YV	Plicamycin	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.13	2.46	2.04	4.36
DCD9BOZ	DM7C8YV	Plicamycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	1.88	3.02	0.5	5.93
DCODEWG	DM7C8YV	Plicamycin	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	3.8	4.15	3.88	6.34
DC0NGWR	DM7C8YV	Plicamycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	4.01	7.77	11.05	11.45
DCZPIWH	DM7C8YV	Plicamycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	0.37	2.35	0.3	0.68
DCLVOU2	DM7C8YV	Plicamycin	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.59	4.77	0.22	0.22
DCE1HF6	DM7C8YV	Plicamycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	3.24	5.98	4.82	3.85
DCLJXU3	DM7C8YV	Plicamycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.33	2.35	0.26	0.27
DCQLR7E	DM7C8YV	Plicamycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.45	2.35	2.97	2.64
DCCV2TV	DM7C8YV	Plicamycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	5.49	6.82	0.3	0.3
DCWYBJH	DM7C8YV	Plicamycin	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	MALME-3M	1.42	1.91	1.8	0.26
DC3VV45	DM7C8YV	Plicamycin	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.28	4.16	4.04	1.81
DC8O2OL	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	8.65	6.17	3.83	5.65
DC5PYG2	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	4.04	7.93	0.97	2.11
DCDCUXO	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	5.48	2.89	1.39	2.84
DC4JOQM	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	8.27	12.18	8.8	10.08
DC8ZX2E	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	4.72	4.95	2.14	4.72
DCT4SIP	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.81	4.16	2.89	4.09
DC5G2SS	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.92	9.9	3.03	0.96
DCOQLZV	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	1.37	2.09	0.24	0.25
DCY3LBW	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	1.86	3.1	2.4	2.68
DCV3CVY	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	1.78	2.01	0.55	1.37
DCXXO7N	DM7C8YV	Plicamycin	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	PC-3	3.65	6.49	3.05	5.28
DC5JZI5	DM7C8YV	Plicamycin	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.7	2.56	1.5	0.68
DCCJPXT	DM7C8YV	Plicamycin	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-8	2.29	4.78	2.47	1.65
DCKX46U	DM7C8YV	Plicamycin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	3.28	5.67	2.24	1.64
DC0FIMY	DM7C8YV	Plicamycin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	1.66	3.98	2.28	1.43
DC3XC3P	DM7C8YV	Plicamycin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	1	1.46	0.4	0.06
DC9HVK7	DM7C8YV	Plicamycin	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.51	4.27	2.96	0.7
DCBLS4D	DM7C8YV	Plicamycin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	5.81	8.69	2.29	1.44
DCK7AYS	DM7C8YV	Plicamycin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	2.89	4.54	0.3	0.41
DCV9LIJ	DM7C8YV	Plicamycin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	2.88	7.97	1.31	1.31
DCUYZ67	DM7C8YV	Plicamycin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-5	2.1	4	1.3	2.72
DC3S8QV	DM7C8YV	Plicamycin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	1.21	2.81	1.94	1.89
DC7Y5DS	DM7C8YV	Plicamycin	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	0.83	1.72	1.42	1.26
DC6NUZ8	DM7C8YV	Plicamycin	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	SYNERGxDB Database	Investigative	IGROV1	0.47	1.69	2.15	2.52
DCC2CUQ	DMH07Y3	Letrozole	Approved	34	DMK0O7U	Flutamide	Approved	34	DMMZMOC	Hydrocortisone	DMUDIR8	Fludrocortisone	Congenital Adrenal Hyperplasia (CAH)	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCYZZS0	DMH07Y3	Letrozole	Approved	34	DMK0O7U	Flutamide	Approved	34	DMMZMOC	Hydrocortisone	.	.	Congenital Adrenal Hyperplasia (CAH)	ClinicalTrials.gov	Phase 4	.	.	.	.	.
DCU90CT	DMH07Y3	Letrozole	Approved	34	DMNP60F	Anastrozole	Approved	34	DMVXFYE	Vinorelbine	.	.	Breast Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DC3E3U8	DMH07Y3	Letrozole	Approved	34	DMTS85L	Capecitabine	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 3	.	.	.	.	.
DCF5OEQ	DMH07Y3	Letrozole	Approved	34	DMNP60F	Anastrozole	Approved	34	DMVXFYE	Vinorelbine	.	.	Breast Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC5VRXS	DMH07Y3	Letrozole	Approved	34	DMHVJFK	Misoprostol	Approved	34	.	.	.	.	Miscarriage	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC6QCIJ	DMH07Y3	Letrozole	Approved	34	DMMX75K	LEE011	Phase 3	25	.	.	.	.	Early Breast Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DC9ZSUV	DMH07Y3	Letrozole	Approved	34	DMLB0EZ	Tamoxifen	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCAZI7U	DMH07Y3	Letrozole	Approved	34	DMZMSPF	Bicalutamide	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCDFSM5	DMH07Y3	Letrozole	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Anatomic Stage I Breast Cancer AJCC v8	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCM2F0J	DMH07Y3	Letrozole	Approved	34	DMTK4LS	Triptorelin	Approved	34	.	.	.	.	Breast Cancer Invasive Nos	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCRF0IM	DMH07Y3	Letrozole	Approved	34	DMTKD7Q	Afatinib	Approved	34	.	.	.	.	Breast Neoplasms	ClinicalTrials.gov	Phase 2	.	.	.	.	.
DCIMZA7	DMH07Y3	Letrozole	Approved	34	DMIXC7G	Zoledronate	Approved	34	DMTK4LS	Triptorelin	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC5SM9V	DMH07Y3	Letrozole	Approved	34	DMKI7RB	Clomifene	Approved	34	.	.	.	.	Infertility	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC61NWM	DMH07Y3	Letrozole	Approved	34	DMIXC7G	Zoledronate	Approved	34	.	.	.	.	Breast Neoplasms	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC9ZJJD	DMH07Y3	Letrozole	Approved	34	DMNP60F	Anastrozole	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCBE6FO	DMH07Y3	Letrozole	Approved	34	DMX302C	BMS-690514	Phase 2	21	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCEWMG0	DMH07Y3	Letrozole	Approved	34	DMML7BE	Xl147	Phase 2	21	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCLZ8LP	DMH07Y3	Letrozole	Approved	34	DMT4QHD	GDC-0032	Phase 3	25	.	.	.	.	Solid Cancers	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCROX04	DMH07Y3	Letrozole	Approved	34	DMTI8YE	Bosutinib	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCU5C0O	DMH07Y3	Letrozole	Approved	34	DMTK4LS	Triptorelin	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCVIW9B	DMH07Y3	Letrozole	Approved	34	DMIXC7G	Zoledronate	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCYLKRD	DMH07Y3	Letrozole	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Metastatic Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC1JH47	DMH07Y3	Letrozole	Approved	34	DMVXFYE	Vinorelbine	Approved	34	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DC896SH	DMH07Y3	Letrozole	Approved	34	DMMQ2OW	Nintedanib	Phase 2 Trial	21	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCCTZ36	DMH07Y3	Letrozole	Approved	34	DMWBZJD	GDC-0068	Phase 3	25	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCF09QX	DMH07Y3	Letrozole	Approved	34	DMKECZD	Temozolomide	Approved	34	.	.	.	.	Brain Tumor	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCHC556	DMH07Y3	Letrozole	Approved	34	DMYZFNH	Sapanisertib	Investigative	0	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCS02AM	DMH07Y3	Letrozole	Approved	34	DMMX75K	LEE011	Phase 3	25	.	.	.	.	Breast Cancer	ClinicalTrials.gov	Phase 1	.	.	.	.	.
DCHQW7C	DMH07Y3	Letrozole	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	6.12	10.26	4.48	3.82
DCFXWJW	DMH07Y3	Letrozole	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	5.04	8.47	5.89	5.84
DC98DAA	DMH07Y3	Letrozole	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	2.24	3.44	1.87	1.18
DC5THDD	DMH07Y3	Letrozole	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	1.05	1.94	0.64	0.61
DCURN9D	DMH07Y3	Letrozole	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	4.29	4.81	0.91	0.91
DCSODBJ	DMH07Y3	Letrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	0.43	6.33	4.4	4.54
DCX45KO	DMH07Y3	Letrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	1.82	4.82	0.52	0.52
DC9G1DO	DMH07Y3	Letrozole	Approved	34	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	3.1	3.52	2.76	0.36
DC8P1EX	DMH07Y3	Letrozole	Approved	34	DM7Q98D	Ruxolitinib	Phase 3 Trial	25	.	.	.	.	Hodgkin lymphoma	ALMANAC Dataset	Investigative	L-1236	76.38	77.99	5.98	11.31
DCHUMAA	DMH07Y3	Letrozole	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	5.25	9.07	3.09	2.44
DCI4ZPZ	DMH07Y3	Letrozole	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	6.53	9.75	4.54	1.51
DCCHMRE	DMH07Y3	Letrozole	Approved	34	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	5.62	11.79	2.55	1.81
DC48QDY	DMH07Y3	Letrozole	Approved	34	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	3.19	4.41	2.2	4.93
DC6XKAE	DMH07Y3	Letrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	0.94	5.67	2.95	2.51
DC4J0LC	DMH07Y3	Letrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	10.68	14.99	8.27	9.84
DCSA3DM	DMH07Y3	Letrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	2.24	2.42	1.34	1.21
DCKFCWO	DMH07Y3	Letrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	3.48	7.16	4.47	2.59
DCN3KLS	DMH07Y3	Letrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	2.12	2.3	1.64	0.78
DCICLK3	DMH07Y3	Letrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	5.53	5.15	5.09	7.47
DC4TGP1	DMH07Y3	Letrozole	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	0.62	3.2	3.6	3.03
DCCZOF0	DMH07Y3	Letrozole	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	1.82	4.6	2.19	3.74
DCMEGAB	DMH07Y3	Letrozole	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	10.84	11.37	11.25	9.34
DCL46FT	DMH07Y3	Letrozole	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	1.79	3.41	1.09	1.09
DCXQ4IH	DMH07Y3	Letrozole	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	1.8	2.8	2.57	1.8
DCPIVBH	DMH07Y3	Letrozole	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	0.69	4.01	3.63	2.42
DCT63MH	DMH07Y3	Letrozole	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	0.45	1.41	0.05	0.05
DCNF142	DMH07Y3	Letrozole	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	3.14	4.54	1.43	1.38
DCWX2AR	DMH07Y3	Letrozole	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	7.32	10.97	6.05	10.54
DCS0JRC	DMH07Y3	Letrozole	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	A498	1.3	4.35	6.83	7.06
DCMQURF	DMH07Y3	Letrozole	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	11.37	15.7	11.66	12.01
DCQT1Y4	DMH07Y3	Letrozole	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	1.38	4.52	5.41	6.09
DCEFSWK	DMH07Y3	Letrozole	Approved	34	DM4OYXE	LIAROZOLE	Phase 2/3	24	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	6.44	7.37	2.66	2.91
DCG64OD	DMH07Y3	Letrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	26.53	22.87	26.88	23.76
DC540QX	DMH07Y3	Letrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	11.27	12.12	12.82	12
DCN3LF8	DMH07Y3	Letrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	22.44	18.06	1.63	18.9
DCLXS2C	DMH07Y3	Letrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	10.46	10.21	0.86	12.9
DCBAUZU	DMH07Y3	Letrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	24.11	23.6	24.61	22.16
DCIE6AG	DMH07Y3	Letrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	24.27	20.33	3.63	21.12
DC25JQI	DMH07Y3	Letrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	21.74	17.12	21.45	20.1
DC545NE	DMH07Y3	Letrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	31.5	29.16	25.36	28.56
DC0YDVK	DMH07Y3	Letrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	28.11	26.15	22.61	26.37
DC4SZCJ	DMH07Y3	Letrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	0.57	3.4	1.05	0.88
DCBCY2Q	DMH07Y3	Letrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	16.22	14.06	15.82	14.87
DCL4918	DMH07Y3	Letrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	8.03	7.53	8.24	7.25
DCOH5JU	DMH07Y3	Letrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	0.36	2.66	1.64	1.56
DCKNISM	DMH07Y3	Letrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	4.54	6.62	2.95	0.84
DCLGNS9	DMH07Y3	Letrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	0.42	2.8	2.03	2.03
DC767YJ	DMH07Y3	Letrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	0.97	1.54	1.32	0.44
DC1H20R	DMH07Y3	Letrozole	Approved	34	DM5JVS3	Isoniazid	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	3.2	4.34	0.22	0.16
DCM5O8O	DMH07Y3	Letrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	0.54	1.93	0.05	0.05
DCFW913	DMH07Y3	Letrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	1.13	2.17	2.51	1.21
DC0YJQ3	DMH07Y3	Letrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	0.04	2.51	1.14	0.86
DCX0XXE	DMH07Y3	Letrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	1.22	3.03	3.82	2.16
DC1N2RZ	DMH07Y3	Letrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	0.61	1.14	4.52	3.62
DCP5TTH	DMH07Y3	Letrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HT29	3.42	7.69	4.35	3.1
DCQGXQY	DMH07Y3	Letrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	0.08	2.8	2.69	1.8
DCKZTTG	DMH07Y3	Letrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	0.41	2.17	0.95	0.7
DCG7T73	DMH07Y3	Letrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	0.87	4.96	2.18	2.46
DC61CHF	DMH07Y3	Letrozole	Approved	34	DM7HXWT	Nilotinib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	3.97	8.26	8.92	9.39
DCAUN1H	DMH07Y3	Letrozole	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	3.61	7.43	4.68	3.37
DC14VA4	DMH07Y3	Letrozole	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	3.87	9.5	5.25	3.83
DC4W88J	DMH07Y3	Letrozole	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	2.14	4.89	3.27	3.27
DCOYDMO	DMH07Y3	Letrozole	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	2.41	4.96	2.02	1.54
DCJH0HP	DMH07Y3	Letrozole	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	0.28	1.73	1.61	0.66
DCXZTNU	DMH07Y3	Letrozole	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	2.33	4.15	2.85	1.55
DCHMW55	DMH07Y3	Letrozole	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	MALME-3M	1.7	3.61	1.38	1.25
DC4VSDM	DMH07Y3	Letrozole	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	6.75	7.52	0.62	0.45
DCYTHE6	DMH07Y3	Letrozole	Approved	34	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	2.38	6.75	7.23	5.78
DC8QUXT	DMH07Y3	Letrozole	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	3.43	0.21	0.89	0.89
DC44ANT	DMH07Y3	Letrozole	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	2.56	3.52	4.46	4.46
DCVJEX1	DMH07Y3	Letrozole	Approved	34	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	2.47	0.85	1.03	0.77
DC5WIRD	DMH07Y3	Letrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	2.71	7.34	7.39	5.26
DCEF62E	DMH07Y3	Letrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	1.27	2.99	1.69	0.7
DC3VAUR	DMH07Y3	Letrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	10.46	14.98	8.66	4.05
DCACT2Y	DMH07Y3	Letrozole	Approved	34	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	0.44	1.82	1.71	0.32
DC4IC79	DMH07Y3	Letrozole	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	4.55	9.11	3.84	5.55
DCR1JC7	DMH07Y3	Letrozole	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	2.46	2.36	0.86	0.11
DCSIZSO	DMH07Y3	Letrozole	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	0.88	4.51	2.38	1.19
DC7ONVS	DMH07Y3	Letrozole	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	16.84	18.62	4.64	4.39
DC754VJ	DMH07Y3	Letrozole	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	0.11	1.36	0.47	0.55
DCGM5X2	DMH07Y3	Letrozole	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	5.31	8.46	7.03	5.28
DC5E5N0	DMH07Y3	Letrozole	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	1.93	3.27	0.52	0.52
DCUEYC8	DMH07Y3	Letrozole	Approved	34	DMDI269	Docetaxel	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	2.1	4.94	2.58	1.07
DCAKM5U	DMH07Y3	Letrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	1.94	1	2.7	5.61
DC16P0C	DMH07Y3	Letrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	4.12	6.73	2.58	1.56
DC5BRSA	DMH07Y3	Letrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	7.89	9.13	0.79	0.95
DC9M7WK	DMH07Y3	Letrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	2.87	7	3.8	2.16
DCSSMWC	DMH07Y3	Letrozole	Approved	34	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	1.31	3.4	1.47	1.28
DCEN74V	DMH07Y3	Letrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	7.67	8.4	4.06	4.46
DC36CTJ	DMH07Y3	Letrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	3.57	6.22	4.56	3.5
DC2D5K9	DMH07Y3	Letrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	5.95	10.47	1.26	4.38
DC22L67	DMH07Y3	Letrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	2.55	7.7	6.55	6.51
DC1BE6T	DMH07Y3	Letrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Mixed endometrioid and clear cell carcinoma	ALMANAC Dataset	Investigative	IGROV1	2.61	7.57	5.68	5.02
DCRBETP	DMH07Y3	Letrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	0.91	3.91	2.36	3.6
DC4MYEK	DMH07Y3	Letrozole	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	3.65	5.66	4.85	8.73
DCNBP7W	DMH07Y3	Letrozole	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	5.42	1.95	1.17	0.79
DC4DE81	DMH07Y3	Letrozole	Approved	34	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	1.42	5.89	5.04	3.63
DC9SZT1	DMH07Y3	Letrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	3.69	11.16	0.34	9.22
DCM0Y0R	DMH07Y3	Letrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	0.54	4.99	2.82	2.76
DCKAK9A	DMH07Y3	Letrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	5.26	9.2	2.34	2.34
DC5TA9C	DMH07Y3	Letrozole	Approved	34	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	0.06	2.32	2.18	2.09
DCGR1K3	DMH07Y3	Letrozole	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	1.1	4.34	0.63	1.64
DC8HJPP	DMH07Y3	Letrozole	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	0.74	4.37	4.35	5.58
DC58R1U	DMH07Y3	Letrozole	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	4.14	4.23	1.78	4.49
DCCKQ6E	DMH07Y3	Letrozole	Approved	34	DMINOX3	Vincristine	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	2.91	4.58	5.73	6.88
DC4HC0B	DMH07Y3	Letrozole	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	7.7	13.82	2.79	2.51
DC4J3Z4	DMH07Y3	Letrozole	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	1.42	4.06	5.52	5.52
DC7T721	DMH07Y3	Letrozole	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	2.08	5.33	2.9	2.77
DC2KLHK	DMH07Y3	Letrozole	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	UACC62	0.57	3.29	2.49	1.97
DCZTV44	DMH07Y3	Letrozole	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	0.66	7.74	4.11	3.92
DC08XET	DMH07Y3	Letrozole	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Prostate carcinoma	ALMANAC Dataset	Investigative	PC-3	2.09	2.98	1.63	0.54
DC6JIXU	DMH07Y3	Letrozole	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioblastoma?	ALMANAC Dataset	Investigative	T98G	17.17	17.17	18.18	18.18
DC081KB	DMH07Y3	Letrozole	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	7.19	8.17	1.43	1.21
DCDT96O	DMH07Y3	Letrozole	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	1.53	5.28	0.56	0.56
DC3RO0Z	DMH07Y3	Letrozole	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.7	2.92	2.88	1.85
DCDFO44	DMH07Y3	Letrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	9.91	11.72	5.94	3.56
DCNXSOS	DMH07Y3	Letrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-4	0.19	1.73	0.06	0.01
DCWMG7I	DMH07Y3	Letrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	1.31	5.59	5.22	4.05
DCMY3T0	DMH07Y3	Letrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	0.11	0.77	3.85	4.03
DCDI7BT	DMH07Y3	Letrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	0.37	3.19	2.19	1.9
DCVMW1A	DMH07Y3	Letrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	5.38	6.83	1.02	0.45
DCN2ZVM	DMH07Y3	Letrozole	Approved	34	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	1.77	6.64	6.41	4.49
DC9V811	DMH07Y3	Letrozole	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	1.49	2.95	3.08	2.88
DC7ZUQD	DMH07Y3	Letrozole	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	3.95	3.25	2.69	4.33
DCUXP29	DMH07Y3	Letrozole	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	2.69	2.17	0.87	1.87
DCC3Z6L	DMH07Y3	Letrozole	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	UO-31	12.52	9.14	6.98	7.31
DC5DFZD	DMH07Y3	Letrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	0.13	1	0.11	1.1
DCX83QM	DMH07Y3	Letrozole	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	6.86	7.44	7.98	4.19
DC1PW12	DMH07Y3	Letrozole	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	3.24	6.62	0.64	0.2
DCF8BB1	DMH07Y3	Letrozole	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	M14	1	7.11	3.14	1.89
DC3Z92P	DMH07Y3	Letrozole	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	7.31	15.84	3.25	4.37
DCTA8H9	DMH07Y3	Letrozole	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	3.67	5	1.63	0.31
DC4EQ1N	DMH07Y3	Letrozole	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	1.88	3.87	0.98	0.71
DC6SW1F	DMH07Y3	Letrozole	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	3.7	4.77	4.71	3.18
DCJ8RR3	DMH07Y3	Letrozole	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	2.75	6.86	9.06	8.53
DCO2EUJ	DMH07Y3	Letrozole	Approved	34	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	2.58	7.65	5.82	3.47
DC7HBXR	DMH07Y3	Letrozole	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	6.01	10.21	3.96	1.7
DCUXQ8L	DMH07Y3	Letrozole	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	25.93	33.83	0.79	0.01
DC7Z1DB	DMH07Y3	Letrozole	Approved	34	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	0.56	3	6.37	0.26
DC2LTCL	DMH07Y3	Letrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	7.11	9.64	2.88	2.8
DCQ412O	DMH07Y3	Letrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	2.52	6.29	4.17	1.12
DCD847N	DMH07Y3	Letrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	1.29	1.62	1.64	1.64
DCIBAVO	DMH07Y3	Letrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	0.47	2.96	2.12	0.12
DCTYT5C	DMH07Y3	Letrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-295	2.66	2.67	0.99	0.56
DCBGHHH	DMH07Y3	Letrozole	Approved	34	DMSG91J	ER819762	Investigative	0	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	UACC-257	0.74	1.6	1.39	0.13
DCZI38G	DMH07Y3	Letrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	17.98	17.43	10.03	11.28
DC0AHZ4	DMH07Y3	Letrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	NCIH23	0.8	7.51	9.53	10.08
DC6VX9J	DMH07Y3	Letrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	28.35	27	7.14	9
DC5DSLM	DMH07Y3	Letrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	10.93	11.9	7.19	12.18
DC4FCQ0	DMH07Y3	Letrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	ALMANAC Dataset	Investigative	CAKI-1	13.12	15.85	6.33	9.53
DC487P2	DMH07Y3	Letrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-539	12.64	11.6	6.32	8.17
DC859JD	DMH07Y3	Letrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	8.67	5.17	0.73	1.01
DCXPA4F	DMH07Y3	Letrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	5	9.57	7	8.34
DCG1EUV	DMH07Y3	Letrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	9.23	11.74	6.44	9.15
DC6L1D2	DMH07Y3	Letrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	ALMANAC Dataset	Investigative	SK-OV-3	1.24	9.38	8.97	8.71
DC1V72L	DMH07Y3	Letrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	9.48	10.75	0.87	7.7
DC73VSJ	DMH07Y3	Letrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Renal cell carcinoma	ALMANAC Dataset	Investigative	SN12C	2.4	16.48	3.45	4.41
DCUG40I	DMH07Y3	Letrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	3.23	7.4	1.7	0.84
DC5IY5U	DMH07Y3	Letrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	CCRF-CEM	11.07	3.47	1.32	0.21
DC677ZX	DMH07Y3	Letrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	5.32	8.05	2.93	2.62
DC410IM	DMH07Y3	Letrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	NCI\\/ADR-RES	5.18	8.14	0.96	0.96
DCVHIP6	DMH07Y3	Letrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	2.01	7.18	1.39	0.84
DC0L05U	DMH07Y3	Letrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Non-small cell lung carcinoma	ALMANAC Dataset	Investigative	HOP-92	2.49	5.09	2.73	2.73
DCJZBEL	DMH07Y3	Letrozole	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	0.07	3.05	2.65	0.6
DCN8NO7	DMH07Y3	Letrozole	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	2.49	4.48	2.91	2.03
DCCJJFI	DMH07Y3	Letrozole	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCC-2998	0.25	4.52	1.79	4.51
DCLPI78	DMH07Y3	Letrozole	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	1.24	9.1	1.75	2.2
DCQKOND	DMH07Y3	Letrozole	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	9.38	16.13	0.89	2.6
DCKSS77	DMH07Y3	Letrozole	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Plasma cell myeloma	ALMANAC Dataset	Investigative	RPMI-8226	2.11	2.08	2.2	5.16
DCJH8G2	DMH07Y3	Letrozole	Approved	34	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	1.01	6.4	5.64	5.38
DC6FCWW	DMH07Y3	Letrozole	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	4.34	5.37	3.38	7.59
DC3CBOU	DMH07Y3	Letrozole	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	Cutaneous melanoma	ALMANAC Dataset	Investigative	SK-MEL-5	0.3	5.43	3.74	5.3
DCVR2UW	DMH07Y3	Letrozole	Approved	34	DMVRLT7	Fludarabine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	8.82	12.14	0.09	10.09
DCPM8SG	DMH07Y3	Letrozole	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	4.48	6.07	0.7	0.38
DCC15A0	DMH07Y3	Letrozole	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT116	0.84	5.07	4.41	4.41
DCCDZUX	DMH07Y3	Letrozole	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Lung adenocarcinoma 	ALMANAC Dataset	Investigative	NCI-H522	2.61	5.09	3.88	3.58
DCHGNEP	DMH07Y3	Letrozole	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Minimally invasive lung adenocarcinoma	ALMANAC Dataset	Investigative	NCI-H322M	0.14	1.11	0.44	0.51
DCPB36T	DMH07Y3	Letrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	0.31	1.67	2.56	2.93
DCA4Z35	DMH07Y3	Letrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Chronic myelogenous leukemia	ALMANAC Dataset	Investigative	K-562	10.79	18.01	10.82	10.76
DC8H2G6	DMH07Y3	Letrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	TK-10	6.97	9.22	2.46	2.02
DCGZ49A	DMH07Y3	Letrozole	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	6.38	7.96	6.8	7.4
DCB0Y5X	DMH07Y3	Letrozole	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR3	6.7	11.39	4.69	5
DCDSZO9	DMH07Y3	Letrozole	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	A549	2.99	6.08	6.98	7.7
DCFVQCX	DMH07Y3	Letrozole	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	5.25	9.49	4.92	5.66
DCMQOAO	DMH07Y3	Letrozole	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	2.27	6.13	0.42	1.07
DCZZ385	DMH07Y3	Letrozole	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	7.66	6.38	5.8	6.28
DCL0X0Z	DMH07Y3	Letrozole	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	0.3	3.73	2.83	2.39
DC4RWV5	DMH07Y3	Letrozole	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	HOP-62	4.98	4.68	4.7	1.65
DCDDPEY	DMH07Y3	Letrozole	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	1.65	3.28	6.64	7.54
DCTYF5J	DMH07Y3	Letrozole	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Melanoma	ALMANAC Dataset	Investigative	SK-MEL-2	3.03	13.1	4.24	3.94
DCWI76F	DMH07Y3	Letrozole	Approved	34	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Papillary renal cell carcinoma	ALMANAC Dataset	Investigative	ACHN	1.98	2.33	0.55	0.84
DC5TE97	DMH07Y3	Letrozole	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	SW-620	1.03	3.91	2.72	2.74
DCEPM0W	DMH07Y3	Letrozole	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	ALMANAC Dataset	Investigative	MOLT-4	0.4	4.07	2.7	3.73
DCE96HM	DMH07Y3	Letrozole	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-8	0.33	5.6	5.14	4.5
DCJ79OL	DMH07Y3	Letrozole	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	EKVX	3.15	8.49	3	2.71
DCFPO5Z	DMH07Y3	Letrozole	Approved	34	DMWVIGP	Digitoxin	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	ALMANAC Dataset	Investigative	OVCAR-5	4.17	7.35	5.51	7.9
DCC7KQW	DMH07Y3	Letrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	DU-145	1.88	5.69	2.2	2.25
DC24Y5I	DMH07Y3	Letrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Adenocarcinoma	ALMANAC Dataset	Investigative	HCT-15	5.06	5.03	1.98	0.95
DC24BHY	DMH07Y3	Letrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Amelanotic melanoma	ALMANAC Dataset	Investigative	MDA-MB-435	2.86	7.84	3.39	3.39
DCTPM83	DMH07Y3	Letrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	ALMANAC Dataset	Investigative	SR	2.12	2.55	1.02	0.55
DCPBH9K	DMH07Y3	Letrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Astrocytoma	ALMANAC Dataset	Investigative	U251	4.47	8.83	8.75	7.82
DCPHO3Y	DMH07Y3	Letrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	ALMANAC Dataset	Investigative	786-0	0.99	2.53	1.32	1.29
DCHDR52	DMH07Y3	Letrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Glioblastoma	ALMANAC Dataset	Investigative	SNB-75	2.26	7.26	5.99	5.06
DC3OQXC	DMH07Y3	Letrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Glioma	ALMANAC Dataset	Investigative	SF-268	5.96	9.87	2.32	0.2
DCX9F86	DMH07Y3	Letrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Large cell lung carcinoma	ALMANAC Dataset	Investigative	NCI-H460	2.97	3.4	0.03	0.12
DCCBWRL	DMH07Y3	Letrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Lung adenocarcinoma	ALMANAC Dataset	Investigative	MDA-MB-231	3.63	6.45	2.33	1.81
DCW8A0O	DMH07Y3	Letrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Malignant melanoma	ALMANAC Dataset	Investigative	LOX IMVI	0.52	5.87	6.37	6.38
DCDGV8Q	DMH07Y3	Letrozole	Approved	34	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	ALMANAC Dataset	Investigative	NCI-H226	0.27	1.99	1.07	0.44
DC1RMIV	DMH07Y3	Letrozole	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Adult acute myeloid leukemia	ALMANAC Dataset	Investigative	HL-60(TB)	0.74	1.38	1.67	2.79
DCGLA15	DMH07Y3	Letrozole	Approved	34	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	7.91	14.79	6.71	6.71
DC2GXBS	DMH07Y3	Letrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.67	5.72	5.83	1.63
DCMBNEQ	DMH07Y3	Letrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.38	5.94	2.06	1.59
DCW2KE0	DMH07Y3	Letrozole	Approved	34	DM2YGNW	Dactinomycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.02	5.34	1.56	1.18
DCZ3QWV	DMH07Y3	Letrozole	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.81	3.38	1	0.28
DC9N9Y5	DMH07Y3	Letrozole	Approved	34	DM3BF9B	DFN-15	Phase 3	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	18.52	23.5	3.59	3.42
DCB9N7U	DMH07Y3	Letrozole	Approved	34	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	2.89	4.46	0.59	0.03
DCD0Y8N	DMH07Y3	Letrozole	Approved	34	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	6.62	8.98	0.88	0.19
DC7YPZF	DMH07Y3	Letrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	18.12	16.45	17.47	17.87
DCXMYNH	DMH07Y3	Letrozole	Approved	34	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	16.62	15.37	17.12	16.46
DCDHS4F	DMH07Y3	Letrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	6.22	8.77	1.15	0.58
DCWGPL8	DMH07Y3	Letrozole	Approved	34	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.87	9.21	0.9	0.72
DCN9OGM	DMH07Y3	Letrozole	Approved	34	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	1.69	4.21	3.39	3.13
DCYH69N	DMH07Y3	Letrozole	Approved	34	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	7.82	10.78	2.55	0.16
DCFGD57	DMH07Y3	Letrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.87	4.72	2.65	4.34
DCSCGV8	DMH07Y3	Letrozole	Approved	34	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.08	1.51	1.16	1.24
DCF2GUB	DMH07Y3	Letrozole	Approved	34	DMH8UF0	SY-1425	Phase 1	17	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.51	8.32	7.2	7.87
DC42FR4	DMH07Y3	Letrozole	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.95	2.02	1.33	0.37
DCWW2I3	DMH07Y3	Letrozole	Approved	34	DMKLAYG	Altretamine	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	3.76	5.91	1.67	0.01
DCHSA7A	DMH07Y3	Letrozole	Approved	34	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	0.64	2.79	1.49	1.44
DC9BSG5	DMH07Y3	Letrozole	Approved	34	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.49	2.97	0.54	1.16
DCJ01KK	DMH07Y3	Letrozole	Approved	34	DM7RJXL	Imatinib	Phase 3 Trial	25	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	13.06	18.68	3.72	3.64
DCMLH89	DMH07Y3	Letrozole	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	2.87	4.77	1.74	2.94
DCDI3MI	DMH07Y3	Letrozole	Approved	34	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	4.82	6.26	1.86	3.2
DCTZBVT	DMH07Y3	Letrozole	Approved	34	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	HS 578T	5.6	10.38	1.58	2.17
DCVBH5F	DMH07Y3	Letrozole	Approved	34	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	12.55	12.36	2.07	8.42
DCR7SQD	DMH07Y3	Letrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	3.93	4.73	1.12	0.42
DC4RTES	DMH07Y3	Letrozole	Approved	34	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.74	2.83	1.05	0.33
DCXMSQ6	DMH07Y3	Letrozole	Approved	34	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.37	3.55	1.84	0.38
DC5AWF5	DMH07Y3	Letrozole	Approved	34	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	3.46	7.28	2.23	2.03
DCNO5GP	DMH07Y3	Letrozole	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.21	2.53	1.66	1.38
DCJGTL7	DMH07Y3	Letrozole	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	1.15	3.42	2.04	0.8
DC1Z0CZ	DMH07Y3	Letrozole	Approved	34	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	3.05	6.64	0.67	0.67
DCFLN1E	DMH07Y3	Letrozole	Approved	34	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.11	1.39	1.51	1.08
DC64H7E	DMH07Y3	Letrozole	Approved	34	DMWTAOI	Estramustine	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.56	2.29	2.65	3.07
DCP9NFL	DMH07Y3	Letrozole	Approved	34	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.01	1.16	1.31	1.21
DC7I819	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM05FXR	Meclofenamic acid	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.56	2.56	16.72	16.72
DCRIISS	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM1TJ8F	Diethylcarbamazine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	29.55	29.55	39.71	39.71
DCOBOY6	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.19	5.19	5.88	5.92
DCFBTFV	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	0.05	2.88	3.27	7.39
DCIMLFW	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.29	5.56	4.35	7.29
DCWHJT9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	2.11	3.46	0.56	3.27
DCZ8IXA	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	0.09	2.77	0.18	0.93
DCFIAN7	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	0.62	4.22	4.7	6.1
DCJ92R4	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	1.92	4.68	4.43	5.09
DCXNNX5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.73	0.77	2.15	2.6
DC5GREU	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.09	2.09	2.86	2.86
DCAZF4G	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM93L4X	Dexmedetomidine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	13.19	13.19	27.21	27.21
DCDSFJ0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.29	2.02	0.8	2.96
DCOY783	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.17	1.04	2.43	4.75
DCXW2S0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.78	2.25	1.94	3.5
DCRP3VF	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.19	1.49	1.18	3.94
DCU4BT1	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	4.37	4.19	1.8	7.21
DCW0QG2	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.6	1.92	0.24	2.81
DC6GYJT	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	1.52	1.96	2.55	5.53
DCBTSP9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.31	5.31	10.4	10.41
DCXUHYR	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	6.16	5.77	6.22	6.51
DCCJUF3	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMCT2YF	Emetine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	9.02	9.02	11.2	11.21
DCO9EQM	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMDASC6	Metformin	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	3.18	3.18	16.43	16.44
DCQ5M3D	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMFGLXB	Phensuximide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.69	0.69	14.02	14.02
DCZLSQ4	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMFNTMY	Fibrates	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.99	5.99	18.95	18.96
DCNA89B	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMFO843	Fluspirilene	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	13.42	13.42	27.7	27.71
DCTLWDD	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	7.06	6.29	1.43	8.75
DCHT0WC	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	2.62	3.29	1.9	5.92
DC9GTNX	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	0.73	8.53	2.8	5.83
DC20EHL	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	2.41	3.27	1.52	4.21
DCUPKVK	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	7.38	7.07	8.88	9.98
DCN7A9H	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.68	1.34	1.5	4.58
DCAYIQX	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMKZJ7T	GINKGOLIDE A	Investigative	0	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	0.61	0.61	14.99	14.99
DCV5BK9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.26	5.26	13.9	13.9
DCGVT54	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	4.04	0.73	1.97	4.4
DCDD3MS	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMNER5S	Bleomycin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.01	0.64	5.98	8.65
DCGUQTH	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	2.96	0.64	2.2	2.92
DCAOWUL	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	1.16	1.18	2.32	2.39
DC3PF9Q	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.31	2.5	3.11	4.19
DCIK4TW	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	2.34	2.25	4.79	6.36
DC2BALQ	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMPZS7U	Oxyphenbutazone	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.65	5.65	11.87	11.87
DCR279X	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMR8ONJ	Leflunomide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	5.83	5.83	7.6	7.6
DCACZBO	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.05	3.94	2.47	6.83
DCVUD6J	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	0.32	0.05	0.5	2.95
DC6L21O	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.68	3.67	2.74	7.3
DCHKH7A	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.29	2.47	1.97	5.38
DC2S90X	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Papillary renal cell carcinoma	DrugCombDB Database	Investigative	ACHN	1.47	3.22	3.43	5.55
DC9M2Y5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	6.15	7.51	6.59	8.18
DCX9JDL	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.4	3.83	1.84	6.66
DCQ9JNR	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	10.07	8.07	4.51	9.06
DCRCD4C	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	3.52	5.63	1.88	6.17
DCVTWGQ	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ewing sarcoma-peripheral primitive neuroectodermal tumour	DrugCombDB Database	Investigative	ES2	10.16	12.2	4.38	15.62
DCLIU04	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	2.81	3.94	3.49	5.94
DCY012P	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	2.42	1.45	1.8	4.57
DC9JZVC	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	2.31	1.88	0.43	4.89
DCL4NCM	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMVP5YE	Doxorubicin	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	2.72	2.72	3.35	3.44
DCK50XM	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMVYXR8	Sumatriptan	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	8.71	8.71	23.58	23.58
DCJJYBS	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMWBHRY	Olmesartan medoxomil	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	49.77	49.77	63.07	63.08
DC4XU37	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMWMPD4	Vorinostat	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	4.68	4.68	5.37	5.4
DCV73TI	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.1	0.75	0.21	2.12
DC3SLHS	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMZ80SB	Azatadine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	KBM-7	64.83	64.83	80.03	80.04
DCK7XSS	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.82	7.52	5.53	5.86
DCXHZOY	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	1.13	3.76	2.34	7.64
DC30Z5K	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM2TEOL	Methotrexate	Phase 1/2 Trial	19	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	1.34	4.18	0.4	1.58
DCHRE1S	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.97	4.32	7.03	10.09
DC8NQQO	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	4.74	0.2	2.03	0.56
DC6WNSL	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	0.74	1.23	0.59	1.33
DCC8BXS	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	1.55	0.94	2.43	6.24
DCNYJIL	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	5.72	6.41	6.17	8.74
DCX5S03	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	4.22	4.71	3.8	7.16
DCZR08E	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	BT-549	3.92	3.58	8.81	10.98
DCC7TWY	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289	4.18	3.85	4.52	7.54
DCRK54K	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.21	1.31	2.86	5.13
DC7OF5M	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	0.37	2.1	0.94	6.91
DCYK5KK	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Colon adenocarcinoma	JAAKS Dataset	Investigative	COLO 205	6.75	6.9	4.7	7.44
DCX353Y	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast and ovarian cancer syndrome	JAAKS Dataset	Investigative	UWB1289+BRCA1	1.26	1.63	4.46	5.93
DC554K3	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	ZR751	5.4	2.43	12.94	16.03
DCMUCGC	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	KPL1	2.28	2.6	5.49	7.13
DCY4LJ6	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Breast carcinoma	JAAKS Dataset	Investigative	OCUBM	2.52	2.69	0.68	8.47
DC4D8JA	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	OV90	1.74	2.46	3.16	8.13
DCI5KPR	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	RKO	11.06	11.67	6.3	14.99
DCL5XRI	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	2.72	3.19	0.42	5.84
DC1MZTG	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Colon carcinoma	JAAKS Dataset	Investigative	KM12	12.07	15.01	7.95	11.45
DCOQX8S	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.61	7.7	6.22	8.24
DC1FPAC	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM25HY3	Ombrabulin	Phase 3	25	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	63.332	61.855	8.377	12.958
DCJP8K0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM2OZ3G	Ixabepilone	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	0.24	1.31	1.49	4.4
DCIEEUC	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM4DOUB	PMID28460551-Compound-2	Patented	15.5	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	MDA-MB-231	3.99	9.14	8.58	11.89
DCTTZP4	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	2.236	1.823	0.948	3.75
DCALZTR	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM61TA4	Arsenic trioxide	Approved	34	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	SK-MEL-2	6.43	7.5	4.08	6.74
DCSTISN	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	3.36	2.51	0.09	7.66
DCNHJHZ	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	21.57	20.89	24.48	25.24
DCQGMIV	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	4.65	3.03	5.35	8.95
DC91IWK	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	COLO320DM	6.03	6.17	4.78	8.61
DCJMOTP	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	3.16	4.37	6.47	9.28
DCF6ISV	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	6.07	5.87	2.11	9.49
DCKZVU9	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	4.11	3.48	3.29	6.62
DCLL2UG	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	4.1	5.61	7.43	10.35
DCY86O0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	RPMI7951	4.01	2.81	1.03	6.16
DCN4BHW	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	8.44	7.1	2.05	7.79
DCUDNPU	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	8.65	7.63	10.11	7.86
DCF1JOZ	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM67EMK	SCH-900776	Phase 2	21	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	1.75	6.99	6.83	7.5
DCQKVOF	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	0.74	1.41	0.1	1.29
DCFCX88	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	3.78	4.14	1.83	4.78
DC8HUWL	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	0.2	1.43	0.57	0.03
DCLAW1L	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	4.24	3.42	4.11	7.71
DCQFK31	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.21	3.73	6.82	8.17
DCAQZW2	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	6.81	5.49	5.16	10.3
DC7E9BG	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	2.6	2.58	3.79	5.99
DCNMWLQ	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMAE6LK	Topetecan	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	0.62	3.43	0.72	3.92
DC100RS	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	2.62	1.46	1.97	2.8
DCCE56W	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	0.02	3.24	2.01	2.02
DCQI67T	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	7.82	4.9	1.66	7.41
DC8EB5I	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	5.96	7.24	4.61	6.52
DC8O1K0	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	8.18	8.52	8.81	11.67
DCDF2GH	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMFH15Z	Bendamustine hydrochloride	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	6.83	12.14	11.96	11.97
DCNMBK8	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	6.82	4.36	4.82	9.08
DCTN9C5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	2.42	4.22	6.47	7.43
DCSLR0M	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	1.86	2	0.54	3.25
DCETOPZ	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-28	4.05	6.42	8.9	9.92
DC43V2K	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.15	1.9	0.98	3.86
DC0Q86I	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMH0ZJE	Mitomycin	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	5.6	11.95	8.71	10.04
DCQYCPU	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMKLAYG	Altretamine	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.97	3.9	1.31	2.83
DC1RUS2	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	3.46	4.01	3.93	7.06
DCT9ZFR	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	3.74	4.08	1.24	6.1
DC0L68I	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HT29	4.64	6.24	0.51	6.87
DC4X7ZW	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	6.65	5.64	1.63	7.46
DCJ4JQG	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	10.84	8.84	6.21	12.14
DCZ1UER	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	0.68	1.09	0.65	3.88
DCYP0SO	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	3.29	7.48	5.46	4.23
DCKTR1W	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMLHEU7	Ridaforolimus	Phase 3	25	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	LNCAP	12.17	6.8	4.14	9.76
DC763Y7	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	2.25	5.11	3.7	2.88
DCFK1RX	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	3.38	2.83	1.82	4.2
DCE3AXA	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A549	3.16	2.3	2.02	4.96
DC9SBLB	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT116	2.77	2.52	3.02	5.15
DCS2K45	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.83	3.71	1.01	5.17
DCS9XJQ	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Cutaneous melanoma	SYNERGxDB Database	Investigative	SK-MEL-5	4.38	4.42	4.3	6.84
DCFAV0W	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	7.18	6.06	3.71	4.44
DCASIEE	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMNO38U	Bortezomib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	3.96	3.45	2.29	7.18
DC9F6QD	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	4.71	6.04	6.44	7.88
DC3BDSK	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	3.23	3.27	3.58	7.65
DCBLUSP	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	M14	2.62	3.07	4.46	4.7
DCYD840	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	1.21	2.71	0.6	0.56
DCVLE7W	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Lung adenocarcinoma	SYNERGxDB Database	Investigative	HOP-62	6.59	6.96	7.35	8.02
DCKJTRS	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Non-small cell lung carcinoma	SYNERGxDB Database	Investigative	HOP-92	1.7	1.1	5.22	6.81
DC8R9Q2	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMOYJFK	Valrubicin	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	2.31	3.87	2.91	3.09
DCXC12P	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	LOX IMVI	1.02	1.45	5.06	8.27
DC4I50L	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMRHGI9	Cisplatin	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	1.89	4.21	2.95	0.48
DC3Z4YC	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	CAOV3	8.37	9.86	0.95	11
DCZ9CKG	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR3	11.36	6.6	8.76	0.8
DCOXVUH	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	A427	1.11	2.2	0.19	6.61
DCDFQQE	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH1650	3.45	4.39	0.84	2.97
DCJMX90	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH2122	3.84	3.56	1.51	7.11
DCRU7O5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH23	6.57	7.48	1.52	11.39
DCB73FG	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	NCIH520	7.19	3.79	2.3	10.66
DCIEL8S	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DLD1	9.05	11.38	7.65	14.66
DC88CP6	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	SW-620	9.16	9.29	3.91	11.72
DCJY8DY	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	A2058	9.83	11.86	0.49	11.14
DCAPECE	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Germ cell tumour	SYNERGxDB Database	Investigative	PA1	8.01	6.07	2.88	9.29
DCI6HDO	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	11.47	12.75	13.8	16.96
DCX03FG	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	A375	15.35	14.88	9.14	18.96
DCDDAOX	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	HT144	0.03	4.18	7.58	9.78
DCI7O5V	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	SKMEL30	4.29	4.34	0.69	7.88
DCQBGBP	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Malignant melanoma	SYNERGxDB Database	Investigative	UACC62	4.03	5.35	2.26	8.49
DCBC6BN	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Mesothelioma	SYNERGxDB Database	Investigative	MSTO	5.42	5.07	4.77	7.77
DCXZ5IX	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Non small cell carcinoma	SYNERGxDB Database	Investigative	SKMES1	15.29	14.06	12.06	16.8
DCMM51T	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian endometrioid adenocarcinoma	SYNERGxDB Database	Investigative	A2780	9.55	7.29	5.95	12.08
DCMW3YK	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Ovarian serous cystadenocarcinoma	SYNERGxDB Database	Investigative	SK-OV-3	17.6	17.48	19.66	16.67
DCM3YKH	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Prostate carcinoma	SYNERGxDB Database	Investigative	VCAP	6.77	13.38	9.9	11.87
DC6XWVV	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMSG91J	ER819762	Investigative	0	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	3.54	4.29	2.53	0.6
DCG46ZI	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCC-2998	1.19	3.04	3.46	7.6
DCPZYHB	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Large cell lung carcinoma	SYNERGxDB Database	Investigative	NCI-H460	1.73	1.54	1.86	5.65
DCAVVER	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Minimally invasive lung adenocarcinoma	SYNERGxDB Database	Investigative	NCI-H322M	3.77	10.69	5.57	5.73
DC2RJZ5	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Lung adenocarcinoma 	SYNERGxDB Database	Investigative	NCI-H522	1.05	1.62	1.59	3.37
DCUQKYP	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	HCT-15	1.01	3.85	3.06	5.88
DC2OH6K	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMTM2IK	Mercaptopurine	Preclinical	2.1	.	.	.	.	Melanoma	SYNERGxDB Database	Investigative	UACC-257	0.04	4.58	2.11	3.29
DCY3FAI	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Adenocarcinoma	SYNERGxDB Database	Investigative	DU-145	2.06	4.68	3.89	5.38
DCM6PTX	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Amelanotic melanoma	SYNERGxDB Database	Investigative	MDA-MB-435	2.69	4.38	2.84	0.66
DCBA02B	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMWNHPC	Aminolevulinic Acid Hydrochloride	Approved	34	.	.	.	.	Pleural epithelioid mesothelioma	SYNERGxDB Database	Investigative	NCI-H226	8.65	11.69	8.97	8.83
DCPUOBH	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMXKDUL	BGT226	Phase 1/2	19	.	.	.	.	Hodgkin lymphoma	SYNERGxDB Database	Investigative	L-1236	84.91	61.13	13.03	1.26
DCQAWUZ	DM9WLN4	10-hydroxycamptothecin	Investigative	0	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	High grade ovarian serous adenocarcinoma	SYNERGxDB Database	Investigative	OVCAR-4	0.04	1.52	0.05	0.81
DCGWBF5	DM3BF9B	DFN-15	Phase 3	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	2.92	7.59	5.45	2.98
DC6W472	DM3BF9B	DFN-15	Phase 3	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	4.07	4.36	0.16	0.09
DCKI8XB	DM3BF9B	DFN-15	Phase 3	25	DM0HXDS	Pentostatin	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	6.62	2.59	0.2	0.45
DC1I3Y7	DM3BF9B	DFN-15	Phase 3	25	DM0YZC6	Fulvestrant	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	6.14	7.93	0.99	0.38
DC4QU8V	DM3BF9B	DFN-15	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	9.99	17.6	4.12	3.49
DC5CNFZ	DM3BF9B	DFN-15	Phase 3	25	DM3BH1Y	Lapatinib	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	4.09	5.92	3.54	0.1
DCBUUV2	DM3BF9B	DFN-15	Phase 3	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	1.54	1.48	0.02	0.12
DCADQ51	DM3BF9B	DFN-15	Phase 3	25	DM4O2Z7	Cyclophosphamide	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.46	3.95	0.44	0.26
DCX9DNQ	DM3BF9B	DFN-15	Phase 3	25	DM58WKG	Panobinostat	Approved	34	.	.	.	.	Diffuse intrinsic pontine glioma	DrugCombDB Database	Investigative	DIPG25	3.27	3.41	2.64	2.2
DCVYL6J	DM3BF9B	DFN-15	Phase 3	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.11	5.35	1.11	0.15
DC7QM5P	DM3BF9B	DFN-15	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	3.51	3.78	5.8	4.82
DC21VBZ	DM3BF9B	DFN-15	Phase 3	25	DMAO80I	Pralatrexate	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	1.19	0.73	0.87	0.87
DC17SWV	DM3BF9B	DFN-15	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	5.42	9.13	2.21	1.84
DCUYSN2	DM3BF9B	DFN-15	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	1.39	2.6	0.7	0.4
DCORIMS	DM3BF9B	DFN-15	Phase 3	25	DMC3P45	Terameprocol	Phase 2	21	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	8.45	11.37	2.77	1.96
DCY4GA0	DM3BF9B	DFN-15	Phase 3	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	7.8	10.4	4.58	1.11
DCPJ7HL	DM3BF9B	DFN-15	Phase 3	25	DMCT3I8	Ifosfamide	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	8.87	10.76	2.52	1.1
DCHG5GF	DM3BF9B	DFN-15	Phase 3	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	23.66	12.92	0.81	0.81
DC0B46S	DM3BF9B	DFN-15	Phase 3	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	14.69	11.48	6.64	6.54
DCKU2OM	DM3BF9B	DFN-15	Phase 3	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	16.38	19.65	18.35	19.72
DCI2C1X	DM3BF9B	DFN-15	Phase 3	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	7.32	12.97	12.16	12.65
DCEK7JE	DM3BF9B	DFN-15	Phase 3	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	13.19	14.3	10.01	9.51
DC3PVRA	DM3BF9B	DFN-15	Phase 3	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	28.81	39.04	20.73	20.73
DC3MEE4	DM3BF9B	DFN-15	Phase 3	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	11.87	11.97	8.5	0.09
DCNQWMS	DM3BF9B	DFN-15	Phase 3	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	5.02	4.43	4.97	4.61
DC4OR4C	DM3BF9B	DFN-15	Phase 3	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	10.42	10.82	5.96	5.96
DCOZMEC	DM3BF9B	DFN-15	Phase 3	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Clear cell renal cell carcinoma 	DrugCombDB Database	Investigative	CAKI-1	6.09	8.76	4.19	4.18
DCDEIWJ	DM3BF9B	DFN-15	Phase 3	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	7.32	8.98	8.76	9.95
DC5WTD9	DM3BF9B	DFN-15	Phase 3	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	3.33	5.63	3.56	3.92
DCAWGAO	DM3BF9B	DFN-15	Phase 3	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	10.8	12.83	12.09	14.29
DCJT5N2	DM3BF9B	DFN-15	Phase 3	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	0.28	6.66	2.68	2.83
DCI5O5A	DM3BF9B	DFN-15	Phase 3	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	14.94	13.29	8.85	8.76
DC9WORA	DM3BF9B	DFN-15	Phase 3	25	DMDI269	Docetaxel	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	10.28	8.49	6.81	6.37
DCI1PGO	DM3BF9B	DFN-15	Phase 3	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	1.94	1	2.7	5.61
DCV0O2D	DM3BF9B	DFN-15	Phase 3	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	3.95	8.88	2.19	1.75
DCCLEVY	DM3BF9B	DFN-15	Phase 3	25	DMDKF3M	Raloxifene	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	4.34	5.46	3.33	0.04
DCKCCAG	DM3BF9B	DFN-15	Phase 3	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	3.65	5.66	4.85	8.73
DCNBVS0	DM3BF9B	DFN-15	Phase 3	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	5.06	12.79	5.36	4.7
DCGHVA0	DM3BF9B	DFN-15	Phase 3	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	2.07	6.5	3.34	1.94
DC0UQNO	DM3BF9B	DFN-15	Phase 3	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.59	3.07	2.61	4.22
DC63B4X	DM3BF9B	DFN-15	Phase 3	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	7.9	12.85	4.71	3.03
DC1W97U	DM3BF9B	DFN-15	Phase 3	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	5.44	6.2	4.49	4.18
DC5MX1Z	DM3BF9B	DFN-15	Phase 3	25	DMGW1ID	Sirolimus	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	2.54	6.32	2.18	4.51
DCFDEJ7	DM3BF9B	DFN-15	Phase 3	25	DMLNFWU	TEM	Phase 2	21	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.76	4.56	0.77	0
DCDZI1K	DM3BF9B	DFN-15	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	4.55	11.65	4.63	8.01
DCTRN7K	DM3BF9B	DFN-15	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	2.54	5.03	2.58	0.99
DCVJANQ	DM3BF9B	DFN-15	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	0.25	4.39	0.62	2
DC7QM1P	DM3BF9B	DFN-15	Phase 3	25	DMM0XGL	Idarubicin	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	SN12C	7.31	6.11	4.42	3.42
DCGILBE	DM3BF9B	DFN-15	Phase 3	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.61	2.81	0.55	0.94
DCSAC1I	DM3BF9B	DFN-15	Phase 3	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	0.92	2.88	1.17	0.43
DCOE0JA	DM3BF9B	DFN-15	Phase 3	25	DMRKE63	Chlorambucil	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	6.91	8.26	0.74	0.74
DCSYGJZ	DM3BF9B	DFN-15	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.73	8.83	6.53	0.12
DC9DHCW	DM3BF9B	DFN-15	Phase 3	25	DMS8IFC	Sorafenib	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	4.64	5.51	0.84	0.24
DC4N4OR	DM3BF9B	DFN-15	Phase 3	25	DMTA5OE	Azacitidine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	11.47	16.89	7.37	12.93
DCNVOIS	DM3BF9B	DFN-15	Phase 3	25	DMTGBAX	Pomalidomide	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.71	6.42	2.45	3.55
DCUUQPO	DM3BF9B	DFN-15	Phase 3	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	5.61	13.01	6.19	3.38
DCG5YAD	DM3BF9B	DFN-15	Phase 3	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	5.04	10.05	4.49	3.62
DC98440	DM3BF9B	DFN-15	Phase 3	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	21.47	17.38	14.27	9.63
DC1ZLKQ	DM3BF9B	DFN-15	Phase 3	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.06	2.13	0.84	0.86
DC7NT7W	DM3BF9B	DFN-15	Phase 3	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.15	0.92	0.33	0.07
DCZ7IPY	DM3BF9B	DFN-15	Phase 3	25	DMTJAEP	Vinflunine	Approved	34	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	6.04	8.09	2.78	1.35
DC6NPUR	DM3BF9B	DFN-15	Phase 3	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Anaplastic large cell lymphoma	DrugCombDB Database	Investigative	SR	5.81	10.69	5.72	2.95
DCMYGI1	DM3BF9B	DFN-15	Phase 3	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	0.13	4.86	1.23	1.39
DCGBUB9	DM3BF9B	DFN-15	Phase 3	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	0.46	4.04	0.03	0.77
DC6PX5G	DM3BF9B	DFN-15	Phase 3	25	DMU8L7C	Mepacrine	Investigative	0	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	1.51	9.83	1.3	1.2
DCPI08Q	DM3BF9B	DFN-15	Phase 3	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	U251	13.87	12.25	9.49	12.85
DCSNZAC	DM3BF9B	DFN-15	Phase 3	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	7.04	10.9	11.57	11.53
DCGNPDY	DM3BF9B	DFN-15	Phase 3	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	A498	3.96	3.47	4.42	4.07
DCSXDDC	DM3BF9B	DFN-15	Phase 3	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	6.01	11.71	12.43	12.48
DCB0A4D	DM3BF9B	DFN-15	Phase 3	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	14.76	13.55	2.26	8.23
DC9MBVJ	DM3BF9B	DFN-15	Phase 3	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-295	7.34	8.95	8.04	8.28
DC3T71J	DM3BF9B	DFN-15	Phase 3	25	DMUOT9V	Taxol	Approved	34	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	0.14	5.52	2.82	3.9
DCU09YS	DM3BF9B	DFN-15	Phase 3	25	DMWGV8N	PMID28870136-Compound-43	Patented	15.5	.	.	.	.	Adult acute myeloid leukemia	DrugCombDB Database	Investigative	HL-60(TB)	0.91	2.63	3.81	3.81
DCRBZSK	DM3BF9B	DFN-15	Phase 3	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Adult T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	MOLT-4	6.23	11.38	7.89	8.03
DCD11NF	DM3BF9B	DFN-15	Phase 3	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Childhood T acute lymphoblastic leukemia	DrugCombDB Database	Investigative	CCRF-CEM	3.26	9.4	4.9	5.02
DCRZMB8	DM3BF9B	DFN-15	Phase 3	25	DMWIDJK	FORMESTANE	Withdrawn from market	12	.	.	.	.	Chronic myelogenous leukemia	DrugCombDB Database	Investigative	K-562	12.86	12.33	5.78	5.82
DCVCLTG	DM3BF9B	DFN-15	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	0.7	1.96	0.21	0.25
DCEVM0C	DM3BF9B	DFN-15	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	0.58	2.79	0.64	0.88
DCQQP4U	DM3BF9B	DFN-15	Phase 3	25	DMXYJ9C	Busulfan	Approved	34	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-539	0.3	2.91	0.98	0.78
DCIDC3Y	DM3BF9B	DFN-15	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Astrocytoma	DrugCombDB Database	Investigative	SNB-19	1.72	6.21	3.23	3.72
DCV0W93	DM3BF9B	DFN-15	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	TK-10	11.43	14.65	5.16	9.85
DCOBAIV	DM3BF9B	DFN-15	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Clear cell renal cell carcinoma	DrugCombDB Database	Investigative	786-0	2.6	9.46	6.22	4.81
DCI10GN	DM3BF9B	DFN-15	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioblastoma	DrugCombDB Database	Investigative	SNB-75	1.52	7.66	0.07	5.16
DCWEVTB	DM3BF9B	DFN-15	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Glioma	DrugCombDB Database	Investigative	SF-268	3.85	8.16	1.5	1.9
DCXDJHG	DM3BF9B	DFN-15	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Plasma cell myeloma	DrugCombDB Database	Investigative	RPMI-8226	2.03	4.09	2	1.02
DC0TJJ3	DM3BF9B	DFN-15	Phase 3	25	DMJV2EK	Dasatinib	Investigative	0	.	.	.	.	Renal cell carcinoma	DrugCombDB Database	Investigative	UO-31	2.31	7.7	1.44	5.42
DCOM1GF	DM3BF9B	DFN-15	Phase 3	25	DM2AZPP	Hepzato	Phase 3	25	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	0.09	2.33	0.53	0.69
DCKLX2T	DM3BF9B	DFN-15	Phase 3	25	DM7C8YV	Plicamycin	Approved	34	.	.	.	.	Invasive ductal carcinoma	JAAKS Dataset	Investigative	T-47D	5.1	7.98	1.3	1.1
DCCGHSA	DM3BF9B	DFN-15	Phase 3	25	DM7XZY5	Triapine	Phase 2	21	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	RXF 393	2.77	6.82	2.76	2.55
DCRWZ5B	DM3BF9B	DFN-15	Phase 3	25	DM9WLN4	10-hydroxycamptothecin	Investigative	0	.	.	.	.	Breast adenocarcinoma	JAAKS Dataset	Investigative	MDA-MB-468	5.31	5.06	3.73	4.62
DCORFBU	DM3BF9B	DFN-15	Phase 3	25	DMCJLD1	SCH 727965	Discontinued in Phase 3	9	.	.	.	.	Carcinoma	JAAKS Dataset	Investigative	MCF7	0.01	1.52	0.77	0.84
DCPTSQD	DM3BF9B	DFN-15	Phase 3	25	DMCJLD1	SCH 727965	Discontinued in Phas